ID,heavy_sequence,light_sequence,heavy_ID,light_ID,heavy_definition,light_definition,organism,reference_authors,reference_title,update_date,cdr_lengths,model,pairing,targets_mentioned,pair_count,heavy_organism_count,umap0,umap1
1UB6_H_L,ALLESGGGLVKPGGSLKLSCTASGITFSRYIMSWVRQIPEKRLEWVASISSGGITYYPDSVAGRFTISRDNVRNILYLQMSSLRSEDTALYYCARGQGRPYWGQGTLVTVSA,AALTQSPVSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPNRFSSSGSGTDFTLRINTVEAEDVGVYYCAQNLELPPTFGAGTKLELK,1UB6_H,1UB6_L,Crystal Structure Of Antibody 19G2 With Sera Ligand,Crystal Structure Of Antibody 19G2 With Sera Ligand,Mus musculus,"Beuscher,A.B.;Wirsching,P.;Lerner,R.A.;Janda,K.;Stevens,R.C.",Structure And Dynamics Of Blue Fluorescent Antibody 19g2 At Blue And Violet Fluorescent Temperatures,30-MAR-2003,8_7_8_11_3_9,1UB6_H_L,Xtal structure,,2,1,18.25524,7.2295537
1FL3_A_B,ALLESGGGLVKPGGSLKLSCTASGITFSRYIMSWVRQIPEKRLEWVASISSGGITYYPDSVAGRFTISRDNVRNILYLQMSSLRSEDTALYYCARGQGRPYWGQGTSVTVSA,AALTQSPVSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPNRFSSSGSGTDFTLRINTVEAEDVGVYYCAQNLELPPTFGAGTKLELK,1FL3_A,1FL3_B,Crystal Structure Of The Blue Fluorescent Antibody (19G2) In Complex With Stilbene Hapten At 277K,Crystal Structure Of The Blue Fluorescent Antibody (19G2) In Complex With Stilbene Hapten At 277K,Mus musculus,"Simeonov,A.;Matsushita,M.;Juban,E.A.;Thompson,E.H.;Hoffman,T.Z.;Beuscher AE,4t.;Taylor,M.J.;Wirsching,P.;Rettig,W.;McCusker,J.K.;Stevens,R.C.;Millar,D.P.;Schultz,P.G.;Lerner,R.A.;Janda,K.D.",Blue-fluorescent antibodies,11-AUG-2000,8_7_8_11_3_9,1FL3_A_B,Xtal structure,,2,1,18.260384,7.232523
5UHY_H_G,AQLQQSGTGLARPGASVKLSCKASGYTFTSYGISWVTQRAGQGLEWIGVIYPRSGNTYYNEKFRGKATLTADKSSSSAYMELRGLTAEDSAVYFCARENYGSVYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQFSSYPYTFGGGTKLEIK,5UHY_H,5UHY_G,A Human Antibody Against Zika Virus Crosslinks The E Protein To Prevent Infection,A Human Antibody Against Zika Virus Crosslinks The E Protein To Prevent Infection,Zika virus,"Hasan,S.S.;Miller,A.;Sapparapu,G.;Fernandez,E.;Klose,T.;Long,F.;Fokine,A.;Porta,J.C.;Jiang,W.;Diamond,M.S.;Crowe JE,Jr.;Kuhn,R.J.;Rossmann,M.G.",A human antibody against Zika virus crosslinks the E protein to prevent infection,12-JAN-2017,8_8_9_6_3_9,5UHY_H_G,Xtal structure,Zika,2,1,0.18338068,-4.1462665
8DMJ_D_E,AVQLQQSGAELMRPGASMKISCKATGYTFSSYWIDWVKQRPGHGLEWIGEILPGSGDTNYNENFKGKAAFTADTSSNTAYMQLTSLTSEDSAVFYCARGGRYHGQGFFDYWGQGTTLTVSS,AIQMTQSPASLSASVGETVTITCRPSENVHIYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSASGTQFSLKINSLQPEDFGSYYCQHFWSIPYTFGGGTKLEIK,8DMJ_D,8DMJ_E,Postfusion Nipah Virus Fusion Protein In Complex With Fab 1H1,Postfusion Nipah Virus Fusion Protein In Complex With Fab 1H1,Mus musculus,"Byrne,P.O.;Blade,E.G.;McLellan,J.S.",Postfusion Nipah virus fusion protein in complex with Fab 1H1,12-JUL-2023,8_8_14_6_3_9,8DMJ_D_E,Xtal structure,,2,1,4.999496,-1.8676317
4GLR_J_K,AVTLDESGGGLQTPGGGLSLVCKASGFTLSSYQMMWVRQAPGKGLEWVAGITSRGGVTGYGSAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKPALDSDQCGFPEAGCIDAWGHGTEVIVSS,HSALTQPTSVSANLGGSVEITCSGSDYDYGWYQQKAPGSAPVTVIYWNDKRPSDIPSRFSGSTSGSTSTLTITGVQAEDEAVYYCGAYDGSAGGGIFGAGTTLTVL,4GLR_J,4GLR_K,Structure Of The Anti-Ptau Fab (Pt231/Ps235_1) In Complex With Phosphoepitope Pt231/Ps235,Structure Of The Anti-Ptau Fab (Pt231/Ps235_1) In Complex With Phosphoepitope Pt231/Ps235,Gallus gallus,"Shih,H.H.;Tu,C.;Cao,W.;Klein,A.;Ramsey,R.;Fennell,B.J.;Lambert,M.;Ni Shuilleabhain,D.;Autin,B.;Kouranova,E.;Laxmanan,S.;Braithwaite,S.;Wu,L.;Ait-Zahra,M.;Milici,A.J.;Dumin,J.A.;LaVallie,E.R.;Arai,M.;Corcoran,C.;Paulsen,J.E.;Gill,D.;Cunningham,O.;Bard,J.;Mosyak,L.;Finlay,W.J.",An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition,14-AUG-2012,8_8_20_4_3_11,4GLR_J_K,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,2,1,14.487068,11.251894
CAD32619,DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWRQGTTLTVSS,DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,CAD32619_H,CAD32619_L,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Mack,M.; Schloendorff,D.; Spring,M.",Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders,27-MAY-2002,8_8_12_5_3_9,AAU96057,Same entry,,2,1,0.17201681,-3.2792692
CAI7934900_CAI7934878,DIQLVSSGPGIVRPGENLNLLCKVTGFSISTEYYEWHWIRQAPGKGMEWIATIYPYGGGTGYAHSLKSRATISSDASKNEFSLQLNSLTAADSAGYFCARGDTV,EPTVTQTGSQSVSLGQTVKLSCSKSSGGIWGIFHWYQQKPGQAPRFVWYGSSTRGEGIPDRFTGSESGNTGSLTISNTQPEDEAVYYCGAWEF,CAI7934900,CAI7934878,"immunoglobulin alpha-2 heavy chain-like, partial [Podarcis lilfordi]",immunoglobulin lambda-1 light chain-like isoform X2 [Podarcis lilfordi],Podarcis lilfordi,"Alioto,T.; Alioto,T.; Gomez Garrido,J.",Direct Submission,23-FEB-2023,10_8_6_7_3_5,FAILED,Unique chain,alpha-2,2,1,16.614346,-9.953478
3VRL_H_L,DVKLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVAIISSGGSYTYYSDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCTRDEGNGNYVEAMDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWSTPRTFGGGTKLEIK,3VRL_H,3VRL_L,Crystal Structure Of Bmj4 P24 Capsid Protein In Complex With A10F9 Fab,Crystal Structure Of Bmj4 P24 Capsid Protein In Complex With A10F9 Fab,Human immunodeficiency virus 1,"Gu,Y.;Cao,F.;Li,S.;Yuan,Y.A.;Xia,N.",Structure Of The Hiv-1 Capsid Protein P24 In Comple The Broad-Spectrum Antibody A10f9,12-APR-2012,8_8_15_6_3_9,3VRL_H_L,Xtal structure,P24; BA2; MRP-1; TSPAN29; CD9; MIC3,2,1,17.8303,7.039084
5DO2_H_L,DVKLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCTRDGNDYDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPRTFGGGTKLEIK,5DO2_H,5DO2_L,Complex Structure Of Mers-Rbd Bound With 4C2 Antibody,Complex Structure Of Mers-Rbd Bound With 4C2 Antibody,Mus musculus,"Li,Y.;Wan,Y.;Liu,P.;Zhao,J.;Lu,G.;Qi,J.;Wang,Q.;Lu,X.;Wu,Y.;Liu,W.;Zhang,B.;Yuen,K.Y.;Perlman,S.;Gao,G.F.;Yan,J.",A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein,10-SEP-2015,8_8_9_6_3_9,5DO2_H_L,Xtal structure,MERS; CoV,2,1,17.85635,7.114146
5B4M_H_L,DVKLVESGGGLVNLGGSLKLSCAASGFTFSRYYMSWVRQTPEKRLELVAAINHNSGRTYYSDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALYYCTRHPLIYHGNYLDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYVTWYQQKPGQPPKLLIYVASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,5B4M_H,5B4M_L,Crystal Structure Of An Fab Against Human Influenza A,Crystal Structure Of An Fab Against Human Influenza A,Mus musculus,"Yuan,Y.A.",Crystal Structure Of An Fab Against Human Influenza,05-APR-2016,8_8_14_10_3_9,5B4M_H_L,Xtal structure,Influenza,2,1,17.676878,6.909491
AAD54389_AAD54391,DVKLVESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTRHHGNWGQGTSVTVSS,GIVMTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELYTFGGGTKLEIK,AAD54389,AAD54391,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Putterman,C.; Deocharan,B.; Diamond,B.",Molecular analysis of the autoantibody response in peptide-induced autoimmunity,26-JUL-2016,8_10_6_10_3_8,AAD54389_AAD54391,Ordered entries,,2,1,13.391833,7.1275415
3FO1_H_L,DVQLLESGPGLVAPSQSLSITCTVSGFSLTNYGVDWVRQPPGKGLEWVGVIWSGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAVYYCAKHWGGYYIPYGMDHWGQGTTVTVSS,ELVMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLAWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKINRVEAEDLGVYYCFQGSHLPPTFGGGTKLEIK,3FO1_H,3FO1_L,Crystal Structure Of Hapten Complex Of Catalytic Elimination Antibody 13G5 (Glu(L39)Ala Mutant),Crystal Structure Of Hapten Complex Of Catalytic Elimination Antibody 13G5 (Glu(L39)Ala Mutant),synthetic construct,"Debler,E.W.;Muller,R.;Hilvert,D.;Wilson,I.A.",An aspartate and a water molecule mediate efficient acid-base catalysis in a tailored antibody pocket,27-DEC-2008,8_7_15_11_3_9,3FO1_H_L,Xtal structure,RPL39; RPL39P42; L39,2,1,22.07444,-6.13793
S30752_S30751,DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYTWHWIRQFPGNKLEWMAYIHYSGNTDFNPSLKSRISITRDTSKNQFFLQLNSVTAEDTATYYCARGYGNYYAMDYWGQGTSVTVSS,DIVMTQSHRFMSTSVGDRVSITCKASQDVTTAVSWYQQKPGQSPKLLIFWASTRHTGVPDRFTGSGSGTDYTLTISSVQAEDLALYYCQQHYSTPLTFGAGTKLELK,S30752,S30751,Ig heavy chain precursor V region - mouse,Ig kappa chain precursor V region - mouse,Mus musculus,"Grant,F.J.; Levin,S.D.; Gilbert,T.; Kindsvogel,W.",Improved RNA sequencing method to determine immunoglobulin mRNA sequence,21-Jan-2000,9_7_12_6_3_9,S30752_S30751,Unique chain,,2,1,11.473091,-12.910104
5WTT_A_B,DVQLQESGPDLVKPSQSPSLTCTVTGYSITSDYSWHWIRQFPGDKLEWMGYIHYSGSTNYNPSLKSRISITRDTSKNQFFLQLSSVTIEDTATYYCARGTIYEGSLDYWGQGTTLTVSS,DVVMTQTPLTLSVTIGQPASISCKSSQSLLYSDGKTYLNWLFQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGIDFKLKISRVEAEDLGVYYCVQGTHFPQTFGGGTKLEIK,5WTT_A,5WTT_B,Structure Of The 093G9 Fab In Complex With The Epitope Peptide,Structure Of The 093G9 Fab In Complex With The Epitope Peptide,Homo sapiens,"Zhong,C.;Huo,R.;Hu,K.;Shen,J.;Li,D.;Li,N.;Ding,J.",Molecular basis for the recognition of CCN1 by monoclonal antibody 093G9,14-DEC-2016,9_7_12_11_3_9,5WTT_A_B,Xtal structure,CYR61; IGFBP10; CCN1; GIG1,2,1,11.515151,-12.884158
7TUF_H_L,DVQLQESGPGLVIPSQSLSLTCTVTGYSITTDYAWNWIRQFPGNRLEWMGYISSSGVTVYNPSLKSRISITRDTSKNQFFLQLISVTTEDTATYYCARRGYYRYDSIDYWGQGTTLTVSS,QIVLSQSPAILSASPGEKVTMTCRATSSVSYIHWYQQKPGSSPKPWIYATSSLTSGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPPTFGGGTKLEIK,7TUF_H,7TUF_L,Crystal Structure Of Tapasin In Complex With Pasta1-Fab,Crystal Structure Of Tapasin In Complex With Pasta1-Fab,Mus musculus,"Jiang,J.;Taylor,D.K.;Kim,E.J.;Boyd,L.F.;Ahmad,J.;Mage,M.G.;Truong,H.V.;Woodward,C.H.;Sgourakis,N.G.;Cresswell,P.;Margulies,D.H.;Natarajan,K.",Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation,07-SEP-2022,9_7_13_5_3_9,7TUF_H_L,Xtal structure,,2,1,11.50973,-12.890804
1202266C_1202266H,DVQLQESGPGLVKPSQSLSLTCSVTGNSITSGYYWSWIRQFPGNKLEWMGYIKYDGNNSYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCARPLYFRHDEEYYDVMDYWGQGT,TLTCRASDDIYSSLSWYQQRQGRSPQLLVYAATNLADGVPSRFSGSGSGTQFSLKINSLQPEDFGNYYCLHFYGAPWTFGGG,1202266C,1202266H,Ig gamma1 HP20,Ig kappa HP20,Mus musculus,"Ollier,P.; Rocca-Serra,J.; Somme,G.; Theze,J.; Fougereau,M.",The idiotypic network and the internal image. Possible regulation of a germline network by paucigene encoded Ab2 (anti-idiotypic) antibodies in the GAT system,01-JAN-1900,9_7_18_6_3_9,1202266C_1202266H,Unique word,GLYAT; ACGNAT; GAT,2,1,11.645062,-12.774199
1202266D_1202266J,DVQLQESGPGLVKPSQSLSLTCSVTGYSIASGYYWSWFRQFPGDKLEWMGYISFDGNINYNPSLKNRISITRDTSKNQFFLRLNSVTPEDTATYFCVRPLYYRFDEEYYYATDYWGQG,SSLIWYQQRQGRSPRLLVYAATYLADGAPSRFSGSGSGTQFSLKINGLQPEDFGSYFCQHFYGAPWTFGGGTKLEIK,1202266D,1202266J,Ig gamma1 HP21,Ig kappa HP21,Mus musculus,"Ollier,P.; Rocca-Serra,J.; Somme,G.; Theze,J.; Fougereau,M.",The idiotypic network and the internal image. Possible regulation of a germline network by paucigene encoded Ab2 (anti-idiotypic) antibodies in the GAT system,01-JAN-1900,9_7_18_2_3_9,1202266D_1202266J,Unique word,GLYAT; ACGNAT; GAT,2,1,11.659178,-12.760006
ASU89886_ASU89898,DVQLQESGPGLVKPSQSLSLTCSVTGYSITRAYYWNWIRQFPGNKLEWMGYILYDGRSDYNPSLKNRVSITRDTSKNQFFLKLNSVTAEDTARYYCTREGNYRAYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVGSDVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTINNMKSEDLADYFCQQYSSYPLTFGAGTKLELK,ASU89886,ASU89898,"anti-HIV fusion peptide monocolonal anitbody heavy chain vFP5.01, partial [Mus musculus]","anti-HIV fusion peptide monocolonal anitbody light chain vFP5.01, partial [Mus musculus]",Mus musculus,"Shen,C.-H.",Direct Submission,09-MAY-2018,9_7_9_6_3_9,ASU89886_ASU89898,Unique word,HIV,2,1,11.665374,-12.7472925
1202266F_1202266M,DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSHNYNPSLKNRISITRDTSKNQFFLKLNSVTIEDTATYYCARPLYYRYDEEYYYAMDYWGQGT,SLKWXQQXQGXSPQLLVYAATNLADGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHFSVPPWTFGGGTKLEIK,1202266F,1202266M,Ig gamma1 HP25,Ig kappa HP25,Mus musculus,"Ollier,P.; Rocca-Serra,J.; Somme,G.; Theze,J.; Fougereau,M.",The idiotypic network and the internal image. Possible regulation of a germline network by paucigene encoded Ab2 (anti-idiotypic) antibodies in the GAT system,01-JAN-1900,9_7_18_2_3_9,FAILED,Unique word,GLYAT; ACGNAT; GAT,2,1,11.687853,-12.734988
7RK1_D_D,DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCATFYDGYDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDYTLTISSVQAEDLALYYCQQHYSTPFTFGSGTKLEIK,7RK1_D,7RK1_D,"Crystal Structure Of The Human Astrovirus Serotype 8 Capsid Spike In Complex With Scfv 3E8, An Astrovirus-Neutralizing Antibody, At 2.05-A Resolution","Crystal Structure Of The Human Astrovirus Serotype 8 Capsid Spike In Complex With Scfv 3E8, An Astrovirus-Neutralizing Antibody, At 2.05-A Resolution",Mus musculus,"Meyer,L.;DuBois,R.M.","Crystal structure of the human astrovirus serotype 8 capsid spike in complex with scFv 3E8, an astrovirus-neutralizing antibody, at 2.05-A resolution",21-JUL-2021,9_7_9_6_3_9,7RK1_D_D,Xtal structure,capsid,2,1,11.638624,-12.771423
4HC1_M_N,DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKNRVSITRDTSKNHFFLKLSSVTTEDTATYYCARASDSDGFAYWGQGTLVTVSA,DILMTQSPSSMSVSLGDTVSFTCHASQGIGRNIGWLQQKPGKSFKGLIYHGTNLKDGVPSRFSGSGSGADYSLTISRIESEDFADYYCIQYVQFPYTFGGGTKLEIK,4HC1_M,4HC1_N,Crystal Structure Of A Loop Deleted Mutant Of Human Madcam-1 D1D2 Complexed With Fab 10G3,Crystal Structure Of A Loop Deleted Mutant Of Human Madcam-1 D1D2 Complexed With Fab 10G3,Mus musculus,"Springer,T.;Yu,Y.;Zhu,J.;Wang,J.-H.;Huang,P.-S.",A Different Fold with an Integrin-Binding Loop Specialized for Flexibility in Mucosal Addressin Cell Adhesion Molecule-1,28-SEP-2012,9_7_11_6_3_9,4HC1_M_N,Xtal structure,Integrin,2,1,11.650913,-12.762258
4OCY_H_L,DVQLQESGPGLVKPSQSLSLTCTVTGFSITSPYAWNWIRQFPGNTLEWMGYISYRGSTTYHPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCSSYGNYGAYSGQGTLVTVS,VLLTQIPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSTRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGAGTQLELK,4OCY_H,4OCY_L,Fab For Methotrexate (Unbound Apo),Fab For Methotrexate (Unbound Apo),Mus musculus,"Gayda,S.;Longenecker,K.L.;Manoj,S.;Judge,R.A.;Saldana,S.C.;Ruan,Q.;Swift,K.M.;Tetin,S.Y.",Water channel in the binding site of a high affinity anti-methotrexate antibody,09-JAN-2014,9_7_9_11_3_9,4OCY_H_L,Xtal structure,methotrexate,2,1,11.478233,-12.922065
2A0L_F_E,DVQLQESGPGLVKPSQSLSLTCTVTGYSITNNYAWNWIRQFPGNKLEWMGYINYSGTTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCVRGYDYFAMDYWGQGTSVTV,QIVLTQSPAIMSASLGDRVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQFHRSLTFGSGTKLE,2A0L_F,2A0L_E,Crystal Structure Of Kvap-33H1 Fv Complex,Crystal Structure Of Kvap-33H1 Fv Complex,Mus musculus,"Lee,S.Y.;Lee,A.;Chen,J.;MacKinnon,R.",Structure of the KvAP voltage-dependent K+ channel and its dependence on the lipid membrane,16-JUN-2005,9_7_11_7_3_8,2A0L_F_E,Xtal structure,,2,1,11.471829,-12.934318
CBL66580_CBL66579,DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYINYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARWIGSSAWYFDVWGAGTTVTV,DVLMTQTPLSLPVSLGDQASISCRSGQNIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFFGVPDRISGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPFTFGSGTKLEIK,CBL66580,CBL66579,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Davis,S.",Pd-1 specific antibodies and uses thereof,21-APR-2010,9_7_13_11_3_9,CBL66580_CBL66579,Ordered entries,,2,1,11.490794,-12.929449
3LEX_H_L,DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWSWIRQFPGNKLEWMGYINYSGYTSYNPSLKSRISITRDTSENQFFLQLHSVTPEDTATYFCAYGNYLPAYWGQGTLVTVSA,DVVMTQTPLSLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLASGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPWTFGGYTKLEIK,3LEX_H,3LEX_L,2F5 Epitope Scaffold Elicited Anti-Hiv-1 Monoclonal Antibody 11F10 In Complex With Hiv-1 Gp41,2F5 Epitope Scaffold Elicited Anti-Hiv-1 Monoclonal Antibody 11F10 In Complex With Hiv-1 Gp41,Human immunodeficiency virus 1,"Ofek,G.;Guenaga,F.J.;Schief,W.R.;Skinner,J.;Baker,D.;Wyatt,R.;Kwong,P.D.",Elicitation of structure-specific antibodies by epitope scaffolds,15-JAN-2010,9_7_9_11_3_9,3LEX_H_L,Xtal structure,Hiv-1,2,1,11.477407,-12.927102
PL0100_PL0101,DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWSWIRQFPGNRLEWMGYITYNGYTTYNPSLKSRFSITRDTSKNQLFLQLSSVTTEDTATYYCARSYDYFDYWGQGTTLTVSS,DIKMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRTKRLVDGVPSRFSGSGSGQEYSLTISSLEYEDMGIYFCLQYDEFLLTFGAGTKLELK,PL0100,PL0101,Ig heavy chain precursor V region (40-140) - mouse,Ig kappa chain precursor V region (40-140) - mouse,Mus musculus,"Near,R.I.; Haber,E.",Characterization of the heavy and light chain immunoglobulin variable region genes used in a set of anti-digoxin antibodies,21-Jan-2000,9_7_9_6_3_9,PL0100_PL0101,Unique chain,digoxin,2,1,11.515227,-12.883813
5E94_B_A,DVQLQESGPGLVKPSQSLSLTCTVTGYSITSTYDWHWIRHFPGNILEWMGYISYSGSTNYNPSLKSRISITHDTSKNRFFLKLNSVTSEDTATYYCARATASFYDGSYYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISSLEQEDVATYFCQQGNTLPFTFGSGTKLEIK,5E94_B,5E94_A,Antibody-Bound Glucagon-Like Peptide-1 Receptor Extracellular Domain,Antibody-Bound Glucagon-Like Peptide-1 Receptor Extracellular Domain,Homo sapiens,"Hennen,S.;Kodra,J.T.;Soroka,V.;Krogh,B.O.;Wu,X.;Kaastrup,P.;Orskov,C.;Ronn,S.G.;Schluckebier,G.;Barbateskovic,S.;Gandhi,P.S.;Reedtz-Runge,S.",Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor,14-OCT-2015,9_7_16_6_3_9,5E94_B_A,Xtal structure,,2,1,11.567126,-12.832381
AAB06746,DVQLQESGPGLVKPSQSLSLTCTVTGYSVTSEYAWNWIRQFPGNKLEWLGYINYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCADRSWFAYWGQGTLVTVSA,VLMTQTPLSLTVSLGDQVSISCRSSQSIEHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGAGTKLELK,AAB06746_H,AAB06746_L,single chain Fv antibody precursor [synthetic construct],single chain Fv antibody precursor [synthetic construct],synthetic construct,"Xiao,X.W.; Chu,P.W.; Frenkel,M.J.; Tabe,L.M.; Shukla,D.D.; Hanna,P.J.; Higgins,T.H.; Muller,W.J.; Ward,C.W.",Antibody-mediated improved resistance to ClYVV and PVY infections in transgenic tobacco plants expressing a single-chain variable region antibody,03-AUG-2010,9_7_8_11_3_9,AAB06746,Same entry,,2,1,11.490101,-12.920099
3G5X_B_A,DVQLQESGPSLVKPSQSLSLTCTVTGYSITSDFAWNWIRQFPGNKLEWMGYISYSGNTRYNPSLKSRISITRDTSKNQFFLQLNSVTIEDTATYYCVTAGRGFPYWGQGTLVTVSA,DILMTQSPSSMSVSLGDTVSITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDEVPSRFSGSGSGADYSLTISSLESEDFADYYCVQYAQFPWTFGGGTKLEIK,3G5X_B,3G5X_A,Antibodies Specifically Targeting A Locally Misfolded Region Of Tumor Associated Egfr,Antibodies Specifically Targeting A Locally Misfolded Region Of Tumor Associated Egfr,Mus musculus,"Garrett,T.P.;Burgess,A.W.;Gan,H.K.;Luwor,R.B.;Cartwright,G.;Walker,F.;Orchard,S.G.;Clayton,A.H.;Nice,E.C.;Rothacker,J.;Catimel,B.;Cavenee,W.K.;Old,L.J.;Stockert,E.;Ritter,G.;Adams,T.E.;Hoyne,P.A.;Wittrup,D.;Chao,G.;Cochran,J.R.;Luo,C.;Lou,M.;Huyton,T.;Xu,Y.;Fairlie,W.D.;Yao,S.;Scott,A.M.;Johns,T.G.",Antibodies specifically targeting a locally misfolded region of tumor associated EGFR,05-FEB-2009,9_7_9_6_3_9,3G5X_B_A,Xtal structure,ERBB; EGFR; ERRP; ERBB1,2,1,11.4637165,-12.9262
5VJO_C_D,DVQLQESGPSLVKPSQTLSLTCSVTGDSFTSDYWSWIRKFPGNRLEYMGYVSYSGSTYYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWDGDYWGQGTLVTVSA,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,5VJO_C,5VJO_D,Complex Between Hyhel10 Fab Fragment Heavy Chain Mutant I29F And Pekin Duck Egg Lysozyme Isoform I (Del-I),Complex Between Hyhel10 Fab Fragment Heavy Chain Mutant I29F And Pekin Duck Egg Lysozyme Isoform I (Del-I),Anas platyrhynchos,"Burnett,D.L.;Langley,D.B.;Schofield,P.;Hermes,J.R.;Chan,T.D.;Jackson,J.;Bourne,K.;Reed,J.H.;Patterson,K.;Porebski,B.T.;Brink,R.;Christ,D.;Goodnow,C.C.",Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination,19-APR-2017,8_7_7_6_3_9,5VJO_C_D,Xtal structure,,2,1,10.701126,-12.795367
3BSZ_N_M,DVQLQESGTVLARPGASVKMSCKASGYSFTSYWMHWIKQRPGQGLEWIGGVYPGDSHTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSGFDYGNEDWGQGTTLTVSS,DIVLTQSPSSLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK,3BSZ_N,3BSZ_M,Crystal Structure Of The Transthyretin-Retinol Binding Protein-Fab Complex,Crystal Structure Of The Transthyretin-Retinol Binding Protein-Fab Complex,Mus musculus,"Monaco,H.L.;Rizzi,M.;Coda,A.",Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein,27-DEC-2007,8_8_11_10_3_9,3BSZ_N_M,Xtal structure,transthyretin,2,1,2.694424,-8.175585
7C4S_J_K,DVQLQQSGAELVRPGASVKLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIDPETGGTAYSQKFKGKATKTADKSSSTAYMELRSLTSEDSAVYYCTIPYYSNLRFAYWGQGTLVTVSS,DIVMTQSPKSMSMSVGERVTLSCKASENVGIFVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTLSSVQAEDLADYYCGQSYNYPLTFGAGTKLELK,7C4S_J,7C4S_K,Sphingosine-1-Phosphate Receptor 3 With A Natural Ligand.,Sphingosine-1-Phosphate Receptor 3 With A Natural Ligand.,Homo sapiens,"Maeda,S.;Shiimura,Y.;Asada,H.;Hirata,K.;Luo,F.;Nango,E.;Tanaka,N.;Toyomoto,M.;Inoue,A.;Aoki,J.;Iwata,S.;Hagiwara,M.",Endogenous agonist-bound S1PR3 structure reveals determinants of G protein-subtype bias,18-MAY-2020,8_8_12_6_3_9,7C4S_J_K,Xtal structure,FLJ37523; C9orf47; EDG3; bA791O21.3; S1PR3; C9orf108; EDG-3,2,1,0.22084367,-3.4787211
1UWX_H_L,DVQLQQSGPELKKPGETVKLSCKASGYTFTNFGLNWMKQAPGKGLKWMGWINTYTGESTYADDFKGRFAFSLETSASTAYLQINNVKNEDTATYFCARGFYYYGSRYFYFDYWGQGTTLTVSS,IVMTQTPASQSASLGESVTITCLASQTIGTWLAWYQQKPGKSPQLLIYAATSLADGVPSRFSGSGSGTKFSFKISSLQAEDFVSYYCQQLSSTPYTFGGGTKLEIK,1UWX_H,1UWX_L,P1.2 Serosubtype Antigen Derived From N. Meningitidis Pora In Complex With Fab Fragment,P1.2 Serosubtype Antigen Derived From N. Meningitidis Pora In Complex With Fab Fragment,Neisseria meningitidis,"Tzitzilonis,C.;Prince,S.M.;Collins,R.F.;Achtman,M.;Feavers,I.M.;Maiden,M.C.;Derrick,J.P.",Structural variation and immune recognition of the P1.2 subtype meningococcal antigen,12-FEB-2004,8_8_16_6_3_9,1UWX_H_L,Xtal structure,meningococcal,2,1,-7.5518966,6.065049
7UVI_A_B,DVQLVESGGGLVKPGGSLRLSCAASGFTFNSYTMNWVRQAPGKGLEWVSSISTNIRYIYYADSVKGRFTISRDNAKNSLFLQMDSLRAEDTAVYYCATIAGPLSLKGDFFFDSWGQGTLVTVSP,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRLLIHGASTRATGIPTRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYANWPPWTFGQGTKVESK,7UVI_A,7UVI_B,Pfs230 Domain 1 Bound By Rupa-55 Fab,Pfs230 Domain 1 Bound By Rupa-55 Fab,Plasmodium falciparum,"Ivanochko,D.;Newton,J.;Julien,J.P.",Pfs230 Domain 1 Bound by Inhibitory RUPA-32 Fab,15-FEB-2023,8_8_17_6_3_10,7UVI_A_B,Xtal structure,,2,1,16.08878,10.048172
4C83_A_B,DVQLVESGGGLVQPGGSRKLSCAASGFTFRRFGMHWVRQSPEKGLEWVAYIGGGSSTIYYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCTRDETGSWFAYWGQGTLVTVS,QIVLSQSPAIMSASPGEKVTMTCSASSSVRYMHWYQQKSGTSPKRWIYDTSKLASGVPTRFSGSGSGTSYSLPISSMEAEDGASYYCQQWNGYPPLTFGGGTKLEMK,4C83_A,4C83_B,Crystal Structure Of The Igg2A Lpt3 In Complex With An 8-Sugar Inner  Core Analogue Of Neisseria Meningitidis,Crystal Structure Of The Igg2A Lpt3 In Complex With An 8-Sugar Inner  Core Analogue Of Neisseria Meningitidis,Mus musculus,"Parker,M.J.;Gomery,K.;Richard,G.;MacKenzie,C.R.;Cox,A.D.;Richards,J.C.;Evans,S.V.",Structural basis for selective cross-reactivity in a bactericidal antibody against inner core lipooligosaccharide from Neisseria meningitidis,29-SEP-2013,8_8_11_5_3_10,4C83_A_B,Xtal structure,,2,1,17.454815,7.880139
6NMU_B_A,DVQLVESGGGVVRPGESLRLSCAASGFSFSSYAMNWVRQAPGEGLEWVSRINSGGGGTDYAESVKGRFTISRDNSENTLYLQMNSLRAEDTAVYYCAKQYDWNSFFDYWGLGALVTVSS,ETVLTQSPATLSVSPGERATLSCRASQTVGSKLAWHQQKPGQAPRLLIYDATNRATGISDRFSGSGSGTDFTLTISSLQTEDSAVYYCQQYYYWPPYRFGGGTKVEIK,6NMU_B,6NMU_A,Kick-Off Fab 115 Anti-Sirp-Alpha Antibody In Complex With Sirp-Alpha Variant 1,Kick-Off Fab 115 Anti-Sirp-Alpha Antibody In Complex With Sirp-Alpha Variant 1,Homo sapiens,"Sim,J.;Sockolosky,J.T.;Sangalang,E.;Izquierdo,S.;Pedersen,D.;Harriman,W.;Wibowo,A.S.;Carter,J.;Madan,A.;Doyle,L.;Harrabi,O.;Kauder,S.E.;Chen,A.;Kuo,T.C.;Wan,H.;Pons,J.","Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPalpha",11-JAN-2019,8_8_12_6_3_10,WFJ33900,Xtal structure,SHPS-1; SIRPalpha; SIRPalpha2; PTPNS1; SIRPA; SIRP; CD172a; SIRP-ALPHA-1; MFR; MYD-1; BIT; SHPS1; P84,2,1,14.0947275,9.708969
6NMS_B_A,DVQLVESGGGVVRPGESLRLSCAASGFTFSSYDMNWVRQAPGEGLEWVSLISGSGEIIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKENNRYRFFDDWGQGTLVTVSS,ETVLTQSPGTLTLSPGERATLTCRASQSVYTYLAWYQEKPGQAPRLLIYGASSRATGIPDRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYDRPPLTFGGGTKVEIK,6NMS_B,6NMS_A,Blocking Fab 136 Anti-Sirp-Alpha Antibody In Complex With Sirp-Alpha Variant 1,Blocking Fab 136 Anti-Sirp-Alpha Antibody In Complex With Sirp-Alpha Variant 1,Homo sapiens,"Sim,J.;Sockolosky,J.T.;Sangalang,E.;Izquierdo,S.;Pedersen,D.;Harriman,W.;Wibowo,A.S.;Carter,J.;Madan,A.;Doyle,L.;Harrabi,O.;Kauder,S.E.;Chen,A.;Kuo,T.C.;Wan,H.;Pons,J.","Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPalpha",11-JAN-2019,8_8_12_6_3_10,6NMS_B_A,Xtal structure,SHPS-1; SIRPalpha; SIRPalpha2; PTPNS1; SIRPA; SIRP; CD172a; SIRP-ALPHA-1; MFR; MYD-1; BIT; SHPS1; P84,2,1,14.116083,9.652606
AEQ73740_AEQ74494,EAKKPGASVKVSCKASGFTHTYDINWVRQAPGQGFEWLGWMNRNNKIAEYAEKFQGRITMTWDTSISTAYMELSSLRFDDTAVYYCAVVAENWFDPWGQGTLVTVS,TLSVSPGERATLSCRASQSVGSDLVWYQQRPGQAPRLLIYRASLRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYRNWPPYTFGQGTKLEIK,AEQ73740,AEQ74494,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,7_8_10_6_3_10,AEQ73740_AEQ74494,Unique source,tetanus,2,1,2.045463,4.235389
AEQ73944_AEQ74703,EAKKPGASVKVSCKASGYTFSSYGVTWVRQAPGQGLEWMGWISPYNGNTKYAQKFQGRVTMTTDTATSTAYMELTSLRSDDTAFYYCARDYSSPYYFDYWGQGTLVT,SSLSASVGDRVTITCRASQSISTYVNWYQQKPGKAPKVLIFAASNLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQESYKIPYTFGPGTKPEIK,AEQ73944,AEQ74703,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_12_6_3_9,AEQ73944_AEQ74703,Unique source,tetanus,2,1,1.4579315,5.3020697
QKY76597_QKY76210,EAQLVESGGGLVQPGRSLRLSCAASGFTFDDSAMHWVRQAPGKGLEWVSGISWNSGNVGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCTKASRYCSSTICYWNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQTGVPSRFSGSGSGTDFTLTIRSLQPEDFASYYCQQSYSTPTFGGGTKVEIK,QKY76597,QKY76210,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_19_6_3_8,QKY76597_QKY76210,Unique source,SARS-CoV-2,2,1,13.0800705,12.0820265
QDK54379_QDK54378,EAQLVESGGVLVQPGRSLKLSCAASGFPFNNYDMAWVRQAPTKGLEWVASIRTGDIGTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCVRPRSVYYGLLLRPYWFFDFWGPGTMVTVSS,QIMLTQQAESLWISPGERVSITCRASQSLLYTDGKHYLSWYQQRPGQTTKALIYHASVRTDGVPTRFIGSGSGSEFTLSIEHVQPEDFAIYYCLQTLKSPYTFGAGTKLELK,QDK54379,QDK54378,"anti-CD1d 1B1 immunoglobulin heavy chain variable region, partial [Rattus norvegicus]","anti-CD1d 1B1 immunoglobulin light chain variable region, partial [Rattus norvegicus]",Rattus norvegicus,"Wang,J.; Zajonc,D.M.",Structural basis of NKT cell inhibition using the TCR blocking anti-CD1d antibody 1B1,16-JUL-2019,8_8_20_11_3_9,QDK54379_QDK54378,Unique chain,CD1d,2,1,14.789221,9.185428
5DRN_A_B,EEQLKESGGRLVAPGTPLTLTCTVSGFDISDYAMIWVRQAPGKGLEWIGIIYGGSNKLAYAKWAKGRFTISRTSTTVDLKITSPTTEDTATYFCARGYGSMDGYDRLNLWGQGTLVTVSS,AAVLTQTPSPVSAAVGGTVTISCQSSETVYRGDWLSWFQKKPGQPPKLLIYDASYLASGVSSRFSGSGSGTHFTLTISGVQCDDAATYYCLGGYYDDADDTFGGGTEVVVK,5DRN_A,5DRN_B,Context-Independent Anti-Hypusine Antibody Fabhpu24 In Complex With Hypusine,Context-Independent Anti-Hypusine Antibody Fabhpu24 In Complex With Hypusine,Oryctolagus cuniculus,"Zhai,Q.;He,M.;Song,A.;Deshayes,K.;Dixit,V.M.;Carter,P.J.",Structural Analysis and Optimization of Context-Independent Anti-Hypusine Antibodies,20-JAN-2016,8_8_15_8_3_11,5DRN_A_B,Xtal structure,Hypusine,2,1,-0.09792166,19.19882
7LR4_A_B,EFQLLQSGPELVKPGASVKISCKASDYSLSDYNMNWVRQRSGKSLEWIGVINPNHGTTHYNQKFKGKATLTVDQSSSTAYMQLTSLTSEDSAVYYCASPIHYGNHVPFDYWGQGTTVTVSS,DIQMTQTTSSLSASLGDRVTISCRTGQDISNYLNWYQQKPDGTVKLLIYFTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGITLPWTFGGGTKLEIK,7LR4_A,7LR4_B,Complex Of Fab 2/1.12 With Domain 3 Of P. Berghei Hap2,Complex Of Fab 2/1.12 With Domain 3 Of P. Berghei Hap2,Plasmodium berghei,"Feng,J.;Dong,X.;DeCosta,A.;Su,Y.;Angrisano,F.;Sala,K.A.;Blagborough,A.M.;Lu,C.;Springer,T.A.",Structural basis of malaria transmission blockade by a monoclonal antibody to gamete fusogen HAP2,15-FEB-2021,8_8_14_6_3_9,7LR4_A_B,Xtal structure,HIP5; HLP; HAP2; HAP1; hHLP1,2,1,2.7119431,-4.00071
4FFV_H_L,EFQLQQSGPELVKPGASVKISCKASGYSFTDYNINWMKQSNGKSLEWIGVVIPKYGTTNYNQKFQGKATLTVDQSSSTAYIQLNSLTSEDSAVYYCTRFRDVFFDVWGTGTTVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVNNMHWYQQKPGSSPKPWLHGTSNLASGVPVRFSGSGSGTSFSLTISRVEAEDAATYFCQQWSNHPPTFGGGTKLEI,4FFV_H,4FFV_L,"Crystal Structure Of Dipeptidyl Peptidase Iv (Dpp4, Dpp-Iv, Cd26) In Complex With 11A19 Fab","Crystal Structure Of Dipeptidyl Peptidase Iv (Dpp4, Dpp-Iv, Cd26) In Complex With 11A19 Fab",Mus musculus,"Tang,J.;Majeti,J.;Sudom,A.;Xiong,Y.;Lu,M.;Liu,Q.;Higbee,J.;Zhang,Y.;Wang,Y.;Wang,W.;Cao,P.;Xia,Z.;Johnstone,S.;Yang,X.;Yu,T.;Sharkov,N.;Walker,N.;Tu,H.;Shen,W.;Wang,Z.;Min,X.",An Inhibitory Antibody Against DPP IV Improves Glucose Tolerance in vivo - Validation of Large Molecule Approach for DPP IV Inhibition,01-JUN-2012,8_8_10_5_3_9,4FFV_H_L,Xtal structure,,2,1,2.7135248,-3.9121165
WGL48051_WGL48080,EFQLQQSGPELVKPGASVKISCKASGYSFTDYNMIWVKQSNGTSLEWIGIINPNYGITNYNQKFKGKATLTLDHSSSTAYMLLNSLTSEDSAVYYCARWGSNYAVYYYYYMDVWGKGTTVTVS,ENELTQSPAIMSASPGEMVTMTCRANSSVSSSYLHWYQQKSGASPKLWVYGTSNLPSGVPARFSGSGSGTSYSLTITSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK,WGL48051,WGL48080,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Caradonna,T.M.; Windsor,I.W.; Roffler,A.A.; Song,S.; Watanabe,A.; Kelsoe,G.; Kuraoka,M.; Schmidt,A.G.",Direct Submission,01-MAY-2023,8_8_17_7_3_9,WGL48051_WGL48080,Unique source,,2,1,2.6668916,-3.9481165
WGL48044_WGL48073,EFQLQQSGPELVKPGASVKISCKASGYSFTDYNMNWVKQSDGKSLEWIGIINPNYGIISYNQKFKGKATLTVDQSSSTAYMQLNSLTSEDSAVYYCARWGNSPYYYYYMDVWGKGTTVTVSS,ENVLTQSPAIMSASPGEKVTMTCRATSSVSSSYLHWYQQKSGASPKLWIYGTSNLASGVPARFSGSGSGTSYSLTISTVEAEDAATYYCQQYSGYPLTFGAGTKLELK,WGL48044,WGL48073,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Caradonna,T.M.; Windsor,I.W.; Roffler,A.A.; Song,S.; Watanabe,A.; Kelsoe,G.; Kuraoka,M.; Schmidt,A.G.",Direct Submission,01-MAY-2023,8_8_15_7_3_9,WGL48044_WGL48073,Unique source,,2,1,2.6580184,-3.9527225
AWH97964_AWH98044,EFQLQQSGPELVRPGASVKISCKASGFSFTDYNLSWVKQINGRSLEWIGVISPNYGPTVYNQKFKGKATLTIDQSSITAYMQLNSLTSEDSAVYYCAFSSRLFGYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSSGNTYLDWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGSGTRLEIK,AWH97964,AWH98044,"anti-HIV-1 fusion peptide immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-HIV-1 fusion peptide immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Xu,K.; Acharya,P.; Kong,R.; Cheng,C.; Chuang,G.-Y.; Liu,K.; Louder,M.K.; ODell,S.; Rawi,R.; Sastry,M.; Shen,C.-H.; Zhang,B.; Zhou,T.; Asokan,M.; Bailer,R.T.; Chambers,M.; Chen,X.; Choi,C.W.; Dandey,V.P.; Doria-Rose,N.A.; Druz,A.; Eng,E.T.; Farney,K.; Foulds,K.E.; Geng,H.; Georgiev,I.S.; Gorman,J.; Hill,K.R.; Jafari,A.J.; Kwon,Y.D.; Lai,Y.-T.; Lemmin,T.; McKee,K.; Ohr,T.Y.; Ou,L.; Peng,D.; Roshan,A.P.; Sheng,Z.; Todd,J.-P.; Tsybovsky,Y.; Viox,E.G.; Wang,Y.; Wei,H.; Yang,Y.; Zhou,A.F.; Chen,R.; Yang,L.; Scorpio,D.G.; McDermott,A.B.; Shapiro,L.; Carragher,B.; Potter,C.S.; Mascola,J.R.; Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,12-MAY-2018,8_8_9_11_3_9,AWH97964_AWH98044,Unique source,HIV,2,1,2.7067184,-3.8753905
AWH97971_AWH98051,EFQLQQSGPELVRPGASVKISCKASGFSFTDYNMSWVKQINGKSLEWIGVISPNYGPTVYNQKFKGKATLTIDQSSITAYLQLNSLTSEDSAVYYCAFSSRLFGYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLDWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGSGTRLEIK,AWH97971,AWH98051,"anti-HIV-1 fusion peptide immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-HIV-1 fusion peptide immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Xu,K.; Acharya,P.; Kong,R.; Cheng,C.; Chuang,G.-Y.; Liu,K.; Louder,M.K.; ODell,S.; Rawi,R.; Sastry,M.; Shen,C.-H.; Zhang,B.; Zhou,T.; Asokan,M.; Bailer,R.T.; Chambers,M.; Chen,X.; Choi,C.W.; Dandey,V.P.; Doria-Rose,N.A.; Druz,A.; Eng,E.T.; Farney,K.; Foulds,K.E.; Geng,H.; Georgiev,I.S.; Gorman,J.; Hill,K.R.; Jafari,A.J.; Kwon,Y.D.; Lai,Y.-T.; Lemmin,T.; McKee,K.; Ohr,T.Y.; Ou,L.; Peng,D.; Roshan,A.P.; Sheng,Z.; Todd,J.-P.; Tsybovsky,Y.; Viox,E.G.; Wang,Y.; Wei,H.; Yang,Y.; Zhou,A.F.; Chen,R.; Yang,L.; Scorpio,D.G.; McDermott,A.B.; Shapiro,L.; Carragher,B.; Potter,C.S.; Mascola,J.R.; Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,12-MAY-2018,8_8_9_11_3_9,AWH97971_AWH98051,Unique source,HIV,2,1,2.713475,-3.9127805
AWH97962_AWH98042,EFQLQQSGPELVRPGASVKISCKASGYSFTDYNMSWVKQSNGKSLEWIGVINPNYGPPIYNQKFKDKATLTADQSSRTAYMQLNSLTSEDSAVYYCAYSSRLFGYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSILHSNGNTYLDWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGSGTKLEIK,AWH97962,AWH98042,"anti-HIV-1 fusion peptide immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-HIV-1 fusion peptide immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Xu,K.; Acharya,P.; Kong,R.; Cheng,C.; Chuang,G.-Y.; Liu,K.; Louder,M.K.; ODell,S.; Rawi,R.; Sastry,M.; Shen,C.-H.; Zhang,B.; Zhou,T.; Asokan,M.; Bailer,R.T.; Chambers,M.; Chen,X.; Choi,C.W.; Dandey,V.P.; Doria-Rose,N.A.; Druz,A.; Eng,E.T.; Farney,K.; Foulds,K.E.; Geng,H.; Georgiev,I.S.; Gorman,J.; Hill,K.R.; Jafari,A.J.; Kwon,Y.D.; Lai,Y.-T.; Lemmin,T.; McKee,K.; Ohr,T.Y.; Ou,L.; Peng,D.; Roshan,A.P.; Sheng,Z.; Todd,J.-P.; Tsybovsky,Y.; Viox,E.G.; Wang,Y.; Wei,H.; Yang,Y.; Zhou,A.F.; Chen,R.; Yang,L.; Scorpio,D.G.; McDermott,A.B.; Shapiro,L.; Carragher,B.; Potter,C.S.; Mascola,J.R.; Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,12-MAY-2018,8_8_9_11_3_9,AWH97962_AWH98042,Unique source,HIV,2,1,2.7201738,-3.8986366
4HFW_B_A,EFQLVESGAEVKKPGASVKVSCKASGYSFTSYYVHWVREAPGEGLEWMGMINPSDGSTYYAQRFQPRVTMTRDTSTTTVFMEMSGLRSEDTAVYYCARGVVGATNEIDFWGQGTTVTVSS,DIRLTQSPSSLSASVGDRVTITCRASQSISNYLNWYQKKPGQAPKLLIYAATSLQSGVPSRFSGSGSGTDFTLTISSVQPEDFATYYCQKTLRTWTFGQGTKVEIK,4HFW_B,4HFW_A,Anti Rotavirus Antibody,Anti Rotavirus Antibody,Homo sapiens,"Aiyegbo,M.S.;Sapparapu,G.;Spiller,B.W.;Eli,I.M.;Wil,D.R.;Kim,R.;Lee,D.E.;Liu,T.;Li,S.;Woods,V.L.;Nannemann,D.P.;J,J.;Stewart,P.L.;Crowe,J.E.",Human Rotavirus Vp6-Specific Antibodies Mediate Intracellular Neutralization By Binding To A Quater Structure In The Transcriptional Pore,05-OCT-2012,8_8_13_6_3_8,4HFW_B_A,Xtal structure,,2,1,1.6015162,3.7683187
4M61_B_A,EIQLQQSGAELVKPGASVKISCKASGYSFTGYNMNWVKQSHGKSLEWIGKINPYYGSTSYNQKFKGQATLTVDKSSSTAYMQLNSLTSEDSAVYYCARGRLRRGGYFDYWGQGTTLTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQHLSSWTFGGGTKLEIK,4M61_B,4M61_A,Crystal Structure Of Unliganded Anti-Dna Fab A52,Crystal Structure Of Unliganded Anti-Dna Fab A52,Mus musculus,"Stanfield,R.L.;Eilat,D.",Crystal structure determination of anti-DNA Fab A52,08-AUG-2013,8_8_13_12_3_8,4M61_B_A,Xtal structure,Dna; DNA,2,1,2.5737689,-4.0384393
CAA37692_CAA37696,EIQLQQSGAELVKPGASVKISCKASGYSFTGYNMNWVKQSHGKSLEWIGNINPYYGGTSYNQQFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCARGITTSTRTWFAYWGQGTLVT,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVGAEDLGVYFCSQSTHVPLTLGAGTKLELK,CAA37692,CAA37696,"Anti-DNA autoantibody (BV16-19), partial [Mus musculus]","anti-DNA autoantibody (BV16-19), partial [Mus musculus]",Mus musculus,"Smith,R.G.; Voss,E.W. Jr.",Variable region primary structures of monoclonal anti-DNA autoantibodies from NZB/NZW F1 mice,26-JUL-2016,8_8_14_11_3_9,CAA37692_CAA37696,Unique word,DNA,2,1,2.56011,-4.1125984
2NR6_F_E,EIQLQQSGAELVKPGASVKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIDPANGNTRYGPKFLGKATITADTSSNTAYLHLNSLTSEDTAVYFCARWVRQMDYWGQGTSVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQIVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYNSPQTFGGGTKLEIK,2NR6_F,2NR6_E,Crystal Structure Of The Complex Of Antibody And The Allergen Bla G 2,Crystal Structure Of The Complex Of Antibody And The Allergen Bla G 2,Mus musculus,"Li,M.;Gustchina,A.;Alexandratos,J.;Wlodawer,A.;Wunschmann,S.;Kepley,C.L.;Chapman,M.D.;Pomes,A.",Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal antibody,01-NOV-2006,8_8_9_6_3_9,2NR6_F_E,Xtal structure,,2,1,-4.694031,0.16429065
4YQX_H_L,EIQLQQSGPELRRPGSSVKLSCKASGYNITDYLIHWVRHRPEHGLEWIGWIDPEDGETRYAQKFQSKATLTADTSSNAAYMQLSSLTPEDTATYFCARSLDSTYIYPFAYWGQGTLVTVSS,DIVMTQSPFSLAVSEGEMVTINCKSSQSLLSSGNQKNYLAWYQQKPGQSPKLLIYYASTGQSGVPDRFIGSGSGTDFTLTISDVQAEDLADYYCLQHYISPPTFGAGTKLELK,4YQX_H,4YQX_L,Mouse Il-2 Bound To Jes6-1 Scfv Fragment,Mouse Il-2 Bound To Jes6-1 Scfv Fragment,Mus musculus,"Spangler,J.B.;Tomala,J.;Luca,V.C.;Jude,K.M.;Dong,S.;Ring,A.M.;Votavova,P.;Pepper,M.;Kovar,M.;Garcia,K.C.",Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms,13-MAR-2015,8_8_14_12_3_9,4YQX_H_L,Xtal structure,,2,1,-5.0892735,0.35724482
1F3D_H_L,EIQLQQSGPELVKPGASVKVSCKASGYSFIDYNIHWVKQSHGKSLEWIGYIVPYSGGTTFNQKFKGKATLTVDKSSSTAFMHLNSLTFEDSAVYYCANDYDGVYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQVSISCRSSQSIFHSDGKTYLEWHLQKPGQSPKLLIYKVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,1F3D_H,1F3D_L,Catalytic Antibody 4B2 In Complex With Its Amidinium Hapten.,Catalytic Antibody 4B2 In Complex With Its Amidinium Hapten.,Mus musculus,"Goncalves,O.;Dintinger,T.;Lebreton,J.;Blanchard,D.;Tellier,C.",Mechanism of an antibody-catalysed allylic isomerization,02-JUN-2000,8_8_8_11_3_9,1F3D_H_L,Xtal structure,,2,1,2.4388616,-4.0425043
7X3C_F_E,EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNIYWVKQSHGKSLEWIGYVDPYNGNTNYNQKFKGKATLTVDKSSSTAFMHLNSLTSEVSTVYYCARGGGYYGGGYYGMDYWGQGTSVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYLHWYQQKPGSSPKPWISATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLSFGGGTKLELK,7X3C_F,7X3C_E,Cryo-Em Structure Of Coxsackievirus B1 Muture Virion In Complex With Nabs 8A10 And 5F5 (Cvb1-M:8A10:5F5),Cryo-Em Structure Of Coxsackievirus B1 Muture Virion In Complex With Nabs 8A10 And 5F5 (Cvb1-M:8A10:5F5),Mus musculus,"Zheng,Q.;Zhu,R.;Yin,Z.;Xu,L.;Sun,H.;Yu,H.;Wu,Y.;Jiang,Y.;Huang,Q.;Huang,Y.;Zhang,D.;Liu,L.;Yang,H.;He,M.;Zhou,Z.;Jiang,Y.;Chen,Z.;Zhao,H.;Que,Y.;Kong,Z.;Zhou,L.;Li,T.;Zhang,J.;Luo,W.;Gu,Y.;Cheng,T.;Li,S.;Xia,N.",Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail,28-SEP-2022,8_8_16_5_3_9,7X3C_F_E,Xtal structure,,2,1,2.481239,-3.945392
1AD9_B_A,EIQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYINWMRQAPGQGLEWIGWIDPGSGNTKYNEKFKGRATLTVDTSTNTAYMELSSLRSEDTAFYFCAREKTTYYYAMDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRSSKSLLHSNGDTFLYWFQQKPGKAPKLLMYRMSNLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCMQHLEYPFTFGQGTKVEVK,1AD9_B,1AD9_A,Igg-Fab Fragment Of Engineered Human Monoclonal Antibody Ctm01,Igg-Fab Fragment Of Engineered Human Monoclonal Antibody Ctm01,Homo sapiens,"Banfield,M.J.;King,D.J.;Mountain,A.;Brady,R.L.",VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs,24-FEB-1997,8_8_13_11_3_9,1AD9_B_A,Xtal structure,,2,1,0.74198145,3.8159878
2ZPK_I_M,EIQLVQSGPEVQKPGETVRISCKASGYTFTTAGMQWVQKMPGKSLKWIGWINTRSGVPKYAEDFKGRFAFSLETSASIAYLHINNLKNEDTATYFCAREGPGFVYWGQGTLVTVSA,TVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIVGTNNRVPGVPPRFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,2ZPK_I,2ZPK_M,Crystal Structure Of P20.1 Fab Fragment In Complex With Its Antigen Peptide,Crystal Structure Of P20.1 Fab Fragment In Complex With Its Antigen Peptide,synthetic construct,"Nogi,T.;Sangawa,T.;Tabata,S.;Nagae,M.;Tamura-Kawakami,K.;Beppu,A.;Hattori,M.;Yasui,N.;Takagi,J.",Novel affinity tag system using structurally defined antibody-tag interaction: application to single-step protein purification,16-JUL-2008,8_8_9_9_3_9,2ZPK_I_M,Xtal structure,,2,1,-7.6665106,6.2391224
UIC72042_UIC72352,ELHLVESGGGLVQPGGSLRLSCAASGFSLSDYWMNWVRQTPGKGPEWVATIKQDGSENYYVDSVKGRFTISRDNAKNSLSLQMNNLRADDTAVFYCVRGGNTAYRAFDRWGQGVQVTVAS,DIVMTQSPDSLAVSLGERATINCKSSHSLLYSSNEKNYLAWYQQKPGQPPKLLIQWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYHEPPTNTFGRGTRLEIK,UIC72042,UIC72352,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_13_12_3_11,UIC72042_UIC72352,Unique source,HCV,2,1,11.133435,7.777458
7RFP_H_L,ELQLVESGGGLVQPGRSLKLSCSASGFIFSNSYMAWVRQAPKKGLEWVATINPSGSRTYYPDSVKGRFTISRDTAKSSLYLQMNSLKSEDTATYYCARHDLSFDYWGQGVMVTVSS,QFTLTQPKSVSGSLRSTITIPCDRSSGGIRDSYVSWYQQHLGRPPLNVIYADDQRPSEVSDRFSGSIDSSSNSASLTITNLQMDDEADYFCQSYDSDFDVYIFGGGTKLTVL,7RFP_H,7RFP_L,Mouse Gitr (Mgitr) With Dta-1 Fab Fragment,Mouse Gitr (Mgitr) With Dta-1 Fab Fragment,Mus musculus,"He,C.;Maniyar,R.R.;Avraham,Y.;Zappasodi,R.;Rusinova,R.;Newman,W.;Heath,H.;Wolchok,J.D.;Dahan,R.;Merghoub,T.;Meyerson,J.R.",Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism,09-MAR-2022,8_8_9_8_3_11,7RFP_H_L,Xtal structure,TNFA; TNF-alpha; TNFSF2; DIF; TNF,2,1,14.879175,9.203389
1OB1_B_A,ELQLVQSGPQLKKPGETVRISCKASGYTFTTAGIQWVQRLPGKDLKWIGWINTHSGVPQYADDFKGRFAFSLETSASTAFLQIINLKNEDTATYFCARNYYRFDGGMDFWGQGTSVTVSS,DIVMTQTPAIMSAFLGERVTMTCTATSSLSSSYLHWYQQKPGSSPKLWIYTTSNLASGVPSRFSGSGSGTSYSLTISSMEAEDAATYYCHQFHHSPYTFGGGTKLEIK,1OB1_B,1OB1_A,Crystal Structure Of A Fab Complex Whith  Plasmodium Falciparum Msp1-19,Crystal Structure Of A Fab Complex Whith  Plasmodium Falciparum Msp1-19,Plasmodium falciparum,"Pizarro,J.C.;Chitarra,V.;Calvet,C.;Verger,D.;Bentley,G.A.","Crystallization and preliminary structural analysis of an antibody complex formed with PfMSP1-19, a malaria vaccine candidate",22-JAN-2003,8_8_13_7_3_9,1OB1_B_A,Xtal structure,Msp1; FLJ14600; ATAD1,2,1,-7.6473737,6.211426
6CJK_B_A,ELVESGGGLVQPGASLTLTCTASGFSFSSDYYMCWVRQAPGKGLEWIACIWTANSISYYARWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGGSGDGQSLWGPGTLVTVSS,DIVMTQTPASVEAAVGGTVAIKCQASQSIRSYLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTQFTLTISGVECDDAATYYCQRNYDSYSGAYYPNGFGGGTEVVVK,6CJK_B,6CJK_A,Anti Hiv Fab 10A,Anti Hiv Fab 10A,Oryctolagus cuniculus,"Bianchi,M.;Turner,H.L.;Nogal,B.;Cottrell,C.A.;Oyen,D.;Pauthner,M.;Bastidas,R.;Nedellec,R.;McCoy,L.E.;Wilson,I.A.;Burton,D.R.;Ward,A.B.;Hangartner,L.",Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization,26-FEB-2018,9_8_11_6_3_15,6CJK_B_A,Xtal structure,HIV,2,1,-0.4128598,18.420094
AVD98730_AVD98665,ELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGEINPNNGGISYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCAPISTVGDAMDYWGQGTSVTVSS,QIVLTQSPAIMSASLGERVTMTCTASSSVRSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPFTFGSGTKLEIK,AVD98730,AVD98665,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Klein,F.; Faderl,M.; Wirz,O.F.; Heiler,S.; Alberti-Servera,L.; Engdahl,C.; Andersson,J.; Rolink,A.",Two distinct pathways in mice generate anti-nuclear antigen reactive B cell repertoires,20-FEB-2018,8_8_12_7_3_9,AVD98730_AVD98665,Unique source,,2,1,2.525645,-4.2827983
AVD98726_AVD98661,ELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGEINPNSGGISYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCAPISTVGDAMDYWGQGTSVTVSS,QIVLTQSPAIMSASLGERVTMTCTASSSVRSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISGMEAEDAATYYCHQYHRSPFTFGSGTKLEIK,AVD98726,AVD98661,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Klein,F.; Faderl,M.; Wirz,O.F.; Heiler,S.; Alberti-Servera,L.; Engdahl,C.; Andersson,J.; Rolink,A.",Two distinct pathways in mice generate anti-nuclear antigen reactive B cell repertoires,20-FEB-2018,8_8_12_7_3_9,AVD98726_AVD98661,Unique source,,2,1,2.536002,-4.2836633
AVD98760_AVD98694,ELVKPGASVKMSCKASGYTFTSYWITWVKQRPGQGLEWIGDIYPGSGSTNYNEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCARSWDYEFWFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,AVD98760,AVD98694,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Klein,F.; Faderl,M.; Wirz,O.F.; Heiler,S.; Alberti-Servera,L.; Engdahl,C.; Andersson,J.; Rolink,A.",Two distinct pathways in mice generate anti-nuclear antigen reactive B cell repertoires,20-FEB-2018,8_8_12_10_3_9,AVD98760_AVD98694,Unique source,,2,1,-0.38716686,-4.057349
4K4M_I_M,ELVKPGTSVKISCKTSGYTFTENTMHWVKQSHGESLDWVGGINTDNGGTTYSQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCSTGYDAMDYWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASKGVDSYGNSFMHWYQQRPGQPPKLLIYLASHLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,4K4M_I,4K4M_M,Crystal Structure Of Pfeba-175 Rii In Complex With A Fab Fragment From Inhibitory Antibody R217,Crystal Structure Of Pfeba-175 Rii In Complex With A Fab Fragment From Inhibitory Antibody R217,PLASMODIUM FALCIPARUM; MUS MUSCULUS,"Chen, E., Paing, M.M., Salinas, N.D., Sim, B.K.L., Tolia, N.H.",Crystal Structure Of Pfeba-175 Rii In Complex With A Fab Fragment From Inhibitory Antibody R217,12-APR-2013,8_8_9_10_3_9,4K4M_I_M,Xtal structure,,2,1,2.540163,-4.333019
AEQ74092_AEQ74852,EMKKPGESLKISCQASGYGFTVYWIGWVRQLPGKGLEWLGMIYPGDSDTRYNPSFQGQVTISADKSVSTTYLQWTGLKASDTAIYYCARHLDSYDVFDGYNLGGYMDVWGKGTMVT,TLSLSPGERATLSCRASQSISTNYLAWYRQKPGQAPRLLIHAASSLATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGSSPQTFGQGTRLDIK,AEQ74092,AEQ74852,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_21_7_3_9,AEQ74092_AEQ74852,Unique source,tetanus,2,1,-12.771219,5.3698564
AEQ74099_AEQ74859,EMKKPGTSVRVSCKTSGGLVFSWVRQAPGQGPEWMGGIITNFGTTTYAQKFQGRVTISADKSTSTLYMDLNNLRSEDTAVYYCARAPPGTSTIAARFNRYFFDSWGQGTLVT,TLSLSPGERATLSCRASQSVNSNNLAWYQRKPGQAPRLLMSGATNRATDIPDRFGGSGSGTDFTLTISRLEPEDFAVYYCHQYGSSDNTFGQGTKLEIK,AEQ74099,AEQ74859,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_21_7_3_9,AEQ74099_AEQ74859,Unique source,tetanus,2,1,21.698809,11.85196
7T25_H_L,EMQLVQSGAEVKKPGESLKISCKGSGYIFATYWIGWVRQMPGKGLEWMGIIYPNDSDTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAMYYCARTRWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,7T25_H,7T25_L,Ospa-Fab 319-44 Complex Structure,Ospa-Fab 319-44 Complex Structure,Borreliella burgdorferi B31,"Rudolph,M.J.",Structural analysis of OspA-31944 complex,14-DEC-2022,8_8_9_7_3_9,QHY11835_QHY11836,Xtal structure,,2,1,-12.372937,5.775511
7RCO_F_E,EQQLVESGGGLVQPGGSLRLSCAVSGFSLSSYTVNWVRQAPGKGLEWIGYISYGGSAYYASWANGRFTISKDSAKNSVYLQMNSLRAEDTAVYFCARHMQVGGAPTGSMAAFDPWGPGTLVTVSS,DAQLTQSPSSLSASVGDRVTITCQSSQSVYNNNYLSWFQQKPGKPPKLLIYGASTLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAGGYSGSSDKYAFGGGTKVEIK,7RCO_F,7RCO_E,Crystal Structure Of Human Tgf-Beta-2 Bound To 4A11.V2 Fab,Crystal Structure Of Human Tgf-Beta-2 Bound To 4A11.V2 Fab,Homo sapiens,"Liang,W.C.;Yin,J.;Lupardus,P.;Zhang,J.;Loyet,K.M.;Sudhamsu,J.;Wu,Y.",Dramatic activation of an antibody by a single amino acid change in framework,07-JUL-2021,8_7_19_8_3_12,7RCO_F_E,Xtal structure,,2,1,15.12213,9.90489
4YAQ_A_B,ERLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIKYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGPDYRNGYYYYDFYDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCNGTSNDVGGYESVSWYQQHPGKAPKVVIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFGTGTKLTVL,4YAQ_A,4YAQ_B,Crystal Structure Of A Computationally Optimized Pg9 Mutant,Crystal Structure Of A Computationally Optimized Pg9 Mutant,Homo sapiens,"Willis,J.R.;Sapparapu,G.;Murrell,S.;Julien,J.P.;Singh,V.;King,H.G.;Xia,Y.;Pickens,J.A.;LaBranche,C.C.;Slaughter,J.C.;Montefiori,D.C.;Wilson,I.A.;Meiler,J.;Crowe JE,Jr.",Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth,17-FEB-2015,8_8_30_9_3_10,4YAQ_A_B,Xtal structure,HIV,2,1,14.036568,14.100479
AJF83856_AJF83855,ESGGGLVKLGGSLKLSCAASGFTFSNYFMSWVRQTPEKRLELVAVITSNGDNTYYPDTVRGRFTISRDNAQNTLYLQMSSLKSEDTALYYCVRRDSSASLYFDYWGQGTT,QTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVANRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGT,AJF83856,AJF83855,"immunoglobulin epsilon heavy chain variable region, partial [Mus musculus]","immunoglobulin E kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Janda,A.; Eryilmaz,E.; Nakouzi,A.; Pohl,M.A.; Bowen,A.; Casadevall,A.",Identical Variable Region in IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences,03-FEB-2015,8_8_13_11_3_9,AJF83856_AJF83855,Unique chain,Polysaccharide,2,1,17.67964,6.888232
S42771_S42772,ESGPGLVKPSQSLSLTCTVSGSSITSDYAWTWIWQFPGNKLEWMGYISYIGATSYNPSLQSRISITRDTSKNHFFLQLNSVTTEDTATYYCAREGSWFFGVWGAGTTVTVSS,VMTQSPLSLPVSLGDQASISCRSSQSLVHTNGNTYLHWYLQKPGQSPKVLIYKVSTRFSGVPDRFSGSGSGTDFTFKISRVEAEDLGVYFCSQSTYVPFTFGSGTKLEIK,S42771,S42772,Ig heavy chain - mouse,Ig kappa chain - mouse,Mus musculus,"Schellekens,G.A.",Direct Submission,21-Jan-2000,9_7_10_11_3_9,S42771_S42772,Unique chain,,2,1,11.502459,-12.888426
6PEH_H_L,ESLEESGGDLVKPGASLTLTCTASGFSFGWNDYMSWVRQAPGKGLEWIGCIYAGSTRSTYYANWAKGRLTISKTSSTAVTLQMTSLTAADTATYFCARGAVTYDGLGGAYLKHFNLWGPGTLVTVSS,AIKMTQTPSSVSAAVGGTVTVNCRASEDIESYLAWYQQKPGQPPKLLIYDTSKLASGVPSRFKGSGSGTQFALTISGVQCDDAATYYCLYGYISSDRIDFGFGGGTELVVK,6PEH_H,6PEH_L,Crystal Structure Of Rabbit Monoclonal Anti-Hiv Antibody 1C2,Crystal Structure Of Rabbit Monoclonal Anti-Hiv Antibody 1C2,Homo sapiens,"Dubrovskaya,V.;Tran,K.;Ozorowski,G.;Guenaga,J.;Wilson,R.;Bale,S.;Cottrell,C.A.;Turner,H.L.;Seabright,G.;O'Dell,S.;Torres,J.L.;Yang,L.;Feng,Y.;Leaman,D.P.;Vazquez Bernat,N.;Liban,T.;Louder,M.;McKee,K.;Bailer,R.T.;Movsesyan,A.;Doria-Rose,N.A.;Pancera,M.;Karlsson Hedestam,G.B.;Zwick,M.B.;Crispin,M.;Mascola,J.R.;Ward,A.B.;Wyatt,R.T.",Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability,20-JUN-2019,9_9_20_6_3_13,6PEH_H_L,Xtal structure,NFL; CMT2E; NF68; PPP1R110; NEFL; HIV; CMT1F,2,1,-0.4113122,18.409327
4GW4_A_B,EVHLSQSGAAVTKPGASVRVSCEASGYKISDHFIHWWRQAPGQGLQWVGWINPKTGQPNNARQFQGRVSLTRQASWDFDTYSFYMDLKAVRSDDTAIYFCARQRSDFWDFDVWGSGTQVTVSS,DIQMTQSPSSLSARVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPARFSGRRWGQEYNLTINNLQPEDVATYFCQVYEFIVPGTRLDLK,4GW4_A,4GW4_B,Crystal Structure Of 3Bnc60 Fab With P61A Mutation,Crystal Structure Of 3Bnc60 Fab With P61A Mutation,Homo sapiens,"Klein,F.;Diskin,R.;Scheid,J.F.;Gaebler,C.;Mouquet,H.;Georgiev,I.S.;Pancera,M.;Zhou,T.;Incesu,R.B.;Fu,B.Z.;Gnanapragasam,P.N.;Oliveira,T.Y.;Seaman,M.S.;Kwong,P.D.;Bjorkman,P.J.;Nussenzweig,M.C.",Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization,31-AUG-2012,8_8_12_3_3_5,4GW4_A_B,Xtal structure,HIV,2,1,2.6309917,4.0775914
7RXL_H_L,EVHLVESGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSSSTYIYYADSVRGRFTISRDNAKNSLYLQMNSLRAEDSAVYYCARRAGGFDAYYFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDKLGDKFACWYQQKPGQSPVLVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKVTVL,7RXL_H,7RXL_L,Fab1488 In Complex With The C-Terminal Alpha-Tsr Domain Of P. Falciparum,Fab1488 In Complex With The C-Terminal Alpha-Tsr Domain Of P. Falciparum,Plasmodium falciparum 3D7,"Beutler,N.;Pholcharee,T.;Oyen,D.;Flores-Garcia,Y.;MacGill,R.S.;Garcia,E.;Calla,J.;Parren,M.;Yang,L.;Volkmuth,W.;Locke,E.;Regules,J.A.;Dutta,S.;Emerling,D.;Early,A.M.;Neafsey,D.E.;Winzeler,E.A.;King,C.R.;Zavala,F.;Burton,D.R.;Wilson,I.A.;Rogers,T.F.",A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum,23-AUG-2021,8_8_14_6_3_9,7RXL_H_L,Xtal structure,,2,1,16.05369,10.075224
1BLN_B_A,EVILVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISSGGGNTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARYYRYEAWFASWGQGTLVTVS,DVLMTQTPVSLSVSLGDQASISCRSSQSIVHSTGNTYLEWYLQKPGQSPKLLIYKISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQASHAPRTFGGGTKLEIK,1BLN_B,1BLN_A,Anti-P-Glycoprotein Fab Mrk-16,Anti-P-Glycoprotein Fab Mrk-16,Mus musculus,"Vasudevan,S.;Johns,K.;Rose,D.R.",Preliminary Crystallographic Analysis of Anti-P-Gl Fab MRK-16 in Complex with its Antigenic Peptide,16-JUL-1998,8_8_12_11_3_9,1BLN_B_A,Xtal structure,CILK1; MRK; ICK; LCK2; MGC46090; KIAA0936; Antigenic,2,1,18.15432,7.152538
7U62_H_L,EVKFLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSRTIYCTPSLKDRFIISRDNAKNTLYLQMSKVRSEDTALYYCARIWIYYGFDAYVMDYWGPGTSVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHLVFGGGTKLTVL,7U62_H,7U62_L,Crystal Structure Of Anti-Heroin Antibody Hy4-1F9 Fab Complexed With Morphine,Crystal Structure Of Anti-Heroin Antibody Hy4-1F9 Fab Complexed With Morphine,Mus musculus,"Rodarte,J.V.;Baehr,C.;Hicks,D.;Liban,T.L.;Weidle,C.;Rupert,P.B.;Jahan,R.;Wall,A.;McGuire,A.T.;Strong,R.K.;Runyon,S.;Pravetoni,M.;Pancera,M.",Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding,11-JAN-2023,8_8_16_9_3_9,7U62_H_L,Xtal structure,nicotine,2,1,19.600403,9.721225
AEQ73727_AEQ74481,EVKKPGASVKVSCKASGYRFTGYYIHWVRLAPGQRLEWMGWINPNTGGTVYAQNFQGRVTMTRDTSIRTAYMEVNRLTSDDTATYYCATWVSRESSFDYWGQGTLVTVS,TLSLSPGERATLSCRASHSVSTSLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLIISSLEPEDFAVYYCQQRSYWYTFGQGTKLEIK,AEQ73727,AEQ74481,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_12_6_3_8,AEQ73727_AEQ74481,Unique source,tetanus,2,1,2.1043925,3.8129056
AEQ74078_AEQ74838,EVKKPGASVKVSCKASGYTFNRYGIAWVRQVPGQGLEWMGWISPNTGHTNYAEKVQGRVTMTTDTATSTAYMELTSLRSDDTAIYFCARDYSSPYHFDYWGQGTLVT,SSLSASVGDRVTISCRASQPISTYLNWYQQKPGKAPKILIFGASRLQSGVPSRFSGSGSGTDFSLTITSLQPEDFATYICQQSKSPPYNFGRGTKLDIK,AEQ74078,AEQ74838,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_12_6_3_9,AEQ74078_AEQ74838,Unique source,tetanus,2,1,1.4609203,5.3129163
AEQ73985_AEQ74744,EVKKPGASVKVSCKASGYTFSSYGVTWVRQAPGQGLEWMGWISPYNGNTKYAQKFQGRVTMTTDTATSTAYMELTSLRSDDTAFYYCARDYSSPYYFDYWGQGTLVT,SSLSASVGDRVTITCRASQSISTYVNWYQQKPGKAPKVLIFAASNLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQESYKIPYTFGPGTKLEIK,AEQ73985,AEQ74744,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_12_6_3_9,AEQ73985_AEQ74744,Unique source,tetanus,2,1,1.4032577,5.308174
AEQ74280_AEQ75039,EVKKPGASVKVSCKTSGYTFTNYFMHWVRQAPGQGLEWMGIINPSGGRTQYAQKFQGRVTMTADTSTSTVYMELSRLRSEDTAVYYCARATLTDWSGRFWFDPWGQGTLVT,TLSLSPGERATLSCRASQSVNSIYLAWYQQRPGRAPRLLIYGASSRPSGIPDRFSGRGSGTDFTLTISRLEPEDVAVYYCQQYDDSGHFTFGPGTKVEIK,AEQ74280,AEQ75039,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_16_7_3_10,AEQ74280_AEQ75039,Unique source,tetanus,2,1,1.2662779,5.1981807
AEQ73558_AEQ74311,EVKKPGASVRVSCKASGYSLKNYGIHWVRQAPGQGLEWMGWISADNGDTTTALNLRGRVSMTTDTSTNTVYMEVKSLRSDDTAIYFCARDFYSGSYRSFDYWGQGTLVTVS,SSLSASLGDRVTITCRASQHISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFTGSGSGADYTLTISSLQPEDFATYYCQQSYSTSWTFGQGTTVGIK,AEQ73558,AEQ74311,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_14_6_3_9,AEQ73558_AEQ74311,Unique source,tetanus,2,1,1.4946834,5.416009
AEQ73626_AEQ74381,EVKKPGESLKISCQASGYGFTVYWIGWVRQLPGKGLEWLGIIYPGDSDTRYNPSFQGQVTISADKSVSTTYLQWSSLKASDTAIYYCARHLDSYDVFTGYNLGGYMDVWGKGTLVTVS,TLSLSPGERATLSCRASQSVSTNYLAWYRQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGSSPQTFGQGTRLEIK,AEQ73626,AEQ74381,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_21_7_3_9,AEQ73626_AEQ74381,Unique source,tetanus,2,1,-12.757609,5.384127
AEQ73542_AEQ74295,EVKKPGESLKISCQASGYGFTVYWIGWVRQPPGKGLEWLGIIYPGDSDTRYNPSFQGQVTISADKSVSTTYLQWSSLKASDTAIYYCARHLDSYDVFTGYNLGGYMDVWGKGTLVTVS,TLSLSPGERATLSCRASQSVSTNYLAWYRQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGSSPQTFGQGTRLEIK,AEQ73542,AEQ74295,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_21_7_3_9,AEQ73542_AEQ74295,Unique source,tetanus,2,1,-12.774141,5.3685164
AEQ74202_AEQ74962,EVKKPGSSVKVSCKAAGGSFTNHGFIWVRQAPGQGLEWLGGIIPMFGTAHYAQRFEGRITITADKSTTTSYMELRSLRSDDTAVYYCARDRLGTREYDWIFYGMEVWGQGTTVT,SSLSASVGDRVTITCQASQDITNYLHWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGRHFTFTISSLQPEDVATYYCQQYDILPLTFGGGTKVEIK,AEQ74202,AEQ74962,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_19_6_3_9,AEQ74202_AEQ74962,Unique source,tetanus,2,1,0.042397454,5.728616
QKK35542_QKK35543,EVKKPGSSVKVSCKASGGMFSDYAISWVRQAPGQRLEWMGGIMPGLGSPGYAQIFRGRATISADVSTSTAYLELTSLKPEDTAVYYCARDPSILNTGNHHWYDLDIWGQGTQVTVSS,DIVMTQSPLSLPVGLGQSASISCRSSQRVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATEWPRTFGQGTKVEIK,QKK35542,QKK35543,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35542_QKK35543,Unique source,SARS-CoV-2,2,1,-6.3685756,-2.705827
AEQ73822_AEQ74574,EVKKPGSSVKVSCKASGGSFNPYDINWVRQAPGQGLEWMGGIIPILGTPRYSQEFQGRLTVTADKSTNTAYMDLSDLRSDDTAMYFCARVREGQQVLVFDSWGQGTLVT,STLSASVGDRVTITCRASQTISRWLAWYQQKPGKAPKLLIYRASGLQSGVPSRFSGSGSETEFTLTISGLQPEDFATYYCQHYNSLRGTFGQGTKVEVK,AEQ73822,AEQ74574,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_14_6_3_9,AEQ73822_AEQ74574,Unique source,tetanus,2,1,0.05893387,5.697681
AEQ73898_AEQ74654,EVKKPGSSVKVSCKVSGGSFSTYSITWVRQAPGQGLEWMGGINPIFATRDYAKKFQGRLTITADESTRTAYMELSSLRSEDTAVYYCGRVLGGTRLYYALNVWGQGTTVT,SSLSASVGDTVTITCRASQGISNFLAWHQQKPGEVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTINGLQPEDVATYYCQKYDSGLIFTFGPGTKVEIK,AEQ73898,AEQ74654,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_10,AEQ73898_AEQ74654,Unique source,tetanus,2,1,0.0061022537,5.740526
AEQ73577_AEQ74332,EVKKPGTSVRVSCKTSGGNVFSWVRQAPGQGPEWMGGIITNFGTTSYAQKFQGRVTFTADKSTNTVYMDLNNLISADTAVYYCARAPRGTSTIAARFNRYFFDSWGQGTLVTVS,TLSLSPGERATLSCRASQSISNLLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRLWYTFGQGTKLEIK,AEQ73577,AEQ74332,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_21_6_3_8,AEQ73577_AEQ74332,Unique source,tetanus,2,1,21.698044,11.851737
AEQ73579_AEQ74334,EVKKPGTSVRVSCKTSGGYVFSWVRQAPGQGPEWMGGIITNFGTTSYAQKFQGRVTFTADKPTNTVYMDLNNLISADTAVYYCARAPRGTSTIAARFNRYFFDSWGQGTLVTVS,TLPLSPGERATLSCRASQSISNLLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRLWYTFGQGTKLEIK,AEQ73579,AEQ74334,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_21_6_3_8,AEQ73579_AEQ74334,Unique source,tetanus,2,1,21.698315,11.851727
AEQ73588_AEQ74343,EVKKPGTSVRVSCKTSGGYVFSWVRQAPGQGPEWMGGIITNFGTTSYAQKFQGRVTFTADKSTNTVYMDLNNLISADTAVYYCARAPRGTSTIAARFNRYFFDSWGQGTLVTVS,TLSLSPGERATLSCRASQSISNLLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRLWYTFGQGTKLEIK,AEQ73588,AEQ74343,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_21_6_3_8,AEQ73588_AEQ74343,Unique source,tetanus,2,1,21.698332,11.851925
AEQ73717_AEQ74471,EVKKPGVSVNVSCKTSGYTFTNYYIHWVRQAPGQGLEWMGVINPTDGNTNYAPKFQARLTMTGDTSTSTVYMDVSSLTSDDTAVYYCARQYCSSASCYVSLRHSGQFYYFMDVWGKGTTVTVS,TLSLSPGERATLSCRASQSLSSSYIAWYQQKPGQAPRLLIFGASTRATGIPARFSGGGSGTDFTLTISRLEPEDFAVYYCQERITFGPGTRLEIK,AEQ73717,AEQ74471,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_26_7_3_5,AEQ73717_AEQ74471,Unique source,tetanus,2,1,1.7620499,4.4097652
1T66_D_C,EVKLDETGGGLVQPGRPMKLSCVASGFTFSDYWMNWVRQSPEKGLEWVAQIRNKPYNYETYYSDSVKGRFTISRDDSKSSVYLQMNNLRAEDMGIYYCTSYGYHGAYWGQGTLVTVS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK,1T66_D,1T66_C,The Structure Of Fab With Intermediate Affinity For Fluorescein.,The Structure Of Fab With Intermediate Affinity For Fluorescein.,Mus musculus,"Terzyan,S.;Ramsland,P.A.;Voss EW,Jr.;Herron,J.N.;Edmundson,A.B.",Three-dimensional structures of idiotypically related Fabs with intermediate and high affinity for fluorescein,05-MAY-2004,8_10_9_11_3_9,1T66_D_C,Xtal structure,,2,1,13.427325,7.100958
7KPJ_A_B,EVKLEESGGDLVKPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARRGFYFDYWGQGTTLTVSS,ETTVTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGQGTKVEIK,7KPJ_A,7KPJ_B,Crystal Structure Of Ruminococcus Gnavus Immunoglobulin Binding Protein In Complex With 338E6 Fab,Crystal Structure Of Ruminococcus Gnavus Immunoglobulin Binding Protein In Complex With 338E6 Fab,Mus musculus,"Borowska,M.T.;Drees,C.;Yarawsky,A.E.;Viswanathan,M.;Ryan,S.M.;Bunker,J.J.;Herr,A.B.;Bendelac,A.;Adams,E.J.",The molecular characterization of antibody binding to a superantigen-like protein from a commensal microbe,11-NOV-2020,8_8_9_6_3_9,7KPJ_A_B,Xtal structure,,2,1,17.739025,7.153115
5MHE_H_L,EVKLEESGGGLVKLGGSLKLSCAASGFTFSSYYMSWVRQTPEKRLELVAAINSNGGSTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALYYCARGDYYGSSLYYYAMDYWGQGTSVTVSS,DIVLNQSPAIMSASPGEKVTMTCNSSSSVSYMHWYQHKPGSSPRLLIYDTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPLTFGAGTKLEIT,5MHE_H,5MHE_L,Crystal Structure Of Anti-T4 Fab Fragment With T4,Crystal Structure Of Anti-T4 Fab Fragment With T4,Mus musculus,"Parkkinen,T.;Rouvinen,J.",Crystal structures of anti-T4 Fab fragment,24-NOV-2016,8_8_17_5_3_9,5MHE_H_L,Xtal structure,,2,1,17.679365,6.8815675
7SQ1_H_L,EVKLEESGGGLVQAGGSMKLSCVASGFSLSNYWMNWVRQSPEKGLEWVAEIRLKPQNYATHYAESVKGRFSISRDDSRSTVYLQMNNLRAEDTGIYYCTRPGYYGHYAMDYWGQGTSVTVSS,DIVLTQSPASLAVSPGQRATISCRPSESVDNYGISFMNWFQQKPGQPPKLLIYAASNRGSGVPARFTGSGSGTDFSLNIHPMEEDDIAMYFCQQSKEVPYTFGGGTKLEIK,7SQ1_H,7SQ1_L,Bg505.Md39Ts Env Trimer In Complex With Fab From Antibody C05,Bg505.Md39Ts Env Trimer In Complex With Fab From Antibody C05,Mus musculus,"Xu,Z.;Walker,S.;Wise,M.C.;Chokkalingam,N.;Purwar,M.;Moore,A.;Tello-Ruiz,E.;Wu,Y.;Majumdar,S.;Konrath,K.M.;Kulkarni,A.;Tursi,N.J.;Zaidi,F.I.;Reuschel,E.L.;Patel,I.;Obeirne,A.;Du,J.;Schultheis,K.;Gites,L.;Smith,T.;Mendoza,J.;Broderick,K.E.;Humeau,L.;Pallesen,J.;Weiner,D.B.;Kulp,D.W.",Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer,04-NOV-2021,8_10_13_10_3_9,7SQ1_H_L,Xtal structure,HIV,2,1,13.393074,7.1525803
5O6V_H_L,EVKLEESGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLELVAATNSDGDSTYYPDSVKGRFTISRDRAKNTLYLQMSSLKSEDTAMYYCTRVLYDYDGEFAYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVTVTCKASQNVGTNVAWYQQKPGQSPKGLIYSASYRYSGVPDRFIGSGSGTDFTLTISNVQSGDLAEYFCQQYNNHPLTFGAGTKLELK,5O6V_H,5O6V_L,The Cryo-Em Structure Of Tick-Borne Encephalitis Virus Complexed With Fab Fragment Of Neutralizing Antibody 19/1786,The Cryo-Em Structure Of Tick-Borne Encephalitis Virus Complexed With Fab Fragment Of Neutralizing Antibody 19/1786,Mus musculus,"Fuzik,T.;Formanova,P.;Ruzek,D.;Yoshii,K.;Niedrig,M.;Plevka,P.",Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody,07-JUN-2017,8_8_13_6_3_9,5O6V_H_L,Xtal structure,,2,1,17.752377,7.219357
6XUD_H_L,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIGNKGNNHATYYAESVKGRFTVSRDDSKSRVYLQMNSLRVEDTGTYYCTTRFAYWGQGTLVTVSA,DIKMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPRTFGGGTKLEIK,6XUD_H,6XUD_L,Apo Ab 1116Ns19.9,Apo Ab 1116Ns19.9,Mus musculus,"Borenstein-Katz,A.;Warszawski,S.;Amon,R.;Eilon,M.;Cohen-Dvashi,H.;Leviatan Ben-Arye,S.;Tasnima,N.;Yu,H.;Chen,X.;Padler-Karavani,V.;Fleishman,S.J.;Diskin,R.",Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies,19-JAN-2020,8_10_6_6_3_9,6XUD_H_L,Xtal structure,CA19,2,1,13.394608,6.9270496
S67945_S67944,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRNKANNHATYYDESVKGRFTISRDDSKSRVYLQMISLRAEDTGLYYCTGEFANWGQGTLVTVSA,DVVMTQTPLSLPVSLGDQASISCRSSQNLVHNNGNTYLYWFLQKSGQSPKLLIYRASIRFSGVPDRFSGSGSETDFTLKISRVEAEDLGVYFCFQGTHVPWTFGGGTKLEIK,S67945,S67944,Ig heavy chain BrE-3 - mouse (fragment),Ig kappa chain BrE-3 - mouse (fragment),Mus musculus,"Couto,J.R.; Blank,E.W.; Peterson,J.A.; Ceriani,R.L.",Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody,21-JAN-2000,8_10_6_11_3_9,S67945_S67944,Unique source,,2,1,13.420037,6.962811
6X5E_B_A,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMNWVRQSPEKGLEWVAEIRSKVINPAIYYAESVKERFTILRDDSKSSVYLQMNSLRAEDTGIYYCSRSTMITTRDPSRYFDVWGAGTTVTVSS,DIQMTQSPTSLSASVGETVTITCRTSENIHNFLTWYQQKQGKSPQVLVYNAKTLPDGVPSRFSGSGSGTQYSLKINSLQPEDFGTYYCQHFWSSPWTFGGGTKLEIK,6X5E_B,6X5E_A,Crystal Structure Of A Lewis-Binding Fab (Ch88.2),Crystal Structure Of A Lewis-Binding Fab (Ch88.2),Mus musculus,"Soliman,C.;Guy,A.J.;Chua,J.X.;Vankemmelbeke,M.;McIntosh,R.S.;Eastwood,S.;Truong,V.K.;Elbourne,A.;Spendlove,I.;Durrant,L.G.;Ramsland,P.A.",Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody,26-MAY-2020,8_10_17_6_3_9,AYJ11060_AYJ11061,Xtal structure,Lewis,2,1,13.412475,6.9686465
7LKI_D_E,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAYMDWVRQSPEKGLEWVAEIRNKANNHATFYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTLQYGTSSWGQGTTLTVSS,DVVMTQTPLTLSVTIGQPASISCKSSQSLLYSNGKTFLNWLFQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTAFTLKISRVEAEDLGVYYCVQGTHFPLTFGAGTKLELK,7LKI_D,7LKI_E,The Crystal Structure Of Epitope Iii Of Hcv Envelop Protein E2 In Complex With Antibody 1H8,The Crystal Structure Of Epitope Iii Of Hcv Envelop Protein E2 In Complex With Antibody 1H8,MUS MUSCULUS; HEPACIVIRUS C,"Deng, L., Zhang, P.",The Crystal Structure Of Epitope Iii Of Hcv Envelop Protein E2 In Complex With Antibody 1H8,02-FEB-2021,8_10_8_11_3_9,7LKI_D_E,Xtal structure,,2,1,13.414256,6.9588194
4X8J_H_L,EVKLEESGGGLVQPGGSMKLSCTASGFTFSDAWMDWVRQSPEKGLEWVAEIRHKANDHAIFYDESVKGRFTISRDDSKNIVYLQMNSLRPEDTGIYYCTSPFAYWGQGTLVTVSA,DIVMTQSQKFMSVTVGDRVSITCKTSQSVGTTIVWYQQKPGQSPKLLIYSASNRHTGVPDRFTGSGSGTDFILTINNVQSEDLADYFCQQYTSYPFTFGSGTKLEIK,4X8J_H,4X8J_L,Crystal Structure Of Murine 12F4 Fab Monoclonal Antibody Against Adamts5,Crystal Structure Of Murine 12F4 Fab Monoclonal Antibody Against Adamts5,Mus musculus,"Larkin,J.;Lohr,T.A.;Elefante,L.;Shearin,J.;Matico,R.;Su,J.L.;Xue,Y.;Liu,F.;Genell,C.;Miller,R.E.;Tran,P.B.;Malfait,A.M.;Maier,C.C.;Matheny,C.J.",Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification,10-DEC-2014,8_10_6_6_3_9,4X8J_H_L,Xtal structure,ADAMTS-5,2,1,13.343268,7.005899
1PKQ_B_A,EVKLHESGAGLVKPGASVEISCKATGYTFSSFWIEWVKQRPGHGLEWIGEILPGRGRTNYNEKFKGKATFTAETSSNTAYMQLSSLTSEDSAVYYCATGNTMVNMPYWGQGTTVTVSS,DIELTQSPSSLAVSAGEKVTMSCKSSQSLLNSGNQKNYLAWYQQKPGLPPKLLIYGASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDHSYPLTFGAGTKLEIK,1PKQ_B,1PKQ_A,Myelin Oligodendrocyte Glycoprotein-(8-18C5) Fab-Complex,Myelin Oligodendrocyte Glycoprotein-(8-18C5) Fab-Complex,Rattus norvegicus,"Breithaupt,C.;Schubart,A.;Zander,H.;Skerra,A.;Huber,R.;Linington,C.;Jacob,U.",Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein,06-JUN-2003,8_8_11_12_3_9,1PKQ_B_A,Xtal structure,,2,1,4.9566045,-1.9123296
S68170_S68171,EVKLHQSGAELKKPGASVKVSCKTSGYTFSSYNINWVRQAPGQGLEWVGWMSVDNGKTRYAQKFQGRVTMTTDTSTSTAYMELRSLTTDDTAVYYCTREGLRGYSGYEVFIFEYWGQGTLVTVSS,DIELTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQMAGQAPVLVVYNDRDRPSGIPERFSGSNFGKTATLTISRVEAGDEADYYCQVWDSYSDHWVFGGGTKVTVL,S68170,S68171,Ig heavy chain V region - human (fragment),Ig lambda chain V region - human (fragment),Homo sapiens,"Boldicke,T.; Haase,B.; Bocher,M.; Lindenmaier,W.",Human monoclonal antibodies to cytomegalovirus. Characterization and recombinant expression of a glycoprotein-B-specific antibody,21-JAN-2000,8_8_18_6_3_11,S68170_S68171,Unique chain,glycoprotein-B; cytomegalovirus,2,1,1.9301349,5.2645164
5NBW_H_L,EVKLHQSGAELVNPGASVKISCKAPGYTFNNYWIEWVKQRPGHGLEWIGEILPGSGRINYNEKFKDKATFTADTSSNTAYMQLSSLTSDDSAVYYCAKKYGDYWGQGTTVTVSS,DIELTQSPSSMYASLGERVTITCKASQDINSYLNWFQQKPGKSPKTLIYHTNRLVDGVPSRFSGSGSGQDYSLIISSLEFEDMGIYYCLQYDEFPYTFGGGTKLELK,5NBW_H,5NBW_L,Crystal Structure Of The Fab Fragment 22F12 In Complex With 3-Hydroxybenzo[A]Pyrene,Crystal Structure Of The Fab Fragment 22F12 In Complex With 3-Hydroxybenzo[A]Pyrene,Mus musculus,"Eichinger,A.;Neumaier,I.;Pschenitza,M.;Niessner,R.;Knopp,D.;Skerra,A.",Tight Molecular Recognition of Benzo[a]pyrene by a High-Affinity Antibody,02-MAR-2017,8_8_7_6_3_9,5NBW_H_L,Xtal structure,,2,1,4.9981318,-1.8665817
1UB5_H_L,EVKLLESGGGLVKPGGSLKLSCTASGITFSRYIMSWVRQIPEKRLEWVASISSGGITYYPDSVAGRFTISRDNVRNILYLQMSSLRSEDTALYYCARGQGRPYWGQGTLVTVSS,DIVMTQAAFSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPNRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIK,1UB5_H,1UB5_L,Crystal Structure Of Antibody 19G2 With Hapten At 100K,Crystal Structure Of Antibody 19G2 With Hapten At 100K,Mus musculus,"Beuscher,A.B.;Wirsching,P.;Lerner,R.A.;Janda,K.;Stevens,R.C.",Structure And Dynamics Of Blue Fluorescent Antibody 19g2 At Blue And Violet Fluorescent Temperatures,30-MAR-2003,8_7_8_11_3_9,1UB5_H_L,Xtal structure,,2,1,18.20346,7.1511273
S06816_S06819,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWILVRQAPGKGLEWIGEINPHSTTIFYTPSLMDKFIISRDNAKNTLYLQMTKVRSEDTALYYCARWGDKYLFDHWGQGTTLTVSS,AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCSLWYSNHLVFGGGTKLTVL,S06816,S06819,Ig heavy chain precursor V region (clone 10C3) - mouse,Ig lambda chain V region (clone 10C3) - mouse,Mus musculus,"Miller,A. 3rd; Glasel,J.A.",Comparative sequence and immunochemical analyses of murine monoclonal anti-morphine antibodies,21-Jan-2000,7_8_11_9_3_9,S06816_S06819,Unique word,morphine,2,1,19.606638,9.724669
1C5D_H_L,EVKLLESGPGLVQPSQTLSLTCTVSGFPLTTNGVSWVRQPPGKGLEWIAAISSGGSPYYNSALKSRLSINRDTSKSQVFLKMNSLQTEDTAIYFCTREDGWNYFDYWGPGTMVTVSS,DIQMTQSPPSLSASLGDKVTITCQASQDINKYIAWYQQKPGKAPRQLIRYTSILVLGTPSRFSGSGSGRDFSFSISNVASEDIASYYCLQYGNLYTFGAGTKLEIK,1C5D_H,1C5D_L,The Crystal Structure Of The Fab Fragment Of A Rat Monoclonal Antibody Against The Main Immunogenic Region Of The Human Muscle Acetylcholine Receptor,The Crystal Structure Of The Fab Fragment Of A Rat Monoclonal Antibody Against The Main Immunogenic Region Of The Human Muscle Acetylcholine Receptor,Rattus norvegicus,"Kontou,M.;Leonidas,D.D.;Vatzaki,E.H.;Tsantili,P.;Mamalaki,A.;Oikonomakos,N.G.;Acharya,K.R.;Tzartos,S.J.",The crystal structure of the Fab fragment of a rat monoclonal antibody against the main immunogenic region of the human muscle acetylcholine receptor,17-NOV-1999,8_7_11_6_3_8,1C5D_H_L,Xtal structure,acetylcholine,2,1,22.191618,-6.027107
S66537_S66536,EVKLQESGAGLVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARDYRYDVWYYAMDYWGQGTTVTVSS,DIELTQSPAIMAASPGEKITITCSVSSSISSKFLHWYQQKPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGSSIPFTFGGGTKLEIK,S66537,S66536,Ig heavy chain V region - mouse (fragment),Ig light chain V region - mouse (fragment),Mus musculus,"Tsiotis,G.; Haase,W.; Engel,A.; Michel,H.",Isolation and structural characterization of trimeric cyanobacterial photosystem I complex with the help of recombinant antibody fragments,20-JUN-2000,8_8_15_7_3_9,S66537_S66536,Unique chain,,2,1,0.93546796,-3.797635
1IGT_D_C,EVKLQESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLEWVAYISNGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCARHGGYYAMDYWGQGTTVTVSS,DIVLTQSPSSLSASLGDTITITCHASQNINVWLSWYQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQGQSYPLTFGGGTKLEIK,1IGT_D,1IGT_C,Structure Of Immunoglobulin,Structure Of Immunoglobulin,Mus musculus,"Harris,L.J.;Larson,S.B.;Hasel,K.W.;Day,J.;Greenwood,A.;McPherson,A.",The three-dimensional structure of an intact monoclonal antibody for canine lymphoma,25-OCT-1996,8_8_11_6_3_9,1IGT_D_C,Xtal structure,,2,1,17.651459,7.0403743
7O30_B_A,EVKLQESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGITDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARDYYGRRYYAMDYWGQGTSVTVSS,DIELTQSPASLAVSLGQRATISCRASKSVSSSGYNYMFWYQQKPGQPPKLLIYLASNLESGVPDRFWGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPLTFGAGTKLEIK,7O30_B,7O30_A,Crystal Structure Of The Anti-Pas Fab 1.1 In Complex With Its Epitope Peptide,Crystal Structure Of The Anti-Pas Fab 1.1 In Complex With Its Epitope Peptide,synthetic construct,"Schilz,J.;Binder,U.;Friedrich,L.;Gebauer,M.;Lutz,C.;Schlapschy,M.;Schiefner,A.;Skerra,A.",Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope,01-APR-2021,8_7_14_10_3_9,7O30_B_A,Xtal structure,Pas,2,1,22.027729,-6.1844416
1NC4_B_A,EVKLQESGPGLVQPSQSLSITCTVSGFSLTDYGVHWVRQSPGKGLEWLGVIWSGGGTAYTAAFISRLNIYKDNSKNQVFFEMNSLQANDTAMYYCARRGSYPYNYFDVWGQGTTVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGNNNRPPGVPARFSGSLIGDKAALTIAGTQTEDEAIYFCALWYSNHWVFGGGTRLTVL,1NC4_B,1NC4_A,Crystal Structure Of Monoclonal Antibody 2D12.5 Fab Complexed With Gd-Dota,Crystal Structure Of Monoclonal Antibody 2D12.5 Fab Complexed With Gd-Dota,Mus musculus,"Corneillie,T.M.;Fisher,A.J.;Meares,C.F.",Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system,04-DEC-2002,8_7_13_9_3_9,1NC4_B_A,Xtal structure,,2,1,22.60225,-5.5964375
1GPO_I_M,EVKLQESGPSLVKPSQTLSLTCSVTGDSITSDFWSWIRQFPGNRLEYMGFVQYSGETAYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTAVYYCANWHGDYWGQGTTVTVSS,DIELTQSPATLSVTPGNSVSISCRASQSLVNEDGNTYLFWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDLAVYFCQQITDWPFTFGGGTKLEIK,1GPO_I,1GPO_M,Crystal Structure Of The Rationally Designed Antibody M41 As A Fab Fragment,Crystal Structure Of The Rationally Designed Antibody M41 As A Fab Fragment,Mus musculus,"Schiweck,W.;Skerra,A.","Fermenter production of an artificial fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling",27-MAR-1997,8_7_7_11_3_9,1GPO_I_M,Xtal structure,,2,1,10.687872,-12.80573
3U9P_H_L,EVKLQESGPSLVQPSQTLSLTCTVSGFSLTSNSVHWVRQPPGQGLEWMGGIWGDGRTDYNSALKSRLSISRDTSKSQVFLKMNSLQTDDTAIYFCTRCRRDSSYVVDAWGQGASVTVSS,DILMTQSPLSLSASLGDKVTITCQASQIIYNYIAWYQQKPGKAPRLLIRYTSTLESGTPSRFSGSGSGRDYSFSISNVESEDIASYYCLQYDNLPYMFGAGTKLELK,3U9P_H,3U9P_L,Crystal Structure Of Murine Siderocalin In Complex With An Fab Fragment,Crystal Structure Of Murine Siderocalin In Complex With An Fab Fragment,Rattus norvegicus,"Correnti,C.;Richardson,V.;Sia,A.K.;Bandaranayake,A.D.;Ruiz,M.;Suryo Rahmanto,Y.;Kovacevic,Z.;Clifton,M.C.;Holmes,M.A.;Kaiser,B.K.;Barasch,J.;Raymond,K.N.;Richardson,D.R.;Strong,R.K.",Siderocalin/Lcn2/NGAL/24p3 does not drive apoptosis through gentisic acid mediated iron withdrawal in hematopoietic cell lines,19-OCT-2011,8_7_13_6_3_9,3U9P_H_L,Xtal structure,apoptosis; LCN2; 24p3; NGAL,2,1,22.126263,-6.1225057
6LBH_C_D,EVKLQESGVELVKPGASVKISCKASGYSFTGYNMNWVKQSHGKSLEWIGNISPYYGTSIYNQNFKGKATLTVDRSSSTAYMQLNSLTSEDSAVYYCARGESFSNYEGYYAMDYWGQGTSVIVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSLVHSDGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK,6LBH_C,6LBH_D,Cryo-Em Structure Of The Mgte Mg2+ Channel Under Mg2+-Free Conditions,Cryo-Em Structure Of The Mgte Mg2+ Channel Under Mg2+-Free Conditions,Mus musculus,"Jin,F.;Sun,M.;Fujii,T.;Yamada,Y.;Wang,J.;Maturana,A.D.;Wada,M.;Su,S.;Ma,J.;Takeda,H.;Kusakizako,T.;Tomita,A.;Nakada-Nakura,Y.;Liu,K.;Uemura,T.;Nomura,Y.;Nomura,N.;Ito,K.;Nureki,O.;Namba,K.;Iwata,S.;Yu,Y.;Hattori,M.",The structure of MgtE in the absence of magnesium provides new insights into channel gating,14-NOV-2019,8_8_17_11_3_9,6LBH_C_D,Xtal structure,MgtE; SLC41A1,2,1,2.4983861,-4.0987234
3DGG_D_C,EVKLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDDTNYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCAREDYYGSRWGYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELLTFGAGTKLELK,3DGG_D,3DGG_C,Crystal Structure Of Fabox108,Crystal Structure Of Fabox108,Homo sapiens,"Nettleship,J.E.;Ren,J.;Rahman,N.;Berrow,N.S.;Hatherley,D.;Barclay,A.N.;Owens,R.J.",A pipeline for the production of antibody fragments for structural studies using transient expression in HEK 293T cells,13-JUN-2008,8_8_12_10_3_8,3DGG_D_C,Xtal structure,TYRO4; HEK; ETK1; HEK4; ETK; EPHA3,2,1,0.9784573,-3.7986677
AAB48333_AAB48316,EVKLVESEGGLVQPGSSMKLSCTVFGFSFSDYYMAWVRQFPEKGLEWVAKINYDGSNTYYLDSLKGRFIISRDNAKNILYLQMSSLKSEDTATYFCSRVNYNGLRRSCFADWGQGTLVTVSA,DIKMTQSPSPMYASLGERVTITCKASQDINNYLSWFQQKPGKSPKTLIYRADRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFYTFGGGTKLEIK,AAB48333,AAB48316,"Ig H-chain V-D-J-region, partial [Mus musculus]","Ig kappa-chain V-J-region, partial [Mus musculus]",Mus musculus,"Marion,T.N.; Tillman,D.M.; Jou,N.T.",Interclonal and intraclonal diversity among anti-DNA antibodies from an (NZB x NZW)F1 mouse,03-MAR-1997,8_8_15_6_3_8,AAB48333_AAB48316,Ordered entries,DNA,2,1,17.509886,7.1666465
7KYL_X_Y,EVKLVESEGGLVQPGSSMKVSCTASGFTFSHYYMAWVRQVPEKGLEWVANINYDGTSTYYLDSLKSRFIISRDNANNILYLQMSSLKSEDTAIYYCAREEGYGNPYPYWYFDVWGTGTTVTVSS,QIVLTQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKSWIYATSNLASGVPTRFSGSGSGTSYSLTISRVEAEDAATYYCQQRSSNPRTFGGGTKLEIK,7KYL_X,7KYL_Y,Powassan Virus Envelope Protein Diii In Complex With Neutralizing Fab Powv-80,Powassan Virus Envelope Protein Diii In Complex With Neutralizing Fab Powv-80,Deer tick virus,"VanBlargan,L.A.;Errico,J.M.;Kafai,N.M.;Burgomaster,K.E.;Jethva,P.N.;Broeckel,R.M.;Meade-White,K.;Nelson,C.A.;Himansu,S.;Wang,D.;Handley,S.A.;Gross,M.L.;Best,S.M.;Pierson,T.C.;Fremont,D.H.;Diamond,M.S.",Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses,08-DEC-2020,8_8_17_5_3_9,7KYL_X_Y,Xtal structure,,2,1,17.443142,7.2142787
5DQJ_H_L,EVKLVESGGDLVKPGGSLKLSCAASGFSFSSHGMSWVRQTPDKRLEWVALISRGGSYTYYSDSVKGRFTISRDNAKNTLYLQMSGLRSEDTAIYYCTRHKGLRRGTNAMDYWGQGTSVTVS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPVRFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPRTFGGGTKLEIK,5DQJ_H,5DQJ_L,Structure Of Unliganded S55-5 Fab,Structure Of Unliganded S55-5 Fab,Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Rodriguez,T.;Bra,L.;Kosma,P.;Brade,H.;Evans,S.V.",Lipid A-Antibody Structures Reveal A Widely-Utilize Specific For Negatively Charged Groups Derived From Unrelated V-Genes,14-SEP-2015,8_8_15_10_3_9,5DQJ_H_L,Xtal structure,,2,1,17.691051,7.0293064
5XCU_D_E,EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLEWVATISRGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARRETYDEKGFAYWGQGTTVTVCS,DIELTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGRDFTLTISSVQAEDLAVYYCQNDNSHPLTFGAGTKLELK,5XCU_D,5XCU_E,Crystal Structure Of 12Ca5 Fv-Clasp Fragment With Its Antigen Peptide,Crystal Structure Of 12Ca5 Fv-Clasp Fragment With Its Antigen Peptide,Homo sapiens,"Arimori,T.;Kitago,Y.;Umitsu,M.;Fujii,Y.;Asaki,R.;Tamura-Kawakami,K.;Takagi,J.","Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability",23-MAR-2017,8_8_13_12_3_9,5XCU_D_E,Xtal structure,,2,1,17.795511,7.254339
AAC04547_AAC04551,EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPAKRLEWVATISRGGGNTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARHRGNYDYGWFAYWGQGTLVTVSA,QIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYDSSPLTFGAGTKLELK,AAC04547,AAC04551,"monoclonal antibody heavy chain, partial [Mus musculus]","monoclonal antibody kappa light chain, partial [Mus musculus]",Mus musculus,"O'Connor,K.C.; Farrell,T.P.; Morikawa,A.; Stollar,B.D.",Anti-DNA antibodies of normal mice immunized with poly(dC) are structurally similar to natural autoantibodies,25-JUL-2016,8_8_14_7_3_9,AAC04547_AAC04551,Unique source,DNA,2,1,18.09702,7.1650352
1KEL_H_L,EVKLVESGGGLGQPGGSLRLSCATSGFTFTDYYFNWARQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQGILYLQMNTLRAEDSATYYCARWGSYAMDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRFSQSIVHSNGNTYLEWYLQKSGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK,1KEL_H,1KEL_L,Catalytic Antibody 28B4 Fab Fragment Complexed With Hapten (1-[N-4'-Nitrobenzyl-N-4'-Carboxybutylamino] Methylphosphonic Acid),Catalytic Antibody 28B4 Fab Fragment Complexed With Hapten (1-[N-4'-Nitrobenzyl-N-4'-Carboxybutylamino] Methylphosphonic Acid),Mus musculus,"Hsieh,L.C.;Stephans,J.C.;Schultz,P.G.",An Efficient Antibody-Catalyzed Monooxygenation Reaction,16-APR-1996,8_10_10_11_3_9,1KEL_H_L,Xtal structure,,2,1,26.056257,4.677577
3LS5_H_L,EVKLVESGGGLVKPGGSLKLSCAASGFTFNNYVMVWLRQTPEKRLEWVASISRGGSTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCVRGTTIVAGDVWGAGTTVTVSS,DIVLTQSPTTMAASPGEKITITCSASSSISSNYLHWYQQKPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGSSIPLTFGAGTKLELK,3LS5_H,3LS5_L,"Anti-Tetrahydrocannabinol Fab Fragment, Free Form","Anti-Tetrahydrocannabinol Fab Fragment, Free Form",Mus musculus,"Niemi,M.H.;Turunen,L.;Pulli,T.;Nevanen,T.K.;Hoyhtya,M.;Soderlund,H.;Rouvinen,J.;Takkinen,K.","A structural insight into the molecular recognition of a (-)-Delta9-tetrahydrocannabinol and the development of a sensitive, one-step, homogeneous immunocomplex-based assay for its detection",12-FEB-2010,8_7_11_7_3_9,3LS5_H_L,Xtal structure,Tetrahydrocannabinol,2,1,18.081507,7.074209
7URL_A_A,EVKLVESGGGLVKPGGSLKLSCAASGFTFSRFGMHWVRQTPEKRLEWVAYISSGSSTIYYADTVKGRFTISRDNAKNTLYLQMSSLRSEDTAIYYCARSGGIERYDGTYYVMDYWGQGTTLTVSS,DIVLTQSPASLTVSLGQRATISCRASESVDYYGKSFMNWYQQKPGQPPKLLIYAASNQGSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSKEVPWTFGAGTKLEIK,7URL_A,7URL_A,The Crystal Structure Of Anti-Hiv_Scfv,The Crystal Structure Of Anti-Hiv_Scfv,Mus musculus,"Zhao,N.;Stasevich,T.;Chen,S.H.;Snow,C.D.",anti-HIV protease intracellular antibody scFv,26-APR-2023,8_8_18_10_3_9,7URL_A_A,Xtal structure,HIV,2,1,17.67465,7.341812
1L7T_H_L,EVKLVESGGGLVKPGGSLKLSCAASGFTFSRYALSWVRQTADKRLEWVASIVSGGNTYYSGSVKGRFTISRDIARNILYLQMSSLRSEDTAMYYCARAYYGYVGLVHWGQGTLVTVSS,DVVVTQTPLSLPVSLGDQASISCRSSEVIVTRNGYTPIEWYLQKPGQSPKLLIYKAYKRFPGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFDGSTVPPKFGGGTKLEIK,1L7T_H,1L7T_L,Crystal Structure Analysis Of The Anti-Testosterone Fab Fragment,Crystal Structure Analysis Of The Anti-Testosterone Fab Fragment,Mus musculus,"Valjakka,J.;Hemminki,A.;Niemi,S.;Soderlund,H.;Takkinen,K.;Rouvinen,J.",Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains,17-MAR-2002,8_7_12_11_3_9,1L7T_H_L,Xtal structure,testosterone,2,1,18.18673,7.1941233
5TLJ_D_C,EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVAYISSGGGNTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCSRHRGNPFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPWTFGGGTKLEIK,5TLJ_D,5TLJ_C,Complex Between Human Cd27 And Fab Fragments Of Antibodies M2177 And M2191,Complex Between Human Cd27 And Fab Fragments Of Antibodies M2177 And M2191,Homo sapiens,"Obmolova,G.;Teplyakov,A.;Malia,T.J.;Wunderler,N.;Kwok,D.;Barone,L.;Sweet,R.;Ort,T.;Scully,M.;Gilliland,G.L.",Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography,11-OCT-2016,8_8_10_10_3_9,AOB49797_AOB49798,Xtal structure,S152; TNFRSF7; CD27; Tp55,2,1,17.916496,7.1006827
1I9J_H_L,EVKLVESGGGLVKPGGSLKLSCAASGFTFSTYALSWVRQTADKRLEWVASIVSGGNTYYSGSVKGRFTISRDIARNILYLQMSSLRSEDTAMYYCAREYYGYVGLAYWGQGTLVTVS,DVVVTQTPLSLPVSLGDQASISCRSSQSIVHSNGNSYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,1I9J_H,1I9J_L,Testosterone Complex Structure Of The Recombinant Monoclonal Wild Type Anti-Testosterone Fab Fragment,Testosterone Complex Structure Of The Recombinant Monoclonal Wild Type Anti-Testosterone Fab Fragment,Mus musculus,"Valjakka,J.;Hemminki,A.;Teerinen,T.;Takkinen,K.;Rouvinen,J.",X-ray studies of recombinant anti-testosterone Fab fragments: the use of PEG 3350 in crystallization,20-MAR-2001,8_7_12_11_3_9,1I9J_H_L,Xtal structure,testosterone; PEG,2,1,18.227129,7.227266
3AB0_B_C,EVKLVESGGGLVKPGGSLKLSCSASGFTFSSYAMSWVRQTPEKRLEWVASISTGGDTHYQDSVKGRFTTSRDNARNILTLQMSSLRSEDTAMYYCARNRGWYFDVWGAGTTVTVSS,QIVLTQSPAIMSASPGEKVTISCSARSSVSYMYWYQQKSGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPPTFGGGTKLEI,3AB0_B,3AB0_C,Crystal Structure Of Complex Of The Bacillus Anthracis Major Spore Surface Protein Bcla With Scfv Antibody Fragment,Crystal Structure Of Complex Of The Bacillus Anthracis Major Spore Surface Protein Bcla With Scfv Antibody Fragment,Mus musculus,"Nuttall,S.D.;Wilkins,M.L.;Streltsov,V.A.;Pontes-Braz,L.;Dolezal,O.;Tran,H.;Liu,C.Q.","Isolation, kinetic analysis, and structural characterization of an antibody targeting the Bacillus anthracis major spore surface protein BclA",28-NOV-2009,8_7_10_5_3_9,3AB0_B_C,Xtal structure,Bacillus,2,1,18.067974,7.020754
5B3J_H_L,EVKLVESGGGLVQPGGSLKLSCAASGITFSSYSMSWVRQTPEKRLEWVAYISNGGSGTYYPDTVKGRFTISRDNAKNSLYLQMSSLRSEDTAMYYCARPSRGGSSYWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGGKVTITCKASQDINKYIAWYQHKPGKGPRLLIQYTSTLQPDIPSRFTGSGSGRDYSFSISNLEPEDIAIYYCLQYDNLYTFGGGTQLEIK,5B3J_H,5B3J_L,Activation Of Nmda Receptors And The Mechanism Of Inhibition By Ifenprodil,Activation Of Nmda Receptors And The Mechanism Of Inhibition By Ifenprodil,Mus musculus,"Tajima,N.;Karakas,E.;Grant,T.;Simorowski,N.;Diaz-Avalos,R.;Grigorieff,N.;Furukawa,H.",Activation of NMDA receptors and the mechanism of inhibition by ifenprodil,01-MAR-2016,8_8_15_6_3_8,5B3J_H_L,Xtal structure,,2,1,17.88988,6.983481
4LU5_I_M,EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYIYWVRQTPEKRLEWVAYISNGGYKTYYPDTVKGRFTISRDNAKNILYLQMSRLKSEDTGIYYCARGMDYWGQGTSVTVSS,DVVMTQTPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGIYYCVQGTHFPYTFGGGTKLEIK,4LU5_I,4LU5_M,Structure Of Murine Igg2A A20G2-Fab In Complex With Vaccinia Antigen A33R At The Resolution Of 2.9 Angstroms,Structure Of Murine Igg2A A20G2-Fab In Complex With Vaccinia Antigen A33R At The Resolution Of 2.9 Angstroms,Mus musculus,"Matho,M.H.;Schlossman,A.;Meng,X.;Benhnia,M.R.;Kaever,T.;Buller,M.;Doronin,K.;Parker,S.;Peters,B.;Crotty,S.;Xiang,Y.;Zajonc,D.M.",Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer,24-JUL-2013,8_8_6_11_3_9,4LU5_I_M,Xtal structure,GPA33; A33,2,1,17.689417,7.0318856
AEK24920_AEK24921,EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLEWVAYINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCARRGLPFHAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTIGNLEPEDIATYYCQQFNKLPPTFGGGTKLEIK,AEK24920,AEK24921,anti-human CD40 12E12 antibody heavy chain [synthetic construct],anti-human CD40 12E12 antibody light chain [synthetic construct],synthetic construct,"Flamar,A.L.; Zurawski,S.; Scholz,F.; Gayet,I.; Ni,L.; Li,X.H.; Klechevsky,E.; Quinn,J.; Oh,S.; Kaplan,D.H.; Banchereau,J.; Zurawski,G.",Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo,15-NOV-2012,8_8_12_6_3_9,AEK24920_AEK24921,Unique word,TNFRSF5; p50; Bp50; CD40,2,1,17.631695,6.9304175
2UUD_J_K,EVKLVESGGGLVQPGGSLRLSCATSGFSFTDYYMAWVRQPPGKALEWLAFIRNKANGYTTDYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARGDYYGAWFAYWGQGTLVTVS,VLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,2UUD_J,2UUD_K,Crystal Structure Of The Tepc15-Vk45.1 Anti-2-Phenyl-5-Oxazolone Nq10- 1.12 Scfv In Complex With The Hapten,Crystal Structure Of The Tepc15-Vk45.1 Anti-2-Phenyl-5-Oxazolone Nq10- 1.12 Scfv In Complex With The Hapten,Mus musculus,"Scotti,C.;Gherardi,E.",Structural basis of affinity maturation of the TEPC15/Vkappa45.1 anti-2-phenyl-5-oxazolone antibodies,02-MAR-2007,8_10_12_11_3_9,2UUD_J_K,Xtal structure,oxazolone,2,1,26.10783,4.730497
UXX19304_UXX19305,EVKLVESGGGLVQPGGSLRLSCATSGFTFTDHYMSWVRQPPGKALEWLGFSRNKANGYTTEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDKGGYDPWFAYWGQGTLVTVSA,DIQMNQSPSSLSASLGDTITITCHASQNINVWLSWYQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQGQSYPLTFGAGTKLELK,UXX19304,UXX19305,"immunoglobulin heavy chain variable region 1A2, partial [Mus musculus]","immunoglobulin light chain variable region 1A2, partial [Mus musculus]",Mus musculus,"Wang,J.",Direct Submission,11-OCT-2022,8_10_13_6_3_9,UXX19304_UXX19305,Unique word,,2,1,26.060371,4.681158
6FLC_B_A,EVKLVESGGGLVQPGGSLSLSCAASGFTFTDYYMTWVRQPPGKALEWLALIRNKASGYTTEYSASVKGRFTISRDNSQSILYLQMNALRAEDSATYYCTRAKWDGHYFDYWGQGTTLTVSS,DIQMTQSPASLSVSVGETVTITCRATKNIYNNLAWYQQKQGRSPQLLVYAATNLADGVPSRFSGSGSGTQFSLRINSLQSEDFGNYYCQHFWHTPWTFGGGTKLEIK,6FLC_B,6FLC_A,2C8 Fab Bound To Ediii Of Denv 2,2C8 Fab Bound To Ediii Of Denv 2,Mus musculus,"Renner,M.;Flanagan,A.;Dejnirattisai,W.;Puttikhunt,C.;Kasinrerk,W.;Supasa,P.;Wongwiwat,W.;Chawansuntati,K.;Duangchinda,T.;Cowper,A.;Midgley,C.M.;Malasit,P.;Huiskonen,J.T.;Mongkolsapaya,J.;Screaton,G.R.;Grimes,J.M.",Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus,25-JAN-2018,8_10_12_6_3_9,6FLC_B_A,Xtal structure,dengue,2,1,26.055328,4.6778884
HVM63_MOUSE_KVM5_MOUSE,EVKLVESGGGLVQPGGSLSLSCATSGFTFIDYYMSWFRQPPGKALEWLGLIRNKGNGYTMEYSASLKGRFTISRDNSQSIVYLHMNTLTAEDSATYYCARVDYGTNYDYWGQGTTLTVSS,DILMTQSQKFLSTSVGDRVSVTCKASQNVGTNVAWYQKKPGQSPKPLMYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQFNRYPLTFGSGTKLELK,HVM63_MOUSE,KVM5_MOUSE,RecName: Full=Ig heavy chain Mem5,RecName: Full=Ig kappa chain V region Mem5,Mus musculus,"Gulati,U.; Hwang,C.C.; Venkatramani,L.; Gulati,S.; Stray,S.J.; Lee,J.T.; Laver,W.G.; Bochkarev,A.; Zlotnick,A.; Air,G.M.",Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98),22-Feb-2023,8_10_11_6_3_9,HVM63_MOUSE_KVM5_MOUSE,Unique word,neuraminidase; H3N2,2,1,26.070953,4.6927032
5MI0_B_C,EVKLVESGGGVVQPGGSRKLSCAASGFTFSDYGMAWVRQAPGKGPEWVTFISNMAYSIYYADTVTGRFTISRENAKNTLHLEMSSLRSEDTAMYYCTRAIFDYAGYWYFDVWGAGTTVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVEYYGTSLMQWFQQKPGQPPRLLIHGASNVQSGVPARFSGSGSGTDFSLNIHPVEEDDFAMYFCQQSTKVPWTFGGGTKLEIK,5MI0_B,5MI0_C,A Thermally Stabilised Version Of Plasmodium Falciparum Rh5,A Thermally Stabilised Version Of Plasmodium Falciparum Rh5,Mus musculus,"Campeotto,I.;Goldenzweig,A.;Davey,J.;Barfod,L.;Marshall,J.M.;Silk,S.E.;Wright,K.E.;Draper,S.J.;Higgins,M.K.;Fleishman,S.J.",One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen,27-NOV-2016,8_8_15_10_3_9,5MI0_B_C,Xtal structure,,2,1,15.168786,9.622671
1JGV_H_L,EVKLVESRGGLVKPGGSLQLSCAASGFTFSGYAMSWFRLTPEKRLEWVASIYNGFRIHYLDSVKGRFTISSDYARNILYLQMSTLRSEDTAMYYCSRGDAYSRYFDVWGAGTTVTVSA,EVVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,1JGV_H,1JGV_L,Structural Basis For Disfavored Elimination Reaction In Catalytic Antibody 1D4,Structural Basis For Disfavored Elimination Reaction In Catalytic Antibody 1D4,Mus musculus,"Larsen,N.A.;Heine,A.;Crane,L.;Cravatt,B.F.;Lerner,R.A.;Wilson,I.A.",Structural basis for a disfavored elimination reaction in catalytic antibody 1D4,26-JUN-2001,8_7_12_11_3_10,1JGV_H_L,Xtal structure,,2,1,18.050053,7.020679
AEQ74137_AEQ74897,EVKMPGSSMKVSCKPSGGTFISHAVSWVRRAPGQGLEWMGGIVPSYGIPDYASRFQGRATISADESTSTVYMELGRLRSEDTAVYYCARDSRTRARGSGGWYRGNVYYYAMDVWGQGTTVT,TLSLSPGERATLSCRATESVTSTYLAWYQQKPGQAPRLLIQGASSRAAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQNGRSPLTFGGGTKVEIK,AEQ74137,AEQ74897,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_26_7_3_9,AEQ74137_AEQ74897,Unique source,tetanus,2,1,-0.009966695,5.752531
A25912_B25912,EVKVIESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARLGGDLHYYAMDYWGQGTSVTVSS,DVVVTQTPLSLPVSFGDQVSISCRSSQSLATSHGITYLSWYLHKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKINTIKPEDLGMYYCLQGSHQPLAFGAGTKLELK,A25912,B25912,Ig heavy chain precursor V region (W3129) - mouse,Ig kappa chain precursor V region (W3129) - mouse (fragment),Mus musculus,"Borden,P.; Kabat,E.A.",Nucleotide sequence of the cDNAs encoding the variable region heavy and light chains of a myeloma protein specific for the terminal nonreducing end of alpha(1----6)dextran,21-Jan-2000,8_8_14_11_3_9,A25912_B25912,Unique chain,,2,1,19.616863,9.735276
CAA37691_CAA37695,EVMLVESGGALVKPGGSLKLSCVASGFTFSNYAMSWVRQTPEKRLEWVAIITPGGNNIYYLDSVKGRFTISRDNARDTLYLQMSSLRSEDTAIYYCTRSRGAYWGQGSLVT,DIVMTQSQKFMSTSVGDRVSVTCKASQNVNTYVAWYQQKPGQSPKALIYSASSRYTGVPDRFTGSGSGTDFTLAISSVQSEDLAEYFCQQYNSYPYTFGGGTKLEIK,CAA37691,CAA37695,"anti-DNA autoantibody (BV17-45), partial [Mus musculus]","anti-DNA autoantibody (BV17-45), partial [Mus musculus]",Mus musculus,"Smith,R.G.; Voss,E.W. Jr.",Variable region primary structures of monoclonal anti-DNA autoantibodies from NZB/NZW F1 mice,26-JUL-2016,8_8_7_6_3_9,CAA37691_CAA37695,Unique word,DNA,2,1,18.052128,7.1499324
4HZL_H_L,EVMLVESGGDLVKPGGSLKLPCAASGFTVSTYAMSWIRQTPEKRLEWVATISSGGSYTYYPDNVKGRFTISRDIAKNTLYLQMSSLRSEDTAMYYCARHPPTVVAGDAMDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSLVHSDGNTYLEWYLQKPGQSPNLLIYKLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,4HZL_H,4HZL_L,Neutralizing Antibody Mab#8 In Complex With The Epitope Ii Of Hcv E2 Envelope Protein,Neutralizing Antibody Mab#8 In Complex With The Epitope Ii Of Hcv E2 Envelope Protein,"Recombinant Hepatitis C virus H77(5'UTR-NS2)/JFH1_V787A,Q1247L","Deng,L.;Zhong,L.;Struble,E.;Duan,H.;Ma,L.;Harman,C.;Yan,H.;Virata-Theimer,M.L.;Zhao,Z.;Feinstone,S.;Alter,H.;Zhang,P.",Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus,15-NOV-2012,8_8_15_11_3_9,4HZL_H_L,Xtal structure,,2,1,17.832012,7.278074
6EJM_I_I,EVMLVESGGGFVKPGGSLKLSCAASGFTFRSYIMSWVRQTPEKRLEWVATISGGGGNTYYPDSVKGRFTISRDNAKNTLYLQLSSLRSEDTALYYCASLTAVGDYWGQGTSVTVSS,DVVMTQTPLTLSVTIGQPASISCKSSQSLFDTDGKTYLTWLLQRPGQSPKRLIYLVSKLASGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCLQGTHFPLTFGAGTKLDLK,6EJM_I,6EJM_I,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With Single Chain Fv Fragment 5,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With Single Chain Fv Fragment 5,Mus musculus,"Nelson,B.;Adams,J.;Kuglstatter,A.;Li,Z.;Harris,S.F.;Liu,Y.;Bohini,S.;Ma,H.;Klumpp,K.;Gao,J.;Sidhu,S.S.",Structure-Guided Combinatorial Engineering Facilitates Affinity and Specificity Optimization of Anti-CD81 Antibodies,22-SEP-2017,8_8_9_11_3_9,6EJM_I_I,Xtal structure,CD81; TAPA-1; TSPAN28; TAPA1,2,1,18.049202,7.045299
8HPJ_B_C,EVMLVESGGGLVKPGGSLKLSCAASGFTFSNYAMSWVRQTPEKRLEWVALISSGGYTYYPDSVKGRFTISRDKARNILHLQMSSLRSEDTAMYFCARGPYDFDDGPPFGNWGQGTLVTVSA,DIVLTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGAGTKLELK,8HPJ_B,8HPJ_C,Crystal Structure Of The Bacterial Oxalate Transporter Oxlt In A Ligand-Free Outward-Facing Form,Crystal Structure Of The Bacterial Oxalate Transporter Oxlt In A Ligand-Free Outward-Facing Form,Mus musculus,"Jaunet-Lahary,T.;Shimamura,T.;Hayashi,M.;Nomura,N.;Hirasawa,K.;Shimizu,T.;Yamashita,M.;Tsutsumi,N.;Suehiro,Y.;Kojima,K.;Sudo,Y.;Tamura,T.;Iwanari,H.;Hamakubo,T.;Iwata,S.;Okazaki,K.I.;Hirai,T.;Yamashita,A.",Structure and mechanism of oxalate transporter OxlT in an oxalate-degrading bacterium in the gut microbiota,15-FEB-2023,8_7_15_6_3_9,8HPJ_B_C,Xtal structure,,2,1,18.21712,7.220029
AAD29598_AAD25035,EVMLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISSGGGNTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARGYYSNYFAYWGQGTLVTVSA,QIVLTQSPAIMSASPGEKVTITCSASSSVSYMHWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPWTFSDGTRLEIK,AAD29598,AAD25035,"anti-myeloperoxidase immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-myeloperoxidase immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Jethwa,H.S.; Clarke,S.H.; Itoh-Lindstrom,Y.; Falk,R.J.; Jennette,J.C.; Nachman,P.H.",Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice,26-JUL-2016,8_8_11_5_3_9,AAD29598_AAD25035,Ordered entries,myeloperoxidase,2,1,18.134747,7.1330094
3I02_B_A,EVMLVESGGGLVQPGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKVKGYTIDYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDMRRFDDGDAMDYWGQGTLVTVS,DIVMTQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLRTFGRGTKLEIK,3I02_B,3I02_A,Crystal Structure Of S54-10 Antibody In Complex With Antigen Kdo(2.4)Kdo(2.4)Kdo,Crystal Structure Of S54-10 Antibody In Complex With Antigen Kdo(2.4)Kdo(2.4)Kdo,Mus musculus,"Brooks,C.L.;Muller-Loennies,S.;Borisova,S.N.;Brade,L.;Kosma,P.;Hirama,T.;Mackenzie,C.R.;Brade,H.;Evans,S.V.",Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition,24-JUN-2009,8_10_15_12_3_8,3I02_B_A,Xtal structure,,2,1,26.09024,4.7117925
2XKN_B_A,EVMLVESGGVLVKPGGSLKLSCAASGFTFSRYAMSWVRQTPEKRLEWVATISSGGSYSYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARDSGGFAYWGQGTLVTVS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVTSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKVEIK,2XKN_B,2XKN_A,Crystal Structure Of The Fab Fragment Of The Anti-Egfr Antibody 7A7,Crystal Structure Of The Fab Fragment Of The Anti-Egfr Antibody 7A7,Mus musculus,"Talavera,A.;Mackenzie,J.;Garrido,G.;Friemann,R.;Lopez-Requena,A.;Moreno,E.;Krengel,U.",Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site,09-JUL-2010,8_8_9_6_3_9,2XKN_B_A,Xtal structure,ERBB; EGFR; ERRP; ERBB1,2,1,18.1015,7.253427
S06817_S06821,EVNLLESGGGLVQPGGSLKVSCAASGFDFSRFWMSWVRQAPGKGLEWIGEINPSSNTINYTPSLKERFIISRDNAKNTLYLQMSKVRPEDTGLYYCAMTKSVYNYGSHYYYFDVWGAGTTVTVSS,AVVTQESILTTSPGETVTLTCRSSTGAVTTSNYANWVQQKPDHLFTSLIGGISNRVPGVPARFSGSLIGDKVALTIIGTQTEDEAIYFCALWYSNHLVFGGGTKLTVL,S06817,S06821,Ig heavy chain V region (clone 11C7) - mouse,Ig lambda chain V region (clone 11C7) - mouse,Mus musculus,"Miller,A. 3rd; Glasel,J.A.",Comparative sequence and immunochemical analyses of murine monoclonal anti-morphine antibodies,21-Jan-2000,8_8_18_9_3_9,S06817_S06821,Unique word,morphine,2,1,19.609222,9.726628
3QHZ_I_M,EVNLRESGPALVKPTQTLTLTCSFSGFSLSTSGMSVSWIRQPPGKALEWLALIDWDDDTYYITYSSSLKTRLTISKDTSKSQVVLTMTNMDPVDTATYYCARTLRVSGDYVRDFDLWGRGTLVTVSS,QPVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVSWYQQVPGTAPKLLIYGNNERPSGVPDRFSGSKSATSASLAISGLQSEDEADYYCAAWDDSLNGFWVFGGGTKLTVL,3QHZ_I,3QHZ_M,Crystal Structure Of Human Anti-Influenza Fab 2D1,Crystal Structure Of Human Anti-Influenza Fab 2D1,Homo sapiens,"Krause,J.C.;Ekiert,D.C.;Tumpey,T.M.;Smith,P.B.;Wilson,I.A.;Crowe JE,Jr.",An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody,26-JAN-2011,10_10_16_8_3_12,3QHZ_I_M,Xtal structure,Influenza,2,1,12.519648,0.47216073
2V17_H_L,EVNLVESGGGLEQSGGSLSLSCAASGFTFTDYYMSWVRQPPGKALEWLALIRNKAKGYTTEYSASVKGRFTISRDNSQSILYLQMNALRAEDSAIYYCARDNGAARATFAYWGQGTLVTVS,DVQITQSPSYLAASPGETITINCRASKSIRKFLAWYREKPGKTNKLLIYSGSTLQSGTPSRFSGSGSGTDFTLTISRLEPEDFAMYYCQQHNDYPLTFGAGTKLELK,2V17_H,2V17_L,Structure Of The Complex Of Antibody Mn423 With A Fragment Of Tau  Protein,Structure Of The Complex Of Antibody Mn423 With A Fragment Of Tau  Protein,Mus musculus,"Sevcik,J.;Skrabana,R.;Dvorsky,R.;Csokova,N.;Iqbal,K.;Novak,M.",X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease,22-MAY-2007,8_10_13_6_3_9,2V17_H_L,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,2,1,26.090261,4.7122087
4YBQ_D_C,EVNLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAHISSGSRTIDYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAIYYCARGNGYYDALDYWGQGTSVTVSS,DIVLTQSPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,4YBQ_D,4YBQ_C,Rat Glut5 With Fv In The Outward-Open Form,Rat Glut5 With Fv In The Outward-Open Form,Mus musculus,"Nomura,N.;Verdon,G.;Kang,H.J.;Shimamura,T.;Nomura,Y.;Sonoda,Y.;Hussien,S.A.;Qureshi,A.A.;Coincon,M.;Sato,Y.;Abe,H.;Nakada-Nakura,Y.;Hino,T.;Arakawa,T.;Kusano-Arai,O.;Iwanari,H.;Murata,T.;Kobayashi,T.;Hamakubo,T.;Kasahara,M.;Iwata,S.;Drew,D.",Structure and mechanism of the mammalian fructose transporter GLUT5,19-FEB-2015,8_8_12_11_3_9,4YBQ_D_C,Xtal structure,GLUT5; SLC2A5,2,1,17.441698,7.8891125
7TCQ_H_L,EVQFQQSGTVLARPGASVKMSCKASGYTFTNYWIHWVKQRPGQGLEYIGGTYPGNGDTTYNQKFKGKAKVTAVTPTSTAYMDLSSLTNEDSAVYYCTRTGSYFDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTISCSATSSVSYIYWYQQRPGSSPKPWIYRTSNLASGVPVRFSGSGSGTSYSLTISNMEAEDAATYYCQQYQSYPPTFGAGTKLELK,7TCQ_H,7TCQ_L,Crystal Structure Of Sars-Cov-2 Neutralizing Antibody Ws6 In Complex With Spike S2 Peptide,Crystal Structure Of Sars-Cov-2 Neutralizing Antibody Ws6 In Complex With Spike S2 Peptide,Severe acute respiratory syndrome coronavirus 2,"Shi,W.;Wang,L.;Zhou,T.;Sastry,M.;Yang,E.S.;Zhang,Y.;Chen,M.;Chen,X.;Choe,M.;Creanga,A.;Leung,K.;Olia,A.S.;Pegu,A.;Rawi,R.;Schon,A.;Shen,C.H.;Stancofski,E.D.;Talana,C.A.;Teng,I.T.;Wang,S.;Corbett,K.S.;Tsybovsky,Y.;Mascola,J.R.;Kwong,P.D.",Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability,03-AUG-2022,8_8_9_5_3_9,7TCQ_H_L,Xtal structure,,2,1,2.7055988,-8.186854
B26471_A26471,EVQGVESGGGLVKPGGSLKLSCAASGFTFSDYYMYWVRQTPEKRLEWVATISDGGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCARDKAYYGNYGDAMDYWGQGTSVTVSS,DIVLTQSPATLSVTPRDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPLTFGAGTKLELK,B26471,A26471,Ig heavy chain precursor V region (MAK33) - mouse,Ig kappa chain precursor V region (MAK33) - mouse,Mus musculus,"Buckel,P.; Hubner-Parajsz,C.; Mattes,R.; Lenz,H.; Haug,H.; Beaucamp,K.",Cloning and nucleotide sequence of heavy- and light-chain cDNAs from a creatine-kinase-specific monoclonal antibody,23-JUL-1999,8_8_16_6_3_9,B26471_A26471,Unique chain,,2,1,17.79266,7.133936
UKB93109_UKB93128,EVQLAESGGGLVKPGGSLRLSCVASGFTFSSNEMHWVRQAPGKGLEWVSVISESGFTTEYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCTRVSIFGQFIVATYFDYWGQGVLVTVSS,QAALTQPRSVSGSPGQSVTISCTGTSSDIGGYNYVSWYQQHPGTAPKLMIYAVSERPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGTVLFGGGTRLTVL,UKB93109,UKB93128,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]","cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",Macaca mulatta,"He,W.T.; Yuan,M.; Callaghan,S.; Musharrafieh,R.; Song,G.; Silva,M.; Beutler,N.; Lee,W.H.; Yong,P.; Torres,J.L.; Melo,M.; Zhou,P.; Zhao,F.; Zhu,X.; Peng,L.; Huang,D.; Anzanello,F.; Ricketts,J.; Parren,M.; Garcia,E.; Ferguson,M.; Rinaldi,W.; Rawlings,S.A.; Nemazee,D.; Smith,D.M.; Briney,B.; Safonova,Y.; Rogers,T.F.; Dan,J.M.; Zhang,Z.; Weiskopf,D.; Sette,A.; Crotty,S.; Irvine,D.J.; Ward,A.B.; Wilson,I.A.; Burton,D.R.; Andrabi,R.",Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques,22-AUG-2022,8_8_17_9_3_8,UKB93109_UKB93128,Unique source,SARS-CoV-2; SARS,2,1,15.098194,10.053426
7V61_I_M,EVQLEESGAELVRPGASVKISCKAFGYTFTNHHINWMKQRPGQGLDWIGYVNPYNDYTKYSQNFKGKATLSVDRSSSTAYMELSSLTSEDSAVYYCARWRDYDRDWYFDVWGAGTTVIVSS,DIVMTQSPATLSVTPGDRVSLSCRASQSIRDYLYWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPYTFGGGTKLEIK,7V61_I,7V61_M,Ace2 -Targeting Monoclonal Antibody As Potent And Broad-Spectrum Coronavirus Blocker,Ace2 -Targeting Monoclonal Antibody As Potent And Broad-Spectrum Coronavirus Blocker,Severe acute respiratory syndrome coronavirus 2,"Yan,R.;Zhang,Y.;Li,Y.;Xia,L.;Guo,Y.;Zhou,Q.",Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2,18-AUG-2021,8_8_14_6_3_9,7V61_I_M,Xtal structure,SARS-CoV-2; ACEH; ACE2,2,1,0.94132274,-3.8231306
6I3Z_H_L,EVQLEESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAIYYCARHAGVHYWGQGTTLTVSS,DIVMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKNLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPWTFGGGTKLESK,6I3Z_H,6I3Z_L,Fab Fragment Of An Antibody Selective For Wild-Type Alpha-1-Antitrypsin In Complex With Its Antigen,Fab Fragment Of An Antibody Selective For Wild-Type Alpha-1-Antitrypsin In Complex With Its Antigen,Mus musculus,"Laffranchi,M.;Elliston,E.L.;Miranda,E.;Perez,J.;Ronzoni,R.;Jagger,A.M.;Heyer-Chauhan,N.;Brantly,M.L.;Fra,A.;Lomas,D.A.;Irving,J.A.",Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin,08-NOV-2018,8_8_8_6_3_9,6I3Z_H_L,Xtal structure,AAT; A1AT; PI; alpha1AT; SERPINA1; alpha-1-antitrypsin; PI1; A1A,2,1,17.910595,7.025363
2Q76_D_C,EVQLEQSGAELMKPGASVKISCKATGYTFTTYWIEWIKQRPGHSLEWIGEILPGSDSTYYNEKVKGKVTFTADASSNTAYMQLSSLTSEDSAVYYCARGDGFYVYWGQGTTLTVSS,DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYTSQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSGSWPRTFGGGTKLDIK,2Q76_D,2Q76_C,Mouse Anti-Hen Egg White Lysozyme Antibody F10.6.6 Fab Fragment,Mouse Anti-Hen Egg White Lysozyme Antibody F10.6.6 Fab Fragment,Mus musculus,"Cauerhff,A.;Goldbaum,F.A.;Braden,B.C.",Structural mechanism for affinity maturation of an anti-lysozyme antibody,06-JUN-2007,8_8_9_6_3_9,2Q76_D_C,Xtal structure,F10,2,1,4.986349,-1.8784891
AHX01225_AHX01237,EVQLIESGGGVVQPGRSLRLSCGASGFSFNNYGMHWVRQAPGKGLEWVAGISFAGIKKYYGTSVKGRFTISRDNSKNNFYLQMNSLRVEDTALYYCARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSTSKIGQNSVSWYQQLPGTAPKLLIYENDRRPSGTPDRFSGSKSGTSATLAITGLQTGDEAEYYCETWDGSGGVFGTGTKVTVL,AHX01225,AHX01237,"anti-HIV-1 immunoglobulin CAP256-VRC26.06 heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin CAP256-VRC26.06 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Doria-Rose,N.A.; Schramm,C.A.; Gorman,J.; Moore,P.L.; Bhiman,J.N.; Dekosky,B.J.; Ernandes,M.J.; Georgiev,I.S.; Kim,H.J.; Pancera,M.; Staupe,R.P.; Altae-Tran,H.R.; Bailer,R.T.; Crooks,E.T.; Cupo,A.; Druz,A.; Garrett,N.J.; Hoi,K.H.; Kong,R.; Louder,M.K.; Longo,N.S.; McKee,K.; Nonyane,M.; O'Dell,S.; Roark,R.S.; Rudicell,R.S.; Schmidt,S.D.; Sheward,D.J.; Soto,C.; Wibmer,C.K.; Yang,Y.; Zhang,Z.; Mullikin,J.C.; Binley,J.M.; Sanders,R.W.; Wilson,I.A.; Moore,J.P.; Ward,A.B.; Georgiou,G.; Williamson,C.; Abdool Karim,S.S.; Morris,L.; Kwong,P.D.; Shapiro,L.; Mascola,J.R.",Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies,25-APR-2014,8_8_38_8_3_9,AHX01225_AHX01237,Unique word,HIV,2,1,14.946873,14.12141
6LYN_A_B,EVQLLESGAELVRPGASVKLSCKTSGYIFTNYWIHWVKQRSGQGLEWIARIYPGTDITYYNEKFKGKATLTVDKSSSSAYMLLSSLKSEDSSVYFCARSGGYWYFDVWGAGTTVTVSS,ELVMTQSPASLAVSLGQRATISCRASKSVSISGYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPYTFGGGTKLEIK,6LYN_A,6LYN_B,Cd146 D4-D5/Aa98 Fab,Cd146 D4-D5/Aa98 Fab,Mus musculus,"Chen,X.;Yan,H.;Liu,D.;Xu,Q.;Duan,H.;Feng,J.;Yan,X.;Xie,C.",Structure basis for AA98 inhibition on the activation of endothelial cells mediated by CD146,14-FEB-2020,8_8_11_10_3_9,6LYN_A_B,Xtal structure,CD146; MCAM; MUC18; METCAM; MelCAM; HEMCAM,2,1,0.37354523,-4.219853
QKK35728_QKK35729,EVQLLESGAEVKKPGSSVKVSCKASGGTFSSDAISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAVYYCARDGPYDSGGYHLNHWGQGTLVTVSS,DIQLTQSPATLSLSPGERATLSCRANQSVSNFLAWYQQKPGQAPRHLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRLTFGGGTKVEIK,QKK35728,QKK35729,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_11,QKK35728_QKK35729,Unique source,SARS-CoV-2,2,1,-0.59279454,5.7495914
QKK35750_QKK35751,EVQLLESGAEVKKPGSSVKVSCKTSGGTFNSYTISWVRQAPGQGLEWMGGIIPILDTPHYAQKFRGRVTITADKSTSTAFMDLSSLTSEDTAVYYCAIRRDYSDYRDFDYWGQGTLVTVSS,QPVLTQSPSASASLGGSVKLTCTLTSGHSTYAIAWHQQQPEKGPRFLMKLNSDGSHNKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCHTWGTDIQVFGGGTKLTVL,QKK35750,QKK35751,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_7_7_9,QKK35750_QKK35751,Unique source,SARS-CoV-2,2,1,-0.8561418,5.6888905
QKK35836_QKK35837,EVQLLESGAEVKKPGSSVKVSCKTSGGTFSTHAISWVRQAPGQGPEWMGGIIPLFGTSEHAQRFQARVKFTADESTSTAYMELSSLTPEDTAVYYCVRDSDPYTATSRNNHYWYGMDVWGQGTTVTVSS,DIQMTQSPLSLPVTLGQPASISCRSSQSVVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTDWPRTFGQGTKVDIK,QKK35836,QKK35837,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35836_QKK35837,Unique source,SARS-CoV-2,2,1,3.08267,-13.221851
AMB38432_AMB38558,EVQLLESGGALVQPGGSLRLSCTASGFTLGHFAMAWVRQAPGKGLEWLSAISGGGGTTYYADSVKGRFTISRDNSKNTLYLQLSGLRAEDTALYFCGKYDSSGHHYVRRMHFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNNLNWYQQKPGKAPKLLMYDASNLEAGVPSRFSGTGSGTDFTFTISSLQAEDIATYYCQQYRNPLLTFGGGTKVEIK,AMB38432,AMB38558,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_16_6_3_9,AMB38432_AMB38558,Unique source,,2,1,14.14449,9.728294
7KM6_h_l,EVQLLESGGDLVKPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARGGEGYYFDYWGQGTTLTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPYTFGGGTKLEIK,7KM6_h,7KM6_l,Apobec3B Antibody 5G7 Fv-Clasp,Apobec3B Antibody 5G7 Fv-Clasp,Homo sapiens,"Tang,H.;Demir,O.;Kurniawan,F.;Brown,W.L.;Shi,K.;Moeller,N.H.;Carpenter,M.A.;Belica,C.;Orellana,K.;Du,G.;LeBeau,A.M.;Amaro,R.E.;Harris,R.S.;Aihara,H.",Structural Characterization of a Minimal Antibody against Human APOBEC3B,02-NOV-2020,8_8_11_12_3_9,7KM6_h_l,Xtal structure,PHRBNL; FLJ21201; APOBEC3B,2,1,17.801184,7.169563
QKK35496_QKK35497,EVQLLESGGGLSRPGGSLRLSCAASGFIASRNCMQWVRQAPGKGLEWVSIICGDEITYIRDSVKGRFTISRDDSKNTLHLEMNSLRADDTAVYYCARATPPGGTTGWPYIDLWGQGTLVTVSS,EIVLTQSPATLSVSPGDGASLSCRASQSVGSNLAWYQQKPGQAPRLLISDASARATGVPARFTGSGSGTDFTLTISSLQSEDFAVYYCHQYNTWPPLTFGGGTKLEIK,QKK35496,QKK35497,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_6_3_10,QKK35496_QKK35497,Unique source,SARS-CoV-2,2,1,12.755218,10.03803
QKK35792_QKK35793,EVQLLESGGGLVKPGGSLRLSCEASGFTFSNYNMNWVRQAPGKGLEWVSSISGSSSYISYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARADRDYDFWSDPPLIDHWGQGTLVTVSS,ETTLTQSPATLSLSPGEGATLSCRASQSVSSSLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCHQRSNWPYTFGQGTKVEIK,QKK35792,QKK35793,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_9,QKK35792_QKK35793,Unique source,SARS-CoV-2,2,1,16.162512,10.053456
AQV03761_AQV03774,EVQLLESGGGLVQPGGSLKLSCAASGFAVNNYPMNWVRQAPGKGLEWVSSIIGSGSRASYADSVKGRFTISRDNGKDIVYLQMNNLRADDTALYYCVKDSSTAWWDKPAASEFDFWGQGTMVTVSS,QLVLTQSPSASASLGASVKLTCTLNSGNTNFAVAWHQQQAGKGPRYLMTINSDGRQSRGDGIPDRFSGSTSGADRYLTISSLHFEDEGDYYCQAWTADLHVFGPGTRVAVV,AQV03761,AQV03774,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Bonsignori,M.; Kreider,E.F.; Fera,D.; Meyerhoff,R.R.; Bradley,T.; Wiehe,K.; Alam,S.M.; Aussedat,B.; Walkowicz,W.E.; Hwang,K.K.; Saunders,K.O.; Zhang,R.; Gladden,M.A.; Monroe,A.; Kumar,A.; Xia,S.M.; Cooper,M.; Louder,M.K.; McKee,K.; Bailer,R.T.; Pier,B.W.; Jette,C.A.; Kelsoe,G.; Williams,W.B.; Morris,L.; Kappes,J.; Wagh,K.; Kamanga,G.; Cohen,M.S.; Hraber,P.T.; Montefiori,D.C.; Trama,A.; Liao,H.X.; Kepler,T.B.; Moody,M.A.; Gao,F.; Danishefsky,S.J.; Mascola,J.R.; Shaw,G.M.; Hahn,B.H.; Harrison,S.C.; Korber,B.T.; Haynes,B.F.",Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies,24-MAR-2017,8_8_19_7_7_9,AQV03761_AQV03774,Unique source,HIV,2,1,13.87239,9.932543
8DY5_A_A,EVQLLESGGGLVQPGGSLRLSCAASGFGFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIHGVTRNWGCGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSLANYYVQWYQQRPGCSPTIVIFANNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDPYSVVFGGGTKLTVL,8DY5_A,8DY5_A,Crystal Structure Of Spfv Cat2200 Lh In Complex With Il-17A,Crystal Structure Of Spfv Cat2200 Lh In Complex With Il-17A,Homo sapiens,"Boucher,L.E.;Prinslow,E.G.;Feldkamp,M.;Yi,F.;Nanjunda,R.;Wu,S.J.;Liu,T.;Lacy,E.R.;Jacobs,S.;Kozlyuk,N.;Del Rosario,B.;Wu,B.;Aquino,P.;Davidson,R.C.;Heyne,S.;Mazzanti,N.;Testa,J.;Diem,M.D.;Gorre,E.;Mahan,A.;Nanda,H.;Gunawardena,H.P.;Gervais,A.;Armstrong,A.A.;Teplyakov,A.;Huang,C.;Zwolak,A.;Chowdhury,P.;Cheung,W.C.;Luo,J.",'Stapling' scFv for multispecific biotherapeutics of superior properties,03-MAY-2023,8_8_11_8_3_9,8DY5_A_A,Xtal structure,,2,1,14.120245,9.658985
8DY1_C_C,EVQLLESGGGLVQPGGSLRLSCAASGFGFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIHGVTRNWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSLANYYVQWYQQRPGSSPTIVIFANNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDPYSVVFGGGTKLTVL,8DY1_C,8DY1_C,Crystal Structure Of Scfv Cat2200 Lh In Complex With Il-17A,Crystal Structure Of Scfv Cat2200 Lh In Complex With Il-17A,Homo sapiens,"Boucher,L.E.;Prinslow,E.G.;Feldkamp,M.;Yi,F.;Nanjunda,R.;Wu,S.J.;Liu,T.;Lacy,E.R.;Jacobs,S.;Kozlyuk,N.;Del Rosario,B.;Wu,B.;Aquino,P.;Davidson,R.C.;Heyne,S.;Mazzanti,N.;Testa,J.;Diem,M.D.;Gorre,E.;Mahan,A.;Nanda,H.;Gunawardena,H.P.;Gervais,A.;Armstrong,A.A.;Teplyakov,A.;Huang,C.;Zwolak,A.;Chowdhury,P.;Cheung,W.C.;Luo,J.",'Stapling' scFv for multispecific biotherapeutics of superior properties,03-MAY-2023,8_8_11_8_3_9,8DY1_C_C,Xtal structure,,2,1,14.073007,9.746899
QKK35660_QKK35661,EVQLLESGGGLVQPGGSLRLSCAASGFIFKNEPMNWIRQFPGKGLEWISNIRDNGNDVYYADSVKGRFTVSRDNAKNSLYLQMNSLRDDDTALYYCVRDTDWAFDSWGQGTLVTVSS,QSALIQPRSVSGSPGQSVTISCTGSSSTFGTDNHISWYQQLPGKVPKLIIHAVSQRPSVVPDRFSGSRSGNTASLTISGLQAEDEADYYCCSSPGTITWVFGGGTKVTVL,QKK35660,QKK35661,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_10_9_3_10,QKK35660_QKK35661,Unique source,SARS-CoV-2,2,1,15.265215,9.803463
QKK35608_QKK35609,EVQLLESGGGLVQPGGSLRLSCAASGFPFSTDAMNWVRQAPGEGLEWVSTISDSGRDTYYAASVRGRFTISRDNSKNTVYLQMNSLRVEDTAVYYCANTNFLDYWGQGTLVTVSS,DIVLTQSPLSLPVTLGQSASISCRSSQGLVHSDGNIYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQATHWPRAFGQGTKLEIK,QKK35608,QKK35609,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_8_11_3_9,QKK35608_QKK35609,Unique source,SARS-CoV-2,2,1,14.138295,9.47457
QKK35622_QKK35623,EVQLLESGGGLVQPGGSLRLSCAASGFPFSTDAMNWVRQAPGEGLEWVSTISDTGRDTYYAASVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCANTNFLDYWGQGTLVTVSS,EIVMTQSPLSLPVTLGQSASISCRSSQGLVHSDGNIYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQATHWPRAFGQGTKVDIK,QKK35622,QKK35623,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_8_11_3_9,QKK35622_QKK35623,Unique source,SARS-CoV-2,2,1,14.079363,9.410892
8CWJ_J_K,EVQLLESGGGLVQPGGSLRLSCAASGFRISDEDMGWVRQAPGKGLEWVSYIDNAGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSHYANPSFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIADYLNWYQQKPGKAPKLLIYYASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGLGMPITFGQGTKVEIK,8CWJ_J,8CWJ_K,Fab Arms Of Antibodies 4C12-B12 And Cr3022 Bound To Pangolin Receptor Binding Domain (Prbd),Fab Arms Of Antibodies 4C12-B12 And Cr3022 Bound To Pangolin Receptor Binding Domain (Prbd),Homo sapiens,"Langley,D.B.;Christ,D.",Neutralization of CoV-2 omicron lineages by affinity-matured class 5 antibodies,24-MAY-2023,8_8_12_6_3_9,8CWJ_J_K,Xtal structure,B12; NDUFB3; CoV,2,1,14.050206,9.6642065
7CBP_D_E,EVQLLESGGGLVQPGGSLRLSCAASGFSFSTYSMHWVRQAPGKGLEWVSAISGEGDSAYYADSVKGRFTISRDNSKNTLYLQMNKVRAEDTAVYYCVGGYSNFYYYYTMDAWGQGTMVTVSS,DIVMTQSPASLSLSPGERATLSCRATQSISTFLAWYQQKPGQAPRLLIYDASTRASGIPARFSGSRSGTDFTLTITRLEPEDFAVYYCQQRYNWPPYSFGQGTKLEIK,7CBP_D,7CBP_E,Cryoem Structure Of Zika Virus With Fab At 4.1 Angstrom,Cryoem Structure Of Zika Virus With Fab At 4.1 Angstrom,Homo sapiens,"Tyagi,A.;Ahmed,T.;Shi,J.;Bhushan,S.",A complex between the Zika virion and the Fab of a broadly cross-reactive neutralizing monoclonal antibody revealed by cryo-EM and single particle analysis at 4.1 A resolution,13-JUN-2020,8_8_15_6_3_10,7CBP_D_E,Xtal structure,Zika,2,1,13.805397,10.05744
AMB38428_AMB38556,EVQLLESGGGLVQPGGSLRLSCAASGFTFANYAMSWVRQAPGQGLEWVSGISGIGDSTYYAYSVKGRFTFSRDNSKNTLYLQMNSLRAEDTAVYYCAKGDGYNAGMVFFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQNIYSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEYTLTISSLQPDDFATYYCQQYNSFSVYTFGPGTKVEIK,AMB38428,AMB38556,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_15_6_3_10,AMB38428_AMB38556,Unique source,,2,1,14.198646,9.70681
QWQ58062_QWQ58107,EVQLLESGGGLVQPGGSLRLSCAASGFTFGAFAMTWVRQAPGKGLEWVSAISGGGGSTYYADSVKGRFTISRDNSKNTLYLQLSGLRAEDTALYYCGKYDSSGHHYVRRMHFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNNLNWYQQKPGKAPKLLMYDASNLEAGVPSRFSGTGSGTDFTFTISSLQPEDIATYYCQQYREPLLTFGGGTKVEIK,QWQ58062,QWQ58107,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Li,L.; Freyn,A.W.; Liu,S.T.H.; Stovicek,O.; Stamper,C.T.; Dugan,H.L.; Tepora,M.E.; Utset,H.A.; Bitar,D.J.; Hamel,N.J.; Changrob,S.; Zheng,N.Y.; Huang,M.; Krammer,F.; Nachbagauer,R.; Palese,P.; Ward,A.B.; Wilson,P.C.",First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,19-JUN-2021,8_8_16_6_3_9,QWQ58062_QWQ58107,Unique source,hemagglutinin; H1N1,2,1,14.07325,9.7621
5VIG_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFKNYAMAWVRQAPGKGLEWVSLLYNSEESTYYADSVKGRFTISRDNSKNTLFLQMNRLRVEDTAVYFCVRDRSNGWSSINLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTMTCRASQTISGWLAWYQQKPGKAPKLLIYQASRLESGIPSRFSGSGSGTEFTLTISSLQPDDVATYYCQQYSTFWTFGLGTKVEIK,5VIG_H,5VIG_L,Crystal Structure Of Anti-Zika Antibody Z006 Bound To Zika Virus Envelope Protein Diii,Crystal Structure Of Anti-Zika Antibody Z006 Bound To Zika Virus Envelope Protein Diii,Zika virus,"Robbiani,D.F.;Bozzacco,L.;Keeffe,J.R.;Khouri,R.;Olsen,P.C.;Gazumyan,A.;Schaefer-Babajew,D.;Avila-Rios,S.;Nogueira,L.;Patel,R.;Azzopardi,S.A.;Uhl,L.F.;Saeed,M.;Sevilla-Reyes,E.E.;Agudelo,M.;Yao,K.H.;Golijanin,J.;Gristick,H.B.;Lee,Y.E.;Hurley,A.;Caskey,M.;Pai,J.;Oliveira,T.;Wunder EA,Jr.;Sacramento,G.;Nery N,Jr.;Orge,C.;Costa,F.;Reis,M.G.;Thomas,N.M.;Eisenreich,T.;Weinberger,D.M.;de Almeida,A.R.;West AP,Jr.;Rice,C.M.;Bjorkman,P.J.;Reyes-Teran,G.;Ko,A.I.;MacDonald,M.R.;Nussenzweig,M.C.",Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico,16-APR-2017,8_8_13_6_3_8,5VIG_H_L,Xtal structure,Zika,2,1,14.073911,9.652195
6E56_G_I,EVQLLESGGGLVQPGGSLRLSCAASGFTFNHYAMTWVRQAPGKGLEWVASSSGSGRSTYYTDSVKGRFSVSRDNSKNTLYLQMNSLRAEDTAVYYCAKSSNYYGSGSYSPDDYYHMDVWGQGTTVTVSG,EIVMTQSPDTLSVSPGERATLSCRASESISSNLAWYQQKPGQVPRLLIYGASTRATGVPARFTGSGSGTEFTLTISSLQSEDFAVYYCQQYNNRLPYTFGQGTKLEIK,6E56_G,6E56_I,Human Antibody H2214 In Complex With Influenza Hemagglutinin A/Aichi/2/1968 (X-31) (H3N2),Human Antibody H2214 In Complex With Influenza Hemagglutinin A/Aichi/2/1968 (X-31) (H3N2),Homo sapiens,"Watanabe,A.;McCarthy,K.R.;Kuraoka,M.;Schmidt,A.G.;Adachi,Y.;Onodera,T.;Tonouchi,K.;Caradonna,T.M.;Bajic,G.;Song,S.;McGee,C.E.;Sempowski,G.D.;Feng,F.;Urick,P.;Kepler,T.B.;Takahashi,Y.;Harrison,S.C.;Kelsoe,G.",Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism,19-JUL-2018,8_8_22_6_3_10,6E56_G_I,Xtal structure,Influenza; H3N2,2,1,14.007576,10.061773
6SRV_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFRYDYHVWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLRADLGLYMDLWGRGTLVTVSS,QSVLTQPPSVSAAPGQKVTVSCSGSSSNIGNHHVSWYQQLPGTAPKLLIYDTTVLSSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDELTSNLVFGGGTKLTVL,6SRV_H,6SRV_L,Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021144,Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021144,HOMO SAPIENS,"Burschowsky, D., Addyman, A., Fiedler, S., Groves, M., Haynes, S., Seewooruthun, C., Carr, M.",Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021144,06-SEP-2019,9_8_13_8_3_11,6SRV_H_L,Xtal structure,,2,1,13.84478,9.767471
7D85_B_C,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL,7D85_B,7D85_C,Crystal Structure Of Anti-Erbb3 Fab Isu104 In Complex With Human Erbb3 Extracellular Domain 3,Crystal Structure Of Anti-Erbb3 Fab Isu104 In Complex With Human Erbb3 Extracellular Domain 3,Homo sapiens,"Hong,M.;Yoo,Y.;Kim,M.;Kim,J.Y.;Cha,J.S.;Choi,M.K.;Kim,U.;Kim,K.;Sohn,Y.;Bae,D.;Cho,H.S.;Hong,S.B.","A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization",07-OCT-2020,8_8_14_8_3_11,QHX45033_QHX45063,Xtal structure,ErbB3,2,1,14.123099,9.840264
6J6Y_B_C,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSTISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLTAYGHVDSWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGTNTVNWYQQLPGTAPKLLIYRNYQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGPHVVFGGGTKLTVL,6J6Y_B,6J6Y_C,Fgfr4 D2 - Fab Complex,Fgfr4 D2 - Fab Complex,synthetic construct,"Bartz,R.;Fukuchi,K.;Ohtsuka,T.;Lange,T.;Gruner,K.;Watanabe,I.;Hayashi,S.;Oda,Y.;Kawaida,R.;Komori,H.;Kashimoto,Y.;Wirtz,P.;Mayer,J.A.;Redondo-Muller,M.;Saito,S.;Takahashi,M.;Hanzawa,H.;Imai,E.;Martinez,A.;Hanai,M.;Haussinger,D.;Chapman,R.W.;Agatsuma,T.;Bange,J.;Abraham,R.","Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity",16-JAN-2019,8_8_11_8_3_13,QYQ09677_QYQ09685,Xtal structure,CD334; JTK2; FGFR4,2,1,14.220466,9.628224
5WHJ_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSEYAMGWVRQAPGKGLEWVSSIGSSGGQTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSQRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCASYAGSGIYVFGTGTKVTVL,5WHJ_H,5WHJ_L,Crystal Structure Of Fab Fragment Of Anti-Fcrn Antibody Dx-2507,Crystal Structure Of Fab Fragment Of Anti-Fcrn Antibody Dx-2507,Homo sapiens,"Kenniston,J.A.;Taylor,B.M.;Conley,G.P.;Cosic,J.;Kopacz,K.J.;Lindberg,A.P.;Comeau,S.R.;Atkins,K.;Bullen,J.;TenHoor,C.;Adelman,B.A.;Sexton,D.J.;Edwards,T.E.;Nixon,A.E.",Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody,17-JUL-2017,8_8_9_9_3_10,QHY89249_QHY89248,Xtal structure,neonatal; Fcrn,2,1,13.825361,9.483271
3SKJ_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYMMAWVRQAPGKGLEWVSRIGPSGGPTHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGYDSGYDYVAVAGPAEYFQHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTEFSLTISGLQPDDFATYYCQQYNSYSRTFGQGTKVEIK,3SKJ_H,3SKJ_L,Structural And Functional Characterization Of An Agonistic Anti-Human Epha2 Monoclonal Antibody,Structural And Functional Characterization Of An Agonistic Anti-Human Epha2 Monoclonal Antibody,Homo sapiens,"Peng,L.;Oganesyan,V.;Damschroder,M.M.;Wu,H.;Dall'Acqua,W.F.",Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody,22-JUN-2011,8_8_21_6_3_9,3SKJ_H_L,Xtal structure,,2,1,14.0806675,9.793735
6FOE_A_B,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK,6FOE_A,6FOE_B,Baxb01 Fab Fragment,Baxb01 Fab Fragment,Homo sapiens,"Schinagl,A.;Kerschbaumer,R.J.;Sabarth,N.;Douillard,P.;Scholz,P.;Voelkel,D.;Hollerweger,J.C.;Goettig,P.;Brandstetter,H.;Scheiflinger,F.;Thiele,M.",Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch,07-FEB-2018,8_8_11_6_3_9,AIB01740_AIB01734,Xtal structure,,2,1,13.653276,9.89468
AFN26941,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFAMSWVRQAPGKGLEWVSTISGSGGYTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGRYNWNYGAFDIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,AFN26941_H,AFN26941_L,anti-myostatin single chain antibody variable region [synthetic construct],anti-myostatin single chain antibody variable region [synthetic construct],synthetic construct,"Wu,B.","Construction, expression and characterization of a human origin single chain antibody against myostatin",14-JUL-2012,8_8_15_6_3_9,AFN26941,Same entry,myostatin,2,1,14.016532,9.792592
CAA06864,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,CAA06864_H,CAA06864_L,"anti-(ED-B) scFV, partial [Homo sapiens]","anti-(ED-B) scFV, partial [Homo sapiens]",Homo sapiens,"Pini,A.; Viti,F.; Santucci,A.; Carnemolla,B.; Zardi,L.; Neri,P.; Neri,D.",Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel,24-JUL-2016,8_8_9_7_3_9,AGJ47047,Same entry,angiogenesis; ED-B,2,1,14.099861,9.512636
8DY0_A_A,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGCGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGCGTKVEIK,8DY0_A,8DY0_A,Crystal Structure Of Spfv Glk1 Hl,Crystal Structure Of Spfv Glk1 Hl,Homo sapiens,"Boucher,L.E.;Prinslow,E.G.;Feldkamp,M.;Yi,F.;Nanjunda,R.;Wu,S.J.;Liu,T.;Lacy,E.R.;Jacobs,S.;Kozlyuk,N.;Del Rosario,B.;Wu,B.;Aquino,P.;Davidson,R.C.;Heyne,S.;Mazzanti,N.;Testa,J.;Diem,M.D.;Gorre,E.;Mahan,A.;Nanda,H.;Gunawardena,H.P.;Gervais,A.;Armstrong,A.A.;Teplyakov,A.;Huang,C.;Zwolak,A.;Chowdhury,P.;Cheung,W.C.;Luo,J.",'Stapling' scFv for multispecific biotherapeutics of superior properties,03-MAY-2023,8_8_12_6_3_9,8DY0_A_A,Xtal structure,,2,1,14.134387,9.683172
7REW_A_B,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAFSGWDVSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVQDGLGPYFYNYGMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTASITCSGDKLGDKYSFWFQQKPGQSPVLVIYHDSKRPSGIPERFSGSNSGDTATLTISGTRAMDEADYYCQAWDSSTYVFGTGTKVTVL,7REW_A,7REW_B,Crystal Structure Of Il-13 In Complex With Mmab3 Fab,Crystal Structure Of Il-13 In Complex With Mmab3 Fab,Macaca fascicularis,"Kielczewska,A.;D'Angelo,I.;Amador,M.S.;Wang,T.;Sudom,A.;Min,X.;Rathanaswami,P.;Pigott,C.;Foltz,I.N.",Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence-based affinity maturation,13-JUL-2021,8_8_16_6_3_9,7REW_A_B,Xtal structure,,2,1,13.913013,10.014826
UNJ20713_UNJ20858,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAIAAAGYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLVLTFGGGTKVEIK,UNJ20713,UNJ20858,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,8_8_13_6_3_9,UNJ20713_UNJ20858,Unique source,SARS-CoV-2,2,1,14.079388,9.843862
UNJ20714_UNJ20859,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALAAAGYWAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLRLTFGGGTKVEIK,UNJ20714,UNJ20859,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,8_8_14_6_3_9,UNJ20714_UNJ20859,Unique source,SARS-CoV-2,2,1,14.222749,9.915269
6AZM_B_A,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGGDSSPAGRTWFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPITFGQGTRLEIK,6AZM_B,6AZM_A,Crystal Structure Of The 580 Germline Antibody Bound To Circumsporozoite Protein Nanp 5-Mer,Crystal Structure Of The 580 Germline Antibody Bound To Circumsporozoite Protein Nanp 5-Mer,Plasmodium falciparum,"Triller,G.;Scally,S.W.;Costa,G.;Pissarev,M.;Kreschel,C.;Bosch,A.;Marois,E.;Sack,B.K.;Murugan,R.;Salman,A.M.;Janse,C.J.;Khan,S.M.;Kappe,S.H.;Adegnika,A.A.;Mordmuller,B.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies,11-SEP-2017,8_8_18_12_3_9,6AZM_B_A,Xtal structure,Malarial,2,1,14.131248,9.855515
6UTA_A_B,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRGPRGVGELFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,6UTA_A,6UTA_B,Crystal Structure Of Z004 Igl Fab In Complex With Zikv Ediii,Crystal Structure Of Z004 Igl Fab In Complex With Zikv Ediii,Zika virus ZIKV/H. sapiens/FrenchPolynesia/10087PF/2013,"Esswein,S.R.;Gristick,H.B.;Jurado,A.;Peace,A.;Keeffe,J.R.;Lee,Y.E.;Voll,A.V.;Saeed,M.;Nussenzweig,M.C.;Rice,C.M.;Robbiani,D.F.;MacDonald,M.R.;Bjorkman,P.J.",Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody,29-OCT-2019,8_8_15_6_3_9,6UTA_A_B,Xtal structure,Zika,2,1,14.149138,9.934256
1603260A_AAB62946,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGQVLYYGSGSYHWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK,1603260A,AAB62946,"Ig V mu,anti-DNA","immunoglobulin kappa light chain V region, partial [Homo sapiens]",Homo sapiens,"Lampman,G.W.; Furie,B.; Schwartz,R.S.; Stollar,B.D.; Furie,B.C.",Amino acid sequence of a platelet-binding human anti-DNA monoclonal autoantibody,24-Jul-2016,8_8_18_6_3_9,1603260A_AAB62946,Unique chain,platelet,2,1,14.21784,10.050996
6GHG_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK,6GHG_H,6GHG_L,Variable Heavy - Variable Light Domain And Fab-Arm Crossmabs With Charged Residue Exchanges,Variable Heavy - Variable Light Domain And Fab-Arm Crossmabs With Charged Residue Exchanges,Homo sapiens,"Regula,J.T.;Imhof-Jung,S.;Molhoj,M.;Benz,J.;Ehler,A.;Bujotzek,A.;Schaefer,W.;Klein,C.",Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly,07-MAY-2018,8_8_8_7_3_9,UOL82687_UOL82688,Xtal structure,,2,1,14.191519,9.598708
CAF32930,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPNTFGQGTKVEIK,CAF32930_H,CAF32930_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Winter,G.M.; Tomlinson,I.D.; Ignatovich,O.D.; Holt,L.D.; de Angelis,E.D.",Ligand,03-MAR-2004,8_8_9_6_3_9,CAF32930,Same entry,,2,1,14.287527,9.584998
4UU9_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDDYEEWPWYYGMDVWGQGTMVTVS,QSALTQPASVSGSPGQSITISCTGTSSDIGGSKYVSWYQQHPGKAPKLIIFDVNRRPSGLSNRFSASKSGNTASLTISGLQAEDEADYYCTSYHPTKTILFGGGTKLTVL,4UU9_H,4UU9_L,Crystal Structure Of The Human C5A In Complex With Medi7814 A  Neutralising Antibody,Crystal Structure Of The Human C5A In Complex With Medi7814 A  Neutralising Antibody,Homo sapiens,"Colley,C.S.;Popovic,B.;Sridharan,S.;Debreczeni,J.E.;Hargeaves,D.;Fung,M.;An,L.L.;Edwards,B.;Arnold,J.;England,E.;Eghobamien,L.;Sivars,U.;Flavell,L.;Renshaw,J.;Wickson,K.;Warrener,P.;Zha,J.;Bonnell,J.;Woods,R.;Wilkinson,T.;Dobson,C.;Vaughan,T.J.",Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors,25-JUL-2014,8_8_17_9_3_10,4UU9_H_L,Xtal structure,C5; C5AR; C5AR1; CPAMD4; C5A; C5R1; C5a; CD88; C5b,2,1,13.87024,10.049666
QKK35664_QKK35665,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGIDGGGGSSYYADSVRGRFTVSRDNSKNMLHLQMNSLRADDTAVYFCAKGDWIRYFDWSLPISFFDYWGQGALVTVSS,QSALTQPASVSGSPGQSITISCTGTNSDISNSYSVSWYQQYPGKAPKLVIFDVINRPSGVSNRFSGSKSGNTASLTISGLQADDEADYYCCSYTRTNTPVLFGGGTKLTVL,QKK35664,QKK35665,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_20_9_3_11,QKK35664_QKK35665,Unique source,SARS-CoV-2,2,1,14.265861,9.994551
VTP59576_VTP59577,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSAISTNGATAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEKGAMGYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQNIVHSTGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHFPFTFGQGTKVEIK,VTP59576,VTP59577,"anti-ETaR antibody heavy chain variable region-codon-optimized, partial [Mus musculus]","anti-ETaR antibody light chain variable region-codon-optimized, partial [Mus musculus]",Mus musculus,"Wang,J.",Direct Submission,19-JUN-2019,8_8_9_11_3_9,VTP59576_VTP59577,Unique chain,ETaR,2,1,14.277706,9.434135
5GRJ_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,5GRJ_H,5GRJ_L,Crystal Structure Of Human Pd-L1 With Monoclonal Antibody Avelumab,Crystal Structure Of Human Pd-L1 With Monoclonal Antibody Avelumab,Homo sapiens,"Liu,K.;Tan,S.;Chai,Y.;Chen,D.;Song,H.;Zhang,C.W.;Shi,Y.;Liu,J.;Tan,W.;Lyu,J.;Gao,S.;Yan,J.;Qi,J.;Gao,G.F.",Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy,11-AUG-2016,8_8_13_9_3_10,QHZ04135_QHZ04136,Xtal structure,CD274; B7-H; B7H1; B7-H1; PDCD1LG1; PDL1; PD-L1,2,1,13.78848,9.458232
6YAX_I_M,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARENFDAFDVWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYSNSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGQVVFGGGTKLTVL,6YAX_I,6YAX_M,Crystal Structure Of Cd32B (Fc Gamma Receptor Iib) In Complex With Human Igg1 Fab Fragment (5C05),Crystal Structure Of Cd32B (Fc Gamma Receptor Iib) In Complex With Human Igg1 Fab Fragment (5C05),HOMO SAPIENS,"Fisher, H., Tews, I., Orr, C.",Crystal Structure Of Cd32B (Fc Gamma Receptor Iib) In Complex With Human Igg1 Fab Fragment (5C05),14-MAR-2020,8_8_10_9_3_12,6YAX_I_M,Xtal structure,,2,1,14.864346,13.027219
7LSI_A_C,EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYVMGWVRQAPGKGLEWVSSIYPSGGATNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGNYFDYWGQGTLVTVSS,QSVLTQPPSVSVSPGQTASITCSGEKLGDEYASWYQQKPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTLLFGGGTKLTVL,7LSI_A,7LSI_C,"Structure Of Kd035, A Vegfr2 Monoclonal Antibody","Structure Of Kd035, A Vegfr2 Monoclonal Antibody",Homo sapiens,"Depetris,R.S.","Structure of KD035, a VEGFR2 monoclonal antibody",18-FEB-2021,8_8_8_6_3_9,AYI09397_AYI09425,Xtal structure,VEGFR; KDR; CD309; VEGFR2; FLK1,2,1,13.785318,9.314561
6YYE_C_C,EVQLLESGGGLVQPGGSLRLSCAASGFTFYSSYMGWVRQAPGKGLEWVSYISSSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGGYYSWGNGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYGVYYPFTFGQGTKLEIK,6YYE_C,6YYE_C,Trem2 Extracellular Domain (19-131) In Complex With Single-Chain Variable Fragment (Scfv-2),Trem2 Extracellular Domain (19-131) In Complex With Single-Chain Variable Fragment (Scfv-2),Homo sapiens,"Szykowska,A.;Chen,Y.;Smith,T.B.;Preger,C.;Yang,J.;Qian,D.;Mukhopadhyay,S.;Wigren,E.;Neame,S.J.;Graslund,S.;Persson,H.;Atkinson,P.J.;Di Daniel,E.;Mead,E.;Wang,J.;Davis,J.B.;Burgess-Brown,N.A.;Bullock,A.N.",Selection and structural characterisation of anti-TREM2 scFvs that reduce levels of shed ectodomain,04-MAY-2020,8_8_15_6_3_10,6YYE_C_C,Xtal structure,Trem2b; TREM-2; Trem2c; TREM2; Trem2a,2,1,13.9791765,9.6776
7KQK_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTLSSYQMMWVRQAPGKGLEWVAGITGRGGVTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPALDSDQCGFPEAGCIDAWGQGTLVTVSS,SELTQDPAVSVALGQTVRITCQGDDSYYGWYQQKPGQAPVTVIYGNDNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGAYDSSGGGGIFGGGTKLTVL,7KQK_H,7KQK_L,Anti-Ptau C21-Abs Fab In Complex With Ptau Peptide,Anti-Ptau C21-Abs Fab In Complex With Ptau Peptide,Homo sapiens,"Mosyak,L.;Brinth,A.",anti-pTau C21-ABS Fab in complex with pTau peptide,16-NOV-2020,8_8_20_4_3_11,7KQK_H_L,Xtal structure,ABS; C21; IRA1; TBLR1; MGC8828; FLJ12894; TBL1XR1; DDX41; DC42,2,1,14.174593,9.902079
7RT9_C_D,EVQLLESGGGLVQPGGSLRLSCAASGYTFTNYWMHWVRQAPGKGLEWVSNIDPSNGGTNYNEKFKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLAWYQQKPGKAPKFLIYNAETLSDGVPSRFRGSGSGTDFALSISSLQPEDFATYYCQHFMYPPFTFGQGTKLEIK,7RT9_C,7RT9_D,Crystal Structures Of Human Pyy And Npy,Crystal Structures Of Human Pyy And Npy,Homo sapiens,"Langley,D.B.;Schofield,P.;Jackson,J.;Herzog,H.;Christ,D.",Crystal structures of human neuropeptide Y (NPY) and peptide YY (PYY),12-AUG-2021,8_8_5_6_3_9,7RT9_C_D,Xtal structure,PYY1; NPY; PYY; PYY4,2,1,13.727256,9.306808
1AD0_B_A,EVQLLESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQAPGKGLEWLGFIGNKANGYTTEYSASVKGRFTISRDKSKSTLYLQMNTLQAEDSAIYYCTRDRGLRFYFDYWGQGTLVTVSS,TVLTQSPSSLSVSVGDRVTITCRASSSVTYIHWYQQKPGLAPKSLIYATSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHWSSKPPTFGQGTKVEVK,1AD0_B,1AD0_A,Fab Fragment Of Engineered Human Monoclonal Antibody A5B7,Fab Fragment Of Engineered Human Monoclonal Antibody A5B7,Homo sapiens,"Banfield,M.J.;King,D.J.;Mountain,A.;Brady,R.L.",VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs,19-FEB-1997,8_10_12_5_3_9,1AD0_B_A,Xtal structure,,2,1,26.054188,4.675712
6WN1_E_F,EVQLLESGGGLVQPGGSLRLSCAVSGFTFRNYALSWVRQAPGKGLDWVSTISASGGATYYADSVKGHFTISRDNSKNILYLDMKSLRAEDTAIYYCARDGGSYTPYFFLDSWGQGALVTVSS,SYELTQPASVSVAPGQTAQITCGGNSIGRKSIHWYQHKPGQAPVLVISYDSDRPSGIPERFSGSNSGNTATLTISKVEAGDEADFYCQVRDSDNDHVVFGGGTKLTVL,6WN1_E,6WN1_F,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 241242,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 241242,Homo sapiens,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,22-APR-2020,8_8_15_6_3_11,6WN1_E_F,Xtal structure,,2,1,14.120606,9.666721
5FUO_H_L,EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGGGTKVEIK,5FUO_H,5FUO_L,Extending The Half-Life Of A Fab Fragment Through Generation Of A  Humanised Anti-Human Serum Albumin (Hsa) Fv Domain: An Investigation  Into The Correlation Between Affinity And Serum Half-Life,Extending The Half-Life Of A Fab Fragment Through Generation Of A  Humanised Anti-Human Serum Albumin (Hsa) Fv Domain: An Investigation  Into The Correlation Between Affinity And Serum Half-Life,Homo sapiens,"Adams,R.;Griffin,L.;Compson,J.E.;Jairaj,M.;Baker,T.;Ceska,T.;West,S.;Zaccheo,O.;Dave,E.;Lawson,A.D.;Humphreys,D.P.;Heywood,S.",Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life,28-JAN-2016,8_7_15_7_3_11,AVC22642,Xtal structure,,2,1,13.949545,9.513765
ANY91783_ANY91179,EVQLLESGGGLVQPGGSLRLSCEASGFTFSSHAMSWVRQAPGKGLEWVSGISGNSGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCTKDRSPPVYDILPGYYSSYYYMDVWGKGTTVTVSS,EIVMTQAPVSLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWLRTFGQGTKLEIK,ANY91783,ANY91179,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_24_6_3_9,ANY91783_ANY91179,Unique source,Influenza,2,1,13.845753,10.128407
6U36_H_L,EVQLLESGGGLVQPGGSLRLSCKASGYTFSSYGMYWVRQAPGKGLEWIGWIDPGSGGTKYNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARERYGYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFGGGTKVEIK,6U36_H,6U36_L,Pcsk9 In Complex With A Fab And Compound 14,Pcsk9 In Complex With A Fab And Compound 14,Homo sapiens,"Petrilli,W.L.;Adam,G.C.;Erdmann,R.S.;Abeywickrema,P.;Agnani,V.;Ai,X.;Baysarowich,J.;Byrne,N.;Caldwell,J.P.;Chang,W.;DiNunzio,E.;Feng,Z.;Ford,R.;Ha,S.;Huang,Y.;Hubbard,B.;Johnston,J.M.;Kavana,M.;Lisnock,J.M.;Liang,R.;Lu,J.;Lu,Z.;Meng,J.;Orth,P.;Palyha,O.;Parthasarathy,G.;Salowe,S.P.;Sharma,S.;Shipman,J.;Soisson,S.M.;Strack,A.M.;Youm,H.;Zhao,K.;Zink,D.L.;Zokian,H.;Addona,G.H.;Akinsanya,K.;Tata,J.R.;Xiong,Y.;Imbriglio,J.E.",From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9,21-AUG-2019,8_8_11_6_3_10,QKO85693_QKO85697,Xtal structure,HCHOLA3; FH3; NARC-1; PCSK9,2,1,13.78127,9.3632145
CAL63912,EVQLLESGGGLVQPGGSLRLSCTASGFVFSDYWMHWVRQAPGKGLVWISRLKSDGSSRSYADFVKGRFTVSRDNVKNTLFLQINSLRAEDTAVYYCARELRGWSIEYWGHGTQVTVSS,ELVLTQSPATLSLSPGERATLFCRASQDISTSLAWYQQKPGQVPRLLIYGTSYRATGISARFSGRGSGTDFTLTISSLEPEDFALYYCQHRRDWPPGATFGQGTRLEIK,CAL63912_H,CAL63912_L,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"toran Garcia,J.L.; lain de Lera,M.T.",Human antibodies with beta-amyloid peptide-binding capacity and their applications,24-OCT-2006,8_8_11_6_3_11,CAL63912,Same entry,beta-amyloid,2,1,13.498995,9.610061
QKK35730_QKK35731,EVQLLESGGGVVNPGGSMRLSCAGSGFTFSDHYMGWIRQAPGKGLEVISYISSSGSFIRDADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARMGPYGSGTFDYWGQGTLVTVSS,DIVMTQTPGTLSVSPGERATLSCRASQIINRSQLGWYQHKPGQPPRLLIFDSSKRATGTPDRFSASGSETDFTLTISGVEPEDSGVYYCLQYSLATTFGPGTKVEIK,QKK35730,QKK35731,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_7_3_8,QKK35730_QKK35731,Unique source,SARS-CoV-2,2,1,15.802523,9.289754
QKK35758_QKK35759,EVQLLESGGGVVQPGRSLRLSCAASGFTFNSYALFWVRQAPGKGLEWVAVVSYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLKTEDTSVYYCARPRSGSYRQAIDYWGLGTLVTVSS,DIRMTQSPSTLSASVGDRVTITCRASQTIGSWLAWYQQKPGKAPNLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSLYTFGQGTKLEIK,QKK35758,QKK35759,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_8,QKK35758_QKK35759,Unique source,SARS-CoV-2,2,1,14.564959,13.657436
6II4_H_L,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYAIHWVRQAPGKGLEWVALISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNGHGSGGEVGSNWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEYNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSANRVFGGGTKLTVL,6II4_H,6II4_L,Crystal Structure Of H7 Hemagglutinin From A/Anhui/1/2013 In Complex With A Human Neutralizing Antibody L4A-14,Crystal Structure Of H7 Hemagglutinin From A/Anhui/1/2013 In Complex With A Human Neutralizing Antibody L4A-14,Homo sapiens,"Huang,K.A.;Rijal,P.;Jiang,H.;Wang,B.;Schimanski,L.;Dong,T.;Liu,Y.M.;Chang,P.;Iqbal,M.;Wang,M.C.;Chen,Z.;Song,R.;Huang,C.C.;Yang,J.H.;Qi,J.;Lin,T.Y.;Li,A.;Powell,T.J.;Jan,J.T.;Ma,C.;Gao,G.F.;Shi,Y.;Townsend,A.R.",Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans,03-OCT-2018,8_8_16_8_3_9,6II4_H_L,Xtal structure,,2,1,14.720063,13.470727
QKK35694_QKK35695,EVQLLESGGGVVQPGRSLRLSCVTSGFDFRPYAMQWVRQAPGKGLEWVAVISHDGVHTGYADSLKGRFTISRDNSKNTLYLQVDSLRPDDSALYYCARDNALQNAQIGYLDYWGQGTLVTVSS,ETTLTQSPATLSVSPGETATLSCRASQSVGRFMGWYQQKPGQAPRLLIFDASNRVTGVPDRFRGSGSGTDFILTINSLEPEDSASYYCQRRGDGYNFGQGTKVEIK,QKK35694,QKK35695,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_8,QKK35694_QKK35695,Unique source,SARS-CoV-2,2,1,14.654247,13.371303
QKK35838_QKK35839,EVQLLESGGGVVQPGTSLRLSCAVSGFMFKNYAIHWVRQAPGKGLEWVAVISFDGSDISYTESVQGRFTISRDNSENMLYLQMNSLRAEDTAMYYCAREPDGIGAAGISGYWGQGTLVTVSS,GIVLTQSPDSLAVSVGERATINCKSSQTVLYSSKNKHYLAWYQQKPGQPPKLLTSSPSTREPGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKVDIK,QKK35838,QKK35839,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_12_3_9,QKK35838_QKK35839,Unique source,SARS-CoV-2,2,1,14.881252,13.457788
QKK35566_QKK35567,EVQLLESGGGVVQPGTSLRLSCVASGFTFSTFAMHWVRQAPGKGLEWVALISFDSTNIRYANSVRGRFTISRDNSKNTLYLEVDSLRIEDTGVYYCARDLPPLDYWGQGTLVTVSS,DIRMTQSPFSLSASVGDRVTITCRASQGFGNRLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSETDFALTISSLQPEDVATYYCQKHDRDPWTFGQGTKVEIK,QKK35566,QKK35567,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_9_6_3_9,QKK35566_QKK35567,Unique source,SARS-CoV-2,2,1,14.817112,13.036177
QKK35776_QKK35777,EVQLLESGGHVVLPGKSLRLSCAGSGFGFPLYAMQWVRRAPGKGLEWVALVSYDSSNIRYADSVKGRFTISRDNSQNTLYLQMDSLRPEDTAMYYCARDNALQDGRPGYFDSWGQGTLVTVSS,DIRLTQSPATLSLSPGERATLSCRASQSINDYLGWYQHRPGQAPRLLIHDASTRAPGIPVRFSGSGSGTDFTLTISSLEPEDSAVYYCQQRFSWYNFGPGTKLEIK,QKK35776,QKK35777,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_8,QKK35776_QKK35777,Unique source,SARS-CoV-2,2,1,14.60111,13.30079
7WVM_A_B,EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR,7WVM_A,7WVM_B,The Complex Structure Of Pd-1 And Cemiplimab,The Complex Structure Of Pd-1 And Cemiplimab,Homo sapiens,"Lu,D.;Xu,Z.;Zhang,D.;Jiang,M.;Liu,K.;He,J.;Ma,D.;Ma,X.;Tan,S.;Gao,G.F.;Chai,Y.",PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy,10-FEB-2022,8_8_10_6_3_9,QPW38525_QPW38529,Xtal structure,PD1; PDCD1; SLEB2; hSLE1; CD279; PD-1,2,1,14.171487,9.4809475
QKK35666_QKK35667,EVQLLESGPGLLKPSETLSLTCTVSGDSVSSGNFYWSWVRRPPGKALEWIAYSHYTGGTNSDPSFMGRVTMSIDPSRNQFSLRLTSVAAADTAVYYCARTTSPLTYSGHWPLFDYWGQGSLVTVSS,DIQLTQSPATLSVSPGERATLSCRASQSVTKHLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSDTEFSLTISSLQSEDFAVYYCQQYYSWPPLTFGGGTKLEIK,QKK35666,QKK35667,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_18_6_3_10,QKK35666_QKK35667,Unique source,SARS-CoV-2,2,1,16.371872,-7.983979
QKK35858_QKK35859,EVQLLESGPGLVKPSETLSLTCTVSGGSINSQYWNWIRQSPGKGLEWIGYVYYSGSTNYNPSLKSRVTMSVDTSKNHFSLNLRSVTAADTAVYYCARGLVVRYFDGFPSGPIIGAFDIWNQGTTVTVSS,ETTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAFNRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRTSTLTFGGGTKVDIK,QKK35858,QKK35859,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_23_6_3_8,QKK35858_QKK35859,Unique source,SARS-CoV-2,2,1,16.00731,-7.9197307
QKK35862_QKK35863,EVQLLESGPGLVKPSETLSLTCTVSGGSISSNNLYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVIIPVDTSKDQFSLRLSSVTAADTAVYYCARHSQKDIVLIPAAQSPIFDYWGQGTLVTVSS,QSVLTQPPSVSATPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL,QKK35862,QKK35863,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_21_8_3_11,QKK35862_QKK35863,Unique source,SARS-CoV-2,2,1,16.801523,-7.948744
QKK35740_QKK35741,EVQLLESGPGLVKPSQTLSLTCTVSNGFISSGEYYWSWIRQSPGKGLEWIGYISHSGSTYYNRSLKSRVTISLDTSRNQFSLNLSSVTAADTAVYYCARDLAKWSYGYYYSGMDVWGQGTTVTVSS,QPVLTQPPSASGTPGQRVTISCSGSYSNIGTNPANWYQQLPGTAPKLLIYNNDQRPSGVPDRFSGSKSGTSASLAISGLQSEDETDYYCATWDDSLNGVVFGGGTKLTVL,QKK35740,QKK35741,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_18_8_3_11,QKK35740_QKK35741,Unique source,SARS-CoV-2,2,1,16.373442,-8.0854025
4ZS6_C_D,EVQLLETGGGLVKPGGSLRLSCAASGFSLSDYYMNWIRQAPGKGLEWVAYISSSSGYTNYGDSVKGRFTISRDHAKNSLYLQMNSLRVEDTAVYYCVRDRDDFWSGYYKHWGLGTLVTVSS,IRMTQSPSFLSASVGDRVTITCRASQDINSFLAWYQQRPGKAPKLLIYGASNLETGVPSRFSGGGSGTDFTLTISSLQPEDIATYYCQQYDKLPTFGQGTRLEIK,4ZS6_C,4ZS6_D,Receptor Binding Domain And Fab Complex,Receptor Binding Domain And Fab Complex,Middle East respiratory syndrome-related coronavirus,"Yu,X.;Zhang,S.;Jiang,L.;Cui,Y.;Li,D.;Wang,D.;Wang,N.;Fu,L.;Shi,X.;Li,Z.;Zhang,L.;Wang,X.",Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27,13-MAY-2015,8_8_14_6_3_8,4ZS6_C_D,Xtal structure,MERS; CoV,2,1,15.881896,9.632852
6KTR_A_B,EVQLLETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDNWQELLFDYWGQGTLVTVSS,QAGLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQTEDEADYYCSSWTRSSGLVFGGGTQLTVL,6KTR_A,6KTR_B,Crystal Structure Of Fibroblast Growth Factor 19 In Complex With Fab,Crystal Structure Of Fibroblast Growth Factor 19 In Complex With Fab,Homo sapiens,"Liu,H.;Zheng,S.;Hou,X.;Liu,X.;Du,K.;Lv,X.;Li,Y.;Yang,F.;Li,W.;Sui,J.",Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects,28-AUG-2019,8_8_12_9_3_10,6KTR_A_B,Xtal structure,,2,1,14.215568,9.701692
6WJU_H_L,EVQLLQSGAELVRSGASVKLSCTASGFNIEDYYMHWMKQRPEQGLEWIGWIDPVNGDTEYAPKFQGKATMTADTSSNTAYLHLNSLTSEDTAVYYCNFYDGYLFAFWGQGTLVTVSA,DIVLTQAAPSVPVTPGESVSISCRSSKSLLHSDGNTYLYWLLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTVFTLRISRLEAEDVGIYYCMQHLEYPFTFGGGTKLEIK,6WJU_H,6WJU_L,Fab Fragment Of Anti-Human Lag3 Antibody (4A10),Fab Fragment Of Anti-Human Lag3 Antibody (4A10),Mus musculus,"Agnihotri,P.;Mishra,A.K.;Mariuzza,R.A.",Fab Fragment of Anti-human LAG3 antibody,14-APR-2020,8_8_10_11_3_9,QBE26290_QBE26294,Xtal structure,CD223; LAG3,2,1,-4.909224,0.36382768
CAO78302,EVQLLQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDSPQNCTNGVCHRGSHVHYYGMDVWGQGTLVTVSS,QSALTQPASAAGCLGQSVTISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYDVNKRPSGVPDRFFASKSGNTASLTVSGLQADDEADYYCASYAGTYSYVFGTGTQLTVL,CAO78302_H,CAO78302_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_26_9_3_10,AEN51971,Same entry,,2,1,2.1790137,3.4615283
CAO78306,EVQLLQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAGQEAHGDGMDVWGQGTTVTVSS,QSALTQPASASGSPGQSITISCTGTSGDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGSTASLTISGLQAEDEADYYCVSYTSRNTYVFGSGTQLTVL,CAO78306_H,CAO78306_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_12_9_3_10,AEN51975,Same entry,,2,1,2.084825,3.7337348
CAO78316,EVQLLQSGAEVKKPGASVRVSCQASGYTFSRYHMHWVRQAPGQGLEWMGVIDPNSGRVSYSQKFQDRVTMTRDTFTSTVYMELNSLRSEDTAVYYCARDRGYCNGGRCFMDAFDYWGQGTTVTVSS,YVLTQPPSASGAPGQRVTISCSGSNSNIGRNWVYWYQQLPGTAPKLLMFRNNERSSGVPDRFSGSKTGTSASLAISGLRSEDEGDYYCASWDDSLHAWVFGGGTQLTVL,CAO78316_H,CAO78316_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_19_8_3_11,AEN51982,Same entry,,2,1,1.7905047,3.6368191
CAO78320,EVQLLQSGGGVVQPGRSLRLSCAASGFSFSNYVMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMKGLRPEDTAVYYCARSSGWYLLFDAFDIWGQGTMVTVSS,DVVMTQSPDSLAVSLGERATINCESSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSETDFTLTISSLQAEDVAVYYCQQYYRIPWTFGQGTKVDIK,CAO78320_H,CAO78320_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_15_12_3_9,AEN51969,Same entry,,2,1,14.589401,13.510732
CAO78315,EVQLLQSGGGVVRPGGSLRLSCAASGFTFDDYGMTWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFAISRDNSKNTLYLQMNSLRAEDTAVYYCAKSRYYDSSGYYYTVRPDAFDIWGQGAMVTVSS,SELTQPPSVSVSPGQTAIITCSGDKLGDKYASWYQHRPGQSPVLVIYQDSRRPSDIPERFSGSNSGNTATLTITEAQALDEADYYCQAWAGRSVVFGGGTQLTVL,CAO78315_H,CAO78315_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_22_6_3_9,AEN51981,Same entry,,2,1,14.114265,9.815294
1P2C_B_A,EVQLQESGAELMKPGASVKISCKATGYTFTTYWIEWIKQRPGHSLEWIGEILPGSDSTYYNEKVKGKVTFTADASSNTAYMQLSSLTSEDSAVYYCARGDGFYVYWGQGTTLTVSS,DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYTSQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSGSWPRTFGGGTKLDIK,1P2C_B,1P2C_A,Crystal Structure Analysis Of An Anti-Lysozyme Antibody,Crystal Structure Analysis Of An Anti-Lysozyme Antibody,Gallus gallus,"Goldbaum,F.A.;Cauerhff,A.;Velikovsky,C.A.;Llera,A.S.;Riottot,M.M.;Poljak,R.J.",Lack of significant differences in association rates and affinities of antibodies from short-term and long-term responses to hen egg lysozyme,15-APR-2003,8_8_9_6_3_9,1P2C_B_A,Xtal structure,Lysozyme,2,1,4.9753537,-1.8708488
7BH8_G_H,EVQLQESGPELVKPGASVKIPCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNGGTIYNQKFKGKATLTVDKSSSTAYMELRSLTSEDTAVYYCARPDYYGSSYGWYFDVWGTGTTVTVSS,DIVITQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPLTFGAGTKLELK,7BH8_G,7BH8_H,3H4-Fab Hla-E-Vl9 Co-Complex,3H4-Fab Hla-E-Vl9 Co-Complex,Homo sapiens,"Li,D.;Brackenridge,S.;Walters,L.C.;Swanson,O.;Harlos,K.;Rozbesky,D.;Cain,D.W.;Wiehe,K.;Scearce,R.M.;Barr,M.;Mu,Z.;Parks,R.;Quastel,M.;Edwards,R.J.;Wang,Y.;Rountree,W.;Saunders,K.O.;Ferrari,G.;Borrow,P.;Jones,E.Y.;Alam,S.M.;Azoitei,M.L.;Gillespie,G.M.;McMichael,A.J.;Haynes,B.F.",Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity,10-JAN-2021,8_8_16_6_3_9,7BH8_G_H,Xtal structure,HLA-E,2,1,2.4136403,-4.292948
CAF32629_CAF32628,EVQLQESGPELVKPGASVKMSCKASGYTFPSYVLHWVKQKPGQGLEWIGYINPYNDGTQYNEKFKGKATLTSDKSSSTAYMELSRLTSEDSAVYYCARGFGGSYGFAYWGQGTLITVSA,DIVMTQSPAIMSASPGEKVTMTCSASSSVSSSYLYWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWNRYPYTFGGGTKLEIK,CAF32629,CAF32628,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Gold,D.V.; Goldenberg,D.M.; Hansen,H.",Monoclonal antibody pam4 and its use for diagnosis and therapy ofpancreatic cancer,01-MAR-2004,8_8_12_7_3_9,CAF32629_CAF32628,Unique chain,,2,1,0.97222114,-3.7911928
QKK35610_QKK35611,EVQLQESGPGLLKPSETLSLTCTVSGSPIASNYWSWVRQPAGKGLEWIGRIDTSPTTDYNPSLKSRVIMSVDTSTSQFSLKMSSVTAADTAVYYCTRSFISFDSSGHPYYYYAMDVWGQGTTVTVSS,EIVMTQSPGTLSLSPGERVTLSCRATQSVSNNHLAWYQQKPGQAPRLLIYGASTTATDIPDRFSGRVAGTDFTLTISRLDPEDFAVYYCHQYGSSPWTFGQGTKVEIK,QKK35610,QKK35611,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_21_7_3_9,QKK35610_QKK35611,Unique source,SARS-CoV-2,2,1,15.701404,-7.9724627
QKK35746_QKK35747,EVQLQESGPGLVKPSETLSLTCAVSGGSVSSDTDYWGWIRQPPGKGLEWIGSIHDSERTYYDPSLKSRVTISVDTSKNQFSLRLSSVTAADTALYFCASRHLDLLPIGSFDVWGRGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKTGKAPELLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYRFPITFGQGTRLEIK,QKK35746,QKK35747,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_15_6_3_9,QKK35746_QKK35747,Unique source,SARS-CoV-2,2,1,16.71008,-8.001293
QKK35534_QKK35535,EVQLQESGPGLVKPSGTLSLTCGVSGVSISSSSWWSWVRQPPGRGLEWIGEISPSGSTSYNPSFRSRLTMSVDKSRNQLSLKLSSVTAADTAVYYCARTQSNDFWSGYYTAAFDLWGQGTMVTVSS,EIVLTQSPGTLSLSPGERASLSCRASQSVSSSYLAWYQHRPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLESEDFAVYYCQQYGNSPRTFGQGTKVDIK,QKK35534,QKK35535,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_19_7_3_9,QKK35534_QKK35535,Unique source,SARS-CoV-2,2,1,15.544585,-7.405047
1AY1_H_L,EVQLQESGPGLVKPYQSLSLSCTVTGYSITSDYAWNWIRQFPGNKLEWMGYITYSGTTDYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARYYYGYWYFDVWGQGTTLTVSS,DIQMTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDSTNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSTYPLTFGAGTKLELK,1AY1_H,1AY1_L,Anti Taq Fab Tp7,Anti Taq Fab Tp7,Mus musculus,"Murali,R.;Helmer-Citterich,M.;Sharkey,D.J.;Scalice,E.R.;Daiss,J.L.;Sullivan,M.A.;Krishna Murthy,H.M.",Structural studies on an inhibitory antibody against Thermus aquaticus DNA polymerase suggest mode of inhibition,13-NOV-1997,9_7_12_5_3_9,1AY1_H_L,Xtal structure,,2,1,11.513905,-12.877366
6PYD_A_B,EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGTTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARARYGYGFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNRNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGAGTKLELK,6PYD_A,6PYD_B,Structure Of 3E9 Antibody Fab Bound To Marinobufagenin,Structure Of 3E9 Antibody Fab Bound To Marinobufagenin,Mus musculus,"Fedorova,O.V.;Simbirtsev,A.S.;Kolodkin,N.I.;Kotov,A.Y.;Agalakova,N.I.;Kashkin,V.A.;Tapilskaya,N.I.;Bzhelyansky,A.;Reznik,V.A.;Frolova,E.V.;Nikitina,E.R.;Budny,G.V.;Longo,D.L.;Lakatta,E.G.;Bagrov,A.Y.","Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension",29-JUL-2019,8_7_11_11_3_9,6PYD_A_B,Xtal structure,marinobufagenin,2,1,10.742479,-12.821761
4KPH_I_M,EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNRLEYMGYINYSGNTFYNPSLKSRISITRDTSKNQYCLQLNSVTTEDTATYYCATYRFNYWGQGTLVTVSA,EIVLTQSPAIMSASLGEEITLTCSASSSVNYMHWYQQKSGTSPKLLIYTTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSSYPTFGGGTKLEIK,4KPH_I,4KPH_M,"Structure Of The Fab Fragment Of N62, A Protective Monoclonal Antibody To The Nonreducing End Of Francisella Tularensis O-Antigen","Structure Of The Fab Fragment Of N62, A Protective Monoclonal Antibody To The Nonreducing End Of Francisella Tularensis O-Antigen",Mus musculus,"Lu,Z.;Rynkiewicz,M.J.;Yang,C.Y.;Madico,G.;Perkins,H.M.;Wang,Q.;Costello,C.E.;Zaia,J.;Seaton,B.A.;Sharon,J.",The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide,13-MAY-2013,8_7_7_5_3_8,4KPH_I_M,Xtal structure,,2,1,10.698336,-12.81343
1NAK_H_L,EVQLQESGPSLVKPSQTLSLTCSVTGVSITSGYWNWIRKFPGNKFEYMGYISKSGSAYYNPSLKSRISFTRDTSKNQFYLKLNSVTTEDTATYYCAIDDFDIWGAGTTVTVSS,DVVMTQSPVSLPVSLGDQASISCRSSQSLGHSSGNTYLHWFLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTFKISRVEAEDLGVYFCFQTTHDPYTFGGGTKLEIK,1NAK_H,1NAK_L,Igg1 Fab Fragment (83.1) Complex With 16-Residue Peptide (Residues 304-321 Of Hiv-1 Gp120 (Mn Isolate)),Igg1 Fab Fragment (83.1) Complex With 16-Residue Peptide (Residues 304-321 Of Hiv-1 Gp120 (Mn Isolate)),synthetic construct,"Stanfield,R.L.;Ghiara,J.B.;Ollmann Saphire,E.;Profy,A.T.;Wilson,I.A.",Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop,27-NOV-2002,8_7_7_11_3_9,1NAK_H_L,Xtal structure,gp120,2,1,10.705447,-12.817071
6LGW_C_D,EVQLQQFGAELVKPGASVKISCKASGYTFTDYNMDWVKQSHGKSLQWIGDISPYYGSTGYSQKFKGKATLTVDRSSSTAYMELRSLTSEDTAVYYCARRNYDGSWFAYWGQGTLVTVSS,ELVMTQSPAILSVSPGERVSFSCRASQIIGTSIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLTINSVESDDIADYYCQQSNSWPVTFGAGTKLELK,6LGW_C,6LGW_D,Structure Of Rabies Virus Glycoprotein In Complex With Neutralizing Antibody 523-11 At Acidic Ph,Structure Of Rabies Virus Glycoprotein In Complex With Neutralizing Antibody 523-11 At Acidic Ph,Lyssavirus rabies,"Yang,F.;Lin,S.;Ye,F.;Yang,J.;Qi,J.;Chen,Z.;Lin,X.;Wang,J.;Yue,D.;Cheng,Y.;Chen,Z.;Chen,H.;You,Y.;Zhang,Z.;Yang,Y.;Yang,M.;Sun,H.;Li,Y.;Cao,Y.;Yang,S.;Wei,Y.;Gao,G.F.;Lu,G.",Structural Analysis of Rabies Virus Glycoprotein Reveals pH-Dependent Conformational Changes and Interactions with a Neutralizing Antibody,06-DEC-2019,8_8_12_6_3_9,6LGW_C_D,Xtal structure,Rabies,2,1,2.556422,-4.123177
5EPM_A_B,EVQLQQPGAELLRPGASVKLSCKASGYTFTNFWMNWVKQRPGQGLELIGMIDPSDSETHYNQMFKDKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARRDYYGILFDYWGQGTTVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHNNGNTYIEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK,5EPM_A,5EPM_B,Ceratotoxin Variant In Complex With Specific Antibody Fab Fragment,Ceratotoxin Variant In Complex With Specific Antibody Fab Fragment,Mus musculus,"Shcherbatko,A.;Rossi,A.;Foletti,D.;Zhu,G.;Bogin,O.;Galindo Casas,M.;Rickert,M.;Hasa-Moreno,A.;Bartsevich,V.;Crameri,A.;Steiner,A.R.;Henningsen,R.;Gill,A.;Pons,J.;Shelton,D.L.;Rajpal,A.;Strop,P.",Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain,11-NOV-2015,8_8_12_11_3_9,5EPM_A_B,Xtal structure,SCN9A; PN1; NENA; NE-NA; ETHA; Nav1.7,2,1,-0.39134732,-3.6303413
5IKC_B_A,EVQLQQSGADLVRPGASVKLSCTASGFDIKDDYVHWVKQRPEQGLEWIGRIDPANGATKYAPKFQDKATLTADTSSNTAYLQLSSLTSEDTAVYYCGRSKYFDSWGQGTTLTVSS,DIVMTQSQKLMSTSVGDRVSITCKASQIVDTAVAWYQQKPGQSPKPLIYLASNRHTGVPDRFTGSGSGTDFTLTINNVQSDDLADYFCLQHWNYPLTFGAGTKLELK,5IKC_B,5IKC_A,X-Ray Strucure Of The N-Terminal Domain Of Human Doublecortin In Complex With Fab,X-Ray Strucure Of The N-Terminal Domain Of Human Doublecortin In Complex With Fab,Homo sapiens,"Burger,D.;Stihle,M.;Sharma,A.;Di Lello,P.;Benz,J.;D'Arcy,B.;Debulpaep,M.;Fry,D.;Huber,W.;Kremer,T.;Laeremans,T.;Matile,H.;Ross,A.;Rufer,A.C.;Schoch,G.;Steinmetz,M.O.;Steyaert,J.;Rudolph,M.G.;Thoma,R.;Ruf,A.",Crystal Structures of the Human Doublecortin C- and N-terminal Domains in Complex with Specific Antibodies,03-MAR-2016,8_8_8_6_3_9,5IKC_B_A,Xtal structure,SH3YL1; DKFZP586F1318; Ray,2,1,-4.69833,0.15808655
4OTX_H_L,EVQLQQSGAELARPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLEWIGAIYPGDGDTRYTQKFKGKATLTADKSSSTAYMQLSSLASEDSAVYYCARRWDYWGQGTTLTVSS,QIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLELK,4OTX_H,4OTX_L,Structure Of The Anti-Francisella Tularensis O-Antigen Antibody N203 Fab Fragment,Structure Of The Anti-Francisella Tularensis O-Antigen Antibody N203 Fab Fragment,Mus musculus,"Lu,Z.;Rynkiewicz,M.J.;Yang,C.Y.;Madico,G.;Perkins,H.M.;Roche,M.I.;Seaton,B.A.;Sharon,J.",Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity,14-FEB-2014,8_8_6_12_3_9,4OTX_H_L,Xtal structure,Francisella,2,1,0.41213334,-3.8407748
1Q0X_H_L,EVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGDTIFNEKFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCARWVLDYYGMDYWGQGTSLTVSS,AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWSNNKLVFGGGTKLTVL,1Q0X_H,1Q0X_L,Anti-Morphine Antibody 9B1 Unliganded Form,Anti-Morphine Antibody 9B1 Unliganded Form,Mus musculus,"Pozharski,E.;Wilson,M.A.;Hewagama,A.;Shanafelt,A.B.;Petsko,G.;Ringe,D.",Anchoring a cationic ligand: the structure of the Fab fragment of the anti-morphine antibody 9B1 and its complex with morphine,17-JUL-2003,8_8_12_9_3_9,1Q0X_H_L,Xtal structure,Morphine; morphine,2,1,5.0202403,-1.8492603
6BPA_E_F,EVQLQQSGAELVKPGASVKLSCTASGFNIKDHFMHWVKQRTAQGLEWIGRIDPEDGETKYAPKFQGTATITADTSSNTAYLQLSSLTSEDTAVYYCARSGSVSSPWFAYWGQGTLVTVSA,ETTVTQSPASLSMALGEKVTIRCITSTDIDDDLNWYQLKPGEPPKLLISEGNTLRPGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSDNLPLTFGAGTKLELK,6BPA_E,6BPA_F,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Monoclonal Antibody 3E9,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Monoclonal Antibody 3E9,Mus musculus,"Gruszczyk,J.;Huang,R.K.;Chan,L.J.;Menant,S.;Hong,C.;Murphy,J.M.;Mok,Y.F.;Griffin,M.D.;Pearson,R.D.;Wong,W.;Cowman,A.F.;Yu,Z.;Tham,W.H.",Cryo-EM structure of an essential Plasmodium vivax invasion complex,22-NOV-2017,8_8_13_6_3_9,6BPA_E_F,Xtal structure,,2,1,-4.777437,0.21282056
4K2U_I_M,EVQLQQSGAELVKPGASVKLSCTASGFNIKDNYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARHYDGYFLYYFEYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTITCRAGQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGSTFPWTFGGGTKLEIK,4K2U_I,4K2U_M,Crystal Structure Of Pfeba-175 F1 In Complex With R218 Antibody Fab Fragment,Crystal Structure Of Pfeba-175 F1 In Complex With R218 Antibody Fab Fragment,Mus musculus,"Chen,E.;Paing,M.M.;Salinas,N.;Sim,B.K.;Tolia,N.H.",Structural and functional basis for inhibition of erythrocyte invasion by antibodies that target Plasmodium falciparum EBA-175,09-APR-2013,8_8_14_6_3_9,4K2U_I_M,Xtal structure,,2,1,-4.7024355,0.17992547
7PI7_E_F,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIDPANGNTYSDPKFQDKATIKADTSSNTAYLQLSSLTSEDTAVYYCARDVLYFDVWGAGTTVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDRTFGGGTKLEIE,7PI7_E,7PI7_F,Pfcyrpa Bound To Monoclonal Antibody Cy.002 Fab Fragment,Pfcyrpa Bound To Monoclonal Antibody Cy.002 Fab Fragment,Gallus gallus,"Ragotte,R.J.;Pulido,D.;Lias,A.M.;Quinkert,D.;Alanine,D.G.W.;Jamwal,A.;Davies,H.;Nacer,A.;Lowe,E.D.;Grime,G.W.;Illingworth,J.J.;Donat,R.F.;Garman,E.F.;Bowyer,P.W.;Higgins,M.K.;Draper,S.J.",Heterotypic interactions drive antibody synergy against a malaria vaccine candidate,19-AUG-2021,8_8_9_10_3_8,7PI7_E_F,Xtal structure,,2,1,-4.67035,0.14215732
3WKM_H_L,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYLHWVKQRPEHGLEWIGRIDPANGNAKYDPKFQDKATITADTSSNTAYLQLNSLTSEDTAVYYCSNRQLGLRGYYYAMDYWGQGTSVSVSS,IVLTQSPVSLAVSLGQRATISCRASESVDSYGDSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK,3WKM_H,3WKM_L,The Periplasmic Pdz Tandem Fragment Of The Rsep Homologue From Aquifex Aeolicus In Complex With The Fab Fragment,The Periplasmic Pdz Tandem Fragment Of The Rsep Homologue From Aquifex Aeolicus In Complex With The Fab Fragment,Mus musculus,"Hizukuri,Y.;Oda,T.;Tabata,S.;Tamura-Kawakami,K.;Oi,R.;Sato,M.;Takagi,J.;Akiyama,Y.;Nogi,T.",A Structure-Based Model of Substrate Discrimination by a Noncanonical PDZ Tandem in the Intramembrane-Cleaving Protease RseP,28-OCT-2013,8_8_16_10_3_9,3WKM_H_L,Xtal structure,,2,1,-4.680692,0.14168479
5AZ2_H_L,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPLNDKTKYDPKFQGKATITADTSSNSAYLQLSSLTSEDTAVYYCSRGGGDPVFVYWGQGTLVTVSA,DIQMTQSPSSLSASLGGKVTITCKASQDINKYIAWYQHKPGKGPRLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLRTFGGGTKLEIK,5AZ2_H,5AZ2_L,"Crystal Structure Of The Fab Fragment Of 9E5, A Murine Monoclonal Antibody Specific For Human Epiregulin","Crystal Structure Of The Fab Fragment Of 9E5, A Murine Monoclonal Antibody Specific For Human Epiregulin",Mus musculus,"Kado,Y.;Mizohata,E.;Nagatoishi,S.;Iijima,M.;Shinoda,K.;Miyafusa,T.;Nakayama,T.;Yoshizumi,T.;Sugiyama,A.;Kawamura,T.;Lee,Y.H.;Matsumura,H.;Doi,H.;Fujitani,H.;Kodama,T.;Shibasaki,Y.;Tsumoto,K.;Inoue,T.","Epiregulin Recognition Mechanisms by Anti-epiregulin Antibody 9E5: STRUCTURAL, FUNCTIONAL, AND MOLECULAR DYNAMICS SIMULATION ANALYSES",16-SEP-2015,8_8_11_6_3_8,5AZ2_H_L,Xtal structure,epiregulin,2,1,-4.707497,0.17804858
S29594_S29593,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPKQGLEWIGRIDPANGYTEYDPKFQGKATITADTSTNTAYLQLSSLTSEDTAVYYCTGGNYAYGMDYWGQGTSVTVSS,DIVMTQAAPSIPVTPGESASISCRSSKSLLHSNGDTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTSFTLRISRVEAEDVGFYFCMQHLEYPYTFGGGTKLEIK,S29594,S29593,Ig gamma chain (WM65) - mouse (fragment),Ig kappa chain (WM65) - mouse (fragment),Mus musculus,"Seymour,R.",Direct Submission,11-Jan-2000,8_8_11_11_3_9,S29594_S29593,Unique chain,,2,1,-4.728409,0.18942522
6BIT_J_L,EVQLQQSGAELVKPGASVKLSCTASGFNIKDYYIHWVQQRTEQGLEWIGRIDPEDGETKYAPKFQDKATITADTSSNTAYLHLSSLTSEDTAVYYCARWGAYWGQGTLVTVSA,EIVLTQSPAIMSASPGEKVTLTCASSSVSSSYLYWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWSSYPRTFGAGTKLELK,6BIT_J,6BIT_L,Sirpalpha Antibody Complex,Sirpalpha Antibody Complex,Homo sapiens,"Ring,N.G.;Herndler-Brandstetter,D.;Weiskopf,K.;Shan,L.;Volkmer,J.P.;George,B.M.;Lietzenmayer,M.;McKenna,K.M.;Naik,T.J.;McCarty,A.;Zheng,Y.;Ring,A.M.;Flavell,R.A.;Weissman,I.L.",Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity,03-NOV-2017,8_8_6_7_3_9,6BIT_J_L,Xtal structure,SHPS-1; SIRPalpha; SIRPalpha2; PTPNS1; SIRPA; SIRP; CD172a; SIRP-ALPHA-1; MFR; MYD-1; BIT; SHPS1; P84,2,1,-4.7819104,0.23192708
6R0X_C_D,EVQLQQSGAELVKPGASVKLSCTASGFNIKETYIHWVKQRPEQGLEWIGRIDPADVYGRYDPKFQGKATITADTSSNSAYLQVSSLTSEDTAVYYCARSYGSSYGIDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSTLHSGVPSRFSGSGSGTDYSLTISNLEQEDVATYFCQQGYTLPWTFGGGTKLEIK,6R0X_C,6R0X_D,The Extracellular Domain Of G6B-B In Complex With Fab Fragment And Dp12 Heparin Oligosaccharide.,The Extracellular Domain Of G6B-B In Complex With Fab Fragment And Dp12 Heparin Oligosaccharide.,Homo sapiens,"Vogtle,T.;Sharma,S.;Mori,J.;Nagy,Z.;Semeniak,D.;Scandola,C.;Geer,M.J.;Smith,C.W.;Lane,J.;Pollack,S.;Lassila,R.;Jouppila,A.;Barr,A.J.;Ogg,D.J.;Howard,T.D.;McMiken,H.J.;Warwicker,J.;Geh,C.;Rowlinson,R.;Abbott,W.M.;Eckly,A.;Schulze,H.;Wright,G.J.;Mazharian,A.;Futterer,K.;Rajesh,S.;Douglas,M.R.;Senis,Y.A.",Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B,13-MAR-2019,8_8_12_6_3_9,6R0X_C_D,Xtal structure,C6orf25; platelet; MPIG6B; G6b-B; G6b; NG31,2,1,-4.7279687,0.18751991
CDM22131_CDM22132,EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK,CDM22131,CDM22132,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"ENDO,K.; KUHURA,M.; YAGI,K.; NAKAMURA,Y.; KATAGIRI,T.; NAKATSURU,S.",Tumor-targeting monoclonal antibodies to FZD10 and uses thereof,03-FEB-2014,8_8_11_6_3_9,CDM22131_CDM22132,Ordered entries,FZD10; CD350,2,1,-4.700083,0.16327506
1JNL_H_L,EVQLQQSGAELVKPGASVRLSCSASGFNIKDTYMFWVKQRPEQGLDWIGRINPANGISKYDPRFQGKATLTADTSSNTAYLQLDNLTSEDTAVYYCAIEKDLPWGQGTLVTVS,QIVMTQTPASLSASVGETVTITCRASGNIYNYLAWYQQKQGKSPQLLVYNAKTLVDGVPLRFSGSGSGTQYSLKINSLQPEDFGNYYCHHFWNTPYTFGGGTKLEIK,1JNL_H,1JNL_L,Crystal Structure Of Fab-Estradiol Complexes,Crystal Structure Of Fab-Estradiol Complexes,Mus musculus,"Monnet,C.;Bettsworth,F.;Stura,E.A.;Le Du,M.H.;Menez,R.;Derrien,L.;Zinn-Justin,S.;Gilquin,B.;Sibai,G.;Battail-Poirot,N.;Jolivet,M.;Menez,A.;Arnaud,M.;Ducancel,F.;Charbonnier,J.B.",Highly specific anti-estradiol antibodies: structural characterisation and binding diversity,24-JUL-2001,8_8_7_6_3_9,1JNL_H_L,Xtal structure,estradiol,2,1,-4.7390795,0.18452461
5W5Z_H_L,EVQLQQSGAELVKPGSSVKISCKASGYTFTNYDMHWIKQRPGSGLEWIGWIYPGNGNTKYNQKFNGKATLTADKSSTTAYMQLSSLTSEDSAVYFCVREGLGITFEYWGQGVKVTVSS,DIQMTQSPSFLSASVGDRVTINCKASQNVNKYLDWYQQNLGEPPKLLIYHTNSLPTGIPSRFSGSGSGTDFTLTISSLQVEDVATYFCLQHDSGLTFGSGTKLEIK,5W5Z_H,5W5Z_L,Crystal Structure Of Baxp168G In Complex With An Activating Antibody At High Resolution,Crystal Structure Of Baxp168G In Complex With An Activating Antibody At High Resolution,Homo sapiens,"Robin,A.Y.;Iyer,S.;Birkinshaw,R.W.;Sandow,J.;Wardak,A.;Luo,C.S.;Shi,M.;Webb,A.I.;Czabotar,P.E.;Kluck,R.M.;Colman,P.M.",Ensemble Properties of Bax Determine Its Function,16-JUN-2017,8_8_11_6_3_8,5W5Z_H_L,Xtal structure,,2,1,0.17276676,-4.381378
6DC9_H_L,EVQLQQSGAELVQPGASVKLSCTASGFNIKDTSMHWVRQRPEQGLEWIGRIAPANGNTKYDPKFQGKATITTDTSSNTAYLQLSSLTSEDTAVYYCSGSGNYDWGQGTTLTVSS,DIQMNQSPSSLSASLGDTITISCHASQNINVWLSWYQQKPGNIPKLLIYEASTLYTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQGQSYPWTFGGGTKLEIK,6DC9_H,6DC9_L,Fab/Epitope Complex Of Human Chimeric Monoclonal Antibody H4E6 Targeting A Phosphorylated Tau Epitope.,Fab/Epitope Complex Of Human Chimeric Monoclonal Antibody H4E6 Targeting A Phosphorylated Tau Epitope.,Homo sapiens,"Chukwu,J.E.;Congdon,E.E.;Sigurdsson,E.M.;Kong,X.P.",Structural characterization of monoclonal antibodies targeting C-terminal Ser(404) region of phosphorylated tau protein,04-MAY-2018,8_8_7_6_3_9,6DC9_H_L,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,2,1,-4.6808214,0.1495779
7SWW_H_L,EVQLQQSGAELVRPGALVKLSCKASGFNIKDYFVHWVKQRPVQGLEWIGWIDPENGNTIYGPKFQGKASLAADTSSNTGYLQLSSLTSEDTAVYYCARWDGYETLDYWGQGTSVTVS,DIVMSQSPSSLAVSVGEKVTMSCQSSQSLLYSNNEKNYLAWYQQKPGHSPKLLLYWASTRESGVPDRFTGSGSGTAFTLTISSVKAEDLAVYYCQQYYNYPYTFGGGTKLEI,7SWW_H,7SWW_L,Sars-Cov-2 Spike Ntd In Complex With Neutralizing Fab Sars2-57 (Local Refinement),Sars-Cov-2 Spike Ntd In Complex With Neutralizing Fab Sars2-57 (Local Refinement),Mus musculus,"Adams,L.J.;VanBlargan,L.A.;Liu,Z.;Gilchuk,P.;Zhao,H.;Chen,R.E.;Raju,S.;Whitener,B.;Shrihari,S.;Jethva,P.N.;Gross,M.L.;Crowe,J.E.;Whelan,S.P.J.;Diamond,M.S.;Fremont,D.H.",A protective antibody targeting the N-terminal domain of SARS-CoV-2 spike recognizes most emerging variants,23-NOV-2022,8_8_11_12_3_9,7SWW_H_L,Xtal structure,SARS-CoV-2,2,1,-4.807057,0.2672126
BDZ85386_BDZ85451,EVQLQQSGAELVRPGASVKLSCTASGFIIKDSLMHWVKQRPEQGLEWIGWIDPEDGETKYAPKFQDKATVTADTSSNTAYLQLSSLTSEDTAIFYCTRDYYDGSPYALDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKVLIYGASNRYTGVPDRFTGSGSVTDFTLTISSVQAEDLADYYCGQSYSYPLTFGAGTKLELK,BDZ85386,BDZ85451,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85386_BDZ85451,Unique source,SARS-CoV-2,2,1,-5.1519647,0.39468846
7LKF_H_L,EVQLQQSGAELVRPGASVKLSCTASGFKIKDDYIHWVKQRPEQGLEWIGRIDPANGHTRYAPKFQDKATITADTSSNTAYLQLSSLTSEDTAVYYCTRYNDYDAFYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQTNTLPWTFGGGTKVEIK,7LKF_H,7LKF_L,Wt Chicken Scap L1-L7 / Fab 4G10 Complex Focused Refinement,Wt Chicken Scap L1-L7 / Fab 4G10 Complex Focused Refinement,Mus musculus,"Kober,D.L.;Radhakrishnan,A.;Goldstein,J.L.;Brown,M.S.;Clark,L.D.;Bai,X.C.;Rosenbaum,D.M.",Scap structures highlight key role for rotation of intertwined luminal loops in cholesterol sensing,02-FEB-2021,8_8_13_6_3_9,7LKF_H_L,Xtal structure,,2,1,-4.75506,0.21512005
S04576_S04573,EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMHWVKQRPEQGLEWIGWIDPENGDTQYASKFQGKATMTADTSSNTTYLQLSSLTSEDTAVYYCTTYGAYAMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSSKYLNWYQQRSGASPKLWIYGTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYHSDPLTFGAGTKLELK,S04576,S04573,Ig heavy chain precursor V region (MRL-histone 7H) - mouse (fragment),Ig kappa chain precursor V region (MRL-histone 7L) - mouse (fragment),Mus musculus,"Kofler,R.; Noonan,D.J.; Strohal,R.; Balderas,R.S.; Moller,N.P.; Dixon,F.J.; Theofilopoulos,A.N.",Molecular analysis of the murine lupus-associated anti-self response: involvement of a large number of heavy and light chain variable region genes,21-JAN-2000,8_8_10_7_3_9,S04576_S04573,Ordered entries,,2,1,-4.9771957,0.37676486
BDZ85362_BDZ85427,EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDPEDGETKYAPKFQGKATLTADASSNTAYLQLSSLTSEDTAIYYCARDYYGGSPYAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGSYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLVDYYCGQSYSYPLTFGAGTKLELK,BDZ85362,BDZ85427,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85362_BDZ85427,Unique source,SARS-CoV-2,2,1,-5.126889,0.38092205
BDZ85372_BDZ85437,EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDPEDGETKYAPKFRDKATVTSDTSSNTAYLQLSSLTSEDTAIYYCSRDYYAGSPYSMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKVLIYGASNRYTGVPDRFTGSGSVTDFTLTISSVQAEDLADYYCGQSYSYPLTFGAGTKLELK,BDZ85372,BDZ85437,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85372_BDZ85437,Unique source,SARS-CoV-2,2,1,-5.158876,0.39101404
BDZ85370_BDZ85435,EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVRQRPEQGLEWIGWIDPEDGETKYAPKFQDRATVTADTSSNTAYLQLSSLSSEDTAIYYCTRDYYDGSPYAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSVTAFTLTISSVQAEDLADYYCGQSYSYPLTFGAGTKLELK,BDZ85370,BDZ85435,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85370_BDZ85435,Unique source,SARS-CoV-2,2,1,-5.1479526,0.3809799
7EAM_H_L,EVQLQQSGAELVRPGASVKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIDPGDGDTEYDPSFQGKATITADTSSNTAYLELSSLTSEDTAVYYCTRFYDYVNYGMDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGSYYCQHFWSTPPWTFGGGTKLEVK,7EAM_H,7EAM_L,Immune Complex Of Sars-Cov-2 Rbd And Cross-Neutralizing Antibody 7D6,Immune Complex Of Sars-Cov-2 Rbd And Cross-Neutralizing Antibody 7D6,Mus musculus,"Li,T.;Xue,W.;Zheng,Q.;Song,S.;Yang,C.;Xiong,H.;Zhang,S.;Hong,M.;Zhang,Y.;Yu,H.;Zhang,Y.;Sun,H.;Huang,Y.;Deng,T.;Chi,X.;Li,J.;Wang,S.;Zhou,L.;Chen,T.;Wang,Y.;Cheng,T.;Zhang,T.;Yuan,Q.;Zhao,Q.;Zhang,J.;McLellan,J.S.;Zhou,Z.H.;Zhang,Z.;Li,S.;Gu,Y.;Xia,N.",Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants,07-MAR-2021,8_8_13_6_3_10,7EAM_H_L,Xtal structure,SARS-CoV-2,2,1,-4.7711544,0.2214124
8D0A_H_L,EVQLQQSGAELVRPGASVKLSCTGSGFNIKDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATMTADTSSNTAYLQLSSLTSEDTAVYYCARPDGYYGDYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSFPLTFGAGTKLELK,8D0A_H,8D0A_L,Crystal Structure Of Human Usp30 In Complex With A Covalent Inhibitor 829 And A Fab,Crystal Structure Of Human Usp30 In Complex With A Covalent Inhibitor 829 And A Fab,Mus musculus,"Song,X.;Butler,J.;Hao,Y.",TBD,01-FEB-2023,8_8_10_6_3_9,8D0A_H_L,Xtal structure,,2,1,-4.673585,0.1353438
5MYX_B_A,EVQLQQSGAELVRPGSSVKISCKASGYIFNNYWINWVKQRPGQGLEWIGQIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAREGYIVYWGQGTLVTVSA,DVVLTQTPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIYVVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCVQGTHFPFTFGSGTKLEIK,5MYX_B,5MYX_A,Structure Of Pyroglutamate-Abeta-Specific Fab C#24 In Complex With Human Abeta-Pe3-18,Structure Of Pyroglutamate-Abeta-Specific Fab C#24 In Complex With Human Abeta-Pe3-18,Homo sapiens,"Piechotta,A.;Parthier,C.;Kleinschmidt,M.;Gnoth,K.;Pillot,T.;Lues,I.;Demuth,H.U.;Schilling,S.;Rahfeld,J.U.;Stubbs,M.T.",Structural and functional analyses of pyroglutamate-amyloid-beta-specific antibodies as a basis for Alzheimer immunotherapy,30-JAN-2017,8_8_8_11_3_9,5MYX_B_A,Xtal structure,amyloid-beta; Abeta,2,1,0.19662726,-4.5448303
7VGR_D_C,EVQLQQSGAELVRPGSSVKISCKGSGYVFSNYWMNWVKQRPGQGLEWIGQIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCASGYLGENYVMDFWGQGTSVTVSS,DIVLTQSPASLTVSLGQRATISCRASESVDSFGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSSEDPYTFGGGTKLEIK,7VGR_D,7VGR_C,Sars-Cov-2 M Protein Dimer (Long Form) In Complex With Yn7756_1 Fab,Sars-Cov-2 M Protein Dimer (Long Form) In Complex With Yn7756_1 Fab,Severe acute respiratory syndrome coronavirus 2,"Zhang,Z.;Ohto,U.;Shimizu,T.",SARS-CoV-2 M protein dimer (long form) in complex with YN7756_1 Fab,03-AUG-2022,8_8_13_10_3_9,7VGR_D_C,Xtal structure,SARS-CoV-2,2,1,0.37272832,-4.6183953
BBE36239_BAQ55490,EVQLQQSGAELVRPGSSVKMSCKSSGYTFTSYGINWVKQRPGQGLEWIGYIYIGYGYIEYNEKFKGKATLTSDTSSRTAYMQLSSLTSEDSAIYFCARWGLIFAMDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGAGTKLELK,BBE36239,BAQ55490,IgE H chain [Mus musculus],IgE L chain kappa [Mus musculus],Mus musculus,"Nakakita,S.; Itoh,A.; Nakakita,Y.; Nonaka,Y.; Ogawa,T.; Nakamura,T.; Nishi,N.",Cooperative Interactions of Oligosaccharide and Peptide Moieties of a Glycopeptide Derived from IgE with Galectin-9,09-Jun-2018,8_8_11_11_3_9,BBE36239_BAQ55490,Unique chain,Galectin-9,2,1,-0.06384134,-4.4511604
2C1O_H_L,EVQLQQSGAELVRPGTSVKLSCKASGYSFTNYWMNWLRQRPGQGLDWIGMIHPSDSETRLNQKFKDKATLTVDRSSSTAYIQLSSPTSEDSAVYYCARDDYDGAFWGQGTLVTVSA,LVMTQSPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIYLVSKLDSGDPDRFTGSGSGTDFTLKISRVEAEDLGIYYCVQGSHFPPTFGAGTKLELK,2C1O_H,2C1O_L,Enaiihis Fab Fragment In The Free Form,Enaiihis Fab Fragment In The Free Form,Mus musculus,"Parkkinen,T.;Nevanen,T.K.;Koivula,A.;Rouvinen,J.",Crystal structures of an enantioselective fab-fragment in free and complex forms,19-SEP-2005,8_8_9_11_3_9,2C1O_H_L,Xtal structure,,2,1,-0.32645547,-3.587717
QKK35560_QKK35561,EVQLQQSGAEVKKPGSSVKVSCKASGGTSSTHAISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQDRVTITADESTSTAYMELSSLRSEDTAVYFCVRDGAYDSSGYYSTQWGQGTLVTVSS,DIVLTQTPATLSLSPGERATLSCRASQSVSNFLAWYQQKPGQPPRLLIYDASNRASGIAARFSGRGSGTDFTLTISSLEPEDFAVYYCQQRRNWPPMYTFGQGTKVEIK,QKK35560,QKK35561,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_11,QKK35560_QKK35561,Unique source,SARS-CoV-2,2,1,-0.59478855,5.8847494
6T3J_A_B,EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK,6T3J_A,6T3J_B,Dual Epitope Targeting By Anti-Dr5 Antibodies,Dual Epitope Targeting By Anti-Dr5 Antibodies,Homo sapiens,"Overdijk,M.B.;Strumane,K.;Beurskens,F.J.;Ortiz Buijsse,A.;Vermot-Desroches,C.;Vuillermoz,B.S.;Kroes,T.;de Jong,B.;Hoevenaars,N.;Hibbert,R.G.;Lingnau,A.;Forssmann,U.;Schuurman,J.;Parren,P.W.;de Jong,R.N.;Breij,E.C.",Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism,11-OCT-2019,8_8_11_6_3_9,6T3J_A_B,Xtal structure,KILLER; DR5; TRAILR2; TRICKB; CD262; TNFRSF10B; TRICK2A; TRAIL-R2,2,1,-4.6101427,0.14474715
3JBQ_H_L,EVQLQQSGAEVVRSGASVKLSCTASGFNIKDYYIHWVKQRPEKGLEWIGWIDEIGDTEYVPKFQGKATMTADTSSNTAYLQLSSLTSEDTAVYYCNAGHDYDRGRFPYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLMIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELK,3JBQ_H,3JBQ_L,"Domain Organization And Conformational Plasticity Of The G Protein Effector, Pde6","Domain Organization And Conformational Plasticity Of The G Protein Effector, Pde6",Mus musculus,"Zhang,Z.;He,F.;Constantine,R.;Baker,M.L.;Baehr,W.;Schmid,M.F.;Wensel,T.G.;Agosto,M.A.","Domain organization and conformational plasticity of the G protein effector, PDE6",17-SEP-2015,8_7_13_6_3_9,3JBQ_H_L,Xtal structure,,2,1,-4.8794146,0.35350868
1A6T_B_A,EVQLQQSGPDLVKPGASVKISCKASGYSFSTYYMHWVKQSHGKSLEWIGRVDPDNGGTSFNQKFKGKAILTVDKSSSTAYMELGSLTSEDSAVYYCARRDDYYFDFWGQGTSLTVSS,SVLSQSPAILSASPGEKVIMTCSPSSSVSYMQWYQQKPGSSPKPWIYSTSNLASGVPGRFSGGGSGTSFSLTISGVEAEDAATYYCQQYSSHPLTFGGGTKLELK,1A6T_B,1A6T_A,Fab Fragment Of Mab1-Ia Monoclonal Antibody To Human Rhinovirus 14 Nim-Ia Site,Fab Fragment Of Mab1-Ia Monoclonal Antibody To Human Rhinovirus 14 Nim-Ia Site,Mus musculus,"Che,Z.;Olson,N.H.;Leippe,D.;Lee,W.M.;Mosser,A.G.;Rueckert,R.R.;Baker,T.S.;Smith,T.J.",Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes,03-MAR-1998,8_8_10_5_3_9,1A6T_B_A,Xtal structure,rhinovirus,2,1,2.4519043,-4.17285
5XBM_E_D,EVQLQQSGPELEKPGASVKISCMASGYSFTGYNMNWVKQSNGKSLEWIGNIDPYYGDTRYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSRGSTSYFYGMDYWGQGTSVTVSS,DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFGSGTKLEIK,5XBM_E,5XBM_D,Structure Of Scarb2-Jl2 Complex,Structure Of Scarb2-Jl2 Complex,Homo sapiens,"Zhang,X.;Yang,P.;Wang,N.;Zhang,J.;Li,J.;Guo,H.;Yin,X.;Rao,Z.;Wang,X.;Zhang,L.",The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection,20-MAR-2017,8_8_15_6_2_9,5XBM_E_D,Xtal structure,LIMPII; HLGP85; LIMP-2; SR-BII; CD36L2; EV71; SCARB2,2,1,2.5278747,-4.0453796
1N4X_H_L,EVQLQQSGPELKKPGETVKISCKATNYAFTDYSMHWVKQAPGGDLKYVGWINTETDEPTFADDFKGRFAFSLDTSTSTAFLQINNLKNEDTATYFCVRDRHDYGEIFTYWGQGTTVTVSA,DILMTQTPLYLPVSLGDQASISCRSSQTIVHNNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSHFPPTFGGGTKLEI,1N4X_H,1N4X_L,Structure Of Scfv 1696 At Acidic Ph,Structure Of Scfv 1696 At Acidic Ph,Mus musculus,"Lescar,J.;Brynda,J.;Fabry,M.;Horejsi,M.;Rezacova,P.;Sedlacek,J.;Bentley,G.A.",Structure of a single-chain Fv fragment of an antibody that inhibits the HIV-1 and HIV-2 proteases,02-NOV-2002,8_8_13_11_3_9,1N4X_H_L,Xtal structure,HIV,2,1,-7.561807,6.127137
1SVZ_B_B,EVQLQQSGPELKKPGETVKISCKATNYAFTDYSMHWVKQAPGGDLKYVGWINTETDEPTFADDFKGRFAFSLDTSTSTAFLQINNLKNEDTATYFCVRDRHDYGEIFTYWGQGTTVTVSS,DILMTQTPLYLPVSLGDQASISCRSSQTIVHNNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSHFPPTFGGGTKLEIK,1SVZ_B,1SVZ_B,Crystal Structure Of The Single-Chain Fv Fragment 1696 In Complex With The Epitope Peptide Corresponding To N-Terminus Of Hiv-2 Protease,Crystal Structure Of The Single-Chain Fv Fragment 1696 In Complex With The Epitope Peptide Corresponding To N-Terminus Of Hiv-2 Protease,synthetic construct,"Rezacova,P.;Brynda,J.;Lescar,J.;Fabry,M.;Horejsi,M.;Sieglova,I.;Sedlacek,J.;Bentley,G.A.",Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide,30-MAR-2004,8_8_13_11_3_9,1JP5_A_A,Xtal structure,HIV,2,1,-7.5460424,6.1052933
CAX48945_CAX48947,EVQLQQSGPELVKPGASLKMSCKASGYSFTDYIILWVKQNHGKSLEWIGHIDPYYGSSNYNLKFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCGRSKRDYFDYWGQGTTLTVSS,DIQMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEIK,CAX48945,CAX48947,"unnamed protein product, partial [synthetic construct]",unnamed protein product [synthetic construct],synthetic construct,"Rother,R.P.; faas Mcknight,S.",Antibodies to cd200 and uses thereof in inhibiting immune responses,23-FEB-2009,8_8_10_6_3_9,AKX75106_AKX75112,Ordered entries,,2,1,2.578477,-3.9823902
5MYO_D_C,EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGVTRYNQKFKGKATLIVDKSSSTAYMELLSLTSEDSAVYYCTREAKREWDETYWGQGTLVTVSA,DVVMTQTPLTLSVTIGQPASISCKSSQSLLYSDGKTYLNWLLQRPGQSPMRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCVQGTHFPFTFGSGTKLEIK,5MYO_D,5MYO_C,Structure Of Pyroglutamate-Abeta-Specific Fab C#6 In Complex With Human Abeta-Pe3-12-Pegb,Structure Of Pyroglutamate-Abeta-Specific Fab C#6 In Complex With Human Abeta-Pe3-12-Pegb,Homo sapiens,"Piechotta,A.;Parthier,C.;Kleinschmidt,M.;Gnoth,K.;Pillot,T.;Lues,I.;Demuth,H.U.;Schilling,S.;Rahfeld,J.U.;Stubbs,M.T.",Structural and functional analyses of pyroglutamate-amyloid-beta-specific antibodies as a basis for Alzheimer immunotherapy,27-JAN-2017,8_8_12_11_3_9,AEU50432_AEU50431,Xtal structure,amyloid-beta; Abeta,2,1,2.3708172,-4.2235937
1XIW_H_G,EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWMGLINPYKGVSTYNQKFKDKATLTVDKSSSTAYMELLSLTSEDSAVYYCARSGYYGDSDWYFDVWGQGTTLTVF,DIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSKFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFAGGTKLEIK,1XIW_H,1XIW_G,Crystal Structure Of Human Cd3-E/D Dimer In Complex With A Ucht1 Single-Chain Antibody Fragment,Crystal Structure Of Human Cd3-E/D Dimer In Complex With A Ucht1 Single-Chain Antibody Fragment,Mus musculus,"Arnett,K.L.;Harrison,S.C.;Wiley,D.C.",Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment,22-SEP-2004,8_8_15_6_3_9,1XIW_H_G,Xtal structure,CD3epsilon; CD3E; CD3-epsilon,2,1,2.341939,-4.211288
7VGS_D_C,EVQLQQSGPELVKPGASMKISCKTSGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGDTSYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCEVINTYWGQGTLVTVSA,DIVMTQSPASLAVSLGQRATISCKASQSIDYDGDNYMNWYQQKPGQPPKLLIYTTSNLESGIPARFSGSGSGTDFTLNIHPVEEGDAATYYCQQNNEDPYTFGGGTKLEIK,7VGS_D,7VGS_C,Sars-Cov-2 M Protein Dimer (Short Form) In Complex With Yn7717_9 Fab,Sars-Cov-2 M Protein Dimer (Short Form) In Complex With Yn7717_9 Fab,Mus musculus,"Zhang,Z.;Ohto,U.;Shimizu,T.",SARS-CoV-2 M protein dimer (short form) in complex with YN7717_9 Fab,03-AUG-2022,8_8_6_10_3_9,7VGS_D_C,Xtal structure,SARS-CoV-2,2,1,2.3566282,-4.2135983
1PG7_Z_Y,EVQLQQSGPELVKPGASVKISCKASGYSFTGHLLNWVKQSHGKNLEWIGLVHPHNGAITYNQKFKDKATLTVDRSSTTAYIELVRLTSNDSAVYYCAREDFRYHYSMDYWGQGTSVTVSS,QAVVTQESALTSSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGVIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,1PG7_Z,1PG7_Y,Murine 6A6 Fab In Complex With Humanized Anti-Tissue Factor D3H44 Fab,Murine 6A6 Fab In Complex With Humanized Anti-Tissue Factor D3H44 Fab,Mus musculus,"Eigenbrot,C.;Meng,Y.G.;Krishnamurthy,R.;Lipari,M.T.;Presta,L.;Devaux,B.;Wong,T.;Moran,P.;Bullens,S.;Kirchhofer,D.",Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation,27-MAY-2003,8_8_13_9_3_9,1PG7_Z_Y,Xtal structure,,2,1,2.3261642,-4.1913753
CCM09770_CCM09769,EVQLQQSGPELVKPGASVKISCKASGYSFTGYYMNWVKQSPEKSLEWIGEMSPSTGRTTYNQNFKAKATLTVDQSSSTAYMQLKSLTSEDSAVYYCARSVPLTTLIEDWYFDVWGTGTTVTVSS,DIQMTQSPASLSASVGATVTITCRTSENIDSYLAWYQQRQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDVARYYCQHYSTTPWTFGGGTQLEIK,CCM09770,CCM09769,"immunoglobulin heavy chain variable region Elec-408, partial [Mus musculus]","immunoglobulin kappa chain variable region Elec-408, partial [Mus musculus]",Mus musculus,"Bourne,Y.; Renault,L.; Essono,S.; Mondielli,G.; Lamourette,P.; Boquet,D.; Grassi,J.; Marchot,P.",Experimental and theoretical structures of monoclonal antibodies that inhibit acetylcholinesterase by targeting the peripheral site and backdoor region,31-OCT-2012,8_8_17_6_3_9,CCM09770_CCM09769,Unique word,,2,1,2.5342116,-4.1119885
AKT73393,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMNWVRQSHGESLEWIGGFTPNNDDIYYNHQFRAKATLTVDKSSSTAFMELRSLTSEDSAVYYCARASFAFWGQGTLVTVSA,DVLMTQTPLSLPVSLGDQASFSCRSSQSLVHSNGNTYLHWYLQKPGQSPKPLIYKVSNRFSGVPDRFRGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPFTFGSGTKLEIK,AKT73393_H,AKT73393_L,"scFv anti-potyvirus capsid protein VH-VL, partial [synthetic construct]","scFv anti-potyvirus capsid protein VH-VL, partial [synthetic construct]",synthetic construct,"Liu,H.L.; Lin,W.F.; Hu,W.C.; Lee,Y.A.; Chang,Y.C.",A Strategy for Generating a Broad-Spectrum Monoclonal Antibody and Soluble Single-Chain Variable Fragments against Plant Potyviruses,08-SEP-2015,8_8_7_11_3_9,AKT73393,Same entry,potyvirus; capsid,2,1,2.429481,-4.3309703
7F0X_B_B,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMYWVKQSHGKSLEWFGGINPNNGDTSYNQKFKGKATLTVDKSSTTAYMDLRSLTSEDSAVYYCARDGYPYYFAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKGLIYSASHRYSGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNTYPWTFGGGTKLEIK,7F0X_B,7F0X_B,A Sars-Cov-2 Neutralizing Antibody,A Sars-Cov-2 Neutralizing Antibody,Mus musculus,"Zhang,G.;Li,X.;Guo,Y.;Wang,Y.;Yuan,S.",A SARS-CoV-2 neutralizingantibody,07-JUN-2021,8_8_13_6_3_9,7F0X_B_B,Xtal structure,SARS-CoV-2,2,1,2.4901528,-4.317045
AAD29605_AAD25042,EVQLQQSGPELVKPGASVKLSCKASGYSFTGYSMHWVKQRPGKSLEWIGDIYPYTGGTTYNQKFKAKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARARGRGALAYWGQGXLVTVSA,DIQMTQSPSSLSASLGGKVTITCKASQDINKHIIWYQHKPGKRPRLLISYTSTLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLSYTFGGGTKLEIK,AAD29605,AAD25042,"anti-DNA immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-DNA immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Jethwa,H.S.; Clarke,S.H.; Itoh-Lindstrom,Y.; Falk,R.J.; Jennette,J.C.; Nachman,P.H.",Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice,26-JUL-2016,8_8_11_6_3_9,FAILED,Ordered entries,myeloperoxidase,2,1,2.4810581,-4.1769934
CAF33393_CAF33542,EVQLQQSGPELVKPGASVKLSCKASGYTFTSSVMHWLKQKSGQGLEWIGYINPYNDGTKYNEKFTAKATLTSDKSSSTVYMELSGLTSEDFAVYYCARSGGLLRGYWYFDVWGAGTTVTVSS,DLVLTQSPATLSVTPGDSVSLSCRASQDITNTLHWYHQKSHESPRLLIKYVSQSISGIPSRFSGSGSGTVFTLSINSVETEDFGVYFCQQSTSWPYTFGGGTKLEIK,CAF33393,CAF33542,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Gille,J.G.; Saint-Remy,J.M.; Jacquemin,M.G.",Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof,04-MAR-2004,8_8_15_6_3_9,AEQ83130_AEQ83129,Unique chain,,2,1,0.9631028,-3.8133452
ACJ23169,EVQLQQSGPELVKPGASVKMSCEASGYTFTSNVMHWVKQKPGQGLEWIGYIHPYNDVIKYNEKFKDKATLTSDKSSSTVYMELSSLTSEDSTVYYCVSDGYYEDYVMDYWGQGTSVTVSS,DIVMTQSPSSLSVSAGEKVTMSCKSSQSLLKSGNQKNYLAWYQQKPGQPPKLLIYEASTRESGVPDRFTGSGSGTDFTLTISSMQADDLAVYYCQNDHSYPYTFGGGTKLEIK,ACJ23169_H,ACJ23169_L,"anti-FMDV single chain antibody, partial [synthetic construct]","anti-FMDV single chain antibody, partial [synthetic construct]",synthetic construct,"Berry,J.D.; Yuan,X.; Nicolas,B.; Ranada,F.; Johnstone,D.; Clavijo,A.; Bratic,J.",Murine Monoclonal Antibody to Foot-and-Mouth Disease Virus A24,26-JUL-2016,8_8_13_12_3_9,ACJ23169,Same entry,FMDV,2,1,0.93808013,-3.7983682
8DJK_H_L,EVQLQQSGPELVKPGASVKMSCKASGYSFTGYFMNWVKQSHGKSLEWIGRINPYNGDTFYNQKFKGKATLTVDKSSRTAHMELRSLTSADSALYFCVRRGEDYGSSYNYWGQGTTVTVSS,DILLTQSPAILSVSPGERVSFSCRASQSIGTSIHWYQQRTNGSPRLVIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSNSWPYTFGGGTKLEIK,8DJK_H,8DJK_L,Hmgcr-Ubiad1 Complex State 2,Hmgcr-Ubiad1 Complex State 2,Mus musculus,"Chen,H.;Qi,X.;Faulkner,R.A.;Schumacher,M.M.;Donnelly,L.M.;DeBose-Boyd,R.A.;Li,X.",Regulated degradation of HMG CoA reductase requires conformational changes in sterol-sensing domain,03-AUG-2022,8_8_13_6_3_9,8DJK_H_L,Xtal structure,,2,1,2.3260121,-4.26629
2PCP_D_C,EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYIHWNKQSHGKSLEWIGYIYPNNGGNGYNHKFKGKATLTVDKSSSTAYMDVRTLTSEDSAVYYCGRSTWDDFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQTIVHSNGNTYLEWYLQKPGQSPKLLIYKVTNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGTHAPYTFGGGTKLEIK,2PCP_D,2PCP_C,Antibody Fab Complexed With Phencyclidine,Antibody Fab Complexed With Phencyclidine,Mus musculus,"Lim,K.;Owens,S.M.;Arnold,L.;Sacchettini,J.C.;Linthicum,D.S.",Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine,02-JUN-1998,8_8_10_11_3_9,2PCP_D_C,Xtal structure,,2,1,2.3917134,-4.171563
BDZ85358_BDZ85423,EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMNWVKQSHGKSLEWIGRVSPSTGGTSYNQKFKGKATLTVDKSLSTAYMQLNSLTSEDSAVYYCGRYDYDLYYYAMDYWGQGTSVTVSS,KIVLTQSPASLAVSLRQRATISCRASESVDSYGNSFMHWYQQRPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTIDPVEPDDAATYYCQQNNEDPWTFGGGTKLEIK,BDZ85358,BDZ85423,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_10_3_9,BDZ85358_BDZ85423,Unique source,SARS-CoV-2,2,1,2.4156291,-4.159409
AAD29587_AAD25024,EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKSKATLTSDKSSSTAYMELSSLTSEDSAVYYCAREDDYDWYFDVWGTGTTVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYRLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCLELTHLPWTFGGGTKLEIK,AAD29587,AAD25024,"anti-myeloperoxidase immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-myeloperoxidase immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Jethwa,H.S.; Clarke,S.H.; Itoh-Lindstrom,Y.; Falk,R.J.; Jennette,J.C.; Nachman,P.H.",Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice,26-JUL-2016,8_8_12_11_3_9,AAD29587_AAD25024,Ordered entries,myeloperoxidase,2,1,0.9399001,-3.793171
AAA39080_S35479,EVQLQQSGPELVKPGASVKMSCKVSGYTFTSYVMHWVKQRPGQGLEWIGYFNPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCASGGWDYFDYWGQGTTLTVSS,DIVLTQSPATLSVTPGDKVSLSCRASQSISNYLHWYQQKSHESPRLLIKYVSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPHTFGSGTKLEIK,AAA39080,S35479,"immunoglobulin gamma-chain, partial [Mus musculus]",Ig kappa chain precursor V region - mouse (fragment),Mus musculus,"Takeda,Y.; Wise,K.S.; Hoffman,R.W.",Nucleotide sequences of immunoglobulin heavy and light chain V-regions from a monoclonal autoantibody specific for a unique set of small nuclear ribonucleoprotein complexes,21-Jan-2000,8_8_10_6_3_9,AAA39080_S35479,Unique chain,,2,1,0.92710936,-3.786023
6H3T_I_M,EVQLQQSGPELVKPGASVKVSCKASGYSFTDYNMCWVKQSHGKSLEWIGYIDPYNGLTSYNPKFKGKATLTVDKSSSTAFMHLNSLTSEDSAVYYCARNYYGRSYAMDYWGQGTSVTVSS,DIVMTQAASSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSFPPTFGGGTKLEIK,6H3T_I,6H3T_M,Schmallenberg Virus Glycoprotein Gc Head Domain In Complex With Scfv 1C11,Schmallenberg Virus Glycoprotein Gc Head Domain In Complex With Scfv 1C11,Bovine Schmallenberg virus BH80/Germany/2011,"Hellert,J.;Aebischer,A.;Wernike,K.;Haouz,A.;Brocchi,E.;Reiche,S.;Guardado-Calvo,P.;Beer,M.;Rey,F.A.",Orthobunyavirus spike architecture and recognition by neutralizing antibodies,19-JUL-2018,8_8_13_12_3_9,6H3T_I_M,Xtal structure,,2,1,2.441955,-4.039043
1NJ9_B_A,EVQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQNHGESLEWIAYIDPSNGDTFYNQKFQGKATVTLDKSSSTAFMHLNSLTSEDSAVYYCARGGGLFAFWGQGTLVTVSA,QAVVTQESALTTSPGETVTLTCRSSTGTITSDNYANWVQEKPDHLFSGLIGVNNARPPGVPARFSGSLTGDKAVLTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,1NJ9_B,1NJ9_A,Cocaine Hydrolytic Antibody 15A10,Cocaine Hydrolytic Antibody 15A10,Mus musculus,"Larsen,N.A.;Heine,A.;de Prada,P.;Redwan,el.;Yeates,T.O.;Landry,D.W.;Wilson,I.A.",Structure determination of a cocaine hydrolytic antibody from a pseudomerohedrally twinned crystal,30-DEC-2002,8_8_9_9_3_9,1NJ9_B_A,Xtal structure,cocaine,2,1,2.4833927,-3.9918563
5VZR_H_L,EVQLQQSGPELVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVFSTYYGNTNYNQKFKGRATMTVDKSSSTAYMELARLTSEDSAIYYCARKSYYVDYVDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLISATSNQGSGVPARFIGSGSGTDFSLNIHPVEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,5VZR_H,5VZR_L,Crystal Structure Of Mers-Cov Neutralizing Antibody G4 Fab,Crystal Structure Of Mers-Cov Neutralizing Antibody G4 Fab,Mus musculus,"Pallesen,J.;Wang,N.;Corbett,K.S.;Wrapp,D.;Kirchdoerfer,R.N.;Turner,H.L.;Cottrell,C.A.;Becker,M.M.;Wang,L.;Shi,W.;Kong,W.P.;Andres,E.L.;Kettenbach,A.N.;Denison,M.R.;Chappell,J.D.;Graham,B.S.;Ward,A.B.;McLellan,J.S.",Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen,29-MAY-2017,8_8_15_10_3_9,5VZR_H_L,Xtal structure,MERS; CoV,2,1,2.969994,-4.548842
CBY65296_CBY65297,EVQLQQSGPEVVKPGVSVKISCKGSGYTFTDYAMHWVKQSPGKSLEWIGVISTKYGKTNYNPSFQGQATMTVDKSSSTAYMELASLKASDSAIYYCARGDDGYSWGQGTSVTVSS,EIVMTQTPLSLPVSLGDRASISCRSGQSLVHSNGNTYLHWYLQKPGQSPKLLIYTVSNRFSGVPDRFSGSGSGSDFTLTISRVEAEDLGVYFCSQNTFVPWTFGGGTKLEIK,CBY65296,CBY65297,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Baurin,N.; Blanche,F.; Cameron,B.; Duchesne,M.; Mikol,V.; Naimi,S.; Pradier,L.; Shi,Y.",Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide,07-DEC-2010,8_8_8_11_3_9,CBY65296_CBY65297,Ordered entries,beta-amyloid,2,1,2.925143,-4.5160584
CBY65307_CBY65305,EVQLQQSGPEVVKPGVSVKISCKGSGYTFTDYAMHWVKQSPGKSLEWIGVISTKYGKTNYNPSFQGQATMTVDKSSSTAYMELASLKASDSAIYYCARGDEGYSWGQGTSVTVSS,EIVMTQTPLSLPVSLGDRASISCRSGQSLVHSNTNTYLHWYLQKPGQSPKLLIYTVSNRFSGVPDRFSGSGSGSDFTLTISRVEAEDLGVYFCSQNTFVPWTFGGGTKLEIK,CBY65307,CBY65305,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Baurin,N.; Blanche,F.; Cameron,B.; Duchesne,M.; Mikol,V.; Naimi,S.; Pradier,L.; Shi,Y.",Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide,07-DEC-2010,8_8_8_11_3_9,CBY65307_CBY65305,Ordered entries,beta-amyloid,2,1,2.9231992,-4.5230126
2GJJ_A_A,EVQLQQSGPEVVKTGASVKISCKASGYSFTGYFINWVKKNSGKSPEWIGHISSSYATSTYNQKFKNKAAFTVDTSSSTAFMQLNSLTSEDSADYYCVRSGNYEEYAMDYWGQGTSVTVSS,DIVLTQTPSSLPVSVGEKVTMTCKSSQTLLYSNNQKNYLAWYQQKPGQSPKLLISWAFTRKSGVPDRFTGSGSGTDFTLTIGSVKAEDLAVYYCQQYSNYPWTFGGGTRLEIK,2GJJ_A,2GJJ_A,Crystal Structure Of A Single Chain Antibody Sca21 Against Her2/Erbb2,Crystal Structure Of A Single Chain Antibody Sca21 Against Her2/Erbb2,Mus musculus,"Hu,S.;Zhu,Z.;Li,L.;Chang,L.;Li,W.;Cheng,L.;Teng,M.;Liu,J.",Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism,31-MAR-2006,8_8_13_12_3_9,2GJJ_A_A,Xtal structure,Her2,2,1,2.531574,-4.0183964
3H3B_D_D,EVQLQQSGPEVVKTGASVKISCKASGYSFTGYFINWVKKNSGKSPEWIGHISSSYATSTYNQKFKNKAAFTVDTSSSTAFMQLNSLTSEDSAVYYCVRSGNYEEYAMDYWGQGTSVTVSS,DIVLTQTPSSLPVSVGEKVTMTCKSSQTLLYSNNQKNYLAWYQQKPGQSPKLLISWAFTRKSGVPDRFTGSGSGTDFTLTIGSVKAEDLAVYYCQQYSNYPWTFGGGTRLEIK,3H3B_D,3H3B_D,Crystal Structure Of The Single-Chain Fv (Scfv) Fragment Of An Anti-Erbb2 Antibody Cha21 In Complex With Residues 1-192 Of Erbb2 Extracellular Domain,Crystal Structure Of The Single-Chain Fv (Scfv) Fragment Of An Anti-Erbb2 Antibody Cha21 In Complex With Residues 1-192 Of Erbb2 Extracellular Domain,Mus musculus,"Zhou,H.;Zha,Z.;Liu,Y.;Zhang,H.;Zhu,J.;Hu,S.;Shen,G.;Cheng,L.;Niu,L.;Greene,M.I.;Teng,M.;Liu,J.",Structural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21,16-APR-2009,8_8_13_12_3_9,3H3B_D_D,Xtal structure,Erbb2,2,1,2.585037,-3.9780269
AAZ93382_ACS44274,EVQLQQSGPVLVKPGASVKMSCKASGYTFTDYYVNWVKQSRGKSLEWLGLIIPSNGGTTYNQKFRGKATLTVDKSSSTAYMELNSLTSEDSAVYYCARRGLTGALFAYWGQGTLVTVSA,DIVMTQSHKFMSTSVGDRVSITCKASQDVTSAVAWFQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYGTPLTFGAGTKLELK,AAZ93382,ACS44274,"anti-ricin A chain heavy chain variable region, partial [Mus musculus]","anti-ricin A chain antibody immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Johnson,C.C.; Song,K.; Pincus,S.H.",Production of Mouse/Human Chimeric Antibodies to Ricin A Chain,26-Jul-2016,8_8_12_6_3_9,AAZ93382_ACS44274,Unique chain,ricin,2,1,2.4088936,-4.24017
1EHL_H_L,EVQLQQSGTVLARPGASVKMSCKASGYSFTSFWMHWVKQRPGQGLEWIGTIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMEVSSLTNEDSAVYYCTRRSGYKYYALDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSLVPTFGGGTKLEIK,1EHL_H,1EHL_L,64M-2 Antibody Fab Complexed With D(5Ht)(6-4)T,64M-2 Antibody Fab Complexed With D(5Ht)(6-4)T,Mus musculus,"Mori,T.;Nakane,M.;Hattori,T.;Matsunaga,T.;Ihara,M.;Nikaido,O.",Simultaneous establishment of monoclonal antibodies specific for either cyclobutane pyrimidine dimer or (6-4)photoproduct from the same mouse immunized with ultraviolet-irradiated DNA,21-FEB-2000,8_8_13_11_3_8,1EHL_H_L,Xtal structure,,2,1,2.7329698,-8.214393
6KDH_H_L,EVQLQQSGTVLARPGASVKMSCKASGYTFTNYWMHWIKQRPGQGLEWIGTIYPGNSDTTYSQKFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCSRRNYGSSYAMDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQNIVHSDGYTYLEWYLQKPGQSPKLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFRGSHVPTFGGGTKLEIK,6KDH_H,6KDH_L,Antibody 64M-5 Fab Including Isoasp In Ligand-Free Form,Antibody 64M-5 Fab Including Isoasp In Ligand-Free Form,Mus musculus,"Yokoyama,H.;Mizutani,R.;Noguchi,S.;Hayashida,N.",Structures of the antibody 64M-5 Fab and its complex with dT(6-4)T indicate induced-fit and high-affinity mechanisms,02-JUL-2019,8_8_13_11_3_8,6KDH_H_L,Xtal structure,,2,1,2.6991854,-8.18044
5NUZ_H_L,EVQLQQSGTVLARPGASVKMSCKASGYTFTSYWMHWIKQRPGQGLEWIGAIYPGDSDTKYNQKFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTRRNTLTGDYFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYTASSQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPYTFGGGTKLEIK,5NUZ_H,5NUZ_L,Junin Virus Gp1 Glycoprotein In Complex With An Antibody Fab Fragment,Junin Virus Gp1 Glycoprotein In Complex With An Antibody Fab Fragment,Argentinian mammarenavirus,"Zeltina,A.;Krumm,S.A.;Sahin,M.;Struwe,W.B.;Harlos,K.;Nunberg,J.H.;Crispin,M.;Pinschewer,D.D.;Doores,K.J.;Bowden,T.A.",Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization,03-MAY-2017,8_8_13_10_3_9,5NUZ_H_L,Xtal structure,Junin,2,1,2.6961544,-8.177998
AEQ29827_AEQ29828,EVQLQQSGTVLARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTRSYYRYDWFAYWGQGTLVTVSA,EIVLTQSPALMAASPGEKVTITCSVSSSISSSNLHWYQQKSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSYPLTFGAGTKLELK,AEQ29827,AEQ29828,"anti-chelated copper monoclonal antibody mu chain, partial [Mus musculus]","anti-chelated copper monoclonal antibody kappa chain, partial [Mus musculus]",Mus musculus,"Li,P.; Li,X.",Cloning and identification of two monoclonal antibodies against chelated copper and zinc respectively and construction of their eukaryotic co-expression plasmids,25-JUL-2016,8_8_12_7_3_9,AEQ29827_AEQ29828,Unique word,chelated,2,1,2.693609,-8.17483
1DN0_B_A,EVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARPPHDTSGHYWNYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCGASQSVSSNYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,1DN0_B,1DN0_A,Structure Of The Fab Fragment From A Human Igm Cold Agglutinin,Structure Of The Fab Fragment From A Human Igm Cold Agglutinin,Homo sapiens,"Cauerhff,A.;Braden,B.C.;Carvalho,J.G.;Aparicio,R.;Polikarpov,I.;Leoni,J.;Goldbaum,F.A.",Three-dimensional structure of the Fab from a human IgM cold agglutinin,15-DEC-1999,8_7_14_7_3_9,1DN0_B_A,Xtal structure,,2,1,16.65554,-10.473456
QVL61760_QVL61759,EVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEVNHSGSTNYNPSLKSRVTISVDTSKNQLSLKLNSVTAADTAVYYCARGNTMVRGVIIPFEYWDKGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,QVL61760,QVL61759,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Song,D.",Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2,24-MAY-2021,8_7_16_6_3_9,QVL61760_QVL61759,Unique chain,SARS-CoV-2,2,1,16.726433,-10.552274
4K3D_I_M,EVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGNTGYNPGLKSRLSITKDNSKSQVSLSVSSVTTEDSATYYCTSVHQETKKYQSCPDGYRERSDCSNRPACGTSDCCRVSVFGNCLTTLPVSYSYTYNYEWHVDVWGQGLLVTVSS,EAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,4K3D_I,4K3D_M,Crystal Structure Of Bovine Antibody Blv1H12 With Ultralong Cdr H3,Crystal Structure Of Bovine Antibody Blv1H12 With Ultralong Cdr H3,Bos taurus,"Wang,F.;Ekiert,D.C.;Ahmad,I.;Yu,W.;Zhang,Y.;Bazirgan,O.;Torkamani,A.;Raudsepp,T.;Mwangi,W.;Criscitiello,M.F.;Wilson,I.A.;Schultz,P.G.;Smider,V.V.",Reshaping antibody diversity,10-APR-2013,8_7_63_8_3_11,4K3D_I_M,Xtal structure,,2,1,13.860099,-9.365558
4K3E_I_M,EVQLRESGPSLVQPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGSTGYNPGLKSRLSITKDNSKSQVSLSVSSVTTEDSATYYCTTVHQETRKTCSDGYIAVDSCGRGQSDGCVNDCNSCYYGWRNCRRQPAIHSYEFHVDAWGRGLLVTVSS,EAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,4K3E_I,4K3E_M,Crystal Structure Of Bovine Antibody Blv5B8 With Ultralong Cdr H3,Crystal Structure Of Bovine Antibody Blv5B8 With Ultralong Cdr H3,Bos taurus,"Wang,F.;Ekiert,D.C.;Ahmad,I.;Yu,W.;Zhang,Y.;Bazirgan,O.;Torkamani,A.;Raudsepp,T.;Mwangi,W.;Criscitiello,M.F.;Wilson,I.A.;Schultz,P.G.;Smider,V.V.",Reshaping antibody diversity,10-APR-2013,8_7_58_8_3_11,4K3E_I_M,Xtal structure,,2,1,13.869502,-9.3607645
AAC52820_AAC52821,EVQLVESGAELMKPGASVKISCKATDYRFSSYWIEWVKQRPGHGLEWIGDILPGSGNTNYNERFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCAIPDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHTNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK,AAC52820,AAC52821,"Ig gamma heavy chain, partial [Mus musculus]","If kappa light chain, partial [Mus musculus]",Mus musculus,"Kwak,J.W.; Lee,D.I.; Choi,B.K.; Cho,W.K.; Lee,S.H.; Park,Y.B.; Han,M.H.",Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabA34) specific for human plasma apolipoprotein A-I,04-OCT-1996,8_8_5_11_3_9,AAC52820_AAC52821,Unique source,apolipoprotein,2,1,5.002242,-1.8642545
QKK35726_QKK35727,EVQLVESGAEVKKPGASVILSCKASGYTVTNYYIHWVRQAPGQGLEWMGWIDPDSGVTNFAEKFQGRVTMTRDTSISTAYMELRWLESDDTAVYYCAKDLITVIRGLGGGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFALYYCLQRSDWHPITFGQGTRLEIK,QKK35726,QKK35727,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_6_3_10,QKK35726_QKK35727,Unique source,SARS-CoV-2,2,1,2.079365,3.6681893
CAO78307,EVQLVESGAEVKKPGASVKVSCKASGYTFTASYMHWVRQAPGQGLEWMGWFNPNSGGTNYAQKFQGRVTMTGDTSTSTGYMELSRLTSDDAXVYYCARDRASAMGVWGQGTLVTVSS,QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNTFLFGGGTQLTVL,CAO78307_H,CAO78307_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_10_9_3_10,FAILED,Same entry,,2,1,2.0487885,3.7567036
CAO78303,EVQLVESGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCVRGSPQNCTNGVCHRGSHVHYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSNRPSGVCNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLEVFGGGTQLTVL,CAO78303_H,CAO78303_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_26_9_3_11,AEN51972,Same entry,,2,1,2.1860166,3.4294105
CAO78319,EVQLVESGAEVKKPGASVRVSCQASGYTFTRYHIHWVRQAPGQGLEWMGVIDPNSGRISYSQKFQDRVTMTRDTSTSTVYMELNSLRSEDTAIYYCARDRGYCNGGRCFMDAFDYWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTIACSGSSSNIGINTVNWYQQIPGTAPKLLIYNNDQRPSGVPDRFSGSKSATSASLAITGLQVDDEADYYCQSYDSSLGGYVFGTGTQLTVL,CAO78319_H,CAO78319_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_19_8_3_11,AEN51984,Same entry,,2,1,1.7868832,3.6604443
5MVZ_H_L,EVQLVESGAEVKKPGESLKISCKGSGYTFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARFVSLDAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLWTFGQGTKVEIK,5MVZ_H,5MVZ_L,Fab 4Ab007 Bound To Interleukin-1-Beta,Fab 4Ab007 Bound To Interleukin-1-Beta,Homo sapiens,"Stark,W.;Seibert,V.","Structure of a novel, fully Human Fab binding to Interleukin 1-beta",17-JAN-2017,8_8_11_6_3_9,5MVZ_H_L,Xtal structure,,2,1,-12.414319,5.750602
QKK35756_QKK35757,EVQLVESGAEVKNPGSSVKISCKSSGGTLGDYAISWVRQAPGLGLEWLGGIMPLHGTTGYSQRFRPRLTITADESARTAYMELTALSSEDSAIYYCARDPSILNTGNHHWYDLDLWGQGTEVTVSS,ETTLTQSPLSLSVTLGQAASISCRPNLGLMHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFAGSGSGTHFTLEISGVEADDVGVYYCMQGTEWPRTFGQGTKLEIK,QKK35756,QKK35757,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35756_QKK35757,Unique source,SARS-CoV-2,2,1,-6.467685,-2.6072326
QKK35732_QKK35733,EVQLVESGAEVRKPGSSVKVSCKATGGTFSSYGITWVRQAPGQGLEWMGRIIPTLGRTNYAQKFQGRVTITADKSTSTAHMELSSLRSEDTAVYYCARDLSTLQPDAIVNFDYWGQGTLVTVSS,QPVLTQSSSASASLGSSVKLTCTLSSGHSSYILAWHQQQPGKAPRFLMKFEVGGRYNKGSGVPDRFSGSSSGADRYLTISNLQSEDEADYYCETWDSNLKGVFGGGTKVTVL,QKK35732,QKK35733,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_7_7_10,QKK35732_QKK35733,Unique source,SARS-CoV-2,2,1,-1.0891078,5.6174183
QKK35514_QKK35515,EVQLVESGAEVRTPGSSVKLSCKASGGTFSTHAFSWVRQAPGQRPEWMGGIIPIFGESKDTQKFQGRVTFTADESTTTVYMELRSLKSDDTAIYYCVRDSDPYTATYRNNHYWYAMDVWGQGTTVTVSS,EIVLTQSPLSLPVTLGQPASISCRSSLRLVHTDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVDIK,QKK35514,QKK35515,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35514_QKK35515,Unique source,SARS-CoV-2,2,1,3.039353,-13.265889
8EEU_H_L,EVQLVESGAGLVQPGGSLRLSCAASGFTFSDSWMSWVRQSPGKGLEWVGRIKGKPDGETAAYAASVKGRFSISRDDSKNTLYLQMNSLKTEDTAVYYCTRDDRTSCRRGVCYAAFHSWGQGVLVTVSS,DIQMTQSPSSLSASAGDRVTLTCRASQAISFYLAWYQQKPGKAPKRLIYDASELQGGVPSRFSGSGSGTDFTLSINSLQPEDSATYFCLQYDSPPFTFGPGTKVEIK,8EEU_H,8EEU_L,Venezuelan Equine Encephalitis Virus-Like Particle In Complex With Fab Skt05,Venezuelan Equine Encephalitis Virus-Like Particle In Complex With Fab Skt05,Macaca fascicularis,"Sutton,M.S.;Pletnev,S.;Callahan,V.;Ko,S.;Tsybovsky,Y.;Bylund,T.;Casner,R.G.;Cerutti,G.;Gardner,C.L.;Guirguis,V.;Verardi,R.;Zhang,B.;Ambrozak,D.;Beddall,M.;Lei,H.;Yang,E.S.;Liu,T.;Henry,A.R.;Rawi,R.;Sch&#xf6;n,A.;Schramm,C.A.;Shen,C.H.;Shi,W.;Stephens,T.;Yang,Y.;Florez,M.B.;Ledgerwood,J.E.;Burke,C.W.;Shapiro,L.;Fox,J.M.;Kwong,P.D.;Roederer,M.",Vaccine elicitation and structural basis for antibody protection against alphaviruses,19-JUL-2023,8_10_19_6_3_9,8DUL_H_L,Xtal structure,,2,1,13.016705,8.485089
ANV21796_ANV21985,EVQLVESGGALVQPGGSLRLSCRVSGFSFSDFGMTWVRQAPGKGLEWVAAITENGGSTYYADSVEGRFIVSRDNSKNTMYLQMNGLGAEDTAVYYCAKDFYGPGPRGNFDYWGQGTPITVSS,AIQMTQSPSSVSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKILIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYDYPLTFGGGTKVEIK,ANV21796,ANV21985,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_15_6_3_9,ANV21796_ANV21985,Unique source,,2,1,14.107012,9.837239
UIC72057_UIC72367,EVQLVESGGALVRPGGSLRLSCAASGFRFRNYWMSWVRQAPGKGLEWVANIKEDGTEKNYVGSVKGRFTISRDNAKNSVSLQINSLRAEDTATYYCARQLLYESSAYRPLDYWGQGTLVTVSS,DIVMTQSPDSLTVSLGERAAINCKSSQSVYYRSNNKNYLAWYQQKPGQPPKMLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQADDVAVYYCQQYYDNSRTFGQGTKLEIK,UIC72057,UIC72367,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_16_12_3_9,UIC72057_UIC72367,Unique source,HCV,2,1,11.170086,7.801205
CAO78311,EVQLVESGGDLIQPGGSLRLSCAASGFTVGSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRDRGDAFDIWGQGTMVTVSS,YALTQPPSVSVAPGKTATITCAGNNIGSNSVYWYQQKPGLAPVLVVYDDSDRPSGMSERFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSDHLYVFGTGTQLTVL,CAO78311_H,CAO78311_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_7_10_6_3_12,AEN51978,Same entry,,2,1,12.579047,10.354288
7DC8_B_A,EVQLVESGGDLVKPGGGLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSQSYHIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARYGKLYSLNWVFDYWGQGTLVTVSS,QSALTQPPSASGSPGQTVTISCTGTSTDVGDYAYVSWYQQHPGKAPKLMIYYVSKKPDGVPDRFSGSKSGNTASLTVSGLQAEDEADYFCSLRSPGPYPLFGGGTKLTVL,7DC8_B,7DC8_A,Crystal Structure Of Switch Ab Fab And Hil6R In Complex With Atp,Crystal Structure Of Switch Ab Fab And Hil6R In Complex With Atp,Homo sapiens,"Mimoto,F.;Tatsumi,K.;Shimizu,S.;Kadono,S.;Haraya,K.;Nagayasu,M.;Suzuki,Y.;Fujii,E.;Kamimura,M.;Hayasaka,A.;Kawauchi,H.;Ohara,K.;Matsushita,M.;Baba,T.;Susumu,H.;Sakashita,T.;Muraoka,T.;Aso,K.;Katada,H.;Tanaka,E.;Nakagawa,K.;Hasegawa,M.;Ayabe,M.;Yamamoto,T.;Tanba,S.;Ishiguro,T.;Kamikawa,T.;Nambu,T.;Kibayashi,T.;Azuma,Y.;Tomii,Y.;Kato,A.;Ozeki,K.;Murao,N.;Endo,M.;Kikuta,J.;Kamata-Sakurai,M.;Ishii,M.;Hattori,K.;Igawa,T.",Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment,23-OCT-2020,8_8_15_9_3_10,7DC8_B_A,Xtal structure,,2,1,16.051458,10.031203
B31790_A31790,EVQLVESGGDLVKPGGSLKLSCAASGFSFSSYGMSWVRQTPDKRLEWVATISNGGGYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDSAMYYCARRERYDENGFAYWGQGTLVTVSA,DIVMTQSPSSLTVTAGEKVTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSNPLTFGGGTKLELK,B31790,A31790,Ig heavy chain V region (17/9) - mouse,Ig kappa chain V region (17/9) - mouse,Mus musculus,"Schulze-Gahmen,U.; Rini,J.M.; Arevalo,J.; Stura,E.A.; Kenten,J.H.; Wilson,I.A.","Preliminary crystallographic data, primary sequence, and binding data for an anti-peptide Fab and its complex with a synthetic peptide from influenza virus hemagglutinin",21-Jan-2000,8_8_13_12_3_9,B31790_A31790,Unique chain,hemagglutinin,2,1,17.82272,7.245278
B34353_A34353,EVQLVESGGDLVKPGGSLKLSCAASGFTFSRCAMSWVRQTPEKRLEWVAGISSGGSYTFYPDTVKGRFIISRDNARNTLSLQMSSLRSEDTAIYYCTRYSSDPFYFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSNQTILLSDGDTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,B34353,A34353,anti-peptide Fab' B13I2 heavy chain - mouse,anti-peptide Fab' B13I2 light chain - mouse,Mus musculus,"Stura,E.A.; Stanfield,R.L.; Fieser,T.M.; Balderas,R.S.; Smith,L.R.; Lerner,R.A.; Wilson,I.A.",Preliminary crystallographic data and primary sequence for anti-peptide Fab' B13I2 and its complex with the C-helix peptide from myohemerythrin,21-Jan-2000,8_8_12_11_3_9,B34353_A34353,Unique chain,peptide,2,1,17.888885,7.1777124
CAD42993_CAD43006,EVQLVESGGDLVQPGGSLRLSCAASGFTFRRYAMSWVRQVPGKGLEWVSVISSSGGSTSYSDSVKGRFTISRDNSQNALSLQMNSLRPEDTAVYYCARDLYCTTTSCYGGYYTWGQGTLVTVST,QSALTQPASVSGSPGQSITMSCIGSSGNIGGFKSVSWYQQHPGKAPKLIIYEVTIRPSGISSRFSGSKSGNTASLTISGLQAEDEGDYYCSSSNAGSNNFIVFGGGTKLTVL,CAD42993,CAD43006,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Raats,J.M.H.",Human recombinant autoantibodies specific for the La (SS-B) autoantigen from patient derived phage display combinatorial antibody libraries,24-JUL-2016,8_8_17_9_3_12,CAD42993_CAD43006,Unique source,,2,1,13.977994,9.886172
QWQ58068_QWQ58113,EVQLVESGGDLVQPGGSLRLSCAGSGFTFSSSWMHWVRQAPGKGLVWVSRINSGGNFKKYADSVRGRFTISRDNTRNTLYLHMSSLRHEDTALYYCARDHDYGDYRGNAYDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYFNWYQQKPGKAPKLLIFDTSKLETGVPSRFSGRQSGTDYTFTISSLQPEDIATYFCQQLDSFGGGTKVEIK,QWQ58068,QWQ58113,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Li,L.; Freyn,A.W.; Liu,S.T.H.; Stovicek,O.; Stamper,C.T.; Dugan,H.L.; Tepora,M.E.; Utset,H.A.; Bitar,D.J.; Hamel,N.J.; Changrob,S.; Zheng,N.Y.; Huang,M.; Krammer,F.; Nachbagauer,R.; Palese,P.; Ward,A.B.; Wilson,P.C.",First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,19-JUN-2021,8_8_16_6_3_5,QWQ58068_QWQ58113,Unique source,hemagglutinin; H1N1,2,1,13.176332,10.062009
7S07_H_L,EVQLVESGGGIVQPGGSLRVSCAASGFSLSDHYMDWVRQAPGRGLEWVGRSRNKENSFTTEFAASVRRRFTISRDDSNSLLHLQMNNLKSEDTAVYFCARVGYYDLWSGYSGNWYIDVWGRGTLVIVSS,DIQMTQSPSSLSASLGDSVTITCRASQTMSNFLNWYQQKPGKAPKFLIYAASRLQSGVPSRFSGSGSGTQFTLTISNLQPEDFATYYCQQSFLFPYTFGGGTKVEVE,7S07_H,7S07_L,Crystal Structure Of Epstein-Barr Virus Glycoprotein Gh/Gl/Gp42-Peptide In Complex With Human Neutralizing Antibodies 769B10 And 769C2,Crystal Structure Of Epstein-Barr Virus Glycoprotein Gh/Gl/Gp42-Peptide In Complex With Human Neutralizing Antibodies 769B10 And 769C2,Homo sapiens,"Chen,W.H.;Kim,J.;Bu,W.;Board,N.L.;Tsybovsky,Y.;Wang,Y.;Hostal,A.;Andrews,S.F.;Gillespie,R.A.;Choe,M.;Stephens,T.;Yang,E.S.;Pegu,A.;Peterson,C.E.;Fisher,B.E.;Mascola,J.R.;Pittaluga,S.;McDermott,A.B.;Kanekiyo,M.;Joyce,M.G.;Cohen,J.I.",Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition,09-NOV-2022,8_10_20_6_3_9,7S07_H_L,Xtal structure,Epstein,2,1,13.295034,8.450982
3FZU_C_D,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENAKNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,3FZU_C,3FZU_D,Igg1 Fab Characterized By H/D Exchange,Igg1 Fab Characterized By H/D Exchange,Homo sapiens,"Houde,D.;Arndt,J.;Domeier,W.;Berkowitz,S.;Engen,J.R.",Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry,26-JAN-2009,10_8_9_6_3_9,3FZU_C_D,Xtal structure,,2,1,14.092752,9.507997
6XXV_A_B,EVQLVESGGGLAKPGGSLRLSCAASGFTFSPYWMYWVRQAPGKGLEWVSVINSGGGITYYTDSVKGRFTISRENAKNTLYLQMDSLRPEDTAVYYCVRDRTYYSGVYYTEDGLDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTVTCRAGQGVSNYLSWYQQKPGKVPKLLIYKASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNIHPYSFGQGTKVEIK,6XXV_A,6XXV_B,Crystal Structure Of A Computationally Designed Immunogen S2_1.2 In Complex With Its Elicited Antibody C57,Crystal Structure Of A Computationally Designed Immunogen S2_1.2 In Complex With Its Elicited Antibody C57,Homo sapiens,"Sesterhenn,F.;Yang,C.;Bonet,J.;Cramer,J.T.;Wen,X.;Wang,Y.;Chiang,C.I.;Abriata,L.A.;Kucharska,I.;Castoro,G.;Vollers,S.S.;Galloux,M.;Dheilly,E.;Rosset,S.;Corthesy,P.;Georgeon,S.;Villard,M.;Richard,C.A.;Descamps,D.;Delgado,T.;Oricchio,E.;Rameix-Welti,M.A.;Mas,V.;Ervin,S.;Eleouet,J.F.;Riffault,S.;Bates,J.T.;Julien,J.P.;Li,Y.;Jardetzky,T.;Krey,T.;Correia,B.E.",De novo protein design enables the precise induction of RSV-neutralizing antibodies,28-JAN-2020,8_8_19_6_3_9,6XXV_A_B,Xtal structure,RSV,2,1,13.954254,10.309186
8FBW_C_D,EVQLVESGGGLAKPGGSLRLSCAASGFTFSRYAIHWVRQAPGKGLEWVSVISSGGSTYYADSVEGRFTISRDNSKNTLSLQMNSLRTEDTAVYYCAKDATPYYYSGGYWYVGNYSFDYWGQGVLVTVSS,QSVLTQPPSASGAPGQSVTISCSGSSSNIGSNYVYWYQQLSGKAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLQSKDEADYYCSAWDSSLNDPLFGGGTRLTVL,8FBW_C,8FBW_D,Crystal Structure Of Siv-1 V2 Antibody Nci05 In Complex With A V2 Peptide,Crystal Structure Of Siv-1 V2 Antibody Nci05 In Complex With A V2 Peptide,Simian immunodeficiency virus,"Stamos,J.D.",Delayed SIVmac251 acquisition by passive administration of monoclonal antibody NCI05 recognizing a CH59-like coil- helical conformation of SIV V2,18-JAN-2023,8_7_23_8_3_11,8FBW_C_D,Xtal structure,SIV,2,1,14.076403,10.185093
8DED_H_L,EVQLVESGGGLAKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVSVISSHYSTYYADSVKGRFTISRDNSKNTVSLQVNSLRAEDTAVYYCAKVGRSGYCTASGCNALLFDWFDVWGPGVLVTVSS,DVVMTQSPLSLPVTPGQPASISCRSSQSLVHSNGNTSLSWYQQKAGHPPRLLIYQVSNRYSGVPDRFSGTGAGTDFTLTISRVETEDVGVYYCGQGAHLPPAFGQGTKVEIK,8DED_H,8DED_L,Cryo-Em Structure Of Western Equine Encephalitis Virus Vlp In Complex With Skw19 Fab,Cryo-Em Structure Of Western Equine Encephalitis Virus Vlp In Complex With Skw19 Fab,Homo,"Sutton,M.",Cryo-EM Structure of Western Equine Encephalitis Virus VLP in complex with SKW19 fab,05-JUL-2023,8_7_24_11_3_9,8DED_H_L,Xtal structure,VHLP; VHLL; VLP,2,1,14.080982,10.159897
APX42345_APX42346,EVQLVESGGGLIKPGQSLTLFCVGFGFNFANDWMGWVRQAPGKGLEWVGRIRRLKDGAKAEYGSSVKGRFTISRDDSKNTLYLHMSSLKVEDTAVYYCTRDEGAPVTRFLEWGSYYYYMAVWGKGTTVTVSS,DIQLTQSPASLSASVGDTVTITCRASQSIKDYINWYQHKSGSAPRLLIYAASTLQSGISSRFTGSGSGTQFTLTINSLQPEDFATYYCQEAYNTNPTLSFGQGTRVDKK,APX42345,APX42346,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Williams,L.D.; Ofek,G.; Schatzle,S.; McDaniel,J.R.; Lu,X.; Nicely,N.I.; Wu,L.; Lougheed,C.S.; Bradley,T.; Louder,M.K.; McKee,K.; Bailer,R.T.; O'Dell,S.; Georgiev,I.S.; Seaman,M.S.; Parks,R.J.; Marshall,D.J.; Anasti,K.; Yang,G.; Nie,X.; Tumba,N.L.; Wiehe,K.; Wagh,K.; Korber,B.; Kepler,T.B.; Alam,S.M.; Morris,L.; Kamanga,G.; Cohen,M.S.; Bonsignori,M.; Xia,S.-M.; Montefiori,D.C.; Kelsoe,G.; Gao,F.; Mascola,J.R.; Moody,M.A.; Saunders,K.O.; Liao,H.-X.; Tomaras,G.D.; Georgiou,G.; Haynes,B.F.",Potent and broad HIV-neutralizing antibodies in memory B cells and plasma,27-JAN-2017,8_10_23_6_3_11,APX42345_APX42346,Unique source,HIV,2,1,12.952468,8.416868
URN46083_URN46118,EVQLVESGGGLIQPGGSLRLSCAAFGLTVSSNYMSWVRQAPGKGLEWVSQIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDVYGVDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTIQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPPFTFGPGTKVEIK,URN46083,URN46118,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",synthetic construct,"Zhao,F.; Keating,C.; Ozorowski,G.; Shaabani,N.; Francino-Urdaniz,I.M.; Barman,S.; Limbo,O.; Burns,A.; Zhou,P.; Ricciardi,M.J.; Woehl,J.; Tran,Q.; Turner,H.L.; Peng,L.; Huang,D.; Nemazee,D.; Andrabi,R.; Sok,D.; Teijaro,J.R.; Whitehead,T.A.; Ward,A.B.; Burton,D.R.; Jardine,J.G.",Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways,06-JUN-2022,8_7_11_6_3_11,URN46083_URN46118,Unique source,SARS-CoV-2,2,1,12.559667,10.775741
QKY76332_QKY75945,EVQLVESGGGLIQPGGSLRLSCAASEVTVSSNYMSWVRQAPGKGLEWVSLIYSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFLRWHDLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINNYLNWYQQKPGKAPKLLIYDASNLETGVPLRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPPVFGGGTKVEIK,QKY76332,QKY75945,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_10_6_3_9,QKY76332_QKY75945,Unique source,SARS-CoV-2,2,1,12.636862,10.4107
QKY76592_QKY76205,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESTQWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASHSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYSQTFGQGTKVEIK,QKY76592,QKY76205,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_6_6_3_9,QKY76592_QKY76205,Unique source,SARS-CoV-2,2,1,12.58109,10.293681
QKK35816_QKK35817,EVQLVESGGGLIQPGGSLRLSCAASGFPFSGTYMTWVRQAPGKGLEWVSIIYSGGDTYYADSVKGRFTISRDNSKNTLFLQMNSLRVEDTAMYYCARDREMAIITERSYGLDVWGQGTMVTVSS,QPVLTQPPSASGTPGQRVTISCSGGSSNIGSNSVNWYQQLPGTAPKLLIYSNSQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNTFRYVFGTGTKVTVL,QKK35816,QKK35817,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_18_8_3_13,QKK35816_QKK35817,Unique source,SARS-CoV-2,2,1,12.631243,10.646089
QWE89727_QWE89728,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSFIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLQEHGMDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHLNSYPPGYTFGQGTKLEIK,QWE89727,QWE89728,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ju,B.; Zhang,Q.; Ge,J.; Wang,X.; Zhang,Z.; Zhang,L.",Direct Submission,09-JUN-2021,8_7_11_6_3_11,QWE89727_QWE89728,Unique source,SARS-CoV-2,2,1,12.565399,10.66362
QYB25450_QYB25519,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGEDVFDIWGQGTMVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPGYTFGQGTKLEIK,QYB25450,QYB25519,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_7_11_6_3_10,QYB25450_QYB25519,Unique source,SARS-CoV-2,2,1,12.633937,10.340578
BAA19453,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVLLCKRDLCDWGQGTLVTVS,SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,BAA19453_H,BAA19453_L,single-chain antibody [Homo sapiens],single-chain antibody [Homo sapiens],Homo sapiens,"Yan,X.; Tang,J.; Liu,Y.; Tian,H.; Tien,P.",Selection of Collagenase IV human scFv antibody from a synthetic phage display library,25-MAR-2006,8_7_6_6_3_11,BAA19453,Same entry,,2,1,12.6495495,10.292467
7N3G_H_L,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYSSGGTDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGTFGQGTKVEIK,7N3G_H,7N3G_L,Crystal Structure Of An Anti-Sars-Cov-2 Human Neutralizing Antibody Fab Fragment C098,Crystal Structure Of An Anti-Sars-Cov-2 Human Neutralizing Antibody Fab Fragment C098,Homo sapiens,"Muecksch,F.;Weisblum,Y.;Barnes,C.O.;Schmidt,F.;Schaefer-Babajew,D.;Lorenzi,J.C.;Flyak,A.I.;DeLaitsch,A.T.;Huey-Tubman,K.E.;Hou,S.;Schiffer,C.A.;Gaebler,C.;Wang,Z.;Da Silva,J.;Poston,D.;Finkin,S.;Cho,A.;Cipolla,M.;Oliveira,T.Y.;Millard,K.G.;Ramos,V.;Gazumyan,A.;Rutkowska,M.;Caskey,M.;Nussenzweig,M.C.;Bjorkman,P.J.;Hatziioannou,T.;Bieniasz,P.D.","Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies",01-JUN-2021,8_7_12_7_3_9,7N3G_H_L,Xtal structure,SARS-CoV-2,2,1,12.564484,10.515383
QWE89729_QWE89730,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRDYYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLHLNSYRTFGLGTKVEIK,QWE89729,QWE89730,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ju,B.; Zhang,Q.; Ge,J.; Wang,X.; Zhang,Z.; Zhang,L.",Direct Submission,09-JUN-2021,8_7_11_6_3_8,QWE89729_QWE89730,Unique source,SARS-CoV-2,2,1,12.6667385,10.687406
7D0C_G_F,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,7D0C_G,7D0C_F,S Protein Of Sars-Cov-2 In Complex Bound With P5A-3A1,S Protein Of Sars-Cov-2 In Complex Bound With P5A-3A1,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_7_11_7_3_9,7D0C_G_F,Xtal structure,SARS-CoV-2,2,1,12.631293,10.245664
7CZQ_J_N,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGPKSITGTAFDIWGQGTIVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYFNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPMYTFGQGTKLEIK,7CZQ_J,7CZQ_N,S Protein Of Sars-Cov-2 In Complex Bound With P2B-1A10,S Protein Of Sars-Cov-2 In Complex Bound With P2B-1A10,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_7_15_6_3_10,7CZQ_J_N,Xtal structure,SARS-CoV-2,2,1,12.556387,10.353789
QKK35794_QKK35795,EVQLVESGGGLIQPGGSLRLSCAASGFTVTDNYMSWVRQAPGKGLEWVSVLYSGGSTYYADAVQGRFSISRDNSKNALYLQMNSLRAEDTAVYYCARGFGNGWSYYFDYWGQGTLVTVSS,DIVLTQTPSSLSASVGDRVTITCRASQTIATYLSWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTIGSLQPEDFATYYCQQSYSIPWTFGQGTKVDIK,QKK35794,QKK35795,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_14_6_3_9,QKK35794_QKK35795,Unique source,SARS-CoV-2,2,1,12.684084,10.237396
7X63_H_L,EVQLVESGGGLIQPGGSLRLSCAASGITVGWNYMSWVRQAPGKGLEWVSVIYPGGSTDYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCARDLGEAGGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGIPSSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK,7X63_H,7X63_L,Sars-Cov-2-Beta-Rbd And Bd-236-Gwp/P-Vk Antibody Complex,Sars-Cov-2-Beta-Rbd And Bd-236-Gwp/P-Vk Antibody Complex,Severe acute respiratory syndrome coronavirus 2,"Shi,R.;Wang,Y.;Wu,Z.;Han,X.;Yan,J.",SARS-CoV-2-Beta-RBD and BD-236-GWP/P-VK antibody complex,08-MAR-2023,8_7_12_7_3_9,7X63_H_L,Xtal structure,SARS-CoV-2; RBD,2,1,12.547062,10.702998
7F7H_C_D,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVIVSS,IQLTQSPSFLSASVGDRVTITCRASQGISSDLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSHPLAFGPGTKVDIK,7F7H_C,7F7H_D,Sars-Cov-2 S Protein Rbd In Complex With A8-1 Fab,Sars-Cov-2 S Protein Rbd In Complex With A8-1 Fab,Severe acute respiratory syndrome coronavirus 2,"Dou,Y.;Jia,Z.;Deng,Y.;Lan,J.;Liu,H.",High throughput isolation of potent neutralizing antibodies from convalescent COVID-19 patients,29-JUN-2021,8_7_11_6_3_9,7F7H_C_D,Xtal structure,COVID,2,1,12.57483,10.80875
5WCC_A_B,EVQLVESGGGLIQPGGSLRLSCSASEFTVSGNYMTWVRQAPGKGLEWVSIIYTGGSTYYADSVKGRFSISRDDSRNTLYLQMNSLRAEDTAVYYCARALKLQFFDWPSHAFDIWGQGTMVTVSS,QSALTQPPSASGSPGQSVTISCTGTRSDIDGYNYVSWYQQHPGKAPKLIISEVNKRPSGVPARFSGSKSGNRASLTVSGLQTEDEADYYCSSYTDTNNFYVFGTGTKVTVL,5WCC_A,5WCC_B,Crystal Structure Of The Broadly Neutralizing Influenza A Antibody Vrc 315 02-1F07 Fab.,Crystal Structure Of The Broadly Neutralizing Influenza A Antibody Vrc 315 02-1F07 Fab.,Homo sapiens,"Andrews,S.F.;Joyce,M.G.;Chambers,M.J.;Gillespie,R.A.;Kanekiyo,M.;Leung,K.;Yang,E.S.;Tsybovsky,Y.;Wheatley,A.K.;Crank,M.C.;Boyington,J.C.;Prabhakaran,M.S.;Narpala,S.R.;Chen,X.;Bailer,R.T.;Chen,G.;Coates,E.;Kwong,P.D.;Koup,R.A.;Mascola,J.R.;Graham,B.S.;Ledgerwood,J.E.;McDermott,A.B.",Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans,29-JUN-2017,8_7_18_9_3_11,5WCC_A_B,Xtal structure,hemagglutinin; Influenza,2,1,12.56341,10.438551
7XSC_A_B,EVQLVESGGGLIQPGGSLRLSCVVSGFTVSSNYMSWIRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDSSQNTLYLQMNSLRAEDTAVYYCARHPYGDHAWGQGTLVTVSS,DIQMTQSPSPLSASVGDRVTITCQASQDIRNFLNWYQQKPGKAPKLLIHDASKLEAGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,7XSC_A,7XSC_B,Crystal Structure Of Sars-Cov-2 Spike Receptor Binding Domain Bound With P5S-2B10,Crystal Structure Of Sars-Cov-2 Spike Receptor Binding Domain Bound With P5S-2B10,Homo sapiens,"Ju,B.;Zhang,Q.;Wang,Z.;Aw,Z.Q.;Chen,P.;Zhou,B.;Wang,R.;Ge,X.;Lv,Q.;Cheng,L.;Zhang,R.;Wong,Y.H.;Chen,H.;Wang,H.;Shan,S.;Liao,X.;Shi,X.;Liu,L.;Chu,J.J.H.;Wang,X.;Zhang,Z.;Zhang,L.",Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants,24-MAY-2023,8_7_9_6_3_9,7XSC_A_B,Xtal structure,SARS-CoV-2,2,1,12.5096855,10.403021
QKK35528_QKK35529,EVQLVESGGGLSQPGGSLRLSCAASGFTVRTYCMNWVRQAPGKGLEWVSLVCGDNIDYYPDSVKGRFSISRDDSKNTLLLHMDSLRVEDTAVYYCARATPPGGGTGWPYFDFWGQGTLVTVSS,DIQVTQSPATVSVSPGEGASLSCRASQSVRSNLAWFQQKPGQAPRLLISDASTRASGVPARFTGSGFGTEFTLTISSLQSEDFAIYYCQQYNTWPPLTFGGGTKVEIK,QKK35528,QKK35529,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_6_3_10,QKK35528_QKK35529,Unique source,SARS-CoV-2,2,1,12.722094,10.028922
QKK35502_QKK35503,EVQLVESGGGLSQPGGSLRLSCAASGFVVKNNCMNWVRQAPGKGLEWVALICADGITYHSDSVTGRFTIYRDESDNTLHLQMDSLRIEDTAVYYCVRASPPGGNTGWPFFEDWGQGTLVTVSS,DIVLTQTPATLSVSPGEGATLSCRASQSVRSNLAWFQQRPGQVPRLLIYDASTRATGVPARFTGSGSGTYFTLTISSLQSEDFAVYYCQQYNSWPPLTFGGGTKLEIK,QKK35502,QKK35503,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_6_3_10,QKK35502_QKK35503,Unique source,SARS-CoV-2,2,1,12.747401,10.080748
6CT7_H_L,EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL,6CT7_H,6CT7_L,Fab Of Anti-A-Synuclein Antibody Biib054 In Complex With Acetylated A-Synuclein Peptide (1-10),Fab Of Anti-A-Synuclein Antibody Biib054 In Complex With Acetylated A-Synuclein Peptide (1-10),Homo sapiens,"Weihofen,A.;Liu,Y.;Arndt,J.W.;Huy,C.;Quan,C.;Smith,B.A.;Baeriswyl,J.L.;Cavegn,N.;Senn,L.;Su,L.;Marsh,G.;Auluck,P.K.;Montrasio,F.;Nitsch,R.M.;Hirst,W.D.;Cedarbaum,J.M.;Pepinsky,R.B.;Grimm,J.;Weinreb,P.H.","Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models",19-DEC-2018,8_10_4_6_3_11,QPV13115_QPV13117,Xtal structure,alpha-synuclein,2,1,13.0563965,8.456237
CAN87421,EVQLVESGGGLVKPEGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSGGGYINYADSLKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCARGRGYCSGGVCYVDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSSLAWYQQKPGQAPRLLIYDASNRAAGIPARFSGSGSGTDFTLTIGRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,CAN87421_H,CAN87421_L,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Throsby,M.; de Kruif,C.A.; Bakker,A.Q.",Method for preparing immunoglobulin libraries,04-JUN-2007,8_8_16_6_3_9,AHL54518,Same entry,,2,1,16.08,9.994937
7LR3_A_B,EVQLVESGGGLVKPGGSLKLSCAASEFTFSDYGMHWVRQAPEKGLEWVASISSGSNSIYYSDTVKGRFTISRDNAKSILFLQMTSLRSEDTAMYYCSREAYFAMDYWGQGTSVTVSS,DIQMTQSPSSLSAILGGKVTITCKASQDIHKYIAWYQHKPGKGPRLLIYYTSTLQPGIPSRFSGSGSGRDYSFSISNLEPEDVATYFCLQYDNLYTFGGGTKVEIE,7LR3_A,7LR3_B,Complex Of Fab 2/6.14 With Domain 3 Of P. Berghei Hap2,Complex Of Fab 2/6.14 With Domain 3 Of P. Berghei Hap2,Mus musculus,"Feng,J.;Dong,X.;DeCosta,A.;Su,Y.;Angrisano,F.;Sala,K.A.;Blagborough,A.M.;Lu,C.;Springer,T.A.",Structural basis of malaria transmission blockade by a monoclonal antibody to gamete fusogen HAP2,15-FEB-2021,8_8_10_6_3_8,7LR3_A_B,Xtal structure,HIP5; HLP; HAP2; HAP1; hHLP1,2,1,17.44012,7.864434
AGO85913,EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGSSYGVLFAYWGQGTLVTVS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGGGTKLEIK,AGO85913_H,AGO85913_L,anti-CD22 scFv-gelonin antibody [synthetic construct],anti-CD22 scFv-gelonin antibody [synthetic construct],synthetic construct,"Tran,M.; Henry,R.E.; Siefker,D.; Van,C.; Newkirk,G.; Kim,J.; Bui,J.; Mayfield,S.P.",Production of anti-cancer immunotoxins in algae: Ribosome inactivating proteins as fusion partners,22-OCT-2013,8_8_16_6_3_9,AGO85913,Same entry,CD22; SIGLEC-2; SIGLEC2,2,1,18.001696,6.951093
CAJ09937_CAJ09936,EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGSSYGVLFAYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGGGTKLEIK,CAJ09937,CAJ09936,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Pastan,I.H.; Ho,M.; Bang,S.H.",Mutated anti-cd22 antibodies and immunoconjugates,22-JUN-2005,8_8_16_6_3_9,ATK86568_ATK86569,Unique chain,cd22,2,1,17.999325,6.975282
2J5L_C_B,EVQLVESGGGLVKPGGSLKLSCAASGFIFSDYYMYWVRQTPEKRLEWVATISDGNSYTYYVDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAIYYCARDGPTDSSGYGGFGYWGQGTLVTVS,SVLSQSPAILSASPGEKVTMTCRARSSVSYMHWYQQKSGSSPKPWIHATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSHPPTFGSGTKLEIK,2J5L_C,2J5L_B,Structure Of A Plasmodium Falciparum Apical Membrane Antigen 1-Fab F8. 12.19 Complex,Structure Of A Plasmodium Falciparum Apical Membrane Antigen 1-Fab F8. 12.19 Complex,Mus musculus,"Igonet,S.;Vulliez-Le Normand,B.;Faure,G.;Riottot,M.M.;Kocken,C.H.;Thomas,A.W.;Bentley,G.A.",Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation,18-SEP-2006,8_8_16_5_3_9,2J5L_C_B,Xtal structure,Plasmodium,2,1,17.907438,7.244577
4U1G_E_F,EVQLVESGGGLVKPGGSLKLSCAASGFTFSDFYMYWVRQTPEKRLEWVATISDGDSYIYYPDSVRGRFTISRDNAKNILFLQMSSLKSEDTAMYFCARDGNGKDGGDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASQSVSTSSYTYFHWYQQKPGQPPKLLIRYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIK,4U1G_E,4U1G_F,Plasmodium Falciparum Reticulocyte-Binding Protein Homologue 5 (Pfrh5) Bound To Monoclonal Antibody Qa1,Plasmodium Falciparum Reticulocyte-Binding Protein Homologue 5 (Pfrh5) Bound To Monoclonal Antibody Qa1,Mus musculus,"Wright,K.E.;Hjerrild,K.A.;Bartlett,J.;Douglas,A.D.;Jin,J.;Brown,R.E.;Illingworth,J.J.;Ashfield,R.;Clemmensen,S.B.;de Jongh,W.A.;Draper,S.J.;Higgins,M.K.",Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies,15-JUL-2014,8_8_15_10_3_9,4U1G_E_F,Xtal structure,basigin,2,1,17.768179,7.2632585
6EK2_H_H,EVQLVESGGGLVKPGGSLKLSCAASGFTFSDYYMHWVRQTPKKRLEWVATISDGGSYTYFLDSVKGRFTISRDNAKNKLDLQMSSLKSEDTGMYYCARDGNKYSAWFAYWGQGTLVTVS,DIQMTQSSSSFSVSLGDRVTITCKASEDIYNRLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDFATYYCQQYWSPPWTFGGGTKLEIK,6EK2_H,6EK2_H,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With Single Chain Fv Fragment 10,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With Single Chain Fv Fragment 10,Mus musculus,"Nelson,B.;Adams,J.;Kuglstatter,A.;Li,Z.;Harris,S.F.;Liu,Y.;Bohini,S.;Ma,H.;Klumpp,K.;Gao,J.;Sidhu,S.S.",Structure-Guided Combinatorial Engineering Facilitates Affinity and Specificity Optimization of Anti-CD81 Antibodies,25-SEP-2017,8_8_13_6_3_9,6EK2_H_H,Xtal structure,CD81; TAPA-1; TSPAN28; TAPA1,2,1,17.93869,7.2240467
5F3B_E_F,EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTSYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQDYAMNYWGQGTLVTVSS,DIEMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLLYSASYRYTGVPDRFTGSGSGTDFTFTISSVNAEDLAVYYCQQHYSTPWTFGGGTKVEIK,5F3B_E,5F3B_F,Structure Of Myostatin In Complex With Chimeric Rk35 Antibody,Structure Of Myostatin In Complex With Chimeric Rk35 Antibody,Homo sapiens,"Apgar,J.R.;Mader,M.;Agostinelli,R.;Benard,S.;Bialek,P.;Johnson,M.;Gao,Y.;Krebs,M.;Owens,J.;Parris,K.;St Andre,M.;Svenson,K.;Morris,C.;Tchistiakova,L.",Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody,02-DEC-2015,8_8_9_6_3_9,5F3B_E_F,Xtal structure,myostatin,2,1,17.995697,7.1645207
3RA7_H_L,EVQLVESGGGLVKPGGSLKLSCAVSGFTFSDYAMSWIRQTPENRLEWVASINIGATYAYYPDSVKGRFTISRDNAKNTLFLQMSSLGSEDTAMYYCARPGSPYEYDKAYYSMAYWGPGTSVTVSS,DVQMTQSTSSLSASLGDRVTISCRASQDIKNYLNWYQQKPGGTVKLLIYYSSTLLSGVPSRFSGRGSGTDFSLTITNLEREDIATYFCQQSITLPPTFGGGTKLEIK,3RA7_H,3RA7_L,Bispecific Digoxigenin Binding Antibodies For Targeted Payload Delivery,Bispecific Digoxigenin Binding Antibodies For Targeted Payload Delivery,Mus musculus,"Metz,S.;Haas,A.K.;Daub,K.;Croasdale,R.;Stracke,J.;Lau,W.;Georges,G.;Josel,H.P.;Dziadek,S.;Hopfner,K.P.;Lammens,A.;Scheuer,W.;Hoffmann,E.;Mundigl,O.;Brinkmann,U.",Bispecific digoxigenin-binding antibodies for targeted payload delivery,27-MAR-2011,8_8_18_6_3_9,AMF11950_AMF11949,Xtal structure,digoxigenin; Digoxigenin,2,1,17.91167,7.0789595
ABV03179,EVQLVESGGGLVKPGGSLKLSCVASGFTFSSYGMNWVRQVPGKGLEWVSDISGSGGSAYYADSVQGRFTISRDNTNNTLYLQINSLRAEDTAVYYCARDHLYYDFWSGFYRAYGMDVWGRGTTVTVSS,DIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRAFGQGTKLEIK,ABV03179_H,ABV03179_L,"anti-human Phlp5 scFv antibody, partial [synthetic construct]","anti-human Phlp5 scFv antibody, partial [synthetic construct]",synthetic construct,"Persson,J.; Augustsson,P.; Laurell,T.; Ohlin,M.",Acoustic microfluidic chip technology to facilitate automation of phage display selection,26-JUL-2016,8_8_21_7_3_6,ABV03179,Same entry,,2,1,13.616544,10.122991
QWQ58069_QWQ58111,EVQLVESGGGLVKPGGSLRISCSSSGFTFSDYTMNWVRQAPGKGLEWVSSISSRSGYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRVRDGDNYWDSVDATYWGYGAFDICGHGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYFAWYQQRPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISGLQAEDVAVYYCQQHFTTPQTFGQGTKVEIK,QWQ58069,QWQ58111,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Li,L.; Freyn,A.W.; Liu,S.T.H.; Stovicek,O.; Stamper,C.T.; Dugan,H.L.; Tepora,M.E.; Utset,H.A.; Bitar,D.J.; Hamel,N.J.; Changrob,S.; Zheng,N.Y.; Huang,M.; Krammer,F.; Nachbagauer,R.; Palese,P.; Ward,A.B.; Wilson,P.C.",First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,19-JUN-2021,8_8_27_12_3_9,QWQ58069_QWQ58111,Unique source,hemagglutinin; H1N1,2,1,16.211758,10.109162
7UVH_A_B,EVQLVESGGGLVKPGGSLRLSCAASGFAFSTYAMSWVRQAPGKGLEWVSSISESSSYTYYTDSVKGRFTISRDNAKKSLFLHMNSLRAEDTAVYYCARSDGLSMIAAPFDYWGQGARVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQSLSISLVWYQQKPGQAPRLLISDASNRAPGIPARFSASGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPITFGQGTRLEMK,7UVH_A,7UVH_B,Pfs230 Domain 1 Bound By Rupa-32 Fab,Pfs230 Domain 1 Bound By Rupa-32 Fab,Plasmodium falciparum,"Ivanochko,D.;Newton,J.;Julien,J.P.",Pfs230 Domain 1 Bound by Inhibitory RUPA-32 Fab,15-FEB-2023,8_8_15_6_3_10,7UVH_A_B,Xtal structure,,2,1,15.997212,9.9702425
AAZ86723,EVQLVESGGGLVKPGGSLRLSCAASGFIFSDHYMAWVRQTPGKGLEWISYISMTSSYTNYADSVKGRFTISRDNAKNSLSLEMNSLRVEDTAVYYCARDRLRNWNDDAFDIWGPGTMVTVSS,QSVLTQPASVSGSPGQSITISCTGTSNDVGGYNFVSWYQKFPGKAPKLIIYDVTNRPSGVSDRFSASKSGNTASLTISGLQAEDEADYYCSSYTGSNSFVIFGGGTKLTVL,AAZ86723_H,AAZ86723_L,"anti-Phl p 5 allergen single chain antibody fragment, partial [synthetic construct]","anti-Phl p 5 allergen single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Andreasson,U.; Flicker,S.; Lindstedt,M.; Valenta,R.; Greiff,L.; Korsgren,M.; Borrebaeck,C.A.; Ohlin,M.",The human IgE-encoding transcriptome to assess antibody repertoires and repertoire evolution,26-JUL-2016,8_8_15_9_3_11,AAZ86723,Same entry,Phl,2,1,15.905483,9.892788
QWQ58064_QWQ58109,EVQLVESGGGLVKPGGSLRLSCAASGFIFSDYTMNWVRQVPGKGLEWVSSISSYSGYIYYADSVKGRFTLSRDNAKKSLYLQMNNLRAEDTAVYYCAKDRVRDGDNDWDSVDATYWGYGVFDTSGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYGSNNKNYFAWYQQKPGQPPKMLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYRIPQTFGQGTKVEIK,QWQ58064,QWQ58109,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Li,L.; Freyn,A.W.; Liu,S.T.H.; Stovicek,O.; Stamper,C.T.; Dugan,H.L.; Tepora,M.E.; Utset,H.A.; Bitar,D.J.; Hamel,N.J.; Changrob,S.; Zheng,N.Y.; Huang,M.; Krammer,F.; Nachbagauer,R.; Palese,P.; Ward,A.B.; Wilson,P.C.",First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,19-JUN-2021,8_8_27_12_3_9,QWQ58064_QWQ58109,Unique source,hemagglutinin; H1N1,2,1,16.208925,10.105227
QKK35774_QKK35775,EVQLVESGGGLVKPGGSLRLSCAASGFIFSDYYMSWIRQAPGKGLEWVSYITGSGRTIHYADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARGHRFLEFPLNYFDPWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCAVTSSDVGSYNLVSWHQQHPGKAPKLMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEAVYYCCSYGGRSTSVVFGGGTKLTVL,QKK35774,QKK35775,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_9_3_11,QKK35774_QKK35775,Unique source,SARS-CoV-2,2,1,15.68903,9.425238
QYB25429_QYB25498,EVQLVESGGGLVKPGGSLRLSCAASGFIFSSSSMNWVRQAPGKGLEWVSSISSSGSYIYYADSVRGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVVPNYYDSRGYYPGAFDIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,QYB25429,QYB25498,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_8_20_6_3_10,QYB25429_QYB25498,Unique source,SARS-CoV-2,2,1,16.225405,10.1369705
7S0X_C_D,EVQLVESGGGLVKPGGSLRLSCAASGFSFSEYRMNWVRQAPGKGLEWVSFISSSGTYIDYADSVKGRFTISRDNVNNSLYLQMNNLRAGDTAVYYCARGMGIAVRRFDYWGQGTLVSVSS,SYVLTQPPSVSVAPGQTAKITCGGNNIGSESVHWYQQKPGQAPVLVVYDDAVRPSGIPERFSGSNSRNTATLTISRVEAGDEAAYYCQVWDSSTVASFGGGTKLTVL,7S0X_C,7S0X_D,Fab352 In Complex With The C-Terminal Alphatsr Domain Of P. Falciparum,Fab352 In Complex With The C-Terminal Alphatsr Domain Of P. Falciparum,Plasmodium falciparum 3D7,"Beutler,N.;Pholcharee,T.;Oyen,D.;Flores-Garcia,Y.;MacGill,R.S.;Garcia,E.;Calla,J.;Parren,M.;Yang,L.;Volkmuth,W.;Locke,E.;Regules,J.A.;Dutta,S.;Emerling,D.;Early,A.M.;Neafsey,D.E.;Winzeler,E.A.;King,C.R.;Zavala,F.;Burton,D.R.;Wilson,I.A.;Rogers,T.F.",A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum,31-AUG-2021,8_8_13_6_3_10,7S0X_C_D,Xtal structure,,2,1,15.951884,10.1291485
QTX15812_QTX15705,EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYSMNWVRQAPGKGLEWVSSISSNSNYIYYADSMKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASNRSPYDSSNYYFDYWGQGTRVTISS,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHHDSLPLTFGGGTKVEIK,QTX15812,QTX15705,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Graham,C.; Seow,J.; Huettner,I.; Khan,H.; Kouphou,N.; Acors,S.; Winstone,H.; Pickering,S.; Galao,R.P.; Dupont,L.; Lista,M.J.; Jimenez-Guardeno,J.M.; Laing,A.G.; Wu,Y.; Joseph,M.; Muir,L.; van Gils,M.J.; Ng,W.M.; Duyvesteyn,H.M.E.; Zhao,Y.; Bowden,T.A.; Shankar-Hari,M.; Rosa,A.; Cherepanov,P.; McCoy,L.E.; Hayday,A.C.; Neil,S.J.D.; Malim,M.H.; Doores,K.J.",Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant,21-APR-2021,8_8_16_6_3_9,QTX15812_QTX15705,Unique source,SARS-CoV-2,2,1,16.185726,10.080835
AMB38422_AMB38550,EVQLVESGGGLVKPGGSLRLSCAASGFTFPGYNMNWVRQAPGKGLEWVSSISSSSSYIYYGDSVKGRFTISRDNAKNSLYLQMNSLRDDDTAVYYCARDLGGRGALTGYWIDSWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSNNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCQQYNNWPRTFGQGTKVEIK,AMB38422,AMB38550,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_17_6_3_9,AMB38422_AMB38550,Unique source,,2,1,16.070044,10.07064
7ZXK_H_L,EVQLVESGGGLVKPGGSLRLSCAASGFTFRSYGMNWVRQAPGKGLEWVSGISSSGSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGGRTSYTATAHNWFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHASAPPTFGGGTKVEIK,7ZXK_H,7ZXK_L,Human Il-27 In Complex With Neutralizing Srf388 Fab Fragment,Human Il-27 In Complex With Neutralizing Srf388 Fab Fragment,Homo sapiens,"Skladanowska,K.;Bloch,Y.;Strand,J.;White,K.F.;Hua,J.;Aldridge,D.;Welin,M.;Logan,D.T.;Soete,A.;Merceron,R.;Murphy,C.;Provost,M.;Bazan,J.F.;Hunter,C.A.;Hill,J.A.;Savvides,S.N.",Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27,02-NOV-2022,8_8_19_12_3_9,7ZXK_H_L,Xtal structure,interleukin,2,1,16.018055,10.026589
QKK35490_QKK35491,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWVRQAPGKGLEWVSSISSSSYMYYADSMKGRFTISRDNAQNSLYLQMSSLRAEDTAVYYCARDFPGDTAVAGTGFNYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQVPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYVFGTGTKVTVL,QKK35490,QKK35491,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_9_3_12,QKK35490_QKK35491,Unique source,SARS-CoV-2,2,1,16.059978,9.945682
AF161589_1,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHRPGRMFRSPYWGQGTLVTVS,SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,AF161589_1_H,AF161589_1_L,single chain Fv antibody against hepatitis C virus non-structural protein 3 [synthetic construct],single chain Fv antibody against hepatitis C virus non-structural protein 3 [synthetic construct],synthetic construct,"Cheng,J.; Zhong,Y.W.; Liu,Y.; Dong,J.; Yang,J.Z.; Zhang,L.X.",Screening and identification of a humanized single chain variable region antibody for hepatitis C virus non-structural 3 protein,28-FEB-2003,8_8_13_6_3_11,AF161589_1,Same entry,,2,1,15.66202,9.404015
QKY76475_QKY76088,EVQLVESGGGLVKPGGSLRLSCAASGFTFSGYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARWLQLRSDYYYFGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSNNLAWYQHKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQCYNWPPWTFGQGTKVEIK,QKY76475,QKY76088,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_17_6_3_10,QKY76475_QKY76088,Unique source,SARS-CoV-2,2,1,16.068243,10.055793
QDF60603_QDF61435,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKGKTDGGTTDYAAPVRGRFTISRDDSKNMLYLQMNSLKTEDTAIYYCTADVIPAATRGVYYYYYYMDVWGEGTTVAVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGLSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYARSSTVVFGGGTKVTVL,QDF60603,QDF61435,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Davis,C.W.; Jackson,K.J.L.; McElroy,A.K.; Halfmann,P.; Huang,J.; Chennareddy,C.; Piper,A.E.; Leung,Y.; Albarino,C.G.; Crozier,I.; Ellebedy,A.H.; Sidney,J.; Sette,A.; Yu,T.; Nielsen,S.C.A.; Goff,A.J.; Spiropoulou,C.F.; Saphire,E.O.; Cavet,G.; Kawaoka,Y.; Mehta,A.K.; Glass,P.J.; Boyd,S.D.; Ahmed,R.",Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection,01-JUL-2019,8_10_21_9_3_10,QDF60603_QDF61435,Unique source,Ebola,2,1,12.993497,8.520077
QQD86942_QQD86943,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSHRMHWVRQAPGKGLEWVSSIISSRTYIYYADSVKGRFTISRDNSGNSLFLQMNSLRVEDTAVYYCARGDYYYDGVASDPHFDNWGQGTLVTVSS,QSVLTQTPSASGTPGQRVTISCSGSRSNIGSNYVYWFQQFPGAAPQLLIYRNIQRPSGVPARFSGSKSDTSASLAISGLRSEDEAHYYCAAWDDSLSGVVFGGGTKVTVL,QQD86942,QQD86943,"anti-tuberculosis immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tuberculosis immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Freund,N.T.",Human Antibodies Targeting a Mycobacterium Transporter Protein Mediate Protection Against Tuberculosis,28-DEC-2020,8_8_18_8_3_11,QQD86942_QQD86943,Unique source,tuberculosis,2,1,16.132202,10.082318
6JJP_D_E,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVATISGGGSYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPDSSGVAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASITCKASQDVETVVAWYLQKPGQSPRLLIYWASTRHTGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQYSRYPWTFGQGTKLEIK,6JJP_D,6JJP_E,Crystal Structure Of Fab Of A Pd-1 Monoclonal Antibody Mw11-H317 In Complex With Pd-1,Crystal Structure Of Fab Of A Pd-1 Monoclonal Antibody Mw11-H317 In Complex With Pd-1,Homo sapiens,"Wang,M.;Wang,J.;Wang,R.;Jiao,S.;Wang,S.;Zhang,J.;Zhang,M.",Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation,26-FEB-2019,8_8_10_6_3_9,6JJP_D_E,Xtal structure,PD1; PDCD1; SLEB2; hSLE1; CD279; PD-1,2,1,14.920103,9.276878
5TLK_H_G,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWIRQAPGKGLEWVSYIDEGGGQTIYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHRGNPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKSVSEGRWSFMHWYQQKPGKAPKLLIYVASRLESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHSRELPWTFGQGTKVEIK,5TLK_H,5TLK_G,Complex Between Human Cd27 And Fab Fragments Of Antibodies M2177 And H2191,Complex Between Human Cd27 And Fab Fragments Of Antibodies M2177 And H2191,Homo sapiens,"Obmolova,G.;Teplyakov,A.;Malia,T.J.;Wunderler,N.;Kwok,D.;Barone,L.;Sweet,R.;Ort,T.;Scully,M.;Gilliland,G.L.",Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography,11-OCT-2016,8_8_10_10_3_9,5TLK_H_G,Xtal structure,S152; TNFRSF7; CD27; Tp55,2,1,15.065653,9.289678
QKY76474_QKY76087,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISNSNSFIYYADSMKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVNGNSNWNFGSYYYYYMDVWGKGTTVTVSS,EIVLTQSPAILSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAFYYCQQRGNWWTFAQGTKVEIK,QKY76474,QKY76087,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_21_6_3_8,QKY76474_QKY76087,Unique source,SARS-CoV-2,2,1,16.178242,10.121616
3H42_H_L,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYISYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYFCARDYDFWSAYYDAFDVWGQGTMVTVSS,ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLISGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,3H42_H,3H42_L,Crystal Structure Of Pcsk9 In Complex With Fab From Ldlr Competitive Antibody,Crystal Structure Of Pcsk9 In Complex With Fab From Ldlr Competitive Antibody,Homo sapiens,"Chan,J.C.;Piper,D.E.;Cao,Q.;Liu,D.;King,C.;Wang,W.;Tang,J.;Liu,Q.;Higbee,J.;Xia,Z.;Di,Y.;Shetterly,S.;Arimura,Z.;Salomonis,H.;Romanow,W.G.;Thibault,S.T.;Zhang,R.;Cao,P.;Yang,X.P.;Yu,T.;Lu,M.;Retter,M.W.;Kwon,G.;Henne,K.;Pan,O.;Tsai,M.M.;Fuchslocher,B.;Yang,E.;Zhou,L.;Lee,K.J.;Daris,M.;Sheng,J.;Wang,Y.;Shen,W.D.;Yeh,W.C.;Emery,M.;Walker,N.P.;Shan,B.;Schwarz,M.;Jackson,S.M.",A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates,17-APR-2009,8_8_16_9_3_11,AEQ82469_AEQ82468,Xtal structure,,2,1,16.155062,10.126662
QYB25462_QYB25532,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVVPYYYDSSGYYPGAFDIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQHYYNWPPWTFGQGTKVDIK,QYB25462,QYB25532,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_8_20_6_3_10,QYB25462_QYB25532,Unique source,SARS-CoV-2,2,1,16.258268,10.152019
QYB25460_QYB25530,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYGDSVKGRFTISRDNAKNSLYLQMNSLRAADTAVYYCARVVPHYYDSSGYYPGAFDMWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYNWPPWTFGQGTKVEIK,QYB25460,QYB25530,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_8_20_6_3_10,QYB25460_QYB25530,Unique source,SARS-CoV-2,2,1,16.283243,10.160457
QBK47482_QBK47556,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISTSKNYKKYADSVKGRFTISRDNAENSLYLQMNSLRAEDTAIYYCARVDYDYIWGSYREKAMDVWGHGTTVTVSS,QSALTQPRSVSGSPGQSVTISCTGTGSDVGGYNYVSWYQQHPGKAPKVIIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYHCCSYAGTYTWVFGGGTKVTVL,QBK47482,QBK47556,immunoglobulin heavy chain [Homo sapiens],immunoglobulin lambda chain [Homo sapiens],Homo sapiens,"Lindner,J.M.; Cornacchione,V.; Sathe,A.; Be,C.; Srinivas,H.; Riquet,E.; Leber,X.C.; Hein,A.; Wrobel,M.B.; Scharenberg,M.; Pietzonka,T.; Wiesmann,C.; Abend,J.; Traggiai,E.",Human Memory B Cells Harbor Diverse Cross-Neutralizing Antibodies against BK and JC Polyomaviruses,13-MAR-2019,8_8_19_9_3_10,QBK47482_QBK47556,Unique source,,2,1,16.207018,10.117362
6OEJ_B_C,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGRGLEWVSSISNTSTYIYYADSVEGRFTLSRDNAKNSLYLQMNSLRAEDTAVYYCARANQHFDWLLSLLGGYHYYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFIGSGSGTDFTLKISRVEAEDVGVFYCMQALQAVGFGPGTKVEIK,6OEJ_B,6OEJ_C,Crystal Structure Of The Non-Neutralizing And Adcc-Potent Antibody C11 In Complex With Hiv-1 Clade A/E Gp120,Crystal Structure Of The Non-Neutralizing And Adcc-Potent Antibody C11 In Complex With Hiv-1 Clade A/E Gp120,Homo sapiens,"Tolbert,W.D.;Van,V.;Sherburn,R.;Tuyishime,M.;Yan,F.;Nguyen,D.N.;Stanfield-Oakley,S.;Easterhoff,D.;Bonsignori,M.;Haynes,B.F.;Moody,M.A.;Ray,K.;Ferrari,G.;Lewis,G.K.;Pazgier,M.",Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial,27-MAR-2019,8_8_24_11_3_8,6OEJ_B_C,Xtal structure,HAKRA; CHDR; AKR1C4; DD4; CDR; 3-alpha-HSD; HIV; MGC22581; C11,2,1,16.172297,10.126519
ASP69756_ASP69797,EVQLVESGGGLVKPGGSLRLSCAASGFTFTNAWLDWVRQAPGKGLEWVGRIKSKTDGGTTDHAAPVKGRFTISRDDSKNTVYLQMNSLKIEDTAVYYCTTGVETYDFWSGYDDHYYDYYFKDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSNNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQSARSFTFGPGTKVDIK,ASP69756,ASP69797,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Landais,E.; Murrell,B.; Briney,B.; Murrell,S.; Rantalainen,K.; Berndsen,Z.T.; Ramos,A.; Wickramasinghe,L.; Smith,M.L.; Eren,K.; de Val,N.; Wu,M.; Cappelletti,A.; Umotoy,J.; Lie,Y.; Wrin,T.; Algate,P.; Chan-Hui,P.Y.; Karita,E.; Ward,A.B.; Wilson,I.A.; Burton,D.R.; Smith,D.; Pond,S.L.K.; Poignard,P.",HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage,29-NOV-2017,8_10_25_7_3_8,ASP69756_ASP69797,Unique source,HIV,2,1,12.960417,8.523022
QYB25463_QYB25533,EVQLVESGGGLVKPGGSLRLSCAASGITFSSYSMNWVRQAPGKGLEWVSSISRSSSFIYYADSVKGRFTISRDTAKNSLYLQMNSLRAEDTAVYYCARAKGHYYDSSGYYPDAFDIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,QYB25463,QYB25533,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_8_20_6_3_10,QYB25463_QYB25533,Unique source,SARS-CoV-2,2,1,16.233885,10.139099
5U4R_H_L,EVQLVESGGGLVKPGGSLRLSCEVSGFTFSDYHATWLRQAPGKGLEWISYISGSGSTTYYADAVKGRFTISRDNAKNSVYLEMSSLRDEDTAVYYCARTRLGDIVQAPGVIGYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQRIRNYLNWYQQKPGRAPKLLIYTASKLQGGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSHETPLTFGQGTKIEVR,5U4R_H,5U4R_L,Crystal Structure Of The Broadly Neutralizing Influenza A Antibody Vrc 315 53-1A09 Fab.,Crystal Structure Of The Broadly Neutralizing Influenza A Antibody Vrc 315 53-1A09 Fab.,Homo sapiens,"Andrews,S.F.;Joyce,M.G.;Chambers,M.J.;Gillespie,R.A.;Kanekiyo,M.;Leung,K.;Yang,E.S.;Tsybovsky,Y.;Wheatley,A.K.;Crank,M.C.;Boyington,J.C.;Prabhakaran,M.S.;Narpala,S.R.;Chen,X.;Bailer,R.T.;Chen,G.;Coates,E.;Kwong,P.D.;Koup,R.A.;Mascola,J.R.;Graham,B.S.;Ledgerwood,J.E.;McDermott,A.B.",Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans,05-DEC-2016,8_8_23_6_3_9,5U4R_H_L,Xtal structure,hemagglutinin; Influenza,2,1,15.70165,9.961881
AMB38440_AMB38566,EVQLVESGGGLVKPGGSLRLSCGASGFSFSSYSMNWVRQAPGKGLEWVSLISRSSSYTDYEDSVKGRFIVSRDNAKNSLYLQMNSLRAEDTAVYYCARPILSGDYVWGQGAFEIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRAPDIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSSTWTFGQGTKVEIK,AMB38440,AMB38566,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_18_7_3_10,AMB38440_AMB38566,Unique source,,2,1,16.256042,10.151248
QVG74166_QVG74167,EVQLVESGGGLVKPGGSLRLSCSASGFTFSSYSMNWVRQAPGQGLEWVSCISHSNTYIHYADSVKGRFTISRDNAKNSLFLQMDSLRAEDTAVYYCARAASHYYDSIGIFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPYTFGQGTKLEIK,QVG74166,QVG74167,"anti-peanut 2S albumin immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-peanut 2S albumin immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehlers,A.M.; den Hartog Jager,C.F.; Knulst,A.C.; Otten,H.G.",Distinction between peanut allergy and tolerance by characterization of B-cell receptor repertoires,18-MAY-2021,8_8_16_6_3_9,QVG74166_QVG74167,Unique source,peanut,2,1,16.195229,10.050967
QKK35840_QKK35841,EVQLVESGGGLVKPGGSLRLSCVASGFTFSDFYMSWIRQAPGKGLEWVSYISGSGDTIYYADSVKGRFTVSRDNAKNSLFLQMSSLGAEDTAMYYCAREMATSFGYYFVLDVWGQGTTVTVSS,EIVMTQTPSSLSASVGDRVTITCRASQSISNYVNWYQQKPGRAPNLLIYAASSLQSGVSSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSTPPEGPTFGPGTKVEIK,QKK35840,QKK35841,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_12,QKK35840_QKK35841,Unique source,SARS-CoV-2,2,1,15.672419,9.437785
APX42333_APX42334,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNTWMSWVRQAPGKGLEWVGRISRNKDGAKTDYAAPVRGRFTISRDDSRDTLYLQMSSLKIEDSGRYFCTADLGEAVVSRFFEWGSYYYYMDFWGKGTTVTVSS,DIQMTQSPSPLSASVGDTVTITCRASQKISDYLNWYQQRPGRAPKILIYAASKLASDVPSRFSGSGYGRDFTLTITGLQPEDFATYYCQEAYSSTPTLTFGQGTRLDLK,APX42333,APX42334,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Williams,L.D.; Ofek,G.; Schatzle,S.; McDaniel,J.R.; Lu,X.; Nicely,N.I.; Wu,L.; Lougheed,C.S.; Bradley,T.; Louder,M.K.; McKee,K.; Bailer,R.T.; O'Dell,S.; Georgiev,I.S.; Seaman,M.S.; Parks,R.J.; Marshall,D.J.; Anasti,K.; Yang,G.; Nie,X.; Tumba,N.L.; Wiehe,K.; Wagh,K.; Korber,B.; Kepler,T.B.; Alam,S.M.; Morris,L.; Kamanga,G.; Cohen,M.S.; Bonsignori,M.; Xia,S.-M.; Montefiori,D.C.; Kelsoe,G.; Gao,F.; Mascola,J.R.; Moody,M.A.; Saunders,K.O.; Liao,H.-X.; Tomaras,G.D.; Georgiou,G.; Haynes,B.F.",Potent and broad HIV-neutralizing antibodies in memory B cells and plasma,27-JAN-2017,8_10_24_6_3_11,APX42333_APX42334,Unique source,HIV,2,1,12.953928,8.471096
AMB38461_AMB38644,EVQLVESGGGLVKPGGSLRVSCAASGFIFGTFGMNWVRQAPGKGLEWVSSISSASASIEYADAVKGRFTISRDNAEKSLYLQMNSLRADDTAVYYCARDGGVPRRYSLDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGAYNLVSWYQQHPGKAPKLMIFDVTNRPSGVSNRFSGSKSGDTASLTISGLQAEDEADYFCSSYTNTRTLLFGGGTKLTVL,AMB38461,AMB38644,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_14_9_3_10,AMB38461_AMB38644,Unique source,,2,1,15.877194,9.886676
QPL06766_QPL06764,EVQLVESGGGLVPPGRSLRLSCTASAFTFADYTMGWVRQAPGKGLEWVASIRTNAYGGTTEYAASVKGRFSVSRDDSKSVAYLQMHSLRSDDTALYYCTRFSFYDSGGPRQFYYGLDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDIIRWLAWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQPDSFPLTFGQGTRLEIK,QPL06766,QPL06764,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_10_20_6_3_9,QPL06766_QPL06764,Unique source,,2,1,13.277909,8.9373045
5GRZ_G_G,EVQLVESGGGLVQCGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVCGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK,5GRZ_G,5GRZ_G,Crystal Structure Of Disulfide-Bonded Diabody,Crystal Structure Of Disulfide-Bonded Diabody,Homo sapiens,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,13-AUG-2016,8_8_12_7_3_9,5GRZ_G_G,Xtal structure,,2,1,13.899904,10.926866
7SHU_E_F,EVQLVESGGGLVQPDGSLRLSCAVSGYNITSGYSWNWIRQTPGKGLEWVASVTYDGSTNYNPSVKGRITISRDGSKNTFYLQMNSLRAEDTAVYYCAKGNNYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASKSVDSDGDSYMNWYQQKPGRAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,7SHU_E,7SHU_F,Ige-Fc In Complex With Omalizumab Variant C02,Ige-Fc In Complex With Omalizumab Variant C02,Homo sapiens,"Pennington,L.F.;Gasser,P.;Kleinboelting,S.;Zhang,C.;Skiniotis,G.;Eggel,A.;Jardetzky,T.S.",Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex,11-OCT-2021,9_7_14_10_3_9,7SHU_E_F,Xtal structure,,2,1,11.703297,10.515674
QKK35744_QKK35745,EVQLVESGGGLVQPGESLRLSCAASGFNFSPYGMNWVRQAPGKGLEWIAYIISGSGTIYYADSVKGRFTISRDNAQSSLYLQMNSLRAEDTAVYYCARGLLDYLHDAFDIWGQGTMVTVSS,EIVLTQSPATLSVSPGERITLSCRASHSVSSNLAWYQQKPGQVPRLLIYGASARATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNYWPPLTFGGGTKVEIK,QKK35744,QKK35745,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_10,QKK35744_QKK35745,Unique source,SARS-CoV-2,2,1,15.541647,9.798076
CAA61440_CAA61441,EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSTMHWVRQASGKGLEWVGRIRNKDNSYATAYAASVKGRFTISRDDSENTAYLQMNSLKIEDTAVYYCTRGSSMVRGVNGYYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYFDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK,CAA61440,CAA61441,"immunoglobulin anti-F(ab')2 variable region heavy chain, partial [Homo sapiens]","immunoglobulin anti-F(ab')2 variable region light chain, partial [Homo sapiens]",Homo sapiens,"Welschof,M.; Terness,P.; Kipriyanov,S.M.; Stanescu,D.; Breitling,F.; Dorsam,H.; Dubel,S.; Little,M.; Opelz,G.",The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody,26-JUL-2016,8_10_18_11_3_9,CAA61440_CAA61441,Unique source,,2,1,13.232844,8.313906
7YIZ_B_A,EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCSNRYYYGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVNTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQYINYPYTFGQGTKLEIK,7YIZ_B,7YIZ_A,Crystal Structure Of Anti-Mpeg H15-2B Fab W104Y Mutant,Crystal Structure Of Anti-Mpeg H15-2B Fab W104Y Mutant,Homo sapiens,"Chang,C.Y.;Nguyen,T.M.T.;Li,Y.C.;Su,Y.C.",Crystal structure of anti-mPEG h15-2b Fab W104Y mutant,02-AUG-2023,8_10_5_6_3_9,7YIZ_B_A,Xtal structure,mPEG; Mpeg,2,1,13.351354,8.126911
4UT6_I_M,EVQLVESGGGLVQPGGSLKLSCAASGFTFSSHWMHWVRQAPGKGLVWVSRTNSDGSSTSYADSVKGRFMISRDNSKNTVYLHMNGLRAEDTAVYFCARDGVRYYYDSTGYYPDNFFQYGLDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGISSDVETYNLVSWYEQHPGKAPKLIIYEASKRPSGVSNRFSGSKSGNTASLAISGLQAEDEADYYCCSYAGGKSLVFGGGTRLTVL,4UT6_I,4UT6_M,Crystal Structure Of Dengue 2 Virus Envelope Glycoprotein In Complex  With The Fab Fragment Of The Broadly Neutralizing Human Antibody Ede2  B7,Crystal Structure Of Dengue 2 Virus Envelope Glycoprotein In Complex  With The Fab Fragment Of The Broadly Neutralizing Human Antibody Ede2  B7,Homo sapiens,"Dejnirattisai,W.;Wongwiwat,W.;Supasa,S.;Zhang,X.;Dai,X.;Rouvinsky,A.;Jumnainsong,A.;Edwards,C.;Quyen,N.T.;Duangchinda,T.;Grimes,J.M.;Tsai,W.Y.;Lai,C.Y.;Wang,W.K.;Malasit,P.;Farrar,J.;Simmons,C.P.;Zhou,Z.H.;Rey,F.A.;Mongkolsapaya,J.;Screaton,G.R.","A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus",18-JUL-2014,8_8_26_9_3_10,4UT6_I_M,Xtal structure,Dengue; dengue,2,1,14.327152,10.502294
CAV32064_CAV32067,EVQLVESGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLELVASINSNGGSTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASGDYWGQGSTLTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,CAV32064,CAV32067,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Pfeifer,A.; Pihlgren,M.; Muhs,A.; Watts,R.",Antibodies,19-DEC-2008,8_8_5_11_3_9,CAV32064_CAV32067,Unique chain,,2,1,17.599472,7.1809
AAW68640_AAW69068,EVQLVESGGGLVQPGGSLRLSCAASDFTFSSYSMNWVRQAPGKGLEWVAYISTSSGTIYYADSVKGRFTISRDNAKNSLYLQMNSLGDEDTAVYYCARDLFFGPLKGLFDSWGQGTLVTV,DVVMTQSPGTLSLSPGERATLSCRASQSLSRTYLAWYQQKPGRAPRLLIYGESGRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYHNSPWTFGQGTKVEIK,AAW68640,AAW69068,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_15_7_3_9,AAW68640_AAW69068,Unique source,tetanus,2,1,15.722879,10.038208
7E5Y_C_B,EVQLVESGGGLVQPGGSLRLSCAASEITVSSNYMNWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDLMEVGGMDVWGQGTTVTVSS,LPVLTQPPSASGTPGQRVTISCSGSSSNVENDNVNWFQQQVPGSTPKLVIYNDRLRPSGVPDRFSGSKSGTSAYLAISGLQSEDEADYYCVAWDASLQSYVFGTGTKVTVL,7E5Y_C,7E5Y_B,Molecular Basis For Neutralizing Antibody 2B11 Targeting Sars-Cov-2 Rbd,Molecular Basis For Neutralizing Antibody 2B11 Targeting Sars-Cov-2 Rbd,Homo sapiens,"Pan,Y.;Du,J.;Liu,J.;Wu,H.;Gui,F.;Zhang,N.;Deng,X.;Song,G.;Li,Y.;Lu,J.;Wu,X.;Zhan,S.;Jing,Z.;Wang,J.;Yang,Y.;Liu,J.;Chen,Y.;Chen,Q.;Zhang,H.;Hu,H.;Duan,K.;Wang,M.;Wang,Q.;Yang,X.",Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries,21-FEB-2021,8_7_12_8_3_11,7E5Y_C_B,Xtal structure,SARS-CoV-2,2,1,12.566051,10.764847
8HN7_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYEMNWVRQAPGKGLEWVSYIHNSGNPVYYADSVKGRFTISRDNAENSLYLQMNSLRAEDTAIYYCARALRYSTSWYDYWGQGTLVTVSS,EIVLTQSPVSLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLFIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,8HN7_B,8HN7_A,Crystal Structure Of Monoclonal Antibody Complexed With Sars-Cov-2 Rbd,Crystal Structure Of Monoclonal Antibody Complexed With Sars-Cov-2 Rbd,Severe acute respiratory syndrome coronavirus 2,"Wang,Z.;Li,D.;Chen,Y.;Sun,Y.;Jin,C.;Hu,C.;Feng,Y.;Su,J.;Ren,L.;Hao,Y.;Wang,S.;Zhu,M.;Liu,Y.;Qi,J.;Zhu,B.;Shao,Y.",Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents,17-MAY-2023,8_8_13_6_3_9,8HN7_B_A,Xtal structure,RBD; SARS-CoV-2; COVID,2,1,15.748859,9.959249
5F72_T_T,EVQLVESGGGLVQPGGSLRLSCAASGFAISASSIHWVRQAPGKCLEWVASIDPETGETLYAKSVAGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARAYAGDGVYYADVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYSFPSTFGCGTKVEIK,5F72_T,5F72_T,De Novo Design And Crystallographic Validation Of Antibodies Targeting A Pre-Selected Epitope,De Novo Design And Crystallographic Validation Of Antibodies Targeting A Pre-Selected Epitope,Homo sapiens,"Liu,X.;Coker,S.;Ceska,T.;Baker,T.",De Novo Design And Crystallographic Validation Of A Targeting A Pre-Selected Epitope,07-DEC-2015,8_8_14_6_3_9,5F72_T_T,Xtal structure,,2,1,9.840676,10.7364025
1TZH_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFDIYDDDIHWVRQAPGKGLEWVAYIAPSYGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRSSDASYSYSAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQASYSSVAWYQQKPGKAPKLLIYAASYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSSASPATFGQGTKVEIK,1TZH_B,1TZH_A,Crystal Structure Of The Fab Yads1 Complexed With H-Vegf,Crystal Structure Of The Fab Yads1 Complexed With H-Vegf,Homo sapiens,"Sidhu,S.S.;Li,B.;Chen,Y.;Fellouse,F.A.;Eigenbrot,C.;Fuh,G.",Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions,09-JUL-2004,8_8_15_6_3_8,1TZH_B_A,Xtal structure,,2,1,9.924338,10.98215
QKK35604_QKK35605,EVQLVESGGGLVQPGGSLRLSCAASGFIFKNEPMNWIRQFPGKGLEWISNIRDNGNDVYYADSVKGRFTVSRDNAKNSLYLQMNSLRDDDTALYYCVRDTDWAFDSWGQGTLVTVSS,QPVLTQPRSVSGSPGQSVTISCTGSSSTFGTDNHISWYQQLPGKVPKLIIHAVSQRPSVVPDRFSGSRSGNTASLTISGLQAEDEADYYCCSSPGTITWVFGGGTKVTVL,QKK35604,QKK35605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_10_9_3_10,QKK35604_QKK35605,Unique source,SARS-CoV-2,2,1,15.321804,9.797185
6NEX_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFIFSSDWMNWVRQAPGKGLEWVANINQDGSEKYYVDSVKGRFTISRDNAQNSLYLQMNSLRAEDTAVYYCAKELGPWGQGTLVTVSS,EAVVIQESALTTSPGGTVILTCRSSTGTITTSNYANWVQKKPNHVFTGLIGATSIRAPGVPVRFSGFLIGGKAALTITGAQTEDDAMYFCALWYNTHYVFGGGTKVTVL,6NEX_B,6NEX_A,Fab Fragement Of Anti-Cocaine Antibody H2E2,Fab Fragement Of Anti-Cocaine Antibody H2E2,Mus musculus,"Tan,K.;Zhou,M.;Ahrendt,A.J.;Duke,N.E.;Tabaja,N.;Ball,W.J.;Kirley,T.L.;Norman,A.B.;Joachimiak,A.;Schiffer,M.;Wilton,R.;Pokkuluri,P.R.","Structural analysis of free and liganded forms of the Fab fragment of a high-affinity anti-cocaine antibody, h2E2",18-DEC-2018,8_8_6_9_3_9,6NEX_B_A,Xtal structure,cocaine,2,1,11.188345,7.8358183
AMB38460_AMB38643,EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWMSWVRQAPGKGLEWVANINQGGSEKQYVDSVKGRFTISRDNAKKSLFLQMNRLRAEDTAVYYCVRVGAYGDTYHDYYGMDVWGQGTTVTVSS,SYELTQAPSVSVAPGQTARITCGGNNIGSKSVQWYQQKPGQAPVMVVFDGSDRPSGIPERFSGANSGNTATLTISRVEAGDEADYHCQVWDSSSERHVVFGGGTKLTVL,AMB38460,AMB38643,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_18_6_3_12,AMB38460_AMB38643,Unique source,,2,1,11.172919,7.8152366
7XIK_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFIVGWNYMSWVRQAPGKGLEWVSVIYPGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCAREAYGMDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGIPSSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPYTFGQGTKLEIK,7XIK_H,7XIK_L,Sars-Cov-2-Omicron-Rbd And B38-Gwp/P-Vk Antibody Complex,Sars-Cov-2-Omicron-Rbd And B38-Gwp/P-Vk Antibody Complex,Homo sapiens,"Shi,R.;Wang,Y.;Wu,Z.;Han,X.;Yan,J.",SARS-CoV-2-Omicron-RBD and B38-GWP/P-VK antibody complex,26-APR-2023,8_7_9_7_3_10,7XIK_H_L,Xtal structure,SARS-CoV-2; RBD,2,1,12.536119,10.6340885
UNJ20708_UNJ20857,EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDYFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLISGASSRAAGIPDRFSGSGSGTDFTLTINRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,UNJ20708,UNJ20857,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,8_7_11_6_3_9,UNJ20708_UNJ20857,Unique source,SARS-CoV-2,2,1,12.727482,10.218109
4CNI_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,4CNI_H,4CNI_L,Crystal Structure Of The Fab Portion Of Olokizumab In Complex With Il- 6,Crystal Structure Of The Fab Portion Of Olokizumab In Complex With Il- 6,Homo sapiens,"Shaw,S.;Bourne,T.;Meier,C.;Carrington,B.;Gelinas,R.;Henry,A.;Popplewell,A.;Adams,R.;Baker,T.;Rapecki,S.;Marshall,D.;Moore,A.;Neale,H.;Lawson,A.",Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling,22-JAN-2014,8_10_11_6_3_9,AEW40878_AEW40879,Xtal structure,interleukin-6,2,1,13.360078,8.369203
7NIV_E_D,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVASISSSSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARAYIWWYQMRQAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSSLITFGQGTKVEIK,7NIV_E,7NIV_D,"Nanodisc Reconstituted Human Abcb4 In Complex With 4B1-Fab And Qa2-Fab (Phosphatidylcholine-Bound, Occluded Conformation)","Nanodisc Reconstituted Human Abcb4 In Complex With 4B1-Fab And Qa2-Fab (Phosphatidylcholine-Bound, Occluded Conformation)",Homo sapiens,"Nosol,K.;Bang-Sorensen,R.;Irobalieva,R.N.;Erramilli,S.K.;Stieger,B.;Kossiakoff,A.A.;Locher,K.P.",Structures of ABCB4 provide insight into phosphatidylcholine translocation,14-FEB-2021,8_8_16_6_3_9,7NIV_E_D,Xtal structure,ABCB4; MDR2; MDR3; PGY3; GBD1; PFIC-3,2,1,9.637484,10.861802
8CAF_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVASISSSYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDPFGWAAHGVGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSYSLITFGQGTKVEIK,8CAF_B,8CAF_A,N8C_Fab3B In Complex With Nedd8-Cul1(Whb),N8C_Fab3B In Complex With Nedd8-Cul1(Whb),Homo sapiens,"Duda, D.M., Yanishevski, D., Henneberg, L.T., Schulman, B.A.",N8C_Fab3B In Complex With Nedd8-Cul1(Whb),13-SEP-2023,8_8_16_6_3_9,8CAF_B_A,Xtal structure,,2,1,9.594581,10.825905
4NNP_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVASIYSYSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARQSSAEIESWYYYSGEAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYYSSPFTFGQGTKVEIK,4NNP_H,4NNP_L,Crystal Structure Of Apo Manganese Abc Transporter Mntc From Staphylococcus Aureus Bound To An Antagonistic Fab Fragment,Crystal Structure Of Apo Manganese Abc Transporter Mntc From Staphylococcus Aureus Bound To An Antagonistic Fab Fragment,Homo sapiens,"Ahuja,S.;Rouge,L.;Swem,D.L.;Sudhamsu,J.;Wu,P.;Russell,S.J.;Alexander,M.K.;Tam,C.;Nishiyama,M.;Starovasnik,M.A.;Koth,C.M.",Structural analysis of bacterial ABC transporter inhibition by an antibody fragment,18-NOV-2013,8_8_21_6_3_10,4NNP_H_L,Xtal structure,,2,1,9.597371,10.871388
4I18_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSMHWVRQAPGQGLEWVAYISPYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYGYVYWNAYSSGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYYSYYYPFTFGQGTKVEIK,4I18_H,4I18_L,Crystal Structure Of Human Prolactin Receptor Complexed With Fab Fragment,Crystal Structure Of Human Prolactin Receptor Complexed With Fab Fragment,Homo sapiens,"Rizk,S.S.;Kouadio,J.L.;Szymborska,A.;Duguid,E.M.;Mukherjee,S.;Zheng,J.;Clevenger,C.V.;Kossiakoff,A.A.",Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling,20-NOV-2012,8_8_18_6_3_11,4I18_H_L,Xtal structure,prolactin,2,1,9.611202,10.836448
6CW3_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSYIHWVRQAPGKGLEWVASIYSYYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWWQGMYEMGYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQGWANLITFGQGTKVEIK,6CW3_C,6CW3_D,"Crystal Structure Of A Yeast Saga Transcriptional Coactivator Ada2/Gcn5 Hat Subcomplex, Crystal Form 2","Crystal Structure Of A Yeast Saga Transcriptional Coactivator Ada2/Gcn5 Hat Subcomplex, Crystal Form 2",Saccharomyces cerevisiae S288C,"Sun,J.;Paduch,M.;Kim,S.A.;Kramer,R.M.;Barrios,A.F.;Lu,V.;Luke,J.;Usatyuk,S.;Kossiakoff,A.A.;Tan,S.",Structural basis for activation of SAGA histone acetyltransferase Gcn5 by partner subunit Ada2,29-MAR-2018,8_8_16_6_3_9,6CW3_C_D,Xtal structure,,2,1,9.524894,10.912196
8DN7_D_H,EVQLVESGGGLVQPGGSLRLSCAASGFNFYYSSIHWVRQAPGKGLEWVASISSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARETYYTEFSWSYSWGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSIVWEPITFGQGTKVEIK,8DN7_D,8DN7_H,The Crystal Structure Of The Pisum Sativum Toc75 Potra Domains In Complex With Fab Ax9,The Crystal Structure Of The Pisum Sativum Toc75 Potra Domains In Complex With Fab Ax9,synthetic construct,"Srinivasan,K.;Erramilli,S.K.;Chakravarthy,S.;Gonzalez,A.;Kossiakoff,A.;Noinaj,N.",Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A.&#xa0;thaliana and P.&#xa0;sativum,17-MAY-2023,8_8_19_6_3_11,8DN7_D_H,Xtal structure,TOCG; FLJ22341; TOC; iRhom2; RHBDF2; RHBDL6; RHBDL5,2,1,9.551047,10.895536
8DN6_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFNFYYYSIHWVRQAPGKGLEWVASISPYSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYGWATYGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHFWELITFGQGTKVEIK,8DN6_C,8DN6_D,The Crystal Structure Of The Arabidopsis Thaliana Toc75 Potra Domains In Complex With Fab Tc2,The Crystal Structure Of The Arabidopsis Thaliana Toc75 Potra Domains In Complex With Fab Tc2,synthetic construct,"Srinivasan,K.;Erramilli,S.K.;Chakravarthy,S.;Gonzalez,A.;Kossiakoff,A.;Noinaj,N.",Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A.&#xa0;thaliana and P.&#xa0;sativum,17-MAY-2023,8_8_13_6_3_9,8DN6_C_D,Xtal structure,TOCG; FLJ22341; TOC; iRhom2; RHBDF2; RHBDL6; RHBDL5,2,1,9.716347,10.805576
6MY5_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTWIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGFMFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIPRRISGYVAWYQQKPGKAPKLLIYWGSYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,6MY5_A,6MY5_B,"Crystal Structure Of The Dimeric Bh1-Fab Variant [Hc-Y33W,Hc-D98F,Hc-G99M,Lc-S30Br]","Crystal Structure Of The Dimeric Bh1-Fab Variant [Hc-Y33W,Hc-D98F,Hc-G99M,Lc-S30Br]",Homo sapiens,"Schrag,J.D.;Picard,M.E.;Gaudreault,F.;Gagnon,L.P.;Baardsnes,J.;Manenda,M.S.;Sheff,J.;Deprez,C.;Baptista,C.;Hogues,H.;Kelly,J.F.;Purisima,E.O.;Shi,R.;Sulea,T.",Binding symmetry and surface flexibility mediate antibody self-association,01-NOV-2018,8_8_13_10_3_9,6MY5_A_B,Xtal structure,,2,1,10.213868,10.991166
6MY4_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTWIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGMMFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIPRRISGYVAWYQQKPGKAPKLLIYWGSYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,6MY4_A,6MY4_B,"Crystal Structure Of The Dimeric Bh1-Fab Variant [Hc-Y33W,Hc-D98M,Hc-G99M,Lc-S30Br]","Crystal Structure Of The Dimeric Bh1-Fab Variant [Hc-Y33W,Hc-D98M,Hc-G99M,Lc-S30Br]",Homo sapiens,"Schrag,J.D.;Picard,M.E.;Gaudreault,F.;Gagnon,L.P.;Baardsnes,J.;Manenda,M.S.;Sheff,J.;Deprez,C.;Baptista,C.;Hogues,H.;Kelly,J.F.;Purisima,E.O.;Shi,R.;Sulea,T.",Binding symmetry and surface flexibility mediate antibody self-association,01-NOV-2018,8_8_13_10_3_9,6MY4_A_B,Xtal structure,,2,1,10.1935425,10.991882
5TDO_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRKAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQEKPGKAPKLLIYSASFLESGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,5TDO_B,5TDO_A,Crystal Structure Of The Fab Fragment Of Anti-Her2 Antibody 4D5 With Redesigned Heavy And Light Chain Interfaces,Crystal Structure Of The Fab Fragment Of Anti-Her2 Antibody 4D5 With Redesigned Heavy And Light Chain Interfaces,Homo sapiens,"Yin,Y.;Carter,P.J.",Crystal Structure Of The Fab Fragment Of Anti-Her2 4d5 With Redesigned Heavy And Light Chain Interface,19-SEP-2016,8_8_13_6_3_9,5TDO_B_A,Xtal structure,Her2,2,1,10.2474165,11.05367
7KF0_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGGSFYYYYMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIPRSISGYVAWYQQKPGKAPKLLIYWGSYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,7KF0_A,7KF0_B,Crystal Structure Of Bh1 Fab Variant (Cdr H3 Loop Design 13_0346) In Complex With Vegf,Crystal Structure Of Bh1 Fab Variant (Cdr H3 Loop Design 13_0346) In Complex With Vegf,Homo sapiens,"Corbeil,C.;Manenda,M.S.;Sulea,T.;Baardsness,J.;Picard,M.-E.;Hogues,H.;Gaudreault,F.;Deprez,C.;Shi,R.;Purisima,E.O.",ADAPTing Antibody H3 Loops to Cognate Antigens Using Human Germline Derived Sequences,13-OCT-2020,8_8_13_10_3_9,7KF0_A_B,Xtal structure,,2,1,10.24377,11.034976
4X4X_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSADFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,4X4X_C,4X4X_D,Retrofitting Antibodies With Stabilizing Mutations. Herceptin Scfv Mutant.,Retrofitting Antibodies With Stabilizing Mutations. Herceptin Scfv Mutant.,Homo sapiens,"Langley,D.B.;Roome,B.;Christ,D.",Retrofitting antibodies with stabilizing mutations,04-DEC-2014,8_8_13_6_3_9,4X4X_C_D,Xtal structure,,2,1,10.216009,11.023827
1FVD_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTLYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLESGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,1FVD_B,1FVD_A,X-Ray Structures Of The Antigen-Binding Domains From Three Variants Of Humanized Anti-P185-Her2 Antibody 4D5 And Comparison With Molecular Modeling,X-Ray Structures Of The Antigen-Binding Domains From Three Variants Of Humanized Anti-P185-Her2 Antibody 4D5 And Comparison With Molecular Modeling,Homo sapiens,"Carter,P.;Presta,L.;Gorman,C.M.;Ridgway,J.B.;Henner,D.;Wong,W.L.;Rowland,A.M.;Kotts,C.;Carver,M.E.;Shepard,H.M.",Humanization of an anti-p185HER2 antibody for human cancer therapy,20-OCT-1992,8_8_13_6_3_9,QCB09542_QCB09541,Xtal structure,Her2; DKFZP586F1318; Ray; SH3YL1,2,1,10.251742,11.067309
3PJS_D_C,EVQLVESGGGLVQPGGSLRLSCAASGFNISSYSIHWVRQAPGKGLEWVASISSYYSSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARQPSYHMYSWWVALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLESGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYYSYSAPVTFGQGTKVEIK,3PJS_D,3PJS_C,Mechanism Of Activation Gating In The Full-Length Kcsa K+ Channel,Mechanism Of Activation Gating In The Full-Length Kcsa K+ Channel,Streptomyces lividans,"Uysal,S.;Cuello,L.G.;Cortes,D.M.;Koide,S.;Kossiakoff,A.A.;Perozo,E.",Mechanism of activation gating in the full-length KcsA K+ channel,10-NOV-2010,8_8_17_6_3_11,3PJS_D_C,Xtal structure,,2,1,9.553928,10.853903
5EII_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNISYSSIHWVRQAPGKGLEWVASISSYYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSRGQASWDYWWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSDDPITFGQGTKVEIK,5EII_H,5EII_L,Structural Determination Of An Protein Complex Of A Fab With Increased Solubility,Structural Determination Of An Protein Complex Of A Fab With Increased Solubility,Homo sapiens,"Bailey,L.J.;Kossiakoff,A.A.;Schaefer,Z.P.",Structural determination of an protein complex of a Fab with increased solubility,29-OCT-2015,8_8_17_6_3_9,5EII_H_L,Xtal structure,,2,1,9.59691,10.859099
5BK2_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFNIYSSSIHWVRQAPGKGLEWVASISSYSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYKYPYWSWYYYWGGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYYYGYPITFGQGTKVEIK,5BK2_C,5BK2_D,Crystal Structure Of Maltose Binding Protein In Complex With A Peristeric Synthetic Antibody,Crystal Structure Of Maltose Binding Protein In Complex With A Peristeric Synthetic Antibody,Homo sapiens,"Mukherjee,S.;Griffin,D.H.;Horn,J.R.;Rizk,S.S.;Nocula-Lugowska,M.;Malmqvist,M.;Kim,S.S.;Kossiakoff,A.A.",Engineered synthetic antibodies as probes to quantify the energetic contributions of ligand binding to conformational changes in proteins,12-SEP-2017,8_8_19_6_3_10,5BK2_C_D,Xtal structure,,2,1,9.531058,10.902812
8DJG_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNIYYSSIHWVRQAPGKGLEWVAYISPYSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYKYGQGHMGAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSNTELVTFGQGTKVEIK,8DJG_A,8DJG_B,Adgrl3-Lectin Domain In Complex With An Activating Synthetic Antibody Fragment,Adgrl3-Lectin Domain In Complex With An Activating Synthetic Antibody Fragment,Homo sapiens,"Kordon,S.P.;Dutka,P.;Adamska,J.M.;Bandekar,S.J.;Leon,K.;Erramilli,S.K.;Adams,B.;Li,J.;Kossiakoff,A.A.;Ara&#xe7;,D.",Isoform- and ligand-specific modulation of the adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder,15-FEB-2023,8_8_15_6_3_9,8DJG_A_B,Xtal structure,LEC3; BG37; GPCR; TGR5; MGC40597; GPR131; GPCR19; LPHN3; ADGRL3; KIAA0768; GPBAR1; M-BAR,2,1,9.767156,10.825643
8J7E_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNIYYSSMHWVRQAPGKGLEWVASISPYSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARPWYPWSYWSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQPWSWGSALITFGQGTKVEIK,8J7E_A,8J7E_B,Crystal Structure Of Bril In Complex With 1B3 Fab,Crystal Structure Of Bril In Complex With 1B3 Fab,Escherichia coli; Homo sapiens,"Zhong, Y.X., Guo, Q., Tao, Y.Y.",Crystal Structure Of Bril In Complex With 1B3 Fab,06-SEP-2023,8_8_15_6_3_12,8J7E_A_B,Xtal structure,,2,1,9.66478,10.855332
7JHH_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNIYYYSIHWVRQAPGKGLEWVASIYPYSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYYPYFISYYSKMEAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSGPITFGQGTKVEIK,7JHH_H,7JHH_L,Cryo-Em Structure Of Atp-Bound Fully Inactive Ampk In Complex With Fab And Nanobody,Cryo-Em Structure Of Atp-Bound Fully Inactive Ampk In Complex With Fab And Nanobody,synthetic construct,"Yan,Y.;Mukherjee,S.;Harikumar,K.G.;Strutzenberg,T.S.;Zhou,X.E.;Suino-Powell,K.;Xu,T.H.;Sheldon,R.D.;Lamp,J.;Brunzelle,J.S.;Radziwon,K.;Ellis,A.;Novick,S.J.;Vega,I.E.;Jones,R.G.;Miller,L.J.;Xu,H.E.;Griffin,P.R.;Kossiakoff,A.A.;Melcher,K.","Structure of an AMPK complex in an inactive, ATP-bound state",20-JUL-2020,8_8_19_6_3_9,7JHH_H_L,Xtal structure,PRKAA2; PRKAA; AMPKa2; AMPK,2,1,9.660023,10.803523
6O3B_G_E,EVQLVESGGGLVQPGGSLRLSCAASGFNIYYYSMHWVRQAPGKGLEWVASIYSSYSYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSSPGADYGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQWAYGPFTFGQGTKVEIK,6O3B_G,6O3B_E,Crystal Structure Of Frizzled 7 Crd In Complex With F6 Fab,Crystal Structure Of Frizzled 7 Crd In Complex With F6 Fab,Homo sapiens,"Raman,S.;Beilschmidt,M.;To,M.;Lin,K.;Lui,F.;Jmeian,Y.;Ng,M.;Fernandez,M.;Fu,Y.;Mascall,K.;Duque,A.;Wang,X.;Pan,G.;Angers,S.;Moffat,J.;Sidhu,S.S.;Magram,J.;Sinclair,A.M.;Fransson,J.;Julien,J.P.","Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies",26-FEB-2019,8_8_13_6_3_9,6O3B_G_E,Xtal structure,,2,1,9.752141,10.768529
5EU7_F_D,EVQLVESGGGLVQPGGSLRLSCAASGFNLYSYSMHWVRQAPGKGLEWVAYIYPYSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESSYFYDGSYSYYDYEGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSYSPLTFGQGTKVEIK,5EU7_F,5EU7_D,Crystal Structure Of Hiv-1 Integrase Catalytic Core In Complex With Fab,Crystal Structure Of Hiv-1 Integrase Catalytic Core In Complex With Fab,Homo sapiens,"Galilee,M.;Britan-Rosich,E.;Griner,S.L.;Uysal,S.;Baumgartel,V.;Lamb,D.C.;Kossiakoff,A.A.;Kotler,M.;Stroud,R.M.;Marx,A.;Alian,A.",The Preserved HTH-Docking Cleft of HIV-1 Integrase Is Functionally Critical,18-NOV-2015,8_8_23_6_3_9,5EU7_F_D,Xtal structure,HIV,2,1,9.530999,10.913415
3DVN_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFNVKTGLIHWVRQAPGKGLEWVAYISPYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAREYYRWYTAIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSSYSSLFTFGQGTKVEIK,3DVN_B,3DVN_A,Crystal Structure Of K63-Specific Fab Apu2.16 Bound To K63-Linked Di-Ubiquitin,Crystal Structure Of K63-Specific Fab Apu2.16 Bound To K63-Linked Di-Ubiquitin,Homo sapiens,"Newton,K.;Matsumoto,M.L.;Wertz,I.E.;Kirkpatrick,D.S.;Lill,J.R.;Tan,J.;Dugger,D.;Gordon,N.;Sidhu,S.S.;Fellouse,F.A.;Komuves,L.;French,D.M.;Ferrando,R.E.;Lam,C.;Compaan,D.;Yu,C.;Bosanac,I.;Hymowitz,S.G.;Kelley,R.F.;Dixit,V.M.",Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies,18-JUL-2008,8_8_13_6_3_11,3DVN_B_A,Xtal structure,polyubiquitin,2,1,9.699447,10.802627
6USF_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNVRSFSIHWVRQAPGKGLEWVAYISSSSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGYWPGEPWWKAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYLYYSLVTFGQGTKVEIK,6USF_H,6USF_L,Cryoem Structure Of Human Alpha4Beta2 Nicotinic Acetylcholine Receptor With Varenicline In Complex With Anti-Bril Synthetic Antibody Bak5,Cryoem Structure Of Human Alpha4Beta2 Nicotinic Acetylcholine Receptor With Varenicline In Complex With Anti-Bril Synthetic Antibody Bak5,Homo sapiens,"Mukherjee,S.;Erramilli,S.K.;Ammirati,M.;Alvarez,F.J.;Fennell,K.F.;Purdy,M.D.;Skrobek,B.M.;Radziwon,K.;Coukos,J.;Kang,Y.;Dutka,P.;Gao,X.;Qiu,X.;Yeager,M.;Eric Xu,H.;Han,S.;Kossiakoff,A.A.",Synthetic antibodies against BRIL as universal fiducial marks for single-particle cryoEM structure determination of membrane proteins,26-OCT-2019,8_8_17_6_3_10,6USF_H_L,Xtal structure,DSPA1; IFITM5; Hrmp1; fragilis4; BRIL,2,1,9.622778,10.894282
4G7V_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNVSSSSIHWVRQAPGKGLEWVASISSYYGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYSWSYAIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYFYWPITFGQGTKVEIK,4G7V_H,4G7V_L,"Crystal Structure Of Voltage Sensing Domain Of Ci-Vsp With Fragment Antibody (R217E, 2.5 A)","Crystal Structure Of Voltage Sensing Domain Of Ci-Vsp With Fragment Antibody (R217E, 2.5 A)",Ciona intestinalis,"Li,Q.;Wanderling,S.;Paduch,M.;Medovoy,D.;Singharoy,A.;McGreevy,R.;Villalba-Galea,C.A.;Hulse,R.E.;Roux,B.;Schulten,K.;Kossiakoff,A.;Perozo,E.",Structural mechanism of voltage-dependent gating in an isolated voltage-sensing domain,20-JUL-2012,8_8_12_6_3_9,4G7V_H_L,Xtal structure,,2,1,9.660752,10.82521
7KEO_E_F,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYSSIHWVRQAPGKGLEWVASIYSYYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYGFAGQPETWYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQAYVEPITFGQGTKVEIK,7KEO_E,7KEO_F,Crystal Structure Of K29-Linked Di-Ubiquitin In Complex With Synthetic Antigen Binding Fragment,Crystal Structure Of K29-Linked Di-Ubiquitin In Complex With Synthetic Antigen Binding Fragment,Homo sapiens,"Yu,Y.;Zheng,Q.;Erramilli,S.K.;Pan,M.;Park,S.;Xie,Y.;Li,J.;Fei,J.;Kossiakoff,A.A.;Liu,L.;Zhao,M.",K29-linked ubiquitin signaling regulates proteotoxic stress response and cell cycle,11-OCT-2020,8_8_17_6_3_9,7KEO_E_F,Xtal structure,,2,1,9.61634,10.8542595
6AZ2_C_E,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYSSIHWVRQAPGKGLEWVAYIYPSSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYSTKLAMDYWGQGTLVTVFN,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSQWYPITFGQGTKVEIK,6AZ2_C,6AZ2_E,Crystal Structure Of Asf1-Fab 12E Complex,Crystal Structure Of Asf1-Fab 12E Complex,Homo sapiens,"Bailey,L.J.;Sheehy,K.M.;Dominik,P.K.;Liang,W.G.;Rui,H.;Clark,M.;Jaskolowski,M.;Kim,Y.;Deneka,D.;Tang,W.J.;Kossiakoff,A.A.",Locking the Elbow: Improved Antibody Fab Fragments as Chaperones for Structure Determination,09-SEP-2017,8_8_12_6_3_9,6AZ2_C_E,Xtal structure,,2,1,9.881648,10.714572
5UEA_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYSSIHWVRQAPGKGLEWVAYIYPSSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYSTKLAMDYWGQGTLVTVVS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSQWYPITFGQGTKVEIK,5UEA_H,5UEA_L,Structure Of Antigen-Fab Complex With Histone Chaperone Asf1,Structure Of Antigen-Fab Complex With Histone Chaperone Asf1,Homo sapiens,"Bailey,L.J.;Kossiakoff,A.A.",Antibody Switch Residue Engineering for Improved Crystallization Chaperones,29-DEC-2016,8_8_12_6_3_9,5UEA_H_L,Xtal structure,,2,1,9.858544,10.697672
6AYZ_B_D,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYYSIHWVRQAPGKGLEWVASIYPYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGYGWALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQDGWSLITFGQGTKVEIK,6AYZ_B,6AYZ_D,Crystal Structure Of Asf1-Fab 12E Complex,Crystal Structure Of Asf1-Fab 12E Complex,Saccharomyces cerevisiae S288C,"Bailey,L.J.;Sheehy,K.M.;Dominik,P.K.;Liang,W.G.;Rui,H.;Clark,M.;Jaskolowski,M.;Kim,Y.;Deneka,D.;Tang,W.J.;Kossiakoff,A.A.",Locking the Elbow: Improved Antibody Fab Fragments as Chaperones for Structure Determination,08-SEP-2017,8_8_10_6_3_9,6AYZ_B_D,Xtal structure,,2,1,9.808356,10.759471
6PI7_C_B,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYYYIHWVRQAPGKGLEWVASIYPYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSHYRPWYKWAYGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQAFWDPITFGQGTKVEIK,6PI7_C,6PI7_B,Crystal Structure Of The Tdrd2 Extended Tudor Domain In Complex With An Antibody Fragment And The Piwil1 Peptide,Crystal Structure Of The Tdrd2 Extended Tudor Domain In Complex With An Antibody Fragment And The Piwil1 Peptide,Homo sapiens,"Chen,S.;Zhang,W.;Min,J.;Liu,K.",Lesson from a Fab-enabled co-crystallization study of TDRD2 and PIWIL1,26-JUN-2019,8_8_17_6_3_9,6PI7_C_B,Xtal structure,CT80.1; TDRD2; TDRKH; HIWI; PIWIL1; PIWI,2,1,9.626809,10.82568
7R0C_D_D,EVQLVESGGGLVQPGGSLRLSCAASGFNVYSSSIHWVRQAPGKCLEWVASISSYYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSRQFWYSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYKYVPVTFGCGTKVEIK,7R0C_D,7R0C_D,Structure Of The Avp-V2R-Arrestin2-Scfv30 Complex,Structure Of The Avp-V2R-Arrestin2-Scfv30 Complex,synthetic construct,"Bous,J.;Fouillen,A.;Orcel,H.;Trapani,S.;Cong,X.;Fontanel,S.;Saint-Paul,J.;Lai-Kee-Him,J.;Urbach,S.;Sibille,N.;Sounier,R.;Granier,S.;Mouillac,B.;Bron,P.",Structure of the vasopressin hormone-V2 receptor-beta-arrestin1 ternary complex,14-SEP-2022,8_8_13_6_3_9,7R0C_D_D,Xtal structure,V2R; DIR; DIR3; AVPR2,2,1,9.596413,10.843636
6SNH_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNVYSSSIHWVRQAPGKGLEWVASISSYSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAREYWSWYSYSYGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYWVGYPITFGQGTKVEIK,6SNH_H,6SNH_L,Cryo-Em Structure Of Yeast Alg6 In Complex With 6Ag9 Fab And Dol25-P-Glc,Cryo-Em Structure Of Yeast Alg6 In Complex With 6Ag9 Fab And Dol25-P-Glc,synthetic construct,"Bloch,J.S.;Pesciullesi,G.;Boilevin,J.;Nosol,K.;Irobalieva,R.N.;Darbre,T.;Aebi,M.;Kossiakoff,A.A.;Reymond,J.L.;Locher,K.P.",Structure and mechanism of the ER-based glucosyltransferase ALG6,24-AUG-2019,8_8_16_6_3_11,6SNH_H_L,Xtal structure,ALG6,2,1,9.514992,10.915272
7TPG_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNVYSSSIHWVRQAPGKGLEWVAYISSYYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARIMFKWVSPNMAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSYYSLVTFGQGTKVEIK,7TPG_H,7TPG_L,Single-Particle Cryo-Em Structure Of The Waal O-Antigen Ligase In Its Ligand Bound State,Single-Particle Cryo-Em Structure Of The Waal O-Antigen Ligase In Its Ligand Bound State,Homo sapiens,"Ashraf,K.U.;Nygaard,R.;Vickery,O.N.;Erramilli,S.K.;Herrera,C.M.;McConville,T.H.;Petrou,V.I.;Giacometti,S.I.;Dufrisne,M.B.;Nosol,K.;Zinkle,A.P.;Graham,C.L.B.;Loukeris,M.;Kloss,B.;Skorupinska-Tudek,K.;Swiezewska,E.;Roper,D.;Clarke,O.B.;Uhlemann,A.C.;Kossiakoff,A.A.;Trent,M.S.;Stansfeld,P.J.;Mancia,F.",Structural basis of lipopolysaccharide maturation by the O-antigen ligase,25-JAN-2022,8_8_16_6_3_9,7TPG_H_L,Xtal structure,,2,1,9.649919,10.81018
6E1K_D_C,EVQLVESGGGLVQPGGSLRLSCAASGFNVYSYSIHWVRQAPGKGLEWVASISSYYSSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYWYWRTSTLGGIDYWGQGTLVTVFN,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSSLITFGQGTKVEIK,6E1K_D,6E1K_C,Structure Of Attpc1(Dde) Reconstituted In Saposin A With Cat06 Fab,Structure Of Attpc1(Dde) Reconstituted In Saposin A With Cat06 Fab,Homo sapiens,"Kintzer,A.F.;Green,E.M.;Dominik,P.K.;Bridges,M.;Armache,J.P.;Deneka,D.;Kim,S.S.;Hubbell,W.;Kossiakoff,A.A.;Cheng,Y.;Stroud,R.M.",Structural basis for activation of voltage sensor domains in an ion channel TPC1,10-JUL-2018,8_8_17_6_3_9,6E1K_D_C,Xtal structure,KIAA1169; TPCN1; FLJ20612; TPC1,2,1,9.584025,10.853505
5CWS_H_G,EVQLVESGGGLVQPGGSLRLSCAASGFNVYSYSIHWVRQAPGKGLEWVASIYSYYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARLTWRSYRGVHALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSSLITFGQGTKVEIK,5CWS_H,5CWS_G,Crystal Structure Of The Intact Chaetomium Thermophilum Nsp1-Nup49-Nup57 Channel Nucleoporin Heterotrimer Bound To Its Nic96 Nuclear Pore Complex Attachment Site,Crystal Structure Of The Intact Chaetomium Thermophilum Nsp1-Nup49-Nup57 Channel Nucleoporin Heterotrimer Bound To Its Nic96 Nuclear Pore Complex Attachment Site,Thermochaetoides thermophila DSM 1495,"Stuwe,T.;Bley,C.J.;Thierbach,K.;Petrovic,S.;Schilbach,S.;Mayo,D.J.;Perriches,T.;Rundlet,E.J.;Jeon,Y.E.;Collins,L.N.;Huber,F.M.;Lin,D.H.;Paduch,M.;Koide,A.;Lu,V.;Fischer,J.;Hurt,E.;Koide,S.;Kossiakoff,A.A.;Hoelz,A.",Architecture of the fungal nuclear pore inner ring complex,28-JUL-2015,8_8_16_6_3_9,5CWS_H_G,Xtal structure,,2,1,9.657975,10.797155
5BK1_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNVYYSSIHWVRQAPGKGLEWVASIYSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAREYHSYVYEPPLYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGSAPSLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSPQGYLVTFGQGTKVEIK,5BK1_H,5BK1_L,Crystal Structure Of Maltose Binding Protein In Complex With An Endosteric Synthetic Antibody,Crystal Structure Of Maltose Binding Protein In Complex With An Endosteric Synthetic Antibody,Escherichia coli,"Mukherjee,S.;Griffin,D.H.;Horn,J.R.;Rizk,S.S.;Nocula-Lugowska,M.;Malmqvist,M.;Kim,S.S.;Kossiakoff,A.A.",Engineered synthetic antibodies as probes to quantify the energetic contributions of ligand binding to conformational changes in proteins,12-SEP-2017,8_8_18_6_3_10,5BK1_H_L,Xtal structure,,2,1,9.558253,10.864792
6BF4_B_C,EVQLVESGGGLVQPGGSLRLSCAASGFPFNRDWMTWVRQAPGKGLEWVANINMDGDKKDYVDSVKGRFTISRDNAKTSLYLQMNSLRAGDTAVYYCARIRQVSKYLQWYPGVFEMWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATIHCKSSQSVLYRPNNRNYVAWYQQKPGQPPRLLIHWASFRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQQYFFLYSFGGGTKLEIN,6BF4_B,6BF4_C,Crystal Structure Of Hiv-1 Clade Ae Strain Cne55 Gp120 Core In Complex With Neutralizing Antibody Vrc-Pg05 That Targets The Center Of The Silent Face On The Outer Domain Of Gp120,Crystal Structure Of Hiv-1 Clade Ae Strain Cne55 Gp120 Core In Complex With Neutralizing Antibody Vrc-Pg05 That Targets The Center Of The Silent Face On The Outer Domain Of Gp120,Homo sapiens,"Zhou,T.;Zheng,A.;Baxa,U.;Chuang,G.Y.;Georgiev,I.S.;Kong,R.;O'Dell,S.;Shahzad-Ul-Hussan,S.;Shen,C.H.;Tsybovsky,Y.;Bailer,R.T.;Gift,S.K.;Louder,M.K.;McKee,K.;Rawi,R.;Stevenson,C.H.;Stewart-Jones,G.B.;Taft,J.D.;Waltari,E.;Yang,Y.;Zhang,B.;Shivatare,S.S.;Shivatare,V.S.;Lee,C.D.;Wu,C.Y.;Mullikin,J.C.;Bewley,C.A.;Burton,D.R.;Polonis,V.R.;Shapiro,L.;Wong,C.H.;Mascola,J.R.;Kwong,P.D.;Wu,X.",A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope,25-OCT-2017,8_8_19_12_3_8,AVC15688_AVC15696,Xtal structure,HIV,2,1,11.151984,7.795046
6OBD_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK,6OBD_H,6OBD_L,Crystal Structure Of Anti-Gld52 Fab Complex With Human Gld52 Peptide Mimetic,Crystal Structure Of Anti-Gld52 Fab Complex With Human Gld52 Peptide Mimetic,Homo sapiens,"Qiu,H.;Wei,R.;Jaworski,J.;Boudanova,E.;Hughes,H.;VanPatten,S.;Lund,A.;Day,J.;Zhou,Y.;McSherry,T.;Pan,C.Q.;Sendak,R.",Engineering an anti-CD52 antibody for enhanced deamidation stability,20-MAR-2019,8_10_5_11_3_8,AUF47999_AUF48000,Xtal structure,CDW52; CD52; EDDM5; HE5,2,1,13.313863,8.151695
7X8Q_C_B,EVQLVESGGGLVQPGGSLRLSCAASGFPIRGSSIHWVRQAPGKGLEWVAATYGWPGSITYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHTYPLWALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQGWPFFTFGQGTKVEIK,7X8Q_C,7X8Q_B,Frizzled-10 Crd In Complex With F10_A9 Fab,Frizzled-10 Crd In Complex With F10_A9 Fab,synthetic construct,"Ge,Q.;Teng,M.;Li,X.;Guo,Q.;Tao,Y.",An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies,18-JAN-2023,8_8_13_6_3_8,7X8Q_C_B,Xtal structure,,2,1,9.847472,10.760288
QVG74543_QVG74544,EVQLVESGGGLVQPGGSLRLSCAASGFSFSDHYLDWVRHAPGKGLEWVARIRSKANSYSTEYAASVKGRFTISRDDSKNSVYLQMNSLRTEDTAMYYCTRPYRAFNWATGHWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTVTCRASQGISSYLAWYQQKPGKAPKLLIYAVSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQVNSFPITFGQGTRLEIK,QVG74543,QVG74544,"anti-peanut 2S albumin immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-peanut 2S albumin immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehlers,A.M.; den Hartog Jager,C.F.; Knulst,A.C.; Otten,H.G.",Distinction between peanut allergy and tolerance by characterization of B-cell receptor repertoires,18-MAY-2021,8_10_13_6_3_9,QVG74543_QVG74544,Unique source,peanut,2,1,13.353506,8.452754
CCE67145_CCE67146,EVQLVESGGGLVQPGGSLRLSCAASGFSFSSYDMHWVRQATGKGLEWVSGIDIAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGDYDGTFDYWGQGTLVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPLRLLFYKISNRFSGVPDRFSGSGAGTDFTLIINRVEAEDVGVYYCMHATQFPITFGQGTRLEIK,CCE67145,CCE67146,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"VEIBY,O.; BABCOOK,J.",Antibodies that bind OV064 and methods of use therefor,23-NOV-2011,8_7_11_11_3_9,CCE67145_CCE67146,Ordered entries,,2,1,16.382275,11.582606
3G6J_H_G,EVQLVESGGGLVQPGGSLRLSCAASGFSFTSSSVSWVRQAPGKGLEWVGLIYPYNGFNYYADSVKGRFTISANTSKNTAYLQMNSLRAEDTAVYYCARNALYGSGGYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYATLPTFEQGTKVEIK,3G6J_H,3G6J_G,C3B In Complex With A C3B Specific Fab,C3B In Complex With A C3B Specific Fab,Homo sapiens,"Katschke KJ,Jr.;Stawicki,S.;Yin,J.;Steffek,M.;Xi,H.;Sturgeon,L.;Hass,P.E.;Loyet,K.M.;Deforge,L.;Wu,Y.;van Lookeren,Ca.;Wiesmann,C.",Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement,06-FEB-2009,8_8_16_6_3_9,3G6J_H_G,Xtal structure,C3a; C3; C3b; CPAMD1; ARMD9,2,1,9.924034,10.738542
4DKF_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFSFTSYGISWVRQAPGKGLEWVSHIDWYGGDTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGGPDYAMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWSEPVTFGQGTKVEIK,4DKF_H,4DKF_L,Crystal Structure Of Human Interleukin-34 Bound To Fab2,Crystal Structure Of Human Interleukin-34 Bound To Fab2,Homo sapiens,"Ma,X.;Lin,W.Y.;Chen,Y.;Stawicki,S.;Mukhyala,K.;Wu,Y.;Martin,F.;Bazan,J.F.;Starovasnik,M.A.",Structural Basis for the Dual Recognition of Helical Cytokines IL-34 and CSF-1 by CSF-1R,03-FEB-2012,8_8_11_6_3_9,4DKF_H_L,Xtal structure,C16orf77; IL34; IL-34; MGC34647; CSF-1R; CSF-1,2,1,10.132051,10.765343
2H9G_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFSIGKSGIHWVRQAPGKGLEWVAVIYPHDGNTAYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRLALVRMWMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK,2H9G_H,2H9G_L,Crystal Structure Of Phage Derived Fab Bdf1 With Human Death Receptor 5 (Dr5),Crystal Structure Of Phage Derived Fab Bdf1 With Human Death Receptor 5 (Dr5),Homo sapiens,"Li,B.;Russell,S.J.;Compaan,D.M.;Totpal,K.;Marsters,S.A.;Ashkenazi,A.;Cochran,A.G.;Hymowitz,S.G.;Sidhu,S.S.",Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists,09-JUN-2006,8_8_13_6_3_9,2H9G_H_L,Xtal structure,KILLER; DR5; TRAILR2; TRICKB; CD262; TNFRSF10B; TRICK2A; TRAIL-R2,2,1,10.008958,10.837974
1ZA3_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFSIYSYSIHWVRQAPGKGLEWVASISPYSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRYSSYYSYYYSSSSYSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYAASYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSSSSPYTFGQGTKVEIK,1ZA3_H,1ZA3_L,The Crystal Structure Of The Ysd1 Fab Bound To Dr5,The Crystal Structure Of The Ysd1 Fab Bound To Dr5,Homo sapiens,"Fellouse,F.A.;Li,B.;Compaan,D.M.;Peden,A.A.;Hymowitz,S.G.;Sidhu,S.S.",Molecular recognition by a binary code,05-APR-2005,8_8_22_6_3_8,1ZA3_H_L,Xtal structure,,2,1,9.520466,10.940854
7U5B_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFSLSSYGVTWVRQAPGKGLEWIGYITSNYGVSYYASWAKSRSTISRDTSKNTVYLQMGSLRAEDMAVYYCARENPDYGYAYDAWGQGTTVTVSS,AIRMTQSPSSFSASTGDRVTITCQASESISNELSWYQQKPGKAPKLLIYYASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAQGFGSSGVENVFGGGTKVEIK,7U5B_A,7U5B_B,Structure Of Human Klk5 Bound To Anti-Klk5 Fab,Structure Of Human Klk5 Bound To Anti-Klk5 Fab,Homo sapiens,"Chavarria-Smith,J.;Chiu,C.P.C.;Jackman,J.K.;Yin,J.;Zhang,J.;Hackney,J.A.;Lin,W.Y.;Tyagi,T.;Sun,Y.;Tao,J.;Dunlap,D.;Morton,W.D.;Ghodge,S.V.;Maun,H.R.;Li,H.;Hernandez-Barry,H.;Loyet,K.M.;Chen,E.;Liu,J.;Tam,C.;Yaspan,B.L.;Cai,H.;Balazs,M.;Arron,J.R.;Li,J.;Wittwer,A.J.;Pappu,R.;Austin,C.D.;Lee,W.P.;Lazarus,R.A.;Sudhamsu,J.;Koerber,J.T.;Yi,T.",Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis,14-DEC-2022,8_8_13_6_3_12,7U5B_A_B,Xtal structure,KLK7; SCCE; KLK-L2; SCTE; KLK5; PRSS6,2,1,12.910031,10.016243
6VRP_A_A,EVQLVESGGGLVQPGGSLRLSCAASGFSLSTSGIGVTWVRQAPGKGLEWLATIWWDDDNRYADSVKGRFTISADTSKNTAYLQMNSLTAEDTAVYYCAQSAITSVTDSAMDHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSKFPWTFGQGTKVEIK,6VRP_A,6VRP_A,Reverse Transcriptase Diabody With R83T Mutation,Reverse Transcriptase Diabody With R83T Mutation,Homo sapiens,"Chesterman,C.;Arnold,E.",Co-crystallization with diabodies: A case study for the introduction of synthetic symmetry,08-FEB-2020,10_7_15_6_3_9,6VRP_A_A,Xtal structure,,2,1,9.947926,10.634049
4LMQ_E_I,EVQLVESGGGLVQPGGSLRLSCAASGFSLTVYSVHWVRQAPGKGLEWVGALWGSGGTEYNSNLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDQGLNYGSLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESISYSLSWYQQKPGKAPKLLIYNAVKLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCKQYWNTPFTFGQGTKVEIK,4LMQ_E,4LMQ_I,Development And Preclinical Characterization Of A Humanized Antibody Targeting Cxcl12,Development And Preclinical Characterization Of A Humanized Antibody Targeting Cxcl12,Homo sapiens,"Zhong,C.;Wang,J.;Li,B.;Xiang,H.;Ultsch,M.;Coons,M.;Wong,T.;Chiang,N.Y.;Clark,S.;Clark,R.;Quintana,L.;Gribling,P.;Suto,E.;Barck,K.;Corpuz,R.;Yao,J.;Takkar,R.;Lee,W.P.;Damico-Beyer,L.A.;Carano,R.D.;Adams,C.;Kelley,R.F.;Wang,W.;Ferrara,N.",Development and preclinical characterization of a humanized antibody targeting CXCL12,10-JUL-2013,8_7_14_6_3_9,4LMQ_E_I,Xtal structure,SDF1B; TLSF-b; TLSF-a; SDF-1b; TPAR1; SDF1; SDF-1a; SDF1A; SCYB12; CXCL12; PBSF,2,1,12.877862,10.119445
AEE36489,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGSIAALRRHAFDIWGQGTMVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLRTFGQGTKVEIK,AEE36489_H,AEE36489_L,"single chain Fv antibody, partial [synthetic construct]","single chain Fv antibody, partial [synthetic construct]",synthetic construct,"Dubrovskaya,V.V.; Khlusevich,Y.A.; Morozova,V.V.; Tikunova,N.V.",Anti-orthopoxvirus human scFv selected from immune phage display library,15-FEB-2012,8_8_15_6_3_9,AEE36489,Same entry,orthopoxvirus,2,1,13.137038,11.981384
5GRY_A_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYACSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVS,DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK,5GRY_A,5GRY_A,Crystal Structure Of Disulfide-Bonded Diabody,Crystal Structure Of Disulfide-Bonded Diabody,Homo sapiens,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,12-AUG-2016,8_8_12_7_3_9,5GRY_A_A,Xtal structure,,2,1,13.8943,10.957587
5GRW_A_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLFAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK,5GRW_A,5GRW_A,Crystal Structure Of Homo-Specific Diabody,Crystal Structure Of Homo-Specific Diabody,Homo sapiens,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,12-AUG-2016,8_8_12_7_3_9,5GRW_A_A,Xtal structure,,2,1,13.851944,10.879723
5GRX_G_G,EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLTACDTAVYYCARFAGGWGAYDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK,5GRX_G,5GRX_G,Crystal Structure Of Disulfide-Bonded Diabody,Crystal Structure Of Disulfide-Bonded Diabody,Homo sapiens,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,12-AUG-2016,8_8_12_7_3_9,5GRX_G_G,Xtal structure,,2,1,13.887998,10.955325
5GS3_H_H,EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGLYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNTLSYTFGQGTKVEIK,5GS3_H,5GS3_H,Crystal Structure Of Diabody,Crystal Structure Of Diabody,Homo sapiens,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,13-AUG-2016,8_8_12_6_3_9,5GS3_H_H,Xtal structure,,2,1,13.899777,10.9305725
7SO7_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFRSYWMHWVRQVPGKGLVWVSCINKEGSSTTYADSVKGRFTISRDNAKNTLYLEMNSLRADDTAVYYCLRGYDVDYWGQGTLVTVSS,QAVLTQPSSLSASPGASVSLTCTLRSAINVGTYRIYWYQQKPGSPPRYLLRYKSGLDKHQGSGVPSRFSGSKDDSANAGILFISGLQSEDEADYYCLIWHSSAVVFGGGTKLTVL,7SO7_H,7SO7_L,Novel Structural Insights For A Pair Of Monoclonal Antibodies Recognizing Non-Overlapping Epitopes Of The Glucosyltransferase Domain Of Clostridium Difficile Toxin B,Novel Structural Insights For A Pair Of Monoclonal Antibodies Recognizing Non-Overlapping Epitopes Of The Glucosyltransferase Domain Of Clostridium Difficile Toxin B,Homo sapiens,"Liu,J.;Kothe,M.;Zhang,J.;Oloo,E.;Stegalkina,S.;Mundle,S.T.;Li,L.;Zhang,J.;Cole,L.E.;Barone,L.;Biemann,H.P.;Kleanthous,H.;Anosova,N.G.;Anderson,S.F.",Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B,29-OCT-2021,8_8_8_9_7_9,7SO7_H_L,Xtal structure,Toxin,2,1,13.776884,9.47921
QVG74189_QVG74190,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNKANSYTTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARTTVTTYLFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,QVG74189,QVG74190,"anti-peanut 2S albumin immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-peanut 2S albumin immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehlers,A.M.; den Hartog Jager,C.F.; Knulst,A.C.; Otten,H.G.",Distinction between peanut allergy and tolerance by characterization of B-cell receptor repertoires,18-MAY-2021,8_10_12_6_3_9,QVG74189_QVG74190,Unique source,peanut,2,1,13.284641,8.416519
7W7Q_A_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYEMHWVRQAPGKGLEWVSGISSDGSDTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHQVLEEAYAFDLWGQGTLVTVSS,IQMTQSPSSLSASVGDRVTITCRASQDISNWLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPWTFGQGTKVEIK,7W7Q_A,7W7Q_A,Crystal Structure Of 1F11S Antibody(Scfv),Crystal Structure Of 1F11S Antibody(Scfv),Mus musculus,"Kim,B.-W.;Woo,J.",Crystal structure of 1F11S antibody(ScFv),07-DEC-2022,8_8_14_6_3_9,7W7Q_A_A,Xtal structure,,2,1,13.897276,10.208056
3U30_F_E,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNTYISWVRQAPGKGLEWVASITPSSGQTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTWLLRWVMDLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSAKFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK,3U30_F,3U30_E,Crystal Structure Of A Linear-Specific Ubiquitin Fab Bound To Linear Ubiquitin,Crystal Structure Of A Linear-Specific Ubiquitin Fab Bound To Linear Ubiquitin,Homo sapiens,"Matsumoto,M.L.;Dong,K.C.;Yu,C.;Phu,L.;Gao,X.;Hannoush,R.N.;Hymowitz,S.G.;Kirkpatrick,D.S.;Dixit,V.M.;Kelley,R.F.",Engineering and structural characterization of a linear polyubiquitin-specific antibody,04-OCT-2011,8_8_12_6_3_9,APN69087_APN69086,Xtal structure,polyubiquitin,2,1,10.103093,10.79522
7CJ2_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSGISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGVGTFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQTISSWLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK,7CJ2_C,7CJ2_D,Crystal Structure Of The Fab Antibody Complexed With Human Ykl-40,Crystal Structure Of The Fab Antibody Complexed With Human Ykl-40,Homo sapiens,"Choi,S.;Na,J.H.;Lee,S.J.;Woo,J.R.;Kim,D.Y.;Lee,W.K.",Crystal structure of the Fab antibody complexed with human YKL-40,09-JUL-2020,8_8_8_6_3_9,7CJ2_C_D,Xtal structure,,2,1,14.113675,9.515973
5BO1_I_M,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGIHWVRQAPGKGLEWVGWITPDGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARAGTLFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYTTATTFGQGTKVEIK,5BO1_I,5BO1_M,Crystal Structure Of A Human Jag1 Fragment In Complex With An Anti-Jag1 Fab,Crystal Structure Of A Human Jag1 Fragment In Complex With An Anti-Jag1 Fab,Homo sapiens,"Lafkas,D.;Shelton,A.;Chiu,C.;de Leon,Bo.;Chen,Y.;Stawicki,S.S.;Siltanen,C.;Reichelt,M.;Zhou,M.;Wu,X.;Eastham-Anderson,J.;Moore,H.;Roose-Girma,M.;Chinn,Y.;Hang,J.Q.;Warming,S.;Egen,J.;Lee,W.P.;Austin,C.;Wu,Y.;Payandeh,J.;Lowe,J.B.;Siebel,C.W.",Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung,26-MAY-2015,8_8_9_6_3_9,AYH90979_AYH90980,Xtal structure,Notch,2,1,10.220549,10.743394
S23624_S23628,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSGYRGGDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPWTFGQGTKVEIK,S23624,S23628,Ig heavy chain V region - human (fragment),Ig kappa chain V region - human (fragment),Homo sapiens,"Olee,T.; Lu,E.W.; Huang,D.F.; Soto-Gil,R.W.; Deftos,M.; Kozin,F.; Carson,D.A.; Chen,P.P.",Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response,21-Jan-2000,8_8_10_6_3_9,S23624_S23628,Ordered entries,,2,1,15.659576,9.842592
QWY12428_QWY12454,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMHWVRQAPGKGLEWVANMKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAGPPPGGEIAMGGSWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGTNAVHWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNAWVFGGGTKLTVL,QWY12428,QWY12454,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Utset,H.A.; Henry,C.; Li,L.; Zheng,N.Y.; Sun,W.; Costa Vieira,M.; Zost,S.; Huang,M.; Hensley,S.E.; Cobey,S.; Palese,P.; Wilson,P.C.",An Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines,29-JUN-2021,8_8_14_8_3_11,QWY12428_QWY12454,Unique source,Antigenic; Influenza,2,1,11.1378765,7.785223
AAW68604_AAW69033,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMHWVRQAPGKGLVWVSRINSDGSSTDYADSVKGRVTISRDNAKNTLYLHMNSLRAEDTAVYYCVRPRGYCADGLCYPALYFYYMDVWGEGTTVTV,EIVMTQSPSSLSASVGDRVTITCRASQGIATYLAWFQQRPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSVPLTFGPGTKVAIK,AAW68604,AAW69033,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_23_6_3_9,AAW68604_AAW69033,Unique source,tetanus,2,1,14.352649,10.499091
6DZR_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQSPEKGLEWVSEIRLRSDNYATHYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTGIYYCRTYFYSFSYWGQGTLVTVSS,ELQMTQSPSSLSASVGDRVTITCRSSQSLLHTYGSPYLNWYLQKPGQSPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYFCSQGTHLPYTFGGGTKVEIK,6DZR_H,6DZR_L,Crystal Structure Of H38C2 K99R Mutation,Crystal Structure Of H38C2 K99R Mutation,Homo sapiens,"Hwang,D.;Nilchan,N.;Nanna,A.R.;Li,X.;Cameron,M.D.;Roush,W.R.;Park,H.;Rader,C.",Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues,05-JUL-2018,8_10_9_11_3_9,6DZR_H_L,Xtal structure,,2,1,13.422051,7.534781
QKY76322_QKY75935,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRLTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGFYYGGADYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVISEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGINRAWVFGGGTKLTVL,QKY76322,QKY75935,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_12_8_3_11,QKY76322_QKY75935,Unique source,SARS-CoV-2,2,1,11.177781,7.8236146
4XXD_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGSSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,4XXD_B,4XXD_A,Crystal Structure Of Mid-Region Amyloid Beta Capture By Solanezumab,Crystal Structure Of Mid-Region Amyloid Beta Capture By Solanezumab,Homo sapiens,"Crespi,G.A.;Hermans,S.J.;Parker,M.W.;Miles,L.A.",Molecular basis for mid-region amyloid-beta capture by leading Alzheimer's disease immunotherapies,30-JAN-2015,8_8_5_11_3_9,4XXD_B_A,Xtal structure,amyloid-beta; Amyloid,2,1,14.750353,9.2505665
1MHP_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYTMSWVRQAPGKGLEWVATISGGGHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGFGDGGYFDVWGQGTLVTVSS,IQLTQSPSSLSASVGDRVTITCSASSSVNHMFWYQQKPGKAPKPWIYLTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQWSGNPWTFGQGTKVEIK,1MHP_H,1MHP_L,Crystal Structure Of A Chimeric Alpha1 Integrin I-Domain In Complex With The Fab Fragment Of A Humanized Neutralizing Antibody,Crystal Structure Of A Chimeric Alpha1 Integrin I-Domain In Complex With The Fab Fragment Of A Humanized Neutralizing Antibody,Mus musculus,"Karpusas,M.;Ferrant,J.;Weinreb,P.H.;Carmillo,A.;Taylor,F.R.;Garber,E.A.",Crystal structure of the alpha1beta1 integrin I domain in complex with an antibody Fab fragment,20-AUG-2002,8_7_12_5_3_9,1MHP_H_L,Xtal structure,Integrin,2,1,13.9170685,9.383336
2B2X_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYTMSWVRQAPGKGLEWVAVISGGGHTYYLDSVEGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGFGDGGYFDVWGQGTLVTVSS,QIQLTQSPSSLSASVGDRVTITCSASSQVNHMFWYQQKPGKAPKPWIYLTSYLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQWSGNPWTFGQGTKVEIK,2B2X_H,2B2X_L,Vla1 Rdeltah I-Domain Complexed With A Quadruple Mutant Of The Aqc2 Fab,Vla1 Rdeltah I-Domain Complexed With A Quadruple Mutant Of The Aqc2 Fab,Mus musculus,"Clark,L.A.;Boriack-Sjodin,P.A.;Eldredge,J.;Fitch,C.;Friedman,B.;Hanf,K.J.;Jarpe,M.;Liparoto,S.F.;Li,Y.;Lugovskoy,A.;Miller,S.;Rushe,M.;Sherman,W.;Simon,K.;Van Vlijmen,H.",Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design,19-SEP-2005,8_7_12_5_3_9,2B2X_H_L,Xtal structure,,2,1,13.89408,9.444587
5X8M_B_C,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK,5X8M_B,5X8M_C,Pd-L1 In Complex With Durvalumab,Pd-L1 In Complex With Durvalumab,Homo sapiens,"Lee,H.T.;Lee,J.Y.;Lim,H.;Lee,S.H.;Moon,Y.J.;Pyo,H.J.;Ryu,S.E.;Shin,W.;Heo,Y.S.",Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab,03-MAR-2017,8_8_14_7_3_9,QHY12629_QHY12603,Xtal structure,CD274; PD1; B7-H; B7H1; B7-H1; PDCD1LG1; PDL1; PD-L1; PDCD1; SLEB2; hSLE1; CD279; PD-1,2,1,11.132803,7.7778883
7X8P_C_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFNMFWVRQAPGKGLEWVAGIDDDGSYPNYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSGGWALGGLITLRWIDAWGQGTLVTVSS,ELTQPPSVSVSPGQTARITCSGDGSIYRVFSYGWYQQKPGQAPVTLIYLNNKRPSGIPERFSGSLSGSTNTLTISGVQAEDEADYYCGSFGNAPLAFGGGTKLTVL,7X8P_C,7X8P_B,Frizzled 2 Crd In Complex With Pf7_A5 Fab,Frizzled 2 Crd In Complex With Pf7_A5 Fab,synthetic construct,"Ge,Q.;Teng,M.;Li,X.;Guo,Q.;Tao,Y.",An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies,01-FEB-2023,8_8_19_8_3_9,7X8P_C_B,Xtal structure,,2,1,14.11531,10.299674
4U6V_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK,4U6V_H,4U6V_L,Mechanisms Of Neutralization Of A Human Anti-Alpha Toxin Antibody,Mechanisms Of Neutralization Of A Human Anti-Alpha Toxin Antibody,Staphylococcus aureus subsp. aureus TCH60,"Oganesyan,V.;Peng,L.;Damschroder,M.M.;Cheng,L.;Sadowska,A.;Tkaczyk,C.;Sellman,B.R.;Wu,H.;Dall'Acqua,W.F.",Mechanisms of Neutralization of a Human Anti-alpha-toxin Antibody,29-JUL-2014,8_7_16_6_3_8,QPW22823_QPW22824,Xtal structure,Toxin,2,1,16.395363,11.617572
4DKE_I_M,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSTWIHWVRQAPGKGLEWVARISPYYYYSDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGLGKGSKRGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFYFPNTFGQGTKVEIK,4DKE_I,4DKE_M,Crystal Structure Of Human Interleukin-34 Bound To Fab1.1,Crystal Structure Of Human Interleukin-34 Bound To Fab1.1,Homo sapiens,"Ma,X.;Lin,W.Y.;Chen,Y.;Stawicki,S.;Mukhyala,K.;Wu,Y.;Martin,F.;Bazan,J.F.;Starovasnik,M.A.",Structural Basis for the Dual Recognition of Helical Cytokines IL-34 and CSF-1 by CSF-1R,03-FEB-2012,8_8_15_6_3_9,4DKE_I_M,Xtal structure,C16orf77; IL34; IL-34; MGC34647; CSF-1R; CSF-1,2,1,10.072646,10.807309
7S0C_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVSAIWGSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRDLAAFTKTAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHDALPWTFGQGTKVEIK,7S0C_H,7S0C_L,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody N-612-017,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody N-612-017,Homo sapiens,"Tanaka,S.;Anders Olson,C.;Barnes,C.O.;Higashide,W.;Gonzalez,M.;Taft,J.;Richardson,A.;Martin-Fernandez,M.;Bogunovic,D.;Gnanapragasam,P.N.;Bjorkman,P.J.;Spilman,P.;Niazi,K.;Rabizadeh,S.;Soon-Shiong,P.",Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display,30-AUG-2021,8_8_16_6_3_9,7S0C_H_L,Xtal structure,SARS-CoV-2,2,1,14.186472,10.202287
5VYF_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGRGYNADYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLEYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLRPEDFATYYCQQYNSYPLTFGGGTKVEIK,5VYF_B,5VYF_A,Structure Of Single Chain Fel D 1 Bound To A Neutralizing Antibody,Structure Of Single Chain Fel D 1 Bound To A Neutralizing Antibody,Felis catus,"Orengo,J.M.;Radin,A.R.;Kamat,V.;Badithe,A.;Ben,L.H.;Bennett,B.L.;Zhong,S.;Birchard,D.;Limnander,A.;Rafique,A.;Bautista,J.;Kostic,A.;Newell,D.;Duan,X.;Franklin,M.C.;Olson,W.;Huang,T.;Gandhi,N.A.;Lipsich,L.;Stahl,N.;Papadopoulos,N.J.;Murphy,A.J.;Yancopoulos,G.D.",Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement,25-MAY-2017,8_8_8_6_3_9,AYI40085_AYI40089,Xtal structure,,2,1,14.195279,9.444127
3KDM_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPGLWDYYYGMDVWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYGVTNRPSGVSNRFSGSKSGNTASLTISGLQAGDEADYYCSSYTSTRTPYVFGTGTKVE,3KDM_H,3KDM_L,Crystal Structure Of Human Anti-Steroid Fab 5F2 In Complex With Testosterone,Crystal Structure Of Human Anti-Steroid Fab 5F2 In Complex With Testosterone,Homo sapiens,"Niemi,M.H.;Takkinen,K.;Amundsen,L.K.;Soderlund,H.;Rouvinen,J.;Hoyhtya,M.",The testosterone binding mechanism of an antibody derived from a naive human scFv library,23-OCT-2009,8_8_15_9_3_11,3KDM_H_L,Xtal structure,testosterone,2,1,13.747113,10.08228
AGP76204,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRKLKKPGPIASWGQGTLVTVSS,SELIQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGTVFGGGTKLTVL,AGP76204_H,AGP76204_L,"anti-interleukin-18 single-chain Fv antibody, partial [synthetic construct]","anti-interleukin-18 single-chain Fv antibody, partial [synthetic construct]",synthetic construct,"Tiumentseva,M.; Morozova,V.; Zakabunin,A.; Korobko,D.; Malkova,N.; Filipenko,M.; Tikunova,N.",Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis,24-MAR-2016,8_8_13_6_3_9,AGP76204,Same entry,interleukin-18,2,1,14.001354,9.750113
3UX9_B_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYIDFGDHMDFWGQGTLVTVSS,VLTQPPSVSGAPGQRVTISCSGSSSNIGSNYVSWYQQLPGTAPKLLIYDNNQRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQVRDNNENEWVFGGGTKLTVL,3UX9_B,3UX9_B,Structural Insights Into A Human Anti-Ifn Antibody Exerting Therapeutic Potential For Systemic Lupus Erythematosus,Structural Insights Into A Human Anti-Ifn Antibody Exerting Therapeutic Potential For Systemic Lupus Erythematosus,Homo sapiens,"Ouyang,S.;Gong,B.;Li,J.Z.;Zhao,L.X.;Wu,W.;Zhang,F.S.;Sun,L.;Wang,S.J.;Pan,M.;Li,C.;Liang,W.;Shaw,N.;Zheng,J.;Zhao,G.P.;Wang,Y.;Liu,Z.J.;Liang,M.",Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus,04-DEC-2011,8_8_12_8_3_11,3UX9_B_B,Xtal structure,IFNA@; IFN; IFNA13; IFN-ALPHA; IFNA1; IFL; IFN-alphaD,2,1,13.861145,9.84433
7S0B_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSLISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLWGSGFFAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDAGTPLTFGQGTKVEIK,7S0B_C,7S0B_D,Structure Of The Sars-Cov-2 Rbd In Complex With Neutralizing Antibody N-612-056,Structure Of The Sars-Cov-2 Rbd In Complex With Neutralizing Antibody N-612-056,Severe acute respiratory syndrome coronavirus 2,"Tanaka,S.;Anders Olson,C.;Barnes,C.O.;Higashide,W.;Gonzalez,M.;Taft,J.;Richardson,A.;Martin-Fernandez,M.;Bogunovic,D.;Gnanapragasam,P.N.;Bjorkman,P.J.;Spilman,P.;Niazi,K.;Rabizadeh,S.;Soon-Shiong,P.",Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display,30-AUG-2021,8_8_14_6_3_9,7S0B_C_D,Xtal structure,SARS-CoV-2,2,1,14.0264,10.065475
4QCI_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYISDDGSLKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPYWYGGQLDLWGQGTLVTVSS,SYELTQPPSVSVAPGQTARISCSGDSLGSYFVHWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAFTHNSDVFGGGTKLTVL,4QCI_H,4QCI_L,Pdgf-B Blocking Antibody Bound To Pdgf-Bb,Pdgf-B Blocking Antibody Bound To Pdgf-Bb,Homo sapiens,"Kuai,J.;Mosyak,L.;Brooks,J.;Cain,M.;Carven,G.J.;Ogawa,S.;Ishino,T.;Tam,M.;Lavallie,E.R.;Yang,Z.;Ponsel,D.;Rauchenberger,R.;Arch,R.;Pullen,N.","Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-beta",12-MAY-2014,8_8_13_6_3_9,AQN64891_AQN64890,Xtal structure,platelet,2,1,13.863486,10.074134
ANV21801_ANV21990,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSAITENGGSTYYADSVKGRFTISRDNSKDTLYLQMNSLRVEDTALYYCAKDNYGAGPRGHFDYWGQVTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKLLIYPASSLQSGVPSRFSGGGSGTDFTLTVSSLQPEDFATYYCLQDYDYPLTFGGGTKVEIK,ANV21801,ANV21990,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_15_6_3_9,ANV21801_ANV21990,Unique source,,2,1,14.2403555,9.828136
4LKC_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCVREGTYYHDSGSDNYYSYGMDVWGQGTTVTVSS,IQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYLITFGQGTRLEIK,4LKC_B,4LKC_A,An Antibody Against The C-Terminal Domain Of Pcsk9 Lowers Ldl Cholesterol Levels In Vivo,An Antibody Against The C-Terminal Domain Of Pcsk9 Lowers Ldl Cholesterol Levels In Vivo,Homo sapiens,"Schiele,F.;Park,J.;Redemann,N.;Luippold,G.;Nar,H.",An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo,07-JUL-2013,8_7_22_6_3_9,4LKC_B_A,Xtal structure,HCHOLA3; FH3; NARC-1; PCSK9,2,1,16.418673,11.63759
USW88775_USW88683,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSTIGTGGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGSSAATIVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPEYTFGQGTKLEIK,USW88775,USW88683,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kumar,S.; Patel,A.; Lai,L.; Chakravarthy,C.; Valanparambil,R.; Davis-Gardner,M.E.; Edara,V.V.; Linderman,S.; Reddy,E.S.; Gottimukkala,K.; Nayak,K.; Dixit,K.; Sharma,P.; Bajpai,P.; Singh,V.; Frank,F.; Cheedarla,N.; Verkerke,H.P.; Neish,A.S.; Roback,J.D.; Mantus,G.; Goel,P.K.; Rahi,M.; Davis,C.W.; Wrammert,J.; Suthar,M.S.; Ahmed,R.; Ortlund,E.; Sharma,A.; Murali-Krishna,K.; Chandele,A.",Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody,06-JUL-2022,8_7_13_6_3_10,USW88775_USW88683,Unique source,SARS-CoV-2; RBD,2,1,16.411722,11.627543
ANV21711_ANV21900,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISNSGTMIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDLRTAVGGPEDPWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQNYNYPYTFGQGTKVEIK,ANV21711,ANV21900,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_14_6_3_9,ANV21711_ANV21900,Unique source,,2,1,15.6948395,9.988399
QKY76471_QKY76084,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSAIYYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCAREARSRYFDWLPSYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDIGGYNYVSWYQQHPGKAPKLLIYDVSNRPSGVSTRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTHVVFGGGTKLTVL,QKY76471,QKY76084,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_19_9_3_11,QKY76471_QKY76084,Unique source,SARS-CoV-2,2,1,15.966216,10.013551
ABS72429,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQVPGKGLEWVSDISGSGGSAYYADSVKGRFTISRDNTNNTLYLQINSLRAEDTAVYYCARDHLYYDFWSGFYRAYGMDVWGQGTTVTVSS,QSALTQPASVSVSPGQTARITCSGDALPNQFVYWYQQKPGQAPLLLIYKDTERPSGIPERFSGSRPGTTVTLTISGVQAEDEADYYCQSADGSASWVFGGGTKLTVL,ABS72429_H,ABS72429_L,"Phl p 5-specific scFv antibody, partial [synthetic construct]","Phl p 5-specific scFv antibody, partial [synthetic construct]",synthetic construct,"Persson,H.; Sadegh,M.K.; Greiff,L.; Ohlin,M.",Delineating the specificity of an IgE-encoding transcriptome,05-AUG-2007,8_8_21_6_3_10,ABS72429,Same entry,,2,1,13.632067,10.143089
5KMV_E_I,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,5KMV_E,5KMV_I,Crystal Structure Of Crenezumab Fab,Crystal Structure Of Crenezumab Fab,HOMO SAPIENS,"Ultsch, M., Wang, W.",Crystal Structure Of Crenezumab Fab,27-JUN-2016,8_8_5_11_3_9,5KMV_E_I,Xtal structure,,2,1,14.830609,9.224514
7CU5_A_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK,7CU5_A,7CU5_A,N-Glycosylation Of Pd-1 And Glycosylation Dependent Binding Of Pd-1 Specific Monoclonal Antibody Camrelizumab,N-Glycosylation Of Pd-1 And Glycosylation Dependent Binding Of Pd-1 Specific Monoclonal Antibody Camrelizumab,Homo sapiens,"Liu,K.F.;Tan,S.G.;Jin,W.J.;Guan,J.W.;Wang,W.L.;Sun,H.;Qi,J.X.;Yan,J.H.;Chai,Y.;Wang,Z.F.;Chu,X.D.;Gao,G.F.",N-Glycosylation of PD-1 and glycosylation dependent binding of PD-1 specific monoclonal antibody camrelizumab,21-AUG-2020,8_8_9_6_3_9,QPY30837_QPY30838,Xtal structure,PD1; PDCD1; SLEB2; hSLE1; CD279; PD-1,2,1,14.894846,9.27443
QKK35592_QKK35593,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSGHDGGTTHYADSVKGRFTISRDDSMNTLSLQMNSLRAEDTAVYYCAKERDLPGRGGYFDHWGQGTLVTVSS,DIRLTQSPDSLALSLGERATINCKSSQSVLFSSNNNNYLGWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYLTPWTFGQGTKVDIK,QKK35592,QKK35593,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_6_15_12_3_9,QKK35592_QKK35593,Unique source,SARS-CoV-2,2,1,13.0016165,10.227163
3L95_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWIHWVRQAPGKGLEWVARINPPNRSNQYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGSGFRWVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYTTPSTFGQGTKVEIK,3L95_B,3L95_A,Crystal Structure Of The Human Notch1 Negative Regulatory Region (Nrr) Bound To The Fab Fragment Of An Antagonist Antibody,Crystal Structure Of The Human Notch1 Negative Regulatory Region (Nrr) Bound To The Fab Fragment Of An Antagonist Antibody,Homo sapiens,"Wu,Y.;Cain-Hom,C.;Choy,L.;Hagenbeek,T.J.;de Leon,G.P.;Chen,Y.;Finkle,D.;Venook,R.;Wu,X.;Ridgway,J.;Schahin-Reed,D.;Dow,G.J.;Shelton,A.;Stawicki,S.;Watts,R.J.;Zhang,J.;Choy,R.;Howard,P.;Kadyk,L.;Yan,M.;Zha,J.;Callahan,C.A.;Hymowitz,S.G.;Siebel,C.W.",Therapeutic antibody targeting of individual Notch receptors,04-JAN-2010,8_8_12_6_3_9,AJN17545_AJN17546,Xtal structure,Notch,2,1,10.103781,10.751342
7D6I_B_C,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRAGWVRGAFDIWGQGTMVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNLWVFGGGTKLTVL,7D6I_B,7D6I_C,A Neutralizing Mab Targeting Receptor-Binding-Domain Of Sars-Cov-2,A Neutralizing Mab Targeting Receptor-Binding-Domain Of Sars-Cov-2,Homo sapiens,"Shi,R.;Qi,J.X.;Gao,G.F.;Yan,J.H.",A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2,30-SEP-2020,8_8_12_8_3_10,7D6I_B_C,Xtal structure,SARS-CoV-2,2,1,11.126902,7.7733655
QOW17450_QOW17451,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINQDGSEKYYVDSVKGRFTISRDNAKNSLYLQVNSLRAEDTAVYYCARDWDYDILTGSWFGAFDIWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK,QOW17450,QOW17451,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Chen,W.",Direct Submission,07-NOV-2020,8_8_19_6_3_9,QOW17450_QOW17451,Unique source,,2,1,11.15676,7.8033524
6X4T_D_F,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,6X4T_D,6X4T_F,Crystal Structure Of Icos-L In Complex With Prezalumab And Vnar Domain,Crystal Structure Of Icos-L In Complex With Prezalumab And Vnar Domain,Orectolobus maculatus,"Rujas,E.;Cui,H.;Sicard,T.;Semesi,A.;Julien,J.P.",Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies,23-MAY-2020,8_8_14_6_3_9,AYJ12195_AYJ12188,Xtal structure,AILIM; CD278; B7-H2; ICOS; ICOSL; ICOS-L; B7H2; KIAA0653; B7h; ICOSLG; B7RP-1; CD275; B7RP1; GL50,2,1,11.129282,7.7804737
QKK35524_QKK35525,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTSAMSWVRQAPGKGLEWVSRIGGGGGRTKYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKCDLVRYFDWLGEENNWFDPWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPETAPKLLIYANGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVLFGGGTKLTVL,QKK35524,QKK35525,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_21_9_3_11,QKK35524_QKK35525,Unique source,SARS-CoV-2,2,1,14.136888,9.98789
5W4L_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSSINNSGRNTFSADSVKGRFTISRDNSKNTLFLVMNSLRAEDTAVYYCAKDLRLGGGSDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNFVSWYQQHPGKAPKLMIYEVSERPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSTTFRVFGGGTKLTVR,5W4L_H,5W4L_L,"Crystal Structure Of The Non-Neutralizing And Adcc-Potent C11-Like Antibody N12-I3 In Complex With Hiv-1 Clade A/E Gp120, The Cd4 Mimetic M48U1, And The Antibody N5-I5.","Crystal Structure Of The Non-Neutralizing And Adcc-Potent C11-Like Antibody N12-I3 In Complex With Hiv-1 Clade A/E Gp120, The Cd4 Mimetic M48U1, And The Antibody N5-I5.",Homo sapiens,"Tolbert,W.D.;Gohain,N.;Alsahafi,N.;Van,V.;Orlandi,C.;Ding,S.;Martin,L.;Finzi,A.;Lewis,G.K.;Ray,K.;Pazgier,M.",Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region,12-JUN-2017,8_8_12_9_3_11,5W4L_H_L,Xtal structure,HAKRA; CHDR; AKR1C4; DD4; CDR; 3-alpha-HSD; HIV; MGC22581; C11,2,1,14.135326,9.580256
4LLY_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRKAPGKGLEWVADVNPNSGGSIYNQEFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,IQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQDKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,4LLY_A,4LLY_B,Crystal Structure Of Pertuzumab Clambda Fab With Variable And Constant Domain Redesigns (Vrd2 And Crd2) At 1.6A,Crystal Structure Of Pertuzumab Clambda Fab With Variable And Constant Domain Redesigns (Vrd2 And Crd2) At 1.6A,Homo sapiens,"Lewis,S.M.;Wu,X.;Pustilnik,A.;Sereno,A.;Huang,F.;Rick,H.L.;Guntas,G.;Leaver-Fay,A.;Smith,E.M.;Ho,C.;Hansen-Estruch,C.;Chamberlain,A.K.;Truhlar,S.M.;Conner,E.M.;Atwell,S.;Kuhlman,B.;Demarest,S.J.",Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface,09-JUL-2013,8_8_12_6_3_9,4LLY_A_B,Xtal structure,,2,1,11.02746,10.399983
4LLW_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRYAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQRKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,4LLW_C,4LLW_D,Crystal Structure Of Pertuzumab Clambda Fab With Variable Domain Redesign (Vrd2) At 1.95A,Crystal Structure Of Pertuzumab Clambda Fab With Variable Domain Redesign (Vrd2) At 1.95A,Homo sapiens,"Lewis,S.M.;Wu,X.;Pustilnik,A.;Sereno,A.;Huang,F.;Rick,H.L.;Guntas,G.;Leaver-Fay,A.;Smith,E.M.;Ho,C.;Hansen-Estruch,C.;Chamberlain,A.K.;Truhlar,S.M.;Conner,E.M.;Atwell,S.;Kuhlman,B.;Demarest,S.J.",Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface,09-JUL-2013,8_8_12_6_3_9,QDB26401_QDB26402,Xtal structure,,2,1,11.0065155,10.376019
8FFE_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFTNSYIHWVRQAPGKGLEWVGWITPYGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGSGHVNAVKNYGYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK,8FFE_H,8FFE_L,Crystal Structure Of Lrp6 E1E2 Domains Bound To Yw210.09 Fab And Engineered Xwnt8 Peptide,Crystal Structure Of Lrp6 E1E2 Domains Bound To Yw210.09 Fab And Engineered Xwnt8 Peptide,Homo sapiens,"Tsutsumi,N.;Hwang,S.;Waghray,D.;Hansen,S.;Jude,K.M.;Wang,N.;Miao,Y.;Glassman,C.R.;Caveney,N.A.;Janda,C.Y.;Hannoush,R.N.;Garcia,K.C.",Structure of the Wnt-Frizzled-LRP6 initiation complex reveals the basis for coreceptor discrimination,08-MAR-2023,8_8_19_6_3_9,AJN15208_AJN15209,Xtal structure,LRP6; ADCAD2,2,1,10.129051,10.750987
4WV1_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRTHLGDGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK,4WV1_B,4WV1_A,Crystal Structure Of The Fgfr2 D2 Domain In Complex With Fab 2B.1.3,Crystal Structure Of The Fgfr2 D2 Domain In Complex With Fab 2B.1.3,Homo sapiens,"Yin,Y.;Djakovic,S.;Marsters,S.;Tien,J.;Peng,J.;Tremayne,J.;Lee,G.;Neve,R.M.;Wu,Y.;Merchant,M.;Ashkenazi,A.;Carter,P.J.",Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity,04-NOV-2014,8_8_20_6_3_9,QCA62978_QCA62970,Xtal structure,CD333; ACH; ECT1; KGFR; CD332; CEK2; FGFR3; FGFR2; JTK4; BEK; TK14; JWS; TK25; CFD1; CEK3; K-SAM,2,1,10.130888,10.748313
5XHV_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTIGDFGIHWVRQAPGKGLEWVAGIWPFGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVNWDGDYMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVGFYVAWYQQKPGKAPKLLISWSSYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPLTFGQGTKVEIK,5XHV_H,5XHV_L,"Crystal Structure Of Fab S40 In Complex With Influenza Hemagglutinin, Ha1 Subunit.","Crystal Structure Of Fab S40 In Complex With Influenza Hemagglutinin, Ha1 Subunit.",Homo sapiens,"Chen,I.C.;Chiu,Y.K.;Yu,C.M.;Lee,C.C.;Tung,C.P.;Tsou,Y.L.;Huang,Y.J.;Lin,C.L.;Chen,H.S.;Wang,A.H.;Yang,A.S.",High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries,24-APR-2017,8_8_13_6_3_9,5XHV_H_L,Xtal structure,Influenza,2,1,10.193102,10.915679
2FJH_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVEIK,2FJH_B,2FJH_A,"Structure Of The B20-4 Fab, A Phage Derived Fab Fragment, In Complex With Vegf","Structure Of The B20-4 Fab, A Phage Derived Fab Fragment, In Complex With Vegf",Homo sapiens,"Fuh,G.;Wu,P.;Liang,W.C.;Ultsch,M.;Lee,C.V.;Moffat,B.;Wiesmann,C.",Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab,02-JAN-2006,8_8_14_6_3_9,2FJH_B_A,Xtal structure,,2,1,10.062275,10.787513
2QQK_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTISGYGIHWVRQAPGKGLEWVAYIYPDSGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAREDFRNRRRLWYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAWAYLPTFGQGTKVEIK,2QQK_H,2QQK_L,Neuropilin-2 A1A2B1B2 Domains In Complex With A Semaphorin-Blocking Fab,Neuropilin-2 A1A2B1B2 Domains In Complex With A Semaphorin-Blocking Fab,Homo sapiens,"Appleton,B.A.;Wu,P.;Maloney,J.;Yin,J.;Liang,W.C.;Stawicki,S.;Mortara,K.;Bowman,K.K.;Elliott,J.M.;Desmarais,W.;Bazan,J.F.;Bagri,A.;Tessier-Lavigne,M.;Koch,A.W.;Wu,Y.;Watts,R.J.;Wiesmann,C.",Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding,26-JUL-2007,8_8_17_6_3_9,AGA38329,Xtal structure,VEGFA; neuropilin; VPF; semaphorin; VEGF-A; VEGF,2,1,10.139266,10.828252
2HFF_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTISSNSIHWVRQAPGKGLEWVAWITPSDGNTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRVCYNRLGVCAGGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRITPPTFGQGTKVEIK,2HFF_B,2HFF_A,Crystal Structure Of Cb2 Fab,Crystal Structure Of Cb2 Fab,Homo sapiens,"Lee,C.V.;Hymowitz,S.G.;Wallweber,H.J.;Gordon,N.C.;Billeci,K.L.;Tsai,S.P.;Compaan,D.M.;Yin,J.;Gong,Q.;Kelley,R.F.;DeForge,L.E.;Martin,F.;Starovasnik,M.A.;Fuh,G.",Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells,23-JUN-2006,8_8_18_6_3_9,2HFF_B_A,Xtal structure,BLYS; TNFSF13B; BAFF; THANK; TALL-1; BR3; TALL1; TNFSF20; CD257,2,1,10.102833,10.789508
6WW5_E_F,EVQLVESGGGLVQPGGSLRLSCAASGFTIYSSSIHWVRQAPGKGLEWVASIYSSSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYNIHYWRWYNPAGQAMDYWGQGTLVTVFN,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQRYGLLVTFGQGTKVEIK,6WW5_E,6WW5_F,Structure Of Vcindy-Na-Fab84 In Nanodisc,Structure Of Vcindy-Na-Fab84 In Nanodisc,Homo sapiens,"Sauer,D.B.;Trebesch,N.;Marden,J.J.;Cocco,N.;Song,J.;Koide,A.;Koide,S.;Tajkhorshid,E.;Wang,D.N.",Structural basis for the reaction cycle of DASS dicarboxylate transporters,07-MAY-2020,8_8_20_6_3_9,6WW5_E_F,Xtal structure,,2,1,9.566728,10.897789
CAO78304,EVQLVESGGGLVQPGGSLRLSCAASGFTLSSYAMHWVRQAPGKGLEWVSTISGGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGRAFDIWGQGTTVTVS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCSSPMISSLSGHVVFGGGTKVTVL,CAO78304_H,CAO78304_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_9_9_3_13,AEN51973,Same entry,,2,1,13.92558,9.714301
6XQ4_E_F,EVQLVESGGGLVQPGGSLRLSCAASGFTVSRNYMSWVRQAPGKGLEWVSIIYSGDDTYYADSVKGRFTISRDNSKNTLYLEMNSLRAEDTAVYYCARGEMGDGYYWAPFDYWGQGTLVTVSG,DIVMTQSPDSLAVSLGERATINCKSSQSLLYSSRNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRLSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSIPLTFGGGTKVEIK,6XQ4_E,6XQ4_F,Human Antibody S8V2-47 In Complex With The Influenza Hemagglutinin Head Domain Of A/Beijing/262/1995(H1N1),Human Antibody S8V2-47 In Complex With The Influenza Hemagglutinin Head Domain Of A/Beijing/262/1995(H1N1),Homo sapiens,"McCarthy,K.R.;Lee,J.;Watanabe,A.;Kuraoka,M.;Robinson-McCarthy,L.R.;Georgiou,G.;Kelsoe,G.;Harrison,S.C.",A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface,09-JUL-2020,8_7_16_12_3_9,6XQ4_E_F,Xtal structure,H1N1; Influenza,2,1,12.690364,10.2204275
QKY76310_QKY75923,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYPGGSAFYADSVKGRFTISRHNSNNTLCLQMNSLRTEDTAVYYCARSYDILTGYRDAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGSDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSGFVVFGGGTKLTVL,QKY76310,QKY75923,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_16_9_3_12,QKY76310_QKY75923,Unique source,SARS-CoV-2,2,1,12.660077,10.275192
UNJ20702_UNJ20855,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFGDFFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGVSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,UNJ20702,UNJ20855,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,8_7_11_6_3_9,UNJ20702_UNJ20855,Unique source,SARS-CoV-2,2,1,12.624839,10.216096
UNJ20701_UNJ20854,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNGDYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGGGTKVEIK,UNJ20701,UNJ20854,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,8_7_11_7_3_9,UNJ20701_UNJ20854,Unique source,SARS-CoV-2,2,1,12.845,10.104411
CAO78310,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVVYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGGTTVWRYYGMDVWGQGTTVTVSS,SYVLTQPPSVSVAPGKTATITCAGNNIGSNSVYWYQQKPGLAPVLVVYDDRDRPSGIPGRFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSDHLYVFGTGTQLTVL,CAO78310_H,CAO78310_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_7_17_6_3_12,AEN51977,Same entry,,2,1,12.740872,10.813796
QYF06299_QYF06451,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARDLVVFGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGETATLSCRASQSVGSSYLTWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPTFGQGTKVEIK,QYF06299,QYF06451,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Tong,P.; Gautam,A.; Windsor,I.W.; Travers,M.; Chen,Y.; Garcia,N.; Whiteman,N.B.; McKay,L.G.; Storm,N.; Malsick,L.E.; Honko,A.N.; Lelis,F.J.; Habibi,S.; Jenni,S.; Cai,Y.; Rennick,L.J.; Duprex,W.P.; McCarthy,K.R.; Lavine,C.L.; Zuo,T.; Lin,J.; Zuiani,A.; Feldman,J.; MacDonald,E.A.; Hauser,B.M.; Griffths,A.; Seaman,M.S.; Schmidt,A.G.; Chen,B.; Neuberg,D.; Bajic,G.; Harrison,S.C.; Wesemann,D.R.",Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike,07-AUG-2021,8_7_11_7_3_8,QYF06299_QYF06451,Unique source,SARS-CoV-2,2,1,12.493317,10.740799
7E7Y_C_D,EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSAVYSGGSTYYADSVKGRFTISRHNSKNTLYLQMKSLRPEDTAIYYCARLINHYYDSSGDGGAFDIWGQGTMVTVSS,LTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQRPGKAPKLILYEVTKRPSGVSNRFSGSKSGNTASLAISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL,7E7Y_C,7E7Y_D,Crystal Structure Of The Sars-Cov-2 S Rbd In Complex With Bd-623 Fab,Crystal Structure Of The Sars-Cov-2 S Rbd In Complex With Bd-623 Fab,Severe acute respiratory syndrome coronavirus 2,"Cao,Y.;Yisimayi,A.;Bai,Y.;Huang,W.;Li,X.;Zhang,Z.;Yuan,T.;An,R.;Wang,J.;Xiao,T.;Du,S.;Ma,W.;Song,L.;Li,Y.;Li,X.;Song,W.;Wu,J.;Liu,S.;Li,X.;Zhang,Y.;Su,B.;Guo,X.;Wei,Y.;Gao,C.;Zhang,N.;Zhang,Y.;Dou,Y.;Xu,X.;Shi,R.;Lu,B.;Jin,R.;Ma,Y.;Qin,C.;Wang,Y.;Feng,Y.;Xiao,J.;Xie,X.S.",Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,28-FEB-2021,8_7_19_9_3_10,7E7Y_C_D,Xtal structure,SARS-CoV-2; RBD,2,1,12.62188,10.334834
6BFT_A_B,EVQLVESGGGLVQPGGSLRLSCAASGYDFDNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTDDLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,6BFT_A,6BFT_B,Structure Of Bevacizumab Fab Mutant In Complex With Vegf,Structure Of Bevacizumab Fab Mutant In Complex With Vegf,Homo sapiens,"Christie,M.;Rouet,R.;Nevoltris,D.;Langley,D.;Schofield,P.;Fabri,L.;Tingey,K.;Lowe,D.;Jermutus,L.;Christ,D.",Stable human IgG antibody therapeutics with native framework structure,27-OCT-2017,8_8_16_6_3_9,6BFT_A_B,Xtal structure,,2,1,10.562227,10.594622
6DF0_H_L,EVQLVESGGGLVQPGGSLRLSCAASGYTFTENTVHWVRQAPGKGLEWIGGINPYYGGSIFSPKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRAGAYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSSSYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSGYRTFGQGTKVEIK,6DF0_H,6DF0_L,Anti-Phosphotyrosine Antibody 4G10-4D5 Fab Complexed With Sulfate,Anti-Phosphotyrosine Antibody 4G10-4D5 Fab Complexed With Sulfate,synthetic construct,"Mou,Y.;Zhou,X.X.;Leung,K.;Martinko,A.J.;Yu,J.Y.;Chen,W.;Wells,J.A.",Engineering Improved Antiphosphotyrosine Antibodies Based on an Immunoconvergent Binding Motif,13-MAY-2018,8_8_11_7_3_8,6DF0_H_L,Xtal structure,Phosphotyrosine,2,1,10.750483,10.4807205
6DEZ_B_A,EVQLVESGGGLVQPGGSLRLSCAASGYTFTEYTMHWVRQAPGKGLEWMGGINPNSGGTRDNQRFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRGPYGNYYNSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSKVPWTFGQGTKVEIK,6DEZ_B,6DEZ_A,Anti-Phosphotyrosine Antibody Py20-4D5 Fab Complexed With Sulfate,Anti-Phosphotyrosine Antibody Py20-4D5 Fab Complexed With Sulfate,synthetic construct,"Mou,Y.;Zhou,X.X.;Leung,K.;Martinko,A.J.;Yu,J.Y.;Chen,W.;Wells,J.A.",Engineering Improved Antiphosphotyrosine Antibodies Based on an Immunoconvergent Binding Motif,13-MAY-2018,8_8_17_6_3_9,6DEZ_B_A,Xtal structure,Phosphotyrosine,2,1,10.849675,10.44462
3DUR_B_A,EVQLVESGGGLVQPGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFSISRDNSQSILYLQMNTLRAEDSATYYCARDGYYADAMDYWGQGTSVTVSS,DIVMTQSPSSLAVSAGEKVTMSCKSSQSLFKSRNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTINGVQAEDLAVYYCKQSYNLRTFGGGTKLELK,3DUR_B,3DUR_A,Crystal Structure Of Sag173-04,Crystal Structure Of Sag173-04,Mus musculus,"Brooks,C.L.;Blackler,R.J.;Gerstenbruch,S.;Kosma,P.;Muller-Loennies,S.;Brade,H.;Evans,S.V.",Pseudo-symmetry and twinning in crystals of homologous antibody Fv fragments,17-JUL-2008,8_10_12_12_3_8,3DUR_B_A,Xtal structure,,2,1,26.046806,4.6675644
4Y5Y_D_E,EVQLVESGGGLVQPGGSLRLSCAVSGFTFSKYWMTWVRQAPGKGLEWVANIKPDGSEKYYVESVKGRFTISRDNAKNSVYLQMNSVRAEDTAVYYCARVSRGGSFSDWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGAYNYVSWYQQHPGKAPKLMIYEVARRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNFAVFGRGTKLTVL,4Y5Y_D,4Y5Y_E,Diabody 330 Complex With Epor,Diabody 330 Complex With Epor,Homo sapiens,"Moraga,I.;Wernig,G.;Wilmes,S.;Gryshkova,V.;Richter,C.P.;Hong,W.J.;Sinha,R.;Guo,F.;Fabionar,H.;Wehrman,T.S.;Krutzik,P.;Demharter,S.;Plo,I.;Weissman,I.L.;Minary,P.;Majeti,R.;Constantinescu,S.N.;Piehler,J.;Garcia,K.C.",Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands,12-FEB-2015,8_8_11_9_3_11,4Y5Y_D_E,Xtal structure,,2,1,11.12979,7.7814054
QPO16037_QPO16154,EVQLVESGGGLVQPGGSLRLSCAVSGLTVSGNYMSWVRQAPGKGLEWVSVLYTNGKTFYADSVKGRFIISRDNAKNTLSLQMNSLRAEDTAVYFCTTNWDFYYYFNNWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGITTWLAWYQQKPGKAPRLLIYQASSLESGVPLRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNNYPYTFGQGTKVEIK,QPO16037,QPO16154,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Dugan,H.L.; Guthmiller,J.J.",Pre-existing immunity shapes distinct antibody landscapes following influenza virus infection and vaccination,14-DEC-2020,8_7_12_6_3_9,QPO16037_QPO16154,Unique source,,2,1,12.688386,10.221897
QPL06806_QPL06807,EVQLVESGGGLVQPGGSLRLSCAVSKFTSDSGWMSWVRLPPGQGLEWIGRLNYRIDDEAVDYAAGMKDKVIISRDVSKNTLFLQLNNLRAGDTAVYYCTTDDHYQSSGYHPFFKTWGQGALVTVSS,QSVLTQPPSVSGAPGQRVTISCTGGSSTLGTDYDVHWYQHVEGTAPKLLIYGNNNRPSGVPDRFSGSRSGTSASLAITGLQAEDEALYYCQSYDGSLGAVVFGGGTKLTVL,QPL06806,QPL06807,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_10_17_9_3_11,QPL06806_QPL06807,Unique source,,2,1,12.982008,8.779364
QKK35830_QKK35831,EVQLVESGGGLVQPGGSLRLSCEASGFNFNSYSMSWVRQAPGKGLEWLSYISSRSSTIKYASSVQGRFTVSRDNAKKSVYLQMNSLRDEDTAVYFCARELDSETYYNYNSLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTISCRASQGISTFLAWFQQRPGKAPKSLIYAASKLQSGVPSRFSGSDSGPDFTLTIDNLRPEDSATYYCKQYNSYPYTFGQGTKLEIK,QKK35830,QKK35831,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_6_3_9,QKK35830_QKK35831,Unique source,SARS-CoV-2,2,1,15.895826,9.946631
6XQ2_F_E,EVQLVESGGGLVQPGGSLRLSCEASGFTFSNYEMNWVRQAPGKGLEWLSYIRSSGTVTSYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLVYTGSYYGMDVWGQGTRVTVSG,AIQLTQSPSSLSASVGDRVTITCRTSQGISTPLAWYQHKPGKSPKLLIHDAFSLESGVPSRFSGSGSGTDFSLTISSVQPEDFATYYCQQFYDYPITFGQGTRLEIR,6XQ2_F,6XQ2_E,Human Antibody S8V2-37 In Complex With The Influenza Hemagglutinin Head Domain Of A/Texas/50/2012(H3N2),Human Antibody S8V2-37 In Complex With The Influenza Hemagglutinin Head Domain Of A/Texas/50/2012(H3N2),Homo sapiens,"McCarthy,K.R.;Lee,J.;Watanabe,A.;Kuraoka,M.;Robinson-McCarthy,L.R.;Georgiou,G.;Kelsoe,G.;Harrison,S.C.",A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface,09-JUL-2020,8_8_15_6_3_9,6XQ2_F_E,Xtal structure,Influenza; H3N2,2,1,15.621727,9.938864
QKY76469_QKY76082,EVQLVESGGGLVQPGGSLRLSCEASGFTFSSSEINWVRQAPGKGLEWVSHISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRSYRSSWYYYYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPVTFGQGTKVEIK,QKY76469,QKY76082,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_17_6_3_9,QKY76469_QKY76082,Unique source,SARS-CoV-2,2,1,15.790644,10.029713
QKK35818_QKK35819,EVQLVESGGGLVQPGGSLRLSCGASGFTFSDYAMSWVRQAPGKGLEWVSTISGSGDKTYYADSLKGRFTNSRDNSKSTLYLQMTSLRAEDTAVYFCAKDRYCSGGSCFYDAFDIWGQGTTVTVSS,ETTLTQSPSSLSASVGDRVNITCRASQSISTYLTWYQQKPGKAPKLLIYGASSLHSGVPSRFTGVGSGTEFTLSISSLQPEDFATYYCQQSYNTFFTFGGGTKVDIK,QKK35818,QKK35819,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_9,QKK35818_QKK35819,Unique source,SARS-CoV-2,2,1,14.042967,9.921249
AST13830_AST13859,EVQLVESGGGLVQPGGSLRLSCIGSEFTFSNYGMNWVRQAPGKGLEWISYITGASATVYYAASVRGRFTISRDNARNSLFLEMNGLRAEDTAVYYCARDRGCNSPTCFVIGYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQTISRYLNWYQQKAGKAPTLLIYDASRLQSGVPSRFSGSGSGTEFTLTISSLQREDFATYYCQQSDSIPALTFGGGTRVDIK,AST13830,AST13859,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Joyce,M.G.; Chambers,M.J.; Gillespie,R.A.; Kanekiyo,M.; Leung,K.; Yang,E.S.; Tsybovsky,Y.; Wheatley,A.K.; Crank,M.C.; Boyington,J.C.; Prabhakaran,M.S.; Narpala,S.R.; Chen,X.; Bailer,R.T.; Chen,G.; Coates,E.; Kwong,P.D.; Koup,R.A.; Mascola,J.R.; Graham,B.S.; Ledgerwood,J.E.; McDermott,A.B.",Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans,15-AUG-2017,8_8_23_6_3_10,AST13830_AST13859,Unique source,hemagglutinin,2,1,15.844688,9.996196
QKK35584_QKK35585,EVQLVESGGGLVQPGGSLRLSCLTSGFSFSSYWMIWVRQAPGKGLEWVANIEPDGNEEYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGPIRHFGLDAFDIWGQGTTVTVSS,QPGLTQPASVSGSPGQSITISCTRTSGDVGDYNSVSWYVSWYQQHPGRAPKLMLYDVSNRPSGVSNRFSGSKLGDTASLTISELQAEDEADYYCSTYTSTSTIFGGGTKLTVL,QKK35584,QKK35585,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_13_3_9,QKK35584_QKK35585,Unique source,SARS-CoV-2,2,1,11.141112,7.79091
QKK35766_QKK35767,EVQLVESGGGLVQPGGSLRLSCSASEFTLRSHAMHWVRQAPGKGLEYVSGISTDGSGRFYADSVKGRFTISRDNSKNKLFLQMSSLRPEDTAVYYCVRDWGSSTHYDVFDLWGQGTMVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSINIYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLITFGQGTRLEIK,QKK35766,QKK35767,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_10,QKK35766_QKK35767,Unique source,SARS-CoV-2,2,1,13.84407,10.229249
QKK35590_QKK35591,EVQLVESGGGLVQPGGSLRLSCSASGFTFSNYAMYWVRQAPGKRPEYVSGISSNGGITYYADSVEGRFTVSRDNSKKSLYLQMSSLRPEDTAVYYCVKDLGATVTYDVFDVWGQGTMVTVSS,DIRVTQSPSSLSATVGDRVTITCRASQTITKYLNWYQQKPGKAPKLLLYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYITPGTFGQGTRLEIK,QKK35590,QKK35591,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_9,QKK35590_QKK35591,Unique source,SARS-CoV-2,2,1,13.876707,10.134875
QKK35864_QKK35865,EVQLVESGGGLVQPGGSLRLSCSASGFTFSRYAMHWVRQAPGKGLEYVSAINLNGDSTYYTDSVRGRFTISRDNSKNTLFLQMSNVRPEDTAFYYCVKDGGYYDSSGPGHWGQGTLVTVSS,DIRVTQSPATLSLSPGERATLSCRASENIAHYLAWYQQKPGQAPRLVIYDASSRATGIPGRFSGSGAGTDFTLTINSLEPEDFAVYYCQQRSNWPQNFGGGTKVDIK,QKK35864,QKK35865,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_9,QKK35864_QKK35865,Unique source,SARS-CoV-2,2,1,13.741516,9.972182
7M6F_C_D,EVQLVESGGGLVQPGGSLRLSCSVSGFTVSSNYMNWVRQAPGKGLEWVSVIYPGGSTFYPDSVKGRFTISRDDSKNTLYLQMNSLRPEDTAAYYCASSRPPIGQLVPGLDLDWFDPWGQGTLVIVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYYVHWYQQHPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSRLSGWVFGGGTKLTVL,7M6F_C,7M6F_D,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg1-22","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg1-22",Homo sapiens,"Scheid,J.F.;Barnes,C.O.;Eraslan,B.;Hudak,A.;Keeffe,J.R.;Cosimi,L.A.;Brown,E.M.;Muecksch,F.;Weisblum,Y.;Zhang,S.;Delorey,T.;Woolley,A.E.;Ghantous,F.;Park,S.M.;Phillips,D.;Tusi,B.;Huey-Tubman,K.E.;Cohen,A.A.;Gnanapragasam,P.N.;Rzasa,K.;Hatziioanno,T.;Durney,M.A.;Gu,X.;Tada,T.;Landau,N.R.;West AP,Jr.;Rozenblatt-Rosen,O.;Seaman,M.S.;Baden,L.R.;Graham,D.B.;Deguine,J.;Bieniasz,P.D.;Regev,A.;Hung,D.;Bjorkman,P.J.;Xavier,R.J.",B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV,25-MAR-2021,8_7_21_9_3_11,7M6F_C_D,Xtal structure,SARS-CoV-2; SARS; CoV,2,1,12.55343,10.31431
7RXJ_A_B,EVQLVESGGGLVQPGGSLRLSCVASGFNFTTYSMNWVRQAPGKGLEWVSYISSHSNLIYYATSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARGGSLHPSAGADWIDPWGQGTLVTVSS,SYELTQAPSVSVSPGQTATITCSGDKLGDKFTSWYQQKPGQSPVLVIYQDSKRPSGIPERFSASNSGNTATLTISGTRAMDEADYYCQAWDSNTYVFGTGTRVAVL,7RXJ_A,7RXJ_B,Fab236 In Complex With The C-Terminal Alpha-Tsr Domain Of P. Falciparum,Fab236 In Complex With The C-Terminal Alpha-Tsr Domain Of P. Falciparum,Plasmodium falciparum 3D7,"Beutler,N.;Pholcharee,T.;Oyen,D.;Flores-Garcia,Y.;MacGill,R.S.;Garcia,E.;Calla,J.;Parren,M.;Yang,L.;Volkmuth,W.;Locke,E.;Regules,J.A.;Dutta,S.;Emerling,D.;Early,A.M.;Neafsey,D.E.;Winzeler,E.A.;King,C.R.;Zavala,F.;Burton,D.R.;Wilson,I.A.;Rogers,T.F.",A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum,23-AUG-2021,8_8_17_6_3_9,7RXJ_A_B,Xtal structure,,2,1,15.877461,9.894481
8DEF_S_T,EVQLVESGGGLVQPGGSLRLSCVASGFTFSDYRMAWVRQATGKGLEWVSTISQPSGTNTYYLDPVKGRFTVSRDNAKNTLYLQMHSLRAEDTAVYYCARVVTESRPPAAWFDVWGPGVLVTVSS,SYELTQPPSVSASPGQTARITCGGINIGSELVHWYQQKPPQAPVLVIYANGERPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQLWDISSDHNYIFGDGTRLTVL,8DEF_S,8DEF_T,Cryo-Em Structure Of Western Equine Encephalitis Virus Vlp In Complex With Skw24 Fab,Cryo-Em Structure Of Western Equine Encephalitis Virus Vlp In Complex With Skw24 Fab,Homo sapiens,"Sutton,M.",Cryo-EM Structure of Western Equine Encephalitis Virus VLP in complex with SKW24 fab,05-JUL-2023,8_9_16_6_3_12,8DEF_S_T,Xtal structure,VHLP; VHLL; VLP,2,1,14.253592,9.928498
4JG0_H_L,EVQLVESGGGLVQPGGSLRLSCVTSGFTFRKFGMSWVRQAPGKGLEWVASISTPRGSTTYYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGYSSTSYAMDYWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCMTSTDIDDDMNWYQQKPGQAPRLLISEGNTLRPGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCLQSFNVPLTFGQGTKVEIK,4JG0_H,4JG0_L,Structure Of Phosphoserine/Threonine (Pstab) Scaffold Bound To Pser Peptide,Structure Of Phosphoserine/Threonine (Pstab) Scaffold Bound To Pser Peptide,synthetic construct,"Koerber,J.T.;Thomsen,N.D.;Hannigan,B.T.;Degrado,W.F.;Wells,J.A.",Nature-inspired design of motif-specific antibody scaffolds,28-FEB-2013,8_9_13_6_3_9,4JG0_H_L,Xtal structure,,2,1,13.944601,9.4358835
5USL_H_L,EVQLVESGGGLVQPGGSLRLSCVVSGFTFSNYWMSWVRQAPGKGLEWVANIKQDGSKKYYVDSVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATLNLELAVDAISEALKWGQGTLVTVSS,YELTQPPSVSVSPGQTARITCSGDALPKQFAYWYQQKPGQAPVVMIYKDSERPSGIPERFSGSSSGTTVTSTISGVQAEDEADYYCQSVDNSGTYEVFGGGTQLTVL,5USL_H,5USL_L,Structure Of Vaccinia Virus D8 Protein Bound To Human Fab Vv304,Structure Of Vaccinia Virus D8 Protein Bound To Human Fab Vv304,Homo sapiens,"Matho,M.H.;Schlossman,A.;Gilchuk,I.M.;Miller,G.;Mikulski,Z.;Hupfer,M.;Wang,J.;Bitra,A.;Meng,X.;Xiang,Y.;Kaever,T.;Doukov,T.;Ley,K.;Crotty,S.;Peters,B.;Hsieh-Wilson,L.C.;Crowe JE,Jr.;Zajonc,D.M.",Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8,13-FEB-2017,8_8_17_6_3_11,5USL_H_L,Xtal structure,,2,1,11.120247,7.7670975
5XCV_A_B,EVQLVESGGGLVQPGRSLKLSCAASGFTFSNYGMAWVRQTPTKGLEWIASISAGGDKTYYGDSVKGRFSISRDNAKTTHYLQMDSLRSEDTATYYCAKTSRVYFDYWGQGVMVTVCS,QFVLTQPNSVSTNLGSTVKLSCKRSTGNIGSNYVNWYQQHEGRSPTTMIYRDDKRPDGVPDRFSGSIDRSSNSALLTINNVQTEDEADYFCHSYSSGIVFGGGTKLTVL,5XCV_A,5XCV_B,Crystal Structure Of Nz-1 Fv-Clasp Fragment With Its Antigen Peptide,Crystal Structure Of Nz-1 Fv-Clasp Fragment With Its Antigen Peptide,Homo sapiens,"Arimori,T.;Kitago,Y.;Umitsu,M.;Fujii,Y.;Asaki,R.;Tamura-Kawakami,K.;Takagi,J.","Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability",23-MAR-2017,8_8_10_8_3_8,5XCV_A_B,Xtal structure,,2,1,14.772195,9.178204
QKK35624_QKK35625,EVQLVESGGGLVQPGRSLRLSCAASGFILDDYAVHWVRLAPGKGLEWVSGITWNSGYLGYADSVKGRFTISRDNAKNSLYLQMNSLRPEDTALYYCAKLGTDHPIGVDVWGQGTTVTVSS,DIVMTQSPLALSVTPGQPASISCKSSQSLLHSDGKTYFYWYLQKPGQSPHLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSIQVPITFGGGTKLEIK,QKK35624,QKK35625,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_11_3_9,QKK35624_QKK35625,Unique source,SARS-CoV-2,2,1,13.103547,12.027189
6PPG_H_L,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,6PPG_H,6PPG_L,Crystal Structure Of Il17Ff Bound To Fab Fragments Of Mcaf5352A,Crystal Structure Of Il17Ff Bound To Fab Fragments Of Mcaf5352A,Homo sapiens,"Tilegenova,C.;Izadi,S.;Yin,J.;Huang,C.S.;Wu,J.;Ellerman,D.;Hymowitz,S.G.;Walters,B.;Salisbury,C.;Carter,P.J.",Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies,06-JUL-2019,8_8_16_6_3_10,AJL36151_AJL36143,Xtal structure,,2,1,13.172659,11.950537
4QF1_H_L,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDSPRGELPFDYWGQGTLVTVSS,YELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFGGGTKLTVL,4QF1_H,4QF1_L,"Crystal Structure Of Unliganded Ch59Ua, The Inferred Unmutated Ancestor Of The Rv144 Anti-Hiv Antibody Lineage Producing Ch59","Crystal Structure Of Unliganded Ch59Ua, The Inferred Unmutated Ancestor Of The Rv144 Anti-Hiv Antibody Lineage Producing Ch59",Homo sapiens,"Wiehe,K.;Easterhoff,D.;Luo,K.;Nicely,N.I.;Bradley,T.;Jaeger,F.H.;Dennison,S.M.;Zhang,R.;Lloyd,K.E.;Stolarchuk,C.;Parks,R.;Sutherland,L.L.;Scearce,R.M.;Morris,L.;Kaewkungwal,J.;Nitayaphan,S.;Pitisuttithum,P.;Rerks-Ngarm,S.;Sinangil,F.;Phogat,S.;Michael,N.L.;Kim,J.H.;Kelsoe,G.;Montefiori,D.C.;Tomaras,G.D.;Bonsignori,M.;Santra,S.;Kepler,T.B.;Alam,S.M.;Moody,M.A.;Liao,H.X.;Haynes,B.F.",Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved,19-MAY-2014,8_8_13_6_3_11,4QF1_H_L,Xtal structure,HIV,2,1,13.122246,12.017189
1W72_I_M,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRGFHYYYYGMDIWGQGTTVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSRSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNMATLTISRVEAGDEADYYCQVWDSRTDHWVFGGGTDLTVL,1W72_I,1W72_M,Crystal Structure Of Hla-A1:Mage-A1 In Complex With Fab-Hyb3,Crystal Structure Of Hla-A1:Mage-A1 In Complex With Fab-Hyb3,Homo sapiens,"Chames,P.;Hufton,S.E.;Coulie,P.G.;Uchanska-Ziegler,B.;Hoogenboom,H.R.",Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library,27-AUG-2004,8_8_15_6_3_11,1W72_I_M,Xtal structure,HLA; MAGE-A1,2,1,13.111625,11.968373
QKY76372_QKY75985,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGTIGYADSVKGRFIISRDNAKNSLYLQMNSLRPEDTALYYCAKDIIRQGEDGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIASYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEEFATYYCQQSYSTPWTFGQGTKVEIK,QKY76372,QKY75985,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_6_3_9,QKY76372_QKY75985,Unique source,SARS-CoV-2,2,1,13.117599,12.007047
QKK35742_QKK35743,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQVPGRGLEWVSGISWNSGTINYADSVMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDGRYCSGISCRTGMDVWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTITCRASRSISSYLNWYQQKPGKAPNLLIYDASTLQSGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCLHTYTTPRTFGQGTKVEIK,QKK35742,QKK35743,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_9,QKK35742_QKK35743,Unique source,SARS-CoV-2,2,1,13.116242,12.01621
7KQH_H_L,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYPMHWVRQVPGKGLEWVSSINWNGGSTDHADSVKGRFTISRDNARNSLYLEMNSLKSEDTALYYCAKDLRASSSMDYYYYSGMDVWGQGTMVTVSG,DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKVLIYDASNLQTGVPSRFSGSGSGTDFIFTISSLKPEDVATYYCQQYENVPITFGQGTRLDIK,7KQH_H,7KQH_L,Antibodies That Engage The Hemagglutinin Receptor-Binding Site Of Influenza B Viruses,Antibodies That Engage The Hemagglutinin Receptor-Binding Site Of Influenza B Viruses,Influenza B virus,"Bajic,G.;Harrison,S.C.",Antibodies That Engage the Hemagglutinin Receptor-Binding Site of Influenza B Viruses,16-NOV-2020,8_8_20_6_3_9,7KQH_H_L,Xtal structure,Influenza,2,1,13.111637,12.06994
QPL06788_QPL06789,EVQLVESGGGLVQPGRSLRLSCALSQFSFYDYDVHWVRQPPGKGLEWVSGLTLNNGNVVYADSVRGRFTISRDNARNSLYLQMNSLRREDTALYYCCQGPNNHSFHIWGQGTMVTVSS,SYELTQPPSVSVAPGQTARIPCTGNNIGTKDVHWYQQKPGQAPALVVYDNTDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDRLSDHLYVFGGGTKVTVL,QPL06788,QPL06789,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_8_11_6_3_12,QPL06788_QPL06789,Unique source,,2,1,13.11894,12.019517
QPL06763_QPL06813,EVQLVESGGGLVQPGRSLRLSCRASGFSIGDYTVSWVRQAPGKGLEWVSSIRTNAYGGTTEYAASVKGRFSISRDDSKKIVSLQVNSLKTEDTAVYYCSRMYFYDSGGPRQFYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDIGNWLAWYQQKPGKAPKLLIYRTSSLQSGVPSRFSGSGSGTQFTLTINRLQPEDFATYYCQQPDSFPLTFGQGTRLEIK,QPL06763,QPL06813,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_10_20_6_3_9,QPL06763_QPL06813,Unique source,,2,1,13.276513,8.943409
QKK35492_QKK35493,EVQLVESGGGLVQPGRSLRLSCSASGFSFGDYAMSWFRQAPGKGLQWVGLIKTRAYGAATDYAASVQGRFIISRDDSKSIAYLQMNSLKTEDTAVYFCAREGTSLGYYYYYAMDVWGHGTTVTVSS,DIVLTQTPSSLSASVGDRVTITCRASQTISYYLNWYQQKVGKAPQLLVYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSVPLTLGQGTKVDIK,QKK35492,QKK35493,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_10_17_6_3_9,QKK35492_QKK35493,Unique source,SARS-CoV-2,2,1,13.266836,8.897659
QPL06904_QPL07012,EVQLVESGGGLVQPGRSLRLSCTVSGFSFDDYAMHWVRQVPGKGLEWVSGCSWNSATKGYADSLKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCAKGYGSGNHYPLAPTLDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTGSDIGDNSYVSWYQKHPGKAPKLMIYDVSNRLSGVSNRFSGSKSGNTASLTISELQAEDEADYYCSAYRSSSTLVVFGGGTKLTVL,QPL06904,QPL07012,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_8_18_9_3_11,QPL06904_QPL07012,Unique source,,2,1,13.121962,12.027848
3CXD_H_L,EVQLVESGGGLVQPKGSLKISCAASGFTFNIYAMNWVRQAPGKGLEWVARIRSQSNNYTTYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRQMGDYWGQGTTLTVSS,IQMTQSPASLSVSVGETVTITCRASENIYSFLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQFSLKINSLQSEDFGTYYCQHFWGTPFTFGSGTKLEIK,3CXD_H,3CXD_L,Crystal Structure Of Anti-Osteopontin Antibody 23C3 In Complex With Its Epitope Peptide,Crystal Structure Of Anti-Osteopontin Antibody 23C3 In Complex With Its Epitope Peptide,synthetic construct,"Du,J.;Hou,S.;Zhong,C.;Lai,Z.;Yang,H.;Dai,J.;Zhang,D.;Wang,H.;Guo,Y.;Ding,J.","Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis",24-APR-2008,8_10_7_6_3_9,3CXD_H_L,Xtal structure,osteopontin,2,1,13.345136,7.7550144
UYI36065_UYI36293,EVQLVESGGGLVQSGGSLRLSCAASGFTFSNYGMNWVRQAPGRGLEWVSYISYGGDSTYYADSVKGRFTISRDNSKNTLSLQMNSLRPEDTAVYYCAKRGLGGTFYNWFDVWGPGVLVTVSS,ETVVTQEPSLSVSPGGTVTLTCGLRSGSVSTSNYPSWFQQTPGQAPRTLIYSTTTRPSGVPDRFSGSILGNKAALTITGTQADDESDYYCSLYMGGGIWVFGGGTRLTVL,UYI36065,UYI36293,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,8_8_15_9_3_10,UYI36065_UYI36293,Unique source,COVID,2,1,13.939284,9.755328
6XQ0_B_C,EVQLVESGGGLVRPGGSLTLTCAGSGFMFRSYDMHWVRQAAGKGLEWVAGMGKGGETFYAGSVKGRFTISRENARNSLYLQMHSLRAGDTAVYYCARALTEWLFQRGTRNHYYYGMDVWGQGTTITVSG,EIVLTQSPGTLSLSPGERATLSCRASQIIDNKYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTEFTLIISRLEPEDLAVYYCQQFGSSVYTFGQGTRLEIK,6XQ0_B,6XQ0_C,Human Antibody S8V2-18 In Complex With The Influenza Hemagglutinin Head Domain Of A/California/7/2009(Nymc-X181)(H1N1),Human Antibody S8V2-18 In Complex With The Influenza Hemagglutinin Head Domain Of A/California/7/2009(Nymc-X181)(H1N1),Homo sapiens,"McCarthy,K.R.;Lee,J.;Watanabe,A.;Kuraoka,M.;Robinson-McCarthy,L.R.;Georgiou,G.;Kelsoe,G.;Harrison,S.C.",A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface,09-JUL-2020,8_7_23_7_3_9,6XQ0_B_C,Xtal structure,H1N1; Influenza,2,1,16.453321,11.672756
QGW50172_QGW50190,EVQLVESGGGLVRPGGSVRLSCAASGFDCSENDMHWVRQVTGKGLEWVASIGGGEMTYYAASAKGRFTVTRQKVKNSLYLQINNLRDDDTGIYYCVRGASSGWHLHYYFGMDLWGRGTTVTVAS,DIVMTQSPLSLAVTLGEPAALSCRSSQSLLQYNGRNYVDWYLQKPGQSPQLLIYLGSHRASGVPDRFSGSGSGKDFTLKISRVEAEDIGVYYCMESLQTPRLTFGGGTKVEIK,QGW50172,QGW50190,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Setliff,I.; Shiakolas,A.R.; Pilewski,K.A.; Murji,A.A.; Ziki,R.; Janowska,K.; Richardson,S.; Mynhardt,C.; Raju,N.; Ronsard,L.; Kanekiyo,M.; Qin,J.; Kramer,K.J.; Greenplate,A.R.; McDonnell,W.J.; Graham,B.S.; Connors,M.; Lingwood,D.; Acharya,P.; Morris,L.; Georgiev,I.S.",High-throughput mapping of B-cell receptor sequences to antigen specificity,17-DEC-2019,8_7_18_11_3_10,QGW50172_QGW50190,Unique source,,2,1,16.413376,11.6512985
QGW50180_QGW50198,EVQLVESGGGLVRPGGSVRLSCAASGFDCTENDMHWVRQVTGKGLEWVASIGGGEMTYYAASAKGRFTVSRQKVRNSVYLQINNLRDDDTGIYYCVRGPSSGWHLHYYFGMDLWGRGTTVTVAS,DIVMTQSPLSLAVTLGEPAALSCRSSQSLLQYNGRNYVDWYLQKPGQSPQLLIYLGSHRASGVPDRFSGSGSGKDFTLKISRVEAEDIGVYYCMESLQTPRLTFGGGTKVEIK,QGW50180,QGW50198,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Setliff,I.; Shiakolas,A.R.; Pilewski,K.A.; Murji,A.A.; Ziki,R.; Janowska,K.; Richardson,S.; Mynhardt,C.; Raju,N.; Ronsard,L.; Kanekiyo,M.; Qin,J.; Kramer,K.J.; Greenplate,A.R.; McDonnell,W.J.; Graham,B.S.; Connors,M.; Lingwood,D.; Acharya,P.; Morris,L.; Georgiev,I.S.",High-throughput mapping of B-cell receptor sequences to antigen specificity,17-DEC-2019,8_7_18_11_3_10,QGW50180_QGW50198,Unique source,,2,1,16.39749,11.6411495
3VE0_A_B,EVQLVESGGGLVTPGGSLKLSCAASGFAFNYYDMFWVRQNTEKRLEWVAYINSGGGNTYYPDTVKGRFTISRDNAKKTLFLQMSSLRSEDTAMYYCARQLYGNSFFDYWGQGTSLTVS,DIVMTQSHKFMSTSVGDRVTITCKASQDVTTAVAWYQQKPGHSPKLLIYWASTRHTGVPDRFTGSGSGTAFTLTLNSVQAEDLALYYCQQHYSTPLTFGAGTKLELK,3VE0_A,3VE0_B,Crystal Structure Of Sudan Ebolavirus Glycoprotein (Strain Boniface) Bound To 16F6,Crystal Structure Of Sudan Ebolavirus Glycoprotein (Strain Boniface) Bound To 16F6,Mus musculus,"Bale,S.;Dias,J.M.;Fusco,M.L.;Hashiguchi,T.;Wong,A.C.;Liu,T.;Keuhne,A.I.;Li,S.;Woods VL,Jr.;Chandran,K.;Dye,J.M.;Saphire,E.O.",Structural basis for differential neutralization of ebolaviruses,06-JAN-2012,8_8_12_6_3_9,3VE0_A_B,Xtal structure,Ebolavirus,2,1,17.988768,6.9574895
7UMS_4_5,EVQLVESGGGPVQPGGSLKLSCAASGFTFSNYEMYWVRQAPGKGLEWVSYISTSPAITYYADSVRGRFTISRDNAKSSLYLHMNSLRAEDTAVYYCATISHQQFSSGWNAWFDPWGQGTLVTVSG,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYRQRPGSAPTTVIYENYQRPSGVPARFSGSIDRSSNSASLTISGLQTDDEADYYCQSYDNNNLWVFGGGTKLTVL,7UMS_4,7UMS_5,Structure Of The Vp5*/Vp8* Assembly From The Human Rotavirus Strain Cdc-9 In Complex With Antibody 41 - Upright Conformation,Structure Of The Vp5*/Vp8* Assembly From The Human Rotavirus Strain Cdc-9 In Complex With Antibody 41 - Upright Conformation,Rotavirus,"Jenni,S.;Li,Z.;Wang,Y.;Bessey,T.;Salgado,E.N.;Schmidt,A.G.;Greenberg,H.B.;Jiang,B.;Harrison,S.C.",Rotavirus VP4 Epitope of a Broadly Neutralizing Human Antibody Defined by Its Structure Bound with an Attenuated-Strain Virion,08-JAN-2009,8_8_18_8_3_10,7UMS_4_5,Xtal structure,,2,1,15.5184145,10.05237
ANV21814_ANV22003,EVQLVESGGGSVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWNSGNMGYADSVKGRFTISRDNARNSLYLQMNSLRAEDTALYYCVKDIFYHGSGSSYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYTDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDASLNAPVFGGGTKLTVL,ANV21814,ANV22003,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_20_8_3_11,ANV21814_ANV22003,Unique source,,2,1,13.128605,11.995434
QKK35802_QKK35803,EVQLVESGGGVVKPGGSLRVSCVGSGFTFSDHYMSWIRQAPGKGLEIISYISTDGSYINDADSVKGRFINSRDNAKNSVYLQLNSLRAEDTAVYYCARMGPSGSGSLDYWGQGSLVTVSS,DIVMTQSPGTLSLSPGERAALSCRASQIVTRSQLAWYQHKPGQPPRLLIYDSSSRATGTPDRFSGSGSGTDFTLTISRLEPEDSAVYYCHQYSGSATFGPGTKVEIK,QKK35802,QKK35803,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_7_3_8,QKK35802_QKK35803,Unique source,SARS-CoV-2,2,1,15.7421055,9.3568735
QKK35880_QKK35881,EVQLVESGGGVVNPGGSLRLSCAGSGFTFSDYYMGWIRQAPGKGLEVVSYISTTGSYIKDADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARMGPYGSGSFDYWGQGTLVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQTVTRSQLAWYQHKPGQPPRLLIYDSSNRATGTPDRFSASGSGTEFTLTITRLEPEDSAVYYCLQYSSATTFGPGTKVDIK,QKK35880,QKK35881,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_7_3_8,QKK35880_QKK35881,Unique source,SARS-CoV-2,2,1,15.766786,9.338831
6A79_H_L,EVQLVESGGGVVQPGGSLKLSCAASGFTFSTYDMSWVRQTPDKRLELVATINSNGGSTYYPDSVKGRFTSSRDNAKNILYLQMSSLKSEDTAMYYCAREALLRPAYYALDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCGASENIYGALTWYQRKQGKSPQLLIYGAINLADDKSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPFTFGSGTKLEIK,6A79_H,6A79_L,Crystal Structure Of The Fifth Immunoglobulin Domain (Ig5) Of Human Robo1 In Complex With The Mutant Scfv Fragment (P103A) Of Murine Monoclonal Antibody B5209B,Crystal Structure Of The Fifth Immunoglobulin Domain (Ig5) Of Human Robo1 In Complex With The Mutant Scfv Fragment (P103A) Of Murine Monoclonal Antibody B5209B,Mus musculus,"Yamashita,T.;Mizohata,E.;Nagatoishi,S.;Watanabe,T.;Nakakido,M.;Iwanari,H.;Mochizuki,Y.;Nakayama,T.;Kado,Y.;Yokota,Y.;Matsumura,H.;Kawamura,T.;Kodama,T.;Hamakubo,T.;Inoue,T.;Fujitani,H.;Tsumoto,K.",Affinity Improvement of a Cancer-Targeted Antibody through Alanine-Induced Adjustment of Antigen-Antibody Interface,02-JUL-2018,8_8_15_6_3_9,6A79_H_L,Xtal structure,,2,1,17.68457,7.042846
8D47_H_L,EVQLVESGGGVVQPGGSLRLSCAASGFNFNNYALHWVRQAPGKGLEWVAIISYEARNKKYGVSVMGRFSISRDNSKSIMYLEMNSLRVEDTGVYYCARDLFLSDYDRSGYDPTRGGFDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQHRFGQAPRLLISGASTRATGIPGRFSGSGSGTEFTLTISSLQSEDVAVYYCQQYGDWPLVTFGGGTKVEIK,8D47_H,8D47_L,Fp.006 Fab In Complex With Sars-Cov-2 Fusion Peptide,Fp.006 Fab In Complex With Sars-Cov-2 Fusion Peptide,Severe acute respiratory syndrome coronavirus 2,"Bianchini,F.;Crivelli,V.;Abernathy,M.E.;Guerra,C.;Palus,M.;Muri,J.;Marcotte,H.;Piralla,A.;Pedotti,M.;Gasparo,R.;Simonelli,L.;Matkovic,M.;Toscano,C.;Biggiogero,M.;Calvaruso,V.;Svoboda,P.;Rinc&#xf3;n,T.C.;Fava,T.;Pode&#x161;vov&#xe1;,L.;Shanbhag,A.A.;Celoria,A.;Sgrignani,J.;Stefanik,M.;H&#xf6;nig,V.;Pranclova,V.;Michalcikova,T.;Prochazka,J.;Guerrini,G.;Mehn,D.;Ciabattini,A.;Abolhassani,H.;Jarrossay,D.;Uguccioni,M.;Medaglini,D.;Pan-Hammarstr&#xf6;m,Q.;Calzolai,L.;Fernandez,D.;Baldanti,F.;Franzetti-Pellanda,A.;Garzoni,C.;Sedlacek,R.;Ruzek,D.;Varani,L.;Cavalli,A.;Barnes,C.O.;Robbiani,D.F.",Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2,21-DEC-2022,8_8_23_6_3_10,8D47_H_L,Xtal structure,SARS-CoV-2,2,1,14.784572,13.72288
QKY76440_QKY76053,EVQLVESGGGVVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSLISGDGGNTYYADSVKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCAKDEMAYPPSHHYYYYYMDVWGKGTTVTVSS,SYELTQPPSVSVSPGQTARITCSTDALPNEYIYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSVDSSGTYPHVIFGGGTKLTVL,QKY76440,QKY76053,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_20_6_3_13,QKY76440_QKY76053,Unique source,SARS-CoV-2,2,1,13.432925,11.417848
5D1Z_G_H,EVQLVESGGGVVQPGGSLRLSCAASGFTFNKFWMNWVRQAPGKGLEWVADIQVDGSEKNYVDSVKGRFTISRDNGKNSLYLQMNSLRAEDTGVYYCARGRYDYWSGYLSPWGQGTLVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGITTYLGWYQQRPGKAPQLLIYAASSLQSGVPPRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNTYPYTFGPGTRLEIK,5D1Z_G,5D1Z_H,Isdb Neat1 Bound By Clone D4-10,Isdb Neat1 Bound By Clone D4-10,Staphylococcus aureus subsp. aureus MSSA476,"Yeung,Y.A.;Foletti,D.;Deng,X.;Abdiche,Y.;Strop,P.;Glanville,J.;Pitts,S.;Lindquist,K.;Sundar,P.D.;Sirota,M.;Hasa-Moreno,A.;Pham,A.;Melton Witt,J.;Ni,I.;Pons,J.;Shelton,D.;Rajpal,A.;Chaparro-Riggers,J.",Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire,04-AUG-2015,8_8_14_6_3_9,5D1Z_G_H,Xtal structure,,2,1,11.171889,7.799265
7X9E_A_B,EVQLVESGGGVVQPGGSLRLSCEASGFSFKDYGMHWIRQTPGKGLEWISRISGDTRGTSYVDSVKGRFIVSRDNSRNSLFLQMNSLRSEDTALYYCAALVIVAAGDDFDLWGQGTVVTVSS,QSALTQPLSVSGSPGQSVTISCTGSSSDIGSYNFVSWYRQYPGKAPKVMIYEVNKRPSGVPVRFSGSKSGNTASLTVSGLQHEDEADYYCCSYGGRNNLIFGGGTKLTVL,7X9E_A,7X9E_B,Crystal Structure Of The 76E1 Fab In Complex With A Sars-Cov-2 Spike Peptide,Crystal Structure Of The 76E1 Fab In Complex With A Sars-Cov-2 Spike Peptide,Severe acute respiratory syndrome coronavirus 2,"Sun,X.;Yi,C.;Zhu,Y.;Ding,L.;Xia,S.;Chen,X.;Liu,M.;Gu,C.;Lu,X.;Fu,Y.;Chen,S.;Zhang,T.;Zhang,Y.;Yang,Z.;Ma,L.;Gu,W.;Hu,G.;Du,S.;Yan,R.;Fu,W.;Yuan,S.;Qiu,C.;Zhao,C.;Zhang,X.;He,Y.;Qu,A.;Zhou,X.;Li,X.;Wong,G.;Deng,Q.;Zhou,Q.;Lu,H.;Ling,Z.;Ding,J.;Lu,L.;Xu,J.;Xie,Y.;Sun,B.",Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2,15-MAR-2022,8_8_14_9_3_10,7X9E_A_B,Xtal structure,SARS-CoV-2,2,1,13.836095,10.303552
8DB4_A_B,EVQLVESGGGVVQPGGSLRLSCVASGFKFQNYGMSWVRQAPGKGLEWVADISGSDESTYYADSVKGRFTISRDTSKNTLHLQMSSPRAEDTALYYCAKATAPAGKYYYYGMDVWGQGTTVTVSS,EIVMTQSPATLSLSPGEIATLSCRASQTVSSYLAWYQLKPGQAPRLLIYDASRRAAGIPARFSGSESGTDFTLTISSLEPEDSAVYYCHQRSNWPPVHTFGQGTKLEIK,8DB4_A,8DB4_B,Crystal Structure Of The Peanut Allergen Ara H 2 Bound By Two Neutralizing Antibodies 22S1 And 13T1,Crystal Structure Of The Peanut Allergen Ara H 2 Bound By Two Neutralizing Antibodies 22S1 And 13T1,Homo sapiens,"LaHood,N.A.;Min,J.;Keswani,T.;Richardson,C.M.;Amoako,K.;Zhou,J.;Marini-Rapoport,O.;Bernard,H.;Hazebrouck,S.;Shreffler,W.G.;Love,J.C.;Pomes,A.;Pedersen,L.C.;Mueller,G.A.;Patil,S.U.",Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy,25-JAN-2023,8_8_17_6_3_11,8DB4_A_B,Xtal structure,,2,1,13.89023,10.243521
QKK35806_QKK35807,EVQLVESGGGVVQPGGSLRLSCVASGFPFGRYAMHWVRQAPGQGLEWLTLISFDSSNIEYSDSVQGRFTISRDNSRNTLFLQMTSLRPEDTAVYFCARDLPPLDYWGQGTLVTVSS,DIRMTQSPSSLSASVGDRVTITCRASQGFGNKVAWYQQKPGTAPKLLIYETSTLQSGVPSRFSGSGSGTEFAFTISSLQPEDGATYYCQKYNRAPWTFGQGTKVEIK,QKK35806,QKK35807,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_9_6_3_9,QKK35806_QKK35807,Unique source,SARS-CoV-2,2,1,14.796108,13.053546
QKK35716_QKK35717,EVQLVESGGGVVQPGKSLRLSCVPSGFSFGTYGMHWVRQAPGKGPEWLAVMWYDGITQYYADSVKGRFTISRDNSKETLYLQMNSLTADDTGIYYCVKDQSSGDRLLYLGYFDLWGPGALVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSIYLAWYQQKPGQAPRLLIYDASNRATGVPARFSGSGSGTDFTLTINNLEPEDFAIYYCQQRAKWPPRVTFGPGTKVDIK,QKK35716,QKK35717,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_11,QKK35716_QKK35717,Unique source,SARS-CoV-2,2,1,14.899862,13.792486
QKK35842_QKK35843,EVQLVESGGGVVQPGRSLRLSCAASEFTFSTYAMHWVRQAPGKGLEWVALISYDGINKYYADSVKGRFAISRDNSKNTLYLQVNSLRADDTAVYYCVRPYSGSYTNWFDLWGQGTLVTVSS,EIVMTQSPGTLSSSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGTSNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSYTFGPGTKLEIK,QKK35842,QKK35843,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_7_3_8,QKK35842_QKK35843,Unique source,SARS-CoV-2,2,1,14.63176,13.580751
5XAJ_A_B,EVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSKTYYGDSVKGRFTISKDNSKKMVNLQMDSLGVEDTAFYYCARGIAGGWAFWGIDLWGQGTLVTVSS,DIVMTQSPGTLSLSPGERATLSCRASQNVYSYLGWYQHKPGRSPRLLIFGVTSRATGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSAYTFGQGTKVEIK,5XAJ_A,5XAJ_B,Structural Mimicry Of The Dengue Virus Envelope Glycoprotein Revealed By The Crystallographic Study Of An Idiotype-Anti-Idiotype Fab Complex.,Structural Mimicry Of The Dengue Virus Envelope Glycoprotein Revealed By The Crystallographic Study Of An Idiotype-Anti-Idiotype Fab Complex.,Homo sapiens,"Wong,Y.H.;Goh,B.C.;Lim,S.Y.;Teo,E.W.;Lim,A.P.;Dedon,P.C.;Hanson,B.J.;MacAry,P.A.;Lescar,J.",Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype Fab complex,13-MAR-2017,8_8_15_6_3_9,5XAJ_A_B,Xtal structure,Dengue; dengue,2,1,15.00977,13.359268
AWH66709_AWH66734,EVQLVESGGGVVQPGRSLRLSCAASGFTFRTVAMHWVRQAPGKGLEWVAVISHAGTSKYYADSVKGRFTISRDNSMNTVYLQMSSLRSEDTAVYFCARDGSFGLDYWGLGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRSDLAWYQQKPGKAPKLLIYGASTLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNDPYTFGQGTKVEIK,AWH66709,AWH66734,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sullivan,N.L.; Ahmed,R.",Breadth and functionality of varicella zoster virus glycoprotein-specific antibodies identified after ZOSTAVAX# vaccination in humans,09-MAY-2018,8_8_10_6_3_9,AWH66709_AWH66734,Unique source,,2,1,14.788221,13.1637335
7WI0_B_D,EVQLVESGGGVVQPGRSLRLSCAASGFTFRTYAMHWVRQAPGKGLEWVAVMWNDGSNKYYADSVKGRFTISRDNSKNTLYLEMNSLRAEDTAVYYCAREGVAAAGSSSDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLYSFGQGTKLEIK,7WI0_B,7WI0_D,Sars-Cov-2 Omicron Variant Spike In Complex With Three Human Neutralizing Antibodies,Sars-Cov-2 Omicron Variant Spike In Complex With Three Human Neutralizing Antibodies,Homo sapiens,"Wang,S.;Sun,H.;Zhang,Y.;Yuan,L.;Wang,Y.;Zhang,T.;Wang,S.;Zhang,J.;Yu,H.;Xiong,H.;Tang,Z.;Liu,L.;Huang,Y.;Chen,X.;Li,T.;Ying,D.;Liu,C.;Chen,Z.;Yuan,Q.;Zhang,J.;Cheng,T.;Li,S.;Guan,Y.;Zheng,Q.;Zheng,Z.;Xia,N.","Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron",01-JAN-2022,8_8_17_6_3_9,7WI0_B_D,Xtal structure,SARS-CoV-2,2,1,14.699437,13.536293
QKK35510_QKK35511,EVQLVESGGGVVQPGRSLRLSCAASGFTFSGYPMHWVRQAPGKGLEWVALISFDGDSKYYTDSVKARFAISRDNSKNTLFLQMNSLRVADTALYYCARAKGGSYSNAFDYWGQGTLVTVSS,EIVLTQSPDSLAVSLGERATINCKSSQSVLYSSNNENCLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYCSTPPYTFGQGTKVDIK,QKK35510,QKK35511,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_12_3_10,QKK35510_QKK35511,Unique source,SARS-CoV-2,2,1,14.659251,13.485796
QKK35778_QKK35779,EVQLVESGGGVVQPGRSLRLSCAASGFTFSKFAMHWVRQAPGKGLEWVAIISYDGSHKNYADSVKGRFTISRDNSKNTVYLQVDSLRAEDTAVYYCALLYGSGSYYNFVFFGWKDGSDAWGPGTTVTVSS,QPVLTQPASVSGSPGQSITISCTGTTSDVGGYDYVSWYQQRPGKAPKLIIYDVINRPSGVSNRFSGSKSGNTASLTISGLQADDETDYYCSSYTSGGTLVFGTGTKLTVL,QKK35778,QKK35779,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_23_9_3_10,QKK35778_QKK35779,Unique source,SARS-CoV-2,2,1,14.36164,13.809926
QKK35810_QKK35811,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVALISYDGDKKYYPDSVRGRFTISRDNSKNTLHLQMNSLRLEDTAVYYCARSYGGSYSTVGYWGQGALVTVSS,QSALIQPRSVSGSPGQSVTISCTGTSSDVGGSNYVSWYQQHPGKAPKLLVYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGTYIFGTGTKLTVL,QKK35810,QKK35811,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_9_3_8,QKK35810_QKK35811,Unique source,SARS-CoV-2,2,1,14.660854,13.422887
6ANP_H_L,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYSWGQGTTVTVGG,EIVLTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK,6ANP_H,6ANP_L,Cat192 Fab Insertion Mutant H5/L0,Cat192 Fab Insertion Mutant H5/L0,Homo sapiens,"Lord,D.M.;Bird,J.J.;Honey,D.M.;Best,A.;Park,A.;Wei,R.R.;Qiu,H.",Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFbeta1 antibody,14-AUG-2017,8_8_16_6_3_9,6ANP_H_L,Xtal structure,TGFbeta1,2,1,14.585519,13.714112
UDP68855_UDP68825,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLSLQMNSLRPEDTAVYYCAKDSPYYYDSSGYYPGYFQDWGQGSLVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQTISDYLNWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPRTFGQGTKVEIK,UDP68855,UDP68825,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Dussupt,V.; Townsley,S.; Donofrio,G.",Direct Submission,03-NOV-2021,8_8_20_6_3_9,UDP68855_UDP68825,Unique source,,2,1,14.912313,13.687998
QRI59085_QRI59099,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPDILTGYYNYYYYGMDVWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGFYVVFGGGTKLTVL,QRI59085,QRI59099,"heavy chain variable region, partial [Homo sapiens]","light chain variable region, partial [Homo sapiens]",Homo sapiens,"Huang,K.-Y.A.",Direct Submission,14-FEB-2021,8_8_20_9_3_13,QRI59085_QRI59099,Unique source,,2,1,14.163236,13.9941435
QKK35702_QKK35703,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGSGRVYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,QKK35702,QKK35703,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_9_12_3_9,QKK35702_QKK35703,Unique source,SARS-CoV-2,2,1,14.844056,13.426201
7LY3_F_E,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVTVIWYDGSNRYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCARAVAGEWYFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALAKHYAYWYRQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSIGSSWVFGGGTKLTVL,7LY3_F,7LY3_E,Crystal Structure Of Sars-Cov-2 S Ntd Bound To S2M28 Fab,Crystal Structure Of Sars-Cov-2 S Ntd Bound To S2M28 Fab,Homo sapiens,"McCallum,M.;De Marco,A.;Lempp,F.A.;Tortorici,M.A.;Pinto,D.;Walls,A.C.;Beltramello,M.;Chen,A.;Liu,Z.;Zatta,F.;Zepeda,S.;di Iulio,J.;Bowen,J.E.;Montiel-Ruiz,M.;Zhou,J.;Rosen,L.E.;Bianchi,S.;Guarino,B.;Fregni,C.S.;Abdelnabi,R.;Foo,S.C.;Rothlauf,P.W.;Bloyet,L.M.;Benigni,F.;Cameroni,E.;Neyts,J.;Riva,A.;Snell,G.;Telenti,A.;Whelan,S.P.;Virgin,H.W.;Corti,D.;Pizzuto,M.S.;Veesler,D.",N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2,05-MAR-2021,8_8_12_6_3_11,7LY3_F_E,Xtal structure,SARS-CoV-2,2,1,14.842432,13.334418
7DEO_A_A,EVQLVESGGGVVQPGRSLRLSCAASGFTFSYYGMHWVRQAPGKGLEWVAVIWYDGSNRFYADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCATDPPGLRFRFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQTPLTFGGGTKVEIK,7DEO_A,7DEO_A,Crystal Structure Of Sars-Cov-2 Rbd In Complex With A Neutralizing Antibody Scfv,Crystal Structure Of Sars-Cov-2 Rbd In Complex With A Neutralizing Antibody Scfv,Severe acute respiratory syndrome coronavirus 2,"Fu,D.;Zhang,G.;Wang,Y.;Zhang,Z.;Hu,H.;Shen,S.;Wu,J.;Li,B.;Li,X.;Fang,Y.;Liu,J.;Wang,Q.;Zhou,Y.;Wang,W.;Li,Y.;Lu,Z.;Wang,X.;Nie,C.;Tian,Y.;Chen,D.;Wang,Y.;Zhou,X.;Wang,Q.;Yu,F.;Zhang,C.;Deng,C.;Zhou,L.;Guan,G.;Shao,N.;Lou,Z.;Deng,F.;Zhang,H.;Chen,X.;Wang,M.;Liu,L.;Rao,Z.;Guo,Y.",Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes,04-NOV-2020,8_8_13_11_3_9,7DEO_A_A,Xtal structure,SARS-CoV-2,2,1,15.059047,13.281426
QKK35820_QKK35821,EVQLVESGGGVVQPGRSLRLSCEASGFTFADYPMHWVRQAPGKGLEWVAVISSHGRSQGYAASVKGRFTFSRDNSQSSLFLQLNSLRVEDTAVYFCAREAQSSGRAGCLDAWGQGTLVTVSS,DIRLTQSPSSLSASVGDRVTITCRASQAIAGWLAWYQQKPGRAPKSLIYRASSLQSGVPSRFSGSGSGTDFSLTISNLQPEDSATYYCQHYDSYPTAFGQGTRLEIK,QKK35820,QKK35821,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_9,QKK35820_QKK35821,Unique source,SARS-CoV-2,2,1,14.811725,13.282054
QAV55001_QAV55341,EVQLVESGGGVVQPGRSLRLSCVASGFTFSDCPMHWVRQAPGRGLEWVAFISFDGSNKNYADSVKGRFTISRDNSKNTLYLQMNSLRVDDTAVYYCARDRGLVVMDDTPDALDMWGQGTMVTISS,DIQMTQSPSSLSASVGDRVIITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQYSAYPLTFGGGTKVEIK,QAV55001,QAV55341,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,Y.; Tan,H.X.; Koutsakos,M.; Jegaskanda,S.; Esterbauer,R.; Tilmanis,D.; Aban,M.; Kedzierska,K.; Hurt,A.C.; Kent,S.J.; Wheatley,A.K.",Cross-lineage protection by human antibodies binding the influenza B hemagglutinin,03-FEB-2019,8_8_18_6_3_9,QAV55001_QAV55341,Unique source,hemagglutinin,2,1,14.634831,13.729812
QKK35574_QKK35575,EVQLVESGGGVVQPGRSLRLSCVASGFTLAPYGMQWVRQAPGKGLEWVAFLSHDGSHLGYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTATYYCARDNVVQQNADNVGYFDFWGQGSLVTVSS,CIRLTQSPATLSLSPGERATLSCRASQSVTSYLAWYQQRPGQAPRLLIYDTSNRVTGVPVRFSGSGYGTDFTLTISSLEPEDFAVYYCQQRGNGYTFGPGTKVEIK,QKK35574,QKK35575,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_8,QKK35574_QKK35575,Unique source,SARS-CoV-2,2,1,14.731523,13.47304
QKK35682_QKK35683,EVQLVESGGGVVQPGRSLRLSCVTSGFDFRPYAMQWVRQAPGKGLEWVAVISHDGVHTGYADSLKGRFTISRDNSKNTLYLQVDSLRPDDSALYYCARDNALQNAQIGYLDYWGQGTLVTVSS,EIVMTQSPATLSVSPGETATLSCRASQSVGRFMGWYQQKPGQAPRLLIFDASNRVTGVPDRFRGSGSGTDFILTINSLEPEDSASYYCQRRGDGYNFGQGTKVEIK,QKK35682,QKK35683,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_8,QKK35682_QKK35683,Unique source,SARS-CoV-2,2,1,14.56192,13.399031
QTX15814_QTX15707,EVQLVESGGGVVQPGRSLRLTCAASGFIFSSYGMHWVRQAPGKGLEWVAVISYDGSYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTKADYYDFWSGYQKTYYYYMDVWGKGTTVTISS,DIQLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPQITFGQGTRLEIK,QTX15814,QTX15707,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Graham,C.; Seow,J.; Huettner,I.; Khan,H.; Kouphou,N.; Acors,S.; Winstone,H.; Pickering,S.; Galao,R.P.; Dupont,L.; Lista,M.J.; Jimenez-Guardeno,J.M.; Laing,A.G.; Wu,Y.; Joseph,M.; Muir,L.; van Gils,M.J.; Ng,W.M.; Duyvesteyn,H.M.E.; Zhao,Y.; Bowden,T.A.; Shankar-Hari,M.; Rosa,A.; Cherepanov,P.; McCoy,L.E.; Hayday,A.C.; Neil,S.J.D.; Malim,M.H.; Doores,K.J.",Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant,21-APR-2021,8_8_22_7_3_10,QTX15814_QTX15707,Unique source,SARS-CoV-2,2,1,14.11456,14.010484
ASY01775_ASY01819,EVQLVESGGGVVRPGESLRLSCEVSGVNINDYDMSWVRQPLGKGLEWVSGIDRKGVGTGYADSVKGRFTISRDNGKNSLYLQMNSLRGEDTALYYCVRDPGDRSGRGHIFNIWGQGTMVTVSL,DIQMTQSPSTLSASIGDRVTITCRASQVIDRSLAWFQQKPGKSPRPLIYKASTLEGGVPSRFSGSGSGTDFTLTVSSLQPDDFANYYCQQYDTYPFTFGPGTTVTLR,ASY01775,ASY01819,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Pieper,K.; Tan,J.; Piccoli,L.; Foglierini,M.; Barbieri,S.; Chen,Y.; Silacci-Fregni,C.; Wolf,T.; Jarrossay,D.; Anderle,M.; Abdi,A.; Ndungu,F.M.; Doumbo,O.K.; Traore,B.; Tran,T.M.; Jongo,S.; Zenklusen,I.; Crompton,P.D.; Daubenberger,C.; Bull,P.C.; Sallusto,F.; Lanzavecchia,A.",Public antibodies to malaria antigens generated by two LAIR1 insertion modalities,12-SEP-2017,8_8_16_6_3_9,ASY01775_ASY01819,Unique source,LAIR-1; CD305; LAIR1,2,1,13.16982,11.657425
QKY76299_QKY75912,EVQLVESGGGVVRPGGSLRLSCAASGFIFDDYDMTWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCAVIMSPIPRYSGYDWAGDAFDIWGQGTMVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQVPILVIYDKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNAVVFGGGTKLTVL,QKY76299,QKY75912,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_22_6_3_11,QKY76299_QKY75912,Unique source,SARS-CoV-2,2,1,13.258662,11.801934
QKY76301_QKY75914,EVQLVESGGGVVRPGGSLRLSCAASGFIFDDYDMTWVRQAPGKGLEWVSGISWNGGNTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCAVIMSPIPRYSGYDWAGGAFDIWGQGTMVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQVPILVIYDKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNAVVFGGGTKLTVL,QKY76301,QKY75914,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_22_6_3_11,QKY76301_QKY75914,Unique source,SARS-CoV-2,2,1,13.244457,11.820039
ANV21745_ANV21934,EVQLVESGGGWVQPGGSLRLSCAASGFSFTTYEMNWVRQAPGKGLEWISYISSSDTTTYYADSVKGRFTISRDNAQNSLYLQMNSLRAEDTAVYYCAREYHDFSSGYPDALDIWGQGTLVTVSS,QFVLTQSPSASGTPGQRVTISCSGSRSNIGSNTVYWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAVSGLRSDDEADYYCAAWDDSVNGHVFGTGTKVAVL,ANV21745,ANV21934,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_17_8_3_11,ANV21745_ANV21934,Unique source,,2,1,15.782419,9.90715
QKK35772_QKK35773,EVQLVESGGHVVLPGKSLRLSCAGSGFGFPLYAMQWVRRAPGKGLEWVALVSYDSSNIRYADSVKGRFTISRDNSQNTLYLQMDSLRPEDTAMYYCARDNALQDGRPGYFDSWGQGTLVTVSS,ETTLTQSPATLSLSPGERATLSCRASQSINDYLGWYQHRPGQAPRLLIHDASTRAPGIPVRFSGSGSGTDFTLTISSLEPEDSAVYYCQQRFSWYNFGPGTKVEIK,QKK35772,QKK35773,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_8,QKK35772_QKK35773,Unique source,SARS-CoV-2,2,1,14.654869,13.295384
CAO78318,EVQLVESGGNLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISASGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCARDSRAYSYGYLYVFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSNDVGSYNLVSWYQQHPGKAPKLLIYEGSKRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCMSYTSSGTPYVFGTGTQLTVL,CAO78318_H,CAO78318_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_17_9_3_11,AEN51983,Same entry,,2,1,14.106297,10.065177
QFZ93619_QFZ93620,EVQLVESGGRVVRPGGSLRLSCAASGFTFDDYGMSWVRQPPGKGLEFVSGLNWNGDITAFTDSVKGRFTISRDNVKSSLYLQMNSLRADDTAFYYCARVRTWGDYTTGEEIINSWYFDLWGRGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQDISSYLAWYQQKPGNAPKLLIYAASLLQSGVPSRFSAFGSGTEFTLTISSLQPEDFATYYCQHLKSYPLFTFGPGTKVDIK,QFZ93619,QFZ93620,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Stadlbauer,D.; Zhu,X.; McMahon,M.; Turner,J.S.; Wohlbold,T.J.; Schmitz,A.J.; Strohmeier,S.; Yu,W.; Nachbagauer,R.; Mudd,P.A.; Wilson,I.A.; Ellebedy,A.H.; Krammer,F.",Broadly protective human antibodies that target the active site of influenza virus neuraminidase,09-NOV-2019,8_8_23_6_3_10,QFZ93619_QFZ93620,Unique source,neuraminidase,2,1,13.251557,11.819357
QKK35654_QKK35655,EVQLVESGGSVVQPGTSLKLSCAGSAGLTITRYAMHWVRQAPGKGLEWVALVSHDGIHIGYSDSVRGRFTISRDNSRNTLYLQMDGLRPEDTAVYYCVRDDVLQHSRPSGPGYFVSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSTFLGWYQQRPGQPPRLLIYDASYRAPDIPVRFSGSGSGTDFTLTINSLEPEDSAVYYCQQRSDGYNFGPGTKLEIK,QKK35654,QKK35655,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_8_19_6_3_8,QKK35654_QKK35655,Unique source,SARS-CoV-2,2,1,14.62276,13.2400255
QKK35538_QKK35539,EVQLVESGPELKKPGSSVRVSCKASGGSFSNFAVSWVRQAPGQRLEWMGGVIPRFGRSEYVQKFQGRVTITVDEAASTAYMELSSLRSEDTAIYYCVLDTTSANPHNWYGMDVWGQGTTVTVSS,DIVMTQTPLSLAVTLGQPASISCRSSHGLVHTNGNTYLNWFHQRPGQPPRRLIYKISNRDSGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCMQGTDWPRTFGQGTKVEIK,QKK35538,QKK35539,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_11_3_9,QKK35538_QKK35539,Unique source,SARS-CoV-2,2,1,-0.6869819,6.076712
2209306A_2209306B,EVQLVESGPGLVAPSQSLSITCTVSGFSLTDYGVSWIRQPPGKGLEWLGVIWAGGSTFYNSALKSRLSINKDNSKSQVFLKMNSLHTDDTAMYYCVKHEDRYDWYFDVWGAGTTVTVSS,QAVVTQESALTTSPGETVTLTCRSNTGAVTTSNYASWVQEKPDHLFTGLIGGTNNRVPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWNSNHWVFGGGTKLTVL,2209306A,2209306B,anti-apolipoprotein B100 antibody:SUBUNIT=heavy chain,anti-apolipoprotein B100 antibody:SUBUNIT=light chain,Mus musculus,"Kwak,J.W.; Choi,B.K.; Lee,D.I.; Kang,Y.K.; Seo,Y.G.; Cho,W.K.; Han,M.H.",Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabB23) specific for human plasma apolipoprotein B-100,01-JAN-1900,8_7_13_9_3_9,2209306A_2209306B,Unique word,apolipoprotein,2,1,22.122204,-6.0908837
QKK35646_QKK35647,EVQLVESGPGLVKPSATLSLTCTVSGGSINNYYWTWVRQSAGKGLEWIGRINTSGSTNYNASLKSRVTMSIDTSKNEFSLRLSSVTAADTAVYYCAREFGVRFLDRSLFGAMDVWGHGATVTVSS,QPVLTQPASVSGSPGQSITISCTGTSSDVGSFNYVSWYQQHPGKAPKLVIYDVYNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVL,QKK35646,QKK35647,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_19_9_3_11,QKK35646_QKK35647,Unique source,SARS-CoV-2,2,1,15.948416,-8.07833
QKK35752_QKK35753,EVQLVESGPGLVKPSETLSLACTVSGGSISNYYWNWVRQPPGKGLEWIGNIYYSGSTTFNPSLKSRVTISVDTSRNQFSLKLSSVTAADTAVYYCARQSSSWYNPYYFDQWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIANNYVQWLQQRPGSSPTTIIYEDNQRPSGVPDRFSGSIDASSNSASLTISGLKTEDEADYYCQSYDSSSQVFGGGTKVTVL,QKK35752,QKK35753,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_15_8_3_9,QKK35752_QKK35753,Unique source,SARS-CoV-2,2,1,16.155989,-7.78304
QKK35522_QKK35523,EVQLVESGPGLVKPSETLSLTCTVSGASVTAGSSYWGWIRQPPGKGLEWIGYMFSSGNTKYNPSLKSRVTISADTSKNQFSLRLSSVTAADTAVYFCARVGWVRYFDWSKPYYYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYYVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSRSGTSASLAITGLQAEDEGDYFCQSYDSSLSASFGGGTKVTVL,QKK35522,QKK35523,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_20_9_3_10,QKK35522_QKK35523,Unique source,SARS-CoV-2,2,1,16.601233,-7.8696847
7Y7J_E_D,EVQLVESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHVRSAYYYGSGSYRDEGNWFDPWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGTRSNIGAGHDVHWYQQLPGTAPKLLIYGNNNRPSGVPDRFSGAKSGTSASLAITGLQAEDEADYYCQSYDRTLTSYVFGTGTKVTVL,7Y7J_E,7Y7J_D,Sars-Cov-2 S Trimer In Complex With 1F Fab,Sars-Cov-2 S Trimer In Complex With 1F Fab,Homo sapiens,"Zhao,S.;Liu,F.;Qiu,S.;Lan,Q.;Wu,Y.;Xu,W.;Ke,J.;Yang,J.;Liu,X.;Wang,K.;Guo,H.;Xia,S.;Zhang,F.;Wang,J.;Hu,X.;Lu,L.;Jiang,S.;Zhao,S.;Liu,L.;Xie,Y.;Yang,X.;Wang,H.;Zhong,G.",A core epitope targeting antibody of SARS-CoV-2,22-FEB-2023,10_7_24_9_3_11,7Y7J_E_D,Xtal structure,SARS-CoV-2,2,1,16.726831,-8.079984
QKK35614_QKK35615,EVQLVESGPGLVKPSGTLSLTCAVSGASVSSDHWWSWVRQSPGKGLEWIGEVYHSGSTNYNPSLKSRVTISLDQSNNQFSLKLTSVTAADTAIYYCATMWGGLCTASNCYGNPMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPRRYAYWYQQRSGQAPVLVIYEDNKRPSGIPERFSAFSSGTRATLTISGAQVEDEADYYCYSTDSTANYKVFGGGTKVTVL,QKK35614,QKK35615,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_20_6_3_11,QKK35614_QKK35615,Unique source,SARS-CoV-2,2,1,15.409896,-7.4511576
QKK35616_QKK35617,EVQLVESGPGLVKPSGTLSLTCAVTGASVSSDHWWSWVRQSPGKGLEWIGEVYHSGSTNYNPSLKSRVTISLDQSNNQFSLKLTSVTAADTAIYYCATMWGGLCTASNCYGNPMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPRRYAYWYQQRSGQAPVLVIYEDNKRPSGIPERFSAFSSGTRATLTISGAQVEDEADYYCYSTDSTANYKVFGGGTKLTVL,QKK35616,QKK35617,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_20_6_3_11,QKK35616_QKK35617,Unique source,SARS-CoV-2,2,1,15.398072,-7.4066906
6C5H_H_L,EVQLVESGPGLVQPSQSLSITCTVSGFSLSTYGVHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSITKDNSKSQVFFKMNSLQPNDTAVYYCDRMRITTDWFAYWGQGTLVTVSA,DVLMTQSPLSLPVSLGDQASISCRSSQTIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFYGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,6C5H_H,6C5H_L,S25-5 Fab In Complex With Chlamydiaceae-Specific Lps Antigen,S25-5 Fab In Complex With Chlamydiaceae-Specific Lps Antigen,Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Brooks,C.L.;MacKenzie,C.R.;Caveney,N.;Van Petegem,F.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",Subtle Changes in the Combining Site of the Chlamydiaceae-Specific mAb S25-23 Increase the Antibody-Carbohydrate Binding Affinity by an Order of Magnitude,16-JAN-2018,8_7_12_11_3_9,6C5H_H_L,Xtal structure,RPS25; S25,2,1,22.599716,-5.5996313
QKK35804_QKK35805,EVQLVESGPTLVKPTQTLTLTCTFSGFSLNTRELGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLSITKDTSKNQVVLTLTNMDPGDTATYYCAHTSELPPRRPYAAFDFWGQGTLVTVSS,SYELTQPPSVSGAPRQKVTISCSGSSANIASNGVNWYQQLPGKAPKLLIYYDDLVSSGVSDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDILNGPVFGGGTKLTVL,QKK35804,QKK35805,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_17_8_3_11,QKK35804_QKK35805,Unique source,SARS-CoV-2,2,1,12.371748,0.3507918
QKK35606_QKK35607,EVQLVESGPTLVKPTQTLTLTCTFSGFSLTTRRQGVGWLRRPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNHVVLSLTNVGPADTATYYCAHTSELPPRRPYAAFDFWGQGTLVTVSS,QSVLTQPPSVSGVPRQKVTISCSGSTANIASNGVNWYQLVPGKAPRLLISYDDLVPSGVSARFSGSKSGTSASLAISGLQAEDEADYYCATWDDILNGPVFGGGTKLTVL,QKK35606,QKK35607,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_17_8_3_11,QKK35606_QKK35607,Unique source,SARS-CoV-2,2,1,12.394227,0.33884108
AST13832_AST13882,EVQLVETGGGLIQPGGSVRLSCAASEFTVGSNFMHWVRQAPGKGLEWVSVIFKGGTAYYADSVRGRFVVSRDDSKNTLFLQMNSLRVDDTAVYFCARDGGLRFLDWPRWGMDVWGQGTTVIVSS,QSALTQPPSASGSLGQSITISCTGTRSDIGAYSYVSWYQQHPGKAPKVIIYEVNKRPSGVPDRFSGSKSGSTASLTVSGLQADDESTYYCSSYAGDKNFVLFGGGTKLTVV,AST13832,AST13882,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Joyce,M.G.; Chambers,M.J.; Gillespie,R.A.; Kanekiyo,M.; Leung,K.; Yang,E.S.; Tsybovsky,Y.; Wheatley,A.K.; Crank,M.C.; Boyington,J.C.; Prabhakaran,M.S.; Narpala,S.R.; Chen,X.; Bailer,R.T.; Chen,G.; Coates,E.; Kwong,P.D.; Koup,R.A.; Mascola,J.R.; Graham,B.S.; Ledgerwood,J.E.; McDermott,A.B.",Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans,15-AUG-2017,8_7_18_9_3_11,AST13832_AST13882,Unique source,hemagglutinin,2,1,12.658362,10.812856
I32513_B32513,EVQLVETGGGLVQPKGSLKLSCPASGFSFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRDAANWSAWFAYWGQGTLVTVSA,DVVMTQIPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGSGTKLEIK,I32513,B32513,Ig heavy chain precursor V region (MRL4) - mouse,Ig kappa chain precursor V region (MRL4) - mouse,Mus musculus,"Kofler,R.; Strohal,R.; Balderas,R.S.; Johnson,M.E.; Noonan,D.J.; Duchosal,M.A.; Dixon,F.J.; Theofilopoulos,A.N.",Immunoglobulin kappa light chain variable region gene complex organization and immunoglobulin genes encoding anti-DNA autoantibodies in lupus mice,21-Jan-2000,8_10_13_11_3_9,I32513_B32513,Unique word,DNA,2,1,13.342342,7.765608
6WJL_H_L,EVQLVETGGGVVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESGYDYVFDYWGQGTLVAVSS,DIQMTQSPSTLSAFVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPITFGQGTRLEIK,6WJL_H,6WJL_L,Crystal Structure Of Glypican-2 Core Protein In Complex With D3 Fab,Crystal Structure Of Glypican-2 Core Protein In Complex With D3 Fab,Homo sapiens,"Raman,S.;Buongervino,S.N.;Lane,M.V.;Zhelev,D.V.;Zhu,Z.;Cui,H.;Martinez,B.;Martinez,D.;Wang,Y.;Upton,K.;Patel,K.;Rathi,K.S.;Navia,C.T.;Harmon,D.B.;Li,Y.;Pawel,B.;Dimitrov,D.S.;Maris,J.M.;Julien,J.P.;Bosse,K.R.",A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope,21-APR-2021,8_8_12_6_3_9,6WJL_H_L,Xtal structure,DKFZp547M109; neuroblastoma; cerebroglycan; GPC2; FLJ38962,2,1,15.616,9.353565
6C5V_H_L,EVQLVQSGADVKKPGASVKVSCKASGYTFIHFGISWVRQAPGQGLEWMGWIDTNNGNTNYAQSLQGRVTMTTDTSTGTAYMELRSLSTDDTAVYFCARALEMGHRSGFPFDYWGQGVLVTVSP,SYELTQPPSVSVAPGQRATITCGGHNIGAKNVHWYQQKPGQAPVLVIQYDSDRPSGIPERFSGSNSGSTATLTISRVEAGDEADYYCQVWDSGRGHPLYVFGGGTKVTVL,6C5V_H,6C5V_L,An Anti-Gh/Gl Antibody That Neutralizes Dual-Tropic Infection Defines A Site Of Vulnerability On Epstein-Barr Virus,An Anti-Gh/Gl Antibody That Neutralizes Dual-Tropic Infection Defines A Site Of Vulnerability On Epstein-Barr Virus,Homo sapiens,"Snijder,J.;Ortego,M.S.;Weidle,C.;Stuart,A.B.;Gray,M.D.;McElrath,M.J.;Pancera,M.;Veesler,D.;McGuire,A.T.",An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus,16-JAN-2018,8_8_16_6_3_13,6C5V_H_L,Xtal structure,Epstein,2,1,1.9111698,5.2645054
QND76010,EVQLVQSGAELAKPGASVKMSCKASGYIFTNYWMHWVKQRPGQGLEWIGYINPSTGYTEYNQRFIDKATLTADKSSSTADMQLNSLTSEDSAVYYCVREGFALDYWGQGTTVTVSS,DIELTQTPSSLSASLGDRVTISCRASQDIRNYLNWYQQKPDGSVKLLIYYTSRLQSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQEGGTLPRTFGGGTKLEIK,QND76010_H,QND76010_L,S-14D5a-MLuc7-H7 [synthetic construct],S-14D5a-MLuc7-H7 [synthetic construct],synthetic construct,"Larionova,M.D.; Markova,S.V.; Tikunova,N.V.; Vysotski,E.S.",The Smallest Isoform of Metridia longa Luciferase as a Fusion Partner for Hybrid Proteins,19-AUG-2020,8_8_9_6_3_9,QND76010,Same entry,,2,1,0.14760272,-3.2504513
ATN96925,EVQLVQSGAELVKPGASVKVSCKASGYAFTTYNMDWVRQAPGQGPEWIGYIDPYNGGTSYNQKFQGKVTMTVDTSITTAYMHLSRLTSDDSAVYYCARMYLPWGQGTLVTVSS,MTQTPLSLSVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKLEIK,ATN96925_H,ATN96925_L,single chain variable fragment antibody [synthetic construct],single chain variable fragment antibody [synthetic construct],synthetic construct,"Ayyar,B.V.; Atassi,M.Z.",Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis,29-OCT-2017,8_8_6_11_3_9,ATN96925,Same entry,HLA,2,1,1.8008875,3.8355484
QKK35602_QKK35603,EVQLVQSGAEMKKPGESLKISCKGSGYSFPNYWIGWVRQMPGKGLEWMAIMWPSDSDTRYSPSFQGQVTISADTSTSTVYLQWGSLKASDTAMYYCVRQRYCSGGSCFLFEDAFEIWGQGTMVTVSS,EIVLTQSPSTLSASVGDRVTITCRASQNVNNWLAWYQQKPGKAPKLLIYEASTLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSQYTFGQGTKVDIK,QKK35602,QKK35603,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_20_6_3_8,QKK35602_QKK35603,Unique source,SARS-CoV-2,2,1,-12.433573,5.7101707
WBW48656_WBW48696,EVQLVQSGAEVKKPGASLKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGIIKPSAGNTRNAQKFQGRVTMTRDTSTSTVYMELSALRFEDTAVYYCARGGVHGLDYWGQGTLVTVSS,QSVLTQPPSVSAPPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIHENNQRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTNLGAFVFGAATRVTVL,WBW48656,WBW48696,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zhou,P.; Song,G.; Liu,H.; Yuan,M.; He,W.T.; Beutler,N.; Zhu,X.; Tse,L.V.; Martinez,D.R.; Schafer,A.; Anzanello,F.; Yong,P.; Peng,L.; Dueker,K.; Musharrafieh,R.; Callaghan,S.; Capozzola,T.; Limbo,O.; Parren,M.; Garcia,E.; Rawlings,S.A.; Smith,D.M.; Nemazee,D.; Jardine,J.G.; Safonova,Y.; Briney,B.; Rogers,T.F.; Wilson,I.A.; Baric,R.S.; Gralinski,L.E.; Burton,D.R.; Andrabi,R.",Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease,09-MAR-2023,8_8_10_8_3_11,WBW48656_WBW48696,Unique source,SARS-CoV-2,2,1,1.5854741,3.8088205
6WIT_H_L,EVQLVQSGAEVKKPGASMKISCKASGYTFTDYSLHWVRQTPGKGLEWMGRVDPEDGESHYAQKFQDRVTITADTSTDTAYMEVRSLRSEDTAMYYCATDHREDGPTYFSGVQWVPFRFWGQGVLVTVSS,VVFTQPHSVSGSPGQTVTISCTRSSGSIDSEYVQWYQQRPGSAPTTLIYKDNQRPSGVPDRFSGSIDSSSNSASLAISGLKSEDEADYYCQSPDGRYNRVFGGGTRLTVL,6WIT_H,6WIT_L,Crystal Structure Of Nhp D15.Sd7 Fab In Complex With 16055 V1V2 1Fd6 Scaffold,Crystal Structure Of Nhp D15.Sd7 Fab In Complex With 16055 V1V2 1Fd6 Scaffold,Homo sapiens,"Liban,T.;Aljedani,S.;Rodarte,J.;Pancera,M.",Crystal structure of NHP D15.SD7 Fab in complex with 16055 V1V2 1FD6 scaffold,10-APR-2020,8_8_22_8_3_10,6WIT_H_L,Xtal structure,,2,1,1.0199835,2.6611872
QKK35632_QKK35633,EVQLVQSGAEVKKPGASVKISCKASGYAFRNNYINWIRQAPGQGLEWMGIINPSAGTSTYAQKFQGRVTMTRDTSTNTVYMEITSLRSEDTATYFCAREARRQVTQWFGEFWGPYNWFDPWGQGTLVTVSS,DIVLTQSPLSLSVTPGQPASISCRSSQSLQHTDGKTYLYWYLQKPGQSPQLLIYELFNRFSGVPERFSGSGSGTDFTLKISRVEAEDVGIYYCMQSIQTPITFGQGTRLEIK,QKK35632,QKK35633,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_24_11_3_9,QKK35632_QKK35633,Unique source,SARS-CoV-2,2,1,1.6501672,3.672436
AAZ86725,EVQLVQSGAEVKKPGASVKVSCKASAYTVANSGVTWVRQAPGQGLEWMGWISGYNGNTKYAEKLQGRVTMTTDTSTNTVYMELRSLRSDDTAVYYCARVSYYESSGYYYVADYYYGMDVWGQGTTVTVSS,QSVLTQPPSTSGTPGQRVTISCSGSRSNIGSNTVDWYQQLPGTAPKLLIYSNDQWPSGVPERFSGSKSGTSASLAINGLQSEDEADYYCAAWDDSLNGLVFGTGTKLTVL,AAZ86725_H,AAZ86725_L,"anti-Phl p 5 allergen single chain antibody fragment, partial [synthetic construct]","anti-Phl p 5 allergen single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Andreasson,U.; Flicker,S.; Lindstedt,M.; Valenta,R.; Greiff,L.; Korsgren,M.; Borrebaeck,C.A.; Ohlin,M.",The human IgE-encoding transcriptome to assess antibody repertoires and repertoire evolution,26-JUL-2016,8_8_23_8_3_11,AAZ86725,Same entry,Phl,2,1,1.9597418,5.136881
7UVF_H_L,EVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWIGRIDPANDNTLYASKFQGRATITADTSTSTAYLELSSLRSEDTAVYYCGRGYGYYVFDHWGQGTLVTVSS,DVQITQSPSSLSASVGDRVTITCRTSRSISQYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVNEFPPTFGQGTKVEIK,7UVF_H,7UVF_L,Crystal Structure Of Zed8 Fab Complex With Cd8 Alpha,Crystal Structure Of Zed8 Fab Complex With Cd8 Alpha,Homo sapiens,"Ogasawara,A.;Kiefer,J.R.;Gill,H.;Chiang,E.;Sriraman,S.;Ferl,G.Z.;Ziai,J.;Bohorquez,S.S.;Guelman,S.;Wang,X.;Yang,J.;Phan,M.M.;Nguyen,V.;Chung,S.;Yu,C.;Tinianow,J.;Waaijer,S.J.H.;De Crespigny,A.;Marik,J.;Boswell,C.A.;Zabka,T.;Staflin,K.;Williams,S.P.","Preclinical development of ZED8, an <sup>89</sup>Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy",12-OCT-2022,8_8_11_6_3_9,7UVF_H_L,Xtal structure,CD8A; CD8,2,1,0.69597447,3.3636756
6OKM_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVINPGSGDTYYSEKFKGRVTLTADTSTSTAYLELSSLRSEDTAVYYCARDRLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCHASQDISSYIVWYQQKPGKSFKGLIYHGTNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVHYAQFPYTFGQGTKVEIK,6OKM_H,6OKM_L,Human Ox40R (Tnfrsf4) Bound To Fab 3C8,Human Ox40R (Tnfrsf4) Bound To Fab 3C8,Homo sapiens,"Yang,Y.;Yeh,S.H.;Madireddi,S.;Matochko,W.L.;Gu,C.;Pacheco Sanchez,P.;Ultsch,M.;De Leon,Bo.;Harris,S.F.;Leonard,B.;Scales,S.J.;Zhu,J.W.;Christensen,E.;Hang,J.Q.;Brezski,R.J.;Marsters,S.;Ashkenazi,A.;Sukumaran,S.;Chiu,H.;Cubas,R.;Kim,J.M.;Lazar,G.A.",Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members,14-APR-2019,8_8_7_6_3_9,QPW23661_QPW23662,Xtal structure,,2,1,1.065513,3.7473826
QKK35738_QKK35739,EVQLVQSGAEVKKPGASVKVSCKASGYSSTNYGFSWVRQAPGQGLEWMGWISVHSGNANFAQKFQGRITMTTDTSTTTAYMELRNLRSDDTATYYCATSASSYSRYYFGLDVWGQGTTVTVSS,DIRMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGVTFGGGTKVDIK,QKK35738,QKK35739,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_11_3_10,QKK35738_QKK35739,Unique source,SARS-CoV-2,2,1,1.9459298,5.123442
5TZT_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQRLEWMGDIYPYNGGTGYNQKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARGGWHAMDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSRQSIVHTNRYTYLAWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKLEIK,5TZT_H,5TZT_L,Crystal Structure Of Human Cd47 Ecd Bound To Fab Of C47B161,Crystal Structure Of Human Cd47 Ecd Bound To Fab Of C47B161,Homo sapiens,"Pietsch,E.C.;Dong,J.;Cardoso,R.;Zhang,X.;Chin,D.;Hawkins,R.;Dinh,T.;Zhou,M.;Strake,B.;Feng,P.H.;Rocca,M.;Santos,C.D.;Shan,X.;Danet-Desnoyers,G.;Shi,F.;Kaiser,E.;Millar,H.J.;Fenton,S.;Swanson,R.;Nemeth,J.A.;Attar,R.M.",Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies,22-NOV-2016,8_8_10_11_3_9,5TZT_H_L,Xtal structure,MER6; OA3; IAP; CD47,2,1,0.9626635,3.5625398
8JBJ_A_B,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWIYWVRQAPGQGLEWMGTIDTSDHKTSYNQKFRGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDFIITVNYPVVDYWGQGTLVTVSS,QIVLTQSPATLSLSPGERATLSCSAGSSVNYMHWFQQKPGQAPRLLIYSTSNLASGVPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRSSLPFTFGQGTKLEIK,8JBJ_A,8JBJ_B,Crystal Structure Of Anti-Pvrig Fab,Crystal Structure Of Anti-Pvrig Fab,Homo sapiens,"Yi,M.;Sun,J.;Sun,H.;Wang,Y.;Hou,S.;Jiang,B.;Xie,Y.;Ji,R.;Xue,L.;Ding,X.;Song,X.;Xu,A.;Huang,C.;Quan,Q.;Song,J.",Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity,21-JUN-2023,8_8_15_5_3_9,8JBJ_A_B,Xtal structure,Pvrig,2,1,1.4299374,3.8233757
7MZH_B_C,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSYYDYWGQGTLVTVSS,QSVLTQPPSVSEAPRQRVTISCSGSSSNIGHNAVHWYQQLPGKAPKLLIYYDDLLPAGVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDILNGPVFGGGTKLTVL,7MZH_B,7MZH_C,Sars-Cov-2 Receptor Binding Domain Bound To Fab Wcsl 119,Sars-Cov-2 Receptor Binding Domain Bound To Fab Wcsl 119,Homo sapiens,"Wheatley,A.K.;Pymm,P.;Esterbauer,R.;Dietrich,M.H.;Lee,W.S.;Drew,D.;Kelly,H.G.;Chan,L.J.;Mordant,F.L.;Black,K.A.;Adair,A.;Tan,H.X.;Juno,J.A.;Wragg,K.M.;Amarasena,T.;Lopez,E.;Selva,K.J.;Haycroft,E.R.;Cooney,J.P.;Venugopal,H.;Tan,L.L.;O Neill,M.T.;Allison,C.C.;Cromer,D.;Davenport,M.P.;Bowen,R.A.;Chung,A.W.;Pellegrini,M.;Liddament,M.T.;Glukhova,A.;Subbarao,K.;Kent,S.J.;Tham,W.H.",Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain,24-MAY-2021,8_8_7_8_3_11,7MZH_B_C,Xtal structure,SARS-CoV-2,2,1,1.8611214,3.8231177
6ID4_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARVTTVIAGPVFDYWGQGTLVTVSS,QAVLTQPSSLSASPGASASLTCTLRSGINVGPYNIYWYQQKPGSPPQYLMRYKSDPDKHQGSAVPSRFSGSKDASANAGILLISGLQSEDEADYYCMIWHNNAWVFGGGTKLTVL,6ID4_H,6ID4_L,Defining The Structural Basis For Human Alloantibody Binding To Human Leukocyte Antigen Allele Hla-A*11:01,Defining The Structural Basis For Human Alloantibody Binding To Human Leukocyte Antigen Allele Hla-A*11:01,Human immunodeficiency virus 1,"Gu,Y.;Wong,Y.H.;Liew,C.W.;Chan,C.E.;Murali,T.M.;Yap,J.;Too,C.T.;Purushotorman,K.;Hamidinia,M.;El Sahili,A.;Goh,A.T.;Teo,R.Z.;Wood,K.J.;Hanson,B.J.;Gascoigne,N.R.;Lescar,J.;Vathsala,A.;MacAry,P.A.",Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01,08-SEP-2018,8_8_14_9_7_9,6ID4_H_L,Xtal structure,HLA-A,2,1,1.6503866,3.794128
5IWL_A_A,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK,5IWL_A,5IWL_A,Cd47-Diabody Complex,Cd47-Diabody Complex,Homo sapiens,"Weiskopf,K.;Jahchan,N.S.;Schnorr,P.J.;Cristea,S.;Ring,A.M.;Maute,R.L.;Volkmer,A.K.;Volkmer,J.P.;Liu,J.;Lim,J.S.;Yang,D.;Seitz,G.;Nguyen,T.;Wu,D.;Jude,K.;Guerston,H.;Barkal,A.;Trapani,F.;George,J.;Poirier,J.T.;Gardner,E.E.;Miles,L.A.;de Stanchina,E.;Lofgren,S.M.;Vogel,H.;Winslow,M.M.;Dive,C.;Thomas,R.K.;Rudin,C.M.;van de,Ri.;Majeti,R.;Garcia,K.C.;Weissman,I.L.;Sage,J.",CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer,22-MAR-2016,8_8_10_11_3_9,5IWL_A_A,Xtal structure,MER6; OA3; IAP; CD47,2,1,0.85962164,3.6169996
6B5O_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKAGNGNTRYSQKFQDRVTITRDTSTTTAYMELSSLRSEDTAVYYCALLTVLTPDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPNLLIYWASTRQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,6B5O_H,6B5O_L,Structure Of Pfcsp Peptide 29 With Human Protective Antibody Cis43,Structure Of Pfcsp Peptide 29 With Human Protective Antibody Cis43,Plasmodium falciparum,"Kisalu,N.K.;Idris,A.H.;Weidle,C.;Flores-Garcia,Y.;Flynn,B.J.;Sack,B.K.;Murphy,S.;Schon,A.;Freire,E.;Francica,J.R.;Miller,A.B.;Gregory,J.;March,S.;Liao,H.X.;Haynes,B.F.;Wiehe,K.;Trama,A.M.;Saunders,K.O.;Gladden,M.A.;Monroe,A.;Bonsignori,M.;Kanekiyo,M.;Wheatley,A.K.;McDermott,A.B.;Farney,S.K.;Chuang,G.Y.;Zhang,B.;Kc,N.;Chakravarty,S.;Kwong,P.D.;Sinnis,P.;Bhatia,S.N.;Kappe,S.H.;Sim,B.K.;Hoffman,S.L.;Zavala,F.;Pancera,M.;Seder,R.A.",A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite,29-SEP-2017,8_8_14_12_3_9,6B5O_H_L,Xtal structure,,2,1,0.1901121,3.1253848
7VYT_B_C,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASRSGSGWFGALDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPGGTFGQGTKVEIK,7VYT_B,7VYT_C,Crystal Structure Of Human Tigit(23-129) In Complex With The Scfv Fragment Of Anti-Tigit Antibody Mg1131,Crystal Structure Of Human Tigit(23-129) In Complex With The Scfv Fragment Of Anti-Tigit Antibody Mg1131,Homo sapiens,"Jeong,B.S.;Nam,H.;Lee,J.;Park,H.Y.;Cho,K.J.;Sheen,J.H.;Song,E.;Oh,M.;Lee,S.;Choi,H.;Yang,J.E.;Kim,M.;Oh,B.H.",Structural and functional characterization of a monoclonal antibody blocking TIGIT,15-NOV-2021,8_8_14_7_3_10,7VYT_B_C,Xtal structure,VSTM3; VSIG9; FLJ39873; TIGIT; DKFZp667A205,2,1,1.4816935,3.7434464
6P9J_H_L,EVQLVQSGAEVKKPGATMKISCKVSGYPFTDYYMHWVQQAPGKGLEWMGLIDPEDGETNYAEKFQGRVTITADTSTDTVYMELSSLRSEDTAVYFCAKPHCSSRTCQRVSGYYFGMDVWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGSSNDVGDYNFVSWYQQHPGKPPKLMIYEVTKRPSGVPDRFFGSKSGNTASLTVSGLQADDEADYYCSSYAGGNSVVFGGGTKLTVL,6P9J_H,6P9J_L,Crystal Structure Of Human Anti Staphylococcus Aureus Antibody Stau-229 Fab,Crystal Structure Of Human Anti Staphylococcus Aureus Antibody Stau-229 Fab,Homo sapiens,"Dong,J.;Crowe,J.E.",crystal structure of human anti staphylococcus aureus antibody STAU-229 Fab,17-JUN-2020,8_8_22_9_3_10,6P9J_H_L,Xtal structure,PPP1R150; STAU; STAU1,2,1,1.0286517,2.7328453
AAW80373,EVQLVQSGAEVKKPGDSLRISCKGSGYTFGGYWIAWVRQIPGKGLEWMGIIYPGDSDTRYSPSFQGQVSISADKSINTAYLQWSSLRASDTAMYYCARKGLRDVEWYDPREDVLDVWGQGTMVTVPS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYNNWPRTFGQGTKVETK,AAW80373_H,AAW80373_L,"anti AD-1 single chain antibody fragment, partial [synthetic construct]","anti AD-1 single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Barrios,Y.; Knor,S.; Lantto,J.; Mach,M.; Ohlin,M.",Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties,26-JUL-2016,8_8_20_7_3_9,AAW80373,Same entry,AD-1; cytomegalovirus,2,1,-12.3822975,5.6397796
AAW80366,EVQLVQSGAEVKKPGDSLRISCKGSGYTFGGYWIAWVRQIPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSINTAYLQWSSLRASDTAMYYCARKGLRDVEWYDPHEDVLDVWGQGTMVTVPS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYGSSPPGFTFGQGTKVETK,AAW80366_H,AAW80366_L,"anti AD-1 single chain antibody fragment, partial [synthetic construct]","anti AD-1 single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Barrios,Y.; Knor,S.; Lantto,J.; Mach,M.; Ohlin,M.",Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties,26-JUL-2016,8_8_20_6_3_11,AAW80366,Same entry,AD-1; cytomegalovirus,2,1,-12.395806,5.6348076
AAW80361,EVQLVQSGAEVKKPGDSLRISCKGSGYTFGGYWIAWVRQIPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSINTAYLQWSSLRASDTAMYYCARKGLRDVEWYDPREDVLDVWGQGTMVTVPS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCLQHNSYPQTFGQGTKVETK,AAW80361_H,AAW80361_L,"anti AD-1 single chain antibody fragment, partial [synthetic construct]","anti AD-1 single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Barrios,Y.; Knor,S.; Lantto,J.; Mach,M.; Ohlin,M.",Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties,26-JUL-2016,8_8_20_6_3_9,AAW80361,Same entry,AD-1; cytomegalovirus,2,1,-12.380941,5.6369886
6FY3_H_L,EVQLVQSGAEVKKPGESLKISCKGFGYSFSTYWIAWVRQMPGKGLEWMGMIYPGDSDTKYSPSLQGQVTISGDKSISTAYLQWSSLKASDTAMYYCARLLNNYDSSGFLYWYLDLWGRGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASDYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDMTNHNWVFGGGTKLTVL,6FY3_H,6FY3_L,"Crystal Structure Of A V2-Directed, Rv144 Vaccine-Like Antibody From Hiv-1 Infection, Cap228-3D, Bound To A Heterologous V2 Peptide","Crystal Structure Of A V2-Directed, Rv144 Vaccine-Like Antibody From Hiv-1 Infection, Cap228-3D, Bound To A Heterologous V2 Peptide",Human immunodeficiency virus 1,"Wibmer,C.K.;Richardson,S.I.;Yolitz,J.;Cicala,C.;Arthos,J.;Moore,P.L.;Morris,L.",Common helical V1V2 conformations of HIV-1 Envelope expose the alpha4beta7 binding site on intact virions,10-MAR-2018,8_8_19_8_3_11,6FY3_H_L,Xtal structure,HIV,2,1,-12.442343,5.670436
4BUH_A_A,EVQLVQSGAEVKKPGESLKISCKGSEYSFPNYWIAWVRQMPGKGLEWMGMIYPGDSDTRYSPSFQGQVNISADKSSRTAFLEWSSLKASDSATYFCARLGGQLWNSYYYYYYMDVWGKGTTVTVSS,YELTQPPSASGTPGQRVTISCSGSSSNIGGNTVNWYQQVPGTAPRLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCEAWDGGLRGGVFGGGTKLTVL,4BUH_A,4BUH_A,Human Ige Against The Major Allergen Bet V 1 - Crystal Structure Of  Clone M0418 Scfv,Human Ige Against The Major Allergen Bet V 1 - Crystal Structure Of  Clone M0418 Scfv,Homo sapiens,"Levin,M.;Davies,A.M.;Liljekvist,M.;Carlsson,F.;Gould,H.J.;Sutton,B.J.;Ohlin,M.",Human IgE against the major allergen Bet v 1--defining an epitope with limited cross-reactivity between different PR-10 family proteins,20-JUN-2013,8_8_19_8_3_11,4BUH_A_A,Xtal structure,,2,1,-12.460724,5.5934424
5A3I_G_H,EVQLVQSGAEVKKPGESLKISCKGSGYSFSDYWIGWVRQMPGEGLEWMGIIYPASSEIRYSPSFQGLVTISRDKSINTASLQWSSLKASDTAIYYCARHASCSARSCYWGPVDYWGQGTLVTVSS,DIVMTQSPLSLPVSPGEPASISCRSSQSLLHGNGYNYLDWYLQKPGQSPRLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK,5A3I_G,5A3I_H,Crystal Structure Of A Complex Formed Between Fld194 Fab And Transmissible Mutant H5 Haemagglutinin,Crystal Structure Of A Complex Formed Between Fld194 Fab And Transmissible Mutant H5 Haemagglutinin,Homo sapiens,"Xiong,X.;Corti,D.;Liu,J.;Pinna,D.;Foglierini,M.;Calder,L.J.;Martin,S.R.;Lin,Y.P.;Walker,P.A.;Collins,P.J.;Monne,I.;Suguitan AL,Jr.;Santos,C.;Temperton,N.J.;Subbarao,K.;Lanzavecchia,A.;Gamblin,S.J.;Skehel,J.J.",Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody,01-JUN-2015,8_8_18_11_3_9,5A3I_G_H,Xtal structure,hemagglutinin,2,1,-12.500735,5.623323
4M6N_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,4M6N_H,4M6N_L,Crystal Structure Of Anti-Il-23 Antibody Cnto1959 At Ph 6.5,Crystal Structure Of Anti-Il-23 Antibody Cnto1959 At Ph 6.5,Homo sapiens,"Teplyakov,A.;Obmolova,G.;Gilliland,G.L.",Crystal Structure Of Anti-Il-23 Antibody Cnto1959 A,09-AUG-2013,8_8_10_9_3_11,UOS91757_UOS91767,Xtal structure,Il-23,2,1,-12.238748,5.749731
4JZJ_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,4JZJ_H,4JZJ_L,Crystal Structure Of Receptor-Fab Complex,Crystal Structure Of Receptor-Fab Complex,Mus musculus,"Broughton,S.E.;Hercus,T.R.;Hardy,M.P.;McClure,B.J.;Nero,T.L.;Dottore,M.;Huynh,H.;Braley,H.;Barry,E.F.;Kan,W.L.;Dhagat,U.;Scotney,P.;Hartman,D.;Busfield,S.J.;Owczarek,C.M.;Nash,A.D.;Wilson,N.J.;Parker,M.W.;Lopez,A.F.",Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody,03-APR-2013,8_8_13_12_3_9,AYI42011_AYI42010,Xtal structure,interleukin,2,1,-12.332316,5.8255734
QKY76532_QKY76145,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNSWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAIYYCATHRCSGGFCYLAYWGQGTLVTVSS,QPVLTQPPSASASLGASVTLTCTLSSGYSNYKVDWYQQRPGKGPRFVMRVGTGGIVGSKGDGIPDRFSVLGSGLNRYLTIKNIQEEDESDYHCGADHGSGSNFVFVVFGGGTKLTVL,QKY76532,QKY76145,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_7_8_14,QKY76532_QKY76145,Unique source,SARS-CoV-2,2,1,-12.489512,5.6788287
7PS4_B_C,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGDSGTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDSAMYYCARSRVGATGGYYDYYMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNLGGNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGTGTKVTVL,7PS4_B,7PS4_C,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-38,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-38,Homo sapiens,"Liu,C.;Zhou,D.;Nutalai,R.;Duyvesteyn,H.M.;Tuekprakhon,A.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Mentzer,A.J.;Wang,B.;Case,J.B.;Zhao,Y.;Skelly,D.T.;Chen,R.E.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Malik,T.;Temperton,N.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Clare,D.K.;Howe,A.;Goulder,P.J.;Fry,E.E.;Diamond,M.S.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants,22-SEP-2021,8_8_18_8_3_11,7PS4_B_C,Xtal structure,SARS-CoV-2,2,1,-12.491431,5.5692716
QKY76570_QKY76183,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSHWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCASALRERGVQLWSVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIFINSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLGALFGGGTKLTVL,QKY76570,QKY76183,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_9_3_10,QKY76570_QKY76183,Unique source,SARS-CoV-2,2,1,-12.483115,5.6344504
QKY76575_QKY76188,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIDWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSTSTAYLQWSSLKASDTAMYYCARRGEAAGIWYFDLWGRGTLVTVSS,QPVLTQPPSASASLGASVTLTCTLSSGYSNYKVDWYQQRPGKGPRFVMRVGTGGIVGSKGDGIPDRFSVLGSGLNRYLTIKNIQEEDESDYHCGADHGSGSNFEYVVFGGGTKLTVL,QKY76575,QKY76188,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_7_8_14,QKY76575_QKY76188,Unique source,SARS-CoV-2,2,1,-12.471746,5.6721497
3WLW_C_D,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREGDGAFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL,3WLW_C,3WLW_D,Molecular Architecture Of The Erbb2 Extracellular Domain Homodimer,Molecular Architecture Of The Erbb2 Extracellular Domain Homodimer,Homo sapiens,"Hu,S.;Sun,Y.;Meng,Y.;Wang,X.;Yang,W.;Fu,W.;Guo,H.;Qian,W.;Hou,S.;Li,B.;Rao,Z.;Lou,Z.;Guo,Y.",Molecular architecture of the ErbB2 extracellular domain homodimer,15-NOV-2013,8_8_10_9_3_10,3WLW_C_D,Xtal structure,,2,1,1.8963994,5.276298
QKY76574_QKY76187,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARPDYSSGWFSYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSNFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPITFGQGTRLEIK,QKY76574,QKY76187,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_17_7_3_9,QKY76574_QKY76187,Unique source,SARS-CoV-2,2,1,-12.493853,5.6446223
AOV81886_AOV81894,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVVADREGFGYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,AOV81886,AOV81894,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Raymond,D.D.; Stewart,S.M.; Lee,J.; Ferdman,J.; Bajic,G.; Do,K.T.; Ernandes,M.J.; Suphaphiphat,P.; Settembre,E.C.; Dormitzer,P.R.; Del Giudice,G.; Finco,O.; Kang,T.H.; Ippolito,G.C.; Georgiou,G.; Kepler,T.B.; Haynes,B.F.; Moody,M.A.; Liao,H.X.; Schmidt,A.G.; Harrison,S.C.",Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain,12-OCT-2016,8_8_18_7_3_9,AOV81886_AOV81894,Unique source,Influenza,2,1,-12.4906435,5.5579047
5I1L_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDGIYGELDFWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIK,5I1L_H,5I1L_L,Crystal Structure Of Human Germline Antibody Ighv5-51/Igkv4-1,Crystal Structure Of Human Germline Antibody Ighv5-51/Igkv4-1,Homo sapiens,"Obmolova,G.;Malia,T.J.;Teplyakov,A.;Sweet,R.W.;Gilliland,G.L.",Protein crystallization with microseed matrix screening: application to human germline antibody Fabs,05-FEB-2016,8_8_12_12_3_9,5I1L_H_L,Xtal structure,,2,1,-12.450115,5.691815
4HWE_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARMPNWGSFDYWGQGTLVTVSS,EVVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYETFGQGTKVEIK,4HWE_H,4HWE_L,Crystal Structure Of Ectodomain 3 Of The Il-13 Receptor Alpha1 In Complex With A Human Neutralizing Monoclonal Antibody Fragment,Crystal Structure Of Ectodomain 3 Of The Il-13 Receptor Alpha1 In Complex With A Human Neutralizing Monoclonal Antibody Fragment,Homo sapiens,"Redpath,N.T.;Xu,Y.;Wilson,N.J.;Fabri,L.J.;Baca,M.;Andrews,A.E.;Braley,H.;Lu,P.;Ireland,C.;Ernst,R.E.;Woods,A.;Forrest,G.;An,Z.;Zaller,D.M.;Strohl,W.R.;Luo,C.S.;Czabotar,P.E.;Garrett,T.P.;Hilton,D.J.;Nash,A.D.;Zhang,J.G.;Nicola,N.A.",Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor alpha1,07-NOV-2012,8_8_11_7_3_5,4HWE_H_L,Xtal structure,Ectodomain; interleukin-13,2,1,-12.389762,5.721902
UOF83921_UOF83922,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYWIGWVRQMPGKGLEWMGIVYPDDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCVRHPGGGDWYFDLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYDSFSWTFGQGTKLEIK,UOF83921,UOF83922,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Song,D.",Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron,30-SEP-2022,9_8_13_6_3_9,UOF83921_UOF83922,Unique source,SARS-CoV-2,2,1,-12.54231,5.777422
3HMX_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,3HMX_H,3HMX_L,Crystal Structure Of Ustekinumab Fab/Il-12 Complex,Crystal Structure Of Ustekinumab Fab/Il-12 Complex,Homo sapiens,"Luo,J.;Wu,S.J.;Lacy,E.R.;Orlovsky,Y.;Baker,A.;Teplyakov,A.;Obmolova,G.;Heavner,G.A.;Richter,H.T.;Benson,J.",Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab,29-MAY-2009,8_8_12_6_3_9,QPX66046_QPX66047,Xtal structure,SGRF; IL23A; IL23P19; IL-23A; P19; IL-23; IL-12,2,1,-12.423621,5.726848
CAJ00024_CAJ00025,EVQLVQSGAEVKKPGESLKISCKVSGYFFTTYWIGWVRQMPGKGLEYMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGNWNCFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRYGSSHTFGQGTKLEIS,CAJ00024,CAJ00025,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Beurskens,F.; Schuurman,J.; Parren,P.; Petersen,J.; Baadsgaard,O.","Human anti il-15 antibody 146b7 inducing monocytes apoptosis, therapeutical uses thereof",03-JUN-2005,8_8_11_7_3_8,CAJ00024_CAJ00025,Unique chain,apoptosis,2,1,-12.367243,5.662728
7SEG_H_L,EVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGAIEPMYGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGSAYYYDFADYWGQGTLVTVSS,SYVLTQPSSVSVAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFGGGTKLTVL,7SEG_H,7SEG_L,Crystal Structure Of The Complex Of Cd16A Bound By An Anti-Cd16A Fab,Crystal Structure Of The Complex Of Cd16A Bound By An Anti-Cd16A Fab,Homo sapiens,"Kakiuchi-Kiyota,S.;Ross,T.;Wallweber,H.A.;Kiefer,J.R.;Schutten,M.M.;Adedeji,A.O.;Cai,H.;Hendricks,R.;Cohen,S.;Myneni,S.;Liu,L.;Fullerton,A.;Corr,N.;Yu,L.;de Almeida,Na.;Zhong,S.;Leong,S.R.;Li,J.;Nakamura,R.;Sumiyoshi,T.;Li,J.;Ovacik,A.M.;Zheng,B.;Dillon,M.;Spiess,C.;Wingert,S.;Rajkovic,E.;Ellwanger,K.;Reusch,U.;Polson,A.G.",A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma,30-SEP-2021,8_8_13_6_3_9,7SEG_H_L,Xtal structure,BCM; BCMA; CD269; TNFRSF17; TNFRSF13A,2,1,1.5548863,3.8198965
7AHU_B_A,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTSWIVWVRQMPGKGLEWMGMIDPSDSFTSYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARLHYYNSEEFDVWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGQSSRTRGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSQLFTFGQGTKLEIK,7AHU_B,7AHU_A,Anti-Fx Fab Of Mim8 In Complex With Human Fxa,Anti-Fx Fab Of Mim8 In Complex With Human Fxa,Homo sapiens,"Ostergaard,H.;Lund,J.;Greisen,P.J.;Kjellev,S.;Henriksen,A.;Lorenzen,N.;Johansson,E.;Roder,G.;Rasch,M.G.;Johnsen,L.B.;Egebjerg,T.;Lund,S.;Rahbek-Nielsen,H.;Gandhi,P.S.;Lamberth,K.;Loftager,M.;Andersen,L.M.;Bonde,A.C.;Stavenuiter,F.;Madsen,D.E.;Li,X.;Holm,T.L.;Ley,C.D.;Thygesen,P.;Zhu,H.;Zhou,R.;Thorn,K.;Yang,Z.;Hermit,M.B.;Bjelke,J.R.;Hansen,B.G.;Hilden,I.","A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice",25-SEP-2020,8_8_13_7_3_10,7AHU_B_A,Xtal structure,,2,1,-12.22644,5.714477
QKK35644_QKK35645,EVQLVQSGAEVKKPGSSMRVSCRVSGGTFITHAMSWVRQAPGQGPEWMGGIVPLFGRASYAQPSQTRVQITADESTSTVYLEVPSLTSEDTAVYYCVRDSEPYTATRSQNHYWYDMDVWGQGTTVTVSS,DIQMTQSPLSLSVTLGQSASISCRASQTVVHSVDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDIGIYYCMQGTDWPRTFGQGTKVEIK,QKK35644,QKK35645,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_12_3_9,QKK35644_QKK35645,Unique source,SARS-CoV-2,2,1,3.0824895,-13.222277
5I16_H_L,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK,5I16_H,5I16_L,Crystal Structure Of Human Germline Antibody Ighv1-69/Igkv3-11,Crystal Structure Of Human Germline Antibody Ighv1-69/Igkv3-11,Homo sapiens,"Obmolova,G.;Malia,T.J.;Teplyakov,A.;Sweet,R.W.;Gilliland,G.L.",Protein crystallization with microseed matrix screening: application to human germline antibody Fabs,05-FEB-2016,8_8_12_6_3_9,5I16_H_L,Xtal structure,,2,1,-0.6068579,5.745007
5XAJ_E_C,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAVGLPVDYWGQGTLVTVSS,YELTQPPSVSVAPGQTARMTCGGNNIGTKSVHWYQQKPGQAPVLVVYNDRDRPSGIPERFSGSNSGNTATLTISRVEDGDEADYFCQVWDNYSDHVIFGGGTKLTVL,5XAJ_E,5XAJ_C,Structural Mimicry Of The Dengue Virus Envelope Glycoprotein Revealed By The Crystallographic Study Of An Idiotype-Anti-Idiotype Fab Complex.,Structural Mimicry Of The Dengue Virus Envelope Glycoprotein Revealed By The Crystallographic Study Of An Idiotype-Anti-Idiotype Fab Complex.,Homo sapiens,"Wong,Y.H.;Goh,B.C.;Lim,S.Y.;Teo,E.W.;Lim,A.P.;Dedon,P.C.;Hanson,B.J.;MacAry,P.A.;Lescar,J.",Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype Fab complex,13-MAR-2017,8_8_8_6_3_11,5XAJ_E_C,Xtal structure,Dengue; dengue,2,1,-0.5444098,5.6972322
QKK35546_QKK35547,EVQLVQSGAEVKKPGSSVKVSCKVSGGRFSDYAISWLRQAPVKGLEWMGGIIPRLNRKGYSQDFQGRLTFTADESTSTAYMELSGLTSEDTAVYYCARDPTFLNSGNHFWYAVDIWGQGTTVTVSS,EIVLTQSPLSLSVTLGQAASISCTCSQTAVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQTTDWPRTFGQGTKLEIK,QKK35546,QKK35547,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35546_QKK35547,Unique source,SARS-CoV-2,2,1,-6.6309485,-2.4376104
QKK35650_QKK35651,EVQLVQSGAEVKKPGSSVKVSCKVSGGTFSNYAISWLRQAPGQGPEWMGGIIPALSKVGYAGKFQARLTFSADELKTTVYMDLSSLTSEDTAVYYCARDPSFLNAGNHFYYDFDVWGQGTMVTVSS,DIRLTQSPLSLPVTLGQPASISCTSSQDVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGSHFTLKISRVEAEDAGIYYCMQGTDWPRTFGQGTKVDIK,QKK35650,QKK35651,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35650_QKK35651,Unique source,SARS-CoV-2,2,1,-6.6312895,-2.44337
6CMG_C_B,EVQLVQSGAEVKKRGSSVKVSCKSSGGTFSNYAINWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARGWGREQLAPHPSQYYYYYYGMDVWGQGTTVTVSS,EIVMTQSPGTPSLSPGERATLSCRASQSIRSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPSFGQGTKVEIK,6CMG_C,6CMG_B,Crystal Structure Of The Hendra Virus Attachment G Glycoprotein Bound To A Potent Cross-Reactive Neutralizing Human Monoclonal Antibody M102.3,Crystal Structure Of The Hendra Virus Attachment G Glycoprotein Bound To A Potent Cross-Reactive Neutralizing Human Monoclonal Antibody M102.3,Homo sapiens,"Xu,K.;Rockx,B.;Xie,Y.;DeBuysscher,B.L.;Fusco,D.L.;Zhu,Z.;Chan,Y.P.;Xu,Y.;Luu,T.;Cer,R.Z.;Feldmann,H.;Mokashi,V.;Dimitrov,D.S.;Bishop-Lilly,K.A.;Broder,C.C.;Nikolov,D.B.",Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody,05-MAR-2018,8_8_25_7_3_8,6CMG_C_B,Xtal structure,Hendra,2,1,-0.90180856,6.1755795
CAO78309,EVQLVQSGGGLIQPGGSLRLSCVASEFNVRSNYMSWVRQAPGKGLEWVSVMYDGGSTYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARGGLGLPTIASWEIWGQGTMVTVSS,SYVLTQPPSVSVAPGKTATITCAGNNIGSNSVYWYQQKPGLAPVLVVYDDRDRPSGIPERFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSDHLYVFGTGTQLTVL,CAO78309_H,CAO78309_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_7_15_6_3_12,AEN51963,Same entry,,2,1,12.49585,10.333185
ASP69768_ASP69808,EVQLVQSGGGLVEPGGSLRLSCAGSGFTFSDAWMHWVRQAPGKGLEWVGHIKTNADGGAAHYAAPVKGRFIISRDDSKNMLYLQMNGLKTEDTAMYYCNTGVESYDFWSDDYSQYQYKYFWDVWGKGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVNSNYLAWYQQKPGQAPRLLIYGTSNRATGIPDRFSGSGSGTDFTLTINRLEPEDFAMYYCQQYTSSCTFGPGTKVDVK,ASP69768,ASP69808,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Landais,E.; Murrell,B.; Briney,B.; Murrell,S.; Rantalainen,K.; Berndsen,Z.T.; Ramos,A.; Wickramasinghe,L.; Smith,M.L.; Eren,K.; de Val,N.; Wu,M.; Cappelletti,A.; Umotoy,J.; Lie,Y.; Wrin,T.; Algate,P.; Chan-Hui,P.Y.; Karita,E.; Ward,A.B.; Wilson,I.A.; Burton,D.R.; Smith,D.; Pond,S.L.K.; Poignard,P.",HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage,29-NOV-2017,8_10_25_7_3_8,ASP69768_ASP69808,Unique source,HIV,2,1,12.955006,8.494019
CBX32738_CBX32737,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,CBX32738,CBX32737,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Wang,Y.; Bishop,W.; Pachter,J.",Anti-IGFR1 antibody therapeutic combinations,13-OCT-2010,8_7_12_6_3_9,CBX32738_CBX32737,Unique chain,IGFR1,2,1,12.916615,10.646952
3S36_H_L,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,3S36_H,3S36_L,Structural Basis For The Function Of Two Anti-Vegf Receptor Antibodies,Structural Basis For The Function Of Two Anti-Vegf Receptor Antibodies,Homo sapiens,"Franklin,M.C.;Navarro,E.C.;Wang,Y.;Patel,S.;Singh,P.;Zhang,Y.;Persaud,K.;Bari,A.;Griffith,H.;Shen,L.;Balderes,P.;Kussie,P.",The structural basis for the function of two anti-VEGF receptor 2 antibodies,17-MAY-2011,8_8_9_6_3_9,QPX85686_QPX85687,Xtal structure,VEGFA; VPF; VEGF-A; VEGF,2,1,16.04025,10.078992
CAL63913,EVQLVQSGGGLVKPGGSLRLSCVGSGFTFTNAWMSWVRQAPGKGLEWVGRMKSKTYGWTTEFATAVEGRFTMSRDDSKNTLYLQMNSLKTEDTAVYYCSTDDYDFWGQGTMVTVSS,ELVMTQSPVSLAVTPGEPASISCRSSQSLLFSNGFHYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGSDFTLKISRVEAEDVGVYYCMQALHNPLTFGGGTKLEIK,CAL63913_H,CAL63913_L,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"toran Garcia,J.L.; lain de Lera,M.T.",Human antibodies with beta-amyloid peptide-binding capacity and their applications,24-OCT-2006,8_10_7_11_3_9,CAL63913,Same entry,beta-amyloid,2,1,13.086416,8.427356
1OPG_H_L,EVQLVQSGGGLVNPGRSLKLSCAASGFTFSSYGMSWVRQTPEKRLEWVAAISGGGTYIHYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCTRHPFYRYDGGNYYAMDHWGQGTSVTVS,LLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPLTFGGGSKLEIK,1OPG_H,1OPG_L,Opg2 Fab Fragment,Opg2 Fab Fragment,Mus musculus,"Celikel,R.;Williamson,M.M.;Ni,C.;Ely,K.R.",Crystallization of the OP-G2 Fab fragment: a fibrinogen mimic with specificity for the platelet glycoprotein IIb/IIIa,28-APR-1995,8_8_18_6_3_9,1OPG_H_L,Xtal structure,platelet,2,1,18.013884,7.0595145
5FGB_E_B,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNILYLQMNSLKAEDTATYYCARAVVFTDSSAYYYSKYFDYWSQGTLVTVSS,YELTQLPSLSVSLGQTASITCSGDNLGDKFVCWYQQKPGQTPVLVMYEDTKRPSGIPERFAGSNSGNTATLTITGTQAMDEADYYCQTWDSSTDVVFGGGTKLTVL,5FGB_E,5FGB_B,Three Dimensional Structure Of Broadly Neutralizing Human Anti - Hepatitis C Virus (Hcv) Glycoprotein E2 Fab Fragment Hc33.4,Three Dimensional Structure Of Broadly Neutralizing Human Anti - Hepatitis C Virus (Hcv) Glycoprotein E2 Fab Fragment Hc33.4,Hepatitis C virus (isolate H),"Keck,Z.Y.;Girard-Blanc,C.;Wang,W.;Lau,P.;Zuiani,A.;Rey,F.A.;Krey,T.;Diamond,M.S.;Foung,S.K.",Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus,20-DEC-2015,8_8_20_6_3_10,5FGB_E_B,Xtal structure,Hepatitis,2,1,13.992917,9.9951515
QKK35796_QKK35797,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSYITRSSDNIYYAESVKGRFTISRDSAKNSLYLHMNSLRDEDTAVYYCARDPGLEYSGNYFSYYYYAMDVWGQGTTVTVSS,EIVMTQSPSSLSASVGDRVTITCRASQSISYYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFILTISSLQPEDIATYYCQHSYSSPPLTFGGGTKVEIK,QKK35796,QKK35797,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_6_3_10,QKK35796_QKK35797,Unique source,SARS-CoV-2,2,1,15.916417,10.021891
AAW68598_AAW69027,EVQLVQSGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSDINGGGGNTHHADSVKGRFSISRDNSQNTLYLQMNSLRADDTAVYYCVKYLWGGYAIDVWGQGTMVTV,EIVMTQSPSSLSASVGARLTITCRASQRINIHLNWYKQTAGQAPKLLIYVASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSTTYYCQQSYITPWTFGQGTKVEIK,AAW68598,AAW69027,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_12_6_3_9,AAW68598_AAW69027,Unique source,tetanus,2,1,14.196999,9.801797
6P3R_C_D,EVQLVQSGGGLVQPGGSLRLSCEASRFTSSSYWITWVRQAPGKGLEWVANIKQDGSEKYFVDSVKGRFTISRDNASNSLYLQMSSLRAEDTAVYYCARGFLERLLLGRQGAYYYGMDVWGQGTTVTVSS,DIVMTQSPFSLSASVGDRVTMTCRASQSISSSLNWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTMPPELTFGGGTKVEIK,6P3R_C,6P3R_D,Crystal Structure Of Human Fab H5.31 In Complex With Influenza A H5N1 Vietnam Hemagglutinin Head Domain,Crystal Structure Of Human Fab H5.31 In Complex With Influenza A H5N1 Vietnam Hemagglutinin Head Domain,Influenza A virus (A/chicken/Vietnam/32/2004(H5N1)),"Dong,J.;Crowe,J.E.",Crystal structure of human Fab H5.31 in complex with influenza A H5N1 Vietnam hemagglutinin head domain,27-MAY-2020,8_8_22_6_3_11,6P3R_C_D,Xtal structure,H5N1; hemagglutinin; Influenza,2,1,11.19016,7.833565
UIC72027_UIC72337,EVQLVQSGGGLVQPGGSLTLSCVASGFTLSNYWMSWVRQTPEKGLEWVANIRQTGRLKYYVDSVKGRFTISRDNAKNSLYLHMASLRADDTAVYYCARGRGSDSGIYFDPWGQGALVTVSS,DIQMTQYPSTLSASVGDRVTITCRASQNINTWLAWYQQKPGRAPKLLISRASSLETGVPSRFSGRGSGTEFTLTISSLQADDSATYYCQQYHFWYTFGQGTKVEI,UIC72027,UIC72337,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_14_6_3_8,UIC72027_UIC72337,Unique source,HCV,2,1,11.145909,7.7892246
2FB4_H_L,EVQLVQSGGGVVQPGRSLRLSCSSSGFIFSSYAMYWVRQAPGKGLEWVAIIWDDGSDQHYADSVKGRFTISRNDSKNTLFLQMDSLRPEDTGVYFCARDGGHGFCSSASCFGPDYWGQGTPVTVSS,QSVLTQPPSASGTPGQRVTISCSGTSSNIGSSTVNWYQQLPGMAPKLLIYRDAMRPSGVPDRFSGSKSGASASLAIGGLQSEDETDYYCAAWDVSLNAYVFGTGTKVTVL,2FB4_H,2FB4_L,"Dir Primaerstruktur Des Kristallisierbaren Monoklonalen Immunoglobulins Igg1 Kol. Ii. Aminosaeuresequenz Der L-Kette, Lambda-Typ, Subgruppe I (German)","Dir Primaerstruktur Des Kristallisierbaren Monoklonalen Immunoglobulins Igg1 Kol. Ii. Aminosaeuresequenz Der L-Kette, Lambda-Typ, Subgruppe I (German)",Homo sapiens,"Colman,P.M.;Deisenhofer,J.;Huber,R.;Palm,W.",Structure Of The Human Antibody Molecule Kol (Immunoglobulin G1). An Electron Density Map At 5 Angstroms Resolution,18-APR-1989,8_8_19_8_3_11,AAE05691_AAE05687,Xtal structure,,2,1,14.696979,13.291605
AAW68466_AAW68886,EVQLVQSGPEVKKPGASVRVSCKASGYSLKNYGIHWVRQAPGQGLEWMGWISADNGDTTTALNLRGRVSMTTDTSTNTVYMEVKSLRSDDTAIYFCARDFYSGSYRSFDYWGQGTLVTV,DVVMTQSPSSLSASLGDRVTITCRASQHISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFTGSGSGADYTLTISSLQPEDFATYYCQQSYSTSWTFGQGTTVGIK,AAW68466,AAW68886,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_14_6_3_9,AAW68466_AAW68886,Unique source,tetanus,2,1,1.5359665,5.4235024
7U0E_A_B,EVQLVQSGPEVKKPGTSARVSCKASGFTSKNTALQWVRQARGQPLEWMGWIDISNYITNYAQKFRGRLTITWDLSASMAYMELSSLRSEDTAVYYCAAVGKDDDVLTGGNKYFDHWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIHEDDKRPSGIPGRFSASSSGTTATLTISGAQVEDEADYYCYSTDTNDNHAFGSGTKLTVL,7U0E_A,7U0E_B,Crystal Structure Of C13C9 Fab In Complex With Sars-Cov-2 S Fusion Peptide,Crystal Structure Of C13C9 Fab In Complex With Sars-Cov-2 S Fusion Peptide,Homo sapiens,"Low,J.S.;Jerak,J.;Tortorici,M.A.;McCallum,M.;Pinto,D.;Cassotta,A.;Foglierini,M.;Mele,F.;Abdelnabi,R.;Weynand,B.;Noack,J.;Montiel-Ruiz,M.;Bianchi,S.;Benigni,F.;Sprugasci,N.;Joshi,A.;Bowen,J.E.;Stewart,C.;Rexhepaj,M.;Walls,A.C.;Jarrossay,D.;Morone,D.;Paparoditis,P.;Garzoni,C.;Ferrari,P.;Ceschi,A.;Neyts,J.;Purcell,L.A.;Snell,G.;Corti,D.;Lanzavecchia,A.;Veesler,D.;Sallusto,F.",ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies,03-AUG-2022,8_8_19_6_3_10,7U0E_A_B,Xtal structure,SARS-CoV-2; ACEH; ACE2,2,1,-0.960652,3.0418515
6PLK_H_L,EVQLVQSGRGLVRPGGSLRLSCAASGFTFSNYAMSWVRQGPGMGLEWVSTITADSDSKYYVDSVKGRFTISRDNSKDTLFLHMTSLRAEDTAVYYCAKDRLSRGVGELYDSWGQGTLVTVSS,DIVMTQSPSTLSASVGDRVTITCRASQSIDVWLAWYQQKPGKAPKLLMYKTSTLQTGVPSRFSGSGSGTEFTLTISSLQTDDFATYYCQKYDSYPWTFGPGTKVEIK,6PLK_H,6PLK_L,Crystal Structure Of Zikv-116 Fab In Complex With Zikv Envelope Diii,Crystal Structure Of Zikv-116 Fab In Complex With Zikv Envelope Diii,Zika virus ZIKV/H. sapiens/FrenchPolynesia/10087PF/2013,"Zhao,H.;Xu,L.;Bombardi,R.;Nargi,R.;Deng,Z.;Errico,J.M.;Nelson,C.A.;Dowd,K.A.;Pierson,T.C.;Crowe,J.E.;Diamond,M.S.;Fremont,D.H.",Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge,01-JUL-2019,8_8_15_6_3_9,6PLK_H_L,Xtal structure,Zika; dengue,2,1,14.056725,9.870737
7JWG_A_B,EVQLVQSGSEVKKPGESLKISCQVSGYSFTSYWIGWVRQMPGKGLERVGFIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGILRYFDWFLDYWGQGTLVTVSS,PSSLSASVGDRVTITCRASQGISSGSAWYQQKPGKAPKLLIYDVSSLESGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQFNSYLLTFGGGTKVEIK,7JWG_A,7JWG_B,Ospa-Fab 221-7 Complex Structure,Ospa-Fab 221-7 Complex Structure,Borreliella burgdorferi B31,"Schiller,Z.A.;Rudolph,M.J.;Toomey,J.R.;Ejemel,M.;LaRochelle,A.;Davis,S.A.;Lambert,H.S.;Kern,A.;Tardo,A.C.;Souders,C.A.;Peterson,E.;Cannon,R.D.;Ganesa,C.;Fazio,F.;Mantis,N.J.;Cavacini,L.A.;Sullivan-Bolyai,J.;Hu,L.T.;Embers,M.E.;Klempner,M.S.;Wang,Y.",Blocking Borrelia burgdorferi transmission from infected ticks to nonhuman primates with a human monoclonal antibody,25-AUG-2020,8_8_14_6_3_9,7JWG_A_B,Xtal structure,,2,1,-12.375491,5.7659826
6W7Y_A_B,EVQLVQSGTEVKKPGESLKISCKGSGYGFITYWIGWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGSGISTPMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSINKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,6W7Y_A,6W7Y_B,Crystal Structure Of Sars-Cov And Sars-Cov-2 Reactive Human Antibody Cr3022,Crystal Structure Of Sars-Cov And Sars-Cov-2 Reactive Human Antibody Cr3022,Homo sapiens,"Chen,W.H.;Joyce,M.G.",Structure and Antigenicity of the SARS-CoV-2 Receptor Binding Domain,19-MAR-2020,8_8_12_12_3_9,6W7Y_A_B,Xtal structure,SARS-CoV-2,2,1,-12.364727,5.7595367
QFQ60922_QFQ60923,EVQLVQSGTEVKRPGESLTISCKTSGYSFSGTWISWVRQMPGKGLEWMGSIYPGDSDTRYHPSFQGHVTISADRSVSTTYLQWSSLKASDTATYYCARSYEDNYGYYDLFFFFDYWGQGALVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISTYLAWYQQKPGKAPKLLIYKAYLLQNGVPSRFSGGGSGTDFTLTISSLQPEDFATYYCQQHNNNPYTFGQGTKVEIK,QFQ60922,QFQ60923,"anti-SIV env immunoglobulin ITS090.03 heavy chain variable region, partial [Macaca mulatta]","anti-SIV env immunoglobulin ITS090.03 kappa chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Gorman,J.; Mason,R.D.; Nettey,L.; Cavett,N.; Chuang,G.Y.; Peng,D.; Tsybovsky,Y.; Verardi,R.; Nguyen,R.; Ambrozak,D.; Biris,K.; LaBranche,C.C.; Ramesh,A.; Schramm,C.A.; Zhou,J.; Bailer,R.T.; Kepler,T.B.; Montefiori,D.C.; Shapiro,L.; Douek,D.C.; Mascola,J.R.; Roederer,M.; Kwong,P.D.",Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields,23-OCT-2019,8_8_19_6_3_9,QFQ60922_QFQ60923,Unique word,SIV; HIV,2,1,-12.350367,5.667739
QKK35870_QKK35871,EVQLVQWGAGLLKPSETLSLRCAVYGGSFNGFYWTWIRQAPGQGLEWIAEINHSGTTNYNPSLKSRVTISIDTSKKQFSLSLKSVTAADTAMYFCARGTISPIVGVPTPVVPRRGRSWFDPWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYENYKRPSGIPDRFSGSKSGTSATLDITGLQTGDEADYYCGTWDSSLSVDNYVFGTGTKLTVL,QKK35870,QKK35871,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_26_8_3_13,QKK35870_QKK35871,Unique source,SARS-CoV-2,2,1,16.685743,-10.537459
AHX01220_AHX01232,EVQVVESGGGVVQPGRSLRLSCTASGFTFSNFAMGWVRQAPGKGLEWVAFISSDGSNKNYGDSVKGRFTISRDNSKNTVFLQMNSLRVEDTALYYCAKDVGDYKSDEWGT,QSVLTQPPSVSAAPGQKVTISCSGSSSTIGNNYVSWYRLLPGTAPKLLIYKNDNRPSGIPDRFSGSKSGTSATLGISGLQTGDEADYYCGTWDTSLSGGGVFGTGTKVTVL,AHX01220,AHX01232,"anti-HIV-1 immunoglobulin CAP256-VRC26.01 heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin CAP256-VRC26.01 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Doria-Rose,N.A.; Schramm,C.A.; Gorman,J.; Moore,P.L.; Bhiman,J.N.; Dekosky,B.J.; Ernandes,M.J.; Georgiev,I.S.; Kim,H.J.; Pancera,M.; Staupe,R.P.; Altae-Tran,H.R.; Bailer,R.T.; Crooks,E.T.; Cupo,A.; Druz,A.; Garrett,N.J.; Hoi,K.H.; Kong,R.; Louder,M.K.; Longo,N.S.; McKee,K.; Nonyane,M.; O'Dell,S.; Roark,R.S.; Rudicell,R.S.; Schmidt,S.D.; Sheward,D.J.; Soto,C.; Wibmer,C.K.; Yang,Y.; Zhang,Z.; Mullikin,J.C.; Binley,J.M.; Sanders,R.W.; Wilson,I.A.; Moore,J.P.; Ward,A.B.; Georgiou,G.; Williamson,C.; Abdool Karim,S.S.; Morris,L.; Kwong,P.D.; Shapiro,L.; Mascola,J.R.",Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies,25-APR-2014,8_8_11_8_3_12,AHX01220_AHX01232,Unique word,HIV,2,1,14.928147,13.216238
AEQ73735_AEQ74489,EVRKPGSSVKVSCKASGGTIKNYAISWVRQAPGQGLEWMGSIIPVFGTPNYAQRFQGRLTITADESTSTVDMQLNNLRSDDTAMYYCAKLPSGSYYDYFDSWGQGTLVTVS,TLSLSPGERATLSCRASQTVSSIYLAWYQQKPGQAPRLLIYSASSRATGIPDRFIGSGSGTDFTLTITRLEPEDSAVYYCQHYGNSLAPPFGGGTKVEIK,AEQ73735,AEQ74489,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_14_7_3_10,AEQ73735_AEQ74489,Unique source,tetanus,2,1,-0.32043073,5.703303
5WDF_A_B,EVRLRESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTLYLEMNNVRTEDTGYYFCARTGKYYDFWFGYPPGEEYFQDWGQGTLVIVSS,SELTQDPAVSVALKQTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,5WDF_A,5WDF_B,Crystal Structure Of 10E8V4-5R+100Cf Fab In Complex With Hiv-1 Gp41 Peptide,Crystal Structure Of 10E8V4-5R+100Cf Fab In Complex With Hiv-1 Gp41 Peptide,Human immunodeficiency virus 1,"Kwon,Y.D.;Chuang,G.Y.;Zhang,B.;Bailer,R.T.;Doria-Rose,N.A.;Gindin,T.S.;Lin,B.;Louder,M.K.;McKee,K.;O'Dell,S.;Pegu,A.;Schmidt,S.D.;Asokan,M.;Chen,X.;Choe,M.;Georgiev,I.S.;Jin,V.;Pancera,M.;Rawi,R.;Wang,K.;Chaudhuri,R.;Kueltzo,L.A.;Manceva,S.D.;Todd,J.P.;Scorpio,D.G.;Kim,M.;Reinherz,E.L.;Wagh,K.;Korber,B.M.;Connors,M.;Shapiro,L.;Mascola,J.R.;Kwong,P.D.",Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody,05-JUL-2017,8_10_22_6_3_12,5WDF_A_B,Xtal structure,HIV,2,1,12.665804,8.881983
UKB93110_UKB93120,EVRLVESGGGLVKPGGSLRLSCVASGFTFSSYEMHWVRQAPGKGLEWVSVISESGATTHYTDSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCTRPQSVTVFGVAATSYEAFDFWGQGLRVTVSS,DIVMTQSPDTLSLSPGETATLSCRASQSVSSYVAWYQQKPEQPPRLLIYGSSSRATGMPDRFSGSGSGTDFTLTISSLEPDDFAVYYCQQYTNWPLTFGGGTKVEIK,UKB93110,UKB93120,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]","cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"He,W.T.; Yuan,M.; Callaghan,S.; Musharrafieh,R.; Song,G.; Silva,M.; Beutler,N.; Lee,W.H.; Yong,P.; Torres,J.L.; Melo,M.; Zhou,P.; Zhao,F.; Zhu,X.; Peng,L.; Huang,D.; Anzanello,F.; Ricketts,J.; Parren,M.; Garcia,E.; Ferguson,M.; Rinaldi,W.; Rawlings,S.A.; Nemazee,D.; Smith,D.M.; Briney,B.; Safonova,Y.; Rogers,T.F.; Dan,J.M.; Zhang,Z.; Weiskopf,D.; Sette,A.; Crotty,S.; Irvine,D.J.; Ward,A.B.; Wilson,I.A.; Burton,D.R.; Andrabi,R.",Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques,22-AUG-2022,8_8_21_6_3_9,UKB93110_UKB93120,Unique source,SARS-CoV-2; SARS,2,1,15.46561,10.055136
4YDL_B_C,EVRLVQSGNQVRKPGASVRISCEASGYKFIDHFIHWVRQVPGHGLEWLGWINPRGGGVNYSRSFQGKLSMTMTRDNFEETAYLDLSKLNPGDTAVYFCARGFAGYEWSFIWGQGTLVIVSS,EIVLTQSPGTLSLSPGETATLSCRTSQGILSNQLAWHQQRRGQPPRLLIYGGSNRAPGIPERFTGSGSGTDFVLTIKRLERDDFAVYYCQILEFFGRGTRVEM,4YDL_B,4YDL_C,Crystal Structure Of Broadly And Potently Neutralizing Antibody C38-Vrc18.02 In Complex With Hiv-1 Clade Ae Strain 93Th057Gp120,Crystal Structure Of Broadly And Potently Neutralizing Antibody C38-Vrc18.02 In Complex With Hiv-1 Clade Ae Strain 93Th057Gp120,Homo sapiens,"Zhou,T.;Lynch,R.M.;Chen,L.;Acharya,P.;Wu,X.;Doria-Rose,N.A.;Joyce,M.G.;Lingwood,D.;Soto,C.;Bailer,R.T.;Ernandes,M.J.;Kong,R.;Longo,N.S.;Louder,M.K.;McKee,K.;O'Dell,S.;Schmidt,S.D.;Tran,L.;Yang,Z.;Druz,A.;Luongo,T.S.;Moquin,S.;Srivatsan,S.;Yang,Y.;Zhang,B.;Zheng,A.;Pancera,M.;Kirys,T.;Georgiev,I.S.;Gindin,T.;Peng,H.P.;Yang,A.S.;Mullikin,J.C.;Gray,M.D.;Stamatatos,L.;Burton,D.R.;Koff,W.C.;Cohen,M.S.;Haynes,B.F.;Casazza,J.P.;Connors,M.;Corti,D.;Lanzavecchia,A.;Sattentau,Q.J.;Weiss,R.A.;West AP,Jr.;Bjorkman,P.J.;Scheid,J.F.;Nussenzweig,M.C.;Shapiro,L.;Mascola,J.R.;Kwong,P.D.",Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors,22-FEB-2015,8_8_12_7_3_5,4YDL_B_C,Xtal structure,HIV; CD4,2,1,2.5830193,4.0158844
6HGU_H_L,EVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLAHIYWDNDRYYNPSLKSRLTISKDTFSNQVFLKITNVDTADTATYYCARSPMNTWGDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQNTHVPLTFGAGTKLELK,6HGU_H,6HGU_L,Crystal Structure Of An Anti-App-Tag Fab,Crystal Structure Of An Anti-App-Tag Fab,Mus musculus,"Goepfert,A.;Lehmann,S.;Blank,J.;Kolbinger,F.;Rondeau,J.M.",Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling,23-AUG-2018,10_7_11_11_3_9,6HGU_H_L,Xtal structure,ML1; IL17R; IL-17RA; hIL-17R; CDw217; IL-17F; IL17RA; CD217; IL17F; ML-1,2,1,11.520607,1.8979646
1IND_H_L,EVTLVESGGDSVKPGGSLKLSCAASGFTLSGETMSWVRQTPEKRLEWVATTLSGGGFTFYSASVKGRFTISRDNAQNNLYLQLNSLRSEDTALYFCASHRFVHWGHGTLVTVS,AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEARYFCALWYSNLWVFGGGTKLTVL,1IND_H,1IND_L,How The Anti-(Metal Chelate) Antibody Cha255 Is Specific For The Metal Ion Of Its Antigen: X-Ray Structures For Two Fab'(Slash)Hapten Complexes With Different Metals In The Chelate,How The Anti-(Metal Chelate) Antibody Cha255 Is Specific For The Metal Ion Of Its Antigen: X-Ray Structures For Two Fab'(Slash)Hapten Complexes With Different Metals In The Chelate,Mus musculus,"Love,R.A.;Villafranca,J.E.;Aust,R.M.;Nakamura,K.K.;Jue,R.A.;Major JG,Jr.;Radhakrishnan,R.;Butler,W.F.",How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate,14-JUN-1993,8_8_7_9_3_9,1IND_H_L,Xtal structure,hapten; SH3YL1; DKFZP586F1318; Ray,2,1,18.173311,7.1173224
S32186_S32189,EVXLVESGGGLVQPGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKANGYTTEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARSYYGSSRYAMDYWGQGTSVTVSS,DVVMTXTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK,S32186,S32189,Ig heavy chain V region - mouse (fragment),Ig kappa chain V region - mouse (fragment),Mus musculus,"Izui,S.",Direct Submission,21-Jan-2000,8_10_14_11_3_9,FAILED,Ordered entries,,2,1,26.033983,4.6543503
AVW80141,EVYLVESGGGLVQPGGSVKLSCSASGFTFSTFPMAWVRQAPTQGLQWVATLSPSGDSTYYRDSVKGRFTISRDNVLNTLYLHMDILRSEDTATYYCTKVGFTTFYFDSWGQGVMVAVSS,DIQMTQSPSFLSASVGDRVTINCKASQNINKYLDWYQQKFGETPKLLIYNINNLHSGVPSRFSGSGSGPDFTLTISSLQPEDVATYFCLQHRTGWTFGGGTKVELR,AVW80141_H,AVW80141_L,anti-CD3 antibody KT3-scFV [synthetic construct],anti-CD3 antibody KT3-scFV [synthetic construct],synthetic construct,"Brameshuber,M.; Kellner,F.; Rossboth,B.K.; Ta,H.; Alge,K.; Sevcsik,E.; Gohring,J.; Axmann,M.; Baumgart,F.; Gascoigne,N.R.J.; Davis,S.J.; Stockinger,H.; Schutz,G.J.; Huppa,J.B.",Monomeric TCRs drive T cell antigen recognition,14-APR-2018,8_8_12_6_3_8,AVW80141,Same entry,CD3,2,1,14.50448,9.301034
QDF61691_QDF62061,GAEVKKPGASLKVSCKASGFTLINYYIHWVRRAPGQGLEWMGIVSPVSGTTSNAPKFQGRVTMTRDTSTNTAYMELTSLKSEDTAIYYCAGGIYGSGGYAGDFWGQGT,PLSLPVTPGEPASISCRSSQSLLHSNGHHYLDWYVQKPGQSPQLVIYVGSIRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQVLQTPFTFGPG,QDF61691,QDF62061,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Davis,C.W.; Jackson,K.J.L.; McElroy,A.K.; Halfmann,P.; Huang,J.; Chennareddy,C.; Piper,A.E.; Leung,Y.; Albarino,C.G.; Crozier,I.; Ellebedy,A.H.; Sidney,J.; Sette,A.; Yu,T.; Nielsen,S.C.A.; Goff,A.J.; Spiropoulou,C.F.; Saphire,E.O.; Cavet,G.; Kawaoka,Y.; Mehta,A.K.; Glass,P.J.; Boyd,S.D.; Ahmed,R.",Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection,01-JUL-2019,8_8_14_11_3_9,QDF61691_QDF62061,Unique source,Ebola,2,1,1.3902099,5.255421
QDF61673_QDF62045,GGGLVQPGGSLRLSCVGSGFIFSSHWMNWVRQAPGKGLEWVANIKGDGSVRQYMESVKGRFTISRDNAKNSMYLQMNSLRPEDTAVYYCMSPWIATEGTGPVWGQGT,PGTLSLSPGERATLSCRASQSVTSGYLAWYQQRPGQAPRLLIYGVSTRATGIPDRFSGSGSGTDFTLTIIGLEPEDFAVYYCQQYDTAPDTFGQG,QDF61673,QDF62045,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Davis,C.W.; Jackson,K.J.L.; McElroy,A.K.; Halfmann,P.; Huang,J.; Chennareddy,C.; Piper,A.E.; Leung,Y.; Albarino,C.G.; Crozier,I.; Ellebedy,A.H.; Sidney,J.; Sette,A.; Yu,T.; Nielsen,S.C.A.; Goff,A.J.; Spiropoulou,C.F.; Saphire,E.O.; Cavet,G.; Kawaoka,Y.; Mehta,A.K.; Glass,P.J.; Boyd,S.D.; Ahmed,R.",Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection,01-JUL-2019,8_8_13_7_3_9,QDF61673_QDF62045,Unique source,Ebola,2,1,11.191132,7.843447
AAB25741_AAB25742,GGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDRELLWFGELLNWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSIEGTFGQGTKVEIK,AAB25741,AAB25742,"rheumatoid factor C6 heavy chain, partial [Homo sapiens]","rheumatoid factor C6 light chain, partial [Homo sapiens]",Homo sapiens,"Ermel,R.W.; Kenny,T.P.; Chen,P.P.; Robbins,D.L.",Molecular analysis of rheumatoid factors derived from rheumatoid synovium suggests an antigen-driven response in inflamed joints,25-JUL-2016,8_8_14_6_3_9,AAB25741_AAB25742,Unique word,,2,1,13.159531,12.011071
CAA54154_CAA54155,GGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAAIKSNGGSTYYPDTVKDRFTISRDNAKNTLYLQMNSLRSEDTALYFCTKGDGYYAWFAYWGQGTLVTVSA,SFSLGASAKLTCTLSSQHSTYTIEWYQQQPLKPPKYVMELKKDGSHSTGDGIPDRFSGSSSGADRYLSISNIQPEDEAIYICGVGDTIKGQFVFVFGGGTKVTVL,CAA54154,CAA54155,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Maier,C.C.; Galin,F.S.; Jarpe,M.A.; Jackson,P.; Krishna,N.R.; Gautam,A.M.; Zhou,S.R.; Whitaker,J.N.; Blalock,J.E.",A V lambda x-bearing monoclonal antibody with similar specificity and sequence to encephalitogenic T cell receptors,26-JUL-2016,8_8_12_7_7_13,CAA54154_CAA54155,Unique chain,,2,1,18.169117,7.2314863
AEQ73547_AEQ74300,GGLVKPGGSLRLSCAASGFSFSNNNMNWVRQTPGKGLEWVASISFGSHYISYADSVKGRFTISRDNARNAVYLQMNSLRVEDTAVYYCTRCRGGTRTYYYMDVWGKGTMVTVS,TLALSPGDRATLSCGASQSVFGDFLAWYQHKPGQAPRLLIYVASTRATGIPDRFSGSGAGTDFTLTISRLEPEDFAVYFCQQYGDSVFTFGQGTKLEIR,AEQ73547,AEQ74300,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_7_3_9,AEQ73547_AEQ74300,Unique source,tetanus,2,1,15.712704,10.493235
AEQ73543_AEQ74296,GGLVKPGGSLRLSCVVSGFPLNRYIMNWVRQTPGKGLEWLSSISSTSSYIYYADSAKGRFTISRDNAKNSLFLQMNSLRAEDTGLYYCASGNTHDYWGQGTLVTVS,SSLSASVGDRVTTTCRTSQSIFINLNWFQQKPGKAPKLLIYSASTLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQIYSQVRTFGQGTKVEIK,AEQ73543,AEQ74296,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_8_6_3_9,AEQ73543_AEQ74296,Unique source,tetanus,2,1,15.762046,10.4022045
AEQ73810_AEQ74562,GGLVKPGGSLRLSCVVSGFSFGNYKMNWARQAPGKGPEWVSSISSQNTYIDYADSVKGRFTISRDNVKSALYLQMNGLRPEDTAVYYCASGNTLDYWGRGTLVT,TLSLSPGERAILSCRASQTVCGNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFTGSGSGTDFTLTIIGLEPEDFAVYYCHQYCYSRTFGQGTKLEIK,AEQ73810,AEQ74562,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_8_7_3_8,AEQ73810_AEQ74562,Unique source,tetanus,2,1,15.7794,10.442728
AEQ74022_AEQ74782,GGLVKPGGSLRLSCVVSGFTLNRYTMNWVRQAPGKGLEWLSSISSTSSYIYYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTALYYCASGNTHDYWGQGTLVT,SSLSASVGDRVTITCRASQTININLNWFQQKPGKAPKLLIYSASTLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQIYSHVRTFGQGTKVEIK,AEQ74022,AEQ74782,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_8_6_3_9,AEQ74022_AEQ74782,Unique source,tetanus,2,1,15.800412,10.382865
AEQ73649_AEQ74404,GGLVQPGGSLKISCSASGFTFRSYGMHWVRQAPVKGLEHVATISAKGESTFYADSVKGRFTISRDNSKNTLHLQMNSLRPEDSAVYYCVKRRRQWLVNSSFDFWGQGTLVTVS,VFPGERVTLSCRASQSIANNLAWYQQGPGQPPSLLIYDASSRAPRVPVRFSGSGSGTEFSLTISSLQAEDFAVYYCQQYHVWPPITFGQGTRLEIK,AEQ73649,AEQ74404,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_10,AEQ73649_AEQ74404,Unique source,tetanus,2,1,14.529912,10.459406
AEQ74216_AEQ74976,GGLVQPGGSLRISCAASGFTFSTYWLNWVRQAPGKGLEWVASIKQDGRDKFYVDSIKGRFTISRDNARNSLYLQMDSLRVEDTAVYFCARAGSSWSLRPTTFDYWGQGTLVT,SSLSASVGDRVTISCRASQGIRNDLGWYQQKAGKAPKLLIYDASNLQDGVPPRFGGSGSGTDFTLTISNLQPEDFATYYCQQFYHYPRTFGQGTKVEIK,AEQ74216,AEQ74976,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_16_6_3_9,AEQ74216_AEQ74976,Unique source,tetanus,2,1,11.101991,7.723857
AEQ73703_AEQ74456,GGLVQPGGSLRLSCAASGFTFSNYWMHWVRQAPGKGLVWVSRINSDGSSTDYADSVKGRVTISRDNAKNTLYLHMNSLRAEDTAVYYCVRPRGYCADGLCYPALYFYYMDVWGEGTTVTVS,SSLSASVGDRVTITCRASQGIATYLAWFQQRPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSVPLTFGPGTKVAIK,AEQ73703,AEQ74456,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_23_6_3_9,AEQ73703_AEQ74456,Unique source,tetanus,2,1,14.711319,10.447607
AEQ73697_AEQ74450,GGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSDINGGGGNTHHADSVKGRFSISRDNSQNTLYLQMNSLRADDTAVYYCVKYLWGGYAIDVWGQGTMVTVS,SSLSASVGARLTITCRASQRINIHLNWYKQTAGQAPKLLIYVASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSTTYYCQQSYITPWTFGQGTKVEIK,AEQ73697,AEQ74450,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_12_6_3_9,AEQ73697_AEQ74450,Unique source,tetanus,2,1,14.51765,10.070545
AEQ73713_AEQ74467,GGLVQPGGSLRVSCAASGFSFSNYAMTWVRQAPGKGLEWVSEISANGGNTYYADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCAKGLIFGVPAYYFDSWGQGTLVTVS,TLSLSPGERATLSCRASHSVSSYLAWYQQKPGQAPRLLIYDASTRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRGNWPRTFGGGTKVEIK,AEQ73713,AEQ74467,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_9,AEQ73713_AEQ74467,Unique source,tetanus,2,1,14.639884,10.34391
ACB47973_ACB48020,GGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKGLEWVARIRSKSSNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRVGIYYGNYAMDYWGQGTSVTVSS,IMSASPGERVTMTCSASSSVSSSYLYWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYSGYPTFGGGTKLEIK,ACB47973,ACB48020,"monoclonal autoantibody heavy chain variable region, partial [Mus musculus]","monoclonal autoantibody light chain variable region, partial [Mus musculus]",Mus musculus,"Carrillo,J.; Puertas,M.C.; Planas,R.; Pastor,X.; Alba,A.; Stratmann,T.; Pujol-Borrell,R.; Ampudia,R.M.; Vives-Pi,M.; Verdaguer,J.",Anti-peripherin B lymphocytes are positively selected during diabetogenesis,26-JUL-2016,8_10_14_7_3_8,ACB47973_ACB48020,Unique source,peripherin,2,1,13.345473,7.7507486
AEQ73816_AEQ74567,GGLVRPGGSLRLSCSASGFPFRDYAFHWVRQAPGKGPEHISAISDDGGNTYYIGSVKGRFTISRDDSQNTVYLQLTSLRSDDTALYFCVKDPRRRTWFFHRSGFDIWGQGTMVT,FLSASVGDKVSITCRASQGISNSLAWYQQKPGKAPKLLISAASTLQSGVSSRFSGSGSGTEFTLTISSLEPEDFATYYCQQFNSYPITFGQGTRLETK,AEQ73816,AEQ74567,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_18_6_3_9,AEQ73816_AEQ74567,Unique source,tetanus,2,1,14.623884,10.538904
AEQ73969_AEQ74729,GGLVRPGGSLTLSCVVSGFSFGNYKMNWVRQTPGKGLEWVSSISSTSTYIDYADSVKGRFTISRDNSKNSLYLQMNSLRGDDTAIYYCTSGVTFDYWGQGTLVT,TLSLSPGERATLSCRAGQSVINNNLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFILIISRLEPEDFAAYFCRQYGSSPTTFGQGTKLEIK,AEQ73969,AEQ74729,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_8_7_3_9,AEQ73969_AEQ74729,Unique source,tetanus,2,1,15.729739,10.491418
AEQ73843_AEQ74596,GGVVQPGGSLRLSCEASGFPFRDYAMHWVRQAPGKGLEWVAVTSFDGRSQNYGDSVKGRFTISRDNSKNTLYLQMNSLRSEDTAIYYCARARLLYCSGGRCDMDYWGQGTLVT,FLAASVGDRVTISCRASQDILTYLAWYQQKPGKAPKVLIYGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLIRYPRTFGQGTRVEIK,AEQ73843,AEQ74596,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_17_6_3_9,AEQ73843_AEQ74596,Unique source,tetanus,2,1,14.780139,12.5933895
AEQ73610_AEQ74365,GGVVQPGRSLRLSCAASGFAFRDYAMHWVRQAPGKGLEWMGVISFNGDQIFYADSMKGRFTISRENSKNTLHLHMNSLRPEDTAVYYCARARLLFCSGGRCDMDSWGQGTLVTVS,FLSASVGDRVTITCRASQDIITYLAWYQQKPGKAPEVLIFGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQIIRYPRTFGQGTRVEIK,AEQ73610,AEQ74365,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_17_6_3_9,AEQ73610_AEQ74365,Unique source,tetanus,2,1,14.7393055,12.59415
AEQ73550_AEQ74303,GGVVQPGRSLRLSCAASGFAFRDYAMHWVRQAPGKGLEWMGVISFNGDQIFYADSMKGRFTISRENSKNTLHLRMNSLRPEDTAVYYCARARLLFCSGGRCDMDSWGQGTLVTVS,FLSASVGDRVTITCRASQDIITYLAWYQQKPGKAPEVLIFGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQIIRYPRTFGQGTRVEIK,AEQ73550,AEQ74303,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_17_6_3_9,AEQ73550_AEQ74303,Unique source,tetanus,2,1,14.750203,12.604743
AEQ73888_AEQ74644,GGVVQPGRSLRLSCAASGFTFSGYTMHWVRQAPGKGLDWVAAISYDGHTRLYADSVKGRFTISRHNSNNTLYLQMNSLKLEDTAVFYCARGGPGNLRVNLGRGVFDFWGQGTLVT,SLFAFVGDRVTITCRASQGISNWLAWYQQKPGKPPKSLIYAASSLQGGVPSRFRGSTSGTDFTLTISNLQPEDFATYYCQQYYSFPLSFGGGTKLEIK,AEQ73888,AEQ74644,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_19_6_3_9,AEQ73888_AEQ74644,Unique source,tetanus,2,1,14.8565645,12.834787
AEQ73728_AEQ74482,GGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSKKYYADSVKGRFTISRDDSKNTLYLEVNSLRVEDTAVYYCARGSGTYSFLDNWGQGTLVTVS,SSLSASVGDRVTITCRASQGVRNDLGWYQQKPGKAPKRLIYGTSTLERGVPSRFSGSGSGTEFTLTISSLQPEDLATYYCLQHNSYPPTFGQGTKVEIK,AEQ73728,AEQ74482,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_12_6_3_9,AEQ73728_AEQ74482,Unique source,tetanus,2,1,14.890098,12.929844
AEQ73725_AEQ74479,GLAKPGGSLRLSCVVSGFTLSSYKMNWVRQAPGKGLEWVSSISSTSAYIDYADSVKGRFTISRDNAKNSLYLEMSSLRATDSAVYYCVSGSSLDYWGQGTLVTVS,SLSASVGDRVTITCRASQSISTNLNWFQQKPGKAPNLLIYSASTLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQTYSPRRTFGQGTKVEIR,AEQ73725,AEQ74479,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_8_6_3_9,AEQ73725_AEQ74479,Unique source,tetanus,2,1,15.78886,10.446637
1202266G_1202266Q,GLEWVSYISSGSSTIYYADTVQGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARAGGDGYYDYVMDYWGQGT,DIVMTQTPLSLPVSLGDQASISCRSSQSIVISNGFTYLEWYLQKPGXXXKLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCFQGIHVPYTFGGGTRLEIK,1202266G,1202266Q,Ig gamma1 HP9,Ig kappa HP9,Mus musculus,"Ollier,P.; Rocca-Serra,J.; Somme,G.; Theze,J.; Fougereau,M.",The idiotypic network and the internal image. Possible regulation of a germline network by paucigene encoded Ab2 (anti-idiotypic) antibodies in the GAT system,01-JAN-1900,1_8_15_11_3_9,FAILED,Unique word,GLYAT; ACGNAT; GAT,2,1,17.52388,8.301715
2115316A_2115316B,GLLKPSETLSLHCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYKTSLKSRVTISLDTSKNLFSLKLSSVTPADTAVYYCARGLLRGGWNDVDYYYGMDVWGQGTTVTVSS,TQSPSSLSASVGDRVTITCRASQSTGSFLNWYQQKPGKAPKLLIYAASSWQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSYSTPLTFGGGTKVEIK,2115316A,2115316B,anti-DNA monoclonal antibody:SUBUNIT=heavy chain,anti-DNA monoclonal antibody:SUBUNIT=kappa,Homo sapiens,"Waisman,A.; Shoenfeld,Y.; Blank,M.; Ruiz,P.J.; Mozes,E.",The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment,01-JAN-1900,8_7_20_6_3_9,2115316A_2115316B,Unique chain,DNA,2,1,16.626179,-10.450881
AEQ74059_AEQ74819,GLLKPSETLSLTCAVYNGSFTVYYWSWTRQPPGKGLEWIGEINHSGDANYNPSLKGRVTMSVDTSKKQFSLKLRSVTAADTAMYYCSRVGPFDPWGQGTLVT,SSLSASLGDRVTITCRASQNINGHLNWFQQRPGKAPKLLIYASSNLQSGVSSRFSGSRSGTDFTLTISSLQPEDFASYYCQQIYNTPYTFGQGTKLEIK,AEQ74059,AEQ74819,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_8_6_3_9,AEQ74059_AEQ74819,Unique source,tetanus,2,1,16.590715,-10.117474
AEQ74069_AEQ74829,GLLKPSETLSLTCAVYNGSFTVYYWSWTRQPPGKGLEWIGEINHSGDANYNPSLKGRVTMSVDTSKNQFFLKLRSVTAADTAMYYCSRVGPFDPWGQGTLVT,SSLSASVGDRVTITCRASQNINSHLNWFQQRPGKAPKLLIYASSSLQSGVSSRFSGSRSGTDFTLTISSLQPEDFASYYCQQIYNTPYTFGQGTKLEIK,AEQ74069,AEQ74829,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_8_6_3_9,AEQ74069_AEQ74829,Unique source,tetanus,2,1,16.577936,-10.047254
ABV55696_ABV55780,GPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARDRGAYWGQGTLVTVSA,LSLPVSLGDQASISCRSSQSIVHSYGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK,ABV55696,ABV55780,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin kappa light chain, partial [Mus musculus]",Mus musculus,"Lange,H.; Zemlin,M.; Tanasa,R.I.; Trad,A.; Weiss,T.; Menning,H.; Lemke,H.",Thymus-independent type 2 antigen induces a long-term IgG-related network memory,26-JUL-2016,8_7_7_11_3_9,ABV55696_ABV55780,Unique source,,2,1,22.162508,-6.0494814
ABV55752_ABV55836,GPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARDRGVYWGQGTLVTVSA,IMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,ABV55752,ABV55836,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin kappa light chain, partial [Mus musculus]",Mus musculus,"Lange,H.; Zemlin,M.; Tanasa,R.I.; Trad,A.; Weiss,T.; Menning,H.; Lemke,H.",Thymus-independent type 2 antigen induces a long-term IgG-related network memory,26-JUL-2016,8_7_7_5_3_9,ABV55752_ABV55836,Unique source,,2,1,22.232796,-5.979309
AMN89315_AMN89700,GPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARDFDVWGAGTT,GTNVGWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNIYPLTFGSGTKLEIK,AMN89315,AMN89700,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Tas,J.M.; Mesin,L.; Pasqual,G.; Targ,S.; Jacobsen,J.T.; Mano,Y.M.; Chen,C.S.; Weill,J.C.; Reynaud,C.A.; Browne,E.P.; Meyer-Hermann,M.; Victora,G.D.",Visualizing antibody affinity maturation in germinal centers,09-MAR-2016,8_7_6_3_3_9,AMN89315_AMN89700,Unique source,,2,1,10.690202,-12.817975
AMN89272_AMN89676,GPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNRLEYMGYISFSGGTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARDFDVWGAGTT,GTNVGWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGSGTKLEIK,AMN89272,AMN89676,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Tas,J.M.; Mesin,L.; Pasqual,G.; Targ,S.; Jacobsen,J.T.; Mano,Y.M.; Chen,C.S.; Weill,J.C.; Reynaud,C.A.; Browne,E.P.; Meyer-Hermann,M.; Victora,G.D.",Visualizing antibody affinity maturation in germinal centers,09-MAR-2016,8_7_6_3_3_9,AMN89272_AMN89676,Unique source,,2,1,10.66706,-12.817811
AMN89230_AMN89646,GPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNRLEYMGYISFSGSTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARDFDVWGAGTT,GTNVGWNQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGSGTKLEIK,AMN89230,AMN89646,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Tas,J.M.; Mesin,L.; Pasqual,G.; Targ,S.; Jacobsen,J.T.; Mano,Y.M.; Chen,C.S.; Weill,J.C.; Reynaud,C.A.; Browne,E.P.; Meyer-Hermann,M.; Victora,G.D.",Visualizing antibody affinity maturation in germinal centers,09-MAR-2016,8_7_6_3_3_9,AMN89230_AMN89646,Unique source,,2,1,10.683909,-12.817206
CAF33001_CAF33000,GSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSFREGPWGQGTLVT,SYVLTQPPSVSVSPGQTARITCSGDALPKKYPYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDS,CAF33001,CAF33000,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Mueller-Hermelink,H.K.; Vollmers,H.",Neoplasm specific antibodies and uses thereof,03-MAR-2004,8_8_9_6_3_5,FAILED,Ordered entries,,2,1,14.444617,9.915452
CAF33003_CAF33002,GSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGAEGWYEYYYYYGMDVWGQGTLV,QSALTQPASLSASPGASASLTCTLRSGINVGTYRIYWYQQKPGSPPQYLLRYKSDSDKQKGSGVPSRFSGSKDASANAGILLISGLQSEDEADYYCMIWHSSAWVFGGGTKLTVL,CAF33003,CAF33002,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Mueller-Hermelink,H.K.; Vollmers,H.",Neoplasm specific antibodies and uses thereof,04-Mar-2004,8_8_19_9_7_9,ADS24540_ADS24539,Ordered entries,,2,1,14.426957,9.986826
CCE67147_CCE67148,GVQLVESGGGLVQPGGSLRLSCAASGFTISRNDMHWVRQATGKGLEWVSAIGTGGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGHMTTFGGFIVIGNGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVRSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYSCQQYNNWPWTFGQGTKVEIK,CCE67147,CCE67148,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"VEIBY,O.; BABCOOK,J.",Antibodies that bind OV064 and methods of use therefor,23-NOV-2011,8_7_20_6_3_9,CCE67147_CCE67148,Ordered entries,,2,1,16.417143,11.639507
5ZXV_C_D,GVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVALISYDISTDYYADSVKGRFTISRDNSKNTIYLQMNNLRTEDTALYYCAGNDYWGQGTLVTVSS,SVLTQSPSASGTPGQRVTISCSGSSSNIGNNYVYWYQQLPGTAPKLLIYWNDQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGAVFGGGTQLTVL,5ZXV_C,5ZXV_D,Structural Definition Of A Unique Neutralization Epitope On The Receptor-Binding Domain Of Mers-Cov Spike Glycoprotein,Structural Definition Of A Unique Neutralization Epitope On The Receptor-Binding Domain Of Mers-Cov Spike Glycoprotein,Homo sapiens,"Zhang,S.;Zhou,P.;Wang,P.;Li,Y.;Jiang,L.;Jia,W.;Wang,H.;Fan,A.;Wang,D.;Shi,X.;Fang,X.;Hammel,M.;Wang,S.;Wang,X.;Zhang,L.",Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein,21-MAY-2018,8_8_5_8_3_11,5ZXV_C_D,Xtal structure,MERS; CoV,2,1,14.970396,13.063195
AEQ73538_AEQ74292,GVVQPGTSLRLSCVVSGFTFRTYGMNWVRQAPGKGLEWLAFVSSDGSDEFYADSVKGRFTVSRDNSKSTLFLKMNSLRADDTAVYYCARDRGAQITLFGAPLIRPSSFDSWGQGTLVTVS,SSLSASVGDRITITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLQPGVPSRFSGSRSGTDFTFTISSLRPEDIATYYCQQYDGPVLTFGGGTKVEIK,AEQ73538,AEQ74292,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_23_6_3_9,AEQ73538_AEQ74292,Unique source,tetanus,2,1,14.87097,12.576488
AEQ73572_AEQ74327,GVVQPGTSLRLSCVVSGFTFRTYGMNWVRQAPGKGLEWPAFVSSDGSDEFYADSVKGRFTVSRDNSKSTLFLKMNSLRADDTAVYYCARDRGAQITLFGAPLIRPSSFDSWGQGTLVTVS,SSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLQPGVPSRFSGSRSGTDFTFTISSLRPEDIATYYCQQYDGPVLTFGGGTKVEIK,AEQ73572,AEQ74327,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_23_6_3_9,AEQ73572_AEQ74327,Unique source,tetanus,2,1,14.892518,12.552784
QCS90283_QCS90290,HVELKQSGPGQVKPLETLSMTCSVSGGSVRQFYWAWIRQSPGKGLEWMGYIYSDGYADYIPSLKSRLTFTLDEPKNRVSLRLTSMTPADAGIYFCGRVGPGGLFDRWRGYHGHKWVDAWGQGLLVTVSS,ETVLTQSPGSLSVALGETATLSCMASQNTDFNYFAWYQQKPGQAPRLLMQGASNRANGFPERFTARGSGTRFTLTIDRVEPDDAAVYYCQQYGRTFGQGTKLHIK,QCS90283,QCS90290,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Schoofs,T.; Barnes,C.O.; Suh-Toma,N.; Golijanin,J.; Schommers,P.; Gruell,H.; West,A.P. Jr.; Bach,F.; Lee,Y.E.; Nogueira,L.; Georgiev,I.S.; Bailer,R.T.; Czartoski,J.; Mascola,J.R.; Seaman,M.S.; McElrath,M.J.; Doria-Rose,N.A.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope,15-AUG-2022,8_7_23_7_3_6,QCS90283_QCS90290,Unique source,HIV,2,1,16.142614,-7.9845223
A32456_B32456,HVHLKESGPVLVAPSQSLSITCTVSGFSLTNYGVHWVRQPPGKGLEWLGVIWAGGNTNYNSALMSRLSISKDNSKSQVFLKMNSLQIDDTAIYYCAKRLERIFYYAMDYWGQGTSVTVSS,ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWVYGTSNLASGVPARFSGGGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELK,A32456,B32456,Ig heavy chain precursor V region - mouse,Ig kappa chain precursor V region - mouse,Mus musculus,"Dombrink-Kurtzman,M.A.; Johnson,L.S.; Riordan,G.S.; Bedzyk,W.D.; Voss,E.W. Jr.",Variable region primary structures of a high affinity anti-fluorescein immunoglobulin M cryoglobulin exhibiting oxazolone cross-reactivity,21-Jan-2000,8_7_14_7_3_9,A32456_B32456,Unique chain,oxazolone,2,1,22.062712,-6.1503453
7SX6_H_L,HVQLVQSGGGVKKIGAAVRISCEVSGYNFMDQFINWVRQAPGQGLEWMGWMNPIYGQVNYSWRFQGRVTMTRDMYTDTAFMELRGLRVDDTAVYYCARGPSGENYPFHYWGQGVRVVVSS,LTQPASMSASPGQSVTISCSGTRHIISAWFQQYPGKPPKLIIFDDDKRPSGVPSRFSASRPGDTASLTISNVQPEDEATYICNTYEFFGGGTKLTVL,7SX6_H,7SX6_L,Crystal Structure Of Broadly Neutralizing Antibody N49P9.3 Fab In Complex With Hiv-1 Clade A/E Strain 93Th057 Gp120 Core,Crystal Structure Of Broadly Neutralizing Antibody N49P9.3 Fab In Complex With Hiv-1 Clade A/E Strain 93Th057 Gp120 Core,Homo sapiens,"Tolbert,W.D.;Pazgier,M.",Crystal structure of broadly neutralizing antibody N49P9.3 Fab in complex with HIV-1 Clade A/E strain 93TH057 gp120 core,30-NOV-2022,8_8_13_4_3_5,7SX6_H_L,Xtal structure,gp120; HIV,2,1,2.598361,4.1531873
4ISV_B_A,IQLVQSGPELKKPGETVRISCKASGYSFTTYGMNWVKQAPGKGLKWMGWINTYSGVPTYADDFKGRFAFSLETSASTAYLQINILKNEDTATYFCARRRSDGYSNYFDYWGQGSTLTVSS,QLVLTQSSSASFSLGASAKLTCTLSRQHSTYTIEWYQQQPLKPPKFVMELKKDGSHSTGDGIPDRFSGSSSGAHRYLSISNIQPEDEAIYICGVGDTIKEQFVYVFGGGTKVTVL,4ISV_B,4ISV_A,"Crystal Structure Of The Fab Fragment Of 1C2, A Monoclonal Antibody Specific For Poly-Glutamine","Crystal Structure Of The Fab Fragment Of 1C2, A Monoclonal Antibody Specific For Poly-Glutamine",Mus musculus,"Klein,F.A.;Zeder-Lutz,G.;Cousido-Siah,A.;Mitschler,A.;Katz,A.;Eberling,P.;Mandel,J.L.;Podjarny,A.;Trottier,Y.","Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10",17-JAN-2013,8_8_14_7_7_13,4ISV_B_A,Xtal structure,,2,1,-7.5573554,6.1425166
CAD43566,IVKLQQSGAELVKPGASVRLSCKASGYTFTEYIIHWIKLRSGQGLEWIGWFYPGSNDIQYNAKFKGKATLTADKSSSTVYMELTGLTSEDSAVYFCARRDDFSGYDALPYWGQGTMVTVSS,DIQMTQSPASLSVSVGETVTITCRTNENIYSNLAWYQQKQGKSPQLLIYAATHLVEGVPSRFSGSGSGTQYSLKITSLQSEDFGNYYCQHFWGTPCTFGGGTKLEIK,CAD43566_H,CAD43566_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Soulillou,J.P.; Laflamme,G.; Vanhove,B.",Anti-cd28 antibody,09-AUG-2002,8_8_14_6_3_9,ADM01859,Same entry,cd28,2,1,0.14731063,-4.283592
CAF33005_CAF33004,KKPGESLRISCKGSGYSFTTYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADTSISTAYLQWSSLKASDTAIYYCAREVYTGRNYYYYGLDVWGQGTLV,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSKRSSNTLVFGGGTKLTVL,CAF33005,CAF33004,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Mueller-Hermelink,H.K.; Vollmers,H.",Neoplasm specific antibodies and uses thereof,03-MAR-2004,8_8_17_9_3_10,ADS24542_ADS24541,Ordered entries,,2,1,-12.590857,5.520504
AFW97810_AFW97883,KLVRPGGSLRLSCSASGFTFGSFAMSWVRQAPGKGLQWVSGISGSGDFLINAESVRGRFDISRDNSRNTLYLEMNTLGPEDTAIYYCVRDRHFRGMTALPGGEHWGQ,TLSASVGDRVTITCRASQNINTWLTWYQQKPGKAPKVLIYGASTLESGVPSRFSGSGSGTVFTLTISSLQPDDFATYYCQLYNSDSAWTFGQ,AFW97810,AFW97883,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Hicar,M.D.",Antibody repertoire analysis utilizing HIV-virus like particles identify novel quaternary epitopes on HIV-1 trimeric envelope,31-JAN-2013,8_8_17_6_3_10,AFW97810_AFW97883,Unique source,HIV,2,1,14.435308,9.890302
CAE84842_CAE84841,KVKLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTTVTVSS,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK,CAE84842,CAE84841,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"de Santis,R.C.; Anastasi,A.M.",Anti-human tenascin monoclonal antibody,11-DEC-2003,8_8_13_11_3_9,ACK09992_ACK09991,Unique chain,tenascin,2,1,2.4138215,-4.057088
CAE06275,KVQLLQSATEVKKPGASVKVSCKAYGYTFTDYGITWVRQAPGQGLEWMGWISAYNGYTNYAQKFQDRITMTTDASTSTAYMELRSLRPDDTAVLYCARDREDASLLRDGHWGQGTLVTVSS,TTLTQSPGTLSLSPGERATLSCRASQIVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISKLEPEDFAVYYCQHYGSSSPW,CAE06275_H,CAE06275_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.P.; Matthews,R.C.",Treatment of micro-organism infection,09-JUL-2003,8_8_14_7_3_9,CAE06275,Same entry,,2,1,1.8378288,5.3064666
UQB62798_UQB62814,KVQLRESGPSLVKPSQTLSLTCTTSGFSLSTYAVGWVRQAPGKALEWVGSIDDYGATCYNLALESRLTINKDRSKSQVSLSVSSVTTEDTASYYCVKYGHRNRGCYLNSWGGGQTYVDAWGQGLLVTVSS,QAVLTQLSSVSGSLGQRVSITCSGSSSNVGTGNYVSWFQQIPGSAPRTLIYGATTRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASYQSGNTAVFGSGTTLTVV,UQB62798,UQB62814,"immunoglobulin heavy chain variable region, partial [Bos taurus]","immunoglobulin light chain variable region, partial [Bos taurus]",Bos taurus,"Heydarchi,B.; Fong,D.S.; Gao,H.; Salazar Quiroz,N.A.; Edwards,J.M.; Gonelli,C.; Grimley,S.; Aktepe,T.E.; Mackenzie,C.; Wales,W.J.; van Gils,M.J.; Cupo,A.; Rouiller,I.; Gooley,P.R.; Moore,J.P.; Sanders,R.W.; Montefiori,D.; Sethi,A.; Purcell,D.F.J.",Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody,14-MAY-2022,8_7_24_9_3_10,UQB62798_UQB62814,Unique source,HIV; CD4,2,1,15.366177,-8.59848
AAW68456_AAW68875,KVQLVESGAEVKKPGSSVKVSCKTSGGSFSTYSITWVRQAPGQGLEWMGGINPIFATRDYAQKFQGRVTITADESTRTVYMELRNLRSEDTAVYYCARVFGGTRLYYALNVWGQGTLVTV,DVVMTQSPSSLSASVGDRVTITCRASQGISNFLAWHQQKPGQVPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTINGLQPEDVATYYCQKYDSGLIFTFGPGTRVEIK,AAW68456,AAW68875,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_15_6_3_10,AAW68456_AAW68875,Unique source,tetanus,2,1,-0.08223318,5.7499614
AAW68535_AAW68959,KVQLVQSGAEVKKPGESLKISCQASGYGFTVYWIGWVRQLPGKGLEWLGIIYPGDSDTRYNPSFQGQVTISADKSVSTTYLQWSSLKASDTAIYYCARHLDSYDVFTGYNLGGYMDVWGKGTTVTV,EIVLTQSPGTLSLSPGERATLSCRASQSVSTNYLAWYRQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGSSPQTFGQGTRLEIK,AAW68535,AAW68959,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_21_7_3_9,AAW68535_AAW68959,Unique source,tetanus,2,1,-12.758939,5.3879886
AAW68453_AAW68871,KVQLVQSGAEVKKPGESLKISCQASGYGFTVYWIGWVRQPPGKGLEWLGIIYPGDSDTRYNPSFQGQVTISADKSVSTTYLQWSSLKASDTAIYYCARHLDSYDVFTGYNLGGYMDVWGKGTLVTV,ETTLTQSPGTLSLSPGERATLSCRASQSVSTNYLAWYRQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGSSPQTFGQGTRLEIK,AAW68453,AAW68871,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_21_7_3_9,AAW68453_AAW68871,Unique source,tetanus,2,1,-12.774844,5.375919
AAW68485_AAW68907,KVQLVQSGAEVKKPGTSVRVSCKTSGGNVFSWVRQAPGQGPEWMGGIITNFGTTSYAQKFQGRVTFTADKSTNTVYMDLNNLISADTAVYYCARAPRGTSTIAARFNRYFFDSWGQGTLVTV,DIQMTQSPATLSLSPGERATLSCRASQSISNLLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRLWYTFGQGTKLEIK,AAW68485,AAW68907,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,4_8_21_6_3_8,AAW68485_AAW68907,Unique source,tetanus,2,1,21.69614,11.850906
AAW68629_AAW69057,KVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSKKYYADSVKGRFTISRDDSKNTLYLEVNSLRVEDTAVYYCARGSGTYSFLDNWGQGTLVTV,DVVMTQSPSSLSASVGDRVTITCRASQGVRNDLGWYQQKPGKAPKRLIYGTSTLERGVPSRFSGSGSGTEFTLTISSLQPEDLATYYCLQHNSYPPTFGQGTKVEIK,AAW68629,AAW69057,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_12_6_3_9,AAW68629_AAW69057,Unique source,tetanus,2,1,14.830077,13.0680685
AAW68601_AAW69030,KVQLVQSGPGLVKASETLSLSCSVSDGSMSSNYWSWIRQSPGKGLEWLGYITYGGTTNYNPSLTSRLTISLDRAEKQFSLRLSAVTAADTAVYYCARVRINLYGALLLSWFDSWGQGTLVTV,DVAMTQSPASLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTITGLQPEDFATYYCQQSDIIPWTFGQGTTVDIK,AAW68601,AAW69030,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_7_18_6_3_9,AAW68601_AAW69030,Unique source,tetanus,2,1,16.167969,-8.038961
AAB26319_AAB26310,LEESGEAVVQPGRSLRLSCAASGFIFRNYAMHWVRQAPGKGLEWVALIKYDGRNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDIGLKGEHYDILTAYGPDYWGQGTLVTVSS,ELTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQRGVPSRFSGSGSGTDFTLSISSLQPEDFATYYCQQSYSIPPLTFGGGTKVEIK,AAB26319,AAB26310,"anti-HIV-1 gp120 immunoglobulin G heavy chain variable region {clone b8} [human, bone marrow, Peptide Recombinant Partial, 125 aa]","anti-HIV-1 gp120 immunoglobulin kappa chain variable region {clone b8} [human, bone marrow, Peptide Recombinant Partial, 108 aa]",Homo sapiens,"Barbas,C.F. III; Collet,T.A.; Amberg,W.; Roben,P.; Binley,J.M.; Hoekstra,D.; Cababa,D.; Jones,T.M.; Williamson,R.A.; Pilkington,G.R.; et al.",Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries,24-JUN-1993,8_8_21_6_3_10,AAB26319_AAB26310,Unique word,gp120; HIV,2,1,14.763092,13.677022
AAB26320_AAB26311,LEESGGGLVKPGGSLRLSCVGSGFTFSSAWMAWVRQAPGRGLEWVGLIKSKADGETTDYATPVKGRFSISRNNLEDTVYLQMDSLRADDTAVYYCATQKPRYFDLLSGQYRRVAGAFDVWGHGTTVTVSP,ELTQSPGTLSLSPGERATLSCRAGQSISSNYLAWYQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLSISRLEPEDFAVYYCQQYGTSPYTFGQGTQLDIK,AAB26320,AAB26311,"anti-HIV-1 gp120 immunoglobulin G heavy chain variable region {clone b6} [human, bone marrow, Peptide Recombinant Partial, 130 aa]","anti-HIV-1 gp120 immunoglobulin kappa chain variable region {clone b6} [human, bone marrow, Peptide Recombinant Partial, 108 aa]",Homo sapiens,"Barbas,C.F. III; Collet,T.A.; Amberg,W.; Roben,P.; Binley,J.M.; Hoekstra,D.; Cababa,D.; Jones,T.M.; Williamson,R.A.; Pilkington,G.R.; et al.",Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries,24-JUN-1993,8_10_24_7_3_9,AAB26320_AAB26311,Unique word,gp120; HIV,2,1,13.0085745,8.584557
AAB26315_AAB26306,LEQSGAEVKKPGASVKVSCQASGYRFSNFVIHWVRQAPGQRFEWMGWINPYNGNKEFSAKFQDRVTFTADTSANTAYMELRSLRSADTAVYYCARVGPYSWDDSPQDNYYMDVWGKGTTVIVSS,ELTQAPGTLSLSPGERATFSCRSSHSIRSRRVRWYQHKPGQAPRLVIHGVSNRASGISDRFSGSGSGTDFTLTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK,AAB26315,AAB26306,"anti-HIV-1 gp120 immunoglobulin G heavy chain variable region {clone b12} [human, bone marrow, Peptide Recombinant Partial, 128 aa]","anti-HIV-1 gp120 immunoglobulin kappa chain variable region {clone b12} [human, bone marrow, Peptide Recombinant Partial, 107 aa]",Homo sapiens,"Barbas,C.F. III; Collet,T.A.; Amberg,W.; Roben,P.; Binley,J.M.; Hoekstra,D.; Cababa,D.; Jones,T.M.; Williamson,R.A.; Pilkington,G.R.; et al.",Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries,24-JUN-1993,8_8_20_7_3_9,AAB26315_AAB26306,Unique word,gp120; HIV,2,1,0.35501418,3.1852095
AAB26318_AAB26309,LEQSGGGVVKPGGSLRLSCEGSGFTFPNAWMTWVRQSPGKGLEWVASIKSKFDGGSPHYAAPVEGRFTISRNDLEDKVFLQMNGLKAEDTGVYYCATRYPRYSEMMGGVRKHFYMDVWGKGTTVSVSS,ELTQSPGTLSLSPGERATLSCRASQRVNSNYLAWYQQKPGQTPRVVIYSTSRRATGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDAQYTFGQGTKLEIK,AAB26318,AAB26309,"anti-HIV-1 gp120 immunoglobulin G heavy chain variable region {clone b11} [human, bone marrow, Peptide Recombinant Partial, 128 aa]","anti-HIV-1 gp120 immunoglobulin kappa chain variable region {clone b11} [human, bone marrow, Peptide Recombinant Partial, 108 aa]",Homo sapiens,"Barbas,C.F. III; Collet,T.A.; Amberg,W.; Roben,P.; Binley,J.M.; Hoekstra,D.; Cababa,D.; Jones,T.M.; Williamson,R.A.; Pilkington,G.R.; et al.",Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries,24-JUN-1993,8_10_22_7_3_9,AAB26318_AAB26309,Unique word,gp120; HIV,2,1,12.973901,8.550191
1ZVO_D_A,LQLQESGPGLVKPSETLSLTCIVSGGPIRRTGYYWGWIRQPPGKGLEWIGGVYYTGSIYYNPSLRGRVTISVDTSRNQFSLNLRSMSAADTAMYYCARGNPPPYYDIGTGSDDGIDVWGQGTTVHVSS,QSVLTQPPSASGTPGQRVTISCFGSSSNIGRYYVYWYQQLPGTTPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLWVFGGGTTLTVL,1ZVO_D,1ZVO_A,Semi-Extended Solution Structure Of Human Myeloma Immunoglobulin D Determined By Constrained X-Ray Scattering,Semi-Extended Solution Structure Of Human Myeloma Immunoglobulin D Determined By Constrained X-Ray Scattering,Homo sapiens,"Sun,Z.;Almogren,A.;Furtado,P.B.;Chowdhury,B.;Kerr,M.A.;Perkins,S.J.",Semi-extended solution structure of human myeloma immunoglobulin D determined by constrained X-ray scattering,02-JUN-2005,10_7_21_8_3_9,1ZVO_D_A,Xtal structure,SH3YL1; DKFZP586F1318; Ray,2,1,16.466179,-8.144669
5K59_E_F,LQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK,5K59_E,5K59_F,Crystal Structure Of Lukgh From Staphylococcus Aureus In Complex With A Neutralising Antibody,Crystal Structure Of Lukgh From Staphylococcus Aureus In Complex With A Neutralising Antibody,Homo sapiens,"Badarau,A.;Rouha,H.;Malafa,S.;Battles,M.B.;Walker,L.;Nielson,N.;Dolezilkova,I.;Teubenbacher,A.;Banerjee,S.;Maierhofer,B.;Weber,S.;Stulik,L.;Logan,D.T.;Welin,M.;Mirkina,I.;Pleban,C.;Zauner,G.;Gross,K.;Jagerhofer,M.;Magyarics,Z.;Nagy,E.",Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies,23-MAY-2016,10_7_11_6_3_9,5K59_E_F,Xtal structure,,2,1,16.421085,-8.17869
7EAJ_F_L,LQQSGAELARPWASVKISCQAFYTFNSYGMQWVKQRPGQGLEWIGTIYPGNGQTSYNQRFKGKATLTADKSPSTAYMQLISLTSEDSAGCFCAVVPTVDFDYWGQGTLVTVS,DIVMSQSPSSLAVSVWEKVTMSCKSSQSLLYSNTQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,7EAJ_F,7EAJ_L,Echovirus3 Empty Expanded Particle In Complex With 5G3 Fab,Echovirus3 Empty Expanded Particle In Complex With 5G3 Fab,Mus musculus,"Feng,R.;Wang,L.;Shi,D.;Zheng,B.;Zhang,L.;Hou,H.;Xia,D.;Cui,L.;Wang,X.;Xu,S.;Wang,K.;Zhu,L.",Structural basis for neutralization of an anicteric hepatitis associated echovirus by a potent neutralizing antibody,07-MAR-2021,8_8_10_12_3_9,7EAJ_F_L,Xtal structure,,2,1,0.37769058,-3.9904716
QEP20207_QEP20855,LVELQQWGAGLLKPSETLSLACAVYNGSFSGYYWTWMRQPPGKGLEWIGEVNHSGSSNYNPSLRSRVTISRDTSKNQFSLKLNSVTAADTAVYYCARAVRINMPVVVRYYYLDVWGHGNKVTVSS,QSMLTQPPSVSGTPGQRVTISCSGSSSNIGMNYVYWYQQFPGTAPKLLIYRDNQRPSGVSDRFSGSKSGTSASLAISGLRSEDEGDYYCATWDDSLSGPVFGGGTQLTVL,QEP20207,QEP20855,"IGH + IGL c314_heavy_IGHV4-34_IGHD2-15_IGHJ6, partial [Homo sapiens]","IGH + IGL c314_light_IGLV1-47_IGLJ7, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_19_8_3_11,QEP20207_QEP20855,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.729227,-10.556393
7T4S_H_I,LVELVESGGGVVQPGRSLRLSCAASGFTFSSDGMHWVRQSPGRGLEWVAFISSDGSTPYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCAKDWALFRWLRTFDHWGQGTLVTVSS,ETVMTQSPATLSVSPGGRATLSCRASQSVGINLAWYQQKPGQAPRLLIYGASTRASGFPARFSGSGSGTEFTLTITSLQSEDFAVYYCQQYNDWPPWTFGQGTKVEIK,7T4S_H,7T4S_I,Cryoem Structure Of The Hcmv Pentamer Gh/Gl/Ul128/Ul130/Ul131A In Complex With Nrp2 And Neutralizing Fabs 8I21 And 13H11,Cryoem Structure Of The Hcmv Pentamer Gh/Gl/Ul128/Ul130/Ul131A In Complex With Nrp2 And Neutralizing Fabs 8I21 And 13H11,Homo sapiens,"Kschonsak,M.;Johnson,M.C.;Schelling,R.;Green,E.M.;Rouge,L.;Ho,H.;Patel,N.;Kilic,C.;Kraft,E.;Arthur,C.P.;Rohou,A.L.;Comps-Agrar,L.;Martinez-Martin,N.;Perez,L.;Payandeh,J.;Ciferri,C.",Structural basis for HCMV Pentamer receptor recognition and antibody neutralization,10-DEC-2021,8_8_15_6_3_10,7T4S_H_I,Xtal structure,HCMV,2,1,14.802094,13.5319805
UYI35981_UYI36318,LVESGGGLVQPGGSLRLLCVASGFQLEDFAMHWVRQSPVRGLEWVSGLGWTGNDPYYADSVKGRFSIFRDNAKNSLYLQMGSLRPEDSAFYYCVKAQTLTPLDDALDFWGQGVRVTVSS,SYELTQPPSVSVSPGQTARITCSGDAVTTKFVSWFQQKAGHSPVLILYEDNKRPSGIPERFSGSSRGTVATLTLSGAQVEDEGDYYCYSKDFTDNERVFGGGTRLTVL,UYI35981,UYI36318,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,8_8_15_6_3_11,UYI35981_UYI36318,Unique source,COVID,2,1,13.104034,11.943741
7MZK_H_L,LVQLVQSGAEVKKPGASVKISCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGGTSYAQKFQGRVTMTRDTSTSTVYMELTSLRSDDTAVYYCAKDRVTIFWGNGMDVWGQGTTVTVSS,DIVMTQSPVSLAVSLGERATIKCKSSQSVLYSSNNKNYLGWYQQKPGQPLRLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYSTTPLTFGGGTKVEIK,7MZK_H,7MZK_L,Sars-Cov-2 Receptor Binding Domain Bound To Fab Wcsl 129 And Fab Pdi 96,Sars-Cov-2 Receptor Binding Domain Bound To Fab Wcsl 129 And Fab Pdi 96,Homo sapiens,"Wheatley,A.K.;Pymm,P.;Esterbauer,R.;Dietrich,M.H.;Lee,W.S.;Drew,D.;Kelly,H.G.;Chan,L.J.;Mordant,F.L.;Black,K.A.;Adair,A.;Tan,H.X.;Juno,J.A.;Wragg,K.M.;Amarasena,T.;Lopez,E.;Selva,K.J.;Haycroft,E.R.;Cooney,J.P.;Venugopal,H.;Tan,L.L.;O Neill,M.T.;Allison,C.C.;Cromer,D.;Davenport,M.P.;Bowen,R.A.;Chung,A.W.;Pellegrini,M.;Liddament,M.T.;Glukhova,A.;Subbarao,K.;Kent,S.J.;Tham,W.H.",Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain,24-MAY-2021,8_8_15_12_3_9,7MZK_H_L,Xtal structure,SARS-CoV-2,2,1,1.67721,3.6698232
5UY3_A_B,LVQSGAEVKKPGSSVKVSCKASGNTFRKYDVHWVRQATGQGLEWVGWMSHEGDKTESAQRFKGRVSFTRDNSASTAYIELRGLTSDDTAIYYCTGGSKHRLRDYVLYDDYGLINQQEWNDYLEFLDVWGHGTAVTVSS,TVVTQSPLSLSVTPGEAASMSCTSTQSLRHSNGANYLAWYQHKPGQSPRLLIRLGSQRASGVPDRFSGSGSGTHFTLKISRVEADDAAIYYCMQGLNRPWTFGKGTKLEIK,5UY3_A,5UY3_B,"Crystal Structure Of Human Fab Pgt144, A Broadly Reactive And Potent Hiv-1 Neutralizing Antibody","Crystal Structure Of Human Fab Pgt144, A Broadly Reactive And Potent Hiv-1 Neutralizing Antibody",Homo sapiens,"Lee,J.H.;Andrabi,R.;Su,C.Y.;Yasmeen,A.;Julien,J.P.;Kong,L.;Wu,N.C.;McBride,R.;Sok,D.;Pauthner,M.;Cottrell,C.A.;Nieusma,T.;Blattner,C.;Paulson,J.C.;Klasse,P.J.;Wilson,I.A.;Burton,D.R.;Ward,A.B.","A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin Structure",23-FEB-2017,8_8_34_11_3_9,5UY3_A_B,Xtal structure,HIV,2,1,2.4510052,3.2085853
AEQ74132_AEQ74892,PGLLKPSETLSLTCTVSGDSITSGTYYWGWIRQPPGKGLEWIGQIYSYSGSTFYDTSLQSRVTISMDKSKNQFSLRLNSVTAADTAVYYCARQTDNWFDPWGQGTLVT,TLSVSPGERATLSCRASQSVSSDLAWYQQKPGQAPRLLIYGASFRATGVPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYKNWPPYTFGQGTKLEIK,AEQ74132,AEQ74892,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_8_10_6_3_10,AEQ74132_AEQ74892,Unique source,tetanus,2,1,16.282562,-8.53988
AEQ73700_AEQ74453,PGLVKASETLSLSCSVSDGSMSSNYWSWIRQSPGKGLEWLGYITYGGTTNYNPSLTSRLTISLDRAEKQFSLRLSAVTAADTAVYYCARVRINLYGALLLSWFDSWGQGTLVTVS,SLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTITGLQPEDFATYYCQQSDIIPWTFGQGTTVDIK,AEQ73700,AEQ74453,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_18_6_3_9,AEQ73700_AEQ74453,Unique source,tetanus,2,1,16.11485,-8.101455
AEQ74093_AEQ74853,PGLVKPSETLSLNCTISGGSIGNYYWSWIRQVPGKGLEWIGYVYLSGSTAYSPSLRSRVTISIDTFKKQFSLKLSSVTAADTAVYYCARGGRYSYGYASFFDYWGQGTLVT,SSLSAAGGDRVTITCRAGQTIKTHLNWYQQKPGKAPELLISASSSLQSGVPSRFSGSGSATDFTLTISSLQREDFATYFCQQSYSLPFTFGGGTKVEIK,AEQ74093,AEQ74853,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_16_6_3_9,AEQ74093_AEQ74853,Unique source,tetanus,2,1,16.204786,-8.645726
AEQ73576_AEQ74331,PGLVKPSETLSLTCAVSGASVSGGDYYWSWIRQPPGKALEWIGYIYYIGSTNYNPSLKSRLSLSVDTAKSQFSLKLSSVTAADTAIYFCARARRTYSGYDSAFDYWGQGTLVTVS,SSLSASVGDRVSITCRASRSVKTYLNWYQQKPGKAPKLLVYGSSSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFGTPYTFGQGTKLDIK,AEQ73576,AEQ74331,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_16_6_3_9,AEQ73576_AEQ74331,Unique source,tetanus,2,1,16.15964,-8.563207
AEQ74155_AEQ74915,PGLVKPSETLSLTCNVSGASMTGYYWAWIRQPPGKGLEWIAYVSFSGDANYNPSLKSRVTVAVDTSKNQVSLKLDSVTTSDTATYYCARPPSWRYHYFGSWGQGTLVT,TLSVSPGESVTLSCRASQSVRSNLAWYQQKPGQSPRLLIYDASTRATGIPARFSGSGSRRDFTLTISGLQSEDFGVYYCQQYDKWPPEPTFGGGTKVEIK,AEQ74155,AEQ74915,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_13_6_3_11,AEQ74155_AEQ74915,Unique source,tetanus,2,1,16.489372,-9.6519575
AEQ73950_AEQ74710,PGLVKPSETLSLTCTVSGDSISGYYWNWIRQPPGKGLEWVGYISYSGSTTYSPALKSRLTISADPSKNQISLKLSSVSAADTAVYYCARRHYCRSTSCYDAFDIWGQGTTVT,SSLSASVGDRVTITCRASQTISDYLNWYQQKPGKAPKLLIYAASGLESGVPSRFSGSGSGTDFTLTISGLQPEDFASYYCQQSFSTLYTFGQGTKLEMK,AEQ73950,AEQ74710,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_17_6_3_9,AEQ73950_AEQ74710,Unique source,tetanus,2,1,16.217655,-8.568474
AEQ74214_AEQ74974,PGLVKPSGTLSLTCTVSGGSISTSQWWSWVRQPPGNGLEWIGEIRLSGSTNYNPSLRSRITISVDNSKNQFSLQLTSVTAADTAVYYCARLPKHYIAEAVTWGQGTLVT,TLSVSAGDRVTITCRASQFISHWVAWYQQKPGKAPNLLIYKASSLKSGVPSRFSGSTSGTEFTLTITSLQPDDFATYYCQQYNSYPITFGQGTRLEIK,AEQ74214,AEQ74974,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,9_7_13_6_3_9,AEQ74214_AEQ74974,Unique source,tetanus,2,1,16.01194,-8.41599
AHX01229_AHX01241,QAILVESGGGVVQPGRSLRLSCAASQFTFSGHGLHWVRQAPGKGLEWVASISFAGTKMDYADSVKGRFAISRDNSKNTLYLQMNSLRVEDTALYYCAKDMREYECEYWTSDYYDFGRPQPCIDRRGVVGIFDMWGQGTMVTVST,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGDNYVSWYQHLPGTAPKLLIYENTRRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDVRPNRGAVFGTGTKVTVL,AHX01229,AHX01241,"anti-HIV-1 immunoglobulin CAP256-VRC26.10 heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin CAP256-VRC26.10 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Doria-Rose,N.A.; Schramm,C.A.; Gorman,J.; Moore,P.L.; Bhiman,J.N.; Dekosky,B.J.; Ernandes,M.J.; Georgiev,I.S.; Kim,H.J.; Pancera,M.; Staupe,R.P.; Altae-Tran,H.R.; Bailer,R.T.; Crooks,E.T.; Cupo,A.; Druz,A.; Garrett,N.J.; Hoi,K.H.; Kong,R.; Louder,M.K.; Longo,N.S.; McKee,K.; Nonyane,M.; O'Dell,S.; Roark,R.S.; Rudicell,R.S.; Schmidt,S.D.; Sheward,D.J.; Soto,C.; Wibmer,C.K.; Yang,Y.; Zhang,Z.; Mullikin,J.C.; Binley,J.M.; Sanders,R.W.; Wilson,I.A.; Moore,J.P.; Ward,A.B.; Georgiou,G.; Williamson,C.; Abdool Karim,S.S.; Morris,L.; Kwong,P.D.; Shapiro,L.; Mascola,J.R.",Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies,25-APR-2014,8_8_37_8_3_12,AHX01229_AHX01241,Unique word,HIV,2,1,14.989155,14.129192
2V7H_H_L,QAQLQQSGAELMKPGASVKISCKATGYTFSNYWIDWIKQRPGHGLEWIGEILPGSGSTNYNEKFRGKATFTADTSSNTAYMQLSSLTSEDSAVYYCTRRGYWAYDFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDINNYLNWYQQKPDGTVKILIYYTSNLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPRTFGGGTKLEIK,2V7H_H,2V7H_L,Crystal Structure Of An Immunogen Specific Anti-Mannopyranoside  Monoclonal Antibody Fab Fragment,Crystal Structure Of An Immunogen Specific Anti-Mannopyranoside  Monoclonal Antibody Fab Fragment,Mus musculus,"Krishnan,L.;Sahni,G.;Kaur,K.J.;Salunke,D.M.",Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry,30-JUL-2007,8_8_12_6_3_9,2V7H_H_L,Xtal structure,Mannopyranoside,2,1,5.010577,-1.8567522
5V6L_I_M,QEQLVESGGGLVKPGGTLTLTCTASGFSFSSGFFMCWVRQAPGKGLEWIGCIYGGSNDNTYYANWAKGRFTISKTSSTTVTLQMTSRTAADTATYFCARDAGTSGYIAYNLWGPGTLVTVSS,ALVMTQTPSSVSAAVGGTVTINCQASEDIQRNLAWYQQKPGQRPKFLIYGVSNLESGVPSRFKGSGSGTEYTLTISDLECDDAATYYCQSALYTSATDICAFGGGTEVVVK,5V6L_I,5V6L_M,Crystal Structure Of Rabbit Anti-Hiv-1 Gp120 V3 Fab 10A37 In Complex With V3 Peptide Jr-Fl,Crystal Structure Of Rabbit Anti-Hiv-1 Gp120 V3 Fab 10A37 In Complex With V3 Peptide Jr-Fl,Human immunodeficiency virus 1,"Pan,R.;Qin,Y.;Banasik,M.;Lees,W.;Shepherd,A.J.;Cho,M.W.;Kong,X.P.",Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120,17-MAR-2017,9_9_14_6_3_13,5V6L_I_M,Xtal structure,gp120; HIV,2,1,-0.39683947,18.411076
7C88_A_B,QGQLQESGPSLVKPSQTLSLTCTVSGDSITRGYWNWIRKHPGKGLEYIGYISYTGSTYSNLSLKSRVTISRDTSKNQYYLKLSSVTAADTAVYYCATSTGWLDPVDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASQNVDTSVAWFQQKPGQPPKALIYSASFRYSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQYYGYPFTFGQGTKLEIK,7C88_A,7C88_B,Complex Structure Of Js003 And Pd-L1,Complex Structure Of Js003 And Pd-L1,Homo sapiens,"Liu,H.;Bi,X.;Zhou,Y.;Shi,R.;Yao,S.;Qi,J.;Feng,H.;Feng,M.;Yan,J.;Tan,S.",Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy,29-MAY-2020,8_7_12_6_3_9,WFK27721_WFK27720,Xtal structure,CD274; B7-H; B7H1; B7-H1; PDCD1LG1; PDL1; PD-L1,2,1,16.379673,-7.7740817
AIO10972_AIO10980,QGQLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLKFDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,AIO10972,AIO10980,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Huang,J.; Kang,B.H.; Pancera,M.; Lee,J.H.; Tong,T.; Feng,Y.; Georgiev,I.S.; Chuang,G.Y.; Druz,A.; Doria-Rose,N.A.; Laub,L.; Sliepen,K.; van Gils,M.J.; de la Pena,A.T.; Derking,R.; Klasse,P.J.; Migueles,S.A.; Bailer,R.T.; Alam,M.; Pugach,P.; Haynes,B.F.; Wyatt,R.T.; Sanders,R.W.; Binley,J.M.; Ward,A.B.; Mascola,J.R.; Kwong,P.D.; Connors,M.",Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface,23-SEP-2014,8_8_16_9_3_10,AIO10972_AIO10980,Unique source,gp120; HIV,2,1,2.2226448,5.2254543
6MUF_D_E,QGQLVQSGATTTKPGSSVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLTSDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,6MUF_D,6MUF_E,Crystal Structure Of Hiv-1 B41 Sosip.664 Prefusion Env Trimer In Complex With Human Antibodies 3H109L And 35O22 At 3.4 Angstrom,Crystal Structure Of Hiv-1 B41 Sosip.664 Prefusion Env Trimer In Complex With Human Antibodies 3H109L And 35O22 At 3.4 Angstrom,Homo sapiens,"Lai,Y.T.;Wang,T.;O'Dell,S.;Louder,M.K.;Schon,A.;Cheung,C.S.;Chuang,G.Y.;Druz,A.;Lin,B.;McKee,K.;Peng,D.;Yang,Y.;Zhang,B.;Herschhorn,A.;Sodroski,J.;Bailer,R.T.;Doria-Rose,N.A.;Mascola,J.R.;Langley,D.R.;Kwong,P.D.",Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry,23-OCT-2018,8_8_16_9_3_10,6MUF_D_E,Xtal structure,HIV,2,1,2.1733735,5.2246733
3LD8_C_B,QIQLQESGPGLVTPSQSLTLTCSVTGDSITSYHWSWIRQFPGKKLEWMGYIYNSGGTDYNPSLKSRVSITREISRNQLFLQLNSVTTEDTATYYCARRDYGTYYFDYWGQGTMVTVSS,DIVMTQSPSSLAVSAGEKVTMSCRSSQSLYYSGIKKNLLAWYQLKPGQSPKLLIYYASTLFTGVPDRFTGSGSGTDYTLTITSVQAEDMGQYFCQQGISNPYTFGAGTKLEIK,3LD8_C,3LD8_B,Structure Of Jmjd6 And Fab Fragments,Structure Of Jmjd6 And Fab Fragments,Cricetulus migratorius,"Hong,X.;Zang,J.;White,J.;Wang,C.;Pan,C.H.;Zhao,R.;Murphy,R.C.;Dai,S.;Henson,P.;Kappler,J.W.;Hagman,J.;Zhang,G.",Interaction of JMJD6 with single-stranded RNA,12-JAN-2010,8_7_12_12_3_9,3LD8_C_B,Xtal structure,JMJD6; KIAA0585; PTDSR; PTDSR1,2,1,11.464859,-12.904144
6LZ4_A_B,QIQLQQSGTVLVKPASSVKISCKASGYSFTSHYMHWIRQQPGQGLEWIGWISPEQGNTKYNQKFDGKATLTADKSSSIAYMQLSSLTSEDSAVYFCVSWEDWSAYWGQGTLVTVCS,DIVLTQSPALTVSLGQRATISCKTNQNVDYYGNSYVHWYQQKPGQKPKLLIYLASNLASGIPARFSGRGSGTDFTLTIDPVEAADTATYYCQQSRDLPNTFGAGTKLELK,6LZ4_A,6LZ4_B,Crystal Structure Of Pmab-1 Fv-Clasp Fragment With Its Antigen Peptide,Crystal Structure Of Pmab-1 Fv-Clasp Fragment With Its Antigen Peptide,Mus musculus,"Wakasa,A.;Kaneko,M.K.;Kato,Y.;Takagi,J.;Arimori,T.",Site-specific epitope insertion into recombinant proteins using the MAP tag system,20-MAY-2020,8_8_9_10_3_9,6LZ4_A_B,Xtal structure,,2,1,0.09690133,-4.351026
ALJ79284,QIQLVQSGAEVAKPGASVKVSCKASGYTFTRYTMHWVRQRPGQGLEWIGYINPSRGYTNYNQKFKDRATLTTDKSTSTAYMELSSLTSEDTAVYYCARYYDDHYCLDYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASSSVSYMNWYQQKSGTAPKRWIYDTSKVASGVPYRFSGSGSGTSYTLTISSLQPEDAATYYCQQWSSNPLTFGGGTKVEIK,ALJ79284_H,ALJ79284_L,immunoglobulin light chain VRC01L/anti-human CD3 scFv fusion protein [synthetic construct],immunoglobulin light chain VRC01L/anti-human CD3 scFv fusion protein [synthetic construct],synthetic construct,"Pegu,A.; Asokan,M.; Wu,L.; Wang,K.; Hataye,J.; Casazza,J.P.; Guo,X.; Shi,W.; Georgiev,I.; Zhou,T.; Chen,X.; O'Dell,S.; Todd,J.P.; Kwong,P.D.; Rao,S.S.; Yang,Z.Y.; Koup,R.A.; Mascola,J.R.; Nabel,G.J.",Activation and lysis of human CD4 cells latently infected with HIV-1,19-OCT-2015,8_8_12_5_3_9,ALJ79284,Same entry,HIV; CD3; CD4,2,1,0.19299047,-3.2009687
6HXW_C_D,QIQLVQSGAEVKKPGASVKVSCKASGYTFASYNMYWVRQAPGQRLEWIGYIDPYNGGSSYNQKFKGRVTLTRDKSASTAYMELSSLRSEDTAVYYCARGYNNYKAWFAYWGQGTLVTVSS,IQMTQSPSSLSASVGDRVTITCKASQSVTNDVAWYQQKPGKAPKLLIYYASNRYTGVPSRFSGSGYGTDFTFTISSLQPEDIATYYCQQDYSSLTFGQGTKLEIK,6HXW_C,6HXW_D,Structure Of Human Cd73 In Complex With Antibody Iph53,Structure Of Human Cd73 In Complex With Antibody Iph53,synthetic construct,"Perrot,I.;Michaud,H.A.;Giraudon-Paoli,M.;Augier,S.;Docquier,A.;Gros,L.;Courtois,R.;Dejou,C.;Jecko,D.;Becquart,O.;Rispaud-Blanc,H.;Gauthier,L.;Rossi,B.;Chanteux,S.;Gourdin,N.;Amigues,B.;Roussel,A.;Bensussan,A.;Eliaou,J.F.;Bastid,J.;Romagne,F.;Morel,Y.;Narni-Mancinelli,E.;Vivier,E.;Paturel,C.;Bonnefoy,N.",Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies,18-OCT-2018,8_8_13_6_3_8,6HXW_C_D,Xtal structure,eNT; ATPDase; ENTPD1; NT5E; CALJA; CD73; CD39; eN; SPG64; NTPDase-1; NT5,2,1,0.90538925,3.600319
6UMX_H_L,QIQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSRKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLYWSHYYGMDVWGQGTTVTVSS,QPVLTQPPSASGTPGQRVTISCSGSSSNIGSNPVHWYQQLPGTAPKLLIYDDNQRPSGVPDRFSGSKSGTSASLVISGLQSDDEADYYCAAWDDSLNSVFGGGTKLTVL,6UMX_H,6UMX_L,Structural Basis For Specific Inhibition Of Extracellular Activation Of Pro/Latent Myostatin By Srk-015,Structural Basis For Specific Inhibition Of Extracellular Activation Of Pro/Latent Myostatin By Srk-015,Homo sapiens,"Dagbay,K.B.;Treece,E.;Streich,F.C.;Jackson,J.W.;Faucette,R.R.;Nikiforov,A.;Lin,S.C.;Boston,C.J.;Nicholls,S.B.;Capili,A.D.;Carven,G.J.",Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015,10-OCT-2019,8_8_19_8_3_10,6UMX_H_L,Xtal structure,myostatin; ZAP-70; SRK; STD; ZAP70,2,1,14.1273985,14.032859
7LFB_H_L,QIQLVQSGPDLKKPGETVKISCRTSGYAFTNYGVNWVKQAPGKGLKWMGWINTNTGQTTYAEEFRGRFAISLETSASTAFLTISNLKNEDSATYFCARLIYDGDYISSDFWGQGTTLTVSS,DIQMTQSPDSLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSRSGRQYSLKISSLHPDDVATYYCQNALSMPYTFGGGTNLETK,7LFB_H,7LFB_L,Fab 7D6 Bound To Apol1 Ntd,Fab 7D6 Bound To Apol1 Ntd,Homo sapiens,"Ultsch,M.;Holliday,M.J.;Gerhardy,S.;Moran,P.;Scales,S.J.;Gupta,N.;Oltrabella,F.;Chiu,C.;Fairbrother,W.;Eigenbrot,C.;Kirchhofer,D.",Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif,16-JAN-2021,8_8_14_6_3_9,7LFB_H_L,Xtal structure,,2,1,-7.532986,6.158114
8IV5_A_B,QIQLVQSGPELKKPGETVKISCKASGYTFTDYGLNWVKQAPGKGLKWMGWINTYSGEPTYNDEFRGRFAFSLETSTITAYLKINNLKNEDTATYFCARGGNWDWYFDVWGAGTTVTVSS,DIVLTQSPATLSVTPGDNVSLSCRASQIISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNTWPLTCGSGTKLELN,8IV5_A,8IV5_B,Cryo-Em Structure Of Sars-Cov-2 Spike Protein In Complex With Double Nabs 8H12 And 1C4 (Local Refinement),Cryo-Em Structure Of Sars-Cov-2 Spike Protein In Complex With Double Nabs 8H12 And 1C4 (Local Refinement),Mus musculus,"Sun,H.;Deng,T.;Zhang,Y.;Lin,Y.;Jiang,Y.;Jiang,Y.;Huang,Y.;Song,S.;Cui,L.;Li,T.;Xiong,H.;Lan,M.;Liu,L.;Li,Y.;Fang,Q.;Yu,K.;Jiang,W.;Zhou,L.;Que,Y.;Zhang,T.;Yuan,Q.;Cheng,T.;Zhang,Z.;Yu,H.;Zhang,J.;Luo,W.;Li,S.;Zheng,Q.;Gu,Y.;Xia,N.","Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD",16-AUG-2023,8_8_12_6_3_9,8IV5_A_B,Xtal structure,SARS-CoV-2; RBD,2,1,-7.512573,6.1182528
5YE4_A_B,QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGKGLKWMGWINTETGEPTYADDFKGRFAFSLETSATTAYLQINNLKNEDTATYFCGRDYWGQGTTLTVSS,DIQMTQSPSSLSASLGDKVTITCRASQDINNYIAWFQHKPGKGPRLLIYYTSTLQPGIPSRFSGSGSGRDYSFSIRNLEPEDIATYYCLQYDNLRTFGGGTKLEIK,5YE4_A,5YE4_B,Crystal Structure Of The Complex Of Di-Acetylated Histone H4 And 1A9D7 Fab Fragment,Crystal Structure Of The Complex Of Di-Acetylated Histone H4 And 1A9D7 Fab Fragment,Homo sapiens,"Handoko,L.;Kaczkowski,B.;Hon,C.C.;Lizio,M.;Wakamori,M.;Matsuda,T.;Ito,T.;Jeyamohan,P.;Sato,Y.;Sakamoto,K.;Yokoyama,S.;Kimura,H.;Minoda,A.;Umehara,T.",JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states,15-SEP-2017,8_8_4_6_3_8,5YE4_A_B,Xtal structure,D6S113E; BRD2-IT1; RING3; FSRG1; NAT; KIAA9001; BRD2,2,1,-7.523827,6.1694975
1FJ1_B_A,QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMYWVKQAPGKGLKRMGWINTETGEPTYADDFKGRFALSLDTSASTAYLHISNLKNEDTATYFCARGLDSWGQGTSVTVSS,DIQMTQSPSSLSATLGGKVTITCKASQDINKYIAWYQHKPGKGPRLLIHYTSTLQPGNPSRFSGSGSGRDYSFSISNLEAEDIAIYYCLQYDNLQRTFGGGTKVEIK,1FJ1_B,1FJ1_A,Lyme Disease Antigen Ospa In Complex With Neutralizing Antibody Fab La-2,Lyme Disease Antigen Ospa In Complex With Neutralizing Antibody Fab La-2,Borreliella burgdorferi B31,"Ding,W.;Huang,X.;Yang,X.;Dunn,J.J.;Luft,B.J.;Koide,S.;Lawson,C.L.",Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA,07-AUG-2000,8_8_6_6_3_9,1FJ1_B_A,Xtal structure,,2,1,-7.5178237,6.1704397
QDM58848_QDM58849,QIQLVQSGPELKKPGETVKISCKASGYTFTNYEINWVQQAPGKGLKLMGWINTYTGEPTSADDFKGRFAFSLETSASTAYLQINNLKNEDAATYFCARGDYYGSSSAWLPYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVRTAVAWYQQKPGQSPKALIFLASNRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCLQHWNYPLTFGGGTKLEIK,QDM58848,QDM58849,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Mcguire,A.",Anti-idiotypic antibodies elicit anti-HIV-1-specific b cell responses,23-JUL-2019,8_8_15_6_3_9,QDM58848_QDM58849,Unique source,HIV,2,1,-7.5380263,6.124943
1NCB_H_L,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLEWMGWINTNTGEPTYGEEFKGRFAFSLETSASTANLQINNLKNEDKATFFCARGEDNFGSLSDYWGQGTTLTVSS,DIVMTQSPKFMSTSVGDRVTITCKASQDVSTAVVWYQQKPGQSPKLLIYWASTRHIGVPDRFAGSGSGTDYTLTISSVQAEDLALYYCQQHYSPPWTFGGGTKLEIK,1NCB_H,1NCB_L,Crystal Structures Of Two Mutant Neuraminidase-Antibody Complexes With Amino Acid Substitutions In The Interface,Crystal Structures Of Two Mutant Neuraminidase-Antibody Complexes With Amino Acid Substitutions In The Interface,Mus musculus,"Colman,P.M.;Laver,W.G.;Varghese,J.N.;Baker,A.T.;Tulloch,P.A.;Air,G.M.;Webster,R.G.",Three-dimensional structure of a complex of antibody with influenza virus neuraminidase,21-JAN-1992,8_8_13_6_3_9,1NCB_H_L,Xtal structure,neuraminidase,2,1,-7.522545,6.186367
CDM22135_CDM22136,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTNTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARGGYGDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPRTFGGGTKLEIK,CDM22135,CDM22136,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"ENDO,K.; KUHURA,M.; YAGI,K.; NAKAMURA,Y.; KATAGIRI,T.; NAKATSURU,S.",Tumor-targeting monoclonal antibodies to FZD10 and uses thereof,03-FEB-2014,8_8_8_10_3_9,CDM22135_CDM22136,Ordered entries,FZD10; CD350,2,1,-7.551034,6.160024
1NCA_H_L,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTNTGEPTYGEEFKGRFAFSLETSASTANLQINNLKNEDTATFFCARGEDNFGSLSDYWGQGTTVTVSS,DIVMTQSPKFMSTSVGDRVTITCKASQDVSTAVVWYQQKPGQSPKLLIYWASTRHIGVPDRFAGSGSGTDYTLTISSVQAEDLALYYCQQHYSPPWTFGGGTKLEIK,1NCA_H,1NCA_L,Refined Crystal Structure Of The Influenza Virus N9 Neuraminidase-Nc41 Fab Complex,Refined Crystal Structure Of The Influenza Virus N9 Neuraminidase-Nc41 Fab Complex,Mus musculus,"Colman,P.M.;Laver,W.G.;Varghese,J.N.;Baker,A.T.;Tulloch,P.A.;Air,G.M.;Webster,R.G.",Three-dimensional structure of a complex of antibody with influenza virus neuraminidase,21-JAN-1992,8_8_13_6_3_9,AAW13176_AAW13146,Xtal structure,neuraminidase; Influenza,2,1,-7.5025845,6.162804
S32187_S32191,QIQLVQSGPELKKPGETVKISCKASGYTFTTSGMSWVKQSLGKGLKWMGWINTYSGVPTYADDFKGRFAFSLETSASIVYLQINNLKNEDTATYFCASWRNYGFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQPEDLAVYYCQQHYSTPYTFGGGTKLEIK,S32187,S32191,Ig heavy chain V region - mouse (fragment),Ig kappa chain V region - mouse (fragment),Mus musculus,"Izui,S.",Direct Submission,21-JAN-2000,8_8_10_6_3_9,S32187_S32191,Ordered entries,,2,1,-7.544226,6.125047
S32190_S32192,QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWMKQAPGKGLKWMGWINTYSGVPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWITTAFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIK,S32190,S32192,Ig heavy chain V region - mouse (fragment),Ig kappa chain V region - mouse (fragment),Mus musculus,"Izui,S.",Direct Submission,21-JAN-2000,8_8_10_6_3_9,S32190_S32192,Ordered entries,,2,1,-7.6223927,6.220551
3S96_C_D,QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWVKQAPGKGFEWMGWINTYSGVPTYVDDFKGRFAFSLETSASTAYLQINNLKNEDTAVYFCARGGDNYLWFAYWGQGTLVTVS,QLVLTQSSSASFSLGASAKLTCTLNSQHSTYTIEWYQQQPLKPPKYVMELKKDGSHSTGDGIPDRFSGSSSGADRYLSISNIQPEDEAIYICGVGDTIKEQFVYVFGGGTKVTVL,3S96_C,3S96_D,Crystal Structure Of 3B5H10,Crystal Structure Of 3B5H10,Mus musculus,"Peters-Libeu,C.;Miller,J.;Rutenber,E.;Newhouse,Y.;Krishnan,P.;Cheung,K.;Hatters,D.;Brooks,E.;Widjaja,K.;Tran,T.;Mitra,S.;Arrasate,M.;Mosquera,L.A.;Taylor,D.;Weisgraber,K.H.;Finkbeiner,S.",Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure,31-MAY-2011,8_8_12_7_7_13,3S96_C_D,Xtal structure,,2,1,-7.5715656,6.1612496
7SYZ_H_L,QIQLVQSGPELKKPGETVKISCTTSGYTFTNYGLNWVKQAPGKGFKWMAWINTYTGEPTYADDFKGRFAFSLETSASTTYLQINNLKNEDMSTYFCARSGYYDGLKAMDYWGQGTSVTVSS,DVLMIQTPLSLPVSLGDQASISCRSSQSLIHINGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGAGTKLELK,7SYZ_H,7SYZ_L,Hendra Virus G Protein Head Domain In Complex With Cross-Neutralizing Murine Antibody Hah1.3,Hendra Virus G Protein Head Domain In Complex With Cross-Neutralizing Murine Antibody Hah1.3,Mus musculus,"Wang,Z.;Dang,H.V.;Amaya,M.;Xu,Y.;Yin,R.;Yan,L.;Hickey,A.C.;Annand,E.J.;Horsburgh,B.A.;Reid,P.A.;Smith,I.;Eden,J.S.;Xu,K.;Broder,C.C.;Veesler,D.",Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant,25-NOV-2021,8_8_14_11_3_9,7SYZ_H_L,Xtal structure,Hendra,2,1,-7.508274,6.1201997
1JGL_H_L,QIQLVQSGPELKKPGETVRISCKASDYSFMTSGMQWVQQMPGKGLKWIGWLNTQSGVPEYAEDFKGRFAFSLETSATTAYLQINNLKNEDTATYFCATWGGNSAYWGQGTTLTVSS,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGTYYCHHFWSTPWTFGGGTKLEVK,1JGL_H,1JGL_L,Crystal Structure Of Immunoglobulin Fab Fragment Complexed With 17-Beta-Estradiol,Crystal Structure Of Immunoglobulin Fab Fragment Complexed With 17-Beta-Estradiol,Mus musculus,"Lamminmaki,U.;Kankare,J.",Crystallization and preliminary X-ray analysis of a recombinant Fab fragment in complex with 17beta-oestradiol,26-JUN-2001,8_8_9_6_3_9,1JGL_H_L,Xtal structure,,2,1,-7.7184157,6.296454
4RGM_H_L,QIQLVQSGPELKKPGETVRISCKASGYIFTIAGIQWVQKMPGRGLRWIGWINTHSGVPEYAEEFKGRFAFSLETSARTAYLQISNLKDEDTATYFCARIYYGNNGGVMDYWGQGTSVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISDYLTWLQQKPDGTIKRLIYVASSLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYANYPWTFGGGTKLEIR,4RGM_H,4RGM_L,Structure Of Staphylococcal Enterotoxin B Bound To The Neutralizing Antibody 20B1,Structure Of Staphylococcal Enterotoxin B Bound To The Neutralizing Antibody 20B1,Mus musculus,"Varshney,A.K.;Wang,X.;Cook,E.;Dutta,K.;Scharff,M.D.;Goger,M.J.;Fries,B.C.","Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock",30-SEP-2014,8_8_14_6_3_9,4RGM_H_L,Xtal structure,,2,1,-7.719811,6.288751
3UBX_H_L,QIQLVQSGPELKKPGETVRISCKASGYSFTNYGMHWVKQAPGKGLKWVGWINTYTGEPTYADDFKGRFAFSLETSASTAYLEINNLKNEDMATYLCASAAGIRWAWFAWWGQGTLVTVS,DIQMTQSSSSFSVSLGDRATITCKASEDIYNRIAWYQQKPGNVPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDVATYYCQHYWSSPLTFGAGTKLELK,3UBX_H,3UBX_L,Crystal Structure Of The Mouse Cd1D-C20:2-Agalcer-L363 Mab Fab Complex,Crystal Structure Of The Mouse Cd1D-C20:2-Agalcer-L363 Mab Fab Complex,Mus musculus,"Yu,E.D.;Girardi,E.;Wang,J.;Mac,T.T.;Yu,K.O.;Van Calenbergh,S.;Porcelli,S.A.;Zajonc,D.M.",Structural basis for the recognition of C20:2-alphaGalCer by the invariant natural killer T cell receptor-like antibody L363,25-OCT-2011,8_8_13_6_3_9,3UBX_H_L,Xtal structure,,2,1,-7.5860934,6.175135
7KGV_C_E,QIQLVQSGPKLSKPGATDKISCAAGGYSFTDYVMNWVKASPLKGLEWNGSINTSNGATTYISAFKGAGSHSVDSSASTAAQQLSALKAADTAVYFCARNFRGNGAMDYWGQGTSVTVSS,DILLTQSPESLSVVVGFYVTITSQASNNITTYSSFIFWYQQKPGQAPKLLIYDSSTLESGIPGRFSGSGSGRDFSLTIAPNQPACGATYEDLQVLIVVRTFGGGTKLEIK,7KGV_C,7KGV_E,Crystal Structure Of Sodium-Coupled Neutral Amino Acid Transporter Slc38A9 In The N-Terminal Plugged Form,Crystal Structure Of Sodium-Coupled Neutral Amino Acid Transporter Slc38A9 In The N-Terminal Plugged Form,Mus musculus,"Lei,H.T.;Mu,X.;Hattne,J.;Gonen,T.",A conformational change in the N terminus of SLC38A9 signals mTORC1 activation,19-OCT-2020,8_8_12_9_3_9,7KGV_C_E,Xtal structure,SLC38A9; FLJ90709,2,1,-7.4389315,6.1820836
6C08_D_E,QIQLVQSGPKLSKPGGTDKISSKASGYSFTDYVMNWVKAGPGKGLEWNGSINTSNGYTTYISAFKGRGSFSVDSSASTAAQQLSVLKAAATAVYFNARNFRGNGAMDYWGQGTSVTVSS,DILMTQSPSSLSVVVGFYVTITSQASNNITTYSSFIFWYQQKPGQAPKLLIYDSSTLESGIPGRFSGSGSGRDFSLTIGPNQPADGATYEDLQYNGEVRTFGGGTKLEIK,6C08_D,6C08_E,Zebrafish Slc38A9 With Arginine Bound In The Cytosol Open State,Zebrafish Slc38A9 With Arginine Bound In The Cytosol Open State,Danio rerio,"Lei,H.T.;Ma,J.;Sanchez Martinez,S.;Gonen,T.",Crystal structure of arginine-bound lysosomal transporter SLC38A9 in the cytosol-open state,28-DEC-2017,8_8_12_9_3_9,6C08_D_E,Xtal structure,SLC38A9; FLJ90709,2,1,-7.451936,6.1838455
QKY76557_QKY76170,QITFKESGPTLVKPTETLTLTCTFSGFSVSTSGEGVGWIRQPPGKALEWLAVIYWDDDKRYSPSLKSRLTITRDTSKNQVVLTMTNMDPVDTATYYCAHRLWFRDAFDIWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRARQSISNYLNWYQQKPGKAPKLLIYAASSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSTFWTFGQGTNVEIK,QKY76557,QKY76170,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,10_7_12_6_3_9,QKY76557_QKY76170,Unique source,SARS-CoV-2,2,1,12.415392,0.3592405
2VQ1_B_A,QITLEESGPGILQPSQTLSLTCSFSGFSLSSSAMSVGWIRQPSGKGLEWLAHIWWNDDKYYNPALKSRLTVSKDSSDNQVFLKIASVVTADTATYYCARIPGFGFDYWGQGTTLTVSS,DVVMTQTPLSLSVSLGDQASISCRSSQSLVHSNGNTFLQWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRMEAEDLGIYFCSQTTHVPWTFGGGTKLEIK,2VQ1_B,2VQ1_A,Anti Trimeric Lewis X Fab54-5C10-A,Anti Trimeric Lewis X Fab54-5C10-A,Mus musculus,"de Geus,D.C.;van Roon,A.M.;Thomassen,E.A.;Hokke,C.H.;Deelder,A.M.;Abrahams,J.P.",Characterization of a diagnostic Fab fragment binding trimeric Lewis X,10-MAR-2008,10_7_10_11_3_9,2VQ1_B_A,Xtal structure,Lewis,2,1,11.497773,1.9119722
7KHF_A_L,QITLKESGPTLVERTQTLTLTCTFSGFSLTTDGLGVGWIRQPPGKALEWLALIYYDDVRRYRPSLKSRLTITKDTSKNRVVLTVTDMDPVDAGTYFCVHASLFNLGSRNVYFRYWGQGTLVSVSS,SYDLTQPPSVSVSPGQTARITCSGDSLARQFASWYQQKPGQSPVLLIYKNIERLSAIPERFSGSTSGTSVTLTISGVQAEDEADYFCQSADDSGSYSLFGTGTRVSVL,7KHF_A,7KHF_L,Cryoem Structure Of Lilrb1 D3D4 Domain-Inserted Antibody Mdb1 Fab In Complex With Plasmodium Rifin (Pf3D7_1373400) V2 Domain,Cryoem Structure Of Lilrb1 D3D4 Domain-Inserted Antibody Mdb1 Fab In Complex With Plasmodium Rifin (Pf3D7_1373400) V2 Domain,Plasmodium falciparum 3D7,"Chen,Y.;Xu,K.;Piccoli,L.;Foglierini,M.;Tan,J.;Jin,W.;Gorman,J.;Tsybovsky,Y.;Zhang,B.;Traore,B.;Silacci-Fregni,C.;Daubenberger,C.;Crompton,P.D.;Geiger,R.;Sallusto,F.;Kwong,P.D.;Lanzavecchia,A.",Structural basis of malaria RIFIN binding by LILRB1-containing antibodies,21-OCT-2020,10_7_17_6_3_11,7KHF_A_L,Xtal structure,LILRB1; CD85; MIR-7; PIR-B; CD85j; ILT2; LIR1; LIR-1; PIRB,2,1,12.401828,0.34311754
QEP19967_QEP20615,QITLKESGPTLVKPTETLTLTCSFSGFSLTTTGVGVAWIRQPPGKALEWLALIYWDDDERYSPSLKTRLTITKDTSKNQVVLTMSNMDPVDSGTYFCAHGGGSRIYSRSVYNFDFWGQGTLVTVSS,SYVLTQAPSQSLAPGQTARITCGGNNIQKKHVHWYQQKPGQAPVLVMSFDTDRPSGIPERFSGSNSGNTATLTISRVEADDEADYYCQVWDTNSDWVFGGGTKLTVL,QEP19967,QEP20615,"IGH + IGL c74_heavy_IGHV2-5_IGHD5-12_IGHJ4, partial [Homo sapiens]","IGH + IGL c74_light_IGLV3-21_IGLJ3, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,10_7_18_6_3_10,QEP19967_QEP20615,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,12.406209,0.3498602
7WEE_H_L,QITLKESGPTLVKPTQTLTLTCNFSGFSLNTYGVGVGWIRQPPGKALEWLALIYWDGDERYGPFFKNKVTIAKDTSKNQVVLTMTNMDPVDTATYYCARHLIPTIFDYWGQGTLVTVSS,SALTQPASVSGSPGQSITISCTGTSSDVGGSNYVSWYQHHPDRAPKLLIYEVTNRPSGVSNRFSGSKSANTASLTISGLQAEDEADYYCSSYTTTSTHILFGGGTKLTV,7WEE_H,7WEE_L,Sars-Cov-2 Omicron Variant Spike Rbd In Complex With Fab Xgv265,Sars-Cov-2 Omicron Variant Spike Rbd In Complex With Fab Xgv265,Homo sapiens,"Wang,K.;Jia,Z.;Bao,L.;Wang,L.;Cao,L.;Chi,H.;Hu,Y.;Li,Q.;Zhou,Y.;Jiang,Y.;Zhu,Q.;Deng,Y.;Liu,P.;Wang,N.;Wang,L.;Liu,M.;Li,Y.;Zhu,B.;Fan,K.;Fu,W.;Yang,P.;Pei,X.;Cui,Z.;Qin,L.;Ge,P.;Wu,J.;Liu,S.;Chen,Y.;Huang,W.;Wang,Q.;Qin,C.F.;Wang,Y.;Qin,C.;Wang,X.",Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants,23-DEC-2021,10_7_11_9_3_11,7WEE_H_L,Xtal structure,SARS-CoV-2,2,1,12.376833,0.32349417
7MMO_A_B,QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL,7MMO_A,7MMO_B,Ly-Cov1404 Neutralizing Antibody Against Sars-Cov-2,Ly-Cov1404 Neutralizing Antibody Against Sars-Cov-2,Severe acute respiratory syndrome coronavirus 2,"Westendorf,K.;Wang,L.;Zentelis,S.;Foster,D.;Vaillancourt,P.;Wiggin,M.;Lovett,E.;van der,Le.;Hendle,J.;Pustilnik,A.;Sauder,J.M.;Kraft,L.;Hwang,Y.;Siegel,R.W.;Chen,J.;Heinz,B.A.;Higgs,R.E.;Kallewaard,N.;Jepson,K.;Goya,R.;Smith,M.A.;Collins,D.W.;Pellacani,D.;Xiang,P.;de Puyraimond,V.;Ricicova,M.;Devorkin,L.;Pritchard,C.;O'Neill,A.;Dalal,K.;Panwar,P.;Dhupar,H.;Garces,F.A.;Cohen,C.;Dye,J.;Huie,K.E.;Badger,C.V.;Kobasa,D.;Audet,J.;Freitas,J.J.;Hassanali,S.;Hughes,I.;Munoz,L.;Palma,H.C.;Ramamurthy,B.;Cross,R.W.;Geisbert,T.W.;Menacherry,V.;Lokugamage,K.;Borisevich,V.;Lanz,I.;Anderson,L.;Sipahimalani,P.;Corbett,K.S.;Yang,E.S.;Zhang,Y.;Shi,W.;Zhou,T.;Choe,M.;Misasi,J.;Kwong,P.D.;Sullivan,N.J.;Graham,B.S.;Fernandez,T.L.;Hansen,C.L.;Falconer,E.;Mascola,J.R.;Jones,B.E.;Barnhart,B.C.",LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants,30-APR-2021,10_7_11_9_3_9,7MMO_A_B,Xtal structure,SARS-CoV-2,2,1,12.406763,0.35743225
7XSA_B_C,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARHRIGYIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGDFNYVSWYQQHPGKAPKLMIYDVTKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYCCSSYTTSSISFGGGTKLTVL,7XSA_B,7XSA_C,Crystal Structure Of Sars-Cov-2 Spike Receptor Binding Domain Bound With P2S-2E9 Fab,Crystal Structure Of Sars-Cov-2 Spike Receptor Binding Domain Bound With P2S-2E9 Fab,Severe acute respiratory syndrome coronavirus 2,"Ju,B.;Zhang,Q.;Wang,Z.;Aw,Z.Q.;Chen,P.;Zhou,B.;Wang,R.;Ge,X.;Lv,Q.;Cheng,L.;Zhang,R.;Wong,Y.H.;Chen,H.;Wang,H.;Shan,S.;Liao,X.;Shi,X.;Liu,L.;Chu,J.J.H.;Wang,X.;Zhang,Z.;Zhang,L.",Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants,10-MAY-2023,10_7_11_9_3_9,7XSA_B_C,Xtal structure,SARS-CoV-2,2,1,12.371648,0.34028527
ANV21736_ANV21925,QITLKESGPTLVKPTQTLTLTCTLSGFSLSTTGVGVGWIRQPPGKALEWLALIYWDDEKHYSPSLKNRLMITKDTSKNQVVLTMTNMDPVDTATYYCVWQYSSAHFHNWGQGTLVTVST,QSALTQPASVSGSPGQSITISCTGTSSDVGSDNLVSWYQQHPGKAPKLMIYDVNKWPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSFTSSSTWVFGGGTKLTVL,ANV21736,ANV21925,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,10_7_11_9_3_10,ANV21736_ANV21925,Unique source,,2,1,12.418832,0.3789972
7WP8_D_C,QLAQSGAELARPGASVKLSCKASGYTFTRYWMQWVKQRPGQGLEWIGAIYPGDGDSRYTQKFKGKATLTADKSSSTAYMQLSSLASEDSAVYYCARRNYYGYDAFAYWGQGTLVTVSA,VMTQSHKFLSTSVGDRVNITCKASQDVDTAVAWYQQKPGQSPKLLISWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSPYPYTFGGGTKLEI,7WP8_D,7WP8_C,Cryo-Em Structure Of Sars-Cov-2 Recombinant Spike Protein Stfk1628X In Complex With Three Neutralizing Antibodies,Cryo-Em Structure Of Sars-Cov-2 Recombinant Spike Protein Stfk1628X In Complex With Three Neutralizing Antibodies,Mus musculus,"Zheng,Q.;Sun,H.;Yuan,Q.;Li,S.;Xia,N.",Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK in complex with three neutralizing antibodies,08-MAR-2023,8_8_13_6_3_9,7WP8_D_C,Xtal structure,SARS-CoV-2,2,1,0.42078397,-3.8767219
5UXQ_H_L,QLEQSGAEVKKPGSSVKVSCKASGNTFSKYDVHWVRQATGQGLEWVGWMSHEGDKTESAQRFKGRVTFTRDTSASTAYMELRGLTSDDTAIYYCTRGSKHRLRDYVLYDDYGLINYQEWNDYLEFLDVWGHGTAVTVSS,TVVTQSPLSLPVTPGEAASMSCTSTQSLRHSNGANYLAWYQHKPGQSPRLLIRLGSQRASGVPDRFSGSGSGTHFTLKISRVEPEDAAIYYCMQGLNRPWTFGKGTKLEIK,5UXQ_H,5UXQ_L,Structure Of Anti-Hiv Trimer Apex Antibody Pgt143,Structure Of Anti-Hiv Trimer Apex Antibody Pgt143,Homo sapiens,"Vujkovic-Cvijin,I.;Deeks,S.G.",Mucosal Microbes Mitigate Maladies,23-FEB-2017,8_8_34_11_3_9,5UXQ_H_L,Xtal structure,Hiv,2,1,2.4302294,3.184096
AAW68626_AAW69054,QLQLQESGGGLAKPGGSLRLSCVVSGFTLSSYKMNWVRQAPGKGLEWVSSISSTSAYIDYADSVKGRFTISRDNAKNSLYLEMSSLRATDSAVYYCVSGSSLDYWGQGTLVTVS,DIQMTQSPPSLSASVGDRVTITCRASQSISTNLNWFQQKPGKAPNLLIYSASTLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQTYSPRRTFGQGTKVEIR,AAW68626,AAW69054,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_8_6_3_9,AAW68626_AAW69054,Unique source,tetanus,2,1,15.826062,10.336244
5DUR_H_L,QLQLQESGLGLVKPSETLSLTCTVSGDSVSSGSYYWSWLRQPPGKGLEWIGNMHGSGHTNYNPSLKSRVTITPDTSKNHFSLRLSSVTAADTAVYYCARALLTTVTTFEYWGQGTLVTVSS,QSALTQPPSVSGAPGQRVTIPCTGGSSNIGAGYSVHWYQQLPGTAPKLLIYGSNSRPSGVPDRFSGSKSGTSASLAITGLRPEDEADYYCQSYDSSLSGSQVFGAGTRVTVL,5DUR_H,5DUR_L,Influenza A Virus H5 Hemagglutinin Globular Head In Complex With Antibody 100F4,Influenza A Virus H5 Hemagglutinin Globular Head In Complex With Antibody 100F4,Influenza A virus (A/Anhui/1/2005(H5N1)),"Zuo,T.;Sun,J.;Wang,G.;Jiang,L.;Zuo,Y.;Li,D.;Shi,X.;Liu,X.;Fan,S.;Ren,H.;Hu,H.;Sun,L.;Zhou,B.;Liang,M.;Zhou,P.;Wang,X.;Zhang,L.",Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection,20-SEP-2015,10_7_13_9_3_12,5DUR_H_L,Xtal structure,H5N1; Influenza,2,1,16.576275,-7.8693733
3Q6G_H_L,QLQLQESGPGLVKPSETLSLTCAVSGGSISNNHWSWIRQPPGKGLEWIGLISGSGGSTDYNPSLKSRVTISTDTSKNQFSLKLSSVTAADTAVYYCARIDVVITSHEDDFGDYYTGEYYGLDSWGQGVVVTVSS,YDLTQARSVSVSPGQTARVTCGGDNIGSKSVQWYQQKPPQAPVLVMSADDERSSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSSSHHMLFGGGTRLTVL,3Q6G_H,3Q6G_L,Crystal Structure Of Fab Of Rhesus Mab 2.5B Specific For Quaternary Neutralizing Epitope Of Hiv-1 Gp120,Crystal Structure Of Fab Of Rhesus Mab 2.5B Specific For Quaternary Neutralizing Epitope Of Hiv-1 Gp120,Macaca mulatta,"Spurrier,B.;Sampson,J.M.;Totrov,M.;Li,H.;O'Neal,T.;Williams,C.;Robinson,J.;Gorny,M.K.;Zolla-Pazner,S.;Kong,X.P.",Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120,31-DEC-2010,8_8_27_6_3_11,3Q6G_H_L,Xtal structure,gp120; HIV,2,1,16.180368,-7.4077473
5USH_D_E,QLQLQESGPGLVKPSETLSLTCTISGDSISSNNYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRRVLLWFGEFQLWGQGTLVTVSS,QSALTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGALFGGGTQLTVL,5USH_D,5USH_E,Structure Of Vaccinia Virus D8 Protein Bound To Human Fab Vv66,Structure Of Vaccinia Virus D8 Protein Bound To Human Fab Vv66,Vaccinia virus,"Matho,M.H.;Schlossman,A.;Gilchuk,I.M.;Miller,G.;Mikulski,Z.;Hupfer,M.;Wang,J.;Bitra,A.;Meng,X.;Xiang,Y.;Kaever,T.;Doukov,T.;Ley,K.;Crotty,S.;Peters,B.;Hsieh-Wilson,L.C.;Crowe JE,Jr.;Zajonc,D.M.",Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8,13-FEB-2017,10_7_15_9_3_11,5USH_D_E,Xtal structure,,2,1,16.787119,-7.9464483
AEF33810_AEF33820,QLQLQESGPGLVKPSETLSLTCTVSGASIDRSTYYWGWIRQPPGKGLEWIANIYYNGRAVYSPSLKSRVTISVDTSKNQFSLKVRSLTAADTAVYYCATRWNYFFDFDYWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIETNYVSWYQQFPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEAEYYCGTWDDNSWVFGGGTKLTVL,AEF33810,AEF33820,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Potzsch,S.; Spindler,N.; Wiegers,A.K.; Fisch,T.; Rucker,P.; Sticht,H.; Grieb,N.; Baroti,T.; Weisel,F.; Stamminger,T.; Martin-Parras,L.; Mach,M.; Winkler,T.H.",B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies,25-JUL-2016,10_7_12_8_3_9,AEF33810_AEF33820,Unique source,Antigenic,2,1,16.585726,-7.999074
6UVO_H_L,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSNYYWGWIRQPPGKGLEWIASIHDSGSIYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHLVWFGELRNNWFDPWGQGTLVTVAS,EIVMTQSPATLSVSPGERATLSCRASQSVNSNLAWYQHKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYNNWPLFGPGTKVDLK,6UVO_H,6UVO_L,Structure Of Antibody 3G12 Bound To The Central Conserved Domain Of Rsv G,Structure Of Antibody 3G12 Bound To The Central Conserved Domain Of Rsv G,Human respiratory syncytial virus A2,"Fedechkin,S.O.;George,N.L.;Nunez Castrejon,A.M.;Dillen,J.R.;Kauvar,L.M.;DuBois,R.M.",Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes,03-NOV-2019,10_7_17_6_3_8,ADR84007_ADR84021,Xtal structure,,2,1,16.786663,-8.034021
7OLY_H_L,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDSLRYGMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYALAPPRTFGGGTKVEIK,7OLY_H,7OLY_L,Structure Of Activin A In Complex With An Actriib-Alk4 Fusion Reveal Insight Into Activin Receptor Interactions,Structure Of Activin A In Complex With An Actriib-Alk4 Fusion Reveal Insight Into Activin Receptor Interactions,Homo sapiens,"Goebel,E.J.;Kattamuri,C.;Gipson,G.R.;Krishnan,L.;Chavez,M.;Czepnik,M.;Maguire,M.C.;Grenha,R.;Hakansson,M.;Logan,D.T.;Grinberg,A.V.;Sako,D.;Castonguay,R.;Kumar,R.;Thompson,T.B.",Structures of activin ligand traps using natural sets of type I and type II TGFbeta receptors,20-MAY-2021,10_7_11_12_3_10,7OLY_H_L,Xtal structure,DPD1; TGFB1; MGC4638; CED; INHBE; TGFB; activin; TGFbeta,2,1,16.588139,-8.142052
QKY76463_QKY76076,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGNGLEWIGSIYYSGSTYYNPSLKGRVSISVDTSKNQFSLKLSSVTAADTAVYYCARILVIFTLNWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSGNPIFGGGTKLTVL,QKY76463,QKY76076,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,10_7_14_8_3_9,QKY76463_QKY76076,Unique source,SARS-CoV-2,2,1,16.78639,-8.037823
6I04_H_L,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSVYYWSWIRQPPGKGLEWIGVIYPSGNTYYSPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTIYDLFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQANSFPPTFGGGTKVEIK,6I04_H,6I04_L,Crystal Structure Of Sema Domain Of The Met Receptor In Complex With Fab,Crystal Structure Of Sema Domain Of The Met Receptor In Complex With Fab,Homo sapiens,"Casaletto,J.B.;Geddie,M.L.;Abu-Yousif,A.O.;Masson,K.;Fulgham,A.;Boudot,A.;Maiwald,T.;Kearns,J.D.;Kohli,N.;Su,S.;Razlog,M.;Raue,A.;Kalra,A.;Hakansson,M.;Logan,D.T.;Welin,M.;Chattopadhyay,S.;Harms,B.D.;Nielsen,U.B.;Schoeberl,B.;Lugovskoy,A.A.;MacBeath,G.","MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM",25-OCT-2018,10_7_10_6_3_9,ARH63973_ARH63955,Xtal structure,HPTA; HGFB; SF; HGF; DFNB39; F-TCF,2,1,16.651989,-8.087848
6PIS_I_M,QLQLQESGPGLVKPSQSLSLACSVTGFSLSTGGYQWTWIRQFPGKKLEWMGYISYAGGITYNPSLKSRISITRDTSKNQFFLQLNTVTTEDTATHYCARVQYSGYGNAYFDVWGQGIQVTVSS,DIQLTQLPSFLSVSPGDKVTITCKASQNINQYLHWYQQKPEEAPKLLIYGASNLQTGIPSRFSGSGYGTDFSLTINSLDSEDVGTYFCQQGYTPRTFGPGTKLEIK,6PIS_I,6PIS_M,Mouse Two Pore Domain K+ Channel Traak (K2P4.1) - Fab Complex Structure,Mouse Two Pore Domain K+ Channel Traak (K2P4.1) - Fab Complex Structure,Cricetulus migratorius,"Brohawn,S.G.;Wang,W.;Handler,A.;Campbell,E.B.;Schwarz,J.R.;MacKinnon,R.",The mechanosensitive ion channel TRAAK is localized to the mammalian node of Ranvier,27-JUN-2019,10_7_15_6_3_8,6PIS_I_M,Xtal structure,K2p4.1; TRAAK; KCNK4,2,1,11.495621,-12.845849
QEP20437_QEP21085,QLQLQESGPGLVRPSETLSLTCTVSGVSIVTTDNYWGWFRQPPGKAPEWLGSVFFSGSAYHNPSLKSRVGVSVDTSRNQFYLRLTSVTAADTAIYYCGRVEGVIVPELQRRVGLGYMTVWGKGTTVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGAYQYVSWYQHFPGKVPKLIIYDVNKRPSGVPARFSGSRSGNTASLSISGLQADDEADYYCSAFAVISTKTTYTVVFGEGTRVTVL,QEP20437,QEP21085,"IGH + IGL c544_heavy_IGHV4-39_IGHD1-1_IGHJ6, partial [Homo sapiens]","IGH + IGL c544_light_IGLV2-11_IGLJ3, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,10_7_22_9_3_15,QEP20437_QEP21085,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.463709,-8.236041
ANV21798_ANV21987,QLQLQESGSGLVKPSQTLSLTCAVSGGSISGSGYSWSWIRQPPGKGLEWIGSFFHSGSTNFNPSLKSRVTISGDRSKNKFSLRLDSVTAADTAVYYCARGSRWNGFYHYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWFQHLPGTAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLAITGLRAEDEGDYYCQSYDNSLSGLYVFGTGTKVTVL,ANV21798,ANV21987,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,10_7_15_9_3_12,ANV21798_ANV21987,Unique source,,2,1,16.469118,-7.739473
1FOR_H_L,QLQQSGAELVRPGSSVKISCKASGYAFSSFWVNWVKQRPGQGLEWIGQIYPGDGDNKYNGKFKGKATLTADKSSTTAYMQLYSLTSEDSAVYFCARSGNYPYAMDYWGQGTSVTVSS,QIVLTQSPAIMSAFPGEKVTITCSATSSVNYMHWFQQKPGTSPKLWIYSSSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPITFGSGTKLEIK,1FOR_H,1FOR_L,Structure Determination Of An Fab Fragment That Neutralizes Human Rhinovirus And Analysis Of The Fab-Virus Complex,Structure Determination Of An Fab Fragment That Neutralizes Human Rhinovirus And Analysis Of The Fab-Virus Complex,Mus musculus,"Smith,T.J.;Olson,N.H.;Cheng,R.H.;Liu,H.;Chase,E.S.;Lee,W.M.;Leippe,D.M.;Mosser,A.G.;Rueckert,R.R.;Baker,T.S.",Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody,24-MAY-1994,8_8_12_5_3_9,1FOR_H_L,Xtal structure,rhinovirus,2,1,0.39243543,-4.698975
QDF60732_QDF61178,QLQVQESGPGLVKPSETLSLTCTVSGGSITSTSDYWGWIRQPPGKGLEWIGGIYESGNTYYNPSLKSRVTISVDSSKNQFSLKLSSVTAADTAVYYCARVEDRGAIYYEIYFDPWGQGTLVIVSS,DIEVTQSPSSVSASVGDRVTITCRASQDISYWLAWYQQKPGKAPNLLIYDASRLQSGVPSRFSGSGSGTHFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,QDF60732,QDF61178,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Davis,C.W.; Jackson,K.J.L.; McElroy,A.K.; Halfmann,P.; Huang,J.; Chennareddy,C.; Piper,A.E.; Leung,Y.; Albarino,C.G.; Crozier,I.; Ellebedy,A.H.; Sidney,J.; Sette,A.; Yu,T.; Nielsen,S.C.A.; Goff,A.J.; Spiropoulou,C.F.; Saphire,E.O.; Cavet,G.; Kawaoka,Y.; Mehta,A.K.; Glass,P.J.; Boyd,S.D.; Ahmed,R.",Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection,01-JUL-2019,10_7_17_6_3_9,QDF60732_QDF61178,Unique source,Ebola,2,1,16.747755,-8.105078
8DW9_C_D,QLVESGAEVKKPGSSVKVSCKASGDTFYTFDISWVRQAPGQGLEWMGGISPVFDAPNYAQKFQDRVTITADKSTSTAYMELSSLRSEDTAIYYCVKPTYSNYVWGIGAFDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGNIYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGDSLWTFGQGTKVEIK,8DW9_C,8DW9_D,Crystal Structure Of Neutralizing Antibody D29 Fab In Complex With Sars-Cov-2 Spike Receptor Binding Domain (Rbd),Crystal Structure Of Neutralizing Antibody D29 Fab In Complex With Sars-Cov-2 Spike Receptor Binding Domain (Rbd),Homo sapiens,"Luo,M.;Zhou,B.;Reddem,E.R.;Tang,B.;Chen,B.;Zhou,R.;Liu,H.;Liu,L.;Katsamba,P.S.;Au,K.K.;Man,H.O.;To,K.K.;Yuen,K.Y.;Shapiro,L.;Dang,S.;Ho,D.D.;Chen,Z.",Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2,07-DEC-2022,8_8_17_7_3_9,8DW9_C_D,Xtal structure,SARS-CoV-2; D29; ELAC1,2,1,-0.8639491,5.9374185
7RA7_H_L,QLVESGGGLVKPGTSLSLTCKASGFDFSDNYYICWVRQAPGKGLEWIGCIFTQNVRTYYANWAKGRFTISKTSSTTVTLQMTSLTVADTATYFCARFSDTGPDYGLGNLWGPGSLVTVSS,DIVMTQTPASVEAAVGGTVTIKCQASQRIGSHVSWYQQKPGQRPKLLIYGASNLESGVPSRFSGSGSGTQFTLTISDLECADAATYYCQATYDPYTGGSYGAGFGGGTAVVVK,7RA7_H,7RA7_L,Crystal Structure Of Rabbit Anti-Hiv Fab 11A,Crystal Structure Of Rabbit Anti-Hiv Fab 11A,Oryctolagus cuniculus,"Ozorowski,G.;Cottrell,C.A.;Oyen,D.;de Val,N.;Copps,J.;Scaring,N.;Polveroni,T.M.;Wilson,I.A.;Ward,A.B.",Limited breadth of anti-HIV Env glycan hole antibodies is further hindered by strain-specific peptide interactions,06-JUL-2022,9_8_15_6_3_15,7RA7_H_L,Xtal structure,HIV,2,1,-0.41695502,18.428885
4PTT_B_A,QLVESGGGVVQPGRSLTLSCAASGFTFSSHGMHWVRQAPGKGLEWVAVIASHGNVNYYADSVKGRFTISRDNSKNTLSLQMDSLRAEDTAVYYCAKESDSCGGDCSRFAFDVWGHGTMVTVSS,EIVLTQSPATLSLSPGERGTLSCRASQSVGTYLAWYQHKPGQAPRPLIYDASRRATGIPARFSGSGSGTDFTLTISGLEPEDVAVYYCQHRDSWPPGATFGGGTKVEIK,4PTT_B,4PTT_A,Crystal Structure Of Anti-23F Strep Fab C05,Crystal Structure Of Anti-23F Strep Fab C05,Homo sapiens,"Bryson,S.;Thomson,C.A.;Risnes,L.F.;Dasgupta,S.;Smith,K.;Schrader,J.W.;Pai,E.F.",Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop Variation,11-MAR-2014,8_8_18_6_3_11,4PTT_B_A,Xtal structure,23F,2,1,14.971074,13.629596
4RX4_H_L,QLVQSGGGVKKPGTSVTISCLASEYTFNEFVIHWIRQAPGQGPVWLGLIKRSGRLMTSYKFQDRLSLRRDRSTGTVFMELRGLRLDDTAVYYCARDGLGEVAPAYLYGIDAWGQGSTVIVTS,EIVLTQSPATLSLSPGERATLSCRASQGLNFVVWYQQKGGQAPRLLIHGPTDRAPGVPDRFSARGSGTEFSLVISSVEPDDFALYYCQEYSSTPYNFGPGTRVERK,4RX4_H,4RX4_L,Crystal Structure Of Vh1-46 Germline-Derived Cd4-Binding Site-Directed Antibody 8Anc134 In Complex With Hiv-1 Clade A Q842.D12 Gp120,Crystal Structure Of Vh1-46 Germline-Derived Cd4-Binding Site-Directed Antibody 8Anc134 In Complex With Hiv-1 Clade A Q842.D12 Gp120,Homo sapiens,"Zhou,T.;Lynch,R.M.;Chen,L.;Acharya,P.;Wu,X.;Doria-Rose,N.A.;Joyce,M.G.;Lingwood,D.;Soto,C.;Bailer,R.T.;Ernandes,M.J.;Kong,R.;Longo,N.S.;Louder,M.K.;McKee,K.;O'Dell,S.;Schmidt,S.D.;Tran,L.;Yang,Z.;Druz,A.;Luongo,T.S.;Moquin,S.;Srivatsan,S.;Yang,Y.;Zhang,B.;Zheng,A.;Pancera,M.;Kirys,T.;Georgiev,I.S.;Gindin,T.;Peng,H.P.;Yang,A.S.;Mullikin,J.C.;Gray,M.D.;Stamatatos,L.;Burton,D.R.;Koff,W.C.;Cohen,M.S.;Haynes,B.F.;Casazza,J.P.;Connors,M.;Corti,D.;Lanzavecchia,A.;Sattentau,Q.J.;Weiss,R.A.;West AP,Jr.;Bjorkman,P.J.;Scheid,J.F.;Nussenzweig,M.C.;Shapiro,L.;Mascola,J.R.;Kwong,P.D.",Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors,08-DEC-2014,8_7_18_5_3_9,4RX4_H_L,Xtal structure,MDS032; p31; SLT1; D12; CD4; HIV; USE1,2,1,1.597525,3.7989807
2YK1_H_L,QMQLLESGPGLVKPSETLSLTCTVSGGSIWGWIRQPPGKGLEWIGSIYSSGSTYYNPSLKSRVTTSVDTSKNQFSLRLSSVTAADTAVYYCVAWFGDLLSLKGVELWGQGTLVTVSS,QSELTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSAWVFGGGTQLDIL,2YK1_H,2YK1_L,Structure Of Human Anti-Nicotine Fab Fragment In Complex With  Nicotine,Structure Of Human Anti-Nicotine Fab Fragment In Complex With  Nicotine,Homo sapiens,"Tars,K.;Kotelovica,S.;Lipowsky,G.;Bauer,M.;Beerli,R.R.;Bachmann,M.F.;Maurer,P.",Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody,25-MAY-2011,4_7_15_8_3_11,2YK1_H_L,Xtal structure,nicotine,2,1,16.646748,-7.833243
6H3U_I_M,QMQLQESGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNKLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCTRWGDGYYLYWYFDVWGAGTTVTVSS,DIQMTQTTSSLSASLGDRVTISCSASQGISYYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPWTFGGGTKLEIK,6H3U_I,6H3U_M,Schmallenberg Virus Glycoprotein Gc Head Domain In Complex With Scfv 4B6,Schmallenberg Virus Glycoprotein Gc Head Domain In Complex With Scfv 4B6,Mus musculus,"Hellert,J.;Aebischer,A.;Wernike,K.;Haouz,A.;Brocchi,E.;Reiche,S.;Guardado-Calvo,P.;Beer,M.;Rey,F.A.",Orthobunyavirus spike architecture and recognition by neutralizing antibodies,19-JUL-2018,9_7_15_6_3_9,6H3U_I_M,Xtal structure,,2,1,11.41898,-12.97282
AAW68628_AAW69056,QMQLVESGAEVKKPGASVKVSCKASGYRFTGYYIHWVRLAPGQRLEWMGWINPNTGGTVYAQNFQGRVTMTRDTSIRTAYMEVNRLTSDDTATYYCATWVSRESSFDYWGQGTLVTV,DVVMTQSPATLSLSPGERATLSCRASHSVSTSLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLIISSLEPEDFAVYYCQQRSYWYTFGQGTKLEIK,AAW68628,AAW69056,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_12_6_3_8,AAW68628_AAW69056,Unique source,tetanus,2,1,2.0839224,3.7610395
6AXL_D_C,QMQLVESGGGVVQPGRSLRLSCTASGFTFSTYAMHWVRQSPGQGLQWVAVISYHSTNKYYEDSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYSSSFFDFWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVAITCRASQSISRWLAWYQQQPGKAPKLLMSGASVLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYFVTFGQGTKVEIK,6AXL_D,6AXL_C,Crystal Structure Of Fab317 Complex,Crystal Structure Of Fab317 Complex,Plasmodium falciparum,"Oyen,D.;Torres,J.L.;Wille-Reece,U.;Ockenhouse,C.F.;Emerling,D.;Glanville,J.;Volkmuth,W.;Flores-Garcia,Y.;Zavala,F.;Ward,A.B.;King,C.R.;Wilson,I.A.",Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein,07-SEP-2017,8_8_12_6_3_9,6AXL_D_C,Xtal structure,C20orf147; NANP; MGC26833; circumsporozoite; HDHD4; dJ694B14.3,2,1,14.923774,13.330314
5LSP_H_L,QMQLVQSGAEVKKPGAPVKVSCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATDATTPYWGMMWWGQGTLVTVSS,DIQMIQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKVLIYDASNLETGVPSRFSGSGSGTEFTLTISNLRPDDFATYYCQQGDSFPLTFGGGTKVEIK,5LSP_H,5LSP_L,107_A07 Fab In Complex With Fragment Of The Met Receptor,107_A07 Fab In Complex With Fragment Of The Met Receptor,Homo sapiens,"DiCara,D.M.;Chirgadze,D.Y.;Pope,A.R.;Karatt-Vellatt,A.;Winter,A.;Slavny,P.;van den,He.;Parthiban,K.;Holland,J.;Packman,L.C.;Mavria,G.;Hoffmann,J.;Birchmeier,W.;Gherardi,E.;McCafferty,J.",Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain,05-SEP-2016,8_8_13_6_3_9,5LSP_H_L,Xtal structure,,2,1,1.0151407,2.6817915
AAW68552_AAW68977,QMQLVQSGGGLVQPGGSLKISCSASGFTFRSYGMHWVRQAPVKGLEHVATISAKGESTFYADSVKGRFTISRDNSKNTLHLQMNSLRPEDSAVYYCVKRRRQWLVNSSFDFWGQGTLVTV,ETTLTQSPATQYVFPGERVTLSCRASQSIANNLAWYQQGPGQPPSLLIYDASSRAPRVPVRFSGSGSGTEFSLTISSLQAEDFAVYYCQQYHVWPPITFGQGTRLEIK,AAW68552,AAW68977,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_15_6_3_10,AAW68552_AAW68977,Unique source,tetanus,2,1,14.353255,10.331199
QKY76288_QKY75901,QMQLVQSGPEVKKPGTSVKVSCKTSGFTFTSSAIQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPHCNRTSCYDAFDLWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,QKY76288,QKY75901,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_16_7_3_9,QKY76288_QKY75901,Unique source,SARS-CoV-2,2,1,-0.99254286,2.9910312
AAW68484_AAW68906,QMQLVQSGPGLVKPSETLSLTCAVSGASVSGGDYYWSWIRQPPGKALEWIGYIYYIGSTNYNPSLKSRLSLSVDTAKSQFSLKLSSVTAADTAIYFCARARRTYSGYDSAFDYWGQGTLVTV,DVVMTQSPSSLSASVGDRVSITCRASRSVKTYLNWYQQKPGKAPKLLVYGSSSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFGTPYTFGQGTKLDIK,AAW68484,AAW68906,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,10_7_16_6_3_9,AAW68484_AAW68906,Unique source,tetanus,2,1,16.166822,-8.320219
8GF2_H_L,QMQLVQSGTEVKKPGESLKISCKGSGYGFIWYWIGWVRQMPGKGLEWMGIIYPGDGETRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAIYYCAGGGGISTPMDVWGQGTTVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVLWSSINKNYLAWYQQKPGQPPKLLIYWASTPESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYKTPYTFGQGTKVEIK,8GF2_H,8GF2_L,Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Antibodies Ecr3022.20 And Cc12.3,Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Antibodies Ecr3022.20 And Cc12.3,Homo sapiens,"Zhao,F.;Yuan,M.;Keating,C.;Shaabani,N.;Limbo,O.;Joyce,C.;Woehl,J.;Barman,S.;Burns,A.;Tran,Q.;Zhu,X.;Ricciardi,M.;Peng,L.;Smith,J.;Huang,D.;Briney,B.;Sok,D.;Nemazee,D.;Teijaro,J.R.;Wilson,I.A.;Burton,D.R.;Jardine,J.G.",Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution,23-AUG-2023,8_8_12_12_3_9,8GF2_H_L,Xtal structure,SARS; SARS-CoV-2; CoV,2,1,-12.351414,5.7781744
CAB92539_CAB92540,QPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARYLGYYFDYWGQGTTLTVSS,GQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPYTFGGGTKLEIK,CAB92539,CAB92540,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Kalinke,U.; Oxenius,A.; Lopez-Macias,C.; Zinkernagel,R.M.; Hengartner,H.",Virus neutralization by germ-line vs. hypermutated antibodies,26-JUL-2016,8_8_10_10_3_9,CAB92539_CAB92540,Unique source,,2,1,17.447561,7.9602957
AEN14395_AEN14412,QPQLQESGPGLVEASETLSLTCTVSGDSTGRCNYFWGWVRQPPGKGLEWIGSLSHCRSYYNTDWTYHNPSLKSRLTISLDTPKNQVFLRLTSVTAADTATYYCARFGGEVLVYRDWPKPAWVDLWGRGTLVTVSS,QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQYPGKAPKLVIYEVNKRPSGVPDRFSGSKSGSTASLTVSGLQADDEGVYYCSSLVGNWDVIFGGGTKLTVL,AEN14395,AEN14412,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.; Huber,M.; Doores,K.J.; Falkowska,E.; Pejchal,R.; Julien,J.P.; Wang,S.K.; Ramos,A.; Chan-Hui,P.Y.; Moyle,M.; Mitcham,J.L.; Hammond,P.W.; Olsen,O.A.; Phung,P.; Fling,S.; Wong,C.H.; Phogat,S.; Wrin,T.; Simek,M.D.; Principal Investigators,P.G.; Koff,W.C.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Broad neutralization coverage of HIV by multiple highly potent antibodies,26-SEP-2011,10_10_21_4_3_10,AEN14395_AEN14412,Unique source,HIV,2,1,17.051363,-7.7126307
AJC50735,QQQLMESGGGLVTPGGTLTLTCTVSGFSLSNYYIVWVRQAPGKGLEWIGAIHPNGNRYYANWAKGRFTISKASSTTVDLKMTSLTASDTATYFCARSGNNDFWGPGTLVTVSS,VGGTVTIKCQASEDIYGFLGWYQQKPGQRPKLLIYSASKLASGVPSRFRGSGSGTEYTLTISGVECDDAATYYCQQYGRYDGVDNTFGGGTEVVVK,AJC50735_H,AJC50735_L,"rabbit anti-human cTnI scFv, partial [synthetic construct]","rabbit anti-human cTnI scFv, partial [synthetic construct]",synthetic construct,"Ayyar,B.V.; Hearty,S.; O'Kennedy,R.",Facile domain rearrangement abrogates expression recalcitrance in a rabbit scFv,12-MAR-2015,8_7_8_6_3_12,AJC50735,Same entry,cTnI,2,1,-0.23827721,18.982872
QHJ89779_QHJ89835,QRRLFQSGTEVKRPGASVKISCRADDDPYTDDDTFTKYYTHWIRQAPGQRPEWLGVISPHFARPIYSYKFQDRLTLTRDSSLTAVYFELRGLQPDDTGIYFCARDPFGDMYPHYNYHMDVWGGGTTVIVSA,EVVLTQSPAILSVSPGDRVILSCKASEGLSSSDLAWYRFKGGQIPTLVIFGTSTRARGTPDRFSGSGSGTDFTLTISRVEPEDFATYYCQRYGGTPITFGGGTTLDKK,QHJ89779,QHJ89835,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Schommers,P.; Gruell,H.; Abernathy,M.E.; Tran,M.-K.; Dingens,A.S.; Gristick,H.B.; Barnes,C.O.; Schoofs,T.; Schlotz,M.; Vanshylla,K.; Kreer,C.; Weiland,D.; Holtick,U.; Scheid,C.; Valter,M.M.; van Gils,M.J.; Sanders,R.W.; Vehreschild,J.J.; Cornely,O.A.; Lehmann,C.; Fatkenheuer,G.; Seaman,M.S.; Bloom,J.D.; Bjorkman,P.J.; Klein,F.",Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody,12-FEB-2020,14_8_18_7_3_9,QHJ89779_QHJ89835,Unique source,HIV,2,1,1.7799455,3.4424016
5M63_H_L,QSLEESGGDLVKPGASLTLTCKASGLDLPSYFMCWVRQAPGKGLEWIACIRSSSNEILYYASWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARDYFGEGDVFYHGGVFGLWGSGTLVTVSS,VVLTQTPSSVSAAVGGSVTISCQSSQSLYNNNRLAWYQQKAGQPPKLLIYKASTLESGVPSRFKGSGAGTQFTLTISDVVCDDAATYYCAGYKSNSDDGTAFGGGTEVVVK,5M63_H,5M63_L,Crystal Structure Of Group B Streptococcus Type Iii Dp2 Oligosaccharide Bound To Fab Nvs-1-19-5,Crystal Structure Of Group B Streptococcus Type Iii Dp2 Oligosaccharide Bound To Fab Nvs-1-19-5,Oryctolagus cuniculus,"Carboni,F.;Adamo,R.;Fabbrini,M.;De Ricco,R.;Cattaneo,V.;Brogioni,B.;Veggi,D.;Pinto,V.;Passalacqua,I.;Oldrini,D.;Rappuoli,R.;Malito,E.;Margarit,I.Y.;Berti,F.",Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide,24-OCT-2016,8_9_19_8_3_12,5M63_H_L,Xtal structure,,2,1,-0.4026486,18.431221
AAO06473_AAO06474,QSLEESGGDLVKPGASLTLTCTASGFSFSINYWICWVRQAPGKGLEWIACIHAGSSGSTYYASWAKGRLTISKISSTTVTLQMTSLTAADTATYFCARADNNVDSVLNLWGPGTLVTISS,ELDLTQTPSSVSATVGGTVTINCQASESISRLLAWYQQKPGQPPKLLIYGASNLEPGVPSRFRGSGSGTEFTLTISGMKAEDAATYYCQSGYYSAGTFGAGTNVEIK,AAO06473,AAO06474,"antibody variable domain, partial [Oryctolagus cuniculus]","antibody variable domain, partial [Oryctolagus cuniculus]",Oryctolagus cuniculus,"Popkov,M.; Mage,R.G.; Alexander,C.B.; Thundivalappil,S.; Barbas,C.F. III; Rader,C.",Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display,24-JUL-2016,9_9_13_6_3_9,AAO06473_AAO06474,Unique source,,2,1,-0.35015413,18.495565
AAO06515_AAO06516,QSVEESGGRLVLPGESLTLTCTVSGFSLDTYAISWVRQTPGKGLEWIGSIYVSGVTNYADWAKGRFTIAKTSTTVDLRMTSLTLEDTATYFCARGDIARAHVYGLWGQGTLVTVSS,ELDMTQTPSSTSAAVGDTVTINCQASQSIGSDLSWFQQKPGQPPKLLIYYTSNLASGVPSRFKGSRSGTQFTLTISGMQREDAATYYCLGDASGTRTFGAGTELEIL,AAO06515,AAO06516,"antibody variable domain, partial [Oryctolagus cuniculus]","antibody variable domain, partial [Oryctolagus cuniculus]",Oryctolagus cuniculus,"Popkov,M.; Mage,R.G.; Alexander,C.B.; Thundivalappil,S.; Barbas,C.F. III; Rader,C.",Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display,24-JUL-2016,8_7_13_6_3_9,AAO06515_AAO06516,Unique source,,2,1,-0.16372295,19.11898
6X1U_H_L,QSVEESGGRLVTPGGSLTLTCTVSGFSLSRYNMGWVRQAPGKGLEWIGWIPFRGSLKYATWATGRFTISRTSTTVDLRMTGLTAADTATYFCVRSSDGFDLWGPGTLVTISS,DMTQTPASVEAVVGGTVTIKCQASRDTGDGLIWYQQKPGQPPKRLIYKASTVASGVPSRFKGRGSGTDFTLTISDLECADAATYYCHSNFYNRWTYGNAFGGGTEVVVK,6X1U_H,6X1U_L,Structure Of Phis Fab (Sc39-4) In Complex With Phis Mimetic Peptide,Structure Of Phis Fab (Sc39-4) In Complex With Phis Mimetic Peptide,synthetic construct,"Kalagiri,R.;Stanfield,R.L.;Meisenhelder,J.;La Clair,J.J.;Fuhs,S.R.;Wilson,I.A.;Hunter,T.",Structural basis for differential recognition of phosphohistidine-containing peptides by 1-pHis and 3-pHis monoclonal antibodies,19-MAY-2020,8_7_9_6_3_13,6X1U_H_L,Xtal structure,,2,1,-0.18310803,19.0721
5DTF_A_B,QSVEESGGRLVTPGTPLTLTCTVSACSLYHCTMNWVRQAPGKGLEWIGDIYTDGNTYYANWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARDSWDASSYYGLDLWGQGTLVTVSS,MTQTPSSVSAAVGGTVTINCQASEDIKRYLAWYQQKPGQPPKLLIYAASKLASGVSSRFKGSGSGTEYTLTISGVQCDDAATYYCQQGYTSSNVNNAFGGGTEVVVK,5DTF_A,5DTF_B,Context-Independent Anti-Hypusine Antibody Fabhpu98.61 In Complex With Hypusine,Context-Independent Anti-Hypusine Antibody Fabhpu98.61 In Complex With Hypusine,synthetic construct,"Zhai,Q.;He,M.;Song,A.;Deshayes,K.;Dixit,V.M.;Carter,P.J.",Structural Analysis and Optimization of Context-Independent Anti-Hypusine Antibodies,18-SEP-2015,8_7_15_6_3_12,5DTF_A_B,Xtal structure,Hypusine,2,1,-0.14736854,19.139812
5C0N_C_D,QSVEESGGRLVTPGTPLTLTCTVSGFSLSTYYMSWVRQAPGKGLEWIGIIYPSGSTYCASWAKGRFTISKASTTVDLKITSPTTEDTATYFCARPDNDGTSGYLSGFGLWGQGTLVTVSS,VVMTQTPASVSEPVGGTVTIKCQASEDISRYLVWYQQKPGQPPKRLIYKASTLASGVPSRFKGSGSGTDFTLTISDLECDDAATYYCQCTYGTYAGSFFYSFGGGTEVVVE,5C0N_C,5C0N_D,Development Of A Monoclonal Antibody Targeting Secreted Ap2 To Treat Diabetes And Fatty Liver Disease,Development Of A Monoclonal Antibody Targeting Secreted Ap2 To Treat Diabetes And Fatty Liver Disease,Oryctolagus cuniculus,"Burak,M.F.;Inouye,K.E.;White,A.;Lee,A.;Tuncman,G.;Calay,E.S.;Sekiya,M.;Tirosh,A.;Eguchi,K.;Birrane,G.;Lightwood,D.;Howells,L.;Odede,G.;Hailu,H.;West,S.;Garlish,R.;Neale,H.;Doyle,C.;Moore,A.;Hotamisligil,G.S.",Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes,12-JUN-2015,8_7_17_6_3_14,5C0N_C_D,Xtal structure,FABP4; aP2; A-FABP,2,1,-0.14182848,19.147346
6LDW_H_L,QSVEESGGRLVTPGTPLTLTCTVSGFSLTSYDMSWVRQAPGKGLEYIGFISSTTGGTYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCAAGSWYNMWGPGTLVTVSS,AQVLTQTPSSVSAAVGGTVTINCQASQSVYNNNWLGWYQQKPGQPPKLLIYKASTLASGVPSRFRGSGSGTQFTLTISDVQCDDAATYYCAGGYNGNIFPFGGGTEVVVT,6LDW_H,6LDW_L,Structure Of Antibody C9 In Complex With Methylated Peptide,Structure Of Antibody C9 In Complex With Methylated Peptide,Homo sapiens,"Ishii,M.;Nakakido,M.;Caaveiro,J.M.;Kuroda,D.;Okumura,C.J.;Maruyama,T.;Entzminger,K.;Tsumoto,K.",Structural basis for antigen recognition by methylated lysine-specific antibodies,23-NOV-2019,8_8_8_8_3_10,6LDW_H_L,Xtal structure,,2,1,-0.15081176,19.131311
CBJ56867,QSVKESEGDLVKPGASLTLTCKASGFDFTWYTMNWVRQAPGKGLEWIACIGAGVYGSNYYASWAKGRFTISKASSTTVTLQMTSLTVADTATYFCARDGINGGYDIWGPGTLVTVSS,ELVMTQTESPVSAAVGGTVTIKCQSSQSVYNNRLAWYQQKPGQRPKLLIYSASTLASGVPSRFKGSGSGTQFTLTISDLEWGDAATYYCHGGYRSNDDRYAFSGGTELEI,CBJ56867_H,CBJ56867_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Braulke,T.; Muller-Loennies,S.",Mannose-6-phosphate-binding antibodies and their uses,17-FEB-2010,8_9_11_7_3_12,CBJ56867,Same entry,,2,1,-0.38450953,18.477522
AAO06760_AAO06761,QSVKESEGGLFKPTDTLTLTCTVSGFSLNNYAITWVRQAPGKHLEWIGWISSGGPAYYASWAKGRFTISKTSTTVDLKMTSLTTEDTATYFCARIDDSYNYFNLWGPGTLVTVSS,ELDMTQTPSSTSTAVGDTVTIKCQASEDIYRNLAWFQQKPGQPPKLLLYAASNLASGVPSRFKGSRSGTEFTLTISGVQREDAATYYCLGSRTNSDRAFGGGTELEIL,AAO06760,AAO06761,"antibody variable domain, partial [Oryctolagus cuniculus]","antibody variable domain, partial [Oryctolagus cuniculus]",Oryctolagus cuniculus,"Popkov,M.; Mage,R.G.; Alexander,C.B.; Thundivalappil,S.; Barbas,C.F. III; Rader,C.",Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display,24-JUL-2016,8_7_12_6_3_10,AAO06760_AAO06761,Unique source,,2,1,-0.16773479,19.098751
6CWT_C_D,QSVKESEGRLVTPGTPLTLTCTGSGFSLSTYAMIWVRQAPGQGVEYIGIINTGGSASYASWAKGRFTISRTSTTVDLKITSPTTEDTATYFCARTRGVNDAYEHAFDPWGPGTLVTVSS,ELVMTQTPSSTSAAVGGTVTINCQASQSIGNALAWYQQKPGQPPKLLISAGSNLASGVPSRFRGSGSGTEYTLTISDVQREDAATYYCLGTYSAIDRAFGAGTNVEIE,6CWT_C,6CWT_D,Hepatitis B Core-Antigen In Complex With Fab E21,Hepatitis B Core-Antigen In Complex With Fab E21,Hepatitis B virus subtype adyw,"Eren,E.;Watts,N.R.;Dearborn,A.D.;Palmer,I.W.;Kaufman,J.D.;Steven,A.C.;Wingfield,P.T.",Structures of Hepatitis B Virus Core- and e-Antigen Immune Complexes Suggest Multi-point Inhibition,30-MAR-2018,8_7_16_6_3_10,6CWT_C_D,Xtal structure,Hepatitis,2,1,-0.1505474,19.12987
7MFR_Y_X,QSVKESGGRLVTPGTPLTLTCKVSGFSLSSYYMNWVRQAPGKGLEWIGIMFPNGKIYYATWAKGRFTISKTSTTVDLKIISPTTEDTATYFCTGDDSGDVNIWGPGTLVTVSS,DIVLTQTASPVSAAVGGTVTINCQSSQSVYTNNRLAWYQQKPGQPAKEMIYGASTLPSGVSSRFKGSGSGTQFALTISDVQADDAATYYCLGTYDCLSADCLAFGGGTKLEIK,7MFR_Y,7MFR_X,Crystal Structure Of A Fab Fragment Bound To Peptide Ggm,Crystal Structure Of A Fab Fragment Bound To Peptide Ggm,Homo sapiens,"Davies,C.W.;Vidal,S.E.;Phu,L.;Sudhamsu,J.;Hinkle,T.B.;Chan Rosenberg,S.;Schumacher,F.R.;Zeng,Y.J.;Schwerdtfeger,C.;Peterson,A.S.;Lill,J.R.;Rose,C.M.;Shaw,A.S.;Wertz,I.E.;Kirkpatrick,D.S.;Koerber,J.T.",Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W,10-APR-2021,8_7_10_8_3_13,7MFR_Y_X,Xtal structure,UBC-16; UBE2W; FLJ11011,2,1,-0.14832674,19.13711
URX40003_URX40042,QTLVQSRAEVKKSGASVRVSCEASGYNFIDHVIHWVRQVPGQRPEWMGWMKPRGGAVNYARSFRGRITLTRQMSMDTDMAYMDLSRLRPDDTAMYYCATRVKLPSSDDYGFDVWGQGTLVKVSA,QSALTQPHSVSGSPGQSVTISCTGLSGYVDVVWYQQHPGRAPKLIIYDVNRRPSGVPDRFSGSKSGNTASLTISGLRAEDEADYFCSSYEFFGGGTRVTVL,URX40003,URX40042,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Barnes,C.O.; Schoofs,T.; Gnanapragasam,P.N.P.; Golijanin,J.; Huey-Tubman,K.E.; Gruell,H.; Schommers,P.; Suh-Toma,N.; Lee,Y.E.; Cetrulo Lorenzi,J.C.; Piechocka-Trocha,A.; Scheid,J.F.; West,A.P. Jr.; Walker,B.D.; Seaman,M.S.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,15-AUG-2022,8_8_16_5_3_5,URX40003_URX40042,Unique source,HIV; CD4,2,1,2.6408765,3.5224388
6LDY_A_B,QTVKESGGRLVTPGGTLTLTCTVSGFSLSRYAMSWVRQAPGEGLEYIGWINTYGSAYYASWVNGRFTISKTSTTMDLKMTSLTAADTATYFCVRWFADGGMDPWGPGTLVTVSS,ALVLTQTPSPVSAAVGGAVSISCQSSQNIYKDNELSWYQQKPGQPPKLLIYKASTLASGVPSRFSGSGSGTQFTLTISGVQCDDAATYYCQGSRYNNGWDSGFGGGTEVVVK,6LDY_A,6LDY_B,Structure Antibody D6 In Complex With Methylated Peptide,Structure Antibody D6 In Complex With Methylated Peptide,Homo sapiens,"Ishii,M.;Nakakido,M.;Caaveiro,J.M.;Kuroda,D.;Okumura,C.J.;Maruyama,T.;Entzminger,K.;Tsumoto,K.",Structural basis for antigen recognition by methylated lysine-specific antibodies,23-NOV-2019,8_7_11_8_3_12,6LDY_A_B,Xtal structure,,2,1,-0.16958503,19.098055
QCT24587,QVELQESGPGILQPSQTLSLTCSFSGFSLSTSGMSVGWIRQPSGEGLEWLADIWWDDKKDYNPSLKSRLTISKDTSSNQVFLKITGVDTADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQLTQSPAIMSASPGEKVTMTCSASSSVGYMHWYQQKSSTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSIQAEDVATYYCFRGSGYPFTFGQGTKLEIK,QCT24587_H,QCT24587_L,single chain antibody precursor [synthetic construct],single chain antibody precursor [synthetic construct],synthetic construct,"Moffett,H.F.; Harms,C.K.; Fitzpatrick,K.S.; Tooley,M.R.; Boonyaratanakornkit,J.; Taylor,J.J.",B cells engineered to express pathogen-specific antibodies protect against infection,28-MAY-2019,10_7_12_5_3_9,QCT24587,Same entry,,2,1,11.506786,1.9054883
7WPH_E_D,QVELQESGPGLVKPSGTLSLTCAVSGGSISSNNWWTWVRQPPGKGLEWIGEIHHSGGTNYNPSLKSRVTMSVDKSKNQFSLNLYSVTAADTAVYYCTRDRAGGTYSGFDFWGQGTLVTVSS,QAVVTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL,7WPH_E,7WPH_D,Sars-Cov2 Rbd Bound To Fab06,Sars-Cov2 Rbd Bound To Fab06,Homo sapiens,"Ku,Z.;Xie,X.;Lin,J.;Gao,P.;El Sahili,A.;Su,H.;Liu,Y.;Ye,X.;Li,X.;Fan,X.;Goh,B.C.;Xiong,W.;Boyd,H.;Muruato,A.E.;Deng,H.;Xia,H.;Jing,Z.;Kalveram,B.K.;Menachery,V.D.;Zhang,N.;Lescar,J.;Shi,P.Y.;An,Z.",Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth,23-JAN-2022,9_7_14_9_3_10,7WPH_E_D,Xtal structure,SARS-CoV-2,2,1,15.61522,-7.371094
6GFE_H_L,QVELQQSGPGLVKPSQTLSLTCAISGDSVSSRSASWSWIRQSPGRGLEWLGRTYYRSHWYYEYAQSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARMDVPSFRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQISNSPPTFGQGTKVEIK,6GFE_H,6GFE_L,High-Resolution Structure Of A Therapeutic Full-Length Anti-Npra Antibody With Exceptional Conformational Diversity,High-Resolution Structure Of A Therapeutic Full-Length Anti-Npra Antibody With Exceptional Conformational Diversity,Homo sapiens,"Blech,M.;Horer,S.;Kuhn,A.B.;Kube,S.;Goddeke,H.;Kiefer,H.;Zang,Y.;Alber,Y.;Kast,S.M.;Westermann,M.;Tully,M.D.;Schafer,L.V.;Garidel,P.",Structure of a Therapeutic Full-Length Anti-NPRA IgG4 Antibody: Dissecting Conformational Diversity,30-APR-2018,10_9_13_7_3_9,6GFE_H_L,Xtal structure,ANPRA; NPRA; GUCY2A; NPR1; ANPa,2,1,15.485763,-4.679837
8CZ8_C_C,QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL,8CZ8_C,8CZ8_C,"Novel Anti-Mesothelin Antibodies Enable Crystallography Of The Intact Mesothelin Ectodo- Main And Engineering Of Potent, T Cell-Engaging Bispecific Therapeutics","Novel Anti-Mesothelin Antibodies Enable Crystallography Of The Intact Mesothelin Ectodo- Main And Engineering Of Potent, T Cell-Engaging Bispecific Therapeutics",Homo sapiens,"Bandaranayake,A.D.;Rupert,P.B.;Lin,I.;Pilat,K.;Ruff,R.O.;Friend,D.J.;Chan,M.K.;Clarke,M.;Carter,J.;Meshinchi,S.;Mehlin,C.;Olson,J.M.;Strong,R.K.;Correnti,C.E.","Novel Anti-Mesothelin Antibodies Enable Crystallographyof the Intact Mesothelin Ectodo-main and Engineering of Potent, T cell-engagingBispecific Therapeutics",07-JUN-2023,8_8_13_9_3_11,Anetumab,Xtal structure,Mesothelin,2,1,-12.505155,5.678688
4DN4_H_L,QVELVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,4DN4_H,4DN4_L,Crystal Structure Of The Complex Between Cnto888 Fab And Mcp-1 Mutant P8A,Crystal Structure Of The Complex Between Cnto888 Fab And Mcp-1 Mutant P8A,Homo sapiens,"Obmolova,G.;Teplyakov,A.;Malia,T.J.;Grygiel,T.L.;Sweet,R.;Snyder,L.A.;Gilliland,G.L.",Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888,08-FEB-2012,8_8_12_7_3_10,4DN4_H_L,Xtal structure,MCAF; GDCF-2; HC11; MCP-1; SMC-CF; MGC9434; CCL2; SCYA2; MCP1,2,1,-0.5637834,5.675042
BAU88531,QVHLEQSGAQLVKPGASVKLSCKASGYTFTSYYMYWVKQRPGQGLEWIGEINPSNGGTNFNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYSAMRAYAMDYWGQGTTVTVSS,DIELTQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFGAGTKLELK,BAU88531_H,BAU88531_L,scFv antibody [synthetic construct],scFv antibody [synthetic construct],synthetic construct,"Yarian,F.; Bandehpour,M.; Ahangarzadeh,S.; Kazemi,B.",Selection of specific antibody against Neisseria menangitidis to meningitis diagnosis,20-OCT-2016,8_8_9_6_3_9,BAU88531,Same entry,,2,1,-0.68103915,-3.9418576
WGM82920_WGM82979,QVHLEQWGAGLLKPSETLALTCAVYGESFSGPFNDFYWSWIRQSPGKGLEWIGEINQYNPALKRRVTMSVDTSKNQFSLKLTSVTAADTAVYFCARGRRSVRWSGGRPPGNNALDVWGQGTTVIVSS,EIVLTQSPDTLSLSPGDAATLSCRTSQTVSSSYLAWYQQRPGQAPRVLISDIYNRATGIPDRFSAGGSGTHFTLTISRLEPQDSAVYYCQQYGVSPPYNFGQGTKLVIN,WGM82920,WGM82979,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,12_2_22_7_3_10,WGM82920_WGM82979,Unique source,HIV,2,1,16.685934,-10.51329
ASP44424_ASP44423,QVHLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGQGLEWIGRIYPGDGKTNYNGKFKGKATLIADKSSSTAYMHLSSLTSVDSAVYFCVKRADWGQGTLVTVSA,NIVLTQSPASLAVSLGQRATLSCRASESVDSYGTSFMHWYQQKSGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,ASP44424,ASP44423,anti-Marburg virus nucleoprotein antibody immunoglobulin gamma heavy chain [synthetic construct],anti-Marburg virus nucleoprotein antibody immunoglobulin gamma light chain [synthetic construct],synthetic construct,"Hempel,F.; Maurer,M.; Brockmann,B.; Mayer,C.; Biedenkopf,N.; Kelterbaum,A.; Becker,S.; Maier,U.G.",From hybridomas to a robust microalgal-based production platform: molecular design of a diatom secreting monoclonal antibodies directed against the Marburg virus nucleoprotein,06-AUG-2017,8_8_5_10_3_9,ASP44424_ASP44423,Unique source,Marburg,2,1,0.35189134,-4.705034
7RD5_B_A,QVHLQQSGPELVKPGASVKISCKASGYTFSDYYINWVRQRPGQGLEWIGWIFPGSGNTYYNKEFKVKATLTVDKSSSTAHMFLSSLTSEDSAVYFCVRRYDYDGFAFWGLGTLVTVSA,DIQMQQSPSSLSASLGDTITITCHASQNINAWLSWYQQKPGNIPKLLIYKASNLYTGVPSRFSGSGSGTRFTLTISSLQPEDIATYYCQQGQSSPYTFGGGTKLEIK,7RD5_B,7RD5_A,Crystal Structure Of Tspan15 Large Extracellular Loop (Tspan15 Lel) In Complex With 1C12 Fab,Crystal Structure Of Tspan15 Large Extracellular Loop (Tspan15 Lel) In Complex With 1C12 Fab,Homo sapiens,"Lipper,C.H.;Gabriel,K.H.;Seegar,T.C.;Durr,K.L.;Tomlinson,M.G.;Blacklow,S.C.",Crystal structure of the Tspan15 LEL domain reveals a conserved ADAM10 binding site,09-JUL-2021,8_8_11_6_3_9,7RD5_B_A,Xtal structure,ADAM10; MADM; HsT18717; CD156C; kuz,2,1,0.09014872,-4.488481
UIC72195_UIC72505,QVHLQQWGAGLLKPSETLSLTCAVYGGPFSGYYWSWIRQSPDKGLEWIGETSHSGRTNYTPSLKSRVTISVDTSKNHVSLSLNSVTAADTAVYYCAREKAHDYDSNPYLTLGAYDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCQATQGINNFLNWYQQKPGTAPKLLIYDASNLETGVPSRFSGSGSGTDFSFTISSLQPEDFATYFCQQYDDLPYTFGQGTKLEIK,UIC72195,UIC72505,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_7_21_6_3_9,UIC72195_UIC72505,Unique source,HCV,2,1,16.666048,-10.495914
QKY76606_QKY76219,QVHLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISGDENNKFYANSVKGRFTISRDNSKNTLSLQMNSLRPEDTARYYCAKGGDSSGWAWDGDNPPTDYWGQGTLVIVSS,DIVMTQSPDFLAVSLGERATINCKSSQSVLHTPKNKNYLAWYKQKPGQPPKVLIYWASTRESGVPERFSGSGSGTDFTLIISSLQAEDAAVYYCQQYYTAPLTFGGGTKVEIK,QKY76606,QKY76219,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_20_12_3_9,QKY76606_QKY76219,Unique source,SARS-CoV-2,2,1,15.010209,13.660105
QKY76522_QKY76135,QVHLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISNDEFNKFYANSVKGRFTISRDNSKNTVYLQLNSLRTEDTARYYCAKGGDGSGWAWDGDNPPTDYWGQGTLVIVSS,DIVMTQSPDFLAVSLGERATISCKSSQSVLYTPKNKNYLAWYKQKPGQPPKVLIYWASTRESGVPDRFSGSGSGTDFTLIISSLQAEDAAVYYCQQYYTAPLTFGGGTRVEIK,QKY76522,QKY76135,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_20_12_3_9,QKY76522_QKY76135,Unique source,SARS-CoV-2,2,1,15.035811,13.627737
B56701_A56701,QVHLVESGGGVVQPGRSLTLSCAASGFTFNSYTFHWVRQTPGKGLEWVAVLAYDGSYQHYADSVKGRFTISRDNSKNTLYLQMNSLRLEDTAVYFCARGQTTVTKIDEDYWGQGTLVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRSFGQGTKVEIK,B56701,A56701,Ig heavy chain V region precursor (HuA) - human (fragment),Ig kappa chain V region precursor (HuA) - human (fragment),Homo sapiens,"Nickerson,K.G.; Tao,M.H.; Chen,H.T.; Larrick,J.; Kabat,E.A.","Human and mouse monoclonal antibodies to blood group A substance, which are nearly identical immunochemically, use radically different primary sequences",21-Jan-2000,8_8_14_6_3_9,B56701_A56701,Unique chain,,2,1,14.90353,13.457707
7UFQ_H_L,QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKGGNGNTRYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAVYYCALLTVITKDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQNILYSSNNKNYLAWYQQKPGQPPKLLFYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,7UFQ_H,7UFQ_L,Structure Of Pfcsp Peptide 21 With Antibody P3-43,Structure Of Pfcsp Peptide 21 With Antibody P3-43,Homo sapiens,"Tripathi,P.;Kwong,P.D.",Structure of PfCSP peptide 21 with antibody P3-43,12-APR-2023,8_8_14_12_3_9,7UFQ_H_L,Xtal structure,PfCSP,2,1,0.22118948,3.132364
7LKG_D_E,QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKGGNGNTRYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAVYYCALLTVITPDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQNILYSSNNKNYLAWYQQKPGQPPKLLFYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,7LKG_D,7LKG_E,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M43.151,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M43.151,Plasmodium falciparum 3D7,"Kratochvil,S.;Shen,C.H.;Lin,Y.C.;Xu,K.;Nair,U.;Da Silva,Pe.;Tripathi,P.;Arnold,J.;Chuang,G.Y.;Melzi,E.;Schon,A.;Zhang,B.;Dillon,M.;Bonilla,B.;Flynn,B.J.;Kirsch,K.H.;Kisalu,N.K.;Kiyuka,P.K.;Liu,T.;Ou,L.;Pancera,M.;Rawi,R.;Reveiz,M.;Seignon,K.;Wang,L.T.;Waring,M.T.;Warner,J.;Yang,Y.;Francica,J.R.;Idris,A.H.;Seder,R.A.;Kwong,P.D.;Batista,F.D.",Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies,02-FEB-2021,8_8_14_12_3_9,7LKG_D_E,Xtal structure,PfCSP; malarial,2,1,0.20058727,3.1690261
QDJ57930_QDJ57973,QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYTMHWVRQAPGQRLEWMGWINAGHGTTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARPTSEGVAGPSRYYWYFDLWGRGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPLTFGGGTKVEIK,QDJ57930,QDJ57973,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cassotta,A.; Mikol,V.; Bertrand,T.; Pouzieux,S.; Le Parc,J.; Ferrari,P.; Dumas,J.; Auer,M.; Deisenhammer,F.; Gastaldi,M.; Franciotta,D.; Silacci-Fregni,C.; Fernandez Rodriguez,B.; Giachetto-Sasselli,I.; Foglierini,M.; Jarrossay,D.; Geiger,R.; Sallusto,F.; Lanzavecchia,A.; Piccoli,L.",A single T cell epitope drives the neutralizing anti-idiotypic antibody response to natalizumab in patients with multiple sclerosis,14-JUL-2019,8_8_20_6_3_10,QDJ57930_QDJ57973,Unique source,,2,1,0.26466233,3.1529202
ANV21673_ANV21862,QVHLVQSGAEVKKPGASVKVSCKTSGYTFTSYDIHWVRQAPGQGLEWMGVINPGAGGTIYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCAREILAVERMFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGAEFTLTISSLQPEDFASYYCLQHFRYPLTFGQGTKLQIK,ANV21673,ANV21862,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_13_6_3_9,ANV21673_ANV21862,Unique source,,2,1,1.5626825,3.869867
4EOW_H_L,QVHLVQSGSELKKPGASVKVSCKASGYSFSRYGIKWVRQAPGQGLEWMGWINTRSGVPAYAQGFTGRFVFSLDTSVDTAFLEISSLKTEDTGIYYCATRPPRFYDKTEYWEDGFDVWGRGTLVTVSS,QSVLTQPPSASGTPGQSVNISCSGSSSNIGNSYVYWYQQLPGTAPKLLIYRNNRRPSGVPDRFSGSKSDTSASLAISGLRSEDEADYYCATWDDSLSGRLFGGGTKLTVL,4EOW_H,4EOW_L,Crystal Structure Of A Disease-Associated Anti-Human Gm-Csf Autoantibody Mb007,Crystal Structure Of A Disease-Associated Anti-Human Gm-Csf Autoantibody Mb007,Homo sapiens,"Blech,M.;Seeliger,D.;Kistler,B.;Bauer,M.M.;Hafner,M.;Horer,S.;Zeeb,M.;Nar,H.;Park,J.E.",Molecular structure of human GM-CSF in complex with a disease-associated anti-human GM-CSF autoantibody and its potential biological implications,16-APR-2012,8_8_20_8_3_11,4EOW_H_L,Xtal structure,GM-CSF; GMCSF; CSF2,2,1,-6.958442,5.593325
6LTG_A_B,QVKLEESGLVAPSQSLSITCTVSGFSLIRYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSRLRISKDNSKSQVFLKMNSLQTDDTAMYYCARDDGITTVVEGYVMDYWGQGTSVTVSS,DIVLTQSPASLAASLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNGVPWTFGGGTKLEIK,6LTG_A,6LTG_B,Crystal Structure Of The Fab Fragment Of Murine Monoclonal Antibody Ohv-3 Against Human Herpesvirus 6B,Crystal Structure Of The Fab Fragment Of Murine Monoclonal Antibody Ohv-3 Against Human Herpesvirus 6B,Mus musculus,"Nishimura,M.;Novita,B.D.;Kato,T.;Handayani Tjan,L.;Wang,B.;Wakata,A.;Lystia Poetranto,A.;Kawabata,A.;Tang,H.;Aoshi,T.;Mori,Y.","Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134",17-JUN-2020,8_7_17_10_3_9,6LTG_A_B,Xtal structure,TNFRSF4; ACT35; OX40; TXGP1L; CD134,2,1,22.112,-6.1007814
6QU9_A_B,QVKLEESGPELVKPGASVKISCKASGYSFIGYYMHWVKQSHVKSLEWIGRINPYNGATRYNQNFQDRATLTVDKSSSTAYMDFHSLTSEDSAVYYCVRWPGDYWGQGTSVTVSS,DIVMTQTPSSLSASLGGKVTITCKASQKINNYIAWYQLKPGKGPRQLIHYTSKLQPGIPSRFSGSGSGSDYSFSISNLEPEDIGTYYCLRYEDLWTFGGGTKLEIK,6QU9_A,6QU9_B,Fab Fragment Of An Antibody That Inhibits Polymerisation Of Alpha-1-Antitrypsin,Fab Fragment Of An Antibody That Inhibits Polymerisation Of Alpha-1-Antitrypsin,Mus musculus,"Faull,S.V.;Elliston,E.L.;Gooptu,B.;Jagger,A.M.;Aldobiyan,I.;Redzej,A.;Badaoui,M.;Heyer-Chauhan,N.;Rashid,S.T.;Reynolds,G.M.;Adams,D.H.;Miranda,E.;Orlova,E.V.;Irving,J.A.;Lomas,D.A.",The structural basis for Z alpha1-antitrypsin polymerization in the liver,26-FEB-2019,8_8_7_6_3_8,6QU9_A_B,Xtal structure,,2,1,2.5060105,-4.129338
CAR79039_CAR79040,QVKLEESGPGLVAPSQSLSITCTVSGFSLSRYSVYWVRQPPGKGLEWLGMMWGGGSTDYNSALKSRLSISKDTSKSQVFLKMNSLRTDDTAMYYCVRTDGDYWGQGTSVTVSS,ELQLTQSPLSLPVSLGDQASISCRSSQSLVNSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK,CAR79039,CAR79040,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"den Hartog,M.T.; van Neerven,R.J.",Deimmunized antagonistic anti-human CD40 monoclonal antibody fromthe ch5D12 antibody,26-SEP-2008,8_7_7_11_3_9,CAR79039_CAR79040,Unique chain,TNFRSF5; p50; Bp50; CD40,2,1,22.1276,-6.085076
S31999_S31983,QVKLLESGAELKNPGASVRVSCKASGYTFNDYHVHWVRQAPGQGLEWVGWINPKNAGTRYSQKFQGRVTMTRDTAISAAYMELTSLKSDDTAVYYCARGVGVGTWGLDYWGQGTLVTVSS,ELVMTQSPSSLSASEGDRVTITCRASRAISTYLNWYQQKPRKAPNLLIYGTSTLQSGVPSRFSGSGFGTDFTLTISSLQPEDFATYFCQQSYSSPYTFGQGTKLEIE,S31999,S31983,Ig heavy chain V region - human (fragment),Ig kappa chain - human (fragment),Homo sapiens,"Portolano,S.; Chazenbalk,G.D.; Hutchison,S.J.; McLachlan,S.M.; Rapoport,B.",Direct Submission,21-Jan-2000,8_8_13_6_3_9,S31999_S31983,Unique chain,,2,1,2.2204242,3.8846207
1CT8_B_A,QVKLLESGAVLVKPGASVKLSCKTSGFTFSSSYINWLKQKPGQSLEWIAWIYAGSGGTVYNQHFTDKARLTVDTSSSTAYMQFSSLTTEDSAIYYCARYRYDEGFAYWGQGTLVTVSA,LVMTQTPATLSVTPGDSVSLSCRASQSVSNKLHWYQQKSHESPRLLIKFASQSIPGIPSRFSGSGSGSDFTLSINSVETEDFGIYFCHQTHGRPLTFGAGTKLELK,1CT8_B,1CT8_A,Catalytic Antibody 7C8 Complex,Catalytic Antibody 7C8 Complex,Mus musculus,"Gigant,B.;Tsumuraya,T.;Fujii,I.;Knossow,M.",Diverse structural solutions to catalysis in a family of antibodies,20-AUG-1999,8_8_11_6_3_9,1CT8_B_A,Xtal structure,,2,1,-0.039947152,-4.2594767
A56446,QVKLQESGAELVKPGASVKLSCTTSGFNIKDTYMHWVKQRPEQGLEWIGRIAPANGITKYDPKFQGKATIAADTSSNTAYLQLSSLTSEDTAVYYCASYYLTRYENYWGQGTTVTVSS,DIELTQSPAIMSASLGEKVTMSCRASSSVNFIYWYQQKSDASPKLWVYYTSHLPPGVPARFSGSGSGNSYSLTISSMEGEDAATYYCQQFTSSPFTFGSGTKLEIK,A56446_H,A56446_L,Ig heavy chain V region (3H-3H scFv) - mouse (strain BALB/C),Ig heavy chain V region (3H-3H scFv) - mouse (strain BALB/C),Mus musculus,"Tang,P.M.; Foltz,L.A.; Mahoney,W.C.; Schueler,P.A.",A high affinity digoxin-binding protein displayed on M13 is functionally identical to the native protein,16-AUG-1996,8_8_11_5_3_9,A56446,Same entry,digoxin,2,1,-4.7008,0.16870318
ACM44032,QVKLQESGGGLVKPRGSLKLSCAASGFTFSSYDMSWVRQTPEKRLEWVASIRSGGYYTLYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCSRDGNDEYFDVWGAGTTVTVSS,DIELTQSPAILSASPGEKVTMTCSANSSVSYMHWYQQKSRTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSKYPFTFGSGTRLEIK,ACM44032_H,ACM44032_L,"anti-clenbuterol scFv antibody, partial [synthetic construct]","anti-clenbuterol scFv antibody, partial [synthetic construct]",synthetic construct,"Pan,K.; Wang,H.; Zhang,H.B.; Liu,H.W.; Lei,H.T.; Huang,L.; Sun,Y.M.",Production and characterization of single chain Fv directed against beta2-agonist clenbuterol,24-JUL-2016,8_8_11_5_3_9,ACM44032,Same entry,clenbuterol,2,1,17.955477,7.090694
4QNP_H_L,QVKLQESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKSNNYATFYADSVKDRFTISRDDSQSMLYLQMHNLKTDDTAMYYCVRPSIYYYASGYLDVWGAGTTVTVSS,QIVLSQSPAILSASPGEKVTMTCRTSSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPFRFSGSGSGTSYSLTISRVEAEDAATYYCQQWNSNPPTFGGGTKLEIK,4QNP_H,4QNP_L,Crystal Structure Of The 2009 Pandemic H1N1 Influenza Virus Neuraminidase With A Neutralizing Antibody,Crystal Structure Of The 2009 Pandemic H1N1 Influenza Virus Neuraminidase With A Neutralizing Antibody,Mus musculus,"Wan,H.;Yang,H.;Shore,D.A.;Garten,R.J.;Couzens,L.;Gao,J.;Jiang,L.;Carney,P.J.;Villanueva,J.;Stevens,J.;Eichelberger,M.C.",Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers,18-JUN-2014,8_10_15_5_3_9,AYJ11007_AYJ11008,Xtal structure,neuraminidase; H1N1; Influenza,2,1,13.344485,7.745238
AAN08114,QVKLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSYNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTASYYCARAYYGNWFAYWGQGTTVTVSS,DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQINSWPLTFGAGTKLEIK,AAN08114_H,AAN08114_L,single chain Fv antibody ScF [synthetic construct],single chain Fv antibody ScF [synthetic construct],synthetic construct,"Guo,J.Q.; You,S.Y.; Li,L.; Zhang,Y.Z.; Huang,J.N.; Zhang,C.Y.",Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli,15-APR-2003,9_7_11_6_3_9,AAN08114,Same entry,,2,1,11.65727,-12.749275
1NC4_D_C,QVKLQESGPGLVQPSQSLSITCTVSGFSLTDYGVHWVRQSPGKGLEWLGVIWSGGGTAYTAAFISRLNIYKDNSKNQVFFEMNSLQANDTAMYYCARRGSYPYNYFDVWGQGTTVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGNNNRPPGVPARFSGSLIGDKAALTIAGTQTEDEAIYFCALWYSNHWVFGGGTRLTVL,1NC4_D,1NC4_C,Crystal Structure Of Monoclonal Antibody 2D12.5 Fab Complexed With Gd-Dota,Crystal Structure Of Monoclonal Antibody 2D12.5 Fab Complexed With Gd-Dota,Mus musculus,"Corneillie,T.M.;Fisher,A.J.;Meares,C.F.",Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system,04-DEC-2002,8_7_13_9_3_9,1NC4_D_C,Xtal structure,,2,1,22.598404,-5.600257
AAB41038_AAB41039,QVKLQQSGAELVRSGASVKLSCTASGFNIKDYYMNWVKQRPEQGLEWIGWIDPENGDTEYAPKFQGKATMTADTSSNTAYLQLSSLTSEDTAVYYCNVGYYGSSSLFDYWGQ,DIELTQSPTTMAASPGEKITITCSANSSISSNYLHWYQQKPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQLGNSIPRTFGGGTKLEIK,AAB41038,AAB41039,"immunoglobulin heavy chain subgroup VH-II variable region, partial [Mus musculus]","immunoglobulin light chain kappa variable region, partial [Mus musculus]",Mus musculus,"Meng,J.; John,T.R.; Kaiser,I.I.",Specificity and binding affinity of an anti-crotoxin combinatorial antibody selected from a phage-displayed library,21-JAN-1997,8_8_13_7_3_9,AAB41038_AAB41039,Unique source,crotoxin,2,1,-4.937385,0.38595286
1I8I_B_A,QVKLQQSGGGLVKPGASLKLSCVTSGFTFRKFGMSWVRQTSDKCLEWVASISTGGYNTYYSDNVKGRFTISRENAKNTLYLQMSSLKSEDTALYYCTRGYSSTSYAMDYWGQGTTVTVS,DIELTQSPASLSVATGEKVTIRCMTSTDIDDDMNWYQQKPGEPPKFLISEGNTLRPGVPSRFSSSGTGTDFVFTIENTLSEDVGDYYCLQSFNVPLTFGCGTKLEIK,1I8I_B,1I8I_A,"Crystal Structure Of Dsfv Mr1 In Complex With The Peptide Antigen Of The Mutant Epidermal Growth Factor Receptor, Egfrviii, At Room Temperature","Crystal Structure Of Dsfv Mr1 In Complex With The Peptide Antigen Of The Mutant Epidermal Growth Factor Receptor, Egfrviii, At Room Temperature",synthetic construct,"Landry,R.C.;Klimowicz,A.C.;Lavictoire,S.J.;Borisova,S.;Kottachchi,D.T.;Lorimer,I.A.;Evans,S.V.","Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII",14-MAR-2001,8_8_13_6_3_9,1I8I_B_A,Xtal structure,EGFRvIII; EGF,2,1,17.751173,7.099982
CAC37850,QVKLQQSGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIGNKGNNHATYYAESVKGRFTVSRDDSKSRVYLQMNSLRVEDTGTYYCTTRFAYWGQGTTVTVSS,DIQMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGGGSGQDYSLTISSLEYEDMGIYYCLQYDEFPRTFGGGTKLEIK,CAC37850_H,CAC37850_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Abken,H.",Polypeptides for detection and elimination of ca19-9 antigen positive cells,01-MAY-2001,8_10_6_6_3_9,CAC37850,Same entry,,2,1,13.4214945,6.9450755
ACN87219,QVKLQQSGTEVVKPGASVKLSCKASGYIFTSYDIDWVRQTPEQGLEWIGWIFPGEGSTEYNEKFKGRATLSVDKSSSTAYMELTRLTSEDSAVYFCARGDYYRRYFDLWGQGTTVTVSS,DIELTQSPAIMSASPGERVTMTCSASSSIRYIYWYQQKPGSSPRLLIYDTSNVAPGVPFRFSGSGSGTSYSLTINRMEAEDAATYYCQEWSGYPYTFGGGTKLELK,ACN87219_H,ACN87219_L,"anti-carbofuran single-chain variable fragment antibody, partial [synthetic construct]","anti-carbofuran single-chain variable fragment antibody, partial [synthetic construct]",synthetic construct,"Wang,H.; Yang,J.Y.; Liu,X.X.; Liang,Y.; Lei,H.T.; Shen,Y.D.; Xu,Y.Z.; Sun,Y.M.","Cloning, expression and identification of anti-carbofuran single chain Fv gene",24-JUL-2016,8_8_12_5_3_9,ABP13051,Same entry,carbofuran,2,1,0.06157623,-4.2648406
7M1C_H_L,QVKLVESGGGVVQPGRSLRLSCAGSGFAFDNYAMHWVRQAPGKGLEWVAVISLEGRNKYYAGPAKGRFSISRDNSRNTVHLQMNSLRPEDTAVYFCARDMRYYYDSNGHYRNRYGMDVWGQGTTVIVSS,DIQMTQSPSSLSASVGDSVTITCQASQDINQFVSWYQQKPGKPPKLLIYDASNLESGVPSRFSGSGSGTHFTFTISSLQPDDIATYYCQQYENLFTFGPGTKVDIK,7M1C_H,7M1C_L,Crystal Structure Of The Hcmv Pentamer-Specific Antibody 1-32,Crystal Structure Of The Hcmv Pentamer-Specific Antibody 1-32,Homo sapiens,"Wrapp,D.;Ye,X.;Ku,Z.;Su,H.;Jones,H.G.;Wang,N.;Mishra,A.K.;Freed,D.C.;Li,F.;Tang,A.;Li,L.;Jaijyan,D.K.;Zhu,H.;Wang,D.;Fu,T.M.;Zhang,N.;An,Z.;McLellan,J.S.",Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies,12-MAR-2021,8_8_22_6_3_8,7M1C_H_L,Xtal structure,neuropilin; HCMV,2,1,14.142291,13.997823
5N7W_H_L,QVKLVQSGAEVKKPGASVKVSCKASGYTFSSYWIAWVRQAPGQGLEWIGEILPGSGSTNYAQKFQGRATMTADTSTSTVYMELSSLRSEDTAVYYCARFPYYYGNWDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIWWYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGFYLPWTFGGGTKVEIK,5N7W_H,5N7W_L,Computationally Designed Functional Antibody,Computationally Designed Functional Antibody,Homo sapiens,"Nimrod,G.;Fischman,S.;Austin,M.;Herman,A.;Keyes,F.;Leiderman,O.;Hargreaves,D.;Strajbl,M.;Breed,J.;Klompus,S.;Minton,K.;Spooner,J.;Buchanan,A.;Vaughan,T.J.;Ofran,Y.",Computational Design of Epitope-Specific Functional Antibodies,21-FEB-2017,8_8_12_6_3_9,5N7W_H_L,Xtal structure,,2,1,1.2835903,4.0488896
QEP20466_QEP21114,QVLLVQSGAEVKTPGSSIKVSCKTSGGTFRGKAVTWARQARGQGPEWMGGFIPPFGTPNYAPKFLGRVTFTMDQSTSTAYMEVRSLTSEDTAIYYCAGGVVTSSMPPRYYMDVWGQGTSVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSALAWYHQNPGKAPKLLIYDASTLQNGVPSRFSGGGSGAEFTLTIHSLQPEDLGTYYCQQYKSYSITFGQGTRLQIK,QEP20466,QEP21114,"IGH + IGL c573_heavy_IGHV1-69_IGHD2-21_IGHJ6, partial [Homo sapiens]","IGH + IGL c573_light_IGKV1-9_IGKJ5, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_17_6_3_9,QEP20466_QEP21114,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,-0.6320827,5.908333
1LK3_I_M,QVNLLQSGAALVKPGASVKLSCKASGYTFTDFYIHWVKQSHGKSLEWIGYINPNSGYTNYNEKFKNKATLTVDKSTSTGYMELSRLTSEDSANYSCTRGVPGNNWFPYWGQGTLVTVSS,DTVLTQPPALTVSPGEKLTISCKASESVTSRMHWYQQKPGQQPKLLIYKASNLASGVPARFSGSGSGTDFTLTIDPVEADDTAIYFCQQSWNGPLTFGAGTKLELK,1LK3_I,1LK3_M,Engineered Human Interleukin-10 Monomer Complexed To 9D7 Fab Fragment,Engineered Human Interleukin-10 Monomer Complexed To 9D7 Fab Fragment,Rattus norvegicus,"Josephson,K.;DiGiacomo,R.;Indelicato,S.R.;Iyo,A.H.;Nagabhushan,T.L.;Parker,M.H.;Walter,M.R.",Design and analysis of an engineered human interleukin-10 monomer,23-APR-2002,8_8_12_6_3_9,1LK3_I_M,Xtal structure,interleukin,2,1,-0.48047498,-3.9373164
1YUH_H_L,QVQFQQSGAELVKPGASVKLSCKASGYTFTSYLMHWIKQRPGRGLEWIGRIDPNNVVTKFNEKFKSKATLTVDKPSSTAYMELSSLTSEDSAVYYCARYAYCRPMDYWGQGTTVTVSS,AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDRLFTGLIGGTNNRGPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,1YUH_H,1YUH_L,Fab Fragment,Fab Fragment,Mus musculus,"Yuhasz,S.C.;Ysern,X.;Strand,M.;Amzel,L.M.",Crystallization and preliminary X-ray diffraction studies of an anti-4-hydroxy-3-nitrophenylacetic acid monoclonal antibody Fab fragment complexed with immunizing and heteroclitic haptens,30-JAN-1996,8_8_11_9_3_9,1YUH_H_L,Xtal structure,4-hydroxy-3-nitrophenylacetic,2,1,-0.7388867,-3.9027784
QKY76349_QKY75962,QVQLAQSGAEVKKPGASVKVSCKAAGYTFTSYDINWVRQATGQGLEWMGWMNSNSGNAGYAQKFQGRVTMTRDTSTSTAYMELSSLTSDDTAVYYCARMRTGWPTHGRPDDFWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNSNIGSYTVNWYQQFPGTAPKLLIYDNNQRTSGVPDRFSGSKSGTSASLAISGLQSEDEANYYCLVWDDSLNGLVFGGGTKLTVL,QKY76349,QKY75962,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_16_8_3_11,QKY76349_QKY75962,Unique source,SARS-CoV-2,2,1,2.1126356,4.239845
5L0Q_C_B,QVQLEESGAELARPGSSVKLSCKASGYTFTNYWLQWVKQRTGQGLEWIGAIYPRDGDAKYSQKFKDKASLTVNESSSTAYMHLSALASEDSAVYYCARANYGLYYAMDRWGQGTSVTVSS,DIFLTQSPANMSVSPGERVSFSCRASQNIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFILSINTVESEDIAVYFCQQSNRWPFTFGSGTKLEV,5L0Q_C,5L0Q_B,Crystal Structure Of The Complex Between Adam10 D+C Domain And A Conformation Specific Mab 8C7.,Crystal Structure Of The Complex Between Adam10 D+C Domain And A Conformation Specific Mab 8C7.,Homo sapiens,"Atapattu,L.;Saha,N.;Chheang,C.;Eissman,M.F.;Xu,K.;Vail,M.E.;Hii,L.;Llerena,C.;Liu,Z.;Horvay,K.;Abud,H.E.;Kusebauch,U.;Moritz,R.L.;Ding,B.S.;Cao,Z.;Rafii,S.;Ernst,M.;Scott,A.M.;Nikolov,D.B.;Lackmann,M.;Janes,P.W.",An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth,28-JUL-2016,8_8_13_6_3_9,5L0Q_C_B,Xtal structure,ADAM10; MADM; HsT18717; CD156C; kuz,2,1,0.4163281,-3.835482
QEP20272_QEP20920,QVQLEESGGGVVQPGGSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIHYDGKSRYYAASVKGRFTVSRDNSKNTLYLQMNSLRTEDTAIYYCAKGRGGPIQLWFHWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWYQQKPGKAPELLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDSATYYCQQYNSYQWTFGQGTKVEIR,QEP20272,QEP20920,"IGH + IGL c379_heavy_IGHV3-30_IGHD5-18_IGHJ4, partial [Homo sapiens]","IGH + IGL c379_light_IGKV1-5_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_13_6_3_9,QEP20272_QEP20920,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,14.963552,13.367463
UIC72238_UIC72548,QVQLEQSGAEVKKPGASVKISCKASGYSFSTYYMHWVRQAPGQGLEWMGITSPSGDYTRYAQKLHGRVIMTTDTSTRTVYMELSSLRSDDTAVYYCARDFAPPGNWYFDLWGRGTQVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSLSSSLAWYQQKPGQAPRLLIYDTSNRASGIPARFSGSGSGTDFTLTITSLEPEDFAVYYCQQHSNEAFGGGTKVEIK,UIC72238,UIC72548,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_14_6_3_7,UIC72238_UIC72548,Unique source,HCV,2,1,1.8721935,3.948849
WAM57778_WAM58014,QVQLEQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQVPGQGLEWMGWINPNSGGTNYALKFQGRVTMTRDTSITTAYMDLSRLISDDTAVYYCAIDRGIGRETYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQIDSSNHLAWYQQKPGQAPRLLIYGASNRATGIPDRFTGSGSGTDLTLTISRLEPEDFAVYYCQQYETFGGGTKLEIK,WAM57778,WAM58014,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Jing,C.; Ye,A.Y.; Kratochvil,S.; Cottrell,C.A.; Jahyun,K.; Williams,A.C.; Francisco,L.V.; Batra,H.; Edward,L.; Zhang,Y.; Barbieri,A.; Manis,J.P.; Haynes,B.F.; Schief,W.R.; Batista,F.D.; Tian,M.",Humanized V(D)J-rearranging and TdT-expressing Mouse Vaccine Models with Physiological HIV-1 Broadly Neutralizing Antibody Precursors,17-DEC-2022,8_8_16_7_3_5,WAM57778_WAM58014,Unique source,HIV,2,1,2.3635628,3.7805552
ADB28036,QVQLKESGPGILQPSQTLSLACSFSGFSLSTFGMSVGWIRQSSGKCLEWLAHIWWNGVKPYNPALKSRLTISRDAFNNLVFLKIASVVTADSATYYCVRWSDGAMDSWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSDGNTYLEWFLQKPGQSPKVLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPPTFGCGTKLEIK,ADB28036_H,ADB28036_L,anti-chloramphenicol single-chain disulfide-stablilized variable fragment [synthetic construct],anti-chloramphenicol single-chain disulfide-stablilized variable fragment [synthetic construct],synthetic construct,"Li,H.J.; Zhao,L.; Chen,W.; Tang,W.; Li,Q.",Direct Submission,17-JAN-2010,10_7_10_11_3_9,ADB28036,Same entry,chloramphenicol,2,1,11.492077,1.929023
1GGI_H_L,QVQLKESGPGILQPSQTLSLTCSFSGFSLSTYGMGVSWIRQPSGKGLEWLAHIFWDGDKRYNPSLKSRLKISKDTSNNQVFLKITSVDTADTATYYCVQEGYIYWGQGTSVTVSS,DIVLTQSPGSLAVSLGQRATISCRASESVDDDGNSFLHWYQQKPGQPPKLLIYRSSNLISGIPDRFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPLTFGAGTKLEIK,1GGI_H,1GGI_L,Crystal Structure Of An Hiv-1 Neutralizing Antibody 50.1 In Complex With Its V3 Loop Peptide Antigen,Crystal Structure Of An Hiv-1 Neutralizing Antibody 50.1 In Complex With Its V3 Loop Peptide Antigen,synthetic construct,"Stura,E.A.;Stanfield,R.L.;Fieser,G.G.;Silver,S.;Roguska,M.;Hincapie,L.M.;Simmerman,H.K.;Profy,A.T.;Wilson,I.A.","Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gp120",02-APR-1993,10_7_7_10_3_9,1GGI_H_L,Xtal structure,gp120; HIV,2,1,11.513393,1.9043697
3KJ4_H_L,QVQLKESGPGLVAPSQSLSISCSVSGFSLSSYGVHWVRQSPGQGLEWLGVIWSGGNTHYNSALMSRLSISKENSKNQVFLKMNSLQTDDTAIYYCARVGIYYEGAWFAYWGQGTLVTVS,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRNRKNYLAWYQQKPGQSPKPLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCMQSYNLFTFGSGTKLEIK,3KJ4_H,3KJ4_L,Structure Of Rat Nogo Receptor Bound To 1D9 Antagonist Antibody,Structure Of Rat Nogo Receptor Bound To 1D9 Antagonist Antibody,Rattus norvegicus,"Weinreb,P.H.;Wen,D.;Qian,F.;Wildes,C.P.;Garber,E.A.;Walus,L.;Jung,M.Y.;Wang,J.;Relton,J.K.;Amatucci,J.;Wang,R.;Porreca,F.;Silvian,L.;Meier,W.;Pepinsky,R.B.;Lee,D.H.",Resolution of disulfide heterogeneity in Nogo receptor I fusion proteins by molecular engineering,02-NOV-2009,8_7_14_12_3_8,3KJ4_H_L,Xtal structure,,2,1,22.192516,-6.0176744
3W13_C_D,QVQLKESGPGLVAPSQSLSITCTVSGFPLTAYGVNWVRQPPGKGLEWLGMIWGDGNTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARDPYGSKPMDYWGQGTSVTV,DIVMSQSPSSLVVSVGEKVTMSCKSSQSLLYSSNQKNFLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYFRYRTFGGGTKLEIK,3W13_C,3W13_D,"Insulin Receptor Ectodomain Construct Comprising Domains L1-Cr In Complex With High-Affinity Insulin Analogue [D-Pro-B26]-Dti-Nh2, Alphact Peptide(693-719) And Fab 83-7","Insulin Receptor Ectodomain Construct Comprising Domains L1-Cr In Complex With High-Affinity Insulin Analogue [D-Pro-B26]-Dti-Nh2, Alphact Peptide(693-719) And Fab 83-7",Homo sapiens,"Menting,J.G.;Whittaker,J.;Margetts,M.B.;Whittaker,L.J.;Kong,G.K.;Smith,B.J.;Watson,C.J.;Zakova,L.;Kletvikova,E.;Jiracek,J.;Chan,S.J.;Steiner,D.F.;Dodson,G.G.;Brzozowski,A.M.;Weiss,M.A.;Ward,C.W.;Lawrence,M.C.",How insulin engages its primary binding site on the insulin receptor,06-NOV-2012,8_7_12_12_3_8,3W13_C_D,Xtal structure,insulin; Ectodomain,2,1,22.06515,-6.147094
4EDX_H_L,QVQLKESGPGLVAPSQSLSITCTVSGFSLIGYDINWVRQPPGKGLEWLGMIWGDGTTDYNSALKSRLSISKDNSKSQVFLKMNSLRTDDTATYSCARGGYYYGTSYYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNHLNWYQQKPDGTVKLLIYYISRFHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQSKTLPYTFGGGTKLEIK,4EDX_H,4EDX_L,Nerve Growth Factor In Complex With Fab From Mouse Mab 911,Nerve Growth Factor In Complex With Fab From Mouse Mab 911,Mus musculus,"La Porte,S.L.;Eigenbrot,C.;Ultsch,M.;Ho,W.H.;Foletti,D.;Forgie,A.;Lindquist,K.C.;Shelton,D.L.;Pons,J.",Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes,27-MAR-2012,8_7_15_6_3_9,4EDX_H_L,Xtal structure,,2,1,22.06284,-6.149
7OO2_C_D,QVQLKESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWGGGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARNYRGFAYWGQGTLVTVSA,ETTVTQSPASLSVATGEKVTIRCITSTDIDDDMTWYQQKPGEPPKLLISEATTLRPGVPSRFSASGYGTDFVFTIENTLSEDVADYYCLQSDNMPYTFGGGTKLEIK,7OO2_C,7OO2_D,Crystal Structure Of An Antibody Targeting The Capsular Polysaccharide Of Serogroup X Neisseria Meningitidis (Menx),Crystal Structure Of An Antibody Targeting The Capsular Polysaccharide Of Serogroup X Neisseria Meningitidis (Menx),Mus musculus,"Pietri,G.P.;Tontini,M.;Brogioni,B.;Oldrini,D.;Robakiewicz,S.;Henriques,P.;Calloni,I.;Abramova,V.;Santini,L.;Malic,S.;Miklic,K.;Lisnic,B.;Bertuzzi,S.;Unione,L.;Balducci,E.;de Ruyck,J.;Romano,M.R.;Jimenez-Barbero,J.;Bouckaert,J.;Jonjic,S.;Rovis,T.L.;Adamo,R.",Elucidating the Structural and Minimal Protective Epitope of the Serogroup X Meningococcal Capsular Polysaccharide,26-MAY-2021,8_7_9_6_3_9,7OO2_C_D,Xtal structure,Polysaccharide,2,1,22.138857,-6.0729823
CAO02304_CAO02305,QVQLKESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWGGGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARSGVREGRAQAWFAYWGQGTLV,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFGGGTKL,CAO02304,CAO02305,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Mateo De Acosta Del Rio,C.M.; Lombardero Valladares,J.; Roque Navarro,L.T.; Lopez Requena,A.",Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors,26-JUN-2007,8_7_16_6_3_9,AJM22099_AJM22100,Ordered entries,Ganglioside,2,1,22.13258,-6.07777
6GFF_N_M,QVQLKESGPGLVAPSQSLSITCTVSGFSLTGYGINWVRQPPGKGLEWLGMIWSDGSTDYNSVLTSRLRISKDNSNSQVFLKMNSLQVDDTARYYCARDRNYYDYDGAMDYWGQGTSVTVSS,DIQVTQSSSYLSVSLGDRVTITCKASDHIKNWLAWYQQKPGIAPRLLVSGATSLEAGVPSRFSGSGSGKNFTLSITSLQTEDVATYYCQQYWSTPWTFGGGTTLEIR,6GFF_N,6GFF_M,Structure Of Garp (Lrrc32) In Complex With Latent Tgf-Beta1 And Mhg-8 Fab,Structure Of Garp (Lrrc32) In Complex With Latent Tgf-Beta1 And Mhg-8 Fab,Mus musculus,"Lienart,S.;Merceron,R.;Vanderaa,C.;Lambert,F.;Colau,D.;Stockis,J.;van der,Wo.;De Haard,H.;Saunders,M.;Coulie,P.G.;Savvides,S.N.;Lucas,S.",Structural basis of latent TGF-beta1 presentation and activation by GARP on human regulatory T cells,30-APR-2018,8_7_15_6_3_9,AYH59222_AYH59223,Xtal structure,CNCG3L; RCNCb; RCNC2; CNGB1B; GAR1; GARP; CNGB1; RP45; CNCG2,2,1,22.036997,-6.175164
CAA37689_CAA37693,QVQLKESGPGLVAPSQSLSITCTVSGFSLTNFAVHWVRQSPGKGLEWLGVIWSDGRTDYNVPFISRLSISKDNSKSQVIFKMNSLQADDTAMYYCARKLRRPAAWFASWGQGTLVT,DVVVTQTPLSPPVSFGDQVSISCRSSQSLANSYGNTYLSWYLHKTGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISTIKPEDLGMYYCLQVTHQPTWTFGGGTKLEIK,CAA37689,CAA37693,"anti-DNA autoantibody (BV16-13), partial [Mus musculus]","anti-DNA autoantibody (BV16-13), partial [Mus musculus]",Mus musculus,"Smith,R.G.; Voss,E.W. Jr.",Variable region primary structures of monoclonal anti-DNA autoantibodies from NZB/NZW F1 mice,26-JUL-2016,8_7_13_11_3_10,CAA37689_CAA37693,Unique word,DNA,2,1,22.57676,-5.6245527
BDZ85346_BDZ85411,QVQLKESGPGLVAPSQSLSITCTVSGFSLTNYAISWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDSSKSQVFLKMNSLQTDDTARYYCARFSYYSYPYAMDYWGQGTSVTVSS,DVVMTQTPLSLSVTIGQPASISCKSSQSLLHSDGKTYLNWLLQRPGQSPKLLIYLVSKLESGIPDRVSGSGSGTDFTLKISRVEVEDLGVYYCLQHTHFPHTFGAGTKLELK,BDZ85346,BDZ85411,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_7_14_11_3_9,BDZ85346_BDZ85411,Unique source,SARS-CoV-2,2,1,22.045406,-6.167436
8EUQ_C_D,QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWAGGSINYNSALMSRLSISKDNFKSQVFLKMSSLQTDDTAMYYCARAYGDYVHYAMDYWGQGTSVTASS,DIQMTQSPSSLSASLGQRVSLTCRASQEISGYLTWLQQKPDGTIKRLVYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYTNYPLTFGAGTKLELK,8EUQ_C,8EUQ_D,Crystal Structure Of Hla-Dra*01:01/Hla-Drb1*04:01 In Complex With C44H10 Fab,Crystal Structure Of Hla-Dra*01:01/Hla-Drb1*04:01 In Complex With C44H10 Fab,Homo sapiens,"Kassardjian,A.;Sun,E.;Sookhoo,J.;Muthuraman,K.;Boligan,K.F.;Kucharska,I.;Rujas,E.;Jetha,A.;Branch,D.R.;Babiuk,S.;Barber,B.;Julien,J.P.",Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses,19-APR-2023,8_7_14_6_3_9,8EUQ_C_D,Xtal structure,HLA-DR; SARS-CoV-2,2,1,22.086123,-6.12625
8DE6_E_F,QVQLKESGPGLVAPSQSLSITCTVSGFSLTVYGVNWIRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQTDDTARYYCARDRSYGGSSAWFGYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTISCRASHDISNYLNWYQQKPDGTLKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDVATYFCQQGNYLPYTFGGGTKLEIK,8DE6_E,8DE6_F,Oligomeric C9 In Complex With Ae11 Fab,Oligomeric C9 In Complex With Ae11 Fab,Homo sapiens,"Bayly-Jones,C.;Ho,B.H.T.;Lau,C.;Leung,E.W.W.;D'Andrea,L.;Lupton,C.J.;Ekkel,S.M.;Venugopal,H.;Whisstock,J.C.;Mollnes,T.E.;Spicer,B.A.;Dunstone,M.A.",The neoepitope of the complement C5b-9 Membrane Attack Complex is formed by proximity of adjacent ancillary regions of C9,08-JAN-2009,8_7_15_6_3_9,8DE6_E_F,Xtal structure,CPAMD4; C5a; C5; C5b,2,1,22.101793,-6.109856
6RPS_N_M,QVQLKESGPGLVQPSETLSLTCTVSGFSLTTYSVSWVRQPSGKGPEWMGRMWYDGDTVYNSALKSRLSISRDTSKNQVFLKMNSLETDETGTYYCTRDFGYFDGSSPFDYWGQGVMVTVSS,DIVLTQSPATLSVTPGESVSLSCRASQGISTSIHWYQQKSNESPRLLIKFASQSISGIPSRFSGSGSGTDFTLSINRVESEDFSVYFCQQTYSLPYTFGAGTKLELK,6RPS_N,6RPS_M,X-Ray Crystal Structure Of Carbonic Anhydrase Xii Complexed With A Theranostic Monoclonal Antibody Fragment,X-Ray Crystal Structure Of Carbonic Anhydrase Xii Complexed With A Theranostic Monoclonal Antibody Fragment,Homo sapiens,"Alterio,V.;Kellner,M.;Esposito,D.;Liesche-Starnecker,F.;Bua,S.;Supuran,C.T.;Monti,S.M.;Zeidler,R.;De Simone,G.",Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex,14-MAY-2019,8_7_15_6_3_9,6RPS_N_M,Xtal structure,SH3YL1; DKFZP586F1318; Ray,2,1,22.126122,-6.0899563
2ARJ_H_L,QVQLKESGPGLVQPSQTLSLTCTVSGFSLTSNSVHWVRQPPGKGLEWMGGIWGDGDTDYNSALKSRLSISRDTSKNQVFLKMNSLQTDDTAIYFCTPLIGSWYFDFWGPGTMVTASS,DIVMTQSPSSLAVSAGERVTLNCKASQNVRNNIAWYQQKPGQSPKLLIYYASYRYTGVPDRFTGDGFGTDFTLAINSVQADDAAFYYCQRIYNSPYTFGAGTKLEL,2ARJ_H,2ARJ_L,Cd8Alpha-Alpha In Complex With Yts 105.18 Fab,Cd8Alpha-Alpha In Complex With Yts 105.18 Fab,Mus musculus,"Shore,D.A.;Teyton,L.;Dwek,R.A.;Rudd,P.M.;Wilson,I.A.",Crystal structure of the TCR co-receptor CD8alphaalpha in complex with monoclonal antibody YTS 105.18 Fab fragment at 2.88 A resolution,19-AUG-2005,8_7_11_6_3_9,2ARJ_H_L,Xtal structure,YRS; YTS; YARS1; YARS; tyrRS,2,1,22.22844,-5.9902472
7S13_I_M,QVQLKESGPGLVQPSQTLSLTCTVSGLSLTNNIVSWIRQPPGKGLEWMGVIWSNGGTDYNSAIKSRLSITRDTSKSQVFLKMNSLQTEDTAMYFCASRDYPGFAYWGQGTLVTVSS,YELIQPPSSSVTLGSTVSLTCVGDELPKRYAYWYQQKPDQSIVRVIYEDSKRPSGISDRFSGSSSGTTATLTIRDAQAEDEADYYCLSTYSDDKLPIFGGGTKLTVL,7S13_I,7S13_M,Crystal Structure Of Fab In Complex With Mouse Cd96 Dimer,Crystal Structure Of Fab In Complex With Mouse Cd96 Dimer,Mus musculus,"Lee,P.S.;Chau,B.;Barman,I.;Bee,C.;Jashnani,A.;Hogan,J.M.;Aguilar,B.;Dollinger,G.;Rajpal,A.;Strop,P.",Antibody blockade of CD96 by distinct molecular mechanisms,31-AUG-2021,8_7_10_6_3_11,7S13_I_M,Xtal structure,CD96; TACTILE,2,1,22.197556,-6.017966
5GS0_X_Y,QVQLKESGPGLVRPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKGRISITRDTSKNQFFLKLNSVTTDDTATYYCARAYIGFAYWGQGTLVTVSS,DIQLTQSTSSLPASLGDRVTISCRAGQDISNHLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGSKLEIK,5GS0_X,5GS0_Y,Crystal Structure Of The Complex Of Tlr3 And Bi-Specific Diabody,Crystal Structure Of The Complex Of Tlr3 And Bi-Specific Diabody,Mus musculus,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,13-AUG-2016,9_7_9_6_3_9,5GS0_X_Y,Xtal structure,,2,1,11.629076,-12.780703
CBY84916,QVQLKQSGPELVKPGASVKISCKASGYAFSRSWMNWVKQRPGQGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQVSSLTSVDSAVYFCARGNTVVVPYTMDYWGQGTSVTVPS,DIVMTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPLTFGSGTKLETK,CBY84916_H,CBY84916_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Schuler,G.; Schwenkert,M.; Doerrie,J.; Schaft,N.",MCSP-aligned scFv antibody fragments and use of same,23-DEC-2010,8_8_14_10_3_9,CBY84916,Same entry,CSPG4A; MEL-CSPG; MCSP; MSK16; NG2; MCSPG; HMW-MAA; CSPG4,2,1,0.42958078,-4.777263
5D96_J_I,QVQLKQSGPGLVAPSQSLSITCTVSGFSLTGYSVIWVRQSPGKGLEWLGMIWGDGRTEYKSALKSRLSITKDNSKSQVFLKMNSLQTDDTARYFCASDSMDPGSFAYWGQGTLVTVSS,DVVMTQTHKFMSTSVGDRVSITCKASQDVSGAVAWYQQKSGQSPKLLISMASQRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYAIPLTFGAGTKLELK,5D96_J,5D96_I,Oxidoreductase Fragment Of Mouse Qsox1 In Complex With A Fab Fragment From An Antibody Targeting Mouse And Human Qsox1,Oxidoreductase Fragment Of Mouse Qsox1 In Complex With A Fab Fragment From An Antibody Targeting Mouse And Human Qsox1,Mus musculus,"Grossman,I.;Ilani,T.;Fleishman,S.J.;Fass,D.",Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma,18-AUG-2015,8_7_12_6_3_9,5D96_J_I,Xtal structure,,2,1,22.137598,-6.0713634
5GZ0_D_C,QVQLKQSGPGLVQPGGSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVS,DIQMTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,5GZ0_D,5GZ0_C,"Crystal Structure Of Fm329, A Recombinant Fab Adopted From Cetuximab","Crystal Structure Of Fm329, A Recombinant Fab Adopted From Cetuximab",Homo sapiens/Mus musculus xenograft,"Sim,D.W.;Kim,J.H.;Kim,Y.P.;Won,H.S.","Crystal structure of FM329, a recombinant Fab adopted from cetuximab",26-SEP-2016,8_7_13_6_3_9,5GZ0_D_C,Xtal structure,,2,1,22.599157,-5.600208
7OXN_H_K,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTSYGIHWVRQSPGKGLEWLGVMWSGGITDFYAAFISRLSISRDISKSQVFFKMNSLQADDTAIYYCARGSRYALDYWGQGTSVSVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK,7OXN_H,7OXN_K,Crystal Structure Of Tap01 In Complex With Cyclised Amyloid Beta Peptide,Crystal Structure Of Tap01 In Complex With Cyclised Amyloid Beta Peptide,Homo sapiens,"Bakrania,P.;Hall,G.;Bouter,Y.;Bouter,C.;Beindorff,N.;Cowan,R.;Davies,S.;Price,J.;Mpamhanga,C.;Love,E.;Matthews,D.;Carr,M.D.;Bayer,T.A.",Discovery of a novel pseudo beta-hairpin structure of N-truncated amyloid-beta for use as a vaccine against Alzheimer's disease,22-JUN-2021,8_7_10_6_3_9,AUE40942_AUE40943,Xtal structure,amyloid-beta; Amyloid,2,1,22.606289,-5.5928063
7RK2_C_C,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTSYGVHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSQVFFKMNSLQANDTAIYYCARNSLLDAMDYWGQGTSVTVSS,IVMTQTPKFLLVSAGDRVTITCKASQSVSNAVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYSSPLTFGAGTKLELK,7RK2_C,7RK2_C,"Crystal Structure Of The Human Astrovirus Serotype 8 Capsid Spike In Complex With Scfv 2D9, An Astrovirus-Neutralizing Antibody, At 2.65-A Resolution","Crystal Structure Of The Human Astrovirus Serotype 8 Capsid Spike In Complex With Scfv 2D9, An Astrovirus-Neutralizing Antibody, At 2.65-A Resolution",Mus musculus,"Meyer,L.;Cuellar,C.;DuBois,R.M.","Crystal structure of the human astrovirus serotype 8 capsid spike in complex with scFv 2D9, an astrovirus-neutralizing antibody, at 2.65-A resolution",21-JUL-2021,8_7_11_6_3_9,7RK2_C_C,Xtal structure,capsid,2,1,22.607712,-5.5915246
8E1M_H_L,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTTYGVHWVRQSPGKGLEWLGVMWRGGSTDFNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCARYGNYDAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDIYGISFMNWFQQKPGQPPKLLIYATSNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPRTFGGGTKLEIK,8E1M_H,8E1M_L,Cryo-Em Structure Of The Endogenous Core Tim23 Complex From S. Cerevisiae,Cryo-Em Structure Of The Endogenous Core Tim23 Complex From S. Cerevisiae,Mus musculus,"Sim,S.I.;Chen,Y.;Lynch,D.L.;Gumbart,J.C.;Park,E.",Structural basis of mitochondrial protein import by the TIM23 complex,21-JUN-2023,8_7_11_10_3_9,8E1M_H_L,Xtal structure,TIM23; TIMM23,2,1,22.588879,-5.610626
WGM83023_WGM83059,QVQLKQWGAGLLKPSETLSLTCAIYGESFTGSWNDQLWNWIRQPPGKGLEWIGEINHNGDINYASSLKSRATVSADRSKNQFSLRLRSVSDADTATYYCARGRRAIQWWAVEPPANYGFDVWSQGTPVIVSS,EIVLTQSPGTLSLSPGEKATLSCRASQTIASTYLAWYQQKPGQPPRLLLHKGYNRATGIPDRFSGSGSGTVYTLTISGLEPDDFAFYYCQHLGTSPPYTFGQGTKVEIK,WGM83023,WGM83059,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,12_7_22_7_3_10,WGM83023_WGM83059,Unique source,HIV,2,1,16.789698,-10.643133
WGM83013_WGM83049,QVQLKQWGAGLLKPSETLSLTCAIYGESFTGSWNDQLWNWIRQPPGKGLEWIGEINHSGDIKYASSLKSRATVSADRSKNQFSLKLRSVSGADTATYYCARGRRAVRWWAVEPPANYGFDVWSQGTPVIVSS,EIVLTQSPGTLSLSPGEKATLSCRASQSIASTYLAWYQQKPGQAPRLLLHQGYNRATGIPDRFSGSGSGTVYTLTISGLEPDDFAVYYCQHLGTSPPYTFGQGTKLEIK,WGM83013,WGM83049,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,12_7_22_7_3_10,WGM83013_WGM83049,Unique source,HIV,2,1,16.73891,-10.612977
WGM82997_WGM83033,QVQLKQWGAGLVKPSETLSLTCTVHGDTLSDYSWNWGVSRSDYYWSWIRQPPGKGLEWIGEINRSGSTQYHPSLKSRVKIVIEVSKNQFSLELSSVTAADTAVYYCARGRRSRQWIGDLPPGNHGLDVWGQGIPVSVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQHKPGQAPRLLISDVYRRATGVPDRFSASGSGTDFTLTISRLEPEDFAVYYCQQYGISSPFNFGQGTKVDIK,WGM82997,WGM83033,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,19_7_22_7_3_10,WGM82997_WGM83033,Unique source,HIV,2,1,16.66223,-10.464715
1C5B_H_L,QVQLLEPGTELVKPGASVKLSCRASGYSFTSYWMHWVKQRPGQGLEWIGLIDPSNGRTNFNDKFKSRATLTVDTSSSTAYMQLSSLTSEDSAVYYCVRIAYWGQGTLVTVSS,EIQLTQSPSSLSASLGERVSLTCRTSQEISGYLSWLQQKPDGTIKRLIYDATKLDSGAPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASFPRTFGGGTKLEIK,1C5B_H,1C5B_L,Decarboxylase Catalytic Antibody 21D8 Unliganded Form,Decarboxylase Catalytic Antibody 21D8 Unliganded Form,synthetic construct,"Hotta,K.;Lange,H.;Tantillo,D.J.;Houk,K.N.;Hilvert,D.;Wilson,I.A.",Catalysis of decarboxylation by a preorganized heterogeneous microenvironment: crystal structures of abzyme 21D8,08-NOV-1999,8_8_5_6_3_9,1C5B_H_L,Xtal structure,,2,1,-0.55670035,-3.9478922
1AXS_B_A,QVQLLESGAELMKPGASVKISCKATGYTFSSFWIEWVKQRPGHGLEWIGEILPGSGGTHYNEKFKGKATFTADKSSNTAYMQLSSLTSEDSAVYYCARGHSYYFYDGDYWGQGTSVTVSS,LVLTQSPSSMYASLGERVTITCKASQDINSYLNWFQQKPGKSPKTLIYRTNRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGSGTKLEIK,1AXS_B,1AXS_A,Mature Oxy-Cope Catalytic Antibody With Hapten,Mature Oxy-Cope Catalytic Antibody With Hapten,Homo sapiens,"Ulrich,H.D.;Mundorff,E.;Santarsiero,B.D.;Driggers,E.M.;Stevens,R.C.;Schultz,P.G.",The interplay between binding energy and catalysis in the evolution of a catalytic antibody,20-OCT-1997,8_8_13_6_3_9,1AXS_B_A,Xtal structure,,2,1,4.98576,-1.8831482
4QT5_H_L,QVQLLESGAELVKPGAPVRLSCKASGYTFTNYWMNWVKQRPGRGLEWIGRIDPSDSETHYNQNFKDKATLTVDKSSSTAYIQLSSLTSEDSAVYYCARSGYWGQGTTLTVSS,LEMTQSPLTLSVTTGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKVDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHSPLTFGAGTKLELK,4QT5_H,4QT5_L,Crystal Structure Of 3Bd10: A Monoclonal Antibody Against The Tsh Receptor,Crystal Structure Of 3Bd10: A Monoclonal Antibody Against The Tsh Receptor,Mus musculus,"Chen,C.R.;Hubbard,P.A.;Salazar,L.M.;McLachlan,S.M.;Murali,R.;Rapoport,B.",Crystal structure of a TSH receptor monoclonal antibody: insight into Graves' disease pathogenesis,07-JUL-2014,8_8_5_11_3_9,4QT5_H_L,Xtal structure,,2,1,-0.5178573,-3.5266979
3FCT_D_C,QVQLLESGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGMIDPNSGGTKYNEKFKSKATLTVDKPSNTAYMQLSSLTSEDSAVYYCTRRDMDYWGAGTTVTVSS,LVMTQTPKFMSTTVGDRVSITCKASQNVGTPVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGGGTKVEIK,3FCT_D,3FCT_C,Mature Metal Chelatase Catalytic Antibody With Hapten,Mature Metal Chelatase Catalytic Antibody With Hapten,Homo sapiens,"Romesberg,F.E.;Santarsiero,B.D.;Spiller,B.;Yin,J.;Barnes,D.;Schultz,P.G.;Stevens,R.C.",Structural and kinetic evidence for strain in biological catalysis,13-JUN-1999,8_8_7_6_3_9,1NGW_B_A,Xtal structure,,2,1,-0.73592395,-3.895512
1G9M_H_L,QVQLLESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYRNNGFLKHWGQGTLVTVTS,LELTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,1G9M_H,1G9M_L,Hiv-1 Hxbc2 Gp120 Envelope Glycoprotein Complexed With Cd4 And Induced Neutralizing Antibody 17B,Hiv-1 Hxbc2 Gp120 Envelope Glycoprotein Complexed With Cd4 And Induced Neutralizing Antibody 17B,Homo sapiens,"Kwong,P.D.;Wyatt,R.;Robinson,J.;Sweet,R.W.;Sodroski,J.;Hendrickson,W.A.",Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody,24-NOV-2000,8_8_21_6_3_11,1G9M_H_L,Xtal structure,gp120; HIV; CD4,2,1,-0.899289,5.595599
5VEB_H_L,QVQLLESGGGLVQPGGSLRLSCAASGFTFSSHGMHWVRQAPGKGLEWVSVISGSGSNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQWGSYAFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAVSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSGTFPPTTFGQGTKVEIK,5VEB_H,5VEB_L,Crystal Structure Of A Fab Binding To Extracellular Domain 5 Of Cadherin-6,Crystal Structure Of A Fab Binding To Extracellular Domain 5 Of Cadherin-6,Homo sapiens,"Bialucha,C.U.;Collins,S.D.;Li,X.;Saxena,P.;Zhang,X.;Durr,C.;Lafont,B.;Prieur,P.;Shim,Y.;Mosher,R.;Lee,D.;Ostrom,L.;Hu,T.;Bilic,S.;Rajlic,I.L.;Capka,V.;Jiang,W.;Wagner,J.P.;Elliott,G.;Veloso,A.;Piel,J.C.;Flaherty,M.M.;Mansfield,K.G.;Meseck,E.K.;Rubic-Schneider,T.;London,A.S.;Tschantz,W.R.;Kurz,M.;Nguyen,D.;Bourret,A.;Meyer,M.J.;Faris,J.E.;Janatpour,M.J.;Chan,V.W.;Yoder,N.C.;Catcott,K.C.;McShea,M.A.;Sun,X.;Gao,H.;Williams,J.;Hofmann,F.;Engelman,J.A.;Ettenberg,S.A.;Sellers,W.R.;Lees,E.","Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers",04-APR-2017,8_8_11_6_3_10,QCB69476_QCB69477,Xtal structure,,2,1,14.276242,10.24132
QKK35748_QKK35749,QVQLLESGGGLVQPGRSLRLSCTASGFRFGDYTMTWFRQAPGKGLEWVGFIRSIAYGGTTEHAASVEGRFIISRDDSKSIAYLQMNSLKAEDTGVYFCTRGSGMFYGSSSGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGTYLAWYQQKHGQAPRLLISDVSKRATGIPARFSGSGSGTDFTLTITSLEPEDFAVYYCQQRTNWPGATFGPGTKVDIK,QKK35748,QKK35749,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_10_16_6_3_10,QKK35748_QKK35749,Unique source,SARS-CoV-2,2,1,13.263518,8.866764
6D11_C_D,QVQLLESGGGMVQPGGSLRLSCTASGFSFSNYGMSWVRQAPGKGPEWVSGISGSSGDTYYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKEGGFCSSATCYYYFDCWGQGTLVTVSS,DIQMTQSPLSLSASVGDRVTITCRATQSINNWLAWYQQKSGKAPKLLIYKASRLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYGSSWTFGQGTKVEIK,6D11_C,6D11_D,Crystal Structure Of 1450 Fab In Complex With Circumsporozoite Protein Nanp5,Crystal Structure Of 1450 Fab In Complex With Circumsporozoite Protein Nanp5,Plasmodium falciparum,"Imkeller,K.;Scally,S.W.;Bosch,A.;Marti,G.P.;Costa,G.;Triller,G.;Murugan,R.;Renna,V.;Jumaa,H.;Kremsner,P.G.;Sim,B.K.;Hoffman,S.L.;Mordmuller,B.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope,11-APR-2018,8_8_18_6_3_8,6D11_C_D,Xtal structure,,2,1,14.129483,9.831167
1A4K_H_L,QVQLLESGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCVQAERLRRTFDYWGAGTTVTVSS,ELVMTQTPLSLPVSLGDQASISCRSSQSLLHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQVTHVPPTFGGGTKLEIK,1A4K_H,1A4K_L,Diels Alder Catalytic Antibody With Transition State Analogue,Diels Alder Catalytic Antibody With Transition State Analogue,Mus musculus,"Romesberg,F.E.;Spiller,B.;Schultz,P.G.;Stevens,R.C.",Immunological origins of binding and catalysis in a Diels-Alderase antibody,30-JAN-1998,8_8_12_11_3_9,1A4K_H_L,Xtal structure,,2,1,-7.4852147,6.078447
1UWG_H_L,QVQLLESGPELVEPGASVKVSCKASAYSITDFNIYWVKQSHGKNLEWIGGIDPHNGGPVYNQKFNGKATLTVDKSSSTAFMHLNSLTSEDSAVYYCAIFYGNFFDYWGPGTTVTVSS,LVMTQSPKFMSTSVGDRVSVTCKASQNVGTHVAWYQQKPGQSPKTLIYSASYRYSGVPDRFTGSGSGTDFTLTIRDVQSEDAAEYFCQQYNLFPVTFGGGTKLEIK,1UWG_H,1UWG_L,Molecular Mechanism Of Enantioselective Proton Transfer To Carbon In Catalytic Antibody 14D9,Molecular Mechanism Of Enantioselective Proton Transfer To Carbon In Catalytic Antibody 14D9,Mus musculus,"Zheng,L.;Baumann,U.;Reymond,J.L.",Molecular mechanism of enantioselective proton transfer to carbon in catalytic antibody 14D9,05-FEB-2004,8_8_10_6_3_9,1UWG_H_L,Xtal structure,,2,1,2.5493243,-3.8941674
8C8T_C_D,QVQLLESGPGLVRPSETLTLTCSVFNSRVSGYYYSWIRQPPGRGLEWIASTHFSLRPSRNPSLLSRVTTSIDTERYQVFLNMRSVTAADTAVYFCARGDASGWRADYFPHWGQGTLVVVSS,QSVLTQPPSASGSPGQSVTISCTGTSSDIGASDYVSWYQQYPGEAPKVIIYDVTKRPSGVPDRFSGSKSGTTASLTVSGLQAEDEADYYCSSDAGRHTLLFGGGTKVTVL,8C8T_C,8C8T_D,Cryo-Em Structure Of Bg505 Sosip.664 Hiv-1 Env Trimer In Complex With Bnabs Eptc112 And 3Bnc117,Cryo-Em Structure Of Bg505 Sosip.664 Hiv-1 Env Trimer In Complex With Bnabs Eptc112 And 3Bnc117,Homo sapiens,"Molinos-Albert,L.M.;Baquero,E.;Bouvin-Pley,M.;Lorin,V.;Charre,C.;Planchais,C.;Dimitrov,J.D.;Monceaux,V.;Vos,M.;veName>ANRS VISCONTI Study Group</CollectiveName>,?.;Hocqueloux,L.;Berger,J.L.;Seaman,M.S.;Braibant,M.;Avettand-Feno&#xeb;l,V.;S&#xe1;ez-Ciri&#xf3;n,A.;Mouquet,H.",Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller,08-JAN-2009,8_7_15_9_3_10,8C8T_C_D,Xtal structure,HIV,2,1,16.470953,-7.655365
QBC73941_QBC74376,QVQLLESGPGVVKPSETLSLTCAVSGDTISSSHYFWSWIRQPRGKGLEWIGSMYSNTETANYNPSLKSRVTISEDTSKNQFSLKLTSVTAADTAVYYCWRERVLALNYHGLDSWGQGVVVTVSS,DIQMTQSPASLSAFVGDRVTISCRASQGIDNNLSWYQQKPGKAPKRLMHRSSTLEAGVPSRFSGSGSGTDYSLTISSLQPEDIAAYFCQQYENFPLTFGGGTKVEVK,QBC73941,QBC74376,"anti-HIV-1 immunoglobulin 0PV-a.s09.wk22 heavy chain variable region, partial [Macaca mulatta]","anti-HIV-1 immunoglobulin 0PV-a.s09.wk22 light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Kong,R.; Duan,H.; Sheng,Z.; Xu,K.; Acharya,P.; Chen,X.; Cheng,C.; Chuang,G.-Y.; Dingens,A.S.; Gorman,J.; Shen,C.-H.; Zhang,B.; Jafari,A.J.; Louder,M.K.; ODell,S.; Rowshan,A.P.; Viox,E.G.; Zhou,T.; Chao,C.W.; Choi,C.W.; Corcoran,M.; Corrigan,A.R.; Dandey,V.P.; Eng,E.T.; Geng,H.; Foulds,K.E.; Gu,Y.; Guo,Y.; Kwon,Y.D.; Lin,B.; Liu,K.; Mason,R.D.; Nason,M.C.; Ohr,T.Y.; Ou,L.; Rawi,R.; Sarfo,E.K.; Schon,A.; Todd,J.P.; Wang,S.; Wang,Y.; Wei,H.; Wu,W.; Comparative Sequencing Program,N.; Mullikin,J.C.; Bailer,R.T.; Doria-Rose,N.A.; Karlsson Hedestam,G.B.; Scorpio,D.G.; Overbaugh,J.; Bloom,J.D.; Carragher,B.; Potter,C.S.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.",Vaccine-Induced Developmental Pathways in Rhesus Macaques for Neutralizing Antibodies Targeting the HIV-1 Fusion Peptide,19-JUL-2019,10_8_15_6_3_9,QBC73941_QBC74376,Unique word,HIV,2,1,16.188688,-7.461652
3J8D_D_D,QVQLLQPGAELVKPGASMKLSCKASGYTFTNWWMHWVRLRPGRGLEWIGRIDPNSDVNKYNEKFENRASLTVDKHSSTAYMQLTSEDSAIYYCARWFFPWYFDVWGTGTTVTVS,NIVLTQSPASLAVSLGQRATISCRASESVDSFIYWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSETDFTLTIDSVETDDAATYYCQQNNEDPYTFGGGTKLEIK,3J8D_D,3J8D_D,Cryoelectron Microscopy Of Dengue-Fab E104 Complex At Ph 5.5,Cryoelectron Microscopy Of Dengue-Fab E104 Complex At Ph 5.5,Dengue virus 2 Thailand/16681/84,"Zhang,X.;Sheng,J.;Austin,S.K.;Hoornweg,T.E.;Smit,J.M.;Kuhn,R.J.;Diamond,M.S.;Rossmann,M.G.",Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers,13-OCT-2014,8_8_11_6_3_9,3J8D_D_D,Xtal structure,Dengue; dengue,2,1,-0.7231022,-3.8989553
AF234252_1_AF234258_1,QVQLLQSAADVKKPGASVKVSCTASGYIFTSYDIDWVRQATGQGLEWMGWMNPNSGNAGFAQKFKGRLTLTRDTSTSTAYMELRRLESEDTAVYYCARSTPHSYSGSGLPPTSDSWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGISPLTFGGGTKLEIK,AF234252_1,AF234258_1,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"van den Brink,E.N.; Turenhout,E.A.; Bovenschen,N.; Heijnen,B.G.; Mertens,K.; Peters,M.; Voorberg,J.",Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII,14-JUL-2016,8_8_19_7_3_9,AHD67840,Unique source,,2,1,2.1382093,4.23061
CAD42984_CAD43017,QVQLLQSAAEVRKPGASVKISCKVSGDTLLELHIHWVRQAPGKGLEWMGALDPEDEETIYAQRFQGRVTMTDDPSTDTAYLELSSLTSDDAAVYYCAVDSGAKAGNYYGLDVWGQGTLVTVST,DIVMTQSPSSLSASVGDRVTITCRASQSISGYLNWYQQKPGKAPKLLIYTASRLQGGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYSFGQGTKLEIK,CAD42984,CAD43017,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Raats,J.M.H.",Human recombinant autoantibodies specific for the La (SS-B) autoantigen from patient derived phage display combinatorial antibody libraries,24-JUL-2016,8_8_16_6_3_9,CAD42984_CAD43017,Unique source,,2,1,1.0260623,2.5135605
AHJ39814_AHJ39739,QVQLLQSGAEVKKPGSSVKVSCKASGGIFRTYAISWVRQAPGQGLEWMGGIIAIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGNGYYHNYFDFWGRGTLVTVSS,LSLSPGERATLSCRASQSVSNNYLAWYQQKPGQAPRLLISGASSRATGIPDRFSGSGSGTDFTLTISRLEREDFAVYYCQQYGSSPRTFGQGTKVEVK,AHJ39814,AHJ39739,"H1/H5 cross-reactive influenza antibody heavy chain VDJ region immunoglobulin, partial [Homo sapiens]","H1/H5 cross-reactive influenza antibody kappa chain VJ region immunoglobulin, partial [Homo sapiens]",Homo sapiens,"Whittle,J.R.; Wheatley,A.K.; Wu,L.; Lingwood,D.; Kanekiyo,M.; Ma,S.S.; Narpala,S.R.; Yassine,H.M.; Frank,G.M.; Yewdell,J.W.; Ledgerwood,J.E.; Wei,C.J.; McDermott,A.B.; Graham,B.S.; Koup,R.A.; Nabel,G.J.",Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages,07-APR-2014,8_8_13_7_3_9,AHJ39814_AHJ39739,Unique source,H5N1,2,1,-0.5679216,5.685294
6KYZ_B_C,QVQLLQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGKGGYDFWSGSGYMDVWGKGTTVTVSS,SYVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL,6KYZ_B,6KYZ_C,Hrv14 3C In Complex With Single Chain Antibody Ydf,Hrv14 3C In Complex With Single Chain Antibody Ydf,Homo sapiens,"Meng,B.;Lan,K.;Xie,J.;Lerner,R.A.;Wilson,I.A.;Yang,B.",Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses,27-MAY-2020,8_8_19_6_3_9,6KYZ_B_C,Xtal structure,rhinovirus,2,1,14.305138,13.829252
5YWO_N_M,QVQLMESGPELKKPGETVKISCTTSGYTFTDYAMHWVKQAPGKGLEWMGWINTATGEPTYAYDFKERFGFSLETSASTAFLQISNLKIEDTATYFCASDGRYWYFGVWGAGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASQSVSTSYMHWYQQKPGQPPRLLIYLVSNLESGVPSRFSGSGSGTDFTLNIHPVEAEDEATYYCQHIR,5YWO_N,5YWO_M,Structure Of Jev-2F2 Fab Complex,Structure Of Jev-2F2 Fab Complex,Mus musculus,"Qiu,X.;Lei,Y.;Yang,P.;Gao,Q.;Wang,N.;Cao,L.;Yuan,S.;Huang,X.;Deng,Y.;Ma,W.;Ding,T.;Zhang,F.;Wu,X.;Hu,J.;Liu,S.L.;Qin,C.;Wang,X.;Xu,Z.;Rao,Z.",Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies,29-NOV-2017,8_8_11_7_3_4,FAILED,Xtal structure,,2,1,-7.517388,6.128659
URX39986_URX40025,QVQLMQSRAEVKKPGASVRVSCEASGYTFIDHFINWVRQAPGQGLEWMGWMNPRGGAVNYSHKFQGRVTMTRYMSIDTDVAYMELRSLKSDDTAVYYCASNVKVSSSTQYVFDVWGQGTMVTVSA,QSALTQPRSVSGSPGQSVTISCTGPHSGVAWYQQHPGKAPKLIIYDINGRPSGVPDRFSGSKSGNTASLTISGLRPEDEADYFCSAFEFFGGGTKLTVL,URX39986,URX40025,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Barnes,C.O.; Schoofs,T.; Gnanapragasam,P.N.P.; Golijanin,J.; Huey-Tubman,K.E.; Gruell,H.; Schommers,P.; Suh-Toma,N.; Lee,Y.E.; Cetrulo Lorenzi,J.C.; Piechocka-Trocha,A.; Scheid,J.F.; West,A.P. Jr.; Walker,B.D.; Seaman,M.S.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,15-AUG-2022,8_8_16_3_3_5,URX39986_URX40025,Unique source,HIV; CD4,2,1,2.6646209,3.5712874
4F9L_D_D,QVQLQESGAELVKPGASVKLSCKASGYTFTRYYLYWVKQRPGQGLEWIGEINPNNGGTKFNEKFKSKATLTVDKSSRTTYIQLSSLTSEDSAVYYCSREDDYDGTPDAMDYWGQGTAVTVSS,DIVLTQSPSSLSASLGDTITITCHASQNINLWLSWYQQRPGNIPKLLIYRASNLHTGVPSRFSGSGSATGFTLTISSLQPEDIATYYCQQGHSYPYTFGGGTKLDIK,4F9L_D,4F9L_D,Crystal Structure Of The Human Btn3A1 Ectodomain In Complex With The 20.1 Single Chain Antibody,Crystal Structure Of The Human Btn3A1 Ectodomain In Complex With The 20.1 Single Chain Antibody,Homo sapiens,"Palakodeti,A.;Sandstrom,A.;Sundaresan,L.;Harly,C.;Nedellec,S.;Olive,D.;Scotet,E.;Bonneville,M.;Adams,E.J.",The molecular basis for modulation of human Vgamma9Vdelta2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies,18-MAY-2012,8_8_15_6_3_9,4F9L_D_D,Xtal structure,BT3.1; BTN3A1; CD277; BTN3.1; Ectodomain; BTF5,2,1,-0.73596907,-3.926132
CAO78301,QVQLQESGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDSPQNCTNGVCHRGSHVHYYGMDVWGQGTLVTVSS,QSALTQPASAAGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVNKRPSGVPDRFSASKSGNTASLTVSGLQADDEADYYCASYAGTYSYVFGTGTQLTVL,CAO78301_H,CAO78301_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_26_9_3_10,AEN51970,Same entry,,2,1,2.1820917,3.4829369
CAC42703,QVQLQESGGDLVQPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLELVATINSNGGSTFYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARRRNYPYYYGSRGYFDYWGQGTTVTVSS,DIELTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRALNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPWTFGGGTKLEIK,CAC42703_H,CAC42703_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Benvenuto,E.; Franconi,R.; Desiderio,A.; Tavladoraki,P.","Stabilizing peptides, polypeptides and antibodies which include them",22-JUN-2001,8_8_18_10_3_9,CAC42703,Same entry,,2,1,17.624212,7.140852
AAC26547,QVQLQESGGGLVKPGGSLKLSCAASGFTFSDYYMYWVRQTPEKRLEWVATISDGGSYTYYPDSVKGRFTISRDNAKNNLYLQMSSLKSEDTAMYYCSRYRYDDAMDYWGQGTTVTVSS,DIELTQSPASLAVSLGQRATISCRASESVDSYGHSFMQWYQQKPGQPPKLLIYRASNLEPGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQSNEDPFTFGSGTKLEIK,AAC26547_H,AAC26547_L,"anti BoNT/A Hc scFv antibody, partial [synthetic construct]","anti BoNT/A Hc scFv antibody, partial [synthetic construct]",synthetic construct,"Amersdorfer,P.; Wong,C.; Chen,S.; Smith,T.; Deshpande,S.; Sheridan,R.; Finnern,R.; Marks,J.D.",Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,24-JUL-2016,8_8_11_10_3_9,AAC26547,Same entry,botulinum; neurotoxin,2,1,17.71635,7.1922445
7S8G_H_L,QVQLQESGGGLVKPGGSLRLSCTASGFNFNKYNMNWVRQAPGKGLEWVSSISALSTYIYYADSLKGRFTVSRDNAKNSLFLQMNSLRDDDTAVYYCAREIRRASTWSADLWGRGTLVTVFN,DIQMTQSPSSLSASVGDRVIITCRASQSISSSLNWYQQKPGKAPKLLIYAAVNLETGVPSRFSGSGFGTDFTLAISNVQPEDFATYYCQQSDTRTFGRGTKLDVK,7S8G_H,7S8G_L,Structure Of Anti-Lasv Fab 25.10C With Fnqi Mutation,Structure Of Anti-Lasv Fab 25.10C With Fnqi Mutation,Homo sapiens,"Enriquez,A.S.;Buck,T.K.;Li,H.;Norris,M.J.;Moon-Walker,A.;Zandonatti,M.A.;Harkins,S.S.;Robinson,J.E.;Branco,L.M.;Garry,R.F.;Saphire,E.O.;Hastie,K.M.",Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies,17-SEP-2021,8_8_14_6_3_7,7S8G_H_L,Xtal structure,CD236; ARHGAP9; 10C; CD236R; GYPC; Ge; MGC1295; GYPD; GPC,2,1,16.06967,10.151902
5UMN_E_F,QVQLQESGGGLVQPGESLRLSCVGSGSSFGESTLSYYAVSWVRQAPGKGLEWLSIINAGGGDIDYADSVEGRFTISRDNSKETLYLQMTNLRVEDTGVYYCAKHMSMQQVPGSGWERADLVGDAFDVWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTLTCQASQDIRKFLNWYQQKPGKGPKLLIYDASNLQRGVPSRFSGGGSGTDFTLIISSLQPEDVGTYYCQQYDGLPFTFGGGTKVVIK,5UMN_E,5UMN_F,"Crystal Structure Of C05 Vpgsgw Mutant Bound To H3 Influenza Hemagglutinin, Ha1 Subunit","Crystal Structure Of C05 Vpgsgw Mutant Bound To H3 Influenza Hemagglutinin, Ha1 Subunit",Homo sapiens,"Wu,N.C.;Grande,G.;Turner,H.L.;Ward,A.B.;Xie,J.;Lerner,R.A.;Wilson,I.A.",In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity,27-JAN-2017,13_8_26_6_3_9,5UMN_E_F,Xtal structure,hemagglutinin; Influenza,2,1,14.178899,10.074661
2NZ9_F_E,QVQLQESGGGLVQPGGSLRLSCAASGFTFSDHYMYWVRQAPGKGLEWVATISDGGSYTYYSDSVEGRFTTSRDNSKNTLYLQMNSLRAEDTAIYYCSRYRYDDAMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATISCRASESVDSYGHSFMQWYQQKPGQAPRLLIYRASNLEPGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQGNEVPFTFGQGTKVEIK,2NZ9_F,2NZ9_E,Crystal Structure Of Botulinum Neurotoxin Type A Complexed With Monoclonal Antibody Ar2,Crystal Structure Of Botulinum Neurotoxin Type A Complexed With Monoclonal Antibody Ar2,Homo sapiens,"Garcia-Rodriguez,C.;Levy,R.;Arndt,J.W.;Forsyth,C.M.;Razai,A.;Lou,J.;Geren,I.;Stevens,R.C.;Marks,J.D.",Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin,22-NOV-2006,8_8_11_10_3_9,2NZ9_F_E,Xtal structure,botulinum; neurotoxin,2,1,14.447496,9.54518
QKK35620_QKK35621,QVQLQESGGGLVQPGGSLRLSCEASGFSFSDFVMHWVRQVPGKGLEWVSRISHDGSITSYVDSVKGRFTVSRDNGKKTLYLQMNSPRTEDTAVYYCARDLAWTFFDYWGHGTLVTVSS,QSVLTQPSSLSASPGASASLTCTLHSGFNVGDHTINWYQQRPGSPPRYLLKYKSDSDKEQGSGVPIRFSGSKDASANAGFLLISGLRSEDEADYYCMIWHDNAVVFGGGTKLTVL,QKK35620,QKK35621,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_11_9_7_9,QKK35620_QKK35621,Unique source,SARS-CoV-2,2,1,13.288329,10.13998
CAL68891_CAL68890,QVQLQESGGGVVQPGRSLRLSCAASGFTFNNFGIHWVRQAPGKGLEWVAVISYDGSDKYYADSVKGRFTISRDNSKNTLNLQMNSLRAEDTAVYYCARDRRYYYHYYGMDVWGQGTMVTVSS,DIVMTQSPLSLSVAPGQPASISCKSSQSLLESYGETYLYWYLQKPGQPPQLLIYAVFKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSMQLPLTFGGGTKVEIK,CAL68891,CAL68890,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Chu,K.; Masuoka,L.",Methods of therapy for B-cell malignancies using human anti-CD40 antibodies,06-NOV-2006,8_8_15_11_3_9,CAL68891_CAL68890,Unique chain,TNFRSF5; p50; Bp50; CD40,2,1,14.171756,13.975169
6PEF_A_B,QVQLQESGPAVMKPSETLSLTCAVSGGSISGDYGWSWIRQAPGKGLEWIAIIFGSSGSTYYSPSLKSRVTISKDTSKNQFSLKLNSVTAADTAVYFCAGSPVRQREQDYWGQGVLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGINYVAWYQQVPGTAPKLLIYDSNKRPSGVSDRFSGSKSGISASLAITGLQTGDEADYYCGVWDTSLTAYIFGAGTRLTVL,6PEF_A,6PEF_B,Vaccine-Elicited Nhp Fp-Targeting Antibody Df2F-A.01 In Complex With Hiv Fusion Peptide (Residue 512-519),Vaccine-Elicited Nhp Fp-Targeting Antibody Df2F-A.01 In Complex With Hiv Fusion Peptide (Residue 512-519),Human immunodeficiency virus 1,"Xu,K.;Liu,K.;Wang,Y.;Kwong,P.D.",Modular recognition of antigens provides a mechanism that improves vaccine-elicited antibody-class frequencies,20-JUN-2019,9_8_12_8_3_11,6PEF_A_B,Xtal structure,,2,1,16.322649,-7.372392
QKG86198_QIC35603,QVQLQESGPAVVKPSETLSLTCAVSGGSVSGHYGWSWIRQAPGKGLEWIGSLHGSSGSTFYNPSLKSRVTISKDTSKNQFSLKLTSVTAADTAVYYCTKDQFGGDGSYSFDLWGHGALVTVSS,ELVMTQTPSSLSASVGDRVTITCRASENVNNYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSYGTPFTFGPGTKLDIK,QKG86198,QIC35603,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin kappa light chain, partial [Macaca mulatta]",Macaca mulatta,"Kuwata,T.",Direct Submission,08-Jun-2020,9_8_15_6_3_9,QKG86198_QIC35603,Unique source,,2,1,16.308338,-7.4005914
4LVN_C_B,QVQLQESGPDLVKPSSSLKLTCTTTGYSISSGYSWHWIRQEPGKSLEWMGYIHYSGSTDYNDSLKARITITRDTASNMFFLQLSSVTSDDTAVYYCVIYRYDGQWVFDDWGAGTTVTVSS,DIVLTQSPATMSASLGQRVSMSCSASSSVSTSYFHWYQQKPGSSPKLWIYSTSNLASGVPGRFSGSGSGTSYSLSISSMEAEDAATYYCHQFHRSPLTFGAGTKLELK,4LVN_C,4LVN_B,Crystal Structure Of Pfsub1-Prodomain-Nimp.M7 Fab Complex,Crystal Structure Of Pfsub1-Prodomain-Nimp.M7 Fab Complex,Plasmodium falciparum,"Withers-Martinez,C.;Strath,M.;Hackett,F.;Haire,L.F.;Howell,S.A.;Walker,P.A.;Evangelos,C.;Dodson,G.G.;Blackman,M.J.",The malaria parasite egress protease SUB1 is a calcium-dependent redox switch subtilisin,26-JUL-2013,9_7_13_7_3_9,4LVN_C_B,Xtal structure,PC4; SUB1; p15; p14,2,1,11.572328,-12.826952
6F7T_B_A,QVQLQESGPELKKPGETVKISCKVSGYPFTNYGMNWVKQAPRKVLKWMGWIDTYTGDPTYADDFKGRFAFSLDTSASTAYLQINNLKNEDTATYFCARGTYWGQGTLVTVSA,QLVLTQSSSASFSLGASAKLTCTLSRQHSTYTIEWYQQQPLKPPKYVMELKKDGSHSTGDGIPDRFSGSSSGADRYLSISNIQEEDEAIYICGVGDTIKEQFVYVFGGGTKVTVL,6F7T_B,6F7T_A,Crystal Structure Of An Fab Fragment In Complex With A Peptide From Bacillus Subtilis Rnase Y,Crystal Structure Of An Fab Fragment In Complex With A Peptide From Bacillus Subtilis Rnase Y,Mus musculus,"Hardouin,P.;Velours,C.;Bou-Nader,C.;Assrir,N.;Laalami,S.;Putzer,H.;Durand,D.;Golinelli-Pimpaneau,B.",Dissociation of the Dimer of the Intrinsically Disordered Domain of RNase Y upon Antibody Binding,11-DEC-2017,8_8_5_7_7_13,6F7T_B_A,Xtal structure,Bacillus,2,1,-7.517652,6.137715
5JYL_D_D,QVQLQESGPELVKPGASVKMSCKASGYSFTAYNMHWVKQSHGKSLEWIGFIDPYSGIITYNQTFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCARRGYYDGGFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDITNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQDSKHPRTFGGGTKLEIK,5JYL_D,5JYL_D,Human P-Cadherin Mec1 With Scfv Tsp7 Bound,Human P-Cadherin Mec1 With Scfv Tsp7 Bound,Mus musculus,"Kudo,S.;Caaveiro,J.M.;Nagatoishi,S.;Miyafusa,T.;Matsuura,T.;Sudou,Y.;Tsumoto,K.",Disruption of cell adhesion by an antibody targeting the cell-adhesive intermediate (X-dimer) of human P-cadherin,14-MAY-2016,8_8_12_6_3_9,5JYL_D_D,Xtal structure,P-cadherin,2,1,2.5882616,-3.9819953
1GGB_H_L,QVQLQESGPGILQPSQTLSLTCSFSGFSLSTYGMGVSWIRQPSGKGLEWLAHIFWDGDKRYNPSLKSRLKISKDTSNNQVFLKITSVDTADTATYYCVQEGYIYWGQGTSVTVSS,DIVLTQSPGSLAVSLGQRATISCRASESVDDDGNSFLHWYQQKPGQPPKLLIYRSSNLISGIPDRFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPLTFGAGTKLEIK,1GGB_H,1GGB_L,Major Antigen-Induced Domain Rearrangements In An Antibody,Major Antigen-Induced Domain Rearrangements In An Antibody,Mus musculus,"Stura,E.A.;Stanfield,R.L.;Fieser,G.G.;Silver,S.;Roguska,M.;Hincapie,L.M.;Simmerman,H.K.;Profy,A.T.;Wilson,I.A.","Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gp120",19-JUL-1993,10_7_7_10_3_9,1GGB_H_L,Xtal structure,gp120; HIV,2,1,11.508485,1.9080464
QEP20405_QEP21053,QVQLQESGPGLLKPSETLSLTCTVSGASIDSHYWSWIRQSPAKGLEWIGDIYWSWGGYGSWTTNYNPSLNNRVIISVDTSKSHISLRLTSLTAADTAIYFCTRCRPHSSSADWNFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTIVCRASRSIGSYLNWYQQKPGEAPKLLIYGTYELETGVPSRFSGSDTGADFTLTISSLQREDFATYYCQQSYDNPYTFGQGTKLEIK,QEP20405,QEP21053,"IGH + IGL c512_heavy_IGHV4-59_IGHD6-6_IGHJ2, partial [Homo sapiens]","IGH + IGL c512_light_IGKV1D-39_IGKJ2, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_13_16_6_3_9,QEP20405_QEP21053,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.139286,-7.767285
QPL06790_QPL06791,QVQLQESGPGLLKPSETLSLTCTVSGGSIGSVTYYYNWIRQPPGKGLESIGSISYTGSTIYNPSLESRLEISVDTSKNQVSLKLSSVTAADTAVYYCATSGCGGDCYHFDFWGRGTLVTVSS,QSVLTQLPSVSGAPGQRVTISCTGSSSNIGADYDVHWYQHLPETAPKLVIYGNTNRPSGVPDRFSGSKSGTSASLVITGLQAEDEADYYCQSFDSSLSGFYVFGTGTKVTVL,QPL06790,QPL06791,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,10_7_14_9_3_12,QPL06790_QPL06791,Unique source,,2,1,16.537779,-7.8273163
QKK35692_QKK35693,QVQLQESGPGLLKPSETLSLTCTVSNSPISSNYWSWIRQPAGKGLEWIGRIDITGNTNYNPSLKSRVIMSVDTSKSQFSLKMTSVTAADTAVYYCARSFISFDSSGHPYYYYAMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGDRVTLFCRASQNIANNHLAWYQQKPGQAPRVLIYGASTTATDIPDRFSGRVSGTDFTLTISRLDPEDFAVYYCHQYGSSPWTFGQGTKLEIK,QKK35692,QKK35693,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_21_7_3_9,QKK35692_QKK35693,Unique source,SARS-CoV-2,2,1,15.809685,-8.010573
QAV52465_QAV52466,QVQLQESGPGLMKPSGTLFLTCAVSGASISSSNWWNWVRQPPGKGLEWIGEIYHDGSVSRNPFLQSRITMSVDKSKNQFSLKLTSVTAADTAVYYCAKRWDSSGWITRHTYDYGVDVWGRGTSVFVAS,QTVVTQEPSLTVSPGGTVTLTCASSAGAVTSDFSPNWFLQKPGQVPRSLIYNTDKRHSWTPARFSGSLIGGKAALTLSGAQPDDEGDYYCLVHYRGAWVFGGGTRLTVL,QAV52465,QAV52466,"anti-HIV-1 immunoglobulin VRC43.03 heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin VRC43.03 lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Kwon,Y.D.; Schramm,C.A.; Law,W.H.; Donofrio,G.; Zhou,K.H.; Gift,S.; Dussupt,V.; Georgiev,I.S.; Chuang,G.-Y.; Sastry,M.; Rawi,R.; Schatzle,S.; McDaniel,J.R.; Lai,Y.-T.; Zhang,B.; Jaronsinski,M.; Ransier,A.; Chenine,A.L.; Asokan,M.; Bailer,R.T.; Cagigi,A.; Cale,E.M.; Darko,S.; Driscoll,J.I.; Druz,A.; Gorman,J.; Laboune,F.; Louder,M.K.; McKee,K.; Moody,M.A.; Owen,C.; Peng,D.; Shen,C.-H.; Shiakolas,A.R.; Tucker,C.; Veradi,R.; Wang,K.; Zhou,T.; Zhou,J.; Georgiou,G.; Alam,S.M.; Haynes,B.F.; Rolland,M.; Matyas,G.R.; Polonis,V.R.; Douek,D.C.; Shapiro,L.; Tovanabutra,S.; Michael,N.L.; Mascola,J.R.; Robb,M.L.; Kwong,P.D.; Doria-Rose,N.A.",Initiation and Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual,12-MAR-2019,9_7_21_9_3_9,QAV52465_QAV52466,Unique word,HIV,2,1,15.385954,-7.3793306
CAA83216_CAA83231,QVQLQESGPGLVAPSQSLSITCTVSGFSLTSYAISWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQIFLKLNSLQTDDAARYFCARDGYSFFDYWGQGTTLTVSS,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,CAA83216,CAA83231,"anti-DNA antibody heavy chain variable region mRNA (4B1 VH), partial [Mus musculus]","immunoglobulin kappa chain V-J region (4B1 VL), partial [Mus musculus]",Mus musculus,"Gilbert,D.; Brard,F.; Margaritte,C.; Delpech,A.; Tron,F.","An idiotype D23-bearing polyspecific, murine anti-DNA monoclonal antibody forms glomerular immune deposits. Pathogenic role of natural autoantibodies?",26-JUL-2016,8_7_10_12_3_8,CAA83216_CAA83231,Unique chain,glomerular,2,1,22.076332,-6.1370163
QPL06794_QPL06797,QVQLQESGPGLVETSETLSLTCTVSGGSISRYYWTWIRRPPGKGLEWIGYIYYSGIVSTKYSPSLQSRVTISLDTSKNQFSLNLSSVTAADTAVYYCAGLGVPAVLRGRWGMDVWGHGATVTVSS,NFMLTQPHSVSESPGKTVTLSCTRSSGSIASYYVQWYQQRPGSAPTTVIYEDNLRPSGVPDRFSGSIDRSSNSASLTISGLKTEDEADYYCQSYDSDNPVVFGGGTKLTV,QPL06794,QPL06797,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_9_17_8_3_10,QPL06794_QPL06797,Unique source,,2,1,16.100132,-7.912399
QAV52461_QAV52462,QVQLQESGPGLVKATGTLSLNCAVSGASISSSNWWNWVRQSPGKGLEWIGEIYHSGTVTYNPSLKTRVTISVDKSRNQFSLKLTSVTAADTAKYYCAKRWDSSGWFSRHSYDYAVDVWGRGTTVIVSS,QTVVTQEPSLTVSPGGTVTLTCASSAGAVTSGHCPSWFQQKPGQVPRALIYCTNNRQSWTPARFSGSLRGGKAALTLSGVQPDDEGDYYCLVQYSGVWVFGGGTKLTVL,QAV52461,QAV52462,"anti-HIV-1 immunoglobulin VRC43.01 heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin VRC43.01 lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Kwon,Y.D.; Schramm,C.A.; Law,W.H.; Donofrio,G.; Zhou,K.H.; Gift,S.; Dussupt,V.; Georgiev,I.S.; Chuang,G.-Y.; Sastry,M.; Rawi,R.; Schatzle,S.; McDaniel,J.R.; Lai,Y.-T.; Zhang,B.; Jaronsinski,M.; Ransier,A.; Chenine,A.L.; Asokan,M.; Bailer,R.T.; Cagigi,A.; Cale,E.M.; Darko,S.; Driscoll,J.I.; Druz,A.; Gorman,J.; Laboune,F.; Louder,M.K.; McKee,K.; Moody,M.A.; Owen,C.; Peng,D.; Shen,C.-H.; Shiakolas,A.R.; Tucker,C.; Veradi,R.; Wang,K.; Zhou,T.; Zhou,J.; Georgiou,G.; Alam,S.M.; Haynes,B.F.; Rolland,M.; Matyas,G.R.; Polonis,V.R.; Douek,D.C.; Shapiro,L.; Tovanabutra,S.; Michael,N.L.; Mascola,J.R.; Robb,M.L.; Kwong,P.D.; Doria-Rose,N.A.",Initiation and Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual,12-MAR-2019,9_7_21_9_3_9,QAV52461_QAV52462,Unique word,HIV,2,1,15.410717,-7.3802724
5FHC_A_B,QVQLQESGPGLVKPSDTLSLTCTVSGGSLSSFYWSWIRQPPGKGLEWIGYIYYSGSPNYSPSLESRVTMSVDTTRNQISLKLDSVTAADTAVYYCVRASRSYYWGSYRPTAFDSWGQGTLVTVSS,YELTQPLSVSVSPGQTAIFTCSGDNLGDKYVCWFQQRPGQSPMLLIYQDNKRPSGIPERFSGSNSGNTATLTISGTQSTDEADYYCQTWDSTVVFGGGTKLTVL,5FHC_A,5FHC_B,Crystal Structure Of Protective Human Antibodies 100 And 114 In Complex With Ebola Virus Fusion Glycoprotein (Gp),Crystal Structure Of Protective Human Antibodies 100 And 114 In Complex With Ebola Virus Fusion Glycoprotein (Gp),Homo sapiens,"Misasi,J.;Gilman,M.S.;Kanekiyo,M.;Gui,M.;Cagigi,A.;Mulangu,S.;Corti,D.;Ledgerwood,J.E.;Lanzavecchia,A.;Cunningham,J.;Muyembe-Tamfun,J.J.;Baxa,U.;Graham,B.S.;Xiang,Y.;Sullivan,N.J.;McLellan,J.S.",Structural and molecular basis for Ebola virus neutralization by protective human antibodies,21-DEC-2015,8_7_19_6_3_8,5FHC_A_B,Xtal structure,Ebola,2,1,16.2366,-7.8640337
5D1Z_D_C,QVQLQESGPGLVKPSETLSLICTVSGGSISSSSYYWGWIRQTPERNLEWIGIIYFSGTTYYNPSLQSRVSMSLDRSTNRFSLRLSSVTAADTAIYYCAKPKSRDRGGPGDDYFGMDVWGQGIMVTVSS,DIQLTQSPSFLSASVADRVTITCRASQAVRSSLAWYQQKPGKAPQLLIYSASTLENGVSSRFSGSGPGTEFTLTISSLQPEDVGTYYCQQLNTYPFTFGPGTKVEIK,5D1Z_D,5D1Z_C,Isdb Neat1 Bound By Clone D4-10,Isdb Neat1 Bound By Clone D4-10,Staphylococcus aureus subsp. aureus MSSA476,"Yeung,Y.A.;Foletti,D.;Deng,X.;Abdiche,Y.;Strop,P.;Glanville,J.;Pitts,S.;Lindquist,K.;Sundar,P.D.;Sirota,M.;Hasa-Moreno,A.;Pham,A.;Melton Witt,J.;Ni,I.;Pons,J.;Shelton,D.;Rajpal,A.;Chaparro-Riggers,J.",Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire,04-AUG-2015,10_7_20_6_3_9,5D1Z_D_C,Xtal structure,,2,1,16.458672,-8.172569
7BQ5_H_L,QVQLQESGPGLVKPSETLSLICTVSGGSISTRDYYWGWIRQTPGKGLEWIGSIYYSGGTYYSPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARQWGNYFDHWGQGSLVTVSS,DIVLTQSPSFLSASVGDRVTITCRASQGIDTYLAWYQQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNNYHFTFGPGTKVDIK,7BQ5_H,7BQ5_L,Zikv Se Bound To Mab Z6,Zikv Se Bound To Mab Z6,Homo sapiens,"Dai,L.;Xu,K.;Li,J.;Huang,Q.;Song,J.;Han,Y.;Zheng,T.;Gao,P.;Lu,X.;Yang,H.;Liu,K.;Xia,Q.;Wang,Q.;Chai,Y.;Qi,J.;Yan,J.;Gao,G.F.",Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch,24-MAR-2020,10_7_10_6_3_9,7BQ5_H_L,Xtal structure,Zika; dengue,2,1,16.646526,-7.985376
ATZ81438_ATZ81442,QVQLQESGPGLVKPSETLSLTCAVSGGSIGDDYYWNWIRQPPGKGLEWIGSIYGSFGGTNYNPSLKSRVTISMDTSKNQFSLNLSSVTAADTAVYYCARGSYNIVVLFGYYFDYWGQGVLVTVSS,QSALTQPPSVSKSLGQSVTISCSGTSSDIGAYNGVSWYQHHSGTAPRLLIYEVSKRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCGSYRSGSTWVFGGGTRLTVL,ATZ81438,ATZ81442,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Williams,W.B.; Zhang,J.; Jiang,C.; Nicely,N.I.; Fera,D.; Luo,K.; Moody,M.A.; Liao,H.X.; Alam,S.M.; Kepler,T.B.; Ramesh,A.; Wiehe,K.; Holland,J.A.; Bradley,T.; Vandergrift,N.; Saunders,K.O.; Parks,R.; Foulger,A.; Xia,S.M.; Bonsignori,M.; Montefiori,D.C.; Louder,M.; Eaton,A.; Santra,S.; Scearce,R.; Sutherland,L.; Newman,A.; Bouton-Verville,H.; Bowman,C.; Bomze,H.; Gao,F.; Marshall,D.J.; Whitesides,J.F.; Nie,X.; Kelsoe,G.; Reed,S.G.; Fox,C.B.; Clary,K.; Koutsoukos,M.; Franco,D.; Mascola,J.R.; Harrison,S.C.; Haynes,B.F.; Verkoczy,L.",Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations,10-DEC-2017,9_8_17_9_3_10,ATZ81438_ATZ81442,Unique source,HIV,2,1,16.404325,-7.410205
ATZ81436_ATZ81440,QVQLQESGPGLVKPSETLSLTCAVSGGSISDDYYWSWIRQPPGKGLEWIGYIYGSGGGTNYNPSLKNRVTISIDTSKNQFSLKLSSVTAADTAVYYCARGSYNIVVLFGYYFDYWGQGVLVTVSS,QSALTQPPSVSKSLGQSVTISCTGTSSDIGGYNGVSWYQQHSGTAPRLLIYEVSKRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCGSYRSGSTWVFGGGTRLTVL,ATZ81436,ATZ81440,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Williams,W.B.; Zhang,J.; Jiang,C.; Nicely,N.I.; Fera,D.; Luo,K.; Moody,M.A.; Liao,H.X.; Alam,S.M.; Kepler,T.B.; Ramesh,A.; Wiehe,K.; Holland,J.A.; Bradley,T.; Vandergrift,N.; Saunders,K.O.; Parks,R.; Foulger,A.; Xia,S.M.; Bonsignori,M.; Montefiori,D.C.; Louder,M.; Eaton,A.; Santra,S.; Scearce,R.; Sutherland,L.; Newman,A.; Bouton-Verville,H.; Bowman,C.; Bomze,H.; Gao,F.; Marshall,D.J.; Whitesides,J.F.; Nie,X.; Kelsoe,G.; Reed,S.G.; Fox,C.B.; Clary,K.; Koutsoukos,M.; Franco,D.; Mascola,J.R.; Harrison,S.C.; Haynes,B.F.; Verkoczy,L.",Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations,10-DEC-2017,9_8_17_9_3_10,ATZ81436_ATZ81440,Unique source,HIV,2,1,16.367462,-7.3801665
UYI35874_UYI36216,QVQLQESGPGLVKPSETLSLTCAVSGGSISSNYWSWIRQSPGKGLEWIGYIYGGSGSTSYNPSLKSRVTISTDTSKNQFSLKLSSVTAADTAVYYCARYSHYYSGSFGYWGQGVLVTVSS,DIVMTQSPDSLAVSLGERVTINCKSSQSLLYSSNNKNYLAWYQQKPGQAPKLLIYWASTRESGVPNRFSGSGSGTDFTLTISGLQAEDVAVYYCQQYYSTPLSFGQGTKVEIK,UYI35874,UYI36216,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,8_8_13_12_3_9,UYI35874_UYI36216,Unique source,COVID,2,1,16.321453,-7.403089
UYI35836_UYI36146,QVQLQESGPGLVKPSETLSLTCAVSGHSINSDNWWSWIRQSPGKGLEWIGYIGGSSGSPYYNLSLKSRVTISKDASENQFSLKLTSVTAADTAVYYCATVFGVYNGYWNSLDFWGQGVLVTVSS,QLVLTQSPAALSLSPGERATLSCRASQTVITYLAWYHQKPGQAPRLLIHSTSSRATGIPDRFSGSGSGTEFTLTISSLEPEDVGVYFCYQYYSEYTFGGGTKVEI,UYI35836,UYI36146,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,9_8_16_6_3_8,UYI35836_UYI36146,Unique source,COVID,2,1,16.310303,-7.3290186
QQZ01810_QQZ01868,QVQLQESGPGLVKPSETLSLTCAVSGYSISGYYWSWIRQPPGKGLEWIGYLHGTGGDSYLNPSLKSRVTLSLDTSKNQFSLKLTSVTAADTAVYYCARDASGHYTGSETYWGQGVLVTVSS,EVVFTQPHSVSGSPGQTVTISCSRSSGSIDSKYVQWYQQRPGSAPTTVIYKDNRRPSGVPDRFSGSIDSSSNSASLTISGLKSEDEADYYCQSADDSYNWVFGGGTRLTVL,QQZ01810,QQZ01868,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Spencer,D.A.; Malherbe,D.C.; Vazquez Bernat,N.; Adori,M.; Goldberg,B.; Dambrauskas,N.; Henderson,H.; Pandey,S.; Cheever,T.; Barnette,P.; Sutton,W.F.; Ackerman,M.E.; Kobie,J.J.; Sather,D.N.; Karlsson Hedestam,G.B.; Haigwood,N.L.; Hessell,A.J.",Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor,03-FEB-2021,8_8_14_8_3_10,QQZ01810_QQZ01868,Unique source,HIV,2,1,16.466028,-7.468439
QQZ01812_QQZ01870,QVQLQESGPGLVKPSETLSLTCAVSGYSISGYYWTWIRQPPGKGLEWIGYIQGSGGSSYLRPSLKSRGTLSVETSKNQFSLKLSSVTAADTAVYYCARLADTVLALWGQGVLVTVSS,DIVMTQTPLSLPITPGEPASISCRSNQSLLHSNGNTYLQWYLQKSGQSPQLLIYGASNRASGVPDRFSGSGSGTDFTLKISKVEAEDVGVYYCMQTLAFPFTFGPGTKLEIK,QQZ01812,QQZ01870,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Spencer,D.A.; Malherbe,D.C.; Vazquez Bernat,N.; Adori,M.; Goldberg,B.; Dambrauskas,N.; Henderson,H.; Pandey,S.; Cheever,T.; Barnette,P.; Sutton,W.F.; Ackerman,M.E.; Kobie,J.J.; Sather,D.N.; Karlsson Hedestam,G.B.; Haigwood,N.L.; Hessell,A.J.",Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor,03-FEB-2021,8_8_10_11_3_9,QQZ01812_QQZ01870,Unique source,HIV,2,1,16.487192,-7.555752
QPL06892_QPL06994,QVQLQESGPGLVKPSETLSLTCAVSGYSISNGYYWGWIRQPPGKGLEWIGNIYHSGSTYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYFCARIYMVRDLEIYYFDSWGQGTLVTVSS,SYELTQPPSVSVAPGKTARITCGGNSIGLKRVHWYQHKPGQAPVLVIHYDSDRPSGIPDRFSGSNSGTAATLTISRVEAGDEADYHCQVWDVSGDHLVFGGGTKLTVL,QPL06892,QPL06994,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,9_7_16_6_3_11,QPL06892_QPL06994,Unique source,,2,1,16.571848,-7.6181846
AAB09446_AAB09450,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYGWSWIRQPPGKGLEWIGYIVVNSGSTDYNPSLKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARARRGSSYVDYWGQGVLVTVSS,DVQMTQSPSSLSGSVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLICCTDRLESGVPSRFSGSGSGTEFTLTISSLQSEDFATYYCQQYHSLSFTFGPGTKLDIK,AAB09446,AAB09450,"immunoglobulin heavy chain, partial [Macaca mulatta]","immunoglobulin light chain, partial [Macaca mulatta]",Macaca mulatta,"Andris,J.S.; Miller,A.B.; Abraham,S.R.; Cunningham,S.; Blancher,A.; Capra,J.D.",Variable Region Gene Segment Utilization in Rhesus Monkey Hybridomas Producing Human Red Blood Cell-Specific Antibodies: Predominance of the VH4 Family but not VH4-21 (V4-34),04-JUN-1996,9_8_12_6_3_9,AAB09446_AAB09450,Unique chain,,2,1,16.36168,-7.4066935
5ADO_H_L,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGLTQSSHNDANWGQGTLTTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVRWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLNPVFGGGTKLE,5ADO_H,5ADO_L,Crystal Structure Of The Paraoxon-Modified A.17 Antibody Fab Fragment  - Light Chain S35R Mutant,Crystal Structure Of The Paraoxon-Modified A.17 Antibody Fab Fragment  - Light Chain S35R Mutant,Homo sapiens,"Smirnov,I.V.;Golovin,A.V.;Chatziefthimiou,S.D.;Stepanova,A.V.;Peng,Y.;Zolotareva,O.I.;Belogurov AA,Jr.;Kurkova,I.N.;Ponomarenko,N.A.;Wilmanns,M.;Blackburn,G.M.;Gabibov,A.G.;Lerner,R.A.",Robotic QM/MM-driven maturation of antibody combining sites,21-AUG-2015,9_7_12_8_3_10,5ADO_H_L,Xtal structure,,2,1,16.66501,-7.636121
6Y1K_H_L,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGLTQSSHNDANWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKRLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLNPVFGGGTKLEIK,6Y1K_H,6Y1K_L,Crystal Structure Of The Unmodified A.17 Antibody Fab Fragment - L47R Mutant,Crystal Structure Of The Unmodified A.17 Antibody Fab Fragment - L47R Mutant,Homo sapiens,"Mokrushina,Y.A.;Golovin,A.V.;Smirnov,I.V.;Chatziefthimiou,S.D.;Stepanova,A.V.;Bobik,T.V.;Zalevsky,A.O.;Zlobin,A.S.;Konovalov,K.A.;Terekhov,S.S.;Stepanov,A.V.;Pipiya,S.O.;Shamborant,O.G.;Round,E.;Belogurov AA,Jr.;Bourenkov,G.;Makarov,A.A.;Wilmanns,M.;Xie,J.;Blackburn,G.M.;Gabibov,A.G.;Lerner,R.A.",Multiscale computation delivers organophosphorus reactivity and stereoselectivity to immunoglobulin scavengers,12-FEB-2020,9_7_12_8_3_10,6Y1K_H_L,Xtal structure,,2,1,16.633749,-7.6334753
CAC07378_CAC07379,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKWSKFDYWGQGTLVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,CAC07378,CAC07379,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Holtet,T.L.; Tempest,P.R.; Williams,A.J.; Jackson,H.","Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof",06-SEP-2000,9_7_10_6_3_11,CAC07378_CAC07379,Unique chain,,2,1,16.591322,-7.581363
QEP20336_QEP20984,QVQLQESGPGLVKPSETLSLTCNVSGASIESHYWSWIRQSPAKGLEWIGDIYRSWGGYGSWTSNHNPSLSHRVTISVDTSKSRISLRLTSLTAADTATYFCTRCRPQSSSADWNFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTIACRTSQSIGSYLNWYQQKPGEAPRLLIYDTYNLESGVPSRFSGSDTGAEFTLTITSLQREDFATYYCQQSYSNPYTFGRGTKLEIK,QEP20336,QEP20984,"IGH + IGL c443_heavy_IGHV4-59_IGHD6-6_IGHJ2, partial [Homo sapiens]","IGH + IGL c443_light_IGKV1D-39_IGKJ2, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_13_16_6_3_9,QEP20336_QEP20984,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.127054,-7.671826
5CEX_D_C,QVQLQESGPGLVKPSETLSLTCSVSGASISDHYWSWIRQSPGKGLEWIGYVYDSGDTNYNPSLKSRVNLSLDTSKNQVSLSLTAVTAADSAIYYCARTQHGRRIYGIVAFREWFTYFYMDVWGQGTPVTVSS,SYVLTQPSQLSVAPGETARISCGGRSLGSRAVQWYQQKPGQAPVLVIYNNQDRPSGIPERFSGSPDSNFGTTATLTISRVEAGDEADYYCHMWDSRSAINWVFGGGTKLTVL,5CEX_D,5CEX_C,"Crystal Structure Of Fab 32H+109L, A Putative Precursor Of The Pgt121 Family Of Potent Hiv-1 Antibodies","Crystal Structure Of Fab 32H+109L, A Putative Precursor Of The Pgt121 Family Of Potent Hiv-1 Antibodies",Homo sapiens,"Garces,F.;Lee,J.H.;de Val,N.;Torrents de,la.;Kong,L.;Puchades,C.;Hua,Y.;Stanfield,R.L.;Burton,D.R.;Moore,J.P.;Sanders,R.W.;Ward,A.B.;Wilson,I.A.",Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans,07-JUL-2015,8_7_26_6_3_12,5CEX_D_C,Xtal structure,HIV,2,1,15.483375,-7.93876
5GJT_H_L,QVQLQESGPGLVKPSETLSLTCSVSGASISSYYWIWIRQPAGKGLEWIGRFYTSGSPNYNPSLRSRVTMSVDTSKNQFSLKLTSVTAADTAVYYCAREEHITFGGVIVRYWGQGTLVTVS,DIQMTQSPATLSASVGDRVSITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGSEFTLTISSLQPDDFAIYYCQQYNSYPWTFGQGTKVEIK,5GJT_H,5GJT_L,Crystal Structure Of H1 Hemagglutinin From A/Washington/05/2011 In Complex With A Neutralizing Antibody 3E1,Crystal Structure Of H1 Hemagglutinin From A/Washington/05/2011 In Complex With A Neutralizing Antibody 3E1,Homo sapiens,"Wang,W.;Sun,X.;Li,Y.;Su,J.;Ling,Z.;Zhang,T.;Wang,F.;Zhang,H.;Chen,H.;Ding,J.;Sun,B.",Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses,01-JUL-2016,8_7_15_6_3_9,5GJT_H_L,Xtal structure,H1N1,2,1,16.38765,-7.756912
UDP68849_UDP68819,QVQLQESGPGLVKPSETLSLTCSVSGDSISSSDYSWGWIRQPPGKGLEWIGTIYYIKNTYYNPSLRSRVTLSVDTSKNLFSLKLSSVTAADTAVYYCARERPPFDVVVVPAARPYNWFDPWGLGTLVIVSS,QSVLMQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLAITGLQADDEADYYCQSYDSSLSGSKVFGGGTKLTVL,UDP68849,UDP68819,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Dussupt,V.; Townsley,S.; Donofrio,G.",Direct Submission,03-NOV-2021,10_7_23_9_3_12,UDP68849_UDP68819,Unique source,,2,1,16.72791,-8.031538
UYI35851_UYI36183,QVQLQESGPGLVKPSETLSLTCTVSGASISSYWWNWIRQPPGKGLEWIGEINGNSGSTNYNPSLKSRVTISKDASKNQFSLKLSSVTAADTAVYYCARDGTYCSGGVCWGQGVLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQGISTYLNWYQQKPGKAPKRLIFAASILESGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQYNSNPFTFGPGTKLDIK,UYI35851,UYI36183,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,8_8_12_6_3_9,UYI35851_UYI36183,Unique source,COVID,2,1,16.25037,-7.4970965
6PHB_D_C,QVQLQESGPGLVKPSETLSLTCTVSGDSMSSYYWSWIRQPAGKGLEWIGRISTSGSTNYNPSLKSRVTMSVDTSNNHFSMRLNSVTAADTAVYYCACSGSYSFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNFLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLRIFTFGPGTKVDIK,6PHB_D,6PHB_C,Pfs25 In Complex With The Human Transmission Blocking Antibody 2530,Pfs25 In Complex With The Human Transmission Blocking Antibody 2530,Homo sapiens,"McLeod,B.;Miura,K.;Scally,S.W.;Bosch,A.;Nguyen,N.;Shin,H.;Kim,D.;Volkmuth,W.;Ramisch,S.;Chichester,J.A.;Streatfield,S.;Woods,C.;Schief,W.R.;Emerling,D.;King,C.R.;Julien,J.P.",Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25,25-JUN-2019,8_7_11_6_3_10,6PHB_D_C,Xtal structure,Pfs25,2,1,16.332857,-7.7545037
8EZK_H_H,QVQLQESGPGLVKPSETLSLTCTVSGFSISSSYYWDWIRQPPGKGLEWIGNIHHTGATYYNPSLKSRVTISIDTANNQFSLRLRSVTAADAAVYYCARGGMGTTKRGWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIRVNYVYWYQQIPGTAPKLLIYRNDQRPSGVPDRFSASKSGTSASLAISGLRSQDEADYYCAAWDDSLTGPVFGGGTKLTVL,8EZK_H,8EZK_H,Pfs25 In Complex With Transmission-Reducing Antibody As01-04,Pfs25 In Complex With Transmission-Reducing Antibody As01-04,Homo sapiens,"Shukla,N.;Tang,W.K.;Coelho,C.H.;Long,C.A.;Healy,S.A.;Sagara,I.;Miura,K.;Duffy,P.E.;Tolia,N.H.",A human antibody epitope map of the malaria vaccine antigen Pfs25,16-AUG-2023,9_7_15_8_3_11,8EZK_H_H,Xtal structure,Pfs25,2,1,16.68073,-7.7065086
7Y71_O_P,QVQLQESGPGLVKPSETLSLTCTVSGGFIGPHYWSWVRQPPGKGLEWIGYIYISGSTNYNPSLKSRLTISVDMSKSQFSLTLSSATAADTAVYYCARGGGYLETGPFEYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLQNNGYNYLAWYLQKPGQSPQLLIYLSSTRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSLQIPGTFGQGTRLEIK,7Y71_O,7Y71_P,Sars-Cov-2 Spike Glycoprotein Trimer Complexed With Fab Fragment Of Anti-Rbd Antibody E7,Sars-Cov-2 Spike Glycoprotein Trimer Complexed With Fab Fragment Of Anti-Rbd Antibody E7,Homo sapiens,"Chia,W.N.;Tan,C.W.;Tan,A.W.K.;Young,B.;Starr,T.N.;Lopez,E.;Fibriansah,G.;Barr,J.;Cheng,S.;Yeoh,A.Y.;Yap,W.C.;Lim,B.L.;Ng,T.S.;Sia,W.R.;Zhu,F.;Chen,S.;Zhang,J.;Kwek,M.S.S.;Greaney,A.J.;Chen,M.;Au,G.G.;Paradkar,P.N.;Peiris,M.;Chung,A.W.;Bloom,J.D.;Lye,D.;Lok,S.;Wang,L.F.",Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor,02-AUG-2023,8_7_14_11_3_9,7Y71_O_P,Xtal structure,SARS,2,1,16.22027,-7.8186145
AMB38319_AMB38489,QVQLQESGPGLVKPSETLSLTCTVSGGSIISDYWSWIRQPAGKRLEWLGRFAPGGSSTYNPSLKSRLTMSVDSSKNHFSLRLRSVTAADTAVYYCARSQWLDVDLSDFYFDFWGQGILVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQTLGNYLNWYQQKPGKAPNLLIYGASNLQSGVPSRFSGSGSGTDFTLTITNLQPEDFATYYCQQTFRSLETFGQGTKVEIK,AMB38319,AMB38489,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_7_17_6_3_9,AMB38319_AMB38489,Unique source,,2,1,16.27998,-7.829577
AMB38472_AMB38648,QVQLQESGPGLVKPSETLSLTCTVSGGSIRSYYWTWIRQSPGKGLEWIGYVYYTGGTEYNSSLKSRVTISVDTSKNQFSLSLSSVTAADTAVYYCARGVSALVSVDYYYYYMDVWGKGTTVTVSS,SYELTQPPSVSVAPGKTARITCGGDNIGTKSVQWYQQRPGQAPLLVIYYNNDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDRNNDPLFGTGTKVTVL,AMB38472,AMB38648,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_7_19_6_3_10,AMB38472_AMB38648,Unique source,,2,1,15.891261,-7.9794292
7MSQ_D_E,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYHWNWIRQPPGKGLEWIGYIYYSGNTNYNPSLKSRVSISTDTSKNQFSLKLSSVTAADTAVYYCVREMRRGYSGYDYWDLYAFDIWGQGTMVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPHTFGQGTKLEIK,7MSQ_D,7MSQ_E,Complex Between The Fab Arm Of Ab-3467 And The Sars-Cov-2 Receptor Binding Domain (Rbd),Complex Between The Fab Arm Of Ab-3467 And The Sars-Cov-2 Receptor Binding Domain (Rbd),Homo sapiens,"Burnett,D.L.;Jackson,K.J.;Langley,D.B.;Aggrawal,A.;Stella,A.O.;Johansen,M.D.;Balachandran,H.;Lenthall,H.;Rouet,R.;Walker,G.;Saunders,B.M.;Singh,M.;Li,H.;Henry,J.Y.;Jackson,J.;Stewart,A.G.;Witthauer,F.;Spence,M.A.;Hansbro,N.G.;Jackson,C.;Schofield,P.;Milthorpe,C.;Martinello,M.;Schulz,S.R.;Roth,E.;Kelleher,A.;Emery,S.;Britton,W.J.;Rawlinson,W.D.;Karl,R.;Schafer,S.;Winkler,T.H.;Brink,R.;Bull,R.A.;Hansbro,P.M.;Jack,H.M.;Turville,S.;Christ,D.;Goodnow,C.C.",Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability,12-MAY-2021,8_7_21_6_3_9,7MSQ_D_E,Xtal structure,SARS-CoV-2,2,1,16.189249,-8.010067
4YK4_C_B,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARRRSDFETVDFIYHYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPLTFGQGTRLEIK,4YK4_C,4YK4_B,Human Antibody 641 I-9 In Complex With Influenza Hemagglutinin H1 Solomon Islands/03/2006,Human Antibody 641 I-9 In Complex With Influenza Hemagglutinin H1 Solomon Islands/03/2006,Influenza A virus (A/Solomon Islands/3/2006(H1N1)),"Schmidt,A.G.;Therkelsen,M.D.;Stewart,S.;Kepler,T.B.;Liao,H.X.;Moody,M.A.;Haynes,B.F.;Harrison,S.C.",Viral receptor-binding site antibodies with diverse germline origins,03-MAR-2015,8_7_19_6_3_9,4YK4_C_B,Xtal structure,Influenza,2,1,15.942159,-7.979643
QKY76476_QKY76089,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDMSKNQFSLKLRSVTAADTAVYYCARAPRERLQWGEYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHAGKAPKLMIYEVIKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAVSTTYVIFGGGTKLTVL,QKY76476,QKY76089,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_17_9_3_11,QKY76476_QKY76089,Unique source,SARS-CoV-2,2,1,16.13583,-7.923025
7CZP_J_N,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKKQFSLKLSSVTAADTAVYYCARLERDWPLDAFDIWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKFMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSNNTFAFGGGTKLTVL,7CZP_J,7CZP_N,S Protein Of Sars-Cov-2 In Complex Bound With P2B-1A1,S Protein Of Sars-Cov-2 In Complex Bound With P2B-1A1,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_7_14_9_3_10,7CZP_J_N,Xtal structure,SARS-CoV-2,2,1,16.245531,-7.9117274
7STS_A_B,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYYQLPMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGRVFGGGTKLTVL,7STS_A,7STS_B,Crystal Structure Of Human Fab S24-1379 In The Complex With The N-Teminal Domain Of Nucleocapsid Protein From Sars Cov-2,Crystal Structure Of Human Fab S24-1379 In The Complex With The N-Teminal Domain Of Nucleocapsid Protein From Sars Cov-2,Homo sapiens,"Kim,Y.;Maltseva,N.;Tesar,C.;Jedrzejczak,R.;Dugan,H.;Stamper,C.;Wilson,P.;Joachimiak,A.;Center for Structural Genomics of Infectious Diseases (CSGID)",Crystal Structure of Human Fab S24-1379 in the Complex with the N-teminal Domain of Nucleocapsid Protein from SARS CoV-2,10-AUG-2022,8_7_11_8_3_11,7STS_A_B,Xtal structure,S24; RPS24; SARS; eS24; CoV,2,1,16.177725,-7.908771
QEP20039_QEP20687,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQTAGKGLEWIGRVYTSGSTNYNPSLKSRVTMSADTSKNQFSLKMSSVTAADTAVYYCARESGTRPAAISGFFVYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLRSGVPSRFSGSGSGTDFTLTISSLQPEDFTTYYCQQSFTTPWTFGQGTKVEIK,QEP20039,QEP20687,"IGH + IGL c146_heavy_IGHV4-4_IGHD2-2_IGHJ6, partial [Homo sapiens]","IGH + IGL c146_light_IGKV1D-39_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_20_6_3_9,QEP20039_QEP20687,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,15.812568,-7.9736953
6IEB_H_L,QVQLQESGPGLVKPSETLSLTCTVSGGSISTYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKTRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSDYGDLIFDYWGQGTLVTVSS,LPVLTQPPSVSVSPGQTASITCSGDKLGDKYVCWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQACDSSTVFGGGTKLTVL,6IEB_H,6IEB_L,Structure Of Rvfv Gn And Human Monoclonal Antibody R15,Structure Of Rvfv Gn And Human Monoclonal Antibody R15,Homo sapiens,"Wang,Q.;Ma,T.;Wu,Y.;Chen,Z.;Zeng,H.;Tong,Z.;Gao,F.;Qi,J.;Zhao,Z.;Chai,Y.;Yang,H.;Wong,G.;Bi,Y.;Wu,L.;Shi,R.;Yang,M.;Song,J.;Jiang,H.;An,Z.;Wang,J.;Yilma,T.D.;Shi,Y.;Liu,W.J.;Liang,M.;Qin,C.;Gao,G.F.;Yan,J.",Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus,10-APR-2019,8_7_12_6_3_8,6IEB_H_L,Xtal structure,,2,1,16.22746,-7.823749
QKK35656_QKK35657,QVQLQESGPGLVKPSETLSLTCTVSGGSMNHYYWSWIRQPPGKGLEGIGYTYYSGSTNYNPSLKSRVTISVDASKNQFSLRLSSVTAADTAVYYCARGSQIDLRGGLGATFFDYWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQQHPGKAPKLTVYDVRNRPSGVSNRFSGSKSGNTASLTISGLQAEDEAHYYCSSYTSTNTVFGGGTKLTVL,QKK35656,QKK35657,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_19_9_3_9,QKK35656_QKK35657,Unique source,SARS-CoV-2,2,1,16.22022,-7.9165936
UIC72326_UIC72636,QVQLQESGPGLVKPSETLSLTCTVSGGSVRSGSYYWSWIRQPPGKGLEWIGCIYYSGSTNHNPSLKSRVTISIDTSKNQFSLKLSSVTAADTAVYYCARVPSRNSRTIYGVAPGYYYYMDVWGKGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYNNWLPAFGQGTKLEIK,UIC72326,UIC72636,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,10_7_24_6_3_9,UIC72326_UIC72636,Unique source,HCV,2,1,15.693938,-7.9871325
QKK35882_QKK35883,QVQLQESGPGLVKPSETLSLTCTVSGGSVSDTPFYWGWIRQPPGKGLEWIGSMYYTGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHPSSIFRGTVFTPYYFDYWGQGTLVTVSS,ETTLTQSPGTLSLSPGERATLSCRASQSVTSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRAPLYTFGLGTKVDIK,QKK35882,QKK35883,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_20_7_3_10,QKK35882_QKK35883,Unique source,SARS-CoV-2,2,1,16.842161,-7.8894563
QKY76383_QKY75996,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSYYWSWIRQPPGKGLECIGYIYYSGSSNYNPSLKSRVTISVDTSKNQFSLKMSSVTAADTAVYYCAGSPVPPTIVGASYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTFSCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGINRWLVFGGGTKLTVL,QKY76383,QKY75996,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,10_7_14_8_3_11,QKY76383_QKY75996,Unique source,SARS-CoV-2,2,1,16.341354,-8.036154
QJU69689_QJU69736,QVQLQESGPGLVKPSETLSLTCTVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTPLSLRLRYNWYFDLWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL,QJU69689,QJU69736,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Seydoux,E.; Homad,L.J.; MacCamy,A.J.; Parks,K.R.; Hurlburt,N.K.; Jennewein,M.F.; Akins,N.R.; Stuart,A.B.; Wan,Y.-H.; Feng,J.; Nelson,R.E.; Singh,S.; Cohen,K.W.; McElrath,M.J.; Englund,J.A.; Chu,H.Y.; Pancera,M.; McGuire,A.T.; Stamatatos,L.",Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual,20-MAY-2020,9_7_17_8_3_11,QJU69689_QJU69736,Unique source,SARS-CoV-2,2,1,16.764181,-7.82188
QEP20274_QEP20922,QVQLQESGPGLVKPSETLSLVCNVSGGSIENYYWSWIRQSPAKGLEWIGDIYRSWGGYGSWTTNHNPGLSHRVTISVDTSRSHISLRLTSLTAADTATYFCTRCRPDSSSADWNFDLWGRGTVVTVSS,DIQMTQSPSSLSASVGDRVTIACRASQSIGSYLNWYQQRPGEAPKLLIYGTYNLESGVPSRFSGSDTGADFTLTITSLQREDFATYYCQQSYSNPYTFGQGTKVDIK,QEP20274,QEP20922,"IGH + IGL c381_heavy_IGHV4-59_IGHD6-6_IGHJ2, partial [Homo sapiens]","IGH + IGL c381_light_IGKV1D-39_IGKJ2, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_13_16_6_3_9,QEP20274_QEP20922,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.110909,-7.672315
ANC49830_ANC49881,QVQLQESGPGLVKPSETLSVTCAVSGVSFSSFWWGWIRQPPGKGLEWVGTIYGSSGRAEYNPSLKSRTTVSRDTSKSQFSLELTSVTAADTAIYYCSRGLFQPNGFSFTLTSYWFDVWGPGVLVTVSS,DIQVTQSPSSLSASVGDTVTITCRASQSISTWLAWYQLKPGKAPKVLIYKASSLESGVPSRFSGSGSGTDFTLTITTLQSEDFATYYCQQYSSKPPTFGQGTKVEFK,ANC49830,ANC49881,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin kappa light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Zhang,R.; Verkoczy,L.; Wiehe,K.; Munir Alam,S.; Nicely,N.I.; Santra,S.; Bradley,T.; Pemble,C.W. IV; Zhang,J.; Gao,F.; Montefiori,D.C.; Bouton-Verville,H.; Kelsoe,G.; Larimore,K.; Greenberg,P.D.; Parks,R.; Foulger,A.; Peel,J.N.; Luo,K.; Lu,X.; Trama,A.M.; Vandergrift,N.; Tomaras,G.D.; Kepler,T.B.; Moody,M.A.; Liao,H.X.; Haynes,B.F.",Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages,09-MAY-2016,8_8_21_6_3_9,ANC49830_ANC49881,Unique source,HIV,2,1,16.428814,-7.3337064
5CEY_B_A,QVQLQESGPGLVKPSETLSVTCIVSGGSISNYYWTWIRQSPGKGLEWIGYISDRETTTYNPSLKSRVVISRDTSKNQLSLKLNSVTAADTAIYYCATARRGQRIYGVVSFGEFFYYYYMDVWGKGTAVTVSS,LSVALGETASISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,5CEY_B,5CEY_A,"Crystal Structure Of Fab 9H+3L, A Putative Precursor Of The Pgt121 Family Of Potent Hiv-1 Antibodies","Crystal Structure Of Fab 9H+3L, A Putative Precursor Of The Pgt121 Family Of Potent Hiv-1 Antibodies",Homo sapiens,"Garces,F.;Lee,J.H.;de Val,N.;Torrents de,la.;Kong,L.;Puchades,C.;Hua,Y.;Stanfield,R.L.;Burton,D.R.;Moore,J.P.;Sanders,R.W.;Ward,A.B.;Wilson,I.A.",Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans,07-JUL-2015,8_7_26_6_3_12,5CEY_B_A,Xtal structure,HIV,2,1,15.5436325,-7.9616685
QPL06799_QPL06798,QVQLQESGPGLVKPSETLTLTCTVSGGSIGSHYWNWIRQSPGKGLEWIGYFYYMGITSYKPSLKSRVTISEDRAKNQFSLRLSSVTAADTAVYYCARGDMARGIVGLWFDSWGQGILVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGADYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQPEDEADYYCQSYDNSLSGSVVFGGGTKLTVL,QPL06799,QPL06798,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_7_16_9_3_12,QPL06799_QPL06798,Unique source,,2,1,16.219362,-7.8980885
6Q18_H_L,QVQLQESGPGLVKPSGTLSLTCAISGGSISSSNWWTWVRQPPGKGLQWIGEIQHGGGTNYNPSLKSRATIFVDVSKNHFSLRLSSVTAADTAVYYCAKVPPYCTSASCPDDYYYHYMDVWGKGTTVTVSG,SSELTQDPAVSVALGQTVRITCQGDSLRGYSASWYQLKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNRASLIITGTQAEDEADYYCNSRDTNGYRPVLFGGGTKLTVL,6Q18_H,6Q18_L,Human Antibody H1244 In Complex With The Influenza Hemagglutinin Head Domain Of A/Beijing/262/95(H1N1),Human Antibody H1244 In Complex With The Influenza Hemagglutinin Head Domain Of A/Beijing/262/95(H1N1),Homo sapiens,"McCarthy,K.R.;Raymond,D.D.;Do,K.T.;Schmidt,A.G.;Harrison,S.C.",Affinity maturation in a human humoral response to influenza hemagglutinin,03-AUG-2019,9_7_23_6_3_12,6Q18_H_L,Xtal structure,hemagglutinin; H1N1; Influenza,2,1,15.380573,-7.445352
QKK35680_QKK35681,QVQLQESGPGLVKPSGTLSLTCAVSGASVSSDHWWSWVRQSPGKGLEWIGEVYHSGSTNYNPSLKSRVTISLDQSNNQFSLKLTSVTAADTAIYYCATMWGGLCTASNCYGNPMDVWGQGTTVTVSS,QPVLTQPPSVSVSPGQTARITCSGDALPRRYAYWYQQRSGQAPVLVIYEDNKRPSGIPERFSAFSSGTRATLTISGAQVEDQADYYCYSTDSTANYKVFGGGTKLTVL,QKK35680,QKK35681,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_20_6_3_11,QKK35680_QKK35681,Unique source,SARS-CoV-2,2,1,15.392558,-7.461405
QGA70363_QGA70590,QVQLQESGPGLVKPSGTLSLTCAVSGDSINIHNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARNAITIFGVVALGEYYYYGMDVWGQGTTVTVSS,DIQMTQSPASLSASVGETVTITCRTSENIYSYLAWYQQKQGKSPQLLVYNGKTLTEGVPSRFSGSGSDTQFSLKINSLQPEDFGYYYCQNHYDTPFTFGSGT,QGA70363,QGA70590,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Steichen,J.M.; Lin,Y.C.; Havenar-Daughton,C.; Pecetta,S.; Ozorowski,G.; Willis,J.R.; Toy,L.; Sok,D.; Liguori,A.; Kratochvil,S.; Torres,J.L.; Kalyuzhniy,O.; Melzi,E.; Kulp,D.W.; Raemisch,S.; Hu,X.; Bernard,S.M.; Georgeson,E.; Phelps,N.; Adachi,Y.; Kubitz,M.; Landais,E.; Umotoy,J.; Robinson,A.; Briney,B.; Wilson,I.A.; Burton,D.R.; Ward,A.B.; Crotty,S.; Batista,F.D.; Schief,W.R.",A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses,11-NOV-2019,9_7_23_6_3_9,QGA70363_QGA70590,Unique source,HIV,2,1,15.399531,-7.461659
QKK35532_QKK35533,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSDWCSWVRQPPGKGPEWIAEISHSGSTNYNPSLKSRVTMSVDRSKNQFSLNLNSVTAADTAVYYCAARIRGATHYDFWSGFWAGPFDIWGQGTTVTVSS,ETTLTQSPGTLSLSPGERATLSCRASQSIGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSAPLYTFGQGTKVEIK,QKK35532,QKK35533,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_23_7_3_10,QKK35532_QKK35533,Unique source,SARS-CoV-2,2,1,15.5309925,-7.4177427
6B0H_D_C,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSHWWSWVRQPPGKGLEWVGEISLSGSTHYGPSLKSRVSISLDKSMNHFSLRLSSVTAADTAVYYCARESRFYGAYFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCWASQGINSYLAWYQQKPGKTPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPCSFGQGTTLEIK,6B0H_D,6B0H_C,Crystal Structure Of Pfs25 In Complex With The Transmission Blocking Antibody 1262,Crystal Structure Of Pfs25 In Complex With The Transmission Blocking Antibody 1262,Homo sapiens,"Scally,S.W.;McLeod,B.;Bosch,A.;Miura,K.;Liang,Q.;Carroll,S.;Reponen,S.;Nguyen,N.;Giladi,E.;Ramisch,S.;Yusibov,V.;Bradley,A.;Lemiale,F.;Schief,W.R.;Emerling,D.;Kellam,P.;King,C.R.;Julien,J.P.",Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25,14-SEP-2017,9_7_13_6_3_9,6B0H_D_C,Xtal structure,Pfs25,2,1,15.814428,-7.4651875
6Q0E_H_L,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARAPPYCSSTSCPDDYYYYYMDVWGKGTTVTVSG,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHPVVFGGGTKLTVL,6Q0E_H,6Q0E_L,Inferred Precursor (Uca) Of The Human Antibody Lineage 652 In Complex With Influenza Hemagglutinin Head Domain Of A/Beijing/262/95(H1N1),Inferred Precursor (Uca) Of The Human Antibody Lineage 652 In Complex With Influenza Hemagglutinin Head Domain Of A/Beijing/262/95(H1N1),Homo sapiens,"McCarthy,K.R.;Raymond,D.D.;Do,K.T.;Schmidt,A.G.;Harrison,S.C.",Affinity maturation in a human humoral response to influenza hemagglutinin,01-AUG-2019,9_7_23_6_3_12,6Q0E_H_L,Xtal structure,hemagglutinin; H1N1; Influenza,2,1,15.381149,-7.440466
QGA70177_QGA70404,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARNAITIFGVVALGEYYYYGMDVWGQGTTVT,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGG,QGA70177,QGA70404,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Steichen,J.M.; Lin,Y.C.; Havenar-Daughton,C.; Pecetta,S.; Ozorowski,G.; Willis,J.R.; Toy,L.; Sok,D.; Liguori,A.; Kratochvil,S.; Torres,J.L.; Kalyuzhniy,O.; Melzi,E.; Kulp,D.W.; Raemisch,S.; Hu,X.; Bernard,S.M.; Georgeson,E.; Phelps,N.; Adachi,Y.; Kubitz,M.; Landais,E.; Umotoy,J.; Robinson,A.; Briney,B.; Wilson,I.A.; Burton,D.R.; Ward,A.B.; Crotty,S.; Batista,F.D.; Schief,W.R.",A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses,11-NOV-2019,9_7_23_6_3_9,QGA70177_QGA70404,Unique source,HIV,2,1,15.329917,-7.4539433
QGA70268_QGA70495,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARNAITIFGVVALGEYYYYGMDVWGQGTTVTVSS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCCQHFWDTPY,QGA70268,QGA70495,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Steichen,J.M.; Lin,Y.C.; Havenar-Daughton,C.; Pecetta,S.; Ozorowski,G.; Willis,J.R.; Toy,L.; Sok,D.; Liguori,A.; Kratochvil,S.; Torres,J.L.; Kalyuzhniy,O.; Melzi,E.; Kulp,D.W.; Raemisch,S.; Hu,X.; Bernard,S.M.; Georgeson,E.; Phelps,N.; Adachi,Y.; Kubitz,M.; Landais,E.; Umotoy,J.; Robinson,A.; Briney,B.; Wilson,I.A.; Burton,D.R.; Ward,A.B.; Crotty,S.; Batista,F.D.; Schief,W.R.",A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses,11-NOV-2019,9_7_23_6_3_9,QGA70268_QGA70495,Unique source,HIV,2,1,15.395548,-7.4242516
QKK35652_QKK35653,QVQLQESGPGLVKPSGTLSLTCAVSGGSITSRDWWSWVRQPPGKGLEWIGEVYHSGSTSYNPSLKSRVTISVDKSKNEFSLKLSSVTAADTAVYYCARAGNIVVMPAAQYYFDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYAASTLQSGVPLRFSGSGSGTDFTLTISSLQPEDFATYYCLQLHNYSSFGGGTKVDIK,QKK35652,QKK35653,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_18_6_3_8,QKK35652_QKK35653,Unique source,SARS-CoV-2,2,1,15.472036,-7.4193974
ANV21692_ANV21881,QVQLQESGPGLVKPSQTLSLSCTVSGGSINSGIYYWSWIRQHPGKGLEWIGNIYYSGDSYYNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARVTHDYFWGSYRRPMRGYFDYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDINTYNYVSWYQQHPGKAPKLMIYEVTKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSLYVFGTGTKVTVL,ANV21692,ANV21881,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,10_7_22_9_3_9,ANV21692_ANV21881,Unique source,,2,1,16.54684,-8.240538
3TNM_A_B,QVQLQESGPGLVKPSQTLSLSCTVSGGSSSSGAHYWSWIRQYPGKGLEWIGYIHYSGNTYYNPSLKSRITISQHTSENQFSLKLNSVTVADTAVYYCARGTRLRTLRNAFDIWGQGTMVTVSS,QSVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQHHPGKAPKLIISEVNNRPSGVPDRFSGSKSGNTASLTVSGLQAEDEAEYYCSSYTDIHNFVFGGGTKLTVL,3TNM_A,3TNM_B,"Crystal Structure Of A32 Fab, An Adcc Mediating Anti-Hiv-1 Antibody","Crystal Structure Of A32 Fab, An Adcc Mediating Anti-Hiv-1 Antibody",Homo sapiens,"Guan,Y.;Pazgier,M.;Sajadi,M.M.;Kamin-Lewis,R.;Al-Darmarki,S.;Flinko,R.;Lovo,E.;Wu,X.;Robinson,J.E.;Seaman,M.S.;Fouts,T.R.;Gallo,R.C.;DeVico,A.L.;Lewis,G.K.",Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding,01-SEP-2011,10_7_15_9_3_10,3TNM_A_B,Xtal structure,HIV; CD4,2,1,16.447231,-8.09998
7T17_J_K,QVQLQESGPGLVKPSQTLSLTCAVSGGSISSGDSYWSWIRQHPGKGLEWIGSIYYSGSTYYNPSLKSRVTIPIDTSKNQFSLKLSSVTAADTAVYYCARHVGDLRVNDAFDIWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQRLPGTPPKLLIYDSDKRPSGIPDRFSGSKSGTSATLGITGLQTGDEGDYYCGTWDRSLSVVVFGGGTKLTVL,7T17_J,7T17_K,Zika Virus Asymmetric Unit Bound With Igm Antibody Dh1017 Fab Fragment,Zika Virus Asymmetric Unit Bound With Igm Antibody Dh1017 Fab Fragment,Zika virus,"Singh,T.;Hwang,K.K.;Miller,A.S.;Jones,R.L.;Lopez,C.A.;Dulson,S.J.;Giuberti,C.;Gladden,M.A.;Miller,I.;Webster,H.S.;Eudailey,J.A.;Luo,K.;Von Holle,T.;Edwards,R.J.;Valencia,S.;Burgomaster,K.E.;Zhang,S.;Mangold,J.F.;Tu,J.J.;Dennis,M.;Alam,S.M.;Premkumar,L.;Dietze,R.;Pierson,T.C.;Ooi,E.E.;Lazear,H.M.;Kuhn,R.J.;Permar,S.R.;Bonsignori,M.",A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization,23-NOV-2022,10_7_15_8_3_11,7T17_J_K,Xtal structure,Zika,2,1,16.646704,-8.024344
6OAN_B_B,QVQLQESGPGLVKPSQTLSLTCNVSGDSINSGDYYWIWIRQPPGKGLEWIGNIYYSGTAYYNPSLKTRLIISIDTSTNQFSLKVTSVTAADTAIYYCARASTTVVSPWLDPWGQGTLVTVSS,YELTQPSSVAVAPGQTARIPCGGDNIESKGVHWYQQKPGQAPVLVVYDDHDRPSGIPERFSGSNSGNTATLTVSRVEAGDEADYYCQVWDTSSEHPVFGGGTKLTVL,6OAN_B,6OAN_B,Structure Of Dbp In Complex With Human Neutralizing Antibody 053054,Structure Of Dbp In Complex With Human Neutralizing Antibody 053054,Homo sapiens,"Urusova,D.;Carias,L.;Huang,Y.;Nicolete,V.C.;Popovici,J.;Roesch,C.;Salinas,N.D.;Dechavanne,S.;Witkowski,B.;Ferreira,M.U.;Adams,J.H.;Gross,M.L.;King,C.L.;Tolia,N.H.",Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP,18-MAR-2019,10_7_14_6_3_11,6OAN_B_B,Xtal structure,DBP; DABP,2,1,16.672617,-8.0628605
7EYC_A_B,QVQLQESGPGLVKPSQTLSLTCTVSGDSITSGYWNWIRQPPGKGLEYIGYIRYSGRTYYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCASVYFTYWGQGTLVTVSS,DVVMTQTPLSLPVTLGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPKRLISLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGSHFPYTFGQGTKLEIK,7EYC_A,7EYC_B,Crystal Structure Of Tau And Acetylated Tau Peptide Antigen,Crystal Structure Of Tau And Acetylated Tau Peptide Antigen,synthetic construct,"Hong,M.;Park,J.",Crystal structure of Tau and acetylated tau peptide antigen,30-MAY-2021,8_7_7_11_3_9,7EYC_A_B,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,2,1,16.426907,-7.68864
QPL06765_QPL06767,QVQLQESGPGLVKPSQTLSLTCTVSGGFLSSSSYYWSWVRQHPEKGLEWIGYIYYSGSPHYNPSLKSRVTISGDTSKNQFSLKLSSVTAADTAVYYCARARLGPYSSSWYIDNWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISNSLAWYQQTPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYDNWLGTFGPGTKVDIK,QPL06765,QPL06767,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,10_7_16_6_3_9,QPL06765_QPL06767,Unique source,,2,1,16.577198,-8.192328
AMB38418_AMB38546,QVQLQESGPGLVKPSQTLSLTCTVSGGSIRSGIHYWSWIRQFPGKGLEWIGLIHYSENTHHNPSLKSRVAMSVDTSKNQFSLTLSSVTAADTAVYYCARAAKESLCIGGSCDSNYEHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQSIRNYLNWYQQKPGKAPKLVIYAVSNLQSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQSYSTLPYTFGQGTKVEIK,AMB38418,AMB38546,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,10_7_25_6_3_10,AMB38418_AMB38546,Unique source,,2,1,16.19808,-8.084332
ANV21706_ANV21895,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLECIGYIHYRGSTYYKPSLKSRVIISIDTSKNQFSLKLSSVTAADTAVYYCARVYGYLWGSYRRPGGYSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQQHPGKAPKLMIYEDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTFVVFGGGTKLTVL,ANV21706,ANV21895,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,10_7_21_9_3_11,ANV21706_ANV21895,Unique source,,2,1,16.564629,-8.270556
ANV21813_ANV22002,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLECIGYIHYRGSTYYKPSLKSRVIISVDTSKNQFSLKLSSVTAADTAVYYCARVYGYLWGSYRRPGGYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQLHPGKAPKLIIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVVFGGGTKLTVL,ANV21813,ANV22002,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,10_7_21_9_3_11,ANV21813_ANV22002,Unique source,,2,1,16.591303,-8.249397
QKY76465_QKY76078,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYFWSWIRQHPGKGLEWIGSIYYSGSTYYNPSLRSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGGSGSYSLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYDNLYSVHFGQGTKLEIK,QKY76465,QKY76078,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,10_7_13_6_3_10,QKY76465_QKY76078,Unique source,SARS-CoV-2,2,1,16.449284,-8.168636
QYB25457_QYB25526,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTWYYYDSSGSFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQILLHSNGYNYLDWYLQKPGQSPQLLLYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPATFGGGTKVEIK,QYB25457,QYB25526,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,10_7_15_11_3_9,QYB25457_QYB25526,Unique source,SARS-CoV-2,2,1,16.600874,-8.235238
6A67_C_D,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGTYYWSWIRHHPGKGLEWIGYIYHSGSAYYNPSLESRVTMSVDTSKNQFSLKLSSVTAADTAIYYCARAENLLSPYLAEGFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSTSNIGSNAVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGSWVFGGGTKLTVL,6A67_C,6A67_D,Crystal Structure Of Influenza A Virus H5 Hemagglutinin Globular Head In Complex With The Fab Of Antibody Fld21.140,Crystal Structure Of Influenza A Virus H5 Hemagglutinin Globular Head In Complex With The Fab Of Antibody Fld21.140,Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)),"Zuo,Y.;Wang,P.;Sun,J.;Guo,S.;Wang,G.;Zuo,T.;Fan,S.;Zhou,P.;Liang,M.;Shi,X.;Wang,X.;Zhang,L.",Complementary recognition of the receptor-binding site of highly pathogenic H5N1 influenza viruses by two human neutralizing antibodies,26-JUN-2018,10_7_17_8_3_12,AFD37734_AFD37735,Xtal structure,H5N1; Influenza,2,1,16.76624,-8.263908
QGR24386_QGR24393,QVQLQESGPGLVKSSETLSLSCTVSGASISSYYWSWVRQSPGKGLEWMGSIYYTGTTTYNPSLKSRLTISVDTSKNQFSLKLNSVTAADTAVYSCAGLDRFNWNDEGDCWGQGTLVTVFS,QSVLTQPPSASGTPGQRVTISCSGSRSNLGRNTVNWYQQLPGVAPKLLIYSNSRRPSGVPDRFSGSKSDTSASLAISGLQSEDEADYYCAAWDDSLNGLYVFGTGTSVTVL,QGR24386,QGR24393,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Donofrio,G.C.; Dussupt,V.; Modjarrad,K.; Michael,N.L.; Barouch,D.H.; Joyce,M.G.; Stephenson,K.",Direct Submission,09-DEC-2019,8_7_14_8_3_12,QGR24386_QGR24393,Unique source,,2,1,16.303967,-7.7206364
8DFG_H_L,QVQLQESGPGLVKSSETLSLTCNVFRGSIGSYYWSWIRQPAGRGLEWIGRVYSNGRANYNPSFKSRVTISVDKSKNQFSLRLTSVTAADTAVYYCAREIYYHDSTGSLYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQTVSSSLAWYQHKPGQAPRLLIYGASTRATGVPVRFSGSGSGTEFTLTINSMHSEDFAIYYCLQFNDWPPTFGQGTKVEIK,8DFG_H,8DFG_L,Crystal Structure Of Potently Neutralizing Human Monoclonal Antibody 42D6 Fab In Complex With Msp1-19,Crystal Structure Of Potently Neutralizing Human Monoclonal Antibody 42D6 Fab In Complex With Msp1-19,Plasmodium falciparum 3D7,"Patel,P.N.;Dickey,T.H.;Hopp,C.S.;Diouf,A.;Tang,W.K.;Long,C.A.;Miura,K.;Crompton,P.D.;Tolia,N.H.",Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion,12-OCT-2022,8_7_18_6_3_9,8DFG_H_L,Xtal structure,Msp1; FLJ14600; ATAD1,2,1,16.142355,-7.869647
6VPY_A_B,QVQLQESGPGLVKSSETLSLTCTVSGGSMGGYYWSWLRQSPVKGLEWIGYIFHTGHTNYNPSLESRVTVSVDTSENQFSLRLRSVTAADTAVYYCASLPRGQLVNAFFDNWGQGTLVTVAS,SYELTQPPSVSVSPGQTASITCSGDKLGDKNACWYQVKPGQSPVVVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSFSTFVFGTGTKVTVL,6VPY_A,6VPY_B,I33M (I3.2 Mutant From Ch103 Lineage),I33M (I3.2 Mutant From Ch103 Lineage),Homo sapiens,"Zhou,J.O.;Zaidi,H.A.;Ton,T.;Fera,D.",The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage,04-FEB-2020,8_7_15_6_3_10,6VPY_A_B,Xtal structure,HIV,2,1,16.143744,-7.9053307
QBC73811_QBC74146,QVQLQESGPGLVRPSETLSLTCAVSGGSISSRNWWSWIRQPPGKGLEWIGYVSGGRDIPNYNPSLKSRVTISKDTSMNQFSLKLTSVTAADTAVYYCAREGMEDFDVWGPGVLVTVSS,DVVMTQSPLSLSITPGQPASISCRSSQSLVHSDGKTYLSWYQQRPGQPPRLLIYQVSNRCSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCGQGVHLPRTFGQGTKVEIK,QBC73811,QBC74146,"anti-HIV-1 immunoglobulin DF1W-a.s34.wk22 heavy chain variable region, partial [Macaca mulatta]","anti-HIV-1 immunoglobulin DF1W-a.s34.wk22 light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Kong,R.; Duan,H.; Sheng,Z.; Xu,K.; Acharya,P.; Chen,X.; Cheng,C.; Chuang,G.-Y.; Dingens,A.S.; Gorman,J.; Shen,C.-H.; Zhang,B.; Jafari,A.J.; Louder,M.K.; ODell,S.; Rowshan,A.P.; Viox,E.G.; Zhou,T.; Chao,C.W.; Choi,C.W.; Corcoran,M.; Corrigan,A.R.; Dandey,V.P.; Eng,E.T.; Geng,H.; Foulds,K.E.; Gu,Y.; Guo,Y.; Kwon,Y.D.; Lin,B.; Liu,K.; Mason,R.D.; Nason,M.C.; Ohr,T.Y.; Ou,L.; Rawi,R.; Sarfo,E.K.; Schon,A.; Todd,J.P.; Wang,S.; Wang,Y.; Wei,H.; Wu,W.; Comparative Sequencing Program,N.; Mullikin,J.C.; Bailer,R.T.; Doria-Rose,N.A.; Karlsson Hedestam,G.B.; Scorpio,D.G.; Overbaugh,J.; Bloom,J.D.; Carragher,B.; Potter,C.S.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.",Vaccine-Induced Developmental Pathways in Rhesus Macaques for Neutralizing Antibodies Targeting the HIV-1 Fusion Peptide,19-JUL-2019,9_8_10_11_3_9,QBC73811_QBC74146,Unique word,HIV,2,1,16.205679,-7.35385
QKK35488_QKK35489,QVQLQESGPGLVRPSETLSLTCTVSGDSVSSSDYHWGWIRQPPGKGLEWIGSIYYGGRSHFNPSLKSRVAIFVDTSNNQFSLRLNSVTASDTAVYFCAGRHQELLPMGSFDMWAQGTTVTVSS,EIVMTQSPSSLSASIGDRVTISCRASQNIGSYLNWYQQRPGKAPNLLIFVASSLQSGVPSRFSGSGSGTDFTLTISSLQAEDFATYYCQQSYTTPITFGQGTRLEIK,QKK35488,QKK35489,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_15_6_3_9,QKK35488_QKK35489,Unique source,SARS-CoV-2,2,1,16.72144,-8.000632
QKK35630_QKK35631,QVQLQESGPGLVRPSETLSLTCTVSRGSISSSYWSWIRQPPGKGLEWIGFMYYSGSTNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAVYYCAKAQGIYYRGWSYWFDPWGQGTLVTVSS,QSVVTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDSDKRPSGIPERFSGSKSATSATLGITGLQTGDEADYYCETWDDSLSAVVFGGGTKLTVL,QKK35630,QKK35631,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_8_3_11,QKK35630_QKK35631,Unique source,SARS-CoV-2,2,1,16.225313,-7.898326
1BVK_B_A,QVQLQESGPGLVRPSQTLSLTCTVSGFSLTGYGVNWVRQPPGRGLEWIGMIWGDGNTDYNSALKSRVTMLKDTSKNQFSLRLSSVTAADTAVYYCARERDYRLDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLAWYQQKPGKAPKLLIYYTTTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSTPRTFGQGTKVEIK,1BVK_B,1BVK_A,Humanized Anti-Lysozyme Fv Complexed With Lysozyme,Humanized Anti-Lysozyme Fv Complexed With Lysozyme,Gallus gallus,"Foote,J.;Winter,G.",Antibody framework residues affecting the conformation of the hypervariable loops,16-SEP-1998,8_7_10_6_3_9,1BVL_A_B,Xtal structure,Lysozyme,2,1,16.15572,-7.727694
UYI35954_UYI36266,QVQLQESGPGVVKPSETLSLTCAVSGGSISGGYGWSWIRQPPGKGLEWIGYIYGSSGSTNYNPSLKNRVTISKDASKKQFSLKLSSVTAADTAVYYCARAAPRGGYFDYWGQGVLVTVSS,QAAPTQYPSVSGSAGQSVTISCTGTSSDIGYYNAVSWYQQHPGKAPKLMIYEVSKRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTGSGTFIFGGGTRLTVL,UYI35954,UYI36266,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,9_8_12_9_3_10,UYI35954_UYI36266,Unique source,COVID,2,1,16.296757,-7.3579345
QBC73916_QBC74349,QVQLQESGPGVVKPSETLSLTCAVSGGTITSGYYWWSWIRQPRGKGLEWIGGVYSNREGTNYNPSLKSRVTISKDTSKNQFSLNLSSVTATDTAVYYCARERVVAHNYYGLDSWGQGVVVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLSWYQQKPGKAPKRLIYHASNLETGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQYDNFPLTFGGGTKVEIK,QBC73916,QBC74349,"anti-HIV-1 immunoglobulin 0PV-a.s157.wk10 heavy chain variable region, partial [Macaca mulatta]","anti-HIV-1 immunoglobulin 0PV-a.s157.wk10 light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Kong,R.; Duan,H.; Sheng,Z.; Xu,K.; Acharya,P.; Chen,X.; Cheng,C.; Chuang,G.-Y.; Dingens,A.S.; Gorman,J.; Shen,C.-H.; Zhang,B.; Jafari,A.J.; Louder,M.K.; ODell,S.; Rowshan,A.P.; Viox,E.G.; Zhou,T.; Chao,C.W.; Choi,C.W.; Corcoran,M.; Corrigan,A.R.; Dandey,V.P.; Eng,E.T.; Geng,H.; Foulds,K.E.; Gu,Y.; Guo,Y.; Kwon,Y.D.; Lin,B.; Liu,K.; Mason,R.D.; Nason,M.C.; Ohr,T.Y.; Ou,L.; Rawi,R.; Sarfo,E.K.; Schon,A.; Todd,J.P.; Wang,S.; Wang,Y.; Wei,H.; Wu,W.; Comparative Sequencing Program,N.; Mullikin,J.C.; Bailer,R.T.; Doria-Rose,N.A.; Karlsson Hedestam,G.B.; Scorpio,D.G.; Overbaugh,J.; Bloom,J.D.; Carragher,B.; Potter,C.S.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.",Vaccine-Induced Developmental Pathways in Rhesus Macaques for Neutralizing Antibodies Targeting the HIV-1 Fusion Peptide,19-JUL-2019,10_8_15_6_3_9,QBC73916_QBC74349,Unique word,HIV,2,1,16.153667,-7.3928223
QAV56025_QAV56420,QVQLQESGPRLVKPSDTLSLTCTVSGGSITSDSHYWGWVRQSPGKGLEWIASTSDSGSTYHNRPIYYNPSLKSRVTISVATSKNQFSLKLRSVTAADTAMYYCVRQWRYSSGSLDCWGQGILVTVSS,QAVVTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGLAPKLLIYSSNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEAHYYCATWDDSLNGVIFGGGTKLTVL,QAV56025,QAV56420,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Smith,S.A.; Burton,S.L.; Kilembe,W.; Lakhi,S.; Karita,E.; Price,M.; Allen,S.; Derdeyn,C.A.",VH1-69 utilizing antibodies are capable of mediating non-neutralizing Fc-mediated effector functions against the Transmitted/Founder gp120,03-FEB-2019,10_13_13_8_3_11,QAV56025_QAV56420,Unique source,gp120,2,1,16.676804,-8.099777
8JUH_A_A,QVQLQESGPSLVKPSQTLSLTCTVSGFSITSDGVLWVRQAPGKALEWVGAIYQNGATYYNPALKSRLSITRDTSKSQVSLSLSSVTTEDTAVYYCARDTDYDGMDVWGRGLLVTVSS,QAVLTQPSSVSGSLGQSVSITCSGSSSNVGYGNYVSWFQQVPGSAPKLLIYGATSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYYCASGDSGSSLVFGSGTRLTVL,8JUH_A,8JUH_A,Crystal Structure Of Scfv Against The Receptor Binding Domine Of Sars-Cov-2 S-Spike Protein,Crystal Structure Of Scfv Against The Receptor Binding Domine Of Sars-Cov-2 S-Spike Protein,Ovis aries,"Ma,Q.Q.;Su,Z.D.;Song,S.K.;Zhang,B.L.;Cheng,X.Y.",Crystal structure of ScFv against the receptor binding domine of SARS-CoV-2 S-spike protein,23-AUG-2023,8_7_11_9_3_10,8JUH_A_A,Xtal structure,SARS-CoV-2,2,1,15.604953,-8.416787
6QN7_A_B,QVQLQESGPSLVKPSQTLSLTCTVSGFSLSSYSVSWVRQAPGKTLEWLGDASNGGIIYYNPALKSRLGITRDNSKSQVSLSLNTITPEDTATYYCAKCSVGDSGSYACTGRKGEYVDAWGQGLLVTVSS,QAVLTQPPSVSGSLGQRVSITCSGSSDNIGIFAVGWYQQVPGSGLRTIIYGNTKRPSGVPDRFSGSKSGNTATLTINSLQAEDEADYFCVCGESKSATPVFGGGTTLTVL,6QN7_A,6QN7_B,Structure Of Bovine Anti-Rsv Hybrid Fab B4Hc-B13Lc,Structure Of Bovine Anti-Rsv Hybrid Fab B4Hc-B13Lc,Bos taurus,"Ren,J.;Nettleship,J.E.;Harris,G.;Mwangi,W.;Rhaman,N.;Grant,C.;Kotecha,A.;Fry,E.;Charleston,B.;Stuart,D.I.;Hammond,J.;Owens,R.J.",The role of the light chain in the structure and binding activity of two cattle antibodies that neutralize bovine respiratory syncytial virus,10-FEB-2019,8_7_23_8_3_11,6QN7_A_B,Xtal structure,Rsv,2,1,15.3925705,-8.580292
QKK35826_QKK35827,QVQLQESGRGLVKPSETLSLTCTVSGGSITSSRYYWGWIRQPPGRNLEWIGSIHYSGTTSYNPSLWSRVAISVDTAQNQFSLRLNSVTAADTAVYYCAAPAPSNHESWSGTDWFDPWGQGILVTVSS,EIVMTQSPASLSASVGDRVTITCRAGQSISTNLCWYQQRQGKAPKLLIYAASSLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGGGTKVDIK,QKK35826,QKK35827,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,10_7_19_6_3_9,QKK35826_QKK35827,Unique source,SARS-CoV-2,2,1,16.80359,-8.020421
5NB5_I_M,QVQLQETGGGLVQPGASMKLSCKASGFTFTRSGMYWVRQRPGQGLEWVAWISPNGGSTDYNDKVKGRATITRDTSSNTAYLQMSSLTSEDTAVYYCARGWGGMRYWGQGTTVTVSS,DIVLTQTPLTLPVSPGQRATISCRASQSVDYRGYSFMQWYQQKPGQPPKLLVYWGSNLESGVPARFSGSGSGTDFTLTIHPVEPEDFATYFCQQSYSTPWTFGGGTKLEIK,5NB5_I,5NB5_M,Principles For Computational Design Of Antibodies,Principles For Computational Design Of Antibodies,synthetic construct,"Baran,D.;Pszolla,M.G.;Lapidoth,G.D.;Norn,C.;Dym,O.;Unger,T.;Albeck,S.;Tyka,M.D.;Fleishman,S.J.",Principles for computational design of binding antibodies,01-MAR-2017,8_8_9_10_3_9,5NB5_I_M,Xtal structure,,2,1,14.059663,9.308267
6X78_H_L,QVQLQQPGAEFVKPGASVRMSCKASGYTFTSYWIAWVKQRPGQGLEWIGDIYPGSGYTNYNGKLKNRATLTVDTSSNTAYMQLSSLTSEDSAVYYCTRGGTTFVAEPWLAYWGQGTLVAVSA,DVVMTQTALTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTRLEIK,6X78_H,6X78_L,Vaccine-Elicited Mouse Fp-Targeting Neutralizing Antibody Vfp48.03 In Complex With Hiv Fusion Peptide (Residue 512-519),Vaccine-Elicited Mouse Fp-Targeting Neutralizing Antibody Vfp48.03 In Complex With Hiv Fusion Peptide (Residue 512-519),Human immunodeficiency virus 1,"Xu,K.;Kwong,P.D.",Distinct Classes of HIV-1 Cross-Clade Neutralizing Antibodies Targeting Fusion Peptide Elicited in Mice by Diverse Immunization Regimens,29-MAY-2020,8_8_15_11_3_9,6X78_H_L,Xtal structure,HIV,2,1,-0.4885431,-4.097838
BAA83334_BAA83408,QVQLQQPGAELVKPGASVKLSCKASGFTFTTYLIHWVKWRPGRGLEWIGRIDPYHGDIKYNESFRSKATLTVDKPSRTAYMQLSSLTSDDSAVYYCATYYYARYFDVWGTGTTVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGATNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,BAA83334,BAA83408,"immunoglobulin H-chain V-region, partial [Mus musculus]","immunoglobulin L-chain V-region, partial [Mus musculus]",Mus musculus,"Furukawa,K.; Akasako-Furukawa,A.; Shirai,H.; Nakamura,H.; Azuma,T.",Junctional amino acids determine the maturation pathway of an antibody,26-JUL-2016,8_8_11_9_3_9,BAA83334_BAA83408,Unique source,,2,1,-0.7800715,-3.875437
1MH5_H_L,QVQLQQPGAELVKPGASVKLSCKASGYTFTSNWINWVKQRPGQGLEWIGNIYPDSYRTNYNEKFKRKATLTVDTSSSTAYMQLSSLTSDDSAVYYCVRKHYSYDGVVYWGQGTLVTVSA,DIVMTQAAPSVSVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGAGTKLELK,1MH5_H,1MH5_L,The Structure Of The Complex Of The Fab Fragment Of The Esterolytic Antibody Ms6-164 And A Transition-State Analog,The Structure Of The Complex Of The Fab Fragment Of The Esterolytic Antibody Ms6-164 And A Transition-State Analog,Mus musculus,"Muranova,T.A.;Ruzheinikov,S.N.;Sedelnikova,S.E.;Moir,A.;Partridge,L.J.;Kakinuma,H.;Takahashi,N.;Shimazaki,K.;Sun,J.;Nishi,Y.;Rice,D.W.",The preparation and crystallization of Fab fragments of a family of mouse esterolytic catalytic antibodies and their complexes with a transition-state analogue,19-AUG-2002,8_8_12_11_3_9,1MH5_H_L,Xtal structure,,2,1,-0.35048053,-4.137023
1MIE_H_L,QVQLQQPGAELVKPGASVKLSCKASGYTFTSSWINWVKQRPGQGLEWIGNVYPGSSSTNYNEKFKNKATLTVDTSSSTAYMQLSSLTSDDSAFYYCVRKDYSWFPYWGQGTLVTVSA,EIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLNWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSETAFTLRTSRVEAEDVGVYYCMQHLEYPFTFGSGTKLELK,1MIE_H,1MIE_L,Crystal Structure Of The Fab Fragment Of Esterolytic Antibody Ms5-393,Crystal Structure Of The Fab Fragment Of Esterolytic Antibody Ms5-393,Mus musculus,"Muranova,T.A.;Ruzheinikov,S.N.;Sedelnikova,S.E.;Moir,A.;Partridge,L.J.;Kakinuma,H.;Takahashi,N.;Shimazaki,K.;Sun,J.;Nishi,Y.;Rice,D.W.",The preparation and crystallization of Fab fragments of a family of mouse esterolytic catalytic antibodies and their complexes with a transition-state analogue,23-AUG-2002,8_8_10_11_3_9,1MIE_H_L,Xtal structure,,2,1,-0.3772324,-4.1094017
4OII_I_M,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKLRPGQGFEWIGDINPNNGGPSYNEKFKRKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTIDDGYRFGYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSASGSGTQYSLKINSLQPEDFGSYYCQHFWSTPRTFGGGTKLEIK,4OII_I,4OII_M,West Nile Virus Ns1 In Complex With Neutralizing 22Ns1 Antibody Fab,West Nile Virus Ns1 In Complex With Neutralizing 22Ns1 Antibody Fab,Mus musculus,"Edeling,M.A.;Diamond,M.S.;Fremont,D.H.",Structural basis of Flavivirus NS1 assembly and antibody recognition,19-JAN-2014,8_8_10_6_3_9,4OII_I_M,Xtal structure,SHP2; PTPN11; BPTP3; SH-PTP2; NS1; PTP2C; SHP-2,2,1,-0.5573191,-3.959751
1FBI_H_L,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQGPGQGLEWIGEIDPSDSYPNYNEKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYYCASLYYYGTSYGVLDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQKKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTIRNLEQEDIATYFCQQGYTLPYTFGGGTKLEIK,1FBI_H,1FBI_L,Crystal Structure Of A Cross-Reaction Complex Between Fab F9.13.7 And Guinea-Fowl Lysozyme,Crystal Structure Of A Cross-Reaction Complex Between Fab F9.13.7 And Guinea-Fowl Lysozyme,Numida meleagris,"Lescar,J.;Riottot,M.M.;Souchon,H.;Chitarra,V.;Bentley,G.A.;Navaza,J.;Alzari,P.M.;Poljak,R.J.","Crystallization, preliminary X-ray diffraction study, and crystal packing of a complex between anti-hen lysozyme antibody F9.13.7 and guinea-fowl lysozyme",19-JAN-1995,8_8_15_6_3_9,1FBI_H_L,Xtal structure,,2,1,-0.45855403,-3.6810846
1Z3G_I_M,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPHSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGWDVAYWGQGTLVTVSA,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPPTFGSGTKLEIN,1Z3G_I,1Z3G_M,Crystal Structure Of Complex Between Pvs25 And Fab Fragment Of Malaria Transmission Blocking Antibody 2A8,Crystal Structure Of Complex Between Pvs25 And Fab Fragment Of Malaria Transmission Blocking Antibody 2A8,Plasmodium vivax Sal-1,"Saxena,A.K.;Singh,K.;Su,H.P.;Klein,M.M.;Stowers,A.W.;Saul,A.J.;Long,C.A.;Garboczi,D.N.",The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms,12-MAR-2005,8_8_8_5_3_9,1Z3G_I_M,Xtal structure,DNALI1; dJ423B22.5; P28; hp28; Pvs25,2,1,-0.40196192,-3.9972808
BAO57647_BAO57664,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCAKGLGGYWGQGTTLTVSS,QAVVTQESALTTSPGGTVILTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTSNRAPGVPVRFSGSLIGDKAALTITGAQTEDDAMYFCALWYSTNYVFGGGTKVTVL,BAO57647,BAO57664,"immunoglobulin heavy chain, V region, partial [Mus musculus]","immunoglobulin light chain, V region, partial [Mus musculus]",Mus musculus,"Murakami,A.; Moriyama,H.; Osako-Kabasawa,M.; Endo,K.; Nishimura,M.; Udaka,K.; Muramatsu,M.; Honjo,T.; Azuma,T.; Shimizu,T.",Low-affinity IgM antibodies lacking somatic hypermutations are produced in the secondary response of C57BL/6 mice to (4-hydroxy-3-nitrophenyl)acetyl hapten,04-APR-2014,8_8_7_9_3_9,BAO57647_BAO57664,Unique source,hapten,2,1,-0.7228497,-3.871945
1A6W_H_L,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARYDYYGSSYFDYWGQGTTVTVSS,AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGNKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,1A6W_H,1A6W_L,B1-8 Fv Fragment Complexed With A (4-Hydroxy-5-Iodo-3-Nitrophenyl) Acetate Compound,B1-8 Fv Fragment Complexed With A (4-Hydroxy-5-Iodo-3-Nitrophenyl) Acetate Compound,Mus musculus,"Simon,T.;Rajewsky,K.",A functional antibody mutant with an insertion in the framework region 3 loop of the VH domain: implications for antibody engineering,03-MAR-1998,8_8_13_9_3_9,1A6W_H_L,Xtal structure,,2,1,-0.72541857,-3.913866
BAA83324_BAA83391,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARYYYGSSYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,BAA83324,BAA83391,"immunoglobulin H-chain V-region, partial [Mus musculus]","immunoglobulin L-chain V-region, partial [Mus musculus]",Mus musculus,"Furukawa,K.; Akasako-Furukawa,A.; Shirai,H.; Nakamura,H.; Azuma,T.",Junctional amino acids determine the maturation pathway of an antibody,26-JUL-2016,8_8_12_9_3_9,BAA83324_BAA83391,Unique source,,2,1,-0.7187727,-3.8849616
BAA83316_BAA83390,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVQQRPGRGLEWIGRVDPNSGGIKYNEKFKNKVTLTVDKPSSTAYMQLSSLTSEDSAVYYCAGYNYGGSTYYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGINNRVPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,BAA83316,BAA83390,"immunoglobulin H-chain V-region, partial [Mus musculus]","immunoglobulin L-chain V-region, partial [Mus musculus]",Mus musculus,"Furukawa,K.; Akasako-Furukawa,A.; Shirai,H.; Nakamura,H.; Azuma,T.",Junctional amino acids determine the maturation pathway of an antibody,26-JUL-2016,8_8_14_9_3_9,BAA83316_BAA83390,Unique source,,2,1,-0.76944405,-3.8912032
CBL66577_CBL66576,QVQLQQPGAELVKPGASVKLSCKASGYTFTTYYLYWVRQRPGQGLEWIGGINPSNGGTNFNEKFKSKATLTVDKSSSTAYMQLNSLTSEDSAVYYCTRRDYRYDRGFDYWGQGTSVTV,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGFNYIHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEDEDAATYYCQHSRELPLTFGAGTKLEIK,CBL66577,CBL66576,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Davis,S.",Pd-1 specific antibodies and uses thereof,21-APR-2010,8_8_13_10_3_9,CBL66577_CBL66576,Ordered entries,,2,1,-0.6688662,-3.9326282
6K4Z_A_A,QVQLQQPGAELVKPGASVKLSCKTSGYTFPYYWMHWVNQRPGRGLEWIGRIDPNGGGTRYSEKFKSKATLTVDKPSNTAYMQLSSLTSEDSAVYYCARGKLGQHFDYWGQGTALTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYVNWVQEKPDHLFTGLVYSTNSRVPGVPARFSGSLIGDKAALTITGAQAEDEAIYFCTLWYSNHWVFGGGTKLTVL,6K4Z_A,6K4Z_A,Single-Chain Fv Antibody Of C6 Complexed With 2-(4-Hydroxy-3-Nitrophenyl)Acetic Acid,Single-Chain Fv Antibody Of C6 Complexed With 2-(4-Hydroxy-3-Nitrophenyl)Acetic Acid,Mus musculus,"Nishiguchi,A.;Numoto,N.;Ito,N.;Azuma,T.;Oda,M.",Three-dimensional structure of a high affinity anti-(4-hydroxy-3-nitrophenyl)acetyl antibody possessing a glycine residue at position 95 of the heavy chain,27-MAY-2019,8_8_11_9_3_9,6K4Z_A_A,Xtal structure,,2,1,-0.7752888,-3.8927011
2XQY_G_L,QVQLQQPGAELVKPGASVKMSCKASGYSFTSYWMNWVKQRPGRGLEWIGRIDPSDNETHYNQDFKDKVTLTVDKSSSTVYIQLSSLTSEDSAVYYCGRLGYVYGFDYWGQGTTLTVSS,DIVLTQSPASLALSLGQRATISCRASKSVSTSGYSYMYWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPWTFGGGTKLEIN,2XQY_G,2XQY_L,Crystal Structure Of Pseudorabies Core Fragment Of Glycoprotein H In  Complex With Fab D6.3,Crystal Structure Of Pseudorabies Core Fragment Of Glycoprotein H In  Complex With Fab D6.3,Mus musculus,"Backovic,M.;DuBois,R.M.;Cockburn,J.J.;Sharff,A.J.;Vaney,M.C.;Granzow,H.;Klupp,B.G.;Bricogne,G.;Mettenleiter,T.C.;Rey,F.A.",Structure of a core fragment of glycoprotein H from pseudorabies virus in complex with antibody,08-SEP-2010,8_8_11_10_3_9,2XQY_G_L,Xtal structure,,2,1,-0.52344096,-3.5525281
4ZSO_D_C,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCAREGLGALLRDLYYWGQGTSVTVSS,QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFCGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,4ZSO_D,4ZSO_C,"Crystal Structure Of A Complex Between B7-H6, A Tumor Cell Ligand For Natural Cytotoxicity Receptor Nkp30, And An Inhibitory Antibody","Crystal Structure Of A Complex Between B7-H6, A Tumor Cell Ligand For Natural Cytotoxicity Receptor Nkp30, And An Inhibitory Antibody",Homo sapiens,"Xu,X.;Li,Y.;Vivier,E.;Chen,Q.;Mariuzza,R.A.","Crystal Structure Of A Complex Between B7-H6, A Tum Ligand For Natural Cytotoxicity Receptor Nkp30, And Inhibitory Antibody",13-MAY-2015,8_8_14_5_3_9,4ZSO_D_C,Xtal structure,DKFZp686O24166; NCR3LG1; B7-H6,2,1,0.14248833,-3.8063288
AAO73029_AAO73030,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSRARAREAMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIK,AAO73029,AAO73030,"anti-meningococcal polysaccharide group C monoclonal antibody 2055.5 immunoglobulin heavy chain, partial [Mus musculus]","anti-meningococcal polysaccharide group C monoclonal antibody 2055.5 immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Garcia-Ojeda,P.A.; Brorson,K.A.; Stein,K.E.",VH and VL gene usage in response to the Neisseria meningitidis group C polysaccharide thymus-independent antigen,25-JUL-2016,8_8_13_5_3_9,AAO73029_AAO73030,Unique word,meningococcal,2,1,0.17290191,-3.8242257
7QT3_A_B,QVQLQQPGAELVKPGASVKVSCKASGYTFTNYWMHWVKQRPGQGLEWIGRIHPSESDTNYNQKFKGKATLTVDNSSSTAYMQLSSLTSEDSAVYYCAMEDYYGSSYEDYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNTYPYTFGGGTKLEIK,7QT3_A,7QT3_B,Antibody Fenab609 - Fentanyl Complex,Antibody Fenab609 - Fentanyl Complex,Mus musculus,"Triller,G.;Vlachou,E.P.;Hashemi,H.;van Straaten,M.;Zeelen,J.P.;Kelemen,Y.;Baehr,C.;Marker,C.L.;Ruf,S.;Svirina,A.;Chandra,M.;Urban,K.;Gkeka,A.;Kruse,S.;Baumann,A.;Miller,A.K.;Bartel,M.;Pravetoni,M.;Stebbins,C.E.;Papavasiliou,F.N.;Verdi,J.P.","A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl",24-MAY-2023,8_8_13_6_3_9,7QT3_A_B,Xtal structure,,2,1,-0.49188358,-3.6973295
6P4Y_H_L,QVQLQQPGAELVMPGASVKLSCKASGYTFTSYWMHWVKQRPGEGLEWIGEIDPSDSYTNDNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARRLYSNSYYYAMDYWGQGTSVTVSS,DIQMTQSPSSLSASLGGKVTITCKASQDIKKYIAWYQHKPGKGPRLLIHYTSTLQPGIPSRFSGSGSGRDYSFSISNLEPVDIATYYCLQYDNLLTFGAGTKLELK,6P4Y_H,6P4Y_L,Crystal Structure Of Anti-Il-7Ralpha 4A10 Fab,Crystal Structure Of Anti-Il-7Ralpha 4A10 Fab,Mus musculus,"Hixon,J.A.;Andrews,C.;Kashi,L.;Kohnhorst,C.L.;Senkevitch,E.;Czarra,K.;Barata,J.T.;Li,W.;Schneider,J.P.;Walsh,S.T.;Durum,S.K.",New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models,29-MAY-2019,8_8_15_6_3_8,QHX10753_QHX10754,Xtal structure,leukemia,2,1,-0.4186929,-3.641358
3ULU_F_E,QVQLQQPGAELVQPGTSVRLSCKASGYIFTTYWIHWVKQRPGQGLEWIGEINPNNGRINYNEKFKTKATLTVDKSSSTAYMQLSSLTSEDSAVYYCTRVGVMITTFPYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSESGTQYSLKINSLQPEDFGSYYCQHFWSTPFTFGSGTKLELK,3ULU_F,3ULU_E,Structure Of Quaternary Complex Of Human Tlr3Ecd With Three Fabs (Form1),Structure Of Quaternary Complex Of Human Tlr3Ecd With Three Fabs (Form1),Homo sapiens,"Luo,J.;Obmolova,G.;Malia,T.J.;Wu,S.J.;Duffy,K.E.;Marion,J.D.;Bell,J.K.;Ge,P.;Zhou,Z.H.;Teplyakov,A.;Zhao,Y.;Lamb,R.J.;Jordan,J.L.;San Mateo,L.R.;Sweet,R.W.;Gilliland,G.L.",Lateral Clustering of TLR3:dsRNA Signaling Units Revealed by TLR3ecd:3Fabs Quaternary Structure,11-NOV-2011,8_8_12_6_3_9,3ULU_F_E,Xtal structure,TLR3; CD283,2,1,-0.49301863,-3.9891057
7E72_A_B,QVQLQQPGAELVRPGASVKLSCKASGYSFTSYWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFMDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCARGLYGNSWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGISLNWLQQEPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYASSPYTFGGGTKLEIK,7E72_A,7E72_B,Crystal Structure Of Tie2-Agonistic Antibody In Complex With Human Tie2 Fn2-3,Crystal Structure Of Tie2-Agonistic Antibody In Complex With Human Tie2 Fn2-3,Homo sapiens,"Jo,G.;Bae,J.;Hong,H.J.;Han,A.R.;Kim,D.K.;Hong,S.P.;Kim,J.A.;Lee,S.;Koh,G.Y.;Kim,H.M.",Structural insights into the clustering and activation of Tie2 receptor mediated by Tie2 agonistic antibody,25-FEB-2021,8_8_8_6_3_9,7E72_A_B,Xtal structure,,2,1,-0.35992905,-3.6113312
4OKV_A_B,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWMNWVKQRPGQGLEWIGLIDPSDSETHYNQMFKDKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGGTYWGQGTTLTVSA,DVVMTQTPLTLSVTIGQPASIACKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIK,4OKV_A,4OKV_B,Crystal Structure Of Anopheline Anti-Platelet Protein With Fab Antibody,Crystal Structure Of Anopheline Anti-Platelet Protein With Fab Antibody,Anopheles stephensi,"Sugiyama,K.;Iyori,M.;Sawaguchi,A.;Akashi,S.;Tame,J.R.H.;Yoshida,S.;Park,S.Y.","The Crystal Structure Of Anopheles Anti-Platelet Pr Powerful Anti-Coagulant, In Complex With An Antibod",23-JAN-2014,8_8_6_11_3_9,4OKV_A_B,Xtal structure,Coagulant; Platelet,2,1,-0.35909232,-3.5659735
CAC80067_CAA10057,QVQLQQPGAELVRPGASVKLSCKASGYTLTTYWMNWFKQRPDQGLEWIGRIDPYDSETHYNQKFKDKAILTVDRSSSTAYMQLSSLTSEDSAVYYCTRFLQITTIIYGMDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQTLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQNTHVPYTFGGGTKLEIK,CAC80067,CAA10057,"immunoglobulin gamma chain, variable region, partial [Mus musculus]","immunoglobulin, kappa chain, variable region, partial [Mus musculus]",Mus musculus,"Fleury,D.; Barrere,B.; Bizebard,T.; Daniels,R.S.; Skehel,J.J.; Knossow,M.",A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site,26-JUL-2016,8_8_15_11_3_9,CAC80067_CAA10057,Unique chain,hemagglutinin,2,1,-0.35694927,-3.5542622
AAA03339_AAA03340,QVQLQQPGPDLLKPGAPVKLSCKASGYTFTDYWMNWVKQRPGRGLEWIGRIDPSDSETHYNQKFKDKATLTVDKSSSTAYIQLSSLTSEDSAVYYCARGGRLGSFAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPRTFGGGTKLEIK,AAA03339,AAA03340,"Ig variable region, heavy chain, partial [Mus musculus]","Ig variable region, light chain, partial [Mus musculus]",Mus musculus,"Hsiao,K.; Bajorath,J.; Harris,L.J.","Humanization of 60.3, an anti-CD18 antibody",26-JUL-2016,8_8_13_10_3_9,AAA03339_AAA03340,Unique chain,CD18; MFI7; LFA-1; MAC-1; ITGB2,2,1,-0.43856862,-3.5795586
PL0208_PL0207,QVQLQQPGSELVRPGASVKLSCKASGYTFTNYWMHWVKQRPGQGLEWIGNIYPGSGDSNYDEKFKSKATLTVDTSSSTAYMQLSGLTSEDSAVYYCARGLAFYFDHWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVRIAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQHCGSYPFTFGSGTKLEIK,PL0208,PL0207,Ig heavy chain precursor V region anti-idiotypic antibody E225 - mouse (strain BALB/c) (fragment),"anti-idiotypic antibody E225, kappa chain V region precursor - mouse (fragment)",Mus musculus,"Souchon,H.; Doyen,N.; Riottot,M.M.; Rougeon,F.; Poljak,R.J.","Nucleotide sequence of the VH, VL regions of an anti-idiotopic antibody reacting with a private idiotope of the anti-lysozyme D1.3 antibody",21-Jan-2000,8_8_10_6_3_9,PL0208_PL0207,Unique source,idiotopic; lysozyme,2,1,-0.4763812,-4.1318145
4KUC_H_D,QVQLQQPGSELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPGSGRTNYDEKFKNKATLTVDTSSSTVYIQVSSLTSEDAAVFYCVRWVYGNFDSALDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISYRASKSVSYMHWNQQKPGQPPRLLIYLGSNLESGVGARFSGSGSGTDFTLNIHPVEEEDAATYYCQHKREYPPTFGQGTKVEIK,4KUC_H,4KUC_D,Crystal Structure Of Ricin-A Chain In Complex With The Antibody 6C2,Crystal Structure Of Ricin-A Chain In Complex With The Antibody 6C2,Mus musculus,"Zhu,Y.;Li,X.;Teng,M.",Structural Insights Into The Neutralization Mechani 6c2 Against Ricin,21-MAY-2013,8_8_14_5_3_9,4KUC_H_D,Xtal structure,,2,1,-0.41352,-4.1532035
1AFV_H_L,QVQLQQPGSVLVRPGASVKLSCKASGYTFTSSWIHWAKQRPGQGLEWIGEIHPNSGNTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARWRYGSPYYFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNLGSGVPARFSGSGSGTDFSLNIHPMEEEDTAMYFCQQSKEVPLTFGAGTKVELK,1AFV_H,1AFV_L,Hiv-1 Capsid Protein (P24) Complex With Fab25.3,Hiv-1 Capsid Protein (P24) Complex With Fab25.3,Mus musculus,"Ehrlich,L.S.;Krausslich,H.G.;Wimmer,E.;Carter,C.A.",Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24),14-MAR-1997,8_8_13_10_3_9,1AFV_H_L,Xtal structure,P24; CHP; BA2; CHP1; p22; SLC9A1BP; p24; capsid; MRP-1; Sid470p; TSPAN29; CD9; MIC3,2,1,-0.6261212,-4.005031
3UJT_H_L,QVQLQQPGSVLVRPGASVKLSCKASGYTFTSSWMHWAKQRPGQGLEWIGEIHPNSGNTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCVRGFAYWGQGTLVTVSA,DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLNSSNQKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSTPFTFGSGTKLEIK,3UJT_H,3UJT_L,"Structure Of The Fab Fragment Of Ab-52, An Antibody That Binds The O-Antigen Of Francisella Tularensis","Structure Of The Fab Fragment Of Ab-52, An Antibody That Binds The O-Antigen Of Francisella Tularensis",Mus musculus,"Rynkiewicz,M.J.;Lu,Z.;Hui,J.H.;Sharon,J.;Seaton,B.A.",Structural Analysis of a Protective Epitope of the Francisella tularensis O-Polysaccharide,08-NOV-2011,8_8_6_12_3_9,3UJT_H_L,Xtal structure,Polysaccharide,2,1,-0.4454645,-4.1393394
7QT2_A_B,QVQLQQPGTDLVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIDPNNGGTNQNEKFKNKATLTVDKSSSTAYMHLSSLTSEDSAVYYCAIEVGYYDYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISDVQSEDLTEYFCEQYNSYPYTFGGGTKLEIK,7QT2_A,7QT2_B,Antibody Fenab208 - Fentanyl Complex,Antibody Fenab208 - Fentanyl Complex,Mus musculus,"Triller,G.;Vlachou,E.P.;Hashemi,H.;van Straaten,M.;Zeelen,J.P.;Kelemen,Y.;Baehr,C.;Marker,C.L.;Ruf,S.;Svirina,A.;Chandra,M.;Urban,K.;Gkeka,A.;Kruse,S.;Baumann,A.;Miller,A.K.;Bartel,M.;Pravetoni,M.;Stebbins,C.E.;Papavasiliou,F.N.;Verdi,J.P.","A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl",24-MAY-2023,8_8_9_6_3_9,7QT2_A_B,Xtal structure,,2,1,-0.708547,-3.9291003
2VWE_E_C,QVQLQQPGTELVKPGASVKLSCKASGYTFTGFWIHWVKQRPGQGLEWIGHINPGNGGTNYNEKFKRMATLTVDKSSSTAYMQLSSLTSEDSAVYYCARSYSNYVRAMDYWGQGTSVTVSS,EIQMTQTTSSLSASLGDRVTISCRASQDISNFLNWYQQKPDGTVKLLIYYTSTLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGKTLPPTFGGGTKLEIK,2VWE_E,2VWE_C,Crystal Structure Of Vascular Endothelial Growth Factor-B In Complex  With A Neutralizing Antibody Fab Fragment,Crystal Structure Of Vascular Endothelial Growth Factor-B In Complex  With A Neutralizing Antibody Fab Fragment,Mus musculus,"Leonard,P.;Scotney,P.D.;Jabeen,T.;Iyer,S.;Fabri,L.J.;Nash,A.D.;Acharya,K.R.",Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment,23-JUN-2008,8_8_13_6_3_9,2VWE_E_C,Xtal structure,,2,1,-0.4002671,-3.9781966
5JYM_D_D,QVQLQQPGTELVKPGASVKLSCKASGYTFTRYWINWVKQRPQGGLEWIGNIYPGSNITNYNEKFKNKATLTVDTSSNTAYMQLSSLTSDDSAVYYCAREGIYDGYFPLFPYWGQGTLVTVSA,NVLTQSPAIMAASPGEKVTMTCSASSSVSSGNFHWYQQKPGTSPKLWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSGYPWTFGGGTKLEIK,5JYM_D,5JYM_D,Human P-Cadherin Ec12 With Scfv Tsp11 Bound,Human P-Cadherin Ec12 With Scfv Tsp11 Bound,Mus musculus,"Kudo,S.;Caaveiro,J.M.;Nagatoishi,S.;Miyafusa,T.;Matsuura,T.;Sudou,Y.;Tsumoto,K.",Disruption of cell adhesion by an antibody targeting the cell-adhesive intermediate (X-dimer) of human P-cadherin,14-MAY-2016,8_8_15_7_3_9,5JYM_D_D,Xtal structure,P-cadherin,2,1,-0.43210644,-4.1310782
6DG2_A_B,QVQLQQPGTELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPRNGRTDFSEKFKSKATLTVDTSSSTAFIQLSSLTSEDSAVYYCARWGYYGSSDYWGQGTALTVSS,DIVVTQSHKFMSTSVGDRVSITCKASQDVSVAVAWYQQKTGQSPKLLIYSASYRITGVPDRFTGSGSGTDFTFTISSVQAEDMAVYYCQQHYSTPPWTFGGGTKLEIK,6DG2_A,6DG2_B,Antigen Binding Fragment Of The Pan-Ebolavirus Monoclonal Antibody 6D6,Antigen Binding Fragment Of The Pan-Ebolavirus Monoclonal Antibody 6D6,Mus musculus,"Milligan,J.C.;Parekh,D.V.;Fuller,K.M.;Igarashi,M.;Takada,A.;Saphire,E.O.",Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein,16-MAY-2018,8_8_11_6_3_10,6DG2_A_B,Xtal structure,Ebolavirus,2,1,-0.73960054,-3.9001393
6H3H_A_B,QVQLQQSAAELARPGASVKMSCKASGYTFTRYTMHWIKQRPGQGLEWIGYINPSSGYTEYNQKFRDKTTLTADKSSSTAYMQLSSLTSEDSAVYYCARGDYRYGGTAYWGQGTLVTVSA,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,6H3H_A,6H3H_B,Fab Fragment Of Antibody Against Fullerene C60,Fab Fragment Of Antibody Against Fullerene C60,Mus musculus,"Osipov,E.M.;Hendrickson,O.D.;Tikhonova,T.V.;Zherdev,A.V.;Solopova,O.N.;Sveshnikov,P.G.;Dzantiev,B.B.;Popov,V.O.",Structure of the Anti-C60 Fullerene Antibody Fab Fragment: Structural Determinants of Fullerene Binding,18-JUL-2018,8_8_12_9_3_9,6H3H_A_B,Xtal structure,C60,2,1,0.12012879,-3.3143554
8CGE_A_A,QVQLQQSDAELVKPGASVKISCKVSGYTFTDHTIHWMKQRPEQGLEWIGYNYPRDGSTKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCAKGFITTVVPSAYWGQGTLVTVSA,DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIK,8CGE_A,8CGE_A,The Crystal Structure Of A Cobalt-Bound Scfv Reveals A Tetrameric Polyhistidine Motif (Tetrhis),The Crystal Structure Of A Cobalt-Bound Scfv Reveals A Tetrameric Polyhistidine Motif (Tetrhis),synthetic construct,"Healey,R.D.;Couillaud,L.;Hoh,F.;Mouhand,A.;Fouillen,A.;Couvineau,P.;Granier,S.;Leyrat,C.","Structure, dynamics and transferability of the metal-dependent polyhistidine tetramerization motif TetrHis for single-chain Fv antibodies",09-AUG-2023,8_8_13_6_3_9,8CGE_A_A,Xtal structure,,2,1,0.22394839,-4.400277
CAF33216,QVQLQQSEGGVVQPGRSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPGMDVWGQGTTVTVSS,DIRMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPQLTFGGRTKVDIK,CAF33216_H,CAF33216_L,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Tedesco,F.; Marzari,R.",Antibodies anti-c5 component of the complement system and their use,04-MAR-2004,8_8_8_12_3_10,AEN40888,Same entry,,2,1,15.439001,9.924327
AAW68641_AAW69069,QVQLQQSGAEAKKPGASVKVSCKASGFTHTYDINWVRQAPGQGFEWLGWMNRNNKIAEYAEKFQGRITMTWDTSISTAYMELSSLRFDDTAVYYCAVVAENWFDPWGQGTLVTV,EIVMTQSPATLSVSPGERATLSCRASQSVGSDLVWYQQRPGQAPRLLIYRASLRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYRNWPPYTFGQGTKLEIK,AAW68641,AAW69069,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,7_8_10_6_3_10,AAW68641_AAW69069,Unique source,tetanus,2,1,2.1780543,4.2210784
6SF6_A_B,QVQLQQSGAELAKPGASVNLSCKASGYTFTNYWVHWVKQRPGQGLEWIGYINPSNTYISYNQQFKDKATLTADKSSSTAYMQLSRLTYEDSSVYYCARGGFFYDYDVWYFDVWGTGTTVTVSS,DVLMTQIPLSLPVSLGDQASISCRSSQNIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK,6SF6_A,6SF6_B,Crystal Structure Of The Mab 15A In Complex With Comp-Epitope P6,Crystal Structure Of The Mab 15A In Complex With Comp-Epitope P6,Rattus norvegicus,"Ge,C.;Tong,D.;Loennblom,E.;Bibo,L.;Hagert,C.;Kastbom,A.;Gjertsson,I.;Dobritzsch,D.;Holmdahl,R.",Antibodies to cartilage oligomeric matrix protein in vivo are pathogenic and clinically relevant in rheumatoid arthritis,01-AUG-2019,8_8_16_11_3_9,6SF6_A_B,Xtal structure,,2,1,0.20700625,-3.3626828
8BE1_A_B,QVQLQQSGAELARPGASVKLSCKASGYTFISNGISWVKQRTGQGLEWIGEIYPRNGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVFFCARDYYYGSFDYWGQGTTLTVSS,DIQMTQSPSSLSASLGERVSLTCRASREISGYLTWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPWTFGGGTKLEIK,8BE1_A,8BE1_B,Sars-Cov-2 Rbd In Complex With A Fab Fragment Of A Neutralising Antibody Mrbd2,Sars-Cov-2 Rbd In Complex With A Fab Fragment Of A Neutralising Antibody Mrbd2,Severe acute respiratory syndrome coronavirus 2,"Fischer,K.;Lulla,A.;So,T.Y.;Pereyra-Gerber,P.;Raybould,M.I.J.;Kohler,T.N.;Kaminski,T.S.;Yam-Puc,J.C.;Hughes,R.;Leiss-Maier,F.;Brear,P.;Matheson,N.J.;Deane,C.M.;Hyvonen,M.;Thaventhiran,J.E.D.;Hollfelder,F.",Microfluidics-enabled fluorescence-activated cell sorting of single pathogen-specific antibody secreting cells for the rapid discovery of monoclonal antibodies,25-JAN-2023,8_8_11_6_3_9,8BE1_A_B,Xtal structure,,2,1,0.19040713,-4.078815
3TT1_I_M,QVQLQQSGAELARPGASVKLSCKASGYTFTDYYINWMKQRTGQGLEWIGEIYPGVGTTYYDEKFKGKATLTADKSSRSAYMQLSSLTSEDSAVYFCARRTVTMGRYAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYGASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,3TT1_I,3TT1_M,Crystal Structure Of Leut In The Outward-Open Conformation In Complex With Fab,Crystal Structure Of Leut In The Outward-Open Conformation In Complex With Fab,Mus musculus,"Krishnamurthy,H.;Gouaux,E.",X-ray structures of LeuT in substrate-free outward-open and apo inward-open states,13-SEP-2011,8_8_14_10_3_9,3TT1_I_M,Xtal structure,,2,1,0.23618431,-4.0902734
7LFA_H_L,QVQLQQSGAELARPGASVKLSCKASGYTFTSHWMQWLKQRPGQGLEWIGAIYPGDGDTKFTQKFKDKATLTADKSSTTAYMQLSSLASEDSAVYYCARENLYGYYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTSGNFANWVQEKPDHLFTGLIGGADNRAPGVPARFSGSLIGDKAALIITGAQTEDEAIYFCALWYSDHWVFGGGTKLTVL,7LFA_H,7LFA_L,Fab 3B6 Bound To Apol1 Ntd,Fab 3B6 Bound To Apol1 Ntd,Homo sapiens,"Ultsch,M.;Holliday,M.J.;Gerhardy,S.;Moran,P.;Scales,S.J.;Gupta,N.;Oltrabella,F.;Chiu,C.;Fairbrother,W.;Eigenbrot,C.;Kirchhofer,D.",Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif,15-JAN-2021,8_8_12_9_3_9,7LFA_H_L,Xtal structure,,2,1,0.43462595,-3.8030083
S01321_S01320,QVQLQQSGAELARPGASVKLSCKASGYTLTSYGISWVKQRTGQGLEWIGEIYPGSGNSYFNEKFKGKATLTVDKSSSTAYLHLSSLTSEDSAVYFCAGPRQVGLLPFGYWGQGTLVTASA,DIQMTQSPASLSVSVGESVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATKLVDGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWDTPFTFGSGTKLEMK,S01321,S01320,Ig gamma-2b chain precursor - mouse,Ig kappa chain precursor - mouse,Mus musculus,"De Waele,P.; Feys,V.; Van de Voorde,A.; Molemans,F.; Fiers,W.",Expression in non-lymphoid cells of mouse recombinant immunoglobulin directed against the tumour marker human placental alkaline phosphatase,21-Jan-2000,8_8_13_6_3_9,S01321_S01320,Unique source,,2,1,0.11506609,-4.142628
ADN42857,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTVTVSA,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN,ADN42857_H,ADN42857_L,CD5L-OKT3scFv-CD14 protein [synthetic construct],CD5L-OKT3scFv-CD14 protein [synthetic construct],synthetic construct,"Pfistershammer,K.; Klauser,C.; Pickl,W.F.; Stockl,J.; Leitner,J.; Zlabinger,G.; Majdic,O.; Steinberger,P.",No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation,25-SEP-2010,8_8_12_5_3_9,ADN42857,Same entry,PDL2; CD5L; Spalpha; PD-L2; Btdc; B7-DC; CD273; bA574F11.2; API6; PDCD1LG2; CD14,2,1,0.16870047,-3.271453
8CT6_H_L,QVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGRTNYDERFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCARPRIYGMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDTYMSWYQQKPGQPPKLLIYAASKLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYFCQQSNEDPWTFGGGTKLEIK,8CT6_H,8CT6_L,1F8 Mab In Complex With The Computationally Optimized Broadly Reactive H1 Influenza Hemagglutinin P1,1F8 Mab In Complex With The Computationally Optimized Broadly Reactive H1 Influenza Hemagglutinin P1,Mus musculus,"Dzimianski,J.V.;Han,J.;Sautto,G.A.;O&#8217;Rourke,S.M.;Cruz,J.M.;Pierce,S.R.;Ecker,J.W.;Carlock,M.A.;Nagashima,K.A.;Mousa,J.J.;Ross,T.M.;Ward,A.B.;DuBois,R.M.",Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine,19-APR-2023,8_8_10_10_3_9,8CT6_H_L,Xtal structure,hemagglutinin; Influenza,2,1,4.952582,-1.9164612
7T82_D_C,QVQLQQSGAELMNPGASVKISCKSTGYKFSSYWIEWVKQRPGHGLEWMGEILPGSGSTNHNEKFKGKAIFTADASSNTAYMELSSLTSEDSAVYYCARTISTATDWFAYWGQGTLVTVSA,DVLMTQTPLSLPVSLGDQASISCRSSQTIVYSDGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRVSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,7T82_D,7T82_C,Crystal Structure Of Leukocidin E/Centyrin S26/Fab B438,Crystal Structure Of Leukocidin E/Centyrin S26/Fab B438,Mus musculus,"Buckley,P.T.;Chan,R.;Fernandez,J.;Luo,J.;Lacey,K.A.;DuMont,A.L.;O'Malley,A.;Brezski,R.J.;Zheng,S.;Malia,T.;Whitaker,B.;Zwolak,A.;Payne,A.;Clark,D.;Sigg,M.;Lacy,E.R.;Kornilova,A.;Kwok,D.;McCarthy,S.;Wu,B.;Morrow,B.;Nemeth-Seay,J.;Petley,T.;Wu,S.;Strohl,W.R.;Lynch,A.S.;Torres,V.J.",Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections,11-JAN-2023,8_8_13_11_3_9,UCY74951_UCY74912,Xtal structure,RPS26; S26; eS26,2,1,4.975444,-1.8952053
CAL49882,QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDTAVYFCVRDSPFFDYWGQGTLLTVSS,DIVLTQSPDSLAVSLGERVTMNCKSSQSLLNSGMRKSFLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIK,CAL49882_H,CAL49882_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Stassen,J.M.; Carmeliet,P.; Collen,D.",Novel anti-plgf antibody,09-OCT-2006,8_8_9_12_3_8,AED12866,Same entry,plgf,2,1,0.11236911,-4.3076663
4RGN_D_E,QVQLQQSGAELVKPGASVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEIDPSDSYINYNQIFEGKATLTVDKSSTTAYLQLSSLTSEDSAVYYCARTAGLLAPMDYWGQGTSVTVSS,DIVMTQSPSSLTVTAGEKVTMTCKSSQSLFNSGNQKNFLTWYQQIPGQPPKLLIYWASTRDSGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYTYPLTFGVGTKLELK,4RGN_D,4RGN_E,"Structure Of Staphylococcal Enterotoxin B Bound To Two Neutralizing Antibodies, 14G8 And 6D3","Structure Of Staphylococcal Enterotoxin B Bound To Two Neutralizing Antibodies, 14G8 And 6D3",Mus musculus,"Varshney,A.K.;Wang,X.;Cook,E.;Dutta,K.;Scharff,M.D.;Goger,M.J.;Fries,B.C.","Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock",30-SEP-2014,8_8_12_12_3_9,4RGN_D_E,Xtal structure,,2,1,-0.41139147,-3.5947566
CAO02306_CAO02307,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTV,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,CAO02306,CAO02307,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Mateo De Acosta Del Rio,C.M.; Lombardero Valladares,J.; Roque Navarro,L.T.; Lopez Requena,A.",Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors,26-JUN-2007,8_8_14_6_3_9,CAO02306_CAO02307,Ordered entries,Ganglioside,2,1,-0.028336352,-4.209275
1NQB_C_C,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARYDYYGSSYFDYWGQGTTVTVSS,DIELTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,1NQB_C,1NQB_C,Trivalent Antibody Fragment,Trivalent Antibody Fragment,Mus musculus,"Pei,X.Y.;Holliger,P.;Murzin,A.G.;Williams,R.L.",The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3,04-APR-1997,8_8_13_11_3_9,1NQB_C_C,Xtal structure,,2,1,-0.6734396,-3.881306
1AJ7_H_L,QVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASYYGIYWGQGTTLTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPRTFGGGTKVEIK,1AJ7_H,1AJ7_L,Immunoglobulin 48G7 Germline Fab Antibody Complexed With Hapten 5-(Para-Nitrophenyl Phosphonate)-Pentanoic Acid. Affinity Maturation Of An Esterolytic Antibody,Immunoglobulin 48G7 Germline Fab Antibody Complexed With Hapten 5-(Para-Nitrophenyl Phosphonate)-Pentanoic Acid. Affinity Maturation Of An Esterolytic Antibody,Mus musculus,"Lesley,S.A.;Patten,P.A.;Schultz,P.G.",A genetic approach to the generation of antibodies with enhanced catalytic activities,15-MAY-1997,8_8_7_6_3_9,1AJ7_H_L,Xtal structure,,2,1,-4.7245035,0.19013868
1HKL_H_L,QVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPKQGLEWIGRIDPANVDTKYDPKFQDKATITADTSSKTTYLQLSSLTSEDTAVYYCASYYGIYWGQGTTLTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEINGYLGWLQQKPDGTIKRLIYAASTLHSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPRTFGGGTKVEIK,1HKL_H,1HKL_L,Free And Liganded Form Of An Esterolytic Catalytic Antibody,Free And Liganded Form Of An Esterolytic Catalytic Antibody,Homo sapiens,"Lesley,S.A.;Patten,P.A.;Schultz,P.G.",A genetic approach to the generation of antibodies with enhanced catalytic activities,20-DEC-1996,8_8_7_6_3_9,1HKL_H_L,Xtal structure,,2,1,-4.7630663,0.23008543
CBL66582_CBL66581,QVQLQQSGAELVKPGASVKMSCKAFGYTFTTYPIEWMKQNHGKSLEWIGNFHPYNDDTKYNEKFKGKAKLTVEKSSTTVYLELSRLTSDDSAVYYCARENYGSHGGFVYWGQGTLVTV,ENVLTQSPAIMSASPGEKVTMTCRASSSVISSYLHWYQQKSGASPKLWIYSTSNLASGVPDRFSGSGSGTSYSLTISSVEAEDAATYYCQQYNGYPLTFGAGTKLEIK,CBL66582,CBL66581,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Davis,S.",Pd-1 specific antibodies and uses thereof,21-APR-2010,8_8_13_7_3_9,CBL66582_CBL66581,Ordered entries,,2,1,1.109147,-3.9223957
S04575_S04574,QVQLQQSGAELVKPGASVKMSCKASGYTFTTYPIEWMKQNHGKSLEWIGNFHPYNDDTKYNEKFKGKATLTVEKSSSTVYLELSRLTSDDSAVYYCARGPITGHYYAMDYWGQGTSVTVSS,DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIK,S04575,S04574,Ig heavy chain precursor V region (MRL-RF24) - mouse (fragment),Ig kappa chain precursor V region (MRL-RF24L) - mouse (fragment),Mus musculus,"Kofler,R.; Noonan,D.J.; Strohal,R.; Balderas,R.S.; Moller,N.P.; Dixon,F.J.; Theofilopoulos,A.N.",Molecular analysis of the murine lupus-associated anti-self response: involvement of a large number of heavy and light chain variable region genes,21-JAN-2000,8_8_14_6_3_9,S04575_S04574,Ordered entries,,2,1,1.3418949,-4.003253
1NMC_H_L,QVQLQQSGAELVKPGASVRMSCKASGYTFTNYNMYWVKQSPGQGLEWIGIFYPGNGDTSYNQKFKDKATLTADKSSNTAYMQLSSLTSEDSAVYYCARSGGSYRYDGGFDYWGQGTTVTVSS,DIELTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQNPDGTVKLLIYYTSNLHSEVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQDFTLPFTFGGGTKLEIR,1NMC_H,1NMC_L,Complex Between Nc10 Anti-Influenza Virus Neuraminidase Single Chain Antibody With A 15 Residue Linker And Influenza Virus Neuraminidase,Complex Between Nc10 Anti-Influenza Virus Neuraminidase Single Chain Antibody With A 15 Residue Linker And Influenza Virus Neuraminidase,Influenza A virus,"Malby,R.L.;Caldwell,J.B.;Gruen,L.C.;Harley,V.R.;Ivancic,N.;Kortt,A.A.;Lilley,G.G.;Power,B.E.;Webster,R.G.;Colman,P.M.;et al.","Recombinant antineuraminidase single chain antibody: expression, characterization, and crystallization in complex with antigen",21-DEC-1997,8_8_15_6_3_9,1NMC_H_L,Xtal structure,Influenza,2,1,0.21632554,-3.704435
S32185_S32188,QVQLQQSGAELVKPGLSVKLSCKASGHTFTEYSIHWVKQRSGQGLEWIGXFYPGNNSIKYTEKFKDKATLTADKSSSTVYMELSRLTSEDSAVYFCARHEGISTVVGRFAYWGXGTLVTASA,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLHWYQQKQDGTVKLLIYYTLRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQANTLPYTFGGGTKLELK,S32185,S32188,Ig heavy chain V region - mouse (fragment),Ig kappa chain V region - mouse (fragment),Mus musculus,"Izui,S.",Direct Submission,21-Jan-2000,8_8_15_6_3_9,FAILED,Ordered entries,,2,1,0.096278794,-4.244853
4U6H_A_B,QVQLQQSGAELVKTGASLRMSCKSSGYTFTRFWMHWIKQSPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADRSSTTAYMQLISLTSGDSAVYYCARSDQTNYLFPYWGQGTLVTVSA,DVVMTQIPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWSLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHDPWTFGGGTKLEIK,4U6H_A,4U6H_B,Vaccinia L1/M12B9-Fab Complex,Vaccinia L1/M12B9-Fab Complex,Vaccinia virus WR,"Kaever,T.;Meng,X.;Matho,M.H.;Schlossman,A.;Li,S.;Sela-Culang,I.;Ofran,Y.;Buller,M.;Crump,R.W.;Parker,S.;Frazier,A.;Crotty,S.;Zajonc,D.M.;Peters,B.;Xiang,Y.",Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein,29-JUL-2014,8_8_12_11_3_9,4U6H_A_B,Xtal structure,,2,1,0.13734397,-3.2697647
1FAI_H_L,QVQLQQSGAELVRAGSSVKMSCKASGYTFTSYGVNWVKQRPGQGLEWIGYINPGKGYLSYNEKFKGKTTLTVDRSSSTAYMQLRSLTSEDAAVYFCARSFYGGSDLAVYYFDSWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEHEDIATYFCQQGSTLPRTFGGGTKLEIK,1FAI_H,1FAI_L,"Three-Dimensional Structure Of Two Crystal Forms Of Fab R19.9, From A Monoclonal Anti-Arsonate Antibody","Three-Dimensional Structure Of Two Crystal Forms Of Fab R19.9, From A Monoclonal Anti-Arsonate Antibody",Mus musculus,"Mariuzza,R.A.;Amit,A.G.;Boulot,G.;Saludjian,P.;Saul,F.A.;Tougard,P.;Poljak,R.J.;Conger,J.;Lamoyi,E.;Nisonoff,A.",Crystallization of the fab fragments of monoclonal anti-p-azophenylarsonate antibodies and their complexes with haptens,27-MAY-1992,8_8_17_6_3_9,AAW13179_AAW13149,Xtal structure,p-azophenylarsonate,2,1,-0.3299791,-4.185829
S24287_S24288,QVQLQQSGAELVRPGASVKLSCKASGYTYTSYWINWVKQRPGQGLEWIGKIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTYYYGSRYEDYAMDHWGQGTSVTVSS,DIQLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIREPYTFGGGTKLEIK,S24287,S24288,Ig heavy chain V region (JS28/32) - mouse,Ig kappa chain V region (JS28/32) - mouse,Mus musculus,"Moncharmont,B.",Direct Submission,20-JUN-2000,8_8_15_10_3_8,S24287_S24288,Unique word,,2,1,-0.35891008,-3.6435013
AWH97992_AWH98072,QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAINPKIAITAYNQKFKGKAILTSDKSSSTVYMELRSLTSEDSAVYYCTRLRLYGFFDVWGTGTTVTVSS,DILMTQTPLSLPVSLGDQASISCRSSQSIVYSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,AWH97992,AWH98072,"anti-HIV-1 fusion peptide immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-HIV-1 fusion peptide immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Xu,K.; Acharya,P.; Kong,R.; Cheng,C.; Chuang,G.-Y.; Liu,K.; Louder,M.K.; ODell,S.; Rawi,R.; Sastry,M.; Shen,C.-H.; Zhang,B.; Zhou,T.; Asokan,M.; Bailer,R.T.; Chambers,M.; Chen,X.; Choi,C.W.; Dandey,V.P.; Doria-Rose,N.A.; Druz,A.; Eng,E.T.; Farney,K.; Foulds,K.E.; Geng,H.; Georgiev,I.S.; Gorman,J.; Hill,K.R.; Jafari,A.J.; Kwon,Y.D.; Lai,Y.-T.; Lemmin,T.; McKee,K.; Ohr,T.Y.; Ou,L.; Peng,D.; Roshan,A.P.; Sheng,Z.; Todd,J.-P.; Tsybovsky,Y.; Viox,E.G.; Wang,Y.; Wei,H.; Yang,Y.; Zhou,A.F.; Chen,R.; Yang,L.; Scorpio,D.G.; McDermott,A.B.; Shapiro,L.; Carragher,B.; Potter,C.S.; Mascola,J.R.; Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,12-MAY-2018,8_8_11_11_3_9,AWH97992_AWH98072,Unique source,HIV,2,1,0.21364534,-3.4687054
AWH97917_AWH97997,QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIVPETGFTAYTQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCSRLRLYWYFDVWGTGTTVTVSS,GVLLTQSPLSLPVSLGDQASISCRSSQSILYSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRVSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,AWH97917,AWH97997,"anti-HIV-1 fusion peptide immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-HIV-1 fusion peptide immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Xu,K.; Acharya,P.; Kong,R.; Cheng,C.; Chuang,G.-Y.; Liu,K.; Louder,M.K.; ODell,S.; Rawi,R.; Sastry,M.; Shen,C.-H.; Zhang,B.; Zhou,T.; Asokan,M.; Bailer,R.T.; Chambers,M.; Chen,X.; Choi,C.W.; Dandey,V.P.; Doria-Rose,N.A.; Druz,A.; Eng,E.T.; Farney,K.; Foulds,K.E.; Geng,H.; Georgiev,I.S.; Gorman,J.; Hill,K.R.; Jafari,A.J.; Kwon,Y.D.; Lai,Y.-T.; Lemmin,T.; McKee,K.; Ohr,T.Y.; Ou,L.; Peng,D.; Roshan,A.P.; Sheng,Z.; Todd,J.-P.; Tsybovsky,Y.; Viox,E.G.; Wang,Y.; Wei,H.; Yang,Y.; Zhou,A.F.; Chen,R.; Yang,L.; Scorpio,D.G.; McDermott,A.B.; Shapiro,L.; Carragher,B.; Potter,C.S.; Mascola,J.R.; Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,12-MAY-2018,8_8_11_11_3_9,AWH97917_AWH97997,Unique source,HIV,2,1,0.25477532,-3.533026
3V7A_E_H,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPRSGDTNSNEKFKGKAILTADKSSSTAYMQLSSLTSDDSAVYFCARSGTTAYFAMDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNVKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGSPPWTFGGGTKLEIK,3V7A_E,3V7A_H,Structural Basis For Broad Detection Of Genogroup Ii Noroviruses By A Monoclonal Antibody That Binds To A Site Occluded In The Viral Particle,Structural Basis For Broad Detection Of Genogroup Ii Noroviruses By A Monoclonal Antibody That Binds To A Site Occluded In The Viral Particle,Norovirus isolates,"Hansman,G.S.;Taylor,D.W.;McLellan,J.S.;Smith,T.J.;Georgiev,I.;Tame,J.R.;Park,S.Y.;Yamazaki,M.;Gondaira,F.;Miki,M.;Katayama,K.;Murata,K.;Kwong,P.D.",Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle,20-DEC-2011,8_8_13_6_3_10,3V7A_E_H,Xtal structure,,2,1,0.17433232,-4.452418
1YNT_D_C,QVQLQQSGAELVRPGVSVKISCKGSGYTFTDYGMHWVKQSHAKSLEWIGIISTYSGDASYNQKFKGKATMTVDKSSSTAYMELARLTSEDSAIYYCARSSTWYYFDYWGQGTTLTVSS,DIQVTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIK,1YNT_D,1YNT_C,Structure Of The Immunodominant Epitope Displayed By The Surface Antigen 1 (Sag1) Of Toxoplasma Gondii Complexed To A Monoclonal Antibody,Structure Of The Immunodominant Epitope Displayed By The Surface Antigen 1 (Sag1) Of Toxoplasma Gondii Complexed To A Monoclonal Antibody,Toxoplasma gondii,"Graille,M.;Stura,E.A.;Bossus,M.;Muller,B.H.;Letourneur,O.;Battail-Poirot,N.;Sibai,G.;Gauthier,M.;Rolland,D.;Le Du,M.H.;Ducancel,F.",Crystal structure of the complex between the monomeric form of Toxoplasma gondii surface antigen 1 (SAG1) and a monoclonal antibody that mimics the human immune response,25-JAN-2005,8_8_11_6_3_9,1YNT_D_C,Xtal structure,Toxoplasma,2,1,2.9372175,-4.53012
7VYR_H_L,QVQLQQSGAEVKKPGSSVKVSCKASGGTFGNWSISWVRQAPGQGLEWMGGIDPSRGEATYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARETEQGGMDVWGQGTTVTVSS,SYELTQPPSVSVAPGKTARITCGGNNIGRKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVYDLFSDYVFGTGTKVEIK,7VYR_H,7VYR_L,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With The D27 Neutralizing Antibody Fab Fragment,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With The D27 Neutralizing Antibody Fab Fragment,Severe acute respiratory syndrome coronavirus 2,"Jeong,B.S.;Cha,J.S.;Hwang,I.;Kim,U.;Adolf-Bryfogle,J.;Coventry,B.;Cho,H.S.;Kim,K.D.;Oh,B.H.",Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants,15-NOV-2021,8_8_11_6_3_10,7VYR_H_L,Xtal structure,SARS-CoV-2,2,1,-0.64097553,5.9249964
4HJ0_C_D,QVQLQQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPTFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAQGPIVGAPTDYWGKGTLVTVSS,SYVLTQPPSASGTPGQRVAISCSGSNSNIGSNTVHWYQQLPGAAPKLLIYSNNQRPSGVPDRFSGSNSGTSASLAISRLQSEDEADYYCAAWDDSLNGVVFGGGTKVTVL,4HJ0_C,4HJ0_D,Crystal Structure Of The Human Gipr Ecd In Complex With Gipg013 Fab At 3-A Resolution,Crystal Structure Of The Human Gipr Ecd In Complex With Gipg013 Fab At 3-A Resolution,Homo sapiens,"Ravn,P.;Madhurantakam,C.;Kunze,S.;Matthews,E.;Priest,C.;O'Brien,S.;Collinson,A.;Papworth,M.;Fritsch-Fredin,M.;Jermutus,L.;Benthem,L.;Gruetter,M.;Jackson,R.H.",Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor,12-OCT-2012,8_8_12_8_3_11,4HJ0_C_D,Xtal structure,,2,1,-0.49746427,5.6652784
7KZC_H_L,QVQLQQSGAEVKKPGSSVKVSCKASGGTFSTYSISWVRQAPGQGLEWMGGIAPSHGFANYAQKFQGRVTITTDESTSTAYMELSSLRSEDTAVYYCARDTATGGMDVWGQGTTVTVSS,SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTYSDYVFGTGTKVTVL,7KZC_H,7KZC_L,Potent Sars-Cov-2 Binding And Neutralization Through Maturation Of Iconic Sars-Cov-1Antibodies,Potent Sars-Cov-2 Binding And Neutralization Through Maturation Of Iconic Sars-Cov-1Antibodies,Homo sapiens,"Langley,D.B.;Christ,D.",Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,10-DEC-2020,8_8_11_6_3_10,7KZC_H_L,Xtal structure,SARS-CoV-2; SARS; CoV,2,1,-0.6177479,5.9290547
CAF34387_CAF34388,QVQLQQSGAEVKKPGSSVKVSCKASGYAFTSYVIHWVRQAPGQGLYWIGYIHPYNGGTKYNEKFKGKATITADESTNTAYMELSSLRSEDSAVYYCARSGGGDPFAYWGQGTTVTVSS,DIQLTQSPSSLSASLGGKVTITCKASQDINKYIGWYQHKPGKGPRLLMHYTSALLPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDDLWTFGGGTKLEIK,CAF34387,CAF34388,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Hansen,H.; Qu,Z.; Goldenberg,D.M.",Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof,06-MAR-2004,8_8_11_6_3_8,CAF34387_CAF34388,Unique chain,,2,1,0.69334614,3.8781881
4F9P_D_D,QVQLQQSGAEVVRPGTSVKVSCKASGYAFTSYLIHWIKQRPGQGLEWIGVINPRSGDSHYNEKFKDRTTLTADQSSSTAYMQLSSLTSDDSAVYFCARSDYGAYWGQGTLVTVSA,DIVLTQSPVTLSVTPGDSVSLSCRASQSISNNLHWYRQKSHESPRLLIKYASQSIFGIPSRFSGSGSGTEFTLSINSVETEDFGIYFCQQSNSWPHTFGTGTKLELK,4F9P_D,4F9P_D,Crystal Structure Of The Human Btn3A1 Ectodomain In Complex With The 103.2 Single Chain Antibody,Crystal Structure Of The Human Btn3A1 Ectodomain In Complex With The 103.2 Single Chain Antibody,Mus musculus,"Palakodeti,A.;Sandstrom,A.;Sundaresan,L.;Harly,C.;Nedellec,S.;Olive,D.;Scotet,E.;Bonneville,M.;Adams,E.J.",The molecular basis for modulation of human Vgamma9Vdelta2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies,19-MAY-2012,8_8_8_6_3_9,4F9P_D_D,Xtal structure,BT3.1; BTN3A1; CD277; BTN3.1; Ectodomain; BTF5,2,1,0.20923354,-4.3924975
4ZFO_H_L,QVQLQQSGGGLVQPGGSLKLSCAASGIDFSRYWMSWVRRAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCASLYYDYGDAMDYWGQGTSVTVSS,DIVMTQSQRFMTTSVGDRVSVTCKASQSVDSNVAWYQQKPRQSPKALIFSASLRFSGVPARFTGSGSGTDFTLTISNLQSEDLAEYFCQQYNNYPLTFGAGTKLELK,4ZFO_H,4ZFO_L,J22.9-Xi: Chimeric Mouse/Human Antibody Against Human Bcma (Cd269),J22.9-Xi: Chimeric Mouse/Human Antibody Against Human Bcma (Cd269),Homo sapiens,"Oden,F.;Marino,S.F.;Brand,J.;Scheu,S.;Kriegel,C.;Olal,D.;Takvorian,A.;Westermann,J.;Yilmaz,B.;Hinz,M.;Daumke,O.;Hopken,U.E.;Muller,G.;Lipp,M.",Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma,21-APR-2015,8_8_13_6_3_9,4ZFO_H_L,Xtal structure,BCM; BCMA; CD269; TNFRSF17; TNFRSF13A,2,1,19.610508,9.728378
QKK35628_QKK35629,QVQLQQSGGGLVQPGGSLRLSCEASGFNFNSYSMSWVRQAPGKGLEWLSYISSRSSTIKYASSVQGRFTVSRDNAKKSVFLQMNSLRDEDTAVYYCARELDSETYYNYNSLDVWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTISCRASQGISTFLAWFQQRPGKAPKSLIYAASKLQSGVPSRFSGSDSGPDFTLTIDNLQPEDSATYYCKQYNSYPYTFGQGTKLEIK,QKK35628,QKK35629,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_6_3_9,QKK35628_QKK35629,Unique source,SARS-CoV-2,2,1,15.894637,9.872306
3IET_D_C,QVQLQQSGGGLVQPGGSMKIFCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRNKANNHETYYAESVKGRFTITRDDSKSRMSLQMNSLRAEDTGIYYCSGGKVRNAYWGQGTTVTVSS,DIQLTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISSVEAEDLGVYFCSQSTHVPTFGGGTKLEIK,3IET_D,3IET_C,Crystal Structure Of 237Mab With Antigen,Crystal Structure Of 237Mab With Antigen,Mus musculus,"Schietinger,A.;Philip,M.;Yoshida,B.A.;Azadi,P.;Liu,H.;Meredith,S.C.;Schreiber,H.",A mutant chaperone converts a wild-type protein into a tumor-specific antigen,23-JUL-2009,8_10_9_11_3_8,3IET_D_C,Xtal structure,,2,1,13.431875,6.90471
5DLM_H_L,QVQLQQSGGGSVKPGGSLKLSCSASGFSLSTYAMSWVRQTPEKRLEWVASMSSGGSLYYPDTVKGRFTISRDTVKNIVYLQMSSLRSEDTAMYYCVRGGYGTSYWGQGTTVTVSS,VLLTQTPLSLPVSLGEQASISCRSSQSIVHSIGDTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSHFPYTFGGGTKLEIK,5DLM_H,5DLM_L,Complex Of Influenza M2E And Antibody,Complex Of Influenza M2E And Antibody,Influenza A virus,"Cho,K.J.;Schepens,B.;Moonens,K.;Deng,L.;Fiers,W.;Remaut,H.;Saelens,X.",Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody,07-SEP-2015,8_7_9_11_3_9,5DLM_H_L,Xtal structure,Influenza,2,1,17.94466,7.1918945
AAW68516_AAW68939,QVQLQQSGGGVVQPGRSLRLSCAASGFAFRDYAMHWVRQAPGKGLEWMGVISFNGDQIFYADSMKGRFTISRENSKNTLHLHMNSLRPEDTAVYYCARARLLFCSGGRCDMDSWGQGTLVTV,EIVMTQSPSFLSASVGDRVTITCRASQDIITYLAWYQQKPGKAPEVLIFGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQIIRYPRTFGQGTRVEIK,AAW68516,AAW68939,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_17_6_3_9,AAW68516_AAW68939,Unique source,tetanus,2,1,14.737277,12.717659
AAW68460_AAW68878,QVQLQQSGGGVVQPGRSLRLSCAASGFAFRDYAMHWVRQAPGKGLEWMGVISFNGDQIFYADSMKGRFTISRENSKNTLHLRMNSLRPEDTAVYYCARARLLFCSGGRCDMDSWGQGTLVTV,EIVMTQSPSFLSASVGDRVTITCRASQDIITYLAWYQQKPGKAPEVLIFGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQIIRYPRTFGQGTRVEIK,AAW68460,AAW68878,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_17_6_3_9,AAW68460_AAW68878,Unique source,tetanus,2,1,14.75653,12.703691
5WYM_A_A,QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISHGGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDFSWRGYYMDVWGKGTLVTVSS,TTLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGGGTKVEIK,5WYM_A,5WYM_A,Crystal Structure Of An Anti-Connexin26 Scfv,Crystal Structure Of An Anti-Connexin26 Scfv,Homo sapiens,"Xu,L.;Carrer,A.;Zonta,F.;Qu,Z.;Ma,P.;Li,S.;Ceriani,F.;Buratto,D.;Crispino,G.;Zorzi,V.;Ziraldo,G.;Bruno,F.;Nardin,C.;Peres,C.;Mazzarda,F.;Salvatore,A.M.;Raspa,M.;Scavizzi,F.;Chu,Y.;Xie,S.;Yang,X.;Liao,J.;Liu,X.;Wang,W.;Wang,S.;Yang,G.;Lerner,R.A.;Mammano,F.",Design and Characterization of a Human Monoclonal Antibody that Modulates Mutant Connexin 26 Hemichannels Implicated in Deafness and Skin Disorders,13-JAN-2017,8_8_13_6_3_9,5WYM_A_A,Xtal structure,Connexin26,2,1,14.390931,13.705557
5U8Q_H_L,QVQLQQSGPDVVRPGVSVKISCKGSGYTFTDYAIHWVKQSHAKSLEWIGVISTYNGNTKYNQKFKGKAAITVDKSSSTAYLELARLTSEDSAIYYCASYGDLYVMDYWGQGTSVTVSS,DIVLTQSPATLSVTPGDSVSLSCRASQTISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPRTFGAGTKLELK,5U8Q_H,5U8Q_L,Structure Of The Ectodomain Of The Human Type 1 Insulin-Like Growth Factor Receptor In Complex With Igf-I,Structure Of The Ectodomain Of The Human Type 1 Insulin-Like Growth Factor Receptor In Complex With Igf-I,Mus musculus,"Xu,Y.;Kong,G.K.;Menting,J.G.;Margetts,M.B.;Delaine,C.A.;Jenkin,L.M.;Kiselyov,V.V.;De Meyts,P.;Forbes,B.E.;Lawrence,M.C.",How ligand binds to the type 1 insulin-like growth factor receptor,14-DEC-2016,8_8_11_6_3_9,5U8Q_H_L,Xtal structure,insulin; Ectodomain,2,1,3.0043275,-4.5732703
4X0K_H_L,QVQLQQSGPEDVKPGASVKISCKASGYSLSTSGMGVNWVKQSPGKGLEWLAHIYWDDDKRYNPSLKSRATLTVDKSSSTVYLELRSLTSEDSSVYYCARRGGSSHYYAMDYWGQGTTVTVSS,DIVMTQTPSSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSLVPPTFGAGTKLELK,4X0K_H,4X0K_L,Engineered Fab Fragment Specific For Eympme (Ee) Peptide,Engineered Fab Fragment Specific For Eympme (Ee) Peptide,Homo sapiens,"Johnson,J.L.;Entzminger,K.C.;Hyun,J.;Kalyoncu,S.;Heaner DP,Jr.;Morales,I.A.;Sheppard,A.;Gumbart,J.C.;Maynard,J.A.;Lieberman,R.L.",Structural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization,21-NOV-2014,10_7_14_11_3_9,4X0K_H_L,Xtal structure,,2,1,1.7781194,-4.365518
6D9G_A_B,QVQLQQSGPELVKLGASVRISCKASGYRFSYSWMNWVKQRPGKGLEWIGRIYPGDGDTKYSGKFKGKATLTADKSSSTVYMQLSSLTSEDSAVYFCARSAYGSEGFAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFLNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTYFSLNIHPMEEDDTAVYFCQQTKGVSWTFGGGTKVEIK,6D9G_A,6D9G_B,"X-Ray Structure Of The Fab Fragment Of 15B8, A Murine Monoclonal Antibody Specific For The Human Serotonin Transporter","X-Ray Structure Of The Fab Fragment Of 15B8, A Murine Monoclonal Antibody Specific For The Human Serotonin Transporter",Mus musculus,"Coleman,J.A.;Yang,D.;Zhao,Z.;Wen,P.C.;Yoshioka,C.;Tajkhorshid,E.;Gouaux,E.",Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport,29-APR-2018,8_8_14_10_3_9,6D9G_A_B,Xtal structure,SH3YL1; DKFZP586F1318; Ray,2,1,0.42883795,-4.7606363
CAC16565_CAC16566,QVQLQQSGPELVKPGALVKISCKASGYSFTSYDINWVKRRPGQGLEWIGWIFPGDGSTNYNEKFKDKATLTADKSSSTAYMQLNSLTSENSAVYFCARDGSMGGFDYWGQGTTVTVSS,DVLMTQTPKFMSTSVGDRVSITCKASQNVRTTVAWYQEKPGQSPKALIYLASNRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCLQHWNYPYTFGGGTKLEIK,CAC16565,CAC16566,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Graeff,H.; Luther,T.; Noack,F.; Magdolen,V.; Mueller,M.; Schmitt,M.; Wilhelm,O.; Albrecht,S.",Diagnostic and therapeutic use of antibodies against the urokinase receptor,16-NOV-2000,8_8_11_6_3_9,CAC16565_CAC16566,Unique chain,,2,1,0.22355887,-4.4904146
3NCY_P_S,QVQLQQSGPELVKPGALVKISCKASGYTFTNYDINWVKQRPGQGLEWIGWIYPGDGSTMYNEKFKGKATLTADKSSSTAYMQLSSLTSENSSVYFCARLDGNYGGWFAYWGQGTSVTVSS,LVMTQSPAIMSASPGEKVTMTCSASSSVNYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSYNPPTFGGGTKLEIK,3NCY_P,3NCY_S,X-Ray Crystal Structure Of An Arginine Agmatine Antiporter (Adic) In Complex With A Fab Fragment,X-Ray Crystal Structure Of An Arginine Agmatine Antiporter (Adic) In Complex With A Fab Fragment,Mus musculus,"Fang,Y.;Jayaram,H.;Shane,T.;Kolmakova-Partensky,L.;Wu,F.;Williams,C.;Xiong,Y.;Miller,C.",Structure of a prokaryotic virtual proton pump at 3.2 A resolution,06-JUN-2010,8_8_13_5_3_9,3NCY_P_S,Xtal structure,SH3YL1; DKFZP586F1318; Ray,2,1,0.20311661,-4.4242153
5F3J_D_D,QVQLQQSGPELVKPGASVKISCKASGYAFISSWMNWVKQRPGKGLEWIGRIYPGDGDTHYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAREETAQTGGFDYWGQGTTLTVSS,DIVITQDELSNPVTSGESVSISCRSSKSLLYQDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVSDRFSGSGSGTDFTLEISRVEAEDVGVYYCQQLVEYPLTFGAGTKLELK,5F3J_D,5F3J_D,Crystal Structure Of Dbp In Complex With Inhibitory Monoclonal Antibody 2D10,Crystal Structure Of Dbp In Complex With Inhibitory Monoclonal Antibody 2D10,Mus musculus,"Chen,E.;Salinas,N.D.;Huang,Y.;Ntumngia,F.;Plasencia,M.D.;Gross,M.L.;Adams,J.H.;Tolia,N.H.",Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein,02-DEC-2015,8_8_13_11_3_9,5F3J_D_D,Xtal structure,,2,1,0.35177463,-4.7482185
CDM22133_CDM22134,QVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGQGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSVDSAVYFCARGGNYGWFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELYTFGGGTKLEIK,CDM22133,CDM22134,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"ENDO,K.; KUHURA,M.; YAGI,K.; NAKAMURA,Y.; KATAGIRI,T.; NAKATSURU,S.",Tumor-targeting monoclonal antibodies to FZD10 and uses thereof,03-FEB-2014,8_8_11_10_3_8,CDM22133_CDM22134,Ordered entries,FZD10; CD350,2,1,0.35248545,-4.6653943
4F2M_C_D,QVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGQGLEWIGRIYPGDGETNYSEKFKGKATLTADKSSSTAYMHLSSLTSVDSAVYFCARGGYRYDPYYAMDYWGQGTSVTVSS,DILLTQSPAILSVSPGERVSLSCRASQSIGTSIHWYQQRTNGSPRPLIKYASESISGIPSRFSGSGSGTDFTLNINSVESEDIADYFCQQTDSWPTTFGAGTKLELK,4F2M_C,4F2M_D,Crystal Structure Of A Tgev Coronavirus Spike Fragment In Complex With The Tgev Neutralizing Monoclonal Antibody 1Af10,Crystal Structure Of A Tgev Coronavirus Spike Fragment In Complex With The Tgev Neutralizing Monoclonal Antibody 1Af10,TGEV virulent Purdue,"Reguera,J.;Santiago,C.;Mudgal,G.;Ordono,D.;Enjuanes,L.;Casasnovas,J.M.",Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies,08-MAY-2012,8_8_15_6_3_9,4F2M_C_D,Xtal structure,,2,1,0.39512053,-4.724139
7UZD_H_L,QVQLQQSGPELVKPGASVKISCKASGYVFSTSWMSWVKQRPGEGPEWIGRIYPRDGHSSSTGKFKDKATLTADKSSNTAYIHLSSLTSEDSAVYFCARDYGYYYFDYWGQGTTLTVSS,DIQMTQSPASLSASVGEAVTITCRLSENVYSFLAWYQQKQGKSPQLLVYRAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGTYYCQHHYGTPPTFGGGTKLEIK,7UZD_H,7UZD_L,"Structure Of The Sars-Cov-2 Rbd In Complex With The Mouse Antibody Fab Fragment, Hsw-2","Structure Of The Sars-Cov-2 Rbd In Complex With The Mouse Antibody Fab Fragment, Hsw-2",Mus musculus,"Fan,C.;Cohen,A.A.;Park,M.;Hung,A.F.;Keeffe,J.R.;Gnanapragasam,P.N.P.;Lee,Y.E.;Gao,H.;Kakutani,L.M.;Wu,Z.;Kleanthous,H.;Malecek,K.E.;Williams,J.C.;Bjorkman,P.J.",Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes,11-JAN-2023,8_8_11_6_3_9,7UZD_H_L,Xtal structure,RBD,2,1,0.40364808,-4.772576
3QUM_H_L,QVQLQQSGPELVKPGASVKISCKVSGYAISSSWMNWVKQRPGQGLEWIGRIYPGDGDTKYNGKFKDKATLTVDKSSSTAYMQLSSLTSVDSAVYFCARDGYRYYFDYWGQGTSVTVSS,DIVMTQTAPSVFVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQHLEYPVTFGAGTKVEIK,3QUM_H,3QUM_L,Crystal Structure Of Human Prostate Specific Antigen (Psa) In Fab Sandwich With A High Affinity And A Pca Selective Antibody,Crystal Structure Of Human Prostate Specific Antigen (Psa) In Fab Sandwich With A High Affinity And A Pca Selective Antibody,Mus musculus,"Muller,B.H.;Savatier,A.;L'hostis,G.;Costa,N.;Bossus,M.;Michel,S.;Ott,C.;Becquart,L.;Ruffion,A.;Stura,E.A.;Ducancel,F.",In Vitro Affinity Maturation of an Anti-PSA Antibody for Prostate Cancer Diagnostic Assay,24-FEB-2011,8_8_11_11_3_9,3QUM_H_L,Xtal structure,APS; KLK3; PSA,2,1,0.39341864,-4.752856
2Y6S_H_L,QVQLQQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGEFYPGTDSTYYTENFKGRATLTADKSSKTAYMQLSSLTSEDSAVYFCATAFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIAPVEEEDAATYYCQHIAELTRTFGGGTKLEIK,2Y6S_H,2Y6S_L,Structure Of An Ebolavirus-Protective Antibody In Complex With Its  Mucin-Domain Linear Epitope,Structure Of An Ebolavirus-Protective Antibody In Complex With Its  Mucin-Domain Linear Epitope,Ebola virus - Zaire (1995),"Olal,D.;Kuehne,A.I.;Bale,S.;Halfmann,P.;Hashiguchi,T.;Fusco,M.L.;Lee,J.E.;King,L.B.;Kawaoka,Y.;Dye JM,Jr.;Saphire,E.O.",Structure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus,25-JAN-2011,8_8_6_10_3_9,2Y6S_H_L,Xtal structure,Ebolavirus; Ebola,2,1,0.38663816,-4.1074705
7WP8_H_L,QVQLQQSGPELVKPGASVRISCKASGYTFTSYYIHWVKQRPGQGLEWIGWIYPGNVKSIYNEKFKGKATLTADKSSNTAYMQLSSLTSEDSAVYFCAGEEHGNYFDFWGQGTTLTVSQ,QIVLSQSPTILSASPGEKVTMTCRANSSVGFMHWCQQKPGSSPKPWIYATSNLASGVPGRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSDPPTFGSGTKLEIK,7WP8_H,7WP8_L,Cryo-Em Structure Of Sars-Cov-2 Recombinant Spike Protein Stfk1628X In Complex With Three Neutralizing Antibodies,Cryo-Em Structure Of Sars-Cov-2 Recombinant Spike Protein Stfk1628X In Complex With Three Neutralizing Antibodies,Mus musculus,"Zheng,Q.;Sun,H.;Yuan,Q.;Li,S.;Xia,N.",Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK in complex with three neutralizing antibodies,08-MAR-2023,8_8_11_5_3_9,7WP8_H_L,Xtal structure,SARS-CoV-2,2,1,0.20984687,-4.4292955
1XGY_H_L,QVQLQQSGPELVRPGASVKISCKASGYTFTDYYINWVKQRPGQGLEWIGWIFPRNGNTKYNEKFKGKATLTVDKSSSTAFMQLSSLTSEDSAVYFCATTVSYVMDYWGQGTTVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFALRISRVEAEDVGVYYCGQMLEHPLTFGTGTKLELK,1XGY_H,1XGY_L,Crystal Structure Of Anti-Meta I Rhodopsin Fab Fragment K42-41L,Crystal Structure Of Anti-Meta I Rhodopsin Fab Fragment K42-41L,synthetic construct,"Piscitelli,C.L.;Angel,T.E.;Bailey,B.W.;Hargrave,P.;Dratz,E.A.;Lawrence,C.M.",Equilibrium between metarhodopsin-I and metarhodopsin-II is dependent on the conformation of the third cytoplasmic loop,17-SEP-2004,8_8_10_11_3_9,1XGY_H_L,Xtal structure,Meta,2,1,0.18800816,-4.3797555
6J15_H_L,QVQLQQSGPELVRPGVSVKISCKGSGHTFTDYALHWVRQSHVKSLEWIGVISSYNGITNYNQRFKGKATMTVDKSSSTAYLELARLTSEDSAIYYCSREEWDVFYYFDYWGQGTTLTVSS,DIMLTQSPLSLPVSLGDQASISCRSSQGIVHSDGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFILKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK,6J15_H,6J15_L,Complex Structure Of Gy-5 Fab And Pd-1,Complex Structure Of Gy-5 Fab And Pd-1,Mus musculus,"Chen,D.;Tan,S.;Zhang,H.;Wang,H.;He,W.;Shi,R.;Tong,Z.;Zhu,J.;Cheng,H.;Gao,S.;Chai,Y.;Qi,J.;Xiao,M.;Yan,J.;Gao,G.F.",The FG Loop of PD-1 Serves as a 'Hotspot' for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy,27-DEC-2018,8_8_13_11_3_9,6J15_H_L,Xtal structure,PD1; PDCD1; SLEB2; hSLE1; CD279; PD-1,2,1,2.9874542,-4.5693774
4N8C_H_L,QVQLQQSGPEVVRPGVSVRISCKGSGYTFTDYAMHWVKQSHAKSLDWIGVIGTDNGNTNYNQKFKGKATMTVDKSSNTAYMELGRLTSEDSAIYYCARRDRDDVWFAYWGQGTLVTVSA,DIVMSQSPSSLAVSVGEKVSMSCKSSQSLFYSSYQKDLLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYFCQQYYTYPLTFGAGTKLELK,4N8C_H,4N8C_L,Three-Dimensional Structure Of The Extracellular Domain Of Matrix Protein 2 Of Influenza A Virus,Three-Dimensional Structure Of The Extracellular Domain Of Matrix Protein 2 Of Influenza A Virus,Influenza A virus (A/Puerto Rico/8/1934(H1N1)),"Cho,K.J.;Schepens,B.;Seok,J.H.;Kim,S.;Roose,K.;Lee,J.H.;Gallardo,R.;Van Hamme,E.;Schymkowitz,J.;Rousseau,F.;Fiers,W.;Saelens,X.;Kim,K.H.",Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody,17-OCT-2013,8_8_12_12_3_9,4N8C_H_L,Xtal structure,Influenza,2,1,2.9881935,-4.57203
AAW68469_AAW68889,QVQLQQSGPGLVKPSETLPLTCTVSGGSFSTYYWSWIRQSPEKGLEWIGYIQNSVNTNYNPSLKSRVIISVDTSNNQFSLKLRSVTAADTAVYYCARVSGWGPRGGIYFDYWGQGTLVTV,DIQMTQSPSSLSASVSDRVTITCRASQSINKFLNWYQQKPGKAPQLLIYAATNLQSGVPSRFSGSGSGTDFTLTISSLQTEDFATYYCQQSYDMPRTFGQGTKVEIK,AAW68469,AAW68889,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_7_16_6_3_9,AAW68469_AAW68889,Unique source,tetanus,2,1,16.150177,-8.239208
5GS0_D_C,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGIIQKRSKWYNNYAVKVKSKITINPDTSKNQFSLQLSSVTPEDTAVYYCARYSYPFYSIDYWGQGTLVTVSS,IVLTQPPSVSVAPGQTARISCSGDNIGSYYVHWYQQKPGQAPVLVIYEDSERPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDDPNFQVFGGGTKLTV,5GS0_D,5GS0_C,Crystal Structure Of The Complex Of Tlr3 And Bi-Specific Diabody,Crystal Structure Of The Complex Of Tlr3 And Bi-Specific Diabody,Mus musculus,"Kim,J.H.;Song,D.H.;Youn,S.J.;Kim,J.W.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface,13-AUG-2016,10_9_12_6_3_10,5GS0_D_C,Xtal structure,,2,1,15.496981,-4.699103
3ULS_B_A,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGIIQKRSKWYNNYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYSYPFYSIDYWGQGTLVTVSS,SVLTQPPSVSVAPGQTARISCSGDNIGSYYVHWYQQKPGQAPVLVIYEDSERPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDDPNFQVFGGGTKLTVL,3ULS_B,3ULS_A,Crystal Structure Of Fab12,Crystal Structure Of Fab12,Homo sapiens,"Luo,J.;Obmolova,G.;Malia,T.J.;Wu,S.J.;Duffy,K.E.;Marion,J.D.;Bell,J.K.;Ge,P.;Zhou,Z.H.;Teplyakov,A.;Zhao,Y.;Lamb,R.J.;Jordan,J.L.;San Mateo,L.R.;Sweet,R.W.;Gilliland,G.L.",Lateral Clustering of TLR3:dsRNA Signaling Units Revealed by TLR3ecd:3Fabs Quaternary Structure,11-NOV-2011,10_9_12_6_3_10,3ULS_B_A,Xtal structure,TLR3; CD283,2,1,15.474321,-4.671081
7O4Y_H_L,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCAREVTGDLEDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSGVPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIK,7O4Y_H,7O4Y_L,M971 Fab In Complex With Anti-Kappa Vhh Domain,M971 Fab In Complex With Anti-Kappa Vhh Domain,Homo sapiens,"Ereno-Orbea,J.;Liu,X.;Sicard,T.;Kucharska,I.;Li,W.;Borovsky,D.;Cui,H.;Feng,Y.;Dimitrov,D.S.;Julien,J.P.",Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22,28-JUL-2021,10_9_14_6_3_9,QHZ11487_QHZ11488,Xtal structure,CD22; SIGLEC-2; SIGLEC2,2,1,15.489775,-4.6836247
8AG1_H_L,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSVSWDWIRQSPSRGLEWLGRTYYRSKWYNEYAVSVESRITINPDTSKNQFSLQLNSVTPEDTAIYFCVRNDYFFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPGYTFGQGTKLEIK,8AG1_H,8AG1_L,Crystal Structure Of A Novel Ox40 Antibody,Crystal Structure Of A Novel Ox40 Antibody,Homo sapiens,"Zhang,J.;Jiang,X.;Gao,H.;Zhang,F.;Zhang,X.;Zhou,A.;Xu,T.;Cai,H.",Structural Basis of a Novel Agonistic Anti-OX40 Antibody,19-JUL-2023,10_9_9_6_3_11,8AG1_H_L,Xtal structure,TNFRSF4; ACT35; OX40; TXGP1L; CD134,2,1,15.486923,-4.6808267
5YAX_A_A,QVQLQQSGPGLVKPSQTLSLTCGISGDSVSSKSAAWNWIRQSPSRGLEWLGRTYYRSKWHNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARGQMGALDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSYYVYWYQQFPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVIFGGGTKLTVL,5YAX_A,5YAX_A,Crystal Structure Of A Human Neutralizing Antibody Bound To A Hbv Pres1 Peptide,Crystal Structure Of A Human Neutralizing Antibody Bound To A Hbv Pres1 Peptide,Hepatitis B virus,"Li,D.;He,W.;Liu,X.;Zheng,S.;Qi,Y.;Li,H.;Mao,F.;Liu,J.;Sun,Y.;Pan,L.;Du,K.;Ye,K.;Li,W.;Sui,J.",A potent human neutralizing antibody Fc-dependently reduces established HBV infections,02-SEP-2017,10_9_10_8_3_11,5YAX_A_A,Xtal structure,HBV,2,1,15.494551,-4.688224
4J4P_H_L,QVQLQQSGPGLVKPSQTLSLTCGISGDSVSSNSAAWNWLRQSPSRGLEWLGRTYYRSKWYNDYAVSMKSRITINPDTSRNQFSLQLNSVTPEDTAVYYCARDGEISYDYYYYGMDVWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNGVNWYQQVPGKPPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGLQSEDEADYYCEAWDDSLDGVVFGGGTKLTVL,4J4P_H,4J4P_L,The Complex Of Human Ige-Fc With Two Bound Fab Fragments,The Complex Of Human Ige-Fc With Two Bound Fab Fragments,Homo sapiens,"Drinkwater,N.;Cossins,B.P.;Keeble,A.H.;Wright,M.;Cain,K.;Hailu,H.;Oxbrow,A.;Delgado,J.;Shuttleworth,L.K.;Kao,M.W.;McDonnell,J.M.;Beavil,A.J.;Henry,A.J.;Sutton,B.J.",Human immunoglobulin E flexes between acutely bent and extended conformations,07-FEB-2013,10_9_17_8_3_11,AYI44633_AYI44634,Xtal structure,,2,1,15.501238,-4.6943245
AF416909_1,QVQLQQSGPRLVKPSGTLSLTCTVSGGSISSSSYYWGWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLQGARGYSYGYGIDYWGQGTLVTVSS,ETTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKLEIK,AF416909_1_H,AF416909_1_L,"recombinant single chain Fv antibody derivative, partial [synthetic construct]","recombinant single chain Fv antibody derivative, partial [synthetic construct]",synthetic construct,"Bangale,Y.; Cavill,D.; Gordon,T.; Planque,S.; Taguchi,H.; Bhatia,G.; Nishiyama,Y.; Arnett,F.; Paul,S.",Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice,22-OCT-2003,10_7_17_6_3_9,AF416909_1,Same entry,,2,1,16.645397,-8.19567
AAW68491_AAW68913,QVQLQQSGPTLVKPTQTLTLTCTLSGFSLYTTGVGVGWIRQPPGKALEWLARIYWDDDERYNPSLKSRLTITKDASKNQVVLKMTNMDPVDTATYYCARTMGVVLPFDYWGQGTLVTV,DVVMTQSPSTLSASVGDRVTITCRASQSIGSWLAWYQQKPGKAPKLLIYKASTLQSETPSRFRGSGSGTEFTLTISSLQPDDFATYYCQQFNSFSPWTFGQGTKVEFK,AAW68491,AAW68913,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,10_7_12_6_3_10,AAW68491_AAW68913,Unique source,tetanus,2,1,12.381564,0.32636014
2G2R_H_L,QVQLQQSGPVLVKPGTSLKMSCKASGYTFTAYYMNWMKQSHGKRLEWIAVINPYNGFTTYNQKFKGKATLTVDKSSNTAYMDLNSLTSEDSAVYYCVPYDYAADRVYWGHGTLVTVS,DVVMTQTPLTLSVTIGQPASISCRSSQSLLYINGKTHLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCLQSTHFPLTFGAGTKLELK,2G2R_H,2G2R_L,Green-Fluorescent Antibody 11G10 In Complex With Its Hapten (Nitro-Stilbene Derivative),Green-Fluorescent Antibody 11G10 In Complex With Its Hapten (Nitro-Stilbene Derivative),Mus musculus,"Tian,F.;Debler,E.W.;Millar,D.P.;Deniz,A.A.;Wilson,I.A.;Schultz,P.G.",The effects of antibodies on stilbene excited-state energetics,16-FEB-2006,8_8_11_11_3_9,2G2R_H_L,Xtal structure,,2,1,2.401925,-4.19671
AAY85980_AAY85981,QVQLQQSGSELMKPGASVQISCKATGYTFSDYWIEWVKQRPGHGLEWIGDILCGTGRTRYNEKLKAMATFTADTSSNTAFMQLSSLTSEDSAVYYCARSASYGDYADYWGHGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLISWASTRHTGVPDRFTGSGSGTDYTLTISSVQAEDLALYYCQQHYTTPLTFGAGTKLELK,AAY85980,AAY85981,"anti-West Nile virus monoclonal antibody heavy chain variable region, partial [Mus musculus]","anti-West Nile virus monoclonal antibody light chain variable region, partial [Mus musculus]",Mus musculus,"Oliphant,T.; Engle,M.; Nybakken,G.E.; Doane,C.; Johnson,S.; Huang,L.; Gorlatov,S.; Mehlhop,E.; Marri,A.; Chung,K.M.; Ebel,G.D.; Kramer,L.D.; Fremont,D.H.; Diamond,M.S.",Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus,26-Jul-2016,8_8_12_6_3_9,ADR90020,Unique chain,,2,1,4.98759,-1.8823457
7C81_H_L,QVQLQQSGSELVRPGASVKLSCRASGYTFTTYWMHWVKQRPGQGLEWIGNIYPHSGNTNYDERFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRDLRGFAYWGQGTTVTVSS,DIELTQSPAIMSASPGEKVTMTCSASSSLRYMHWYQQKSGTSPKRWIYDTYNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGAGTKLELK,7C81_H,7C81_L,E30 F-Particle In Complex With 6C5,E30 F-Particle In Complex With 6C5,Mus musculus,"Wang,K.;Zheng,B.;Zhang,L.;Cui,L.;Su,X.;Zhang,Q.;Guo,Z.;Guo,Y.;Zhang,W.;Zhu,L.;Zhu,F.;Rao,Z.;Wang,X.",Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B,28-MAY-2020,8_8_9_5_3_9,7C81_H_L,Xtal structure,,2,1,-0.4186372,-4.1362824
6AJ7_H_L,QVQLQQSGTELAKPGASVKMSCKASGYTFTNYWMHWFKQRPGQGLEWIGYVNPNTDYTDYNHKFKDKATLTADKSSSTAYMQLSSLTSEDSAVYFCARGTFGNYASFAYWGQGTLV,DIQMIQSPSSMFASLGDRVSLSCRASQDIRGNLDWYQQKPGGTIKLLIYSTSNLNSGVPSRFSGSGSGSDYSLTISSLESEDFADYYCLQRNAYPLTFGGGTKLEIK,6AJ7_H,6AJ7_L,The Structure Of Enterovirus D68 Mature Virion In Complex With Fab 15C5,The Structure Of Enterovirus D68 Mature Virion In Complex With Fab 15C5,enterovirus D68,"Zheng,Q.;Zhu,R.;Xu,L.;He,M.;Yan,X.;Liu,D.;Yin,Z.;Wu,Y.;Li,Y.;Yang,L.;Hou,W.;Li,S.;Li,Z.;Chen,Z.;Li,Z.;Yu,H.;Gu,Y.;Zhang,J.;Baker,T.S.;Zhou,Z.H.;Graham,B.S.;Cheng,T.;Li,S.;Xia,N.",Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization,27-AUG-2018,8_8_13_6_3_9,6AJ7_H_L,Xtal structure,enterovirus,2,1,0.12782694,-3.314229
7W71_H_L,QVQLQQSRAELARPGASVKMSCKASGYTFTTYTMQWVKQRPGQALEWIGYINPGSGYAKNNQKFKDKATLTADKSSSTAYMQLSSLTSDDSAVYYCARSGSFFDYWGQGTTLTVSS,DIVLTQSPAILSVTPGDSVSLSCRASQSVSSNLHWYQQRSHESPRLLITYAFQSISGIPSRFSGNGSGTDFTLNINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,7W71_H,7W71_L,Crystal Structure Of The Pdz-C Domain Of E. Coli Rsep In Complex With 12C7 Fab,Crystal Structure Of The Pdz-C Domain Of E. Coli Rsep In Complex With 12C7 Fab,Mus musculus,"Imaizumi,Y.;Takanuki,K.;Miyake,T.;Takemoto,M.;Hirata,K.;Hirose,M.;Oi,R.;Kobayashi,T.;Miyoshi,K.;Aruga,R.;Yokoyama,T.;Katagiri,S.;Matsuura,H.;Iwasaki,K.;Kato,T.;Kaneko,M.K.;Kato,Y.;Tajiri,M.;Akashi,S.;Nureki,O.;Hizukuri,Y.;Akiyama,Y.;Nogi,T.",Mechanistic insights into intramembrane proteolysis by <i>E. coli</i> site-2 protease homolog RseP,07-SEP-2022,8_8_9_6_3_9,7W71_H_L,Xtal structure,,2,1,0.15256076,-3.3317697
6WQO_B_C,QVQLQQWGAGLLKPSETLALTCTVYGGSSSGYYWNWIRQSPGKGLEWIGEISDSGSTIYNPSLESRVTMSVDTSKNQFSLKLTSVTAADTAVYYCAKAILTRYNWLDPWSQGTLVTVSS,DIVMTQSPSSLSASVGDRISISCRASQGVNSALAWYQQKPGKAPKLLIYDASTLESGVPSRFSGSGSGTDFALTINSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,6WQO_B,6WQO_C,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 283284,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 283284,Homo sapiens,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,29-APR-2020,8_7_13_6_3_9,6WQO_B_C,Xtal structure,,2,1,16.710596,-10.539435
QKK35690_QKK35691,QVQLQQWGAGLLKPSETLSLICDVYGGSFNGFYWSWIRQPPGKGLEWIGEISHDGSTNYSPSLKSRVSISIDTSKKQFSLKLRSVTAADTAMYYCARGMTSPVVHLYSSGRPSRWFDFWGQGTLVTVSS,QPVLTQPASVSGSPGQSSTLSCSGTSSDVGSYDLVSWYQQHPGKAPKLMIYEGTKRPSGVSDRFSGSTSGNTASLTISGLQAEDEANYYCCSYAGSGTWIFGGGTKLTVL,QKK35690,QKK35691,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_23_9_3_10,QKK35690_QKK35691,Unique source,SARS-CoV-2,2,1,16.726286,-10.565025
5DRX_H_L,QVQLQQWGAGLLKPSETLSLNCAVYGESFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADAAIYYCARGYADTPVFRRYYYYGMDVWAKGTTVTVSS,DIVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSDRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPYTFGQGTKVEIK,5DRX_H,5DRX_L,Crystal Structure Of The Bcr Fab Fragment From Subset #4 Case Cll240,Crystal Structure Of The Bcr Fab Fragment From Subset #4 Case Cll240,Homo sapiens,"Minici,C.;Gounari,M.;Ubelhart,R.;Scarfo,L.;Duhren-von Minden,M.;Schneider,D.;Tasdogan,A.;Alkhatib,A.;Agathangelidis,A.;Ntoufa,S.;Chiorazzi,N.;Jumaa,H.;Stamatopoulos,K.;Ghia,P.;Degano,M.",Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia,16-SEP-2015,8_7_20_11_3_10,5DRX_H_L,Xtal structure,,2,1,16.588049,-10.432528
QKK35518_QKK35519,QVQLQQWGAGLLKPSETLSLSCAVYGGSFSGFYWSWIRQPPGKGLEWIGEINHSGSANYNPSLMSRVTISMDTSKKQFSLQLRSVTAADTAVYYCARGQESPIVGVTGRWFDPWGQGTLVTVSS,QPVLTQPASVSGSPGQSVTISCTGTSSDVGSYSDVGNYVSWYQHHPGKAPKLMIYEVRTRPSWVSTRFSGSKSGTTASLTISGLQAEDEADYYCCSYAGASPFVVFGGGTKLTVL,QKK35518,QKK35519,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_18_13_3_11,QKK35518_QKK35519,Unique source,SARS-CoV-2,2,1,16.69491,-10.5337305
CAD92032_CAD92031,QVQLQQWGAGLLKPSETLSLSCAVYGGSFSGYYWNWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQLSLKLSSVTAADTAVYYCARGEIVV,ITCQGDSLRSFYASWYQQKPGQAPVLVIYGKSNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHM,CAD92032,CAD92031,"rearranged VH4-34 V gene segment, partial [Homo sapiens]","rearranged Vl3l gene segment, partial [Homo sapiens]",Homo sapiens,"Tinguely,M.; Rosenquist,R.; Sundstroem,C.; Amini,R.M.; Kuppers,R.; Hansmann,M.L.; Brauninger,A.",Analysis of a clonally related mantle cell and Hodgkin lymphoma indicates Epstein-Barr virus infection of a Hodgkin/Reed-Sternberg cell precursor in a germinal center,25-JUL-2016,8_7_7_6_3_10,CAD92032_CAD92031,Unique chain,Epstein,2,1,16.628712,-10.251968
QKK35808_QKK35809,QVQLQQWGAGLLKPSETLSLTCAVNGGSFNNYYWSWIRQPPGKGPEWIGEVVHSGSTTYNPSLKSRVTISIDMSKNQFALKLNSVTAADTAVYYCARGFTFTYSDFLTGQRTFEYWGQGTLVTVSS,QSALIQPASVSGSPGQSITISCTGTSSDVGRYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEAAYYCSSYISDIKLVVFGGGTKLTVL,QKK35808,QKK35809,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_20_9_3_11,QKK35808_QKK35809,Unique source,SARS-CoV-2,2,1,16.691553,-10.528515
7MYT_A_B,QVQLQQWGAGLLKPSETLSLTCAVNGGSFSIYYWSWIRQPPGKGLDWIGEINQSGSTNYNPSLKSRVTMSVDTSKSQFSLRMTSVTAADTAIYYCARAPRIRWGSYRLKQTNFDSWGQGTLVTVFN,QSALTQPASVSGSPGQSITISCTGTSNDVGDYDYVSWYQLHPGKAPKLLIFDVSRRPSGVSDRFSGSKSGDTASLTISGLQAEDEADYYCSSYTGSSTYVFGTGTKVSVL,7MYT_A,7MYT_B,Crystal Structure Of Hpv L1-Directed B25.M05 Fab,Crystal Structure Of Hpv L1-Directed B25.M05 Fab,Homo sapiens,"Singh,S.;Pancera,M.;Rodarte,J.;Carter,J.",Structural Characterization of Immune Responses to HPV vaccination,09-NOV-2022,8_7_20_9_3_10,7MYT_A_B,Xtal structure,HPV,2,1,16.628614,-10.451952
QKY76331_QKY75944,QVQLQQWGAGLLKPSETLSLTCAVSGGSFSAYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVGYSQGYYYYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFSLTISSLQPEDFATYSCQQSYTTLLTFGGGTKVEIK,QKY76331,QKY75944,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_16_6_3_9,QKY76331_QKY75944,Unique source,SARS-CoV-2,2,1,16.573587,-10.400677
ANY91436_ANY90977,QVQLQQWGAGLLKPSETLSLTCAVYGDSFNGYYWTWIRQPPGKGLEWIGEINRSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARYPLYYDSRGVFYQKVTAYAMDVWGQGTTVTVSS,DIQLTQSPVSLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLHSYPRTFGQGTKLEIN,ANY91436,ANY90977,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_7_24_6_3_9,ANY91436_ANY90977,Unique source,Influenza,2,1,16.646074,-10.47368
QKK35594_QKK35595,QVQLQQWGAGLLKPSETLSLTCAVYGGSFRGFYWTWIRQPPGKGLEWIGEVSHSGETNYNPSLKSRVTISVDTSKNQFSLNLISVTAADTSVYYCARGYTAPIIREVPITFRPRWFDPWGQGTPVTVSS,QPVLTQPASVSGSPGQSITISCTGTSSDVGNYNVVSWYQQHPGKAPQLFIYEDTKRPSGVSDRFSGSKSGITASLTISRLQPEDEADYYCCSYAVSGTVLFGGGTKVTVL,QKK35594,QKK35595,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_23_9_3_10,QKK35594_QKK35595,Unique source,SARS-CoV-2,2,1,16.695204,-10.533357
7UM3_I_M,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHNGNTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK,7UM3_I,7UM3_M,Crystal Structure Of A Fab In Complex With A Peptide Derived From The Lag-3 D1 Domain Loop Insertion,Crystal Structure Of A Fab In Complex With A Peptide Derived From The Lag-3 D1 Domain Loop Insertion,Homo sapiens,"Thudium,K.;Selby,M.;Zorn,J.A.;Rak,G.;Wang,X.T.;Bunch,R.T.;Hogan,J.M.;Strop,P.;Korman,A.J.","Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab",07-SEP-2022,8_7_14_6_3_9,QDA90666_QDA90667,Xtal structure,LAG-3; C1orf215; Lag; LAP18; STMN1; OP18; FLJ32206; PP19; PR22; SMN; PP17,2,1,16.70001,-10.518545
QKK35520_QKK35521,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGFHWSWIRQPPGKGLEWIGEVNHSGSTKYNPSLKSRVTVSVDTSKNQFSLRLSSVTAADTAIYYCARGSLSREYDFLTAPQNGPWFDSWGQGALVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNLGNNYVSWYQQLPGTAPKLLIYDNHKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDSSLSVVVFGGGTKVTVL,QKK35520,QKK35521,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_23_8_3_11,QKK35520_QKK35521,Unique source,SARS-CoV-2,2,1,16.796408,-10.6368685
QKK35852_QKK35853,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGFYWTWIRQPPGKGLEWIGEINHSGSSNYDLSLKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGMISPRIPRTTRQRWFDTWGQGTLVTVSS,QPGLTQPASVSGSPGQSITISCTGTSGDVGSDNLVSWYQRHPGKAPKLMIYEGSKRPSGVSHRFSGSNSGNTASLTISGLQAEDDADYYCCSYAGDDTVVFGGGTKLTVL,QKK35852,QKK35853,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_20_9_3_10,QKK35852_QKK35853,Unique source,SARS-CoV-2,2,1,16.674288,-10.551252
QKY76477_QKY76090,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGHYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARPPQAARIHYYYYMDVWGKGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNYWPPLTFGGGTKVEIK,QKY76477,QKY76090,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_17_6_3_10,QKY76477_QKY76090,Unique source,SARS-CoV-2,2,1,16.632746,-10.463085
QEP19998_QEP20646,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIDHGGSTSYSPSLKSRVTISVDTSKNQFSLKLSSVTAADTAIYYCARHSYLYYYASGSYGDNWFDSWGQGTLVTVSS,DIQMTQSPSSLSAAVGDRVTITCRASQGISNSLAWYQQKPGKAPKLLLYATSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYTFGQGTKVQIK,QEP19998,QEP20646,"IGH + IGL c105_heavy_IGHV4-34_IGHD3-10_IGHJ5, partial [Homo sapiens]","IGH + IGL c105_light_IGKV1D-13_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_21_6_3_5,QEP19998_QEP20646,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.720488,-10.552973
8EE1_B_C,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRGSSSSFDYWGQGTLVTVSS,ETTLTQSPGTLSLSPGERATLSCRASQSVSSYYLAWYQQKPGQAPRLLMYGASNRATGIPDRFSGSGSGTDFTLTIARLEPEDFAVYFCQQYGTSPQTFGQGTNVEIK,8EE1_B,8EE1_C,Ks-At Didomain From Module 2 Of The 6-Deoxyerythronolide B Synthase In Complex With Antibody Fragment Aa5,Ks-At Didomain From Module 2 Of The 6-Deoxyerythronolide B Synthase In Complex With Antibody Fragment Aa5,Homo sapiens,"Guzman,K.M.;Cogan,D.P.;Brodsky,K.L.;Soohoo,A.M.;Li,X.;Sevillano,N.;Mathews,I.I.;Nguyen,K.P.;Craik,C.S.;Khosla,C.",Discovery and Characterization of Antibody Probes of Module 2 of the 6-Deoxyerythronolide B Synthase,31-MAY-2023,8_7_12_7_3_9,8EE1_B_C,Xtal structure,,2,1,16.701529,-10.520143
6MHR_A_B,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,6MHR_A,6MHR_B,Structure Of The Human 4-1Bb / Urelumab Fab Complex,Structure Of The Human 4-1Bb / Urelumab Fab Complex,Homo sapiens,"Chin,S.M.;Kimberlin,C.R.;Roe-Zurz,Z.;Zhang,P.;Xu,A.;Liao-Chan,S.;Sen,D.;Nager,A.R.;Oakdale,N.S.;Brown,C.;Wang,F.;Yang,Y.;Lindquist,K.;Yeung,Y.A.;Salek-Ardakani,S.;Chaparro-Riggers,J.",Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab,18-SEP-2018,8_7_15_6_3_11,UCY82111_UCY82112,Xtal structure,ILA; 4-1BB; TNFSF9; 4-1BB-L; CD137; CD137L; TNFRSF9; 4-1BBL,2,1,16.660324,-10.502771
QEP20238_QEP20886,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSTYYWTWIRQPPGKGLEWIGEINHSGSTNYNPSLKGRVTISVDTSKNQFSLRLTSVTAADTAVFYCAGRPGYNYHYFDYWGQGTLVTASS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGRAPKLLMYGNNNRPSGVPDRFSGSESGPSASLAITGLQAEDEADYYCQSYDNSQSVPWVFGGGTKLTVL,QEP20238,QEP20886,"IGH + IGL c345_heavy_IGHV4-34_IGHD5-24_IGHJ4, partial [Homo sapiens]","IGH + IGL c345_light_IGLV1-40_IGLJ3, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_13_9_3_12,QEP20238_QEP20886,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.634695,-10.4382925
ANI87827_ANI87814,QVQLQQWGAGLLKPSETLSLTCAVYNESLSAFSWSWIRQFPGQGLEWIGEIDHTTSSNYNPSLKRRINISIDTSKKQFSLKLYSVTAADTAVYYCARGGRKVYHAYWSGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSAKNLAWYQQKPGQTPRLLMYGVSLRNTGVPDRFSGSGSGTDFTLTISRLEPEDSAVYFCQQYGTSPTFGQGTKVEIK,ANI87827,ANI87814,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"MacLeod,D.T.; Choi,N.M.; Briney,B.; Garces,F.; Ver,L.S.; Landais,E.; Murrell,B.; Wrin,T.; Kilembe,W.; Liang,C.H.; Ramos,A.; Bian,C.B.; Wickramasinghe,L.; Kong,L.; Eren,K.; Wu,C.Y.; Wong,C.H.; Kosakovsky Pond,S.L.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch,12-JUN-2016,8_7_22_7_3_8,ANI87827_ANI87814,Unique source,HIV,2,1,16.840607,-10.677486
QKK35854_QKK35855,QVQLQQWGAGLLKPSETLSLTCGVYGGSFSGYFWSWIRQSPGKGLEWIGEINHSRSMSYNPSLKSRITMSVDTSKNQFSLNLNSVTAADTAVYFCARGKAHRNDFWSGYYPHWFDPWGQGILVTVSS,DIVLTQSPGTLSLSPGERVTLSCRASQSISSNYLAWYQQKPGQAPRLLISDASSRATGIPDRFSGSGSGADFTLIISRLEPEDFAVYFCHQYGGSPTTFGQGTKVEIK,QKK35854,QKK35855,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_21_7_3_9,QKK35854_QKK35855,Unique source,SARS-CoV-2,2,1,16.734829,-10.568728
QKK35634_QKK35635,QVQLQQWGAGLLKPSETLSLTCGVYGVSFSDYYWSWIRQPPGKGLEWIGEINHSGITNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGLISYTLWLRESYFDYWGQGTLVTVSS,DIRVTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKIGQPPKLLIYWASIRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTFGGGTKLEIK,QKK35634,QKK35635,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_18_12_3_9,QKK35634_QKK35635,Unique source,SARS-CoV-2,2,1,16.689144,-10.520436
UIC72311_UIC72621,QVQLQQWGAGLLKPSETLSLTCSVYGGPFRDYFWTWIRQPPGKGLEWIAEINHSGSTNYNPSLQSRITISIDTSKNQFSLSVKSLTAADTAVYYCARGSAPSGRGHNWFDPWGQGTLVTVSS,DIQMTQSPPSLSASVGDRVTITCRASQNIRNYLNWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTHFTLTISSLQAEDFATYYCQQSYRMPPIFGGGTKVEIK,UIC72311,UIC72621,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_7_16_6_3_9,UIC72311_UIC72621,Unique source,HCV,2,1,16.73846,-10.56923
WGM83017_WGM83053,QVQLQQWGAGLLKPSETLSVTCAIYGDSLSDYSWKWGVSRDDYYWTWIRQSPGKRLEWIGEINRGGNTKYNPSLSSRVKMSIDASKNQFSLRMRSVTDTDTGIYYCARGRRSRQWIGDLPPGNQGLDVWGQGTTVIVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSSYLAWYQHKPGQAPRLLISDVYRRASGVPDRFSGSGSGTEFTLTISRLEPEDFAIYYCQQYGSSPPYTFGQGTKVEIK,WGM83017,WGM83053,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,19_7_22_7_3_10,WGM83017_WGM83053,Unique source,HIV,2,1,16.668173,-10.497136
CAJ13443_CAJ13444,QVQLQQWGAGLLKTSETLSLTCAVYGGSFNNYNWTWIRQPPGKGLEWIGQINHSGTTNYNPSLKSRVTMSIDPSENQFSLKVRSVTAADTAIYYCVRGSPESSGNYWGHFQYWGQGTLATVSS,DIVMTQSPDSLSVSLGERATINCKSSQSVLYSSHNKNYLAWYQQKPGQPPRLLIYWASTRESGVPDRFSGSGSGTDFTLTINTLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,CAJ13443,CAJ13444,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"McCann,K.J.; Johnson,P.; Stevenson,F.K.; Ottensmeier,C.H.",Universal glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?,14-JUL-2016,8_7_17_12_3_9,CAJ13443_CAJ13444,Unique source,,2,1,16.717358,-10.508819
QKK35722_QKK35723,QVQLQQWGAGVLKPSETLSLTCAVYGGSFRGFFWSWIRQPPGKGLEWIGQITHSGSTNYNSSLKSRLTISVDTSKNQFSLNLSSVTAADTAIYYCARGQGGYDLRRVGYGLTSWFDPWGQGILVTVSS,QSVLIQPASVSGSPGQSITISCTGSSSDVGSYNLVSWYQQHPGKAPKLMIYEGYKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSAVVVVFGGGTKLTVL,QKK35722,QKK35723,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_22_9_3_12,QKK35722_QKK35723,Unique source,SARS-CoV-2,2,1,16.74602,-10.588068
4YWG_I_M,QVQLQQWGPGLLKPSETLSLTCAVYGGSFGRYYWSWIRQSSGEGLEWLGQIDHTGSTTYNPSLKGRVTISIDSSTNQFSLKVTSVIAADTAVYYCARAPSGYPGVSLYQYYGLDVWGQGTTVTVSS,DTVMTQSPATLSVSPGERVTLSCRASQIINTNLAWYQKRPGQAPRLLIYAASARATGIPARFSGSGSGTEFTLTISGLQSEDSAVYYCQQYKHWPPYTFGRGTKLEIR,4YWG_I,4YWG_M,Crystal Structure Of 830A In Complex With V1V2,Crystal Structure Of 830A In Complex With V1V2,Human immunodeficiency virus 1,"Pan,R.;Gorny,M.K.;Zolla-Pazner,S.;Kong,X.P.",The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel,20-MAR-2015,8_7_20_6_3_10,4YWG_I_M,Xtal structure,gp120; HIV,2,1,16.653576,-10.480554
ANI87831_ANI87818,QVQLQQWGTGLLKPSESLFLTCAVYNESMSAFSWSWIRQSADKGLEWIGEIDHLQHVNYNPSLTGRFTISIDTSKNQFSLRFFSVIAADAAMYYCARGGRKVYHAYWTGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGETASLSCRASQSVSDKNLAWYQQRPGLPPRLLIYGVSLKNTGVPDRFSGSGSGTNFTLTITSLESEDSAVYFCQQYGSSPTFGQGTKVEIK,ANI87831,ANI87818,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"MacLeod,D.T.; Choi,N.M.; Briney,B.; Garces,F.; Ver,L.S.; Landais,E.; Murrell,B.; Wrin,T.; Kilembe,W.; Liang,C.H.; Ramos,A.; Bian,C.B.; Wickramasinghe,L.; Kong,L.; Eren,K.; Wu,C.Y.; Wong,C.H.; Kosakovsky Pond,S.L.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch,12-JUN-2016,8_7_22_7_3_8,ANI87831_ANI87818,Unique source,HIV,2,1,16.834696,-10.671943
ANV21797_ANV21986,QVQLQRWGGGLLKPSETLSLTCAVYGGSISGYYWTWIRQPPGKGLEWIGEIDHSENVNHNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAVYYCARVAYYLWGSYRRPGGYYMDVWGEGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGYYNLVSWYQQHPGKAPKLIIYEVTKRPSGVSYRFSGSKSDNTASLTISGLQAEDEADYYCCSYTSGSTSPYVFGSGTTVSVL,ANV21797,ANV21986,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_7_21_9_3_12,ANV21797_ANV21986,Unique source,,2,1,16.591663,-10.412031
QEP19910_QEP20558,QVQLRESGPGRVKPSDTLSLTCSVSGAAITDNFWTWIRQSPGKGLEWIGRVAHGRSPTYDPFLQRRVSISLDRSKNQFSLTVNSVTAADTAVYYCARAERKRLSVIAFDVWGPGTLVTVSS,SYELTQPPSVSVAPGETASITCGGQNIGSKGIHWYQQKSGQAPMLVVYDDDERPSGIPERFSGSHSGDTATLTVSGVEAGDEADYYCQLWDQRYDHFVFGGGTKLTVL,QEP19910,QEP20558,"IGH + IGL c17_heavy_IGHV4-59B_IGHD3-9_IGHJ3, partial [Homo sapiens]","IGH + IGL c17_light_IGLV3-21_IGLJ3, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_15_6_3_11,QEP19910_QEP20558,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.047333,-7.614633
QHI42979_QHI43034,QVQLRESGPSLVKPSQTLFLTCTVSGFSLTSYSVNWVRQTPGKMLECLGGIATSGSTGYNPVLKSRLRITKDNSKSQVSLSVSNVTPEDTATYYCAKWSSRGGYDCGVHSSDYSYLDAWGQGLLVTVSS,QAVLTQPSSVSASLGQRVSITCSGSSSNIGRYGATWYQQVPGSGLRTIIYGSSRRPSGVPDRFSGSKSGNTVTLTISSLQPEDEADYFCAAYDISTNAVFGSGTTLTLL,QHI42979,QHI43034,"Ig heavy chain variable region, partial [Bos taurus]","Ig lamda chain variable region, partial [Bos taurus]",Bos taurus,"Li,K.; Wang,S.; Cao,Y.; Bao,H.; Li,P.; Sun,P.; Bai,X.; Fu,Y.; Ma,X.; Zhang,J.; Li,D.; Chen,Y.; Liu,X.; An,F.; Wu,F.; Lu,Z.; Liu,Z.",Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage,22-JAN-2020,8_7_23_8_3_10,QHI42979_QHI43034,Unique source,,2,1,15.3813715,-8.589668
QHI42976_QHI43031,QVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGSTGYNPGLKSRLSITKDNSKSRVSLSVSSVTTEDSATYYCTTVYHETSRTCPDGYIYDPGCGGSWVCSRLFPTDRCIVGRTTTYEWYVDAWGQGLLVTVSS,QAVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRISGSRSGNTATLTISSVQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,QHI42976,QHI43031,"Ig heavy chain variable region, partial [Bos taurus]","Ig lamda chain variable region, partial [Bos taurus]",Bos taurus,"Li,K.; Wang,S.; Cao,Y.; Bao,H.; Li,P.; Sun,P.; Bai,X.; Fu,Y.; Ma,X.; Zhang,J.; Li,D.; Chen,Y.; Liu,X.; An,F.; Wu,F.; Lu,Z.; Liu,Z.",Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage,22-JAN-2020,8_7_50_8_3_11,QHI42976_QHI43031,Unique source,,2,1,13.889016,-9.343633
5E99_H_L,QVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGTAGYNPGLKTRLSITKDNSKSQVSLTVSSVATEDSATYYCVTVYQKTTQKKNCPDDYTECYGGACDGTGCCSGSCGGASACRDWWPYRSICSSDNTYTYEFHVDAWGQGLLVTVSS,QAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,5E99_H,5E99_L,Bovine Fab Fragment F08_B11,Bovine Fab Fragment F08_B11,Bos taurus,"Stanfield,R.L.;Wilson,I.A.;Smider,V.V.",Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies,14-OCT-2015,8_7_65_8_3_11,5E99_H_L,Xtal structure,,2,1,13.860546,-9.364756
7D3M_H_L,QVQLRESGPSLVKPSQTLSLTCTASGLSLSDKAVGWVRRAPTKALEWLGSIDTGSSTGYNPGLKSRLSITKDNSRNQVSLTITSVTTEDSATYYCATVHQHTSEKRTCPRAYRPDCAARWDCPGGADCGYCNFGAGSYGRCTPFTLTYTFENYVHTWGQGLLVTVSS,QAVLTQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTNRASGVPDRFSGSRAGNTATLSISSLQAEDEAEYFCASPEDSSSNANFGSGTTLTVL,7D3M_H,7D3M_L,Foot And Mouth Disease Virus O/Tibet/99-Bound The Single Chain Fragmen Antibody R50,Foot And Mouth Disease Virus O/Tibet/99-Bound The Single Chain Fragmen Antibody R50,Bos taurus,"He,Y.;Lou,Z.",FOOT AND MOUTH DISEASE VIRUS O/TIBET/99-BOUND THE SINGLE CHAIN FRAGMEN ANTIBODY R50,19-SEP-2020,8_7_61_8_3_11,7D3M_H_L,Xtal structure,,2,1,13.862756,-9.363752
8BS8_H_L,QVQLRESGPSLVKPSQTLSLTCTASGSSLSDEAVGWVRQAPGKSLEWLGSIDTGGNTGYNPNLKTRLSITKDNSKSQVSLSMSSVTPEDSATYFCATVHQETHQTCPDGYNSGDDCGRGNWDCGTLDCWRCDWGGFCRASTDYRSVTATYTYEWYIDTWGQGLLVTVSS,QGVLTQPSSVSGSLGQRVSITCSGSSSNVGRGYVSWYQMTPGSAPRTLIYGDTNRASGVPDRFSASRSGNTATLTISSLQAEDEADYFCASAEGSSSNAVFGSGTTLTVL,8BS8_H,8BS8_L,Bovine Naive Ultralong Antibody Abd08 Collected At 100K,Bovine Naive Ultralong Antibody Abd08 Collected At 100K,Bos taurus,"Mikolajek,H.;Sanchez-Weatherby,J.;Sandy,J.;Gildea,R.J.;Campeotto,I.;Cheruvara,H.;Clarke,J.D.;Foster,T.;Fujii,S.;Paulsen,I.T.;Shah,B.S.;Hough,M.A.",Protein-to-structure pipeline for ambient-temperature in situ crystallography at VMXi,24-MAY-2023,8_7_63_8_3_11,8BS8_H_L,Xtal structure,,2,1,13.861052,-9.364599
QHI42955_QHI43010,QVQLRESGPSLVKPSQTLSLTCTISGFSLSSYTIGWVRQAPGKALEWIGDMSNGGMPYYNPALKSRLSITKHNSKSQVRLSVSSVTPEDTATYYCAKSRYTGDGSIGLYGVDAWGQGLLITVSS,QAVLTQPSSVSGSLGQRVSITCSGTYSNVGTGNYVSWFQQIPGSAPRTLIYSVTNRASGVPDRFSGSRSGHTATLTISSLQAEDEADYFCLSWQSGNTALFGSGTTLTVL,QHI42955,QHI43010,"Ig heavy chain variable region, partial [Bos taurus]","Ig lamda chain variable region, partial [Bos taurus]",Bos taurus,"Li,K.; Wang,S.; Cao,Y.; Bao,H.; Li,P.; Sun,P.; Bai,X.; Fu,Y.; Ma,X.; Zhang,J.; Li,D.; Chen,Y.; Liu,X.; An,F.; Wu,F.; Lu,Z.; Liu,Z.",Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage,22-JAN-2020,8_7_18_9_3_10,QHI42955_QHI43010,Unique source,,2,1,15.38878,-8.577707
7FEI_H_L,QVQLRESGPSLVKPSQTLSLTCTVSGFSLSDYAVGWVRQAPGKALEFLGSISTGGNTGYNPALKSRLSITKDNSKNQVSLSLSSVTTEDTATYYCTKSIHSYSVFEYTYMQYVDAWGQGLLVPVSS,QAVLTQPSSVSGSLGQRVSITCSGSSNNIGRYDVGWYQQIPGSGLRTIIYASKNRPSGVPDRFSGSRSGNTATLTISSLQAEDEADYFCATGDYSSSTSVFGSGTTLTVL,7FEI_H,7FEI_L,Complex Of Fmdv A/Wh/Cha/09 And Bovine Neutralizing Scfv Antibody R55,Complex Of Fmdv A/Wh/Cha/09 And Bovine Neutralizing Scfv Antibody R55,Bos taurus,"He,Y.;Li,K.;Wang,L.;Sun,Z.;Cao,Y.;Li,P.;Sun,P.;Bao,H.;Zhou,S.;Wang,S.;Bai,X.;Liu,X.;Zhao,L.;Fan,X.;Liu,Z.;Lu,Z.;Yang,C.;Lou,Z.",Structures of Foot-and-Mouth Disease Virus with Bovine Neutralizing Antibodies Reveal the Determinant of Intraserotype Cross-Neutralization,20-JUL-2021,8_7_20_8_3_11,7FEI_H_L,Xtal structure,,2,1,15.373453,-8.592118
6D9W_H_L,QVQLTESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLVVIWSDGSTTYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAREPPYGYWGQGTTLTVSS,DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYVSQSSSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPRTFGGGTKLEIK,6D9W_H,6D9W_L,"Crystal Structure Of Deinococcus Radiodurans Mnth, An Nramp-Family Transition Metal Transporter, In The Inward-Open Apo State","Crystal Structure Of Deinococcus Radiodurans Mnth, An Nramp-Family Transition Metal Transporter, In The Inward-Open Apo State",Mus musculus,"Bozzi,A.T.;Zimanyi,C.M.;Nicoludis,J.M.;Lee,B.K.;Zhang,C.H.;Gaudet,R.",Structures in multiple conformations reveal distinct transition metal and proton pathways in an Nramp transporter,30-APR-2018,8_7_8_6_3_9,6D9W_H_L,Xtal structure,,2,1,22.121098,-6.091828
URX40002_URX40041,QVQLTQSRAEVKKSGASVRVSCEASGYTFIDHFINWVRQAPGQGLEWMGWMNPRGGAVNYAKRFQGRVTMTRYMSIDTDVAYMELRSLRSDDTAVYYCASNVKVPSSTQFVFDVWGQGTMVRVSA,QSALTQPRSVSGSPGQSVTISCTGRHSGVAWYQQHPGKAPKLLIYDVNGRPSGVPDRFSGSKSDNTASLTISDLRPEDEADYFCSAFEFFGGGTKLTVL,URX40002,URX40041,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Barnes,C.O.; Schoofs,T.; Gnanapragasam,P.N.P.; Golijanin,J.; Huey-Tubman,K.E.; Gruell,H.; Schommers,P.; Suh-Toma,N.; Lee,Y.E.; Cetrulo Lorenzi,J.C.; Piechocka-Trocha,A.; Scheid,J.F.; West,A.P. Jr.; Walker,B.D.; Seaman,M.S.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,15-AUG-2022,8_8_16_3_3_5,URX40002_URX40041,Unique source,HIV; CD4,2,1,2.5803013,3.5685399
PL0105_PL0106,QVQLVASGAEVNKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISVYNGDTNYAQNLQGRVTMTTDTSTSTAYMELRNLRSDDTAVYYCARAPGYCSGGGCYRGDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQRPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,PL0105,PL0106,anti-PR2 erythrocyte autoantibody heavy chain precursor - human (fragment),Ig kappa chain precursor V-J-C region (LS1) - human (fragment),Homo sapiens,"Silberstein,L.E.; Litwin,S.; Carmack,C.E.",Relationship of variable region genes expressed by a human B cell lymphoma secreting pathologic anti-Pr2 erythrocyte autoantibodies,21-Jan-2000,8_8_18_6_3_9,PL0105_PL0106,Unique chain,Pr2; PR2,2,1,1.9562916,5.2043877
QEP20413_QEP21061,QVQLVEFGGGVVQPGRSLRLSCAGFGFTFSSYGMHWVRQAPGRGLEWVAVIWYDGSNKYYADSVKGRFTISRDNAKNTLYLQMNSLRADDTAVYYCAKDSVGYCSSSSCYDLAHWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRATQSISSSYLAWYQQKPGQAPRLLIYGASNRAAGIPDRFSGSGSGTDFSLTISRLEPEDFAVYYCQQYSRSPLTFGQGTKVEIK,QEP20413,QEP21061,"IGH + IGL c520_heavy_IGHV3-30_IGHD2-2_IGHJ4, partial [Homo sapiens]","IGH + IGL c520_light_IGKV3-20_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_18_7_3_9,QEP20413_QEP21061,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,15.065059,13.750364
QKK35658_QKK35659,QVQLVESGAEVKKPGSSVKISCKISGDTFSTNAISWLRQAPGREPEWMGGIVPLVGPASYAQRPQGRLTITADEFTNTAYLELNSLRSEDTATYYCARDSDPYTATRRHNHYWYAMDVWGQGTTVTVSS,DIRLTQTPLSLPVTLGQPASISCRSSQIAMHSDGNTYLSWFHQRPGQPPRRLIYKISNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGTFYCMQGTDWPRTFGQGTKVDIK,QKK35658,QKK35659,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35658_QKK35659,Unique source,SARS-CoV-2,2,1,3.0577266,-13.247006
QKK35762_QKK35763,QVQLVESGAEVKKPGSSVKVSCKASGGTLSDYAISWVRQAPGQGLEWMGGIMPIFGSPGYAEIFQGRVTITADESKSTVYMELTSLRSEDTAVYYCARDPSILDTGNHHWYDLDIWGQGTMVTVSS,EIVMTQSPLSLPVSLGQPASISCRSSQSVIHTDGNTYLNWYHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSVTDFTLKISRVEAEDVGVYYCMQGTEWPRTFGQGTKVEIK,QKK35762,QKK35763,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35762_QKK35763,Unique source,SARS-CoV-2,2,1,-6.4390693,-2.6359258
QKK35700_QKK35701,QVQLVESGAEVKKPGSSVRVSCKASGGTFRKSAISWVRQAPGQGFEWMGGIIPTLDRRGFAQKFQDRLTMTADEFTSTAYMDLSDLRSDDTAVYYCARDASFPNTGNHFWYDFDLWGQGTTVTVSS,ETTLTQSPVTLPVTLGQPASISCTSSRWLVHTNGNTYLNWFHQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLQISRVEAEDVGVYYCMQGTEWPRTFGQGTKLEIK,QKK35700,QKK35701,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35700_QKK35701,Unique source,SARS-CoV-2,2,1,-6.6325593,-2.4340768
QKK35790_QKK35791,QVQLVESGAEVKRPGASVKVSCKASGYAFSDYYMHWVRQAPGQGPEWMGWINPNSGDTGYPQKFRGWVTMTRDTSVSTAYMELKRLKSDDTAVYYCASGPNYFDYWGQGTLVTVSS,SYVLTQPPSVSVSPGQTARITCSADGLPKQYSYWYQQKPGQAPVMVIYKDTERPSGIPERFSGSSSGTTATLTISGVQAEDEADYYCQSADSNDSSPVFGGGTQLTVL,QKK35790,QKK35791,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_9_6_3_11,QKK35790_QKK35791,Unique source,SARS-CoV-2,2,1,2.2333395,3.7978451
AAW68636_AAW69064,QVQLVESGAEVRKPGSSVKVSCKASGGTIKNYAISWVRQAPGQGLEWMGSIIPVFGTPNYAQRFQGRLTITADESTSTVDMQLNNLRSDDTAMYYCAKLPSGSYYDYFDSWGQGTLVTV,EIVLTQSPGTLSLSPGERATLSCRASQTVSSIYLAWYQQKPGQAPRLLIYSASSRATGIPDRFIGSGSGTDFTLTITRLEPEDSAVYYCQHYGNSLAPPFGGGTKVEIK,AAW68636,AAW69064,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_14_7_3_10,AAW68636_AAW69064,Unique source,tetanus,2,1,-0.47307447,5.6655245
QKK35562_QKK35563,QVQLVESGGDLVKPGRSLRLSCTASGFTIGDYAMTWFRQAPGKGLECVAVIRSRAFGGTTEYAASVKGRFIVSRDDSNSVAFLQMNSLKTEDTAVYYCSRDLRRGYYDSNGHQQFDLWGQGTLVTVSS,DIRLTQSPATLSLSPGERATLSCRASQSIGYYLAWFQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRTNWPYTFGQGTKVEIK,QKK35562,QKK35563,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_10_19_6_3_9,QKK35562_QKK35563,Unique source,SARS-CoV-2,2,1,13.278896,8.871281
QKK35832_QKK35833,QVQLVESGGEVKKPGASVKVSCKASGYTLSSYPISWVRQAPGHGLEWMGWINTYNGRTNYEQMLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVVFRHGQYDDSSGRLAFDIWGQGTMVTVSS,EIVMTQSPSSLSASVGDSVTITCRASQSISNYLNWYQDKPGKAPELLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSDSWTFGQGTKVDIK,QKK35832,QKK35833,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_21_6_3_9,QKK35832_QKK35833,Unique source,SARS-CoV-2,2,1,1.848909,5.260327
6WAS_H_L,QVQLVESGGGLAKPGGSLRLSCAASGITFSEDYMHWVRQASGKGLEWVSRISYDSDNTWYADSVKGRFTISRENAKNTLYLQMDSLRAEDTAVYYCARAPVWTGYTSLDVWGRGVLVTVSS,QVVFSQPHSVSGSPGQTVTISCTRSSGSIDNEYVRWYQQRPGSVPTIVIYKDNQRPSGVPDRFSGSIDSSSNSASLAISGLQSEDEADYYCQSSDDNFNWVFGGGTRLTVL,6WAS_H,6WAS_L,Structure Of D19.Pa8 Fab In Complex With 1Fd6 16055 V1V2 Scaffold,Structure Of D19.Pa8 Fab In Complex With 1Fd6 16055 V1V2 Scaffold,Homo sapiens,"Aljedani,S.S.;Liban,T.J.;Tran,K.;Phad,G.;Singh,S.;Dubrovskaya,V.;Pushparaj,P.;Martinez-Murillo,P.;Rodarte,J.;Mileant,A.;Mangala Prasad,V.;Kinzelman,R.;O'Dell,S.;Mascola,J.R.;Lee,K.K.;Karlsson Hedestam,G.B.;Wyatt,R.T.;Pancera,M.",Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization,26-MAR-2020,8_8_14_8_3_10,6WAS_H_L,Xtal structure,HIV,2,1,14.052488,10.512204
8E1G_H_L,QVQLVESGGGLIQPGGSLRLSCAASEFIVSSNYMSWVRQAPGKGLEWVSLLYSGGTTYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAMYYCARDRGPWLHDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASQDINKYCNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTINSLQPEDIATYYCQQYDNLPPTFGGGTKVEIK,8E1G_H,8E1G_L,Sars-Cov-2 Rbd In Complex With Omicron-Neutralizing Antibody 2A10,Sars-Cov-2 Rbd In Complex With Omicron-Neutralizing Antibody 2A10,Severe acute respiratory syndrome coronavirus 2,"Hastie,K.M.;Yu,X.;Ana-Sosa-Batiz,F.;Zyla,D.S.;Harkins,S.S.;Hariharan,C.;Wasserman,H.;Zandonatti,M.A.;Miller,R.;Maule,E.;Kim,K.;Valentine,K.M.;Shresta,S.;Saphire,E.O.",Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6&#xa0;months before Omicron emergence,28-JUN-2023,8_7_11_6_3_9,8E1G_H_L,Xtal structure,,2,1,12.618787,10.349865
QKK35878_QKK35879,QVQLVESGGGLSQPGGSLRLSCATSGFAVRNNCMNWVRQAPGKGLEWVSLICGDGITYHSDSVKGRFIISRDDSENALHLQMNSLRVEDTAVYYCVKASPPGGNTGWPFFHYWGQGTLVTVSS,ETTLTQSPAILSVSPGEGATLSCRASQSVRSNLAWFQQRPGQVPRLLIYDASNRATGVPARFSGSGFGTEFTLTISSLQSEDFAVYYCQQYNNWPPLTFGGGTKVDIK,QKK35878,QKK35879,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_6_3_10,QKK35878_QKK35879,Unique source,SARS-CoV-2,2,1,12.750806,10.074824
ANV21800_ANV21989,QVQLVESGGGLVKPGGSLRLSCAASGFSFSDYYMTWIRQAPGKGLQWVSYISSSGGITYYADSVKGRFTISRDNAKDSLYLQMESLRAEDTAVYYCAKDGRINYSGSGSPPYYFGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVIITCRASQSISNYLHWYQQKPGKAPRLLIFAASSLQSGVPSRFSGGGSGTDFTLTISSLQPEDFATYYCQQTYTTPYTFGQGSKVEIK,ANV21800,ANV21989,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_22_6_3_9,ANV21800_ANV21989,Unique source,,2,1,15.730768,9.587796
QKK35876_QKK35877,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMIWIRQAPGKGLEWLSYISHTASTIYYADSVKGRFTISRDNAKNSLFLQMNSLTAEDTAVYYCARDRGSGVIDPWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISHYLNWYQQKPGKAPKLLIYAASNLQSGVPSRFSGNGSGTDFTLTISSLQPEDFATYFCQQSYSTPLTFGGGTKVDIK,QKK35876,QKK35877,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_11_6_3_9,QKK35876_QKK35877,Unique source,SARS-CoV-2,2,1,15.7071705,9.418477
QPF16748_QPF16749,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDFSHQQLVPSWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,QPF16748,QPF16749,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ju,B.; Zhang,Q.; Ge,J.; Wang,X.; Zhang,Z.; Zhang,L.",Direct Submission,23-NOV-2020,8_8_12_6_3_9,QPF16748_QPF16749,Unique source,SARS-CoV-2,2,1,15.722091,9.435283
7WUR_E_F,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISTGSSHTDYADSVKGRFTISRDNTKNSLYLQLNSLRDEDTAVYYCASGYRFSYVSYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFTGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPAWTFGQGTKVEI,7WUR_E,7WUR_F,Cryoem Structure Of Sns1 Complexed With Fab5E3,Cryoem Structure Of Sns1 Complexed With Fab5E3,Homo sapiens,"Shu,B.;Ooi,J.S.G.;Tan,A.W.K.;Ng,T.S.;Dejnirattisai,W.;Mongkolsapaya,J.;Fibriansah,G.;Shi,J.;Kostyuchenko,V.A.;Screaton,G.R.;Lok,S.M.","CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever",21-DEC-2022,8_8_11_7_3_10,7WUR_E_F,Xtal structure,SHP2; PTPN11; BPTP3; dengue; SH-PTP2; NS1; PTP2C; SHP-2,2,1,15.67344,9.391361
7K7R_E_D,QVQLVESGGGLVKPGGSLRLSCVSSGFTFSNYWMSWVRQAPGGGLEWVANINQDGSEKYYVDSVKGRFTSSRDNTKNSLFLQLNSLRAEDTGIYYCTRDPPYFDNWGQGTLVTVSS,DVVLTQSPLSLPVILGQPASISCRSSQSLVYSDGRTYLNWFQQRPGQSPRRLIYKISKRDSGVPERFSGSGSGTDFTLEISRVEAEDVGIYYCMQGSHWPVTFGQGTKVEIK,7K7R_E,7K7R_D,Ebna1 Peptide Aa386-405 With Fab Ms39P2W174,Ebna1 Peptide Aa386-405 With Fab Ms39P2W174,Human gammaherpesvirus 4,"Lanz,T.V.;Robinson,W.H.;Jude,K.M.",The B Cell Repertoire in Multiple Sclerosis Reveals Molecular Mimicry between EBNA1 and GlialCAM,23-SEP-2020,8_8_9_11_3_9,7K7R_E_D,Xtal structure,,2,1,11.095601,7.74269
AAB34101_I69017,QVQLVESGGGLVKPGGSVRLSCAASGFTLSDYGVSSVRQPPGKGLEWLSGISGGGSTVYYADSVKGRFTISRDNSKTQLYLQMNSLRAEDTAVYYCARGRGGYYDYIWGSTQYWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCRASHDIGSYLAWYQQKPEKAPESLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPITFGQGTKVLIK,AAB34101,I69017,"anti-HIV1 envelope protein gp120 V3 loop monoclonal antibody H chain V region, partial [Homo sapiens]",anti-HIV1 envelope protein gp120 V3 loop monoclonal antibody L chain V region - human (fragment),Homo sapiens,"Chin,L.T.; Duenas,M.; Levi,M.; Hinkula,J.; Wahren,B.; Borrebaeck,C.A.",Molecular characterization of a human anti-HIV 1 monoclonal antibody revealed a CD26-related motif in CDR2,26-Jul-2016,8_8_17_6_3_9,AAB34101_I69017,Unique chain,ADCP2; DPPIV; HIV1; CD26; gp120; HIV; DPP4,2,1,13.685885,9.914712
QES69310,QVQLVESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK,QES69310_H,QES69310_L,"VHalphaCD3(diL2K)-scFvalphaCD45 bispecific antibody, partial [synthetic construct]","VHalphaCD3(diL2K)-scFvalphaCD45 bispecific antibody, partial [synthetic construct]",synthetic construct,"Stuhler,G.; Banaszek,A.; Nowotny,B.",Direct Submission,28-SEP-2019,8_8_14_10_3_9,QES69310,Same entry,,2,1,19.61095,9.72943
6GLW_C_D,QVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGISWNGGSTYYAESMKGRFTISRDNAKNTLYLQMNSLKSEDTAVYYCAKDRNLGYRLGYPYDYWGQGTQVTVSS,QSVLTQPPSVSGSPGETVTISCAGTSSDVGYGNYVSWYQQLPGMAPRLLIYEVNKRASGITDRFSGSKSGNTASLTISGLQSEDEGDYYCASYRSSNNAVFGGGTHLTVL,6GLW_C,6GLW_D,"Structure Of Galectin-10 In Complex With The Fab Fragment Of A Charcot-Leyden Crystal Solubilizing Antibody, 1D11","Structure Of Galectin-10 In Complex With The Fab Fragment Of A Charcot-Leyden Crystal Solubilizing Antibody, 1D11",Lama glama,"Persson,E.K.;Verstraete,K.;Heyndrickx,I.;Gevaert,E.;Aegerter,H.;Percier,J.M.;Deswarte,K.;Verschueren,K.H.;Dansercoer,A.;Gras,D.;Chanez,P.;Bachert,C.;Goncalves,A.;Van Gorp,H.;De Haard,H.;Blanchetot,C.;Saunders,M.;Hammad,H.;Savvides,S.N.;Lambrecht,B.N.",Protein crystallization promotes type 2 immunity and is reversible by antibody treatment,23-MAY-2018,8_8_16_9_3_10,UCW66382_UCW66383,Xtal structure,,2,1,13.985939,10.323722
3G6A_H_L,QVQLVESGGGLVQPGGSLRLSCAASGFTFNSYWINWVRQAPGKGLEWVSGIAYDSSNTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGLGAFHWDMQPDYWGQGTLVTVSS,SYELTQPPSVSVAPGQTARISCSGDNIGGTFVSWYQQKPGQAPVLVIYDDNDRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCGTWDMVTNNVFGGGTKLTVL,3G6A_H,3G6A_L,Crystal Structure Of Anti-Il-13 Antibody Cnto607,Crystal Structure Of Anti-Il-13 Antibody Cnto607,Homo sapiens,"Teplyakov,A.;Obmolova,G.;Wu,S.J.;Luo,J.;Kang,J.;O'Neil,K.;Gilliland,G.L.",Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607,06-FEB-2009,8_8_15_6_3_10,3G6A_H_L,Xtal structure,interleukin-13,2,1,13.917858,10.921038
QKK35710_QKK35711,QVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMTWVRQAPGKGLKWVSGINPSGDATFYTDSVKGQFTISRDNSKNILYLQMNRLRADDTAIYYCAKGLSFYGSGSDAFDVWGQGTTVTVSS,DIQLTQSPSTLSASVGDSVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLETGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYKSPLSFGGGTKVEIK,QKK35710,QKK35711,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_8,QKK35710_QKK35711,Unique source,SARS-CoV-2,2,1,14.026897,9.999301
QKK35736_QKK35737,QVQLVESGGGLVQPGGSLRLSCAASGFTFSNYNMVWVRQAPGKGLEWISYISSSSSTIYYADSVKGRFIISRDNAKNSLHLQMNSLRDEDTAVYYCVRDYCNSVSCYTYYYIGMDVWGQGTTVTVSS,DIQLTQSPSAMSASVGDRVTITCRASQGINDNLAWFQQKPGKVPKRLIYAASNLQNGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIK,QKK35736,QKK35737,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_20_6_3_9,QKK35736_QKK35737,Unique source,SARS-CoV-2,2,1,15.809612,9.9515705
8DF5_H_L,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,DIQMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,8DF5_H,8DF5_L,Sars-Cov-2 Beta Rbd In Complex With Human Ace2 And S304 Fab And S309 Fab,Sars-Cov-2 Beta Rbd In Complex With Human Ace2 And S304 Fab And S309 Fab,Severe acute respiratory syndrome coronavirus 2,"Starr,T.N.;Greaney,A.J.;Hannon,W.W.;Loes,A.N.;Hauser,K.;Dillen,J.R.;Ferri,E.;Farrell,A.G.;Dadonaite,B.;McCallum,M.;Matreyek,K.A.;Corti,D.;Veesler,D.;Snell,G.;Bloom,J.D.",Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution,03-AUG-2022,8_7_14_6_3_10,8DF5_H_L,Xtal structure,SARS-CoV-2,2,1,16.396381,11.608554
5D72_M_N,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS,IELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSWDSTGLVFGGGTKLTVL,5D72_M,5D72_N,"Crystal Structure Of Mor04252, A Neutralizing Anti-Human Gm-Csf Antibody Fab Fragment In Complex With Human Gm-Csf","Crystal Structure Of Mor04252, A Neutralizing Anti-Human Gm-Csf Antibody Fab Fragment In Complex With Human Gm-Csf",Homo sapiens,"Eylenstein,R.;Weinfurtner,D.;Hartle,S.;Strohner,R.;Bottcher,J.;Augustin,M.;Ostendorp,R.;Steidl,S.",Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody,13-AUG-2015,8_10_8_6_2_9,5D72_M_N,Xtal structure,GM-CSF; GMCSF; CSF2,2,1,13.842028,9.24915
8GUZ_A_B,QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREEGGWIFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASRSVRRELAWYQQKPGQAPELLIYGASTRETGIPARFSGSGSGTDFTLTINSLEAEDAATYYCQQYRDPPGTFGGGTKVEIK,8GUZ_A,8GUZ_B,Crystal Structure Of Anti-Fixa Igg Fab With Fast-Ig Mutations,Crystal Structure Of Anti-Fixa Igg Fab With Fast-Ig Mutations,Homo sapiens,"Koga,H.;Yamano,T.;Betancur,J.;Nagatomo,S.;Ikeda,Y.;Yamaguchi,K.;Nabuchi,Y.;Sato,K.;Teranishi-Ikawa,Y.;Sato,M.;Hirayama,H.;Hayasaka,A.;Torizawa,T.;Haraya,K.;Sampei,Z.;Shiraiwa,H.;Kitazawa,T.;Igawa,T.;Kuramochi,T.",Efficient production of bispecific antibody by FAST-Ig<sup>TM</sup> and its application to NXT007 for the treatment of hemophilia A,28-JUN-2023,8_8_15_6_3_9,8GUZ_A_B,Xtal structure,FASTK; FAST,2,1,14.248414,9.917244
QKK35486_QKK35487,QVQLVESGGGLVQPGGSLRLSCSASGFTFSRFAMHWVRQAPGKGLEYVSAINLNGDSTYYTDSVRGRFTISRDNSKNTLYLQMSSVRPDDTAFYYCVKDGGYYDSSGPGHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENIAHYLAWYQQKPGQAPRLVIYDASSRATGIPGRFSGSGAGTDFTLTINSLEPEDFAVYYCQQRSNWPQNFGGGTKVEIK,QKK35486,QKK35487,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_9,QKK35486_QKK35487,Unique source,SARS-CoV-2,2,1,13.828918,9.990281
7ZFD_A_B,QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQVPGKGLEWVSGISWNSGSIVYADFVKGRFTIARDNAKNSLFLQMNSLRAEDTALYYCAKSTALRHQYYYGMDVWGQGTTVTVSS,AIQMTQSPSSLSASVGDRVTITCRTSQTISSYLNWYQQKPGKAPKLLIYDASSLQSGVPSRFSGSGYGTDFTLTISSLQPEDFATYFCQQSYNTPYAFGQGTKVEIK,7ZFD_A,7ZFD_B,Sars-Cov-2 Omicron Rbd In Complex With Omi-25 Fab,Sars-Cov-2 Omicron Rbd In Complex With Omi-25 Fab,Homo sapiens,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,01-APR-2022,8_8_16_6_3_9,7ZFD_A_B,Xtal structure,,2,1,13.105464,12.03325
5B71_D_C,QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK,5B71_D,5B71_C,Crystal Structure Of Complement C5 In Complex With Sky59,Crystal Structure Of Complement C5 In Complex With Sky59,Homo sapiens,"Fukuzawa,T.;Sampei,Z.;Haraya,K.;Ruike,Y.;Shida-Kawazoe,M.;Shimizu,Y.;Gan,S.W.;Irie,M.;Tsuboi,Y.;Tai,H.;Sakiyama,T.;Sakamoto,A.;Ishii,S.;Maeda,A.;Iwayanagi,Y.;Shibahara,N.;Shibuya,M.;Nakamura,G.;Nambu,T.;Hayasaka,A.;Mimoto,F.;Okura,Y.;Hori,Y.;Habu,K.;Wada,M.;Miura,T.;Tachibana,T.;Honda,K.;Tsunoda,H.;Kitazawa,T.;Kawabe,Y.;Igawa,T.;Hattori,K.;Nezu,J.","Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases",03-JUN-2016,9_8_15_6_3_12,AVA86703_AVA86708,Xtal structure,,2,1,13.008776,10.205699
QVG74128_QVG74129,QVQLVESGGGVVQPGGSLRLSCAASGFTFSSYAIHWVRQAPGKGLEWVALISSDGSYKTYADSVKGRFTISRDNSKHTLYLQMSSLRTEDTAVYYCARDSSALEIYNRFDPWGQGTLVTVSS,AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSYPPLTFGGGTKVEIK,QVG74128,QVG74129,"anti-peanut 2S albumin immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-peanut 2S albumin immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehlers,A.M.; den Hartog Jager,C.F.; Knulst,A.C.; Otten,H.G.",Distinction between peanut allergy and tolerance by characterization of B-cell receptor repertoires,18-MAY-2021,8_8_15_6_3_10,QVG74128_QVG74129,Unique source,peanut,2,1,14.883056,13.58621
QPL06779_QPL06780,QVQLVESGGGVVQPGGSLTLSCPASGVSFTNYGMYWVRQAPGRGLEWVAFIRYDGGHKDYVDSVKGRFTISRDNSKNTVLLQMDSLRPEDTALYYCAKSSVWNGYYIGYDYFDYWGQGILVTVSS,DIQMTQSPSSLSASVGDSVTITCRASQSVSNYLNWYQQTPGKAPKLLIYGASGLQSGVPSRFSGSGSETDFTLTISNLQPEDFGTYYCQQSYKSPLTFGPGTKVDIK,QPL06779,QPL06780,"immunglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Wilson,P.C.",Direct Submission,08-DEC-2020,8_8_18_6_3_9,QPL06779_QPL06780,Unique source,,2,1,15.082816,13.371924
6CO3_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,6CO3_H,6CO3_L,Aducanumab Abeta Complex,Aducanumab Abeta Complex,Homo sapiens,"Arndt,J.W.;Qian,F.;Smith,B.A.;Quan,C.;Kilambi,K.P.;Bush,M.W.;Walz,T.;Pepinsky,R.B.;Bussiere,T.;Hamann,S.;Cameron,T.O.;Weinreb,P.H.",Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta,10-MAR-2018,8_8_17_6_3_9,6CO3_H_L,Xtal structure,amyloid-beta; Abeta,2,1,14.195699,13.939447
7DWT_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFIFSNYGMHWVRQAPGKGLEWVAVISYDGSDKRYADSVRGRFTISRDNSKNTLFLQVTSLRAEDTAVYYCAKELSGYDPGFEYWGQGTPVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYESYATFGQGTKVDIK,7DWT_H,7DWT_L,Cryo-Em Structure Of Dengue Virus Serotype 1 Strain Westpac 74 In Complex With Human Antibody 1C19 Fab At 37 Deg C (Class 1 Particle),Cryo-Em Structure Of Dengue Virus Serotype 1 Strain Westpac 74 In Complex With Human Antibody 1C19 Fab At 37 Deg C (Class 1 Particle),Homo sapiens,"Fibriansah,G.;Lim,E.X.Y.;Marzinek,J.K.;Ng,T.S.;Tan,J.L.;Huber,R.G.;Lim,X.N.;Chew,V.S.Y.;Kostyuchenko,V.A.;Shi,J.;Anand,G.S.;Bond,P.J.;Crowe,J.E. Jr.;Lok,S.M.",Antibody affinity versus dengue morphology influences neutralization,18-JAN-2021,8_8_13_6_3_8,7DWT_H_L,Xtal structure,Dengue; dengue,2,1,15.065452,13.512541
6WM9_B_C,QVQLVESGGGVVQPGRSLRLSCAASGFMFNSYGMHWVRQAPGKGLEWMAFISYDGSDDYYGDSVKGRITISRDNSKNTLFLHINSLRTEDTAVYYCAKESNYGENAFDVWGHGTMVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSNDVGFYNFVSWYQHHPGKAPKLMIYDVTERPSGVPDRFSGSKSGNTASLTISGLQAEDEAEYYCCSYAGTYTFVFGHGTKVTVL,6WM9_B,6WM9_C,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 237235,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 237235,Plasmodium vivax Sal-1,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,20-APR-2020,8_8_13_9_3_10,6WM9_B_C,Xtal structure,,2,1,14.882648,13.53617
ANV21805_ANV21994,QVQLVESGGGVVQPGRSLRLSCAASGFNFSRYAIHWVRQAPGKGLEWVSVIDYDGSDKYYADSVKGRFTMSRDNSKNTLYLQMNSLRAEDTALYYCVRSQQWLVRSYHYYYGMDVWGQGTTVTVSS,ENVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASHRATGIPDRFSGSGSGTDFTLTISRLQPEDFAVYYCQQCGNSPPYTFGQGTKVEIK,ANV21805,ANV21994,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_19_7_3_10,ANV21805_ANV21994,Unique source,,2,1,14.149799,13.973171
QKY76396_QKY76009,QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYVMNWVRQAPGKGLEWVAVISYDGSSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDIDSGYDPTPVFDYWGQGTLVTVSS,DIQMTQSPSSLSACVGDRVTITCRASQSISSYLNWYQQKPGKGPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSLSITFGQGTRLEIK,QKY76396,QKY76009,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_16_6_3_10,QKY76396_QKY76009,Unique source,SARS-CoV-2,2,1,14.67534,13.569227
6NZ7_G_I,QVQLVESGGGVVQPGRSLRLSCAASGFSFSTSVIHWVRQTPGKGLEWLAVISYDGSNKYYADSVQGRFTISRDNSNNTLYLQVNSLRPEDTAVYYCARGITVFGLLIINSAMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISYNLAWYQQKPGRVPNLLIHAASRLQSGAPFRFSGSGSGTDFTLTISSLQPEDVATYYCQKYDSVPLTFGQGTKVEIK,6NZ7_G,6NZ7_I,Crystal Structure Of Broadly Neutralizing Influenza A Antibody 429 B01 In Complex With Hemagglutinin Hong Kong 1968,Crystal Structure Of Broadly Neutralizing Influenza A Antibody 429 B01 In Complex With Hemagglutinin Hong Kong 1968,Homo sapiens,"Matsuda,K.;Huang,J.;Zhou,T.;Sheng,Z.;Kang,B.H.;Ishida,E.;Griesman,T.;Stuccio,S.;Bolkhovitinov,L.;Wohlbold,T.J.;Chromikova,V.;Cagigi,A.;Leung,K.;Andrews,S.;Cheung,C.S.;Pullano,A.A.;Plyler,J.;Soto,C.;Zhang,B.;Yang,Y.;Joyce,M.G.;Tsybovsky,Y.;Wheatley,A.;Narpala,S.R.;Guo,Y.;Darko,S.;Bailer,R.T.;Poole,A.;Liang,C.J.;Smith,J.;Alexander,J.;Gurwith,M.;Migueles,S.A.;Koup,R.A.;Golding,H.;Khurana,S.;McDermott,A.B.;Shapiro,L.;Krammer,F.;Kwong,P.D.;Connors,M.",Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine,13-FEB-2019,8_8_18_6_3_9,6NZ7_G_I,Xtal structure,Influenza,2,1,14.323803,13.751203
7TN9_G_H,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK,7TN9_G,7TN9_H,Structure Of The Inmazeb Cocktail And Resistance To Escape Against Ebola Virus,Structure Of The Inmazeb Cocktail And Resistance To Escape Against Ebola Virus,Mus musculus,"Rayaprolu,V.;Fulton,B.O.;Rafique,A.;Arturo,E.;Williams,D.;Hariharan,C.;Callaway,H.;Parvate,A.;Schendel,S.L.;Parekh,D.;Hui,S.;Shaffer,K.;Pascal,K.E.;Wloga,E.;Giordano,S.;Negron,N.;Ni,M.;Copin,R.;Atwal,G.S.;Franklin,M.;Boytz,R.M.;Donahue,C.;Davey,R.;Baum,A.;Kyratsous,C.A.;Saphire,E.O.",Structure of the Inmazeb cocktail and resistance to Ebola virus escape,25-JAN-2023,8_8_9_6_3_10,QRJ96643_QRJ96647,Xtal structure,Ebola,2,1,15.019862,13.284568
QYB25435_QYB25505,QVQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALGTYCSGGSCYSGTVDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLISDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDIK,QYB25435,QYB25505,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_8_20_6_3_9,QYB25435_QYB25505,Unique source,SARS-CoV-2,2,1,15.088053,13.871187
QKK35648_QKK35649,QVQLVESGGGVVQPGRSLRLSCAASGFTFSAFAMHWVRQAPGKGLEWVTIISYDGSNEYYADSVQGRFSISRDNSKNTLFLQMSSLRTEDTAIYYCARAGGYLSAFDIWGQGTTVTVSS,DIRLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPNLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSGWTFGQGTKVEIK,QKK35648,QKK35649,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_12_6_3_8,QKK35648_QKK35649,Unique source,SARS-CoV-2,2,1,14.795184,13.276843
4C2I_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSAYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLHLQMNSLRAEDTAIYYCARDKNPGTKPYYHYGMDVWGQGTTVTVSS,QSVLTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQFPGKAPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGLQSEDEAYYYCAAWDDSLIGVVFGGGTKLTVL,4C2I_H,4C2I_L,Cryo-Em Structure Of Dengue Virus Serotype 1 Complexed With Fab Fragments Of Human Antibody 1F4,Cryo-Em Structure Of Dengue Virus Serotype 1 Complexed With Fab Fragments Of Human Antibody 1F4,Homo sapiens,"Fibriansah,G.;Tan,J.L.;Smith,S.A.;de Alwis,A.R.;Ng,T.S.;Kostyuchenko,V.A.;Ibarra,K.D.;Wang,J.;Harris,E.;de Silva,A.;Crowe JE,Jr.;Lok,S.M.",A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface,18-AUG-2013,8_8_18_8_3_11,4C2I_H_L,Xtal structure,Dengue; dengue,2,1,14.182236,13.948516
QKY76436_QKY76049,QVQLVESGGGVVQPGRSLRLSCAASGFTFSDYAMHWVRQAPGKGLEWVADISFDGSNKYYADSVKGRFTISRDSSENTLYLQMDSLRADDTAVYYCARDLSTTWYLEMWGPDAFDIWGQGTVVTVSS,DIQMTQSPSTLSASIGDRVTITCRASQSISSWLAWYQQIPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,QKY76436,QKY76049,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_20_6_3_9,QKY76436_QKY76049,Unique source,SARS-CoV-2,2,1,14.692236,13.698842
1HEZ_D_C,QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVALISYDESNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVKFYDPTAPNDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,1HEZ_D,1HEZ_C,Antibody-Antigen Complex,Antibody-Antigen Complex,Finegoldia magna,"Bottomley,S.P.;Beckingham,J.A.;Murphy,J.P.;Atkinson,M.;Atkinson,T.;Hinton,R.J.;Gore,M.G.","Cloning, expression and purification of Ppl-1, a kappa-chain binding protein, based upon protein L from Peptostreptococcus magnus",27-NOV-2000,8_8_14_6_3_9,1HEZ_D_C,Xtal structure,,2,1,15.045466,13.596199
7SU0_I_M,QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVTFISYDGHNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQEVGESELAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,7SU0_I,7SU0_M,Crystal Structure Of An Acidic Ph-Selective Ipilimumab Variant Ipi.105 In Complex With Ctla-4,Crystal Structure Of An Acidic Ph-Selective Ipilimumab Variant Ipi.105 In Complex With Ctla-4,Homo sapiens,"Lee,P.S.;MacDonald,K.G.;Massi,E.;Chew,P.V.;Bee,C.;Perkins,P.;Chau,B.;Thudium,K.;Lohre,J.;Nandi,P.;Deyanova,E.G.;Barman,I.;Gudmundsson,O.;Dollinger,G.;Sproul,T.;Engelhardt,J.J.;Strop,P.;Rajpal,A.",Improved therapeutic index of an acidic pH-selective antibody,15-NOV-2021,8_8_11_7_3_9,7SU0_I_M,Xtal structure,,2,1,14.802247,13.174969
5WI9_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGIHWVRQAPGKGLEWVAVIWYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRAAAGLHYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQSGSSPLTFGGGTEVEIK,5WI9_H,5WI9_L,Crystal Structure Of Kl With An Agonist Fab,Crystal Structure Of Kl With An Agonist Fab,Homo sapiens,"Min,X.;Weiszmann,J.;Johnstone,S.;Wang,W.;Yu,X.;Romanow,W.;Thibault,S.;Li,Y.;Wang,Z.",Agonistic beta-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions,18-JUL-2017,8_8_17_7_3_9,5WI9_H_L,Xtal structure,FGF21,2,1,14.1732435,13.975288
6DKJ_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,6DKJ_H,6DKJ_L,Human Gipr Ecd And Fab Complex,Human Gipr Ecd And Fab Complex,Homo sapiens,"Killion,E.A.;Wang,J.;Yie,J.;Shi,S.D.;Bates,D.;Min,X.;Komorowski,R.;Hager,T.;Deng,L.;Atangan,L.;Lu,S.C.;Kurzeja,R.J.;Sivits,G.;Lin,J.;Chen,Q.;Wang,Z.;Thibault,S.A.;Abbott,C.M.;Meng,T.;Clavette,B.;Murawsky,C.M.;Foltz,I.N.;Rottman,J.B.;Hale,C.;Veniant,M.M.;Lloyd,D.J.",Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models,29-MAY-2018,8_8_13_6_3_9,6DKJ_H_L,Xtal structure,GLP-1R; GIPR; GLP1R,2,1,15.031392,13.247385
AAF14196_AAF14207,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAAIWYDGSNKYYADSVKGRFTISRDNSKNTLYMQMNSLRAEDTAVYYCAREGRWVRYTTVTTIGYYFDYWGQGTLVTVSS,QTVVTQEPSFSVSPGGTVTLTCGLSSGSVSTSYYPSWYQQTPGQAPRTLIYTTNTRSSGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMGGVWVFGGGTKLTVL,AAF14196,AAF14207,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Perera,W.S.; Moss,M.T.; Urbaniak,S.J.",V(D)J germline gene repertoire analysis of monoclonal D antibodies and the implications for D epitope specificity,26-JUL-2016,8_8_21_9_3_9,AAF14196_AAF14207,Unique source,,2,1,14.936809,13.514792
QYF06313_QYF06465,QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYAMQWVRQAPGKGLEWVAVISYDGNNRYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPPGYYDSSGYYQTPEYFQHWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGVGYDVHWYQQFPGTVPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,QYF06313,QYF06465,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Tong,P.; Gautam,A.; Windsor,I.W.; Travers,M.; Chen,Y.; Garcia,N.; Whiteman,N.B.; McKay,L.G.; Storm,N.; Malsick,L.E.; Honko,A.N.; Lelis,F.J.; Habibi,S.; Jenni,S.; Cai,Y.; Rennick,L.J.; Duprex,W.P.; McCarthy,K.R.; Lavine,C.L.; Zuo,T.; Lin,J.; Zuiani,A.; Feldman,J.; MacDonald,E.A.; Hauser,B.M.; Griffths,A.; Seaman,M.S.; Schmidt,A.G.; Chen,B.; Neuberg,D.; Bajic,G.; Harrison,S.C.; Wesemann,D.R.",Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike,07-AUG-2021,8_8_22_9_3_11,QYF06313_QYF06465,Unique source,SARS-CoV-2,2,1,14.915316,13.782602
6LUN_C_D,QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIWYDGTNKDYTDSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREDWAEAFDMWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTITFGQGTRLEIK,6LUN_C,6LUN_D,Nn2101 Antibody Fab Fragment,Nn2101 Antibody Fab Fragment,Homo sapiens,"Kim,J.O.;Kim,H.N.;Kim,K.H.;Baek,E.J.;Park,J.Y.;Ha,K.;Heo,D.R.;Seo,M.D.;Park,S.G.",Development and characterization of a fully human antibody targeting SCF/c-kit signaling,30-JAN-2020,8_8_11_11_3_8,6LUN_C_D,Xtal structure,SCF; SF; DFNA69; Kitl; SLF; MGF; KL-1; KITLG; FPH2,2,1,14.863992,13.499098
QKK35564_QKK35565,QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVIYSDGRNEYYADSVKGRFTISRDNSKNTLHLQMNSLGAADTAVYYCARDPGPITFFDWSPDKSRKSYYDYNGMDVWGQGTTVTVSS,QPGLTQEPSLTVSPGGTVTLTCGSSAGAVTSGHYPYWFQQKPGQAPRTLIYDTNNKYSWTPARFSGSLLGGKAALTLSGAQPEDEAEYFCFLSYRGAPPVFGGGTHLTVL,QKK35564,QKK35565,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_29_9_3_10,QKK35564_QKK35565,Unique source,SARS-CoV-2,2,1,14.110085,14.023713
QKY76670_QKY76283,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYALFWVRQAPGKGLEWVAVISYDGNNKYYADSVRGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCARPYTGSYKSYMDVWGKGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNSLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSISWTFGQGTKVEIK,QKY76670,QKY76283,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_12_3_9,QKY76670_QKY76283,Unique source,SARS-CoV-2,2,1,14.358136,13.764725
QKY76674_QKY76287,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAGISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADTMVRGTYFEYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYCCSSYTSSRAVLFGGGTKLTVL,QKY76674,QKY76287,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_9_3_10,QKY76674_QKY76287,Unique source,SARS-CoV-2,2,1,14.778682,13.450305
QJU69692_QJU69758,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSISGSYLGAFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYTFGQGTKLEIK,QJU69692,QJU69758,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Seydoux,E.; Homad,L.J.; MacCamy,A.J.; Parks,K.R.; Hurlburt,N.K.; Jennewein,M.F.; Akins,N.R.; Stuart,A.B.; Wan,Y.-H.; Feng,J.; Nelson,R.E.; Singh,S.; Cohen,K.W.; McElrath,M.J.; Englund,J.A.; Chu,H.Y.; Pancera,M.; McGuire,A.T.; Stamatatos,L.",Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual,20-MAY-2020,8_8_14_6_3_7,QJU69692_QJU69758,Unique source,SARS-CoV-2,2,1,14.683014,13.55604
QKY76473_QKY76086,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDQEWFRELFLFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGPGTKVDIK,QKY76473,QKY76086,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_15_6_3_9,QKY76473_QKY76086,Unique source,SARS-CoV-2,2,1,14.702094,13.335051
ANV21804_ANV21993,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISFDGSNKYYTDSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCAKDRPARGVTSGYYYYYGVDVWGHGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLFYFNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,ANV21804,ANV21993,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_21_8_3_11,ANV21804_ANV21993,Unique source,,2,1,14.109939,14.07263
3F12_B_A,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGKCAGGSCYSGLLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPWTFGQGTKVEIK,3F12_B,3F12_A,Germline V-Genes Sculpt The Binding Site Of A Family Of Antibodies Neutralizing Human Cytomegalovirus,Germline V-Genes Sculpt The Binding Site Of A Family Of Antibodies Neutralizing Human Cytomegalovirus,Homo sapiens,"Thomson,C.A.;Bryson,S.;McLean,G.R.;Creagh,A.L.;Pai,E.F.;Schrader,J.W.",Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus,27-OCT-2008,8_8_18_6_3_10,3F12_B_A,Xtal structure,cytomegalovirus,2,1,15.076617,13.825103
AHX01214_AHX01217,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLGESENEEWATDYYDFSIGYPGQDPRGVVGAFDIWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGGVFGTGTKVTVL,AHX01214,AHX01217,"anti-HIV-1 immunoglobulin CAP256-VRC26.UCA heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin CAP256-VRC26.UCA light chain variable region, partial [Homo sapiens]",Homo sapiens,"Doria-Rose,N.A.; Schramm,C.A.; Gorman,J.; Moore,P.L.; Bhiman,J.N.; Dekosky,B.J.; Ernandes,M.J.; Georgiev,I.S.; Kim,H.J.; Pancera,M.; Staupe,R.P.; Altae-Tran,H.R.; Bailer,R.T.; Crooks,E.T.; Cupo,A.; Druz,A.; Garrett,N.J.; Hoi,K.H.; Kong,R.; Louder,M.K.; Longo,N.S.; McKee,K.; Nonyane,M.; O'Dell,S.; Roark,R.S.; Rudicell,R.S.; Schmidt,S.D.; Sheward,D.J.; Soto,C.; Wibmer,C.K.; Yang,Y.; Zhang,Z.; Mullikin,J.C.; Binley,J.M.; Sanders,R.W.; Wilson,I.A.; Moore,J.P.; Ward,A.B.; Georgiou,G.; Williamson,C.; Abdool Karim,S.S.; Morris,L.; Kwong,P.D.; Shapiro,L.; Mascola,J.R.",Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies,17-Nov-2014,8_8_37_8_3_12,AHX01214_AHX01217,Unique word,HIV,2,1,14.958756,14.0455265
AEL31296_AEL31313,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSQLRSLLYFDWLSQGYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTFGQGTKVEIK,AEL31296,AEL31313,"anti-Influenza A hemagglutinin heavy chain variable region, partial [Homo sapiens]","anti-Influenza A immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Corti,D.; Voss,J.; Gamblin,S.J.; Codoni,G.; Macagno,A.; Jarrossay,D.; Vachieri,S.G.; Pinna,D.; Minola,A.; Vanzetta,F.; Silacci,C.; Fernandez-Rodriguez,B.M.; Agatic,G.; Bianchi,S.; Giacchetto-Sasselli,I.; Calder,L.; Sallusto,F.; Collins,P.; Haire,L.F.; Temperton,N.; Langedijk,J.P.; Skehel,J.J.; Lanzavecchia,A.",A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,25-JUL-2016,8_8_22_12_3_9,AEL31296_AEL31313,Unique source,hemagglutinin; Influenza,2,1,15.071171,14.010048
CCE67143_CCE67144,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTSGIAAFDYWGQGTLVTVSS,DNVMTQSPDSLAVFLGERATINCKSSQSVLYNSNYKNYLAWYQQKPGQPPKLLFYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNTPLTFGGGTKVEIK,CCE67143,CCE67144,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"VEIBY,O.; BABCOOK,J.",Antibodies that bind OV064 and methods of use therefor,23-NOV-2011,8_8_11_12_3_9,CCE67143_CCE67144,Ordered entries,,2,1,15.006932,13.406713
QKY76663_QKY76276,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSKKDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQSQGAYILTGYRGYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQFLIYLGSNRASGVPDRFSGSGSGTDFILKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,QKY76663,QKY76276,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_21_11_3_9,QKY76663_QKY76276,Unique source,SARS-CoV-2,2,1,14.089042,14.068307
6O23_C_D,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALDDASSTSCCALDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYFTFGPGTKVDIK,6O23_C,6O23_D,Crystal Structure Of 2243 Fab In Complex With Circumsporozoite Protein Nanp5,Crystal Structure Of 2243 Fab In Complex With Circumsporozoite Protein Nanp5,Plasmodium falciparum,"Murugan,R.;Scally,S.W.;Costa,G.;Mustafa,G.;Thai,E.;Decker,T.;Bosch,A.;Prieto,K.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs,22-FEB-2019,8_8_17_6_3_8,6O23_C_D,Xtal structure,circumsporozoite,2,1,15.102187,13.636405
7CZT_I_M,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWFHTGGYFDYWGQGTLVTVSS,QPVLTQPPSSSASPGESARLTCTLPSDINVSSYNIYWYQQKPGSPPRYLLYYYSDSDKGQGSGVPSRFSGSKDASANTGILLISGLQSEDEADYYCMIWPSNALYVFGTGTKVTVL,7CZT_I,7CZT_M,S Protein Of Sars-Cov-2 In Complex Bound With P5A-2G9,S Protein Of Sars-Cov-2 In Complex Bound With P5A-2G9,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_8_12_9_7_10,7CZT_I_M,Xtal structure,SARS-CoV-2,2,1,14.858348,13.357795
8FG0_C_D,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSYKSYIESVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCALGYSSGQGTLDNWGQGTLVTVSS,DVVMTQSPLSLAVTLGQPASISCRSTQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSESGTDFTLKISRVEAEDVGLYYCMQGTHWPWTFGQGTKVEIK,8FG0_C,8FG0_D,"Crystal Structure Of The 3764 Fab In Complex With The C-Terminal Pfcsp Linker, Pfcsp281-294.","Crystal Structure Of The 3764 Fab In Complex With The C-Terminal Pfcsp Linker, Pfcsp281-294.",Plasmodium falciparum,"Oludada,O.E.;Costa,G.;Burn Aschner,C.;Obraztsova,A.S.;Prieto,K.;Canetta,C.;Hoffman,S.L.;Kremsner,P.G.;Mordm&#xfc;ller,B.;Murugan,R.;Julien,J.P.;Levashina,E.A.;Wardemann,H.",Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies,10-MAY-2023,8_8_13_11_3_9,8FG0_C_D,Xtal structure,,2,1,14.978917,13.309129
4LF3_B_A,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLESGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK,4LF3_B,4LF3_A,Inhibitory Mechanism Of An Allosteric Antibody Targeting The Glucagon Receptor,Inhibitory Mechanism Of An Allosteric Antibody Targeting The Glucagon Receptor,Homo sapiens,"Mukund,S.;Shang,Y.;Clarke,H.J.;Madjidi,A.;Corn,J.E.;Kates,L.;Kolumam,G.;Chiang,V.;Luis,E.;Murray,J.;Zhang,Y.;Hotzel,I.;Koth,C.M.;Allan,B.B.",Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor,26-JUN-2013,8_8_21_6_3_9,QPX66543_QPX66562,Xtal structure,glucagon,2,1,14.14617,14.045009
6ULE_A_B,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQTTGKGLEWVAIIWHDGSKKYYADSVKGRLTISRDNSKNTLYLQMNSLRVEDTALYYCARVGDYSDFKYGAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPNLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYWTFGQGTRVEIK,6ULE_A,6ULE_B,Crystal Structure Of 2541 Fab In Complex With Circumsporozoite Protein Nanp5,Crystal Structure Of 2541 Fab In Complex With Circumsporozoite Protein Nanp5,Plasmodium falciparum,"Murugan,R.;Scally,S.W.;Costa,G.;Mustafa,G.;Thai,E.;Decker,T.;Bosch,A.;Prieto,K.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs,10-JUN-2020,8_8_16_6_3_8,6ULE_A_B,Xtal structure,circumsporozoite,2,1,14.744548,13.654749
QKY76595_QKY76208,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLAWVALISYDGYNKYYADSVRGRFTISRINSKNTLSLQMNSLRAEDTAVYYCARGSAGNYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQTITNYLNWYQLKSGRAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK,QKY76595,QKY76208,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_6_3_9,QKY76595_QKY76208,Unique source,SARS-CoV-2,2,1,14.23512,13.857409
QKY76470_QKY76083,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMIGLRAEDTAVYYCARDWAPTYYDMPSAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGKTARITCGGNNIGNKGVHWYQQKPGQAPVLVVDDDSDRPSGIPERFSGSNSGNTATLIISSVEVGDEADFYCQVWDSSSDHPGVFGGGTKLTVL,QKY76470,QKY76083,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_17_6_3_12,QKY76470_QKY76083,Unique source,SARS-CoV-2,2,1,14.673891,13.63825
QKY76668_QKY76281,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYYCAKDGSIAAADYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLHSSNNKDSLVWYQQKPGQPPKLLIYWASSRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPWTFGQGTKVEIK,QKY76668,QKY76281,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_11_12_3_9,QKY76668_QKY76281,Unique source,SARS-CoV-2,2,1,14.938433,13.3845825
USW88737_USW88645,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLGSYCGGTSCYAGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDTNNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDLATYYCLQYDNLPFTFGGGTKVEIK,USW88737,USW88645,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kumar,S.; Patel,A.; Lai,L.; Chakravarthy,C.; Valanparambil,R.; Davis-Gardner,M.E.; Edara,V.V.; Linderman,S.; Reddy,E.S.; Gottimukkala,K.; Nayak,K.; Dixit,K.; Sharma,P.; Bajpai,P.; Singh,V.; Frank,F.; Cheedarla,N.; Verkerke,H.P.; Neish,A.S.; Roback,J.D.; Mantus,G.; Goel,P.K.; Rahi,M.; Davis,C.W.; Wrammert,J.; Suthar,M.S.; Ahmed,R.; Ortlund,E.; Sharma,A.; Murali-Krishna,K.; Chandele,A.",Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody,06-JUL-2022,8_8_20_6_3_9,USW88737_USW88645,Unique source,SARS-CoV-2; RBD,2,1,15.067389,13.916803
AMB38435_AMB38561,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVMSWDGSQKYYVDSVKGRFTISRDNSKDTLYLQMNSLRAEDTAVYYCAKDWGPRILYYFTSGSYSPLDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLTFGGGTKVEIK,AMB38435,AMB38561,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_22_7_3_8,AMB38435_AMB38561,Unique source,,2,1,15.124515,13.951911
4G6J_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPAKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,4G6J_H,4G6J_L,Crystal Structure Of Human Il-1Beta In Complex With The Therapeutic Antibody Binding Fragment Of Canakinumab,Crystal Structure Of Human Il-1Beta In Complex With The Therapeutic Antibody Binding Fragment Of Canakinumab,Homo sapiens,"Blech,M.;Peter,D.;Fischer,P.;Bauer,M.M.;Hafner,M.;Zeeb,M.;Nar,H.",One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta,19-JUL-2012,8_8_11_6_3_9,4G6J_H_L,Xtal structure,interleukin,2,1,14.867602,13.197523
QKY76657_QKY76270,QVQLVESGGGVVQPGRSLRLSCAASGFTFSYYPMHWLWVRQAPGKGLEWVAVTSYDGTNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGATNFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTANITCGGNNIGRKSVHWYQQKSGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPEWVFGGGTKLTVL,QKY76657,QKY76270,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,10_8_10_6_3_13,QKY76657_QKY76270,Unique source,SARS-CoV-2,2,1,14.896999,13.258487
QEP20057_QEP20705,QVQLVESGGGVVQPGRSLRLSCAASGFTFTESGMHWVRQAPGKGLEWVALIWFDGSQKYYGDSVKGRFTISRDNSNNTLYLQMNSLRPEDTAVYYCAKDSCSGTTCYFALESWGQGTLVTVSS,EIVLTQSPDLQSVSPKGKVTITCRASQYIGSSLHWYQQKPGQSPKLLIRYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCHQSNNLPWTFGQGTKVEIK,QEP20057,QEP20705,"IGH + IGL c164_heavy_IGHV3-30_IGHD2-2_IGHJ4, partial [Homo sapiens]","IGH + IGL c164_light_IGKV6-21_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_16_6_3_9,QEP20057_QEP20705,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,15.086935,13.672552
UIC72036_UIC72346,QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYAMHWVRQAPGKGLECVALVSKDGSDKYYADSVKGRFAISRDNSENTLSLQMNNLRVEDTAVYYCAGSWGMDIWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSESLLYSDGYTYLNWFQQRPGQSPRRLIYQVSKRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGQGTKVEVK,UIC72036,UIC72346,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_8_11_3_9,UIC72036_UIC72346,Unique source,HCV,2,1,14.455923,13.749283
6XPZ_B_C,QVQLVESGGGVVQPGRSVRLTCAGSGFSFSNFGMNWVRQAPGKGLEWLAIISYDGSKKWYADSVKGRFTISRDDAKNTLFLQMNSLTAEDTAVYYCSKDRGDVWSGYYRGGDYHYYFGMDVWGQGTTVTVSG,DIQMTQSPSSLSTSVGDRVTITCQASQDISNFLNWYQQKPGKAPELLIYDASYLQGGVPSRFSGSGSGTDFSFTISSLQPEDIATYYCQQYNSLPITFGQGTRLEIK,6XPZ_B,6XPZ_C,Human Antibody S1V2-83 In Complex With The Influenza Hemagglutinin Head Domain Of A/Moscow/10/1999(H3N2),Human Antibody S1V2-83 In Complex With The Influenza Hemagglutinin Head Domain Of A/Moscow/10/1999(H3N2),Homo sapiens,"McCarthy,K.R.;Lee,J.;Watanabe,A.;Kuraoka,M.;Robinson-McCarthy,L.R.;Georgiou,G.;Kelsoe,G.;Harrison,S.C.",A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface,09-JUL-2020,8_8_25_6_3_9,6XPZ_B_C,Xtal structure,Influenza; H3N2,2,1,14.058153,14.064127
QKK35868_QKK35869,QVQLVESGGGVVQPGTSLRLSCAATGFTFTTYPMHWVRQAPGKGLEWVAVISYDGMNQYYADFLKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCARAYGGNYQNHFDHWGQGTLVTVSS,DIVLTQTPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTMWTFGQGTKVEIK,QKK35868,QKK35869,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_12_3_8,QKK35868_QKK35869,Unique source,SARS-CoV-2,2,1,14.885494,13.474416
6WNO_E_F,QVQLVESGGGVVQSGKSLRVSCAASGFTFSSYGMHWVRQAPGKGLEWVAFISYDGDNKYSADSVKGRLTISRDNSKNTLYLQMNSLRPEDTAVYYCAKESNYGENAFDIWGQGTMVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGFYNFVSWYQHHPGKAPKLIIYDVSERPSGVPDRFSGSKSGNTASLSISGLQPEDEADYYCCSYAGTYTFVFGSGTKVTVL,6WNO_E,6WNO_F,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 243244,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 243244,Homo sapiens,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,23-APR-2020,8_8_13_9_3_10,6WNO_E_F,Xtal structure,,2,1,15.0819235,13.43562
2A9N_H_L,QVQLVESGGNLVQPGGSLRLSCAASGFTFGSFSMSWVRQAPGGGLEWVAGLSARSSLTHYADSVKGRFTISRDNAKNSVYLQMNSLRVEDTAVYYCARRSYDSSGYAGHFYSYMDVWGQGTLVTVS,SVLTQPSSVSAAPGQKVTISCSGSTSNIGNNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNSASLDISGLQSEDEADYYCAAWDDSLSEFLFGTGTKLTVL,2A9N_H,2A9N_L,A Mutation Designed To Alter Crystal Packing Permits Structural Analysis Of A Tight-Binding Fluorescein-Scfv Complex,A Mutation Designed To Alter Crystal Packing Permits Structural Analysis Of A Tight-Binding Fluorescein-Scfv Complex,Homo sapiens,"Honegger,A.;Spinelli,S.;Cambillau,C.;Pluckthun,A.",A mutation designed to alter crystal packing permits structural analysis of a tight-binding fluorescein-scFv complex,12-JUL-2005,8_8_20_8_3_11,2A9N_H_L,Xtal structure,,2,1,15.816106,9.931617
2A9M_H_L,QVQLVESGGNLVQPGGSLRLSCAASGFTFGSFSMSWVRQAPGGGLEWVAGLSARSSLTHYADSVKGRFTISRDNAKNSVYLQMNSLRVEDTAVYYCARRSYDSSGYWGHFYSYMDVWGQGTLVTVS,SVLTQPSSVSAAPGQKVTISCSGSTSNIGNNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNSASLDISGLQSEDEADYYCAAWDDSLSEFLFGTGTKLTVL,2A9M_H,2A9M_L,Structural Analysis Of A Tight-Binding Fluorescein-Scfv; Apo Form,Structural Analysis Of A Tight-Binding Fluorescein-Scfv; Apo Form,Homo sapiens,"Honegger,A.;Spinelli,S.;Cambillau,C.;Pluckthun,A.",A mutation designed to alter crystal packing permits structural analysis of a tight-binding fluorescein-scFv complex,12-JUL-2005,8_8_20_8_3_11,2A9M_H_L,Xtal structure,,2,1,15.784763,9.898896
ANV21799_ANV21988,QVQLVESGGRLVTPGGSLRLSCVVSGFPFSDYYMSWIRQTPGKGLEWLSYISSSGDTKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYHCARDGNINYDGSGSPPYYYGMAVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTVTCRTNQRIDNFLHWFQRKPGKAPNLLIYAASNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSTPYTFGQGTKLEIR,ANV21799,ANV21988,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_22_6_3_9,ANV21799_ANV21988,Unique source,,2,1,15.786759,9.592434
QKK35678_QKK35679,QVQLVESGGSVVQPGTSLKLSCAGSAGLTITRYAMHWVRQAPGKGLEWVALVSHDGIHIGYSDSVRGRFTISRDNSRNTLYLQMDGLRPEDTAVYYCVRDDVLQHSRPSGPGYFVSWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSTFLGWYQQRPGQPPRLLIYDASYRAPDIPVRFSGSGSGTDFTLTINSLEPEDSAVYYCQQRSDGYNFGPGTKLEIK,QKK35678,QKK35679,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_8_19_6_3_8,QKK35678_QKK35679,Unique source,SARS-CoV-2,2,1,14.623709,13.279616
6UIG_B_C,QVQLVESGPGLVKPSQTLSLTCTVSGGSINSSHSFWSWIRQPAGKGLEWIGRIYSTGNSNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAVYYCARESLWNPDYYYYMDVWGKGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSFSSHLNWYQQKPGRAPDLLIYAASSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSYSVPYTFGQGTKLQIK,6UIG_B,6UIG_C,Crystal Structure Of Human Monoclonal Antibody H7.200 In Complex With H7N9 Hemagglutinin Ha1,Crystal Structure Of Human Monoclonal Antibody H7.200 In Complex With H7N9 Hemagglutinin Ha1,Homo sapiens,"Dong,J.;Gilchuk,I.;Li,S.;Irving,R.;Goff,M.T.;Turner,H.L.;Ward,A.B.;Carnahan,R.H.;Crowe JE,Jr.",Anti-influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface,30-SEP-2019,10_7_16_6_3_9,6UIG_B_C,Xtal structure,hemagglutinin,2,1,15.984695,-7.9625754
QKK35704_QKK35705,QVQLVESGPGLVRPSGTLSVTCAVSGDSISSDYWCTWVRQSPGKGLEWIGKISHSGSLNYNPSLKSRVTMSVDKSKNHFSLKLASVTAADTAVYYCARVRIGASHHNFWSGYYTDAFDIWGQGTTVTVSS,DIVVTQSPGTLSLSPGERAALSCRASQSVGNNYLAWYQQKPGQAPRLLIYGATSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPVYTFGQGTKVEIK,QKK35704,QKK35705,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_23_7_3_10,QKK35704_QKK35705,Unique source,SARS-CoV-2,2,1,15.4668,-7.366965
7PS7_A_B,QVQLVESGPGQVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSAYYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVFYCARHAAPSPGDNWFDPWGQGTLVTVSS,QSVLTQPPSVSVSPGQTARITCSGDALSTQNGNWYQQKPGQAPVMVICKDSERPSGIPERFSGSRSGTTVTLTISGVQAEDEADYHCQSADNRAHVVFGGGTKLTVL,7PS7_A,7PS7_B,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-40 Fab,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-40 Fab,Homo sapiens,"Liu,C.;Zhou,D.;Nutalai,R.;Duyvesteyn,H.M.;Tuekprakhon,A.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Mentzer,A.J.;Wang,B.;Case,J.B.;Zhao,Y.;Skelly,D.T.;Chen,R.E.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Malik,T.;Temperton,N.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Clare,D.K.;Howe,A.;Goulder,P.J.;Fry,E.E.;Diamond,M.S.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants,22-SEP-2021,10_7_15_6_3_10,7PS7_A_B,Xtal structure,SARS-CoV-2,2,1,16.806221,-8.09509
8BBO_H_L,QVQLVESGPGRVKPSQTLSLTCTVSGDSINSGINYWNWIRQPAGKELEWIGRIFTSGTTHYNPSLKSRVTISVDRSKNEFSLTLNSVTAADTAVYFCGRGGTDDYVDYWGQGTLVTVSS,AIQMTQSPSTLSASVGDRVTITCRASQDINSWLAWYQQKPGKAPKLLIYDASSLHSGVPTRFSGSGSGTEFTLTISSLQPDDFASYYCQQYKSYRTFGRGTKVEIK,8BBO_H,8BBO_L,Sars-Cov-2 Delta-Rbd Complexed With Ba.2-36 Fab,Sars-Cov-2 Delta-Rbd Complexed With Ba.2-36 Fab,Homo sapiens,"Dijokaite-Guraliuc,A.;Das,R.;Zhou,D.;Ginn,H.M.;Liu,C.;Duyvesteyn,H.M.E.;Huo,J.;Nutalai,R.;Supasa,P.;Selvaraj,M.;de Silva,T.I.;Plowright,M.;Newman,T.A.H.;Hornsby,H.;Mentzer,A.J.;Skelly,D.;Ritter,T.G.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;veName>OPTIC consortium</CollectiveName>,?.;Roemer,C.;Peacock,T.P.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Fry,E.E.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses,22-MAR-2023,10_7_11_6_3_8,8BBO_H_L,Xtal structure,SARS-CoV-2,2,1,16.51851,-7.6754003
QKQ15178_QKQ15262,QVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLERAGGMDVWGQGTMVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLYTFGQGTKVDIK,QKQ15178,QKQ15262,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",Homo sapiens,"Brouwer,P.J.M.; Caniels,T.G.; van der Straten,K.; Snitselaar,J.L.; Aldon,Y.; Bangaru,S.; Torres,J.L.; Okba,N.M.A.; Claireaux,M.; Kerster,G.; Bentlage,A.E.A.; van Haaren,M.M.; Guerra,D.; Burger,J.A.; Schermer,E.E.; Verheul,K.D.; van der Velde,N.; van der Kooi,A.; van Schooten,J.; van Breemen,M.J.; Bijl,T.P.L.; Sliepen,K.; Aartse,A.; Derking,R.; Bontjer,I.; Kootstra,N.A.; Wieringa,W.J.; Vidarsson,G.; Haagmans,B.L.; Ward,A.B.; de Bree,G.J.; Sanders,R.W.; van Gils,M.J.",Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability,15-JUN-2020,8_7_12_7_3_8,QKQ15178_QKQ15262,Unique source,SARS-CoV-2; COVID,2,1,12.561062,10.623991
QKQ15213_QKQ15297,QVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYTGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAHVDTAMVESGAFDIWGQGTRVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVTKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL,QKQ15213,QKQ15297,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",Homo sapiens,"Brouwer,P.J.M.; Caniels,T.G.; van der Straten,K.; Snitselaar,J.L.; Aldon,Y.; Bangaru,S.; Torres,J.L.; Okba,N.M.A.; Claireaux,M.; Kerster,G.; Bentlage,A.E.A.; van Haaren,M.M.; Guerra,D.; Burger,J.A.; Schermer,E.E.; Verheul,K.D.; van der Velde,N.; van der Kooi,A.; van Schooten,J.; van Breemen,M.J.; Bijl,T.P.L.; Sliepen,K.; Aartse,A.; Derking,R.; Bontjer,I.; Kootstra,N.A.; Wieringa,W.J.; Vidarsson,G.; Haagmans,B.L.; Ward,A.B.; de Bree,G.J.; Sanders,R.W.; van Gils,M.J.",Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability,15-JUN-2020,8_7_17_9_3_10,QKQ15213_QKQ15297,Unique source,SARS-CoV-2; COVID,2,1,12.599284,10.518506
6ANI_I_M,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,6ANI_I,6ANI_M,Coltuximab Fab In Complex With Anti-Kappa Vhh Domain,Coltuximab Fab In Complex With Anti-Kappa Vhh Domain,Homo sapiens,"Ereno-Orbea,J.;Sicard,T.;Cui,H.;Carson,J.;Hermans,P.;Julien,J.P.",Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments,13-AUG-2017,8_8_13_5_3_7,ATK04435_ATK04434,Xtal structure,Kappa,2,1,-0.34830052,-3.5704284
4YDJ_A_B,QVQLVQPGTAMKSLGSSLTITCRVSGDDLGSFHFGTYFMIWVRQAPGQGLEYMGGILPSTKTPTYAHKFRGRVSISAPGVPPVLSLALTNLTYDDTATYFCARERGRHFEPKNRDNLEGKFFDLWGRGTFVRVS,QSALTQPASVSGSPGQSINISCAGRSDRVSWYQQRPNGVPKLLMFDVYRRPSGVSDRFSGSHSGDTAFLTISGLQTEDEADYYCTSHPYAFGAGTKVNVL,4YDJ_A,4YDJ_B,Crystal Structure Of Broadly And Potently Neutralizing Antibody 44-Vrc13.01 In Complex With Hiv-1 Clade Ae Strain 93Th057 Gp120,Crystal Structure Of Broadly And Potently Neutralizing Antibody 44-Vrc13.01 In Complex With Hiv-1 Clade Ae Strain 93Th057 Gp120,Homo sapiens,"Zhou,T.;Lynch,R.M.;Chen,L.;Acharya,P.;Wu,X.;Doria-Rose,N.A.;Joyce,M.G.;Lingwood,D.;Soto,C.;Bailer,R.T.;Ernandes,M.J.;Kong,R.;Longo,N.S.;Louder,M.K.;McKee,K.;O'Dell,S.;Schmidt,S.D.;Tran,L.;Yang,Z.;Druz,A.;Luongo,T.S.;Moquin,S.;Srivatsan,S.;Yang,Y.;Zhang,B.;Zheng,A.;Pancera,M.;Kirys,T.;Georgiev,I.S.;Gindin,T.;Peng,H.P.;Yang,A.S.;Mullikin,J.C.;Gray,M.D.;Stamatatos,L.;Burton,D.R.;Koff,W.C.;Cohen,M.S.;Haynes,B.F.;Casazza,J.P.;Connors,M.;Corti,D.;Lanzavecchia,A.;Sattentau,Q.J.;Weiss,R.A.;West AP,Jr.;Bjorkman,P.J.;Scheid,J.F.;Nussenzweig,M.C.;Shapiro,L.;Mascola,J.R.;Kwong,P.D.",Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors,22-FEB-2015,13_8_23_3_3_6,4YDJ_A_B,Xtal structure,HIV; CD4,2,1,-0.7144899,5.570516
7RD3_H_L,QVQLVQSEAEVKKPGASVKVSCKASGYTFTRYAMHWVRQAPGQRLEWMGWIKAGNGDTRYSQKFQGRVTITRDTSASTVYMEMSSLRSEDTAVYYCALLTVITSDDAFDIWGQGTMVTVSL,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLVYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,7RD3_H,7RD3_L,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M42.126,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M42.126,Plasmodium falciparum,"Kratochvil,S.;Shen,C.H.;Lin,Y.C.;Xu,K.;Nair,U.;Da Silva,Pe.;Tripathi,P.;Arnold,J.;Chuang,G.Y.;Melzi,E.;Schon,A.;Zhang,B.;Dillon,M.;Bonilla,B.;Flynn,B.J.;Kirsch,K.H.;Kisalu,N.K.;Kiyuka,P.K.;Liu,T.;Ou,L.;Pancera,M.;Rawi,R.;Reveiz,M.;Seignon,K.;Wang,L.T.;Waring,M.T.;Warner,J.;Yang,Y.;Francica,J.R.;Idris,A.H.;Seder,R.A.;Kwong,P.D.;Batista,F.D.",Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies,09-JUL-2021,8_8_14_12_3_9,7RD3_H_L,Xtal structure,PfCSP; malarial,2,1,0.19681557,3.114754
7QF1_C_B,QVQLVQSEAEVKKPGSSVKVSCKASGGTYSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLPYYYDSSGYYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSNPWTFGQGTKVEIK,7QF1_C,7QF1_B,Crystal Structure Of The Sars-Cov-2 Rbd In Complex With The Human Antibody Cv2.6264,Crystal Structure Of The Sars-Cov-2 Rbd In Complex With The Human Antibody Cv2.6264,Homo sapiens,"Fernandez,I.;Rey,F.A.",Potent antibodies against SARS-CoV-2 isolated from a patient,03-DEC-2021,8_8_17_6_3_9,7QF1_C_B,Xtal structure,CRIM3; SARS-CoV-2; Cv2; BMPER,2,1,-0.954222,5.681
4LSR_H_L,QVQLVQSGAAVRKPGASVTVSCKFAEDDDYSPYWVNPAPEHFIHFLRQAPGQQLEWLAWMNPTNGAVNYAWYLNGRVTATRDRSMTTAFLEVKSLRSDDTAVYYCARAQKRGRSEWAYAHWGQGTPVVVSS,DIQMTQSPSSLSASLGDRVTITCQASRGIGKDLNWYQQKAGKAPKLLVSDASTLEGGVPSRFSGSGFHQDFSLTISSLQAEDVATYFCQQYETFGQGTKVDIK,4LSR_H,4LSR_L,Crystal Structure Of Broadly And Potently Neutralizing Antibody Vrc-Ch31 In Complex With Hiv-1 Clade A/E Stran 93Th057 Gp120 With Loop D And Loop V5 From Clade A Strain Ker_2018_11,Crystal Structure Of Broadly And Potently Neutralizing Antibody Vrc-Ch31 In Complex With Hiv-1 Clade A/E Stran 93Th057 Gp120 With Loop D And Loop V5 From Clade A Strain Ker_2018_11,Homo sapiens,"Zhou,T.;Zhu,J.;Wu,X.;Moquin,S.;Zhang,B.;Acharya,P.;Georgiev,I.S.;Altae-Tran,H.R.;Chuang,G.Y.;Joyce,M.G.;Do Kwon,Y.;Longo,N.S.;Louder,M.K.;Luongo,T.;McKee,K.;Schramm,C.A.;Skinner,J.;Yang,Y.;Yang,Z.;Zhang,Z.;Zheng,A.;Bonsignori,M.;Haynes,B.F.;Scheid,J.F.;Nussenzweig,M.C.;Simek,M.;Burton,D.R.;Koff,W.C.;Mullikin,J.C.;Connors,M.;Shapiro,L.;Nabel,G.J.;Mascola,J.R.;Kwong,P.D.","Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies",23-JUL-2013,17_8_15_6_3_5,4LSR_H_L,Xtal structure,HIV,2,1,2.5270145,4.2054014
QKK35662_QKK35663,QVQLVQSGADVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWLGVIHPSGGSTTFAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARVLAGSSHEWQLTHDAFDIWGQGTTVTVSS,DIRMTQSPDSLAVSLGERATINCRTSQSVLYSSNNKNYLGWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVDIK,QKK35662,QKK35663,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_20_12_3_9,QKK35662_QKK35663,Unique source,SARS-CoV-2,2,1,1.6842178,3.680899
QEP20360_QEP21008,QVQLVQSGAEARKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWVGGIITLSGTANYAQNFQGRVTITTDDSSNTAYMELSGLRSEDTAVYYCAREYVRHNGWYELGSAFDMWGQGTRVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNSLAWYQQRPGKVPKLLIYDASTLQSGVPSRFSGSGSETDFTLTISSLQPEDVATYFCQKYNSAPRTFGQGTKVEIK,QEP20360,QEP21008,"IGH + IGL c467_heavy_IGHV1-69_IGHD6-19_IGHJ3, partial [Homo sapiens]","IGH + IGL c467_light_IGKV1-27_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_19_6_3_9,QEP20360_QEP21008,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,-0.8602479,5.8898315
QIH48174_QIH48175,QVQLVQSGAELKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGPEWMGWINPNSGGTNSAQKFQDRVTMTRDTSINTAYMELNRLRYDDTAAYYCARGGWISLYYDSSGYPNFDQWGQGPLITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKDPKLMIYEVNKRASGVSIRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGSKLTVL,QIH48174,QIH48175,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48174_QIH48175,Unique source,HIV,2,1,2.7076774,2.9052427
QKK35770_QKK35771,QVQLVQSGAELKKPGSSVKVSCKASGGTFYNSAFSWLRHAPGQGPEWMGGITPSLGRVGYSERFLARLTITADESTSTVYMELTSLASEDTAVYYCARDASIVGTGNHLWYGLDFWGHGTTVTVSS,ETTLTQSPLFLPVTLGQPASISCTSSVHVVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTYFTLKISRVEAEDVGVYYCMQGTDWPRTFGQGTKVDIK,QKK35770,QKK35771,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35770_QKK35771,Unique source,SARS-CoV-2,2,1,-6.550652,-2.5219634
QKK35782_QKK35783,QVQLVQSGAELKKPGSSVRVSCKAAGGTLTNYAISWVRQAPGQGFEWMGGIMPVSHTAGYAQKFQGRVTFTADESATTAYMDLTSLRPEDTAIYYCARDPSIHYTGNHHWYDLDIWGQGTMVTVSS,DIQLTQSPLSLPVTLGQPASISCRSSQRIVHTDGNTYLNWFLQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQGTEWPRTFGQGTKVEIK,QKK35782,QKK35783,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35782_QKK35783,Unique source,SARS-CoV-2,2,1,-6.455904,-2.6193032
QKK35686_QKK35687,QVQLVQSGAELKKPGSSVRVSCKAAGGTLTNYAISWVRQAPGQGFEWMGGIMPVSHTAGYAQKFQGRVTFTADESATTAYMDLTSLRPEDTAIYYCARDPSIHYTGNHHWYDLDIWGQGTTVTVSS,DIRVTQSPLSLPVTLGQPASISCRSSQRIVHTDGNTYLNWFLQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQGTEWPRTFGQGTKVDIK,QKK35686,QKK35687,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35686_QKK35687,Unique source,SARS-CoV-2,2,1,-6.486332,-2.5891428
5KEM_B_C,QVQLVQSGAELKPPGASVKVSCKPSGYTFTDYYIHWVRQAPGQGLEWMGWINPKSGETHYAQKFRGWVTLTRDTSISTTYMDLTRLKSDDTAVYFCARGDLETTIFFYNAVDVWGQGTLVT,DIQMTQSPSSLSASVGDRVTITCRATESIGIYLNWYQRKPGKAPNLLIFATSSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCQQGFSSPFSFGQGTRLEIK,5KEM_B,5KEM_C,Ebov Sgp In Complex With Variable Fab Domains Of Iggs C13C6 And Bdbv91,Ebov Sgp In Complex With Variable Fab Domains Of Iggs C13C6 And Bdbv91,"Ebola virus - Mayinga, Zaire, 1976","Pallesen,J.;Murin,C.D.;de Val,N.;Cottrell,C.A.;Hastie,K.M.;Turner,H.L.;Fusco,M.L.;Flyak,A.I.;Zeitlin,L.;Crowe JE,Jr.;Andersen,K.G.;Saphire,E.O.;Ward,A.B.",Structures of Ebola virus GP and sGP in complex with therapeutic antibodies,09-JUN-2016,8_8_17_6_3_9,5KEM_B_C,Xtal structure,GP; RNF130; G1RZFP; Ebola; GOLIATH,2,1,2.2092218,3.693456
WBW48677_WBW48717,QVQLVQSGAEMKKPGASVKISCKASGYTFTSDYMHWVRQAPGQGLEWMGIVNPSGSGTRYAQKFQGRVTMTRDTPTKTFYIELTRLKSDDTAVYYCASGILTGLFDYWGQGTLVTVSS,DVVMTQSPGTLSLSAGERATLSCRASQTMTKNYVAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLAPEDFAVYYCLQYGSSPPIFTFGPGTKVEIK,WBW48677,WBW48717,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","cross-reactive anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Zhou,P.; Song,G.; Liu,H.; Yuan,M.; He,W.T.; Beutler,N.; Zhu,X.; Tse,L.V.; Martinez,D.R.; Schafer,A.; Anzanello,F.; Yong,P.; Peng,L.; Dueker,K.; Musharrafieh,R.; Callaghan,S.; Capozzola,T.; Limbo,O.; Parren,M.; Garcia,E.; Rawlings,S.A.; Smith,D.M.; Nemazee,D.; Jardine,J.G.; Safonova,Y.; Briney,B.; Rogers,T.F.; Wilson,I.A.; Baric,R.S.; Gralinski,L.E.; Burton,D.R.; Andrabi,R.",Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease,09-MAR-2023,8_8_11_7_3_11,WBW48677_WBW48717,Unique source,SARS-CoV-2,2,1,1.9489548,3.8761127
3X3F_H_L,QVQLVQSGAEMKKPGASVKVSCKTSGYTFTNYKINWVRQAPGQGLEWMGWMNPDTDSTGYPQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARSYGSGSYYRDYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,3X3F_H,3X3F_L,Trail-R2 Extracellular Region Complexed To A Fab Fragment From Human Agonist Antibody Kmtr2,Trail-R2 Extracellular Region Complexed To A Fab Fragment From Human Agonist Antibody Kmtr2,Homo sapiens,"Tamada,T.;Shinmi,D.;Ikeda,M.;Yonezawa,Y.;Kataoka,S.;Kuroki,R.;Mori,E.;Motoki,K.",TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2,20-JAN-2015,8_8_19_6_3_9,ABJ48586_ABJ48587,Xtal structure,TL2; CD253; TRAIL; Apo-2L; TNFSF10,2,1,2.026822,4.168231
7Y0C_A_B,QVQLVQSGAEMKKPGSSVKVSCQASGGTFSTYVISWVRQAPGQGLEWMGGIIPIFNTPHYAQKFQGRVTITADESTSTAYMELSSLTSGDTAVYYCARVSQWELLVYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSINSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGVSPRWTFGQGTKVEIK,7Y0C_A,7Y0C_B,Crystal Structure Of Bd55-1403 And Sars-Cov-2 Omicron Rbd,Crystal Structure Of Bd55-1403 And Sars-Cov-2 Omicron Rbd,Severe acute respiratory syndrome coronavirus 2,"Cao,Y.;Jian,F.;Zhang,Z.;Yisimayi,A.;Hao,X.;Bao,L.;Yuan,F.;Yu,Y.;Du,S.;Wang,J.;Xiao,T.;Song,W.;Zhang,Y.;Liu,P.;An,R.;Wang,P.;Wang,Y.;Yang,S.;Niu,X.;Zhang,Y.;Gu,Q.;Shao,F.;Hu,Y.;Yin,W.;Zheng,A.;Wang,Y.;Qin,C.;Jin,R.;Xiao,J.;Xie,X.S.",Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents,28-SEP-2022,8_8_11_7_3_10,7Y0C_A_B,Xtal structure,SARS,2,1,-0.44109076,5.6587467
QKK35530_QKK35531,QVQLVQSGAEMRKPGSSVKVSCKASGGTFSRYCFSWVRQAPGQRLEWMGGIMSILGAHYAQKFQGRVTFTADESTNTAYMELISLTSEDTAVYYCAREEPSGTYHNYYGLDVWGQGTTVTVSS,DIRLTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLNWFQQRPGQSPRRLIYEVSNRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRSFGGGTKVEIK,QKK35530,QKK35531,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_17_11_3_9,QKK35530_QKK35531,Unique source,SARS-CoV-2,2,1,-0.74089694,6.054249
QIH48254_QIH48255,QVQLVQSGAEVEKPGASVKVSCKASGYTLSDYYLHWMRQAPGQGLEWMGWINPNRGGANSAQKFQGRVTMTRDTSINTAYMEVTRLRSDDTAVYYCARGGWISLYYDSSGYPNFDSWGQGTLVTVSS,QSALTQPASVSGSPGQSITMSCTGTSSDVGSYSLVSWYQQHPGKAPKLMIYEVSKRASGVSNRFSGSKSGNTASLTISGLQAEDVADYFCCSYAGSSTVIFGGGTKVTVL,QIH48254,QIH48255,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48254_QIH48255,Unique source,HIV,2,1,2.7368567,2.8685017
QKK35828_QKK35829,QVQLVQSGAEVKGPGASVKVSCKVSGYSFITYDITWVRQAPGQGLEWMGWISTKSGDTRYAQNVQGRVTMTTDTSTNTAYMELRNLKSDDTALYYCARTTPRGWEQWPVLEYWGQGTLVTVSS,DIQVTQSPATLSVSPGERVTLSCRASQSISNTLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCHQYNKWPPITFGGGTKVEIK,QKK35828,QKK35829,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_10,QKK35828_QKK35829,Unique source,SARS-CoV-2,2,1,1.971485,5.2006125
7M6H_E_G,QVQLVQSGAEVKKAGASVKVSCKASGYTFTSYDINWVRQASGQGLEWMGWMNPISGNTGYAQKFQGRVTMTRNTSITTAYMELSSLRSEDTAVYFCARGGRYCSSTTCYSGVGMDVWGQGTTVTVPS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYHQLPGTAPKFLIYGNSNRPSGVPDRFSGSKSGTSASLAITRLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,7M6H_E,7M6H_G,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg7-20","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg7-20",Homo sapiens,"Scheid,J.F.;Barnes,C.O.;Eraslan,B.;Hudak,A.;Keeffe,J.R.;Cosimi,L.A.;Brown,E.M.;Muecksch,F.;Weisblum,Y.;Zhang,S.;Delorey,T.;Woolley,A.E.;Ghantous,F.;Park,S.M.;Phillips,D.;Tusi,B.;Huey-Tubman,K.E.;Cohen,A.A.;Gnanapragasam,P.N.;Rzasa,K.;Hatziioanno,T.;Durney,M.A.;Gu,X.;Tada,T.;Landau,N.R.;West AP,Jr.;Rozenblatt-Rosen,O.;Seaman,M.S.;Baden,L.R.;Graham,D.B.;Deguine,J.;Bieniasz,P.D.;Regev,A.;Hung,D.;Bjorkman,P.J.;Xavier,R.J.",B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV,25-MAR-2021,8_8_20_9_3_11,7M6H_E_G,Xtal structure,SARS-CoV-2; SARS; CoV,2,1,2.0417843,4.2723694
3MLW_H_L,QVQLVQSGAEVKKAGESLEISCKGSGYTFTDHWIAWVRQVPGKGLEWMGMIYPGDSDTRYSPSLQGRVTMSADKTLSTAYLQWSRLEASDTAMYYCARLHYSDRSGSYFNDVFHMWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGNSSNIENNYVYWYQQLPGSTPKLLIFRDDQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDDSRGGPDYVFGTGTKVTVL,3MLW_H,3MLW_L,Crystal Structure Of Anti-Hiv-1 V3 Fab 1006-15D In Complex With An Mn V3 Peptide,Crystal Structure Of Anti-Hiv-1 V3 Fab 1006-15D In Complex With An Mn V3 Peptide,HIV-1 M:B_MN,"Jiang,X.;Burke,V.;Totrov,M.;Williams,C.;Cardozo,T.;Gorny,M.K.;Zolla-Pazner,S.;Kong,X.P.",Conserved structural elements in the V3 crown of HIV-1 gp120,18-APR-2010,8_8_19_8_3_13,3MLW_H_L,Xtal structure,gp120; HIV,2,1,-12.573295,5.5588894
QKK35814_QKK35815,QVQLVQSGAEVKKAGSSVKVSCKASGGPFSSFAISWVRQAPGQGLEWLGGIMTVFGPAHYAQKSRDRISITADESTSTSYLELSSLTSDDTAVYYCAAEERSGTNHNYYGLDVWGQGTTVTVSS,ETTLTQSPLFLPVTLGQPASISCRSSQRLVHTNGNTYLNWFQQRPGHSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTEWPRTFGGGTKLEIK,QKK35814,QKK35815,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_11_3_9,QKK35814_QKK35815,Unique source,SARS-CoV-2,2,1,-0.7502596,6.0475216
6LNT_P_Q,QVQLVQSGAEVKKPGASLKVSCKASGYTFTSYGLSWVRQAPGQGLEWMGWITPYNGNTKYTQKLQGRVTMTTDTSTSTVYMELRSLRSDDTAVYYCARDSGTYAFYFDYWGQGTLVTVSS,SYELTQPLSVSVALGQTASITCGGNNIGSKNVHWYQQKPGQAPVLVIYKYVNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTYVFGTGTKVTVL,6LNT_P,6LNT_Q,Cryo-Em Structure Of Immature Zika Virus In Complex With Human Antibody Dv62.5 Fab,Cryo-Em Structure Of Immature Zika Virus In Complex With Human Antibody Dv62.5 Fab,Homo sapiens,"Tan,T.Y.;Fibriansah,G.;Kostyuchenko,V.A.;Ng,T.S.;Lim,X.X.;Zhang,S.;Lim,X.N.;Wang,J.;Shi,J.;Morais,M.C.;Corti,D.;Lok,S.M.",Capsid protein structure in Zika virus reveals the flavivirus assembly process,02-JAN-2020,8_8_13_6_3_9,6LNT_P_Q,Xtal structure,Zika,2,1,1.8585732,5.2338157
7JTF_A_B,QVQLVQSGAEVKKPGASVKLSCKASGFTFRIYAISWVRQAPGQGLEWMGEIVPLGGITNYAQNFQGRAAITADTSINTAYMELSSLRSDDTAVYYCARVRTALVGPREGIFDFWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVSITCRASQTISTYLAWYQQKPGKVPKLLIYTASTLETGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHDSHPYSFGQGTKVEIK,7JTF_A,7JTF_B,Structure Of Hepatitis C Virus Envelope Glycoprotein E2 Core From Genotype 6A Bound To Broadly Neutralizing Antibody Rm2-01,Structure Of Hepatitis C Virus Envelope Glycoprotein E2 Core From Genotype 6A Bound To Broadly Neutralizing Antibody Rm2-01,Recombinant Hepatitis C virus HK6a/JFH-1,"Tzarum,N.;Chen,F.;Lin,X.;Giang,E.;Velazquez-Moctezuma,R.;Augestad,E.H.;Nagy,K.;He,L.;Davidson,E.;Chavez,D.;Prentoe,J.;Stanfield,R.L.;Lanford,R.;Bukh,J.;Wilson,I.A.;Zhu,J.;Law,M.",HCV Env immunization elicits a rapid VH1-69-like broadly neutralizing antibody response in rhesus macaques,17-AUG-2020,8_8_17_6_3_9,7JTF_A_B,Xtal structure,Hepatitis; HCV,2,1,-0.3649794,5.646179
QPI12137_QPI12165,QVQLVQSGAEVKKPGASVKLSCKASGYAFTIYSINWVRQAPGQGLEWMGWINPRNGRIGYAQKFQGRVTMTRDTSTSIAYMELGSLRSEDTAVYFCARGRLELTASHFDNWGQGVPVTVSS,DIVMTQTPLSLPVTPGEPAAISCRSSQSLLDRADGNTYLDWYLQKPGQSPQLLIYEVSNRASGVPDRFSGSGSDTDFTLKISRVEAEDVGVYYCMQGLEFPYSFGQGTKVEIK,QPI12137,QPI12165,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin kappa light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Roark,R.S.; Li,H.; Williams,W.B.; Chug,H.; Mason,R.D.; Gorman,J.; Wang,S.; Lee,F.H.; Rando,J.; Bonsignori,M.; Hwang,K.K.; Saunders,K.O.; Wiehe,K.; Moody,M.A.; Hraber,P.T.; Wagh,K.; Giorgi,E.E.; Russell,R.M.; Bibollet-Ruche,F.; Liu,W.; Connell,J.; Smith,A.G.; DeVoto,J.; Murphy,A.I.; Smith,J.; Ding,W.; Zhao,C.; Chohan,N.; Okumura,M.; Rosario,C.; Ding,Y.; Lindemuth,E.; Bauer,A.M.; Bar,K.J.; Ambrozak,D.; Chao,C.W.; Chuang,G.Y.; Geng,H.; Lin,B.C.; Louder,M.K.; Nguyen,R.; Zhang,B.; Lewis,M.G.; Raymond,D.; Doria-Rose,N.A.; Schramm,C.A.; Douek,D.C.; Roederer,M.; Kepler,T.B.; Kelsoe,G.; Mascola,J.R.; Kwong,P.D.; Korber,B.T.; Harrison,S.C.; Haynes,B.F.; Hahn,B.H.; Shaw,G.M.",Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth,29-NOV-2020,8_8_14_12_3_9,QPI12137_QPI12165,Unique source,HIV,2,1,2.0568259,4.3186193
7DET_D_D,QVQLVQSGAEVKKPGASVKLSCKASGYSFTSYWVNWVRQAPGQGLEWIGMIHPSDSETRLNQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCARADGYEWYFDVWGRGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSGTDFTLTINPVEANDVANYYCQQSNEDPWTFGQGTKVEIK,7DET_D,7DET_D,Crystal Structure Of Sars-Cov-2 Rbd In Complex With A Neutralizing Antibody Scfv,Crystal Structure Of Sars-Cov-2 Rbd In Complex With A Neutralizing Antibody Scfv,Mus musculus,"Fu,D.;Zhang,G.;Wang,Y.;Zhang,Z.;Hu,H.;Shen,S.;Wu,J.;Li,B.;Li,X.;Fang,Y.;Liu,J.;Wang,Q.;Zhou,Y.;Wang,W.;Li,Y.;Lu,Z.;Wang,X.;Nie,C.;Tian,Y.;Chen,D.;Wang,Y.;Zhou,X.;Wang,Q.;Yu,F.;Zhang,C.;Deng,C.;Zhou,L.;Guan,G.;Shao,N.;Lou,Z.;Deng,F.;Zhang,H.;Chen,X.;Wang,M.;Liu,L.;Rao,Z.;Guo,Y.",Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes,05-NOV-2020,8_8_12_10_3_9,7DET_D_D,Xtal structure,SARS-CoV-2,2,1,0.7965352,3.7400925
7N8Q_H_L,QVQLVQSGAEVKKPGASVKLSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPKTGNTGYAQKFQGRVTMTRDTSTSTAYMELSSLRSEDTAVYYCATYRIIAAVGYRYFQYWGQGALVTVSS,AIQMTQSPSSLSASVGDKVTITCRASQGFGNYLAWYQQKPGKVPKLLIYAATTLQSEVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPFTFGQGTRLEIK,7N8Q_H,7N8Q_L,Rhesusized Rv305 Dh677.3 Fab Bound To Clade A/E 93Th057 Hiv-1 Gp120 Core.,Rhesusized Rv305 Dh677.3 Fab Bound To Clade A/E 93Th057 Hiv-1 Gp120 Core.,Macaca mulatta,"Tolbert,W.D.;Nguyen,D.N.;Tuyishime,M.;Crowley,A.R.;Chen,Y.;Jha,S.;Goodman,D.;Bekker,V.;Mudrak,S.V.;DeVico,A.L.;Lewis,G.K.;Theis,J.F.;Pinter,A.;Moody,M.A.;Easterhoff,D.;Wiehe,K.;Pollara,J.;Saunders,K.O.;Tomaras,G.D.;Ackerman,M.;Ferrari,G.;Pazgier,M.",Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s,15-JUN-2021,8_8_16_6_3_9,7N8Q_H_L,Xtal structure,HIV,2,1,2.0184548,4.241844
6DB7_I_M,QVQLVQSGAEVKKPGASVKVSCEASGYTFAKFAIHWVRQAPRQGLEWMGWINGDDGKTEYSQKFQDRVTMTRDTSASTVYMELSSLRSEDTALYYCARAMYPDTVTGNDNPAPPPFEGDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKEYAYWYQQKSGQAPVLVIYEDTRRPSGIPERFSGSSSGTMATLTVSGAHVDDEADYYCYSRDTSANQWVFGGGTKLTVL,6DB7_I,6DB7_M,Crystal Structure Of Anti-Hiv-1 V3 Fab 1334 In Complex With A Hiv-1 Gp120 V3 Peptide From Mn Strain,Crystal Structure Of Anti-Hiv-1 V3 Fab 1334 In Complex With A Hiv-1 Gp120 V3 Peptide From Mn Strain,Human immunodeficiency virus 1,"Chan,K.W.;Pan,R.;Costa,M.;Gorny,M.K.;Wang,S.;Lu,S.;Kong,X.P.",Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection,02-MAY-2018,8_8_24_6_3_11,6DB7_I_M,Xtal structure,gp120; HIV,2,1,0.2941933,3.147425
6T3J_C_D,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTKVEIK,6T3J_C,6T3J_D,Dual Epitope Targeting By Anti-Dr5 Antibodies,Dual Epitope Targeting By Anti-Dr5 Antibodies,Homo sapiens,"Overdijk,M.B.;Strumane,K.;Beurskens,F.J.;Ortiz Buijsse,A.;Vermot-Desroches,C.;Vuillermoz,B.S.;Kroes,T.;de Jong,B.;Hoevenaars,N.;Hibbert,R.G.;Lingnau,A.;Forssmann,U.;Schuurman,J.;Parren,P.W.;de Jong,R.N.;Breij,E.C.",Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism,11-OCT-2019,8_8_11_5_3_9,QNB72485_QNB72486,Xtal structure,KILLER; DR5; TRAILR2; TRICKB; CD262; TNFRSF10B; TRICK2A; TRAIL-R2,2,1,0.6432735,3.4768195
8F0L_H_L,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQRLEWMGWIDLENANTIYDAKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDAYGRYFYDVWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNARTGKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYSRRTFGGGTKVEIK,8F0L_H,8F0L_L,Crystal Structure Of The Human T Cell Receptor Cd3(Epsilon) N-Terminal Peptide Complexed With Adi-26906 Fab,Crystal Structure Of The Human T Cell Receptor Cd3(Epsilon) N-Terminal Peptide Complexed With Adi-26906 Fab,Homo sapiens,"Liu,C.Y.;Ahonen,C.L.;Brown,M.E.;Zhou,L.;Welin,M.;Krauland,E.M.;Pejchal,R.;Widboom,P.F.;Battles,M.B.",Structure-based engineering of a novel CD3&#x3b5;-targeting antibody for reduced polyreactivity,29-MAR-2023,8_8_12_12_3_8,8F0L_H_L,Xtal structure,CD3,2,1,0.7022695,3.3867626
UPX75909_UPX76319,QVQLVQSGAEVKKPGASVKVSCKASGFPFTVYTIHWVRQAPGQRLEWVGWINVGNGNTRYSQKFQVRVTITRDTSASTVYMELSRLRSEDTAVYYCARGNSYYFDYWGQGTLVTVSS,QPVLTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDTKRPSGIPERYSGSNSGNTATLTISGTQAMDEADYYCQAWDSSHVVFGGGTKVTVL,UPX75909,UPX76319,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Laura,W.",Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination,10-MAY-2022,8_8_10_6_3_9,UPX75909_UPX76319,Unique source,SARS-CoV-2,2,1,0.37910187,3.2163553
6PBV_D_C,QVQLVQSGAEVKKPGASVKVSCKASGFTFTDYAMHWVRQAPGQRLEWMGWINAGNGYTKYSQKFQDRLTITRDTFASTVYMELSSLRSEDTTVYYCARDGFCPSNTCSGYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVSWYQQHPGKAPKLMIYDVNTRPSGVSIRFSASKSGNTASLTVSGLQAEDEAVYYCSSYAGSSTWVFGGGTKLTVL,6PBV_D,6PBV_C,Crystal Structure Of Fab668 Complex,Crystal Structure Of Fab668 Complex,Plasmodium falciparum 3D7,"Oyen,D.;Torres,J.L.;Aoto,P.C.;Flores-Garcia,Y.;Binter,S.;Pholcharee,T.;Carroll,S.;Reponen,S.;Wash,R.;Liang,Q.;Lemiale,F.;Locke,E.;Bradley,A.;King,C.R.;Emerling,D.;Kellam,P.;Zavala,F.;Ward,A.B.;Wilson,I.A.",Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein,14-JUN-2019,8_8_19_9_3_10,UCW47907_UCW47911,Xtal structure,circumsporozoite,2,1,0.253892,3.1492333
5I5K_X_Y,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,5I5K_X,5I5K_Y,Structure Of Complement C5 In Complex With Eculizumab,Structure Of Complement C5 In Complex With Eculizumab,Homo sapiens,"Schatz-Jakobsen,J.A.;Zhang,Y.;Johnson,K.;Neill,A.;Sheridan,D.;Andersen,G.R.",Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway,15-FEB-2016,8_8_15_6_3_9,UOS82532,Xtal structure,,2,1,1.2555594,3.983622
7FCP_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYIFTSYSMHWVRQAPGQGLEWMGTIKPSDDSTNYAQKFQGRVSMTRDTSTSTVYMELSSLRYEDTAVYYCAREARGYYDRSGYYHPGYFDYWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYEVSDRPSGVSSRFSGSKSGNTASLTISGLQAEDEADYYCFSYTTSTTWVFGGGTKLTVL,7FCP_H,7FCP_L,Crystallographic Structure Of Two Neutralizing Antibodies In Complex With Sars-Cov-2 Spike Receptor-Binding Domain (Rbd),Crystallographic Structure Of Two Neutralizing Antibodies In Complex With Sars-Cov-2 Spike Receptor-Binding Domain (Rbd),Homo sapiens,"Zou,J.;Li,L.;Zheng,P.;Liang,W.;Hu,S.;Zhou,S.;Wang,Y.;Zhao,J.;Yuan,D.;Liu,L.;Wu,D.;Xu,M.;Zhang,F.;Zhu,M.;Wu,Z.;Cao,X.;Ni,M.;Ling,X.;Wu,Y.;Kuang,Z.;Hu,M.;Li,J.;Li,X.;Guo,X.;Xu,T.;Jiang,H.;Gao,C.;Yu,M.;Liu,J.;Zhong,N.;Zhou,J.;Huang,J.A.;Jin,T.;He,J.",Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance,15-JUL-2021,8_8_21_9_3_10,7FCP_H_L,Xtal structure,SARS-CoV-2,2,1,1.7703079,3.5529535
7AMR_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYKFTGFVMHWVRQAPGQGLEWMGFINPYNDDIQSNERFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGNGYNFDGAYRFFDFWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQRLVHSNGNTYLHWYLQKPGQSPRLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKLEIK,7AMR_H,7AMR_L,Crystal Structure Of The Complex Of The Kfn Mutant Of Jovi-1 Fab With Human Trbc1,Crystal Structure Of The Complex Of The Kfn Mutant Of Jovi-1 Fab With Human Trbc1,Homo sapiens,"Ferrari,M.;Baldan,V.;Wawrzyniecka,P.;Bulek,A.;Kinna,A.;Ma,B.;Bugda,R.;Akbar,Z.;Srivast,S.;Ghongane,P.;Gannon,I.;Robson,M.;Sillibourne,J.;Jha,R.;Lim,W.;Hopkins,J.;Welin,M.;Surade,S.;Dyson,M.;Pule,M.",Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies,09-OCT-2020,8_8_17_11_3_9,7AMR_H_L,Xtal structure,TCRBC2; TRBC1; TCRBC1; BV05S1J2.2; TRBC2,2,1,2.233409,3.7330484
5VQM_D_C,QVQLVQSGAEVKKPGASVKVSCKASGYPFTNYFMHWVRQAPGQRLEWIGRINPYNGATSYSLNFRDKATITLDKSASTAYMELSSLRSEDTAVYYCARSTITSPLLDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGTSIHWYQQKPGQAPRLLIKFASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNKWPFTFGQGTKLEIK,5VQM_D,5VQM_C,Clostridium Difficile Tcdb-Gtd Bound To Pa41 Fab,Clostridium Difficile Tcdb-Gtd Bound To Pa41 Fab,Homo sapiens,"Kroh,H.K.;Chandrasekaran,R.;Zhang,Z.;Rosenthal,K.;Woods,R.;Jin,X.;Nyborg,A.C.;Rainey,G.J.;Warrener,P.;Melnyk,R.A.;Spiller,B.W.;Lacy,D.B.",A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells,09-MAY-2017,8_8_12_6_3_9,AKX39986_AKX39987,Xtal structure,TcdB,2,1,0.5997633,3.5240471
ANY91869_ANY91264,QVQLVQSGAEVKKPGASVKVSCKASGYSFSSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVFYCARDRPHILTGFDFDYWGQGTLVTVSS,DVVMTQSPVSLPVTLGQPASISCRSSQGLVYIDGNTYLNWFQQRPGQSPRRLIYNVFTRDSGVPDRFSGSGSGTDFTLKITTVEAEDVGVYYCMQGTHWPYTFGQGTKLEIK,ANY91869,ANY91264,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_15_11_3_9,ANY91869_ANY91264,Unique source,Influenza,2,1,1.8203654,5.337561
QKY76293_QKY75906,QVQLVQSGAEVKKPGASVKVSCKASGYTFGSFDINWVRQATGQGLEWMGRMNSNSGNTAYAQKFQGRVTMTRDTSTNTAYMELSSLRSEDTAMYYCARMRSGWPTHGRPDDFWGRGTLVTVSS,QSVLTQAPSASGTPGQRVTISCSGSNSNIGSYTINWYQQLPGTAPKLLIYGNDQRTSGVPDRFSGSKFGTSASLAISGLQSEDENNYYCAVWDDSLNGLVFGGGTKLTVL,QKY76293,QKY75906,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_16_8_3_11,QKY76293_QKY75906,Unique source,SARS-CoV-2,2,1,1.9652812,4.10915
ANV21803_ANV21992,QVQLVQSGAEVKKPGASVKVSCKASGYTFKTFDIHWVRQAPGQGLEWLGIINPSAGTIIYAQKFQGRLTVTRDTSTSIVYMELSSLRSEDTAVYYCAREKLDRRREFDYWGQGTLVTVSS,DIQMTQSPSSLSAFVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYVASSLQRGVPSRFSDSGSGTEFTLTISSLQPEDFATYYCLQHYSYPYTFGQGTKLEIK,ANV21803,ANV21992,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_13_6_3_9,ANV21803_ANV21992,Unique source,,2,1,1.5447165,3.9727926
7ST5_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK,7ST5_H,7ST5_L,Structure Of Fab Cc-95251 In Complex With Sirp-Alpha,Structure Of Fab Cc-95251 In Complex With Sirp-Alpha,Homo sapiens,"Fenalti,G.","Discovery and preclinical activity of CC-95251, a SIRP-alpha antibody mediating tumor cell phagocytosis, in combination with target therapies",17-MAY-2023,8_8_13_6_3_9,Anzurstobart,Xtal structure,SHPS-1; SIRPalpha; SIRPalpha2; PTPNS1; SIRPA; SIRP; CD172a; SIRP-ALPHA-1; MFR; MYD-1; BIT; SHPS1; P84,2,1,1.9389622,5.1997848
QKK35550_QKK35551,QVQLVQSGAEVKKPGASVKVSCKASGYTFSLFHVHWVRQAPGQGLEWMGWINPHNGDTTFAERFQGRVALTRDTSINTAYMELSRLTSDDTAVYFCARDFGVRYDDSRQLMKYCDSWGQGTLVTVSS,NFMLTQPHSVSESPGKAVIISCTRSSGNIASNFVQWYQQRPGSSPTPVIYEDKLRPSGVPDRFSGSIDRSSNSASLTISGLKTEDEADYYCQSYDSGNLVVFGGGTKLTVL,QKK35550,QKK35551,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_20_8_3_10,QKK35550_QKK35551,Unique source,SARS-CoV-2,2,1,2.3048124,3.578052
7T5O_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFSSYDINWVRQAPGQGLEWMGWMSPNSGNTGYAQKFQGRVTMTRSTSMSTAYMELSSLRSEDTAVYFCARMSSSLTNYLDYWGQGTLVTVSS,SYVLTQPPSVAVAPGQTARIRCGENDIGSKNVHWYQQKSGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSTGDHPDVVFGGGTKLTVL,7T5O_H,7T5O_L,Vflip Spike Trimer With Gar03,Vflip Spike Trimer With Gar03,Homo sapiens,"Sobti,M.;Stewart,A.G.;Rouet,R.;Langley,D.B.",VFLIP Spike Trimer with GAR03,25-JAN-2023,8_8_13_6_3_13,7T5O_H_L,Xtal structure,,2,1,2.0584207,4.258506
QKK35500_QKK35501,QVQLVQSGAEVKKPGASVKVSCKASGYTFSSYDINWVRQATGQGLEWMGWMSPNTGDTGYAHKFQGRVRMTSNTSISTAYMELNSLTSEDTAVYYCARRGNNFGYYYYYTVDVWGQGTTVTVSS,DIRLTQSPSSLSASVGDRVTIACRASQSVSNYLNWYQQKPGKAPKLLIYAASSLQNGVPSRFGGSGSGTDFTLTISSLQPEDFATYYCQQCYSYPPTFGHGTKVEIK,QKK35500,QKK35501,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_6_3_9,QKK35500_QKK35501,Unique source,SARS-CoV-2,2,1,2.090022,4.273364
5UMI_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQRLEWMGDINPKYDIIGHNPKFMGRVTITRDTSASTAYMELSSLRSEDTAVYYCARSDRGWYFDVWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVNYMNWYQQKPGQAPRPLIYATSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSRTFGGGTKLEIK,5UMI_A,5UMI_B,Clostridium Difficile Tcda-Crops Bound To Pa50 Fab,Clostridium Difficile Tcda-Crops Bound To Pa50 Fab,Homo sapiens,"Kroh,H.K.;Chandrasekaran,R.;Rosenthal,K.;Woods,R.;Jin,X.;Ohi,M.D.;Nyborg,A.C.;Rainey,G.J.;Warrener,P.;Spiller,B.W.;Lacy,D.B.",Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface,27-JAN-2017,8_8_11_5_3_7,5UMI_A_B,Xtal structure,TcdA,2,1,0.9818759,3.562339
4YHM_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTGFTLKISRVEAEDVGVYYCFQASHVPYTFGGGTKLEIK,4YHM_H,4YHM_L,Reversal Agent For Dabigatran,Reversal Agent For Dabigatran,Homo sapiens,"Schiele,F.;van Ryn,J.;Litzenburger,T.;Ritter,M.;Seeliger,D.;Nar,H.",Structure-guided residence time optimization of a dabigatran reversal agent,27-FEB-2015,8_8_12_11_3_9,ATJ22419_ATJ22422,Xtal structure,,2,1,1.0023404,3.7168634
QKY76295_QKY75908,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWINPNSRGTNYAQKFQGRVTMTRDTSISTVYMELSRLTSDDTAVYYCARVVVLGYGRPNNYYDGRNVWDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVIISCSGSSSNIGSNTVKWYHQLPGTAPKLLICSNNQRPSGVPDRFSGSKSDTSASLAISGLQSEDEADYYCAAWDDSLNALVFGGGTKLTVL,QKY76295,QKY75908,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_23_8_3_11,QKY76295_QKY75908,Unique source,SARS-CoV-2,2,1,2.370682,3.377203
QKK35712_QKK35713,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYVHWVRQVPGQGLEWMGWISPDSGDTIRAQNFQGRVTMTRDTSMNTAYMEVNRLRTDDTAIYYCARDLISVIRGLGGGMDVWGQGTTVTVSS,DIQVTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWHPITFGQGTRLEIK,QKK35712,QKK35713,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_6_3_10,QKK35712_QKK35713,Unique source,SARS-CoV-2,2,1,2.1265085,3.5994854
7UA8_H_H,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEYYMHWVRQAPGQGLEWMGWINPKSGDTKFPQRFQGRVTLTRDTSISTVYMELTRLRSDDTAVYYCARGNFRDYYFASWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNINIYLNWYQQKPGKAPKLLIYAASSLQSGVPSTFSGSGSGTDFALTISSLQPEDFATYYCQQSYSSPLTFGGGTKVEIK,7UA8_H,7UA8_H,Pfs230 D1 Domain In Complex With 230Al-20,Pfs230 D1 Domain In Complex With 230Al-20,Homo sapiens,"Tang,W.K.;Coelho,C.H.;Miura,K.;Nguemwo Tentokam,B.C.;Salinas,N.D.;Narum,D.L.;Healy,S.A.;Sagara,I.;Long,C.A.;Duffy,P.E.;Tolia,N.H.",A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine,15-FEB-2023,8_8_12_6_3_9,7UA8_H_H,Xtal structure,Pfs230D1,2,1,2.3849177,3.983197
UOH21948_UOH22326,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGHFMHWVRQAPGQGLEWMGWINPNSGGPNYAQQFQGRVTLTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIK,UOH21948,UOH22326,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Lee,J.H.; Nakao,C.; Appel,M.; Le,A.; Landais,E.; Kalyuzhniy,O.; Hu,X.; Liguori,A.; Mullen,T.M.; Groschel,B.; Abbott,R.K.; Sok,D.; Schief,W.R.; Crotty,S.",Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer,11-APR-2022,8_8_14_6_3_5,UOH21948_UOH22326,Unique source,HIV,2,1,2.6058197,4.1165905
QOQ51841_QOQ51808,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYHMNWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQENYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYKFGGGTKLEIK,QOQ51841,QOQ51808,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Lin,Y.R.; Parks,K.R.; Weidle,C.; Naidu,A.S.; Khechaduri,A.; Riker,A.O.; Takushi,B.; Chun,J.H.; Borst,A.J.; Veesler,D.; Stuart,A.; Agrawal,P.; Gray,M.; Pancera,M.; Huang,P.S.; Stamatatos,L.",HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors,28-OCT-2020,8_8_14_12_3_5,QOQ51841_QOQ51808,Unique source,HIV,2,1,2.5811167,4.1556964
7AMQ_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYVMHWVRQAPGQGLEWMGFINPYNDDIQSNERFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGAGYNFDGAYRFFDFWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQRLVHSNGNTYLHWYLQKPGQSPRLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKLEIK,7AMQ_H,7AMQ_L,Crystal Structure Of The Complex Of Hujovi-1 Fab With The Human Trbc2,Crystal Structure Of The Complex Of Hujovi-1 Fab With The Human Trbc2,Homo sapiens,"Ferrari,M.;Baldan,V.;Wawrzyniecka,P.;Bulek,A.;Kinna,A.;Ma,B.;Bugda,R.;Akbar,Z.;Srivast,S.;Ghongane,P.;Gannon,I.;Robson,M.;Sillibourne,J.;Jha,R.;Lim,W.;Hopkins,J.;Welin,M.;Surade,S.;Dyson,M.;Pule,M.",Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies,09-OCT-2020,8_8_17_11_3_9,7AMQ_H_L,Xtal structure,TCRBC2; TRBC1; TCRBC1; BV05S1J2.2; TRBC2,2,1,2.2598822,3.7216914
QOQ51840_QOQ51807,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMDWVRQAPGQGLEWMGWINPKSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKDSDYNWDFQHWGQGTLVTVSS,DIVMSQSPSSLAVSIGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYETFGGGTKLEIK,QOQ51840,QOQ51807,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Lin,Y.R.; Parks,K.R.; Weidle,C.; Naidu,A.S.; Khechaduri,A.; Riker,A.O.; Takushi,B.; Chun,J.H.; Borst,A.J.; Veesler,D.; Stuart,A.; Agrawal,P.; Gray,M.; Pancera,M.; Huang,P.S.; Stamatatos,L.",HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors,28-OCT-2020,8_8_14_12_3_5,QOQ51840_QOQ51807,Unique source,HIV,2,1,2.5381513,4.088269
CAO78305,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSIGTVYMELSSLTSDDTAMYYCARNNVAMGYTMDVWGQGTMVTVSS,QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKTPKLLIYEVSSRPSGVSNRFSGSKPGNTASLTISGLQAEDEADYYCISYTSSNTWVFGGGTQLTVL,CAO78305_H,CAO78305_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_13_9_3_10,AEN51974,Same entry,,2,1,2.137677,3.6654277
5TGB_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDGWYSSGWYFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIK,5TGB_H,5TGB_L,"Structure Of Chimeric 02-Cb Fab, A Vrc01-Like Germline Antibody","Structure Of Chimeric 02-Cb Fab, A Vrc01-Like Germline Antibody",Homo sapiens,"Yacoob,C.;Pancera,M.;Vigdorovich,V.;Oliver,B.G.;Glenn,J.A.;Feng,J.;Sather,D.N.;McGuire,A.T.;Stamatatos,L.",Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors,27-SEP-2016,8_8_14_6_3_5,5TGB_H_L,Xtal structure,HIV,2,1,2.1552978,3.6651564
5O7P_B_A,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,5O7P_B,5O7P_A,Her3 In Complex With Fab Mf3178,Her3 In Complex With Fab Mf3178,Homo sapiens,"Geuijen,C.A.;De Nardis,C.;Maussang,D.;Rovers,E.;Gallenne,T.;Hendriks,L.J.;Visser,T.;Nijhuis,R.;Logtenberg,T.;de Kruif,J.;Gros,P.;Throsby,M.",Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade,09-JUN-2017,8_8_17_6_3_9,QRK74523_QRK74521,Xtal structure,LCCS2; p185(erbB2); ERBB2; HER2; NGL; c-ERB2; HER3; NEU; ERBB3; HER-2; CD340; MLN-19; c-ERB-2,2,1,2.132345,3.5863495
UZP82083_UZP82084,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARERNWGVPDAFDIWGQGTMVTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREDPYTFGGGTKLEIK,UZP82083,UZP82084,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Caradonna,T.M.; Ronsard,L.; Yousif,A.S.; Windsor,I.W.; Hecht,R.; Bracamonte-Moreno,T.; Roffler,A.A.; Maron,M.J.; Maurer,D.P.; Feldman,J.; Marchiori,E.; Barnes,R.M.; Rohrer,D.; Lonberg,N.; Oguin,T.H. III; Sempowski,G.D.; Kepler,T.B.; Kuraoka,M.; Lingwood,D.; Schmidt,A.G.",An epitope-enriched immunogen expands responses to a conserved viral site,23-NOV-2022,8_8_14_10_3_9,UZP82083_UZP82084,Unique source,,2,1,2.259486,3.6898623
5U15_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGTLVTVS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVIFGGGTKLTVL,5U15_A,5U15_B,Crystal Structure Of Dh270.Uca3 (Unliganded) From The Dh270 Broadly Neutralizing N332-Glycan Dependent Lineage,Crystal Structure Of Dh270.Uca3 (Unliganded) From The Dh270 Broadly Neutralizing N332-Glycan Dependent Lineage,Homo sapiens,"Bonsignori,M.;Kreider,E.F.;Fera,D.;Meyerhoff,R.R.;Bradley,T.;Wiehe,K.;Alam,S.M.;Aussedat,B.;Walkowicz,W.E.;Hwang,K.K.;Saunders,K.O.;Zhang,R.;Gladden,M.A.;Monroe,A.;Kumar,A.;Xia,S.M.;Cooper,M.;Louder,M.K.;McKee,K.;Bailer,R.T.;Pier,B.W.;Jette,C.A.;Kelsoe,G.;Williams,W.B.;Morris,L.;Kappes,J.;Wagh,K.;Kamanga,G.;Cohen,M.S.;Hraber,P.T.;Montefiori,D.C.;Trama,A.;Liao,H.X.;Kepler,T.B.;Moody,M.A.;Gao,F.;Danishefsky,S.J.;Mascola,J.R.;Shaw,G.M.;Hahn,B.H.;Harrison,S.C.;Korber,B.T.;Haynes,B.F.",Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies,27-NOV-2016,8_8_20_9_3_10,5U15_A_B,Xtal structure,HIV,2,1,2.5431232,3.1277745
WAM57656_WAM57892,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARPGTGWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDVATYYCQQYETFGGGTKLEIK,WAM57656,WAM57892,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Jing,C.; Ye,A.Y.; Kratochvil,S.; Cottrell,C.A.; Jahyun,K.; Williams,A.C.; Francisco,L.V.; Batra,H.; Edward,L.; Zhang,Y.; Barbieri,A.; Manis,J.P.; Haynes,B.F.; Schief,W.R.; Batista,F.D.; Tian,M.",Humanized V(D)J-rearranging and TdT-expressing Mouse Vaccine Models with Physiological HIV-1 Broadly Neutralizing Antibody Precursors,17-DEC-2022,8_8_11_6_3_5,WAM57656_WAM57892,Unique source,HIV,2,1,2.0833848,3.787129
8E1P_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRMRSQDREWDFQHWGQGTLVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEEDADYYCSSYEFFGGGTKVFVL,8E1P_H,8E1P_L,Crystal Structure Of Bg505 Sosip.V4.1-Gt1.2 Trimer In Complex With Gl-Pgv20 And Pgt124 Fabs,Crystal Structure Of Bg505 Sosip.V4.1-Gt1.2 Trimer In Complex With Gl-Pgv20 And Pgt124 Fabs,Human immunodeficiency virus 1,"Caniels,T.G.;Medina-Ram&#xed;rez,M.;Zhang,J.;Sarkar,A.;Kumar,S.;LaBranche,A.;Derking,R.;Allen,J.D.;Snitselaar,J.L.;Capella-Pujol,J.;S&#xe1;nchez,I.D.M.;Yasmeen,A.;Diaz,M.;Aldon,Y.;Bijl,T.P.L.;Venkatayogi,S.;Martin Beem,J.S.;Newman,A.;Jiang,C.;Lee,W.H.;Pater,M.;Burger,J.A.;van Breemen,M.J.;de Taeye,S.W.;Rantalainen,K.;LaBranche,C.;Saunders,K.O.;Montefiori,D.;Ozorowski,G.;Ward,A.B.;Crispin,M.;Moore,J.P.;Klasse,P.J.;Haynes,B.F.;Wilson,I.A.;Wiehe,K.;Verkoczy,L.;Sanders,R.W.",Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions,08-JAN-2009,8_8_15_9_3_5,8E1P_H_L,Xtal structure,HIV,2,1,2.4694097,3.9574962
4HK0_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGLEPRSVDYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,4HK0_A,4HK0_B,Uca Fab (Unbound) From Ch65-Ch67 Lineage,Uca Fab (Unbound) From Ch65-Ch67 Lineage,Homo sapiens,"Schmidt,A.G.;Xu,H.;Khan,A.R.;O'Donnell,T.;Khurana,S.;King,L.R.;Manischewitz,J.;Golding,H.;Suphaphiphat,P.;Carfi,A.;Settembre,E.C.;Dormitzer,P.R.;Kepler,T.B.;Zhang,R.;Moody,M.A.;Haynes,B.F.;Liao,H.X.;Shaw,D.E.;Harrison,S.C.",Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody,14-OCT-2012,8_8_19_6_3_11,QWX37043_QWX37044,Xtal structure,,2,1,2.1666253,3.5767145
7WC0_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARGWATYYDILTGYSLFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTPHVVFGGGTKLTVL,7WC0_H,7WC0_L,Crystal Structure Of Fab Region Of Tau-2212 Neutralizing Sars-Cov-2,Crystal Structure Of Fab Region Of Tau-2212 Neutralizing Sars-Cov-2,Homo sapiens,"Li,R.;Mor,M.;Ma,B.;Clark,A.E.;Alter,J.;Werbner,M.;Lee,J.C.;Leibel,S.L.;Carlin,A.F.;Dessau,M.;Gal-Tanamy,M.;Croker,B.A.;Xiang,Y.;Freund,N.T.",Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies,10-AUG-2022,8_8_19_9_3_12,7WC0_H_L,Xtal structure,SARS-CoV-2,2,1,2.4163718,3.2526083
AOR52395_AOR52396,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARRGYSGYDWFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNFGQGTKVEIK,AOR52395,AOR52396,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sok,D.; Briney,B.; Jardine,J.G.; Kulp,D.W.; Menis,S.; Pauthner,M.; Wood,A.; Lee,E.-C.; Le,K.M.; Jones,M.; Ramos,A.; Kalyuzhniy,O.; Adachi,Y.; Kubitz,M.; MacPherson,S.; Bradley,A.; Friedrich,G.A.; Schief,W.R.; Burton,D.R.",Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice,21-FEB-2019,8_8_13_6_3_5,AOR52395_AOR52396,Ordered entries,HIV,2,1,2.2173338,3.679356
AOR52362_AOR52361,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARVFYGSGSYWYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFETFGPGTKVEIK,AOR52362,AOR52361,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sok,D.; Briney,B.; Jardine,J.G.; Kulp,D.W.; Menis,S.; Pauthner,M.; Wood,A.; Lee,E.-C.; Le,K.M.; Jones,M.; Ramos,A.; Kalyuzhniy,O.; Adachi,Y.; Kubitz,M.; MacPherson,S.; Bradley,A.; Friedrich,G.A.; Schief,W.R.; Burton,D.R.",Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice,21-FEB-2019,8_8_15_7_3_5,AOR52362_AOR52361,Ordered entries,HIV,2,1,2.2159274,3.6690068
QOQ51835_QOQ51802,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMNWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYEMFGGGTKLEIK,QOQ51835,QOQ51802,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Lin,Y.R.; Parks,K.R.; Weidle,C.; Naidu,A.S.; Khechaduri,A.; Riker,A.O.; Takushi,B.; Chun,J.H.; Borst,A.J.; Veesler,D.; Stuart,A.; Agrawal,P.; Gray,M.; Pancera,M.; Huang,P.S.; Stamatatos,L.",HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors,28-OCT-2020,8_8_14_12_3_5,QOQ51835_QOQ51802,Unique source,HIV,2,1,2.5756178,4.0846357
QOQ51836_QOQ51803,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMNWVRQAPGQGLEWMGWINPKSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNEKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYETFGGGTKLEIK,QOQ51836,QOQ51803,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Lin,Y.R.; Parks,K.R.; Weidle,C.; Naidu,A.S.; Khechaduri,A.; Riker,A.O.; Takushi,B.; Chun,J.H.; Borst,A.J.; Veesler,D.; Stuart,A.; Agrawal,P.; Gray,M.; Pancera,M.; Huang,P.S.; Stamatatos,L.",HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors,28-OCT-2020,8_8_14_12_3_5,QOQ51836_QOQ51803,Unique source,HIV,2,1,2.5423038,4.106434
QOQ51842_QOQ51809,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMNWVRQAPGQGLEWMGWINPNNGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVSS,DIVMSQSPSSLAVSVGEKVTMNCKSSQSLLYSSNQENYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYKFGGGTKLEIK,QOQ51842,QOQ51809,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Lin,Y.R.; Parks,K.R.; Weidle,C.; Naidu,A.S.; Khechaduri,A.; Riker,A.O.; Takushi,B.; Chun,J.H.; Borst,A.J.; Veesler,D.; Stuart,A.; Agrawal,P.; Gray,M.; Pancera,M.; Huang,P.S.; Stamatatos,L.",HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors,28-OCT-2020,8_8_14_12_3_5,QOQ51842_QOQ51809,Unique source,HIV,2,1,2.5630312,4.142514
QOQ51838_QOQ51805,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMNWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVSS,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTASGSGTDFTLTISSVKAEDLALYYCQQYYKFGAGTKLEIK,QOQ51838,QOQ51805,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Lin,Y.R.; Parks,K.R.; Weidle,C.; Naidu,A.S.; Khechaduri,A.; Riker,A.O.; Takushi,B.; Chun,J.H.; Borst,A.J.; Veesler,D.; Stuart,A.; Agrawal,P.; Gray,M.; Pancera,M.; Huang,P.S.; Stamatatos,L.",HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors,28-OCT-2020,8_8_14_12_3_5,QOQ51838_QOQ51805,Unique source,HIV,2,1,2.5062177,4.0845985
QKK35638_QKK35639,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNDGFVWVRQAPGQVPEWMGWISVHTGDTIYAQRFQGRVTMTTDTSTRTSYMELMSLRSDDTAVYYCARDYGDGPPDHWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGLPPKLLIYWASTRKSGVSDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPLFTFGPGTKVDIK,QKK35638,QKK35639,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_11_12_3_10,QKK35638_QKK35639,Unique source,SARS-CoV-2,2,1,1.8742037,5.218201
6DB5_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYAIHWVRQAPGHRLEWMGWINGGDGNTKYSQKLQGRVTITRDTSASTAYMELSSLRSEDSAVYYCMRAYYYGSRGLVDDALDVWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDELPKKYAYWYQEKSGQAPVLIIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCFSTDSSGDLWVFGGGTKLTVL,6DB5_H,6DB5_L,Crystal Structure Of Anti-Hiv-1 V3 Fab Ta6 In Complex With A Hiv-1 Gp120 V3 Peptide From Ny5 Strain,Crystal Structure Of Anti-Hiv-1 V3 Fab Ta6 In Complex With A Hiv-1 Gp120 V3 Peptide From Ny5 Strain,Human immunodeficiency virus 1,"Chan,K.W.;Pan,R.;Costa,M.;Gorny,M.K.;Wang,S.;Lu,S.;Kong,X.P.",Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection,02-MAY-2018,8_8_18_6_3_11,6DB5_H_L,Xtal structure,gp120; HIV,2,1,0.23788878,3.1275532
7RD4_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYAIHWVRQAPGQRLEWMGWINAGNGNTRYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAVYYCALLTVITPDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQNIFFSSNNKNYLAWYQQIPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIQ,7RD4_A,7RD4_B,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M43.149,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M43.149,Plasmodium falciparum,"Kratochvil,S.;Shen,C.H.;Lin,Y.C.;Xu,K.;Nair,U.;Da Silva,Pe.;Tripathi,P.;Arnold,J.;Chuang,G.Y.;Melzi,E.;Schon,A.;Zhang,B.;Dillon,M.;Bonilla,B.;Flynn,B.J.;Kirsch,K.H.;Kisalu,N.K.;Kiyuka,P.K.;Liu,T.;Ou,L.;Pancera,M.;Rawi,R.;Reveiz,M.;Seignon,K.;Wang,L.T.;Waring,M.T.;Warner,J.;Yang,Y.;Francica,J.R.;Idris,A.H.;Seder,R.A.;Kwong,P.D.;Batista,F.D.",Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies,09-JUL-2021,8_8_14_12_3_9,7RD4_A_B,Xtal structure,PfCSP; malarial,2,1,0.21187234,3.111858
7XY8_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSDFMHWVRQAPGQGLEWMGWIYPGDGDTEYNQKFQGRVTLTRDTSISTAYMELSRLRSDDTAVYYCARGRGYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAIKPLIYYTSNLQSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQYDSSPRTFGGGTKVEIK,7XY8_H,7XY8_L,Crystal Structure Of Antibody Fab Fragment In Complex With Cd147(Emmpirin),Crystal Structure Of Antibody Fab Fragment In Complex With Cd147(Emmpirin),synthetic construct,"Fukuchi,K.;Nanai,K.;Yuita,H.;Maru,C.;Tsukada,J.;Ishigami,M.;Nagai,Y.;Nakano,Y.;Yoshimura,C.;Yoneda,K.;Amano,M.;Nakamura,K.;Oda,Y.;Nishigohri,H.;Yamamoto,S.;Ohnishi-Totoki,Y.;Inaki,K.;Komori,H.;Nakano,R.;Kanari,Y.;Nishida,A.;Matsui,Y.;Funo,S.;Takahashi,S.;Ohtsuka,T.;Agatsuma,T.",Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals,23-NOV-2022,8_8_10_6_3_9,7XY8_H_L,Xtal structure,EMPRIN; OK; BSG; EMMPRIN; CD147,2,1,2.0131407,3.8868685
3C09_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYAGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,3C09_H,3C09_L,Crystal Structure The Fab Fragment Of Matuzumab (Fab72000) In Complex With Domain Iii Of The Extracellular Region Of Egfr,Crystal Structure The Fab Fragment Of Matuzumab (Fab72000) In Complex With Domain Iii Of The Extracellular Region Of Egfr,Homo sapiens,"Schmiedel,J.;Blaukat,A.;Li,S.;Knochel,T.;Ferguson,K.M.",Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization,18-JAN-2008,8_8_14_5_3_9,3C09_H_L,Xtal structure,ERBB; EGFR; ERRP; ERBB1,2,1,0.9281799,3.6913757
5NHR_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,5NHR_A,5NHR_B,"Crystal Structure Of The Activin Receptor Type-2B Ligand Binding Domain In Complex With Bimagrumab Fv, Cubic Crystal Form","Crystal Structure Of The Activin Receptor Type-2B Ligand Binding Domain In Complex With Bimagrumab Fv, Cubic Crystal Form",Homo sapiens,"Morvan,F.;Rondeau,J.M.;Zou,C.;Minetti,G.;Scheufler,C.;Scharenberg,M.;Jacobi,C.;Brebbia,P.;Ritter,V.;Toussaint,G.;Koelbing,C.;Leber,X.;Schilb,A.;Witte,F.;Lehmann,S.;Koch,E.;Geisse,S.;Glass,D.J.;Lach-Trifilieff,E.",Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy,22-MAR-2017,8_8_8_9_3_11,AQN07635_AQN07630,Xtal structure,INHBE; MGC4638; ActRIIA; activin,2,1,1.8614364,4.013482
7UFN_B_C,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKAGNGNTRYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAVYYCALLTVIRQDDTFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQNILYSSNNKNYLAWYQQKPGQAPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,7UFN_B,7UFN_C,Structure Of Pfcsp Peptide 21 With Antibody P3-21,Structure Of Pfcsp Peptide 21 With Antibody P3-21,Plasmodium falciparum,"Tripathi,P.;Kwong,P.D.",Structure of PfCSP peptide 21 with antibody P3-21,12-APR-2023,8_8_14_12_3_9,7UFN_B_C,Xtal structure,PfCSP,2,1,0.2072555,3.112318
7LKB_B_C,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKAGNGNTRYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAVYYCALLTVITPDDTFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQNILYSSNNKNYLAWYQQKPGQAPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,7LKB_B,7LKB_C,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M42.127,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M42.127,Plasmodium falciparum 3D7,"Kratochvil,S.;Shen,C.H.;Lin,Y.C.;Xu,K.;Nair,U.;Da Silva,Pe.;Tripathi,P.;Arnold,J.;Chuang,G.Y.;Melzi,E.;Schon,A.;Zhang,B.;Dillon,M.;Bonilla,B.;Flynn,B.J.;Kirsch,K.H.;Kisalu,N.K.;Kiyuka,P.K.;Liu,T.;Ou,L.;Pancera,M.;Rawi,R.;Reveiz,M.;Seignon,K.;Wang,L.T.;Waring,M.T.;Warner,J.;Yang,Y.;Francica,J.R.;Idris,A.H.;Seder,R.A.;Kwong,P.D.;Batista,F.D.",Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies,02-FEB-2021,8_8_14_12_3_9,7LKB_B_C,Xtal structure,PfCSP; malarial,2,1,0.19895798,3.1116853
6B5L_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKAGNGNTRYSQKFQDRVTITRDTSTTTAYMELSSLRSEDTAVYYCALLTVLTPDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPNLLIYWASTRQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSSPLTFGGGTKVEIK,6B5L_H,6B5L_L,Structure Of Pfcsp Peptide 20 With Human Protective Antibody Cis43,Structure Of Pfcsp Peptide 20 With Human Protective Antibody Cis43,Plasmodium falciparum,"Kisalu,N.K.;Idris,A.H.;Weidle,C.;Flores-Garcia,Y.;Flynn,B.J.;Sack,B.K.;Murphy,S.;Schon,A.;Freire,E.;Francica,J.R.;Miller,A.B.;Gregory,J.;March,S.;Liao,H.X.;Haynes,B.F.;Wiehe,K.;Trama,A.M.;Saunders,K.O.;Gladden,M.A.;Monroe,A.;Bonsignori,M.;Kanekiyo,M.;Wheatley,A.K.;McDermott,A.B.;Farney,S.K.;Chuang,G.Y.;Zhang,B.;Kc,N.;Chakravarty,S.;Kwong,P.D.;Sinnis,P.;Bhatia,S.N.;Kappe,S.H.;Sim,B.K.;Hoffman,S.L.;Zavala,F.;Pancera,M.;Seder,R.A.",A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite,29-SEP-2017,8_8_14_12_3_9,QYR87465_QYR87466,Xtal structure,,2,1,0.23638718,3.1513147
7RCS_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAIHWVRQAPGQRLEWMGWIKAGNGNTRYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAGYYCALLTVITPDDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERASINCKSSQNILFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYICHQYYSSPLTFGGGTKVEIK,7RCS_A,7RCS_B,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M43.160,Crystal Structure Of Pfcsp Peptide 21 With Vaccine-Elicited Human Anti-Malaria Antibody M43.160,Plasmodium falciparum,"Kratochvil,S.;Shen,C.H.;Lin,Y.C.;Xu,K.;Nair,U.;Da Silva,Pe.;Tripathi,P.;Arnold,J.;Chuang,G.Y.;Melzi,E.;Schon,A.;Zhang,B.;Dillon,M.;Bonilla,B.;Flynn,B.J.;Kirsch,K.H.;Kisalu,N.K.;Kiyuka,P.K.;Liu,T.;Ou,L.;Pancera,M.;Rawi,R.;Reveiz,M.;Seignon,K.;Wang,L.T.;Waring,M.T.;Warner,J.;Yang,Y.;Francica,J.R.;Idris,A.H.;Seder,R.A.;Kwong,P.D.;Batista,F.D.",Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies,08-JUL-2021,8_8_14_12_3_9,7RCS_A_B,Xtal structure,PfCSP; malarial,2,1,0.20279692,3.1325989
7M6G_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGWVSAYNGNTNYAQKLQGRVTMTTDTSTNTAYMELRSLRSDDTAIYYCAIPYSSVTFDCWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSGTFLAWYQQKPGQAPRLLISGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRPTFGQGTKLEIK,7M6G_H,7M6G_L,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg7-15","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg7-15",Homo sapiens,"Scheid,J.F.;Barnes,C.O.;Eraslan,B.;Hudak,A.;Keeffe,J.R.;Cosimi,L.A.;Brown,E.M.;Muecksch,F.;Weisblum,Y.;Zhang,S.;Delorey,T.;Woolley,A.E.;Ghantous,F.;Park,S.M.;Phillips,D.;Tusi,B.;Huey-Tubman,K.E.;Cohen,A.A.;Gnanapragasam,P.N.;Rzasa,K.;Hatziioanno,T.;Durney,M.A.;Gu,X.;Tada,T.;Landau,N.R.;West AP,Jr.;Rozenblatt-Rosen,O.;Seaman,M.S.;Baden,L.R.;Graham,D.B.;Deguine,J.;Bieniasz,P.D.;Regev,A.;Hung,D.;Bjorkman,P.J.;Xavier,R.J.",B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV,25-MAR-2021,8_8_11_7_3_9,7M6G_H_L,Xtal structure,SARS-CoV-2; SARS; CoV,2,1,1.7991581,5.359488
6OL5_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARVGPYCGGDSPQDNYYMDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSSYTFGQGTKLEIK,6OL5_H,6OL5_L,Structure Of Iglb12 Fab In Complex With Anti-Idiotype Ib3 Fab,Structure Of Iglb12 Fab In Complex With Anti-Idiotype Ib3 Fab,Homo sapiens,"Bancroft,T.;DeBuysscher,B.L.;Weidle,C.;Schwartz,A.;Wall,A.;Gray,M.D.;Feng,J.;Steach,H.R.;Fitzpatrick,K.S.;Gewe,M.M.;Skog,P.D.;Doyle-Cooper,C.;Ota,T.;Strong,R.K.;Nemazee,D.;Pancera,M.;Stamatatos,L.;McGuire,A.T.;Taylor,J.J.",Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes,15-APR-2019,8_8_20_7_3_9,6OL5_H_L,Xtal structure,HIV,2,1,0.25959554,3.140949
QDF60697_QDF61152,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGWISVNSGNTIYEQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREDGDLFYYGMDVWGQGTTVTVSS,AIQMTQSPSSVSASVGDRVTITCRASQAFGNWLAWYQQHPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFALTISSLQPEDFATYYCLQANSFPRTFGQGTRLEIK,QDF60697,QDF61152,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Davis,C.W.; Jackson,K.J.L.; McElroy,A.K.; Halfmann,P.; Huang,J.; Chennareddy,C.; Piper,A.E.; Leung,Y.; Albarino,C.G.; Crozier,I.; Ellebedy,A.H.; Sidney,J.; Sette,A.; Yu,T.; Nielsen,S.C.A.; Goff,A.J.; Spiropoulou,C.F.; Saphire,E.O.; Cavet,G.; Kawaoka,Y.; Mehta,A.K.; Glass,P.J.; Boyd,S.D.; Ahmed,R.",Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection,01-JUL-2019,8_8_14_6_3_9,QDF60697_QDF61152,Unique source,Ebola,2,1,1.9058757,5.0618386
4HCR_M_N,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK,4HCR_M,4HCR_N,Crystal Structure Of Human Madcam-1 D1D2 Complexed With Fab Pf-547659,Crystal Structure Of Human Madcam-1 D1D2 Complexed With Fab Pf-547659,Homo sapiens,"Springer,T.;Yu,Y.;Zhu,J.;Wang,J.-H.;Huang,P.-S.",A Different Fold with an Integrin-Binding Loop Specialized for Flexibility in Mucosal Addressin Cell Adhesion Molecule-1,01-OCT-2012,8_8_17_11_3_9,QRL84463,Xtal structure,Integrin,2,1,1.9116127,5.0370827
UNJ20699_UNJ20928,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGELLGWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL,UNJ20699,UNJ20928,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,8_8_12_9_3_10,UNJ20699_UNJ20928,Unique source,SARS-CoV-2,2,1,1.8862569,5.23624
7YIX_C_C,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDKGWNSEGSLEYWGQGTLVTVSS,DIVMTQSPSSVSASVGDRVTITCRASQGISNWLGWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQAYSLPLTFGGGTKLEIK,7YIX_C,7YIX_C,The Cryo-Em Structure Of Human Tissue Nonspecific Alkaline Phosphatase And Single-Chain Fragment Variable (Scfv) Complex.,The Cryo-Em Structure Of Human Tissue Nonspecific Alkaline Phosphatase And Single-Chain Fragment Variable (Scfv) Complex.,Homo sapiens,"Yu,Y.;Rong,K.;Yao,D.;Zhang,Q.;Cao,X.;Rao,B.;Xia,Y.;Lu,Y.;Shen,Y.;Yao,Y.;Xu,H.;Ma,P.;Cao,Y.;Qin,A.",The structural pathology for hypophosphatasia caused by malfunctional tissue non-specific alkaline phosphatase,16-AUG-2023,8_8_14_6_3_9,7YIX_C_C,Xtal structure,,2,1,1.875662,5.245874
7WN8_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGTVYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSLSRNHLAWYQQKPGQPPRLLIHWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHTQNTWTFGQGTKVEIK,7WN8_H,7WN8_L,Crystal Structure Of Antibody (Bc31M5) Binds To Cd47,Crystal Structure Of Antibody (Bc31M5) Binds To Cd47,Homo sapiens,"Li,Y.;Wang,W.;Zheng,S.;Sui,J.",Crystal structure of antibody BC31M5 binds to Leukocyte surface antigen CD47,25-JAN-2023,8_8_9_7_3_9,7WN8_H_L,Xtal structure,MER6; OA3; IAP; CD47,2,1,1.9104196,5.2463403
4YPG_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,4YPG_H,4YPG_L,Structural Insights Into The Neutralization Properties Of A Human Anti-Interferon Monoclonal Antibody,Structural Insights Into The Neutralization Properties Of A Human Anti-Interferon Monoclonal Antibody,Homo sapiens,"Oganesyan,V.;Peng,L.;Woods,R.M.;Wu,H.;Dall'Acqua,W.F.","Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab",12-MAR-2015,8_8_9_7_3_9,ADR90086_ADR90089,Xtal structure,Interferon; interferon,2,1,1.8595234,5.2196245
QKK35724_QKK35725,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWLGVIHPSGGSTTFAQKFQGRVTMTRDTSTSTVYMELGSLRSDDTAVYYCARVLAGSSHEWQLTHDAFDIWGQGTTVTVSS,DIRVTQSPDSLAVSLGERATINCRTSQSVLYSSNNKNYLGWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVDIK,QKK35724,QKK35725,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_20_12_3_9,QKK35724_QKK35725,Unique source,SARS-CoV-2,2,1,1.7404461,3.7376125
7K8W_N_S,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKLQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARANHETTMDTYYYYYYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYKYVSWYQRHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTSVVFGGGTQLTVL,7K8W_N,7K8W_S,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C119","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C119",Homo sapiens,"Barnes,C.O.;Jette,C.A.;Abernathy,M.E.;Dam,K.A.;Esswein,S.R.;Gristick,H.B.;Malyutin,A.G.;Sharaf,N.G.;Huey-Tubman,K.E.;Lee,Y.E.;Robbiani,D.F.;Nussenzweig,M.C.;West AP,Jr.;Bjorkman,P.J.",SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,27-SEP-2020,8_8_20_9_3_11,7K8W_N_S,Xtal structure,SARS-CoV-2,2,1,1.7033644,3.6494691
ANV21802_ANV21991,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYDIHWVRQAPGQGLEWLGLINPSAGSTSYAQMFQGRVTVTRDTSTSTVHMDLSSLTSEDTAVYYCAREKLQRRREFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGEAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATFYCLQHYSYPYTFGQGTRLEIK,ANV21802,ANV21991,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_13_6_3_9,ANV21802_ANV21991,Unique source,,2,1,1.5599213,3.907863
QIH48176_QIH48177,QVQLVQSGAEVKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGLEWMGWINPKRGGSNSAQKFQDRVTMTRDTSINTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGPLITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKDPKLMIYEVNKRASGVSIRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSIVIFGGGSKLTVL,QIH48176,QIH48177,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48176_QIH48177,Unique source,HIV,2,1,2.7394168,2.8673558
QIH48346_QIH48347,QVQLVQSGAEVKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGPEWMGWINPNSGGSNDAQKLQGRVTMTRDTSISTAYMELSSLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGNYNLVSWYQQHPGKAPKLMVYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGTKLTVL,QIH48346,QIH48347,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48346_QIH48347,Unique source,HIV,2,1,2.6645076,2.9652307
6BTJ_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTLTRYYFHWVRQAPGQGFEWMGIINPNGGGTSYAQKFGDRVIMTSDMSTSTIYMELSSLRSEDTAVYYCARDMPYYHDSGGPLFDLWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCRPSQSISTFLNWYEQKPGKAPKLLIYDASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSFSTPYTFGQGTRLEIK,6BTJ_A,6BTJ_B,"Crystal Structure Of Pan-H7, Anti-Hemagglutinin Monoclonal Antibody H7.5 (Fab Fragment)","Crystal Structure Of Pan-H7, Anti-Hemagglutinin Monoclonal Antibody H7.5 (Fab Fragment)",Homo sapiens,"Andrew,B.W.;Ian,A.W.;James,E.C.;Hannah,T.;Shanshan,L.;Jesper,P.;Sandhya,B.","Crystal structure of pan-H7, anti-hemagglutinin monoclonal antibody H7.5 (Fab fragment)",06-DEC-2017,8_8_17_6_3_9,6BTJ_A_B,Xtal structure,hemagglutinin,2,1,1.9329886,3.6881666
3U0T_D_C,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,3U0T_D,3U0T_C,Fab-Antibody Complex,Fab-Antibody Complex,Homo sapiens,"La Porte,S.L.;Bollini,S.S.;Lanz,T.A.;Abdiche,Y.N.;Rusnak,A.S.;Ho,W.H.;Kobayashi,D.;Harrabi,O.;Pappas,D.;Mina,E.W.;Milici,A.J.;Kawabe,T.T.;Bales,K.;Lin,J.C.;Pons,J.",Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease,29-SEP-2011,8_8_9_11_3_9,AEH63892_AEH63893,Xtal structure,beta-amyloid,2,1,1.6441705,3.815848
S23623_S23626,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTAYQMHWVRQAPGQGLEWMGWINPNSGGTGYGQKFQGRVTLTRDTSISTAYMELSRLTSDDTAVYYCAIEYFYDGSDLKPSDVFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNSNIGGNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEAAYYCAAWDDSLNGHVLFGGGTKLTVL,S23623,S23626,Ig heavy chain V region precursor - human (fragment),Ig lambda chain V region - human (fragment),Homo sapiens,"Olee,T.; Lu,E.W.; Huang,D.F.; Soto-Gil,R.W.; Deftos,M.; Kozin,F.; Carson,D.A.; Chen,P.P.",Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response,21-Jan-2000,8_8_19_8_3_12,S23623_S23626,Ordered entries,,2,1,2.4091132,3.6396384
6WYR_H_L,QVQLVQSGAEVKKPGASVKVSCKTSGYTFNNYDINWVRQAAGQGLEWMGWMNPYSGNTGYAQKFQGRVTMTRNISITTVYMELSSLRSEDTAVYYCAREVRGDTGYGGGSDYWGQGTLVTVSS,SYELTQPPSVSLSPGQTATITCSGDKLDDNYVCWYQQKPGQSPVLVIYQDTMRPSGIPERFSGSNSGNIATLTISGTQAVDEADYYCQAWDGSTVVFGGGTRLTVL,6WYR_H,6WYR_L,"Crystal Structure Of Anti-Muscle Specific Kinase (Musk) Fab, Musk1A","Crystal Structure Of Anti-Muscle Specific Kinase (Musk) Fab, Musk1A",Homo sapiens,"Fichtner,M.L.;Vieni,C.;Redler,R.L.;Kolich,L.;Jiang,R.;Takata,K.;Stathopoulos,P.;Suarez,P.A.;Nowak,R.J.;Burden,S.J.;Ekiert,D.C.;O'Connor,K.C.",Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis,13-MAY-2020,8_8_16_6_3_9,6WYR_H_L,Xtal structure,Muscle,2,1,2.0331602,4.250368
6UR5_A_B,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTAYYLHWVRQAPGQGFEWMAWINPNTGDTNYAQKFQGRVTLSRDTSITTAYMELTRLRSDDTAVYYCAKDLTLMYVFDSGWARGAHDYYGMDVWGQGTTVAVSG,PSALTQPASVSGSPGQSVTISCTGTNSDVGTFDLVSWYQQYPGKAPKLIIYEGSRRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSVVFGGGTKLTVL,6UR5_A,6UR5_B,Resurfaced Influenza Hemagglutinin In Complex With A Broadly Neutralizing Antibody,Resurfaced Influenza Hemagglutinin In Complex With A Broadly Neutralizing Antibody,Homo sapiens,"Bajic,G.;Maron,M.J.;Caradonna,T.M.;Tian,M.;Mermelstein,A.;Fera,D.;Kelsoe,G.;Kuraoka,M.;Schmidt,A.G.",Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope,10-JUN-2020,8_8_26_9_3_8,6UR5_A_B,Xtal structure,Influenza,2,1,2.2292686,3.446515
6AZZ_F_E,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTDYYIHWVRQAPGQGLEWMGWINPTDGGTNYAQKFQDWVTMTRDTSITTAYMELSRLRSDGTAVYFCARDRITTAAPFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGSNIGSKSVHWYQQKPGQTPMLVIYYDYDRPSGIPERFSGSNSGSTATLTISRVEAGDEADYYCQVWDSSSDHVWVFGGGTTLTVL,6AZZ_F,6AZZ_E,Crystal Structure Of Pfs25 In Complex With The Transmission Blocking Antibody 1190,Crystal Structure Of Pfs25 In Complex With The Transmission Blocking Antibody 1190,Plasmodium falciparum,"Scally,S.W.;McLeod,B.;Bosch,A.;Miura,K.;Liang,Q.;Carroll,S.;Reponen,S.;Nguyen,N.;Giladi,E.;Ramisch,S.;Yusibov,V.;Bradley,A.;Lemiale,F.;Schief,W.R.;Emerling,D.;Kellam,P.;King,C.R.;Julien,J.P.",Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25,13-SEP-2017,8_8_13_6_3_12,6AZZ_F_E,Xtal structure,Pfs25,2,1,2.1544216,3.8018508
QKK35714_QKK35715,QVQLVQSGAEVKKPGASVKVSCKTSGYTFTGHYIHWVRQAPGQGLEWMGWINPASGDTNYAQKFQGRVTKTRDTSITTAYMELNRLRSDDTAVYYCARGGPLPWSDLDIVGTFDYWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCRASQSISSSLNWYQQKPGKAPTLLIYTASNLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPGFGPGTKVDIK,QKK35714,QKK35715,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_6_3_8,QKK35714_QKK35715,Unique source,SARS-CoV-2,2,1,2.373596,3.4138834
CAA11829_CAA11830,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELPVHWVGQAPGKGLEWVGSFDPESGESIYAREFQGSVTMTADTSTDIAYMELSSLRSDDTAVYYCAVPDPDAFDIWGQGTMVTVSS,EIALTQSPGTLSLSPGERATLSCRASQSFSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQKYGTSAITFGQGTRLEIK,CAA11829,CAA11830,"IgG VH, partial [Homo sapiens]","IgG VL, partial [Homo sapiens]",Homo sapiens,"Jacquemin,M.G.; Desqueper,B.G.; Benhida,A.; Vander Elst,L.; Hoylaerts,M.F.; Bakkus,M.; Thielemans,K.; Arnout,J.; Peerlinck,K.; Gilles,J.G.; Vermylen,J.; Saint-Remy,J.M.",Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor,26-JUL-2016,8_8_10_7_3_9,CAA11829_CAA11830,Unique chain,,2,1,0.99709713,2.5646806
QKY76472_QKY76085,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEDAETIYAQQFQGRVTMTEDTSTDTAYMELSSLKSEDTALYYCATGFAVFGRAAVPYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCFGDKLGDKYACWFQQKPGQSPVLIIYQGAKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL,QKY76472,QKY76085,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_6_3_9,QKY76472_QKY76085,Unique source,SARS-CoV-2,2,1,1.0277305,2.525084
QJU69710_QJU69743,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATAPPYSPPSSWFDPWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSASYVFGTGTKVTVL,QJU69710,QJU69743,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Seydoux,E.; Homad,L.J.; MacCamy,A.J.; Parks,K.R.; Hurlburt,N.K.; Jennewein,M.F.; Akins,N.R.; Stuart,A.B.; Wan,Y.-H.; Feng,J.; Nelson,R.E.; Singh,S.; Cohen,K.W.; McElrath,M.J.; Englund,J.A.; Chu,H.Y.; Pancera,M.; McGuire,A.T.; Stamatatos,L.",Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual,20-MAY-2020,8_8_15_8_3_12,QJU69710_QJU69743,Unique source,SARS-CoV-2,2,1,1.0235916,2.5401597
6IEK_B_C,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDREDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIDPIRYNWNYGDYWGQGTLVTVSS,LPVLTQPPSSSASPGESARLTCTLPSDISVSSYNIYWYQQKPGSPPRFLLYYYSDSDKGQGSGVPSRFSGSKDASDNTGILLISGLQSEDEADYYCMIWPSNAWVFGGGTKLTVL,6IEK_B,6IEK_C,Structure Of Rvfv Gn And Human Monoclonal Antibody R12,Structure Of Rvfv Gn And Human Monoclonal Antibody R12,Homo sapiens,"Wang,Q.;Ma,T.;Wu,Y.;Chen,Z.;Zeng,H.;Tong,Z.;Gao,F.;Qi,J.;Zhao,Z.;Chai,Y.;Yang,H.;Wong,G.;Bi,Y.;Wu,L.;Shi,R.;Yang,M.;Song,J.;Jiang,H.;An,Z.;Wang,J.;Yilma,T.D.;Shi,Y.;Liu,W.J.;Liang,M.;Qin,C.;Gao,G.F.;Yan,J.",Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus,10-APR-2019,8_8_14_9_7_9,6IEK_B_C,Xtal structure,,2,1,1.0254222,2.5315948
QKK35494_QKK35495,QVQLVQSGAEVKKPGASVKVSCRASGYTFSGYDINWVRQATGQGLEWMGWMNPNSGDTGYAHKFQGRVTMTRNSSISTAYMELSSLTSEDTAVYFCAREKKSFGPQYYYGSGEDWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCRASQSISNYLYWYQQKPGKAPKLLIYVASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYNFGQGTKVDIK,QKK35494,QKK35495,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_9,QKK35494_QKK35495,Unique source,SARS-CoV-2,2,1,2.108992,4.2770805
QIH48244_QIH48245,QVQLVQSGAEVKKPGASVMVSCKASGYTLTDYYMHWVRQAPGQGLEWMGWINPNSGGTNSALRFQGRVTMSRDTSINTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDSWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNFVSWYQQHPGKAPKLMIYEVSKRASGFSSRFSGSKSGNAAALTISGLQTEDAADYYCCSYAGSSTVIFGGGSKLTVL,QIH48244,QIH48245,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48244_QIH48245,Unique source,HIV,2,1,2.6573884,2.9744077
QMI58158_QMI58175,QVQLVQSGAEVKKPGASVRVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISDGTNYAQKFQGWVTMTRDTSISTVYMELSRLRSDDTAVYYCARGGSRCSGGNCYGWAYDAFDIWGQGTMITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADCYCSSYTSSSTFVFGTGTKVTVL,QMI58158,QMI58175,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_22_9_3_10,QMI58158_QMI58175,Unique source,SARS-CoV-2,2,1,2.2746294,3.4789548
5CHN_A_B,QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYFMHWVRQAPGQGLEWMAITYPGGGSPSYAPQFQGRLTMTDDTSATTVYMDLSDLTSKDTAVYYCARGAHRSIGTTPLDSWGQGTLVTVSS,IVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSNRLSGVPDRFSGSGSGTDFTLKISRVETEDVGVYYCMQSIQVPLYTFGQGTRLEIK,5CHN_A,5CHN_B,Fab Fragments Of Chikungunya Virus Neutralizing Human Monoclonal Antibody 5M16,Fab Fragments Of Chikungunya Virus Neutralizing Human Monoclonal Antibody 5M16,Homo sapiens,"Long,F.;Fong,R.H.;Austin,S.K.;Chen,Z.;Klose,T.;Fokine,A.;Liu,Y.;Porta,J.;Sapparapu,G.;Akahata,W.;Doranz,B.J.;Crowe JE,Jr.;Diamond,M.S.;Rossmann,M.G.",Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity,10-JUL-2015,8_8_15_11_3_10,5CHN_A_B,Xtal structure,Chikungunya,2,1,1.6375757,3.8049698
CAO78313,QVQLVQSGAEVKKPGASVRVSCQASGYTFSRYHMHWVRQAPGQGLEWMGVIDPNSGRVSYSQKFQDRVTMTRDTSTSTVYMELNSPRSEDTAVYYCARDRGYCNGGRCFMDAFDYWGQGTMVTVSS,SYVLTHPPSLSGAPGQSITISCTGSSSNIGAGFHIHWYQQFPKTAPKLLIYGSSNRPSGVPDRFSGSRSGSSGSLAITGLQADDEADYYCVGWDGSLSGYVFGTGTQLTVL,CAO78313_H,CAO78313_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_19_9_3_11,AEN51967,Same entry,,2,1,1.7507217,3.627928
4FQK_E_F,QVQLVQSGAEVKKPGASVRVSCRASGYIFTESGITWVRQAPGQGLEWMGWISGYSGDTKYAQKLQGRVTMTKDTSTTTAYMELRSLRYDDTAVYYCARDVQYSGSYLGAYYFDYWSPGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGTNYVYWYQQFPGTAPKLLIYRSYQRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKLTVL,4FQK_E,4FQK_F,Influenza B/Brisbane/60/2008 Hemagglutinin Fab Cr8059 Complex,Influenza B/Brisbane/60/2008 Hemagglutinin Fab Cr8059 Complex,Homo sapiens,"Dreyfus,C.;Laursen,N.S.;Kwaks,T.;Zuijdgeest,D.;Khayat,R.;Ekiert,D.C.;Lee,J.H.;Metlagel,Z.;Bujny,M.V.;Jongeneelen,M.;van der,Vl.;Lamrani,M.;Korse,H.J.;Geelen,E.;Sahin,O.;Sieuwerts,M.;Brakenhoff,J.P.;Vogels,R.;Li,O.T.;Poon,L.L.;Peiris,M.;Koudstaal,W.;Ward,A.B.;Wilson,I.A.;Goudsmit,J.;Friesen,R.H.",Highly conserved protective epitopes on influenza B viruses,25-JUN-2012,8_8_18_8_3_11,4FQK_E_F,Xtal structure,Influenza,2,1,1.8605641,5.261117
5F9W_B_C,QVQLVQSGAEVKKPGASVTVSCQASGYTFTNYYVHWVRQAPGQGLQLMGWIDPSWGRTNYAQNFQGRITMTRDTSTSTVYMEMRSLRSEDTAVYYCARNVATEGSLLHYDYWGQGTLVTVS,EIVLTQSPATLSVSPGERATLSCRASQSVRSNLAWYQQRPGQAPRLLIYGTSTRATGVPARFSGRGSGTEFTLAISSMQSEDFAVYLCLQYNNWWTFGQGTKVEIK,5F9W_B,5F9W_C,Crystal Structure Of Broadly Neutralizing Vh1-46 Germline-Derived Cd4-Binding Site-Directed Antibody Ch235 In Complex With Hiv-1 Clade A/E 93Th057 Gp120,Crystal Structure Of Broadly Neutralizing Vh1-46 Germline-Derived Cd4-Binding Site-Directed Antibody Ch235 In Complex With Hiv-1 Clade A/E 93Th057 Gp120,Homo sapiens,"Bonsignori,M.;Zhou,T.;Sheng,Z.;Chen,L.;Gao,F.;Joyce,M.G.;Ozorowski,G.;Chuang,G.Y.;Schramm,C.A.;Wiehe,K.;Alam,S.M.;Bradley,T.;Gladden,M.A.;Hwang,K.K.;Iyengar,S.;Kumar,A.;Lu,X.;Luo,K.;Mangiapani,M.C.;Parks,R.J.;Song,H.;Acharya,P.;Bailer,R.T.;Cao,A.;Druz,A.;Georgiev,I.S.;Kwon,Y.D.;Louder,M.K.;Zhang,B.;Zheng,A.;Hill,B.J.;Kong,R.;Soto,C.;Mullikin,J.C.;Douek,D.C.;Montefiori,D.C.;Moody,M.A.;Shaw,G.M.;Hahn,B.H.;Kelsoe,G.;Hraber,P.T.;Korber,B.T.;Boyd,S.D.;Fire,A.Z.;Kepler,T.B.;Shapiro,L.;Ward,A.B.;Mascola,J.R.;Liao,H.X.;Kwong,P.D.;Haynes,B.F.",Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody,10-DEC-2015,8_8_15_6_3_8,5F9W_B_C,Xtal structure,HIV; CD4,2,1,1.62018,3.9393575
7BBJ_M_N,QVQLVQSGAEVKKPGDSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGAIYPGLSDTTYNQKFKGKVTMTRDTSTSTVYMKLSSLRSEDTAVYYCARLLDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRSYLNWHQQKPGKAPKLLIWYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGETLPWTFGQGTKLEIK,7BBJ_M,7BBJ_N,Cd73 In Complex With The Humanized Antagonistic Antibody Mab19,Cd73 In Complex With The Humanized Antagonistic Antibody Mab19,synthetic construct,"Wurm,M.;Schaaf,O.;Reutner,K.;Ganesan,R.;Mostbock,S.;Pelster,C.;Bottcher,J.;de Andrade Pereira,B.;Taubert,C.;Alt,I.;Serna,G.;Auguste,A.;Stadermann,K.B.;Delic,D.;Han,F.;Capdevila,J.;Nuciforo,P.G.;Kroe-Barrett,R.;Adam,P.J.;Vogt,A.B.;Hofmann,I.",A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway,17-DEC-2020,8_8_10_6_3_9,7BBJ_M_N,Xtal structure,eNT; CALJA; NT5E; CD73; eN; NT5,2,1,0.9482004,3.671996
QKK35706_QKK35707,QVQLVQSGAEVKKPGESLKISCKASGYSFTNYWVGWVRQMPAKGLEWMGIIWPDDSDTRYRPSFQGQVTISVDKSISTAYLHWNSLKASDNGMYFCARAPLASCSGGRCPTYNRFDLWGQGTLVTVSS,QPVLTQPPSVSAAPGQKVTISCSGSSSNIENNYVSWYQQLPGAAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDFSLSAGVFGGGTKLTVL,QKK35706,QKK35707,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_21_8_3_11,QKK35706_QKK35707,Unique source,SARS-CoV-2,2,1,-12.462262,5.698149
6I07_B_B,QVQLVQSGAEVKKPGESVKISCKASGYTFTNYGMNWVRQQPGQCLKWMGWINTYTGESTYADDFKGRFAFSLDTSASTAYLQLSSLRSEDTAVYFCARFAIKGDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSTKSLLHSDGITYLYWYLQKPGQSPQLLIYQLSNLASGVPDRFSSSGSGTDFTLKISRVEAEDEGVYYCAQNLEIPRTFGCGTKLEIK,6I07_B,6I07_B,Crystal Structure Of Epcam In Complex With Scfv,Crystal Structure Of Epcam In Complex With Scfv,Homo sapiens,"Casaletto,J.B.;Geddie,M.L.;Abu-Yousif,A.O.;Masson,K.;Fulgham,A.;Boudot,A.;Maiwald,T.;Kearns,J.D.;Kohli,N.;Su,S.;Razlog,M.;Raue,A.;Kalra,A.;Hakansson,M.;Logan,D.T.;Welin,M.;Chattopadhyay,S.;Harms,B.D.;Nielsen,U.B.;Schoeberl,B.;Lugovskoy,A.A.;MacBeath,G.","MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM",25-OCT-2018,8_8_9_11_3_9,6I07_B_B,Xtal structure,HPTA; HGFB; SF; HGF; DFNB39; F-TCF,2,1,-7.2374797,5.886573
6P9I_C_D,QVQLVQSGAEVKKPGSSLKVSCKVSGGNLRSYGISWVRQAPGQGLEWMGVIIPIFGTPTYAQKFQGRVTLAADDSNNIVFMELSSLRSEDTAVYYCARDWPSITVAVDATNYGMDVWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSNDVGYYDHVSWYQQHPGKAPKFIIYDVSKRPSGVPDRFSGSKSDNTASLTISGLQAEDEADYYCCSFAGSYTYVFGTGTKVTVL,6P9I_C,6P9I_D,Crystal Structure Of Human Anti Staphylococcus Aureus Antibody Stau-399 Fab,Crystal Structure Of Human Anti Staphylococcus Aureus Antibody Stau-399 Fab,Homo sapiens,"Dong,J.;Crowe,J.E.",crystal structure of human anti staphylococcus aureus antibody STAU-399 Fab,17-JUN-2020,8_8_20_9_3_10,6P9I_C_D,Xtal structure,PPP1R150; STAU; STAU1,2,1,-0.7685271,5.999727
QKK35498_QKK35499,QVQLVQSGAEVKKPGSSMKLSCKASGINFRSYSFSWVRQAPGQGLEWMGGVIPYFPTANYAEKFRGRVTATADESTGTVYLEMSSLRSEDTAVYYCASEYFDGRSYHSFCGLDVWGQGTLVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQGLAHSNGNTYLNWFHQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTEWPRTFGQGTKVEIK,QKK35498,QKK35499,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_11_3_9,QKK35498_QKK35499,Unique source,SARS-CoV-2,2,1,-0.6542017,5.9540486
QKK35708_QKK35709,QVQLVQSGAEVKKPGSSMKVSCKASGVNFRSYSFSWVRQAPGQGLEWMGGVIPYFPTANYADKFRDRVTITADESTGTVYLDMSSLRSEDTAVYFCASEYFDGRSYHSFCGLDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQGLVHTNGNLYLNWFHQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCMQGTEWPRTFGQGTKVEIK,QKK35708,QKK35709,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_11_3_9,QKK35708_QKK35709,Unique source,SARS-CoV-2,2,1,-0.6961568,5.9861164
QKK35784_QKK35785,QVQLVQSGAEVKKPGSSMRVSCRVSGGTFITHAMSWVRQAPGQGPEWMGGIVPLFGRASYAQPSQTRVQITADESTSTVYLEVPSLTSEDTAVYYCVRDSEPYTATRSQNHYWYDMDVWGQGTTVTVSS,ETTLTQSPLSLSVTLGQSASISCRASQTVVHSVDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDIGIYYCMQGTDWPRTFGQGTKVEIK,QKK35784,QKK35785,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_12_3_9,QKK35784_QKK35785,Unique source,SARS-CoV-2,2,1,3.0864244,-13.21794
QKK35696_QKK35697,QVQLVQSGAEVKKPGSSVEVSCKVSGGTFRDYAISWVRQAPGQRLEWMGGIMPGLGSPAYAQIFGDRVTISADTSTSTAYLQVTNLRPEDTAVYYCARDPSILNTGNHHWYDLDMWGQGTTVTVSS,DIRMTQSPLSLPVDLGQSASISCRSSQRVVHTNGNTYLHWFHQRPGQAPRRLIYKVSNRESGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATDWPRTFGQGTKLEIK,QKK35696,QKK35697,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35696_QKK35697,Unique source,SARS-CoV-2,2,1,-6.326105,-2.7490427
QKK35856_QKK35857,QVQLVQSGAEVKKPGSSVKISCKISGDTFSTNAISWLRQAPGREPEWMGGIVPLVGPASYAQRPQGRLTITADEFTNTAYLELNSLRSEDTATYYCARDSDPYTATRRHNHYWYAMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQIAMHSDGNTYLSWFHQRPGQPPRRLIYKISNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGTFYCMQGTDWPRTFGQGTKVEIK,QKK35856,QKK35857,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35856_QKK35857,Unique source,SARS-CoV-2,2,1,3.0495536,-13.254069
QRW38897_QRW39058,QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYAINWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCATGRYTYGYGYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRTFGQGTKLEIK,QRW38897,QRW39058,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Li,H.",Direct Submission,24-FEB-2021,8_8_15_7_3_8,QRW38897_QRW39058,Unique source,SARS-CoV-2,2,1,-0.93364316,5.586378
QKY76335_QKY75948,QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYTINWVRQAPGQGLEWMGRIIPILGIPNYAQKFQGRVTITADKSTSTAFMELSSLRSEDTAVYYCARGRGYSNYGASYYMDVWGKGTTVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPETAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,QKY76335,QKY75948,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_17_9_3_11,QKY76335_QKY75948,Unique source,SARS-CoV-2,2,1,-1.0466772,5.86883
QKK35576_QKK35577,QVQLVQSGAEVKKPGSSVKVSCKASGGMFRDYAISWLRQAPGQRLEWMGGIMPAFGAPGYAQIFRGRATISADVSTTTAYLELTSLMPDDTAVYYCARDPSILNTGNHHWYDLDLWGQGTTVTVSS,ETTLTQSPLSLPVGLGQSASISCRSSQRVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATEWPRTFGQGTKVDIK,QKK35576,QKK35577,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35576_QKK35577,Unique source,SARS-CoV-2,2,1,-6.3979387,-2.676385
QKK35582_QKK35583,QVQLVQSGAEVKKPGSSVKVSCKASGGMFSDYAISWVRQAPGQRLEWMGGIMPGLGSPAYAQIFRGRVTISADISTSTAYLEVTSLRPEDTAVYYCARDPSILNTGNHHWYDLDMWGQGTTVTVSS,DIQMTQSPLSLPVDLGQSASISCRSSQRVVHTNGNTYLHWFHQRPGQAPRRLIYKVSNRESGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATDWPRTFGQGTKVEIK,QKK35582,QKK35583,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35582_QKK35583,Unique source,SARS-CoV-2,2,1,-6.3908,-2.6830795
QKK35588_QKK35589,QVQLVQSGAEVKKPGSSVKVSCKASGGMFSDYAISWVRQAPGQRLEWMGGIMPGLGSPAYAQSFGGRVTISADISTSTAYLEVTSLRPEDTAVYYCARDPSILNTGNHHWYDLDMWGQGTMVTVSS,DIRLTQSPLSLPVDLGQSASISCRSSQTVVHTNGNTYLHWFHQRPGQAPRRLIYKVSNRESGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATDWPRTFGQGTKVDIK,QKK35588,QKK35589,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35588_QKK35589,Unique source,SARS-CoV-2,2,1,-6.3882146,-2.6871226
QKK35780_QKK35781,QVQLVQSGAEVKKPGSSVKVSCKASGGMFTDYAISWVRQAPGQRLEWMGGILPAFAASGSPGYAPIFRGRATFSADVSTSTAYLELTNLKPEDTAVYYCARDPSILNTGNHHWYDLDLWGQGTEVTVSS,DIQMTQSPLSLPVGLGQSASISCRSSQWVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATEWPRTFGQGTKVEIK,QKK35780,QKK35781,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_11_19_11_3_9,QKK35780_QKK35781,Unique source,SARS-CoV-2,2,1,-6.3996973,-2.6870062
QKK35670_QKK35671,QVQLVQSGAEVKKPGSSVKVSCKASGGMFTDYAISWVRQAPGQRLEWMGGIMPGLGSPAYAQIFRDRATISADVSTSTAYLELTSLKPEDTAVYYCARDPSILNTGNHHWYDLDIWGQGTTVTVSS,DIQLTQSPLSLPVGLGQSASISCRSSQRVVHTDGNTYLNWYHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQSTDWPRTFGQGTKLEIK,QKK35670,QKK35671,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35670_QKK35671,Unique source,SARS-CoV-2,2,1,-6.378766,-2.697121
QKK35672_QKK35673,QVQLVQSGAEVKKPGSSVKVSCKASGGMFTDYAISWVRQAPGQRPEWMGGIMPGLGSPAYAQIFRGRATISADLSTSTAYLELTSLKPEDTAVYYCARDPSILNTGNHHWYDLDIWGQGTMVTVSS,DIVLTQSPLSLPVGLGQSASISCRSSQRVVHTDGNTYLHWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGTEWPRTFGQGTKLEIK,QKK35672,QKK35673,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35672_QKK35673,Unique source,SARS-CoV-2,2,1,-6.389071,-2.687099
QKK35676_QKK35677,QVQLVQSGAEVKKPGSSVKVSCKASGGMISDYAISWVRQAPGQRLEWMGGIMPAFGSPGYAQIFRGRATISADVSTNTAYLELTSLNPDDTAVYYCARDPSILNTGNHHWYDLDMWGQGTMVTVSS,DIQVTQSPLSLPVGLGQSASISCRSSQRVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATEWPRTFGQGTKVDIK,QKK35676,QKK35677,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35676_QKK35677,Unique source,SARS-CoV-2,2,1,-6.3603234,-2.7162092
QKK35844_QKK35845,QVQLVQSGAEVKKPGSSVKVSCKASGGMLSDYAISWVRQAPGQRLEWMGGIMPAFGSPGYAQIFRGRATISADVSTSTAYLELTSLKPEDTAVYYCARDPSILNTGNHHWYDLDIWGQGTMVTVSS,DIVMTQSPLSLPVGLGQSASISCRSSQRVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATEWPRTFGQGTKVEIK,QKK35844,QKK35845,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35844_QKK35845,Unique source,SARS-CoV-2,2,1,-6.3963923,-2.6797924
QKK35636_QKK35637,QVQLVQSGAEVKKPGSSVKVSCKASGGSLRDYAISWVRQAPGQGPEWMGGIMPIFGTAGYAQKFQGRVKFTADESATTAYMELTGLRSEDSAVYFCARDPSILNTGNHHWYDLDIWGQGTTVTVSS,EIVMTQTPLSLPVTLGQPASISCRSSQFVSHTDGNTYLNWFQQRPGQSPRRLIYKVSKRDSGVPDRFSGSGSGTDFTLTISRVEAEDVGVYYCMQATEWPRTFGQGTKVEYQ,QKK35636,QKK35637,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35636_QKK35637,Unique source,SARS-CoV-2,2,1,-6.4381094,-2.6368732
7KFE_G_I,QVQLVQSGAEVKKPGSSVKVSCKASGGTFDTYAISWVRQAPGQGLEWMGGIIPVLGIVDYAQKFQGRVTITAAKFTNIAYMELSSLRSEDAAVYYCARGLRSLSPRGQEGPTPAPGWRRAQYHYYYMDVWGTGTLVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGPDFTLTISRLEPEDFAVYYCQQYGSSPGTFGGGTKVEIK,7KFE_G,7KFE_I,Bundibugyo Virus Gp (Mucin Deleted) Bound To Antibody Fab Bdbv-329,Bundibugyo Virus Gp (Mucin Deleted) Bound To Antibody Fab Bdbv-329,Bundibugyo ebolavirus,"Murin,C.D.;Gilchuk,P.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Shen,X.;Bruhn,J.F.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Williamson,L.E.;Copps,J.;Alkutkar,T.;Flyak,A.I.;Bukreyev,A.;Crowe JE,Jr.;Ward,A.B.",Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies,13-OCT-2020,8_8_33_7_3_9,7KFE_G_I,Xtal structure,,2,1,-1.0422764,5.9830594
8DNN_B_C,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYAFSWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSTRELPEVVDWYFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSAPLTFGGGTKVEIK,8DNN_B,8DNN_C,Crystal Structure Of Neutralizing Antibody 80 In Complex With Sars-Cov-2 Receptor Binding Domain,Crystal Structure Of Neutralizing Antibody 80 In Complex With Sars-Cov-2 Receptor Binding Domain,Homo sapiens,"Muthuraman,K.;Kucharska,I.;Ivanochko,D.;Julien,J.P.",Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain,24-MAY-2023,8_8_17_12_3_9,8DNN_B_C,Xtal structure,SARS-CoV-2,2,1,-0.83380777,5.795756
3MA9_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYAFSWVRQAPGQGLEWMGSIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYFDTYNNYGFANWGQGTLVTVSS,IELTQPPSVSVVPGQTARISCSGDNIPYEYASWYQQKPGQAPVLVIYGDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCASWDSMTVDGVFGGGTKLTVL,3MA9_H,3MA9_L,Crystal Structure Of Gp41 Derived Protein Complexed With Fab 8066,Crystal Structure Of Gp41 Derived Protein Complexed With Fab 8066,Homo sapiens,"Gustchina,E.;Li,M.;Louis,J.M.;Anderson,D.E.;Lloyd,J.;Frisch,C.;Bewley,C.A.;Gustchina,A.;Wlodawer,A.;Clore,G.M.",Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41,23-MAR-2010,8_8_14_6_3_11,3MA9_H_L,Xtal structure,HIV,2,1,-0.55387217,5.693201
7UVS_A_B,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNSYGISWVRQAPGQGLEWVGGIIPSFGTADYAQKFQGRVTFTTDTSTSTAYMEVSSLRSEDTAVYYCAGSSWSSGTYYGRSAYWGQGTLVTVSS,EIVMTQSPASLALSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAGDVAVYHCQQYYSTPYSFGQGTKLEIK,7UVS_A,7UVS_B,Pfs230 Domain 1 Bound By Lmiv230-02 Fab,Pfs230 Domain 1 Bound By Lmiv230-02 Fab,Plasmodium falciparum,"Ivanochko,D.;Julien,J.P.",Pfs230 domain 1 bound by LMIV230-02 Fab,15-FEB-2023,8_8_16_12_3_9,7UVS_A_B,Xtal structure,,2,1,-0.565785,5.7481537
7MLH_C_A,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNTYSLSWVRQAPGQGLEWMGGIIPNFGRGNYAQKFQGRVTITADESSAYMELSSLRSEDTAVYYCATFRLTGYSGSGSYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQNINNWLAWYQQKPGKAPNLLIYKASTLETGVPSRFSGSGSGTEFTLTISSLQPDDLATYYCQQYHSHRTFGQGTKVEVK,7MLH_C,7MLH_A,Crystal Structure Of Human Ige (2F10) In Complex With Der P 2.0103,Crystal Structure Of Human Ige (2F10) In Complex With Der P 2.0103,Dermatophagoides pteronyssinus,"Khatri,K.;Richardson,C.M.;Glesner,J.;Kapingidza,A.B.;Mueller,G.A.;Zhang,J.;Dolamore,C.;Vailes,L.D.;Wunschmann,S.;Peebles,R.S.;Chapman,M.D.;Smith,S.A.;Chruszcz,M.;Pomes,A.",Human IgE monoclonal antibody recognition of mite allergen Der p 2 defines structural basis of an epitope for IgE cross-linking and anaphylaxis <i>in vivo</i>,28-APR-2021,8_8_14_6_3_8,7MLH_C_A,Xtal structure,,2,1,-0.5014278,5.7199016
UIC72118_UIC72428,QVQLVQSGAEVKKPGSSVKVSCKASGGTFRSYTFSWVRQAPGHGLEWMGGIISVGNSATYAQKFQGRVTITADKSTSTVYMELSGLTSEDTAIYFCARDGNFDWRTARNEQNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTLTCRASQTIGNFLNWYQQKPGRAPKLLVYGASNLQSGVPSRFSGSGSGTDFTLTISSLEPEDFATYYCQQTYNSPRVTFGQGTRLDIK,UIC72118,UIC72428,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_20_6_3_10,UIC72118_UIC72428,Unique source,HCV,2,1,-0.81877005,5.6836815
5CZX_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFRTYAMHWVRQAPGQGLEWMGGIVPYHGITDYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDDYSTYAFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIASYLAWYQQKPGKAPKLLIYDASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYKTPYTFGQGTKVEIK,5CZX_H,5CZX_L,Crystal Structure Of Notch3 Nrr In Complex With 20358 Fab,Crystal Structure Of Notch3 Nrr In Complex With 20358 Fab,Homo sapiens,"Bernasconi-Elias,P.;Hu,T.;Jenkins,D.;Firestone,B.;Gans,S.;Kurth,E.;Capodieci,P.;Deplazes-Lauber,J.;Petropoulos,K.;Thiel,P.;Ponsel,D.;Hee Choi,S.;LeMotte,P.;London,A.;Goetcshkes,M.;Nolin,E.;Jones,M.D.;Slocum,K.;Kluk,M.J.;Weinstock,D.M.;Christodoulou,A.;Weinberg,O.;Jaehrling,J.;Ettenberg,S.A.;Buckler,A.;Blacklow,S.C.;Aster,J.C.;Fryer,C.J.",Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies,01-AUG-2015,8_8_12_6_3_9,QKO44219_QKO44226,Xtal structure,CADASIL; NOTCH3; CASIL; leukemia,2,1,-0.38764533,5.39816
6C6Z_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSIYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGGHQGYCSGGSCYDFDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPAFGGGTKLEIK,6C6Z_H,6C6Z_L,Crystal Structure Of Potent Neutralizing Antibody Cdc2-C2 In Complex With Mers-Cov S1 Rbd,Crystal Structure Of Potent Neutralizing Antibody Cdc2-C2 In Complex With Mers-Cov S1 Rbd,Homo sapiens,"Wang,L.;Shi,W.;Chappell,J.D.;Joyce,M.G.;Zhang,Y.;Kanekiyo,M.;Becker,M.M.;van Doremalen,N.;Fischer,R.;Wang,N.;Corbett,K.S.;Choe,M.;Mason,R.D.;Van Galen,J.G.;Zhou,T.;Saunders,K.O.;Tatti,K.M.;Haynes,L.M.;Kwong,P.D.;Modjarrad,K.;Kong,W.P.;McLellan,J.S.;Denison,M.R.;Munster,V.J.;Mascola,J.R.;Graham,B.S.",Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape,19-JAN-2018,8_8_20_11_3_8,QDB31402_QDB31403,Xtal structure,Antigenic,2,1,-0.90268385,5.8016734
UIC72274_UIC72584,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRFGISWVRQAPGQGLEWMGGIIPKFGTTNYAQKFQGRVTITADKSTNIAYLEVSSLTSEDTAVYYCAREVAPSNSFFLSWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMISEVTERPSGVSARFSGSKSGNTASLTISGLQAEDEADYFCCSYARGSTYWIFGGGTKLTVL,UIC72274,UIC72584,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_17_9_3_11,UIC72274_UIC72584,Unique source,HCV,2,1,-0.6353784,5.732169
UFQ05771_UFQ05772,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSDAINWVRQAPGQGLEWMGRIIPIFGVADYAQKFQGRVTLTADKSTSTAYMDLSSLRSEDTAVFYCARERGDYSNFWYFDLWGRGTLVTVSS,DIQMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPYTFGQGTKVEIK,UFQ05771,UFQ05772,"anti-CD25 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-CD25 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Song,D.; Liu,X.; Dong,C.; Wang,Q.; Sha,C.; Liu,C.; Ning,Z.; Han,J.; Liu,H.; Zong,M.; Zhao,Y.; Li,Y.; Liu,G.; Shao,X.; Dou,C.",Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity,06-DEC-2021,8_8_15_12_3_9,UFQ05771_UFQ05772,Unique source,CD25; IL2R; IDDM10; IL2RA,2,1,-0.95316863,5.684002
7WI0_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSFAISWVRQAPGQGLEWMGGIIPIYGTANYAQKFQGRVTITADESTSTAYMDLSSLRSEDTAVYYCARDGSSTYYPHNWFDPWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVFGTGTKVTVL,7WI0_H,7WI0_L,Sars-Cov-2 Omicron Variant Spike In Complex With Three Human Neutralizing Antibodies,Sars-Cov-2 Omicron Variant Spike In Complex With Three Human Neutralizing Antibodies,Homo sapiens,"Wang,S.;Sun,H.;Zhang,Y.;Yuan,L.;Wang,Y.;Zhang,T.;Wang,S.;Zhang,J.;Yu,H.;Xiong,H.;Tang,Z.;Liu,L.;Huang,Y.;Chen,X.;Li,T.;Ying,D.;Liu,C.;Chen,Z.;Yuan,Q.;Zhang,J.;Cheng,T.;Li,S.;Guan,Y.;Zheng,Q.;Zheng,Z.;Xia,N.","Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron",01-JAN-2022,8_8_16_9_3_10,7WI0_H_L,Xtal structure,SARS-CoV-2,2,1,-0.7242388,5.873399
B32274_A32274,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAFSWVRQAPGQGLEWMGGIIPFLGTTHYAQKFQDRVTITTDESTRTAYMELHILRSEDTAIYYCARDQSLENIEVVPLDPNYFYDGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSNELAWYQQKPGQAPRLLISGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAMYYCQQYGSTPRTFGQGTKVEIK,B32274,A32274,Ig heavy chain precursor V-I region (EVI-15) - human (fragment),Ig kappa chain precursor V-III region (EVI-15) - human,Homo sapiens,"Newkirk,M.M.; Gram,H.; Heinrich,G.F.; Ostberg,L.; Capra,J.D.; Wasserman,R.L.",Complete protein sequences of the variable regions of the cloned heavy and light chains of a human anti-cytomegalovirus antibody reveal a striking similarity to human monoclonal rheumatoid factors of the Wa idiotypic family,21-Jan-2000,8_8_25_7_3_9,B32274_A32274,Unique chain,FLJ23091; GPR177; WLS; mig-14; C1orf139; MRP; EVI; cytomegalovirus,2,1,-0.84254074,6.180693
5WL2_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARHGNYYYYSGMDVWGQGTTVTVSS,QSVLTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQLPGKAPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGAVFGGGTQLTVL,5WL2_H,5WL2_L,Vh1-69 Germline Antibody With Cdr H3 Sequence Of Cr9114,Vh1-69 Germline Antibody With Cdr H3 Sequence Of Cr9114,Homo sapiens,"Wilson,I.A.;Lang,S.;Kurosawa,Y.;Ohshima,N.;Ota,T.;Abadejos,J.;Lee,P.S.;Nemazee,D.","Anti-idiotypic antibody K1-18 engages VH1-69 precursor and affinity-matured, anti-stem antibodies through mimicry of the HA stem",25-JUL-2017,8_8_14_8_3_11,5WL2_H_L,Xtal structure,stem,2,1,-0.7443479,5.9660444
4M62_I_M,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGTTGSGWLGKPIGAFAYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSTFGQGTKVEIK,4M62_I,4M62_M,Ontogeny Of Recognition Specificity And Functionality For The Anti-Hiv Neutralizing Antibody 4E10,Ontogeny Of Recognition Specificity And Functionality For The Anti-Hiv Neutralizing Antibody 4E10,Salmonella enterica,"Finton,K.A.;Friend,D.;Jaffe,J.;Gewe,M.;Holmes,M.A.;Larman,H.B.;Stuart,A.;Larimore,K.;Greenberg,P.D.;Elledge,S.J.;Stamatatos,L.;Strong,R.K.",Ontogeny of Recognition Specificity and Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10,08-AUG-2013,8_8_20_7_3_9,4M62_I_M,Xtal structure,HIV,2,1,-0.88070744,5.905771
4XAK_D_E,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTASYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVGYCSSTSCNRGAFDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,4XAK_D,4XAK_E,Crystal Structure Of Potent Neutralizing Antibody M336 In Complex With Mers Co-V Rbd,Crystal Structure Of Potent Neutralizing Antibody M336 In Complex With Mers Co-V Rbd,Homo sapiens,"Ying,T.;Prabakaran,P.;Du,L.;Shi,W.;Feng,Y.;Wang,Y.;Wang,L.;Li,W.;Jiang,S.;Dimitrov,D.S.;Zhou,T.",Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody,15-DEC-2014,8_8_18_6_3_9,QHX54798,Xtal structure,MERS; CoV,2,1,-0.845477,5.9370055
CBX51870,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPLFDTSNYAQNFQGRITITADKSTSTAYMELSSLRFEDTAIYYCARDNPLLLAMDVWGKGTTVTVSS,DIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIK,CBX51870_H,CBX51870_L,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Shiver,J.; Miller,M.; Geleziunas,R.; Hazuda,D.; Kim,P.; Root,M.; Eckert,D.; Lennard,S.; Bianchi,E.",Human antibodies interacting with hiv gp41,31-OCT-2010,8_8_12_6_3_9,ADR90815,Same entry,,2,1,-0.668355,5.9230185
7M6I_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIISMFGIANNAQKFQGRLTITADTSTSTAYMELSSLRSEDTAVYYCARGPYYYDSGGYYLDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSGYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPRTFGQGTRLEIK,7M6I_H,7M6I_L,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg1-24","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg1-24",Homo sapiens,"Scheid,J.F.;Barnes,C.O.;Eraslan,B.;Hudak,A.;Keeffe,J.R.;Cosimi,L.A.;Brown,E.M.;Muecksch,F.;Weisblum,Y.;Zhang,S.;Delorey,T.;Woolley,A.E.;Ghantous,F.;Park,S.M.;Phillips,D.;Tusi,B.;Huey-Tubman,K.E.;Cohen,A.A.;Gnanapragasam,P.N.;Rzasa,K.;Hatziioanno,T.;Durney,M.A.;Gu,X.;Tada,T.;Landau,N.R.;West AP,Jr.;Rozenblatt-Rosen,O.;Seaman,M.S.;Baden,L.R.;Graham,D.B.;Deguine,J.;Bieniasz,P.D.;Regev,A.;Hung,D.;Bjorkman,P.J.;Xavier,R.J.",B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV,25-MAR-2021,8_8_16_7_3_9,7M6I_H_L,Xtal structure,SARS-CoV-2; SARS; CoV,2,1,-0.74958634,5.5681257
QEP20392_QEP21040,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGRIIPIFGTPNYAQQFQGRVTIGADISTSTAYMELSSLRSEDTAVYYCARDGEVVVVPSTIPQYYYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGVGNDLGWYQQKPGKAPKRLIYVASNLQSGVPSRFSGSGSGTEFTLTISNLQPEDFATYFCLQHNSFPRTFGQGTKVEIK,QEP20392,QEP21040,"IGH + IGL c499_heavy_IGHV1-69_IGHD2-2_IGHJ6, partial [Homo sapiens]","IGH + IGL c499_light_IGKV1-17_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_22_6_3_9,QEP20392_QEP21040,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,-0.91992813,6.0903196
5XMH_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYPISWVRQAPGQGLEWVGGIIPLFGTANYAQRFQGRVTITADESTRTAYMEVSTLRSEDTAVYYCARGIASAGTPDYFFYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQRPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,5XMH_H,5XMH_L,Crystal Structure Of An Igm Rheumatoid Factor Yes8C In Complex With Igg1 Fc,Crystal Structure Of An Igm Rheumatoid Factor Yes8C In Complex With Igg1 Fc,Homo sapiens,"Shiroishi,M.;Ito,Y.;Shimokawa,K.;Lee,J.M.;Kusakabe,T.;Ueda,T.",Structure-function analyses of a stereotypic rheumatoid factor unravel the structural basis for germline-encoded antibody autoreactivity,15-MAY-2017,8_8_15_7_3_9,5XMH_H_L,Xtal structure,,2,1,-0.4505978,5.6789536
QKY76337_QKY75950,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYSITWVRQAPGQGLEWMGRIIPVLGIANYAQKFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARVGVSGFKSGSNWYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTLSCTGSNSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSDSVFGGGTKVTVL,QKY76337,QKY75950,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_18_9_3_11,QKY76337_QKY75950,Unique source,SARS-CoV-2,2,1,-1.0041734,5.5580254
6VGR_C_D,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK,6VGR_C,6VGR_D,Crystal Structure Of Human Dipeptidase 3 In Complex With Fab Of Sc-003,Crystal Structure Of Human Dipeptidase 3 In Complex With Fab Of Sc-003,Homo sapiens,"Hayashi,K.;Longenecker,K.L.;Koenig,P.;Prashar,A.;Hampl,J.;Stoll,V.;Vivona,S.",Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity,13-MAY-2020,8_8_16_7_3_9,QBE30019_QBE30018,Xtal structure,DPEP3,2,1,0.71208227,3.9962456
QKK35872_QKK35873,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTHAISWVRQAPGHGPEWLGGIIPLFGTSESAQRFQARVKITADESTSTAYMELSSLTSEDTAVYYCVRDSDPYTATSRNNHYWYAMDVWGQGTTVTVSS,DIVLTQSPLSLPVTLGQPASISCRSSQSVVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTDWPRTFGQGTKVDIK,QKK35872,QKK35873,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35872_QKK35873,Unique source,SARS-CoV-2,2,1,3.078195,-13.226674
QKK35848_QKK35849,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTHAISWVRQAPGHGPEWLGGILPLFGTSESAQRFQARVKITADESTSTAYMELSSLTSEDTAVYYCVRDSDPYTATSRNNHYWYAMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQSVVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTDWPRTFGQGTKVEIK,QKK35848,QKK35849,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35848_QKK35849,Unique source,SARS-CoV-2,2,1,3.0541968,-13.250654
QKK35798_QKK35799,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTHAISWVRQAPGHGPEWMGGIIPLFGTSESAQRFQARVRFTADESTSTAYMELSSLTSEDTAVYYCVRDSDPYTATSRNNHYWYDMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQIVVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTDWPRTFGQGTKVDIK,QKK35798,QKK35799,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35798_QKK35799,Unique source,SARS-CoV-2,2,1,3.0685585,-13.236306
QKK35768_QKK35769,QVQLVQSGAEVKKPGSSVKVSCKASGGTLADYAISWVRQAPGQGLEWMGGIKPLHGAAGYSQHFRGRLSITADESASTAYMELTGLRSEDTAMYYCARDPSILNTGNHHWYDLDLWGQGTMVTVSS,DIRLTQSPLSLPVTLGQAASISCKSSHFIVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLEISGVEAEDVGVYYCMQGTEWPRTFGQGTKVDIK,QKK35768,QKK35769,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35768_QKK35769,Unique source,SARS-CoV-2,2,1,-6.473232,-2.6019833
QKK35552_QKK35553,QVQLVQSGAEVKKPGSSVKVSCKASGGTLADYAISWVRQAPGQGLEWMGGIKPLHGAAGYSQLFRGRLSITADESASTAYMELTGLTSDDTAMYYCARDPSILNTGNHHWYDLDLWGQGTTVTVSS,DIQMTQSPLSLPVTLGQAASISCRSSQPIPHTDGNTYLNWFHQRPGQSPRRLIHKVSNRDSGVPDRFSGSGSGLDFTLEISGVEAEDVGIYYCMQGTEWPRTFGQGTKVEIK,QKK35552,QKK35553,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35552_QKK35553,Unique source,SARS-CoV-2,2,1,-6.470842,-2.6038933
QKK35642_QKK35643,QVQLVQSGAEVKKPGSSVKVSCKASGGTLSDYAISWVRQAPGQGLEWMGGIMPVFGSPGYAEIFQGRLTITADESRSTAYMELTSLRSEDTAVYYCARDPSILNTGPHHWYDLDIWGPGTTVTVSS,DIVMTQSPLSLPVSLGQPASISCRSSQSVVHTDGNTYLNWYQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSVTDFTLKISRVEAEDVAVYYCMQGTEWPRTFGQGTKVDIK,QKK35642,QKK35643,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35642_QKK35643,Unique source,SARS-CoV-2,2,1,-6.470668,-2.6043744
QKK35788_QKK35789,QVQLVQSGAEVKKPGSSVKVSCKASGGTLSHYAISWVRQAPGQGLEWMGGIMPVSGTVGYAQKFQGRVKFTADEYASTAYMELTNLRSEDSAVYFCARDPSIVDSGPHHWYDLDIWGQGTMVTVSS,DIRMTQSPLSLPVTLGQPASISCRSSQFVVHTDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQATEWPRTFGQGTKVDIK,QKK35788,QKK35789,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35788_QKK35789,Unique source,SARS-CoV-2,2,1,-6.461969,-2.6133866
6KVA_h_l,QVQLVQSGAEVKKPGSSVKVSCKASGGTLSSYAISWVRQAPGQGPEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRPDDTAVYYCASGYCSRTRCYDYWGQGTLVTVSS,QAVLTQPSSLSASPGASVSLTCTLRSGINVGAYRIYWYQQKPGSPPQFLLRYKSDSDKQQGSGVPSRFSGSRDASANAGILLISGLRSEDEADYYCAIWHSSAWVFGGGTQLTVL,6KVA_h,6KVA_l,Structure Of Anti-Hcxcr2 Abn48-2 In Complex With Its Cxcr2 Epitope,Structure Of Anti-Hcxcr2 Abn48-2 In Complex With Its Cxcr2 Epitope,Homo sapiens,"Shi,X.;Wan,Y.;Wang,N.;Xiang,J.;Wang,T.;Yang,X.;Wang,J.;Dong,X.;Dong,L.;Yan,L.;Li,Y.;Liu,L.;Hou,S.;Zhong,Z.;Wilson,I.A.;Yang,B.;Yang,G.;Lerner,R.A.",Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms,03-SEP-2019,8_8_13_9_7_9,6KVA_h_l,Xtal structure,IL8RB; CXCR2; CMKAR2; CD182,2,1,2.2857704,3.9209602
6KVF_A_C,QVQLVQSGAEVKKPGSSVKVSCKASGGTLSSYAISWVRQAPGQGPEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRPDDTAVYYCASGYCSSTSCYDYWGQGTLVTVSS,QAVLTQPSSLSASPGASVSLTCTLRSGINVGAYRIYWYQQKPGSPPQFLLRYKSDSDKQQGSGVPSRFSGSRDASANAGILLISGLRSEDEADYYCAIWHSSAWVFGGGTQLTVL,6KVF_A,6KVF_C,Structure Of Anti-Hcxcr2 Abn48 In Complex With Its Cxcr2 Epitope,Structure Of Anti-Hcxcr2 Abn48 In Complex With Its Cxcr2 Epitope,Homo sapiens,"Shi,X.;Wan,Y.;Wang,N.;Xiang,J.;Wang,T.;Yang,X.;Wang,J.;Dong,X.;Dong,L.;Yan,L.;Li,Y.;Liu,L.;Hou,S.;Zhong,Z.;Wilson,I.A.;Yang,B.;Yang,G.;Lerner,R.A.",Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms,04-SEP-2019,8_8_13_9_7_9,6KVF_A_C,Xtal structure,IL8RB; CXCR2; CMKAR2; CD182,2,1,2.2912853,3.8821826
6WO5_G_I,QVQLVQSGAEVKKPGSSVKVSCKASGGTLSSYGISWVRQAPGQGLEWLGGSIPILGTSVYAQKFQGRVTMTADESTSTAHMELSSLRFDDTAIYYCAGVREGMAAISGKNAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGYGTEFTLTISSLQPEDVATYYCQQHDNLPLTFGGGTKVEIK,6WO5_G,6WO5_I,Structure Of Hepatitis C Virus Envelope Glycoprotein E2 Core From Genotype 1A Bound To Neutralizing Antibody 212.1.1 And Non Neutralizing Antibody E1,Structure Of Hepatitis C Virus Envelope Glycoprotein E2 Core From Genotype 1A Bound To Neutralizing Antibody 212.1.1 And Non Neutralizing Antibody E1,Hepatitis C virus (isolate H),"Tzarum,N.;Giang,E.;Kadam,R.U.;Chen,F.;Nagy,K.;Augestad,E.H.;Velazquez-Moctezuma,R.;Keck,Z.Y.;Hua,Y.;Stanfield,R.L.;Dreux,M.;Prentoe,J.;Foung,S.K.;Bukh,J.;Wilson,I.A.;Law,M.",An alternate conformation of HCV E2 neutralizing face as an additional vaccine target,24-APR-2020,8_8_18_6_3_9,6WO5_G_I,Xtal structure,Hepatitis; HCV,2,1,-0.7544311,5.977614
QKK35544_QKK35545,QVQLVQSGAEVKKPGSSVKVSCKASGGTSSTHAISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQDRVTITADESTSTAYMELSSLRSEDTAVYFCVRDGAYDSSGYYSTQWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSNFLAWYQQKPGQPPRLLIYDASNRASGIAARFSGRGSGTDFTLTISSLEPEDFAVYYCQQRRNWPPMYTFGQGTKLEIK,QKK35544,QKK35545,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_11,QKK35544_QKK35545,Unique source,SARS-CoV-2,2,1,-0.6013736,5.8796363
6XP6_H_G,QVQLVQSGAEVKKPGSSVKVSCKASGGTVRSRVHAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDVQRMGMDVWGQGTTVTVSS,DIQMTQSPSSVSTSVGDRVTITCRASQDISNWLAWYQQKPGKAPKLLIYDSSTLQSGVPSRFSGSGSGTDFTLTISTLQPEDFATYYCQQFNSYPLTFGGGTKVDIK,6XP6_H,6XP6_G,3C11-Dq2-Glia-A2 Complex,3C11-Dq2-Glia-A2 Complex,Triticum aestivum,"Frick,R.;Hoydahl,L.S.;Petersen,J.;du Pre,M.F.;Kumari,S.;Berntsen,G.;Dewan,A.E.;Jeliazkov,J.R.;Gunnarsen,K.S.;Frigstad,T.;Vik,E.S.;Llerena,C.;Lundin,K.E.;Yaqub,S.;Jahnsen,J.;Gray,J.J.;Rossjohn,J.;Sollid,L.M.;Sandlie,I.;Loset,G.A.",A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation,08-JUL-2020,10_8_11_6_3_9,6XP6_H_G,Xtal structure,,2,1,-0.58821017,5.9404535
8ATH_E_F,QVQLVQSGAEVKKPGSSVKVSCKASGYIFTNYNIHWVKKSPGQGLEWIGAIYPGNGDAPYSQKFQGKATLTADTSTSTTYMELSSLRSEDTAVYYCVRANWDVAFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDIDRYMAWYQDKPGKAPRLLIHDTSTLQSGVPSRFSGSGSGRDYTLTISNLEPEDFATYYCLQYDNLWTFGGGTKVEIK,8ATH_E,8ATH_F,Crystal Structure Of Lamp1 In Complex With Fab-B.,Crystal Structure Of Lamp1 In Complex With Fab-B.,Homo sapiens,"Pruvost,T.;Mathieu,M.;Dubois,S.;Maill&#xe8;re,B.;Vigne,E.;Nozach,H.",Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold,01-MAR-2023,8_8_11_6_3_8,AVC34290_AVC34289,Xtal structure,LAMP-1,2,1,0.7632438,3.805099
6NOV_C_D,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,6NOV_C,6NOV_D,A Fab Derived From Ixekizumab,A Fab Derived From Ixekizumab,Homo sapiens,"Chow,C.K.;Allan,B.W.;Chai,Q.;Atwell,S.;Lu,J.",Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure,16-JAN-2019,8_8_12_11_3_9,ADT45184_ADT45183,Xtal structure,,2,1,0.54043293,4.0540066
6IAS_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQGLEWMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRSEDTAVYYCARRGRYGLYAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTRPWTFGGGTKVEIK,6IAS_H,6IAS_L,Structure Of Human Nkp46 In Complex With Antibody Nkp46-1 And Nkp46-4,Structure Of Human Nkp46 In Complex With Antibody Nkp46-1 And Nkp46-4,synthetic construct,"Gauthier,L.;Morel,A.;Anceriz,N.;Rossi,B.;Blanchard-Alvarez,A.;Grondin,G.;Trichard,S.;Cesari,C.;Sapet,M.;Bosco,F.;Rispaud-Blanc,H.;Guillot,F.;Cornen,S.;Roussel,A.;Amigues,B.;Habif,G.;Caraguel,F.;Arrufat,S.;Remark,R.;Romagne,F.;Morel,Y.;Narni-Mancinelli,E.;Vivier,E.",Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity,27-NOV-2018,8_8_13_6_3_9,6IAS_H_L,Xtal structure,,2,1,0.6460663,3.945162
7Q4Q_B_A,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSGYWMNWVRQAPGQGLEWIGQIYPGDGDTNYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSITTVVLDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCRASQSVSTSGYSFMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEMPLTFGQGTKLEIK,7Q4Q_B,7Q4Q_A,Magacizumab Fab Fragment In Complex With Human Lrg1 Epitope,Magacizumab Fab Fragment In Complex With Human Lrg1 Epitope,Homo sapiens,"Gutierrez-Fernandez,J.;Javaid,F.;De Rossi,G.;Chudasama,V.;Greenwood,J.;Moss,S.E.;Luecke,H.","Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential",01-NOV-2021,8_8_11_10_3_9,QKP00720_QKP00723,Xtal structure,LRG1; LRG,2,1,0.63286656,3.9318104
5KN5_D_E,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSIVHSTGNTYLEWYQQKPGQPPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFHGTHVPYTFGGGTKVEIK,5KN5_D,5KN5_E,Tgfalpha/Epiregulin Complex With Neutralizing Antibody Ly3016859,Tgfalpha/Epiregulin Complex With Neutralizing Antibody Ly3016859,Homo sapiens,"Boyles,J.S.;Atwell,S.;Druzina,Z.;Heuer,J.G.;Witcher,D.R.",Structural basis of selectivity and neutralizing activity of a TGFalpha/epiregulin specific antibody,27-JUN-2016,8_8_11_11_3_9,AHE15531_AHE15533,Xtal structure,TGFalpha,2,1,0.6288954,3.9391105
3HC0_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYYLHWVRQAPGQGLEWMGWIYPGNVHAQYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSWEGFPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGINVAWYQQKPGKAPKSLISSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQYDTYPFTFGQGTKVEIK,3HC0_H,3HC0_L,Bha10 Igg1 Wild-Type Fab - Antibody Directed At Human Ltbr,Bha10 Igg1 Wild-Type Fab - Antibody Directed At Human Ltbr,Homo sapiens,"Jordan,J.L.;Arndt,J.W.;Hanf,K.;Li,G.;Hall,J.;Demarest,S.;Huang,F.;Wu,X.;Miller,B.;Glaser,S.;Fernandez,E.J.;Wang,D.;Lugovskoy,A.",Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules,05-MAY-2009,8_8_9_6_3_9,ACK04245_ACK04241,Xtal structure,,2,1,0.62479,3.946044
QKK35508_QKK35509,QVQLVQSGAEVKKPGSSVKVSCKISGGTFKNSAFSWARQVPGQGFQWMGGIIPMFGVPHSVQMFQGRVTLTADESTSAVYMELSGLTSDDTAVYYCAREEYSGTVHNFFGMDVWGQGTTVTVSS,DIRMTQSPLSLPVTRGQPASISCRSSHNVVHSDGKTYLNWFHQRPGQAPRRLIYQVSKRDSGVPDRFSGSGSGSDFTLTISRVEAEDVGVYYCMQGTDWPRSFGGGTKVEIK,QKK35508,QKK35509,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_11_3_9,QKK35508_QKK35509,Unique source,SARS-CoV-2,2,1,-0.66308814,5.989402
QKK35764_QKK35765,QVQLVQSGAEVKKPGSSVKVSCKTSGATYKNSAFSWARQAPGQGFQWMGGIIPLFGVPHYVQMFQGRVTITADESTSAVYMELSGLTSDDTAVYYCAREEYSGTVHNFFGMDVWGQGTTVTVSS,DIVMTQSPLSLPVSRGQSASISCRSSHSVVHSDGKTYVNWFHQRPGQAPRRLIYQVSKRDSGVPDRFSGSGSGFDFTLKISRVEAEDVGVYFCMQGTDWPRSFGGGTKVDIK,QKK35764,QKK35765,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_11_3_9,QKK35764_QKK35765,Unique source,SARS-CoV-2,2,1,-0.5891043,6.1122246
QKK35734_QKK35735,QVQLVQSGAEVKKPGSSVKVSCKTSGGSFTSYVLSWVRQAPGQGLEWMGRIVPNLGVANYAQKFQDRVTITADKSTTTAYLELRSLRSEDTAVYYCARDLYYDNGGYNYLDYWGPGTLVTVSS,QPVLTQSSSASASLGSSVKLTCTLRSGHSSYIIAWHQQQPGKAPRFLMKVGHSGSYNKGSGVPDRFSGSRSGADHYLTISNLQPDDEADYYCEAWDNNNLGVFSGGTKVTVL,QKK35734,QKK35735,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_7_7_10,QKK35734_QKK35735,Unique source,SARS-CoV-2,2,1,-0.9859901,5.633714
AHJ39756_AHJ39695,QVQLVQSGAEVKKPGSSVKVSCKTSGGTFSTYAISWMRQAPGQGLEWMGGIIPIFGTPRYAPKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARVSGDYKAYYYYGLDVWGQGTTVTVSS,PVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQATQFPLTFGQGTKVEIK,AHJ39756,AHJ39695,"H1/H5 cross-reactive influenza antibody heavy chain VDJ region immunoglobulin, partial [Homo sapiens]","H1/H5 cross-reactive influenza antibody kappa chain VJ region immunoglobulin, partial [Homo sapiens]",Homo sapiens,"Whittle,J.R.; Wheatley,A.K.; Wu,L.; Lingwood,D.; Kanekiyo,M.; Ma,S.S.; Narpala,S.R.; Yassine,H.M.; Frank,G.M.; Yewdell,J.W.; Ledgerwood,J.E.; Wei,C.J.; McDermott,A.B.; Graham,B.S.; Koup,R.A.; Nabel,G.J.",Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages,07-APR-2014,8_8_17_11_3_9,AHJ39756_AHJ39695,Unique source,H5N1,2,1,-0.7288075,6.068197
QKK35572_QKK35573,QVQLVQSGAEVKKPGSSVKVSCKVSGGMFSDYAISWVRQAPGQRLEWMGGIMPGLGSPAYAQIFRGRVTISADISTSTAYLEVTSLRPEDTAVYYCARDPSILNTGNHHWYDLDMWGQGTTVTVSS,ETTLTQSPLSLPVDLGQSASISCRSSQRVVHTNGNTYLHWFHQRPGQAPRRLIYKVSNRESGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQATDWPRTFGQGTKVEIK,QKK35572,QKK35573,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35572_QKK35573,Unique source,SARS-CoV-2,2,1,-6.38185,-2.6928604
QKK35800_QKK35801,QVQLVQSGAEVKKPGSSVKVSCKVSGGRFSDYAISWLRQAPVKGLEWMGGIIPRLNRKGYSQDFQGRLTFTADESTSTAYMELSGLTSEDTAVYYCARDPTFLNSGNHFWYAVDIWGQGTTVTVSS,DIRLTQSPLSLSVTLGQAASISCTCSQTAVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQTTDWPRTFGQGTKVEIK,QKK35800,QKK35801,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35800_QKK35801,Unique source,SARS-CoV-2,2,1,-6.62427,-2.4433842
QKK35558_QKK35559,QVQLVQSGAEVKKPGSSVKVSCKVSGGTFSNYAISWLRQAPGQGPEWMGGIIPALSRVGYARKFQARLTISADELTTTAYMDLSSLTSEDTAVYYCARDPSFLNTGNHFWYDFDMWGQGTTVTVSS,DIQLTQSPLSLPVTLGQPASISCTSSQNVVHTDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGSHFTLKISRVEAEDVGIYYCMQGTDWPRTFGQGTKVEIK,QKK35558,QKK35559,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35558_QKK35559,Unique source,SARS-CoV-2,2,1,-6.625197,-2.4452233
QKK35850_QKK35851,QVQLVQSGAEVKKPGSSVKVSCKVSGGTFSNYAISWLRQAPGQGPEWMGGIIPALSRVGYVRKFQARLTISADELTTTAYMDLSSLTSEDTAVYYCARDPSFLNTGNHFWYDFDLWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCTSSQTVVHTDRNTYLNWYHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGSHFTLKISRVEAEDVGVYYCMQGTEWPRTFGQGTKLEIK,QKK35850,QKK35851,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35850_QKK35851,Unique source,SARS-CoV-2,2,1,-6.6058865,-2.4652727
QKK35860_QKK35861,QVQLVQSGAEVKKPGSSVKVSCKVSGGTFSSHAISWVRQAPGQRPEWMGGIMPIFGESKDTQKFQGRVTFTVDESTNTAYMELTSLKSEDTAIYYCVRDPDPYTATVRHNHYWHGMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQAASISCRSSQAVVHSDGNTYLNWFQQRPGQPPRRLIYKVSNRDSGVPDRFSGSGSGTVFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVEIK,QKK35860,QKK35861,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35860_QKK35861,Unique source,SARS-CoV-2,2,1,3.0478675,-13.25723
QKK35698_QKK35699,QVQLVQSGAEVKKPGSSVKVSCRVSGGRFSDYAFSWLRQAPVKGLEWMGGIIPRLDRKGYSHIFQDRLTFTADESTSTTYMELSGLTSDDTAVYYCARDPTFLNSGNHFWYDVDIWGQGTTVTVSS,DIVMTQSPLSLSVTLGQAASISCTCSQTAVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKINRVEAEDVGIYYCMQTTDWPRTFGQGTKVEIK,QKK35698,QKK35699,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35698_QKK35699,Unique source,SARS-CoV-2,2,1,-6.665926,-2.4035108
CAX69303,QVQLVQSGAEVKKPGSSVQVSCKASGGTFSMYGFNWVRQAPGHGLEWMGGIIPIFGTSNYAQKFRGRVTFTADQATSTAYMELTNLRSDDTAVYYCARDFGPDWEDGDSYDGSGRGFFDFWGQGTLVTVSS,DIVLTQSPGTLSLSAGERATLSCRASQSVSSGSLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTIGRLEPEDLAVYYCQQYGTSPYTFGQGTKVDIK,CAX69303_H,CAX69303_L,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"Clark,K.R.; Johnson,P.R.",Antibody gene transfer and recombinant AAV therefor,09-APR-2009,8_8_24_7_3_9,CAX69303,Same entry,,2,1,-0.8500267,5.4489017
5W4L_D_E,QVQLVQSGAEVKKPGSSVRVSCKASGGSFSRYTVNWVRQAPGQGLEWMARFIPIFNMPDYAPKFQGRITITADESTSTAYLELSSLTSDDTAVYYCASRQHHEYFQEWGQGTLVTVSS,EIVLTQSPGTLSMSPGERATLSCRASRTVSSSNLAWYQQKPGQAPRLLIYDVSSRATGIPDRFSGRGSGTDFTLTISRLEPEDFAVYYCQQYGTSPLTFGGGTKVEIK,5W4L_D,5W4L_E,"Crystal Structure Of The Non-Neutralizing And Adcc-Potent C11-Like Antibody N12-I3 In Complex With Hiv-1 Clade A/E Gp120, The Cd4 Mimetic M48U1, And The Antibody N5-I5.","Crystal Structure Of The Non-Neutralizing And Adcc-Potent C11-Like Antibody N12-I3 In Complex With Hiv-1 Clade A/E Gp120, The Cd4 Mimetic M48U1, And The Antibody N5-I5.",Homo sapiens,"Tolbert,W.D.;Gohain,N.;Alsahafi,N.;Van,V.;Orlandi,C.;Ding,S.;Martin,L.;Finzi,A.;Lewis,G.K.;Ray,K.;Pazgier,M.",Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region,12-JUN-2017,8_8_11_7_3_9,5W4L_D_E,Xtal structure,HAKRA; CHDR; AKR1C4; DD4; CDR; 3-alpha-HSD; HIV; MGC22581; C11,2,1,-0.46232203,5.760886
UIC72041_UIC72351,QVQLVQSGAEVKKPGSSVRVSCTASGGTFSSYSLTWVRQAPGQVLEWMGGIIPMSGAETYAQKFQGRVTITADESTSTAYMELTNLRSEDTATYYCASGSPTYGAPWIFWGQGTLVTVSS,DIQMTQSPSSLSQSVGDRVTITCRASQSIGRYLNWYQQKPGKAPKLLIYAASSLQSGVSSRFSGSASGTDFTLTISSLQTEDSATYYCQQTYSMLITFGQGTRLEIK,UIC72041,UIC72351,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_13_6_3_9,UIC72041_UIC72351,Unique source,HCV,2,1,-0.6261125,5.6643
6UUL_A_B,QVQLVQSGAEVKKPGSSVTISCKPVGGTFTNFAIHWVRQAPGQGLEWVGGRVPVVGIYKYGKKFHDRLRLYEDDPMKTVFLELRSLTSDDTGVYYCTRWRGCGMCPYDTSSYYNDASDVWGPGTKVIVSA,EIVLTQSPVTLSLSSGETGTLSCRASQNISSSWIAWYQQRRGQVPRLLISAASARAAGIPDRFTGRGSGTDFTLTITRLEPEDLGVYSCQYYGGSFFTFGPGTQVDVK,6UUL_A,6UUL_B,Crystal Structure Of Broad And Potent Hiv-1 Neutralizing Antibody 438-D5,Crystal Structure Of Broad And Potent Hiv-1 Neutralizing Antibody 438-D5,Homo sapiens,"Kumar,S.;Ju,B.;Shapero,B.;Lin,X.;Ren,L.;Zhang,L.;Li,D.;Zhou,Z.;Feng,Y.;Sou,C.;Mann,C.J.;Hao,Y.;Sarkar,A.;Hou,J.;Nunnally,C.;Hong,K.;Wang,S.;Ge,X.;Su,B.;Landais,E.;Sok,D.;Zwick,M.B.;He,L.;Zhu,J.;Wilson,I.A.;Shao,Y.",A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite,30-OCT-2019,8_8_23_7_3_9,6UUL_A_B,Xtal structure,HIV,2,1,-0.96880126,6.1361995
QKK35548_QKK35549,QVQLVQSGAEVKKPGSSVTVSCKVSGGRFSDYAISWLRQAPVEGLEWMGGIIPHLNKKGYSQKFQDRITFTADESTSTAYMELSGLTSEDTAIYYCARDPTFLNTGNHFWYAVDIWGQGTTVTVSS,ETTLTQSPLSLSVTLGQAASISCTCSQSAVHSDGNTYFNWFHQRPGQSPRRLIYKVSNRDSGVPERFSGSGSGTHFTLIISRVEAEDVGVYYCMQTTDWPRTFGQGTKVDIK,QKK35548,QKK35549,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35548_QKK35549,Unique source,SARS-CoV-2,2,1,-6.661679,-2.4074516
AAW68487_AAW68909,QVQLVQSGAEVKKPGTSVRVSCKTSGGYVFSWVRQAPGQGPEWMGGIITNFGTTSYAQKFQGRVTFTADKPTNTVYMDLNNLISADTAVYYCARAPRGTSTIAARFNRYFFDSWGQGTLVTV,EIVMTQSPATLPLSPGERATLSCRASQSISNLLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRLWYTFGQGTKLEIK,AAW68487,AAW68909,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,4_8_21_6_3_8,AAW68487_AAW68909,Unique source,tetanus,2,1,21.696444,11.851105
QKK35846_QKK35847,QVQLVQSGAEVKMPGSSVKVSCKVSGGRFSDYAISWLRQAPLEGLEWMGGIVPHLNRKGYSQKFQDRLTFTADDSTSTAYMELSGLTSEDTAVYYCARDPTFLNTGNHFWYAVDIWGQGTTVTVSS,DIRLTQSPLSLSVTLGQAASISCTCSQSAVHSDGTTYFNWFHQRPGQSPRRLIYKVSNRDSGVPDRFIGSGSGTHFTLKISRVEAEDVGVYYCMQTTDWPRTFGQGTKVEIK,QKK35846,QKK35847,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_11_3_9,QKK35846_QKK35847,Unique source,SARS-CoV-2,2,1,-6.623641,-2.4463427
QWQ58066_QWQ58108,QVQLVQSGAEVKRPGASLKVSCKASGYSFTTYGITWVRQAPGQGLEWMGWISTYNGYTNYAQRLQGRVTMTTDTSTGTAYLELRSLTYDDTAVYYCARRGDYGDYRGDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDVSNYLNWYQQKPGKAPKLLIYDTSNLETGVPSRFSGTGSGTDFTFTISSLQPEDVATYFCQQVFTFGPGTKVDIK,QWQ58066,QWQ58108,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Li,L.; Freyn,A.W.; Liu,S.T.H.; Stovicek,O.; Stamper,C.T.; Dugan,H.L.; Tepora,M.E.; Utset,H.A.; Bitar,D.J.; Hamel,N.J.; Changrob,S.; Zheng,N.Y.; Huang,M.; Krammer,F.; Nachbagauer,R.; Palese,P.; Ward,A.B.; Wilson,P.C.",First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,19-JUN-2021,8_8_16_6_3_5,QWQ58066_QWQ58108,Unique source,hemagglutinin; H1N1,2,1,1.9342617,5.2887597
ANY91548_ANY91069,QVQLVQSGAEVKRPGASVKVSCKASGYTFSSFGISWVRQAPGQGLEWLGWISGYTGNTDYAQKFQGRVTMTTDTSTNTAYMELRSLRSDDTAVYYCARDKKQGEVVLPAASFRWFAPWGQGTLVTVSS,DIQMTQGPVSLSASVGDRVTITCRASQSIARFLNWYQQKPGRAPKLLIYYASSLESGGPSRFSGRGSGTDFTLTISALQPEDFATYYCQQSYSAPYTFGQGTNLEIK,ANY91548,ANY91069,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_21_6_3_9,ANY91548_ANY91069,Unique source,Influenza,2,1,1.8933005,5.321801
ANY91538_ANY91060,QVQLVQSGAEVKRPGASVKVSCKASGYTFTSFGISWVRQAPGQGLEWLGWISGYTGNTDYAQKFQGRVTMTTDTSTNTAYMELRSLRSDDTAVYYCARDKKQGEVVLPAASFRWFAPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIARFLNWYQQKPGRAPKLLIYYASSLESGGPSRFSGRGSGTDFTLTISALQPEDFATYYCQQSYSAPYTFGQGTNLEIK,ANY91538,ANY91060,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_21_6_3_9,ANY91538_ANY91060,Unique source,Influenza,2,1,1.9562263,5.3846416
UIC72058_UIC72368,QVQLVQSGAEVKRPGSSVKVSCKASGDTVTSQVISWVRQAPGQGLEWMGMIIPVFERTKMAQKFQDRMSLTADRSTSTVSMELKSLTSEDTAVYYCATTDMVFRGIVGGLPSAYYFDHWGQGALVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSISTYLAWYQQKPGQSPRLLIYDASKRAAGIPPRFSGSGSGTDFTLTISSLEPEDFAFYYCQQRANWPPVTFGQGTRLEIQ,UIC72058,UIC72368,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_22_6_3_10,UIC72058_UIC72368,Unique source,HCV,2,1,-0.70764893,5.542773
7COE_H_L,QVQLVQSGAEVKRPGSSVKVSCKTSGGTFNNNAINWVRQAPGQGLEWMGGIIPFFGIAKYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDLPRESSYGSGSYYTHYYAMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCGASQSVSSSYLAWYQQKPGLAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,7COE_H,7COE_L,Crystal Structure Of Receptor Binding Domain Of Mers-Cov And Knih90-F1 Fab Complex,Crystal Structure Of Receptor Binding Domain Of Mers-Cov And Knih90-F1 Fab Complex,Middle East respiratory syndrome-related coronavirus,"Jang,T.H.;Park,W.J.;Lee,H.;Woo,H.M.;Lee,S.Y.;Kim,K.C.;Kim,S.S.;Hong,E.;Song,J.;Lee,J.Y.",The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections,04-AUG-2020,8_8_24_7_3_9,7COE_H_L,Xtal structure,,2,1,-0.90016896,6.146576
6P9H_H_L,QVQLVQSGAEVKRPGSSVRVSCKDSGDSFRRYVINWVRQAPGQGLEWMGGIIPIFDKAKSVQKFQDRLTITADESTSTSYMELSSLTSEDTAVYYCARKEDGRRDDVFDIWGQGTLVTVSS,EIVMTQSPATLSVSLGERATLSCRASHSVGSSLAWYQQKPGLAPRLLIYGVSTRATGIPARFSGSGSATEFTLTISSLQSEDLAAYHCQQYDNWPFTFGQGTKLEIK,6P9H_H,6P9H_L,Crystal Structure Of Human Anti Staphylococcus Aureus Antibody Stau-281 Fab In Complex With Isdb Neat2 Domain,Crystal Structure Of Human Anti Staphylococcus Aureus Antibody Stau-281 Fab In Complex With Isdb Neat2 Domain,Homo sapiens,"Dong,J.;Crowe,J.E.",Crystal structure of human anti staphylococcus aureus antibody STAU-281 Fab in complex with IsdB NEAT2 domain,17-JUN-2020,8_8_14_6_3_9,6P9H_H_L,Xtal structure,PPP1R150; STAU; STAU1,2,1,-0.6094827,5.71558
6UQR_C_C,QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK,6UQR_C,6UQR_C,Complex Of Ige And Ligelizumab,Complex Of Ige And Ligelizumab,Homo sapiens,"Gasser,P.;Tarchevskaya,S.S.;Guntern,P.;Brigger,D.;Ruppli,R.;Zbaren,N.;Kleinboelting,S.;Heusser,C.;Jardetzky,T.S.;Eggel,A.",The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab,21-OCT-2019,8_8_16_6_3_9,ACS02769_ACS02768,Xtal structure,IgE,2,1,0.6258293,4.0801773
QKK35874_QKK35875,QVQLVQSGAEVREPGSSVKLSCKTSGGPFSTHAFSWVRQAPGQRPEWMGGIMPVFGESKDTQKFKGRVTFTADASTTTTYMELRSLKSDDTAIYYCVRDSDPYTATSSHNHYWYAMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQVLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGIDFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVDIK,QKK35874,QKK35875,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35874_QKK35875,Unique source,SARS-CoV-2,2,1,3.028607,-13.276622
QKK35822_QKK35823,QVQLVQSGAEVREPGSSVKLSCKTSGGTFSTHAISWVRQAPGQRPEWMGGIMPIFGESKDTQKFQGRVTFTADESTTTAYMELRSLKSDDTAIYYCVRDSDPYTATVRSNHYWYAMDVWGQGTTVTVSS,ETTLTQSPLSLAVTLGQPASISCRSSLGLVHTNGNTYLNWFQQRPGQSPRRLIYRVSNRDSGVPDRFSGSGSVTDFTLTISRVEAEDIGVYYCMQGTEWPRTFGQGTKVEIK,QKK35822,QKK35823,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35822_QKK35823,Unique source,SARS-CoV-2,2,1,3.049252,-13.255985
CBX51867,QVQLVQSGAEVRKPGASVKVSCKASGDTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAIYYCARDNPTLLGSDYWGKGTLVTVSS,DIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIK,CBX51867_H,CBX51867_L,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Shiver,J.; Miller,M.; Geleziunas,R.; Hazuda,D.; Kim,P.; Root,M.; Eckert,D.; Lennard,S.; Bianchi,E.",Human antibodies interacting with hiv gp41,31-OCT-2010,8_8_12_6_3_9,ADR90812,Same entry,,2,1,-0.57445824,5.793334
6PHF_A_B,QVQLVQSGAEVRKPGASVKVSCKASGYSFTSYILNWVRQATGQGLEWMGWMNPDSNNTEYAQKFQGRVTITRDTSISTVYMELSGLRSEDTAVYYCARHSFKSNTGFDYWGQGTQVTVSS,SYELSQPPSVSVSAGQTASITCSGDKLGGKYGYWYQQRPGQSPILVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDISTNWVFGGGTKLTVL,6PHF_A,6PHF_B,Pfs25 In Complex With The Human Transmission Blocking Antibody 2587,Pfs25 In Complex With The Human Transmission Blocking Antibody 2587,Homo sapiens,"McLeod,B.;Miura,K.;Scally,S.W.;Bosch,A.;Nguyen,N.;Shin,H.;Kim,D.;Volkmuth,W.;Ramisch,S.;Chichester,J.A.;Streatfield,S.;Woods,C.;Schief,W.R.;Emerling,D.;King,C.R.;Julien,J.P.",Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25,25-JUN-2019,8_8_13_6_3_10,6PHF_A_B,Xtal structure,Pfs25,2,1,2.0845804,4.1357684
6DL8_A_B,QVQLVQSGAEVRKPGASVKVSCKASGYTFTDNYIHWVRQAPGQGLEWMGWIHPNSGATKYAQKFEGWVTMTRDTSISTVYMELSRSRSDDTAVYYCARAGLHPTTTEYYYYGMDVWGQGTAVTVSS,SALTQPPSVSVAPGQTATITCGGNNIGRKRVDWFQQKPGQAPVLVVYEDSDRPSGIPERFSDSNSGTTATLTISRVEAGDEADYYCQVWDSDSDHVVFGGGTKLTVL,6DL8_A,6DL8_B,Crystal Structure Of An Influenza A Hemagglutinin Antibody Fab Variant Ch67:1203D4 Chimera,Crystal Structure Of An Influenza A Hemagglutinin Antibody Fab Variant Ch67:1203D4 Chimera,Homo sapiens,"Dong,J.;Finn,J.A.;Crowe,J.E.",Crystal Structure of an influenza A hemagglutinin antibody Fab variant CH67:1203d4 chimera,31-MAY-2018,8_8_19_6_3_11,6DL8_A_B,Xtal structure,hemagglutinin; Influenza,2,1,2.1480393,3.513967
QKK35684_QKK35685,QVQLVQSGAEVRKPGSSVKLSCKASGGIFSTHAISWVRQAPGQRPEWMGGIIPIFGESKDTRKFQGRVTFTADESTTTAYMELRSLKSDDTAIYYCVLDSDPYTATFSHNHYWYAMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQGLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVEIK,QKK35684,QKK35685,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35684_QKK35685,Unique source,SARS-CoV-2,2,1,3.0389028,-13.26623
QKK35568_QKK35569,QVQLVQSGAEVRKPGSSVKLSCKASGGTFSTHAISWVRQAPGQRPEWMGGIIPIFGESKDTQKFQGRVTFTADESTTTAYMELRSLRSDDTAIYYCVRDSDPYTTTFSHNHYWYAMDVWGQGTTVTVSS,DIVMTQSPLSLPVTLGQPASISCRSSQRLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVEIK,QKK35568,QKK35569,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35568_QKK35569,Unique source,SARS-CoV-2,2,1,3.00179,-13.303447
QKK35526_QKK35527,QVQLVQSGAEVRKPGSSVKLSCKASGGTFSTHAISWVRQAPGQRPEWMGGIMPIFGESKDTQKFQGRVTFTADESTTTAYMELRSLKSDDTAIYYCVRDSDPYTATVRNNHYWYALDVWGPGTMVTVSS,DIQLTQSPLSLPVTLGQPASISCRSSQHLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGIDFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVEIK,QKK35526,QKK35527,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35526_QKK35527,Unique source,SARS-CoV-2,2,1,3.0246894,-13.280695
QKK35506_QKK35507,QVQLVQSGAEVRKPGSSVKLSCKASGGTFSTHAISWVRQAPGQRPEWMGGIMPIFGESKDTQKFQGRVTFTADESTTTAYMELRSLRSDDTAIYYCVRDSDPYTATVTSNHYWYAMDVWGQGTTVTVSS,ETTLTQSPLSLPVTLGQPASISCRSSQGLVHSNGNTYVNWFHQRPGQSPRRLIYEVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTEWPRTFGQGTKVDIK,QKK35506,QKK35507,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35506_QKK35507,Unique source,SARS-CoV-2,2,1,3.0171468,-13.288129
QKK35612_QKK35613,QVQLVQSGAEVRKPGSSVKLSCRASGGTFHTYTVNWVRQAPGQGLEWLGGIIPIFGTPTYAQRFQGKVSITADSSTNTVFMELTSLTSEDTAVYYCTRETGTDEFDFWGQGALVTVSS,DIRLTQSPATLSLSPGERATLSCRASQSVSSSLAWYQQKPGQAPRLLIYEASNRATGVPARFSGSGSGTDFTLAISSLEPEDFAVYYCQHRSNWPPRYTFGQGTKVEIK,QKK35612,QKK35613,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_11_6_3_11,QKK35612_QKK35613,Unique source,SARS-CoV-2,2,1,-0.5240178,5.636812
QKY76604_QKY76217,QVQLVQSGAEVRKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPVFGTANYAQKFQGRVTITADKSTSTAFMELNSLRSEDTAVYYCARIGSYPEYFQHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSFLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHYRSNWPPVLTFGGGTKVEIE,QKY76604,QKY76217,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_12_6_3_11,QKY76604_QKY76217,Unique source,SARS-CoV-2,2,1,-0.585196,5.583003
5TQA_H_L,QVQLVQSGAQMKNPGASVKVSCAPSGYTFTDFYIHWLRQAPGQGLQWMGWMNPQTGRTNTARNFQGRVTMTRDTSIGTAYMELRSLTSDDTAIYYCTTGGWISLYYDSSYYPNFDHWGQGTLLTVS,QSALTQPASVSGSPGQSITISCTGTKYDVGSHDLVSWYQQYPGKVPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLRAEDEADYYCCSFGGSATVVCGGGTKVTVL,5TQA_H,5TQA_L,Crystal Structure Of Dh270.6 (Unliganded) From The Dh270 Broadly Neutralizing N332-Glycan Dependent Lineage,Crystal Structure Of Dh270.6 (Unliganded) From The Dh270 Broadly Neutralizing N332-Glycan Dependent Lineage,Homo sapiens,"Bonsignori,M.;Kreider,E.F.;Fera,D.;Meyerhoff,R.R.;Bradley,T.;Wiehe,K.;Alam,S.M.;Aussedat,B.;Walkowicz,W.E.;Hwang,K.K.;Saunders,K.O.;Zhang,R.;Gladden,M.A.;Monroe,A.;Kumar,A.;Xia,S.M.;Cooper,M.;Louder,M.K.;McKee,K.;Bailer,R.T.;Pier,B.W.;Jette,C.A.;Kelsoe,G.;Williams,W.B.;Morris,L.;Kappes,J.;Wagh,K.;Kamanga,G.;Cohen,M.S.;Hraber,P.T.;Montefiori,D.C.;Trama,A.;Liao,H.X.;Kepler,T.B.;Moody,M.A.;Gao,F.;Danishefsky,S.J.;Mascola,J.R.;Shaw,G.M.;Hahn,B.H.;Harrison,S.C.;Korber,B.T.;Haynes,B.F.",Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies,23-OCT-2016,8_8_20_9_3_10,5TQA_H_L,Xtal structure,HIV,2,1,2.923511,2.676839
QKK35586_QKK35587,QVQLVQSGDEMKKPGSSVKVSCKASGDTFSTHAISWVRQAPGQGPEWMGGIIPLFGTASYAQTSQSRVKITADESTSTAYMELSSLTSEDTAVYYCVRDSDPYTATSRNNHYWYGMDVWGQGTTVTVSS,DIQMTQSPLSLPVTLGQPASISCRASQTVVHTNGNTYLNWFHQRPGQSPRRLIYEVSNRDSGVPDRFSGSGSGTDFTLSISRVEAEDIGVYYCMQGTDWPRTFGPGTKVEIK,QKK35586,QKK35587,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35586_QKK35587,Unique source,SARS-CoV-2,2,1,3.08576,-13.219144
QKK35812_QKK35813,QVQLVQSGGDSVNPGGSLRLSCAGSGFSVRDVWMSWVRQAPGKGLEWIGRIKSEADGGSSDYRASLKDRFSIWRDASKNTLYLQVNGLQTEDTAIYFCSWNDVGWAFTFWGQGTLVTVSS,QSVLTQPPSVSGSPGQSVSISCSGTSSDFGNYNRISWYQQTPGTAPKVIIYEVNSRPSGVPDRFSGSKSGNTASLTITGLQAEDEADYYCCSYRSDNTYIFGGGTKVTVL,QKK35812,QKK35813,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_10_11_9_3_10,QKK35812_QKK35813,Unique source,SARS-CoV-2,2,1,13.019669,8.720555
7ZQT_C_D,QVQLVQSGGGIGQPGGSLRLACEASGFTFNLFEMAWVRQAPGQSLEVISYIGSSGSTTRYADSVKGRFIVSRDNDKESMFLQLNSLRVDDTATYFCARLNGWAGSGLDHWGQGTLVAVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLWTFGQGTKVEIK,7ZQT_C,7ZQT_D,Helicobacter Pylori Adhesin Baba Bound To Neutralising Human Antibody.,Helicobacter Pylori Adhesin Baba Bound To Neutralising Human Antibody.,Homo sapiens,"Remaut,H.",Helicobacter pylori adhesin BabA bound to neutralising human antibody,17-MAY-2023,8_8_13_6_3_9,AEP60450_AEP60451,Xtal structure,,2,1,15.638715,9.698354
7KN3_M_N,QVQLVQSGGGLIQPGGSLRLSCAASGFTVSLSHMNWVRQAPGKGLEWVSITYGDGNSDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREYYYGMDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSLPLTFGGGTKLEIK,7KN3_M,7KN3_N,Crystal Structure Of Sars-Cov-2 Spike Protein Receptor-Binding Domain Complexed With A Pre-Pandemic Antibody S-B8 Fab,Crystal Structure Of Sars-Cov-2 Spike Protein Receptor-Binding Domain Complexed With A Pre-Pandemic Antibody S-B8 Fab,Homo sapiens,"Qiang,M.;Ma,P.;Li,Y.;Liu,H.;Harding,A.;Min,C.;Wang,F.;Liu,L.;Yuan,M.;Ji,Q.;Tao,P.;Shi,X.;Li,Z.;Li,T.;Wang,X.;Zhang,Y.;Wu,N.C.;Lee,C.D.;Zhu,X.;Gilbert-Jaramillo,J.;Zhang,C.;Saxena,A.;Huang,X.;Wang,H.;James,W.;Dwek,R.A.;Wilson,I.A.;Yang,G.;Lerner,R.A.",Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago,04-NOV-2020,8_7_10_12_3_9,7KN3_M_N,Xtal structure,SARS-CoV-2,2,1,12.599336,10.713801
3BN9_D_C,QVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARPYLTYPQRRGPQNVSPFDNWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHGNLPYTFGDGTKVEIK,3BN9_D,3BN9_C,Crystal Structure Of Mt-Sp1 In Complex With Fab Inhibitor E2,Crystal Structure Of Mt-Sp1 In Complex With Fab Inhibitor E2,Homo sapiens,"Farady,C.J.;Egea,P.F.;Schneider,E.L.;Darragh,M.R.;Craik,C.S.",Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition,13-DEC-2007,8_8_21_6_3_9,3BN9_D_C,Xtal structure,,2,1,13.955124,9.837752
8DB4_C_D,QVQLVQSGGGLVKPGGSLRLSCTASGFSFSDSYMSWIRQAPGKGLEWLTYISGSGEIISYADSVKGRFTISRDNAKKSVYLQMDSLRAEDTAVYYCARPSDYFETSEELDWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPNLLIYAASSLHSGVPSRFRGSGSGTDFTLTITSLQPDDFATYYCHQSYSAPRTFGQGTKLEIK,8DB4_C,8DB4_D,Crystal Structure Of The Peanut Allergen Ara H 2 Bound By Two Neutralizing Antibodies 22S1 And 13T1,Crystal Structure Of The Peanut Allergen Ara H 2 Bound By Two Neutralizing Antibodies 22S1 And 13T1,Homo sapiens,"LaHood,N.A.;Min,J.;Keswani,T.;Richardson,C.M.;Amoako,K.;Zhou,J.;Marini-Rapoport,O.;Bernard,H.;Hazebrouck,S.;Shreffler,W.G.;Love,J.C.;Pomes,A.;Pedersen,L.C.;Mueller,G.A.;Patil,S.U.",Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy,25-JAN-2023,8_8_14_6_3_9,8DB4_C_D,Xtal structure,,2,1,15.74566,9.383387
QKK35754_QKK35755,QVQLVQSGGGLVQPGESLRLSCAASGFNFSPYGMNWVRQAPGKGLEWIAYIISGSGTIYYADSVKGRFTISRDNAQSSLYLQMNSLRAEDTAVYYCARGLLDYLHDAFDIWGQGTMVTVSS,DIVLTQSPATLSVSPGERITLSCRASHSVSSNLAWYQQKPGQVPRLLIYGASARATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNYWPPLTFGGGTKVEIK,QKK35754,QKK35755,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_10,QKK35754_QKK35755,Unique source,SARS-CoV-2,2,1,15.589141,9.845521
6N8D_D_B,QVQLVQSGGGLVQPGGSLRLSCAASGFAFSNHGMHWVRQAPGKGLEWLSYISGSTGAIHYANSVKGRFTISRDNARNSLDLQMNSLGDEDTAVYYCARDGPRPDGTGYAGPSNDYWGQGTLVSVSS,EIVLTQSPASLSLSPGERATLSCKASRSISIYLAWYQQKPGQAPRLLIYDASYRAIGIPARFSGSGSGTDFTLTISNLEPEDFAVYYCQHRSSWPALTFGGGTKVEIK,6N8D_D,6N8D_B,Crystal Structure Of Gii.4 2002 Norovirus P Domain In Complex With Neutralizing Human Antibody A1431,Crystal Structure Of Gii.4 2002 Norovirus P Domain In Complex With Neutralizing Human Antibody A1431,Homo sapiens,"Lindesmith,L.C.;McDaniel,J.R.;Changela,A.;Verardi,R.;Kerr,S.A.;Costantini,V.;Brewer-Jensen,P.D.;Mallory,M.L.;Voss,W.N.;Boutz,D.R.;Blazeck,J.J.;Ippolito,G.C.;Vinje,J.;Kwong,P.D.;Georgiou,G.;Baric,R.S.",Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination,29-NOV-2018,8_8_19_6_3_10,6N8D_D_B,Xtal structure,,2,1,15.816766,9.919708
QKK35760_QKK35761,QVQLVQSGGGLVQPGGSLRLSCAASGFIFSGHWMSWVRQAPGKGLEWVANIKQDGREKHYVDSVKGRFTISRDNAKNSVSLQMNSLRAEDTAVYYCVRQNVAIQYYYYAMDVWGQGTTVTVSS,ETTLTQSPGTLSVSPGERATLSCRASQSVISNLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGTEFTLTIASLQSEDFAVYYCQQYHHWPPYTFGQGTKVDIK,QKK35760,QKK35761,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_10,QKK35760_QKK35761,Unique source,SARS-CoV-2,2,1,11.156218,7.795658
CAO78317,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRENSKNTLYLQMNSLRAEDTAVYYCARQTRVRAFDIWGQGTMVTVSS,DIQMTQSPSALSASVGGRVTITCRASQSTSSDLNWYQQRPGKAPKLLISVASTLQSDVPSRFSGSGSGTDFSLTISSLQPEDFATYFCQQSYSTPYTFGQGTKVDIK,CAO78317_H,CAO78317_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_11_6_3_9,AEN51968,Same entry,,2,1,13.980489,9.736894
QKK35600_QKK35601,QVQLVQSGGGLVQPGGSLRLSCSASGFTFNTYAMHWVRQAPGKRLEYVSSITRDGAGKFYADSVKGRFTISRDNSKNTLYQQMSSLRPEDTAVYYCVREGQQWLGLYFDHWGQGALVTVSS,DIRVTQSPSSLSASVGDRVTITCRASQTINNYLNWYQQKPGKAPNLLIYAASTLQNGVPSRFSGSGSGTDFTLTISSVQPEDFATYYCQQTYITPTWTFGQGTKVEIK,QKK35600,QKK35601,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_10,QKK35600_QKK35601,Unique source,SARS-CoV-2,2,1,13.867683,10.546259
QKK35626_QKK35627,QVQLVQSGGGLVQPGGSLRLSCSASGFTFNTYTMHWVRQAPGKGLEYVSAISSNGVVTYYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVKALYSSSWCPFDYWGQGALVTVSS,DIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATNIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNLWPYTFGQGTKVDIK,QKK35626,QKK35627,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_14_6_3_9,QKK35626_QKK35627,Unique source,SARS-CoV-2,2,1,13.893583,10.098782
7KBA_H_L,QVQLVQSGGGLVQPGGSLRVSCAASGFSFSDHDMDWVRQAPGKGFEWVGRSRNKDYSSTTEYAASVRGRFTISRHTSEDLLYLELNTVKTEDTAVYFCARGPHHSDRSGYYGGTFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVIITCRASQGISSWLAWYQQKPGRAPRLLIYDASTLESGVPSRFSGRGSGTEFTLTINSLQPEDFATYYCQQGNMFPLTFGGGTKVEIK,7KBA_H,7KBA_L,Crystal Structure Of The Hcmv Pentamer-Specific Fab 2-18,Crystal Structure Of The Hcmv Pentamer-Specific Fab 2-18,Homo sapiens,"Wrapp,D.;Ye,X.;Ku,Z.;Su,H.;Jones,H.G.;Wang,N.;Mishra,A.K.;Freed,D.C.;Li,F.;Tang,A.;Li,L.;Jaijyan,D.K.;Zhu,H.;Wang,D.;Fu,T.M.;Zhang,N.;An,Z.;McLellan,J.S.",Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies,01-OCT-2020,8_10_19_6_3_9,7KBA_H_L,Xtal structure,neuropilin; HCMV,2,1,13.290229,8.468648
QKK35570_QKK35571,QVQLVQSGGGLVQPGGSLRVSCSASGFTFSSFAMHWVRQAPGKGLEYVAGISDNGHTTMYADSVKGRFTISRDNSKNTLYLQLSSLRPEDTAVYFCVKDNVILPGAIVRPQFDYWGQGTLVTVSS,ETTLTQSPASVSASVGDRVTISCRASQGIGRWLAWYQQKPGRAPKLLIFSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPFTFGGGTKVEIK,QKK35570,QKK35571,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_9,QKK35570_QKK35571,Unique source,SARS-CoV-2,2,1,13.90415,10.140495
6XPR_B_C,QVQLVQSGGGLVRPGGSLRLSCAASGFTFSSAWMTWVRQAPGKGLEWVANIKEDGSEKYYVDSVKGRFSISRDNAKNSLYLQISSLRAEDTAVYYCARRFVERLWGQSKPYDAVDIWGQGTMVTVSG,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASNLQSGVPSRFSGSGSGTDFALTISSLQPEDFASYYCQQSYSPVTTFGGGTKVEIK,6XPR_B,6XPR_C,Human Antibody D2 H1-1/H3-1 H3 In Complex With The Influenza Hemagglutinin Head Domain Of A/Texas/50/2012(H3N2),Human Antibody D2 H1-1/H3-1 H3 In Complex With The Influenza Hemagglutinin Head Domain Of A/Texas/50/2012(H3N2),Homo sapiens,"McCarthy,K.R.;Lee,J.;Watanabe,A.;Kuraoka,M.;Robinson-McCarthy,L.R.;Georgiou,G.;Kelsoe,G.;Harrison,S.C.",A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface,08-JUL-2020,8_8_20_6_3_9,6XPR_B_C,Xtal structure,H1F1; HIST1H1A; H1-1; H1.1; Influenza; H1a; H3N2,2,1,11.168465,7.807348
6N81_H_L,QVQLVQSGGGMVQPGGSLSLSCAASGFTLSNYAMTWVRQAPGKGLEWVSSIGGSGGTTYYADSVKGRFTISRDSSMNTLYLQMSNLRAGDTAVYYCAKDKTRTLRLGYSGMDVWGQGTTVTVSS,DIRLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPDLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFGNYYCQQSFSTPRTFGQGTKVELK,6N81_H,6N81_L,Crystal Structure Of Gii.4 2002 Norovirus P Domain In Complex With Cross-Reactive Human Antibody A1227,Crystal Structure Of Gii.4 2002 Norovirus P Domain In Complex With Cross-Reactive Human Antibody A1227,Homo sapiens,"Lindesmith,L.C.;McDaniel,J.R.;Changela,A.;Verardi,R.;Kerr,S.A.;Costantini,V.;Brewer-Jensen,P.D.;Mallory,M.L.;Voss,W.N.;Boutz,D.R.;Blazeck,J.J.;Ippolito,G.C.;Vinje,J.;Kwong,P.D.;Georgiou,G.;Baric,R.S.",Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination,28-NOV-2018,8_8_17_6_3_9,6N81_H_L,Xtal structure,,2,1,13.717767,10.057752
6M58_C_D,QVQLVQSGGGPVKPGGSLRLSCAASGFMFRAYSMNWVRQAPGKGLEWVSSISSSGRYIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARETVMAGKALDYWGQGTLVTVSS,DIVLTQSPGTLSLSPGETATLSCRASQSVGSNLAWYQQKPGQAPRLLIYGASTGATGVPARFSGSRSGTDFTLTITSLQPEDFATYYCQQYYSFLAKTFGQGTQLEIK,6M58_C,6M58_D,Crystal Structure Of A Complex Between Human Serum Albumin And The Antibody Fab Sl335,Crystal Structure Of A Complex Between Human Serum Albumin And The Antibody Fab Sl335,Homo sapiens,"Cho,S.Y.;Han,J.;Cha,S.H.;Yoon,S.I.","Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics",10-MAR-2020,8_8_13_6_3_10,6M58_C_D,Xtal structure,,2,1,16.015427,10.11174
4YDV_H_L,QVQLVQSGGGVFKPGGSLRLSCEASGFTFTEYYMTWVRQAPGKGLEWLAYISKNGEYSKYSPSSNGRFTISRDNAKNSVFLQLDRLSADDTAVYYCARADGLTYFSELLQYIFDLWGQGARVTVSS,DIVLAQSPDSLAVSPGERATIHCKSSQTLLYSSNNRHSIAWYQQRPGQPPKLLLYWASMRLSGVPDRFSGSGSGTDFTLTINNLQAEDVAIYYCHQYSSHPPTFGHGTRVELR,4YDV_H,4YDV_L,Structure Of The Antibody 7B2 That Captures Hiv-1 Virions,Structure Of The Antibody 7B2 That Captures Hiv-1 Virions,Homo sapiens,"Santra,S.;Tomaras,G.D.;Warrier,R.;Nicely,N.I.;Liao,H.X.;Pollara,J.;Liu,P.;Alam,S.M.;Zhang,R.;Cocklin,S.L.;Shen,X.;Duffy,R.;Xia,S.M.;Schutte,R.J.;Pemble Iv,C.W.;Dennison,S.M.;Li,H.;Chao,A.;Vidnovic,K.;Evans,A.;Klein,K.;Kumar,A.;Robinson,J.;Landucci,G.;Forthal,D.N.;Montefiori,D.C.;Kaewkungwal,J.;Nitayaphan,S.;Pitisuttithum,P.;Rerks-Ngarm,S.;Robb,M.L.;Michael,N.L.;Kim,J.H.;Soderberg,K.A.;Giorgi,E.E.;Blair,L.;Korber,B.T.;Moog,C.;Shattock,R.J.;Letvin,N.L.;Schmitz,J.E.;Moody,M.A.;Gao,F.;Ferrari,G.;Shaw,G.M.;Haynes,B.F.",Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques,23-FEB-2015,8_8_19_12_3_9,4YDV_H_L,Xtal structure,SGNE1; SCG5; 7B2; HIV; SgV,2,1,15.842582,9.404698
5DRZ_H_L,QVQLVQSGGGVVKPGASSRLSCAASGFTFTDYYMSWIRQAPGKGLEWVAYITKDGSEKKYADSLQHRFAVSRDNANNLVFLQLNTVEDDDTGVYYCARDDGYYDRSGYYGVFDLWGQGIRVTVSS,LLTQSPDSLAVTLGETATITCRSSRNILHSLNNKNYLAWYQQRPGQAPKLLVIWASMRVSGVADRFSGSGSGTDFALTISSLQPEDAAVYYCQHYYTTHRTFGQGTRVEIR,5DRZ_H,5DRZ_L,Crystal Structure Of Anti-Hiv-1 Antibody F240 Fab In Complex With Gp41 Peptide,Crystal Structure Of Anti-Hiv-1 Antibody F240 Fab In Complex With Gp41 Peptide,HIV-1 M:B_ARV2/SF2,"Gohain,N.;Tolbert,W.D.;Orlandi,C.;Richard,J.;Ding,S.;Chen,X.;Bonsor,D.A.;Sundberg,E.J.;Lu,W.;Ray,K.;Finzi,A.;Lewis,G.K.;Pazgier,M.",Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240,16-SEP-2015,8_8_18_12_3_9,5DRZ_H_L,Xtal structure,Hiv-1; gp41,2,1,15.754583,9.40065
QKK35540_QKK35541,QVQLVQSGGGVVNPGGSLRLSCVGSGFTFSDYYMGWIRQAPGKGLEVISYISSTGSYIRDADSVKGRFTISRDNAENSVYLQMNSLRGEDTAVYYCARMGPYGSGSFDYWGLGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVTRSQLAWYQHKPGQPPRLLIYDSSKRATGSPDRFSASGSGTDFTLTISGLEPEDTGIYYCLQYSDATTFGPGTKLEIK,QKK35540,QKK35541,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_7_3_8,QKK35540_QKK35541,Unique source,SARS-CoV-2,2,1,15.76503,9.321469
QKK35596_QKK35597,QVQLVQSGGGVVNPGGSMRLSCAGSGFTFSDHYMGWIRQAPGKGLEVISYISSSGSFIRDADSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARMGPYGSGTFDYWGQGTLVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQIINRSQLGWYQHKPGQAPRLLIFDSSKRATGTPDRFSASGSETDFTLTISGVEPEDSGVYYCLQYSLATTFGPGTKVDIK,QKK35596,QKK35597,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_13_7_3_8,QKK35596_QKK35597,Unique source,SARS-CoV-2,2,1,15.818144,9.312059
AEL31302_AEL31311,QVQLVQSGGGVVPPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGNYKYYADSVRGRFTISRDNSKNTLNLDMNSLRTEDTALYYCAKDSQLRSLLYFDWLSQGYFDHWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSVSSNNKNFLAWYQEKPGQPPKVLIYWASARESGVPDRFSGSGSGTDFTLTISGLQAEDVAVYYCQQHYRTPPTFGQGTKVEIK,AEL31302,AEL31311,"anti-Influenza A hemagglutinin heavy chain variable region, partial [Homo sapiens]","anti-Influenza A immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Corti,D.; Voss,J.; Gamblin,S.J.; Codoni,G.; Macagno,A.; Jarrossay,D.; Vachieri,S.G.; Pinna,D.; Minola,A.; Vanzetta,F.; Silacci,C.; Fernandez-Rodriguez,B.M.; Agatic,G.; Bianchi,S.; Giacchetto-Sasselli,I.; Calder,L.; Sallusto,F.; Collins,P.; Haire,L.F.; Temperton,N.; Langedijk,J.P.; Skehel,J.J.; Lanzavecchia,A.",A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,25-JUL-2016,8_8_22_10_3_9,AEL31302_AEL31311,Unique source,hemagglutinin; Influenza,2,1,15.086637,14.02491
QKK35866_QKK35867,QVQLVQSGGGVVQPGGSLRLSCADSGNAFIANPMHWVRQAPGKGLEWLALISTDGNNRHYADSVKGRFTFSRDNSKNSLYLQMDSLRPEDTGVYYCARESRSSGRAGCFDSWGQGTLVTVSS,DIRLTQSPSSLSASVGDRVTITCRASQDISSWLAWYQQKSGKAPKSLIYAASSLQNGVPSRFSGSRSGTDFTLTISSLQPEDLGTYYCQQYDSYPVTFGQGTRLEIK,QKK35866,QKK35867,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_9,QKK35866_QKK35867,Unique source,SARS-CoV-2,2,1,14.783486,13.401457
QES69308,QVQLVQSGGGVVQPGGSLRVSCAASGVTLSDYGMHWVRQAPGKGLEWMAFIRNDGSDKYYADSVKGRFTISRDNSKKTVSLQMSSLRAEDTAVYYCAKNGESGPLDYWYFDLWGRGTLVTVSS,DVVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDFATYYCQQYSSFPLTFGGGTKVDIK,QES69308_H,QES69308_L,"VLalphaCD3(diL2K)-scFvalphaHLAA2 bispecific antibody, partial [synthetic construct]","VLalphaCD3(diL2K)-scFvalphaHLAA2 bispecific antibody, partial [synthetic construct]",synthetic construct,"Stuhler,G.; Banaszek,A.; Nowotny,B.",Direct Submission,28-SEP-2019,8_8_16_6_3_9,QES69308,Same entry,,2,1,15.012324,13.55254
QKK35718_QKK35719,QVQLVQSGGGVVQPGKSLRLSCVASGFSFGTYGMHWVRQAPGKGPEWLAVMWYDGITQYYADSVKGRFTISRDNSKETLYLQMNSLTADDTGVYYCVKDQSSGDRLLYLGYFDLWGPGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSIYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTINNLEPEDFAIYYCQQRAKWPPRVIFGPGTKVEIK,QKK35718,QKK35719,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_18_6_3_11,QKK35718_QKK35719,Unique source,SARS-CoV-2,2,1,14.848629,13.840223
QKK35504_QKK35505,QVQLVQSGGGVVQPGRSLKLSCVVSGFSFSHYGMNWVRQAPGKGLEWVAVMSYDGSDKYYADSVKGRFTISRDISKNTLYLEMNSLRTEDTAVYYCAKKGSPYCGVDCYKGYFDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCQASQDIRKCLNWYQHIPGKAPKLLIHDASSLESGVPSRFSGSGSGTDFSFTINSLHPEDIATYYCQQFEDLPITFGQGTRLEIK,QKK35504,QKK35505,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_19_6_3_9,QKK35504_QKK35505,Unique source,SARS-CoV-2,2,1,15.06651,13.873921
7TOW_H_L,QVQLVQSGGGVVQPGRSLRLSCAASGFNFGDFGMHWVRQAPGKGLEWVAVISYEGRNKNHADSVRGRFTISRDNSRNMLYLQMNSLRRGDTAVYYCAKENRDRNYDSWSASYSDYYYGMDVWGQGTTVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGIDRYLAWYQQKPGSAPKLLIYAASTLQSGVPSRFSGSGSETDFTLTISSLQPDDFATYYCQQLSTYPTITFGQGTRLEIK,7TOW_H,7TOW_L,Antibody Dh1058 Fab Fragment Bound To Sars-Cov-2 Fusion Peptide,Antibody Dh1058 Fab Fragment Bound To Sars-Cov-2 Fusion Peptide,Severe acute respiratory syndrome coronavirus 2,"Gobeil,S.M.;Henderson,R.;Stalls,V.;Janowska,K.;Huang,X.;May,A.;Speakman,M.;Beaudoin,E.;Manne,K.;Li,D.;Parks,R.;Barr,M.;Deyton,M.;Martin,M.;Mansouri,K.;Edwards,R.J.;Eaton,A.;Montefiori,D.C.;Sempowski,G.D.;Saunders,K.O.;Wiehe,K.;Williams,W.;Korber,B.;Haynes,B.F.;Acharya,P.",Structural diversity of the SARS-CoV-2 Omicron spike,24-JAN-2022,8_8_25_6_3_10,7TOW_H_L,Xtal structure,SARS-CoV-2,2,1,14.087826,14.0242195
CAO78314,QVQLVQSGGGVVQPGRSLRLSCAASGFSFSNYVMHWVRQAPGKGLEWVAVISHDGSNKYYADSVKGRFTISRDNSKNTLYLQMKSLRPEDTAVYYCARSSGWYLLFDAFDIWGQGTMVTVSS,DIQMTQSPDSLPVSLGERATINCRSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYRIPWTFGQGTKVEIK,CAO78314_H,CAO78314_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_15_12_3_9,AEN51980,Same entry,,2,1,14.561098,13.478994
CAV31697_CAV31698,QVQLVQSGGGVVRPGGSLRLSCAASGFSFIDYGMSWVRQVPGKGLEWVAGMNWSGDKKGHAESVKGRFIISRDNAKNTLYLEMSSLRVEDTALYFCARGEYSNRFDPRGRGTLVTVSS,DIVMTQTPLSLPVTLGQPASLSCRSSQSLVFTDGNTYLNWFQQRPGQSPRRLIYKVSSRDPGVPDRFSGTGSGTDFTLEISRVEAEDIGVYYCMQGTHWPPIFGQGTKVEIK,CAV31697,CAV31698,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Esslinger,C.; Kuenzle,S.; Abela,I.; Nitsch,R.M.; Moch,H.; Goebels,N.; Jaeger,D.; Zippelius,A.; Knuth,A.",Method of providing human tumor-specific antibodies,19-DEC-2008,8_8_11_11_3_9,CAV31697_CAV31698,Unique chain,,2,1,14.689274,12.93049
QKK35598_QKK35599,QVQLVQSGGNVVQPGGSLRLSCVGSEFSITFFAMQWVRRTPGKGLEWVALVSHDGSNIRYSDSVKGRFIISRDNAKNTLYLQLDSLTPEDTGIYYCARDHALQNGRPGYFDSWGQGSQVTVSS,DIQLTQSPATLSLSPGERATLSCRASPSVFTFLAWYQQRPGQPPRLLIHDVSNRAPGIPARFSGSGSGTDFTLIISSLEPDDSAVYFCQQRSDGYNFGPGTKVDIK,QKK35598,QKK35599,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_16_6_3_8,QKK35598_QKK35599,Unique source,SARS-CoV-2,2,1,14.587969,13.296052
QIH48148_QIH48149,QVQLVQSGPELKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGPEWMGWINPNSGGTNSAQKFQDRVTMTRDTSINTAYMELNRLKYDDTAAYYCARGGWISLYYDSSGYPNFDCWGQGPLITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKDPKLMIYEVSKRASGVSIRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGSKLTVL,QIH48148,QIH48149,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48148_QIH48149,Unique source,HIV,2,1,2.8097394,2.799151
3O2W_H_L,QVQLVQSGPELKKPGETVKISCKASGYMFTNYGMNWVKQAPGKALKWMGWINPYTGESTFADDFKGRFAFFLETSATTAYLQINNLKNEDTATYFCARGTTIVRAFDYWGQGTSVTVSS,ELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKFLIYKVSNRFSGVPDRFSGSGSGTDFILKISRVEAEDLGVYFCSQSTHFFPTFGGGTKLEIK,3O2W_H,3O2W_L,Crystal Structure Of The 1E9 Phel89Ser/Leuh47Trp/Meth100Bphe Fab In Complex With A 39A11 Transition State Analog,Crystal Structure Of The 1E9 Phel89Ser/Leuh47Trp/Meth100Bphe Fab In Complex With A 39A11 Transition State Analog,Homo sapiens,"Verdino,P.;Aldag,C.;Jonsson,S.;Hilvert,D.;Wilson,I.A.",Crystal Structure Of The 1e9 Phel89serLEUH47TRPME Fab In Complex With A 39a11 Transition State Analog,22-JUL-2010,8_8_12_11_3_9,3O2W_H_L,Xtal structure,,2,1,-7.5031147,6.0978155
QKK35554_QKK35555,QVQLVQSGPELKKPGSSVRVSCKASGGSISSYAISWVRQAPGQRLEWMGGVLPMMGRESPVQKFKDRVTIAADESTSTAYMELRSLSAEDTAVYYCVVDTTMADPHNWYGLDVWGQGTTVTVSS,EIVMTQTPLSLPVTLGQPASISCRSSHGLVHTNGNTYLNWFHQRPGQPPRRLIYQVSHRDSGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCMQGTDWPRTFGQGTKVDIK,QKK35554,QKK35555,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_11_3_9,QKK35554_QKK35555,Unique source,SARS-CoV-2,2,1,-0.6311733,6.03137
CAC32381_CAC32380,QVQLVQSGPEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYGEDFKGRFAFSLDTSASTAYMELSSLRSEDTAVYFCARFGNYVDYWGQGSLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKNLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLKISRVEAEDVGVYYCAQNLEIPRTFGQGTKVEIK,CAC32381,CAC32380,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Knick,V.C.; Stimmel,J.B.; Thurmond,L.M.",Combination of an anti-ep-cam antibody with a chemotherapeutic agent,02-MAR-2001,8_8_9_11_3_9,AEF68645_AEF68644,Unique chain,ep-cam,2,1,-7.1113586,5.786161
QEP20172_QEP20820,QVQLVQSGPEVKKPGSSVKVSCKASGGTFSTFPIAWVRQAPGQGLEWMGTITPLVNKITYAQKFQGRVTMTADTSTKTFYLELNTLRSDDTSVYFCARVPTTVTAAWLDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGKYLAWYQQKPGQAPRLLIHDASNRATGIPDRFRGSGSGTDFTLTIANLEPADVAVYFCQQRSHFVYSFGQGTKLEIK,QEP20172,QEP20820,"IGH + IGL c279_heavy_IGHV1-69_IGHD4-17_IGHJ5, partial [Homo sapiens]","IGH + IGL c279_light_IGKV3-11_IGKJ2, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_14_6_3_9,QEP20172_QEP20820,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,-0.35065198,5.592274
7JIE_C_D,QVQLVQSGPEVKKPGSSVKVSCKASGGTVSSYAISWVRQAPGQGLEWMGGIIPIFDTTNYAQKFQGRVTITADESTGTSDMELSSLRSEDTAVYYCARDRVPSYSPSRRFSTKGAMWGKYGMDVWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISKVEAEDVGVYYCMQALQTPRTFGQGTKVEIK,7JIE_C,7JIE_D,Structure Of Gii.4 P-Domain In Complex With Noro-320 Fab,Structure Of Gii.4 P-Domain In Complex With Noro-320 Fab,Homo sapiens,"Alvarado,G.;Salmen,W.;Ettayebi,K.;Hu,L.;Sankaran,B.;Estes,M.K.;Venkataram Prasad,B.V.;Crowe JE,Jr.",Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses,23-JUL-2020,8_8_28_11_3_9,7JIE_C_D,Xtal structure,,2,1,-0.81838477,6.1529603
QKK35640_QKK35641,QVQLVQSGPEVKKPGSSVRVSCKVSGGPFSSYGVSWARQAPEKGLEWMGGVLPIFGTVGYVHKFQGRVTITADESTSTVYMALSSLRSEDTAVYYCVLDTTMSHPHNWYGMDVWGHGTTVTVSS,DIVMTQSPLSLPVTLGQPASISCRSSHSLVHTNGNTYLNWFQQRPGQPPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEADDVGIYYCMQGTDWPRTFGQGTKVDIK,QKK35640,QKK35641,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_11_3_9,QKK35640_QKK35641,Unique source,SARS-CoV-2,2,1,-0.6625573,5.9697065
QNT09659_QNT09677,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTSSAMQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSTNCYDAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,QNT09659,QNT09677,"anti SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti SARS-CoV-2 immunoglobulin kappa chain, partial [Homo sapiens]",Homo sapiens,"Kreye,J.; Reincke,S.M.; Kornau,H.-C.; Sanchez-Sendin,E.; Corman,V.M.; Liu,H.; Yuan,M.; Wu,N.C.; Zhu,X.; Lee,C.-C.D.; Trimpert,J.; Hoeltje,M.; Dietert,K.; Stoeffler,L.; von Wardenburg,N.; van Hoof,S.; Homeyer,M.A.; Hoffmann,J.; Abdelgawad,A.; Gruber,A.D.; Bertzbach,L.D.; Vladimirova,D.; Li,L.Y.; Barthel,P.C.; Skriner,K.; Hocke,A.C.; Hippenstiel,S.; Witzenrath,M.; Suttorp,N.; Kurth,F.; Franke,C.; Endres,M.; Schmitz,D.; Jeworowski,L.M.; Richter,A.; Schmidt,M.L.; Schwarz,T.; Mueller,M.A.; Drosten,C.; Wendisch,D.; Sander,L.E.; Osterrieder,N.; Wilson,I.A.; Pruess,H.",A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model,24-SEP-2020,8_8_16_7_3_9,QNT09659_QNT09677,Unique source,SARS-CoV-2; COVID,2,1,-0.9954151,2.9885905
UKB89161_UKB89242,QVQLVQSGPEVKKPGTSVKVSCKASGITFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSGGTCHDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,UKB89161,UKB89242,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,Reincke SM; Yuan M; Kornau HC; Corman VM; van Hoof S; Sanchez-Sendin E; Ramberger M; Yu W; Hua Y; Tien H; Schmidt ML; Schwarz T; Jeworowski LM; Brandl SE; Rasmussen HF; Homeyer MA; Stoffler L; Barner M; Kunkel D; Huo S; Horler J; von Wardenburg N; Kroidl I; Eser TM; Wieser A; Geldmacher C; Hoelscher M; Ganzer H; Weiss G; Schmitz D; Drosten C; Pruss H; Wilson IA; Kreye J,SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies,07-FEB-2022,8_8_16_7_3_9,UKB89161_UKB89242,Unique source,SARS-CoV-2,2,1,-0.9984884,2.9826026
QNR06535_QNR06579,QVQLVQSGPEVRAPGASVTVSCKTSGYSFTDFFIHWVRQAPGQGLEWMGWLNPIFGAVNYAHKYQGRITLTRDTSMKTAYMQLTNLRSDDTAVFYCVRKRVYDEYDWDWAYWGQGTLVTVSA,EIVLTQSPGILSLSPGERATLSCRTSQDVGSNSLAWYQEKPGQAPRLLVYGASNRATGVPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYEYFGRGTKVQVD,QNR06535,QNR06579,"anti-HIV1 immunoglobulin 2413a heavy chain variable region, partial [Mus musculus]","anti-HIV1 immunoglobulin 2413a light chain variable region, partial [Mus musculus]",Mus musculus,"Chen,X.; Zhou,T.; Schmidt,S.D.; Duan,H.; Cheng,C.; Gu,Y.; Louder,M.; Shen,C.-H.; Chuang,G.-Y.; Sheng,Z.; Zheng,X.; Doria-Rose,N.A.; Shapiro,L.; Tian,M.; Alt,F.W.; Kwong,P.D.; Mascola,J.R.",Maturation from Germline to >50% Neutralization Breadth for VRC01-Class Antibodies in a Human Antibody Gene Knock in Mouse Model,06-JAN-2021,8_8_15_7_3_5,QNR06535_QNR06579,Unique word,HIV1,2,1,2.4686773,4.0382633
7PS0_H_L,QVQLVQSGPGLVKPSQTLSLTCSVSDGSISSSDYYWSWIRQPPGKGLEWIGYIYYTGSTYYNPSLKSRVSISVDRSKNQFSLKLSSVTAADTAVYYCARLVVPSPKGSWFDPWGQGTLVTVSS,SYELTQPASVSGSPGQSITISCTGTSIDVGNYNLASWYQQHPGKAPKLIIYEGSRRPSGVSNRFSGAKSGNTASLTISGLQAEDEADYYCCSYVGSSTYVFGSGTKVTVL,7PS0_H,7PS0_L,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-24 Fabs,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-24 Fabs,Homo sapiens,"Liu,C.;Zhou,D.;Nutalai,R.;Duyvesteyn,H.M.;Tuekprakhon,A.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Mentzer,A.J.;Wang,B.;Case,J.B.;Zhao,Y.;Skelly,D.T.;Chen,R.E.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Malik,T.;Temperton,N.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Clare,D.K.;Howe,A.;Goulder,P.J.;Fry,E.E.;Diamond,M.S.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants,22-SEP-2021,10_7_15_9_3_10,7PS0_H_L,Xtal structure,SARS-CoV-2,2,1,16.650871,-8.217122
QKK35556_QKK35557,QVQLVQSGPGLVRPSGTLSLTCAVSGDSISGDYWCTWVRQTPGKGLEWIGKISHSGSINYNPSLKSRITMSVDKSKNQFSLKLNSVTAADTAMYYCARVRVGASHHNFWSGYYTDAFDIWGQGTTVTVSS,ETTLTQSPGTLSLSPGERATLSCRASQSVGNNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPVYTFGQGTKVEIK,QKK35556,QKK35557,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,9_7_23_7_3_10,QKK35556_QKK35557,Unique source,SARS-CoV-2,2,1,15.500624,-7.4074006
AAA18889_AAA20144,QVQLVQSGSELKKPGASVKISCKASGYSFSSHAINWVRQAPGQGLQWMGWINTNTGSPTYAQGFTGRFVFSLDTSVSTAYLQITSLTAEDTGMYFCAKESHSSALDLDYWGQGTLVTVSS,SYELTQPPSVSVSPGHTARITCSGDALPKKYAYWYQQKSGQAPMLVIYEDSKRPSGIPERFSGSSSGTMATLIISGAQVEDEADYYCFSADYSGNHSFGTGTRVTVL,AAA18889,AAA20144,"immunoglobulin heavy chain VDJ region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Fang,Q.; Kannapell,C.C.; Gaskin,F.; Solomon,A.; Koopman,W.J.; Fu,S.M.","Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VH gene segment usage and preferential usage of V lambda IIIb",27-Jul-1994,8_8_13_6_3_10,AAA18889_AAA20144,Ordered entries,,2,1,-6.9502597,5.5851083
QJU69701_QJU69766,QVQLVQSGSELKKPGASVKLSCQASGYSFTNHAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTTYLHISSLKAEDTAVYYCARASARPGVATNLDFWGQGTLVVVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIDNYLNWYQQKPGKAPKLLIYAASRLHSGVPSRFSGSGSGTDFTLIISSLQPEDLATYYCQQSYSNPLTFGPGTKVDIR,QJU69701,QJU69766,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Seydoux,E.; Homad,L.J.; MacCamy,A.J.; Parks,K.R.; Hurlburt,N.K.; Jennewein,M.F.; Akins,N.R.; Stuart,A.B.; Wan,Y.-H.; Feng,J.; Nelson,R.E.; Singh,S.; Cohen,K.W.; McElrath,M.J.; Englund,J.A.; Chu,H.Y.; Pancera,M.; McGuire,A.T.; Stamatatos,L.",Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual,20-MAY-2020,8_8_15_6_3_9,QJU69701_QJU69766,Unique source,SARS-CoV-2,2,1,-6.942713,5.5775657
7WKX_A_C,QVQLVQSGSELKKPGASVKVSCKASEYIFTNYGMNWVKQAPGQGFEWMGWIDTNTGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTATYYCANYGWGYFDYWGQGTTVTVSS,DVVMTQTPPSLPVNPGEPASISCRSSQSLVHSNGYTYLHWYLQKPGQSPQLLIYKVSNHLSGVPDRFSGSGSGTDFTLKISWVEAEDVGVYFCSQSTHVPYTFGGGTKLEIK,7WKX_A,7WKX_C,Il-17A In Complex With The Humanized Antibody Hb0017,Il-17A In Complex With The Humanized Antibody Hb0017,Homo sapiens,"Xu,J.G.;Jia,H.;Chen,S.;Xu,J.;Zhan,Y.;Yu,H.;Wang,W.;Kang,X.;Cui,X.;Feng,Y.;Chen,X.;Xu,W.;Pan,X.;Wei,X.;Li,H.;Wang,Y.;Xia,S.;Liu,X.;Yang,L.;He,Y.;Zhu,X.",Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases,12-JAN-2022,8_8_10_11_3_9,7WKX_A_C,Xtal structure,CTLA8; IL-17A; IL17; IL-17; IL17A,2,1,-6.976763,5.612916
5CGY_C_D,QVQLVQSGSELKKPGASVKVSCKASGYSFTSYSINWVRQAPGQGPEWMGWIDTNTGNPTYAQDFAGRFVFSLDTSVTTAYLQISSLKAGDTAVYYCATYYVDLWGSYRQDYYGMDVWGHGTLVTVSS,SVVTQPPSVSGTPGQGVTISCSGGSSNIGSNPVNWYQMVPGTAPKLLLYTNNQRPSGVPDRFSGSKSGTSASLAINGLQSEDEADYYCAVWDDSLSGRWVFGGGTKVTVL,5CGY_C,5CGY_D,Fab Fragment Of Chikungunya Virus Neutralizing Human Monoclonal Antibody 4J21,Fab Fragment Of Chikungunya Virus Neutralizing Human Monoclonal Antibody 4J21,Homo sapiens,"Long,F.;Fong,R.H.;Austin,S.K.;Chen,Z.;Klose,T.;Fokine,A.;Liu,Y.;Porta,J.;Sapparapu,G.;Akahata,W.;Doranz,B.J.;Crowe JE,Jr.;Diamond,M.S.;Rossmann,M.G.",Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity,09-JUL-2015,8_8_20_8_3_12,5CGY_C_D,Xtal structure,Chikungunya,2,1,-6.9471784,5.5818906
QKY76682_QKY76710,QVQLVQSGSELKKPGASVKVSCKASGYTFLRFAMNWLRQAPGQGLEWMGWIDTNTGTPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARSLRGANLVPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDVSNYLNWYQQQPGKAPKLLIYDAFNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,QKY76682,QKY76710,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kreer,C.; Zehner,M.; Weber,T.; Ercanoglu,M.S.; Gieselmann,L.; Rohde,C.; Halwe,S.; Korenkov,M.; Schommers,P.; Vanshylla,K.; Di Cristanziano,V.; Janicki,H.; Brinker,R.; Ashurov,A.; Kraehling,V.; Kupke,A.; Cohen-Dvashi,H.; Koch,M.; Eckert,J.M.; Lederer,S.; Pfeifer,N.; Wolf,T.; Vehreschild,M.J.G.T.; Wendtner,C.; Diskin,R.; Gruell,H.; Becker,S.; Klein,F.",Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients,08-JUL-2020,8_8_11_6_3_9,QKY76682_QKY76710,Unique source,SARS-CoV-2; COVID,2,1,-6.9422293,5.5774746
QKK35688_QKK35689,QVQLVQSGSELKKPGASVKVSCKASGYTFSNYAMNWVRQAPGQGPEWMGWIDTNTGNPTYAQGFIGRFVFSLDTSVNTAYLLIGSLEAEDTAVYYCAREEHYDFSSGYFRPAYWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCRAGHTISTYLNWYQQKPGKAPKILISGASSLQSGVPSRFSGSGSGTDFTLTIGSLQPEDFATYYCQQSYSTPYTFGQGTKVDIK,QKK35688,QKK35689,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_6_3_9,QKK35688_QKK35689,Unique source,SARS-CoV-2,2,1,-6.9252825,5.5608153
6U9S_A_B,QVQLVQSGSELKKPGASVKVSCKASGYTFTDDSIHWVRQAPGQGLEWMGWINTETGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARLSPVVVIFIYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCKSSQSLLHSRTRKNYLAWYLQKPGQSPQLLIYWASTRESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCKQSYNLYAFGQGTKLEIK,6U9S_A,6U9S_B,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With 5A6 Fab,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With 5A6 Fab,Homo sapiens,"Susa,K.J.;Seegar,T.C.;Blacklow,S.C.;Kruse,A.C.",A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking,13-MAY-2020,8_8_12_12_3_8,QRJ74242_QRJ74245,Xtal structure,CD81; CD19; TAPA-1; TSPAN28; TAPA1,2,1,-6.974651,5.6110325
3T2N_H_L,QVQLVQSGSELKKPGASVKVSCKASGYTFTDYSMRWVRQAPGQGLEWMGWINTETGSPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARGFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAFRGLIGDTNNRAPWTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNHFIFGSGTKVTVL,3T2N_H,3T2N_L,Human Hepsin Protease In Complex With The Fab Fragment Of An Inhibitory Antibody,Human Hepsin Protease In Complex With The Fab Fragment Of An Inhibitory Antibody,Homo sapiens,"Koschubs,T.;Dengl,S.;Durr,H.;Kaluza,K.;Georges,G.;Hartl,C.;Jennewein,S.;Lanzendorfer,M.;Auer,J.;Stern,A.;Huang,K.S.;Packman,K.;Gubler,U.;Kostrewa,D.;Ries,S.;Hansen,S.;Kohnert,U.;Cramer,P.;Mundigl,O.",Allosteric antibody inhibition of human hepsin protease,22-JUL-2011,8_8_6_9_3_9,3T2N_H_L,Xtal structure,,2,1,-7.001848,5.640874
8GX9_P_M,QVQLVQSGSELKKPGASVKVSCKASGYTFTTYVMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTASLQISSLKAEDTAVYYCSCEITTLGGMDVWGQGTTVTVSS,SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSISDHRVFGGGTKLTVL,8GX9_P,8GX9_M,Crystal Structure Of Sars-Cov-2 Rbd With P2C-1F11 And P2B-1G5,Crystal Structure Of Sars-Cov-2 Rbd With P2C-1F11 And P2B-1G5,Homo sapiens,"Wang,X.;Zhang,L.;Ge,J.",Crystal structure of SARS-CoV-2 antibody P2C-1F11 and RBD,12-OCT-2022,8_8_12_6_3_11,8GX9_P_M,Xtal structure,SARS-CoV-2; RBD,2,1,-6.9604917,5.5959177
7YI6_D_B,QVQLVQSGSELKKPGASVRISCKASGYSFTSLSMNWVRQAPGQGLEWMGWISTKSGDPTYAQAFTGRFVFSLDTSVNTAYLQINSLEAGDTAVYYCARGQPPVGWTFDYWGQGTLVTVSS,ALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLIIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL,7YI6_D,7YI6_B,Bnab 3D1 In Complex With 6-Mer Hr1 Peptide From Hcov-229E S Protein,Bnab 3D1 In Complex With 6-Mer Hr1 Peptide From Hcov-229E S Protein,Homo sapiens,"Yan,L.;Yang,G.",Cross-reactive epitopes between HIV and Coronavirus revealed by 3D1,30-AUG-2023,8_8_13_9_3_10,7YI6_D_B,Xtal structure,HIV,2,1,-6.921234,5.556514
5I9Q_B_C,QVQLVQSGTAVKRPGASVRVSCQASGYTFTDYFIYWWRQAPGQGLEWLGWINPLTSQPSYPSRFQGRLTLTRDTFDEMLYMDLRGLRSDDTGIYFCARRHSDYCDFDIWGSGTQIIVSS,DIQMTQSPSSLSASVGDKVTITCQTSAGYLNWYQQRRGRAPKLLMYDGSRLVTGVPSRFSGRRWGTQYNLTIGSLQPEDIATYYCQVYEFFGPGTRLDLK,5I9Q_B,5I9Q_C,Crystal Structure Of 3Bnc55 Fab In Complex With 426C.Tm4Deltav1-3 Gp120,Crystal Structure Of 3Bnc55 Fab In Complex With 426C.Tm4Deltav1-3 Gp120,Homo sapiens,"Scharf,L.;West,A.P.;Sievers,S.A.;Chen,C.;Jiang,S.;Gao,H.;Gray,M.D.;McGuire,A.T.;Scheid,J.F.;Nussenzweig,M.C.;Stamatatos,L.;Bjorkman,P.J.",Structural basis for germline antibody recognition of HIV-1 immunogens,20-FEB-2016,8_8_12_3_3_5,QFP23772_QFP23771,Xtal structure,HIV,2,1,2.59249,4.068393
UIC72276_UIC72586,QVQLVQSGTEVKKPGSSVKVSCKASGDRFSSSAVSWVRQAPGQGLEWVGGINPILKTPDYAQRLQGRVTISADESTNTAYMELGSLRSEDTAVYYCTATVTWVGCRGGACYGPFDYWGPGTQVTVSS,EIVLTQSPGTLSLSPGERATFSCKASQSVSNSYIAWYRQKPGQPPRLLIYGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCHLYGGSPSRTFGQGTKVEIK,UIC72276,UIC72586,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_20_7_3_10,UIC72276_UIC72586,Unique source,HCV,2,1,-0.9351263,5.6944013
6EHY_B_B,QVQLVQSGTEVKSPGSSVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAPGYSNAYYFDYWGQGTLVTVSS,DIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIK,6EHY_B,6EHY_B,Scfv Abvance: Increasing Our Knowledge Of Antibody Structural Space To Enable Faster And Better Decision Making In Drug Discovery,Scfv Abvance: Increasing Our Knowledge Of Antibody Structural Space To Enable Faster And Better Decision Making In Drug Discovery,Homo sapiens,"Hargreaves,D.",scFvAbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery,15-SEP-2017,8_8_14_6_3_9,6EHY_B_B,Xtal structure,,2,1,-0.70562875,5.474261
ANY91885_ANY91280,QVQLVQTGAEVKKPGASVKVSCQASGYRFSSYGITWVRQAPGQGLEWMGWISAYNGHTNYAQKFQARVTMTTDTSTSTASMELRGLRSDDSAIYYCARDQRDILTGGLFDCWGQGTLVTVSS,DVVMTQAPVSLPVTLGQPASISCRSSQGLVFIDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGGGTKVEIK,ANY91885,ANY91280,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_15_11_3_9,ANY91885_ANY91280,Unique source,Influenza,2,1,1.8632959,5.302493
QDF60664_QDF61130,QVQLVQTGAEVKKPGSSVKVSCKATGGTFSTSGISWVRQAPGQGLEWMGRIIPMLGIPNYAQNFQGRVTISADRSTTTAYMELSSLRSEDTAVYYCATDGPSGTYFDYWGQGTLVTVSL,DIQLTQSPSFLSASVGDKVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLPSGVPSRFSGSGSGTEFTLTISSLQPEDVAVYHCQQLKSYPLTFGGGTKVEIK,QDF60664,QDF61130,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Davis,C.W.; Jackson,K.J.L.; McElroy,A.K.; Halfmann,P.; Huang,J.; Chennareddy,C.; Piper,A.E.; Leung,Y.; Albarino,C.G.; Crozier,I.; Ellebedy,A.H.; Sidney,J.; Sette,A.; Yu,T.; Nielsen,S.C.A.; Goff,A.J.; Spiropoulou,C.F.; Saphire,E.O.; Cavet,G.; Kawaoka,Y.; Mehta,A.K.; Glass,P.J.; Boyd,S.D.; Ahmed,R.",Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection,01-JUL-2019,8_8_12_6_3_9,QDF60664_QDF61130,Unique source,Ebola,2,1,-0.8114268,5.520251
QKK35536_QKK35537,QVQLVQWGAGLLKPSETLSLTCAVYGGSFSGFHWSWIRQPPGKGLEWIGEINHSGSTKYNPSLKSRVTISVDTSKNQFSLRLRSVTAADTAIYYCARGSLSREYDFLTAPQNGPWFDSWGQGALVTVSS,QPVLTQPPSVSAAPGQKVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSVVVFGGGTKLTVL,QKK35536,QKK35537,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_7_23_8_3_11,QKK35536_QKK35537,Unique source,SARS-CoV-2,2,1,16.769598,-10.611783
6Z06_H_L,QVQMKESGGGLVQPGKSLKLSCAASGFTFSDFWMSWVRQPSGKGLEWVARINTNGDTTHYTDDMKGRFTISRDNAKTTLYLEMSPLKSEDTAMYYCTRDRLGPFDYWGQGTTVTVSS,DIVMTQSPAFPPVSLGDTVTITCQASQSVYKNLAWYQQKPGKSPRLLIFGMSSLADGVPSRFSASGSDKQYSLKIRGLQPEDAAIYYCQQHYIAPYTFGAGTRLEIK,6Z06_H,6Z06_L,Crystal Structure Of Puumala Virus Gc In Complex With Fab 4G2,Crystal Structure Of Puumala Virus Gc In Complex With Fab 4G2,Puumala orthohantavirus,"Rissanen,I.;Stass,R.;Krumm,S.A.;Seow,J.;Hulswit,R.J.;Paesen,G.C.;Hepojoki,J.;Vapalahti,O.;Lundkvist,A.;Reynard,O.;Volchkov,V.;Doores,K.J.;Huiskonen,J.T.;Bowden,T.A.",Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein,07-MAY-2020,8_8_10_6_3_9,6Z06_H_L,Xtal structure,,2,1,17.617727,7.2698727
6GLX_C_D,QVQRQESGPGLVKPSQTLSLTCTVSGGSITTSYYAWSWIRQPPGKGLEWMGVIASDGSTYYSPSLKSRTSISRDTSKNQFSLQLSSVTPEDTAVYYCALYIRGSSWSGWSAYDYWGQGTQVTVSS,QPVLNQPSAVSVSLGQTARITCQGGNFGYYYGSWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGGTATLTISRAQAEDEADYYCQSADSSDNPVFGGGTHLTVL,6GLX_C,6GLX_D,"Structure Of Galectin-10 In Complex With The Fab Fragment Of A Charcot-Leyden Crystal Solubilizing Antibody, 4E8","Structure Of Galectin-10 In Complex With The Fab Fragment Of A Charcot-Leyden Crystal Solubilizing Antibody, 4E8",Lama glama,"Persson,E.K.;Verstraete,K.;Heyndrickx,I.;Gevaert,E.;Aegerter,H.;Percier,J.M.;Deswarte,K.;Verschueren,K.H.;Dansercoer,A.;Gras,D.;Chanez,P.;Bachert,C.;Goncalves,A.;Van Gorp,H.;De Haard,H.;Blanchetot,C.;Saunders,M.;Hammad,H.;Savvides,S.N.;Lambrecht,B.N.",Protein crystallization promotes type 2 immunity and is reversible by antibody treatment,23-MAY-2018,10_7_17_6_3_10,UCW66386_UCW66387,Xtal structure,,2,1,16.45604,-8.082484
QEP20212_QEP20860,QVQVQESGPGLVKPSETLSLSCNVSGGSVKNFYWSWIRQTPGKRLEWIGNVFTDGRTTFNPSLESRATISVEAPKNLLSLYLTSVTARDTAIYYCARLRYTYDFWTRFYPTDGFDLWGQGRQVIVSS,DIVMTQSPDSLAVSLGERATINCRSSQSLLRSSSGKNYLAWYHLKPGQPPKLLVSWANIRESGVPDRFSGRGSGADFTLIIDDLRSEDVGLYYCQQFYSIPPWTFGQGTKVEIN,QEP20212,QEP20860,"IGH + IGL c319_heavy_IGHV4-59B_IGHD3-3_IGHJ2, partial [Homo sapiens]","IGH + IGL c319_light_IGKV4-1_IGKJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_21_12_3_10,QEP20212_QEP20860,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,2,1,16.400372,-8.221788
ANV21812_ANV22001,QVQVVESGGGVVQPGRSLRLSCAASGFTFSSSGMHWVRQAPGKGLEWVAVISYDGRNKYYADSVRGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAKDLANCGGDCYANSWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSGQSLVYSDANTYLNWFQQRPGQSPRRLIYNVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK,ANV21812,ANV22001,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_15_11_3_9,ANV21812_ANV22001,Unique source,,2,1,15.046569,13.647413
QXI90070_QXI90071,QVQVVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCVRETVDGMDVWGQGTTVTVSS,NIQMTQSPSAMSASVGDSVTITCRARQDINNYLAWFQQKPGKVPKHLIYAASSLLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKLEIK,QXI90070,QXI90071,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]","anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Peter,A.S.; Roth,E.; Schulz,S.R.; Fraedrich,K.; Steinmetz,T.; Damm,D.; Hauke,M.; Richel,E.; Mueller-Schmucker,S.; Habenicht,K.; Eberlein,V.; Issmail,L.; Uhlig,N.; Dolles,S.; Gruner,E.; Peterhoff,D.; Ciesek,S.; Hoffmann,M.; Pohlmann,S.; McKay,P.F.; Shattock,R.J.; Wolfel,R.; Socher,E.; Wagner,R.; Eichler,J.; Sticht,H.; Schuh,W.; Neipel,F.; Ensser,A.; Mielenz,D.; Tenbusch,M.; Winkler,T.H.; Grunwald,T.; Uberla,K.; Jack,H.M.",A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model,17-AUG-2021,8_8_10_6_3_9,QXI90070_QXI90071,Unique source,SARS-CoV-2,2,1,14.6036825,13.569919
QKY76655_QKY76268,QVQVVQSGAEVKKPGASVKVSCKASGYTFKNYGISWVRQAPGQGLEWMGWISAYTGNTNYAQKFQGRMTMTTDTSTGTGYMELRSLRSDDTAVYYCARVQRRRLDYWGQGTLVIVSS,DIVVTQTPLSLSVTPGQPASISCKSSETLLHSDGKTYLSWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKIGRVEAEDVGLYYCMQSIQLAFGQGTRLEIE,QKY76655,QKY76268,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_10_11_3_7,QKY76655_QKY76268,Unique source,SARS-CoV-2,2,1,1.9007916,5.2592106
7E7X_H_L,QVQVVQSGAEVKKPGASVKVSCKVSGYTLIEISIHWVRQAPGKGLEWMGGFDPEAGETIYAQKFQGRVTMTEDTSTDTAYMEVSSLRSEDTAVYYCATGPAIAAAETNWFDLWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVSWYQQHPGKAPKLMIYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL,7E7X_H,7E7X_L,Sars-Cov-2 Spike Protein N Terminal Domain In Complex With N11 Fab,Sars-Cov-2 Spike Protein N Terminal Domain In Complex With N11 Fab,Homo sapiens,"Cao,Y.;Yisimayi,A.;Bai,Y.;Huang,W.;Li,X.;Zhang,Z.;Yuan,T.;An,R.;Wang,J.;Xiao,T.;Du,S.;Ma,W.;Song,L.;Li,Y.;Li,X.;Song,W.;Wu,J.;Liu,S.;Li,X.;Zhang,Y.;Su,B.;Guo,X.;Wei,Y.;Gao,C.;Zhang,N.;Zhang,Y.;Dou,Y.;Xu,X.;Shi,R.;Lu,B.;Jin,R.;Ma,Y.;Qin,C.;Wang,Y.;Feng,Y.;Xiao,J.;Xie,X.S.",Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,28-FEB-2021,8_8_16_9_3_10,7E7X_H_L,Xtal structure,SARS-CoV-2; RBD,2,1,1.0294333,2.5057354
URX40009_URX40048,QVRLEQSGAEVKKPGASVRVSCEASDDTFNDDLIHWVRQAPGQGLKWMGWINLKTSGVNYARNFQGRITLTRQRTIDTDRAYMDLRSLKSDDTAMYYCAVKVLRTSSSGYGFNVWGQGTRVTVVT,QSALTQPRSVSGSPGQSVTISCTGIRGDVAWYQQRPGKAPKLMIYDVNKRPSGVPDRFSGSKSGNTASLIISGLQADDEAHYHCSSYEYFGGGTQLTVL,URX40009,URX40048,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Barnes,C.O.; Schoofs,T.; Gnanapragasam,P.N.P.; Golijanin,J.; Huey-Tubman,K.E.; Gruell,H.; Schommers,P.; Suh-Toma,N.; Lee,Y.E.; Cetrulo Lorenzi,J.C.; Piechocka-Trocha,A.; Scheid,J.F.; West,A.P. Jr.; Walker,B.D.; Seaman,M.S.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,15-AUG-2022,8_8_16_4_3_5,URX40009_URX40048,Unique source,HIV; CD4,2,1,2.5691347,3.625349
3B9K_H_L,QVRLQESGPGLVQPSQTLSLTCSVSGFSLISDSVHWVRQPPGKGLEWMGGIWADGSTEYNSALKSRLSISRDTSKSQGFLKMNSLQTDDTAIYFCTSNRESYYFDYWGQGTMVTVSS,DIKMTQSPASLSASLGDKVTITCQASQNIDKYIAWYQQKPGKAPRQLIHYTSTLVSGTPSRFSGSGSGRDYTFSISSVESEDIASYYCLQYDTLYTFGAGTKLELK,3B9K_H,3B9K_L,Crystal Structure Of Cd8Alpha-Beta In Complex With Yts 156.7 Fab,Crystal Structure Of Cd8Alpha-Beta In Complex With Yts 156.7 Fab,Mus musculus,"Shore,D.A.;Issafras,H.;Landais,E.;Teyton,L.;Wilson,I.A.",The crystal structure of CD8 in complex with YTS156.7.7 Fab and interaction with other CD8 antibodies define the binding mode of CD8 alphabeta to MHC class I,05-NOV-2007,8_7_11_6_3_8,3B9K_H_L,Xtal structure,CD8A; CD8,2,1,22.236729,-5.9823394
4OLU_H_L,QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRGGAVSYARQLQGRVTMTRDMYSETAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGQGTPVTVSS,EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYTLTISNLESGDFGVYYCQQYEFFGQGTKVQV,4OLU_H,4OLU_L,Crystal Structure Of Antibody Vrc07 In Complex With Clade A/E 93Th057 Hiv-1 Gp120 Core,Crystal Structure Of Antibody Vrc07 In Complex With Clade A/E 93Th057 Hiv-1 Gp120 Core,Homo sapiens,"Rudicell,R.S.;Kwon,Y.D.;Ko,S.Y.;Pegu,A.;Louder,M.K.;Georgiev,I.S.;Wu,X.;Zhu,J.;Boyington,J.C.;Chen,X.;Shi,W.;Yang,Z.Y.;Doria-Rose,N.A.;McKee,K.;O'Dell,S.;Schmidt,S.D.;Chuang,G.Y.;Druz,A.;Soto,C.;Yang,Y.;Zhang,B.;Zhou,T.;Todd,J.P.;Lloyd,K.E.;Eudailey,J.;Roberts,K.E.;Donald,B.R.;Bailer,R.T.;Ledgerwood,J.;Mullikin,J.C.;Shapiro,L.;Koup,R.A.;Graham,B.S.;Nason,M.C.;Connors,M.;Haynes,B.F.;Rao,S.S.;Roederer,M.;Kwong,P.D.;Mascola,J.R.;Nabel,G.J.",Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo,25-JAN-2014,8_8_18_4_3_5,4OLU_H_L,Xtal structure,HIV,2,1,2.7809534,4.1987767
7M7W_C_D,QVRLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTVYLQWSSLKASDTAMYYCARQWSHYTYDYYYWGQGTLVTISS,QSVLTQPASVSGSPGQSITISCTGISSDVGGYNSVSWYQQHPGKAPKLMIYDVTNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPPYVFGTGTKVSVL,7M7W_C,7M7W_D,Antibodies To The Sars-Cov-2 Receptor-Binding Domain That Maximize Breadth And Resistance To Viral Escape,Antibodies To The Sars-Cov-2 Receptor-Binding Domain That Maximize Breadth And Resistance To Viral Escape,Severe acute respiratory syndrome coronavirus 2,"Starr,T.N.;Czudnochowski,N.;Zatta,F.;Park,Y.J.;Liu,Z.;Addetia,A.;Pinto,D.;Beltramello,M.;Hernandez,P.;Greaney,A.J.;Marzi,R.;Glass,W.G.;Zhang,I.;Dingens,A.S.;Bowen,J.E.;Wojcechowskyj,J.A.;De Marco,A.;Rosen,L.E.;Zhou,J.;Montiel-Ruiz,M.;Kaiser,H.;Tucker,H.;Housley,M.P.;di Iulio,J.;Lombardo,G.;Agostini,M.;Sprugasci,N.;Culap,K.;Jaconi,S.;Meury,M.;Dellota,E.;Cameroni,E.;Croll,T.I.;Nix,J.C.;Havenar-Daughton,C.;Telenti,A.;Lempp,F.A.;Pizzuto,M.S.;Chodera,J.D.;Hebner,C.M.;Whelan,S.P.;Virgin,H.W.;Veesler,D.;Corti,D.;Bloom,J.D.;Snell,G.",Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,29-MAR-2021,8_8_13_9_3_12,7M7W_C_D,Xtal structure,SARS-CoV-2,2,1,-12.370983,5.644932
QGW50127_QGW50156,QVRLVQSGTLLKTIGSSMRISCEASGYNFVDFFIQWFRHVPGRGFEWIGWLNPHGGAVNFGGNFRDRVTLTRKVSDTDAATIFMEMRGLTPADTATYYCVRRGHCDHCYEWTLQHWGQGTLVVVSP,EVVLTQSPDTLSVSPGEVGTLFCRANQGVSSLAWYQHKHGQPPRLVIYDTSRRASGIPDRFTGSGSGTNFFLTITRLEPEDFGVYFCQDRQSFGQGTKVDMK,QGW50127,QGW50156,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Setliff,I.; Shiakolas,A.R.; Pilewski,K.A.; Murji,A.A.; Ziki,R.; Janowska,K.; Richardson,S.; Mynhardt,C.; Raju,N.; Ronsard,L.; Kanekiyo,M.; Qin,J.; Kramer,K.J.; Greenplate,A.R.; McDonnell,W.J.; Graham,B.S.; Connors,M.; Lingwood,D.; Acharya,P.; Morris,L.; Georgiev,I.S.",High-throughput mapping of B-cell receptor sequences to antigen specificity,17-DEC-2019,8_8_16_5_3_5,QGW50127_QGW50156,Unique source,,2,1,2.7736735,4.219856
2R56_I_M,QVSLRESGGGLVQPGRSLRLSCTASGFTFRHHGMTWVRQAPGKGLEWVASLSGSGTKTHFADSVKGRFTISRDNSNNTLYLQMDNVRDEDTAIYYCAKAKRVGATGYFDLWGRGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQGISSRLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYHSYPWTFGQGTKLEIK,2R56_I,2R56_M,Crystal Structure Of A Recombinant Ige Fab Fragment In Complex With Bovine Beta-Lactoglobulin Allergen,Crystal Structure Of A Recombinant Ige Fab Fragment In Complex With Bovine Beta-Lactoglobulin Allergen,Homo sapiens,"Niemi,M.;Jylha,S.;Laukkanen,M.L.;Soderlund,H.;Makinen-Kiljunen,S.;Kallio,J.M.;Hakulinen,N.;Haahtela,T.;Takkinen,K.;Rouvinen,J.",Molecular interactions between a recombinant IgE antibody and the beta-lactoglobulin allergen,03-SEP-2007,8_8_14_6_3_9,2R56_I_M,Xtal structure,,2,1,14.111614,9.783892
QKK35578_QKK35579,QVTLKESGAEVKKPGSSVKVSCKTSGGTFSTHAISWVRQAPGQGPEWMGGIIPLFGTSQHAQRFQARVKFTADESTNTAYMELSSLTPEDTAVYYCVRDSDPYTATSRNNHYWYGMDVWGHGTTVTVSS,EIVMTQSPLSLPVTLGQPASISCRSSQSVVHSDGNTYLNWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDIGVYYCMQGTDWPRTFGQGTKLEIK,QKK35578,QKK35579,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_22_11_3_9,QKK35578_QKK35579,Unique source,SARS-CoV-2,2,1,3.066152,-13.238802
5MES_H_L,QVTLKESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQVGATWAFDIWGQGTLVTVS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNAWVFGGGTKLTVL,5MES_H,5MES_L,Mcl1 Fab Complex In Complex With Compound 29,Mcl1 Fab Complex In Complex With Compound 29,Homo sapiens,"Johannes,J.W.;Bates,S.;Beigie,C.;Belmonte,M.A.;Breen,J.;Cao,S.;Centrella,P.A.;Clark,M.A.;Cuozzo,J.W.;Dumelin,C.E.;Ferguson,A.D.;Habeshian,S.;Hargreaves,D.;Joubran,C.;Kazmirski,S.;Keefe,A.D.;Lamb,M.L.;Lan,H.;Li,Y.;Ma,H.;Mlynarski,S.;Packer,M.J.;Rawlins,P.B.;Robbins,D.W.;Shen,H.;Sigel,E.A.;Soutter,H.H.;Su,N.;Troast,D.M.;Wang,H.;Wickson,K.F.;Wu,C.;Zhang,Y.;Zhao,Q.;Zheng,X.;Hird,A.W.",Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors,16-NOV-2016,8_8_12_8_3_11,5MES_H_L,Xtal structure,BCL2L3; Mcl-1; MCL1,2,1,16.003403,10.167467
QKK35674_QKK35675,QVTLKESGGGLVQPGGSLRLSCAASGFTVNSYGMSWVRQAPGKGLEWVSGFKSRSDRPDYAESVKGRFTISRDTSKNTVYLEMIGLRAEDTATYYCVRMDWMEWMKYYFDSWGQGALVTVSS,ETTLTQSPVTLSVSPGERATLSCRASQSVISNLAWYQQKPGQAPRLLIFGASTRATGVPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPSLTFGGGTKLEIK,QKK35674,QKK35675,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_15_6_3_10,QKK35674_QKK35675,Unique source,SARS-CoV-2,2,1,13.342431,10.174795
3IFN_H_L,QVTLKESGPGILKPSQTLSLTCSFSGFSLSTSGMSVGWIRQPSGKGLEWLAHIWWDDDKYYNPSLKSRLTISKDTSRNQVFLKITSVDTADTATYYCARRTTTADYFAYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQSSHVPLTFGAGTKLELK,3IFN_H,3IFN_L,X-Ray Structure Of Amyloid Beta Peptide:Antibody (Abeta1-40:12A11) Complex,X-Ray Structure Of Amyloid Beta Peptide:Antibody (Abeta1-40:12A11) Complex,Homo sapiens,"Basi,G.S.;Feinberg,H.;Oshidari,F.;Anderson,J.;Barbour,R.;Baker,J.;Comery,T.A.;Diep,L.;Gill,D.;Johnson-Wood,K.;Goel,A.;Grantcharova,K.;Lee,M.;Li,J.;Partridge,A.;Griswold-Prenner,I.;Piot,N.;Walker,D.;Widom,A.;Pangalos,M.N.;Seubert,P.;Jacobsen,J.S.;Schenk,D.;Weis,W.I.",Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease,24-JUL-2009,10_7_12_11_3_9,AJN82844_AJN82843,Xtal structure,SH3YL1; DKFZP586F1318; Ray; Amyloid,2,1,11.527064,1.885224
4F37_H_L,QVTLKESGPGILQPSQTLSLTCSFSGFSLRTSRVGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLESRLTISKDTSRNQVFLKITSVDTADTATYYCARRGFYGRKYEVNHFDYWGQGTTLTVSS,DIVMTQTPLSLPVSLGDQASISCRSSQTILHSNGNTYLEWYLQKPGQSPNLLIYKVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSRVPLTFGAGTKLELK,4F37_H,4F37_L,Structure Of The Tethered N-Terminus Of Alzheimer'S Disease A Peptide,Structure Of The Tethered N-Terminus Of Alzheimer'S Disease A Peptide,Mus musculus,"Nisbet,R.M.;Nuttall,S.D.;Robert,R.;Caine,J.M.;Dolezal,O.;Hattarki,M.;Pearce,L.A.;Davydova,N.;Masters,C.L.;Varghese,J.N.;Streltsov,V.A.",Structural studies of the tethered N-terminus of the Alzheimer's disease amyloid-beta peptide,09-MAY-2012,10_7_17_11_3_9,4F37_H_L,Xtal structure,amyloid-beta,2,1,11.494406,1.8511524
1ETZ_B_A,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGEGLEWLADIWWNDKKYYNPSLKSRLTVSKDTSSNQVFLKITSVDTSDTATYHCARRTFSYYYGSSFYYFDNWGQGTTLTVSS,AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYAIWVQEKPDHLFSGLIGGTNNRVPGVPARFSGSLIGDKAALTVTGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,1ETZ_B,1ETZ_A,"The Three-Dimensional Structure Of An Anti-Sweetener Fab, Nc10.14, Shows The Extent Of Structural Diversity In Antigen Recognition By Immunoglobulins","The Three-Dimensional Structure Of An Anti-Sweetener Fab, Nc10.14, Shows The Extent Of Structural Diversity In Antigen Recognition By Immunoglobulins",Mus musculus,"Guddat,L.W.;Shan,L.;Anchin,J.M.;Linthicum,D.S.;Edmundson,A.B.",Local and transmitted conformational changes on complexation of an anti-sweetener Fab,13-APR-2000,10_7_18_9_3_9,1ETZ_B_A,Xtal structure,sweetener; Sweetener,2,1,11.505454,1.9066885
3RKD_D_C,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDVKRYSPALKSRLTISKDTSSSQLFLKIASVDTADTATYYCARIKSVITTGDYALDYWGQGTSVAVSS,DIQMTQSPASLSVSVGETVTITCRASEIIYSNLAWYQQKQGKSPQLLVYSATNLAEGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGNPWTFGGGTKLEIK,3RKD_D,3RKD_C,Hepatitis E Virus E2S Domain (Genotype I) In Complex With A Neutralizing Antibody,Hepatitis E Virus E2S Domain (Genotype I) In Complex With A Neutralizing Antibody,Mus musculus,"Tang,X.;Yang,C.;Gu,Y.;Song,C.;Zhang,X.;Wang,Y.;Zhang,J.;Hew,C.L.;Li,S.;Xia,N.;Sivaraman,J.",Structural basis for the neutralization and genotype specificity of hepatitis E virus,18-APR-2011,10_7_16_6_3_9,AQN63129_AQN63128,Xtal structure,Hepatitis,2,1,11.497775,1.9221221
6YWC_A_B,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVFLKITSVDTADTATYYCARLYGFTYGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATIFCRASQSVDYNGISYMHWFQQKPGQPPKLLIYAASNPESGIPARFTGSGSGTDFTLNIHPVEEEDAATYYCQQIIEDPWTFGGGTKLEIK,6YWC_A,6YWC_B,De Novo Designed Protein 4E1H_95 In Complex With 101F Antibody,De Novo Designed Protein 4E1H_95 In Complex With 101F Antibody,synthetic construct,"Yang,C.;Sesterhenn,F.;Bonet,J.;van Aalen,E.A.;Scheller,L.;Abriata,L.A.;Cramer,J.T.;Wen,X.;Rosset,S.;Georgeon,S.;Jardetzky,T.;Krey,T.;Fussenegger,M.;Merkx,M.;Correia,B.E.",Bottom-up de novo design of functional proteins with complex structural features,29-APR-2020,10_7_12_10_3_9,6YWC_A_B,Xtal structure,,2,1,11.505075,1.9087067
3MCK_H_L,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVFLKITSVDTTDTATYYCTRSSGSIVIATGFAYWGQGTLVTVS,DVMMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLEWYMQKPGQSPMLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISSVEAEDLGVFYCFQGSRVPLTFGAGTKLELK,3MCK_H,3MCK_L,Crystal Structure Of Anti-Beta-Amyloid Antibody C705,Crystal Structure Of Anti-Beta-Amyloid Antibody C705,Mus musculus,"Almagro,J.C.;Beavers,M.P.;Hernandez-Guzman,F.;Maier,J.;Shaulsky,J.;Butenhof,K.;Labute,P.;Thorsteinson,N.;Kelly,K.;Teplyakov,A.;Luo,J.;Sweet,R.;Gilliland,G.L.",Antibody modeling assessment,29-MAR-2010,10_7_15_11_3_9,3MCK_H_L,Xtal structure,Amyloid,2,1,11.513935,1.8997718
3U9U_A_B,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYGIGVGWIRQPSGKGLEWLAHIWWNDNKYYNIALRSRLTISKDTSNNQVFLKIASVDTADTATYYCARIPDDHYFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK,3U9U_A,3U9U_B,Crystal Structure Of Extracellular Domain Of Human Erbb4/Her4 In Complex With The Fab Fragment Of Mab1479,Crystal Structure Of Extracellular Domain Of Human Erbb4/Her4 In Complex With The Fab Fragment Of Mab1479,Homo sapiens,"Hollmen,M.;Liu,P.;Kurppa,K.;Wildiers,H.;Reinvall,I.;Vandorpe,T.;Smeets,A.;Deraedt,K.;Vahlberg,T.;Joensuu,H.;Leahy,D.J.;Schoffski,P.;Elenius,K.",Proteolytic processing of ErbB4 in breast cancer,19-OCT-2011,10_7_11_11_3_9,3U9U_A_B,Xtal structure,,2,1,11.499376,1.9146453
3L5W_B_A,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYGMGVGWIRQPSGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSGSQVFLKIASVDTSDTATYYCARMGSDYDVWFDYWGQGTLVTVS,DVQITQSPSYLAASPGETITLNCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYFCQQHNEYPYTFGGGTKLEIK,3L5W_B,3L5W_A,Crystal Structure Of The Complex Between Il-13 And C836 Fab,Crystal Structure Of The Complex Between Il-13 And C836 Fab,Homo sapiens,"Fransson,J.;Teplyakov,A.;Raghunathan,G.;Chi,E.;Cordier,W.;Dinh,T.;Feng,Y.;Giles-Komar,J.;Gilliland,G.;Lollo,B.;Malia,T.J.;Nishioka,W.;Obmolova,G.;Zhao,S.;Zhao,Y.;Swanson,R.V.;Almagro,J.C.",Human framework adaptation of a mouse anti-human IL-13 antibody,22-DEC-2009,10_7_13_6_3_9,3L7E_B_A,Xtal structure,MGC116786; BHR1; MGC116788; IL13; ALRH; MGC116789; IL-13; P600,2,1,11.509721,1.9015199
3AAZ_H_L,QVTLKESGPTLVKPTQTLTLTCTFSGFSLRTSRVGVSWIRQPPGKALEWLAHIYWDDDKRYNPSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARRGFYGRKYEVNHFDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGHTYLEWYLQKPGQSPRLLIYQVSTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASLVPLTFGQGTKLEIK,3AAZ_H,3AAZ_L,Crystal Structure Of The Humanized Recombinant Fab Fragment Of A Murine; Antibody,Crystal Structure Of The Humanized Recombinant Fab Fragment Of A Murine; Antibody,Homo sapiens,"Robert,R.;Streltsov,V.A.;Newman,J.;Pearce,L.A.;Wark,K.L.;Dolezal,O.",Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment,28-NOV-2009,10_7_17_11_3_9,3AAZ_H_L,Xtal structure,Abeta,2,1,12.414361,0.39338198
AAF14199_AAF14209,QVTLKESGPVLVKPTETLTLTCTVSGFSLSNAKMGVSWIRQPPGKALEWLAHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARIFTITYSNYVLQYYYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQSYRTPAWTFGQGTKVEIK,AAF14199,AAF14209,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Perera,W.S.; Moss,M.T.; Urbaniak,S.J.",V(D)J germline gene repertoire analysis of monoclonal D antibodies and the implications for D epitope specificity,26-JUL-2016,10_7_21_6_3_10,AAF14199_AAF14209,Unique source,,2,1,12.530666,0.44997534
UYI35714_UYI36360,QVTLRESGPAIVKPTQTLTLTCTFSGFSLTSSGMTVAWVRQPPGKALEWLALLYWDDDKRYSPSLKTRLTIARDISRDQVVLSLTNVGPEDTATYFCVRGLTLIPFDSWGQGVLVAVSS,SSELTQDPTVSVALGQTVKITCQGDSLRSRHGNWYQQKPGQAPLLVVFGNKHRPSGIPERFSGSNSDNSASLTIRGVQVEDEADYYCGSWDISGSHWIFGGGTRLTVL,UYI35714,UYI36360,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,10_7_11_6_3_11,UYI35714_UYI36360,Unique source,COVID,2,1,12.433717,0.37663084
QNR09202_QNR09230,QVTLRESGPALVKPTQILTLTCSFSGFSLSTSGMCVSWIRQPPGKALEWLARIDWDDNKNYNTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARQLHGDYVRGVFDIWGQGTMVTVSS,SYVLTQSPSVSVAPGQTARITCGGKNIGLKSVHWYQQKPGQAPVLVVYADSDRPSGIPERFSGSNSANTATLTISRVEVGDEADYYCQVWDSSSDHLGVFGGGTKLTVL,QNR09202,QNR09230,"immunoglobulin FISW-a.01 heavy chain variable region, partial [Homo sapiens]","immunoglobulin FISW-a.01 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cheung,C.S.; Fruehwirth,A.; Paparoditis,P.C.G.; Shen,C.H.; Foglierini,M.; Joyce,M.G.; Leung,K.; Piccoli,L.; Rawi,R.; Silacci-Fregni,C.; Tsybovsky,Y.; Verardi,R.; Wang,L.; Wang,S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Chuang,G.Y.; Corti,D.; Mascola,J.R.; Shapiro,L.; Kwong,P.D.; Lanzavecchia,A.; Zhou,T.",Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation,16-SEP-2020,10_7_15_6_3_12,QNR09202_QNR09230,Unique word,Influenza,2,1,12.528809,0.4821112
QKY76353_QKY75966,QVTLRESGPALVKPTQTLSLTCTFSGFSLGTSGMCVSWIRQPPGKALEWLARIDWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGVVTYDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIAGYLNWYQQKPGKAPKLLIYGTTSLQSGVPVRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPGTFGQGTRLEIK,QKY76353,QKY75966,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,10_7_9_6_3_9,QKY76353_QKY75966,Unique source,SARS-CoV-2,2,1,12.5290365,0.48769677
QNR09222_QNR09250,QVTLRESGPALVKPTQTLTLTCTFSGFSLATSGMCVSWIRQPPGKALEWLALINWDDDKYYNTSLKTRLTISKDPSKNQVVLTLTHMDPVDTATYYCARLPYGDFGRMFDYWGQGALVTVSS,SYVLTQPPSVSVAPGQTARITCGGTNIGLKHVHWYQQKPGQAPVLVVYDDSDRPSGIPARFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPVVFGGGTQLAVL,QNR09222,QNR09250,"immunoglobulin FISW-o.02 heavy chain variable region, partial [Homo sapiens]","immunoglobulin FISW-o.02 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cheung,C.S.; Fruehwirth,A.; Paparoditis,P.C.G.; Shen,C.H.; Foglierini,M.; Joyce,M.G.; Leung,K.; Piccoli,L.; Rawi,R.; Silacci-Fregni,C.; Tsybovsky,Y.; Verardi,R.; Wang,L.; Wang,S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Chuang,G.Y.; Corti,D.; Mascola,J.R.; Shapiro,L.; Kwong,P.D.; Lanzavecchia,A.; Zhou,T.",Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation,16-SEP-2020,10_7_14_6_3_12,QNR09222_QNR09250,Unique word,Influenza,2,1,12.516666,0.4695877
QNR09204_QNR09232,QVTLRESGPALVKPTQTLTLTCTFSGFSLNTSGMCVSWIRQPPGKALEWLALIDWDDNTYYRTSLKTRLTISKDTSKNQVVLTMANMDPVDTATFYCARTLYGDYAGGNFDSWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNDIGFKSVHWYQQTPGQAPILVIYSDSARPSGIPERFSGFNSGNTATLTISRVEAGDEADYYCQVWDRSSDVVFGGGTKLTVL,QNR09204,QNR09232,"immunoglobulin FISW-c.01 heavy chain variable region, partial [Homo sapiens]","immunoglobulin FISW-c.01 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cheung,C.S.; Fruehwirth,A.; Paparoditis,P.C.G.; Shen,C.H.; Foglierini,M.; Joyce,M.G.; Leung,K.; Piccoli,L.; Rawi,R.; Silacci-Fregni,C.; Tsybovsky,Y.; Verardi,R.; Wang,L.; Wang,S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Chuang,G.Y.; Corti,D.; Mascola,J.R.; Shapiro,L.; Kwong,P.D.; Lanzavecchia,A.; Zhou,T.",Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation,16-SEP-2020,10_7_15_6_3_10,QNR09204_QNR09232,Unique word,Influenza,2,1,12.521685,0.4739313
QNR09221_QNR09249,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMCVGWIRQPPGKALEWLALINWDDIKYYSTSLKTRVTISKDTPKNQVVLTMTNMDPEDTAMYYCARLRYGDFGRTFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTATFTCNGNNIGLKGVHWYQQKPGQAPVLVVHDDSDRPSGIPARFSGSNSGNTATLTISRVEAGDEADYYCQVWESSSDHPVVLGGGTKLTVL,QNR09221,QNR09249,"immunoglobulin FISW-o.01 heavy chain variable region, partial [Homo sapiens]","immunoglobulin FISW-o.01 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cheung,C.S.; Fruehwirth,A.; Paparoditis,P.C.G.; Shen,C.H.; Foglierini,M.; Joyce,M.G.; Leung,K.; Piccoli,L.; Rawi,R.; Silacci-Fregni,C.; Tsybovsky,Y.; Verardi,R.; Wang,L.; Wang,S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Chuang,G.Y.; Corti,D.; Mascola,J.R.; Shapiro,L.; Kwong,P.D.; Lanzavecchia,A.; Zhou,T.",Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation,16-SEP-2020,10_7_14_6_3_12,QNR09221_QNR09249,Unique word,Influenza,2,1,12.514237,0.46876
7KN4_M_N,QVTLRESGPGLVKPSETLSLTCAVSGGSLSSVNYYWSWIRQHPGKGLEWIGYIYYSGSTNYNPSLKSRVTMSLDTSKNQFSLKLSSVTAADTAVYYCATPGAIMGALHIWGQGTLVTVSS,QAVLTQPSSASSTPGQRVIISCSGSSSNIGSNTVSWYQQVPGAAPKLLIYFDYRRPSGVPDRFSGTRSGTSASLGISGLQSEDEADYYCAAWDDSLSAWVFGRGTKLTVL,7KN4_M,7KN4_N,Crystal Structure Of Sars-Cov-2 Spike Protein Receptor-Binding Domain Complexed With A Pre-Pandemic Antibody S-E6 Fab,Crystal Structure Of Sars-Cov-2 Spike Protein Receptor-Binding Domain Complexed With A Pre-Pandemic Antibody S-E6 Fab,Homo sapiens,"Qiang,M.;Ma,P.;Li,Y.;Liu,H.;Harding,A.;Min,C.;Wang,F.;Liu,L.;Yuan,M.;Ji,Q.;Tao,P.;Shi,X.;Li,Z.;Li,T.;Wang,X.;Zhang,Y.;Wu,N.C.;Lee,C.D.;Zhu,X.;Gilbert-Jaramillo,J.;Zhang,C.;Saxena,A.;Huang,X.;Wang,H.;James,W.;Dwek,R.A.;Wilson,I.A.;Yang,G.;Lerner,R.A.",Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago,04-NOV-2020,10_7_12_8_3_11,7KN4_M_N,Xtal structure,SARS-CoV-2,2,1,16.471956,-7.9845753
UIC72278_UIC72588,QVTLRESGPVLVKPTETLTLTCTISGFSLSPGRMGVTWIRQPPGKALEWLAHIFSNDEKSYSTSLKNRLTISKGTSNSQVVLTMTNTGPVDTATYYCARTTRTTRTRLHQALPHYFDPWGPGIKVIVSS,DIQMTQSPSSLSASVGDRVTITCRASQTISSYLNWYQQEPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISGLQPEDFATYYCQQSYSLPRTFGQGTKVEI,UIC72278,UIC72588,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,10_7_21_6_3_9,UIC72278_UIC72588,Unique source,HCV,2,1,12.504263,0.39652726
CCA61654_CCA61655,RITLKESGPPLVKPTQTLTLTCSFSGFSLSDFGVGVGWIRQPPGKALEWLAIIYSDDDKRYSPSLNTRLTITKDTSKNQVVLVMTRVSPVDTATYFCAHRRGPTTLFGVPIARGPVNAMDVWGQGITVTISS,ALQLTQSPSSLSASVGDRITITCRASQGVTSALAWYRQKPGSPPQLLIYDASSLESGVPSRFSGSGSGTEFTLTISTLRPEDFATYYCQQLHFYPHTFGGGTRVDVR,CCA61654,CCA61655,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"CLARK,K.; JOHNSON,P.J.",Antibody gene transfer and recombinant AAV therefor,05-APR-2011,10_7_24_6_3_9,CCA61654_CCA61655,Unique chain,,2,1,12.368409,0.3216005
AUD54205_AUD54472,SCAASGFTFSNYGMSWVRQTPDKRLEWVATISYGVGYTFYADSVRGRFTISRDNAKNTLYLQMSSLKSEDSAMFYCARRGRYDVSGLDYWGQGTLVTVSA,VTMRCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPGRFTGSGAGTDFTLTISSVQAEDLAVYYCQNDYINPLTFGGGTKLELK,AUD54205,AUD54472,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD54205_AUD54472,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,2,1,17.68986,8.3921
AUD54022_AUD54064,SCAASGFTFSSYGMSWVRQTPDKRLEWVATISNGGGYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDSAMYYCARRERYDENGFAYWGQGTLVTVSA,VTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCQNDYSNPLTFGGGTKLELK,AUD54022,AUD54064,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD54022_AUD54064,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,2,1,17.722765,8.363752
AUD54163_AUD54391,SCAASGFTFSSYGMSWVRQTPDKRLEWVATISYGVGYTFYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDSAMYYCSRRERYDENGFAYWGQGTLVTVSA,VTMSCTSSQSLFNSGKQKNYLTWYQQKSGQPPKVLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYINPLTFGGGTKLELK,AUD54163,AUD54391,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD54163_AUD54391,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,2,1,17.712484,8.388701
AUD53876_AUD53959,SCAASGFTFSTYGMSWVRQTPDKRLEWVATISNGGGYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDSAMYYCARRERYDENGFAYWGQGTLVTVSA,VTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSNPLTFGGGTKLELK,AUD53876,AUD53959,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD53876_AUD53959,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,2,1,17.706337,8.3776455
AAK16595,SGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQAPEKRLEWVASINYGGDTYYPDNVKGRFTISRDNAGNILFLQMSSLRSEDTAMYYCARVSYYGRTYHYAMDYWGQGTTVTVSS,DIELTQSPALMAASPGEKVTITCSVSSSISSSNLHWYQQKSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISNMEAEDAATYYCQQWSSYPLTFGSGTKLEIK,AAK16595_H,AAK16595_L,"IgM ScFv antibody, partial [Mus musculus]","IgM ScFv antibody, partial [Mus musculus]",Mus musculus,"Chen,L.; Li,G.; Tang,L.; Wang,J.; Ge,X.R.",The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv,14-JUL-2016,8_7_16_7_3_9,AAK16595,Same entry,,2,1,17.852095,7.019806
3JCX_H_L,SGPGLVQPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVS,LMTQIPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK,3JCX_H,3JCX_L,Canine Parvovirus Complexed With Fab E,Canine Parvovirus Complexed With Fab E,Rattus norvegicus,"Organtini,L.J.;Lee,H.;Iketani,S.;Huang,K.;Ashley,R.E.;Makhov,A.M.;Conway,J.F.;Parrish,C.R.;Hafenstein,S.",Near-Atomic Resolution Structure of a Highly Neutralizing Fab Bound to Canine Parvovirus,21-MAR-2016,8_7_16_6_3_9,3JCX_H_L,Xtal structure,,2,1,22.258493,-5.9521785
6I9I_H_L,TGSLEESGGRLVTPGTPLTLTCTVSGIDPNSDHMSWVRQAPGKGLEWIAIIYASGTTYYASWAKGRFTISKTSTTVDLRIASPTTEDTATYFCATYPNYPTDNLWGQGTLVTVSG,GMTQTPSPVSAAVGGTVTINCQASQSVYNNYLLSWYQQKPGQPPKRLIYSASTLASGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLGSYDGNSADCLAFGGGTEVVVK,6I9I_H,6I9I_L,Rift Valley Fever Virus Gn In Complex With A Neutralizing Antibody Fragment,Rift Valley Fever Virus Gn In Complex With A Neutralizing Antibody Fragment,Rift Valley fever virus,"Allen,E.R.;Krumm,S.A.;Raghwani,J.;Halldorsson,S.;Elliott,A.;Graham,V.A.;Koudriakova,E.;Harlos,K.;Wright,D.;Warimwe,G.M.;Brennan,B.;Huiskonen,J.T.;Dowall,S.D.;Elliott,R.M.;Pybus,O.G.;Burton,D.R.;Hewson,R.;Doores,K.J.;Bowden,T.A.",A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus,23-NOV-2018,8_7_11_8_3_13,6I9I_H_L,Xtal structure,,2,1,-0.13748933,19.15437
AF157758_1_AF157759_1,TLDESGGGLQTPGGTLSLVCKASGFTFSSYGMQWVRQAPGKGLEYIASISRTGRYTGYGAAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYFCAKAACSHSYESGCIDAWGHGTEVIVSS,LTQPSSVSANPGETVKITCSGGGDNYGWYQQKAPGSAPVTLIYDNTNRPSNIPSRFSGSGSGSTGTLTITGVRVEDEAVYYCGSRDSRGVGIFGAGTTLTVL,AF157758_1,AF157759_1,"scFV antibody V-heavy region, partial [synthetic construct]","scFV antibody V-light region, partial [synthetic construct]",synthetic construct,"Andris-Widhopf,J.; Rader,C.; Steinberger,P.; Fuller,R.; Barbas,C.F. III",Methods for the generation of chicken monoclonal antibody fragments by phage display,26-JUL-2016,8_8_16_4_3_10,AF157758_1_AF157759_1,Unique source,,2,1,14.494656,11.246661
AEQ74204_AEQ74964,TLVKPTQTLTLTCSFSGFSIDTTGVGVGWIRQHPGKALDWLAVIYWDDNKRFSPSLKSRLTITKDTSKNQVVLTMTNVDPEDTATYYCARSVFPVLPFDFWGQGTLVT,TLSASVGDRVTITCRASQSVSGRLAWYQQKPGKAPNLLIYKASTVQSGVPSRFRGSGSGTEFTLTISSLQPDDFATYYCQEYSNYSGTFGQGTRVDIK,AEQ74204,AEQ74964,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_12_6_3_9,AEQ74204_AEQ74964,Unique source,tetanus,2,1,12.292683,0.19512206
AEQ74205_AEQ74965,TLVKPTQTLTLTCSFSGFSIDTTGVGVGWIRQPPGKALDWLAVIYWDDNKRFSPSLKSRLTITKDTSKNQVVLTMTNVDPEDTATYYCARSVFPVLPFDFWGQGTLVT,TLSASVGDRVTITCRASQSVSGRLAWYQQKPGKAPNLLIYKASTVQSGVPSRFRGSGSGTEFTLTISSLQPDDFATYYCQEYSNYSGTFGQGTRVDIK,AEQ74205,AEQ74965,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_12_6_3_9,AEQ74205_AEQ74965,Unique source,tetanus,2,1,12.316859,0.24016355
AEQ74226_AEQ74986,TVKPTQTLTLTCSFSGFTLSSSGVGVGWIRQPPGKALEWLALISWNDDNRYSPSLQSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARTVVPAGVGFDYWGQGTLVT,TLPASVGDRVTITCRASQSVSNRLAWYQQKPGKAPKLLIFKASTLQAGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSSYDFGQGTKLEIK,AEQ74226,AEQ74986,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_13_6_3_10,AEQ74226_AEQ74986,Unique source,tetanus,2,1,12.342564,0.21925554
5CSZ_H_L,VELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,5CSZ_H,5CSZ_L,Crystal Structure Of Gantenerumab Fab Fragment In Complex With Abeta 1-11,Crystal Structure Of Gantenerumab Fab Fragment In Complex With Abeta 1-11,Homo sapiens,"Bohrmann,B.;Baumann,K.;Benz,J.;Gerber,F.;Huber,W.;Knoflach,F.;Messer,J.;Oroszlan,K.;Rauchenberger,R.;Richter,W.F.;Rothe,C.;Urban,M.;Bardroff,M.;Winter,M.;Nordstedt,C.;Loetscher,H.",Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta,23-JUL-2015,8_8_19_7_3_9,5CSZ_H_L,Xtal structure,amyloid-beta; Abeta,2,1,14.00557,9.911662
5VOB_H_L,VELVESGGGVVQPGRSLRLSCAASGFTFSSDGMHWVRQSPGRGLEWVAFISSDGSTPYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCAKDWALFRWLRTFDHWGQGTLVTVSS,ETVMTQSPATLSVSPGGRATLSCRASQSVGINLAWYQQKPGQAPRLLIYGASTRASGFPARFSGSGSGTEFTLTITSLQSEDFAVYYCQQYNDWPPWTFGQGTKVEIK,5VOB_H,5VOB_L,Crystal Structure Of Hcmv Pentamer In Complex With Neutralizing Antibody 8I21,Crystal Structure Of Hcmv Pentamer In Complex With Neutralizing Antibody 8I21,Homo sapiens,"Chandramouli,S.;Malito,E.;Nguyen,T.;Luisi,K.;Donnarumma,D.;Xing,Y.;Norais,N.;Yu,D.;Carfi,A.",Structural basis for potent antibody-mediated neutralization of human cytomegalovirus,02-MAY-2017,8_8_15_6_3_10,5VOB_H_L,Xtal structure,cytomegalovirus,2,1,14.820804,13.497301
1IGY_B_A,VKLQESGAELARPGASVKMSCKASGYTFTTYTIHWIKQRPGQGLEWIGYINPSSVYTNYNQRFKDKATLTRDRSSNTANIHLSSLTSDDSAVYYCVREGEVPYWGQGTTVTVSS,SKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,1IGY_B,1IGY_A,Structure Of Immunoglobulin,Structure Of Immunoglobulin,Mus musculus,"Harris,L.J.;Skaletsky,E.;McPherson,A.",Crystallization of intact monoclonal antibodies,09-OCT-1997,8_8_8_6_3_9,1IGY_B_A,Xtal structure,,2,1,0.10850697,-3.2580066
4J8R_B_A,VKLQESGGEVVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGDTNYNEKFKGKATLTADKSSSTAYMQLNSLTSDDSAVYFCARSGAAAPTYYAMDYWGQGVSVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQVGTALAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLSDYFCQQYSSYPTFGGGTKLEIK,4J8R_B,4J8R_A,Structure Of An Octapeptide Repeat Of The Prion Protein Bound To The Pom2 Fab Antibody Fragment,Structure Of An Octapeptide Repeat Of The Prion Protein Bound To The Pom2 Fab Antibody Fragment,Mus musculus,"Swayampakula,M.;Baral,P.K.;Aguzzi,A.;Kav,N.N.;James,M.N.",The crystal structure of an octapeptide repeat of the prion protein in complex with a Fab fragment of the POM2 antibody,14-FEB-2013,8_8_15_5_3_8,4J8R_B_A,Xtal structure,,2,1,0.30934164,-4.4868155
AHK61068_AHK61051,VKLQESGGGLVQPGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKANGYTTEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDGNPFAYWGQGTLVTVSA,DVKMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK,AHK61068,AHK61051,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Park,I.H.; Choi,J.E.; Lin,J.; Kim,K.-H.; Nahm,M.H.; Shin,J.-S.","Molecular Characterization of Anti-Colominic acid Mouse Antibodies Which Are Cross-protective to Neisseria meningitidis groups B, C, and Y",05-MAR-2014,8_10_9_11_3_9,AHK61068_AHK61051,Unique source,Colominic,2,1,26.061422,4.6824903
2211401A_2211401B,VKLQESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTWYDGSYWGQGTTVTVSS,DXXMTQTPSSFSVSLGDRVTITCKASEDIYNRLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDVATYYCQQYWSTPYTFGGGTKLEIK,2211401A,2211401B,anti-human interferon-gamma receptor antibody:SUBUNIT=heavy chain,anti-human interferon-gamma receptor antibody:SUBUNIT=kappa,Mus musculus,"Bridges,A.; Birch,A.; Williams,G.; Aguet,M.; Schlatter,D.; Huber,W.; Garotta,G.; Robinson,J.A.",Variable region cDNA sequences and characterization of murine anti- human interferon gamma receptor monoclonal antibodies that inhibit receptor binding by interferon gamma,01-JAN-1900,8_10_7_6_3_9,FAILED,Unique chain,interferon-gamma,2,1,13.416844,7.11245
AF486643_1_AF486644_1,VKLQESGPELVKPGASVRISCKASGYTFTSYYIHWVKQRPGQGLEWIGWIYPGNVNTKYNEKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARGGVSYAMDYWGQGTSVTVSS,DIVMTQDALTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIK,AF486643_1,AF486644_1,"monoclonal antibody HmenB3 heavy chain variable region, partial [Mus musculus]","monoclonal antibody HmenB3 light chain variable region, partial [Mus musculus]",Mus musculus,"Shin,J.S.; Yu,J.; Lin,J.; Zhong,L.; Bren,K.L.; Nahm,M.H.",Peptide mimotopes of pneumococcal capsular polysaccharide of 6B serotype: a peptide mimotope can bind to two unrelated antibodies,26-JUL-2016,8_8_11_11_3_9,AF486643_1_AF486644_1,Unique word,pneumococcal,2,1,0.19041465,-4.3456845
AAB17415_AAB17416,VKLQESGPGILKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDDKYYNPSLKSRLTISKDTSRNQVFLKITSVDTADTATYYCVRRAPLYGNHAMDYWGQGTTVTVSS,DVKMIQTPSSFSVSLGDRVTITCKASEDIYNRLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDVATYYCQQYWSTWTFGGGTKLEIK,AAB17415,AAB17416,"IgG Vh region, partial [Mus musculus]","IgG Vk region, partial [Mus musculus]",Mus musculus,"Bridges,A.; Birch,A.; Williams,G.; Aguet,M.; Schlatter,D.; Huber,W.; Garotta,G.; Robinson,J.A.",Variable region cDNA sequences and characterization of murine anti-human interferon gamma receptor monoclonal antibodies that inhibit receptor binding by interferon gamma,24-OCT-1996,10_7_14_6_3_8,AAB17415_AAB17416,Ordered entries,,2,1,11.528337,1.8857654
1YED_H_L,VKLQQSGPELVRPGTSVKLSCKTSGYIFTSYWIHWLKQSSGQGLEWIARIYPGTGGTYYNEKFKGKATLTADKSSSTAYMQLSSLKSEDSAVYFCTRWGFTTVRENYYAMDYWGQGTLVTVSS,DIVMTQSPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIYLVSKLESGVPDRFTGSGSGTDFTLKISRVEAADLGVYYCVQGTHFPYTFGGGTKLEI,1YED_H,1YED_L,Structure Of A Catalytic Antibody Igg2A Fab Fragment (D2.4),Structure Of A Catalytic Antibody Igg2A Fab Fragment (D2.4),Mus musculus,"Charbonnier,J.B.;Golinelli-Pimpaneau,B.;Gigant,B.;Tawfik,D.S.;Chap,R.;Schindler,D.G.;Kim,S.H.;Green,B.S.;Eshhar,Z.;Knossow,M.",Structural convergence in the active sites of a family of catalytic antibodies,15-APR-1997,8_8_17_11_3_9,1YED_H_L,Xtal structure,,2,1,0.40337905,-4.211053
8FAB_B_A,VKLVQAGGGVVQPGRSLRLSCIASGFTFSNYGMHWVRQAPGKGLEWVAVIWYNGSRTYYGDSVKGRFTISRDNSKRTLYMQMNSLRTEDTAVYYCARDPDILTAFSFDYWGQGVLVTVSS,YELTQPPSVSVSPGQTARITCSANALPNQYAYWYQQKPGRAPVMVIYKDTQRPSGIPQRFSSSTSGTTVTLTISGVQAEDEADYYCQAWDNSASIFGGGTKLTVL,8FAB_B,8FAB_A,Crystal Structure Of The Fab Fragment From The Human Myeloma Immunoglobulin Igg Hil At 1.8 Angstroms Resolution,Crystal Structure Of The Fab Fragment From The Human Myeloma Immunoglobulin Igg Hil At 1.8 Angstroms Resolution,Homo sapiens,"Rossi,G.;Choi,T.K.;Nisonoff,A.",Crystals of fragment Fab': preparation from pepsin digests of human IgG myeloma proteins,23-MAR-1992,8_8_14_6_3_9,8FAB_B_A,Xtal structure,,2,1,15.07319,13.362902
AEQ73992_AEQ74751,VLVKPTETLTLTCTVSGFSLSNPKMGVSWIRQPPGKALEWLAHTFSNDENSYTPSLSSRLTISKDTSKSQVVLTMTKMDPADTGTYYCARINGNVKIFGMVLPRGWFDPWGQGTLVT,SSLSASVGDRVTITCQASQDITHYLNWYQLKPGKAPKLLIYDASNLATGVPPRFSGSRSGTDFSFTISGLQPEDVATYYCQQYDTLPLSFGGGTKVQIK,AEQ73992,AEQ74751,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_21_6_3_9,AEQ73992_AEQ74751,Unique source,tetanus,2,1,12.629178,0.00311382
AEQ73960_AEQ74720,VLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLAHTFSNDEDSYTPSLSSRLTISKDTSKSQVVLTITNMDPVDTGTYYCARINGNVTIFGMVLPRGWFDPWGQGTLVT,SSLSASVGDRVTITCQASQDITHYLNWYQVKPGKAPKLLIYDASNLATGVPPRFSGSRTGTDFSFTISSLQPEDVATYSCQQYDTLPLSFGGGTKVQIK,AEQ73960,AEQ74720,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_21_6_3_9,AEQ73960_AEQ74720,Unique source,tetanus,2,1,12.62555,0.028931392
AEQ73702_AEQ74455,VLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLAHTFSNDENSYTPSLRNRLTISKDTSKSQVVLTMTNMDPVDTGTYYCARINGNVTIFGMILPRGWFDPWGQGTLVTVS,SSLSASVGHRVTITCQASQDITNYLNWYQLKPGKAPKLLIYDASNLATGVPPRFSGSRSGTHFTFTISSLQPEDVATYYCQQYDTLPLSFGGGTKVQIK,AEQ73702,AEQ74455,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_21_6_3_9,AEQ73702_AEQ74455,Unique source,tetanus,2,1,12.623835,0.03554061
AEQ73789_AEQ74540,VLVKPTETLTLTCTVSGFSLSNPRMGVSWIRQPPGKALEWLAHTFSNGENSYTPSLSSRLTISKDTSKRQVVLTMTNMDPVDTGTYYCARINGNVTIFGMVLPRGWFDPWGQGTLVTVS,SSLSASVGDRVTITCQASQDITNYLNWYQLKPGKAPKLLIYDASNLATGVPPRFSGSRSGTDFSFTISSLQPEDVATYYCQQYDTLPLSFGGGTKVQIK,AEQ73789,AEQ74540,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_21_6_3_9,AEQ73789_AEQ74540,Unique source,tetanus,2,1,12.601416,0.054160357
URX39994_URX40033,VLVQSRAEVKKPGASVRVSCEASGYNFIDHFIHWVRQVPGQRPEWMGWMKPRGGAVNYARSFRGRITLTRQMSMDTDMAYMDLSRLRPDDTAVYYCATRVKLPSSDDYGFDVWGQGTLVKVSA,QSALTQPHSVSGSPGQSVTISCTGLSGYVDVVWYQQHPGRAPKLIIYDVNRRPSGVPDRFSGSKSGNTASLTISGLRAEDEADYFCSSYEFFGGGTRVTVL,URX39994,URX40033,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Barnes,C.O.; Schoofs,T.; Gnanapragasam,P.N.P.; Golijanin,J.; Huey-Tubman,K.E.; Gruell,H.; Schommers,P.; Suh-Toma,N.; Lee,Y.E.; Cetrulo Lorenzi,J.C.; Piechocka-Trocha,A.; Scheid,J.F.; West,A.P. Jr.; Walker,B.D.; Seaman,M.S.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,15-AUG-2022,8_8_16_5_3_5,URX39994_URX40033,Unique source,HIV; CD4,2,1,2.6911063,3.4912095
ADB84846,VNLEVSGGGLVKPGGSLKLSCAAFGFTFSSYAMSWVRQTPEKRLEWVATINSNGGSTYYPDSVKGRFTISRDNAKNILYLQMSSLKSEDTAMYYCTRVDYRYDRHYAMDYWGQGTSVTVSS,DIVISQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPPTFGAGTKLELK,ADB84846_H,ADB84846_L,"anti-Eimeria acervulina merozoite immunoglobulin single-chain variable fragment, partial [synthetic construct]","anti-Eimeria acervulina merozoite immunoglobulin single-chain variable fragment, partial [synthetic construct]",synthetic construct,"Zhao,Y.; Amer,S.; Wang,J.; Wang,C.; Gao,Y.; Kang,G.; Bao,Y.; He,H.; Qin,J.","Construction, screening and identification of a phage display antibody library against the Eimeria acervulina merozoite",25-JUL-2016,8_8_15_5_3_9,ADB84846,Same entry,Eimeria,2,1,17.695032,7.0254865
3NZ8_H_L,VQLEESGPELVKPGALVKISCKASGYTFTTYDINWVKQRPGQGLEWIGWIYPGDGSNKYNEKFKDKATLTVDKSSSTAYMHLSSLTSENSAVYFCARGYGKNVYAMDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQTIVHSNGYTYLDWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGSGTKLEIK,3NZ8_H,3NZ8_L,Crystal Structure Of The Hiv-2 Neutralizing Fab Fragment 7C8,Crystal Structure Of The Hiv-2 Neutralizing Fab Fragment 7C8,Mus musculus,"Uchtenhagen,H.;Friemann,R.;Raszewski,G.;Spetz,A.L.;Nilsson,L.;Achour,A.",Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125,16-JUL-2010,8_8_13_11_3_9,3NZ8_H_L,Xtal structure,HIV,2,1,0.19695492,-4.4358063
ABY65253_ABY65276,VQLEQSGGGLAEPGGSLRLSCAASGFTFSDYYMDWVRQAPGKGLEWVARISTGGGTTWYADSVKGRFSISRDNGNNTLDLQMNSLRAEDTAVYYCARTRGSLEYWGQGALVTVSS,QPGLTQPPSVSGDPGQKVTLSCTGSRSNIGTYYVHWYQQLPGTAPKLLIYETNKRPSGVSDRFSGSKSGTSASLTITGLQPGDEADYFCGAWDNSLSAYIFGAETRLTVL,ABY65253,ABY65276,"immunoglobulin heavy chain variable region, partial [Macaca fascicularis]","immunoglobulin light chain variable region, partial [Macaca fascicularis]",Macaca fascicularis,"Pelat,T.; Hust,M.; Lefranc,M.-P.; Dubel,S.; Thullier,P.","Selection of a macaque scFv with human-like framework regions, high affinity, and that neutralizes the ricin toxin",26-JUL-2016,8_8_9_8_3_11,ABY65253_ABY65276,Unique source,,2,1,14.125965,9.455824
2BRR_H_L,VQLEQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKERFAFSLETSASAAYLQINNLKNEDTATYFCARDYYGSTYPYYAMDYWGQGTTVTVSS,NVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPYTFGGGTKLEIK,2BRR_H,2BRR_L,Complex Of The Neisserial Pora P1.4 Epitope Peptide And Two Fab- Fragments (Antibody Mn20B9.34),Complex Of The Neisserial Pora P1.4 Epitope Peptide And Two Fab- Fragments (Antibody Mn20B9.34),Neisseria meningitidis,"Oomen,C.J.;Hoogerhout,P.;Kuipers,B.;Vidarsson,G.;van Alphen,L.;Gros,P.",Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design,11-MAY-2005,8_8_16_7_3_9,2BRR_H_L,Xtal structure,PorA; meningococcal,2,1,-7.546914,6.0731125
7T0L_G_K,VQLKQSGPGLVQPSQSLSLTCTVSGFSLTSYGVHWVRQPPGKGLEWLGVIWSGGSTDYNAAFISRLSIRKDNSKSQVFFKMNSLQADDTAIYYCARTFTTSTSAWFAYWGQGTLVTVSA,SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYSSPPWTFGGGTKLEIR,7T0L_G,7T0L_K,Hla-B*27:05 In Complex With The Pan-Hla-Ia Monoclonal Antibody W6/32,Hla-B*27:05 In Complex With The Pan-Hla-Ia Monoclonal Antibody W6/32,Mus musculus,"Vivian,J.P.",HLA-B*27:05 in complex with the pan-HLA-Ia monoclonal antibody W6/32,07-DEC-2022,8_7_14_6_3_10,7T0L_G_K,Xtal structure,HLA; AS; HLA-B,2,1,22.574118,-5.62587
UZH31267_UZH31268,VQLLEESGGGAVQPGRSLRLSCEASGFSFNSYGMHWVRQAPGKGLEWVAAIWYSGSDRDYADSVKGRFSISRDNSKNTLYLQMNSLRAEDTAVYYCARDPHCTGGVCDAFDLWGQGTMVTVSS,ELQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK,UZH31267,UZH31268,"anti-SARS-CoV-2 S protein immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 S protein immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,Z.; Zhang,P.; Matsuoka,Y.; Tsybovsky,Y.; West,K.; Santos,C.; Boyd,L.F.; Nguyen,H.; Pomerenke,A.; Stephens,T.; Olia,A.S.; De Giorgi,V.; Holbrook,M.R.; Gross,R.; Postnikova,E.; Garza,N.L.; Johnson,R.F.; Margulies,D.H.; Kwong,P.D.; Alter,H.J.; Buchholz,U.J.; Lusso,P.; Farci,P.",Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants,14-NOV-2022,8_8_16_6_3_9,UZH31267_UZH31268,Unique source,SARS-CoV-2,2,1,14.811061,13.568004
UZH31265_UZH31266,VQLLEQSGAEVKKPGASVKVSCKASGDTFTGYYMHWVRQAPGQGLEWMGWINPNSGVTNYAQKFQGWVTMTRDTSISTVYMELNRLRSDDTAVYYCAREETIVGATPPYGLDVWGQGTTVTVSS,ELVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPVTFGQGTRLEIK,UZH31265,UZH31266,"anti-SARS-CoV-2 S protein immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 S protein immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,Z.; Zhang,P.; Matsuoka,Y.; Tsybovsky,Y.; West,K.; Santos,C.; Boyd,L.F.; Nguyen,H.; Pomerenke,A.; Stephens,T.; Olia,A.S.; De Giorgi,V.; Holbrook,M.R.; Gross,R.; Postnikova,E.; Garza,N.L.; Johnson,R.F.; Margulies,D.H.; Kwong,P.D.; Alter,H.J.; Buchholz,U.J.; Lusso,P.; Farci,P.",Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants,14-NOV-2022,8_8_17_6_3_10,UZH31265_UZH31266,Unique source,SARS-CoV-2,2,1,2.2119799,3.6340432
4G6A_C_D,VQLLEQSGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNLSLRSRISITRDTSKNQYYLQLNSVTTEDTATYYCALITTTTYAMDYWGQGTTVTVSS,LTLTQSPASLAVSLGQRATISCRASESVDGYGNSFLHWFQQKPGQPPKLLIYLASNLNSGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNVDPWTFGGGTKLEIK,4G6A_C,4G6A_D,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Broadly Neutralizing Antibody Ap33,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Broadly Neutralizing Antibody Ap33,Homo sapiens,"Kong,L.;Giang,E.;Nieusma,T.;Robbins,J.B.;Deller,M.C.;Stanfield,R.L.;Wilson,I.A.;Law,M.",Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33,18-JUL-2012,8_7_12_10_3_9,4G6A_C_D,Xtal structure,Hepatitis; Antigenic,2,1,10.726806,-12.831657
4QHU_B_A,VQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISLTSGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQLTLDVWGQGTLVTVSS,QSVLTQPPSVSVAPGQTARISCSGDNLGDKYANWYQQKPGQAPVLVIYDDIDRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCGSYDFFLGMIVFGGGTKLTVL,4QHU_B,4QHU_A,Crystal Structure Of Il-17A/Fab6785 Complex,Crystal Structure Of Il-17A/Fab6785 Complex,Homo sapiens,"Luo,J.;Gilliland,G.L.;Malia,T.;Obmolova,G.;Teplyakov,A.",Il-17a Asymmetry In A Complex With A Neutralizing A Fab6785 Reveals A Potential Mechanism Of Receptor Differentiation,29-MAY-2014,8_8_8_6_3_11,4QHU_B_A,Xtal structure,,2,1,14.205989,9.470241
AYP67187_AYP67388,VQLLESGGGLVQPGGSLRLSCEASGFRFSNYGMSWVRQAPGKGLEWVSSISGSGESTYYADSVKGRFTISRDNSKNTLYLQLNSLRAEDTAVYFCAKDLVVVVVYGTFDSWGQGILVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVTSSLAWYQQRPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWPPITFGQGTRLEIK,AYP67187,AYP67388,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_15_6_3_10,AYP67187_AYP67388,Unique source,,2,1,14.281717,9.895099
S24289_S24290,VQLQESGAELVKPGASVKLSCTASVFNIQDTYMHWVRQRPKQGLEWIGRIDPANGNTHFDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARWAGYYFDYWGQGTTLTVSS,DIQLTQSPASLSASVGETVTITCRASENIYSYLVWYQQKQGKSPRLLVYSAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGTPLTFGAGTKLELK,S24289,S24290,Ig gamma chain V region (JS34/32) - mouse,Ig kappa chain V region (JS34/32) - mouse,Mus musculus,"Moncharmont,B.",Direct Submission,20-JUN-2000,8_8_10_6_3_9,S24289_S24290,Unique word,,2,1,-4.6576705,0.12753746
2XZA_H_L,VQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGLTQSSHNDANWGQGTLTTVSS,SVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLNPVFGGGTKLE,2XZA_H,2XZA_L,Crystal Structure Of Recombinant A.17 Antibody Fab Fragment,Crystal Structure Of Recombinant A.17 Antibody Fab Fragment,Homo sapiens,"Smirnov,I.;Carletti,E.;Kurkova,I.;Nachon,F.;Nicolet,Y.;Mitkevich,V.A.;Debat,H.;Avalle,B.;Belogurov AA,Jr.;Kuznetsov,N.;Reshetnyak,A.;Masson,P.;Tonevitsky,A.G.;Ponomarenko,N.;Makarov,A.A.;Friboulet,A.;Tramontano,A.;Gabibov,A.",Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics,24-NOV-2010,9_7_12_8_3_10,2XZA_H_L,Xtal structure,,2,1,16.691895,-7.6144376
4HS6_B_A,VQLQESGPGLVKPSETLSLTCTVSGDSITSGYWNWIRQPPGRALEWMGYISYSGSTYYSLSLRSRITISRDTSKNQYSLRLSSVTAADTAMYYCALITTSTYAMDYWGQGTTVTVSS,DIVLTQSPSSLSASVGDRVTITCRASESVDGYGYSFLHWFQQKPGKAPKLLIYLASNLNSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNNVDPWTFGQGTKLEIK,4HS6_B,4HS6_A,Hepatitus C Envelope Glycoprotein E2 Fragment 412-423 With Humanized And Affinity-Matured Antibody Mrct10.V362,Hepatitus C Envelope Glycoprotein E2 Fragment 412-423 With Humanized And Affinity-Matured Antibody Mrct10.V362,Hepacivirus C,"Pantua,H.;Diao,J.;Ultsch,M.;Hazen,M.;Mathieu,M.;McCutcheon,K.;Takeda,K.;Date,S.;Cheung,T.K.;Phung,Q.;Hass,P.;Arnott,D.;Hongo,J.A.;Matthews,D.J.;Brown,A.;Patel,A.H.;Kelley,R.F.;Eigenbrot,C.;Kapadia,S.B.",Glycan shifting on hepatitis C virus (HCV) e2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies,29-OCT-2012,8_7_12_10_3_9,4HS6_B_A,Xtal structure,HCV,2,1,16.579355,-7.859785
AYP67217_AYP67439,VQLQESGPGLVKPSETLSLTCTVSGGSISDSSDYWGWIRQPPGKGPEWLGSMSPSGITYYSPSLKSRVTMSVDTSKKQFSLRLSYVTAADTAIYYCTRDRDIVSRGGFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISRFLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTHFTLTISSLQPEDFATYYCQQSYSNLPYTFGQGTKVEIK,AYP67217,AYP67439,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,10_7_14_6_3_10,AYP67217_AYP67439,Unique source,,2,1,16.638643,-8.064993
4NPY_B_A,VQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTLHGRRIYGIVAFKEWFTYYYMDVWGKGTTVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSRGPTNWVFGGGTKLTVL,4NPY_B,4NPY_A,"Crystal Structure Of Germline Fab Pgt121, A Putative Precursor Of The Broadly Reactive And Potent Hiv-1 Neutralizing Antibody","Crystal Structure Of Germline Fab Pgt121, A Putative Precursor Of The Broadly Reactive And Potent Hiv-1 Neutralizing Antibody",Homo sapiens,"Sok,D.;Laserson,U.;Laserson,J.;Liu,Y.;Vigneault,F.;Julien,J.P.;Briney,B.;Ramos,A.;Saye,K.F.;Le,K.;Mahan,A.;Wang,S.;Kardar,M.;Yaari,G.;Walker,L.M.;Simen,B.B.;St John,E.P.;Chan-Hui,P.Y.;Swiderek,K.;Kleinstein,S.H.;Alter,G.;Seaman,M.S.;Chakraborty,A.K.;Koller,D.;Wilson,I.A.;Church,G.M.;Burton,D.R.;Poignard,P.",The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies,22-NOV-2013,8_7_26_6_3_12,4NPY_B_A,Xtal structure,HIV,2,1,15.605418,-7.957533
2DQF_B_A,VQLQESGPSLVKPSQTLSLTCSVTGDSITSDAWSWIRKFPGNRLEYMGYVSASGSTYYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWDGDYWGQGTLVTVS,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,2DQF_B,2DQF_A,Crystal Structure Of Hyhel-10 Fv Mutant (Y33Ay53A) Complexed With Hen Egg Lysozyme,Crystal Structure Of Hyhel-10 Fv Mutant (Y33Ay53A) Complexed With Hen Egg Lysozyme,Gallus gallus,"Shiroishi,M.;Tsumoto,K.;Tanaka,Y.;Yokota,A.;Nakanishi,T.;Kondo,H.;Kumagai,I.",Structural consequences of mutations in interfacial Tyr residues of a protein antigen-antibody complex. The case of HyHEL-10-HEL,25-MAY-2006,8_7_7_6_3_9,2DQF_B_A,Xtal structure,,2,1,10.668461,-12.794013
4UIL_H_L,VQLQESGTVLARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTRERGLYYGSSSFDYWGQGTTLTVSS,DIVMTQTTSSLSASLGDRVTISCRASQDISNYLSWYQQKPDGTVKVLIYYTSKLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK,4UIL_H,4UIL_L,Crystal Structure Of Quinine-Dependent Fab 314.1 With Quinine,Crystal Structure Of Quinine-Dependent Fab 314.1 With Quinine,Mus musculus,"Zhu,J.;Zhu,J.;Bougie,D.W.;Aster,R.H.;Springer,T.A.",Structural basis for quinine-dependent antibody binding to platelet integrin alphaIIbbeta3,30-MAR-2015,8_8_15_6_3_9,4UIL_H_L,Xtal structure,platelet,2,1,2.6880467,-8.170347
2C1P_B_A,VQLQQSGAELVRPGTSVKLSCKASGYSFTNYWMNWLRQRPGQGLDWIGMIHPSDSETRLNQKFKDKATLTVDRSSSTAYIQLSSPTSEDSAVYYCARDDYDGAFWGQGTLVTVSA,LVMTQSPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIYLVSKLDSGDPDRFTGSGSGTDFTLKISRVEAEDLGIYYCVQGSHFPPTFGAGTKLELK,2C1P_B,2C1P_A,Fab-Fragment Of Enantioselective Antibody Complexed With Finrozole,Fab-Fragment Of Enantioselective Antibody Complexed With Finrozole,Mus musculus,"Parkkinen,T.;Nevanen,T.K.;Koivula,A.;Rouvinen,J.",Crystal structures of an enantioselective fab-fragment in free and complex forms,19-SEP-2005,8_8_9_11_3_9,2C1P_B_A,Xtal structure,,2,1,-0.34915468,-3.5859988
AHK61075_AHK61058,VQLQQSGGGLVQPGGSMKLSCVASGFTFSDYWMNWVRQSPEKGLEWVAEIRLKSTNYATHYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCARDYFAVDYWGQGTSVTVSS,DVQMIQTPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPRTFGGGTKLEIK,AHK61075,AHK61058,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Park,I.H.; Choi,J.E.; Lin,J.; Kim,K.-H.; Nahm,M.H.; Shin,J.-S.","Molecular Characterization of Anti-Colominic acid Mouse Antibodies Which Are Cross-protective to Neisseria meningitidis groups B, C, and Y",05-MAR-2014,8_10_9_6_3_9,AHK61075_AHK61058,Unique source,Colominic,2,1,13.373103,7.1893077
5DYO_H_L,VQLQQSGPELVKPGASVKMSCKASGYTFSTSVIHWVKQKPGQGLEWIGYIFPYNYGTQYNEEFRGKATLTSDKSSNTAYMELSSLTSEDSAVYYCASRSGPWGQGTTLTVSS,DVVMTQTPLTLSITIGQPVSISCKSSQSLFASDGRTYLNWLLQRPGQSPERLIYLVSNLDSGVLDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPQTFGGGTKLEIK,5DYO_H,5DYO_L,Fab43.1 Complex With Flourescein,Fab43.1 Complex With Flourescein,Mus musculus,"Gayda,S.;Longenecker,K.L.;Judge,R.A.;Swift,K.M.;Manoj,S.;Linthicum,D.S.;Tetin,S.Y.","Three-dimensional structure, binding, and spectroscopic characteristics of the monoclonal antibody 43.1 directed to the carboxyphenyl moiety of fluorescein",25-SEP-2015,8_8_6_11_3_9,5DYO_H_L,Xtal structure,,2,1,1.0141772,-3.8006737
4QEX_I_M,VQLQQSGPELVKPGTSVKISCKTSGYTFTENTMHWVKQSHGESLDWVGGINTDNGGTTYSQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCSTGYDAMDYWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASKGVDSYGNSFMHWYQQRPGQPPKLLIYLASHLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPFTFGSGTKLEIK,4QEX_I,4QEX_M,Crystal Structure Of Pfeba-175 Rii In Complex With A Fab Fragment From Inhibitory Antibody R217,Crystal Structure Of Pfeba-175 Rii In Complex With A Fab Fragment From Inhibitory Antibody R217,Mus musculus,"Chen,E.;Paing,M.M.;Salinas,N.;Sim,B.K.;Tolia,N.H.",Structural and functional basis for inhibition of erythrocyte invasion by antibodies that target Plasmodium falciparum EBA-175,19-MAY-2014,8_8_9_10_3_9,4QEX_I_M,Xtal structure,,2,1,2.537469,-4.3764257
1UYW_H_L,VQLQQSGPELVKPGTSVKISCKTSGYTFTEYTIHWVKEAGGKSLAWIGGIDPNSGGTNYSPNFKGKATLTVDKSSSTAYMDLRSLSSEDSAVYFCARIYHYDGYFDVWGAGTAVTVSS,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLELK,1UYW_H,1UYW_L,Crystal Structure Of The Antiflavivirus Fab4G2,Crystal Structure Of The Antiflavivirus Fab4G2,Mus musculus,"Martinez-Fleites,C.;Ortiz-Lombardia,M.;Taylor,E.J.;Gil-Valdes,J.;Chinea,G.;Davies,G.",Crystal Structure Of The Antiflavivirus Fab4g2,03-MAR-2004,8_8_12_6_3_9,1UYW_H_L,Xtal structure,,2,1,2.507841,-4.3753657
5F89_H_L,VQLQQSGPGLVKPSQTLSLTCNVYGVAISNEDYYWTWIRQHPGKGLEWIGDIYYNSGTTHYNPSLKSRASVSVDLSRNQFTLKVTSVTTADAAVYYCAREASTKITDDGGAFDFWGRGTMVTVSS,QSALTQPASVSGSPGQSISISCTGTSSDIGGYKYVSWYQQHPGRAPKLIIYDVIKRPSGISDRFSGSKSANTASLTISGLQAGDEASYYCSSYTTKKTSFFGPATRAYVFGSGTQVTVL,5F89_H,5F89_L,Structure Of The Unliganded Fab From Hiv-1 Neutralising Antibody Cap248-2B That Binds To The Gp120 C-Terminus - Gp41 Interface,Structure Of The Unliganded Fab From Hiv-1 Neutralising Antibody Cap248-2B That Binds To The Gp120 C-Terminus - Gp41 Interface,Homo sapiens,"Wibmer,C.K.;Gorman,J.;Ozorowski,G.;Bhiman,J.N.;Sheward,D.J.;Elliott,D.H.;Rouelle,J.;Smira,A.;Joyce,M.G.;Ndabambi,N.;Druz,A.;Asokan,M.;Burton,D.R.;Connors,M.;Abdool Karim,S.S.;Mascola,J.R.;Robinson,J.E.;Ward,A.B.;Williamson,C.;Kwong,P.D.;Morris,L.;Moore,P.L.",Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape,09-DEC-2015,10_8_17_9_3_19,5F89_H_L,Xtal structure,gp120; HIV,2,1,16.550245,-8.219357
1QLR_D_C,VQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARPPHDTSGHYWNYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCGASQSVSSNYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,1QLR_D,1QLR_C,Crystal Structure Of The Fab Fragment   Of A Human Monoclonal Igm Cold Agglutinin,Crystal Structure Of The Fab Fragment   Of A Human Monoclonal Igm Cold Agglutinin,Homo sapiens,"Leoni,J.;Ghiso,J.;Goni,F.;Frangione,B.","The primary structure of the Fab fragment of protein KAU, a monoclonal immunoglobulin M cold agglutinin",11-SEP-1999,8_7_14_7_3_9,1QLR_D_C,Xtal structure,,2,1,16.639025,-10.467892
3CMO_H_L,VQLSQSGTVLARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRWPHYYGGSRYYFDYWGQGTTLTVSS,DIVMTQSSSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVELLIYYTSRLQSGVPSRFSGSGSGSDYSLTISNLVPEDIATYYCQQYSKLFTFGSGTKLEIK,3CMO_H,3CMO_L,Hiv Neutralizing Monoclonal Antibody Yz18,Hiv Neutralizing Monoclonal Antibody Yz18,Mus musculus,"Jin,L.;Prasad,V.;Paul,S.",Hiv Neutralizing Monoclonal Antibody Yz18,24-MAR-2008,8_8_16_6_3_8,3CMO_H_L,Xtal structure,,2,1,2.681841,-8.162628
AAD46603_AAD46604,VQLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLGSEDTAMYYCARQGTGVGYGNYNYWGQGTTV,IVMTQSPSSLSASLGDTITITCHASQNINVWLSWYQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQGQSYPYTFGGGTKLEI,AAD46603,AAD46604,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Hu,T.S.; Qian,Y.C.; Yang,Y.G.; Hu,Y.L.; Qu,X.M.; Yang,S.L.",Preparation and cDNA sequence analysis of two novel monoclonal antibodies against magaininII,26-JUL-2016,8_8_14_6_3_9,AAD46603_AAD46604,Unique source,,2,1,17.775871,7.200462
AMB38420_AMB38548,VQLVESGGGLVKPGGSLRLSCAASGFIFSDYYMSWIRQAPGKGLEWVSFITPSSSYTDYSDSVKGRFTISRDNAKNSLYLQMSSLRAEDTAVYYCARTENSGYDLVRVWGQGTLVTVSS,DIQMTQSPSSLSASIGDRVTITCQTSQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIGTYYCQQYDTFGQGTRLEIK,AMB38420,AMB38548,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_13_6_3_5,AMB38420_AMB38548,Unique source,,2,1,15.652625,9.397925
8HN6_A_B,VQLVESGGGLVQPGESLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYAGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDMAIYYCARDLSYYGMDVWGQGTTVTVSS,DIQLTQFPFSLSASVGDRVTITCRASQGISTYLAWYQQKPGRAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQLLNSYPVHFGQGTKLEIK,8HN6_A,8HN6_B,Crystal Structure Of Monoclonal Antibody Complexed With Sars-Cov-2 Rbd,Crystal Structure Of Monoclonal Antibody Complexed With Sars-Cov-2 Rbd,Severe acute respiratory syndrome coronavirus 2,"Wang,Z.;Li,D.;Chen,Y.;Sun,Y.;Jin,C.;Hu,C.;Feng,Y.;Su,J.;Ren,L.;Hao,Y.;Wang,S.;Zhu,M.;Liu,Y.;Qi,J.;Zhu,B.;Shao,Y.",Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents,17-MAY-2023,8_7_11_6_3_9,8HN6_A_B,Xtal structure,RBD; SARS-CoV-2; COVID,2,1,12.54803,10.766489
4TTD_C_D,VQLVESGGGLVQPGGPLRLSCAASGFTISSNYMSWVRQAPGKGLEWVSAIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGPGDSIVYWGKGTLVTVSS,QSVLTQPPSVSGAPGQRVSISCTGRSSNIGAGYDVHWYQQLPGKAPKLLIYGNTNRPSGVPVRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLRGSVFGGGTKLTVL,4TTD_C,4TTD_D,Structure Of A Lysozyme Antibody Complex,Structure Of A Lysozyme Antibody Complex,Homo sapiens,"Wensley,B.",Structure Of A Lysozyme Antibody Complex,20-JUN-2014,8_7_11_9_3_11,4TTD_C_D,Xtal structure,,2,1,12.720389,10.156444
8AS2_H_L,VQLVESGGGLVQPGGSLRLSCAASGFNVYSSSIHWVRQAPGKGLEWVASISSYYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSRQFWYSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYKYVPVTFGQGTKVEIK,8AS2_H,8AS2_L,Structure Of Arrestin2 In Complex With 4P Ccr5 Phosphopeptide And Fab30,Structure Of Arrestin2 In Complex With 4P Ccr5 Phosphopeptide And Fab30,Phage display vector pTDisp,"Isaikina,P.;Petrovic,I.;Jakob,R.P.;Sarma,P.;Ranjan,A.;Baruah,M.;Panwalkar,V.;Maier,T.;Shukla,A.K.;Grzesiek,S.",A key GPCR phosphorylation motif discovered in arrestin2&#x22c5;CCR5 phosphopeptide complexes,07-JUN-2023,8_8_13_6_3_9,8AS2_H_L,Xtal structure,BG37; CD195; CKR5; GPCR; TGR5; CMKBR5; M-BAR; GPR131; MGC40597; GPCR19; CC-CKR-5; CKR-5; IDDM22; GPBAR1; CCR5,2,1,9.652935,10.790656
5AUM_A_B,VQLVESGGGLVQPKESLKISCAAFGVTFSNVAMYWVRQAPGKGLEWVARIRTKPNNYATYYADSVKGRFTISRDDSKSMVYLQMDNLKTEDTAMYYCTAEVATDWGQGVMVTVSS,DVVLTQAPPTLSATIGQSVSISCRSSQSLLHRNGNTYLNWLLQRPGQPPQLLIYLVSRLESGVPNRFSGSGSGTAFTLKISGLEAEDLGVYYCVQGTHAPLTFGSGTKLEIK,5AUM_A,5AUM_B,Crystal Structure Of A Fab Fragment With The Ligand Peptide,Crystal Structure Of A Fab Fragment With The Ligand Peptide,Potyviridae,"Kitago,Y.;Takagi,J.",Crystal structure of a Fab fragment with the ligand peptide,30-APR-2015,8_10_7_11_3_9,5AUM_A_B,Xtal structure,,2,1,13.343108,7.7927423
AYP67091_AYP67295,VQLVESGGGVVQPGRSLRLSCATSGFIFSRYAIHWVRQAPGKGLEWVAVISNDGTKEECADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCARDATQYGYETNWFFDSWGRGLLVTVSS,SYELTQPASVSVSPGQTANITCSGDKLGDKYTSWYQQKPGQAPVLVIYQDTKRPSGIPERFFGSSSGDAATLTISGTQAMDEADYYCQAWVWDSRVVFGGGTKLTVL,AYP67091,AYP67295,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_17_6_3_10,AYP67091_AYP67295,Unique source,,2,1,14.791319,13.398431
AYP67099_AYP67303,VQLVESGGRLVQPGGSLRLSCAASGFIFSNYWMHWVRQAPGKGLVWVSRINSDGSSIVYADSVKGRFTVSRDNAKNTLYLQMNSLRAEDTAVYYCAREPYHPPQFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIDTYLNWYRQQPGRPPKLLIYSAANLPSGVPSRFSGSGSGADFTLTISGLQPEDFATFYCQQSYRSPPTFGGGTKVEIK,AYP67099,AYP67303,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_12_6_3_9,AYP67099_AYP67303,Unique source,,2,1,13.388422,9.853081
AOR08251,VQLVESGPGLVKPSETLSLTCAVSGVSISDDYYWTWIRQSPGKGLEWLGYIYGSGGDTNYSPSLKGRVTISMDTSKNQFSLNLNSMTAADTAAYYCAREEMAAAGYLDSWGQGVLVTVSS,ELTQPPSVSVSPGQTARISCGGDNLGSTWVHWYQQKPPQAPVVVINFDGDRPSGIPERFSGSKSGSTATLTISGVEAGDEADYYCQVWDGASDHRIFGGGTKLTVL,AOR08251_H,AOR08251_L,"single-chain variable fragment antibody, partial [synthetic construct]","single-chain variable fragment antibody, partial [synthetic construct]",synthetic construct,"Fofana,I.B.F.; Johnson,W.E.",Preferential germline VH usage observed with antibodies targeting gp120 but not gp41-ectodomain in an SIVmac239 infected macaque,24-SEP-2016,9_8_13_6_3_11,AOR08251,Same entry,gp120,2,1,16.34191,-7.333831
4RFO_H_L,VQLVESGPGLVKPSQTLSLTCTVSGASISSGGYFWSWIRQHPGKGLEWIGNIYYIGNTYYNPSLKSRLTISVDTTQNQFSLKLTSVTAADTAVYYCARVPRLRGGNYFDSWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCTGTSSDVGGYKYVSWYQQHPDKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL,4RFO_H,4RFO_L,Crystal Structure Of The Adcc-Potent Antibody N60-I3 Fab In Complex With Hiv-1 Clade A/E Gp120 And M48U1,Crystal Structure Of The Adcc-Potent Antibody N60-I3 Fab In Complex With Hiv-1 Clade A/E Gp120 And M48U1,Homo sapiens,"Gohain,N.;Tolbert,W.D.;Acharya,P.;Yu,L.;Liu,T.;Zhao,P.;Orlandi,C.;Visciano,M.L.;Kamin-Lewis,R.;Sajadi,M.M.;Martin,L.;Robinson,J.E.;Kwong,P.D.;DeVico,A.L.;Ray,K.;Lewis,G.K.;Pazgier,M.",Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1,26-SEP-2014,10_7_14_9_3_10,4RFO_H_L,Xtal structure,gp120; HIV,2,1,16.577421,-8.318731
AMB38379_AMB38632,VQLVQSGAEVKKPGASVKVSCKASGYIFTGYYMEWVRQAPGQGLEWMGWINPNTGVTKYAQKFQGRVTMTRDTSLSTAYMELINLRSDDTAIYYCAKDRAWLVYDDGSDVWGQGTMVTVSS,SYELTQPPSVSVSPGQTAIITCSGDILGDTYACWYQQKPGQSPVLVIYHDFKRPSGIPERFSGSNSGKTATLTITGTQAMDEADYFCQTWDGGALFGGGTKLTVL,AMB38379,AMB38632,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_15_6_3_8,AMB38379_AMB38632,Unique source,,2,1,2.1661355,3.6539037
AYP67084_AYP67285,VQLVQSGAEVKKPGASVKVSCKTSGYTFTIYEINWVRQATGQGLEWMGTMNPNSATTGSAQKFQGRLTMTGNTSLRTTYMELSSLTSEDTAVYYCARLVSCGGDCYYFDSWGQGTLVTVSS,SYELTQAPSVSVAPGQTARIPCGGNNIGTKSVHWYQQRPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSGDQFGGGTKLTVL,AYP67084,AYP67285,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_15_6_3_9,AYP67084_AYP67285,Unique source,,2,1,1.9985093,4.241604
AYP67183_AYP67391,VQLVQSGAEVKKPGASVRLSCKASGFRFTNYYFNWVRQAPGQGLEWMGIINPSGGATTYAQKFQGRVTMTRDTSTSTVYMELGSLRSEDTAVYYCARMATLTASYFYSYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQSVSSSYVAWYQQKPGQAPRLLIYAASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPALTFGGGTKVEIK,AYP67183,AYP67391,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_18_7_3_10,AYP67183_AYP67391,Unique source,,2,1,1.6628937,3.6797452
AMB38469_AMB38590,VQLVQSGAEVKKPGASVRVSCKASGYTLSNFGIGWVRQAPGQGLEWVGWISAYTANTHYAQKFQDRVTVTTDTSTSTAYMELRSLGFDDTAVYYCARIEGAANYYYMDVWGGGTTVTVSS,DIQMTQSPSSLAASVGDRVTITCRASQNIRSYLNWYQQKPGKAPSLLIYAASSLQSGVTSRFNGSGSGTDFSLTIASLQPADFATYFCQQSYSTPVTFGRGTKVEIK,AMB38469,AMB38590,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_14_6_3_9,AMB38469_AMB38590,Unique source,,2,1,1.9527831,5.1686134
AYP67223_AYP67405,VQLVQSGAEVKKPGESLKISCKGSGYSFTSFWIAWVRQMPGKGLEWMGIIYPGDSETRYSPSFQGQVTISADKSISTAYLQWTSLKAADTAIYYCARPQCTAGGCYSGYYALEVWGHGTTVTVSS,DIQMTQSPSSLSVSVGDSITITCRPSDFISNNLNWYQQKPGKAPKLLIYDASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPLTFGGGTKVEIK,AYP67223,AYP67405,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_19_6_3_9,AYP67223_AYP67405,Unique source,,2,1,-12.458437,5.58054
AYP67219_AYP67441,VQLVQSGAEVKKPGESLKISCRASGYSFSSDWIGWVRQMPGKGLEWMGIIFPDDSDTRYSPSFEGQVTISADESISTAYLQWSSLKASDSAFYYCARAPGIWSDRFTFHSPMFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRTSQSVTSDDLAWYQQKPGQAPRLLIYGAYTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSQYTFGQGTKVEIK,AYP67219,AYP67441,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Henry,C.; Zheng,N.-Y.; Huang,M.; Cabanov,A.; Rojas,K.T.; Kaur,K.; Andrews,S.F.; Palm,A.-K.E.; Chen,Y.-Q.; Li,Y.; Hoskova,K.; Utset,H.A.; Vieira,M.C.; Wrammert,J.; Ahmed,R.; Holden-Wiltse,J.; Topham,D.J.; Treanor,J.T.; Cobey,S.; Krammer,F.; Hensley,S.E.; Greenberg,H.; He,X.-S.; Wilson,P.C.",Elderly individuals no longer adapt their B cell responses to influenza efficiently,06-NOV-2018,8_8_20_7_3_9,AYP67219_AYP67441,Unique source,,2,1,-12.374103,5.719313
QRG34584_QRG34716,VQLVQSGAEVKKPGSSVKVSCEAAGDTVTNFPITWVRQAPGQGPEWMGGIIPVFGAATYAQKFQGRVTIAADATMNTAYMELTGLRSEDTAVYYCVRCNLGSLFGGSCYGWFDSWGQGTLVTVSS,IVLTQSPGTLSVSPGERATLSCRASQSVSSRNLAWYQQRPGQAPRLLISGASSRATGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYGSSPHTFGQGTKVEIK,QRG34584,QRG34716,"immunoglobulin variable region, partial [Homo sapiens]","immunoglobulin variable region, partial [Homo sapiens]",Homo sapiens,"Salinas,E.; Boisvert,M.; Upadhyay,A.A.; Bedard,N.; Nelson,S.A.; Bruneau,J.; Derdeyn,C.A.; Marcotrigiano,J.; Evans,M.J.; Bosinger,S.E.; Shoukry,N.H.; Grakoui,A.",Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion,10-FEB-2021,8_8_19_7_3_9,QRG34584_QRG34716,Unique source,,2,1,-0.9093163,5.8864536
AMB38466_AMB38587,VQLVQSGAEVKKPGSSVKVSCKASGDTFSNYAISWVRQAPGQGLEWMGGIIPIFRTAKYAQRFQGRVTMITDESTSTSYMELSSLRSDDTAVYYCAGVLTAFTDREPQYFLYYMDIWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVYPSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLIVSRLEPEDFAVYYCQQYGDSPLTFGGGTKVEIK,AMB38466,AMB38587,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Huang,Y.; Kaur,K.; Popova,L.I.; Ho,I.Y.; Pauli,N.T.; Henry Dunand,C.J.; Taylor,W.M.; Lim,S.; Huang,M.; Qu,X.; Lee,J.H.; Salgado-Ferrer,M.; Krammer,F.; Palese,P.; Wrammert,J.; Ahmed,R.; Wilson,P.C.",Immune history profoundly affects broadly protective B cell responses to influenza,02-FEB-2016,8_8_21_7_3_9,AMB38466_AMB38587,Unique source,,2,1,-0.79657817,6.097332
AIT38896_AIT38895,VQLVQSGAEVKKPGSSVKVSCKASGGTFSSHGLSWVRQAPGQGLEWMGDIIVTFGRVNYAQKFQGRVTITADEWTSTAYMELSSLRSDDTAVYYCARESQDPYVQPPAMYYLDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAPYDVHWYQHRPGTAPKLLIYGNVNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGFWVFGGGTKLTVL,AIT38896,AIT38895,"immunoglobulin G heavy chain variable region, partial [Homo sapiens]","immunoglobulin G heavy chain variable region, partial [Homo sapiens]",Homo sapiens,"Pauli,N.T.; Kim,H.K.; Falugi,F.; Huang,M.; Dulac,J.; Henry Dunand,C.; Zheng,N.Y.; Kaur,K.; Andrews,S.F.; Huang,Y.; DeDent,A.; Frank,K.M.; Charnot-Katsikas,A.; Schneewind,O.; Wilson,P.C.",Staphylococcus aureus infection induces protein A-mediated immune evasion in humans,15-OCT-2014,8_8_19_9_3_12,AIT38896_AIT38895,Unique source,,2,1,-0.5386764,5.5956435
5CIP_A_B,VQLVQSGAEVKRPGSSVTVSCKASGGSFSTYALSWVRQAPGRGLEWMGGVIPLLTITNYAPRFQGRITITADRSTSTAYLELNSLRPEDTAVYYCAREGTTGWGWLGKPIGAFAHWGQGTLVTVSS,EIVLTQSPGTQSLSPGERATLSCRASQSVGNNKLAWYQQRPGQAPRLLIYGASSRPSGVADRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGQSLSTFGQGTKVEVK,5CIP_A,5CIP_B,Crystal Structure Of Unbound 4E10,Crystal Structure Of Unbound 4E10,Homo sapiens,"Rujas,E.;Gulzar,N.;Morante,K.;Tsumoto,K.;Scott,J.K.;Nieva,J.L.;Caaveiro,J.M.",Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10,13-JUL-2015,8_8_20_7_3_9,5CIP_A_B,Xtal structure,HIV,2,1,-0.85710454,5.794699
1NBV_H_L,VQPVETGGGLVQPKGSLKLSCAASGFSFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYADSVKDRFTISRDDSQNMLYLQMNNLKTEDTAMYYCVRDQTGTAWFAYWGQGTLVTVS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPLTFGAGTKLELK,1NBV_H,1NBV_L,An Autoantibody To Single-Stranded Dna: Comparison Of The Three-Dimensional Structures Of The Unliganded Fab And A Deoxynucleotide-Fab Complex,An Autoantibody To Single-Stranded Dna: Comparison Of The Three-Dimensional Structures Of The Unliganded Fab And A Deoxynucleotide-Fab Complex,Mus musculus,"Gibson,A.L.;Herron,J.N.;Ballard,D.W.;Voss EW,Jr.;He,X.M.;Patrick,V.A.;Edmundson,A.B.",Crystallographic characterization of the Fab fragment of a monoclonal anti-ss-DNA antibody,16-MAR-1993,8_10_12_11_3_9,1NBV_H_L,Xtal structure,ss-DNA,2,1,13.333657,7.7779207
7MZJ_H_L,VVQLVESGGGLVKPGGSLRLSCAASGFTFSYAWMSWVRQAPGKGLEWVGRIKRKSDGGTTDYAAPVKGRFTISRDDSKNTLYLQMSSLKTEDTAVYYCTTDLCRSTSCEHDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTVTCRASQSIRSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPAITFGQGTRVQIK,7MZJ_H,7MZJ_L,Sars-Cov-2 Receptor Binding Domain Bound To Fab Wcsl 129 And Fab Pdi 93,Sars-Cov-2 Receptor Binding Domain Bound To Fab Wcsl 129 And Fab Pdi 93,Homo sapiens,"Wheatley,A.K.;Pymm,P.;Esterbauer,R.;Dietrich,M.H.;Lee,W.S.;Drew,D.;Kelly,H.G.;Chan,L.J.;Mordant,F.L.;Black,K.A.;Adair,A.;Tan,H.X.;Juno,J.A.;Wragg,K.M.;Amarasena,T.;Lopez,E.;Selva,K.J.;Haycroft,E.R.;Cooney,J.P.;Venugopal,H.;Tan,L.L.;O Neill,M.T.;Allison,C.C.;Cromer,D.;Davenport,M.P.;Bowen,R.A.;Chung,A.W.;Pellegrini,M.;Liddament,M.T.;Glukhova,A.;Subbarao,K.;Kent,S.J.;Tham,W.H.",Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain,24-MAY-2021,8_10_17_6_3_10,7MZJ_H_L,Xtal structure,SARS-CoV-2,2,1,12.959703,8.538895
S15672_S15673,XVQLQXSGTELERSGASVKLSCTASGFNIKDYYMHWMKQRPDQGLEWIGWIDPENDDVQYAPKFQGKATMTADTSSNTAYLQLTSLTFEDTAVYFCNSWGSDFDHWGQGTTVTVSS,DIQLTQSPLSLPVTLGDQASISCRSSQTLVHTDGNTYLEWFLQKPGQSPKLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHLPRTFGGGTKLEI,S15672,S15673,Ig heavy chain V region - mouse (fragment),Ig kappa chain V region - mouse (fragment),Mus musculus,"Tempest,P.R.; Bremner,P.; Lambert,M.; Taylor,G.; Furze,J.M.; Carr,F.J.; Harris,W.J.",Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo,21-JAN-2000,8_8_9_11_3_9,FAILED,Unique chain,,2,1,-4.8564315,0.30946338
CAA80378_CAA80379,XVXLQXSGPGLVQPSQSLSITCTVSGFSLTGYGVHWVRQSPGRGLEWLGVIWRGGSTDYNAAFMSRLRITKDNSKSQVFFKLNSLRADDTAIYYCAKNLGIPTFLYSLDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVDTFVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQSYIFPPTLGGGTKLEIK,CAA80378,CAA80379,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Tempest,P.R.; Barbanti,E.; Bremner,P.; Carr,F.J.; Ghislieri,M.; Rifaldi,B.; Marcucci,F.","A humanized anti-tumor necrosis factor-alpha monoclonal antibody that acts as a partial, competitive antagonist of the template antibody",25-JUL-2016,8_7_15_6_3_9,FAILED,Unique chain,tumor,2,1,22.606058,-5.5928726
8FE4_H_L,AAQLQESGPELVKPGASVKISCKASGYTFTDYFINWVRQSHGKSLEWIGDFYPNNRGPTYNQKFEGKATLTVDKSSSTAYMELRSLTSDDSAVYYCARGLWDAWLSYWGQGTLVTVSA,AIVATQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPTRFSGSGSGTSYSFTISSMEAEDAATYYCQQYHNYPRTFGGGTK,8FE4_H,8FE4_L,"Structure Of Dengue Virus (Denv2) In Complex With Prm13, An Anti-Prm Monoclonal Antibody","Structure Of Dengue Virus (Denv2) In Complex With Prm13, An Anti-Prm Monoclonal Antibody",Mus musculus,"A Dowd,K.;Sirohi,D.;D Speer,S.;VanBlargan,L.A.;Chen,R.E.;Mukherjee,S.;Whitener,B.M.;Govero,J.;Aleshnick,M.;Larman,B.;Sukupolvi-Petty,S.;Sevvana,M.;Miller,A.S.;Klose,T.;Zheng,A.;Koenig,S.;Kielian,M.;Kuhn,R.J.;Diamond,M.S.;Pierson,T.C.",prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis,01-FEB-2023,8_8_11_5_3_9,8FE4_H_L,Xtal structure,Dengue; dengue,3,1,2.4703443,-4.2656913
AWK57404_AWK57409,ADLVQSGAVVKKPGDSVRISCEAQGYRFPDYIIHWIRRAPGQGPEWMGWMNPMGGQVNIPWKFQGRVSMTRDTSIETAFLDLRGLKSDDTAVYYCVRDRSNGSGKRFESSNWFLDLWGRGTAVTIQS,QSALTQPRSVSASPGQSVTISCTGTHNLVSWCQHQPGRAPKLLIYDFNKRPSGVPDRFSGSGSGGTASLTITGLQDDDDAEYFCWAYEAFGGGTKLTVL,AWK57404,AWK57409,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sajadi,M.M.; Dashti,A.; Rikhtegaran Tehrani,Z.; Tolbert,W.D.; Seaman,M.S.; Ouyang,X.; Gohain,N.; Pazgier,M.; Kim,D.; Cavet,G.; Yared,J.; Redfield,R.R.; Lewis,G.K.; DeVico,A.L.",Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses,22-MAY-2018,8_8_21_3_3_5,AWK57404_AWK57409,Unique source,HIV,3,1,2.4348898,3.6193726
5VIY_H_G,AEQLVESGGGLVPPGRSLRLSCSASGFYFPDYAMAWVRQAPGQGLQWVGFMRGWAYGGSAQFAAFAVGKFAISRDDGRNVVYLDVKNPTFEDTGVYFCAREQRNKDYRYGQEGFGYSYGMDVWGRGTTVVVST,DIHMTQSPVSLSASVGDRVTITCRASHFIANYVNWYQQKPGKAPTLLIFESSTLQRGVPSRFSAYGDGTEFTLSINTLQPEDFASYICQQSHSPPVTFGAGTRVDQK,5VIY_H,5VIY_G,Bg505 Sosip.664 In Complex With Broadly Neutralizing Antibodies Bg1 And 8Anc195,Bg505 Sosip.664 In Complex With Broadly Neutralizing Antibodies Bg1 And 8Anc195,Homo sapiens,"Wang,H.;Gristick,H.B.;Scharf,L.;West,A.P.;Galimidi,R.P.;Seaman,M.S.;Freund,N.T.;Nussenzweig,M.C.;Bjorkman,P.J.",Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies,17-APR-2017,8_10_24_6_3_9,5VIY_H_G,Xtal structure,HIV,3,1,13.278483,9.004087
CBX46830_CBX46831,AVQLQQSGPELEKPGASVKISCKASGYSFTGYNMNWVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSVGPMDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQKQGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFGGGTELEIK,CBX46830,CBX46831,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Heider,K.; Borges,E.; Ostermann,E.",Anti-CD37 antibodies,28-OCT-2010,8_8_9_6_3_9,CBX46830_CBX46831,Unique chain,CD37; TSPAN26,3,1,2.5748162,-4.117017
7MMN_D_E,CVQLVESGGGVVQPGRSLRLSCAASGFSFSHYAMHWVRQAPGKGLEWVAVISYDGENTYYADSVKGRFSISRDNSKNTVSLQMNSLRPEDTALYYCARDRIVDDYYYYGMDVWGQGATVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIKKYLNWYHQKPGKVPELLMHDASNLETGVPSRFSGRGSGTDFTLTISSLQPEDIGTYYCQQYDNLPPLTFGGGTKVEIK,7MMN_D,7MMN_E,Crystal Structure Of The Prefusion Rsv F Glycoprotein Bound By Human Antibody Am14,Crystal Structure Of The Prefusion Rsv F Glycoprotein Bound By Human Antibody Am14,Homo sapiens,"Harshbarger,W.;Abeyrathne,P.D.;Tian,S.;Huang,Y.;Chandramouli,S.;Bottomley,M.J.;Malito,E.",Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein,29-APR-2021,8_8_16_6_3_10,7MMN_D_E,Xtal structure,RSV,3,1,14.18037,13.939323
7N65_C_D,DIRIAESGGGLVQPGESLRLACEIIELGFRRAWTTWVRQAPGKGLEWVADINEDGSEKKYGPSVTGRFTISRDNGKNLVFLQMNSLRVEDTATYYCAREAYHLVYDDRIPRGNWFDPWGPGTLVTVSS,QSVLTQPPSVSGAPGQRVVISCTGSRSNIGAGYDVHWYQQSPGKVPRIIIYGSNSRSSGVPARFSGSKSGTSASLAITGLQAEDEADYYCQSYDTTLTASVFGGGTK,7N65_C,7N65_D,Complex Structure Of Hiv Superinfection Fab Qa013.2 And Bg505.Sosip.664,Complex Structure Of Hiv Superinfection Fab Qa013.2 And Bg505.Sosip.664,Homo sapiens,"Shipley,M.M.;Mangala Prasad,V.;Doepker,L.E.;Dingens,A.S.;Ralph,D.K.;Harkins,E.;Dhar,A.;Arenz,D.;Chohan,V.;Weight,H.;Mandaliya,K.;Bloom,J.D.;Matsen Iv,F.;Lee,K.K.;Overbaugh,J.M.",Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection,07-JUN-2021,8_8_21_9_3_11,7N65_C_D,Xtal structure,HIV,3,1,11.119937,7.7662544
CAB76947_CAB76948,DVHLQESGPGLVKPSQSLSLTCYVTGYSITSGYYWTWIRQFPGNKLEWMGYISYDGSNNYNPSLKNRISITRDTSKNQFFLKLNSVTAEDTASYYCAAFYYDYDFFFDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTLTCSASSTITSSFLYWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSLEAEDGASYFCHQWETFPRTFGGGTKLEIK,CAB76947,CAB76948,"immunoglobulin heavy chain, partial [Mus musculus]","immunoglobulin light chain, partial [Mus musculus]",Mus musculus,"Daniels,P.S.; Jeffries,S.; Yates,P.; Schild,G.C.; Rogers,G.N.; Paulson,J.C.; Wharton,S.A.; Douglas,A.R.; Skehel,J.J.; Wiley,D.C.",The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies,26-JUL-2016,9_7_13_7_3_9,CAB76947_CAB76948,Unique chain,haemagglutinin,3,1,11.632917,-12.781212
6N5E_G_F,DVKLVESGEGLVKPGGSLKLSCAASGFTFSGYDMSWVRQTPEKRLEWVAYISSGGDYIYYADTVKGRFTISRDNARNTLYLQMSSLKSEDTAMYYCTRDSDYYGSRVWFAYWGQGTLVTVSG,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWFSNHWVFGGGTKLTVL,6N5E_G,6N5E_F,Broadly Protective Antibodies Directed To A Subdominant Influenza Hemagglutinin Epitope,Broadly Protective Antibodies Directed To A Subdominant Influenza Hemagglutinin Epitope,Mus musculus,"Bajic,G.;Maron,M.J.;Adachi,Y.;Onodera,T.;McCarthy,K.R.;McGee,C.E.;Sempowski,G.D.;Takahashi,Y.;Kelsoe,G.;Kuraoka,M.;Schmidt,A.G.",Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope,21-NOV-2018,8_8_15_9_3_9,6N5E_G_F,Xtal structure,Influenza,3,1,18.095097,6.9685345
6N5D_C_D,DVKLVESGEGLVKPGGSLKLSCAASGFTFSSYDMSWVRQTPEKRLEWVAYISSGGDYIYYADTVKGRFTISRDNARNTLYLQMSSLKSEDTAMYYCTRVGEYDAWFAYWDQGTLVTVSG,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFAGLIGGTKNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,6N5D_C,6N5D_D,Broadly Protective Antibodies Directed To A Subdominant Influenza Hemagglutinin Epitope,Broadly Protective Antibodies Directed To A Subdominant Influenza Hemagglutinin Epitope,Mus musculus,"Bajic,G.;Maron,M.J.;Adachi,Y.;Onodera,T.;McCarthy,K.R.;McGee,C.E.;Sempowski,G.D.;Takahashi,Y.;Kelsoe,G.;Kuraoka,M.;Schmidt,A.G.",Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope,21-NOV-2018,8_8_12_9_3_9,6N5D_C_D,Xtal structure,Influenza,3,1,18.152431,7.048578
1FE8_H_L,DVKLVQSGPGLVAPSQSLSITCTVSGFSLTTYGVSWVRQPPGKGLEWLGVIWGDGNTTYHSALISRLSISKDNSRSQVFLKLNSLHTDDTATYYCAGNYYGMDYWGQGTSVTVSS,DIAMTQTTSSLSASLGQKVTISCRASQDIGNYLNWYQQKPDGTVRLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLESEDIATYFCQNGGTNPWTFGGGTKLEVK,1FE8_H,1FE8_L,Crystal Structure Of The Von Willebrand Factor A3 Domain In Complex With A Fab Fragment Of Igg Ru5 That Inhibits Collagen Binding,Crystal Structure Of The Von Willebrand Factor A3 Domain In Complex With A Fab Fragment Of Igg Ru5 That Inhibits Collagen Binding,Mus musculus,"Huizinga,E.G.;Martijn van,de.;Kroon,J.;Sixma,J.J.;Gros,P.",Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding,21-JUL-2000,8_7_9_6_3_9,1FE8_H_L,Xtal structure,,3,1,22.06614,-6.145907
7KI6_H_L,DVQLQESGPGLVKPSQSLSLTCSVTGYSITSDYYWNWIRQFPGNKLEWMGYVTYDGSNNYNPSLKNRISITRDSSKNQFFLKLNSVISEDTATYYCARFGSSYWAMDYWGQGTSLTVSS,QIVLTQSPAIMSASLGEAITLTCSASSSVSYMHWYQQKSGTSPKLLIYSTSNLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWYSYPWTFGGGTKLEIK,7KI6_H,7KI6_L,Structure Of The Hev F Glycoprotein In Complex With The 1F5 Neutralizing Antibody,Structure Of The Hev F Glycoprotein In Complex With The 1F5 Neutralizing Antibody,Mus musculus,"Dang,H.V.;Cross,R.W.;Borisevich,V.;Bornholdt,Z.A.;West,B.R.;Chan,Y.P.;Mire,C.E.;Da Silva,S.C.;Dimitrov,A.S.;Yan,L.;Amaya,M.;Navaratnarajah,C.K.;Zeitlin,L.;Geisbert,T.W.;Broder,C.C.;Veesler,D.",Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins,23-OCT-2020,9_7_12_5_3_9,7KI6_H_L,Xtal structure,Hendra,3,1,11.6516,-12.761433
1HQ4_D_C,DVQLQESGPGLVKPSQSLSLTCTVTGYSITSGYAWNWIRQFPGNKLEWMGYIRYSGDTRYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCAIGYGNSDYWGQGTLVTVSA,DIVLTQSPTIMSVSPGEKVTLTCSASSSVSSNYVYWYQQKPGSSPKVWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCLQWSSFPYTFGGGTKLELK,1HQ4_D,1HQ4_C,Structure Of Native Catalytic Antibody Ha5-19A4,Structure Of Native Catalytic Antibody Ha5-19A4,Mus musculus,"Paschall,C.M.",Polyene Cyclization Reactions,14-DEC-2000,9_7_9_7_3_9,1HQ4_D_C,Xtal structure,,3,1,11.432638,-12.968003
6HX4_H_L,DVQLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISSGGDYTYSPDSVKGRFTISRDNAKSTLYLQMSSLKSEDTAMFYCSRAEFITTATWGVYAMDYWGQGTSVTVSS,DIVLTQSPDSLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIK,6HX4_H,6HX4_L,Fab Fragment Of A Native Monomer-Selective Antibody In Complex With Alpha-1-Antitrypsin,Fab Fragment Of A Native Monomer-Selective Antibody In Complex With Alpha-1-Antitrypsin,Mus musculus,"Elliston,E.L.K.;Miranda,E.;Perez,J.;Jagger,A.M.;Irving,J.A.;Lomas,D.A.",Characterisation of a monoclonal antibody conformationally-selective for native alpha-1-antitrypsin,15-OCT-2018,8_8_18_10_3_9,6HX4_H_L,Xtal structure,AAT; A1AT; PI; alpha1AT; SERPINA1; alpha-1-antitrypsin; PI1; A1A,3,1,17.884254,7.095701
1BZ7_B_A,DVQLVESGGGLVQPGGSRKLSCAASGFTFSNFGMHWVRQAPEKGLEWVAYISSGGSSINYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAIYYCTRGGTGTRSLYYFDYWGQGATLIVSS,DIQMTQITSSLSVSLGDRVIISCRASQDIGNFLNWYQQKPDGSLKLLIYYTSRLQSGVPSRFSGWGSGTDYSLTISNLEEEDIATFFCQQGKTLPYTFGGGTKLEIK,1BZ7_B,1BZ7_A,Fab Fragment From Murine Ascites,Fab Fragment From Murine Ascites,Mus musculus,"Kaminski,M.J.;MacKenzie,C.R.;Mooibroek,M.J.;Dahms,T.E.;Hirama,T.;Houghton,A.N.;Chapman,P.B.;Evans,S.V.",The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains,06-NOV-1998,8_8_15_6_3_9,1BZ7_B_A,Xtal structure,tumor,3,1,17.445492,7.8970194
3J42_K_L,DVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARWGNYPHYAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLTCKASENVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQSYSTPYTFGGGTKLEIK,3J42_K,3J42_L,Obstruction Of Dengue Virus Maturation By Fab Fragments Of The 2H2 Antibody,Obstruction Of Dengue Virus Maturation By Fab Fragments Of The 2H2 Antibody,Mus musculus,"Wang,Z.;Li,L.;Pennington,J.G.;Sheng,J.;Yap,M.L.;Plevka,P.;Meng,G.;Sun,L.;Jiang,W.;Rossmann,M.G.",Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody,13-JUN-2013,8_8_13_6_3_9,3J42_K_L,Xtal structure,Dengue; dengue,3,1,17.43666,7.8920193
6Y9B_J_N,DVQVQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYISNSGSTSYNPSLKSRISITRDTSKNQFFLQLISVTTEDTATYYCARERNYDYDDYYYAMDYWGQGTTLTVSA,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYRSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYNYPRTFGGGTKLEIK,6Y9B_J,6Y9B_N,Cryo-Em Structure Of Trimeric Human Steap1 Bound To Three Fab120.545 Fragments,Cryo-Em Structure Of Trimeric Human Steap1 Bound To Three Fab120.545 Fragments,Homo sapiens,"Oosterheert,W.;Gros,P.",Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1),20-MAY-2020,9_7_17_12_3_9,6Y9B_J_N,Xtal structure,STEAP1; STEAP; PRSS24,3,1,11.581492,-12.838031
QGW50176_QGW50194,EAQLEESGGKLVQPGGSLRLSCSASGFSLEDNDMHWVRQGEGRGLEWVSSIGSSGDTYYADSIKGRFTISRDNGRNSVYLQIKTLNVGDTAVYFCIRGPESGWFYHYYFGLGVWGRGTTVTVSS,MIMLTQSPLSLAVTPGEPASISCRSSQSLLLGNGRNYLDWYVQRPGQSPQLLIYLASHRAPGVPDRFSGSGSGTDFTLKISRVEADDVGFYYCMQARQTPRLSFGEGTKVEIK,QGW50176,QGW50194,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Setliff,I.; Shiakolas,A.R.; Pilewski,K.A.; Murji,A.A.; Ziki,R.; Janowska,K.; Richardson,S.; Mynhardt,C.; Raju,N.; Ronsard,L.; Kanekiyo,M.; Qin,J.; Kramer,K.J.; Greenplate,A.R.; McDonnell,W.J.; Graham,B.S.; Connors,M.; Lingwood,D.; Acharya,P.; Morris,L.; Georgiev,I.S.",High-throughput mapping of B-cell receptor sequences to antigen specificity,17-DEC-2019,8_7_18_11_3_10,QGW50176_QGW50194,Unique source,,3,1,16.347477,11.641851
7UMN_H_L,EFQLQQSGPELVKPGASVKISCKASGYSFTDYNMNWVKQSDGKSLEWIGIINPNYGIISYNQKFKGKATLTVDQSSSTAYMQLNSLTSEDSAVYYCARWGNSPYYYYYMDVWGKGTTVTVSG,ENVLTQSPAIMSASPGEKVTMTCRATSSVSSSYLHWYQQKSGASPKLWIYGTSNLASGVPARFSGSGSGTSYSLTISTVEAEDAATYYCQQYSGYPLTFGAGTKLELK,7UMN_H,7UMN_L,H1 Solomon Islands 2006 Hemagglutinin In Complex With Ab36,H1 Solomon Islands 2006 Hemagglutinin In Complex With Ab36,Mus musculus,"Carradona,T.",H1 Solomon Islands 2006 hemagglutinin in complex with Ab36,19-APR-2023,8_8_15_7_3_9,7UMN_H_L,Xtal structure,hemagglutinin,3,1,2.6223247,-3.9671838
2B1H_H_L,EIQLEQSGAEVKKSGESLKISCQTSGYSFSDYWIGWVRQMPGKGLEWMGIFYPGDSDSRYSPSFEGQVTMSADRSTNTAHLQWSSLKPSDTALYYCARLGGDYEDSGADAFDFWGQGTLVTVSS,QSVLTQPPSASGTPGQRISISCSGTSSNVENNYVYWYQHLPGTAPKLLIYRNDHRSSGIPDRFSASKSGTSASLAISGLRPEDEGDYYCAAWDDSRGGPDWVFGGGTKLTVL,2B1H_H,2B1H_L,Crystal Structure Analysis Of Anti-Hiv-1 V3 Fab 2219 In Complex With Ug29 Peptide,Crystal Structure Analysis Of Anti-Hiv-1 V3 Fab 2219 In Complex With Ug29 Peptide,synthetic construct,"Stanfield,R.L.;Gorny,M.K.;Zolla-Pazner,S.;Wilson,I.A.",Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity,15-SEP-2005,8_8_17_8_3_13,2B1H_H_L,Xtal structure,HIV,3,1,-12.418021,5.656107
5YWY_H_L,EIQLQQSGPELVKPGASVKVSCKASGFPFSTYNIYWVIQSHGKSLEWIGYIDPYNGGTSYNQKFRGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARRWYTYDGDWFAYWGQGTLVTVSA,DIKMTQSPSSMYVSLGERVTITCKASQDINRYLSWFQQKPGKSPKTLIYRANRMLDGVPSRFSGSGSGQDYSLTISSLEYEDMGNYYCLQYDEFPFTFGSGTKLEIK,5YWY_H,5YWY_L,Crystal Structure Of The Clinically Important Gpcr In Complex With Functional Antibody.,Crystal Structure Of The Clinically Important Gpcr In Complex With Functional Antibody.,Mus musculus,"Toyoda,Y.;Morimoto,K.;Suno,R.;Horita,S.;Yamashita,K.;Hirata,K.;Sekiguchi,Y.;Yasuda,S.;Shiroishi,M.;Shimizu,T.;Urushibata,Y.;Kajiwara,Y.;Inazumi,T.;Hotta,Y.;Asada,H.;Nakane,T.;Shiimura,Y.;Nakagita,T.;Tsuge,K.;Yoshida,S.;Kuribara,T.;Hosoya,T.;Sugimoto,Y.;Nomura,N.;Sato,M.;Hirokawa,T.;Kinoshita,M.;Murata,T.;Takayama,K.;Yamamoto,M.;Narumiya,S.;Iwata,S.;Kobayashi,T.",Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface,30-NOV-2017,8_8_14_6_3_9,QHX88702_QHX88703,Xtal structure,EP4; PTGER4,3,1,2.4028106,-3.9430535
AEQ73573_AEQ74328,ELKKPGASVRISCKASEKCDIHWVRQAPGQGLEWMGWISADDGGTTTALNLRGRVSMTTDRATNTVYMELKSLRSGDTAIYFCARDFYSGTYRSFDYWGQGTLVTVS,SSLSASLGDRVSITCRASQHISNYINWYQQKPGKAPKLLIYAASTLQSGVPSRFTGSGSGADYTLTITSLQPEDFATYYCQQSYGTSWTFGQGTTVEIK,AEQ73573,AEQ74328,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_14_6_3_9,AEQ73573_AEQ74328,Unique source,tetanus,3,1,1.5078121,5.4237576
AEQ74172_AEQ74932,EMKQAGSSVKVSCKASGGSFSNYPFSWVRQAPGQGLEWMGGIIPILGTARYPQKFQGRVTITVDKSTGTTYMELSDLRSDDTAVYFCALRDGNNFVYFDYWGQGTLVT,SSLSASVGDRVTLACRASQFISNYLAWYQQKPGKAPKLLIYKGSGLQSGVPSRFSGSGSGTEFNLTISSLQPDDFATYYCQQYNSLQGTFGQGTKLEIK,AEQ74172,AEQ74932,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_13_6_3_9,AEQ74172_AEQ74932,Unique source,tetanus,3,1,0.05653445,5.7002454
7LLK_G_H,EMRLEESGGALVKPGGSLRLSCVASGFKLSEWSLMWVRQAPGKGLQWVSSISLNQDYISYAGSVRGRFDVFRDRTQTSLLLNMNKLKTEDTGVYFCARVHAWRYFDWVNRRSPVEKVLSIDLWGRGTLVTVSS,TSGATQPPSVSVSKGETARITCSGVELSSQYVSWYRQRPGQSPVLVMFHNNSRASRIPERFSASDSGDTATLTIAGAQDVDEAEYYCQTWDSKNYVTFGGGTKLTVL,7LLK_G,7LLK_H,Cryo-Em Structure Of Q23.17_Ds-Sosip In Complex With Glycan276-Dependent Broadly Neutralizing Antibody 179Nc75 Fab,Cryo-Em Structure Of Q23.17_Ds-Sosip In Complex With Glycan276-Dependent Broadly Neutralizing Antibody 179Nc75 Fab,Homo sapiens,"Cottrell,C.A.;Manne,K.;Kong,R.;Wang,S.;Zhou,T.;Chuang,G.Y.;Edwards,R.J.;Henderson,R.;Janowska,K.;Kopp,M.;Lin,B.C.;Louder,M.K.;Olia,A.S.;Rawi,R.;Shen,C.H.;Taft,J.D.;Torres,J.L.;Wu,N.R.;Zhang,B.;Doria-Rose,N.A.;Cohen,M.S.;Haynes,B.F.;Shapiro,L.;Ward,A.B.;Acharya,P.;Mascola,J.R.;Kwong,P.D.",Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies,04-FEB-2021,8_8_26_6_3_10,7LLK_G_H,Xtal structure,HIV,3,1,16.247276,10.132809
3MME_H_L,EQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVL,3MME_H,3MME_L,"Structure And Functional Dissection Of Pg16, An Antibody With Broad And Potent Neutralization Of Hiv-1","Structure And Functional Dissection Of Pg16, An Antibody With Broad And Potent Neutralization Of Hiv-1",Homo sapiens,"Pancera,M.;McLellan,J.S.;Wu,X.;Zhu,J.;Changela,A.;Schmidt,S.D.;Yang,Y.;Zhou,T.;Phogat,S.;Mascola,J.R.;Kwong,P.D.",Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1,19-APR-2010,8_8_30_9_3_10,3MME_H_L,Xtal structure,HIV,3,1,14.00567,14.12129
4AEI_H_L,EVHLVESGGGLVKPGGSLKLSCAASGFTFSGYYMYWVRQTPEKRLEWVASISDGGSFTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSDDTAMYYCSRPDDYSYDGFAYWGQGTLVTVS,DVLMTQSPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGAGTKLELK,4AEI_H,4AEI_L,Crystal Structure Of The Aahii-Fab4C1 Complex,Crystal Structure Of The Aahii-Fab4C1 Complex,Mus musculus,"Fabrichny,I.P.;Mondielli,G.;Conrod,S.;Martin-Eauclaire,M.F.;Bourne,Y.;Marchot,P.",Structural Insights into Antibody Sequestering and Neutralizing of Na+ Channel alpha-Type Modulator from Old World Scorpion Venom,10-JAN-2012,8_8_13_11_3_9,4AEI_H_L,Xtal structure,,3,1,18.018578,7.273276
6MNS_A_B,EVHLVESGGGLVQPGGSLRLSCEVSGLTFSNSWMSWVRQAPGKGLEWVGFIKTKADGGTAAYAESVKGRFTISRDDSKNTVFLQMKSLKTEDTAVYYCQGAVVISHEYIEIWGQGALVTVSS,QSVLTQPPSASEAARKSVTISCSGGSSNIGDDSVSWYQQVPGTAPKLLIYYNDRRASGVSDRFSGSKSGTSASLAINGLQSEDEADYYCAAWDDSLSAYIFGSGTRLTVL,6MNS_A,6MNS_B,Rhesus Macaque Anti-Hiv V3 Antibody Dh753 With Gp120 V3 Zam18 Peptide,Rhesus Macaque Anti-Hiv V3 Antibody Dh753 With Gp120 V3 Zam18 Peptide,Macaca mulatta,"Han,Q.;Jones,J.A.;Nicely,N.I.;Reed,R.K.;Shen,X.;Mansouri,K.;Louder,M.;Trama,A.M.;Alam,S.M.;Edwards,R.J.;Bonsignori,M.;Tomaras,G.D.;Korber,B.;Montefiori,D.C.;Mascola,J.R.;Seaman,M.S.;Haynes,B.F.;Saunders,K.O.",Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations,02-OCT-2018,8_10_13_8_3_11,6MNS_A_B,Xtal structure,HIV,3,1,13.001067,8.4736
AEQ74212_AEQ74972,EVKKPGASVKVSCKTSGYSFTRYGLSWVRQAPGQGLEWMGWISPYNGHTNYAQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDWNQGSGIYYISDWGQGTLVT,SSLSASVGDRVTITCRASQSISNYFNWYQQKPGEAPNLLIYGASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYHCQQTYRTPYTFGQGTKVEIK,AEQ74212,AEQ74972,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_9,AEQ74212_AEQ74972,Unique source,tetanus,3,1,1.3832532,5.3196607
AEQ74080_AEQ74840,EVKKPGSSVKVSCKASGGSFSTYAITWVRQAPGQGLEWMGGIIPIFASRDYAQKFQGRVTITADESTRTVYMELSSLRSEDTAVYYCARVLGGTRLYYAQNVWGQGTTVT,SSLSASVGDRVTITCRASQGISNFLAWYQQKPGKVPELLIYGASTLQSGVPSRFSGSGSGTDFTLTINSLQPEDVATYYCQKYDSGLRFTFGPGTKVDIK,AEQ74080,AEQ74840,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_10,AEQ74080_AEQ74840,Unique source,tetanus,3,1,0.012972227,5.7444496
AEQ73951_AEQ74711,EVKKPGSSVKVSCKASGVTFSTNRISWVRQAPGQGLEWMGGITPILGPANYAQRFQDRITITADESTSTVYMEMRSLRFEDTALYFCARGKDCRSNNCYLSERNNWFDPWGQGTLVT,TLSASVGDRVTITCRASQTISTWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYFLTFGGGTKVEIK,AEQ73951,AEQ74711,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_22_6_3_9,AEQ73951_AEQ74711,Unique source,tetanus,3,1,0.081746556,5.7011456
AEQ73549_AEQ74302,EVKKPGSSVKVSCKSSGGYVFSWVRQAPGQGLEWMGGIISNFRTAEYARKFQGRVTMTADTSTNTIYMELTSLTSEDTAVYFCVSAPRDTSTIAARFNRYFFDTWGQGTLVTVS,TLSLSPGERATLSCRASRSVNSNNLAWYQQKPDQAPRLLMYGASSRATGIPDRFTGSGSGTDFTLTISRLEPEDFAVYYCHQYGASDNTFGQGTKLEIK,AEQ73549,AEQ74302,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_21_7_3_9,AEQ73549_AEQ74302,Unique source,tetanus,3,1,21.681885,11.840122
AEQ73862_AEQ74617,EVKKPGTSVRVSCKTSGGYVFSWVRQAPGHGPEWMGGIITNFGTATYAQKFQGRVSITADTSTNTFYMDLNNLKSDDTAVYYCASAPRDTSTIAARFNRYFFDFWGPGTLVT,TLSLSPGERATLSCRASQSVNSNNLAWYQQKPGQAPRLLVSGATNRATDIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYGSSENTFGQGTKLEIR,AEQ73862,AEQ74617,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,4_8_21_7_3_9,AEQ73862_AEQ74617,Unique source,tetanus,3,1,21.698381,11.851674
1WZ1_H_L,EVKLEESGGGLVQPGGSMKLSCATSGFTFSDAWMDWVRQSPEKGLEWVAEIRNKANNHATYYAESVKGRFTISRDDSKRRVYLQMNTLRAEDTGIYYCTGIYYHYPWFAYWGQGTLVTVSA,DVVMTQTPLSLPVSLGNQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPFTFGSGTKLEIK,1WZ1_H,1WZ1_L,Crystal Structure Of The Fv Fragment Complexed With Dansyl-Lysine,Crystal Structure Of The Fv Fragment Complexed With Dansyl-Lysine,Mus musculus,"Nakasako,M.;Oka,T.;Mashumo,M.;Takahashi,H.;Shimada,I.;Yamaguchi,Y.;Kato,K.;Arata,Y.",Conformational dynamics of complementarity-determining region H3 of an anti-dansyl Fv fragment in the presence of its hapten,21-FEB-2005,8_10_12_11_3_9,1WZ1_H_L,Xtal structure,hapten,3,1,13.417699,6.939722
6E4Y_H_L,EVKLEESGGGLVQPGGSMKLSCVASRFTLSKYWMNWVRQSPEKGLEWVAQIRLKSDNYATHYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTGEIFVNWGQGTLVTVSA,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGAGTKLELK,6E4Y_H,6E4Y_L,"Anti-Pcsk9 Fab 6E2 Bound To The N-Terminal Peptide From Pcsk9, Unmodified","Anti-Pcsk9 Fab 6E2 Bound To The N-Terminal Peptide From Pcsk9, Unmodified",Homo sapiens,"Ultsch,M.;Li,W.;Eigenbrot,C.;Di Lello,P.;Lipari,M.T.;Gerhardy,S.;AhYoung,A.P.;Quinn,J.;Franke,Y.;Chen,Y.;Kong Beltran,M.;Peterson,A.;Kirchhofer,D.",Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain,10-APR-2019,8_10_7_11_3_9,6E4Y_H_L,Xtal structure,HCHOLA3; FH3; NARC-1; PCSK9,3,1,13.431488,7.111948
3FO9_H_L,EVKLEESGGGLVQPGGSMKLSCVVSGLTFSRFWMSWVRQSPEKGLEWVAEIRLKSDNYATHYAESVKGKFTISRDDSKSRLYLQMNSLRTEDTGIYYCKIYFYSFSYWGQGTLVTVSA,LVMTQTPLSLPVSLGDQASISCRSSQSLVHSYGNTFLNWYLQKSGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQGTHVPYTFGGGTKLEIK,3FO9_H,3FO9_L,"Crystal Structure Of Aldolase Antibody 33F12 Fab' In Complex With Hapten 1,3-Diketone","Crystal Structure Of Aldolase Antibody 33F12 Fab' In Complex With Hapten 1,3-Diketone",Mus musculus,"Zhu,X.;Tanaka,F.;Lerner,R.A.;Barbas CF,3r.;Wilson,I.A.",Direct observation of an enamine intermediate in amine catalysis,29-DEC-2008,8_10_9_11_3_9,3FO9_H_L,Xtal structure,,3,1,13.418019,7.2434726
7BSC_H_L,EVKLQESGPGLVRPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYISYDGRSNYNPSLKNRISITRDTSKNQFFLKLNFVTTEDTATYYCASFYYYTSRPLVYWGQGTLLTVSS,EIVLTQSPASLAVSLGQRATISCRASESVEYSGTSLMHWYQQKPGQPPKLLIYAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKVPYTFGGGTKLELK,7BSC_H,7BSC_L,Complex Structure Of 1G5.3 Fab Bound To Denv2 Ns1C,Complex Structure Of 1G5.3 Fab Bound To Denv2 Ns1C,Homo sapiens,"Modhiran,N.;Song,H.;Liu,L.;Bletchly,C.;Brillault,L.;Amarilla,A.A.;Xu,X.;Qi,J.;Chai,Y.;Cheung,S.T.;Traves,R.;Setoh,Y.X.;Bibby,S.;Scott,C.A.;Freney,M.E.;Newton,N.D.;Khromykh,A.A.;Chappell,K.J.;Muller,D.A.;Stacey,K.J.;Landsberg,M.J.;Shi,Y.;Gao,G.F.;Young,P.R.;Watterson,D.",A broadly protective antibody that targets the flavivirus NS1 protein,30-MAR-2020,9_7_13_10_3_9,7BSC_H_L,Xtal structure,SHP2; PTPN11; BPTP3; SH-PTP2; NS1; PTP2C; SHP-2,3,1,11.63318,-12.780764
6BPB_A_B,EVKLVESEGGLVQPGSSMKFSCTASGFTFSDYYMAWVRQVPGKGLEWVANINYDGSTPDYLDSLKSRFIISRDNAKNILYLQMSSLKSEDTATYYCARETVVGSFDYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTINNVQSEDLAYFCQQYNSYPYTFGGGTKLEIK,6BPB_A,6BPB_B,Plasmodium Vivax Invasion Blocking Monoclonal Antibody 4F7,Plasmodium Vivax Invasion Blocking Monoclonal Antibody 4F7,Mus musculus,"Gruszczyk,J.;Huang,R.K.;Chan,L.J.;Menant,S.;Hong,C.;Murphy,J.M.;Mok,Y.F.;Griffin,M.D.;Pearson,R.D.;Wong,W.;Cowman,A.F.;Yu,Z.;Tham,W.H.",Cryo-EM structure of an essential Plasmodium vivax invasion complex,22-NOV-2017,8_8_11_6_3_9,6BPB_A_B,Xtal structure,,3,1,17.43326,7.200643
3V4U_H_L,EVKLVESEGGLVQPGSSMKLSCTASGFTFSDYYMAWVRQVPEKGLEWVANINYDGSSTYYLDSLKGRFIISRDIAKNILYLQMSSLRCEDTATYYCARLTNGYLDVWGAGTTVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPTFGGGTKLEIK,3V4U_H,3V4U_L,Structure Of A Monoclonal Antibody Complexed With Its Mhc-I Antigen,Structure Of A Monoclonal Antibody Complexed With Its Mhc-I Antigen,Mus musculus,"Mage,M.G.;Dolan,M.A.;Wang,R.;Boyd,L.F.;Revilleza,M.J.;Robinson,H.;Natarajan,K.;Myers,N.B.;Hansen,T.H.;Margulies,D.H.",The Peptide-receptive transition state of MHC class I molecules: insight from structure and molecular dynamics,15-DEC-2011,8_8_10_11_3_8,3V4U_H_L,Xtal structure,,3,1,17.459335,7.198209
6BPE_E_F,EVKLVESEGGLVQPGSSMNLSCTASGFTFSDYYMAWVRQVPDKGLEWVASVSYDGSITYYLDSLKSRFIISRDNVKNILNLQMSSLKSEDTATYYCTRVTVVDSFDYWGQGTTLTVSS,DIVMTQSQKFMSTSIGVRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRNSGVPDRFTGSGSGTEFTLTISNVQSEDLAEYFCQQYDSYPYPFGGGTKLEIK,6BPE_E,6BPE_F,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Monoclonal Antibody 6H1,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Monoclonal Antibody 6H1,Plasmodium vivax Sal-1,"Gruszczyk,J.;Huang,R.K.;Chan,L.J.;Menant,S.;Hong,C.;Murphy,J.M.;Mok,Y.F.;Griffin,M.D.;Pearson,R.D.;Wong,W.;Cowman,A.F.;Yu,Z.;Tham,W.H.",Cryo-EM structure of an essential Plasmodium vivax invasion complex,22-NOV-2017,8_8_11_6_3_9,6BPE_E_F,Xtal structure,,3,1,17.499355,7.2381577
5TZU_H_L,EVKLVESGGDLVKPGGSLKLSCAASGFTFSGYGMSWVRQTPDKRLEWVATITSGGTYTYYPDSVKGRFTISRDNAKNTLYLQIDSLKSEDTAIYFCARSLAGNAMDYWGQGTSVTVSS,DIVMTQSPATLSVTPGDRVSLSCRASQTISDYLHWYQQKSHESPRLLIKFASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHGFPRTFGGGTKLEIK,5TZU_H,5TZU_L,Crystal Structure Of Human Cd47 Ecd Bound To Fab Of B6H12.2,Crystal Structure Of Human Cd47 Ecd Bound To Fab Of B6H12.2,Homo sapiens,"Pietsch,E.C.;Dong,J.;Cardoso,R.;Zhang,X.;Chin,D.;Hawkins,R.;Dinh,T.;Zhou,M.;Strake,B.;Feng,P.H.;Rocca,M.;Santos,C.D.;Shan,X.;Danet-Desnoyers,G.;Shi,F.;Kaiser,E.;Millar,H.J.;Fenton,S.;Swanson,R.;Nemeth,J.A.;Attar,R.M.",Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies,22-NOV-2016,8_8_11_6_3_9,QRK95603_QRK95598,Xtal structure,MER6; OA3; IAP; CD47,3,1,17.794874,7.171537
6XLI_A_B,EVKLVESGGDLVKPGGSLKLSCAASGFTFSSYAMSWVRQNPEKRLEWVASISKGGNTYYPNSVKGRFTISRDNARNILYLQMSSLRSEDTALYYCARGWGDYGWFAYWGQVTLVTVSA,DIKMTQSPSSMYASLGERVTITCKASQDINRYLNWFQQKPGKSPKTLIYRANRLLDGVPSRFSGSGSGQDYSLTISSLDYEDMGIYYCLQYDEFPLTFGDGTKLELK,6XLI_A,6XLI_B,Crystal Structure Of Anti-Tau Antibody Pt3 Fab+Pt212/Pt217-Tau Peptide,Crystal Structure Of Anti-Tau Antibody Pt3 Fab+Pt212/Pt217-Tau Peptide,Homo sapiens,"Van Kolen,K.;Malia,T.J.;Theunis,C.;Nanjunda,R.;Teplyakov,A.;Ernst,R.;Wu,S.J.;Luo,J.;Borgers,M.;Vandermeeren,M.;Bottelbergs,A.;Wintmolders,C.;Lacy,E.;Maurin,H.;Larsen,P.;Willems,R.;Van De,Ca.;Triana-Baltzer,G.;Slemmon,R.;Galpern,W.;Trojanowski,J.Q.;Sun,H.;Mercken,M.H.","Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody",28-JUN-2020,8_7_12_6_3_9,AYH58122_AYH58123,Xtal structure,Tau; Phospho,3,1,18.2172,7.2205453
4ODW_H_L,EVKLVESGGGLVKLGGSLKLSCAASGFTFSSYYMSWVRQTPEKRLELVAAINSNGGNTYYPDTVKGLFTISRDNAKNTLYLQMSRLKSEDTALYYCTRLYGNYVRIHTMDYWGQGTSVTVSS,DIVLTQSTSSLSASLGDRVTITCRASQDIRNYLSWYQQRPDGTVKLLIYYTSKLHSGVPSRFSGSGSGTDYSLTITNLEQEDIATYFCQQGKTLPLYTFGGGTKLEIK,4ODW_H,4ODW_L,Unliganded Fab Structure Of Lipid A-Specific Antibody A6,Unliganded Fab Structure Of Lipid A-Specific Antibody A6,Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Rodriguez,T.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",Structural Basis for Antibody Recognition of Lipid A: INSIGHTS TO POLYSPECIFICITY TOWARD SINGLE-STRANDED DNA,10-JAN-2014,8_8_15_6_3_10,4ODW_H_L,Xtal structure,,3,1,17.67695,6.8615484
3UTZ_C_D,EVKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWIRQTPEKRLEWVATISSGGSYTYYPDSVKGRFTISKDNARNTLYLQMSSLRSGDTALYYCTRFRYDGWYFDVWGQGTTVTVSS,VLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTFLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQASHVPPTFGSGTKLEIK,3UTZ_C,3UTZ_D,Endogenous-Like Inhibitory Antibodies Targeting Activated Metalloproteinase Motifs Show Therapeutic Potential,Endogenous-Like Inhibitory Antibodies Targeting Activated Metalloproteinase Motifs Show Therapeutic Potential,Mus musculus,"Sela-Passwell,N.;Kikkeri,R.;Dym,O.;Rozenberg,H.;Margalit,R.;Arad-Yellin,R.;Eisenstein,M.;Brenner,O.;Shoham,T.;Danon,T.;Shanzer,A.;Sagi,I.",Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential,27-NOV-2011,8_8_12_11_3_9,3UTZ_C_D,Xtal structure,,3,1,18.072163,6.961953
5H35_H_I,EVKLVESGGGLVKPGGSLKLSCAASGFGFTIYDMSWVRQTPEKRLEWVAYMSSGRGNTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCTRGAFYYGYGFAYWGQGTLVTVS,DIVMTQTPLSLPVSLGDQASISCRSSQFIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK,5H35_H,5H35_I,Crystal Structures Of The Tric Trimeric Intracellular Cation Channel Orthologue From Sulfolobus Solfataricus,Crystal Structures Of The Tric Trimeric Intracellular Cation Channel Orthologue From Sulfolobus Solfataricus,Mus musculus,"Kasuya,G.;Hiraizumi,M.;Maturana,A.D.;Kumazaki,K.;Fujiwara,Y.;Liu,K.;Nakada-Nakura,Y.;Iwata,S.;Tsukada,K.;Komori,T.;Uemura,S.;Goto,Y.;Nakane,T.;Takemoto,M.;Kato,H.E.;Yamashita,K.;Wada,M.;Ito,K.;Ishitani,R.;Hattori,M.;Nureki,O.",Crystal structures of the TRIC trimeric intracellular cation channel orthologues,20-OCT-2016,8_8_13_11_3_9,5H35_H_I,Xtal structure,DFNB49; MARVELD2; MRVLDC2; FLJ30532; TRIC,3,1,18.062876,6.9676294
2DTM_H_L,EVKLVESGGGLVKPGGSLKLSCAASGFTFSNYAMSWVRQTPEKRLEWVVSISSGGSIYYLDSVKGRFTVSRDNARNILYLQMTSLRSEDTAMYFCARVSHYDGSRDWYFDVWGAGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQTIVHSNGDTYLDWFLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,2DTM_H,2DTM_L,Thermodynamic And Structural Analyses Of Hydrolytic Mechanism By Catalytic Antibodies,Thermodynamic And Structural Analyses Of Hydrolytic Mechanism By Catalytic Antibodies,Mus musculus,"Kristensen,O.;Vassylyev,D.G.;Tanaka,F.;Morikawa,K.;Fujii,I.",A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution,13-JUL-2006,8_7_16_11_3_9,2DTM_H_L,Xtal structure,,3,1,18.029459,6.9891567
6LFV_A_A,EVKLVESGGGLVKPGGSLKLSCAASGFTFSTYGMSWVRQTPEKRLEWVASISGGGDTYYTDIVKGRVTISRDNDRNILYLQMSSLRSEDTAMYHCTRGALVRLPHYYSMDYWGQGTSVTVSS,DIQMTQTASSLSASLGDRVTISCRASQYINNYLNWYQQKPDGTVTLLIYYTSILHSGVPSRFIGSGSGTDYSLTISNLDQEDIATYFCQQGYTLPLTFGAGTKLELK,6LFV_A,6LFV_A,Crystal Structure Of Pcb4Scfv(Hn56D),Crystal Structure Of Pcb4Scfv(Hn56D),Mus musculus,"Nakamura,T.;Morioka,H.",Crystal structure of PCB4scFv(hN56D),03-DEC-2019,8_7_16_6_3_9,6LFV_A_A,Xtal structure,,3,1,17.998346,6.9746156
3CFC_H_L,EVKLVESGGGLVKPGGSLKLSCTASGITFSRYIMSWVRQIPEKRLEWVASISSGGITYYPDSVKGRFTISRDNVRNILYLQMSSLRSEDTALYYCARGQGRPYWGQGTLVTVSS,DIVMTQAAFSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIK,3CFC_H,3CFC_L,High-Resolution Structure Of Blue Fluorescent Antibody Ep2-19G2,High-Resolution Structure Of Blue Fluorescent Antibody Ep2-19G2,Mus musculus,"Debler,E.W.;Kaufmann,G.F.;Meijler,M.M.;Heine,A.;Mee,J.M.;Pljevaljcic,G.;Di Bilio,A.J.;Schultz,P.G.;Millar,D.P.;Janda,K.D.;Wilson,I.A.;Gray,H.B.;Lerner,R.A.",Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex,03-MAR-2008,8_7_8_11_3_9,3CFC_H_L,Xtal structure,,3,1,18.200977,7.208059
7DKJ_C_D,EVKLVESGGGLVQPGGSLRLSCGTSGFTLTDDYMTWVRQPPGKALEWLGFIRDRANGYTTEYSASVKGRFTISRDNSQSIVYLQMNTLRVEDSATYYCARPKGYFPYAMDYWGQGTSVIVCS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPWTFGGGTKLEIK,7DKJ_C,7DKJ_D,Hemagglutinin Influenza A Virus (A/Okuda/1957(H2N2) Bound With A Neutralizing Antibody,Hemagglutinin Influenza A Virus (A/Okuda/1957(H2N2) Bound With A Neutralizing Antibody,Mus musculus,"Makino-Okamura,C.;Hata,H.;Watanabe,T.;Kim,S.;Hebrard,M.;Sato,R.;Yan,M.;Onodera,T.;Takahashi,Y.;Li,Q.;Taylor,T.;Okuno,Y.;Kurosaki,T.;Tomabechi,Y.;Uchikubo-Kamo,T.;Kamada,K.;Shirouzu,M.;Fukuyama,H.",Hemagglutinin Influenza A virus (A/Okuda/1957(H2N2) bound with a neutralizing antibody,24-NOV-2020,8_10_13_6_3_9,7DKJ_C_D,Xtal structure,H2N2; Influenza,3,1,26.067192,4.689124
4HLZ_I_J,EVKLVESGGGLVQPGGSLRLSCGTSGFTLTDDYMTWVRQPPGKALEWLGFIRDRANGYTTEYSASVKGRFTISRDNSQSIVYLQMNTLRVEDSATYYCARPKGYFPYAMDYWGQGTSVIVSS,DIQMTQSPASQSASLGESVTITCLASQTIGTWLAWYQQKPGKSPQLLIYAATSLADGVPSRFSGSGSGTKFSFKISSLQAEDFVSYYCQQLYSTPWTFGGGTRLEIK,4HLZ_I,4HLZ_J,Crystal Structure Of Fab C179 In Complex With A H2N2 Influenza Virus Hemagglutinin,Crystal Structure Of Fab C179 In Complex With A H2N2 Influenza Virus Hemagglutinin,Mus musculus,"Dreyfus,C.;Ekiert,D.C.;Wilson,I.A.",Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin,17-OCT-2012,8_10_13_6_3_9,4HLZ_I_J,Xtal structure,hemagglutinin; H2N2; Influenza,3,1,26.03616,4.657563
3V0W_H_L,EVKLVESGGGLVQPGGSLSLSCAASGFTFSDYYMTWVRQAPGKAPEWLALIRNKRNGDTAEYSASVKGRFTISRDYSRSILHLQMNALRTEDSATYYCVRQGRGYTLDYWGQGTSVTVSS,DIQMNQSPSSLSASLGDTISITCRASQNINIWLSWYQQKPGNVPKLLIYKASNLHTGVPSRFSGSGSGTDFTLIISSLQPEDIATYYCLQGQSYPRTFGGGTKLEIK,3V0W_H,3V0W_L,Crystal Structure Of Fab Wn1 222-5 In Complex With Lps,Crystal Structure Of Fab Wn1 222-5 In Complex With Lps,Mus musculus,"Gomery,K.;Muller-Loennies,S.;Brooks,C.L.;Brade,L.;Kosma,P.;Di Padova,F.;Brade,H.;Evans,S.V.",Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS,08-DEC-2011,8_10_11_6_3_9,QCA53636,Xtal structure,VWS; IRF6; OFC6; VWS1; Toll-like; LPS,3,1,26.062807,4.684823
3HZM_B_A,EVKLVESGGGLVQSGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLAFIRNKAKGYTTEYSSSVKGRFTISRDNSQSFLYLQMNTLRAEDSATYYCARDINPGSDGYYDALDYWGQGTSVTVS,DIVMTQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLRTFGGGTKLELK,3HZM_B,3HZM_A,Crystal Structure Of S73-2 Antibody In Complex With Antigen Kdo,Crystal Structure Of S73-2 Antibody In Complex With Antigen Kdo,Mus musculus,"Brooks,C.L.;Muller-Loennies,S.;Borisova,S.N.;Brade,L.;Kosma,P.;Hirama,T.;Mackenzie,C.R.;Brade,H.;Evans,S.V.",Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition,23-JUN-2009,8_10_17_12_3_8,3HZM_B_A,Xtal structure,,3,1,26.099825,4.721071
5TQ0_H_L,EVKLVESGPELKKPGETVKISCKASGFTFTNYGMNWVKQAPGKGLKWMGWINIYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARGYDYEGYFDYWGQGTTLTVSS,DIVMTQAPATLSVTPGDRVSLSCRASQSIADYLYWYQQKSHESPRLLLKYASQSISGIPSRFSGSGSGSDFTLTINSVEPEDVGMYYCQNGHSFPRTFGGGTKLEIK,5TQ0_H,5TQ0_L,Crystal Structure Of Amino Terminal Domains Of The Nmda Receptor Subunit Glun1 And Glun2A In The Presence Of Edta,Crystal Structure Of Amino Terminal Domains Of The Nmda Receptor Subunit Glun1 And Glun2A In The Presence Of Edta,Mus musculus,"Romero-Hernandez,A.;Simorowski,N.;Karakas,E.;Furukawa,H.",Molecular Basis for Subtype Specificity and High-Affinity Zinc Inhibition in the GluN1-GluN2A NMDA Receptor Amino-Terminal Domain,21-OCT-2016,8_8_12_6_3_9,5TQ0_H_L,Xtal structure,GRIN1; NMDAR1; GluN2A; GluN1; GRIN2A; NMDAR2A,3,1,-7.5423036,6.121617
6A9K_B_A,EVMLVESGGGLVKPGGSLKLSCAASEFTFSTYIMSWVRQTPEKRLEWVATISSSGTYTYYRDSVKGRFTVSRDNANNILYLQMSSLRSEDTALYYCARRDYYDGFTYWGQGTLVTVSA,DLLMAQTPLSLPVSLGDQASISCRSSQSLVHSSGNTYLEWYLQKPGQSPKLLIYKISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQTSHVPPTFGGGTKLEIK,6A9K_B,6A9K_A,Crystal Structure Of The Complex Of The Hydrolytic Antibody Fab 9C10 With A Transition-State Analog,Crystal Structure Of The Complex Of The Hydrolytic Antibody Fab 9C10 With A Transition-State Analog,Mus musculus,"Tsuchiya,Y.;Fujii,I.;Tada,T.;Yamaguchi,A.;Tsumuraya,T.;Kumon,A.",Crystal structure of the complex of the hydrolytic antibody Fab 9C10 with a transition-state analog,13-JUL-2018,8_8_11_11_3_9,6A9K_B_A,Xtal structure,,3,1,18.194784,7.205097
6YE3_D_E,EVMLVESGGGLVKPGGSLKLSCAASGFSFSNYAMSWVRQTPERRLEWVALISGGGSYSYYPDSLKGRFTISRDSARNSLYLQMSSLRSEDTAMYYCARHMGYNDYLAWFAYWGQGTLVTVSA,DIVMTQSPSSLAVSVGQKVTMSCKSSQSLLNSANQKNYLAWYQQKPGQSPKLLIYFASTRESGVPDRFIGSGSGTDFTLNISSVQAEDLADYFCQQYYSAPPWTFGGGTKLEIK,6YE3_D,6YE3_E,Il-2 In Complex With A Fab Fragment From Ufka-20,Il-2 In Complex With A Fab Fragment From Ufka-20,Homo sapiens,"Karakus,U.;Sahin,D.;Mittl,P.R.;Mooij,P.;Koopman,G.;Boyman,O.",Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species,23-MAR-2020,8_8_15_12_3_10,6YE3_D_E,Xtal structure,IL-2; TCGF; IL2,3,1,18.15238,7.195937
BAA75650_BAA75651,EVMLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPERRLEWVATITTRGYTFYPDSVKGRFTVSRDNARNTLNLQMSSLRSEDTAMFYCTREGLLLDYFTMDYWGQGTSVTVSS,DVVMTQTPLSLSVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSSRFSGFPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPFTFGSGTKLEIK,BAA75650,BAA75651,"immunoglobulin heavy chain V region, partial [Mus musculus]","immunoglobulin light chain V region, partial [Mus musculus]",Mus musculus,"Suzuki,Y.; Shimada,N.; Niwa,R.; Yokoi,M.; Nakajima,M.; Murofushi,N.; Yamaguchi,I.",Preparation and application of anti-idiotypic antibody against anti-gibberellin A4 antibody,26-JUL-2016,8_7_14_11_3_9,BAA75650_BAA75651,Ordered entries,gibberellin,3,1,18.022804,6.9855943
7LF8_H_L,EVMLVESGGGLVRPGGSLKLSCTASGFTFSRCAMSWVRQTPEKRLEWVSAISRDSTYTYYSDSVKGRFTVSRDNAKNTLYLQMSSLRSEDTAMYYCARQIDDYYVDALDYWGQGTSVTVSS,DVQITQSPSYLAASPGETITINCRASKIISKYLAWYQEKPGKTIKLLIYSGFTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFGAGTKLEIK,7LF8_H,7LF8_L,Fab 6D12 Bound To Apol2 Ntd,Fab 6D12 Bound To Apol2 Ntd,Homo sapiens,"Ultsch,M.;Holliday,M.J.;Gerhardy,S.;Moran,P.;Scales,S.J.;Gupta,N.;Oltrabella,F.;Chiu,C.;Fairbrother,W.;Eigenbrot,C.;Kirchhofer,D.",Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif,15-JAN-2021,8_8_14_6_3_9,7LF8_H_L,Xtal structure,,3,1,18.019796,7.109472
AAS45198_AAS45197,EVMLVESGPGLVAPSQSLSITCTVSGFSLSDYGVSWIRQPPGKGLEWLGVIWGDGSTYYASALKFRLTISKDSSKSQVFLNMHSLQTDDSAMYYCAKHTYGGPGDSWGQGTSVTVSS,DIQMTQSPSSLAVSPGEKVTMSCRSSQSLFNSRTRKNYLAWYQQKPGQSPTKLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAIYYCKQSYDLPTFGAGTKLELK,AAS45198,AAS45197,"immunoglubulin heavy chain variable region, partial [Mus musculus]","immunoglubulin light chain variable region, partial [Mus musculus]",Mus musculus,"Zhu,X.; Tanaka,F.; Hu,Y.; Heine,A.; Fuller,R.; Zhong,G.; Olson,A.J.; Lerner,R.A.; Barbas,C.F. III; Wilson,I.A.","The Origin of Enantioselectivity in Aldolase Antibodies: Crystal Structure, Site-directed Mutagenesis, and Computational Analysis",26-JUL-2016,8_7_11_12_3_8,AAS45198_AAS45197,Unique source,,3,1,22.076889,-6.1357584
4RGN_B_C,EVNLIESGGDLVKPGGSLKLSCATSGFTFSAYGLSWVRQTPERRLEWVASISGGGSVYYPDSVKGRFTISRDTAGDILFLQMNSLRSEDSAIYYCVRDLYGDYVGRYAYWGQGTLVIVS,DIVMTQSPATLSVTPGDRVSLSCRASQSIGDYLHWYQQKSHESPRLLINYASQSISGIPSRFSGSGSGSDFTLIINSVEPEDVGVYYCQNGHSFPYTFGGGTKLEIR,4RGN_B,4RGN_C,"Structure Of Staphylococcal Enterotoxin B Bound To Two Neutralizing Antibodies, 14G8 And 6D3","Structure Of Staphylococcal Enterotoxin B Bound To Two Neutralizing Antibodies, 14G8 And 6D3",Mus musculus,"Varshney,A.K.;Wang,X.;Cook,E.;Dutta,K.;Scharff,M.D.;Goger,M.J.;Fries,B.C.","Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock",30-SEP-2014,8_7_14_6_3_9,4RGN_B_C,Xtal structure,,3,1,18.24755,7.2783027
1F4W_H_L,EVQLEESGGGLVTPGGSLRLSCAASGYVFSTYDMSWVRQTPEKRLEWVAFISSGGGRTSYPDTVKGRFTISRDDAKNTLYLQMSSLQSEDTAMYYCTRHFYAVLDYWGRGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGTVTTSNYANWVQEKPDHLFTGLIGATNNRAAGVPVRFSGSLIGGKAALTITGAQTEDEAIYFCALWYSGHWVFGGGTKLTVL,1F4W_H,1F4W_L,Crystal Structure Of An Anti-Carbohydrate Antibody Directed Against Vibrio Cholerae O1 In Complex With Antigen,Crystal Structure Of An Anti-Carbohydrate Antibody Directed Against Vibrio Cholerae O1 In Complex With Antigen,Mus musculus,"Villeneuve,S.;Souchon,H.;Riottot,M.M.;Mazie,J.C.;Lei,P.;Glaudemans,C.P.;Kovac,P.;Fournier,J.M.;Alzari,P.M.",Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity,10-JUN-2000,8_8_10_9_3_9,1F4W_H_L,Xtal structure,Carbohydrate; carbohydrate,3,1,17.787827,6.9634805
2OK0_H_L,EVQLEESGPELVKPGASVKISCKASGYTFTDYYMNWLRQKPGQGLEWIGWVYPGSIKYNEKFKDKATLTADTSSSIVYMHLSSLTSDDNAVYFCTRWTYGSSFDYWGEGTLLTVSS,DILMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPTLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHIPLTFGAGTKLEVK,2OK0_H,2OK0_L,Fab Ed10-Dna Complex,Fab Ed10-Dna Complex,Mus musculus,"Sanguineti,S.;Centeno Crowley,J.M.;Lodeiro Merlo,M.F.;Cerutti,M.L.;Wilson,I.A.;Goldbaum,F.A.;Stanfield,R.L.;de Prat-Gay,G.",Specific recognition of a DNA immunogen by its elicited antibody,15-JAN-2007,8_6_11_11_3_9,2OK0_H_L,Xtal structure,,3,1,0.1979924,-4.3532357
1A3L_H_L,EVQLEESGPELVRPGTSVKISCKASGYTFTNYWLGWVKQRPGHGFEWIGDIYPGGVYTTNNEKFRGKAILTADTSSSTAYMQLSSLTSEDSAVYFCARAGGYYTGGDYWGQGTSVTVSS,DIVLTQAAFSNPVTLGASASISCRSSKSLLNSNGIIHMYWYLQKPGQSPQLLIYQMSKLASGAPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK,1A3L_H,1A3L_L,Catalysis Of A Disfavored Reaction: An Antibody Exo Diels-Alderase-Tsa-Inhibitor Complex At 1.95 A Resolution,Catalysis Of A Disfavored Reaction: An Antibody Exo Diels-Alderase-Tsa-Inhibitor Complex At 1.95 A Resolution,Mus musculus,"Heine,A.;Stura,E.A.;Yli-Kauhaluoma,J.T.;Gao,C.;Deng,Q.;Beno,B.R.;Houk,K.N.;Janda,K.D.;Wilson,I.A.",An antibody exo Diels-Alderase inhibitor complex at 1.95 angstrom resolution,22-JAN-1998,8_8_12_11_3_9,1A3L_H_L,Xtal structure,,3,1,-0.029906936,-4.504679
7EH5_E_P,EVQLEESGPGLVQPSQSLSITCTVSDFSLTTYGVHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSQVFFKMNSLQTNDTAIYYCARMGDGYYVGAMDYWGQGTSVTVSS,DIQLTQSPAILSVSPGERVSFSCRASQSIGTSIHWYQQRTNGSPRHLIKYASESISGIPSRFSGSGSGTDFTLTINGVESEDIADYYCQQGHNWPLTFGAGTKLELK,7EH5_E,7EH5_P,"Cryo-Em Structure Of Sars-Cov-2 S-D614G Variant In Complex With Neutralizing Antibodies, Rbd-Chab15 And Rbd-Chab45","Cryo-Em Structure Of Sars-Cov-2 S-D614G Variant In Complex With Neutralizing Antibodies, Rbd-Chab15 And Rbd-Chab45",Homo sapiens,"Yang,T.J.;Yu,P.Y.;Chang,Y.C.;Liang,K.H.;Tso,H.C.;Ho,M.R.;Chen,W.Y.;Lin,H.T.;Wu,H.C.;Hsu,S.D.",Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function,28-MAR-2021,8_7_14_6_3_9,7EH5_E_P,Xtal structure,SARS-CoV-2,3,1,22.594332,-5.6051183
AAT73719_AAT73728,EVQLEESGTVLARPGASVKMSCKASGYTFTTYRMHWIKQRPGQGLEWIGAIYPGNSDTTYNQKFKDKAKLTAVTSTSSAYMELSSLTNEDSAVYFCTREGIPQLLRTLDYWGQGTSVTVSS,DILMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQEKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYVSYPWTFGGGTKLEIK,AAT73719,AAT73728,"immunoglobulin gamma heavy chain variable region, partial [Mus musculus]","immunoglobulin gamma light chain variable region, partial [Mus musculus]",Mus musculus,"Gubbins,M.J.; Plummer,F.A.; Yuan,X.Y.; Johnstone,D.; Drebot,M.; Andonova,M.; Andonov,A.; Berry,J.D.",Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus,26-JUL-2016,8_8_14_6_3_9,AAT73719_AAT73728,Unique source,SARS,3,1,2.6970809,-8.18028
CAB43004_CAB43011,EVQLLEQSGAEVKKPGSSVKVSCQVFGDTFSRYTIQWLRQAPGQGPEWMGNIIPVYNTPNYAQKFQGRLSITADDSTSTAYMELSSLRSEDTAVYFCARVVIPNAIRHTMGYYFDYWGQGTLVTVSS,AELTQSPATLSLSPGERATLSCRASQSVNKYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISNLEPEDFAVYYCQQRSDWVTFGGGTKVEIK,CAB43004,CAB43011,"anti-HCV E2 antibody, VH segment, partial [Homo sapiens]","anti-HCV E2 antibody, VK segment, partial [Homo sapiens]",Homo sapiens,"Allander,T.; Drakenberg,K.; Beyene,A.; Rosa,D.; Abrignani,S.; Houghton,M.; Widell,A.; Grillner,L.; Persson,M.A.",Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81,26-JUL-2016,8_8_19_6_3_8,CAB43004_CAB43011,Unique source,CD81; TAPA-1; TSPAN28; TAPA1; HCV,3,1,-0.7943769,5.6405582
1RHH_B_A,EVQLLEQSGAEVKKPGSSVQVSCKASGGTFSMYGFNWVRQAPGHGLEWMGGIIPIFGTSNYAQKFRGRVTFTADQATSTAYMELTNLRSDDTAVYYCARDFGPDWEDGDSYDGSGRGFFDFWGQGTLVTVSS,ELVLTQSPGTLSLSAGERATLSCRASQSVSSGSLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTIGRLEPEDLAVYYCQQYGTSPYTFGQGTKLEIK,1RHH_B,1RHH_A,Crystal Structure Of The Broadly Hiv-1 Neutralizing Fab X5 At 1.90 Angstrom Resolution,Crystal Structure Of The Broadly Hiv-1 Neutralizing Fab X5 At 1.90 Angstrom Resolution,Homo sapiens,"Darbha,R.;Phogat,S.;Labrijn,A.F.;Shu,Y.;Gu,Y.;Andrykovitch,M.;Zhang,M.Y.;Pantophlet,R.;Martin,L.;Vita,C.;Burton,D.R.;Dimitrov,D.S.;Ji,X.",Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope,14-NOV-2003,8_8_24_7_3_9,AFC01606_AFC01605,Xtal structure,HIV,3,1,-0.9326013,5.5305758
6SRX_I_M,EVQLLESGGGLVQPGGSLRLSCAASGFTFRYEVAAWVRQAPGKGLEWVSAISGPIPKGYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLRADLGLYMDLWGRGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNHYVSWYQQLPGTAPKLLIYDNSERTAGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDELTSNLVFGGGTKLTVL,6SRX_I,6SRX_M,Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021158,Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021158,HOMO SAPIENS,"Burschowsky, D., Addyman, A., Fiedler, S., Groves, M., Haynes, S., Seewooruthun, C., Carr, M.",Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021158,06-SEP-2019,8_8_13_8_3_11,6SRX_I_M,Xtal structure,,3,1,13.844497,9.76353
CBX46825,EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYIMWWVRQAPGKGLEWVSVISPSGGDTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAGDYWGQGTLVTVSS,QSELTQPPSASGTPGQGVTISCSGSSSNIGSNTVQWYQQFPGRAPKLLIYSNNRRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSVVVFGGGTKLTVL,CBX46825_H,CBX46825_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Pan,Q.; Birks,C.W.; Sivakumar,P.V.",Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination,28-OCT-2010,8_8_6_8_3_11,CBX46825,Same entry,,3,1,14.015273,9.295247
7DHA_C_B,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,7DHA_C,7DHA_B,Crystal Structure Of Cd38 In Complex With Daratumumab,Crystal Structure Of Cd38 In Complex With Daratumumab,Homo sapiens,"Lee,H.T.;Kim,Y.;Park,U.B.;Jeong,T.J.;Lee,S.H.;Heo,Y.S.","Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma",13-NOV-2020,8_8_15_6_3_9,AOD90621_AOD90617,Xtal structure,cADPR1; CD38,3,1,14.133594,9.9877
7R40_D_F,EVQLLESGGGLVQPGGSLRLSCVASGFTFSSYVMSWVRQAPGKGLEWVAAISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGTYYYGSGSFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSFHNYLAWYQQKPGRAPRLLIFDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRFNWPLTFGGGTKVEIK,7R40_D,7R40_F,Structure Of The Sars-Cov-2 Spike Glycoprotein In Complex With The 87G7 Antibody Fab Fragment,Structure Of The Sars-Cov-2 Spike Glycoprotein In Complex With The 87G7 Antibody Fab Fragment,Homo sapiens,"Du,W.;Hurdiss,D.L.;Drabek,D.;Mykytyn,A.Z.;Kaiser,F.K.;Gonzalez-Hernandez,M.;Munoz-Santos,D.;Lamers,M.M.;van Haperen,R.;Li,W.;Drulyte,I.;Wang,C.;Sola,I.;Armando,F.;Beythien,G.;Ciurkiewicz,M.;Baumgartner,W.;Guilfoyle,K.;Smits,T.;van der Lee,J.;van Kuppeveld,F.J.M.;van Amerongen,G.;Haagmans,B.L.;Enjuanes,L.;Osterhaus,A.D.M.E.;Grosveld,F.;Bosch,B.J.",An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern,08-FEB-2022,8_8_13_6_3_9,7R40_D_F,Xtal structure,SARS-CoV-2; ACEH; ACE2,3,1,14.250738,9.698139
6SS0_I_M,EVQLLESGGGLVRPGGSLRLSCAASEFTFRYDYHVWVRQAPGKGLEWVSAISGSGGSTYYADSVKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLRADLGLYMDLWGRGTLVTVSS,QSVLTQPPSVSAAPGQKVAVSCSGSSSNIGSHYVSWYQQLPGTAPKLLIYDNSERTSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDELTSNLVFGGGTRLTVL,6SS0_I,6SS0_M,Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021181,Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021181,HOMO SAPIENS,"Burschowsky, D., Addyman, A., Fiedler, S., Groves, M., Haynes, S., Seewooruthun, C., Carr, M.",Structure Of The Arginase-2-Inhibitory Human Antigen-Binding Fragment Fab C0021181,06-SEP-2019,9_8_13_8_3_11,6SS0_I_M,Xtal structure,,3,1,13.887249,9.739122
8D21_H_L,EVQLLESGGGLVRPGGSLRLSCKASGFSFSRHGLSWVRQAPGKGLEWVSSISGSSLSRYYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVFYCVKDRLDTAVPRGWFDSWGQGILVTVSS,EIVMTQSPATLSVSPGDRATLSCRASQSVSTELAWYQQKPGQAPRLLIYGASTRATDIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYNNWPPITFGQGTRLEIK,8D21_H,8D21_L,"Cryo-Em Structure Of The Vrc321 Clinical Trial, Vaccine-Elicited, Human Antibody 1B06 In Complex With A Stabilized Nc99 Ha Trimer","Cryo-Em Structure Of The Vrc321 Clinical Trial, Vaccine-Elicited, Human Antibody 1B06 In Complex With A Stabilized Nc99 Ha Trimer",Homo sapiens,"Andrews,S.F.;Cominsky,L.Y.;Shimberg,G.D.;Gillespie,R.A.;Gorman,J.;Raab,J.E.;Brand,J.;Creanga,A.;Gajjala,S.R.;Narpala,S.;Cheung,C.S.F.;Harris,D.R.;Zhou,T.;Gordon,I.;Holman,L.;Mendoza,F.;Houser,K.V.;Chen,G.L.;Mascola,J.R.;Graham,B.S.;Kwong,P.D.;Widge,A.;Dropulic,L.K.;Ledgerwood,J.E.;Kanekiyo,M.;McDermott,A.B.",An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans,12-APR-2023,8_8_16_6_3_10,8D21_H_L,Xtal structure,hemagglutinin,3,1,14.235856,9.766122
7X08_H_L,EVQLLESGGGQIQPGGSLRLSCAASGFSFISNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAFYYCARGLIRGIIMTGAFDIWDEGTMVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGSNYVSWYQQHPGKAPKLMISEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNWVFGGGTKLTVL,7X08_H,7X08_L,S Protein Of Sars-Cov-2 In Complex With 2G1,S Protein Of Sars-Cov-2 In Complex With 2G1,Homo sapiens,"Ma,H.;Guo,Y.;Tang,H.;Tseng,C.K.;Wang,L.;Zong,H.;Wang,Z.;He,Y.;Chang,Y.;Wang,S.;Huang,H.;Ke,Y.;Yuan,Y.;Wu,M.;Zhang,Y.;Drelich,A.;Kempaiah,K.R.;Peng,B.H.;Wang,A.;Yang,K.;Yin,H.;Liu,J.;Yue,Y.;Xu,W.;Zhu,S.;Ji,T.;Zhang,X.;Wang,Z.;Li,G.;Liu,G.;Song,J.;Mu,L.;Xiang,Z.;Song,Z.;Chen,H.;Bian,Y.;Zhang,B.;Chen,H.;Zhang,J.;Liao,Y.;Zhang,L.;Yang,L.;Chen,Y.;Gilly,J.;Xiao,X.;Han,L.;Jiang,H.;Xie,Y.;Zhou,Q.;Zhu,J.",Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD,09-MAR-2022,8_7_16_9_3_10,7X08_H_L,Xtal structure,SARS-CoV-2; RBD,3,1,12.522447,10.431101
6ORP_D_E,EVQLLESGPGLVKPSETLSLTCAVSGGSISSSNWWSWIRQPPGKGLEWIGNIGGSSGNTYYNPSLKSRVTISKDTSKNQFSLKLNSVTAADTAVYYCARDSSGWPWDNRFDVWGAGVLVTVSS,QSALTQPPSVSGAPGQRVTLSCTGSTSNIGGFYVQWYQQLPGTAPKLLIYENNKRPSGLSDRFSGSQSGTSASLTITGLQSEDEADYYCQSYDNSLSAQVFGGGTRLTVL,6ORP_D,6ORP_E,Modified Bg505 Sosip-Based Immunogen Rc1 In Complex With The Elicited V3-Glycan Patch Antibody Ab897Nhp,Modified Bg505 Sosip-Based Immunogen Rc1 In Complex With The Elicited V3-Glycan Patch Antibody Ab897Nhp,Macaca mulatta,"Escolano,A.;Gristick,H.B.;Abernathy,M.E.;Merkenschlager,J.;Gautam,R.;Oliveira,T.Y.;Pai,J.;West AP,Jr.;Barnes,C.O.;Cohen,A.A.;Wang,H.;Golijanin,J.;Yost,D.;Keeffe,J.R.;Wang,Z.;Zhao,P.;Yao,K.H.;Bauer,J.;Nogueira,L.;Gao,H.;Voll,A.V.;Montefiori,D.C.;Seaman,M.S.;Gazumyan,A.;Silva,M.;McGuire,A.T.;Stamatatos,L.;Irvine,D.J.;Wells,L.;Martin,M.A.;Bjorkman,P.J.;Nussenzweig,M.C.",Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques,30-APR-2019,9_8_15_8_3_11,6ORP_D_E,Xtal structure,HIV,3,1,16.254274,-7.322494
6ORQ_H_L,EVQLQESGGDLVKPGGSLKLSCAASGFTFSRYGMSWVRQTPDKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHGITTVGVAMDYWGQGTYSHVSS,DIVMTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGAGTKLELK,6ORQ_H,6ORQ_L,Modified Bg505 Sosip-Based Immunogen Rc1 In Complex With The Elicited V3-Glycan Patch Antibody Ab275Mur,Modified Bg505 Sosip-Based Immunogen Rc1 In Complex With The Elicited V3-Glycan Patch Antibody Ab275Mur,Human immunodeficiency virus 1,"Escolano,A.;Gristick,H.B.;Abernathy,M.E.;Merkenschlager,J.;Gautam,R.;Oliveira,T.Y.;Pai,J.;West AP,Jr.;Barnes,C.O.;Cohen,A.A.;Wang,H.;Golijanin,J.;Yost,D.;Keeffe,J.R.;Wang,Z.;Zhao,P.;Yao,K.H.;Bauer,J.;Nogueira,L.;Gao,H.;Voll,A.V.;Montefiori,D.C.;Seaman,M.S.;Gazumyan,A.;Silva,M.;McGuire,A.T.;Stamatatos,L.;Irvine,D.J.;Wells,L.;Martin,M.A.;Bjorkman,P.J.;Nussenzweig,M.C.",Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques,30-APR-2019,8_8_14_10_3_9,6ORQ_H_L,Xtal structure,HIV,3,1,17.798515,7.175847
5KEL_Q_U,EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVS,DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK,5KEL_Q,5KEL_U,Ebov Gp In Complex With Variable Fab Domains Of Iggs C2G4 And C13C6,Ebov Gp In Complex With Variable Fab Domains Of Iggs C2G4 And C13C6,Homo sapiens,"Pallesen,J.;Murin,C.D.;de Val,N.;Cottrell,C.A.;Hastie,K.M.;Turner,H.L.;Fusco,M.L.;Flyak,A.I.;Zeitlin,L.;Crowe JE,Jr.;Andersen,K.G.;Saphire,E.O.;Ward,A.B.",Structures of Ebola virus GP and sGP in complex with therapeutic antibodies,09-JUN-2016,8_10_12_6_3_9,5KEL_Q_U,Xtal structure,GP; RNF130; G1RZFP; Ebola; GOLIATH,3,1,13.392131,7.1407104
5KEN_G_H,EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVS,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK,5KEN_G,5KEN_H,Ebov Gp In Complex With Variable Fab Domains Of Iggs C4G7 And C13C6,Ebov Gp In Complex With Variable Fab Domains Of Iggs C4G7 And C13C6,Homo sapiens,"Pallesen,J.;Murin,C.D.;de Val,N.;Cottrell,C.A.;Hastie,K.M.;Turner,H.L.;Fusco,M.L.;Flyak,A.I.;Zeitlin,L.;Crowe JE,Jr.;Andersen,K.G.;Saphire,E.O.;Ward,A.B.",Structures of Ebola virus GP and sGP in complex with therapeutic antibodies,09-JUN-2016,8_8_12_6_3_9,5KEN_G_H,Xtal structure,GP; RNF130; G1RZFP; Ebola; GOLIATH,3,1,2.527936,-4.1630197
8FE3_H_L,EVQLQESGPELVKPGTSVKMSCKASGYTFTDYNIHWVKQSHGKSLEWIGYINPNNGGNKYTQKFEGRATLTVGKSSSTAYMELRSLTSEDSAVYYCARSPMYFYYDGSYYFDYWGQGTSLSVSS,DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTFGA,8FE3_H,8FE3_L,"Structure Of Dengue Virus (Denv2) In Complex With Prm12, An Anti-Prm Monoclonal Antibody","Structure Of Dengue Virus (Denv2) In Complex With Prm12, An Anti-Prm Monoclonal Antibody",Dengue virus type 2,"A Dowd,K.;Sirohi,D.;D Speer,S.;VanBlargan,L.A.;Chen,R.E.;Mukherjee,S.;Whitener,B.M.;Govero,J.;Aleshnick,M.;Larman,B.;Sukupolvi-Petty,S.;Sevvana,M.;Miller,A.S.;Klose,T.;Zheng,A.;Koenig,S.;Kielian,M.;Kuhn,R.J.;Diamond,M.S.;Pierson,T.C.",prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis,01-FEB-2023,8_8_17_10_3_7,8FE3_H_L,Xtal structure,Dengue; dengue,3,1,2.4328985,-4.247542
6W4S_H_L,EVQLQESGPGLAKPSQTLSLTCSVTGSSITSDYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSQISITRDTSKNHYYLQLNSVTTEDTATYYCARQGLRNWYFDVWGTGTTVTVSS,DIVLTQSPASLPVSLGQRATISCRASKSVSASAYSYMHWYQQKPGQPPKPLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHNRELPYTFGGGTKLEIK,6W4S_H,6W4S_L,Structure Of Apo Human Ferroportin In Lipid Nanodisc,Structure Of Apo Human Ferroportin In Lipid Nanodisc,Mus musculus,"Billesbolle,C.B.;Azumaya,C.M.;Kretsch,R.C.;Powers,A.S.;Gonen,S.;Schneider,S.;Arvedson,T.;Dror,R.O.;Cheng,Y.;Manglik,A.",Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms,11-MAR-2020,8_7_12_10_3_9,6W4S_H_L,Xtal structure,ferroportin; hepcidin,3,1,10.750139,-12.839019
7MDP_H_I,EVQLQESGPGLVKPPGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGSSSWYDLGPFDYWGQGTLVTVSS,SVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDERLSGWVFGGGTKLTVL,7MDP_H,7MDP_I,Kras G12C In Complex With G-2897,Kras G12C In Complex With G-2897,Homo sapiens,"Davies,C.W.;Oh,A.J.;Mroue,R.;Steffek,M.;Bruning,J.M.;Xiao,Y.;Feng,S.;Jayakar,S.;Chan,E.;Arumugam,V.;Uribe,S.C.;Drummond,J.;Frommlet,A.;Lu,C.;Franke,Y.;Merchant,M.;Koeppen,H.;Quinn,J.G.;Malhotra,S.;Do,S.;Gazzard,L.;Purkey,H.E.;Rudolph,J.;Mulvihill,M.M.;Koerber,J.T.;Wang,W.;Evangelista,M.",Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors,05-APR-2021,9_7_15_8_3_11,7MDP_H_I,Xtal structure,K-Ras4B; KRAS; KRAS1; KRAS2,3,1,15.598369,-7.401573
6L8T_C_D,EVQLQESGPGLVKPSQTLSLTCAVSGSSITYGYHWNWIRQFPGNKLEWIGYISYDGSVLYNPSLENRVTITRDTSKNQFFLKLSSVTAEDTAKYYCASGFDHWGQGTTLTVSS,DVVMTQSPLSLPVTLGEPASISCRSSQSLVHSYGDTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVETEDLGVYYCSQNTHVPYTFGGGTKLEIK,6L8T_C,6L8T_D,Crystal Structure Of The Fab Fragment Of A Humanized Hbv Therapeutic Antibody,Crystal Structure Of The Fab Fragment Of A Humanized Hbv Therapeutic Antibody,Homo sapiens,"Zhou,B.;Xia,L.;Zhang,T.;You,M.;Huang,Y.;He,M.;Su,R.;Tang,J.;Zhang,J.;Li,S.;An,Z.;Yuan,Q.;Luo,W.;Xia,N.",Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development,07-NOV-2019,9_7_6_11_3_9,QPT91640_QPT91791,Xtal structure,HBV,3,1,11.602451,-12.792377
6C5K_H_L,EVQLQESGPGLVQPSQSLSITCTVSGFSLTTYGVHWVRQSPGKGLEWLGVIWSGGTTEYNAAFISRLSISKDNSKSQVFFKMNSLQTNDTAIYFCVRMRITTDWFAYWGQGTLVTVSA,DVLMTQTPLSLPVSLGDQASISCRSSQTIVHKNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAADLGVYYCFQGSHVPYTFGGGTKLEIK,6C5K_H,6C5K_L,S25-23 Fab In Complex With Chlamydiaceae Lps (Crystal Form 2),S25-23 Fab In Complex With Chlamydiaceae Lps (Crystal Form 2),Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Brooks,C.L.;MacKenzie,C.R.;Caveney,N.;Van Petegem,F.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",Subtle Changes in the Combining Site of the Chlamydiaceae-Specific mAb S25-23 Increase the Antibody-Carbohydrate Binding Affinity by an Order of Magnitude,16-JAN-2018,8_7_12_11_3_9,6C5K_H_L,Xtal structure,RPS25; S25,3,1,22.598503,-5.600943
1MJU_H_L,EVQLQQPGAELVKPGASVKLSCKASGYTFTNYWINWVKQRPGQGLEWIGNIYPGSSYTHYNEKFKNKATLTVDTSSSTAYMQLSSLTSDDSAVYYCANKLGWFPYWGQGTLVTVSA,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGAGTKLELK,1MJU_H,1MJU_L,1.22 Angstrom Resolution Crystal Structure Of The Fab Fragment Of Esterolytic Antibody Ms6-12,1.22 Angstrom Resolution Crystal Structure Of The Fab Fragment Of Esterolytic Antibody Ms6-12,Mus musculus,"Muranova,T.A.;Ruzheinikov,S.N.;Sedelnikova,S.E.;Moir,A.;Partridge,L.J.;Kakinuma,H.;Takahashi,N.;Shimazaki,K.;Sun,J.;Nishi,Y.;Rice,D.W.",The preparation and crystallization of Fab fragments of a family of mouse esterolytic catalytic antibodies and their complexes with a transition-state analogue,28-AUG-2002,8_8_9_11_3_9,1MJU_H_L,Xtal structure,,3,1,-0.38333008,-4.1017427
5GIR_A_B,EVQLQQPGAELVRPGASVKLSCKASGYTFTSYWMNWVKQRPGQGLECIGMIHPSDGETRLNQKFKDKATLTLDKSSSTAYMQLSSPTSEDSAVYYCTTHFDYWGQGTTLTVSS,DIVLIQSPATLSVTPGDSVSLSCRASQRISNNLHWYQQKSHESPRLLIRYTSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPFTFGSGTKLEMK,5GIR_A,5GIR_B,Crystal Structure Of A Fab Fragment With Its Ligand Peptide,Crystal Structure Of A Fab Fragment With Its Ligand Peptide,Homo sapiens,"Kitago,Y.;Kaneko,M.K.;Ogasawara,S.;Kato,Y.;Takagi,J.","Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1",24-JUN-2016,8_8_6_6_3_9,5GIR_A_B,Xtal structure,IDH1,3,1,-0.33627048,-3.613473
3KJ6_H_L,EVQLQQSGAELARPGASVKLSCKASGYIFTDYYINWVRQRTGQGFEWIGEIYPGSGNIDYNERFKDKATLTADKSSSTAYMQLSSLTSEDSAVYFCVRGFGYWGQGTTLTVSS,DIKMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFIGTGSGQDYSLTISSLDYADMGIYYCLQYDEFPYTFGGGTKLEIK,3KJ6_H,3KJ6_L,Crystal Structure Of A Methylated Beta2 Adrenergic Receptor-Fab Complex,Crystal Structure Of A Methylated Beta2 Adrenergic Receptor-Fab Complex,Mus musculus,"Bokoch,M.P.;Zou,Y.;Rasmussen,S.G.;Liu,C.W.;Nygaard,R.;Rosenbaum,D.M.;Fung,J.J.;Choi,H.J.;Thian,F.S.;Kobilka,T.S.;Puglisi,J.D.;Weis,W.I.;Pardo,L.;Prosser,R.S.;Mueller,L.;Kobilka,B.K.",Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor,02-NOV-2009,8_8_6_6_3_9,AED76242_AED76243,Xtal structure,TUBB4B; TUBB2C; Beta2,3,1,0.25016472,-4.0822587
ABC55343_ABC55326,EVQLQQSGAELMKSGASVKISCKATGYTFSSYWIEWIKQRPGHGLEWIGEILPGSGSTNYNEKFKGKATVTTDTSSNTAYMQFSSLTSEDSAVYYCARWYDGHFDYWGQGTTLTVSS,DVVMTQTPSSLSASRGDRVTISCSASQAISKYLNWYQQKPDGTVKLLINYTSRLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYNKLPYTFGGGTKLEIK,ABC55343,ABC55326,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Valadon,P.; Garnett,J.D.; Testa,J.E.; Bauerle,M.; Oh,P.; Schnitzer,J.E.",Screening phage display libraries for organ-specific vascular immunotargeting in vivo,26-JUL-2016,8_8_10_6_3_9,ABC55343_ABC55326,Unique source,,3,1,4.9944377,-1.8715036
15C8_H_L,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQKPEQGLEWIAQIDPANGNTKYDPKFQGKATITADTSSNTAYLHLSSLTSEDSAVYYCAADPPYYGHGDYWGQGTTLTVSS,DIVLTQSPAIMSASLGERVTMTCTASSSVSSSNLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPYTFGGGTKLEIK,15C8_H,15C8_L,"Catalytic Antibody 5C8, Free Fab","Catalytic Antibody 5C8, Free Fab",Mus musculus,"Gruber,K.;Wilson,I.A.",Direct Submission,18-MAR-1998,8_8_12_7_3_9,15C8_H_L,Xtal structure,,3,1,-4.682474,0.15026435
AIQ78243,EVQLQQSGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSADYYCARSNYYGSSYWFFDVWGAGTTVTVSS,DIVLTQSPAILSASPGEKVTMTCRASSSVNYMDWYQKKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGGGTKLEIK,AIQ78243_H,AIQ78243_L,"anti-CD20 scFv/SNAP fusion protein, partial [synthetic construct]","anti-CD20 scFv/SNAP fusion protein, partial [synthetic construct]",synthetic construct,"Robinson-Mosher,A.; Chen,J.H.; Way,J.; Silver,P.A.",Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding,03-DEC-2015,8_8_15_5_3_9,AIQ78243,Same entry,RIC-4; bA416N4.2; RIC4; SEC9; SNAP-25; CD20; dJ1068F16.2; FMC7; MS4A1; SNAP25; Bp35; SNAP; B1,3,1,0.20832922,-3.6842644
6KS2_B_A,EVQLQQSGAELVRPGASVKLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIDPETGGTVYNQKFKGKATLTADISSTTAYMELRSLTSEDSAVYFCISEDIDESKDYWGQGTTLTVSS,DIVMTQSPSSLAVSAGEKVTLSCKSSQSLFNSRTRKNYLAWYQQKPGLSPTLLIYWASTRKSGVPDRFTGSGSGTDFTLTITSVQAEDLAVYYCKQSYYLRTFGGGTKLEIK,6KS2_B,6KS2_A,Structure Of Anti-Ghrelin Receptor Antibody,Structure Of Anti-Ghrelin Receptor Antibody,Mus musculus,"Shiimura,Y.;Horita,S.;Hamamoto,A.;Asada,H.;Hirata,K.;Tanaka,M.;Mori,K.;Uemura,T.;Kobayashi,T.;Iwata,S.;Kojima,M.",Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode,23-AUG-2019,8_8_11_12_3_8,6KS2_B_A,Xtal structure,MTLRP; GHRL; obestatin; ghrelin,3,1,0.21676815,-3.4818718
BDZ85376_BDZ85441,EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDIEDGETKCAPKFQDRATITADTSSNTAYLQLSSLTSEDTAIYYCARDYYGGSPYAMDNWGQGTSVTVSS,NIVMTQSPRSMSMSVGERVTLNCKASEIVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSVTDFTLTISTVQAEDLADYYCGQSYSYPLTFGAGTKLELK,BDZ85376,BDZ85441,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85376_BDZ85441,Unique source,SARS-CoV-2,3,1,-5.144385,0.38307482
BDZ85373_BDZ85438,EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDPEDGETKYAPKFQDKATVTADTSSNTAYLQLSSLTSEDTAIYYCTRDYYDGSPYAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSVTDFTLTISSVQAEDLADYYCGQSYSYPLTFGAGTKLELK,BDZ85373,BDZ85438,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85373_BDZ85438,Unique source,SARS-CoV-2,3,1,-5.1200876,0.38006824
AAP75579_AAP75580,EVQLQQSGPDLVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNNGGARYNQNFKGKATLTADKSSSTAYMELRSLTSEDSAVYYCASRSNWYFGVWGAGTTVTVSS,IMSASPGEKVTITCSASSSVNYIHWFQQKPGTSPKLWIYSTSSLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPFTFGSGTKLEIK,AAP75579,AAP75580,"monoclonal antibody CP1092.23 heavy chain VDJ region, partial [Mus musculus]","monoclonal antibody CP1092.23 light chain VJ region, partial [Mus musculus]",Mus musculus,"Garcia-Ojeda,P.A.; Krasnokutsky,M.V.; Stein,K.E.; Shapiro,M.A.",VH and VL gene usage in response to the Neisseria meningitidis group C tetanus toxoid conjugate vaccine,30-JUN-2003,8_8_10_5_3_9,AAP75579_AAP75580,Unique word,tetanus,3,1,2.4742107,-4.326137
6CXC_G_J,EVQLQQSGPELVKPGASVKISCKASGYAFSNSWMSWVKQRPGKGLEWIGRLFPADGDITYNGHFKDKAALTADKSSNTAYIQLSSLTSEDSAVYFCARMDNSEVFWGQGTLVTVSA,DILLTQSQKFMSTSVGDRVSITCKASQNVRTGVSWYQRKPGQSPKALIYLASNRHTGVPDRFTGRGSGTDFTLTISEVQSEDLADYFCLQHWTVPYTFGGGTKLEIK,6CXC_G,6CXC_J,3.9A Cryo-Em Structure Of Murine Antibody Bound At A Novel Epitope Of Respiratory Syncytial Virus Fusion Protein,3.9A Cryo-Em Structure Of Murine Antibody Bound At A Novel Epitope Of Respiratory Syncytial Virus Fusion Protein,Human respiratory syncytial virus A2,"Xie,Q.;Wang,Z.;Ni,F.;Chen,X.;Ma,J.;Patel,N.;Lu,H.;Liu,Y.;Tian,J.H.;Flyer,D.;Massare,M.J.;Ellingsworth,L.;Glenn,G.;Smith,G.;Wang,Q.",Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein,02-APR-2018,8_8_9_6_3_9,6CXC_G_J,Xtal structure,,3,1,0.3585939,-4.7171326
7UPA_H_L,EVQLQQSGPELVKPGASVKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPFIGGTRYNQKFKGKATLTVDKSSRTAYMELLSLTSEDSAVYYCAREADYDWYFDVWGAGTTVTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLHWYQQKPDGTVNLLIFYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPRTFGGGTKLEIK,7UPA_H,7UPA_L,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 1H8,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 1H8,Mus musculus,"Byrne,P.O.;McLellan,J.S.",Prefusion-stabilized Nipah virus fusion protein complexed with Fab 1H8,08-JAN-2009,8_8_12_6_3_9,7UPA_H_L,Xtal structure,,3,1,2.3945372,-4.213127
7SRS_Q_P,EVQLQQSGPELVKPGASVKLSCKASGYTFTSSWMHWVKQRPGQGLEWIGNIYPSNGGTNYNERFKSKATLTVDRSSNTAYMQLSSLTSEDSAVYFCARFGSFITTILTTYYNPVDYWGQGTTLTVSS,DIVLIQSPAIMSASPGEKVTITCSASSSVSYMHWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPLTFGAGTKLEIK,7SRS_Q,7SRS_P,5-Ht2B Receptor Bound To Lsd In Complex With Beta-Arrestin1 Obtained By Cryo-Electron Microscopy (Cryoem),5-Ht2B Receptor Bound To Lsd In Complex With Beta-Arrestin1 Obtained By Cryo-Electron Microscopy (Cryoem),Mus musculus,"Cao,C.;Barros-Alvarez,X.;Zhang,S.;Kim,K.;Damgen,M.A.;Panova,O.;Suomivuori,C.M.;Fay,J.F.;Zhong,X.;Krumm,B.E.;Gumpper,R.H.;Seven,A.B.;Robertson,M.J.;Krogan,N.J.;Huttenhain,R.;Nichols,D.E.;Dror,R.O.;Skiniotis,G.;Roth,B.L.",Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD,21-SEP-2022,8_8_20_5_3_9,7SRS_Q_P,Xtal structure,DNAS1L3; LSD; DNASE1L3,3,1,-0.7407031,-3.907093
CAA10004_CAA10003,EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMKWVKQSHGKSLEWIGDINPNNGGTGYNQKFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCANDYGSTYGFAYWGQGTLVTVSA,DMVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLKSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIK,CAA10004,CAA10003,"F124 immunoglobulin heavy chain variable region, partial [Mus musculus]","F124 immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Passafiume,M.; Vulliez-le Normand,B.; Riottot,M.M.; Bentley,G.A.","Sequence analysis of a monoclonal antibody specific for the preS2 region of hepatitis B surface antigen, and the cloning, expression and characterisation of its single-chain Fv construction",26-JUL-2016,8_8_12_10_3_9,CAA10004_CAA10003,Unique chain,,3,1,2.4894621,-4.212899
7LAB_Y_X,EVQLVESGAEVKKPGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATSSGPSRLCGGGSCYHSFDYWGQGTLVTVSS,LTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTWTFGQGTKVEIK,7LAB_Y,7LAB_X,Structure Of Sars-Cov-2 S Protein In Complex With N-Terminal Domain Antibody Dh1052,Structure Of Sars-Cov-2 S Protein In Complex With N-Terminal Domain Antibody Dh1052,Homo sapiens,"Li,D.;Edwards,R.J.;Manne,K.;Martinez,D.R.;Schafer,A.;Alam,S.M.;Wiehe,K.;Lu,X.;Parks,R.;Sutherland,L.L.;Oguin,T.H.;McDanal,C.;Perez,L.G.;Mansouri,K.;Gobeil,S.M.;Janowska,K.;Stalls,V.;Kopp,M.;Cai,F.;Lee,E.;Foulger,A.;Hernandez,G.E.;Sanzone,A.;Tilahun,K.;Jiang,C.;Tse,L.V.;Bock,K.W.;Minai,M.;Nagata,B.M.;Cronin,K.;Gee-Lai,V.;Deyton,M.;Barr,M.;Holle,T.V.;Macintyre,A.N.;Stover,E.;Feldman,J.;Hauser,B.M.;Caradonna,T.M.;Scobey,T.D.;Rountree,W.;Wang,Y.;Moody,M.A.;Cain,D.W.;DeMarco,C.T.;Denny,T.;Woods,C.W.;Petzold,E.W.;Schmidt,A.G.;Teng,I.T.;Zhou,T.;Kwong,P.D.;Mascola,J.R.;Graham,B.S.;Moore,I.N.;Seder,R.;Andersen,H.;Lewis,M.G.;Montefiori,D.C.;Sempowski,G.D.;Baric,R.S.;Acharya,P.;Haynes,B.F.;Saunders,K.O.",The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates,06-JAN-2021,8_8_21_7_3_10,7LAB_Y_X,Xtal structure,SARS-CoV-2,3,1,1.0278494,2.7408853
CAV14532,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYXARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14532_H,CAV14532_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,FAILED,Same entry,,3,1,-11.870303,5.353763
CAV14525,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWSSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DIQMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQKPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14525_H,CAV14525_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,ADL98452,Same entry,,3,1,-11.86091,5.361028
CAV14565,EVQLVESGAEVKKPGESLRISCKGSGYIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14565_H,CAV14565_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,ADL98469,Same entry,,3,1,-11.856377,5.3456063
CAV14523,EVQLVESGAEVKKPGESLRISCKGSGYSISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14523_H,CAV14523_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,ADL98451,Same entry,,3,1,-11.929233,5.4231386
CAV14535,EVQLVESGAEVKKPGESLRISCKGSGYSISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGRVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14535_H,CAV14535_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,ADL98456,Same entry,,3,1,-11.906497,5.389175
CAV14537,EVQLVESGAEVKKPGESLRISCKGSGYSISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGRVTISADKSINTAYLQWSSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASSGISRYLAWYQQKPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14537_H,CAV14537_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,ADL98457,Same entry,,3,1,-11.876892,5.376497
7ZR9_F_G,EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAINWVRQAPGQGLEWMGGIIPIFRTPHYAQKFQGRVTITADESTGTAYMELSSLRSEDTAVYYCASPSCGGDCPQYLKSSKLDWYFDLWGRGTLVTVSS,VIWMTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPLTFGQGTRLEIK,7ZR9_F,7ZR9_G,Omi-2 Fab In Complex With Sars-Cov-2 Beta Spike Glycoprotein,Omi-2 Fab In Complex With Sars-Cov-2 Beta Spike Glycoprotein,Homo sapiens,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,03-MAY-2022,8_8_24_7_3_9,7ZR9_F_G,Xtal structure,,3,1,-0.92283726,5.673737
6J11_F_G,EVQLVESGAEVVKPGASVKMSCKASGYPFTSYNIHWIKQTPGQGLEWIGAIYPGNGDTSYTQKFKVKATLTSDKSSSTAYMQLSSLTSEDSAVYFCARYGNYPSYAMDYWGQGTSVTVSS,DIVMTQSPASLTVSLGQRATISCRASKSVSASGYNYLHWYQQRPGQPPKLLIYLAFNLESGVPARFNGSGSGTDFTLNIHPVEEEDAATYYCQHSRDLPFTFGSGTKLEIK,6J11_F,6J11_G,Mers-Cov Spike N-Terminal Domain And 7D10 Scfv Complex,Mers-Cov Spike N-Terminal Domain And 7D10 Scfv Complex,Mus musculus,"Zhou,H.;Chen,Y.;Zhang,S.;Niu,P.;Qin,K.;Jia,W.;Huang,B.;Zhang,S.;Lan,J.;Zhang,L.;Tan,W.;Wang,X.",Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein,27-DEC-2018,8_8_13_10_3_9,6J11_F_G,Xtal structure,MERS; CoV,3,1,0.19781408,-3.922076
8G4T_H_L,EVQLVESGEGLVQPGGSLRLSCAASGFTFSSHAMHWVRQAPGKGLEYVSAISSEGGSTYYADSVRGRFIISRDNSKNTLYLQMGSLRAEDMAVYYCARVTGDYNWYFDLWGRGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQGVSSNLAWYQQKPGQAPRLLIHGASTRATGSPARFSGSGSGTEFTLTISSLQSEDFAVYSCQQYHNWPWTFGQGTKVEIK,8G4T_H,8G4T_L,Vaccine-Elicited Human Antibody 2C09 In Complex With Hiv-1 Envelope Trimer Bg505 Ds-Sosip,Vaccine-Elicited Human Antibody 2C09 In Complex With Hiv-1 Envelope Trimer Bg505 Ds-Sosip,Homo sapiens,"Wang,S.;Matassoli,F.;Zhang,B.;Liu,T.;Shen,C.H.;Bylund,T.;Johnston,T.;Henry,A.R.;Teng,I.T.;Tripathi,P.;Becker,J.E.;Changela,A.;Chaudhary,R.;Cheng,C.;Gaudinski,M.;Gorman,J.;Harris,D.R.;Lee,M.;Morano,N.C.;Novik,L.;O'Dell,S.;Olia,A.S.;Parchment,D.K.;Rawi,R.;Roberts-Torres,J.;Stephens,T.;Tsybovsky,Y.;Wang,D.;Van Wazer,D.J.;Zhou,T.;Doria-Rose,N.A.;Koup,R.A.;Shapiro,L.;Douek,D.C.;McDermott,A.B.;Kwong,P.D.",HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide,12-JUL-2023,8_8_13_6_3_9,8G4T_H_L,Xtal structure,HIV,3,1,13.719558,9.761326
2ADI_B_A,EVQLVESGGDLVKPGGSLKLSCAASGFTFSSYGMSWVRQTPDKGLEWVATISSGGSYTYYPDNVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHEDGNWNYFDYWGQGTTLTVSS,TTVTQSPASLSVAIGEKVTIRCITSTDIDDDMNWYQQKPGEPPKFFISEGNTLRPGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSDTLPLTFGSGTKLEIK,2ADI_B,2ADI_A,Crystal Structure Of Monoclonal Anti-Cd4 Antibody Q425 In Complex With Barium,Crystal Structure Of Monoclonal Anti-Cd4 Antibody Q425 In Complex With Barium,Mus musculus,"Zhou,T.;Hamer,D.H.;Hendrickson,W.A.;Sattentau,Q.J.;Kwong,P.D.",Interfacial metal and antibody recognition,20-JUL-2005,8_8_13_6_3_9,2ADI_B_A,Xtal structure,Cd4,3,1,17.687288,7.179944
8DPM_I_J,EVQLVESGGDLVQPGGSLRLSCAASGITLSGVWMNWVRQAPGKGLEWIGRIKSTSDGGRADFAAPARGRFTMSRDESKNKLFLQMNNLGIEDTGMYYCFTRVQRDGTKDDFWGRGTLVTVSS,QSVLTQPPSVSGAPGQTVTISCTGSYSNIGAGYDVQWYQHLPGTAPKLLIYDNVHRPSGVPDRFSGSKSGTSASLAITGLQTEDEADYYCQSYDSRLRDQWVFGGGTKLTVL,8DPM_I,8DPM_J,Structure Of Ebov Gp Lacking The Mucin-Like Domain With 9.20.1A2 Fab And 6D6 Scfv Bound,Structure Of Ebov Gp Lacking The Mucin-Like Domain With 9.20.1A2 Fab And 6D6 Scfv Bound,Homo sapiens,"Yu,X.;Saphire,E.O.",The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus,19-JUL-2023,8_10_13_9_3_12,8DPM_I_J,Xtal structure,Ebola,3,1,13.003584,8.586641
8EEE_H_L,EVQLVESGGGLAKPGGSLRLSCAASGFTFSDYYMDWVRQAPGKGLEWVSRISNGGGSTWYADSVKGRFTISRENAKNTLYLQMNSLRAEDTAVYYCARERYCSGGVCYAGTKYFDYWGQGVLVTVSS,QPVLTQPPSLSASPGASARLPCTLSSDLSVGSKNMYWYQQKPGSAPRLFLYYYSDSDKQLGPGVPNRVSGSKETSSNTAFLLISGLQPEDEADYYCQVYDSSANWVFGGGTRLTVL,8EEE_H,8EEE_L,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz104-D In Complex With Zikv E Glycoprotein,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz104-D In Complex With Zikv E Glycoprotein,Macaca mulatta,"Sankhala,R.S.;Dussupt,V.;Donofrio,G.;Gromowski,G.D.;De La Barrera,R.A.;Larocca,R.A.;Mendez-Rivera,L.;Lee,A.;Choe,M.;Zaky,W.;Mantus,G.;Jensen,J.L.;Chen,W.H.;Gohain,N.;Bai,H.;McCracken,M.K.;Mason,R.D.;Leggat,D.;Slike,B.M.;Tran,U.;Jian,N.;Abbink,P.;Peterson,R.;Mendes,E.A.;Freitas de Oliveira Franca,R.;Calvet,G.A.;Bispo de Filippis,A.M.;McDermott,A.;Roederer,M.;Hernandez,M.;Albertus,A.;Davidson,E.;Doranz,B.J.;Rolland,M.;Robb,M.L.;Lynch,R.M.;Barouch,D.H.;Jarman,R.G.;Thomas,S.J.;Modjarrad,K.;Michael,N.L.;Krebs,S.J.;Joyce,M.G.",Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes,30-AUG-2023,8_8_20_9_7_10,8EEE_H_L,Xtal structure,Zika,3,1,14.134656,10.283402
6XGC_I_J,EVQLVESGGGLAKPGGSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWISGINSGGGSTWYTASVKGRFTISRDNSKSTLSLQMNSLRTEDTAVYYCAKDGGNAIFGLVITNYGLDSWGQGAVVTVSS,QSVLTQPPSASGAPGQSVTISCSGSSSNFGSNHVYWYQQLSGKAPKLLIYNNNRRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSVWDSSLNNVLFGGGTRLTVL,6XGC_I,6XGC_J,Cryoem Structure Of Influenza Hemagglutinin A/Michigan/45/2015 In Complex With Cyno Antibody 1C4,Cryoem Structure Of Influenza Hemagglutinin A/Michigan/45/2015 In Complex With Cyno Antibody 1C4,Macaca fascicularis,"Darricarrere,N.;Qiu,Y.;Kanekiyo,M.;Creanga,A.;Gillespie,R.A.;Moin,S.M.;Saleh,J.;Sancho,J.;Chou,T.H.;Zhou,Y.;Zhang,R.;Dai,S.;Moody,A.;Saunders,K.O.;Crank,M.C.;Mascola,J.R.;Graham,B.S.;Wei,C.J.;Nabel,G.J.",Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates,17-JUN-2020,8_8_20_8_3_11,6XGC_I_J,Xtal structure,Influenza,3,1,13.970644,10.155954
7R8N_M_N,EVQLVESGGGLIQAGGSLRLSCAASGFGVRNNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTVFLQMNSLRAEDTAVYYCAREGDVEGFSDLWSGYSRDRYYFDYWGQGTLVTVSS,QSVLTQPASVSGSPGQSITFSCTGTSSDVGGYNYVSWYQQYPGKAPKLLIYDVTNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSFTSSNTRVFGTGTKVTVL,7R8N_M,7R8N_N,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody C051,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody C051,Homo sapiens,"Muecksch,F.;Weisblum,Y.;Barnes,C.O.;Schmidt,F.;Schaefer-Babajew,D.;Lorenzi,J.C.;Flyak,A.I.;DeLaitsch,A.T.;Huey-Tubman,K.E.;Hou,S.;Schiffer,C.A.;Gaebler,C.;Wang,Z.;Da Silva,J.;Poston,D.;Finkin,S.;Cho,A.;Cipolla,M.;Oliveira,T.Y.;Millard,K.G.;Ramos,V.;Gazumyan,A.;Rutkowska,M.;Caskey,M.;Nussenzweig,M.C.;Bjorkman,P.J.;Hatziioannou,T.;Bieniasz,P.D.","Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies",26-JUN-2021,8_7_25_9_3_10,7R8N_M_N,Xtal structure,SARS-CoV-2,3,1,12.66981,10.322957
AMN09586_AMN09587,EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTYYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS,DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK,AMN09586,AMN09587,"mAb114 immunoglobulin heavy chain variable region, partial [Homo sapiens]","mAb114 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Corti,D.; Misasi,J.; Mulangu,S.; Stanley,D.A.; Kanekiyo,M.; Wollen,S.; Ploquin,A.; Doria-Rose,N.A.; Staupe,R.P.; Bailey,M.; Shi,W.; Choe,M.; Marcus,H.; Thompson,E.A.; Cagigi,A.; Silacci,C.; Fernandez-Rodriguez,B.; Perez,L.; Sallusto,F.; Vanzetta,F.; Agatic,G.; Cameroni,E.; Kisalu,N.; Gordon,I.; Ledgerwood,J.E.; Mascola,J.R.; Graham,B.S.; Muyembe-Tamfun,J.J.; Trefry,J.C.; Lanzavecchia,A.; Sullivan,N.J.",Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody,02-MAR-2016,8_7_13_6_3_9,AMN09586_AMN09587,Unique word,Ebola,3,1,16.366173,11.585284
7S4S_H_L,EVQLVESGGGLIQPGGSLRLSCAASGFIVSRNYMIWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLEVAGAIDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGATSRATGTPDRFSGSGSGTDFTLTINRLEPEDFAVYYCQQYGSSPGYTFGQGTKLEIK,7S4S_H,7S4S_L,Crystal Structure Of Sars-Cov-2 S Receptor-Binding Domain (Rbd) In Complex Cov11 Fab,Crystal Structure Of Sars-Cov-2 S Receptor-Binding Domain (Rbd) In Complex Cov11 Fab,Homo sapiens,"Tolbert,W.D.;Pazgier,M.",Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab,09-SEP-2021,8_7_12_7_3_10,7S4S_H_L,Xtal structure,SARS-CoV-2; RBD,3,1,12.536099,10.408921
QWE89725_QWE89726,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCARALQVGATSDYFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDETDYYCQSCDSSLSVVVFGGGTKLTVL,QWE89725,QWE89726,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ju,B.; Zhang,Q.; Ge,J.; Wang,X.; Zhang,Z.; Zhang,L.",Direct Submission,09-JUN-2021,8_7_15_9_3_11,QWE89725_QWE89726,Unique source,SARS-CoV-2,3,1,12.640587,10.300106
7KFV_F_G,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGATYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDVSGYRYGLDYWGQGTLVTVSG,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLISYPGTFGQGTKLEIK,7KFV_F,7KFV_G,Structural Basis For A Germline-Biased Antibody Response To Sars-Cov-2 (Rbd:C1A-B12 Fab),Structural Basis For A Germline-Biased Antibody Response To Sars-Cov-2 (Rbd:C1A-B12 Fab),Homo sapiens,"Clark,S.A.;Clark,L.E.;Pan,J.;Coscia,A.;McKay,L.G.;Shankar,S.;Johnson,R.I.;Griffiths,A.;Abraham,J.",Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2,15-OCT-2020,8_7_14_6_3_9,7KFV_F_G,Xtal structure,SARS-CoV-2; B12; NDUFB3,3,1,12.566606,10.388489
QYB25426_QYB25466,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPLFGPGTKVDIK,QYB25426,QYB25466,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_7_11_6_3_8,QYB25426_QYB25466,Unique source,SARS-CoV-2,3,1,12.569417,10.673084
7KFW_C_D,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRDNSKNTVFLQMNSLRAEDTAVYYCARGDVSGYRYGLDYWGQGTLVTVSG,DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPGTFGQGTKLEIK,7KFW_C,7KFW_D,Structural Basis For A Germline-Biased Antibody Response To Sars-Cov-2 (Rbd:C1A-B3 Fab),Structural Basis For A Germline-Biased Antibody Response To Sars-Cov-2 (Rbd:C1A-B3 Fab),Homo sapiens,"Clark,S.A.;Clark,L.E.;Pan,J.;Coscia,A.;McKay,L.G.;Shankar,S.;Johnson,R.I.;Griffiths,A.;Abraham,J.",Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2,15-OCT-2020,8_7_14_6_3_9,7KFW_C_D,Xtal structure,SARS-CoV-2,3,1,12.6744175,10.383496
USW88727_USW88635,EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYAGGSTFYADSVKGRFTISRDNSKNTLYLQMSSLRVEDTAVYYCARDLDYYGMDVWGRGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISTYLAWYQQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAAYYCQQVNSYPPITFGPGTKVDIK,USW88727,USW88635,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kumar,S.; Patel,A.; Lai,L.; Chakravarthy,C.; Valanparambil,R.; Davis-Gardner,M.E.; Edara,V.V.; Linderman,S.; Reddy,E.S.; Gottimukkala,K.; Nayak,K.; Dixit,K.; Sharma,P.; Bajpai,P.; Singh,V.; Frank,F.; Cheedarla,N.; Verkerke,H.P.; Neish,A.S.; Roback,J.D.; Mantus,G.; Goel,P.K.; Rahi,M.; Davis,C.W.; Wrammert,J.; Suthar,M.S.; Ahmed,R.; Ortlund,E.; Sharma,A.; Murali-Krishna,K.; Chandele,A.",Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody,06-JUL-2022,8_7_11_6_3_10,USW88727_USW88635,Unique source,SARS-CoV-2; RBD,3,1,12.552599,10.773979
3U46_A_B,EVQLVESGGGLIRPGGSLRLSCKGSGFIFENFGFGWVRQGPGKGLEWVSGTNWNGGDSRYGDSVKGRFTISRDNSNNFVYLQMNSLRPEDTAIYYCARGTDYTIDDQGIRYQGSGTFWYFDVWGRGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQNVHPRYFAWYQQKRGQSPRLLIHSGSTRAAGIADRFSGGGSGMHFTLTITRVEPEDFAVYFCQQYGGSPYTFGQGTRVELR,3U46_A,3U46_B,Ch04H/Ch02L P212121,Ch04H/Ch02L P212121,Homo sapiens,"McLellan,J.S.;Pancera,M.;Carrico,C.;Gorman,J.;Julien,J.P.;Khayat,R.;Louder,R.;Pejchal,R.;Sastry,M.;Dai,K.;O'Dell,S.;Patel,N.;Shahzad-ul-Hussan,S.;Yang,Y.;Zhang,B.;Zhou,T.;Zhu,J.;Boyington,J.C.;Chuang,G.Y.;Diwanji,D.;Georgiev,I.;Kwon,Y.D.;Lee,D.;Louder,M.K.;Moquin,S.;Schmidt,S.D.;Yang,Z.Y.;Bonsignori,M.;Crump,J.A.;Kapiga,S.H.;Sam,N.E.;Haynes,B.F.;Burton,D.R.;Koff,W.C.;Walker,L.M.;Phogat,S.;Wyatt,R.;Orwenyo,J.;Wang,L.X.;Arthos,J.;Bewley,C.A.;Mascola,J.R.;Nabel,G.J.;Schief,W.R.;Ward,A.B.;Wilson,I.A.;Kwong,P.D.",Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9,07-OCT-2011,8_8_26_7_3_9,3U46_A_B,Xtal structure,gp120; HIV,3,1,13.289972,11.381958
7BEP_D_F,EVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSYIRSSGHTIYYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARGGVLRFLEWPLNAFDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNNALGTFGQGTKVEIK,7BEP_D,7BEP_F,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In A Ternary Complex With Covox-384 And S309 Fabs,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In A Ternary Complex With Covox-384 And S309 Fabs,Homo sapiens,"Dejnirattisai,W.;Zhou,D.;Ginn,H.M.;Duyvesteyn,H.M.;Supasa,P.;Case,J.B.;Zhao,Y.;Walter,T.S.;Mentzer,A.J.;Liu,C.;Wang,B.;Paesen,G.C.;Slon-Campos,J.;Lopez-Camacho,C.;Kafai,N.M.;Bailey,A.L.;Chen,R.E.;Ying,B.;Thompson,C.;Bolton,J.;Fyfe,A.;Gupta,S.;Tan,T.K.;Gilbert-Jaramillo,J.;James,W.;Knight,M.;Carroll,M.W.;Skelly,D.;Dold,C.;Peng,Y.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Klenerman,P.;Temperton,N.;Hall,D.R.;Williams,M.A.;Paterson,N.G.;Bertram,F.K.;Siebert,C.A.;Clare,D.K.;Howe,A.;Radecke,J.;Song,Y.;Townsend,A.R.;Huang,K.A.;Fry,E.E.;Mongkolsapaya,J.;Diamond,M.S.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antigenic anatomy of SARS-CoV-2 receptor binding domain,24-DEC-2020,8_8_18_6_3_9,7BEP_D_F,Xtal structure,SARS-CoV-2,3,1,15.737159,9.527675
6TYS_C_D,EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYDMSWVRQTPEKRLEWVAMISSGGSYSYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARQGDYAWFAYWGQGTLVTVSS,DIQMTQSPASQSASLGESVTITCLASQTIGTWLAWYQQKPGKSPQLLIYAATSLADGVPSRFSGSGSGTKFSFKISSLQAEDFVSYYCQQFYSTPFTFGGGTKLEIK,6TYS_C,6TYS_D,A Potent Cross-Neutralizing Antibody Targeting The Fusion Glycoprotein Inhibits Nipah Virus And Hendra Virus Infection,A Potent Cross-Neutralizing Antibody Targeting The Fusion Glycoprotein Inhibits Nipah Virus And Hendra Virus Infection,Mus musculus,"Dang,H.V.;Chan,Y.P.;Park,Y.J.;Snijder,J.;Da Silva,S.C.;Vu,B.;Yan,L.;Feng,Y.R.;Rockx,B.;Geisbert,T.W.;Mire,C.E.;Broder,C.C.;Veesler,D.",An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections,09-AUG-2019,8_8_11_6_3_9,6TYS_C_D,Xtal structure,Hendra,3,1,17.987556,7.223889
6PE8_H_L,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,6PE8_H,6PE8_L,Crystal Structure Of Cd40/Abbv-323 Fab Complex,Crystal Structure Of Cd40/Abbv-323 Fab Complex,Homo sapiens,"Argiriadi,M.A.;Benatuil,L.;Dubrovska,I.;Egan,D.A.;Gao,L.;Greischar,A.;Hardman,J.;Harlan,J.;Iyer,R.B.;Judge,R.A.;Lake,M.;Perron,D.C.;Sadhukhan,R.;Sielaff,B.;Sousa,S.;Wang,R.;McRae,B.L.",CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches,20-JUN-2019,8_8_9_12_3_9,QBE00805_QBE00797,Xtal structure,TNFRSF5; p50; Bp50; CD40,3,1,15.351292,9.710135
AEB61477,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSFRRLGTNKSNWGQGTLVTVSS,SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVFGGGTKLTVL,AEB61477_H,AEB61477_L,"anti-interleukin-18 single-chain Fv antibody, partial [synthetic construct]","anti-interleukin-18 single-chain Fv antibody, partial [synthetic construct]",synthetic construct,"Vikhrova,M.A.; Shveygert,M.V.; Khrapov,E.A.; Filipenko,M.L.; Gileva,I.P.; Morozova,V.V.; Tikunova,N.V.",Selection of naturally occurring autoantibodies to interleukin-18 from phage display library,25-JUL-2016,8_8_13_6_3_10,AEB61477,Same entry,interleukin-18,3,1,15.6962185,9.466392
8DPL_F_G,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMNWVRQAPGKGLEWVGRIKSKTDGGAADYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYFCTTVYRYNYDSVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVYWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSFDSSLRDSWVFGGGTKLTVL,8DPL_F,8DPL_G,Structure Of Ebov Gp Lacking The Mucin-Like Domain With 2.1.1D5 Scfv And 6D6 Scfv Bound,Structure Of Ebov Gp Lacking The Mucin-Like Domain With 2.1.1D5 Scfv And 6D6 Scfv Bound,"Ebola virus - Mayinga, Zaire, 1976","Yu,X.;Saphire,E.O.",The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus,19-JUL-2023,8_10_11_9_3_12,8DPL_F_G,Xtal structure,Ebola,3,1,12.986098,8.482793
7TJQ_I_M,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISASSSYSDYADSAKGRFTISRDNAKTSLFLQMNSLRAEDTAIYFCARARATGYSSITPYFDIWGQGTLVTVSS,VVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSASKSGTSASLAITGLQAEDEADYYCQSYDRSLSGVFGTGTKVTVL,7TJQ_I,7TJQ_M,San27-14 Bound To A Antigenic Site V On Prefusion-Stabilized Hmpv F,San27-14 Bound To A Antigenic Site V On Prefusion-Stabilized Hmpv F,Homo sapiens,"Rush,S.A.;Brar,G.;Hsieh,C.L.;Chautard,E.;Rainho-Tomko,J.N.;Slade,C.D.;Bricault,C.A.;Kume,A.;Kearns,J.;Groppo,R.;Mundle,S.T.;Zhang,L.;Casimiro,D.;Fu,T.M.;DiNapoli,J.M.;McLellan,J.S.",Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus,14-SEP-2022,8_8_17_9_3_10,7TJQ_I_M,Xtal structure,Antigenic,3,1,16.169147,10.106542
QYB25430_QYB25499,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSGSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYFCARVVPHYYDSSGYYPGAFDIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYYNWPPWTFGQGTKVDIK,QYB25430,QYB25499,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_8_20_6_3_10,QYB25430_QYB25499,Unique source,SARS-CoV-2,3,1,16.284409,10.208378
5U68_F_F,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARARATGYNSITPYFDIWGQGTLVTVSS,QSVVTQTPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSASKSGTSASLAITGLQAEDEADYYCQSYDRSLSGVFGTGTKVTVL,5U68_F,5U68_F,Structural Basis For Antibody Cross-Neutralization Of Respiratory Syncytial Virus And Human Metapneumovirus,Structural Basis For Antibody Cross-Neutralization Of Respiratory Syncytial Virus And Human Metapneumovirus,Homo sapiens,"Wen,X.;Mousa,J.J.;Bates,J.T.;Lamb,R.A.;Crowe JE,Jr.;Jardetzky,T.S.",Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus,07-DEC-2016,8_8_17_9_3_10,5U68_F_F,Xtal structure,,3,1,16.176289,10.079791
QDJ57948_QDJ57984,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSSISRSTPYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLWSPDSNYYDQSAFDIWGQGTMVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSNYASWYQQKPGQAPLLVIYGKNYRPSGIPDRFSGSYSGNTASLTISGAQAEDEADYYCNSRDSSGDHPVVFGGGTNLTVL,QDJ57948,QDJ57984,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cassotta,A.; Mikol,V.; Bertrand,T.; Pouzieux,S.; Le Parc,J.; Ferrari,P.; Dumas,J.; Auer,M.; Deisenhammer,F.; Gastaldi,M.; Franciotta,D.; Silacci-Fregni,C.; Fernandez Rodriguez,B.; Giachetto-Sasselli,I.; Foglierini,M.; Jarrossay,D.; Geiger,R.; Sallusto,F.; Lanzavecchia,A.; Piccoli,L.",A single T cell epitope drives the neutralizing anti-idiotypic antibody response to natalizumab in patients with multiple sclerosis,14-JUL-2019,8_8_19_6_3_12,QDJ57948_QDJ57984,Unique source,,3,1,16.287363,10.115457
QKK35484_QKK35485,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISSDGYNTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAVAGTGFEYWGQGTLVTVSS,QPVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYVFGTGTKVTVL,QKK35484,QKK35485,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Direct Submission,29-JUN-2021,8_8_17_9_3_12,QKK35484_QKK35485,Unique source,SARS-CoV-2,3,1,16.072035,9.924229
8C7V_A_B,EVQLVESGGGLVKPGGSLRLSCAASGYTFTDNYIHWVRQAPGKGLEWIGYINPSSAYAHYNEKFKTRFTISVDKAKNSAYLQMNSLRAEDTAVYYCTRRYYSAMPFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDIYSGLAWYQQKPGKVPKLLIYDSSTLHTGVPSRFSGTGSGTDYTLTISSLQPEDVATYFCQQNYDFPLTFGQGTKLEIK,8C7V_A,8C7V_B,Phage Display Derived Serum Albumin Binding Knob Domain Engineered Within A Novel Vh Framework 3 Bispecific Antibody Format,Phage Display Derived Serum Albumin Binding Knob Domain Engineered Within A Novel Vh Framework 3 Bispecific Antibody Format,Cricetulus griseus,"Adams,R.;Joyce,C.;Kuravskiy,M.;Harrison,K.;Ahdash,Z.;Balmforth,M.;Chia,K.;Marceddu,C.;Coates,M.;Snowden,J.;Goursaud,E.;M&#xe9;nochet,K.;van den Elsen,J.;Payne,R.J.;Lawson,A.D.G.;Scott-Tucker,A.;Macpherson,A.",Serum albumin binding knob domains engineered within a V<sub>H</sub> framework III bispecific antibody format and as chimeric peptides,07-JUN-2023,8_8_12_6_3_9,UCY50159,Xtal structure,,3,1,10.787692,10.479732
6VPX_M_O,EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTV,YELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVL,6VPX_M,6VPX_O,Nanodisc Of Full-Length Hiv-1 Envelope Glycoprotein Clone Amc011 In Complex With One Pgt151 Fab And Three 10E8 Fabs,Nanodisc Of Full-Length Hiv-1 Envelope Glycoprotein Clone Amc011 In Complex With One Pgt151 Fab And Three 10E8 Fabs,Homo sapiens,"Rantalainen,K.;Berndsen,Z.T.;Antanasijevic,A.;Schiffner,T.;Zhang,X.;Lee,W.H.;Torres,J.L.;Zhang,L.;Irimia,A.;Copps,J.;Zhou,K.H.;Kwon,Y.D.;Law,W.H.;Schramm,C.A.;Verardi,R.;Krebs,S.J.;Kwong,P.D.;Doria-Rose,N.A.;Wilson,I.A.;Zwick,M.B.;Yates JR,3r.;Schief,W.R.;Ward,A.B.",HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies,04-FEB-2020,8_10_22_6_3_12,6VPX_M_O,Xtal structure,HIV,3,1,12.655128,8.858927
ASP69778_ASP69816,EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSS,EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRLGQSPRLLIYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFTFGPGTRVDLK,ASP69778,ASP69816,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Landais,E.; Murrell,B.; Briney,B.; Murrell,S.; Rantalainen,K.; Berndsen,Z.T.; Ramos,A.; Wickramasinghe,L.; Smith,M.L.; Eren,K.; de Val,N.; Wu,M.; Cappelletti,A.; Umotoy,J.; Lie,Y.; Wrin,T.; Algate,P.; Chan-Hui,P.Y.; Karita,E.; Ward,A.B.; Wilson,I.A.; Burton,D.R.; Smith,D.; Pond,S.L.K.; Poignard,P.",HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage,29-NOV-2017,8_10_25_7_3_8,ASP69778_ASP69816,Unique source,HIV,3,1,12.931042,8.461015
UYI35991_UYI36340,EVQLVESGGGLVLPGGSLRLSCVASGLSFDNSWMTWVRQAPGRGLEWVARIKRKFDGETADYVASVNGRFNISRDDSQNVVFLEMNRLKSEDTAVYYCTTAHSGGWQDYVDSWGQGVLVTVSS,SSELTQPASVSVSPGQTAKITCSGSLLTFSYSHWYQQKPGQAPLLLIYKDTVRASGIPERFSGSSSGTTVTLTISGVQTEDEADYYCFSGDDSKDVFGGGTKLTVL,UYI35991,UYI36340,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,8_10_14_6_3_9,UYI35991_UYI36340,Unique source,COVID,3,1,12.910894,8.425033
USW88753_USW88661,EVQLVESGGGLVQPGGSLRLSCAASEITVSRNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSRNTLYLQMNSLRADDTAVYYCARDYGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSETDFTLTISRLEPEDFAVYFCQQYGSSPRTFGQGTKLEIK,USW88753,USW88661,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kumar,S.; Patel,A.; Lai,L.; Chakravarthy,C.; Valanparambil,R.; Davis-Gardner,M.E.; Edara,V.V.; Linderman,S.; Reddy,E.S.; Gottimukkala,K.; Nayak,K.; Dixit,K.; Sharma,P.; Bajpai,P.; Singh,V.; Frank,F.; Cheedarla,N.; Verkerke,H.P.; Neish,A.S.; Roback,J.D.; Mantus,G.; Goel,P.K.; Rahi,M.; Davis,C.W.; Wrammert,J.; Suthar,M.S.; Ahmed,R.; Ortlund,E.; Sharma,A.; Murali-Krishna,K.; Chandele,A.",Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody,06-JUL-2022,8_7_11_6_3_9,USW88753_USW88661,Unique source,SARS-CoV-2; RBD,3,1,12.704919,10.200484
7NC0_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYDMSWVRQAPGKGLEWVATISSGGSYTYYLDSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCAPTTVVPFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVRTVVAWYQQKPGKAPKTLIYLASNRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCLQHWSYPLTFGQGTKVEIK,7NC0_H,7NC0_L,"The Structure Of The Humanised A33 Fab C226S Variant, An Immunotherapy Candidate For Colorectal Cancer","The Structure Of The Humanised A33 Fab C226S Variant, An Immunotherapy Candidate For Colorectal Cancer",Homo sapiens,"Tang,J.;Zhang,C.;Dalby,P.;Kozielski,F.","The structure of the humanised A33 Fab C226S variant, an immunotherapy candidate for colorectal cancer",28-JAN-2021,8_8_10_6_3_9,7NC0_H_L,Xtal structure,GPA33; A33,3,1,14.422529,9.364323
7NIW_C_B,EVQLVESGGGLVQPGGSLRLSCAASGFNLYSSYIHWVRQAPGKGLEWVAYISSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSFSINGSYSWWWDQAAYGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQGYSKLITFGQGTKVEIK,7NIW_C,7NIW_B,"Nanodisc Reconstituted Human Abcb4 In Complex With 4B1-Fab (Posaconazole-Bound, Inward-Open Conformation)","Nanodisc Reconstituted Human Abcb4 In Complex With 4B1-Fab (Posaconazole-Bound, Inward-Open Conformation)",Homo sapiens,"Nosol,K.;Bang-Sorensen,R.;Irobalieva,R.N.;Erramilli,S.K.;Stieger,B.;Kossiakoff,A.A.;Locher,K.P.",Structures of ABCB4 provide insight into phosphatidylcholine translocation,14-FEB-2021,8_8_23_6_3_9,7NIW_C_B,Xtal structure,ABCB4; MDR2; MDR3; PGY3; GBD1; PFIC-3,3,1,9.458233,10.956964
6KN9_F_F,EVQLVESGGGLVQPGGSLRLSCAASGFNLYYSSMHWVRQAPGKGLEWVASIYSSYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSSFSHGYGWYGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYGYHYAGLITFGQGTKVEIK,6KN9_F,6KN9_F,Crystal Structure Of Human Interleukin 18 Receptor Beta Extracellular Domain In Complex With An Antagonistic Scfv,Crystal Structure Of Human Interleukin 18 Receptor Beta Extracellular Domain In Complex With An Antagonistic Scfv,Homo sapiens,"Liu,S.;Miersch,S.;Li,P.;Bai,B.;Liu,C.;Qin,W.;Su,J.;Huang,H.;Pan,J.;Sidhu,S.S.;Wu,D.",A Synthetic Human Antibody Antagonizes IL-18Rbeta Signaling Through an Allosteric Mechanism,05-AUG-2019,8_8_16_6_3_12,6KN9_F_F,Xtal structure,,3,1,9.678049,10.774853
AIU96012_AIU96189,EVQLVESGGGLVQPGGSLRLSCAASGFNVSDNYMTWVRQAPGKGLEWVSVIYNDGRTYHLDSVRGRFTISRDKSKNTLYLQMNSLTAEDAAVYYCARDRRFC,QSVLTQPPSVSGAPGQRVTISCTGTNSNVGAGYYVHWYQQFPGRAPKLLIYADNIRSSGVPDRFSGYNSGNSASLVITGLQAEDEADYFCQSYDDTLSGSG,AIU96012,AIU96189,"immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Tan,Y.C.; Blum,L.K.; Kongpachith,S.; Ju,C.H.; Cai,X.; Lindstrom,T.M.; Sokolove,J.; Robinson,W.H.",High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination,03-NOV-2014,8_7_7_9_3_7,AIU96012_AIU96189,Unique source,,3,1,12.650522,10.309697
QWQ58065_QWQ58110,EVQLVESGGGLVQPGGSLRLSCAASGFSFSSFWMHWVRQVPGKGLLWVARINNDGTFTTYADSVKGRFTISRDNAKNTLNLHMSNLRVEDSALYFCVRDNDYGDYRGNAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDMSNYLNWYQQKSGKAPKLLIYDTSKLEAGVPSRFSGSGFGTHYVLSITSLQPEDIATYYCEQLHTFGGGTKVEIK,QWQ58065,QWQ58110,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Li,L.; Freyn,A.W.; Liu,S.T.H.; Stovicek,O.; Stamper,C.T.; Dugan,H.L.; Tepora,M.E.; Utset,H.A.; Bitar,D.J.; Hamel,N.J.; Changrob,S.; Zheng,N.Y.; Huang,M.; Krammer,F.; Nachbagauer,R.; Palese,P.; Ward,A.B.; Wilson,P.C.",First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes,19-JUN-2021,8_8_16_6_3_5,QWQ58065_QWQ58110,Unique source,hemagglutinin; H1N1,3,1,13.160107,9.978019
6VUN_B_B,EVQLVESGGGLVQPGGSLRLSCAASGFSLSTSGIGVTWVRQAPGKGLEWLATIWWDDDNRYADSVKGRFTISADTSKNTAYLQMNSLCAEDTAVYYCAQSAITSVTDSAMDHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSKFPWTFGQGTKVEIK,6VUN_B,6VUN_B,Reverse Transcriptase Diabody With R83C Mutation,Reverse Transcriptase Diabody With R83C Mutation,Homo sapiens,"Chesterman,C.;Arnold,E.",Co-crystallization with diabodies: A case study for the introduction of synthetic symmetry,16-FEB-2020,10_7_15_6_3_9,6VUN_B_B,Xtal structure,,3,1,9.952675,10.663647
6M3C_K_J,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYYLNWVRQAPGKGLEWVGDIRLKSNNYEKHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREGDYFDYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCKASESVDSFGATFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLTINPVEADDTANYYCQQNNEDPYTFGQGTKLEIK,6M3C_K,6M3C_J,Hapc-H1573 Fab Complex,Hapc-H1573 Fab Complex,Homo sapiens,"Zhao,X.Y.;Wilmen,A.;Wang,D.;Wang,X.;Bauzon,M.;Kim,J.Y.;Linden,L.;Li,L.;Egner,U.;Marquardt,T.;Moosmayer,D.;Tebbe,J.;Gluck,J.M.;Ellinger,P.;McLean,K.;Yuan,S.;Yegneswaran,S.;Jiang,X.;Evans,V.;Gu,J.M.;Schneider,D.;Zhu,Y.;Xu,Y.;Mallari,C.;Hesslein,A.;Wang,Y.;Schmidt,N.;Gutberlet,K.;Ruehl-Fehlert,C.;Freyberger,A.;Hermiston,T.;Patel,C.;Sim,D.;Mosnier,L.O.;Laux,V.",Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia,03-MAR-2020,8_10_9_10_3_9,6M3C_K_J,Xtal structure,,3,1,13.346857,8.283842
8EE8_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSDGMSWVRQAPGKGLEWVSYISSGGATTYYADSVKGRFTISRDNSKNTLSLQMNSLRGEDTAVYYCAKDITAPGRNGLDSWGQGVVVTVSS,QSVLTQPPSLSASPGASARLPCTLSSDLNVGTKNMYWYQQKPGSAPRLFLYYYSDSDKQLGPGVPNRVSGSKETSSNTAFLLISGLQPEDEADYYCQVYDNSARVFGGGTRLTVL,8EE8_H,8EE8_L,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz100-C In Complex With Zikv E Glycoprotein,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz100-C In Complex With Zikv E Glycoprotein,Macaca mulatta,"Sankhala,R.S.;Dussupt,V.;Donofrio,G.;Gromowski,G.D.;De La Barrera,R.A.;Larocca,R.A.;Mendez-Rivera,L.;Lee,A.;Choe,M.;Zaky,W.;Mantus,G.;Jensen,J.L.;Chen,W.H.;Gohain,N.;Bai,H.;McCracken,M.K.;Mason,R.D.;Leggat,D.;Slike,B.M.;Tran,U.;Jian,N.;Abbink,P.;Peterson,R.;Mendes,E.A.;Freitas de Oliveira Franca,R.;Calvet,G.A.;Bispo de Filippis,A.M.;McDermott,A.;Roederer,M.;Hernandez,M.;Albertus,A.;Davidson,E.;Doranz,B.J.;Rolland,M.;Robb,M.L.;Lynch,R.M.;Barouch,D.H.;Jarman,R.G.;Thomas,S.J.;Modjarrad,K.;Michael,N.L.;Krebs,S.J.;Joyce,M.G.",Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes,30-AUG-2023,8_8_14_9_7_9,8EE8_H_L,Xtal structure,Zika,3,1,14.136148,10.028853
6II8_J_K,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLLWFGELLFEGFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNVVFGGGTKLTVL,6II8_J,6II8_K,Crystal Structure Of H7 Hemagglutinin From A/Anhui/1/2013 In Complex With A Human Neutralizing Antibody L4B-18,Crystal Structure Of H7 Hemagglutinin From A/Anhui/1/2013 In Complex With A Human Neutralizing Antibody L4B-18,Homo sapiens,"Huang,K.A.;Rijal,P.;Jiang,H.;Wang,B.;Schimanski,L.;Dong,T.;Liu,Y.M.;Chang,P.;Iqbal,M.;Wang,M.C.;Chen,Z.;Song,R.;Huang,C.C.;Yang,J.H.;Qi,J.;Lin,T.Y.;Li,A.;Powell,T.J.;Jan,J.T.;Ma,C.;Gao,G.F.;Shi,Y.;Townsend,A.R.",Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans,03-OCT-2018,8_8_18_8_3_9,6II8_J_K,Xtal structure,,3,1,14.07072,10.156236
7S0D_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSYISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRWASGWLAFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQAYAYPLTFGQGTKVEIK,7S0D_H,7S0D_L,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody N-612-014,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody N-612-014,Homo sapiens,"Tanaka,S.;Anders Olson,C.;Barnes,C.O.;Higashide,W.;Gonzalez,M.;Taft,J.;Richardson,A.;Martin-Fernandez,M.;Bogunovic,D.;Gnanapragasam,P.N.;Bjorkman,P.J.;Spilman,P.;Niazi,K.;Rabizadeh,S.;Soon-Shiong,P.",Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display,30-AUG-2021,8_8_14_6_3_9,7S0D_H_L,Xtal structure,SARS-CoV-2,3,1,14.272641,10.00735
QKY76408_QKY76021,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDLHWVRQGTGKRLEWVSAIGTAGDTYYLGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARVLYDSSGFYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYEIPPWTFGQGTKVEIK,QKY76408,QKY76021,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_16_6_3_10,QKY76408_QKY76021,Unique source,SARS-CoV-2,3,1,16.40035,11.609295
7TN9_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK,7TN9_A,7TN9_B,Structure Of The Inmazeb Cocktail And Resistance To Escape Against Ebola Virus,Structure Of The Inmazeb Cocktail And Resistance To Escape Against Ebola Virus,Mus musculus,"Rayaprolu,V.;Fulton,B.O.;Rafique,A.;Arturo,E.;Williams,D.;Hariharan,C.;Callaway,H.;Parvate,A.;Schendel,S.L.;Parekh,D.;Hui,S.;Shaffer,K.;Pascal,K.E.;Wloga,E.;Giordano,S.;Negron,N.;Ni,M.;Copin,R.;Atwal,G.S.;Franklin,M.;Boytz,R.M.;Donahue,C.;Davey,R.;Baum,A.;Kyratsous,C.A.;Saphire,E.O.",Structure of the Inmazeb cocktail and resistance to Ebola virus escape,25-JAN-2023,8_7_12_12_3_9,QRJ96587_QRJ96591,Xtal structure,Ebola,3,1,16.40994,11.608759
5VZX_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,5VZX_H,5VZX_L,Crystal Structure Of Crenezumab Fab,Crystal Structure Of Crenezumab Fab,Homo sapiens,"Ultsch,M.;Li,B.;Maurer,T.;Mathieu,M.;Adolfsson,O.;Muhs,A.;Pfeifer,A.;Pihlgren,M.;Bainbridge,T.W.;Reichelt,M.;Ernst,J.A.;Eigenbrot,C.;Fuh,G.;Atwal,J.K.;Watts,R.J.;Wang,W.",Structure of Crenezumab Complex with Abeta Shows Loss of beta-Hairpin,29-MAY-2017,8_8_5_11_3_9,AOH00228_AOH00225,Xtal structure,Abeta,3,1,14.834659,9.2297
SZF07074_SZF07075,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK,SZF07074,SZF07075,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"MCGARVEY,O.; RATNASWAMY,G.; SUN,Y.; VAN,S.M.R.",PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF,21-OCT-2021,8_8_10_6_3_9,SZF07074_SZF07075,Unique chain,191P4D12,3,1,15.6896715,9.954579
7PR0_C_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPGGITAAGTSVLFGYYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPITWTFGQGTKVDIK,7PR0_C,7PR0_B,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Fd-5D Fab,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Fd-5D Fab,Homo sapiens,"Huang,K.A.;Zhou,D.;Tan,T.K.;Chen,C.;Duyvesteyn,H.M.;Zhao,Y.;Ginn,H.M.;Qin,L.;Rijal,P.;Schimanski,L.;Donat,R.;Harding,A.;Gilbert-Jaramillo,J.;James,W.;Tree,J.A.;Buttigieg,K.;Carroll,M.;Charlton,S.;Lien,C.E.;Lin,M.Y.;Chen,C.P.;Cheng,S.H.;Chen,X.;Lin,T.Y.;Fry,E.E.;Ren,J.;Ma,C.;Townsend,A.R.;Stuart,D.I.",Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2,20-SEP-2021,8_8_22_11_3_11,7PR0_C_B,Xtal structure,RBD; SARS-CoV-2,3,1,15.760081,9.992077
8GHO_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLEWIGEIKPSNELTNVHEKFKDRFTISVDKAKNSAYLQMNSLRAEDTAVYYCTRTITTTEGYWFFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASESVDYYGSSLLQWYQQKPGKAPKLLIYAASKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTRKAYTFGQGTKLEIK,8GHO_A,8GHO_B,Gucy2C-Peptide Bound To Anti-Gucy2C-Scfv Antibody,Gucy2C-Peptide Bound To Anti-Gucy2C-Scfv Antibody,Homo sapiens,"Rampuria,P.;Mosyak,L.;Root,A.R.;Svenson,K.;Agostino,M.J.;LaVallie,E.R.",Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3,30-AUG-2023,8_8_15_10_3_8,8GHO_A_B,Xtal structure,GUC2C; STAR; GUCY2C,3,1,10.809611,10.409316
7DZY_O_P,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVANINQDGGEKYYVDSVRGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDPYDLYGDYGGTFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDFTLTISSLQSEDFALYYCQQYNNWWRTFGQGTKVEIN,7DZY_O,7DZY_P,Spike Protein From Sars-Cov2 With Fab Fragment Of Enhancing Antibody 2490,Spike Protein From Sars-Cov2 With Fab Fragment Of Enhancing Antibody 2490,Homo sapiens,"Liu,Y.;Soh,W.T.;Kishikawa,J.I.;Hirose,M.;Nakayama,E.E.;Li,S.;Sasai,M.;Suzuki,T.;Tada,A.;Arakawa,A.;Matsuoka,S.;Akamatsu,K.;Matsuda,M.;Ono,C.;Torii,S.;Kishida,K.;Jin,H.;Nakai,W.;Arase,N.;Nakagawa,A.;Matsumoto,M.;Nakazaki,Y.;Shindo,Y.;Kohyama,M.;Tomii,K.;Ohmura,K.;Ohshima,S.;Okamoto,T.;Yamamoto,M.;Nakagami,H.;Matsuura,Y.;Nakagawa,A.;Kato,T.;Okada,M.;Standley,D.M.;Shioda,T.;Arase,H.",An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies,26-JAN-2021,8_8_17_6_3_9,7DZY_O_P,Xtal structure,SARS-CoV-2,3,1,11.193,7.8403435
4Y5V_D_E,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKPDGSEKYYVDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCARVSRGGSYSDWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYIYVSWYQQHPGKAPKLMIYDVSRRPSGISDRFSGSKSGNTASLTISGLQAEDEADYYCNSYTTLSTWLFGGGTKVTVL,4Y5V_D,4Y5V_E,Diabody 305 Complex With Epor,Diabody 305 Complex With Epor,Homo sapiens,"Moraga,I.;Wernig,G.;Wilmes,S.;Gryshkova,V.;Richter,C.P.;Hong,W.J.;Sinha,R.;Guo,F.;Fabionar,H.;Wehrman,T.S.;Krutzik,P.;Demharter,S.;Plo,I.;Weissman,I.L.;Minary,P.;Majeti,R.;Constantinescu,S.N.;Piehler,J.;Garcia,K.C.",Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands,12-FEB-2015,8_8_11_9_3_10,4Y5V_D_E,Xtal structure,,3,1,11.197677,7.8341756
4ZFF_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQFLSSFGVAWYQQKPGKAPKLLIYGASSLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGLLSPLTFGQGTKVEIK,4ZFF_A,4ZFF_B,Dual-Acting Fab 5A12 In Complex With Vegf,Dual-Acting Fab 5A12 In Complex With Vegf,Homo sapiens,"Koenig,P.;Lee,C.V.;Sanowar,S.;Wu,P.;Stinson,J.;Harris,S.F.;Fuh,G.",Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration,21-APR-2015,8_8_13_7_3_9,4ZFF_A_B,Xtal structure,,3,1,10.148163,10.835094
7TN9_Q_R,EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK,7TN9_Q,7TN9_R,Structure Of The Inmazeb Cocktail And Resistance To Escape Against Ebola Virus,Structure Of The Inmazeb Cocktail And Resistance To Escape Against Ebola Virus,Mus musculus,"Rayaprolu,V.;Fulton,B.O.;Rafique,A.;Arturo,E.;Williams,D.;Hariharan,C.;Callaway,H.;Parvate,A.;Schendel,S.L.;Parekh,D.;Hui,S.;Shaffer,K.;Pascal,K.E.;Wloga,E.;Giordano,S.;Negron,N.;Ni,M.;Copin,R.;Atwal,G.S.;Franklin,M.;Boytz,R.M.;Donahue,C.;Davey,R.;Baum,A.;Kyratsous,C.A.;Saphire,E.O.",Structure of the Inmazeb cocktail and resistance to Ebola virus escape,25-JAN-2023,8_8_11_6_3_8,QRJ96608_QRJ96612,Xtal structure,Ebola,3,1,14.077755,9.638684
QJU69682_QJU69681,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,QJU69682,QJU69681,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Shi,R.; Yan,J.; Wang,Q.",A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus,23-MAY-2020,8_7_13_6_3_11,QJU69682_QJU69681,Unique source,SARS-CoV-2,3,1,12.789808,10.35998
6U8K_F_G,EVQLVESGGGLVQPGGSLRLSCAASGFYISYSSIHWVRQAPGKGLEWVASISPSSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSRYSRYRRGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSSSPYTFGQGTKVEIK,6U8K_F,6U8K_G,Crystal Structure Of Hepatitis C Virus Ires Junction Iiiabc In Complex With Fab Hcv3,Crystal Structure Of Hepatitis C Virus Ires Junction Iiiabc In Complex With Fab Hcv3,Homo sapiens,"Koirala,D.;Lewicka,A.;Koldobskaya,Y.;Huang,H.;Piccirilli,J.A.",Synthetic Antibody Binding to a Preorganized RNA Domain of Hepatitis C Virus Internal Ribosome Entry Site Inhibits Translation,05-SEP-2019,8_8_14_6_3_9,6U8K_F_G,Xtal structure,Hepatitis,3,1,9.732841,10.817041
QKY76366_QKY75979,EVQLVESGGGLVQPGGSLRLSCAASGLTVRSNYMTWVRQTPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDLVTYGLDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISNYLAWYQQKPGTAPNLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQLLNSHPLTFGQGTRLEIK,QKY76366,QKY75979,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_7_11_6_3_9,QKY76366_QKY75979,Unique source,SARS-CoV-2,3,1,12.535454,10.745987
ANY92042_ANY91414,EVQLVESGGGLVQPGGSLRLSCSASGFDVSNYAMHWVRQAPGKGLEYVSLISSNGFSTFYTDSVKGRFIISRDNSKNTLYLQMSSLRPEDTAVYYCVKAESHDFWSGYNWGQGTLVTVSS,DVVMTQSPVSLPVTLGQPASISCRSSQGLVYSDGNTYLSWFHQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKIRRVEAEDVGIYYCMQGSHWPPTFGQGTKVEIK,ANY92042,ANY91414,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_13_11_3_9,ANY92042_ANY91414,Unique source,Influenza,3,1,13.610519,9.975596
8G4M_D_E,EVQLVESGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAISGNGDSTYYADSVRGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVKQAAYCTRTSCYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQGVSSKLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHNWPYTFGQGTKLEIK,8G4M_D,8G4M_E,Vaccine-Elicited Human Antibody 2C06 In Complex With Hiv-1 Envelope Trimer Bg505 Ds-Sosip,Vaccine-Elicited Human Antibody 2C06 In Complex With Hiv-1 Envelope Trimer Bg505 Ds-Sosip,Homo sapiens,"Wang,S.;Matassoli,F.;Zhang,B.;Liu,T.;Shen,C.H.;Bylund,T.;Johnston,T.;Henry,A.R.;Teng,I.T.;Tripathi,P.;Becker,J.E.;Changela,A.;Chaudhary,R.;Cheng,C.;Gaudinski,M.;Gorman,J.;Harris,D.R.;Lee,M.;Morano,N.C.;Novik,L.;O'Dell,S.;Olia,A.S.;Parchment,D.K.;Rawi,R.;Roberts-Torres,J.;Stephens,T.;Tsybovsky,Y.;Wang,D.;Van Wazer,D.J.;Zhou,T.;Doria-Rose,N.A.;Koup,R.A.;Shapiro,L.;Douek,D.C.;McDermott,A.B.;Kwong,P.D.",HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide,12-JUL-2023,8_8_17_6_3_9,8G4M_D_E,Xtal structure,HIV,3,1,13.829426,10.169424
QKY76661_QKY76274,EVQLVESGGGLVQPGGSLRLSCVASGFTFSFYWMSWVRQAPGKGLEWVANIKQDGGEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLSGSSWDFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQRPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTGVFGTGTKVTVL,QKY76661,QKY76274,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_12_6_3_9,QKY76661_QKY76274,Unique source,SARS-CoV-2,3,1,11.115732,7.756344
QKY76464_QKY76077,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMNWVRQPPGKGLEWVSGISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAMYYCAKGRGAGYTSYMDVWGKGTTVTVSS,SYVLTQPPSVSVAPGKTARITCEGNNIGSKSVHWYQQKPGQAPVLVVYDDSGRPSGIPERFSGSNSGNTATLTISRVEAGDEADYFCQVWDSSSDHHVVFGGGTKLTVL,QKY76464,QKY76077,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_6_3_12,QKY76464_QKY76077,Unique source,SARS-CoV-2,3,1,13.148049,11.981177
3GIZ_H_L,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,3GIZ_H,3GIZ_L,Crystal Structure Of The Fab Fragment Of Anti-Cd20 Antibody Ofatumumab,Crystal Structure Of The Fab Fragment Of Anti-Cd20 Antibody Ofatumumab,Homo sapiens,"Du,J.;Yang,H.;Guo,Y.;Ding,J.",Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20,07-MAR-2009,8_8_15_6_3_9,QKO84302_QKO84293,Xtal structure,CD20; FMC7; MS4A1; Bp35; B1,3,1,13.1808815,11.94817
QQD86938_QQD86939,EVQLVESGGGLVQPGRSLRLSCTDSGFTFSEYALSWVRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTISRDDSKSVAYLQMNSLKTEDTAVYFCTGPRPYYDSSGYYPYYFDYWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGSRSDVGGYDYVSWYQQHPGRVPKLMIYDVTKRPSGVPDRFSGSRSGNTASLTISGLQADDEADYYCSSFAGSSTYVVFGGGTTLTVL,QQD86938,QQD86939,"anti-tuberculosis immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tuberculosis immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Freund,N.T.",Human Antibodies Targeting a Mycobacterium Transporter Protein Mediate Protection Against Tuberculosis,28-DEC-2020,8_10_19_9_3_11,QQD86938_QQD86939,Unique source,tuberculosis,3,1,13.260518,8.882187
8BBN_H_L,EVQLVESGGGLVQPGRSLRLSCVASGFTFEDYAMHWVRQVPGKGPEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMSSLRVEDTALYYCVKDRHYDSAGYLVNGFHIWGQGTMVTVSS,DIQLTQSPSSLSASVRDRVTITCRASQSIDTYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQTYSYPVTFGQGTKVDIK,8BBN_H,8BBN_L,Sars-Cov-2 Delta-Rbd Complexed With Ba.2-10 And Ey6A Fabs,Sars-Cov-2 Delta-Rbd Complexed With Ba.2-10 And Ey6A Fabs,Homo sapiens,"Dijokaite-Guraliuc,A.;Das,R.;Zhou,D.;Ginn,H.M.;Liu,C.;Duyvesteyn,H.M.E.;Huo,J.;Nutalai,R.;Supasa,P.;Selvaraj,M.;de Silva,T.I.;Plowright,M.;Newman,T.A.H.;Hornsby,H.;Mentzer,A.J.;Skelly,D.;Ritter,T.G.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;veName>OPTIC consortium</CollectiveName>,?.;Roemer,C.;Peacock,T.P.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Fry,E.E.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses,22-MAR-2023,8_8_18_6_3_9,8BBN_H_L,Xtal structure,SARS-CoV-2,3,1,13.118395,12.0243845
7UPD_B_E,EVQLVESGGGLVQPKGSLKLSCAASGFIFNTYAMHWVRQAPGKGLEWVARIRSKSSNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVREGGYYFDYWGQGTTLTVSA,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLHVSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPWPFGGGTKLEIK,7UPD_B,7UPD_E,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 2B12,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 2B12,Mus musculus,"Byrne,P.O.;McLellan,J.S.",Prefusion-stabilized Nipah virus fusion protein complexed with Fab 2B12,29-MAR-2023,8_10_10_12_3_9,7UPD_B_E,Xtal structure,,3,1,13.34411,7.7507043
CCM09772_CCM09771,EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKGLEWVARIRSKSNKYATHYADSVKDRFTISRDDSQTMLYLQMNNLKTEDTAMYYCVREGSYYDSSYGAMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYHQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLSVSSVEAEDAATYYCQQYNSHPMTFGGGTKLEIK,CCM09772,CCM09771,"immunoglobulin heavy chain variable region Elec-410, partial [Mus musculus]","immunoglobulin kappa chain variable region Elec-410, partial [Mus musculus]",Mus musculus,"Bourne,Y.; Renault,L.; Essono,S.; Mondielli,G.; Lamourette,P.; Boquet,D.; Grassi,J.; Marchot,P.",Experimental and theoretical structures of monoclonal antibodies that inhibit acetylcholinesterase by targeting the peripheral site and backdoor region,31-OCT-2012,8_10_16_5_3_9,CCM09772_CCM09771,Unique word,,3,1,13.343398,7.737762
7KR5_O_P,EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKGLEWVARIRTKSNNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRQKYGNYFDYWGQGTTLTVSS,DVVMTQSQKFMSTSVGDRVSVTCKASQNVGINVAWYQQKPGQSPKALINSASYRNSGVPDRFTGGGSGTDFTLTINNVQSEDLAEYFCQQCNSYPLTFGAGTKLELR,7KR5_O,7KR5_P,Cryo-Em Structure Of The Crac Channel Orai In An Open Conformation; H206A Gain-Of-Function Mutation In Complex With An Antibody,Cryo-Em Structure Of The Crac Channel Orai In An Open Conformation; H206A Gain-Of-Function Mutation In Complex With An Antibody,Mus musculus,"Hou,X.;Outhwaite,I.R.;Pedi,L.;Long,S.B.",Cryo-EM structure of the calcium release-activated calcium channel Orai in an open conformation,18-NOV-2020,8_10_11_6_3_9,7KR5_O_P,Xtal structure,,3,1,13.33521,7.7884007
UYI36070_UYI36300,EVQLVESGGGLVQSGGSLRLSCAASGFTFSTYGMSWVRQPPGRGLEWVSYISYGGDSTYYADSVKGRFTISRDNSKNTLSLQMNSLRPEDTAVYYCAKRGLGGTLYNWFDVWGPGVLVTVSS,ETVVTQEPSLSVSPGGTVTLTCGLRSGSVSTSNYPSWFQQTPGQAPRTLIYSTTTRPSGVPDRFSGSILGNKAALTITGTQADDESDYYCSLYIGSGIWVFGGGTRLTVL,UYI36070,UYI36300,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,8_8_15_9_3_10,UYI36070_UYI36300,Unique source,COVID,3,1,14.181056,9.766695
6AMJ_H_L,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYSWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK,6AMJ_H,6AMJ_L,Cat192 Fab Wild Type,Cat192 Fab Wild Type,Homo sapiens,"Lord,D.M.;Bird,J.J.;Honey,D.M.;Best,A.;Park,A.;Wei,R.R.;Qiu,H.",Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFbeta1 antibody,09-AUG-2017,8_8_16_6_3_9,QHZ37669_QHZ37673,Xtal structure,TGFbeta1,3,1,14.476373,13.805826
7YCK_C_D,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANGFGEYYYYAMDVWGQGTTVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQRRPGSAPTTVIYEDNQRPSGVPDRFSASIDSSSNSASLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL,7YCK_C,7YCK_D,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Fp-12A Fab,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Fp-12A Fab,Homo sapiens,"Huang,K.A.;Chen,X.;Mohapatra,A.;Nguyen,H.T.V.;Schimanski,L.;Tan,T.K.;Rijal,P.;Vester,S.K.;Hills,R.A.;Howarth,M.;Keeffe,J.R.;Cohen,A.A.;Kakutani,L.M.;Wu,Y.M.;Shahed-Al-Mahmud,M.;Chou,Y.C.;Bjorkman,P.J.;Townsend,A.R.;Ma,C.",Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2,01-FEB-2023,8_8_14_8_3_9,7YCK_C_D,Xtal structure,SARS-CoV-2,3,1,14.300357,13.8430395
8F0I_C_D,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDEGTMTTYFDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPWTFGQGTKVEIK,8F0I_C,8F0I_D,Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Human Antibody Cova309-22,Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Human Antibody Cova309-22,Homo sapiens; Severe acute respiratory syndrome coronavirus 2,"Yuan, M., Wilson, I.A.",Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Human Antibody Cova309-22,13-SEP-2023,8_8_13_6_3_10,8F0I_C_D,Xtal structure,,3,1,14.815722,13.439011
UDP68861_UDP68831,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPLGSNYFNYDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLEYSDGNTYLNWFQQRPGQSPRRLIYKVSKRDSGVPDRFSGSGSGSDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,UDP68861,UDP68831,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Dussupt,V.; Townsley,S.; Donofrio,G.",Direct Submission,03-NOV-2021,8_8_17_11_3_9,UDP68861_UDP68831,Unique source,,3,1,14.669584,13.723954
ASY01751_ASY01817,EVQLVESGGGVVRPGESLRLSCEVSGVNINDYDMSWVRQFLGKGLEWVSGIDRKGVGTGYADSVKGRFTISRDHAKNSLYLQMNSLRGEDTALYYCVRDPGDTSGRGHIFNVWGQGTMVTVSL,DIQMTQSPSTLSASIGDRVTITCRASQIIDRSLAWYQQKPGKSPKALIYKASNLEGGVPSRFSGSGSGTDFTLTVSSLQPDDFANYYCQQYDTYPFTFGPGTTVTLR,ASY01751,ASY01817,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Pieper,K.; Tan,J.; Piccoli,L.; Foglierini,M.; Barbieri,S.; Chen,Y.; Silacci-Fregni,C.; Wolf,T.; Jarrossay,D.; Anderle,M.; Abdi,A.; Ndungu,F.M.; Doumbo,O.K.; Traore,B.; Tran,T.M.; Jongo,S.; Zenklusen,I.; Crompton,P.D.; Daubenberger,C.; Bull,P.C.; Sallusto,F.; Lanzavecchia,A.",Public antibodies to malaria antigens generated by two LAIR1 insertion modalities,12-SEP-2017,8_8_16_6_3_9,ASY01751_ASY01817,Unique source,LAIR-1; CD305; LAIR1,3,1,13.187202,11.690141
QKY76525_QKY76138,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSAINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARRRSSSRYSSGWYMYYYYMDVWGKGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSVSTWLAWYQQKPGKAPNLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYSGTFGQGTKVEIK,QKY76525,QKY76138,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_22_6_3_9,QKY76525_QKY76138,Unique source,SARS-CoV-2,3,1,13.293806,11.774209
7XIC_K_L,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARVGYCGGDCYSLSLAGFPDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSYNLAWYQQKPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPYTFGQGTKLEIK,7XIC_K,7XIC_L,S-Ecd (Omicron) In Complex With Sts165,S-Ecd (Omicron) In Complex With Sts165,Homo sapiens,"Li,Y.;Fan,Q.;Zhou,B.;Shen,Y.;Zhang,Y.;Cheng,L.;Qi,F.;Song,S.;Guo,Y.;Yan,R.;Ju,B.;Zhang,Z.",Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants,12-APR-2022,8_8_21_6_3_10,7XIC_K_L,Xtal structure,SARS-CoV-2,3,1,13.280544,11.778119
7LEY_D_E,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYGMTWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARDRRRGSYGSDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPQLLISAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPRTFGQGTKVEIK,7LEY_D,7LEY_E,Trimeric Human Arginase 1 In Complex With Mab5,Trimeric Human Arginase 1 In Complex With Mab5,Homo sapiens,"Palte,R.L.;Juan,V.;Gomez-Llorente,Y.;Bailly,M.A.;Chakravarthy,K.;Chen,X.;Cipriano,D.;Fayadat-Dilman,L.;Gathiaka,S.;Greb,H.;Hall,B.;Handa,M.;Hsieh,M.;Kofman,E.;Lin,H.;Miller,J.R.;Nguyen,N.;O'Neil,J.;Shaheen,H.;Sterner,E.;Strickland,C.;Sun,A.;Taremi,S.;Scapin,G.",Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action,15-JAN-2021,8_8_16_6_3_9,7LEY_D_E,Xtal structure,,3,1,13.347374,11.726917
ANV21742_ANV21931,EVQLVESGGGWVQPGGSLRLSCAASGFSFSSYEMNWVRQAPGKGLEWISYISSSDTTTYYADSVKGRFTISRDNAQKSLYLQMNSLRAEDTAVYYCAREYHDFSSGYPDALDIWGQGTLVTVSS,QFVLTQSPSASGTPGQRVTISCSGSRSNIGSNTVYWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAVSGLRFDDEADYYCAAWDDSVNGHVFGTGTKVTVL,ANV21742,ANV21931,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_17_8_3_11,ANV21742_ANV21931,Unique source,,3,1,15.700476,9.970007
QFZ93618_QFZ93622,EVQLVESGGRVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEFVSGLNWNGDITAFTDSVKGRFTISRDNAKSSLYLQMNSLRADDTAFYYCARVRTWGEYTTREEPIHSWYFDLWGRGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQDISSFLAWYQQKPGNAPKVLIYAASLLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPLFTFGPGTKVDIK,QFZ93618,QFZ93622,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Stadlbauer,D.; Zhu,X.; McMahon,M.; Turner,J.S.; Wohlbold,T.J.; Schmitz,A.J.; Strohmeier,S.; Yu,W.; Nachbagauer,R.; Mudd,P.A.; Wilson,I.A.; Ellebedy,A.H.; Krammer,F.",Broadly protective human antibodies that target the active site of influenza virus neuraminidase,09-NOV-2019,8_8_23_6_3_10,QFZ93618_QFZ93622,Unique source,neuraminidase,3,1,13.273482,11.806313
AAW68481_AAW68903,EVQLVESGPELKKPGASVRISCKASEKCDIHWVRQAPGQGLEWMGWISADDGGTTTALNLRGRVSMTTDRATNTVYMELKSLRSGDTAIYFCARDFYSGTYRSFDYWGQGTLVTV,DVVMTQSPSSLSASLGDRVSITCRASQHISNYINWYQQKPGKAPKLLIYAASTLQSGVPSRFTGSGSGADYTLTITSLQPEDFATYYCQQSYGTSWTFGQGTTVEIK,AAW68481,AAW68903,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,4_8_14_6_3_9,AAW68481_AAW68903,Unique source,tetanus,3,1,1.5170035,5.4294615
7ZF5_D_F,EVQLVESGPEVKKPGTSVKVSCKASGFSFSMSAMQWVRRARGQRLEWIGWIVPGSGNANYAQKFQERVTITRDESTNTGYMELSSLRSEDTAVYYCAAPHCNKTNCYDAFDIWGQGTMVTVSS,AIRMTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFILTINRLEPEDLAVYYCQQFGSSPWTFGQGTKVDIK,7ZF5_D,7ZF5_F,Sars-Cov-2 Omicron Rbd In Complex With Omi-12 And Beta-54 Fabs,Sars-Cov-2 Omicron Rbd In Complex With Omi-12 And Beta-54 Fabs,Homo sapiens,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,01-APR-2022,8_8_16_7_3_9,7ZF5_D_F,Xtal structure,,3,1,-1.0008937,2.9833686
7KDE_H_L,EVQLVESGPGLVKASETLSLTCTVSGYNIRSNNWWSWVRQPPGKGLEWIGGVYANSEITNYNSSLKSRVSISQDAWRNKFSLKLKSVTDADTAVYYCVRGPNHWEYFDSGNNEYFEFWGQGALVTVSS,QSALTQPPSVSGAPGQRVTISCTGTSSNIENYHAFWYQQFSGMAPKLLIRDNDKRPSGVSDRFSGSKSGASASLTITGLQTDDEADYYCQSYDSGLRSYIFASGTRLTVL,7KDE_H,7KDE_L,Bg505 Sosip.664 In Complex With The V3-Targeting Rhesus Macaque Antibody 1485 And Human Gp120-Gp41 Interface Antibody 8Anc195,Bg505 Sosip.664 In Complex With The V3-Targeting Rhesus Macaque Antibody 1485 And Human Gp120-Gp41 Interface Antibody 8Anc195,Homo sapiens,"Wang,Z.;Barnes,C.O.;Gautam,R.;Cetrulo Lorenzi,J.C.;Mayer,C.T.;Oliveira,T.Y.;Ramos,V.;Cipolla,M.;Gordon,K.M.;Gristick,H.B.;West,A.P.;Nishimura,Y.;Raina,H.;Seaman,M.S.;Gazumyan,A.;Martin,M.;Bjorkman,P.J.;Nussenzweig,M.C.;Escolano,A.",A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch,08-OCT-2020,9_8_20_8_3_11,7KDE_H_L,Xtal structure,HIV,3,1,15.803885,-7.478266
6ORO_D_E,EVQLVETGGGLVQPGGSLKLSCAASGFTFSSYGMNWVRQAPGKGLEWVSGINSGGGTKYYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCAKSPWGQSTSFEYFEFWGQGALVTVSS,QTVVTQPRSVSVSQGQTARITCGGDNIGSEAVQWYQQKPAQAPVLVIYDDSERPSGIPDRFSGSKSGNTATLTISGVEAGDEADYYCQVWDSSSDHPLFGGGTRLTVL,6ORO_D,6ORO_E,Modified Bg505 Sosip-Based Immunogen Rc1 In Complex With The Elicited V3-Glycan Patch Antibody Ab874Nhp,Modified Bg505 Sosip-Based Immunogen Rc1 In Complex With The Elicited V3-Glycan Patch Antibody Ab874Nhp,Macaca mulatta,"Escolano,A.;Gristick,H.B.;Abernathy,M.E.;Merkenschlager,J.;Gautam,R.;Oliveira,T.Y.;Pai,J.;West AP,Jr.;Barnes,C.O.;Cohen,A.A.;Wang,H.;Golijanin,J.;Yost,D.;Keeffe,J.R.;Wang,Z.;Zhao,P.;Yao,K.H.;Bauer,J.;Nogueira,L.;Gao,H.;Voll,A.V.;Montefiori,D.C.;Seaman,M.S.;Gazumyan,A.;Silva,M.;McGuire,A.T.;Stamatatos,L.;Irvine,D.J.;Wells,L.;Martin,M.A.;Bjorkman,P.J.;Nussenzweig,M.C.",Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques,30-APR-2019,8_8_16_6_3_11,6ORO_D_E,Xtal structure,HIV,3,1,14.209056,9.7725935
5O14_C_D,EVQLVQSGAELKKPGESLKISCKASGYTFTNYWVVWVRQMPGEGLEWMGSIHPRDSDARYSLSFEGRVTFSVDKSTTTAYLQWSSLKVSDSAIYYCARLSQVSGWSPWVGPWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISVSLNWYQQKPGKAPKVLIYAASRLQSGIPSRFSGSGSGSHFTLTISSLQPEDFATYYCQETYSDLMYTFGQGTKVEIK,5O14_C,5O14_D,Co-Crystal Structure Of A Cross-Reactive Bactericidal Human Antibody Targeting Meningococcal Vaccine Antigen Factor H Binding Protein,Co-Crystal Structure Of A Cross-Reactive Bactericidal Human Antibody Targeting Meningococcal Vaccine Antigen Factor H Binding Protein,Homo sapiens,"Lopez-Sagaseta,J.;Beernink,P.T.;Bianchi,F.;Santini,L.;Frigimelica,E.;Lucas,A.H.;Pizza,M.;Bottomley,M.J.",Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp,18-MAY-2017,8_8_15_6_3_10,5O14_C_D,Xtal structure,meningococcal,3,1,-12.441369,5.701504
1T04_B_A,EVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK,1T04_B,1T04_A,Three Dimensional Structure Of A Humanized Anti-Ifn-Gamma Fab In C2 Space Group,Three Dimensional Structure Of A Humanized Anti-Ifn-Gamma Fab In C2 Space Group,Homo sapiens,"Bourne,P.C.;Terzyan,S.S.;Cloud,G.;Landolfi,N.F.;Vasquez,M.;Edmundson,A.B.",Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms,07-APR-2004,8_8_10_6_3_9,1T04_B_A,Xtal structure,IFNA@; IFN; IFNA13; IFN-ALPHA; IFNA1; IFL; IFN-alphaD,3,1,0.7390202,3.786724
8SAU_C_D,EVQLVQSGAEMKNPGASVKVSCAASGYGFTDFYIHWVRLAPGHGLQWMGWMNPKTGRTNNAQDFQGRVTLTRDTSIGTAYMELRRLTSDDTAVYYCVTGGWISPYYDSSYYPNFDHWGQGTLITVS,QSALTQPASVSGSPGQSITISCTGTSYDVAKFDLVSWFQQHPGKAPKYMIYEVNKWPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCCSFGGSATVVCGGGTKVTVL,8SAU_C,8SAU_D,Cryoem Structure Of Dh270.4-Ch848.10.17,Cryoem Structure Of Dh270.4-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,08-JAN-2009,8_8_20_9_3_10,8SAU_C_D,Xtal structure,HIV,3,1,2.9316113,2.668775
8CIM_D_E,EVQLVQSGAEVKEPGSSVKVSCKASGGSFSTSGISWVRQAPGQGLEWMGVIIPIQGTGNYAQKFQGRVTITADESTTTVYMELSSLRSDDTALYYCARDQHIYDSSGHGGLWFDPWGQGTLVTVSS,AIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKVLIYGASSLHSGVPSRFSGSGSGTDFTLTISRLQPEDFATYYCQQSHSSPRSFGGGTKVEIK,8CIM_D,8CIM_E,Ba.2-07 Fab In Complex With Sars-Cov-2 Ba.2.12.1 Spike Glycoprotein,Ba.2-07 Fab In Complex With Sars-Cov-2 Ba.2.12.1 Spike Glycoprotein,Homo sapiens,"Duyvesteyn,H.M.E.;Screaton,G.;Ren,J.;Stuart,D.I.;Fry,E.E.",Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2,05-JUL-2023,8_8_19_6_3_9,8CIM_D_E,Xtal structure,RBD; SARS-CoV-2,3,1,-0.7369991,5.8190856
7SJN_D_E,EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTV,DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK,7SJN_D,7SJN_E,Htra1:Fab15H6.V4 Complex,Htra1:Fab15H6.V4 Complex,Homo sapiens,"Gerhardy,S.;Ultsch,M.;Tang,W.;Green,E.;Holden,J.K.;Li,W.;Estevez,A.;Arthur,C.;Tom,I.;Rohou,A.;Kirchhofer,D.",Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration,07-SEP-2022,8_8_12_5_3_9,7SJN_D_E,Xtal structure,ARMD7; HTRA1; IGFBP5-protease; HtrA; PRSS11,3,1,0.9494295,3.681139
7PS3_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSITTGYMELSSLRSDDTALYYCARVGAHDYYDSSDNWFDPWGQGTLVTVFS,DIQMTQSPSSVSASVGDRLTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,7PS3_H,7PS3_L,Crystal Structure Of Antibody Beta-32 Fab,Crystal Structure Of Antibody Beta-32 Fab,Homo sapiens,"Liu,C.;Zhou,D.;Nutalai,R.;Duyvesteyn,H.M.;Tuekprakhon,A.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Mentzer,A.J.;Wang,B.;Case,J.B.;Zhao,Y.;Skelly,D.T.;Chen,R.E.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Malik,T.;Temperton,N.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Clare,D.K.;Howe,A.;Goulder,P.J.;Fry,E.E.;Diamond,M.S.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants,22-SEP-2021,8_8_18_6_3_9,7PS3_H_L,Xtal structure,SARS-CoV-2,3,1,2.404708,3.3095098
5NH3_I_M,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,5NH3_I,5NH3_M,Crystal Structure Of The Activin Receptor Type-2A Ligand Binding Domain In Complex With Bimagrumab Fv,Crystal Structure Of The Activin Receptor Type-2A Ligand Binding Domain In Complex With Bimagrumab Fv,Homo sapiens,"Morvan,F.;Rondeau,J.M.;Zou,C.;Minetti,G.;Scheufler,C.;Scharenberg,M.;Jacobi,C.;Brebbia,P.;Ritter,V.;Toussaint,G.;Koelbing,C.;Leber,X.;Schilb,A.;Witte,F.;Lehmann,S.;Koch,E.;Geisse,S.;Glass,D.J.;Lach-Trifilieff,E.",Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy,21-MAR-2017,8_8_8_9_3_11,5NH3_I_M,Xtal structure,INHBE; MGC4638; ActRIIA; activin,3,1,1.8847135,3.9536204
3J70_M_N,EVQLVQSGAEVKKPGATVKISCKASGYTFSDFYMYWVRQAPGKGLEWMGLIDEDADTMYAEKFRGRVTITADTSTDTGYLELRSEDTAVYYCAADPWELNNVWGQGTLVSVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISTWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFSLTINSLQPEDFATYYCQQANSFFTFGGGTKVEIK,3J70_M,3J70_N,"Model Of Gp120, Including Variable Regions, In Complex With Cd4 And 17B","Model Of Gp120, Including Variable Regions, In Complex With Cd4 And 17B",Human immunodeficiency virus 1,"Rasheed,M.;Bettadapura,R.;Bajaj,C.",Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State,22-APR-2014,8_7_10_6_3_8,3J70_M_N,Xtal structure,HIV; CD4,3,1,1.0538955,3.0643935
5ANM_H_L,EVQLVQSGAEVKKPGATVKISCKVYGYIFTDYNIYWVRQAPGKGLEWMGLIDPDNGETFYAEKFQGRATMTADTSSDRAYMELSSLRFEDTAVYYCATVMGKWIKGGYDYWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNFNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSPTLTSPFGTGTKLTVL,5ANM_H,5ANM_L,Crystal Structure Of Ige Fc In Complex With A Neutralizing Antibody,Crystal Structure Of Ige Fc In Complex With A Neutralizing Antibody,Homo sapiens,"Cohen,E.S.;Dobson,C.L.;Kack,H.;Wang,B.;Sims,D.A.;Lloyd,C.O.;England,E.;Rees,D.G.;Guo,H.;Karagiannis,S.N.;O'Brien,S.;Persdotter,S.;Ekdahl,H.;Butler,R.;Keyes,F.;Oakley,S.;Carlsson,M.;Briend,E.;Wilkinson,T.;Anderson,I.K.;Monk,P.D.;von Wachenfeldt,K.;Eriksson,P.O.;Gould,H.J.;Vaughan,T.J.;May,R.D.",A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma,07-SEP-2015,8_8_14_9_3_11,5ANM_H_L,Xtal structure,,3,1,1.0565258,2.8688228
AAW80375,EVQLVQSGAEVKKPGDSLRISCKGSGYTFGGYWIAWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVSISADKSINTAYLQWSSLRASDTAMYYCARKGLRDVEWYDPREDVLDVWGQGTMVTVPS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGMPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYGSSPLTFGQGTKVETK,AAW80375_H,AAW80375_L,"anti AD-1 single chain antibody fragment, partial [synthetic construct]","anti AD-1 single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Barrios,Y.; Knor,S.; Lantto,J.; Mach,M.; Ohlin,M.",Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties,26-JUL-2016,8_8_20_6_3_9,AAW80375,Same entry,AD-1; cytomegalovirus,3,1,-12.41581,5.6214414
7LUC_N_O,EVQLVQSGAEVKKPGESLKISCKGSADSFTNHWIGWVRQTPGKGLEWMGMIYPGDSDTRYSPSFQGQVTLSVDKSVTTVYLQWNSLKASDTAIYYCARQVGGVVVAEPPPYYYYGMDAWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTLTCRASQSIATFLNWFQQRPGKAPKLLMFDASKLQTGVPSRFSGSGSGTHFTLTISTLQPEDFATYYCQQSYDLPLTFGPGTKVEIK,7LUC_N,7LUC_O,Cryo-Em Structure Of Rsv Pref Bound By Fabs 32.4K And 01.4B,Cryo-Em Structure Of Rsv Pref Bound By Fabs 32.4K And 01.4B,Homo sapiens,"Mukhamedova,M.;Wrapp,D.;Shen,C.H.;Gilman,M.S.;Ruckwardt,T.J.;Schramm,C.A.;Ault,L.;Chang,L.;Derrien-Colemyn,A.;Lucas,S.A.;Ransier,A.;Darko,S.;Phung,E.;Wang,L.;Zhang,Y.;Rush,S.A.;Madan,B.;Stewart-Jones,G.B.;Costner,P.J.;Holman,L.A.;Hickman,S.P.;Berkowitz,N.M.;Doria-Rose,N.A.;Morabito,K.M.;DeKosky,B.J.;Gaudinski,M.R.;Chen,G.L.;Crank,M.C.;Misasi,J.;Sullivan,N.J.;Douek,D.C.;Kwong,P.D.;Graham,B.S.;McLellan,J.S.;Mascola,J.R.",Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses,22-FEB-2021,8_8_22_6_3_9,7LUC_N_O,Xtal structure,,3,1,-12.528461,5.54571
7V2A_E_D,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRHMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISVDTSISTAYLQWSSLKASDTAMYYCTRHQYGYNYGYFYYYIDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNPVSWYRQVPGTAPKLLIYDNNKRPSGIPDRFSGSKSGASATLGITGLQTGDEADYYCGTWHTSLSSGVFGGGTKLTVL,7V2A_E,7V2A_D,Sars-Cov-2 Spike Trimer In Complex With Xg014 Fab,Sars-Cov-2 Spike Trimer In Complex With Xg014 Fab,Homo sapiens,"Liu,Z.;Xu,W.;Chen,Z.;Fu,W.;Zhan,W.;Gao,Y.;Zhou,J.;Zhou,Y.;Wu,J.;Wang,Q.;Zhang,X.;Hao,A.;Wu,W.;Zhang,Q.;Li,Y.;Fan,K.;Chen,R.;Jiang,Q.;Mayer,C.T.;Schoofs,T.;Xie,Y.;Jiang,S.;Wen,Y.;Yuan,Z.;Wang,K.;Lu,L.;Sun,L.;Wang,Q.",An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope,07-AUG-2021,8_8_18_8_3_11,7V2A_E_D,Xtal structure,CoV,3,1,-12.526239,5.538851
3ULU_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWVGWVRQMPGKGLEWMGFIDPSDSYTNYAPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARELYQGYMDTFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGLYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNTLSYTFGQGTKVEIK,3ULU_H,3ULU_L,Structure Of Quaternary Complex Of Human Tlr3Ecd With Three Fabs (Form1),Structure Of Quaternary Complex Of Human Tlr3Ecd With Three Fabs (Form1),Homo sapiens,"Luo,J.;Obmolova,G.;Malia,T.J.;Wu,S.J.;Duffy,K.E.;Marion,J.D.;Bell,J.K.;Ge,P.;Zhou,Z.H.;Teplyakov,A.;Zhao,Y.;Lamb,R.J.;Jordan,J.L.;San Mateo,L.R.;Sweet,R.W.;Gilliland,G.L.",Lateral Clustering of TLR3:dsRNA Signaling Units Revealed by TLR3ecd:3Fabs Quaternary Structure,11-NOV-2011,8_8_14_6_3_9,AOH98400_AOH98276,Xtal structure,TLR3; CD283,3,1,-12.265223,5.7604766
7R8M_H_L,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGVAVDWYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSALYVFGTGTKVTVL,7R8M_H,7R8M_L,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody C032,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody C032,Homo sapiens,"Muecksch,F.;Weisblum,Y.;Barnes,C.O.;Schmidt,F.;Schaefer-Babajew,D.;Lorenzi,J.C.;Flyak,A.I.;DeLaitsch,A.T.;Huey-Tubman,K.E.;Hou,S.;Schiffer,C.A.;Gaebler,C.;Wang,Z.;Da Silva,J.;Poston,D.;Finkin,S.;Cho,A.;Cipolla,M.;Oliveira,T.Y.;Millard,K.G.;Ramos,V.;Gazumyan,A.;Rutkowska,M.;Caskey,M.;Nussenzweig,M.C.;Bjorkman,P.J.;Hatziioannou,T.;Bieniasz,P.D.","Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies",26-JUN-2021,8_8_12_9_3_12,7R8M_H_L,Xtal structure,SARS-CoV-2,3,1,-12.46844,5.7630463
4RIR_A_B,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLGGRYYYDSSGYYYFDYWGQGTLVTVSS,MLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSSWVFGGGTKLTVL,4RIR_A,4RIR_B,Structural Analysis Of The Unmutated Ancestor Of The Hiv-1 Envelope V2 Region Antibody Ch58 Isolated From An Rv144 Hiv-1 Vaccine Efficacy Trial Vaccinee And Associated With Decreased Transmission Risk,Structural Analysis Of The Unmutated Ancestor Of The Hiv-1 Envelope V2 Region Antibody Ch58 Isolated From An Rv144 Hiv-1 Vaccine Efficacy Trial Vaccinee And Associated With Decreased Transmission Risk,Homo sapiens,"Nicely,N.I.;Wiehe,K.;Kepler,T.B.;Jaeger,F.H.;Dennison,S.M.;Rerks-Ngarm,S.;Nitayaphan,S.;Pitisuttithum,P.;Kaewkungwal,J.;Robb,M.L.;O'Connell,R.J.;Michael,N.L.;Kim,J.H.;Liao,H.X.;Munir Alam,S.;Hwang,K.K.;Bonsignori,M.;Haynes,B.F.",Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee,07-OCT-2014,8_8_19_8_3_9,4RIR_A_B,Xtal structure,HIV,3,1,-12.411061,5.6675014
7M6E_D_C,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARTQWGYNYGSHFFYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSDHVYWYQQLPGTAPKLFIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLSGYVFGTGTKVTVL,7M6E_D,7M6E_C,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg10-19","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, Bg10-19",Homo sapiens,"Scheid,J.F.;Barnes,C.O.;Eraslan,B.;Hudak,A.;Keeffe,J.R.;Cosimi,L.A.;Brown,E.M.;Muecksch,F.;Weisblum,Y.;Zhang,S.;Delorey,T.;Woolley,A.E.;Ghantous,F.;Park,S.M.;Phillips,D.;Tusi,B.;Huey-Tubman,K.E.;Cohen,A.A.;Gnanapragasam,P.N.;Rzasa,K.;Hatziioanno,T.;Durney,M.A.;Gu,X.;Tada,T.;Landau,N.R.;West AP,Jr.;Rozenblatt-Rosen,O.;Seaman,M.S.;Baden,L.R.;Graham,D.B.;Deguine,J.;Bieniasz,P.D.;Regev,A.;Hung,D.;Bjorkman,P.J.;Xavier,R.J.",B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV,25-MAR-2021,8_8_18_8_3_11,7M6E_D_C,Xtal structure,SARS-CoV-2; SARS; CoV,3,1,-12.484848,5.5745134
7XDL_K_J,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYYWIGWVRQMPGKGLEWMGIVYPDDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCVRHPGGGDWYFDLWGRGTLVTVS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYDSFSWTFGQGTKLE,7XDL_K,7XDL_J,Cryo-Em Structure Of Sars-Cov-2 Delta Spike Protein In Complex With Ba7208 And Ba7125 Fab,Cryo-Em Structure Of Sars-Cov-2 Delta Spike Protein In Complex With Ba7208 And Ba7125 Fab,Homo sapiens,"Wang,Y.;Yan,A.;Song,D.;Dong,C.;Rao,M.;Gao,Y.;Qi,R.;Ma,X.;Wang,Q.;Xu,H.;Liu,H.;Han,J.;Duan,M.;Liu,S.;Yu,X.;Zong,M.;Feng,J.;Jiao,J.;Zhang,H.;Li,M.;Yu,B.;Wang,Y.;Meng,F.;Ni,X.;Li,Y.;Shen,Z.;Sun,B.;Shao,X.;Zhao,H.;Zhao,Y.;Li,R.;Zhang,Y.;Du,G.;Lu,J.;You,C.;Jiang,H.;Zhang,L.;Wang,L.;Dou,C.;Liu,Z.;Zhao,J.",Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5,15-MAR-2023,9_8_13_6_3_9,7XDL_K_J,Xtal structure,SARS-CoV-2,3,1,-12.549635,5.784692
QNT09666_QNT09684,EVQLVQSGAEVKKPGESLKISCQGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGESDTRYSSSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARIRGVYSSGWIGGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRQWTFGQGTKVEIK,QNT09666,QNT09684,"anti SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti SARS-CoV-2 immunoglobulin kappa chain, partial [Homo sapiens]",Homo sapiens,"Kreye,J.; Reincke,S.M.; Kornau,H.-C.; Sanchez-Sendin,E.; Corman,V.M.; Liu,H.; Yuan,M.; Wu,N.C.; Zhu,X.; Lee,C.-C.D.; Trimpert,J.; Hoeltje,M.; Dietert,K.; Stoeffler,L.; von Wardenburg,N.; van Hoof,S.; Homeyer,M.A.; Hoffmann,J.; Abdelgawad,A.; Gruber,A.D.; Bertzbach,L.D.; Vladimirova,D.; Li,L.Y.; Barthel,P.C.; Skriner,K.; Hocke,A.C.; Hippenstiel,S.; Witzenrath,M.; Suttorp,N.; Kurth,F.; Franke,C.; Endres,M.; Schmitz,D.; Jeworowski,L.M.; Richter,A.; Schmidt,M.L.; Schwarz,T.; Mueller,M.A.; Drosten,C.; Wendisch,D.; Sander,L.E.; Osterrieder,N.; Wilson,I.A.; Pruess,H.",A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model,24-SEP-2020,8_8_16_6_3_11,QNT09666_QNT09684,Unique source,SARS-CoV-2; COVID,3,1,-12.5342865,5.67188
7TL0_D_E,EVQLVQSGAEVKKPGESLRISCKSSGYTFTTYWITWVRQMPGKGLEWMGRIDPSDSYTDYSPSFKGHVTISVDKSINTAYLQWGSLKSSDTAIFYCARQASSGKIYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQGINYYLNWYQQKPGKAPKVLIYDASDLETGVPSRFSGGGSGTHFTFTISSLQTEDIGTYYCQQYDNLPFTFGQGTRLEIK,7TL0_D,7TL0_E,Cryo-Em Structure Of Hmpv Pref Bound By Fabs Mpe8 And San32-2,Cryo-Em Structure Of Hmpv Pref Bound By Fabs Mpe8 And San32-2,Homo sapiens,"Rush,S.A.;Brar,G.;Hsieh,C.L.;Chautard,E.;Rainho-Tomko,J.N.;Slade,C.D.;Bricault,C.A.;Kume,A.;Kearns,J.;Groppo,R.;Mundle,S.T.;Zhang,L.;Casimiro,D.;Fu,T.M.;DiNapoli,J.M.;McLellan,J.S.",Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus,14-SEP-2022,8_8_13_6_3_9,7TL0_D_E,Xtal structure,,3,1,-12.121874,5.596487
AOV81890_AOV81898,EVQLVQSGAEVKKPGESLTISCKGSGYSFSSYWIGWVRRMPGKGLEWMGIINPRDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVVADREGFGYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGEGATLSCRASQSVDSSSLAWYQQKPGQAPRLLIFAGSSRATGIPDRFSGKTSGTDFTLTISRLEPEDFAVYYCQQCGNSPWTFGQGTKVEIK,AOV81890,AOV81898,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Raymond,D.D.; Stewart,S.M.; Lee,J.; Ferdman,J.; Bajic,G.; Do,K.T.; Ernandes,M.J.; Suphaphiphat,P.; Settembre,E.C.; Dormitzer,P.R.; Del Giudice,G.; Finco,O.; Kang,T.H.; Ippolito,G.C.; Georgiou,G.; Kepler,T.B.; Haynes,B.F.; Moody,M.A.; Liao,H.X.; Schmidt,A.G.; Harrison,S.C.",Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain,12-OCT-2016,8_8_18_7_3_9,AOV81890_AOV81898,Unique source,Influenza,3,1,-12.40686,5.5175853
6LXK_J_K,EVQLVQSGAEVKKPGSSVKVSCKASGGPFSSYGFSWVRQAPGQGLEWMGGIIPVYGTTNYAQKFQGRVTITADESTSTAYMELSSLKSEDTAVYYCARDLQRTPMVDRIIGSYYYYNGLDVWGQGTTVTVSS,QSVLTQPASVSGSPGQSITISCTGASSDVGDYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGDTASLTISGLQAEDEADYYCSSYTRSSSVVFGGGTKLTVL,6LXK_J,6LXK_K,Crystal Structure Of Z2B3 D102R Fab In Complex With Influenza Virus Neuraminidase From A/Serbia/Ns-601/2014 (H1N1),Crystal Structure Of Z2B3 D102R Fab In Complex With Influenza Virus Neuraminidase From A/Serbia/Ns-601/2014 (H1N1),Homo sapiens,"Jiang,H.;Peng,W.;Qi,J.;Chai,Y.;Song,H.;Bi,Y.;Rijal,P.;Wang,H.;Oladejo,B.O.;Liu,J.;Shi,Y.;Gao,G.F.;Townsend,A.R.;Wu,Y.",Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus,11-FEB-2020,8_8_25_9_3_10,6LXK_J_K,Xtal structure,neuraminidase; H1N1; Influenza,3,1,-0.8138447,6.1402736
6RCO_A_B,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFATTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARDKHSWSYAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGLRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLIHSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVL,6RCO_A,6RCO_B,Pfrh5-Binding Monoclonal Antibody R5.004,Pfrh5-Binding Monoclonal Antibody R5.004,Homo sapiens,"Alanine,D.G.;Quinkert,D.;Kumarasingha,R.;Mehmood,S.;Donnellan,F.R.;Minkah,N.K.;Dadonaite,B.;Diouf,A.;Galaway,F.;Silk,S.E.;Jamwal,A.;Marshall,J.M.;Miura,K.;Foquet,L.;Elias,S.C.;Labbe,G.M.;Douglas,A.D.;Jin,J.;Payne,R.O.;Illingworth,J.J.;Pattinson,D.J.;Pulido,D.;Williams,B.G.;de Jongh,W.A.;Wright,G.J.;Kappe,S.H.;Robinson,C.V.;Long,C.A.;Crabb,B.S.;Gilson,P.R.;Higgins,M.K.;Draper,S.J.",Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies,11-APR-2019,8_8_13_8_3_11,6RCO_A_B,Xtal structure,,3,1,-0.5655202,5.731149
7V3L_D_E,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAICWVRQAPGQGLEWMGGIIPFFGTVNYAQKFQGRVTITADESTSTVYMELSSLRSEDTAVYYCANSYCSSTNCYRYYQNGLDVWGQGTTVTVSS,AIRMTQSPVTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLQSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYDNYSQLTFGPGTKLEIK,7V3L_D,7V3L_E,Mers S Ectodomain Trimer In Complex With Neutralizing Antibody 6516,Mers S Ectodomain Trimer In Complex With Neutralizing Antibody 6516,Homo sapiens,"Wang,X.;Zhao,J.;Wang,Z.;Wang,Y.;Zeng,J.",MERS S ectodomain trimer in complex with neutralizing antibody 6516,17-AUG-2022,8_8_20_6_3_10,7V3L_D_E,Xtal structure,MERS; Ectodomain,3,1,-0.7997508,6.1580396
6WH9_E_F,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARAPNYGDYVAFDIWGQGTTVTVSS,QTVVIQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCLLSYSGALWVFGGGTKLTVL,6WH9_E,6WH9_F,Ketoreductase From Module 1 Of The 6-Deoxyerythronolide B Synthase (Kr1) In Complex With Antibody Fragment (Fab) 1D10,Ketoreductase From Module 1 Of The 6-Deoxyerythronolide B Synthase (Kr1) In Complex With Antibody Fragment (Fab) 1D10,Saccharopolyspora erythraea,"Cogan,D.P.;Li,X.;Sevillano,N.;Mathews,I.I.;Matsui,T.;Craik,C.S.;Khosla,C.",Antibody Probes of Module 1 of the 6-Deoxyerythronolide B Synthase Reveal an Extended Conformation During Ketoreduction,07-APR-2020,8_8_14_9_3_10,6WH9_E_F,Xtal structure,,3,1,1.9006913,5.2825904
7ZFB_C_D,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGLGLEWMGGVIPILSAKHYAQRFQGRVTITADKSTGTAYMELSSLRSEDTAVYYCARDILHHDDLWGRFYYDGMDVWGQGTTVTVSS,QSVVTQPPSASGTPGQRVTISCSGSSSDIGSNTVNWYQQLPGTAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYFCAAWDESLNGRVFGGGTKLTVL,7ZFB_C,7ZFB_D,"Sars-Cov-2 Omicron Rbd In Complex With Nanobody C1, Omi-18 And Omi-31 Fabs","Sars-Cov-2 Omicron Rbd In Complex With Nanobody C1, Omi-18 And Omi-31 Fabs",Severe acute respiratory syndrome coronavirus 2,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,01-APR-2022,8_8_21_8_3_11,7ZFB_C_D,Xtal structure,,3,1,-0.86046773,6.1244187
CAM36398_CAM36399,EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK,CAM36398,CAM36399,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Ambrosino,D.; Babcock,G.J.; Broering,T.; Graziano,R.; Hernandez,H.J.; Lowy,I.; Mandell,R.; Molrine,D.; Thomas,W.D.; Zhang,H.F.",Antibodies against clostridium difficile toxins and uses thereof,01-MAR-2007,8_8_12_7_3_9,AOD80042_AOD80041,Ordered entries,,3,1,-12.411441,5.760052
AOV81892_AOV81900,EVQLVQSGAEVKMPGESLRISCKVSGYNFVKFWIAWVRQKPGKGLEWMGVIHPGDSDSTYNPSFQGHVSISADKSINTAYLQWNSLKASDTAMYFCARVVGDREGFGYHYGLDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVFSTFLAWYQQKPGQAPRLLIYAASRRAAGIPDRFSGSESGTDFTLTISRLEPEDFAVYYCQQSESSPWTFGQGTKVDIK,AOV81892,AOV81900,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Raymond,D.D.; Stewart,S.M.; Lee,J.; Ferdman,J.; Bajic,G.; Do,K.T.; Ernandes,M.J.; Suphaphiphat,P.; Settembre,E.C.; Dormitzer,P.R.; Del Giudice,G.; Finco,O.; Kang,T.H.; Ippolito,G.C.; Georgiou,G.; Kepler,T.B.; Haynes,B.F.; Moody,M.A.; Liao,H.X.; Schmidt,A.G.; Harrison,S.C.",Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain,12-OCT-2016,8_8_18_7_3_9,AOV81892_AOV81900,Unique source,Influenza,3,1,-12.219806,5.4627585
8EE5_H_L,EVQLVQSGAEVKRPGESLKISCKTSGYSFTSYWISWVRQMPGKGLEWMGAIDPSDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDSATYYCAKEGIAARSLDVWGRGVLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWFQQKPGQSPVLIIYEDSKRPSGIPERFSGSSSGTVATLTISGAQVEDEADYYCYSTDSSGYHGLFGGGTRLTVL,8EE5_H,8EE5_L,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz119-D In Complex With Zikv E Glycoprotein,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz119-D In Complex With Zikv E Glycoprotein,Macaca mulatta,"Sankhala,R.S.;Dussupt,V.;Donofrio,G.;Gromowski,G.D.;De La Barrera,R.A.;Larocca,R.A.;Mendez-Rivera,L.;Lee,A.;Choe,M.;Zaky,W.;Mantus,G.;Jensen,J.L.;Chen,W.H.;Gohain,N.;Bai,H.;McCracken,M.K.;Mason,R.D.;Leggat,D.;Slike,B.M.;Tran,U.;Jian,N.;Abbink,P.;Peterson,R.;Mendes,E.A.;Freitas de Oliveira Franca,R.;Calvet,G.A.;Bispo de Filippis,A.M.;McDermott,A.;Roederer,M.;Hernandez,M.;Albertus,A.;Davidson,E.;Doranz,B.J.;Rolland,M.;Robb,M.L.;Lynch,R.M.;Barouch,D.H.;Jarman,R.G.;Thomas,S.J.;Modjarrad,K.;Michael,N.L.;Krebs,S.J.;Joyce,M.G.",Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes,30-AUG-2023,8_8_12_6_3_11,8EE5_H_L,Xtal structure,Zika,3,1,-12.4186,5.730285
3IYW_H_L,EVQLVQSGAEVRKPGASTKVSCKASGYTFTHYYMHWVRQAPGQGLEWMGIINPSGGSTTYAQKLQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDWGSNYVWGSYPKYWGQGTLVTVSS,QSVLTQPSSVSGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL,3IYW_H,3IYW_L,West Nile Virus In Complex With Fab Fragments Of Mab Cr4354 (Fitted Coordinates Of Envelope Proteins And Fab Fragments Of One Icosahedral Asu),West Nile Virus In Complex With Fab Fragments Of Mab Cr4354 (Fitted Coordinates Of Envelope Proteins And Fab Fragments Of One Icosahedral Asu),Homo sapiens,"Kaufmann,B.;Vogt,M.R.;Goudsmit,J.;Holdaway,H.A.;Aksyuk,A.A.;Chipman,P.R.;Kuhn,R.J.;Diamond,M.S.;Rossmann,M.G.",Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354,18-JUN-2010,8_8_16_8_3_11,3IYW_H_L,Xtal structure,,3,1,1.6117296,3.7183065
5VK2_D_E,EVQLVQSGGGLVKAGGSLRLSCAASGFTFSTYSMNWIRQAPGKGLEWVASISSRSGSHINYVDSVKGRFTISRDNARDLLYLQMNSLRVDDSALYYCARDRRSGTSPLPLDVWGQGTTVTVFS,QSALTQPASVSGSPGQSITISCTGTGSDIGGYNFVSWYQQYPGKAPKLIIYEVRIRASGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYSIHSPWVFGGGTKLTVL,5VK2_D,5VK2_E,Structural Basis For Antibody-Mediated Neutralization Of Lassa Virus,Structural Basis For Antibody-Mediated Neutralization Of Lassa Virus,Lassa virus Josiah,"Hastie,K.M.;Zandonatti,M.A.;Kleinfelter,L.M.;Heinrich,M.L.;Rowland,M.M.;Chandran,K.;Branco,L.M.;Robinson,J.E.;Garry,R.F.;Saphire,E.O.",Structural basis for antibody-mediated neutralization of Lassa virus,20-APR-2017,8_9_15_9_3_10,UOS75578_UOS75594,Xtal structure,,3,1,16.0442,9.958839
AAZ86721,EVQLVQSGGGLVKPGGSLRLSCAASGFIFSDHYMAWVRQTPGKGLEWISYISMTSSYTNYADSVKGRFTISRDNAKNSLSLEMNSLRVEDTAVYYCARDRLRNWNDDAFDIWGPGTMVTVSS,YELTQPASVSGSPGQSITISCTGTPSDIGTYPYVSWYQQHPDRAPKLLIYGVTNRPSGVSNRFSGSKSGNTASLTISELQAEDEADYYCSSYTLTSIVVFGGGTKLTVL,AAZ86721_H,AAZ86721_L,"anti-Phl p 5 allergen single chain antibody fragment, partial [synthetic construct]","anti-Phl p 5 allergen single chain antibody fragment, partial [synthetic construct]",synthetic construct,"Andreasson,U.; Flicker,S.; Lindstedt,M.; Valenta,R.; Greiff,L.; Korsgren,M.; Borrebaeck,C.A.; Ohlin,M.",The human IgE-encoding transcriptome to assess antibody repertoires and repertoire evolution,26-JUL-2016,8_8_15_9_3_10,AAZ86721,Same entry,Phl,3,1,15.878126,9.882942
6E65_H_L,EVQLVQSGGGLVQPGGSLRLSCAASGFTFNNYWMSWVRQAPGKGLEWVSSISNIGGTIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRDLRMSDYFDYWGQGTMVTVSS,NFMLTQPHSVSESPGKTVTISCTRSTGNIGSNYVSWYQQRPGSSPTTVIYRDDQRPSGVPDRFSGSIDRSSNSASLTISGLKTEDEADYYCHSYSTGMYIFGGGTKLTVL,6E65_H,6E65_L,Crystal Structure Of Malaria Transmission-Blocking Antigen Pfs48/45 6C In Complex With Antibody 85Rf45.1,Crystal Structure Of Malaria Transmission-Blocking Antigen Pfs48/45 6C In Complex With Antibody 85Rf45.1,Homo sapiens,"Kundu,P.;Semesi,A.;Jore,M.M.;Morin,M.J.;Price,V.L.;Liang,A.;Li,J.;Miura,K.;Sauerwein,R.W.;King,C.R.;Julien,J.P.",Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45,23-JUL-2018,8_8_12_8_3_9,6E65_H_L,Xtal structure,,3,1,14.198714,9.300061
8DMH_F_E,EVQLVQSGGGLVRPGGSLRLSCAAAGFTFKRYSMNWVRQAPGRGLEWVSSITSRGGSKTYYADVVKGRFTVSRDNAKQSLYLQMNSLRAEDTAIYFCARSLHSTSQPSYMDVWGRKITVIVSS,DIVLTQSPGTLSLSPGERATLSCRASQSVISYYVAWYQHKGGQAPRLLIYGASSRATGVPDRFSGSGSGTDFTLTISSLEPEDFALYYCQYYGSSPLWAFGQGTKVEIK,8DMH_F,8DMH_E,Lymphocytic Choriomeningitis Virus Glycoprotein In Complex With Neutralizing Antibody M28,Lymphocytic Choriomeningitis Virus Glycoprotein In Complex With Neutralizing Antibody M28,Lymphocytic choriomeningitis mammarenavirus,"Moon-Walker,A.;Zhang,Z.;Zyla,D.S.;Buck,T.K.;Li,H.;Diaz Avalos,R.;Schendel,S.L.;Hastie,K.M.;Crotty,S.;Saphire,E.O.",Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus,12-APR-2023,8_9_15_7_3_10,8DMH_F_E,Xtal structure,,3,1,15.848451,10.073258
7UL7_H_L,EVQLVQSGGGLVRPGGSLRLSCAAAGFTFKSYSMNWVRQAPGRGLEWVSSITSRGGSKTYYADVVKGRFTVSRDNAKQSLYLQMNSLRAEDTAIYFCARSRHSTSQPSYMDVWGRKITVIVSS,DIVLTQSPGTLSLSPGERATLSCRASQSVISYYVAWYQHKGGQAPRLLIYGASSRATGVPDRFSGSGSGTDFTLTISSLEPEDFALYYCQYYGSSPLWAFGQGTKVEIK,7UL7_H,7UL7_L,Lineage I (Pinneo) Lassa Virus Glycoprotein Bound To 18.5C-M30 Fab,Lineage I (Pinneo) Lassa Virus Glycoprotein Bound To 18.5C-M30 Fab,Lassa mammarenavirus,"Buck,T.K.;Enriquez,A.S.;Schendel,S.L.;Zandonatti,M.A.;Harkins,S.S.;Li,H.;Moon-Walker,A.;Robinson,J.E.;Branco,L.M.;Garry,R.F.;Saphire,E.O.;Hastie,K.M.",Neutralizing Antibodies against Lassa Virus Lineage I,04-APR-2022,8_9_15_7_3_10,7UL7_H_L,Xtal structure,,3,1,15.923793,10.124382
AAS19425_AAS19432,EVQLVQSGGGVVQPGKSLRLSCAASGFAFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRSYYLDYWGQGTLVTVSS,TTLTQSPATLSLSPGERATLSCRASQSVRSNLAWYQQKPGQAPRPLIYDASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQRSNWPPTFGQGTKVEVK,AAS19425,AAS19432,"anti-SARS S protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS S protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sui,J.; Li,W.; Murakami,A.; Tamin,A.; Matthews,L.J.; Wong,S.K.; Moore,M.J.; Tallarico,A.S.; Olurinde,M.; Choe,H.; Anderson,L.J.; Bellini,W.J.; Farzan,M.; Marasco,W.A.",Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association,28-AUG-2006,8_8_10_6_3_9,AAS19425_AAS19432,Unique source,SARS,3,1,14.559597,13.259158
AAW68467_AAW68887,EVQLVQSGPGLVKPSETLSLTCAVSGASVSGGDYYWSWIRQPPGKALEWIGYIYYIGSTNYNPSLKSRLSLSVDTAKSQFSLKLSSVTAADTAIYFCARARRTYSGYDSAFDYWGQGTLVTV,DVVMTQSPSSLSASVGDRVSITCRASRSVKTYLNWYQQKPGKAPKLLVYGSSSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFGTPYTFGQGTKLDTK,AAW68467,AAW68887,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,10_7_16_6_3_9,AAW68467_AAW68887,Unique source,tetanus,3,1,16.239582,-8.269315
6RCV_H_G,EVQLVQSGSDLKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWVGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARESPNYYDSSGYYSGYYFDYWGQGTLVTVSS,SYELTQPPSVSVAPGQTATITCGGKNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHRVFGGGTKLTVL,6RCV_H,6RCV_G,Pfrh5 Bound To Monoclonal Antibodies R5.011 And R5.016,Pfrh5 Bound To Monoclonal Antibodies R5.011 And R5.016,Homo sapiens,"Alanine,D.G.;Quinkert,D.;Kumarasingha,R.;Mehmood,S.;Donnellan,F.R.;Minkah,N.K.;Dadonaite,B.;Diouf,A.;Galaway,F.;Silk,S.E.;Jamwal,A.;Marshall,J.M.;Miura,K.;Foquet,L.;Elias,S.C.;Labbe,G.M.;Douglas,A.D.;Jin,J.;Payne,R.O.;Illingworth,J.J.;Pattinson,D.J.;Pulido,D.;Williams,B.G.;de Jongh,W.A.;Wright,G.J.;Kappe,S.H.;Robinson,C.V.;Long,C.A.;Crabb,B.S.;Gilson,P.R.;Higgins,M.K.;Draper,S.J.",Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies,11-APR-2019,8_8_21_6_3_11,6RCV_H_G,Xtal structure,,3,1,-6.9461846,5.581368
8DG9_H_L,EVQVVESGGGLVKPGGSLRLSCAASGFPFSSYKMDWVRQAPGKGLEWVSSISASGSYINYADSVKGRFTISRDNAKNSLYLQMKSLRADDTAVYFCARDGGRELSPFEKWGQGILVTVSS,QSVLTQPPSVSGAPGQRVTISCTGTNSNIGTGYDVHWYQQLPGTAPKVVLFDNNNRPSGVPDRFSGSKSGTSAALAITGLQAEDEAVYYCQSYDKSLGGWVFGGGTKLTVL,8DG9_H,8DG9_L,Cryo-Em Structure Of Rsv Prefusion F Trimer In Complex With Three Mxr Fabs,Cryo-Em Structure Of Rsv Prefusion F Trimer In Complex With Three Mxr Fabs,Homo sapiens,"Cab&#xe1;n,M.;Rodarte,J.V.;Bibby,M.;Gray,M.D.;Taylor,J.J.;Pancera,M.;Boonyaratanakornkit,J.",Cross-protective antibodies against common endemic respiratory viruses,22-FEB-2023,8_8_13_9_3_11,8DG9_H_L,Xtal structure,,3,1,16.01978,9.942287
5WDU_D_E,EVRLSQSGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFQGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVS,VLTQSPATLSLSPGETAIISCRTSQSGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKVQVD,5WDU_D,5WDU_E,"Hiv-1 Env Bg505 Sosip.664 H72C-H564C Trimer In Complex With Bnabs Pgt122 Fab, 35O22 Fab And Nih45-46 Scfv","Hiv-1 Env Bg505 Sosip.664 H72C-H564C Trimer In Complex With Bnabs Pgt122 Fab, 35O22 Fab And Nih45-46 Scfv",Homo sapiens,"Torrents de la Pe&#xf1;a,A.;Julien,J.P.;de Taeye,S.W.;Garces,F.;Guttman,M.;Ozorowski,G.;Pritchard,L.K.;Behrens,A.J.;Go,E.P.;Burger,J.A.;Schermer,E.E.;Sliepen,K.;Ketas,T.J.;Pugach,P.;Yasmeen,A.;Cottrell,C.A.;Torres,J.L.;Vavourakis,C.D.;van Gils,M.J.;LaBranche,C.;Montefiori,D.C.;Desaire,H.;Crispin,M.;Klasse,P.J.;Lee,K.K.;Moore,J.P.;Ward,A.B.;Wilson,I.A.;Sanders,R.W.",Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization,06-JUL-2017,8_8_18_4_3_5,5WDU_D_E,Xtal structure,HIV,3,1,2.8048065,4.208
AGV79281_AGV79280,EVRLVQSGAEVKKPGASVRVSCAASGYTFTDFDIHWLRQAPGRGLEWMGWVRPLGGGVSYARQFQGRVTMTRDFYIDTAFMDFRNLKMDDTALYFCARMGAAREWDFQYWGQGTRVLVSS,QSALTQPASVSGSPGQSITISCTASSDFRGFSSVSWYQQVPGRAPKLLIFSVNRRPSGISHRFSGSKSGNTASLTISGLQIEDEADYHCNAYEFFGGGTKVFVL,AGV79281,AGV79280,"anti-HIV-1 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV-1 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zhou,T.; Zhu,J.; Wu,X.; Moquin,S.; Zhang,B.; Acharya,P.; Georgiev,I.S.; Altae-Tran,H.R.; Chuang,G.Y.; Joyce,M.G.; Do Kwon,Y.; Longo,N.S.; Louder,M.K.; Luongo,T.; McKee,K.; Schramm,C.A.; Skinner,J.; Yang,Y.; Yang,Z.; Zhang,Z.; Zheng,A.; Bonsignori,M.; Haynes,B.F.; Scheid,J.F.; Nussenzweig,M.C.; Simek,M.; Burton,D.R.; Koff,W.C.; Mullikin,J.C.; Connors,M.; Shapiro,L.; Nabel,G.J.; Mascola,J.R.; Kwong,P.D.","Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies",22-SEP-2013,8_8_13_8_3_5,AGV79281_AGV79280,Unique source,HIV,3,1,2.590658,4.061594
AEQ74103_AEQ74863,GGLVKPGGSLRLSCAASGFTFRNSNMNWVRQAPGKGLEWISSISFSSDYIYYADSVKGRFTISRDNAKNSLYLQMNSLSAEDTAVYFCARCRGGTRHYYYLDVWGRGTTVT,TLSLSPGERGTLSCRASQSVSSFLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTINRLEPEDLAVYFCQQYVSSFSTFGQGTKVEIK,AEQ74103,AEQ74863,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_9,AEQ74103_AEQ74863,Unique source,tetanus,3,1,15.718988,10.471108
AEQ73540_AEQ74294,GGLVKPGGSLRLSCAASGSSFSNNNMNWVRQTPGKGLEWVASISFGSHYISYADSVKGRFTISRDNARNAVYLQMNSLRVEDTAVYYCTRCRGGTRTYYYMDVWGKGTLVTVS,TLALSPGDRATLSCGASQSVFGDFLAWYQHKPGQAPRLLIYGASTRATGIPDRFSGSGAGTDFTLTISRLEPEDFAVYFCQQYGDSVFTFGQGTKLEIK,AEQ73540,AEQ74294,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_7_3_9,AEQ73540_AEQ74294,Unique source,tetanus,3,1,15.70363,10.476317
AEQ73966_AEQ74726,GGLVKPGGSLRLSCGASGFTFRNSNMHWVRQAPGKGLEWVSSITSTGHYIHYADSVKGRFTISRDNAENSLYLQMNSLRAEDTAVYFCARYRGGTRGYYYMDVWGKGTTVT,TLSLSPGERASLSCRASETVYSNFLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYASSPPITFGPGTSVEIK,AEQ73966,AEQ74726,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_7_3_10,AEQ73966_AEQ74726,Unique source,tetanus,3,1,15.644742,10.534895
AEQ73739_AEQ74493,GGLVQPGGSLRLSCAASDFTFSSYSMNWVRQAPGKGLEWVAYISTSSGTIYYADSVKGRFTISRDNAKNSLYLQMNSLGDEDTAVYYCARDLFFGPLKGLFDSWGQGTLVTVS,TLSLSPGERATLSCRASQSLSRTYLAWYQQKPGRAPRLLIYGESGRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYHNSPWTFGQGTKVEIK,AEQ73739,AEQ74493,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_7_3_9,AEQ73739_AEQ74493,Unique source,tetanus,3,1,15.557377,10.27199
AEQ73945_AEQ74704,GGVVQPGRSLRLSCVASGFSFNKHIMHWVRQAPGKGLEWLAVMWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLTVEDTAVYYCARARGPYSGTYYATGWWGQGTLVT,SSLSASVGGRVTITCQASQDINNYLHWYQQKPGKAPKLLIYDASNLEVGVPSRFSGTGSGTHFTFTINSLHPDDVATYYCQQYHNLPLTFGPGTKVDIR,AEQ73945,AEQ74704,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_16_6_3_9,AEQ73945_AEQ74704,Unique source,tetanus,3,1,14.866185,12.814448
AWK57403_AWK57408,GLMQSGAVMKNSGASVRVSCQADGYDFIDYVIHWFRQRRGEGLEWLGWMNPSGGGTNYPRPFQGKVTMTRDTSTETAYLDVRGLTYDDTAVYYCVRDRANGSGRRRFESVNWFLDLWGRGTQITVVS,QSALTQPRSVSASPGQSVTISCTGTHNYVSWCQQKPGQAPKLLIYDFNKRPSGVSDRFSGSTSGNTASLTISGLQADDEGHYFCWAFENIGGGTKLTVL,AWK57403,AWK57408,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sajadi,M.M.; Dashti,A.; Rikhtegaran Tehrani,Z.; Tolbert,W.D.; Seaman,M.S.; Ouyang,X.; Gohain,N.; Pazgier,M.; Kim,D.; Cavet,G.; Yared,J.; Redfield,R.R.; Lewis,G.K.; DeVico,A.L.",Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses,22-MAY-2018,8_8_22_3_3_5,AWK57403_AWK57408,Unique source,HIV,3,1,2.4744577,3.6003885
3J93_H_L,GTELVKPGASAGVKLSCKASGYTFTNYDMNWVRQRPEQGLEWIGWIFPGDGSTRYNEKFKGKATLTTDKSSSTAYQLNRLTSEDSAVYFCARRGFHGSYSFAYWGQGTLVTVS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTALAWYQQIPGQSPKLLIYSASNRYTGVPDRFTASGSGTDFTFTISSVQAEDLALYYCQQHYTTPWTFGGGTKLEIK,3J93_H,3J93_L,Fitting Of Fab Into The Cryoem Density Map Of Ev71 Procapsid In Complex With Fab22A12,Fitting Of Fab Into The Cryoem Density Map Of Ev71 Procapsid In Complex With Fab22A12,Mus musculus,"Shingler,K.L.;Cifuente,J.O.;Ashley,R.E.;Makhov,A.M.;Conway,J.F.;Hafenstein,S.",The enterovirus 71 procapsid binds neutralizing antibodies and rescues virus infection in vitro,02-DEC-2014,8_8_13_6_3_9,3J93_H_L,Xtal structure,enterovirus,3,1,-0.00012438443,-4.202577
AEQ74037_AEQ74797,GVVQPGTSLRLSCVVSGFTFRTYGMNWVRQAPGKGLEWLAFVSSDGSDEFYADSVKGRFTVSRDNSKSTLFLKMNSLRADDTAVYYCARDRGAQITLFGAPLIRPSSFDSWGQGTLVT,SSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLQPGVPSRFSGSRSGTDFTFTISSLRPEDIATYYCQQYDGPVLTFGGGTKVEIK,AEQ74037,AEQ74797,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_23_6_3_9,AEQ74037_AEQ74797,Unique source,tetanus,3,1,14.863423,12.563364
7WTI_H_L,ITLKESGPTLVKPTQTLTLTCAFSGFSLNTGGAGVGWIRQPPGKALEWLALIYWDGDKRYNPSLKSRLAIIMDTSKNRVVLTMTNMDPVDTATYYCAHHKIEYIFDYWGQGTLVAVSS,ALTQPASVSGSPGQSITVSCTGTSSDLGNFQYVSWYQHHPGKAPKLLIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYTTTTIPVAFGGGTKLTVL,7WTI_H,7WTI_L,Sars-Cov-2 Omicron Variant Spike In Complex With Fab Xgv264,Sars-Cov-2 Omicron Variant Spike In Complex With Fab Xgv264,Homo sapiens,"Wang,L.;Fu,W.;Bao,L.;Jia,Z.;Zhang,Y.;Zhou,Y.;Wu,W.;Wu,J.;Zhang,Q.;Gao,Y.;Wang,K.;Wang,Q.;Qin,C.;Wang,X.","Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages",21-DEC-2022,10_7_11_9_3_11,7WTI_H_L,Xtal structure,SARS-CoV-2,3,1,12.371926,0.35702378
6WT3_H_L,KVQLQQSGAELVKPGASVKLSCKASGYTFTEYIIHWVKQKSGQGLEWIGWFYPGSGNIKYNEKFKDKATLTADKSSSTVYMELSRLTSEDSAVYFCARHEDRNYYSYWDYWGQGTTLTVSS,QIVLTQSPALMSASPGEKVTMTCSASSSVSNMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,6WT3_H,6WT3_L,Structural Basis For The Binding Of Monoclonal Antibody 5D2 To The Tryptophan-Rich Lipid-Binding Loop In Lipoprotein Lipase,Structural Basis For The Binding Of Monoclonal Antibody 5D2 To The Tryptophan-Rich Lipid-Binding Loop In Lipoprotein Lipase,Mus musculus,"Luz,J.G.;Birrane,G.;Young,S.G.;Meiyappan,M.;Ploug,M.",Structural basis for the binding of monoclonal antibody 5D2 to thetryptophan-rich lipid-binding loop in lipoprotein lipase,01-MAY-2020,8_8_14_5_3_9,6WT3_H_L,Xtal structure,,3,1,0.110667154,-4.2242036
AAW68451_AAW68870,KVQLVESGGGLVKPGGSLRLSCAASGSSFSNNNMNWVRQTPGKGLEWVASISFGSHYISYADSVKGRFTISRDNARNAVYLQMNSLRVEDTAVYYCTRCRGGTRTYYYMDVWGKGTLVTV,EIVMTQSPGTLALSPGDRATLSCGASQSVFGDFLAWYQHKPGQAPRLLIYGASTRATGIPDRFSGSGAGTDFTLTISRLEPEDFAVYFCQQYGDSVFTFGQGTKLEIK,AAW68451,AAW68870,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_15_7_3_9,AAW68451_AAW68870,Unique source,tetanus,3,1,15.757389,10.45926
AAW68644_AAW69073,KVQLVQSGAEVKKPGVSVNVSCKTSGYTFTNYYIHWVRQAPGQGLEWMGVINPTDGNTNYAPKFQARLTMTGDTSTSTVYMDVSSLTSDDTAVYYCARQYCSSASCYVSLRHSGQFYYFMDVWGKGTTVTV,EIVLTQFPGTLSLSPGERATLSCRASQSLSSSYIAWYQQKPGQAPRLLIFGASTRATGIPARFSGGGSGTDFTLTVSRLEPEDFAVYYCQERITFGPGTRLEIK,AAW68644,AAW69073,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_26_7_3_5,AAW68644_AAW69073,Unique source,tetanus,3,1,2.0575795,3.9177113
AAW68510_AAW68933,KVQLVQSGPEVKKPGASVRVSCKASGYSFKNYGIHWVRQAPGQGLEWMGWISADNGDTTTALNLRGRVSMTTDTSTNTVYMEVKSLRSDDTAIYFCARDFYSGSYRSFDYWGQGTLVTV,DIQLTQSPSSLSASLGDRVTITCRASQHISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFTGSGSGADYTLTISSLQPEDFATYYCQQSYSTSWTFGQGTTVEIK,AAW68510,AAW68933,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,8_8_14_6_3_9,AAW68510_AAW68933,Unique source,tetanus,3,1,1.4873638,5.4363923
6U59_H_L,LEESGGGLVQPEGSLTLTCKASGFDFSDYHVQWVRQSPGKGLEFIGGIAYTGNIYYASWAKGRFTISKTSSTTVTLQMTTLTAADTATYFCARAYGYASAPYAQYFNLWGPGTLVTVSS,DIVMTQTPASVSEPVGGTVTINCQASQSRGNNYLSWYQQKPGQSPSLLIYRTSTLASGVPSRFKGSGSGTQFTLTISDLECADAATYYCLYGYYSSRNPDFAFGGGTEVVVK,6U59_H,6U59_L,Hiv-1 B41 Sosip.664 In Complex With Rabbit Antibody 13B,Hiv-1 B41 Sosip.664 In Complex With Rabbit Antibody 13B,Oryctolagus cuniculus,"Yang,Y.R.;McCoy,L.E.;van Gils,M.J.;Andrabi,R.;Turner,H.L.;Yuan,M.;Cottrell,C.A.;Ozorowski,G.;Voss,J.;Pauthner,M.;Polveroni,T.M.;Messmer,T.;Wilson,I.A.;Sanders,R.W.;Burton,D.R.;Ward,A.B.",Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits,27-AUG-2019,8_7_17_7_3_13,6U59_H_L,Xtal structure,HIV,3,1,-0.43264857,18.404264
1UWE_H_L,LLAQSGPELVKPGASVKISCAASAYSITDFTIYWVKQSHGDSLEWIGGIDPHNGGGAYNQKFRVKATLTVDTSSSTAYIHLNSLTSEDSAVYYCAIFYGNFFDYWGQGTTVTVSS,DNVMTQSPSFMSTSVGDRVSVTCAASQNVGTNVAWYQQKPGQPPKALIYSTSYRYSGVPDRFTGSGSGTDFTLTISNVNSEDLAEYFCQQYNIYPVTFGGGTKLEIK,1UWE_H,1UWE_L,Molecular Mechanism Of Enantioselective Proton Transfer To Carbon In Catalytic Antibody 14D9,Molecular Mechanism Of Enantioselective Proton Transfer To Carbon In Catalytic Antibody 14D9,Mus musculus,"Zheng,L.;Baumann,U.;Reymond,J.L.",Molecular mechanism of enantioselective proton transfer to carbon in catalytic antibody 14D9,05-FEB-2004,8_8_10_6_3_9,1UWE_H_L,Xtal structure,,3,1,2.5165632,-3.8952572
6II9_P_Q,LQLQEWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGGTNYNPSLKSRVTISVDTSNNQFSLKLSSVTAADTAVYYCARGVWEGSGSDNFDYWGQGTLVTVSS,ALTQPPSVSGAPGQRVTISCTGSSSNIGAGFDVHWYQQLPGTAPKLLIYGNSFRPSGVPDRFSGSKSGTSASLAIAGLQAEDEADYYCQSYDSSLSGVVFGGGTKLTVL,6II9_P,6II9_Q,Crystal Structure Of H7 Hemagglutinin From A/Anhui/1/2013 In Complex With A Human Neutralizing Antibody L3A-44,Crystal Structure Of H7 Hemagglutinin From A/Anhui/1/2013 In Complex With A Human Neutralizing Antibody L3A-44,Homo sapiens,"Huang,K.A.;Rijal,P.;Jiang,H.;Wang,B.;Schimanski,L.;Dong,T.;Liu,Y.M.;Chang,P.;Iqbal,M.;Wang,M.C.;Chen,Z.;Song,R.;Huang,C.C.;Yang,J.H.;Qi,J.;Lin,T.Y.;Li,A.;Powell,T.J.;Jan,J.T.;Ma,C.;Gao,G.F.;Shi,Y.;Townsend,A.R.",Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans,03-OCT-2018,8_7_15_9_3_11,6II9_P_Q,Xtal structure,,3,1,16.692995,-10.504948
7UR4_F_G,LVQSGGGVVRPGTSLRVSCAAFDFNFRDYGMHWVRQAPGKGLEWVAGIWYDGSNKDYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVYYCARDPRTHREGALSHFDSWGQGTLVTVSS,ELTQDPAVSVALGQTVRITCQGDSLRNYFAGWYQQKPGQAPLLVLYGENIRPSGIPDRFSGSSSGNTVSLTITGAQAEDEADYYCNSRDNSGNHWVFGGGTRLTVL,7UR4_F,7UR4_G,Cryo-Em Structure Of The Neutralizing Antibody Mpv467 In Complex With Prefusion Human Metapneumovirus F Glycoprotein,Cryo-Em Structure Of The Neutralizing Antibody Mpv467 In Complex With Prefusion Human Metapneumovirus F Glycoprotein,Homo sapiens,"Banerjee,A.;Huang,J.;Rush,S.A.;Murray,J.;Gingerich,A.D.;Royer,F.;Hsieh,C.L.;Tripp,R.A.;McLellan,J.S.;Mousa,J.J.",Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus,21-APR-2022,8_8_17_6_3_11,7UR4_F_G,Xtal structure,,3,1,14.701542,13.497124
7SGF_H_L,NSQLEESGGGLVQTEGSLTLTCTASGFSFSNNDYICWVRQAPGKGLEWIGCIYSDYGFSFFATWAKDRFSGSKTSSTTVTLQGTGLTAADTATYFCVKTYVSRFGYYIRWDYFDLWGPGTLVIVSS,DQVMTQTPSPVSAAVGGTVSISCQSSKSVHNENFLSWYQQKPGQRPKLLIYRASTLASGVPSRFKGSGSGTQFTLTISDVQCDDAATYYCAGGDIQSSDDVFGGGTEVVVQ,7SGF_H,7SGF_L,Lassa Virus Glycoprotein Construct (Josiah Gpc-I53-50A) In Complex With Lava01 Antibody,Lassa Virus Glycoprotein Construct (Josiah Gpc-I53-50A) In Complex With Lava01 Antibody,Oryctolagus cuniculus,"Brouwer,P.J.M.;Antanasijevic,A.;Ronk,A.J.;M&#xfc;ller-Kr&#xe4;uter,H.;Watanabe,Y.;Claireaux,M.;Perrett,H.R.;Bijl,T.P.L.;Grobben,M.;Umotoy,J.C.;Schriek,A.I.;Burger,J.A.;Tejjani,K.;Lloyd,N.M.;Steijaert,T.H.;van Haaren,M.M.;Sliepen,K.;de Taeye,S.W.;van Gils,M.J.;Crispin,M.;Strecker,T.;Bukreyev,A.;Ward,A.B.;Sanders,R.W.",Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection,12-OCT-2022,9_8_19_8_3_11,7SGF_H_L,Xtal structure,,3,1,-0.3819891,18.453508
6X98_F_E,NSQLVESGGGLVKPGGTLTLTCKASGFSLSDSYWMCWVRQAPGKGLEWVACVFTGNGKAYYARWVEGRFTISRSTSLNTATLQMTSLTAADTATYFCARGDYDDPLDGVATLWGPGTLVTVSS,DIVMTQTPSSVSAAVGGTVTINCQASESIYSGLAWYQQKPGQPPKLLIYRASTLTSGVSSRFKGSGSGARFTLTINDLECADAATYYCQSCYDTTIGTYGSWAFGGGTEVVVK,6X98_F,6X98_E,Cryo-Em Model Of Hiv-1 Env Bg505 Sosip.664 In Complex With Rabbit Monoclonal Antibody 11B Fragment Antigen Binding Variable Domain,Cryo-Em Model Of Hiv-1 Env Bg505 Sosip.664 In Complex With Rabbit Monoclonal Antibody 11B Fragment Antigen Binding Variable Domain,Oryctolagus cuniculus,"Ozorowski,G.;Cottrell,C.A.;de Val,N.;Scaringi,N.;Polveroni,T.M.;Ward,A.B.",Limited breadth of anti-HIV Env glycan hole antibodies is further hindered by strain-specific peptide interactions,02-JUN-2020,9_8_15_6_3_15,6X98_F_E,Xtal structure,HIV,3,1,-0.3899295,18.43383
6X97_J_K,NSQLVESGGGLVKPGTSLSLTCKASGFDFSDNYYICWVRQAPGKGLEWIGCIFTQNVRTYYANWAKGRFTISKTSSTTVTLQMTSLTVADTATYFCARFSDTGPDYGLGNLWGPGSLVTVSS,DIVMTQTPASVEAAVGGTVTIKCQASQRIGSHVSWYQQKPGQRPKLLIYGASNLESGVPSRFSGSGSGTQFTLTISDLECADAATYYCQATYDPYTGGSYGAGFGGGTAVVVK,6X97_J,6X97_K,Cryo-Em Model Of Hiv-1 Env Bg505 Sosip.664 In Complex With Rabbit Monoclonal Antibody 11A Fragment Antigen Binding Variable Domain,Cryo-Em Model Of Hiv-1 Env Bg505 Sosip.664 In Complex With Rabbit Monoclonal Antibody 11A Fragment Antigen Binding Variable Domain,Oryctolagus cuniculus,"Ozorowski,G.;Cottrell,C.A.;de Val,N.;Scaringi,N.;Polveroni,T.M.;Ward,A.B.",Limited breadth of anti-HIV Env glycan hole antibodies is further hindered by strain-specific peptide interactions,02-JUN-2020,9_8_15_6_3_15,6X97_J_K,Xtal structure,HIV,3,1,-0.405797,18.461674
6X96_J_K,NSQLVESGGGLVQPGASLTLTCTASGFSFSSDYYMCWVRQAPGKGLEWIACIWTANSISYYARWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGGSGDGQSLWGPGTLVTVSS,DIVMTQTPASVEAAVGGTVAIKCQASQSIRSYLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTQFTLTISGVECDDAATYYCQRNYDSYSGAYYPNGFGGGTEVVVK,6X96_J,6X96_K,Cryo-Em Model Of Hiv-1 Env Bg505 Sosip.664 In Complex With Rabbit Monoclonal Antibody 10A Fragment Antigen Binding Variable Domain,Cryo-Em Model Of Hiv-1 Env Bg505 Sosip.664 In Complex With Rabbit Monoclonal Antibody 10A Fragment Antigen Binding Variable Domain,Oryctolagus cuniculus,"Ozorowski,G.;Cottrell,C.A.;de Val,N.;Scaringi,N.;Polveroni,T.M.;Ward,A.B.",Limited breadth of anti-HIV Env glycan hole antibodies is further hindered by strain-specific peptide interactions,02-JUN-2020,9_8_11_6_3_15,6X96_J_K,Xtal structure,HIV,3,1,-0.3574551,18.478338
AEQ73959_AEQ74719,PGLVKPSETLSLTCTFSGASSSTHYWNWIRQPPGKGLEWIGYISYSGSTDYNPSLKSRVSLSADTSKSQFSLKLTSVTAADTAVYYCAREEFTSSSRWFDPWGQGTLVT,SSLSASVGDRVTITCRASQSISNYLNWYQQKAGKAPKVLISAASSLQSGVPSRFSGSGYGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTNLEIK,AEQ73959,AEQ74719,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_14_6_3_9,AEQ73959_AEQ74719,Unique source,tetanus,3,1,16.242092,-8.621269
AEQ74209_AEQ74969,PGLVKPSQTLSLTCSVSRGSISSGNYYWTWIRQRPGRGLEWIGYIDDSGSTFYNPSLKSRLSISRDTSKNQFSLKLISVTAADTAVYYCARDMGSRVAAPLDYWGQGTLVT,SVSASIGDRVTLTCRASRDINIWVAWYQQKPGKAPKLLIHAASTLQSGVPSRFSGSGSGTDFTLTINNLQPEDVATYFCQQALSFPVTFGGGTKVELK,AEQ74209,AEQ74969,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_14_6_3_9,AEQ74209_AEQ74969,Unique source,tetanus,3,1,16.233334,-8.577464
4RQQ_B_A,QAQLVQSGPEVRKPGTSVKVSCKAPGNTLKTYDLHWVRSVPGQGLQWMGWISHEGDKKVIVERFKAKVTIDWDRSTNTAYLQLSGLTSGDTAVYYCAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFWGQGTAVTVSS,DFVLTQSPHSLSVTPGESASISCKSSHSLIHGDRNNYLAWYVQKPGRSPQLLIYLASSRASGVPDRFSGSGSDKDFTLKISRVETEDVGTYYCMQGRESPWTFGQGTKVDIK,4RQQ_B,4RQQ_A,"Crystal Structure Of Human Fab Pgdm1400, A Broadly Reactive And Potent Hiv-1 Neutralizing Antibody","Crystal Structure Of Human Fab Pgdm1400, A Broadly Reactive And Potent Hiv-1 Neutralizing Antibody",Homo sapiens,"Sok,D.;van Gils,M.J.;Pauthner,M.;Julien,J.P.;Saye-Francisco,K.L.;Hsueh,J.;Briney,B.;Lee,J.H.;Le,K.M.;Lee,P.S.;Hua,Y.;Seaman,M.S.;Moore,J.P.;Ward,A.B.;Wilson,I.A.;Sanders,R.W.;Burton,D.R.",Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex,04-NOV-2014,8_8_34_11_3_9,4RQQ_B_A,Xtal structure,HIV,3,1,2.4380178,3.1593797
ADA54565_ADA54570,QEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVL,ADA54565,ADA54570,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.; Phogat,S.K.; Chan-Hui,P.Y.; Wagner,D.; Phung,P.; Goss,J.L.; Wrin,T.; Simek,M.D.; Fling,S.; Mitcham,J.L.; Lehrman,J.K.; Priddy,F.H.; Olsen,O.A.; Frey,S.M.; Hammond,P.W.; Kaminsky,S.; Zamb,T.; Moyle,M.; Koff,W.C.; Poignard,P.; Burton,D.R.",Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target,24-JUL-2016,8_8_30_9_3_10,ADA54565_ADA54570,Unique source,HIV,3,1,13.976441,14.144869
6UDK_M_N,QGRLFQSGTEVKRPGASVKISCRADDDPYTDDDTFTKYYTHWIRQAPGQPPEWLGVISPHFARPIYSYKFRDRLTLTRDSSLTAVYFELRGLQPDDTGIYFCARDPFGDMYPHYNYHMDVWGGGTTVIVSS,EIVLTQSPAILSVSPGDRVILSCKASEGLSSSDLAWYRFKGGQIPTLVIFGASNRARGTPDRFSGSGSGTDFTLTINRVEPEDFATYYCQRYGGTPITFGGGTKVDIK,6UDK_M,6UDK_N,Hiv-1 Bnab 1-55 In Complex With Modified Bg505 Sosip-Based Immunogen Rc1 And 10-1074,Hiv-1 Bnab 1-55 In Complex With Modified Bg505 Sosip-Based Immunogen Rc1 And 10-1074,Human immunodeficiency virus 1,"Schommers,P.;Gruell,H.;Abernathy,M.E.;Tran,M.K.;Dingens,A.S.;Gristick,H.B.;Barnes,C.O.;Schoofs,T.;Schlotz,M.;Vanshylla,K.;Kreer,C.;Weiland,D.;Holtick,U.;Scheid,C.;Valter,M.M.;van Gils,M.J.;Sanders,R.W.;Vehreschild,J.J.;Cornely,O.A.;Lehmann,C.;Fatkenheuer,G.;Seaman,M.S.;Bloom,J.D.;Bjorkman,P.J.;Klein,F.",Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody,19-SEP-2019,14_8_18_7_3_9,6UDK_M_N,Xtal structure,HIV,3,1,1.7570657,3.555031
7KC1_H_L,QIQLQQSGPGLVKPSQTLSLTCSISGDTVTNNYAAWDWIRQSPTRGLEWLGRTFYRSKWYKEYALSVKSRLTISPDTSKNQISLQLSSVTPEDTAVYYCARAGITIFGLITGGLDYWGQGSLVTVSS,MTQSPSSLSASVGDRVTITCRTSQSLSSYTHWYQQKPGKAPKLLIYAASSRGSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRTFGQGTKVEIK,7KC1_H,7KC1_L,Cryo-Em Structure Of Srr2899884.46167H+Medi8852L Fab In Complex With Victoria Ha,Cryo-Em Structure Of Srr2899884.46167H+Medi8852L Fab In Complex With Victoria Ha,Homo sapiens,"Chuang,G.Y.;Shen,C.H.;Cheung,C.S.;Gorman,J.;Creanga,A.;Joyce,M.G.;Leung,K.;Rawi,R.;Wang,L.;Yang,E.S.;Yang,Y.;Zhang,B.;Zhang,Y.;Kanekiyo,M.;Zhou,T.;DeKosky,B.J.;Graham,B.S.;Mascola,J.R.;Kwong,P.D.",Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses,04-OCT-2020,10_9_17_6_3_5,7KC1_H_L,Xtal structure,Influenza,3,1,15.48935,-4.6838613
7UOP_H_L,QIQLVQSGPELKKPGETVKISCKASGYTFRNYGVNWVKQGPGKDLKWMGWINTLNGEPTYADDFKRRFAFSLETSATTAFLQINNLKNEDTATYFCARTFYDGYYYAMDYWGQGTSVTVSA,ENVLTQSPTIMAASLGQKVTMTCSANSSVSSSYLHWYHQKSGASPKPLIHRTSNLASGVPARFIGSGSGTSFSLTISSVEAEDDATYYCQQWSGYPFITFGSGTKLEIK,7UOP_H,7UOP_L,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 4H3,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 4H3,Mus musculus,"Byrne,P.O.;McLellan,J.S.",Prefusion-stabilized Nipah virus fusion protein complexed with Fab 4H3,29-MAR-2023,8_8_14_7_3_10,7UOP_H_L,Xtal structure,,3,1,-7.532399,6.1170673
2W60_A_B,QIQLVQSGPELKKPGETVKISCKASGYTFTDYSIHWVKQAPGKGLKWMGWINTETGEPTYTDDFKGRFAFSLESSASTAFLQINNLKNEDTATYFCARATTATELAYWGQGTLVTVS,DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPLTFGAGTKLELK,2W60_A,2W60_B,Anti Citrullinated Collagen Type 2 Antibody Acc4,Anti Citrullinated Collagen Type 2 Antibody Acc4,Mus musculus,"Uysal,H.;Bockermann,R.;Nandakumar,K.S.;Sehnert,B.;Bajtner,E.;Engstrom,A.;Serre,G.;Burkhardt,H.;Thunnissen,M.M.;Holmdahl,R.",Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis,16-DEC-2008,8_8_11_11_3_9,2W60_A_B,Xtal structure,,3,1,-7.5305567,6.155563
1TPX_B_C,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNLVKQAPGKGFEWMGWINTFTGEPTYADDFKGRFVFSLDTSASTAYLQINNLKNEDTATYFFTRGTDYWGQGTTLTVSS,DVVMSQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSRLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGIYFCWQGSHFPQTFGGGTKLEIK,1TPX_B,1TPX_C,"Ovine Recombinant Prp(114-234), Arq Variant In Complex With The Fab Of The Vrq14 Antibody","Ovine Recombinant Prp(114-234), Arq Variant In Complex With The Fab Of The Vrq14 Antibody",Mus musculus,"Eghiaian,F.;Grosclaude,J.;Lesceu,S.;Debey,P.;Doublet,B.;Treguer,E.;Rezaei,H.;Knossow,M.",Insight into the PrPC-->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants,16-JUN-2004,8_8_6_11_3_9,1TPX_B_C,Xtal structure,,3,1,-7.5202856,6.1910224
7URF_O_P,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVRQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKDEDMATYFCARVWNYDYYFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQVSISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK,7URF_O,7URF_P,Human Hhat H379C In Complex With Shh N-Terminal Peptide,Human Hhat H379C In Complex With Shh N-Terminal Peptide,Mus musculus,"Liu,Y.;Qi,X.;Donnelly,L.;Elghobashi-Meinhardt,N.;Long,T.;Zhou,R.W.;Sun,Y.;Wang,B.;Li,X.",Mechanisms and inhibition of Porcupine-mediated Wnt acylation,20-JUL-2022,8_8_12_11_3_9,7URF_O_P,Xtal structure,,3,1,-7.529502,6.0955853
4R0L_H_L,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMTWVKQAPRKGLKWMGWINTYTGRPTYADDFKGRFAFSLETSASTAYLQINNLKHEDTATYFCASLGEDFWGQGTTLTVSS,DIVMTQAAPSVPVTPGESVSISCRSTKSLLHSNGNTYLYWFLQRPGQSPQRLIYYMSNLASGVPDRFSGRGSGTDFTLRISRVEAEDAGVYYCMQSLEYPYTFGGGTKLEIK,4R0L_H,4R0L_L,"Anti-Canine Cd28 Antibody, 1C6, Bound Canine Cd28","Anti-Canine Cd28 Antibody, 1C6, Bound Canine Cd28",Mus musculus,"Rosinski,S.L.;Storb,R.;Strong,R.K.;Sale,G.E.;Stone,D.M.;Gewe,M.M.;Friend,D.J.;Abrams,V.K.;Randolph-Habecker,J.;Graves,S.S.",Anti-CD28 Antibody-Initiated Cytokine Storm in Canines,31-JUL-2014,8_8_7_11_3_9,4R0L_H_L,Xtal structure,CD28,3,1,-7.578371,6.1810346
4KI5_C_D,QIQLVQSGPELKKPGKTVKISCKASDYTFTDYSLHWVKQAPGKGLKWMGWINTETGDPAYADDFKGRFAFSLETSVRTAYLQINNLKNEDTAIYFCAREDDGLASWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSTVSYMYWYQQKPGSSPRFLISDTSNLASGVPVRFSGSGSGTSYSLTISRIEAEDAATYYCQHWSSYPLTFGGGTKLELK,4KI5_C,4KI5_D,Cystal Structure Of Human Factor Viii C2 Domain In A Ternary Complex With Murine Inhbitory Antibodies 3E6 And G99,Cystal Structure Of Human Factor Viii C2 Domain In A Ternary Complex With Murine Inhbitory Antibodies 3E6 And G99,Homo sapiens,"Walter,J.D.;Werther,R.A.;Brison,C.M.;Cragerud,R.K.;Healey,J.F.;Meeks,S.L.;Lollar,P.;Spiegel PC,Jr.",Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes,01-MAY-2013,8_8_9_5_3_9,4KI5_C_D,Xtal structure,,3,1,-7.622633,6.2254047
5XCQ_A_B,QIQLVQSGPEVQKPGETVRISCKASGYTFTTAGMQWVQKMPGKSLKWIGWINTRSGVPKYAEDFKGRFAFSLETSASIAYLHINNLKNEDTATYFCAREGPGFVYWGQGTLVTVSS,QTVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIVGTNNRVPGVPPRFSGSLIEDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,5XCQ_A,5XCQ_B,Crystal Structure Of P20.1 Fv-Clasp Fragment With Its Antigen Peptide,Crystal Structure Of P20.1 Fv-Clasp Fragment With Its Antigen Peptide,Homo sapiens,"Arimori,T.;Kitago,Y.;Umitsu,M.;Fujii,Y.;Asaki,R.;Tamura-Kawakami,K.;Takagi,J.","Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability",23-MAR-2017,8_8_9_9_3_9,QHZ43209_QHZ43210,Xtal structure,,3,1,-7.654874,6.229766
4JRE_H_L,QIQLVQSGPGLKKPGQTVKISCKASGYSFTDYGMNWVKQAPGKGLEWMGWINTSNGYTTYGAAFKGRFSFSVDNSASTAYLQLSNLKTADTAVYFCARSWYNRAMDYWGQGTSVTVSS,DILMTQSPSSLSVSVGSSVTITCQASQNITNYIVWYQQKPGQAPKLLIYYTSTLESGIPSRFSGSGSGRDYSFTISNLQPEDVATYYCLQYNSLLTFGGGTKLEIK,4JRE_H,4JRE_L,Crystal Structure Of Nitrate/Nitrite Exchanger Nark With Nitrite Bound,Crystal Structure Of Nitrate/Nitrite Exchanger Nark With Nitrite Bound,Mus musculus,"Zheng,H.;Wisedchaisri,G.;Gonen,T.",Crystal structure of a nitrate/nitrite exchanger,21-MAR-2013,8_8_11_6_3_8,4JRE_H_L,Xtal structure,,3,1,-7.4028316,6.237356
2HMI_D_C,QITLKESGPGIVQPSQPFRLTCTFSGFSLSTSGIGVTWIRQPSGKGLEWLATIWWDDDNRYNPSLKSRLTVSKDTSNNQAFLNMMTVETADTAIYYCAQSAITSVTDSAMDHWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCSASQDISSYLNWYQQKPEGTVKLLIYYTSSLHSGVPSAFSGSGSGTDYSLTISNLEPEDFATYYCQQYSKFPWTFGGGTKLEIK,2HMI_D,2HMI_C,Hiv-1 Reverse Transcriptase/Fragment Of Fab 28/Dna Complex,Hiv-1 Reverse Transcriptase/Fragment Of Fab 28/Dna Complex,Mus musculus,"Arnold,E.;Jacobo-Molina,A.;Nanni,R.G.;Williams,R.L.;Lu,X.;Ding,J.;Clark AD,Jr.;Zhang,A.;Ferris,A.L.;Clark,P.;et al.",Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations,10-APR-1998,10_7_15_6_3_9,2HMI_D_C,Xtal structure,HIV,3,1,11.436174,2.0123308
AEN14392_AEN14409,QLHLQESGPGLVKPPETLSLTCSVSGASINDAYWSWIRQSPGKRPEWVGYVHHSGDTNYNPSLKRRVTFSLDTAKNEVSLKLVDLTAADSATYFCARALHGKRIYGIVALGELFTYFYMDVWGKGTAVTVSS,SMSVSPGETAKISCGKESIGSRAVQWYQQKPGQPPSLIIYNNQDRPAGVPERFSASPDFRPGTTATLTITNVDAEDEADYYCHIYDARGGTNWVFDRGTTLTVL,AEN14392,AEN14409,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.; Huber,M.; Doores,K.J.; Falkowska,E.; Pejchal,R.; Julien,J.P.; Wang,S.K.; Ramos,A.; Chan-Hui,P.Y.; Moyle,M.; Mitcham,J.L.; Hammond,P.W.; Olsen,O.A.; Phung,P.; Fling,S.; Wong,C.H.; Phogat,S.; Wrin,T.; Simek,M.D.; Principal Investigators,P.G.; Koff,W.C.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Broad neutralization coverage of HIV by multiple highly potent antibodies,26-SEP-2011,8_7_26_6_3_12,AEN14392_AEN14409,Unique source,HIV,3,1,15.466192,-7.9327106
2Z92_A_B,QLLESGPDLVKPSQSLSLTCTVTGYSITSGYNWHWIRQFPGNKLEWMGYIHYRGTTNYNTSLKSRISITRDSSKNQFFLQLNSVTTEDTATYYCACDDFYSDYWGQGTIVTVSS,LVMTQTPAIMSASPGEKVTMTCSASSSVSSVHWYQQKSGTSPKRWIYDTSKLPSGVPGRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGAGTKLEVK,2Z92_A,2Z92_B,Crystal Structure Of The Fab Fragment Of Anti-Ciguatoxin Antibody 10C9 In Complex With Ctx3C_Abcde,Crystal Structure Of The Fab Fragment Of Anti-Ciguatoxin Antibody 10C9 In Complex With Ctx3C_Abcde,Mus musculus,"Ui,M.;Tanaka,Y.;Tsumuraya,T.;Fujii,I.;Inoue,M.;Hirama,M.;Tsumoto,K.",How protein recognizes ladder-like polycyclic ethers. Interactions between ciguatoxin (CTX3C) fragments and its specific antibody 10C9,14-SEP-2007,9_7_9_5_3_9,2Z92_A_B,Xtal structure,Ciguatoxin,3,1,11.523756,-12.873684
5ACO_G_J,QLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVRQPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSVTAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSS,SALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVL,5ACO_G,5ACO_J,Cryo-Em Structure Of Pgt128 Fab In Complex With Bg505 Sosip.664 Env  Trimer,Cryo-Em Structure Of Pgt128 Fab In Complex With Bg505 Sosip.664 Env  Trimer,Homo sapiens,"Lee,J.H.;de Val,N.;Lyumkis,D.;Ward,A.B.",Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy,17-AUG-2015,10_13_21_4_3_10,5ACO_G_J,Xtal structure,HIV,3,1,16.994547,-7.7296185
CAA38306_CAA38307,QLQLQESGPGLVKPSETLSLTCTVSGGSISRGSHYWGWIRQPPGKGLEWIGSIYYSGNTYFNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLGPDDYTLDGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDSLSAVIFGGGTKLTVL,CAA38306,CAA38307,"Ig heavy chain precursor, partial [Homo sapiens]","Ig light chain precursor, partial [Homo sapiens]",Homo sapiens,"Harindranath,N.; Goldfarb,I.S.; Ikematsu,H.; Burastero,S.E.; Wilder,R.L.; Notkins,A.L.; Casali,P.",Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient,26-JUL-2016,10_7_15_8_3_11,CAA38306_CAA38307,Unique source,T1; CD5; LEU1,3,1,16.413857,-8.1921625
6WOR_H_L,QLQLVQSGAEVRKPGSSVKVSCKASGGTYNGEVISWVRQAPGEGLEWLGVFIPMFGIADYAQKFHGRVTISADRTTSTTYMELSSLRSEDTAIYYCAKVLQVGRNLVVRPLDLWGQGTLVTVSS,EIVLTQSPGILSLSPGERATLSCRASRTISRTHLAWYQQKPGQAPRLLIYGVSSRAIGIPDRFSGSGSGADFTLTISRLEPEDFAVYYCHQYGNSPQTFGQGTKLEIK,6WOR_H,6WOR_L,Structure Of The Broadly Neutralizing Antibody Hc1Am,Structure Of The Broadly Neutralizing Antibody Hc1Am,Homo sapiens,"Tzarum,N.;Giang,E.;Kadam,R.U.;Chen,F.;Nagy,K.;Augestad,E.H.;Velazquez-Moctezuma,R.;Keck,Z.Y.;Hua,Y.;Stanfield,R.L.;Dreux,M.;Prentoe,J.;Foung,S.K.;Bukh,J.;Wilson,I.A.;Law,M.",An alternate conformation of HCV E2 neutralizing face as an additional vaccine target,25-APR-2020,8_8_17_7_3_9,6WOR_H_L,Xtal structure,HCV,3,1,-0.7496905,5.964321
QKY76695_QKY76723,QLQVQESGPGLVKPSETLSLTCTVSGASISSNHYFWGWIRQPPGKGLAWIGSMHYSGSTYYNPSLKSRVTISVDTSKNQLSLKLSSVTAADTAVYYCARGVNYYDRNGYYRNDGFDIRGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYEQKPGKAPKRLIYAASSLESGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPFTFGPGTRVDIK,QKY76695,QKY76723,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kreer,C.; Zehner,M.; Weber,T.; Ercanoglu,M.S.; Gieselmann,L.; Rohde,C.; Halwe,S.; Korenkov,M.; Schommers,P.; Vanshylla,K.; Di Cristanziano,V.; Janicki,H.; Brinker,R.; Ashurov,A.; Kraehling,V.; Kupke,A.; Cohen-Dvashi,H.; Koch,M.; Eckert,J.M.; Lederer,S.; Pfeifer,N.; Wolf,T.; Vehreschild,M.J.G.T.; Wendtner,C.; Diskin,R.; Gruell,H.; Becker,S.; Klein,F.",Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients,08-JUL-2020,10_7_20_6_3_9,QKY76695_QKY76723,Unique source,SARS-CoV-2; COVID,3,1,16.603067,-8.194033
6DID_K_E,QLVESGGGLVQPGASLTLTCTASGFSFSSDYYMCWVRQAPGKGLEWIACIWTANSISYYARWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGGSGDGQSLWGPGTLVTVSS,DIVMTQTPASVEAAVGGTVAIKCQASQSIRSYLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTQFTLTISGVECDDAATYYCQRNYDSYSGAYYPNGFGGGTEVVVK,6DID_K,6DID_E,Hiv Env Bg505 Sosip With Polyclonal Fabs From Immunized Rabbit #3417 Post-Boost#1,Hiv Env Bg505 Sosip With Polyclonal Fabs From Immunized Rabbit #3417 Post-Boost#1,Oryctolagus cuniculus,"Bianchi,M.;Turner,H.L.;Nogal,B.;Cottrell,C.A.;Oyen,D.;Pauthner,M.;Bastidas,R.;Nedellec,R.;McCoy,L.E.;Wilson,I.A.;Burton,D.R.;Ward,A.B.;Hangartner,L.",Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization,23-MAY-2018,9_8_11_6_3_15,6DID_K_E,Xtal structure,HIV,3,1,-0.4600952,18.3741
6WXL_K_J,QLVQSGAEVKKPGASVKVSCKASGYTFTGYYLHWVRQAPGQGLEWMGRINPDTGGTNYAQKFQGRVSMTRDMSISTHYMELSRLTSDDTAVYYCATKRGAVTAMVYYYFYGMDVWGQGTTVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSHSLLHLNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALRTPPGLTFGGGTKVDIK,6WXL_K,6WXL_J,"Cryo-Em Structure Of The Vrc315 Clinical Trial, Vaccine-Elicited, Human Antibody 1D12 In Complex With An H7 Sh13 Ha Trimer","Cryo-Em Structure Of The Vrc315 Clinical Trial, Vaccine-Elicited, Human Antibody 1D12 In Complex With An H7 Sh13 Ha Trimer",Influenza A virus (A/Shanghai/JS01/2013(H7N9)),"Cheung,C.S.;Gorman,J.;Andrews,S.F.;Rawi,R.;Reveiz,M.;Shen,C.H.;Wang,Y.;Harris,D.R.;Nazzari,A.F.;Olia,A.S.;Raab,J.;Teng,I.T.;Verardi,R.;Wang,S.;Yang,Y.;Chuang,G.Y.;McDermott,A.B.;Zhou,T.;Kwong,P.D.",Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite,11-MAY-2020,8_8_20_11_3_11,6WXL_K_J,Xtal structure,hemagglutinin,3,1,2.0404847,3.6082258
8GTO_H_L,QLVQSGAEVKKPGSSVKVSCKASGDTFSSYTFSWVRQAPGQGLEWMGRSIPIVGKAIYAQEFQGRVTISADRSTTTVYMELSSLRSDDTAVYYCARDQSGFDFFYYDHWGQGTLVAV,QSVLTQPPSASGTPGQRVTISCSGSGSNIGSNTINWYQQLPGTAPKVLIYRNNERPSGVPDRFSGSKSGTSASLTISGLQSEDEAYYHCAAWDDSLNGPVFGGGTKLTVL,8GTO_H,8GTO_L,Cryo-Em Structure Of Omicron Ba.5 S Protein In Complex With Xgv282,Cryo-Em Structure Of Omicron Ba.5 S Protein In Complex With Xgv282,Homo sapiens,"Chi,X.;Guo,Y.;Zhang,G.;Sun,H.;Zhang,J.;Li,M.;Chen,Z.;Han,J.;Zhang,Y.;Zhang,X.;Fan,P.;Zhang,Z.;Wang,B.;Zai,X.;Han,X.;Hao,M.;Fang,T.;Xu,J.;Wu,S.;Chen,Y.;Fang,Y.;Dong,Y.;Sun,B.;Zhang,J.;Li,J.;Zhao,G.;Yu,C.;Zhou,Q.;Chen,W.",Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination,12-JUL-2023,8_8_14_8_3_11,8GTO_H_L,Xtal structure,SARS-CoV-2,3,1,-0.804675,5.476552
4FQC_H_L,QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSLVAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGNGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,4FQC_H,4FQC_L,Crystal Structure Of Pgt121 Fab Bound To A Complex-Type Sialylated N-Glycan,Crystal Structure Of Pgt121 Fab Bound To A Complex-Type Sialylated N-Glycan,Homo sapiens,"Mouquet,H.;Scharf,L.;Euler,Z.;Liu,Y.;Eden,C.;Scheid,J.F.;Halper-Stromberg,A.;Gnanapragasam,P.N.;Spencer,D.I.;Seaman,M.S.;Schuitemaker,H.;Feizi,T.;Nussenzweig,M.C.;Bjorkman,P.J.",Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies,25-JUN-2012,8_7_26_6_3_12,UOJ74370,Xtal structure,HIV,3,1,15.495298,-7.9307094
7PC2_O_P,QMQLVESGGGVVQPGRSLRLSCAASRFDFNRFGMHWVRQAPGKGLEWVAYMSYDGGDRYYADSVKGRFTISRDNSKSTLHLQMDSLRPEDTAVYYCAKDDILGDCSTSHCYWGYYYQGMDVWGHGTTVTVSS,EIVMTQSPDTLSVSPGERVTLSCRASQSVGSNLVWYQQKPGQSTRVLIYGASTRAATVPARFSGGGSGTEFTLTISSVQSEDFAVYYCYHYNNWPRGSFGQGTKLEIK,7PC2_O,7PC2_P,Hiv-1 Env (Bg505 Sosip.664) In Complex With The Iga Bnab 7-269 And The Antibody 3Bnc117.,Hiv-1 Env (Bg505 Sosip.664) In Complex With The Iga Bnab 7-269 And The Antibody 3Bnc117.,Homo sapiens,"Lorin,V.;Fernandez,I.;Masse-Ranson,G.;Bouvin-Pley,M.;Molinos-Albert,L.M.;Planchais,C.;Hieu,T.;Pehau-Arnaudet,G.;Hrebik,D.;Girelli-Zubani,G.;Fiquet,O.;Guivel-Benhassine,F.;Sanders,R.W.;Walker,B.D.;Schwartz,O.;Scheid,J.F.;Dimitrov,J.D.;Plevka,P.;Braibant,M.;Seaman,M.S.;Bontems,F.;Di Santo,J.P.;Rey,F.A.;Mouquet,H.",Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller,03-AUG-2021,8_8_25_6_3_10,7PC2_O_P,Xtal structure,HIV,3,1,14.120814,14.03765
7E3K_F_G,QMQLVQSGPEVKKPGTSVKVSCKASGFTFSGSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQRFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSTSCRDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPWTFGQGTKVEIK,7E3K_F,7E3K_G,Ultrapotent Sars-Cov-2 Neutralizing Antibodies With Protective Efficacy Against Newly Emerged Mutational Variants,Ultrapotent Sars-Cov-2 Neutralizing Antibodies With Protective Efficacy Against Newly Emerged Mutational Variants,Homo sapiens,"Li,T.;Han,X.;Gu,C.;Guo,H.;Zhang,H.;Wang,Y.;Hu,C.;Wang,K.;Liu,F.;Luo,F.;Zhang,Y.;Hu,J.;Wang,W.;Li,S.;Hao,Y.;Shen,M.;Huang,J.;Long,Y.;Song,S.;Wu,R.;Mu,S.;Chen,Q.;Gao,F.;Wang,J.;Long,S.;Li,L.;Wu,Y.;Gao,Y.;Xu,W.;Cai,X.;Qu,D.;Zhang,Z.;Zhang,H.;Li,N.;Gao,Q.;Zhang,G.;He,C.;Wang,W.;Ji,X.;Tang,N.;Yuan,Z.;Xie,Y.;Yang,H.;Zhang,B.;Huang,A.;Jin,A.",Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,09-FEB-2021,8_8_16_7_3_9,7E3K_F_G,Xtal structure,SARS-CoV-2,3,1,-1.0055847,2.981644
AEN14396_AEN14413,QPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVRQPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSVTAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSS,QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVL,AEN14396,AEN14413,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.; Huber,M.; Doores,K.J.; Falkowska,E.; Pejchal,R.; Julien,J.P.; Wang,S.K.; Ramos,A.; Chan-Hui,P.Y.; Moyle,M.; Mitcham,J.L.; Hammond,P.W.; Olsen,O.A.; Phung,P.; Fling,S.; Wong,C.H.; Phogat,S.; Wrin,T.; Simek,M.D.; Principal Investigators,P.G.; Koff,W.C.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Broad neutralization coverage of HIV by multiple highly potent antibodies,26-SEP-2011,10_13_21_4_3_10,QHZ10911,Unique source,HIV,3,1,17.01881,-7.706949
6P65_H_L,QSLEESGGDLVKPGASLTLTCTASGFSFGWNDYMSWVRQAPGKGLEWIGCIYAGSTRSTYYANWAKGRLTISKTSSTAVTLQMTSLTAADTATYFCARGAVTYDGLGGAYLKHFNLWGPGTLVTVSS,AIKMTQTPSSVSAAVGGTVTVNCRASEDIESYLAWYQQKPGQPPKLLIYDTSKLASGVPSRFKGSGSGTQFALTISGVQCDDAATYYCLYGYISSDRIDFGFGGGTELVVK,6P65_H,6P65_L,Hiv Env 16055 Nfl Td 2Cc+ In Complex With Antibody 1C2 Fragment Antigen Binding,Hiv Env 16055 Nfl Td 2Cc+ In Complex With Antibody 1C2 Fragment Antigen Binding,Oryctolagus cuniculus,"Dubrovskaya,V.;Tran,K.;Ozorowski,G.;Guenaga,J.;Wilson,R.;Bale,S.;Cottrell,C.A.;Turner,H.L.;Seabright,G.;O'Dell,S.;Torres,J.L.;Yang,L.;Feng,Y.;Leaman,D.P.;Vazquez Bernat,N.;Liban,T.;Louder,M.;McKee,K.;Bailer,R.T.;Movsesyan,A.;Doria-Rose,N.A.;Pancera,M.;Karlsson Hedestam,G.B.;Zwick,M.B.;Crispin,M.;Mascola,J.R.;Ward,A.B.;Wyatt,R.T.",Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability,31-MAY-2019,9_9_20_6_3_13,6P65_H_L,Xtal structure,NFL; CMT2E; NF68; PPP1R110; NEFL; HIV; CMT1F,3,1,-0.39616865,18.439922
6P62_C_D,QSLEESGGGLVKPGGTLTLTCKASGIDFTSGYDMCWVRQAPGKGLEWVACIYLGDGNTYYASWAKGQFTISKTSSTTVTLQMTSLTAADTATYFCARFAGYRYSVWSYPDLWGPGTLVTVSS,DIVMTQTPASVEADVGGTVTIKCQASQRIVNLVAWYQHKPGQPPKLLIIGASDLASGVPSRFSGSGYGTEFTLTISDLECADAATYFCQSAYNGDGDNAFGGGTEVVVK,6P62_C,6P62_D,Hiv Env Bg505 Nfl Td+ In Complex With Antibody E70 Fragment Antigen Binding,Hiv Env Bg505 Nfl Td+ In Complex With Antibody E70 Fragment Antigen Binding,Oryctolagus cuniculus,"Dubrovskaya,V.;Tran,K.;Ozorowski,G.;Guenaga,J.;Wilson,R.;Bale,S.;Cottrell,C.A.;Turner,H.L.;Seabright,G.;O'Dell,S.;Torres,J.L.;Yang,L.;Feng,Y.;Leaman,D.P.;Vazquez Bernat,N.;Liban,T.;Louder,M.;McKee,K.;Bailer,R.T.;Movsesyan,A.;Doria-Rose,N.A.;Pancera,M.;Karlsson Hedestam,G.B.;Zwick,M.B.;Crispin,M.;Mascola,J.R.;Ward,A.B.;Wyatt,R.T.",Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability,31-MAY-2019,9_8_16_6_3_11,6P62_C_D,Xtal structure,NFL; CMT2E; NF68; PPP1R110; NEFL; HIV; CMT1F,3,1,-0.42524004,18.406614
7NKS_C_D,QSLVESGGDLVKPEGSLTLTCTASGFSFSSTHWICWVRQAPGKGLEWIACIYVGNTYDSYYANWAKGRFTISKTSSTTVTLQMTTLTAADTATYFCARSGSVFGVVSLWGPGTLVTVSS,GQVLTQTPASVSEPVEGTVTIKCQASQSINNWLSWYQQRPGQPPKLLIYDASTVASGVSSRFKGSGSGTEFTLTISDLECADAATYACQSYGYGISITDNSAFGGGTEVVVR,7NKS_C,7NKS_D,Structure Of The Hantaan Virus Gn Glycoprotein Ectodomain In Complex With Fab Htn-Gn1,Structure Of The Hantaan Virus Gn Glycoprotein Ectodomain In Complex With Fab Htn-Gn1,Hantaan orthohantavirus,"Rissanen,I.;Krumm,S.A.;Stass,R.;Whitaker,A.;Voss,J.E.;Bruce,E.A.;Rothenberger,S.;Kunz,S.;Burton,D.R.;Huiskonen,J.T.;Botten,J.W.;Bowden,T.A.;Doores,K.J.",Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen,18-FEB-2021,9_9_12_6_3_14,7NKS_C_D,Xtal structure,Ectodomain,3,1,-0.3791587,18.459738
7RAI_I_M,QSQLVQSGAEMKTSGSSVRVSCKDSGGFFPYAGFRWVRQAPGQGFEWMGGVIPADGTKHYAPKFQARMKMTVVESSRTLYMELRSLTSTDTATYFCARLQCAGFSCEMDSGPFDLWGQGTQVTVPS,DIQMTQSPSTVAAFVGGNVTLSCRTSQGVGNRLAWYQQKPGKPPRLLISRASNRHGGVPARFSGGGSGTIFTLTIKGLQSDDFATFFCQQYYDSRETFGQGSRVMME,7RAI_I,7RAI_M,Cryo-Em Structure Of M4008_N1 Fab In Complex With Bg505 Ds-Sosip.664 Env Trimer,Cryo-Em Structure Of M4008_N1 Fab In Complex With Bg505 Ds-Sosip.664 Env Trimer,Homo sapiens,"Chan,K.W.;Luo,C.C.;Lu,H.;Wu,X.;Kong,X.P.",A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1,01-JUL-2021,8_8_19_6_3_9,7RAI_I_M,Xtal structure,HIV,3,1,-0.8054153,5.99382
5DMG_E_F,QSVEESGGRLVTPGTPLTLTCTVSGFSLSSNAINWVRQAPGKGLEWIGYIAVSGNTYYASWAKGRFTISKASTTVDLKMTSPTAEDTGTYFCGKSNIWGPGTLVTVS,AQVLTQTTSPVSAAVGSTVTISCQSSQSVRTNKLAWFQQKPGQPPKRLIYSASTLDFGVPSRFSASGSGTQFTLTISDVQCDDAATYYCLGYFDCSIADCVAFGGGTEVVVK,5DMG_E,5DMG_F,X-Ray Structure Of The Fab Fragment Of The Anti Tau Antibody Rb86 In Complex With The Phosphorylated Tau Peptide (416-430),X-Ray Structure Of The Fab Fragment Of The Anti Tau Antibody Rb86 In Complex With The Phosphorylated Tau Peptide (416-430),Homo sapiens,"Bujotzek,A.;Lipsmeier,F.;Harris,S.F.;Benz,J.;Kuglstatter,A.;Georges,G.",VH-VL orientation prediction for antibody humanization candidate selection: A case study,08-SEP-2015,8_7_5_7_3_13,5DMG_E_F,Xtal structure,SH3YL1; DKFZP586F1318; Ray,3,1,-0.17622094,19.099607
WGM82925_WGM82955,QTQLQQWGAGLLKPSETLSLTCAIYGESFTGSWNDQLWNWIRQPPGKGLEWIGEINHSGNTKYESSLKSRVTVSADRSKNQFSLKLTSVSAADTAVYYCVRGRRAVQWWAVEPPANYGFDVWSQGTTVTVSA,EVVLTQSPGTLSLSPGERATLSCRASQSISSTYLAWYQQKPGQAPRLLLHQGYTRATGIPDRFSASGSGTVFTLTISRLEPDDFAVYYCQHFGTSPPYTFGQGTRLEI,WGM82925,WGM82955,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,12_7_22_7_3_10,WGM82925_WGM82955,Unique source,HIV,3,1,16.81976,-10.665192
5D9Q_F_E,QVHLQESGPGLVKPSETLSLTCQVSGTLVRDNYWSWIRQPLGKQPEWIGYVHDSGDTNYNPSLKSRVHLSLDKSKNLVSLRLTGVTAADSAIYYCATTKHGRRIYGVVAFKEWFTYFYMDVWGKGTSVTVSS,VSVAPGQTARITCGEESLGSRSVIWYQQRPGQAPSLIIYNNNDRPSGIPDRFSGSPGSTFGTTATLTITSVEAGDEADYYCHIWDSRRPTNWVFGEGTTLIVL,5D9Q_F,5D9Q_E,Crystal Structure Of The Bg505 Sosip Gp140 Hiv-1 Env Trimer In Complex With The Broadly Neutralizing Fab Pgt122 And Scfv Nih45-46,Crystal Structure Of The Bg505 Sosip Gp140 Hiv-1 Env Trimer In Complex With The Broadly Neutralizing Fab Pgt122 And Scfv Nih45-46,Homo sapiens,"Jardine,J.G.;Sok,D.;Julien,J.P.;Briney,B.;Sarkar,A.;Liang,C.H.;Scherer,E.A.;Henry Dunand,C.J.;Adachi,Y.;Diwanji,D.;Hsueh,J.;Jones,M.;Kalyuzhniy,O.;Kubitz,M.;Spencer,S.;Pauthner,M.;Saye-Francisco,K.L.;Sesterhenn,F.;Wilson,P.C.;Galloway,D.M.;Stanfield,R.L.;Wilson,I.A.;Burton,D.R.;Schief,W.R.",Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design,18-AUG-2015,8_7_26_6_3_12,5D9Q_F_E,Xtal structure,HIV,3,1,15.478061,-7.9142356
7U9G_G_D,QVHLQESGPGLVKPSETLSLTCTVSGDSMNNFYWGWIRQPAGKGLEWIGYIYYSGTTNYNPSLKSRVTISIDTSKNQFSLKVNSVTAADTAVYYCARDSGDYVSYYYYGMDVWGPGTTVTVSS,QSVLTQSPSASDTPGQRVTISCSGSSSNIGSNYVYWYQQFPGTAPKLLIYKSDKRPSGVPDRFSGSTSGTSASLAISGLRSEDEADYYCAAWDNRLSGWLFGGGTKLTVL,7U9G_G,7U9G_D,Rabies Virus Glycoprotein Pre-Fusion Trimer In Complex With Neutralizing Antibody Rva122,Rabies Virus Glycoprotein Pre-Fusion Trimer In Complex With Neutralizing Antibody Rva122,Homo sapiens,"Callaway,H.M.;Zyla,D.;Larrous,F.;de Melo,G.D.;Hastie,K.M.;Avalos,R.D.;Agarwal,A.;Corti,D.;Bourhy,H.;Saphire,E.O.",Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody,20-JUL-2022,8_7_17_8_3_11,QPV12343_QPV12344,Xtal structure,Rabies,3,1,15.973611,-8.024191
CCD21802_CCD21803,QVHLQQSGAELMKPGASVKISCKATGYTFTSYWIEWVKQRPGHGLEWLGEILPGSGYIHYNEKFKGKATFTTDTSSNTAYMQLSSLTSEDSAVYYCSRALALYAMDYWGQGTSVTVSS,DIVMTQATPSIPVTPGESVSISCRSNKSLLHSNGNTYLYWFLQRPGQSPRLLIFRMSNLASGVPDRFSGSGSGTAFTLRISRVEAADVGIYFCLQHLEYPFTFGAGTKLELK,CCD21802,CCD21803,"immunoglobulin heavy chain SG/19, partial [Mus musculus]","immunoglobulin light chain SG/19, partial [Mus musculus]",Mus musculus,"Nagae,M.; Re,S.; Mihara,E.; Nogi,T.; Sugita,Y.; Takagi,J.",Crystal structure of alpha5beta1 integrin ectodomain: atomic details of the fibronectin receptor,28-SEP-2012,8_8_11_11_3_9,CCD21802_CCD21803,Unique chain,alpha5beta1,3,1,4.993643,-1.8764501
8EJJ_H_L,QVHLQQWGTGLLKPSETLSLTCAVYGGSISSYYWSWIRQPPGKGLEWIGEISHSGSTNYNPSLKSRVTISVDTSKNQLSLKLRSVTAADTAVYYCARGRDCRSVSCYVSSPENWFDPWGQGTPITVSS,YELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVMVIYKDSERPSGIPERFSGSNSGTTVTLTISGVQAEDEADYYCQSADSDGTYRVFGGGTKVTVL,8EJJ_H,8EJJ_L,Lassa Virus Glycoprotein Complex (Josiah) Bound To S370.7 Fab,Lassa Virus Glycoprotein Complex (Josiah) Bound To S370.7 Fab,Homo sapiens,"Perrett,H.R.;Brouwer,P.J.M.;Hurtado,J.;Newby,M.L.;Liu,L.;M&#xfc;ller-Kr&#xe4;uter,H.;M&#xfc;ller Aguirre,S.;Burger,J.A.;Bouhuijs,J.H.;Gibson,G.;Messmer,T.;Schieffelin,J.S.;Antanasijevic,A.;Boons,G.J.;Strecker,T.;Crispin,M.;Sanders,R.W.;Briney,B.;Ward,A.B.",Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies,07-JUN-2023,8_7_22_6_3_11,8EJJ_H_L,Xtal structure,,3,1,16.762348,-10.5549
CCD30917_CCD30918,QVHLSQSGAAVTKPGASVRVSCEASGYKISDHFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRQASWDFDTYSFYMDLKAVRSDDTAIYFCARQRSDFWDFDVWGSGTQVTVSS,DIQMTQSPSSLSARVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPARFSGRRWGQEYNLTINNLQPEDVATYFCQVYEFIVPGTRLDLK,CCD30917,CCD30918,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Scheid,J.F.; Mouquet,H.; Ueberheide,B.; Diskin,R.; Klein,F.; Oliveira,T.Y.; Pietzsch,J.; Fenyo,D.; Abadir,A.; Velinzon,K.; Hurley,A.; Myung,S.; Boulad,F.; Poignard,P.; Burton,D.R.; Pereyra,F.; Ho,D.D.; Walker,B.D.; Seaman,M.S.; Bjorkman,P.J.; Chait,B.T.; Nussenzweig,M.C.",Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding,25-JUL-2016,8_8_12_3_3_5,CCD30917_CCD30918,Unique source,HIV; CD4,3,1,2.5821874,4.003627
4DW2_H_L,QVKLQESGGDLVKPGGSLKLSCSASGFTFSRYAMSWVRQTPEKRLEWVASITNGGSTYYSDSVKGRFIISRDNARNILSLQMSSLRSEDTAMYYCERGELTYAMDYWGQGTTVTVSS,DIELTQSPAIMSASPGEKVTMTCRASSTVSFHYLHWYQQKSGASPKLWIYATSNLASGVPARFSGSGSGTSYSLTISSVETEDAATYYCQHYSAYPRTFGGGTKLEIK,4DW2_H,4DW2_L,The Crystal Structure Of Upa In Complex With The Fab Fragment Of Mab-112,The Crystal Structure Of Upa In Complex With The Fab Fragment Of Mab-112,Mus musculus,"Jiang,L.;Botkjaer,K.A.;Andersen,L.M.;Yuan,C.;Andreasen,P.A.;Huang,M.",Rezymogenation of active urokinase induced by an inhibitory antibody,24-FEB-2012,8_7_11_7_3_9,4DW2_H_L,Xtal structure,,3,1,17.917688,7.1573524
CCD30927_CCD30928,QVQLEQSGTAVRKPGASVTLSCQASGYNFVKYIIHWVRQKPGLGFEWVGMIDPYRGRPWSAHKFQGRLSLSRDTSMEILYMTLTSLKSDDTATYFCARAEAASDSHSRPIMFDHWGQGSLVTVSS,QSALTQPPSASGAPGQRVTISCSGGPSNVGGNYVYWYRQFPGTAPTLLILRDDQRPSGVPDRFSASKSGNSASLAISGLRPDDEGFYFCATYDSDGSIRLFGGGTALTVL,CCD30927,CCD30928,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Scheid,J.F.; Mouquet,H.; Ueberheide,B.; Diskin,R.; Klein,F.; Oliveira,T.Y.; Pietzsch,J.; Fenyo,D.; Abadir,A.; Velinzon,K.; Hurley,A.; Myung,S.; Boulad,F.; Poignard,P.; Burton,D.R.; Pereyra,F.; Ho,D.D.; Walker,B.D.; Seaman,M.S.; Bjorkman,P.J.; Chait,B.T.; Nussenzweig,M.C.",Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding,25-JUL-2016,8_8_18_8_3_11,CCD30927_CCD30928,Unique source,HIV; CD4,3,1,1.6300939,4.099025
7M8L_N_Q,QVQLHESGPGLVKPSQTLSLTCTVSGGSINSAGYYWTWIRQHPGKGLEWIGYIDYTGRTYYNPSLESRVIISIDTSKNHFSLRLTSVSAADTAVYYCARESSWVSELGRDNWGQGTLVTVSS,EIVMTQSPATLPVSPGEGATLSCRASQSVFTNLAWYQQKPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTYGQGTRVEVK,7M8L_N,7M8L_Q,Ebov Gp Bound To Rebov-442 And Rebov-515 Fabs,Ebov Gp Bound To Rebov-442 And Rebov-515 Fabs,Homo sapiens,"Gilchuk,P.;Murin,C.D.;Cross,R.W.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Borisevich,V.;Agans,K.N.;Geisbert,J.B.;Zost,S.J.;Nargi,R.S.;Sutton,R.E.;Suryadevara,N.;Bombardi,R.G.;Carnahan,R.H.;Bukreyev,A.;Geisbert,T.W.;Ward,A.B.;Crowe JE,Jr.",Pan-ebolavirus protective therapy by two multifunctional human antibodies,30-MAR-2021,10_7_14_6_3_9,7M8L_N_Q,Xtal structure,,3,1,16.699059,-8.196647
ADB28034,QVQLKESGPGILQPSQTLSLACSFSGFSLSTFGMSVGWIRQSSGKGLEWLAHIWWNGVKPYNPALKSRLTISRDAFNNLVFLKIASVVTADSATYYCVRWSDGAMDSWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSDGNTYLEWFLQKPGQSPKVLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCFQGSHVPPTFGGGTKLEIK,ADB28034_H,ADB28034_L,anti-chloramphenicol single-chain variable fragment antibody [synthetic construct],anti-chloramphenicol single-chain variable fragment antibody [synthetic construct],synthetic construct,"Li,H.J.; Zhao,L.; Chen,W.; Tang,W.; Li,Q.",Direct Submission,17-JAN-2010,10_7_10_11_3_9,ADB28034,Same entry,chloramphenicol,3,1,11.502953,1.9152521
3MJ8_B_A,QVQLKESGPGLLQPSQTLSLTCTVSGISLSDYGVHWVRQAPGKGLEWMGIIGHAGGTDYNSNLKSRVSISRDTSKSQVFLKLNSLQQEDTAMYFCARHFYTYFDVWGQGIQVTVSS,YTLTQPPLVSVALGQKATITCSGDKLSDVYVHWYQQKAGQAPVLVIYEDNRRPSGIPDHFSGSNSGNMATLTISKAQAGDEADYYCQSWDGTNSAWVFGSGTKVTVL,3MJ8_B,3MJ8_A,"Crystal Structure Of Hl4E10 Fab, A Hamster Ab Stimulatory For Gammadelta T Cells","Crystal Structure Of Hl4E10 Fab, A Hamster Ab Stimulatory For Gammadelta T Cells",Cricetulus migratorius,"Verdino,P.;Witherden,D.A.;Podshivalova,K.;Rieder,S.E.;Havran,W.L.;Wilson,I.A.","cDNA sequence and Fab crystal structure of HL4E10, a hamster IgG lambda light chain antibody stimulatory for gammadelta T cells",12-APR-2010,8_7_10_6_3_11,3MJ8_B_A,Xtal structure,,3,1,22.21121,-6.0072446
7KI4_H_L,QVQLKESGPGLVAPSQSLSITCTVSGFSLASYGVHWVRQPPGKGLEWLGVIWTGGSTNYNSALMSRLSINRDNSKSQVFLKLNSLQTDDTAIYYCARDRGYGYGGFAYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQHKQGKSPQLLVYNAKSLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGTPWTFGGGTKLEIK,7KI4_H,7KI4_L,Structure Of The Niv F Glycoprotein In Complex With The 12B2 Neutralizing Antibody,Structure Of The Niv F Glycoprotein In Complex With The 12B2 Neutralizing Antibody,Mus musculus,"Dang,H.V.;Cross,R.W.;Borisevich,V.;Bornholdt,Z.A.;West,B.R.;Chan,Y.P.;Mire,C.E.;Da Silva,S.C.;Dimitrov,A.S.;Yan,L.;Amaya,M.;Navaratnarajah,C.K.;Zeitlin,L.;Geisbert,T.W.;Broder,C.C.;Veesler,D.",Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins,23-OCT-2020,8_7_13_6_3_9,7KI4_H_L,Xtal structure,Hendra,3,1,22.22755,-5.983106
BDZ85351_BDZ85416,QVQLKESGPGLVAPSQSLSITCTVSGFSLINYAISWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARYSYYSYDVGFGYWGQGTTLTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSIVHSDGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFSLKISRVETEDLGVYYCFQASHVPWTFGGGTKLEIK,BDZ85351,BDZ85416,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_7_14_11_3_9,BDZ85351_BDZ85416,Unique source,SARS-CoV-2,3,1,22.050924,-6.1619287
BDZ85345_BDZ85410,QVQLKESGPGLVAPSQSLSITCTVSGFSLINYAITWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDSSKSQVFLKMNSLQTDDTARYYCARFSYYSFPYAMDYWGQGTSVTVSS,DVVMTQTPLSLSVTIGQPASISCKSSQSLLHSDGKTYLNWLLQRPGQSPKLLIYLVSKLESGIPDRVSGSGSGTDFTLKISRVEVEDLGVYYCVQHTHFPHTFGAGTKLELK,BDZ85345,BDZ85410,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_7_14_11_3_9,BDZ85345_BDZ85410,Unique source,SARS-CoV-2,3,1,22.018047,-6.195009
6CXY_H_L,QVQLKESGPGLVAPSQSLSITCTVSGFSLSRYGVHWVRQPPGKGLEWLGMMWGGGNTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCASSNYVLGYAMDYWGQGTSVTVSS,DIVMTQSPSSLAMSVGQKVTMNCKSSQSLLNSSNQKNYLAWYQQKPGQSPKLLIYFTSTRGSGVPDRFIGSGSGTDFTLTISSVEAEDLADYFCQQHYRTPHTFGGGTKVEIK,6CXY_H,6CXY_L,Crystal Structure Of Human E-Cadherin Bound By Mouse Monoclonal Antibody Fab Mab-1_19A11,Crystal Structure Of Human E-Cadherin Bound By Mouse Monoclonal Antibody Fab Mab-1_19A11,Mus musculus,"Dranow,D.M.;Phan,J.N.;Maker,A.Y.;Schecterson,L.C.;Mangio,R.S.;Gumbiner,B.M.;Lorimer,D.D.;Horanyi,P.S.;Edwards,T.E.",Crystal Structure of Human E-cadherin bound by mouse monoclonal antibody Fab mAb-1_19A11,04-APR-2018,8_7_13_12_3_9,6CXY_H_L,Xtal structure,HPT-1; CDH17; cadherin,3,1,22.084602,-6.1285696
4J1U_F_E,QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVSWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKHTYGGPGDSWGQGTSVTVSS,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPTKLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYDLPTFGAGTKLELK,4J1U_F,4J1U_E,Crystal Structure Of Antibody 93F3 Unstable Variant,Crystal Structure Of Antibody 93F3 Unstable Variant,Mus musculus,"Wang,F.;Sen,S.;Zhang,Y.;Ahmad,I.;Zhu,X.;Wilson,I.A.;Smider,V.V.;Magliery,T.J.;Schultz,P.G.",Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation,02-FEB-2013,8_7_11_12_3_8,4J1U_F_E,Xtal structure,,3,1,22.1125,-6.10083
7K9H_H_L,QVQLKQSGPGLVAPSQSLSITCTVSGFSLINYAISWVRQPPGKGLEWLGVIWTGGGTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARKDYYGRYYGMDYWGQGTSVTVS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHWVFGGGTKLTVL,7K9H_H,7K9H_L,"Sars-Cov-2 Spike In Complex With Neutralizing Fab 2B04 (One Up, Two Down Conformation)","Sars-Cov-2 Spike In Complex With Neutralizing Fab 2B04 (One Up, Two Down Conformation)",Mus musculus,"Errico,J.M.;Zhao,H.;Chen,R.E.;Liu,Z.;Case,J.B.;Ma,M.;Schmitz,A.J.;Rau,M.J.;Fitzpatrick,J.A.;Shi,P.Y.;Diamond,M.S.;Whelan,S.P.;Ellebedy,A.H.;Fremont,D.H.",Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD,29-SEP-2020,8_7_14_9_3_9,7K9H_H_L,Xtal structure,SARS-CoV-2; RBD,3,1,22.016418,-6.196475
6ARU_C_B,QVQLKQSGPGLVQPSQSLSITCTVSGFDLTDYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYADESIDGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,6ARU_C,6ARU_B,Structure Of Cetuximab Fab Mutant In Complex With Egfr Extracellular Domain,Structure Of Cetuximab Fab Mutant In Complex With Egfr Extracellular Domain,Homo sapiens,"Christie,M.;Christ,D.",Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain,23-AUG-2017,8_7_13_6_3_9,6ARU_C_B,Xtal structure,ERBB; EGFR; ERRP; ERBB1,3,1,22.58484,-5.6147375
5MHS_H_F,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYAIHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNFKSQVFFKMNSLQSNDTAIYYCARKEELYGYDGYLFFDVWGAGTTVTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYMQWYQQKPGQPPKLLIYLASNLESGVPVRFSGSGSGTDFTLNIHPVEEEDAAIYYCQHSRELPPTFGAGTKLELK,5MHS_H,5MHS_F,T1L Reovirus Sigma1 Complexed With 5C6 Fab Fragments,T1L Reovirus Sigma1 Complexed With 5C6 Fab Fragments,Mus musculus,"Dietrich,M.H.;Ogden,K.M.;Katen,S.P.;Reiss,K.;Sutherland,D.M.;Carnahan,R.H.;Goff,M.;Cooper,T.;Dermody,T.S.;Stehle,T.",Structural Insights into Reovirus sigma1 Interactions with Two Neutralizing Antibodies,25-NOV-2016,8_7_17_10_3_9,5MHS_H_F,Xtal structure,,3,1,22.571394,-5.6278563
WGM82991_WGM83027,QVQLKQWGAGLLKPSETLSLTCTVYGDSLSDYSWSWGVSRSDYYWSWIRQPPGKGLEWIGEINRSGSTKYNPSLKSRVSILIEASKNQFSLKLPSVTAADTAVYYCARGRRSRQWIGELPPGNYGLDVWGQGTPVSVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQHKPGQAPRLLISDVYRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK,WGM82991,WGM83027,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Joyce,C.; Murrell,S.; Murrell,B.; Omorodion,O.; Ver,L.S.; Carrico,N.; Bastidas,R.; Nedellec,R.; Bick,M.; Woehl,J.; Zhao,F.; Burns,A.; Barman,S.; Appel,M.; Ramos,A.; Wickramasinghe,L.; Eren,K.; Vollbrecht,T.; Smith,D.M.; Pond,S.L.K.; McBride,R.; Worth,C.; Batista,F.; Sok,D.; Poignard,P.; Briney,B.; Wilson,I.A.; Landais,E.; Burton,D.R.",Antigen pressure from two founder viruses induces multiple insertions at a single position to generate broadly neutralizing HIV antibodies,01-MAY-2023,19_7_22_7_3_10,WGM82991_WGM83027,Unique source,HIV,3,1,16.640936,-10.481347
AVE00954_AVE00955,QVQLLESGGGVVRPGGSLRLSCAASGFNFEDFGMSWVRQAPGKGLEWVSSISWNGANIGYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAIDWYRDDYYKMDVWGKGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASRSIRSALAWYQHKPGQAPRLLIFGASTRATGIPARFSGSGSGTDFTLTVSSIRSEDSAVYYCQQYDFWYTFGQGTKLEIK,AVE00954,AVE00955,"anti-Lipoaribinomannan IgVH immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-Lipoaribinomannan IgVk immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Choudhary,A.; Patel,D.; Pinter,A.","Characterization of the antigenic heterogeneity of lipoarabinomannan (LAM), the major surface glycolipid of Mycobacterium tuberculosis, and complexity of antibody specificities towards this antigen",16-FEB-2018,8_8_14_6_3_8,AVE00954_AVE00955,Unique source,hamartin; lipoarabinomannan; TSC; tuberculosis; TSC1; Lipoaribinomannan; LAM; KIAA0243,3,1,13.218407,11.903916
QBC73812_QBC74147,QVQLLESGPGLVRPSETLSLTCAVSGGSISSRNWWSWIRQPPGKGLEWIGYVSGGRDIPNYNPSLKSRVTISKDTSMNQFSLKLTSVTAADTAVYYCAREGMEDFDVWGPGVLVTVSS,DVVMTQSPLSLSITPGQPASISCRSSQSLVHSDGKTYLSWYQQKPGQPPRLLIYQVSNRCSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCGQGVHLPRTFGQGTKVEIK,QBC73812,QBC74147,"anti-HIV-1 immunoglobulin DF1W-a.s35.wk22 heavy chain variable region, partial [Macaca mulatta]","anti-HIV-1 immunoglobulin DF1W-a.s35.wk22 light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Kong,R.; Duan,H.; Sheng,Z.; Xu,K.; Acharya,P.; Chen,X.; Cheng,C.; Chuang,G.-Y.; Dingens,A.S.; Gorman,J.; Shen,C.-H.; Zhang,B.; Jafari,A.J.; Louder,M.K.; ODell,S.; Rowshan,A.P.; Viox,E.G.; Zhou,T.; Chao,C.W.; Choi,C.W.; Corcoran,M.; Corrigan,A.R.; Dandey,V.P.; Eng,E.T.; Geng,H.; Foulds,K.E.; Gu,Y.; Guo,Y.; Kwon,Y.D.; Lin,B.; Liu,K.; Mason,R.D.; Nason,M.C.; Ohr,T.Y.; Ou,L.; Rawi,R.; Sarfo,E.K.; Schon,A.; Todd,J.P.; Wang,S.; Wang,Y.; Wei,H.; Wu,W.; Comparative Sequencing Program,N.; Mullikin,J.C.; Bailer,R.T.; Doria-Rose,N.A.; Karlsson Hedestam,G.B.; Scorpio,D.G.; Overbaugh,J.; Bloom,J.D.; Carragher,B.; Potter,C.S.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.",Vaccine-Induced Developmental Pathways in Rhesus Macaques for Neutralizing Antibodies Targeting the HIV-1 Fusion Peptide,19-JUL-2019,9_8_10_11_3_9,QBC73812_QBC74147,Unique word,HIV,3,1,16.195229,-7.290873
CCD30919_CCD30920,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS,DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK,CCD30919,CCD30920,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Scheid,J.F.; Mouquet,H.; Ueberheide,B.; Diskin,R.; Klein,F.; Oliveira,T.Y.; Pietzsch,J.; Fenyo,D.; Abadir,A.; Velinzon,K.; Hurley,A.; Myung,S.; Boulad,F.; Poignard,P.; Burton,D.R.; Pereyra,F.; Ho,D.D.; Walker,B.D.; Seaman,M.S.; Bjorkman,P.J.; Chait,B.T.; Nussenzweig,M.C.",Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding,25-JUL-2016,8_8_12_3_3_5,CCD30919_CCD30920,Unique source,HIV; CD4,3,1,2.5764353,4.0402927
6CDI_3_4,QVQLLQSGAELVRPGASVTLSCKASGYAFSDYEIHWVKQTPVRGLDWIGAFDPKSGASASNQKVKGRAILTADKSSSTAYMELRSLTSEDSAVYYCTRLRYFGYFDVWGTGTTVTVSP,DVLMTQTPLSLPVSLGGQASISCRSSQSVVYSDGDTYLEWYLQKPGQSPKLLIYKVSRRFSGVPDRFSGSGSGTDFTLKISRVETEDLGVYYCFQGSHVPYTFGGGTKLEIK,6CDI_3,6CDI_4,"Cryo-Em Structure At 3.6 A Resolution Of Vaccine-Elicited Antibody Vfp16.02 In Complex With Hiv-1 Env Bg505 Ds-Sosip, And Antibodies Vrc03 And Pgt122","Cryo-Em Structure At 3.6 A Resolution Of Vaccine-Elicited Antibody Vfp16.02 In Complex With Hiv-1 Env Bg505 Ds-Sosip, And Antibodies Vrc03 And Pgt122",Homo sapiens,"Xu,K.;Acharya,P.;Kong,R.;Cheng,C.;Chuang,G.Y.;Liu,K.;Louder,M.K.;O'Dell,S.;Rawi,R.;Sastry,M.;Shen,C.H.;Zhang,B.;Zhou,T.;Asokan,M.;Bailer,R.T.;Chambers,M.;Chen,X.;Choi,C.W.;Dandey,V.P.;Doria-Rose,N.A.;Druz,A.;Eng,E.T.;Farney,S.K.;Foulds,K.E.;Geng,H.;Georgiev,I.S.;Gorman,J.;Hill,K.R.;Jafari,A.J.;Kwon,Y.D.;Lai,Y.T.;Lemmin,T.;McKee,K.;Ohr,T.Y.;Ou,L.;Peng,D.;Rowshan,A.P.;Sheng,Z.;Todd,J.P.;Tsybovsky,Y.;Viox,E.G.;Wang,Y.;Wei,H.;Yang,Y.;Zhou,A.F.;Chen,R.;Yang,L.;Scorpio,D.G.;McDermott,A.B.;Shapiro,L.;Carragher,B.;Potter,C.S.;Mascola,J.R.;Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,08-FEB-2018,8_8_11_11_3_9,6CDI_3_4,Xtal structure,HIV,3,1,0.222862,-3.4664896
7UOV_H_L,QVQLQESGAGLLKPSETLSLSCTVDGESFNGFFWTWIRQPPGKGLEWIGEINHLASTGYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARGYS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQHKPGQAPRLLIYGASKRATGIPSRFSGSGSGTDFSLTISSLEPEDFAVYYCQHRSDWRTTFGQGTRLEI,7UOV_H,7UOV_L,Native Lassa Glycoprotein In Complex With Neutralizing Antibodies 12.1F And 37.2D,Native Lassa Glycoprotein In Complex With Neutralizing Antibodies 12.1F And 37.2D,Homo sapiens,"Li,H.;Buck,T.;Zandonatti,M.;Yin,J.;Moon-Walker,A.;Fang,J.;Koval,A.;Heinrich,M.L.;Rowland,M.M.;Diaz Avalos,R.;Schendel,S.L.;Parekh,D.;Zyla,D.;Enriquez,A.;Harkins,S.;Sullivan,B.;Smith,V.;Chukwudozie,O.;Watanabe,R.;Robinson,J.E.;Garry,R.F.;Branco,L.M.;Hastie,K.M.;Saphire,E.O.",A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus,02-NOV-2022,8_7_5_6_3_9,7UOV_H_L,Xtal structure,,3,1,16.613647,-10.141565
6P95_D_E,QVQLQESGGGLVKAGGSLRLSCAASGFMFERYSLHWVRQTPGKGLEWVSSISSLSGSHINYADSVKGRFTISRDNAKNSLSLQMNSLRVEDTAIYYCARDRRSGSSPVPLDVWGQGTTVTVSS,LPVLTQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQQHPGKAPKLIIYEVKIRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYFCSSYSTNSPWVFGGGTKVTVL,6P95_D,6P95_E,Structure Of Lassa Virus Glycoprotein In Complex With Fab 25.6A,Structure Of Lassa Virus Glycoprotein In Complex With Fab 25.6A,Lassa virus Josiah,"Hastie,K.M.;Cross,R.W.;Harkins,S.S.;Zandonatti,M.A.;Koval,A.P.;Heinrich,M.L.;Rowland,M.M.;Robinson,J.E.;Geisbert,T.W.;Garry,R.F.;Branco,L.M.;Saphire,E.O.",Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization,09-JUN-2019,8_9_15_9_3_10,UOS75573_UOS75589,Xtal structure,,3,1,16.134415,9.949694
1BFV_H_L,QVQLQESGGGLVNLGGSMTLSCVASGFTFNTYYMSWVRQTPEKTLELVAAINSDGEPIYYPDTLKGRVTISRDNAKKTLYLQMSSLNFEDTALYYCARLNYAVYGMDYWGQGTTVTVSS,DIELTQSPPSLPVSLGDQVSISCRSSQSLVSNNRRNYLHWYLQKPGQSPKLVIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVAAEDLGLYFCSQSSHVPLTFGSGTKLEIK,1BFV_H,1BFV_L,Monoclonal Antibody Fragment Fv4155 From E. Coli,Monoclonal Antibody Fragment Fv4155 From E. Coli,Mus musculus,"Trinh,C.H.;Hemmington,S.D.;Verhoeyen,M.E.;Phillips,S.E.",Antibody fragment Fv4155 bound to two closely related steroid hormones: the structural basis of fine specificity,27-MAY-1997,8_8_12_11_3_9,1BFV_H_L,Xtal structure,,3,1,17.622066,6.888087
7KQB_K_J,QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLITMVRGEDYWGQGTLVTVSS,DIQLTQSPSSLSASVGHRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNLPRTFGGGTKLEVL,7KQB_K,7KQB_J,Sars-Cov-2 Spike Glycoprotein:Fab 5A6 Complex I,Sars-Cov-2 Spike Glycoprotein:Fab 5A6 Complex I,Homo sapiens,"Asarnow,D.;Wang,B.;Lee,W.H.;Hu,Y.;Huang,C.W.;Faust,B.;Ng,P.M.;Ngoh,E.Z.;Bohn,M.;Bulkley,D.;Pizzorno,A.;Ary,B.;Tan,H.C.;Lee,C.Y.;Minhat,R.A.;Terrier,O.;Soh,M.K.;Teo,F.J.;Yeap,Y.Y.;Seah,S.G.;Chan,C.E.;Connelly,E.;Young,N.J.;Maurer-Stroh,S.;Renia,L.;Hanson,B.J.;Rosa-Calatrava,M.;Manglik,A.;Cheng,Y.;Craik,C.S.;Wang,C.I.",Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia,14-NOV-2020,8_8_12_6_3_9,7KQB_K_J,Xtal structure,SARS-CoV-2,3,1,14.697957,12.963115
CAO78312,QVQLQESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSVISGSGHTTNYADSVKGRVTISRDNSKNTLYLQINSLRADDTAVYYCARDVLVLQNAFDIWGQGTTVTVSS,DVVMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYICQQSYSRPLTFGGGTKVEIK,CAO78312_H,CAO78312_L,"unnamed protein product, partial [Escherichia coli]","unnamed protein product, partial [Escherichia coli]",Escherichia coli,"Minenkova,O.; Pavoni,E.",Method of improving the antibody selection capacity in phage-display library,10-JUL-2007,8_8_13_6_3_9,AEN51966,Same entry,,3,1,13.877431,9.65755
AEN14397_AEN14414,QVQLQESGPGLVKPAETLSLTCSVSGESINTGHYYWGWVRQVPGKGLEWIGHIHYTTAVLHNPSLKSRLTIKIYTLRNQITLRLSNVTAADTAVYHCVRSGGDILYYYEWQKPHWFSPWGPGIHVTVSS,QSALTQPPSASGSLGQSVTISCNGTSSDIGGWNFVSWYQQFPGRAPRLIIFEVNKRPSGVPGRFSGSKSGNSASLTVSGLQSDDEGQYFCSSLFGRWDVVFGGGTKLTVL,AEN14397,AEN14414,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.; Huber,M.; Doores,K.J.; Falkowska,E.; Pejchal,R.; Julien,J.P.; Wang,S.K.; Ramos,A.; Chan-Hui,P.Y.; Moyle,M.; Mitcham,J.L.; Hammond,P.W.; Olsen,O.A.; Phung,P.; Fling,S.; Wong,C.H.; Phogat,S.; Wrin,T.; Simek,M.D.; Principal Investigators,P.G.; Koff,W.C.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Broad neutralization coverage of HIV by multiple highly potent antibodies,26-SEP-2011,10_7_21_9_3_10,AEN14397_AEN14414,Unique source,HIV,3,1,16.565075,-7.797536
6XSK_I_K,QVQLQESGPGLVKPSEILSLTCAVSGGSFSSYCWGWIRQPPGKGLEWIGSICGSGGSNYLNPSLKSRVTLSVDTSKNQFSLILNSVTAADTAVYYCAREGITIFGVVIPRVLDSWGQGAVVTVSS,DIQMTQSPSSLSASVGDTVTITCRASQSISSWLAWYQQKPGKAPNLLIYRASTLQSGVPSRFSGSGSGTDFTLTISSLQSEDFATYFCQQSTSSPFTFGPGTKLDIK,6XSK_I,6XSK_K,Cryo-Em Structure Of Vaccine-Elicited Rhesus Vh6-1 Antibody 789-203-3C12 In Complex With Stabilized Si06 (A/Solomon Islands/3/06) Influenza Hemagglutinin Trimer,Cryo-Em Structure Of Vaccine-Elicited Rhesus Vh6-1 Antibody 789-203-3C12 In Complex With Stabilized Si06 (A/Solomon Islands/3/06) Influenza Hemagglutinin Trimer,Macaca mulatta,"Moin,S.M.;Boyington,J.C.;Boyoglu-Barnum,S.;Gillespie,R.A.;Cerutti,G.;Cheung,C.S.;Cagigi,A.;Gallagher,J.R.;Brand,J.;Prabhakaran,M.;Tsybovsky,Y.;Stephens,T.;Fisher,B.E.;Creanga,A.;Ataca,S.;Rawi,R.;Corbett,K.S.;Crank,M.C.;Karlsson Hedestam,G.B.;Gorman,J.;McDermott,A.B.;Harris,A.K.;Zhou,T.;Kwong,P.D.;Shapiro,L.;Mascola,J.R.;Graham,B.S.;Kanekiyo,M.",Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses,15-JUL-2020,8_8_18_6_3_9,6XSK_I_K,Xtal structure,hemagglutinin; Influenza,3,1,16.591894,-7.633743
QEP20394_QEP21042,QVQLQESGPGLVKPSETLLLTCTVSGGSISHHYWHWIRQAPGKGLEWIGYVYYSGSTKYHPSLKSRITISLDSSKNQFSLKLPSMTAADTAIYYCSRGHYDILTGALDSWGQGILVTVSS,EIVMTQSPVTLSVSPGDRATLSCRASESISDNVAWYQQRPGQAPRLLLYGSFTRATGVPARFSGSGSGTEFTLTISGLQSEDFALYYCQHQVSFGPGTKVEIK,QEP20394,QEP21042,"IGH + IGL c501_heavy_IGHV4-59B_IGHD3-9_IGHJ4, partial [Homo sapiens]","IGH + IGL c501_light_IGKV3-15_IGKJ3, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_14_6_3_5,QEP20394_QEP21042,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,3,1,16.183334,-7.8405023
6PDX_M_N,QVQLQESGPGLVKPSETLSLTCAVSGASISSFYWSWIRQSPGKGLEWIAYIYYSGKTQYNPAVTGRATISLQNWNNHVALRVNSVTAADTAIYSCARHTLAYHYDDEGYMQPGDAFDLWGQGTMVTVSS,QSVLTQPPSVSAPAGQMVTIPCSGSSSDIGKSFVSWYQQLPGTAPKLVIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEAVYYCGTWDSSLIWVFGGGTKLTVL,6PDX_M,6PDX_N,Crystal Structure Of C585 Fab In Complex With Influenza Virus Hemagglutinin From A/Switzerland/9715293/2013 (H3N2),Crystal Structure Of C585 Fab In Complex With Influenza Virus Hemagglutinin From A/Switzerland/9715293/2013 (H3N2),Homo sapiens,"Qiu,Y.;Stegalkina,S.;Zhang,J.;Boudanova,E.;Park,A.;Zhou,Y.;Prabakaran,P.;Pougatcheva,S.;Ustyugova,I.V.;Vogel,T.U.;Mundle,S.T.;Oomen,R.;Delagrave,S.;Ross,T.M.;Kleanthous,H.;Qiu,H.",Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth,19-JUN-2019,8_7_23_8_3_10,6PDX_M_N,Xtal structure,Influenza; H3N2,3,1,16.205101,-8.074852
6U3Z_C_D,QVQLQESGPGLVKPSETLSLTCAVSGASISSNYWSWIRQPPGKGLEWIGRIYDPTDSTDYNPSLESRATISKDTSKNHFSLTLSSVTAADTAVYFCARGLWSGYFFWFDVWGPGVLVTVSS,DIQMTQSPSSLSASVGDSVTVTCRASQGIDKELSWYQQKPGKAPTLLIYAASSLQTGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCLQDYATPYSFGQGTKVEIK,6U3Z_C,6U3Z_D,Structure Of Vd20_5A4 Fab,Structure Of Vd20_5A4 Fab,Macaca mulatta,"Phad,G.E.;Pushparaj,P.;Tran,K.;Dubrovskaya,V.;Adori,M.;Martinez-Murillo,P.;Vazquez Bernat,N.;Singh,S.;Dionne,G.;O'Dell,S.;Bhullar,K.;Narang,S.;Sorini,C.;Villablanca,E.J.;Sundling,C.;Murrell,B.;Mascola,J.R.;Shapiro,L.;Pancera,M.;Martin,M.;Corcoran,M.;Wyatt,R.T.;Karlsson Hedestam,G.B.",Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses,22-AUG-2019,8_8_14_6_3_9,6U3Z_C_D,Xtal structure,HIV,3,1,16.349419,-7.354757
8DUN_H_L,QVQLQESGPGLVKPSETLSLTCAVSGDSISNNYWTWIRHFPGKGLEWIGRIYGDAGSTDYNPSLKSRVTISMDLSKNQFSLDLTSVTVADTALYYCASRTTVADNWFDVWGPGVLVTVSS,DIQMTQSPSSLSASVGDTVTITCRATQSISSLLAWYQYKPGKAPKLLIYQASSLHIGVPSRFSGSGSGTDFTLTISSLQSEDFATYYCQQHDSRPWTFGQGTKVDIK,8DUN_H,8DUN_L,Cryo-Em Structure Of Antibody Skw11 In Complex With Western Equine Encephalitis Virus Spike (Local Refinement From Vlp Particles),Cryo-Em Structure Of Antibody Skw11 In Complex With Western Equine Encephalitis Virus Spike (Local Refinement From Vlp Particles),Macaca fascicularis,"Sutton,M.S.;Pletnev,S.;Callahan,V.;Ko,S.;Tsybovsky,Y.;Bylund,T.;Casner,R.G.;Cerutti,G.;Gardner,C.L.;Guirguis,V.;Verardi,R.;Zhang,B.;Ambrozak,D.;Beddall,M.;Lei,H.;Yang,E.S.;Liu,T.;Henry,A.R.;Rawi,R.;Sch&#xf6;n,A.;Schramm,C.A.;Shen,C.H.;Shi,W.;Stephens,T.;Yang,Y.;Florez,M.B.;Ledgerwood,J.E.;Burke,C.W.;Shapiro,L.;Fox,J.M.;Kwong,P.D.;Roederer,M.",Vaccine elicitation and structural basis for antibody protection against alphaviruses,05-JUL-2023,8_8_13_6_3_9,8DUN_H_L,Xtal structure,,3,1,16.288406,-7.4383903
6WZT_H_L,QVQLQESGPGLVKPSETLSLTCAVSGGTFSAYYWGWIRQPPGKGLEWIGSISGGSGSTDYSPSLKSRATISRDTSKNQFSLKLTSVTAADTAVYYCVRKYWGDYYANWFDVWGPGVLVTVSS,DIQMTQSPSSLSASVGDTVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLQGGVPSRFSGSGSGSDFTLTISSLQSEDFATYYCQQYSGRPPTFGQGTKVEIK,6WZT_H,6WZT_L,Cryoem Structure Of Influenza Hemagglutinin A/Victoria/361/2011 In Complex With Cyno Antibody 3B10,Cryoem Structure Of Influenza Hemagglutinin A/Victoria/361/2011 In Complex With Cyno Antibody 3B10,Macaca fascicularis,"Darricarrere,N.;Qiu,Y.;Kanekiyo,M.;Creanga,A.;Gillespie,R.A.;Moin,S.M.;Saleh,J.;Sancho,J.;Chou,T.H.;Zhou,Y.;Zhang,R.;Dai,S.;Moody,A.;Saunders,K.O.;Crank,M.C.;Mascola,J.R.;Graham,B.S.;Wei,C.J.;Nabel,G.J.",Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates,14-MAY-2020,8_8_15_6_3_9,6WZT_H_L,Xtal structure,Influenza,3,1,16.359648,-7.458434
2JIX_H_L,QVQLQESGPGLVKPSETLSLTCTVSGASISSYYWSWIRQPPGKGLEWIGYIGGEGSTNYNPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARERLGIGDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPPTFGQGTKVEIK,2JIX_H,2JIX_L,Crystal Structure Of Abt-007 Fab Fragment With The Soluble Domain Of  Epo Receptor,Crystal Structure Of Abt-007 Fab Fragment With The Soluble Domain Of  Epo Receptor,Homo sapiens,"Liu,Z.;Stoll,V.S.;Devries,P.J.;Jakob,C.G.;Xie,N.;Simmer,R.L.;Lacy,S.E.;Egan,D.A.;Harlan,J.E.;Lesniewski,R.R.;Reilly,E.B.",A potent erythropoietin-mimicking human antibody interacts through a novel binding site,02-JUL-2007,8_7_10_6_3_9,2JIX_H_L,Xtal structure,erythropoietin,3,1,16.190193,-7.6748614
7CZW_H_L,QVQLQESGPGLVKPSETLSLTCTVSGDSVSSGSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERCYYGSGRAPRCVWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVVFGGGTKLTVL,7CZW_H,7CZW_L,S Protein Of Sars-Cov-2 In Complex Bound With P5A-2G7,S Protein Of Sars-Cov-2 In Complex Bound With P5A-2G7,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,10_7_20_9_3_11,7CZW_H_L,Xtal structure,SARS-CoV-2,3,1,16.320164,-8.216361
5TH9_J_N,QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK,5TH9_J,5TH9_N,"Structure Determination Of A Potent, Selective Antibody Inhibitor Of Human Mmp9 (Gs-5745 Bound To Mmp-9)","Structure Determination Of A Potent, Selective Antibody Inhibitor Of Human Mmp9 (Gs-5745 Bound To Mmp-9)",Homo sapiens,"Appleby,T.C.;Greenstein,A.E.;Hung,M.;Liclican,A.;Velasquez,M.;Villasenor,A.G.;Wang,R.;Wong,M.H.;Liu,X.;Papalia,G.A.;Schultz,B.E.;Sakowicz,R.;Smith,V.;Kwon,H.J.","Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9",29-SEP-2016,8_7_9_6_3_9,AVA51861_AVA51866,Xtal structure,CLG4B; MMP9,3,1,22.087645,-6.1216116
4JN2_H_L,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK,4JN2_H,4JN2_L,An Antidote For Dabigatran,An Antidote For Dabigatran,Mus musculus,"Schiele,F.;van Ryn,J.;Canada,K.;Newsome,C.;Sepulveda,E.;Park,J.;Nar,H.;Litzenburger,T.",A specific antidote for dabigatran: functional and structural characterization,14-MAR-2013,8_7_16_11_3_9,AJO27352,Xtal structure,,3,1,16.206968,-7.717773
QEP20423_QEP21071,QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIERQPYYYFYMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDSSLSAGVFGGGTKLTVL,QEP20423,QEP21071,"IGH + IGL c530_heavy_IGHV4-59B_IGHD6-25_IGHJ6, partial [Homo sapiens]","IGH + IGL c530_light_IGLV1-51_IGLJ2, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_7_15_8_3_11,QEP20423_QEP21071,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,3,1,15.888681,-7.9423695
1U6A_H_L,QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQSPGKGLQWIGYIYYSGSTNYSPSLKSRVTISVETAKNQFSLKLTSMTAADTAVYYCARGPVPAVFYGDYRLDPWGQGTLVTVSS,EIVLTQSPGTLSLSAGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRVEPEDFAVYYCQQYDNSVCTFGQGTKLEIK,1U6A_H,1U6A_L,Crystal Structure Of The Broadly Neutralizing Anti-Hiv Fab F105,Crystal Structure Of The Broadly Neutralizing Anti-Hiv Fab F105,Homo sapiens,"Wilkinson,R.A.;Piscitelli,C.;Teintze,M.;Cavacini,L.A.;Posner,M.R.;Lawrence,C.M.","Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120",29-JUL-2004,8_7_17_7_3_9,1U6A_H_L,Xtal structure,gp120; HIV; CD4,3,1,16.064363,-7.929238
7CZX_I_M,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYISYSGSTNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAVYYCASNGQYYDILTGQPPDYWYFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK,7CZX_I,7CZX_M,S Protein Of Sars-Cov-2 In Complex Bound With P5A-1B9,S Protein Of Sars-Cov-2 In Complex Bound With P5A-1B9,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_7_22_12_3_9,7CZX_I_M,Xtal structure,SARS-CoV-2,3,1,16.121473,-7.8949313
QPF16744_QPF16745,QVQLQESGPGLVKPSETLSLTCTVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKTRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAVVGIVVVPAAGRRAFDIWGQGTMVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLVFGGGTKLTVL,QPF16744,QPF16745,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ju,B.; Zhang,Q.; Ge,J.; Wang,X.; Zhang,Z.; Zhang,L.",Direct Submission,23-NOV-2020,9_7_20_9_3_10,QPF16744_QPF16745,Unique source,SARS-CoV-2,3,1,16.65109,-7.866365
ANC49860_ANC49911,QVQLQESGPGLVKPSETLSVTCAVSGVSFSSFWWGWIRQSPGKGLEWIGTIYGSSGRGEYNPSLKSRTTISRDTSKSQISLELTSVTAADTAIYYCSRGLFQPAGFTFTLTSYWFDVWGPGVPVTVSS,DIQVTQSPSSLSASVGDTVTISCRTSQSISTWLAWYQVKPGKAPKLLIYTASSLASGVPSRFSGSGSGTDFTLTISSLQSEDFATYYCQQYISLPPTFGLGTKVEIK,ANC49860,ANC49911,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin kappa light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Zhang,R.; Verkoczy,L.; Wiehe,K.; Munir Alam,S.; Nicely,N.I.; Santra,S.; Bradley,T.; Pemble,C.W. IV; Zhang,J.; Gao,F.; Montefiori,D.C.; Bouton-Verville,H.; Kelsoe,G.; Larimore,K.; Greenberg,P.D.; Parks,R.; Foulger,A.; Peel,J.N.; Luo,K.; Lu,X.; Trama,A.M.; Vandergrift,N.; Tomaras,G.D.; Kepler,T.B.; Moody,M.A.; Liao,H.X.; Haynes,B.F.",Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages,09-MAY-2016,8_8_21_6_3_9,ANC49860_ANC49911,Unique source,HIV,3,1,16.397715,-7.323987
6OKQ_D_C,QVQLQESGPGLVKPSETLSVTCRVSGGSLDLYYWSWIRQPPGKGLQWIGFVYFDGSYGDYDPSLRSRVTISADMSKNQISLRLKSVTPADTAVYYCARLGPGGIFDRWTGHYGDKWLDPWGQGTLVTVSS,IDLTQSPRTLSLSAGERATLLCRASQSVSNVALAWYQHKPGQAPRLLLHEASTRATGIPDRFIGSGSGRDFTLTITSLEPEDFAVYYCQLSGRRLGQGTKVEIK,6OKQ_D,6OKQ_C,Crystal Structure Of The Sf12 Fab,Crystal Structure Of The Sf12 Fab,Homo sapiens,"Schoofs,T.;Barnes,C.O.;Suh-Toma,N.;Golijanin,J.;Schommers,P.;Gruell,H.;West AP,Jr.;Bach,F.;Lee,Y.E.;Nogueira,L.;Georgiev,I.S.;Bailer,R.T.;Czartoski,J.;Mascola,J.R.;Seaman,M.S.;McElrath,M.J.;Doria-Rose,N.A.;Klein,F.;Nussenzweig,M.C.;Bjorkman,P.J.",Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope,14-APR-2019,8_8_23_7_3_6,6OKQ_D_C,Xtal structure,HIV,3,1,16.106356,-7.909727
AOT82812_AOT82813,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARDRDDLSPFDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEIK,AOT82812,AOT82813,"anti-ZIKV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-ZIKV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Wang,Q.; Yang,H.; Liu,X.; Dai,L.; Ma,T.; Qi,J.; Wong,G.; Peng,R.; Liu,S.; Li,J.; Li,S.; Song,J.; Liu,J.; He,J.; Yuan,H.; Xiong,Y.; Liao,Y.; Li,J.; Yang,J.; Tong,Z.; Griffin,B.D.; Bi,Y.; Liang,M.; Xu,X.; Qin,C.; Cheng,G.; Zhang,X.; Wang,P.; Qiu,X.; Kobinger,G.; Shi,Y.; Yan,J.; Gao,G.F.",Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus,27-DEC-2016,9_7_12_6_3_9,AOT82812_AOT82813,Unique source,Zika; ZIKV,3,1,15.626062,-7.435472
6DFH_H_L,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARNAITIFGVVIIGEYYYYGMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYWVFGGGTKLTVL,6DFH_H,6DFH_L,Bg505 Md64 N332-Gt2 Sosip Trimer In Complex With Germline-Reverted Bg18 Fragment Antigen Binding,Bg505 Md64 N332-Gt2 Sosip Trimer In Complex With Germline-Reverted Bg18 Fragment Antigen Binding,Homo sapiens,"Steichen,J.M.;Lin,Y.C.;Havenar-Daughton,C.;Pecetta,S.;Ozorowski,G.;Willis,J.R.;Toy,L.;Sok,D.;Liguori,A.;Kratochvil,S.;Torres,J.L.;Kalyuzhniy,O.;Melzi,E.;Kulp,D.W.;Raemisch,S.;Hu,X.;Bernard,S.M.;Georgeson,E.;Phelps,N.;Adachi,Y.;Kubitz,M.;Landais,E.;Umotoy,J.;Robinson,A.;Briney,B.;Wilson,I.A.;Burton,D.R.;Ward,A.B.;Crotty,S.;Batista,F.D.;Schief,W.R.",A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses,14-MAY-2018,9_7_23_6_3_11,6DFH_H_L,Xtal structure,HIV,3,1,15.370896,-7.434961
6PCU_I_H,QVQLQESGPGLVKPSQTLSLTCSVSGVSLSGGSYTWNWIRQPAGKGLEWIGRIFTSGSTNYNPSLKGRLTMSIDTSKNQLSLRLSSVTAADTAVYYCVADYYYSVPDVWGQGTPVTVSS,QPVLTQPPSASASLGASVTLTCTLSSGYSNYKVDWYQQRPGKGPRFVMRVGTGGIVGSKGDGIADRFSVSGSGLNRSLTIKNIQEEDESDYHCGADHGSGDNFVRVFGGGTKLTVL,6PCU_I,6PCU_H,Vp8* Of A G2P[4] Human Rotavirus In Complex With Scfv Antibody 9,Vp8* Of A G2P[4] Human Rotavirus In Complex With Scfv Antibody 9,Homo sapiens,"Feng,N.;Hu,L.;Ding,S.;Sanyal,M.;Zhao,B.;Sankaran,B.;Ramani,S.;McNeal,M.;Yasukawa,L.L.;Song,Y.;Prasad,B.V.;Greenberg,H.B.",Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells,18-JUN-2019,10_7_11_7_8_13,6PCU_I_H,Xtal structure,,3,1,16.389494,-7.81861
4N90_H_I,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK,4N90_H,4N90_I,"Crystal Structure Of Ternary Complex Of Trail, Dr5, And Fab Fragment From A Dr5 Agonist Antibody","Crystal Structure Of Ternary Complex Of Trail, Dr5, And Fab Fragment From A Dr5 Agonist Antibody",Homo sapiens,"Graves,J.D.;Kordich,J.J.;Huang,T.H.;Piasecki,J.;Bush,T.L.;Sullivan,T.;Foltz,I.N.;Chang,W.;Douangpanya,H.;Dang,T.;O'Neill,J.W.;Mallari,R.;Zhao,X.;Branstetter,D.G.;Rossi,J.M.;Long,A.M.;Huang,X.;Holland,P.M.",Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity,18-OCT-2013,10_7_14_7_3_9,4N90_H_I,Xtal structure,TL2; AIH1; CD253; TRAIL; AMELX; Apo-2L; TNFSF10; AMG,3,1,16.271822,-8.19777
UNJ20730_UNJ20865,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSSGYFWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSLTAADTAVYYCARVGSGRAFDIWGQGTMVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSLSDSYLAWYQQKPGQAPRLLIYNASSRATGIPDRFSGSGSGTDFTLTISRLAPEDFAVYYCQYYGSSLFGQGTRLEIK,UNJ20730,UNJ20865,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Ercanoglu,M.S.; Gieselmann,L.; Dahling,S.; Poopalasingam,N.; Detmer,S.; Koch,M.; Korenkov,M.; Halwe,S.; Kluver,M.; Di Cristanziano,V.; Janicki,H.; Schlotz,M.; Worczinski,J.; Gathof,B.; Gruell,H.; Zehner,M.; Becker,S.; Vanshylla,K.; Kreer,C.; Klein,F.",No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults,23-MAR-2022,10_7_11_7_3_7,UNJ20730_UNJ20865,Unique source,SARS-CoV-2,3,1,16.584202,-8.235308
2VL5_C_D,QVQLQQPGADLVRPGVSVKLSCKASGYTFTSYWMNWVKQRPGQGLEWIGMIHPSDSETRLSQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCARLKPGGTWFAYWGQGTLVTVSA,DIVLTQSPASLTVSLGQRATISCRASKSVDSYGNSFMEWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK,2VL5_C,2VL5_D,Structure Of Anti-Collagen Type Ii Fab Ciic1,Structure Of Anti-Collagen Type Ii Fab Ciic1,Mus musculus,"Uysal,H.;Sehnert,B.;Nandakumar,K.S.;Boiers,U.;Burkhardt,H.;Holmdahl,R.;Thunnissen,M.M.",The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: structure to function analysis,08-JAN-2008,8_8_12_10_3_9,2VL5_C_D,Xtal structure,Collagen,3,1,-0.37549075,-3.627899
7UI0_H_L,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWIHWVKQGPGQGLEWIGMIHPNSGITHYNEKFKTKATLTVDKSSSTAYMQLSSLTSEDSAVCYCARGSSSGSAWFAYWGQGTLVTVSA,DIQMTQSSSYLSESLGGRVTITCKASDHINNWLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDVATYYCQQYWSSPLTFGAGTKLELK,7UI0_H,7UI0_L,Post-Fusion Ectodomain Of Hsv-1 Gb In Complex With Hsv010-13 Fab,Post-Fusion Ectodomain Of Hsv-1 Gb In Complex With Hsv010-13 Fab,Mus musculus,"Kuraoka,M.;Aschner,C.B.;Windsor,I.W.;Mahant,A.M.;Garforth,S.J.;Kong,S.L.;Achkar,J.M.;Almo,S.C.;Kelsoe,G.;Herold,B.C.",A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice,08-JAN-2009,8_8_13_6_3_9,7UI0_H_L,Xtal structure,herpes; Ectodomain,3,1,-0.4917877,-4.0011764
7UZ6_H_L,QVQLQQPGAELVKPGASVKMSCKASGYNFNHYWISWVKQRPGQGLEWIGDIYPLSHFTTYNEKFTNRATLTVDTSSTTAYMQLNSLTSDDSAVFYCARWDYFDSRTFDYWGQGTTLTVSS,DILLTQFPAILSVSPGERVSFSCRASQTIGTNIHWYQQRINGSPRLLIKYASESISGIPSRFSGSGSGTDFSLSINNVESEDIADYYCQQINSWPLTFGAGTKLDLK,7UZ6_H,7UZ6_L,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Mouse Antibody Fab Fragment, M8A-28","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Mouse Antibody Fab Fragment, M8A-28",Mus musculus,"Fan,C.;Cohen,A.A.;Park,M.;Hung,A.F.;Keeffe,J.R.;Gnanapragasam,P.N.P.;Lee,Y.E.;Gao,H.;Kakutani,L.M.;Wu,Z.;Kleanthous,H.;Malecek,K.E.;Williams,J.C.;Bjorkman,P.J.",Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes,07-DEC-2022,8_8_13_6_3_9,7UZ6_H_L,Xtal structure,RBD,3,1,-0.69296855,-4.003175
7ZOR_I_M,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYWITWVIQRPGQGLEWIGDIYCGSDTMHYNEKFKNKATLTVDTSSSTAYMQLSSLTSEDSAVYYCARWWDYGSSYDYFDYWGQGTTLTVSS,DIKMTQSPSSMYASLGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEIK,7ZOR_I,7ZOR_M,Crystal Structure Of Anti-Siglec-15 Fab,Crystal Structure Of Anti-Siglec-15 Fab,Homo sapiens,"Lenza,M.P.;Egia-Mendikute,L.;Anto&#xf1;ana-Vildosola,A.;Soares,C.O.;Coelho,H.;Corzana,F.;Bosch,A.;Manisha,P.;Quintana,J.I.;Oyenarte,I.;Unione,L.;Moure,M.J.;Azkargorta,M.;Atxabal,U.;Sobczak,K.;Elortza,F.;Sutherland,J.D.;Barrio,R.;Marcelo,F.;Jim&#xe9;nez-Barbero,J.;Palazon,A.;Ere&#xf1;o-Orbea,J.",Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b,28-JUN-2023,8_8_15_6_3_9,7ZOR_I_M,Xtal structure,Siglec,3,1,-0.71138257,-3.9679224
7UZ4_H_L,QVQLQQPGAELVLPGASVKLSCKASGYTFTNYWMHWVKQRPGHGLEWIGEIDPFDTYIKINQKFKGKSTLTVDTSSSTAYMQLSSLTSEDSAVYYCARPDSSGYPVYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVGTYIAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTNYTLTISSVQAEDLALYHCQQHYSTPYTFGGGTKLEIK,7UZ4_H,7UZ4_L,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Mouse Antibody Fab Fragment, M8A-3","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Mouse Antibody Fab Fragment, M8A-3",Mus musculus,"Fan,C.;Cohen,A.A.;Park,M.;Hung,A.F.;Keeffe,J.R.;Gnanapragasam,P.N.P.;Lee,Y.E.;Gao,H.;Kakutani,L.M.;Wu,Z.;Kleanthous,H.;Malecek,K.E.;Williams,J.C.;Bjorkman,P.J.",Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes,07-DEC-2022,8_8_14_6_3_9,7UZ4_H_L,Xtal structure,RBD,3,1,-0.6914037,-3.8201983
6Y54_O_P,QVQLQQPGSELVRPGASVKLSCKASGYTFTNYWMHWVKQRPGQGLEWIGNIYPGSGTTNYNEKFKRKATLTVDTSSNTAYMELSSLTSEDSAVYFCTVVRMDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLIYSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQNTHIPYTFGGGTKLEIK,6Y54_O,6Y54_P,Crystal Structure Of A Neisseria Meningitidis Serogroup A Capsular Oligosaccharide Bound To A Functional Fab,Crystal Structure Of A Neisseria Meningitidis Serogroup A Capsular Oligosaccharide Bound To A Functional Fab,Mus musculus,"Dello Iacono,L.;Henriques,P.;Adamo,R.",Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide,24-FEB-2020,8_8_7_11_3_9,6Y54_O_P,Xtal structure,,3,1,-0.44418857,-4.141303
6BB4_I_M,QVQLQQSDAELVKPGASVKISCKASGYTFTDRTIHWVKQRPEQGLEWIGYIYPGDDSTKYNDMFKAKATLTADKSSNTAYMQLNSLTSDDSAVYFCARRGTMDYWGQGTSVTVSS,DVQMIQSPSSLSASLGDIVTMTCQASQDTSINLNWFQQKPGKAPKLLIYGASNLEDGVPSRFSGSRYGTDFTLTISSLEDEDMATYFCLQHTYLPFTFGSGTKLEIK,6BB4_I,6BB4_M,Fab/Epitope Complex Of Mouse Monoclonal Antibody C5.2 Targeting A Phospho-Tau Epitope.,Fab/Epitope Complex Of Mouse Monoclonal Antibody C5.2 Targeting A Phospho-Tau Epitope.,Homo sapiens,"Chukwu,J.E.;Pedersen,J.T.;Pedersen,L.O.;Volbracht,C.;Sigurdsson,E.M.;Kong,X.P.",Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein,16-OCT-2017,8_8_8_6_3_9,QKP08836_QKP08835,Xtal structure,,3,1,0.26511833,-4.3923826
6CDE_H_L,QVQLQQSGADLVRPGASVTLSCKASGYTFTDYEMHWMKQTPVHGLEWIGAIVPETGYTAYNQKFKGKAILTADKSSNTVYMQFRSLTSEDSAVYYCSRLKLLGYFDVWGTGTTVTVSP,DVLMTQTPLSLPVSLGDQASISCKSSQSIVYKDGNSYLEWYLQKVGQSPKLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGTHLPYTFGGGTKLEMK,6CDE_H,6CDE_L,"Cryo-Em Structure At 3.8 A Resolution Of Vaccine-Elicited Antibody Vfp20.01 In Complex With Hiv-1 Env Bg505 Ds-Sosip, And Antibodies Vrc03 And Pgt122","Cryo-Em Structure At 3.8 A Resolution Of Vaccine-Elicited Antibody Vfp20.01 In Complex With Hiv-1 Env Bg505 Ds-Sosip, And Antibodies Vrc03 And Pgt122",Human immunodeficiency virus 1,"Xu,K.;Acharya,P.;Kong,R.;Cheng,C.;Chuang,G.Y.;Liu,K.;Louder,M.K.;O'Dell,S.;Rawi,R.;Sastry,M.;Shen,C.H.;Zhang,B.;Zhou,T.;Asokan,M.;Bailer,R.T.;Chambers,M.;Chen,X.;Choi,C.W.;Dandey,V.P.;Doria-Rose,N.A.;Druz,A.;Eng,E.T.;Farney,S.K.;Foulds,K.E.;Geng,H.;Georgiev,I.S.;Gorman,J.;Hill,K.R.;Jafari,A.J.;Kwon,Y.D.;Lai,Y.T.;Lemmin,T.;McKee,K.;Ohr,T.Y.;Ou,L.;Peng,D.;Rowshan,A.P.;Sheng,Z.;Todd,J.P.;Tsybovsky,Y.;Viox,E.G.;Wang,Y.;Wei,H.;Yang,Y.;Zhou,A.F.;Chen,R.;Yang,L.;Scorpio,D.G.;McDermott,A.B.;Shapiro,L.;Carragher,B.;Potter,C.S.;Mascola,J.R.;Kwong,P.D.",Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1,08-FEB-2018,8_8_11_11_3_9,6CDE_H_L,Xtal structure,HIV,3,1,0.22358172,-3.4489374
AEI70742_AEI70741,QVQLQQSGAELAKPGASVKMSCKTSGYSFSSYWMHWVKQRPGQGLEWIGYINPSTGYTENNQKFKDKVTLTADKSSNTAYMQLNSLTSEDSAVYYCARSGRLYFDVWGAGTTVTVSS,DIVLTQSPPSLAVSLGQRATISCRASESIDLYGFTFMHWYQQKPGQPPKILIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQTHEDPYTFGGGTKLEIK,AEI70742,AEI70741,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Stura,E.A.; Muller,B.H.; Bossus,M.; Michel,S.; Jolivet-Reynaud,C.; Ducancel,F.",Crystal structure of human prostate-specific antigen (PSA) in a sandwich antibody complex,25-JUL-2016,8_8_10_10_3_9,AEI70742_AEI70741,Unique chain,APS; KLK3; PSA,3,1,0.10872603,-3.270494
7U63_H_L,QVQLQQSGAELARPGASVKLSCKASGYTSTDYYINWVKQRTGQGLEWIGEIYPGSGNTYYNEKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCTRGGVYYGYDDAWFVYWGQGTLVTVSA,QAVVTQESALTTSPGETVTLTCRSSTGAVTSSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHLVFGGGTKLTVL,7U63_H,7U63_L,Crystal Structure Anti-Oxycodone Antibody Hy2-A12 Fab Complexed With Oxycodone,Crystal Structure Anti-Oxycodone Antibody Hy2-A12 Fab Complexed With Oxycodone,Mus musculus,"Rodarte,J.V.;Baehr,C.;Hicks,D.;Liban,T.L.;Weidle,C.;Rupert,P.B.;Jahan,R.;Wall,A.;McGuire,A.T.;Strong,R.K.;Runyon,S.;Pravetoni,M.;Pancera,M.",Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding,11-JAN-2023,8_8_16_9_3_9,7U63_H_L,Xtal structure,nicotine,3,1,0.17667046,-4.148494
AAB97656_AAB97657,QVQLQQSGAELMKPGASVKISCKATGYTFSSFWIEWVKQRPGHGLEWIGEILPGSGGTHYNEKFKGKATFTADKSSNTAYMQLSSLTSEDSAVYYCARGHSYYFYDGDYWGQGTSVTVSS,DIKMTQSPSSMYASLGERVTITCKASQDINSYLNWFQQKPGKSPKTLIYRTNRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGSGTKLEIK,AAB97656,AAB97657,"IgG heavy chain variable region, partial [Mus musculus]","IgG kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Ulrich,H.D.; Mundorff,E.; Santarsiero,B.D.; Driggers,E.M.; Stevens,R.C.; Schultz,P.G.",The interplay between binding energy and catalysis in the evolution of a catalytic antibody,24-JUL-2016,8_8_13_6_3_9,AAB97656_AAB97657,Unique chain,,3,1,5.009603,-1.8778511
7UPK_H_L,QVQLQQSGAELVRPGTSVKISCKASGYTFTNYWLGWVKQRPGHGLEWIGDIYRGGGYTNYNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAVYFCATRDGYFDYWGQGTTLTVSS,DIQMTQSSSSFSVSLGDRTTITCKASEDIYNRLAWFQQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDVATYYCQQYWSSPWTFGGGTKLEIK,7UPK_H,7UPK_L,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 1A9,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 1A9,Mus musculus,"Byrne,P.O.;McLellan,J.S.",Prefusion-stabilized Nipah virus fusion protein complexed with Fab 1A9,29-MAR-2023,8_8_9_6_3_9,7UPK_H_L,Xtal structure,,3,1,-0.042684913,-4.418938
7TUG_H_L,QVQLQQSGAELVRPGTSVKMSCKAAGYTFTNYWIGWIKQRPGHGLEWIGDIYPGGGYTNYNEKFKVKATLTADTSSVTAYMQLSSLTSEDSAIYYCTREGNYGFAYWGQGTLVTVSA,DIVMTQSPSSLAMSVGQKVTLSCKSSQSLLNSINQKNYLAWYQQKPGQSPKMLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSTPLTFGAGTKLELK,7TUG_H,7TUG_L,Crystal Structure Of Tapasin In Complex With Pasta2-Fab,Crystal Structure Of Tapasin In Complex With Pasta2-Fab,Mus musculus,"Jiang,J.;Taylor,D.K.;Kim,E.J.;Boyd,L.F.;Ahmad,J.;Mage,M.G.;Truong,H.V.;Woodward,C.H.;Sgourakis,N.G.;Cresswell,P.;Margulies,D.H.;Natarajan,K.",Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation,07-SEP-2022,8_8_10_12_3_9,7TUG_H_L,Xtal structure,,3,1,-0.21975678,-4.4741397
6FLB_H_L,QVQLQQSGAEVARPGASVKLSCKASGYTFTSYWLQWVKQRPGQGLEWIGAIWPGDDDTRYAQKFQGKATMTADKSSSTAYIQLSNLASEDSAVYYCARKGGFAMDYWGQGTSVTVSS,NIVMTQSPTSLAVSLGQRATISCRASESVDSFGKSFMHFYQQKPGQPPKLLIHLASNLESGVPARFTGRGSRTDFTLTIDPVEADDAATYYCQQNNEVPFTFGSGTKLEVK,6FLB_H,6FLB_L,3H5 Fab Bound To Ediii Of Denv 2 Xtal Form 2,3H5 Fab Bound To Ediii Of Denv 2 Xtal Form 2,Mus musculus,"Renner,M.;Flanagan,A.;Dejnirattisai,W.;Puttikhunt,C.;Kasinrerk,W.;Supasa,P.;Wongwiwat,W.;Chawansuntati,K.;Duangchinda,T.;Cowper,A.;Midgley,C.M.;Malasit,P.;Huiskonen,J.T.;Mongkolsapaya,J.;Screaton,G.R.;Grimes,J.M.",Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus,25-JAN-2018,8_8_10_10_3_9,6FLB_H_L,Xtal structure,dengue,3,1,0.39298376,-3.797971
7K8V_M_N,QVQLQQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYMQWSSLKASDTAMYYCARSFRDDPRIAVAGPADAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISYWLAWYQQKPGKAPKLLIYQASSLESGVPSRFSGSESGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,7K8V_M,7K8V_N,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C110","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C110",Homo sapiens,"Barnes,C.O.;Jette,C.A.;Abernathy,M.E.;Dam,K.A.;Esswein,S.R.;Gristick,H.B.;Malyutin,A.G.;Sharaf,N.G.;Huey-Tubman,K.E.;Lee,Y.E.;Robbiani,D.F.;Nussenzweig,M.C.;West AP,Jr.;Bjorkman,P.J.",SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,27-SEP-2020,8_8_21_6_3_9,7K8V_M_N,Xtal structure,SARS-CoV-2,3,1,-12.462013,5.6950183
2ZCL_H_L,QVQLQQSGDDLVKPGASVKLSCKASGYTFTTYYINWMRQRPGQGLEWIGRIAPASGTTYSSEMFKDKATLTVDTSSNTAYIQLSSLSSEDSAVYFCARADYGFNSGEAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKLLIFAASNLASGIPARLSGSGSGTDFTLNIQPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,2ZCL_H,2ZCL_L,Crystal Structure Of Human Prostate Specific Antigen Complexed With An Activating Antibody,Crystal Structure Of Human Prostate Specific Antigen Complexed With An Activating Antibody,Mus musculus,"Menez,R.;Michel,S.;Muller,B.H.;Bossus,M.;Ducancel,F.;Jolivet-Reynaud,C.;Stura,E.A.","Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody",09-NOV-2007,8_8_15_10_3_9,2ZCL_H_L,Xtal structure,,3,1,-0.1564614,-4.0651755
CAX46365_CAX46366,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,CAX46365,CAX46366,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Goodman,S.; Hahn,D.; Mitjans,F.; Adan,J.; Lo,K.M.",Engineered anti-alpha v- integrin hybrid antibodies,16-FEB-2009,8_8_11_6_3_9,CAX46365_CAX46366,Unique chain,,3,1,0.84221095,3.7604573
S12953_S12954,QVQLQQSGGGLVQPGRSLKLSCVVSGFTFSNYGMNWIRQTPGKGLEWVAYISSGSSYLYYAETVKGRFTISRDNAKNTLYLQMTSLRSEDTALYYCARHEGTGTDFFDYWGQGTTVTVSS,DIQLTQSPHSLSASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYASSLQDGVPSRFSGSGSGTQFSLKISNMQPEDEGVYYCQQAYKYPSTFGAGTKLEIK,S12953,S12954,Ig heavy chain V region (Y13-259) - rat,Ig kappa chain V region (Y13-259) - rat,Rattus norvegicus,"Werge,T.M.; Biocca,S.; Cattaneo,A.",Intracellular immunization. Cloning and intracellular expression of a monoclonal antibody to the p21ras protein,21-Jan-2000,8_8_13_6_3_9,S12953_S12954,Unique word,p21ras,3,1,15.52497,9.602661
4NKO_F_E,QVQLQQSGPEDVKPGASVKISCKASGYTFTDYYMNWVKQSPGKGLEWIGDINPNNGGTSYNQKFKGRATLTVDKSSSTAYMELRSLTSEDSSVYYCAASSPYSMRAAMDYWGQGTTVTVSA,DIVMTQTPSSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSLVPPTFGAGTKLELK,4NKO_F,4NKO_E,Crystal Structure Of Engineered Anti-Ee Scfv Antibody Fragment,Crystal Structure Of Engineered Anti-Ee Scfv Antibody Fragment,Mus musculus,"Kalyoncu,S.;Hyun,J.;Pai,J.C.;Johnson,J.L.;Entzminger,K.;Jain,A.;Heaner DP,Jr.;Morales,I.A.;Truskett,T.M.;Maynard,J.A.;Lieberman,R.L.",Effects of protein engineering and rational mutagenesis on crystal lattice of single chain antibody fragments,12-NOV-2013,8_8_14_11_3_9,4NKO_F_E,Xtal structure,,3,1,2.4023936,-4.231717
7UHZ_H_L,QVQLQQSGPELVKPGASVKLSCKASGYSFTTYDINWVKERPGQGLEWIGWIYPREGSTNYNEKFRGKATLTADTSSSTAYMELHSLTSEDSAVYFCATYGSSRYYTMDYWGQGTSVTVSS,DIVLTQSPTSLAVSLGQRATISCRASESVDNFGISFMNWFQQKPGQPPKLLIYAASNLGSGVPARFSGSGSGTDFSLNIHPMEDDDTAMYFCQQSKEVPLTFGAGTKLELK,7UHZ_H,7UHZ_L,Post-Fusion Ectodomain Of Hsv-1 Gb In Complex With Bmpc-23 Fab,Post-Fusion Ectodomain Of Hsv-1 Gb In Complex With Bmpc-23 Fab,Human alphaherpesvirus 1 strain KOS,"Kuraoka,M.;Aschner,C.B.;Windsor,I.W.;Mahant,A.M.;Garforth,S.J.;Kong,S.L.;Achkar,J.M.;Almo,S.C.;Kelsoe,G.;Herold,B.C.",A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice,08-JAN-2009,8_8_13_10_3_9,7UHZ_H_L,Xtal structure,herpes; Ectodomain,3,1,0.18299353,-4.4033494
AIL25363,QVQLQQSGPEVVRPGVSVKISCKGSGYTFTDYGMHWVKQSHAKSLEWIGVISTYNGYTNYNQKFKGKATMTVDKSSSTAYMELARLTSEDSAIYYCARAYYGNLYYAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASKSVSTSSYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFILNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK,AIL25363_H,AIL25363_L,P4A8 (ScFv)-PE38 [synthetic construct],P4A8 (ScFv)-PE38 [synthetic construct],synthetic construct,"Keshtvarz,M.; Douraghi,M.; Pourmand,M.R.; Salimian,J.; Amani,J.",Direct Submission,30-AUG-2014,8_8_14_10_3_9,AIL25363,Same entry,,3,1,2.9942536,-4.573507
7Q9J_E_F,QVQLQQSGPGLVKPSETLSLTCTVSGASISNYYWSWIRQPPGKGLEWVGYIYYTGSTNHNPSLKSRVTISLDTSKNQFSLRLSSVTAADTAVYYCARAYCSGGSCFDTFDIWGQGTMVTVSS,SYELTQPPSVSVAPGQTARITCGGNNIGSKSVHWFQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTASLTISRVEAGDEADYYCQVWDSASDSGVFGTGTKLTVP,7Q9J_E,7Q9J_F,Beta-26 Fab In Complex With Sars-Cov-2 Beta-Spike Glycoprotein,Beta-26 Fab In Complex With Sars-Cov-2 Beta-Spike Glycoprotein,Homo sapiens,"Liu,C.;Zhou,D.;Nutalai,R.;Duyvesteyn,H.M.;Tuekprakhon,A.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Mentzer,A.J.;Wang,B.;Case,J.B.;Zhao,Y.;Skelly,D.T.;Chen,R.E.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Malik,T.;Temperton,N.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Clare,D.K.;Howe,A.;Goulder,P.J.;Fry,E.E.;Diamond,M.S.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants,12-NOV-2021,8_7_16_6_3_11,7Q9J_E_F,Xtal structure,SARS-CoV-2,3,1,16.187471,-8.028305
AST13834_AST13862,QVQLQQSGPRLVKPSQTLSLTCAISGDSVSSSSAVWTWIRQSPSRGLEWLGRTYYRSKWYDDYAVSVQGRITINPDTSKNQISLQLNSVTPDDTAVYYCARSSINIFGVFVMAMDVWGQGTAVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQTVYNSYLAWYQQKPGQAPTLLIYGTSTRATGVPDRFSGSGSGTVFTLTISRLEPEDFAVYFCQQYSTSPRALTFGGGTKVEIK,AST13834,AST13862,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Joyce,M.G.; Chambers,M.J.; Gillespie,R.A.; Kanekiyo,M.; Leung,K.; Yang,E.S.; Tsybovsky,Y.; Wheatley,A.K.; Crank,M.C.; Boyington,J.C.; Prabhakaran,M.S.; Narpala,S.R.; Chen,X.; Bailer,R.T.; Chen,G.; Coates,E.; Kwong,P.D.; Koup,R.A.; Mascola,J.R.; Graham,B.S.; Ledgerwood,J.E.; McDermott,A.B.",Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans,15-AUG-2017,10_9_17_7_3_11,AST13834_AST13862,Unique source,hemagglutinin,3,1,15.500911,-4.6931105
2NTF_H_L,QVQLQQSGSELVRPGASVKLSCKASGYTFTTYWIHWVKQRPGQGLEWIGTIYPGSDNTYYDEKFKNKATLTVDTSSSTAFMQLSSLTSEDSAVYFCTRGSLYYNNYGWFGYWGQGTLVTVSA,QAVVTQESALTTSPGETVTLTCRSSTGAVTTRNYANWVQEKPDHFFTGLIGDTNNRAPGVPARFSGSLIGHKAALTITGAQTEDESVYFCALWYSNHWVFGGGTKLTVL,2NTF_H,2NTF_L,Crystal Structure Of A Quorum-Quenching Antibody In Complex With An N-Acyl-L-Homoserine Lactone Analog,Crystal Structure Of A Quorum-Quenching Antibody In Complex With An N-Acyl-L-Homoserine Lactone Analog,Mus musculus,"Debler,E.W.;Kaufmann,G.F.;Kirchdoerfer,R.N.;Mee,J.M.;Janda,K.D.;Wilson,I.A.",Crystal structures of a quorum-quenching antibody,07-NOV-2006,8_8_15_9_3_9,2NTF_H_L,Xtal structure,,3,1,-0.30280086,-4.145461
ANY91448_ANY90988,QVQLQQWGAGLLKPSETLSLTCAVFGDSFNGYYWTWIRQPPGKGLEWIGEINRGGDTNYNPSLKSRVTVSVDTSKNQFSLKLTSVTAADTAVYYCARYPLYYDSRGVFYHKVTAYAMDVWGQGTTVTVSS,DIQLTQSPVSLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPGLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLHSYPRTFGQGTKLEIN,ANY91448,ANY90988,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_7_24_6_3_9,ANY91448_ANY90988,Unique source,Influenza,3,1,16.591326,-10.415007
7UC8_H_H,QVQLQQWGAGLLKPSETLSLTCAVSGASFSGYSWTWIRQSPGKGLEWIGEIDYRGSTNYNPSLKSRVTMSVDTPKNQFSLNLTSLTAADTAIYYCAKGYGGVTLVRGAKINWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSRYLAWYQQKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYAKSPWTFGQGTKVEIK,7UC8_H,7UC8_H,Pfs230 D1 Domain In Complex With 230As-73,Pfs230 D1 Domain In Complex With 230As-73,Homo sapiens,"Tang,W.K.;Coelho,C.H.;Miura,K.;Nguemwo Tentokam,B.C.;Salinas,N.D.;Narum,D.L.;Healy,S.A.;Sagara,I.;Long,C.A.;Duffy,P.E.;Tolia,N.H.",A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine,15-FEB-2023,8_7_20_7_3_9,7UC8_H_H,Xtal structure,Pfs230D1,3,1,16.770443,-10.599725
ANI87829_ANI87816,QVQLQQWGAGLLKPSETLSLTCAVYGESFSAFSWSWIRQPPGKGLEWIGEIDHTGSANYNPSLKSRISMSVDTSMNQFSLELLSMTVADTAVYYCARGGRKVYHAYWSGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGTLSLSAGERATLSCRASQSVSARNLAWYQQKPGQAPRLLLYGVSIRNTGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGDSPTFGQGTKVEIK,ANI87829,ANI87816,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"MacLeod,D.T.; Choi,N.M.; Briney,B.; Garces,F.; Ver,L.S.; Landais,E.; Murrell,B.; Wrin,T.; Kilembe,W.; Liang,C.H.; Ramos,A.; Bian,C.B.; Wickramasinghe,L.; Kong,L.; Eren,K.; Wu,C.Y.; Wong,C.H.; Kosakovsky Pond,S.L.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch,12-JUN-2016,8_7_22_7_3_8,ANI87829_ANI87816,Unique source,HIV,3,1,16.861076,-10.698146
ANI87825_ANI87812,QVQLQQWGAGLLKPSETLSLTCAVYGESFSAFSWSWIRQPPGKGLEWIGEVDHSGSTNYNPSLKSRVTISVDTSKNQFFLKLVSLTAADTAVYYCARGGRKVYHPYWTGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSAKNLAWYQQKPGQAPRLLMYGVSIKNTGVSDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKVEIK,ANI87825,ANI87812,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"MacLeod,D.T.; Choi,N.M.; Briney,B.; Garces,F.; Ver,L.S.; Landais,E.; Murrell,B.; Wrin,T.; Kilembe,W.; Liang,C.H.; Ramos,A.; Bian,C.B.; Wickramasinghe,L.; Kong,L.; Eren,K.; Wu,C.Y.; Wong,C.H.; Kosakovsky Pond,S.L.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch,12-JUN-2016,8_7_22_7_3_8,ANI87825_ANI87812,Unique source,HIV,3,1,16.808043,-10.644279
ANI87821_ANI87808,QVQLQQWGAGLLKPSETLSLTCAVYGGSLSGNFWSWIRQPPGKGLEWIGEINHSGETNHNPSLKRRVTLSVDTSKNQFSLKLSSVTAADTAVYYCARGGPKVYYEYWSGYVNNCFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATVSCRASQSVSASNLAWYQQKPGQAPRLLIYGVSSRPTGIPDRFSGSGSGTDFTLTVSRLEPEDFAVYYCQQYGSSPTFGQGTKVEIK,ANI87821,ANI87808,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"MacLeod,D.T.; Choi,N.M.; Briney,B.; Garces,F.; Ver,L.S.; Landais,E.; Murrell,B.; Wrin,T.; Kilembe,W.; Liang,C.H.; Ramos,A.; Bian,C.B.; Wickramasinghe,L.; Kong,L.; Eren,K.; Wu,C.Y.; Wong,C.H.; Kosakovsky Pond,S.L.; Wilson,I.A.; Burton,D.R.; Poignard,P.",Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch,12-JUN-2016,8_7_22_7_3_8,ANI87821_ANI87808,Unique source,HIV,3,1,16.77601,-10.611472
6DFG_H_L,QVQLRESGPGLVKPSETLSLSCTVSNDSRPSDHSWTWVRQSPGKALEWIGDIHYNGATTYNPSLRSRVRIELDQSIPRFSLKMTSMTAADTGMYYCARNAIRIYGVVALGEWFHYGMDVWGQGTAVTVSS,SSELTQPPSVSVSPGQTARITCSGAPLTSRFTYWYRQKPGQAPVLIISRSSQRSSGWSGRFSASWSGTTVTLTIRGVQADDEADYYCQSSDTSDSYKMFGGGTKLTVL,6DFG_H,6DFG_L,Bg505 Md39 Sosip Trimer In Complex With Mature Bg18 Fragment Antigen Binding,Bg505 Md39 Sosip Trimer In Complex With Mature Bg18 Fragment Antigen Binding,Homo sapiens,"Steichen,J.M.;Lin,Y.C.;Havenar-Daughton,C.;Pecetta,S.;Ozorowski,G.;Willis,J.R.;Toy,L.;Sok,D.;Liguori,A.;Kratochvil,S.;Torres,J.L.;Kalyuzhniy,O.;Melzi,E.;Kulp,D.W.;Raemisch,S.;Hu,X.;Bernard,S.M.;Georgeson,E.;Phelps,N.;Adachi,Y.;Kubitz,M.;Landais,E.;Umotoy,J.;Robinson,A.;Briney,B.;Wilson,I.A.;Burton,D.R.;Ward,A.B.;Crotty,S.;Batista,F.D.;Schief,W.R.",A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses,14-MAY-2018,9_7_23_6_3_11,6DFG_H_L,Xtal structure,HIV,3,1,15.443713,-7.6440187
6E9I_C_D,QVQLRESGPSLVKPSQTLSLTCTASGLSLSDKAVGWVRQAPGKALEWLGSIDTGGSAGYNPGLKSRVSITKDNSKSQVSLSVRGVTTEDSATYYCTTVHQKTQLTKSCPDGYSDCYGCGAYCPYGCSGDDCYSYSSYGGYTYSSYSSTYIYEFFVDAWGQGLLVTVSS,EAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,6E9I_C,6E9I_D,The Crystal Structure Of Bovine Ultralong Antibody Bov-4,The Crystal Structure Of Bovine Ultralong Antibody Bov-4,Bos taurus,"Dong,J.;Finn,J.A.;Larsen,P.A.;Smith,T.P.;Crowe JE,Jr.",Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains,01-AUG-2018,8_7_62_8_3_11,6E9I_C_D,Xtal structure,,3,1,13.860344,-9.365599
AAW68459_AAW68877,QVQLVESGAEVKKPGSSVKVSCKSSGGYVFSWVRQAPGQGLEWMGGIISNFRTAEYARKFQGRVTMTADTSTNTIYMELTSLTSEDTAVYFCVSAPRDTSTIAARFNRYFFDTWGQGTLVTV,EIVLTQSPGTLSLSPGERATLSCRASRSVNSNNLAWYQQKPDQAPRLLMYGASSRATGIPDRFTGSGSGTDFTLTISRLEPEDFAVYYCHQYGASDNTFGQGTKLEIK,AAW68459,AAW68877,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Meijer,P.J.; Andersen,P.S.; Haahr Hansen,M.; Steinaa,L.; Jensen,A.; Lantto,J.; Oleksiewicz,M.B.; Tengbjerg,K.; Poulsen,T.R.; Coljee,V.W.; Bregenholt,S.; Haurum,J.S.; Nielsen,L.S.",Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing,26-JUL-2016,4_8_21_7_3_9,AAW68459_AAW68877,Unique source,tetanus,3,1,21.684917,11.846182
7ZFB_J_K,QVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMTWVRQAPGKGLEWVSLLYAGGSAFYADSVKGRFTISRDNSKNTLYLLMNSLRVGDTAVYYCARDLQVYGMDVWGQGTTVTVSS,SYELTQPPSVSVAPGQTARITCGGNNDGAKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTITRIEAGDEADYYCQVWDSSRDHVFGTGTKVTVL,7ZFB_J,7ZFB_K,"Sars-Cov-2 Omicron Rbd In Complex With Nanobody C1, Omi-18 And Omi-31 Fabs","Sars-Cov-2 Omicron Rbd In Complex With Nanobody C1, Omi-18 And Omi-31 Fabs",Severe acute respiratory syndrome coronavirus 2,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,01-APR-2022,8_7_11_6_3_10,7ZFB_J_K,Xtal structure,,3,1,12.53933,10.822742
7NEG_H_L,QVQLVESGGGLIQPGGSLRLSCAASGLTVNRNYMSWIRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAIYYCARDFYEGSFDIWGQGTMVTVSS,AIQLTQSPSFLSASIGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFASYYCQQLNSYPAPVFGPGTKVDIK,7NEG_H,7NEG_L,Crystal Structure Of The N501Y Mutant Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-269 Fab,Crystal Structure Of The N501Y Mutant Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-269 Fab,Severe acute respiratory syndrome coronavirus 2,"Supasa,P.;Zhou,D.;Dejnirattisai,W.;Liu,C.;Mentzer,A.J.;Ginn,H.M.;Zhao,Y.;Duyvesteyn,H.M.;Nutalai,R.;Tuekprakhon,A.;Wang,B.;Paesen,G.C.;Slon-Campos,J.;Lopez-Camacho,C.;Hallis,B.;Coombes,N.;Bewley,K.R.;Charlton,S.;Walter,T.S.;Barnes,E.;Dunachie,S.J.;Skelly,D.;Lumley,S.F.;Baker,N.;Shaik,I.;Humphries,H.E.;Godwin,K.;Gent,N.;Sienkiewicz,A.;Dold,C.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Klenerman,P.;Crook,D.;Lambe,T.;Clutterbuck,E.;Bibi,S.;Flaxman,A.;Bittaye,M.;Belij-Rammerstorfer,S.;Gilbert,S.;Hall,D.R.;Williams,M.A.;Paterson,N.G.;James,W.;Carroll,M.W.;Fry,E.E.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera,04-FEB-2021,8_7_11_6_3_10,7NEG_H_L,Xtal structure,SARS-CoV-2,3,1,12.612549,10.378892
5J3D_H_L,QVQLVESGGGLIQPGGSLRLSCAVSGFTVSSKYMTWVRQAPGKGLEWVSVIYGGGSTYYADSVVGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASRLGVRATTGDLDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYSWWTFGQGTKVDIK,5J3D_H,5J3D_L,Crystal Structure Of Human Fab 14N4 In Complex With Post-Fusion Rsv F,Crystal Structure Of Human Fab 14N4 In Complex With Post-Fusion Rsv F,Homo sapiens,"Mousa,J.J.;Sauer,M.F.;Sevy,A.M.;Finn,J.A.;Bates,J.T.;Alvarado,G.;King,H.G.;Loerinc,L.B.;Fong,R.H.;Doranz,B.J.;Correia,B.E.;Kalyuzhniy,O.;Wen,X.;Jardetzky,T.S.;Schief,W.R.;Ohi,M.D.;Meiler,J.;Crowe JE,Jr.",Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein,30-MAR-2016,8_7_15_6_3_10,5J3D_H_L,Xtal structure,,3,1,12.594474,10.366553
8C3V_H_L,QVQLVESGGGLVKPGGSLRLSCAASGFTFRYAWMNWVRQAPGKGLEWVGRIRSKTDGETTDHAAPVKGRFAISRDDSENTLYLQMNSLKTEDTAVYYCTTDWVRGTLLEHDAYDVWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQSISTFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQREDFATYYCQQSYSMSSFGGGTKVEIK,8C3V_H,8C3V_L,Sars-Cov-2 Delta-Rbd Complexed With Ba.2-13 Fab And C1 Nanobody,Sars-Cov-2 Delta-Rbd Complexed With Ba.2-13 Fab And C1 Nanobody,Homo sapiens,"Dijokaite-Guraliuc,A.;Das,R.;Zhou,D.;Ginn,H.M.;Liu,C.;Duyvesteyn,H.M.E.;Huo,J.;Nutalai,R.;Supasa,P.;Selvaraj,M.;de Silva,T.I.;Plowright,M.;Newman,T.A.H.;Hornsby,H.;Mentzer,A.J.;Skelly,D.;Ritter,T.G.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;veName>OPTIC consortium</CollectiveName>,?.;Roemer,C.;Peacock,T.P.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Fry,E.E.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses,22-MAR-2023,8_10_17_6_3_8,8C3V_H_L,Xtal structure,SARS-CoV-2,3,1,12.939535,8.535336
QNT09657_QNT09675,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARARGSSGWYRIGTRWGNWFDPWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSNVVFGGGTMLTVL,QNT09657,QNT09675,"anti SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti SARS-CoV-2 immunoglobulin lambda chain, partial [Homo sapiens]",Homo sapiens,"Kreye,J.; Reincke,S.M.; Kornau,H.-C.; Sanchez-Sendin,E.; Corman,V.M.; Liu,H.; Yuan,M.; Wu,N.C.; Zhu,X.; Lee,C.-C.D.; Trimpert,J.; Hoeltje,M.; Dietert,K.; Stoeffler,L.; von Wardenburg,N.; van Hoof,S.; Homeyer,M.A.; Hoffmann,J.; Abdelgawad,A.; Gruber,A.D.; Bertzbach,L.D.; Vladimirova,D.; Li,L.Y.; Barthel,P.C.; Skriner,K.; Hocke,A.C.; Hippenstiel,S.; Witzenrath,M.; Suttorp,N.; Kurth,F.; Franke,C.; Endres,M.; Schmitz,D.; Jeworowski,L.M.; Richter,A.; Schmidt,M.L.; Schwarz,T.; Mueller,M.A.; Drosten,C.; Wendisch,D.; Sander,L.E.; Osterrieder,N.; Wilson,I.A.; Pruess,H.",A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model,24-SEP-2020,8_8_22_9_3_10,QNT09657_QNT09675,Unique source,SARS-CoV-2; COVID,3,1,15.725857,9.487261
1DEE_B_A,QVQLVESGGGVVQPGKSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVALISYDESNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVKFYDPTAPNDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,1DEE_B,1DEE_A,Crystal Structure At 2.7A Resolution Of A Complex Between A Staphylococcus Aureus Domain And A Fab Fragment Of A Human Igm Antibody,Crystal Structure At 2.7A Resolution Of A Complex Between A Staphylococcus Aureus Domain And A Fab Fragment Of A Human Igm Antibody,Staphylococcus aureus,"Graille,M.;Stura,E.A.;Corper,A.L.;Sutton,B.J.;Taussig,M.J.;Charbonnier,J.B.;Silverman,G.J.",Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity,15-NOV-1999,8_8_14_6_3_9,1DEE_B_A,Xtal structure,,3,1,15.042632,13.605336
7WVD_G_H,QVQLVESGGGVVQPGRSLRLSCAASGFPFSSYGMHWVRQAPGKGLEWVAGVSYDGSYKYYADSVKGRFTISRDSSKSTLYLQMNSLRPEDTAVYYCARPSAIFGIYIILNGLDVWGQGTTVTVS,EIVLTQSPSSVSASVGDRVTITCRATQGISSWLAWYQQKPGKPPKLLIFGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQAHSFPLTFGGGTKVEIK,7WVD_G,7WVD_H,Crystal Structure Of H14 Complexed With Sia28,Crystal Structure Of H14 Complexed With Sia28,Homo sapiens,"Chen,Y.;Wang,F.;Yin,L.;Jiang,H.;Lu,X.;Bi,Y.;Zhang,W.;Shi,Y.;Burioni,R.;Tong,Z.;Song,H.;Qi,J.;Gao,G.F.",Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes,18-JAN-2023,8_8_18_6_3_9,7WVD_G_H,Xtal structure,hemagglutinin; H17; FOXRED1,3,1,14.269424,13.896641
3IDY_B_C,QVQLVESGGGVVQPGRSLRLSCAASGFTFRNYAMHWVRQAPGKGLEWVALIKYDGRNKYYADSVKGRFSISRDNSKNTLYLEMNSLRAEDTAVYYCARDIGLKGEHYDILTAYGPDYWGQGALVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIRNYLNWYQQKPGKAPKLLIYDASNSETGVPSRFSGSGSGRDFTFTISSLQPEDVATYYCQQHQNVPLTTFGGGTKVEIK,3IDY_B,3IDY_C,"Crystal Structure Of Hiv-Gp120 Core In Complex With Cd4-Binding Site Antibody B13, Space Group C2221","Crystal Structure Of Hiv-Gp120 Core In Complex With Cd4-Binding Site Antibody B13, Space Group C2221",Homo sapiens,"Chen,L.;Kwon,Y.D.;Zhou,T.;Wu,X.;O'Dell,S.;Cavacini,L.;Hessell,A.J.;Pancera,M.;Tang,M.;Xu,L.;Yang,Z.Y.;Zhang,M.Y.;Arthos,J.;Burton,D.R.;Dimitrov,D.S.;Nabel,G.J.;Posner,M.R.;Sodroski,J.;Wyatt,R.;Mascola,J.R.;Kwong,P.D.",Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120,22-JUL-2009,8_8_21_6_3_10,3IDY_B_C,Xtal structure,CI-13KD-B; CD4; UQOR13; B13; NUFM; NDUFA5; gp120; HIV; CI-13kB,3,1,14.783884,13.739782
USW88771_USW88679,QVQLVESGGGVVQPGRSLRLSCAASGFTFRSYGMHWVRQAPGKGLEWVAFISYDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSAGHCTGGVCYTAGGIDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRNSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCHSYDSDNVVFGGGTKLTVL,USW88771,USW88679,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kumar,S.; Patel,A.; Lai,L.; Chakravarthy,C.; Valanparambil,R.; Davis-Gardner,M.E.; Edara,V.V.; Linderman,S.; Reddy,E.S.; Gottimukkala,K.; Nayak,K.; Dixit,K.; Sharma,P.; Bajpai,P.; Singh,V.; Frank,F.; Cheedarla,N.; Verkerke,H.P.; Neish,A.S.; Roback,J.D.; Mantus,G.; Goel,P.K.; Rahi,M.; Davis,C.W.; Wrammert,J.; Suthar,M.S.; Ahmed,R.; Ortlund,E.; Sharma,A.; Murali-Krishna,K.; Chandele,A.",Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody,06-JUL-2022,8_8_22_8_3_9,USW88771_USW88679,Unique source,SARS-CoV-2; RBD,3,1,15.020936,13.833669
6O24_A_B,QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVALIWYDGTNKYYTDSVKGRFTISRDNSKNTLFLQMNSVRAEDTAVYYCARDAHYSDSSGYSSWGYFDYWGQGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIFDASIRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWYTFGQGTKLEIK,6O24_A,6O24_B,Crystal Structure Of 4498 Fab In Complex With Circumsporozoite Protein Nanp3 And Anti-Kappa Vhh Domain,Crystal Structure Of 4498 Fab In Complex With Circumsporozoite Protein Nanp3 And Anti-Kappa Vhh Domain,Plasmodium falciparum,"Murugan,R.;Scally,S.W.;Costa,G.;Mustafa,G.;Thai,E.;Decker,T.;Bosch,A.;Prieto,K.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs,22-FEB-2019,8_8_20_6_3_8,6O24_A_B,Xtal structure,circumsporozoite,3,1,15.028569,13.568701
5Y0A_D_E,QVQLVESGGGVVQPGRSLRLSCAASGFTFSKYGMHWVRQAPGKGLEWVAVISYEGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSGTQYYDTTGYEYRGLEYFGYWGQGTLVTVS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKRGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSRWTFGQGTKVEIK,5Y0A_D,5Y0A_E,Cryo-Em Structure Of Zika Virus Complexed With Fab Of Zka190 At Ph 8.0 And 37 Celsius Degree,Cryo-Em Structure Of Zika Virus Complexed With Fab Of Zka190 At Ph 8.0 And 37 Celsius Degree,Homo sapiens,"Wang,J.;Bardelli,M.;Espinosa,D.A.;Pedotti,M.;Ng,T.S.;Bianchi,S.;Simonelli,L.;Lim,E.X.;Foglierini,M.;Zatta,F.;Jaconi,S.;Beltramello,M.;Cameroni,E.;Fibriansah,G.;Shi,J.;Barca,T.;Pagani,I.;Rubio,A.;Broccoli,V.;Vicenzi,E.;Graham,V.;Pullan,S.;Dowall,S.;Hewson,R.;Jurt,S.;Zerbe,O.;Stettler,K.;Lanzavecchia,A.;Sallusto,F.;Cavalli,A.;Harris,E.;Lok,S.M.;Varani,L.;Corti,D.",A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential,15-JUL-2017,8_8_23_7_3_9,5Y0A_D_E,Xtal structure,Zika,3,1,15.043842,13.868096
QKY76420_QKY76033,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVMSYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKNLGPYCSGGTCYSLVGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYANLPFTFGPGTKVDIK,QKY76420,QKY76033,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_20_6_3_9,QKY76420_QKY76033,Unique source,SARS-CoV-2,3,1,15.050811,13.965472
7K8Z_M_N,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,7K8Z_M,7K8Z_N,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C135","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C135",Homo sapiens,"Barnes,C.O.;Jette,C.A.;Abernathy,M.E.;Dam,K.A.;Esswein,S.R.;Gristick,H.B.;Malyutin,A.G.;Sharaf,N.G.;Huey-Tubman,K.E.;Lee,Y.E.;Robbiani,D.F.;Nussenzweig,M.C.;West AP,Jr.;Bjorkman,P.J.",SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,27-SEP-2020,8_8_12_6_3_9,7K8Z_M_N,Xtal structure,SARS-CoV-2,3,1,14.823487,13.247299
7MXP_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKFYADSVKGRFTISRDNSKNTLYLQMTSLRAEDTAVYYCARADYGDFFFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALSKHYGYWYQQKPGQAPVLVIFKDSERPSGIPERFSGSSSGTTITLTVSGVQAEDEADYYCQSADSSATYWVFGGGTKLTV,7MXP_H,7MXP_L,Cryo-Em Structure Of Ntd-Directed Neutralizing Antibody Lp5 Fab In Complex With Sars-Cov-2 S2P Spike,Cryo-Em Structure Of Ntd-Directed Neutralizing Antibody Lp5 Fab In Complex With Sars-Cov-2 S2P Spike,Homo sapiens,"Madan,B.;Reddem,E.R.;Wang,P.;Casner,R.G.;Nair,M.S.;Huang,Y.;Fahad,A.S.;de Souza,M.O.;Banach,B.B.;L&#xf3;pez Acevedo,S.N.;Pan,X.;Nimrania,R.;Teng,I.T.;Bahna,F.;Zhou,T.;Zhang,B.;Yin,M.T.;Ho,D.D.;Kwong,P.D.;Shapiro,L.;DeKosky,B.J.",Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2,19-MAY-2021,8_8_12_6_3_11,7MXP_H_L,Xtal structure,MBTPS2; SARS-CoV-2; KFSD; S2P,3,1,15.005742,13.392612
5GGV_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,5GGV_H,5GGV_L,Ctla-4 In Complex With Tremelimumab Fab,Ctla-4 In Complex With Tremelimumab Fab,Homo sapiens,"Lee,J.Y.;Lee,H.T.;Shin,W.;Chae,J.;Choi,J.;Kim,S.H.;Lim,H.;Won Heo,T.;Park,K.Y.;Lee,Y.J.;Ryu,S.E.;Son,J.Y.;Lee,J.U.;Heo,Y.S.",Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy,16-JUN-2016,8_8_18_6_3_9,QPY58328,Xtal structure,,3,1,14.126123,14.018612
7PNM_I_E,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYVMHWVRQAPGKGLEWVAVIWFDGDNKYYADSVKARFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPQWLDYHDLDVWGQGTTVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSQSLLHSNGYKYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGSDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK,7PNM_I,7PNM_E,Human Coronavirus Oc43 Spike Glycoprotein Ectodomain In Complex With The 46C12 Antibody Fab Fragment,Human Coronavirus Oc43 Spike Glycoprotein Ectodomain In Complex With The 46C12 Antibody Fab Fragment,Homo sapiens,"Wang,C.;Hesketh,E.L.;Shamorkina,T.M.;Li,W.;Franken,P.J.;Drabek,D.;van Haperen,R.;Townend,S.;van Kuppeveld,F.J.M.;Grosveld,F.;Ranson,N.A.;Snijder,J.;de Groot,R.J.;Hurdiss,D.L.;Bosch,B.J.",Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes,07-SEP-2021,8_8_14_11_3_9,7PNM_I_E,Xtal structure,Antigenic; Ectodomain,3,1,14.343317,13.753791
6O25_A_B,QVQLVESGGGVVQPGRSLRLSCEASGFTFSSYGIHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAGYSNYGHYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPTFGQGTKVEIK,6O25_A,6O25_B,Crystal Structure Of 3945 Fab In Complex With Circumsporozoite Protein Nanp3 And Anti-Kappa Vhh Domain,Crystal Structure Of 3945 Fab In Complex With Circumsporozoite Protein Nanp3 And Anti-Kappa Vhh Domain,Plasmodium falciparum,"Murugan,R.;Scally,S.W.;Costa,G.;Mustafa,G.;Thai,E.;Decker,T.;Bosch,A.;Prieto,K.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs,22-FEB-2019,8_8_14_7_3_9,6O25_A_B,Xtal structure,circumsporozoite,3,1,14.981306,13.5737295
6DCV_H_L,QVQLVESGPEMRKPGESLKISCKTSGYIFSDYWTAWVRQLPGKGLQWMGIIYSGDSDTRYHPSVQGHVTMSTDSSLTTAYLQWSSLKASDTGIYYCARLDARVDAGWQLDSWGQGTLVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSVFSRDNNKNYLAWYQHKSGQPPKLLFFWASSRESGVSDRFSGSGSGTDFTLTIDNLQAEDVALYYCQHYFNTPHNFGQGTKLEIK,6DCV_H,6DCV_L,Crystal Structure Of Human Anti-Tau Antibody Cbtau-27.1,Crystal Structure Of Human Anti-Tau Antibody Cbtau-27.1,Homo sapiens,"Apetri,A.;Crespo,R.;Juraszek,J.;Pascual,G.;Janson,R.;Zhu,X.;Zhang,H.;Keogh,E.;Holland,T.;Wadia,J.;Verveen,H.;Siregar,B.;Mrosek,M.;Taggenbrock,R.;Ameijde,J.;Inganas,H.;van Winsen,M.;Koldijk,M.H.;Zuijdgeest,D.;Borgers,M.;Dockx,K.;Stoop,E.J.;Yu,W.;Brinkman-van der,Li.;Ummenthum,K.;van Kolen,K.;Mercken,M.;Steinbacher,S.;de Marco,D.;Hoozemans,J.J.;Wilson,I.A.;Koudstaal,W.;Goudsmit,J.",A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities,08-MAY-2018,8_8_15_12_3_9,QDB31530_QDB31531,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,3,1,-12.497748,5.795831
7KF9_G_J,QVQLVESGPGLVKPSQTLSLICTVSGGSISSGDFYWSWIRQPPGKGLEWIGFFYYSGITYYNPSLKSRVSISRDTSTNQFSLKLRSVTAADTAVYYCARVRGGRITLGQGDMYYYSGMDVWGQGTLVTVSS,QSVLTQPPSASGTPGQRVSISCSGSRSNIGGNTVDWYQQLPGTDPKLLIYSNDQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGHWVFGGGTKLTVL,7KF9_G,7KF9_J,"Ebola Virus Gp (Mucin Deleted, Makona Strain) Bound To Antibody Fab Ebov-296 And Ebov-515","Ebola Virus Gp (Mucin Deleted, Makona Strain) Bound To Antibody Fab Ebov-296 And Ebov-515",Homo sapiens,"Murin,C.D.;Gilchuk,P.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Shen,X.;Bruhn,J.F.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Williamson,L.E.;Copps,J.;Alkutkar,T.;Flyak,A.I.;Bukreyev,A.;Crowe JE,Jr.;Ward,A.B.",Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies,13-OCT-2020,10_7_23_8_3_12,7KF9_G_J,Xtal structure,Ebola,3,1,16.171942,-8.183442
4XNZ_H_L,QVQLVESGSAMRKPGSSVKISCRASGFNFREYSIHWVRLIPGRGLEWMGWIKGMWGAVNYARQLQGRVSMTRQLSQDPDDPDWGVAYLDFSGLTSGDTGEYFCVRKGPSCPHCGDFHWQHWGQGTLVVVS,EIVLTQSPGTLSVSPGERATLFCKASQGGNSLSWYQKRRGQPPRLLIYDTSRRASGIPDRFVGSGSGTDFSLTITKVDRDDFALYFCQQFEFFGLGTALEIN,4XNZ_H,4XNZ_L,Crystal Structure Of Broadly And Potently Neutralizing Antibody Vrc06B In Complex With Hiv-1 Clade A/E Strain 93Th057 Gp120,Crystal Structure Of Broadly And Potently Neutralizing Antibody Vrc06B In Complex With Hiv-1 Clade A/E Strain 93Th057 Gp120,Homo sapiens,"Wu,X.;Zhang,Z.;Schramm,C.A.;Joyce,M.G.;Kwon,Y.D.;Zhou,T.;Sheng,Z.;Zhang,B.;O'Dell,S.;McKee,K.;Georgiev,I.S.;Chuang,G.Y.;Longo,N.S.;Lynch,R.M.;Saunders,K.O.;Soto,C.;Srivatsan,S.;Yang,Y.;Bailer,R.T.;Louder,M.K.;Mullikin,J.C.;Connors,M.;Kwong,P.D.;Mascola,J.R.;Shapiro,L.",Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection,16-JAN-2015,8_8_17_5_3_5,4XNZ_H_L,Xtal structure,HIV,3,1,2.7447445,4.1948147
ACB47985_ACB48032,QVQLVETGGGLVRPGNSLKLSCVTSGFTFSNYRMHWLRQPPGKRLEWIAVITVKSDNYGANYAESVKGRFAISRDDSKSSVYLEMNRLREEDTATYFCSRGERIYYDYDGDAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYYCGQSYSYPFTFGTGTKLEIK,ACB47985,ACB48032,"monoclonal autoantibody heavy chain variable region, partial [Mus musculus]","monoclonal autoantibody light chain variable region, partial [Mus musculus]",Mus musculus,"Carrillo,J.; Puertas,M.C.; Planas,R.; Pastor,X.; Alba,A.; Stratmann,T.; Pujol-Borrell,R.; Ampudia,R.M.; Vives-Pi,M.; Verdaguer,J.",Anti-peripherin B lymphocytes are positively selected during diabetogenesis,26-JUL-2016,8_10_17_6_3_9,ACB47985_ACB48032,Unique source,peripherin,3,1,13.368319,7.218686
8SB1_C_D,QVQLVQSGAEMKKPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWMGWINPNTGRTNSAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCATGGWIGLYYDSSGYPNFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGSYNLVSWYQQHPGKAPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVVFGGGTKLTVL,8SB1_C,8SB1_D,Cryoem Structure Of Dh270.I3-Ch848.10.17,Cryoem Structure Of Dh270.I3-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SB1_C_D,Xtal structure,HIV,3,1,2.6918917,2.960516
8SB4_C_D,QVQLVQSGAEMKKPGASVRVSCKASGYTFTDYYIHWVRQAPGQGPEWMGWINPSTGRTNSPQKFQGRVTMTRDTSISTAYMDLNRLTSDDTAMYYCTTGGWIGLYSDTSGYPNFDYWGQGTLVTVS,QSALTQPASVSGSPGQSITISCTGTNYDVGSYNLVSWYQQHPGKVPKYIIYEVNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEATYYCCSYAGSSIIFFGGGTKLTVI,8SB4_C,8SB4_D,Cryoem Structure Of Dh270.1-Ch848.10.17,Cryoem Structure Of Dh270.1-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,08-JAN-2009,8_8_20_9_3_10,8SB4_C_D,Xtal structure,HIV,3,1,2.6695695,2.9752412
QEP20540_QEP21188,QVQLVQSGAEMKKPGSSLKASCKASGGTFSGYAVTWARQAPGQGLEWMGGFVFPFGTPNFAQKFQGRATISTDASAGTVYMELHSLTSEDTAIYFCARGVVTNKMPPRYYMDVWGHGTAVSVSS,DIQLTQSPSFLSASVGDRVTITCRASQDISSFLAWYHQKPGEAPKLLISTASTLQSGVPSRFSGSGSGTQFSLTIHSLQAEDFGNYYCQQFKSYMITFGQGTRLEIK,QEP20540,QEP21188,"IGH + IGL c647_heavy_IGHV1-69_IGHD2-21_IGHJ6, partial [Homo sapiens]","IGH + IGL c647_light_IGKV1-9_IGKJ5, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_17_6_3_9,QEP20540_QEP21188,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,3,1,-0.74766713,6.0076914
8SB5_C_D,QVQLVQSGAEMKNPGASVKVSCAASGYTFTDFYIHWVRLAPGQGLQWMGWMNPKTGRTNNAQNFQGRVTMTRDTSIGTAYMELRSLTSDDTAVYYCVTGGWISLYYDSSYYPNFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGKFDLVSWYQQHPGKAPKYMIYEVNKWPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCCSFGGSATVVCGGGTKVTVL,8SB5_C,8SB5_D,Cryoem Structure Of Dh270.I1.6-Ch848.10.17,Cryoem Structure Of Dh270.I1.6-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SB5_C_D,Xtal structure,HIV,3,1,2.9147532,2.683906
8SB2_C_D,QVQLVQSGAEMKNPGASVKVSCAASGYTFTDFYIHWVRQAPGQGLQWMGWMNPKTGRTNTAQNFQGRVTMTRDTSIGTAYMELRSLTSDDTAVYYCATGGWISLYYDSSYYPNFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGSYDLVSWYQQHPGKAPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSFGGSATVVCGGGTKVTVL,8SB2_C,8SB2_D,Cryoem Structure Of Dh270.I2-Ch848.10.17,Cryoem Structure Of Dh270.I2-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SB2_C_D,Xtal structure,HIV,3,1,2.9094257,2.695306
AEL30599_AEL30600,QVQLVQSGAEVKETGESLNISCKVSGNNFPSYYISWVRQMPGNGLEWMGRIDPSDSDTNYRPSFQGHVTISADKSTSTAYLQWRSLKASDTAMYYCARRATYYYGSGSYFDAFDIWGQGTMVTVSS,EIVMTQSPLTLPVTPGAPASISCRSSQSLLHSDGYNYLDWYLQKPGQSPQLLIYLGSHRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPDFGQGTRLEIK,AEL30599,AEL30600,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Hu,H.; Voss,J.; Zhang,G.; Buchy,P.; Zuo,T.; Wang,L.; Wang,F.; Zhou,F.; Wang,G.; Tsai,C.; Calder,L.; Gamblin,S.J.; Zhang,L.; Deubel,V.; Zhou,B.; Skehel,J.J.; Zhou,P.",A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses,22-FEB-2012,8_8_19_11_3_8,AEL30599_AEL30600,Unique source,H5N1; Influenza,3,1,-12.282369,5.756965
QPI12135_QPI12163,QVQLVQSGAEVKKPGASVKLSCKASGYAFTIYSINWVRQAPGQGLEWMGWINPRNGRIGYAQKFQDRVTMTRDTSTSIAYMELGSLRSEDTAVYFCARGRLELTASHFDNWGQGVPVTVSS,DIVMTQSPLSLPVTPGEPAAISCRSSQSLLDRADGNTYLDWYLQKPGQSPQLLIYEVSNRASGVPDRFSGSGSDTDFTLKISRVEAEDVGVYYCMQGLEFPYSFGQGTKVEIK,QPI12135,QPI12163,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin kappa light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Roark,R.S.; Li,H.; Williams,W.B.; Chug,H.; Mason,R.D.; Gorman,J.; Wang,S.; Lee,F.H.; Rando,J.; Bonsignori,M.; Hwang,K.K.; Saunders,K.O.; Wiehe,K.; Moody,M.A.; Hraber,P.T.; Wagh,K.; Giorgi,E.E.; Russell,R.M.; Bibollet-Ruche,F.; Liu,W.; Connell,J.; Smith,A.G.; DeVoto,J.; Murphy,A.I.; Smith,J.; Ding,W.; Zhao,C.; Chohan,N.; Okumura,M.; Rosario,C.; Ding,Y.; Lindemuth,E.; Bauer,A.M.; Bar,K.J.; Ambrozak,D.; Chao,C.W.; Chuang,G.Y.; Geng,H.; Lin,B.C.; Louder,M.K.; Nguyen,R.; Zhang,B.; Lewis,M.G.; Raymond,D.; Doria-Rose,N.A.; Schramm,C.A.; Douek,D.C.; Roederer,M.; Kepler,T.B.; Kelsoe,G.; Mascola,J.R.; Kwong,P.D.; Korber,B.T.; Harrison,S.C.; Haynes,B.F.; Hahn,B.H.; Shaw,G.M.",Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth,29-NOV-2020,8_8_14_12_3_9,QPI12135_QPI12163,Unique source,HIV,3,1,2.0728223,4.340886
7LUC_F_G,QVQLVQSGAEVKKPGASVKLSCQASGYTFNNYGVSWLRQAPGQGLEWMGWISAYNGNKKYAPKFQGRLTLTTVTSTGTAYMELRSLKSDDTALYFCARDPPAVAAAMFDFWGQGTQVTVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSLVLSDGNTYLSWFHQRPGHSPRRLIYRISHRDSGVPDRFSGSESGTDFTLKISRVEAEDVGIYYCMQGTHWPRTFGQGTKVEIK,7LUC_F,7LUC_G,Cryo-Em Structure Of Rsv Pref Bound By Fabs 32.4K And 01.4B,Cryo-Em Structure Of Rsv Pref Bound By Fabs 32.4K And 01.4B,Homo sapiens,"Mukhamedova,M.;Wrapp,D.;Shen,C.H.;Gilman,M.S.;Ruckwardt,T.J.;Schramm,C.A.;Ault,L.;Chang,L.;Derrien-Colemyn,A.;Lucas,S.A.;Ransier,A.;Darko,S.;Phung,E.;Wang,L.;Zhang,Y.;Rush,S.A.;Madan,B.;Stewart-Jones,G.B.;Costner,P.J.;Holman,L.A.;Hickman,S.P.;Berkowitz,N.M.;Doria-Rose,N.A.;Morabito,K.M.;DeKosky,B.J.;Gaudinski,M.R.;Chen,G.L.;Crank,M.C.;Misasi,J.;Sullivan,N.J.;Douek,D.C.;Kwong,P.D.;Graham,B.S.;McLellan,J.S.;Mascola,J.R.",Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses,22-FEB-2021,8_8_14_11_3_9,7LUC_F_G,Xtal structure,,3,1,1.8502712,5.188887
WAM57760_WAM57996,QVQLVQSGAEVKKPGASVKVSCKASGDTFTDYYMHWVRQVPGQGLEWMGWINPNSGGTNYAHKFQDRVIMTRDTSISTAYMELSRLRSDDTAVYYCARYLRGWFFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQIVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPERFSGSGSGTDFTLTISRLEPEDVAVYYCQQYETFGGGTKLEIR,WAM57760,WAM57996,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Jing,C.; Ye,A.Y.; Kratochvil,S.; Cottrell,C.A.; Jahyun,K.; Williams,A.C.; Francisco,L.V.; Batra,H.; Edward,L.; Zhang,Y.; Barbieri,A.; Manis,J.P.; Haynes,B.F.; Schief,W.R.; Batista,F.D.; Tian,M.",Humanized V(D)J-rearranging and TdT-expressing Mouse Vaccine Models with Physiological HIV-1 Broadly Neutralizing Antibody Precursors,17-DEC-2022,8_8_11_7_3_5,WAM57760_WAM57996,Unique source,HIV,3,1,2.173257,3.7699625
8DY6_C_D,QVQLVQSGAEVKKPGASVKVSCKASGYRFTDHYIHWVRQAPGQGPEWMGWINTSSGRSNFAQKFQGRVTMTRDTSISTAYMELNRLKSDDTAVYYCTTGSWISLYYDSSGYPNFDYWGQGTLVTVT,QSALTQPASVSGSPGQPITISCTGTSYDVGNYDLVSWYQQHPGNAPKYMIYEVTKRPAGISNRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGTKVTVL,8DY6_C,8DY6_D,Vaccine Elicited Antibody Mu89+S27Y Bound To Ch848.D949.10.17_N133D_N138T.Ds.Sosip.664 Hiv-1 Env Trimer,Vaccine Elicited Antibody Mu89+S27Y Bound To Ch848.D949.10.17_N133D_N138T.Ds.Sosip.664 Hiv-1 Env Trimer,Mus musculus,"Wiehe,K.;Saunders,K.O.;Stalls,V.;Cain,D.;Venkatayogi,S.;Martin Beem,J.S.;Berry,M.;Evangelous,T.;Henderson,R.;Hora,B.;Xia,S.;Jiang,C.;Newman,A.;Bowman,C.;Lu,X.;Bryan,M.E.;Bal,J.;Sanzone,A.;Chen,H.;Eaton,A.;Tomai,M.A.;Fox,C.B.;Tam,Y.;Barbosa,C.;Bonsignori,M.;Muramatsu,H.;Alam,S.M.;Montefiori,D.;Williams,W.B.;Pardi,N.;Tian,M.;Weisman,D.;Alt,F.W.;Acharya,P.;Haynes,B.F.",Mutation-Guided Vaccine Design: A Strategy for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction,08-JAN-2009,8_8_20_9_3_10,8DY6_C_D,Xtal structure,HIV,3,1,2.6749141,2.9916866
8SB0_C_D,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWMAWINPTTGRTNSARKFQGRVTMTRDTSISTAYMELRRLRSDDTAVYYCARGGWIGLYVDYSGYPNFDSWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGSYNLVSWYQQHPGKAPKLMIYEVSKWPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVIFGGGTKLTVL,8SB0_C,8SB0_D,Cryoem Structure Of Dh270.I4.6-Ch848.10.17,Cryoem Structure Of Dh270.I4.6-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SB0_C_D,Xtal structure,HIV,3,1,2.7216504,2.918527
8SAZ_C_D,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWMGWINPNTGRTNSAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWIGLYYDSSGYPNFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVVFGGGTKLTVL,8SAZ_C,8SAZ_D,Cryoem Structure Of Dh270.I5.6-Ch848.10.17,Cryoem Structure Of Dh270.I5.6-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,08-JAN-2009,8_8_20_9_3_10,8SAZ_C_D,Xtal structure,HIV,3,1,2.6678822,2.949617
4YHO_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGWDYFDYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIK,4YHO_H,4YHO_L,Reversal Agent For Dabigatran,Reversal Agent For Dabigatran,Homo sapiens,"Schiele,F.;van Ryn,J.;Litzenburger,T.;Ritter,M.;Seeliger,D.;Nar,H.",Structure-guided residence time optimization of a dabigatran reversal agent,27-FEB-2015,8_8_12_11_3_9,ATJ22420_ATJ22421,Xtal structure,,3,1,1.063379,3.6934834
7UMM_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPNTGGTVYAQTFQARVTMTRDTSISTAYMELIRLRSDDTAVYYCARERGTGAPDAFNIWGQGTLVTVSG,DIVMTQSPASLAVSLGQRATISCRASKSVSTSGYSYIHWYQQKPGQPPKLLIYLATNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRDTPYTFGGGTKLEIK,7UMM_H,7UMM_L,H1 Solomon Islands 2006 Hemagglutinin In Complex With Ab109,H1 Solomon Islands 2006 Hemagglutinin In Complex With Ab109,Mus musculus,"Caradonna,T.M.;Ronsard,L.;Yousif,A.S.;Windsor,I.W.;Hecht,R.;Bracamonte-Moreno,T.;Roffler,A.A.;Maron,M.J.;Maurer,D.P.;Feldman,J.;Marchiori,E.;Barnes,R.M.;Rohrer,D.;Lonberg,N.;Oguin,T.H.;Sempowski,G.D.;Kepler,T.B.;Kuraoka,M.;Lingwood,D.;Schmidt,A.G.",An epitope-enriched immunogen expands responses to a conserved viral site,23-NOV-2022,8_8_14_10_3_9,7UMM_H_L,Xtal structure,,3,1,2.2446256,3.7468047
AOT82816_AOT82817,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGRINPNSGGTNYAQKFEGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTGIAAAGFVFDYWGQGTLVTVSS,DIVMTQSPATLSVSPGERATLSCRASQSVISNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWWTFGQGTKVEIK,AOT82816,AOT82817,"anti-ZIKV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-ZIKV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Wang,Q.; Yang,H.; Liu,X.; Dai,L.; Ma,T.; Qi,J.; Wong,G.; Peng,R.; Liu,S.; Li,J.; Li,S.; Song,J.; Liu,J.; He,J.; Yuan,H.; Xiong,Y.; Liao,Y.; Li,J.; Yang,J.; Tong,Z.; Griffin,B.D.; Bi,Y.; Liang,M.; Xu,X.; Qin,C.; Cheng,G.; Zhang,X.; Wang,P.; Qiu,X.; Kobinger,G.; Shi,Y.; Yan,J.; Gao,G.F.",Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus,27-DEC-2016,8_8_14_6_3_8,AOT82816_AOT82817,Unique source,Zika; ZIKV,3,1,2.1148045,3.7587962
6XOC_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNCDYNWDFQHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIK,6XOC_H,6XOC_L,Crystal Structure Of Glvrc01 Fab In Complex With Anti-Idiotypic Iv4 Fab,Crystal Structure Of Glvrc01 Fab In Complex With Anti-Idiotypic Iv4 Fab,Homo sapiens,"Seydoux,E.;Wan,Y.H.;Feng,J.;Wall,A.;Aljedani,S.;Homad,L.J.;MacCamy,A.J.;Weidle,C.;Gray,M.D.;Brumage,L.;Taylor,J.J.;Pancera,M.;Stamatatos,L.;McGuire,A.T.",Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies,06-JUL-2020,8_8_14_6_3_5,6XOC_H_L,Xtal structure,,3,1,2.509552,4.053273
4JDV_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKYCTARDYYNWDFQHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIK,4JDV_A,4JDV_B,Crystal Structure Of Germ-Line Precursor Of Nih45-46 Fab,Crystal Structure Of Germ-Line Precursor Of Nih45-46 Fab,Homo sapiens,"Scharf,L.;West AP,Jr.;Gao,H.;Lee,T.;Scheid,J.F.;Nussenzweig,M.C.;Bjorkman,P.J.;Diskin,R.",Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody,25-FEB-2013,8_8_18_6_3_5,4JDV_A_B,Xtal structure,gp120; HIV,3,1,2.46885,3.9541557
7UGN_G_J,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCATQLELDSSAGYAFDIWGQGTMVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYEYFGGGTKLTVL,7UGN_G,7UGN_J,Cryo-Em Structure Of Bg24 Inferred Germline Fabs With Germline Cdr3S And 10-1074 Fabs In Complex With Hiv-1 Env Immunogen Bg505-Sosipv4.1-Gt1 - Class 1,Cryo-Em Structure Of Bg24 Inferred Germline Fabs With Germline Cdr3S And 10-1074 Fabs In Complex With Hiv-1 Env Immunogen Bg505-Sosipv4.1-Gt1 - Class 1,Homo sapiens,"Dam,K.A.;Barnes,C.O.;Gristick,H.B.;Schoofs,T.;Gnanapragasam,P.N.P.;Nussenzweig,M.C.;Bjorkman,P.J.",HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design,26-OCT-2022,8_8_16_9_3_5,7UGN_G_J,Xtal structure,HIV; CD4,3,1,2.3546722,3.5524652
8SAW_C_D,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGRTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVIFGGGTKLTVL,8SAW_C,8SAW_D,Cryoem Structure Of Dh270.Uca.G57R-Ch848.10.17Dt,Cryoem Structure Of Dh270.Uca.G57R-Ch848.10.17Dt,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SAW_C_D,Xtal structure,HIV,3,1,2.5639825,3.1055613
AF397065_1,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARSRRNWGQGTLVTVS,SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,AF397065_1_H,AF397065_1_L,HBV core single chain Fv antibody [synthetic construct],HBV core single chain Fv antibody [synthetic construct],synthetic construct,"Zhong,Y.; Cheng,J.; Wang,G.; Cheng,X.",Direct Submission,09-AUG-2001,8_8_6_6_3_11,AF397065_1,Same entry,HBV,3,1,0.2983542,3.1808455
QLI33945_QLI33946,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPGGGSTTYAQKFQGRVTMTSDTSTSTVYMELSSLRSEDTAMYYCARGAIPPNSRAEIDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERVTLSCRASQSVSSNLAWCQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYNWPLTFGGGTKVEIK,QLI33945,QLI33946,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Eun-Hyung Lee,F.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Rothlauf,P.W.; Bloyet,L.M.; Whelan,S.P.J.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E. Jr.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,20-JUL-2020,8_8_15_6_3_9,QLI33945_QLI33946,Unique source,SARS-CoV-2,3,1,1.5895394,3.7878728
QIH48262_QIH48263,QVQLVQSGAEVKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGLEWMGWINPKRGGSNSAQKFQDRVTMTRDTSINTAYMELTSLRSDDTAVYYCARGGWISLYYDSSGYPNFDCWGQGPLITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKDPKLMIYEVNKRASGVSIRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGSKLTVL,QIH48262,QIH48263,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48262_QIH48263,Unique source,HIV,3,1,2.7607195,2.8506167
QIH48302_QIH48303,QVQLVQSGAEVKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGLEWMGWINPKRGGSNSAQKFQDRVTMTRDTSINTAYMELTSLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGPLITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKDPKLMIYEVNKRASGVSIRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGSKLTVL,QIH48302,QIH48303,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48302_QIH48303,Unique source,HIV,3,1,2.773109,2.8334832
CBX32702_CBX32700,QVQLVQSGAEVKKPGASVKVSCKASGYVFTDYGMNWVRQAPGQGLEWMGWINTYIGEPIYAQKFQGRVTFTLDTSTSTAYMELSSLRSEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,CBX32702,CBX32700,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Athwal,D.; Brown,D.; Weir,A.; Popplewell,A.; Chapman,A.; King,D.","Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof",13-OCT-2010,8_8_11_6_3_9,CBX32702_CBX32700,Ordered entries,,3,1,1.6674936,4.2169404
CAD38454,QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIK,CAD38454_H,CAD38454_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Pfizenmaier,K.; Wajant,H.; Moosmayer,D.; Wueest,T.","Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)",08-JUL-2002,8_8_17_12_3_9,AKX26848,Same entry,apoptosis,3,1,0.8853097,3.6080625
QMI58164_QMI58180,QVQLVQSGAEVKKPGASVKVSCKVSGYTLIELSMHWVRQAPGKGLEWMGGFDPEDVETIYAQQFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGWAYKSTWYFGYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSRMGFGGGTKLTVL,QMI58164,QMI58180,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_14_9_3_9,QMI58164_QMI58180,Unique source,SARS-CoV-2,3,1,1.0459138,2.491989
7LCN_B_D,QVQLVQSGAEVKKPGASVKVSCKVSGYTLPELSMHWVRQAPGKGLEWMGGFHPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGSPFGVVTDWFDPWGRGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNPYVFGTGTKVTVL,7LCN_B,7LCN_D,Structure Of Sars-Cov-2 S Protein In Complex With N-Terminal Domain Antibody Dh1050.1,Structure Of Sars-Cov-2 S Protein In Complex With N-Terminal Domain Antibody Dh1050.1,Homo sapiens,"Li,D.;Edwards,R.J.;Manne,K.;Martinez,D.R.;Schafer,A.;Alam,S.M.;Wiehe,K.;Lu,X.;Parks,R.;Sutherland,L.L.;Oguin,T.H.;McDanal,C.;Perez,L.G.;Mansouri,K.;Gobeil,S.M.;Janowska,K.;Stalls,V.;Kopp,M.;Cai,F.;Lee,E.;Foulger,A.;Hernandez,G.E.;Sanzone,A.;Tilahun,K.;Jiang,C.;Tse,L.V.;Bock,K.W.;Minai,M.;Nagata,B.M.;Cronin,K.;Gee-Lai,V.;Deyton,M.;Barr,M.;Holle,T.V.;Macintyre,A.N.;Stover,E.;Feldman,J.;Hauser,B.M.;Caradonna,T.M.;Scobey,T.D.;Rountree,W.;Wang,Y.;Moody,M.A.;Cain,D.W.;DeMarco,C.T.;Denny,T.;Woods,C.W.;Petzold,E.W.;Schmidt,A.G.;Teng,I.T.;Zhou,T.;Kwong,P.D.;Mascola,J.R.;Graham,B.S.;Moore,I.N.;Seder,R.;Andersen,H.;Lewis,M.G.;Montefiori,D.C.;Sempowski,G.D.;Baric,R.S.;Acharya,P.;Haynes,B.F.;Saunders,K.O.",The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates,11-JAN-2021,8_8_15_9_3_11,7LCN_B_D,Xtal structure,SARS-CoV-2,3,1,1.0186933,2.5175033
QIH48462_QIH48463,QVQLVQSGAEVKKPGASVKVSCQTSGYTFTSYFMHWVRQVPGLGLAWMGMIDPSGGRTTYAQKFQGRVSMTRDTSTNTVYMELSSLRSEDTAVYYCARDVETEGSLLHFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKLGQAPRLLIYDASTRATGIPVRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNDWWTFGQGTKVEIK,QIH48462,QIH48463,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_15_6_3_8,QIH48462_QIH48463,Unique source,HIV,3,1,1.5597327,3.934759
7SWD_I_I,QVQLVQSGAEVKKPGASVKVSCRTSGYTFSSYNIHWVRQAPGQGLEWMGVINPYGRSTTLYARRFRDRVTMTRDTSTSTVYMELSSLRSEDTAVYFCGRLYSGAPYGLDVWGQGSTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYVDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVETEDVGIYYCMQGLQTPLTFGGGTKVEIK,7SWD_I,7SWD_I,Structure Of Ebov Gp Lacking The Mucin-Like Domain With 1C11 Scfv And 1C3 Fab Bound,Structure Of Ebov Gp Lacking The Mucin-Like Domain With 1C11 Scfv And 1C3 Fab Bound,Ebola virus - Gabon (1994-1997),"Milligan,J.C.;Davis,C.W.;Yu,X.;Ilinykh,P.A.;Huang,K.;Halfmann,P.J.;Cross,R.W.;Borisevich,V.;Agans,K.N.;Geisbert,J.B.;Chennareddy,C.;Goff,A.J.;Piper,A.E.;Hui,S.;Shaffer,K.C.L.;Buck,T.;Heinrich,M.L.;Branco,L.M.;Crozier,I.;Holbrook,M.R.;Kuhn,J.H.;Kawaoka,Y.;Glass,P.J.;Bukreyev,A.;Geisbert,T.W.;Worwa,G.;Ahmed,R.;Saphire,E.O.",Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses,19-NOV-2021,8_9_13_11_3_9,7SWD_I_I,Xtal structure,,3,1,1.5042266,3.8617918
UIC72194_UIC72504,QVQLVQSGAEVKKPGASVTVSCKASGYTFTSYGVTWVRQAPGQGLEWMGWISPFNGNTNSVQKFQGRVTLTTETSTSMAFLEIRNLRSDDTAVYYCARGGGGHVVVPPGRWDYYIGLDVWGQGTTVTVSS,DIQVTQSPSSVSASVGDRVTITCRASQNFNNYLNWYQQKPGKAPKLLIYGVSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQGTFGPGTRVDI,UIC72194,UIC72504,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_23_6_3_4,UIC72194_UIC72504,Unique source,HCV,3,1,1.8875396,5.1550946
7YRN_D_E,QVQLVQSGAEVKKPGESLKISCKGSGYTFTNYWIGWVRQMPGAGLEWMAIIFPRDSYSAYSPSFQGRVTISVDKSISTAYLHWSSLEASDTAVYYCAIYNDLRSGNSWGQGTPLIVSS,DIQMTQSPSSLSASVGDRVTITCRASQSITKYLNWYQQKPGRAPKLLIHTTSTLQSGVPSRFSGSGSGTDFTLTISSLQLEDFGTYYCQQSFSTLWTFGQGTKLDIK,7YRN_D,7YRN_E,Cyro-Em Structure Of Hcmv Glycoprotein B In Complex With 1B03 Fab,Cyro-Em Structure Of Hcmv Glycoprotein B In Complex With 1B03 Fab,Homo sapiens,"Wu,C.;Wang,H.;Zhu,S.;Liao,H.",Cyro-EM structure of HCMV glycoprotein B in complex with 1B03 Fab,08-JAN-2009,8_8_11_6_3_9,7YRN_D_E,Xtal structure,HCMV,3,1,-12.454632,5.765036
7YCL_A_B,QVQLVQSGAEVKKPGESLRISCKGSGYSFTNYWISWVRQMPGKGLEWMGRIDPSDSYINYSPSFQGHATISADKSISTAYLQWGSLKASDTAMYYCARGRNYLDSRGRFDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKSGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDSLGFTFGPGTKVEIR,7YCL_A,7YCL_B,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Is-9A Fab,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Is-9A Fab,Severe acute respiratory syndrome coronavirus 2,"Huang,K.A.;Chen,X.;Mohapatra,A.;Nguyen,H.T.V.;Schimanski,L.;Tan,T.K.;Rijal,P.;Vester,S.K.;Hills,R.A.;Howarth,M.;Keeffe,J.R.;Cohen,A.A.;Kakutani,L.M.;Wu,Y.M.;Shahed-Al-Mahmud,M.;Chou,Y.C.;Bjorkman,P.J.;Townsend,A.R.;Ma,C.",Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2,01-FEB-2023,8_8_15_6_3_9,7YCL_A_B,Xtal structure,SARS-CoV-2,3,1,-11.96649,5.455085
AKH36542_AKH36496,QVQLVQSGAEVKKPGSSVKVSCEASGVTSSSYTISWVRLAPGQGLEWMGRITPIFDITNYAQKFQGRVTLTADKSTGTTYMELSSLRSDDTAVYYCARDKSDVVVVTSIRPAYYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQTISSWLAWYQQKSGTAPKLLIYKASSIVSGVPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYNSSPETFGQGTKVEIK,AKH36542,AKH36496,"anti-HIV-1 V2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-HIV-1 V2 immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Li,L.; Wang,X.H.; Williams,C.; Volsky,B.; Steczko,O.; Seaman,M.S.; Luthra,K.; Nyambi,P.; Nadas,A.; Giudicelli,V.; Lefranc,M.P.; Zolla-Pazner,S.; Gorny,M.K.","A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site",20-MAY-2015,8_8_23_6_3_9,AKH36542_AKH36496,Unique source,HIV; CD4,3,1,-0.99904615,6.1495485
7U0C_A_B,QVQLVQSGAEVKKPGSSVKVSCKASGGSFSSNAISWVRQAPGQGLEWMGGINPVLGIGNYAEKFQGRVTITADNPTSTSYLELRSLRSEDTAVYYCATLHPRLCRGGTCWGWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQNINNYLNWYQQKPGKAPKVLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHSTVRTFGQGTKVEIK,7U0C_A,7U0C_B,Crystal Structure Of Broadly Neutralizing Antibody Hepc3.4,Crystal Structure Of Broadly Neutralizing Antibody Hepc3.4,Homo sapiens,"Bozhanova,N.G.;Flyak,A.I.;Brown,B.P.;Ruiz,S.E.;Salas,J.;Rho,S.;Bombardi,R.G.;Myers,L.;Soto,C.;Bailey,J.R.;Crowe,J.E.;Bjorkman,P.J.;Meiler,J.",Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals,17-FEB-2022,8_8_19_6_3_9,7U0C_A_B,Xtal structure,HCV,3,1,-0.9621584,5.645099
7KEX_G_J,QVQLVQSGAEVKKPGSSVKVSCKASGGTFIDYTYNWVRQAPGQGLVWMGRVVPGLGLSSYAQQFEDRVTITAAKSTSTVYMELRGLTSEDTAMYYCARDTASFGWLPFAFWGQGTLVTVSS,QTVMTQSPGTLSLSPGERATLSCGVSQSISSTYFAWYQQKVGQAPRLLIYGASNRASGIPDRFSGSASGTDFTLTISRVEPEDFAVYYCQQYGSSPTFGQGTRLEIK,7KEX_G,7KEX_J,"Ebola Virus Gp (Mucin Deleted, Makona Strain) Bound To Antibody Fab Ebov-293","Ebola Virus Gp (Mucin Deleted, Makona Strain) Bound To Antibody Fab Ebov-293",Ebola virus,"Murin,C.D.;Gilchuk,P.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Shen,X.;Bruhn,J.F.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Williamson,L.E.;Copps,J.;Alkutkar,T.;Flyak,A.I.;Bukreyev,A.;Crowe JE,Jr.;Ward,A.B.",Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies,13-OCT-2020,8_8_14_7_3_8,7KEX_G_J,Xtal structure,Ebola,3,1,-0.55260175,5.398333
6VN1_J_N,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNFAISWVRQAPGQGLEWMGRIMPLFVTSTYAQKFQGRVTISADASTSTAYMELSSLRSDDTAMYYCARDITAPGAAPTPLNFYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQTISTWLAWYQQTPRKAPKLMIYKASILENGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYKSYPWTFGQGTKVEI,6VN1_J,6VN1_N,A 2.8 Angstrom Cryo-Em Structure Of A Glycoprotein B-Neutralizing Antibody Complex Reveals A Critical Domain For Herpesvirus Fusion Initiation,A 2.8 Angstrom Cryo-Em Structure Of A Glycoprotein B-Neutralizing Antibody Complex Reveals A Critical Domain For Herpesvirus Fusion Initiation,Human alphaherpesvirus 3,"Oliver,S.L.;Xing,Y.;Chen,D.H.;Roh,S.H.;Pintilie,G.D.;Bushnell,D.A.;Sommer,M.H.;Yang,E.;Carfi,A.;Chiu,W.;Arvin,A.M.",A glycoprotein B-neutralizing antibody structure at 2.8 A uncovers a critical domain for herpesvirus fusion initiation,29-JAN-2020,8_8_21_6_3_9,6VN1_J_N,Xtal structure,,3,1,-0.90123093,6.0996623
2JB6_B_A,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGNIEPYFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYFMSYKHLSDYWGQGTLVTVSS,ALTQPASVSGSPGQSITISCTGTSSDVGSNNYVSWYQQHPGKAPKLMIYGGSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCRSWDSNLSYSVFGGGTKLTVL,2JB6_B,2JB6_A,"Fab Fragment In Complex With Small Molecule Hapten, Crystal Form-2","Fab Fragment In Complex With Small Molecule Hapten, Crystal Form-2",Homo sapiens,"Hillig,R.C.;Baesler,S.;Urlinger,S.;Stark,Y.;Bauer,S.;Badock,V.;Huber,M.;Bahr,I.;Schirner,M.;Licha,K.",Crystallization and molecular-replacement solution of a diagnostic fluorescent dye in complex with a specific Fab fragment,03-DEC-2006,8_8_13_9_3_11,2JB6_B_A,Xtal structure,,3,1,-0.48051503,5.6393824
7KFH_G_J,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRDIFSWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTVFMELSGLRSEDTAVYFCARGPPLRGERSWFGESEKYDYFYMDVWGKGTTVTVSS,QIVLTQSPGTLSLSPGERATLSCRASQSVSNSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLSISRLEPEDFAVYYCQQYGTSPCTFGQGTKLEIK,7KFH_G,7KFH_J,"Ebola Virus Gp (Mucin Deleted, Makona Strain) Bound To Antibody Fab Ebov-437","Ebola Virus Gp (Mucin Deleted, Makona Strain) Bound To Antibody Fab Ebov-437",Homo sapiens,"Murin,C.D.;Gilchuk,P.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Shen,X.;Bruhn,J.F.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Williamson,L.E.;Copps,J.;Alkutkar,T.;Flyak,A.I.;Bukreyev,A.;Crowe JE,Jr.;Ward,A.B.",Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies,13-OCT-2020,8_8_26_7_3_9,7KFH_G_J,Xtal structure,Ebola,3,1,-1.1122078,5.9525676
QKY76667_QKY76280,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIIWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYVELSSLRSEDTAVYYCARIGHFDSSGYYLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSFLAWYQQKPGQAPRLLIYDASNRPTGIPARFTGSGSGTDFTLTISSLEPEDFAVYYCQHRTNWPPLFTFGPGTKVDIK,QKY76667,QKY76280,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_15_6_3_11,QKY76667_QKY76280,Unique source,SARS-CoV-2,3,1,-0.6077983,5.8674393
QKY76672_QKY76285,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGAANYAQNFQGRVTITADESTSTGYMQLSSLRFEDTAVYYCARTSHYDSSGSYFEYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLDPEDFAVYYCHKRSNWPPSLTFGGGTKVEIK,QKY76672,QKY76285,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_15_6_3_11,QKY76672_QKY76285,Unique source,SARS-CoV-2,3,1,-0.8345816,5.7008185
5CBA_A_B,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREPDYYDSSGYYPIDAFDIWGQGTTVTVSS,QSALTQPASVSASPGQSITISCTGTSSDVGAYDWVSWYQQHPGKAPKLLIFDVNNRPSGVSHRFSGSKSGNTASLTISGLQAEDEADYYCSSYTRRDTYVFGTGTKVTVL,5CBA_A,5CBA_B,3B4 In Complex With Cxcl13 - 3B4-Cxcl13,3B4 In Complex With Cxcl13 - 3B4-Cxcl13,Homo sapiens,"Tu,C.;Terraube,V.;Tam,A.S.;Stochaj,W.;Fennell,B.J.;Lin,L.;Stahl,M.;LaVallie,E.R.;Somers,W.;Finlay,W.J.;Mosyak,L.;Bard,J.;Cunningham,O.",A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv),30-JUN-2015,8_8_20_9_3_10,5CBA_A_B,Xtal structure,,3,1,-0.8300754,6.003703
7R8O_M_N,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARREAYGPRDYYYYYGMDVWGQGTTVTVSS,QSALTQPPSASASLGASVTLTCTLSSGYSNYKVDWYQQRPGKGPRFVMRVGTGGIVGSKGDGIPDRFSVLGSGLNRYLTIKNIQEEDESDYHCGADQGSGSNFVGVFGGGTKLTVG,7R8O_M,7R8O_N,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody C548,Structure Of The Sars-Cov-2 S 6P Trimer In Complex With Neutralizing Antibody C548,Homo sapiens,"Muecksch,F.;Weisblum,Y.;Barnes,C.O.;Schmidt,F.;Schaefer-Babajew,D.;Lorenzi,J.C.;Flyak,A.I.;DeLaitsch,A.T.;Huey-Tubman,K.E.;Hou,S.;Schiffer,C.A.;Gaebler,C.;Wang,Z.;Da Silva,J.;Poston,D.;Finkin,S.;Cho,A.;Cipolla,M.;Oliveira,T.Y.;Millard,K.G.;Ramos,V.;Gazumyan,A.;Rutkowska,M.;Caskey,M.;Nussenzweig,M.C.;Bjorkman,P.J.;Hatziioannou,T.;Bieniasz,P.D.","Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies",26-JUN-2021,8_8_19_7_8_13,7R8O_M_N,Xtal structure,SARS-CoV-2,3,1,-0.8551131,6.14534
8EB2_J_L,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYHIHWVRQAPGQGLEWIGWIYPGNVNTEYNEKFKGKATITADESTNTAYMELSSLRSEDTAVYYCAREEITYAMDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRSSQSIVHSNGNTYLEWYQQKPGKAPKLLIYKVSNRFSGVPARFSGSGSGTEFTLTISSLQPDDFATYYCFQGSHVPRTFGQGTKVEVK,8EB2_J,8EB2_L,Structure Of Hla-A*02:01 In Complex With Ny-Eso-1 Peptide And Pa2.1 Fab,Structure Of Hla-A*02:01 In Complex With Ny-Eso-1 Peptide And Pa2.1 Fab,Homo sapiens,"Mock,J.Y.;Winters,A.;Riley,T.P.;Bruno,R.;Naradikian,M.S.;Sharma,S.;Jette,C.A.;Elshimali,R.;Gahrs,C.;Toledo-Warshaviak,D.;West,A.P.;Kamb,A.;Hamburger,A.E.",HLA-A&#x2217;02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen,30-NOV-2022,8_8_11_11_3_9,8EB2_J_L,Xtal structure,HLA-A,3,1,0.65213656,3.8911994
3NFP_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,3NFP_H,3NFP_L,Crystal Structure Of The Fab Fragment Of Therapeutic Antibody Daclizumab In Complex With Il-2Ra (Cd25) Ectodomain,Crystal Structure Of The Fab Fragment Of Therapeutic Antibody Daclizumab In Complex With Il-2Ra (Cd25) Ectodomain,Homo sapiens,"Yang,H.;Wang,J.;Du,J.;Zhong,C.;Zhang,D.;Guo,H.;Guo,Y.;Ding,J.",Structural basis of immunosuppression by the therapeutic antibody daclizumab,10-JUN-2010,8_8_9_5_3_9,QHX97319_QHX97386,Xtal structure,Ectodomain,3,1,0.7362745,3.799071
QHQ73565,QVQLVQSGAEVKKPGSSVKVSCKDSGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTTNYAQQFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAVAADWLDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRFTFGPGTKVDIK,QHQ73565_H,QHQ73565_L,Hu19-CD28Z receptor protein [synthetic construct],Hu19-CD28Z receptor protein [synthetic construct],synthetic construct,"Brudno,J.N.; Lam,N.; Vanasse,D.; Shen,Y.W.; Rose,J.J.; Rossi,J.; Xue,A.; Bot,A.; Scholler,N.; Mikkilineni,L.; Roschewski,M.; Dean,R.; Cachau,R.; Youkharibache,P.; Patel,R.; Hansen,B.; Stroncek,D.F.; Rosenberg,S.A.; Gress,R.E.; Kochenderfer,J.N.",Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma,02-FEB-2020,8_8_12_7_3_9,QDB10370,Same entry,CD19; CXADR; CAR,3,1,-0.58894324,5.800231
7UAR_F_G,QVQLVQSGAEVKKPGSSVKVSCKTSGGTFNSFAINWVRQAPGQGPEWMGRVIPVLEIANYAQKFQGRITITADKSTSTAYMELSSLTSEDTAIYYCARHHIAVAQPYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQHLPGTAPKLLMSSDDQRPSGVPARFSGSKSGTSASLAISGLRSEDEADYYCASWDDRLNGVVFGGGTKLTVL,7UAR_F,7UAR_G,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Neutralizing Antibody Fab Fragment, C1717","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Neutralizing Antibody Fab Fragment, C1717",Homo sapiens,"Wang,Z.;Muecksch,F.;Cho,A.;Gaebler,C.;Hoffmann,H.H.;Ramos,V.;Zong,S.;Cipolla,M.;Johnson,B.;Schmidt,F.;DaSilva,J.;Bednarski,E.;Ben Tanfous,T.;Raspe,R.;Yao,K.;Lee,Y.E.;Chen,T.;Turroja,M.;Milard,K.G.;Dizon,J.;Kaczynska,A.;Gazumyan,A.;Oliveira,T.Y.;Rice,C.M.;Caskey,M.;Bieniasz,P.D.;Hatziioannou,T.;Barnes,C.O.;Nussenzweig,M.C.",Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins,13-MAR-2022,8_8_14_8_3_11,7UAR_F_G,Xtal structure,SARS,3,1,-0.7342501,5.642467
6W5D_H_L,QVQLVQSGAEVKKPGSSVKVSCKTSGGTYGTYSINWVRQAPGQGLEWMGAIIPIFGKTNYAQKFQGRVTITADASTSTAYMELGSLTSEDTAMYYCARVEDTALDHYFDYWGQGALVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSGDVGTYNYVSWYQQLPGKAPKLMIYDVTRRPSGVPDRFSGSKSGNTASLTISGLQADDEADYYCCSYAGTLTWVFGGGTKLTVL,6W5D_H,6W5D_L,Crystal Structure Of Fab Rsb1,Crystal Structure Of Fab Rsb1,Homo sapiens,"Harshbarger,W.;Tian,S.;Wahome,N.;Balsaraf,A.;Bhattacharya,D.;Jiang,D.;Pandey,R.;Tungare,K.;Friedrich,K.;Mehzabeen,N.;Biancucci,M.;Chinchilla-Olszar,D.;Mallett,C.P.;Huang,Y.;Wang,Z.;Bottomley,M.J.;Malito,E.;Chandramouli,S.",Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F,13-MAR-2020,8_8_14_9_3_10,6W5D_H_L,Xtal structure,,3,1,-0.53411007,5.6061277
QRE55753_QRE55754,QVQLVQSGAEVKKPGSSVKVSCKVSGGIFNRETINWVRQAPGQGLEWMGRITPIVDVPNYPRKFRGRVTITADKSTSTVYMELSGLRFEDTAIYFCARFRGHNYFDPWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGGKSVHWYQQKPGQAPVLVVYDDRDRPSGIPERFSGSNSGDTASLTISRVDAGDEADYFCQVWDNASDEAVFGGGTKLTVL,QRE55753,QRE55754,"anti-Hendra virus RBP immunoglobulin heavy chain, partial [Homo sapiens]","anti-Hendra virus RBP immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Dong,J.; Cross,R.W.; Doyle,M.P.; Kose,N.; Mousa,J.J.; Annand,E.J.; Borisevich,V.; Agans,K.N.; Sutton,R.; Nargi,R.; Majedi,M.; Fenton,K.A.; Reichard,W.; Bombardi,R.G.; Geisbert,T.W.; Crowe,J.E. Jr.",Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein,08-FEB-2021,8_8_11_6_3_11,QRE55753_QRE55754,Unique source,RBP; Hendra; RENBP; RNBP,3,1,-0.78323233,5.5558434
7KEW_G_J,QVQLVQSGAEVKKPGSSVKVSCRASGDSFSRKYGISWVRQAPGQGFEWMGTIMPIVGLTTSAQKFQGRVTITADKSTSTAHMELNSLTSEDTAIYYCARDEIIGARPHWFDSWGQGTLVTVSS,EIVMTQSPAIMSVSPGKRATLSCRASQSVSSNLAWYQRKPGQAPRLLIYGSSTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCLQYYNWPRTFGQGTKVEIK,7KEW_G,7KEW_J,Bundibugyo Virus Gp (Mucin Deleted) Bound To Antibody Fab Bdbv-43,Bundibugyo Virus Gp (Mucin Deleted) Bound To Antibody Fab Bdbv-43,Bundibugyo ebolavirus,"Murin,C.D.;Gilchuk,P.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Shen,X.;Bruhn,J.F.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Williamson,L.E.;Copps,J.;Alkutkar,T.;Flyak,A.I.;Bukreyev,A.;Crowe JE,Jr.;Ward,A.B.",Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies,13-OCT-2020,9_8_15_6_3_9,7KEW_G_J,Xtal structure,,3,1,-0.66108465,5.578075
5JO4_A_B,QVQLVQSGAEVKKPGSSVKVSCRASGGTGGTFSAYAFTWVRQAPGQGLEWMGGITGMFGTANYAQKFQGRVTITADELTSTAYMELSSLTSEDTALYYCARGLYYYESSLDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSLSSKYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYSCQQYDGVPRTFGQGTTVEIK,5JO4_A,5JO4_B,Antibody Fab Fragment Complex,Antibody Fab Fragment Complex,Homo sapiens,"Avnir,Y.;Zhang,Z.;Prachanronarong,K.;Schiffer,C.A.;Marasco,W.A.",Structural Basis of an Influenza Hemagglutinin Stem-Directed Antibody Retaining the G6 Idiotype,01-MAY-2016,11_8_13_7_3_9,5JO4_A_B,Xtal structure,Influenza,3,1,-0.5048458,5.741014
5XRQ_H_L,QVQLVQSGAEVKKPGSSVRVSCKASGDTFSSYSITWVRQAPGHGLQWMGGIFPIFGSTNYAQKFDDRLTITTDDSSRTVYMELTSLRLEDTAVYYCARGASKVEPAAPAYSDAFDMWGQGTLVTVSS,DIVMTQSPGTLSLSPGERATLSCRTSQGVSSSYLAWYQQKPGQAPRLLISGSSSRATGIPDRFSGSGSGRDFTLTISRLEPEDSAVYYCQQYATSPTFGQGTRVEIK,5XRQ_H,5XRQ_L,Crystal Structure Of Human Monoclonal Antibody H3V-47,Crystal Structure Of Human Monoclonal Antibody H3V-47,Homo sapiens,"Bangaru,S.;Zhang,H.;Gilchuk,I.M.;Voss,T.G.;Irving,R.P.;Gilchuk,P.;Matta,P.;Zhu,X.;Lang,S.;Nieusma,T.;Richt,J.A.;Albrecht,R.A.;Vanderven,H.A.;Bombardi,R.;Kent,S.J.;Ward,A.B.;Wilson,I.A.;Crowe JE,Jr.",A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA,09-JUN-2017,8_8_20_7_3_8,5XRQ_H_L,Xtal structure,,3,1,-0.8132398,5.7161765
QIH48430_QIH48431,QVQLVQSGAEVKNPGASVKVSCKASGYTFSGYYIHWVRQAPGQGLEWMGLINPSGGSTTYAPKFQGRVAMTRDTSTSTVYMELSSLRSEDTAVYYCARDVETEGSLLHFEFWGQGTLVTVSS,EIVLTQSPATLSVSPGERASLSCRASQSISSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYSCQQYDDWWTFGQGTKVEIK,QIH48430,QIH48431,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_15_6_3_8,QIH48430_QIH48431,Unique source,HIV,3,1,1.5863436,3.8693352
6UM6_K_L,QVQLVQSGAQMKNPGASVKVSCAPSGYTFTDFYIHWLRQAPGQGLQWMGWMNPQTGRTNTARNFQGRVTMTRDTSIGTAYMELRSLTSDDTAIYYCTTGGWISLYYDSSYYPNFDHWGQGTLLTVSG,QSALTQPASVSGSPGQSITISCTGTKYDVGSHDLVSWYQQYPGKVPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLRAEDEADYYCCSFGGSATVVCGGGTKVTVL,6UM6_K,6UM6_L,Cryo-Em Structure Of Hiv-1 Neutralizing Antibody Dh270.6 In Complex With Ch848 10.17Dt Env,Cryo-Em Structure Of Hiv-1 Neutralizing Antibody Dh270.6 In Complex With Ch848 10.17Dt Env,Homo sapiens,"Saunders,K.O.;Wiehe,K.;Tian,M.;Acharya,P.;Bradley,T.;Alam,S.M.;Go,E.P.;Scearce,R.;Sutherland,L.;Henderson,R.;Hsu,A.L.;Borgnia,M.J.;Chen,H.;Lu,X.;Wu,N.R.;Watts,B.;Jiang,C.;Easterhoff,D.;Cheng,H.L.;McGovern,K.;Waddicor,P.;Chapdelaine-Williams,A.;Eaton,A.;Zhang,J.;Rountree,W.;Verkoczy,L.;Tomai,M.;Lewis,M.G.;Desaire,H.R.;Edwards,R.J.;Cain,D.W.;Bonsignori,M.;Montefiori,D.;Alt,F.W.;Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-OCT-2019,8_8_20_9_3_10,6UM6_K_L,Xtal structure,HIV,3,1,2.9083412,2.693148
CAD38456,QVQLVQSGGGMVEPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKAGGGTAEYAAPVKGRFTISRDDSQNTLYLQMNSLKTDDTAVYYCTTHVYGAPRNWGQGSLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYVQLPGTAPKLLIYDNNKRFSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDGSLREAVFGGGTKVTVL,CAD38456_H,CAD38456_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Pfizenmaier,K.; Wajant,H.; Moosmayer,D.; Wueest,T.","Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)",08-JUL-2002,8_10_10_8_3_11,AKX26850,Same entry,apoptosis,3,1,12.981339,8.529851
4PY7_A_B,QVQLVQSGGGVVQPGRSLRLSCAASEFTFRMYATHWVRQAPGKGLEWVALISYDGSNKYYADSVKGRFTISRDNSMNTVYLQMNTLRPEDTAVYYCARDLGGYFIRGIMDVWGQGTLVTVSS,ELQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK,4PY7_A,4PY7_B,Crystal Structure Of Fab 3.1,Crystal Structure Of Fab 3.1,Homo sapiens,"Wyrzucki,A.;Dreyfus,C.;Kohler,I.;Steck,M.;Wilson,I.A.;Hangartner,L.",Alternative Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a VH3-30-Encoded Heterosubtypic Antibody,26-MAR-2014,8_8_15_6_3_9,4PY7_A_B,Xtal structure,Influenza,3,1,14.400582,13.678021
6VI0_H_L,QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRWGAVNYARPLQGRVTMTRQLSQDPDDPDWGTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS,LTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVD,6VI0_H,6VI0_L,Cryo-Em Structure Of Vrc01.23 In Complex With Hiv-1 Env Bg505 Ds.Sosip,Cryo-Em Structure Of Vrc01.23 In Complex With Hiv-1 Env Bg505 Ds.Sosip,Homo sapiens,"Kwon,Y.D.;Asokan,M.;Gorman,J.;Zhang,B.;Liu,Q.;Louder,M.K.;Lin,B.C.;McKee,K.;Pegu,A.;Verardi,R.;Yang,E.S.;Program,V.P.;Carlton,K.;Doria-Rose,N.A.;Lusso,P.;Mascola,J.R.;Kwong,P.D.",A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention,10-JAN-2020,8_8_14_4_3_5,6VI0_H_L,Xtal structure,HIV,3,1,2.7858279,4.2089024
8CW9_C_D,QVQLVQSGPALVKSTQTLTLTCTFSGFALTTSGMCVSWVRQPPGKALEWLARIDWEDNTYYSTSLKTRVTISKDPSKNQVVLTMTNMDPVDTATYYCARSYITDWKKDWFFDLWGRGTLVTVSS,SYELIQLPSVSVSPGQTARIPCSGDGLPKKYAHWYQQKAGQAPILLMYKDSERPSGIPERFSAFSSGTTVTMTISGVQEEDEADYYCQSGDSTDTSVIFGGGTKVTVL,8CW9_C,8CW9_D,Prefusion-Stabilized Hmpv Fusion Protein Bound To Adi-61026 And Mpe8 Fabs,Prefusion-Stabilized Hmpv Fusion Protein Bound To Adi-61026 And Mpe8 Fabs,Homo sapiens,"Rappazzo,C.G.;Hsieh,C.L.;Rush,S.A.;Esterman,E.S.;Delgado,T.;Geoghegan,J.C.;Wec,A.Z.;Sakharkar,M.;M&#xe1;s,V.;McLellan,J.S.;Walker,L.M.",Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein,10-AUG-2022,10_7_16_6_3_11,8CW9_C_D,Xtal structure,,3,1,12.542596,0.4980474
2O5Y_H_L,QVQLVQSGPELKKPGETVKISCKASGYMFTNYGMNWVKQAPGKALKWMGWINPYTGESTFADDFKGRFAFFLETSATTAYLQINNLKNEDTATYFCARGTTIVWAMDYWGQGTSVTVSS,ELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKFLIYKVSNRFSGVPDRFSGSGSGTDFILKISRVEAEDLGVYFCFQSTHFFPTFGGGTKLEIK,2O5Y_H,2O5Y_L,Crystal Structure Of The 1E9 Leuh47Trp/Argh100Trp Fab Progesterone Complex,Crystal Structure Of The 1E9 Leuh47Trp/Argh100Trp Fab Progesterone Complex,Homo sapiens,"Verdino,P.;Aldag,C.;Hilvert,D.;Wilson,I.A.",Closely related antibody receptors exploit fundamentally different strategies for steroid recognition,06-DEC-2006,8_8_12_11_3_9,2O5Y_H_L,Xtal structure,,3,1,-7.4822288,6.0850234
6OE4_E_F,QVQLVQSGPGLVKPSQTLALTCTVSGASINSDNYYWTWIRQRPGGGLEWIGHISYTGNTYYTPSLKSRLSMSLETSQSQFSLRLTSVTAADSAVYFCAACGAYVLISNCGWFDSWGQGTQVTVSS,EIVMTQSPSSLSASIGDRVTITCQASQDISTYLNWYQQKPGQAPRLLIYGASNLETGVPSRFTGSGYGTDFSVTISSLQPEDIATYYCQQYQYLPYTFAPGTKVEIK,6OE4_E,6OE4_F,Prefusion Rsv F Monomer Bound By Neutralizing Antibody Cr9501,Prefusion Rsv F Monomer Bound By Neutralizing Antibody Cr9501,Homo sapiens,"Gilman,M.S.;Furmanova-Hollenstein,P.;Pascual,G.;B van,'t.;Langedijk,J.P.;McLellan,J.S.",Transient opening of trimeric prefusion RSV F proteins,27-MAR-2019,10_7_17_6_3_9,6OE4_E_F,Xtal structure,RSV,3,1,16.691055,-8.293382
QIH48258_QIH48259,QVQLVQSGSEVKKPGASVKVSCKASGYTLTDYYIHWVRQAPGQGLEWMGWINPKRGGSNSAQKFQDRVTMTRDTSINTAYMELSSLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGPLITVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKDPKLMIYEVNKRASGVSIRFSGSKSANTASLTISGLQAEDAADYYCCSYAGSSTVIFGGGSKLTVL,QIH48258,QIH48259,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin lambda chain variable region, partial [Mus musculus]",Mus musculus,"Saunders,K.O.; Wiehe,K.; Tian,M.; Acharya,P.; Bradley,T.; Alam,S.M.; Go,E.P.; Scearce,R.; Sutherland,L.; Henderson,R.; Hsu,A.L.; Borgnia,M.J.; Chen,H.; Lu,X.; Wu,N.R.; Watts,B.; Jiang,C.; Easterhoff,D.; Cheng,H.L.; McGovern,K.; Waddicor,P.; Chapdelaine-Williams,A.; Eaton,A.; Zhang,J.; Rountree,W.; Verkoczy,L.; Tomai,M.; Lewis,M.G.; Desaire,H.R.; Edwards,R.J.; Cain,D.W.; Bonsignori,M.; Montefiori,D.; Alt,F.W.; Haynes,B.F.",Targeted selection of HIV-specific antibody mutations by engineering B cell maturation,09-MAR-2020,8_8_20_9_3_10,QIH48258_QIH48259,Unique source,HIV,3,1,2.7212365,2.8688085
QEP20417_QEP21065,QVQLVQSGSEVKRPGSSVRVSCKVSGGSLRNYAISWVRQAPGQGLAWMGGIIPIFGTPSYAQTFQGRLTITTDESTTTAYMDLGSLRSEDTAVYYCASFNYYDSSAYYHSSHYLDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSGFDIGTNPVNWYQKFPGTAPKVVIYNTDQRPSGVPDRFSGSKSGASASLAISGLQSEDEAEYYCGVWDDSLYVFGTGTTVTVL,QEP20417,QEP21065,"IGH + IGL c524_heavy_IGHV1-69_IGHD3-22_IGHJ6, partial [Homo sapiens]","IGH + IGL c524_light_IGLV1-44_IGLJ1, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_20_8_3_9,QEP20417_QEP21065,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,3,1,-0.6976918,6.0886974
6DZL_H_K,QVQLVQSGVTLVQPGGSLRVSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGLGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHRVWAAGYHFDYWGQGALVTVS,DIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGEAPKLLISDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSSPTFGGGTKVEIK,6DZL_H,6DZL_K,Ebola Virus Makona Variant Gp (Mucin-Deleted) In Complex With Pan-Ebolavirus Human Antibody Adi-15878 Fab,Ebola Virus Makona Variant Gp (Mucin-Deleted) In Complex With Pan-Ebolavirus Human Antibody Adi-15878 Fab,Homo sapiens,"Murin,C.D.;Bruhn,J.F.;Bornholdt,Z.A.;Copps,J.;Stanfield,R.;Ward,A.B.",Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop,05-JUL-2018,8_8_15_6_3_8,6DZL_H_K,Xtal structure,Ebolavirus; Ebola,3,1,14.288433,10.159096
7UGQ_G_J,QVQLVQSRAEVKKPGASVKVSCEASGYNFVDHYIHWVRQAPGQAPQWVGWMNPRGGGVAYSQRFQGRVTMTRDTSIDTAYMQLNRLTSGDTAVYYCATQVKLDSSAGYPFDIWGQGTMVTVSS,SALTQPRSVSGSPGQSVNISCTGTSSDVGGYNYVSWYQQHPGRAPKLIIYEVNRRPSGVSDRFSGSKSGNTASLTISGLRTEDEADYFCSAFEYFGGGTKLTVL,7UGQ_G,7UGQ_J,Cryo-Em Structure Of Bg24 Fabs With An Inferred Germline Cdrl1 And 10-1074 Fabs In Complex With Hiv-1 Env 6405-Sosip.664,Cryo-Em Structure Of Bg24 Fabs With An Inferred Germline Cdrl1 And 10-1074 Fabs In Complex With Hiv-1 Env 6405-Sosip.664,Homo sapiens,"Dam,K.A.;Barnes,C.O.;Gristick,H.B.;Schoofs,T.;Gnanapragasam,P.N.P.;Nussenzweig,M.C.;Bjorkman,P.J.",HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design,09-NOV-2022,8_8_16_9_3_5,7UGQ_G_J,Xtal structure,HIV; CD4,3,1,2.6552746,3.4210622
7UCG_D_E,QVQLVQSRAEVKKPGASVKVSCEASGYNFVDHYIHWVRQAPGQRPQWVGWMNPQWGQVNYARTFQGRVTMTRDTSIDTAYMQLNRLTSGDTAVYYCATQVKLDSSAGYPFDIWGQGTMVTVSS,QSALTQPRSVSGSPGQSVNISCTGAYSGLGWYQQHPGRAPKLIIYEVNRRPSGVSDRFSGSKSGNTASLTISGLRTEDEADYFCSAFEYFGEGTKLTVL,7UCG_D,7UCG_E,Structure Of The Bg505 Sosip.664 Trimer In Complex With Neutralizing Antibody Fab Fragments 10-1074 And Bg24,Structure Of The Bg505 Sosip.664 Trimer In Complex With Neutralizing Antibody Fab Fragments 10-1074 And Bg24,Homo sapiens,"Barnes,C.O.;Schoofs,T.;Gnanapragasam,P.N.P.;Golijanin,J.;Huey-Tubman,K.E.;Gruell,H.;Schommers,P.;Suh-Toma,N.;Lee,Y.E.;Cetrulo Lorenzi,J.C.;Piechocka-Trocha,A.;Scheid,J.F.;West,A.P.;Walker,B.D.;Seaman,M.S.;Klein,F.;Nussenzweig,M.C.;Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,17-AUG-2022,8_8_16_4_3_5,7UCG_D_E,Xtal structure,CD4,3,1,2.6613178,3.3997512
7WN2_H_L,QVQMVESGGGLVRPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWISYISSSGSSMNYADSVKGRFTISRDNAKNSLFLQMNSLRAEDTAVYYCAREFDLTKIIMVPPYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKVLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLKSYPLTFGGGTKVEIT,7WN2_H,7WN2_L,Crystal Structure Of Sars-Cov-2 Spike Receptor-Binding Domain (Rbd) In Complex With Ncv2Sg53 Fab,Crystal Structure Of Sars-Cov-2 Spike Receptor-Binding Domain (Rbd) In Complex With Ncv2Sg53 Fab,Homo sapiens,"Shitaoka,K.;Higashiura,A.;Kawano,Y.;Yamamoto,A.;Mizoguchi,Y.;Hashiguchi,T.;Nishimichi,N.;Huang,S.;Ito,A.;Ohki,S.;Kanda,M.;Taniguchi,T.;Yoshizato,R.;Azuma,H.;Kitajima,Y.;Yokosaki,Y.;Okada,S.;Sakaguchi,T.;Yasuda,T.",Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants,19-APR-2023,8_8_15_6_3_9,7WN2_H_L,Xtal structure,SARS-CoV-2,3,1,15.629349,9.334955
6PCI_I_L,QVQVEESGGGVVQPGGSLRLSCAASGFMFSNYGMHWVRQAPGKGLEWMAFIRYDDSKKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKELLQVYTSAWGEGHSYYYALDVWGLGTAVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISNWLAWYQQKPGKAPELLIYTASILQSGVSSRFSGSGSGTDFTLTISSLQPEDSATYYCQQGKSFPYTFGQGTKLEIK,6PCI_I,6PCI_L,Ebov Gpdmuc (Makona) In Complex With Rebov-520 And Rebov-548 Fabs,Ebov Gpdmuc (Makona) In Complex With Rebov-520 And Rebov-548 Fabs,Homo sapiens,"Gilchuk,P.;Murin,C.D.;Milligan,J.C.;Cross,R.W.;Mire,C.E.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Altman,P.X.;Hui,S.;Gunn,B.M.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Turner,H.L.;Alkutkar,T.;Flinko,R.;Orlandi,C.;Carnahan,R.;Nargi,R.;Bombardi,R.G.;Vodzak,M.E.;Li,S.;Okoli,A.;Ibeawuchi,M.;Ohiaeri,B.;Lewis,G.K.;Alter,G.;Bukreyev,A.;Saphire,E.O.;Geisbert,T.W.;Ward,A.B.;Crowe JE,Jr.",Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization,17-JUN-2019,8_8_24_6_3_9,6PCI_I_L,Xtal structure,Ebolavirus,3,1,14.505054,14.020285
8EEV_H_L,QVQVQESGPGLVKPSETLSLTCAVSSGSINDDSYYWTWIRQSPGKGLEWLGFIHGGTGKSFYNPSLESRVTISKDTSRNQFSLTLSSVSAADTAVYYCARSHFCSNTFCYGWFDVWGPGIRVTVSS,DVVMTQTPLSLPITPGEPASISCRSSQSLLHSNGNTYLHWYLQKPGQSPQLLIYGGSNRASGVPDRFSGSGSGTDFTLKISKVEAEDVGVYYCVQAIAFPWTFGQGTKVEIK,8EEV_H,8EEV_L,Venezuelan Equine Encephalitis Virus-Like Particle In Complex With Fab Skt-20,Venezuelan Equine Encephalitis Virus-Like Particle In Complex With Fab Skt-20,Macaca fascicularis,"Sutton,M.S.;Pletnev,S.;Callahan,V.;Ko,S.;Tsybovsky,Y.;Bylund,T.;Casner,R.G.;Cerutti,G.;Gardner,C.L.;Guirguis,V.;Verardi,R.;Zhang,B.;Ambrozak,D.;Beddall,M.;Lei,H.;Yang,E.S.;Liu,T.;Henry,A.R.;Rawi,R.;Sch&#xf6;n,A.;Schramm,C.A.;Shen,C.H.;Shi,W.;Stephens,T.;Yang,Y.;Florez,M.B.;Ledgerwood,J.E.;Burke,C.W.;Shapiro,L.;Fox,J.M.;Kwong,P.D.;Roederer,M.",Vaccine elicitation and structural basis for antibody protection against alphaviruses,19-JUL-2023,10_8_17_11_3_9,8EEV_H_L,Xtal structure,,3,1,16.335766,-7.3458147
7TJQ_A_B,QVRLEQSGADVKKPGASVRVSCKASGYTFNGYYIHWVRQAPGQGLEWMGWINPYTGETNYAQTFRGRVTLTRDTSLKTLHLDLISLRSGDTAIYYCARGNCSISGCYYSWLDHWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLIYEASSLERGVPSRFSGSGSGTGFTLTISSLQPDDFATYFCQQYNTYPRTFGQGTKVEIK,7TJQ_A,7TJQ_B,San27-14 Bound To A Antigenic Site V On Prefusion-Stabilized Hmpv F,San27-14 Bound To A Antigenic Site V On Prefusion-Stabilized Hmpv F,Homo sapiens,"Rush,S.A.;Brar,G.;Hsieh,C.L.;Chautard,E.;Rainho-Tomko,J.N.;Slade,C.D.;Bricault,C.A.;Kume,A.;Kearns,J.;Groppo,R.;Mundle,S.T.;Zhang,L.;Casimiro,D.;Fu,T.M.;DiNapoli,J.M.;McLellan,J.S.",Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus,14-SEP-2022,8_8_17_6_3_9,7TJQ_A_B,Xtal structure,Antigenic,3,1,2.2854164,3.7892537
ANV21811_ANV22000,QVTLKESGPALMAPTQTLTLTCTFSGFSLSTHGMRVSWIRQPPGKALEWLARIDWDDDKFYSTSLKTRLTISKDTSKNQVVLTMTNMHPVDTATYFCAQIYYFDSSYTDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSSPWTFGQGTKVEIK,ANV21811,ANV22000,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,10_7_13_12_3_9,ANV21811_ANV22000,Unique source,,3,1,12.533708,0.48370302
7UR6_H_L,QVTLKESGPALVKPTQTLTLTCTFSGFSMSNFGSGIYWIRQPPGKALEWLAGIYWTDSKYYNLSLKTRLTISKDTSKSQVILIMTNMDPVDTATYYCADIRGRYYYSNGFLFDVVGVESWGQGVVVTVSS,QSVLTQPPSASEAARKTVTISCSGSRSNIGSNSVSWYKQVPGTAPKLLIKYNDQRPSGVSDRFSGSKSGTSASLAISGLQTEDEADYYCATWDDSLNGYIFGVGTRLIVL,7UR6_H,7UR6_L,"Cryo-Em Structure Of Shiv-Elicited, Fp-Directed Rhesus Fab Rm6561.Dh1021.14 In Complex With Stabilized Hiv-1 Env Ce1176 Ds-Sosip.664","Cryo-Em Structure Of Shiv-Elicited, Fp-Directed Rhesus Fab Rm6561.Dh1021.14 In Complex With Stabilized Hiv-1 Env Ce1176 Ds-Sosip.664",Macaca mulatta,"Gorman,J.;Kwong,P.D.","Cryo-EM structure of SHIV-elicited, FP-directed Rhesus Fab RM6561.DH1021.14 in complex with stabilized HIV-1 Env Ce1176 DS-SOSIP.664",26-APR-2023,10_7_22_8_3_11,7UR6_H_L,Xtal structure,HIV,3,1,12.438004,0.4002647
UYI35726_UYI36349,QVTLKESGPALVTPTQTLTLTCSFSGFSLTTTGMSVGWIRQAPGKALEWLALIYWDDDKRYRTSLKSRLIISKDTAKNQVVLTMTDMDPTATATYYCARKPSTDAFDFWGQGLRVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYPTWYQQKPGQAPVMVVYGYNYRPSGIPERFSGSSSGNTASLTISGAQVEDEADYYCGTWGISETQYVFGAGTRLTVL,UYI35726,UYI36349,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,10_7_11_6_3_11,UYI35726_UYI36349,Unique source,COVID,3,1,12.41643,0.35670045
2IPU_G_K,QVTLKESGPGILKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDDRSYNPSLKSQLTISKDAARNQVFLRITSVDTADTATYYCVRRAHTTVLGDWFAYWGQGTLVTVS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGAGTKLELK,2IPU_G,2IPU_K,Pfa1 Fab Fragment Complexed With Abeta 1-8 Peptide,Pfa1 Fab Fragment Complexed With Abeta 1-8 Peptide,synthetic construct,"Gardberg,A.S.;Dice,L.T.;Ou,S.;Rich,R.L.;Helmbrecht,E.;Ko,J.;Wetzel,R.;Myszka,D.G.;Patterson,P.H.;Dealwis,C.",Molecular basis for passive immunotherapy of Alzheimer's disease,12-OCT-2006,10_7_15_11_3_9,2IPU_G_K,Xtal structure,Abeta; PPP1R30; FLJ10252; CT110; Pfa1; GPATCH2; GPATC2,3,1,11.516518,1.9014555
AAD29590_AAD25027,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTFGMGVGWIRQPSGKGLEWLAHIWWDDDKYYNPALKSRLTISKETSKNQVFLKIANVDTADTATYYCVRDWDFFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIIHSNGNTYLEWYLKKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPFTFGAGTKLELK,AAD29590,AAD25027,"anti-myeloperoxidase immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-myeloperoxidase immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Jethwa,H.S.; Clarke,S.H.; Itoh-Lindstrom,Y.; Falk,R.J.; Jennette,J.C.; Nachman,P.H.",Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice,26-JUL-2016,10_7_9_11_3_9,AAD29590_AAD25027,Ordered entries,myeloperoxidase,3,1,11.477224,1.935738
7T3M_D_L,QVTLKESGPTRVKPTQTLTLTCTFSGFSLSTTGVGVGWIRQPPGKALEWLALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARISGSGYFYPFDIWGQGTTVTVSS,FMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKAEDEADYYCQSYDSSSLWVFGGGTKLTVL,7T3M_D,7T3M_L,"Sars-Cov-2 S (Spike Glycoprotein) D614G With Three (3) Rbds Up, Bound To Antibody 2-7 Scfv, Composite Map","Sars-Cov-2 S (Spike Glycoprotein) D614G With Three (3) Rbds Up, Bound To Antibody 2-7 Scfv, Composite Map",Escherichia coli,"Chang,M.R.;Tomasovic,L.;Kuzmina,N.A.;Ronk,A.J.;Byrne,P.O.;Johnson,R.;Storm,N.;Olmedillas,E.;Hou,Y.J.;Sch&#xe4;fer,A.;Leist,S.R.;Tse,L.V.;Ke,H.;Coherd,C.;Nguyen,K.;Kamkaew,M.;Honko,A.;Zhu,Q.;Alter,G.;Saphire,E.O.;McLellan,J.S.;Griffiths,A.;Baric,R.S.;Bukreyev,A.;Marasco,W.A.",IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern,24-AUG-2022,10_7_14_8_3_10,7T3M_D_L,Xtal structure,SARS-CoV-2,3,1,12.382572,0.32919642
3W9D_A_B,QVTLKQSGAEVKKPGSSVKVSCTASGGTLRTYGVSWVRQAPGQGLEWLGRTIPLFGKTDYAQKFQGRVTITADKSMDTSFMELTSLTSEDTAVYYCARDLTTLTSYNWWDLWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSSQLAWYQQKPGQAPRLLISGASNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGGGTKVEIK,3W9D_A,3W9D_B,Structure Of Human Monoclonal Antibody E317 Fab,Structure Of Human Monoclonal Antibody E317 Fab,Homo sapiens,"Lee,C.C.;Lin,L.L.;Chan,W.E.;Ko,T.P.;Lai,J.S.;Wang,A.H.",Structural basis for the antibody neutralization of herpes simplex virus,03-APR-2013,8_8_15_7_3_8,AFQ88629,Xtal structure,herpes,3,1,-0.48460704,5.508563
QNR09223_QNR09251,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMCLTWIRRPPGKALEWLALIDWDDNKYYNTSLRTRLTISKDTSKNQVVLKVTDMDPVDTGTYYCARMLYGDLGGRFDPWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCGGNNIGIKNVHWYQQRPGQAPVLVIYTDINRPSGIPERFSGSNSGNTATLIISKAQAGDEADYFCQVWDSNTVVFGGGTKLTVL,QNR09223,QNR09251,"immunoglobulin LPAF-a.01 heavy chain variable region, partial [Homo sapiens]","immunoglobulin LPAF-a.01 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cheung,C.S.; Fruehwirth,A.; Paparoditis,P.C.G.; Shen,C.H.; Foglierini,M.; Joyce,M.G.; Leung,K.; Piccoli,L.; Rawi,R.; Silacci-Fregni,C.; Tsybovsky,Y.; Verardi,R.; Wang,L.; Wang,S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Chuang,G.Y.; Corti,D.; Mascola,J.R.; Shapiro,L.; Kwong,P.D.; Lanzavecchia,A.; Zhou,T.",Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation,16-SEP-2020,10_7_14_6_3_9,QNR09223_QNR09251,Unique word,Influenza,3,1,12.523623,0.4773679
6VY2_H_L,RLFQSGGGVSRPGGSLRVNCGASGFTVRTHYMYWLRQSPGKGLEWVAFMNSGGSVSYVDSVRGRFSVSRDNPANAMVLQMDALKIEDTGTYYCARELREAWYGDLRDYSGLDVWGRGTIVSISS,QSALAQPPSVSGSPGQSVTITCTGINDYGAAYKFVSWYQQHPGKEPRLIMKNVKDRWSVTPNRFSGSTSGNTASLTISNLQSDDEAQYFCAVYAGGFTFPRLGGGTKLSVL,6VY2_H,6VY2_L,Cryo-Em Structure Of M1214_N1 Fab In Complex With Ch505 Tf Chimeric Sosip.664 Env Trimer,Cryo-Em Structure Of M1214_N1 Fab In Complex With Ch505 Tf Chimeric Sosip.664 Env Trimer,Homo sapiens,"Jia,M.;Liberatore,R.A.;Guo,Y.;Chan,K.W.;Pan,R.;Lu,H.;Waltari,E.;Mittler,E.;Chandran,K.;Finzi,A.;Kaufmann,D.E.;Seaman,M.S.;Ho,D.D.;Shapiro,L.;Sheng,Z.;Kong,X.P.;Bieniasz,P.D.;Wu,X.",VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA,25-FEB-2020,8_7_20_9_3_11,6VY2_H_L,Xtal structure,HIV,3,1,12.7150955,10.609772
6VO0_H_L,RQLVESGGGLVQPEGSLTLTCKASGFSFSRSQYMCWVRQAPGKGLEWITCVYPDDDTPYYATWAKGRFTISKTSSTTVTLRLTSLTEADTATYFCARTSGFGGYSYAAHGVDLWGPGTLV,DIVMTQTPASVSEPVGGTVTIKCQASHNIRSYLSWYQQKVGQPPKRLIYETSNLASGVPSRFAGSGSGTEFTLTISDLECADAATYYCQSNFGLSDSRTYNFGGGTEVVVK,6VO0_H,6VO0_L,Bg505 Sosip.V5.2 In Complex With Rabbit Fab 43A2,Bg505 Sosip.V5.2 In Complex With Rabbit Fab 43A2,Human immunodeficiency virus 1,"Nogal,B.;McCoy,L.E.;van Gils,M.J.;Cottrell,C.A.;Voss,J.E.;Andrabi,R.;Pauthner,M.;Liang,C.H.;Messmer,T.;Nedellec,R.;Shin,M.;Turner,H.L.;Ozorowski,G.;Sanders,R.W.;Burton,D.R.;Ward,A.B.",HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite,29-JAN-2020,9_8_18_6_3_13,6VO0_H_L,Xtal structure,HIV,3,1,-0.40532213,18.426132
AUD54187_AUD54420,SCAASGFAFSTYGMSWVRQTPDKRLEWVATISYGVGYTFYPDSVKGRFTISRDNAKNTLYLLMTSLKSEDSAMYYCTRRERYDENGFAYWGQGTLVTVSA,VTMSCTSSQSLFNSRKQKNCLIWYQQKPGQPPKVLIYWASTRESGVPDRFTGSGSGTYFTLTISSVQAEDLAVYYCQNDYINPLTFGGGTKLELK,AUD54187,AUD54420,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD54187_AUD54420,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,3,1,17.705135,8.357959
AUD54195_AUD54456,SCAASGFTFSSYGMSWVRQTPDKRLEWVATISYGVGYTFYADSVRGRFTISRDNAKNTLYLQMSSLKSEDSAMFYCARRERYDENGFAYWGQGTLVTVSA,VTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKVLIYWASTRESGVPVRFTGSGAGTDFTLTISSVQAEDLAVYYCQNDYINPLTFGGGTKLELK,AUD54195,AUD54456,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD54195_AUD54456,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,3,1,17.724655,8.396892
AEQ73536_AEQ74290,TLVKPTQTLTLTCTLSGFSLYTTGVGVGWIRQPPGKALEWLARIYWDDDERYNPSLKSRLTITKDASKNQVVLKMTNMDPVDTATYYCARTMGVVLPFDYWGQGTLVTVS,STLSASVGDRVTITCRASQSIGSWLAWYQQKPGKAPKLLIYKASTLQSETPSRFRGSGSGTEFTLTISSLQPDDFATYYCQQFNSFSPWTFGQGTKVEFK,AEQ73536,AEQ74290,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_12_6_3_10,AEQ73536_AEQ74290,Unique source,tetanus,3,1,12.356862,0.26191077
AF451974_1,VKLQQSGAELVKPGASVRLSCKASGYTFTEYIIHWIKLRSGQGLEWIGWFYPGSNDIQYNAKFKGKATLTADKSSSTVYMELTGLTSEDSAVYFCARRDDFSGYDALPYWGQGTMVTVSS,DIQMTQSPASLSVSVGETVTITCRTNENIYSNLAWYQQKQGKSPQLLIYAATHLVEGVPSRFSGSGSGTQYSLKITSLQSEDFGNYYCQHFWGTPCTFGGGTKLEIK,AF451974_1_H,AF451974_1_L,"single chain Fv anti-human CD28 antibody scFv28.3, partial [synthetic construct]","single chain Fv anti-human CD28 antibody scFv28.3, partial [synthetic construct]",synthetic construct,"Vanhove,B.; Laflamme,G.; Coulon,F.; Mougin,M.; Vusio,P.; Haspot,F.; Tiollier,J.; Soulillou,J.P.",Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody,26-JUL-2016,8_8_14_6_3_9,AF451974_1,Same entry,IDDM12; CD152; CTLA-4; CELIAC3; CD28; CTLA4; CD; GSE,3,1,0.17821412,-4.2610755
3OPZ_I_M,VKLQQSGVELVRPGTSVKMSCKAVGYTFTYDWIGWVKQRPGHGLEWIGDIYLGGGYINYNEKFKGKVILTADTSSSTAYMQLSSLTSEDSAIYYCARGHYDGSYFDYWGQGTTLTVSS,DVLMTQTPTIMSASIGEEITLTCSASSSVSHMHWYQHKSGTSPKLLIYITSYLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYCHQWSTFPSTFGSGTKLEIK,3OPZ_I,3OPZ_M,Crystal Structure Of Trans-Sialidase In Complex With The Fab Fragment Of A Neutralizing Monoclonal Igg Antibody,Crystal Structure Of Trans-Sialidase In Complex With The Fab Fragment Of A Neutralizing Monoclonal Igg Antibody,Mus musculus,"Buschiazzo,A.;Muia,R.;Larrieux,N.;Pitcovsky,T.;Mucci,J.;Campetella,O.",Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors,02-SEP-2010,8_8_12_5_3_9,3OPZ_I_M,Xtal structure,,3,1,-0.19709373,-4.4904222
7CWT_I_J,VKLVESGGGLVKPGGSLRLSCAASGFTFTNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYGGGGTVDYWGQGTLVTVS,IVLTQSPTLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGIPSRFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRIFGQGTKVEIL,7CWT_I,7CWT_J,Sars-Cov-2 Spike Protein In Complex With Hb27 And Fc05 Fab Cocktail,Sars-Cov-2 Spike Protein In Complex With Hb27 And Fc05 Fab Cocktail,Homo sapiens,"Wang,N.;Sun,Y.;Feng,R.;Wang,Y.;Guo,Y.;Zhang,L.;Deng,Y.Q.;Wang,L.;Cui,Z.;Cao,L.;Zhang,Y.J.;Li,W.;Zhu,F.C.;Qin,C.F.;Wang,X.",Structure-based development of human antibody cocktails against SARS-CoV-2,31-AUG-2020,8_8_13_10_3_9,7CWT_I_J,Xtal structure,SARS-CoV-2,3,1,14.820406,9.309235
3CVH_H_L,VLLQQSGPELVKPGASVKIPCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNGGTIYNQKFKGKATLTVDKSSSAAYMEVRSLTSEDTAVYYCARKPYYGNFAWFAYWGQGTLVTVSA,IQVTQSSSSFSVSLGDRVTITCKASEDIYNRLAWYQQKPGNAPRLLISGATSLETGVPDRFSGSGSRKDYTLIITSLQTEDVATYYCQQYWSTPLTFGAGTKLELK,3CVH_H,3CVH_L,How Tcr-Like Antibody Recognizes Mhc-Bound Peptide,How Tcr-Like Antibody Recognizes Mhc-Bound Peptide,Mus musculus,"Mareeva,T.;Martinez-Hackert,E.;Sykulev,Y.",How a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptide,18-APR-2008,8_8_14_6_3_9,3CVH_H_L,Xtal structure,,3,1,2.45266,-4.2293997
1YNK_H_L,VQLLESGAELMKPGASVQISCKATGYTFSEYWIEWVKERPGHGLEWIGEILPGSGRTNYREKFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCTRGYSSMDYWGQGTSVTVSA,ELVMTQSPLSLPVSLGDQASISCRPSQSLVHSNGNTYLHWYLQKPGQSPKLLIYRVSNRFSGVPDRFSGSGSGTAFTLKISRVEAEDLGVYFCSQGTHVPYTFGGGTKLELK,1YNK_H,1YNK_L,Identification Of Key Residues Of The Nc6.8 Fab Antibody Fragment Binding To Synthetic Sweeteners: Crystal Structure Of Nc6.8 Co-Crystalized With High Potency Sweetener Compound Sc45647,Identification Of Key Residues Of The Nc6.8 Fab Antibody Fragment Binding To Synthetic Sweeteners: Crystal Structure Of Nc6.8 Co-Crystalized With High Potency Sweetener Compound Sc45647,Mus musculus,"Gokulan,K.;Khare,S.;Ronning,D.R.;Linthicum,S.D.;Sacchettini,J.C.;Rupp,B.",Cocrystal structures of NC6.8 Fab identify key interactions for high potency sweetener recognition: implications for the design of synthetic sweeteners,24-JAN-2005,8_8_9_11_3_9,1YNK_H_L,Xtal structure,,3,1,4.9863815,-1.8819289
ABY65264_ABY65287,VQLLESGPGLVKPSETLSLTCAVSGGSLSGGYGWGWIRQPPGKGLEWIGNIFTSSGSTHYDPSLKSRVTISTDTSKNQFSLNLRSMTAADTAVYYCAKAARICTGLDCYEGSFDSWGQGVLVTVSS,QPVLTQPPSASEAARKSVTISCSGSNSNIGGNSVSWYQQVPGTGPKLLMYYNDQRASGVSDRFSGSKSGTSASLAIRGLRTEDEADYYCAAWDESLNTYIFGGGTRLTVL,ABY65264,ABY65287,"immunoglobulin heavy chain variable region, partial [Macaca fascicularis]","immunoglobulin light chain variable region, partial [Macaca fascicularis]",Macaca fascicularis,"Pelat,T.; Hust,M.; Lefranc,M.-P.; Dubel,S.; Thullier,P.","Selection of a macaque scFv with human-like framework regions, high affinity, and that neutralizes the ricin toxin",26-JUL-2016,9_8_19_8_3_11,ABY65264_ABY65287,Unique source,,3,1,16.363224,-7.3272514
2AJ3_F_E,VQLLESGPGVVKPSETLSLTCTVSGASVNNYYWTWVRQPPGKGLEWIGNVYDSGDTNYNPSLSSRLSLSMDTSKNQFSLRLSSVTAADTATYYCARYHRHFIRGPLSFDYWGRGTLVTVSS,LQMTQSPSFLSASVGDRVSITCRASQDIQKFLAWYQLTPGDAPKLLMYSASTLQSGVPSRFSGSGSGTEFTLTISGLQPEDFATYYCQHLKRYPYTFGQGTKLEIS,2AJ3_F,2AJ3_E,Crystal Structure Of A Cross-Reactive Hiv-1 Neutralizing Cd4-Binding Site Antibody Fab M18,Crystal Structure Of A Cross-Reactive Hiv-1 Neutralizing Cd4-Binding Site Antibody Fab M18,Homo sapiens,"Prabakaran,P.;Gan,J.;Wu,Y.Q.;Zhang,M.Y.;Dimitrov,D.S.;Ji,X.",Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs,01-AUG-2005,8_7_16_6_3_9,2AJ3_F_E,Xtal structure,HIV; CD4,3,1,16.247938,-7.733377
7UPB_B_E,VQLQQSGAELMRPGASMKISCKATGYTFSSYWIDWVKQRPGHGLEWIGEILPGSGDTNYNENFKGKAAFTADTSSNTAYMQLTSLTSEDSAVFYCARGGRYHGQGFFDYWGQGTTLTVSS,IQMTQSPASLSASVGETVTITCRPSENVHIYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSASGTQFSLKINSLQPEDFGSYYCQHFWSIPYTFGGGTKLEIK,7UPB_B,7UPB_E,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 1H1,Prefusion-Stabilized Nipah Virus Fusion Protein Complexed With Fab 1H1,Mus musculus,"Byrne,P.O.;McLellan,J.S.",Prefusion-stabilized Nipah virus fusion protein complexed with Fab 1H1,29-MAR-2023,8_8_14_6_3_9,7UPB_B_E,Xtal structure,,3,1,4.996192,-1.8717495
4R9Y_N_M,VQLQQSGAELVKPGASVKLSCKASGYTFTNYFIYWVKQRPGQGLEWIGEINPRNGDTDFNEKFESRATLTVDKSSSTAYMQLSSLTSEDSAIYYCTRSPYGNNYGFTYWGQGTLVTVSA,DIQMIQSQKFMSTSVGDRVTVTCKASQNVGTNVAWYQQKPGQSPNALIYSASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYNSYPLTFGTGTKLDLK,4R9Y_N,4R9Y_M,Crystal Structure Of Kkofab In Complex With Platelet Factor 4,Crystal Structure Of Kkofab In Complex With Platelet Factor 4,Mus musculus,"Cai,Z.;Yarovoi,S.V.;Zhu,Z.;Rauova,L.;Hayes,V.;Lebedeva,T.;Liu,Q.;Poncz,M.;Arepally,G.;Cines,D.B.;Greene,M.I.",Atomic description of the immune complex involved in heparin-induced thrombocytopenia,08-SEP-2014,8_8_13_6_3_9,4R9Y_N_M,Xtal structure,,3,1,-0.68554723,-3.9517
1UM4_H_L,VQLQQSGPVLVKPGGSVKMSCKASEYTLTSYLFQWVKQKSGQGLEWIGYIYPYNGGTRYNEKFRGKATLTSDKSSNTAYLELSSLTSEDSAVYYCARSSMSDPGANWGPGTLVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLYWLQQKPDGTIKRLIYAGSTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASYPRTFGGGTKVEIK,1UM4_H,1UM4_L,Catalytic Antibody 21H3 With Hapten,Catalytic Antibody 21H3 With Hapten,Mus musculus,"Beuscher Iv,A.E.;Reuter,J.;Olson,A.J.;Romesberg,F.E.;Schultz,P.G.;Wirsching,P.;Janda,K.D.;Lerner,R.A.;Stevens,R.C.",Structural Studies Of An Efficient Catalytic Antibody Operating By Ping-Pong And Induced Fit Mechanisms,23-SEP-2003,8_8_11_6_3_9,1UM4_H_L,Xtal structure,,3,1,0.9248422,-3.7654104
8DER_X_Y,VQLVESGGGLAKPGGSLRLSCAAAGFRFSDFHMHWVRQAPGKGLEWVSRISHGGVTTRFADSVKGRFTISRENAKNTLYLQMDNLRAEDTAVYYCARDSPYWGDYSHSLDVWGRGVLVTVSS,PMRLTQPRSVSVSPGQTARITCGGDNIGSKSVHWYQQKPPQAPVLVIYDDRARPSGIPERFSGSKSGNTATLAISGVEAGDEADYYCQVWDSSSDVLFGGGTRLT,8DER_X,8DER_Y,Cryo-Em Local Refinement Of Antibody Skv16 In Complex With Veev Alphavirus Spike Glycoprotein,Cryo-Em Local Refinement Of Antibody Skv16 In Complex With Veev Alphavirus Spike Glycoprotein,Macaca,"Sutton,M.S.;Pletnev,S.;Callahan,V.;Ko,S.;Tsybovsky,Y.;Bylund,T.;Casner,R.G.;Cerutti,G.;Gardner,C.L.;Guirguis,V.;Verardi,R.;Zhang,B.;Ambrozak,D.;Beddall,M.;Lei,H.;Yang,E.S.;Liu,T.;Henry,A.R.;Rawi,R.;Sch&#xf6;n,A.;Schramm,C.A.;Shen,C.H.;Shi,W.;Stephens,T.;Yang,Y.;Florez,M.B.;Ledgerwood,J.E.;Burke,C.W.;Shapiro,L.;Fox,J.M.;Kwong,P.D.;Roederer,M.",Vaccine elicitation and structural basis for antibody protection against alphaviruses,28-JUN-2023,8_8_16_6_3_10,8DER_X_Y,Xtal structure,,3,1,14.003966,10.375167
7JW0_D_C,VQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQTTGKGLEWVSTIGTAGDTYYPDSVKGRFTISREDAKNSLYLQMNSLRAGDTAVYYCARGDSSGYYYYFDYWGQGTLLTVSS,DIEMTQSPSSLSAAVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYVSPTYTFGPGTKVDIK,7JW0_D,7JW0_C,Sars-Cov-2 Spike In Complex With The S304 Neutralizing Antibody Fab Fragment,Sars-Cov-2 Spike In Complex With The S304 Neutralizing Antibody Fab Fragment,Homo sapiens,"Piccoli,L.;Park,Y.J.;Tortorici,M.A.;Czudnochowski,N.;Walls,A.C.;Beltramello,M.;Silacci-Fregni,C.;Pinto,D.;Rosen,L.E.;Bowen,J.E.;Acton,O.J.;Jaconi,S.;Guarino,B.;Minola,A.;Zatta,F.;Sprugasci,N.;Bassi,J.;Peter,A.;De Marco,A.;Nix,J.C.;Mele,F.;Jovic,S.;Rodriguez,B.F.;Gupta,S.V.;Jin,F.;Piumatti,G.;Lo Presti,G.;Pellanda,A.F.;Biggiogero,M.;Tarkowski,M.;Pizzuto,M.S.;Cameroni,E.;Havenar-Daughton,C.;Smithey,M.;Hong,D.;Lepori,V.;Albanese,E.;Ceschi,A.;Bernasconi,E.;Elzi,L.;Ferrari,P.;Garzoni,C.;Riva,A.;Snell,G.;Sallusto,F.;Fink,K.;Virgin,H.W.;Lanzavecchia,A.;Corti,D.;Veesler,D.",Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology,24-AUG-2020,8_7_14_6_3_10,7JW0_D_C,Xtal structure,SARS-CoV-2,3,1,16.381674,11.596839
7YR1_H_L,VQLVESGGGLVQPGGSLRLSCSASGLTVSSNHMTWVRQAPGKGLEWVSVIYRGGSTYYADSVKGRLTISRDNSKNTLYLQMNSLRAEDTAVYYCARAQGGWELPGAGYYYFYGMDVWGQGTTVTVS,IVMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQQSFSTSFTFGPGTKVDI,7YR1_H,7YR1_L,Sars-Cov-2 Ba.2.75 S Trimer In Complex With Xg2V024,Sars-Cov-2 Ba.2.75 S Trimer In Complex With Xg2V024,Homo sapiens,"Cao,Y.;Song,W.;Wang,L.;Liu,P.;Yue,C.;Jian,F.;Yu,Y.;Yisimayi,A.;Wang,P.;Wang,Y.;Zhu,Q.;Deng,J.;Fu,W.;Yu,L.;Zhang,N.;Wang,J.;Xiao,T.;An,R.;Wang,J.;Liu,L.;Yang,S.;Niu,X.;Gu,Q.;Shao,F.;Hao,X.;Meng,B.;Gupta,R.K.;Jin,R.;Wang,Y.;Xie,X.S.;Wang,X.",Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75,19-OCT-2022,8_7_22_6_3_9,7YR1_H_L,Xtal structure,,3,1,12.643251,10.749869
3D69_H_L,VQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAIISYDGSKKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARASIAAARVLDYWGRGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSTSNIGNNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNSASLDISGLQSEDEADYYCAAWDDSLSEFLFGTGTKLTVL,3D69_H,3D69_L,Crystal Structure Of The Fab Fragment Of An Anti-Factor Ix Antibody 10C12,Crystal Structure Of The Fab Fragment Of An Anti-Factor Ix Antibody 10C12,Homo sapiens,"Huang,M.;Furie,B.C.;Furie,B.",Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody,19-MAY-2008,8_8_13_8_3_11,3D69_H_L,Xtal structure,,3,1,14.924185,13.349202
4M5Z_H_L,VQLVESGPGLVKPSDILSLTCAVSGYSISSNYYWGWIRQPPGKGLEWIGSIYHSGSTYYKPSLESRLGISVDTSKNQFSLKLSFVSAADTAVYYCARHVRSGYPDTAYYFDKWGQGTLVTVSS,SYVLTQPPSVSVAPGETARISCGGNNIGTKVLHWYQQTPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEVGDEADYYCQVWDISTDQAVFGGGTKLTVL,4M5Z_H,4M5Z_L,"Crystal Structure Of Broadly Neutralizing Antibody 5J8 Bound To 2009 Pandemic Influenza Hemagglutinin, Ha1 Subunit","Crystal Structure Of Broadly Neutralizing Antibody 5J8 Bound To 2009 Pandemic Influenza Hemagglutinin, Ha1 Subunit",Homo sapiens,"Hong,M.;Lee,P.S.;Hoffman,R.M.;Zhu,X.;Krause,J.C.;Laursen,N.S.;Yoon,S.I.;Song,L.;Tussey,L.;Crowe JE,Jr.;Ward,A.B.;Wilson,I.A.",Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site,08-AUG-2013,9_7_17_6_3_11,4M5Z_H_L,Xtal structure,H1N1; Influenza,3,1,16.663412,-7.5917335
7SOB_G_I,VQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYNGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,VLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGT,7SOB_G,7SOB_I,Sars-Cov-2 S B.1.617.1 Kappa Variant + S309 + S2L20 Global Refinement,Sars-Cov-2 S B.1.617.1 Kappa Variant + S309 + S2L20 Global Refinement,Homo sapiens,"McCallum,M.;Walls,A.C.;Sprouse,K.R.;Bowen,J.E.;Rosen,L.E.;Dang,H.V.;De Marco,A.;Franko,N.;Tilles,S.W.;Logue,J.;Miranda,M.C.;Ahlrichs,M.;Carter,L.;Snell,G.;Pizzuto,M.S.;Chu,H.Y.;Van Voorhis,W.C.;Corti,D.;Veesler,D.",Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants,29-OCT-2021,8_8_20_7_3_8,7SOB_G_I,Xtal structure,SARS-CoV-2,3,1,1.920475,5.290861
6MLM_E_I,VQLVQSGAEVKKPGASVKVSCKASGYTLTRYYFHWVRQAPGQGFEWMGIINPNGGGTSYAQKFGDRVIMTSDMSTSTIYMELSSLRSEDTAVYYCARDMPYYHDSGGPLFDLWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCRPSQSISTFLNWYEQKPGKAPKLLIYDASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSFSTPYTFGQGTRLEIK,6MLM_E,6MLM_I,H7 Ha0 In Complex With Fv From H7.5 Igg,H7 Ha0 In Complex With Fv From H7.5 Igg,Homo sapiens,"Turner,H.L.;Pallesen,J.;Lang,S.;Bangaru,S.;Urata,S.;Li,S.;Cottrell,C.A.;Bowman,C.A.;Crowe JE,Jr.;Wilson,I.A.;Ward,A.B.",Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains,27-SEP-2018,8_8_17_6_3_9,6MLM_E_I,Xtal structure,hemagglutinin,3,1,1.9098555,3.6639023
7XDB_D_E,VQLVQSGAEVKKPGESLKISCKGSGYSFTSYYWIGWVRQMPGKGLEWMGIVYPDDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCVRHPGGGDWYFDLWGRGTLVTV,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYDSFSWTFGQGTKLEI,7XDB_D,7XDB_E,Cryo-Em Structure Of Sars-Cov-2 Omicron Spike Protein In Complex With Ba7208 Fab,Cryo-Em Structure Of Sars-Cov-2 Omicron Spike Protein In Complex With Ba7208 Fab,Homo sapiens,"Wang,Y.;Yan,A.;Song,D.;Dong,C.;Rao,M.;Gao,Y.;Qi,R.;Ma,X.;Wang,Q.;Xu,H.;Liu,H.;Han,J.;Duan,M.;Liu,S.;Yu,X.;Zong,M.;Feng,J.;Jiao,J.;Zhang,H.;Li,M.;Yu,B.;Wang,Y.;Meng,F.;Ni,X.;Li,Y.;Shen,Z.;Sun,B.;Shao,X.;Zhao,H.;Zhao,Y.;Li,R.;Zhang,Y.;Du,G.;Lu,J.;You,C.;Jiang,H.;Zhang,L.;Wang,L.;Dou,C.;Liu,Z.;Zhao,J.",Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5,01-MAR-2023,9_8_13_6_3_9,7XDB_D_E,Xtal structure,SARS-CoV-2,3,1,-12.499439,5.7781534
7S6J_C_D,VQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILDRVMYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAIDSDTYVEQSHFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPSLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQPLTFGGGTKVEIK,7S6J_C,7S6J_D,J08 Fragment Antigen Binding In Complex With Sars-Cov-2-6P-Mut2 S Protein (Conformation 1),J08 Fragment Antigen Binding In Complex With Sars-Cov-2-6P-Mut2 S Protein (Conformation 1),Homo sapiens,"Torres,J.L.;Ozorowski,G.;Andreano,E.;Liu,H.;Copps,J.;Piccini,G.;Donnici,L.;Conti,M.;Planchais,C.;Planas,D.;Manganaro,N.;Pantano,E.;Paciello,I.;Pileri,P.;Bruel,T.;Montomoli,E.;Mouquet,H.;Schwartz,O.;Sala,C.;De Francesco,R.;Wilson,I.A.;Rappuoli,R.;Ward,A.B.",Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody,14-SEP-2021,8_8_18_6_3_5,7S6J_C_D,Xtal structure,SARS-CoV-2,3,1,-0.9502057,5.5954065
7TZ5_H_N,VQLVQSGAEVKKPGSSVKVSCKASGVTFTYYTISWVRQAPGQGLEWMGGIMPMFGTPNYAQKFQGRVTITADEPTSTIYMMLSSLRSEDTAVYYCASLGNYESGGYHPYFEYWGHGTLVTVSS,SVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPRLLIYGNSNRPSGVPDRFSGSRSGTSASLAITGLQAEDEADYYCQSYDNSLSGSGVFGGGTKL,7TZ5_H,7TZ5_N,Cryo-Em Structure Of Antibody Tj5-5 Bound To H3 Cobra Tj5 Hemagglutinin,Cryo-Em Structure Of Antibody Tj5-5 Bound To H3 Cobra Tj5 Hemagglutinin,Influenza A virus (A/New York/01/2010(H3N2)),"Abbadi,N.;Nagashima,K.;Pena-Briseno,A.;Ross,T.M.;Mousa,J.J.",Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies,06-JUL-2022,8_8_17_9_3_12,7TZ5_H_N,Xtal structure,Influenza,3,1,-0.82018137,5.537564
8CSJ_H_L,VQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKTEDTAVYYCARELWFGELLSGDFDYWGQGTLVTVSS,SVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKIIIYDNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGRVFGGGTKLTVL,8CSJ_H,8CSJ_L,Cryo-Em Structure Of Ntd-Directed Non-Neutralizing Antibody 4-33 In Complex With Prefusion Sars-Cov-2 Spike Glycoprotein,Cryo-Em Structure Of Ntd-Directed Non-Neutralizing Antibody 4-33 In Complex With Prefusion Sars-Cov-2 Spike Glycoprotein,Homo sapiens,"Reddem,E.R.;Shapiro,L.",Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV-2 spike glycoprotein,08-JAN-2009,8_8_16_9_3_11,8CSJ_H_L,Xtal structure,SARS-CoV-2,3,1,-6.9361963,5.5716023
6DZM_J_L,VQLVQSGVTLVQPGGSLRVSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGLGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHRVWAAGYHFDYWGQGALVTVS,DIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGEAPKLLISDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSSPTFGGGTKVEIK,6DZM_J,6DZM_L,Bundibugyo Virus Gp (Mucin-Deleted) In Complex With Pan-Ebolavirus Human Antibody Adi-15878 Fab,Bundibugyo Virus Gp (Mucin-Deleted) In Complex With Pan-Ebolavirus Human Antibody Adi-15878 Fab,Homo sapiens,"Murin,C.D.;Bruhn,J.F.;Bornholdt,Z.A.;Copps,J.;Stanfield,R.;Ward,A.B.",Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop,05-JUL-2018,8_8_15_6_3_8,6DZM_J_L,Xtal structure,Ebolavirus,3,1,14.343362,10.224393
7UGP_G_J,VQLVQSRAEVKKPGASVKVSCEASGYNFVDHYIHWVRQAPGQRPQWVGWMNPRGGGVAYSQRFQGRVTMTRDTSIDTAYMQLNRLTSGDTAVYYCATQVKLDSSAGYPFDIWGQGTMVTV,SALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYEYFGGGTKLTVL,7UGP_G,7UGP_J,Cryo-Em Structure Of Bg24 Fabs With An Inferred Germline Light Chain And 10-1074 Fabs In Complex With Hiv-1 Env Immunogen Bg505-Sosipv4.1-Gt1 Containing The N276 Gp120 Glycan- Class 1,Cryo-Em Structure Of Bg24 Fabs With An Inferred Germline Light Chain And 10-1074 Fabs In Complex With Hiv-1 Env Immunogen Bg505-Sosipv4.1-Gt1 Containing The N276 Gp120 Glycan- Class 1,Homo sapiens,"Dam,K.A.;Barnes,C.O.;Gristick,H.B.;Schoofs,T.;Gnanapragasam,P.N.P.;Nussenzweig,M.C.;Bjorkman,P.J.",HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design,09-NOV-2022,8_8_16_9_3_5,7UGP_G_J,Xtal structure,HIV; CD4,3,1,2.6524968,3.4423962
8DWO_H_L,VVQLVQSGAEVKRPGESLRISCKTSGYRFTDIWINWVRQRPGKGLEWMGSIYLDDSDIRFNPSFQGHVTISADKSTSTTYLQWSSLKASDTATYFCARSVWSGYYIGWFDVWGPGVLVTVSS,DVVMTQTPLSLPVTPGEPASISCRSSQSLLDSNGNTYLHWYLQKPGQSPQLLIYGGSNRASGVPDRFSGSGSGTDFTLTINNVEAGDVGTYYCMQVIQVPLTFGGGTKVDIK,8DWO_H,8DWO_L,Cryo-Em Structure Of Eastern Equine Encephalitis Virus In Complex With Ske26 Fab,Cryo-Em Structure Of Eastern Equine Encephalitis Virus In Complex With Ske26 Fab,Macaca fascicularis,"Sutton,M.S.;Pletnev,S.;Callahan,V.;Ko,S.;Tsybovsky,Y.;Bylund,T.;Casner,R.G.;Cerutti,G.;Gardner,C.L.;Guirguis,V.;Verardi,R.;Zhang,B.;Ambrozak,D.;Beddall,M.;Lei,H.;Yang,E.S.;Liu,T.;Henry,A.R.;Rawi,R.;Sch&#xf6;n,A.;Schramm,C.A.;Shen,C.H.;Shi,W.;Stephens,T.;Yang,Y.;Florez,M.B.;Ledgerwood,J.E.;Burke,C.W.;Shapiro,L.;Fox,J.M.;Kwong,P.D.;Roederer,M.",Vaccine elicitation and structural basis for antibody protection against alphaviruses,19-JUL-2023,8_8_15_11_3_9,8DWO_H_L,Xtal structure,,3,1,-12.319229,5.720398
7PI2_E_F,AVTLDESGGGLQTPGGALSLVCKGSGFFSFSSYTMQWVRQAPGKGLEWVASISSGGGTNYGAAVKGRATISRDNGQSTLRLQLNNLRAEDTGTYYCAKHGVNGCDWSYSVGCVDAWGHGTEVIVSS,ALTQPSSVSANPGETVKITCSGGSSSYYGWYQQKSPGSAPVTLIYNNQKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYFCGSRDNSGGIFGAGTTLTVL,7PI2_E,7PI2_F,Pfcyrpa Bound To Monoclonal Antibody Cy.003 Fab Fragment,Pfcyrpa Bound To Monoclonal Antibody Cy.003 Fab Fragment,Gallus gallus,"Ragotte,R.J.;Pulido,D.;Lias,A.M.;Quinkert,D.;Alanine,D.G.W.;Jamwal,A.;Davies,H.;Nacer,A.;Lowe,E.D.;Grime,G.W.;Illingworth,J.J.;Donat,R.F.;Garman,E.F.;Bowyer,P.W.;Higgins,M.K.;Draper,S.J.",Heterotypic interactions drive antibody synergy against a malaria vaccine candidate,19-AUG-2021,9_7_19_4_3_9,7PI2_E_F,Xtal structure,,4,1,14.481554,11.241262
6T9E_A_B,DLQLVESGGGLVKPGGSLRLSCAADGWWFGYTDMSWVRQAPGKGLEWVGSISYKGGSTYYNTKFIGRFTISRDDDTNTLYLQMNSLRAEDTAVYYCARDDGYFDTWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCHGSYWLSNYLAWYQQKPGKAPKLLIYDGKEREHGVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGQGTKLEIK,6T9E_A,6T9E_B,Crystal Structure Of A Bispecific Dutafab In Complex With Human Pdgf,Crystal Structure Of A Bispecific Dutafab In Complex With Human Pdgf,HOMO SAPIENS,"Kimbung, R., Logan, D.T., Beckmann, R., Jensen, K., Speck, J., Fenn, S., Kettenberger, H.",Crystal Structure Of A Bispecific Dutafab In Complex With Human Pdgf,28-OCT-2019,8_8_9_6_3_9,6T9E_A_B,Xtal structure,,4,1,13.112175,9.969814
AAT81538_AAT81540,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYFMSWVRQTPEKRLELVAVITSNGDNTYYPDTVKGRFTISRDNAQNTLYLQMSSLKSEDTALYYCARRDSSASLYFDYWGQGTTLTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVANRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK,AAT81538,AAT81540,"immunoglobulin gamma 1 heavy chain variable region, partial [Mus musculus]","immunoglobulin gamma 1 light chain variable region, partial [Mus musculus]",Mus musculus,"Torres,M.; May,R.; Scharff,M.D.; Casadevall,A.",Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype,11-FEB-2005,8_8_13_11_3_9,AAT81538_AAT81540,Unique word,,4,1,17.64089,6.8518
7ZWI_B_C,DVKLVESGGGLVKLGGSLKLSCAASGFTFSSYYMSWVRQTPEKRLELVAAINNNGGSTYYPDTVKGRFTISRDNAKNTLNLQMNSLKSEDTALYYCTRQHYGNLYFFDYWGQGTTLTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKPWIQATSSLASGVPARFSGSGSGTSYSLSISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK,7ZWI_B,7ZWI_C,Pfs48/45 C-Terminal Domain Bound To Fab Fragment Of Monoclonal Antibody 32F3,Pfs48/45 C-Terminal Domain Bound To Fab Fragment Of Monoclonal Antibody 32F3,Mus musculus,"Ko,K.T.;Lennartz,F.;Mekhaiel,D.;Guloglu,B.;Marini,A.;Deuker,D.J.;Long,C.A.;Jore,M.M.;Miura,K.;Biswas,S.;Higgins,M.K.",Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies,19-MAY-2022,8_8_13_5_3_9,7ZWI_B_C,Xtal structure,,4,1,17.654726,6.850688
6NMR_A_B,DVQLLESGGGVVQPGGSLRLSCAASGFSFSNFAMTWVRQAPGEGLEWVSTIGSGDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSTVSWSGDFFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATFSCRASQNVKNDLAWYQQRPGQAPRLLIYAARIRETGIPERFSGSGSGTEFTLTITSLQSEDFAVYYCQQYYDWPPFTFGGGTKVEIK,6NMR_A,6NMR_B,Blocking Fab 119 Anti-Sirp-Alpha Antibody In Complex With Sirp-Alpha Variant 1,Blocking Fab 119 Anti-Sirp-Alpha Antibody In Complex With Sirp-Alpha Variant 1,Homo sapiens,"Sim,J.;Sockolosky,J.T.;Sangalang,E.;Izquierdo,S.;Pedersen,D.;Harriman,W.;Wibowo,A.S.;Carter,J.;Madan,A.;Doyle,L.;Harrabi,O.;Kauder,S.E.;Chen,A.;Kuo,T.C.;Wan,H.;Pons,J.","Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPalpha",11-JAN-2019,8_6_15_6_3_10,6NMR_A_B,Xtal structure,SHPS-1; SIRPalpha; SIRPalpha2; PTPNS1; SIRPA; SIRP; CD172a; SIRP-ALPHA-1; MFR; MYD-1; BIT; SHPS1; P84,4,1,14.165259,9.775461
CAJ18079_CAJ18078,DVQLQESGPGLVKPSQSLSLTCSVTGYSITGGYLWNWIRQFPGNKLEWMGYISYDGTNNYKPSLKDRISITRDTSKNQFFLKLNSVTNEDTATYYCARYGRVFFDYWGQGTTLTVSS,DVLMTQIPLSLPVSLGDQASISCRSSQSIVHSNGNTYLQWYLQKPGQSPKLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISSVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK,CAJ18079,CAJ18078,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Goetsch,L.; Corvaia,N.; Duflos,A.; Haeuw,J.F.; Leger,O.; Beck,A.",Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof,13-JUL-2006,9_7_10_11_3_9,CAJ18079_CAJ18078,Unique chain,insulin,4,1,11.612208,-12.793483
UZH31854_UZH31833,DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAYYWNWIRQFPGKKLEWMGYLLYDGSTGYNPSLKNRISITRDTSKNQFFLKLNSVTPEDTATYYCSREGNNRSYWGQGTTLIVSS,DIVMTQSHRFMSTSVGDRVSITCKASQSVDTAVAWYQQKPGQSPKLLIYWASTRHPGVPDRFTGSGSGTDFILTISNVQSEDLADYFCHQFDRYPLTFGDGTKLELK,UZH31854,UZH31833,"anti-HIV fusion peptide monocolonal anitbody 7314-vFP52.02 heavy chain variable region, partial [Mus musculus]","anti-HIV fusion peptide monocolonal anitbody 7314-vFP52.02 light chain variable region, partial [Mus musculus]",Mus musculus,"Sastry,M.; Changela,A.; Gorman,J.; Xu,K.; Chuang,G.-Y.; Shen,C.-H.; Cheng,C.; Geng,H.; O'Dell,S.; Ou,L.; Rawi,R.; Reveiz,M.; Stewart-Jones,G.B.E.; Wang,S.; Zhang,B.; Zhou,T.; Biju,A.; Chambers,M.; Chen,X.; Corrigan,A.R.; Lin,B.C.; Louder,M.K.; Mckee,K.; Nazzari,A.F.; Parchment,D.K.; Sarfo,E.K.; Stephens,T.; Stuckey,J.; Tsybovsky,Y.; Verardi,R.; Wang,Y.; Zheng,C.-Y.; Production Program,V.; Doria-Rose,N.A.; Mcdermott,A.B.; Mascola,J.R.; Kwong,P.D.",Diverse Murine Vaccinations Reveal Distinct Antibody Classes Targeting Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization,11-APR-2023,9_7_9_6_3_9,UZH31854_UZH31833,Unique word,HIV,4,1,11.667975,-12.746342
5TR1_I_M,DVQLQESGPGLVKPSQSLSLTCTVTGDSVTSDYAWSWIRQFPGKKLEWMGYITYSGNTIYNPSLKSRISITRDTSKNQFFLQLKSVIIEDTATYYCSRGVDYWGQGTSVTVSS,DIVMTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKTLIYWASYRYSGVPDRFTGSGSGTDFTLAISNVQSEDLAEYFCQQYNSYPLTFGSGTKLELK,5TR1_I,5TR1_M,"Cryo-Electron Microscopy Structure Of A Bovine Clc-K Chloride Channel, Alternate (Class 2) Conformation","Cryo-Electron Microscopy Structure Of A Bovine Clc-K Chloride Channel, Alternate (Class 2) Conformation",Mus musculus,"Park,E.;Campbell,E.B.;MacKinnon,R.",Structure of a CLC chloride ion channel by cryo-electron microscopy,25-OCT-2016,9_7_6_6_3_9,5TR1_I_M,Xtal structure,CLC; MGC149659; Gal-10; LGALS10,4,1,11.448878,-12.951312
5VJQ_C_D,DVQLQESGPSLVKPSQTLSLTCSVTGDSFTSDYWSWIRKFPGNRLEYMGYVTFSGSTYYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWDGDYWGQGTLVTVSA,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEIK,5VJQ_C,5VJQ_D,"Complex Between Hyhel10 Fab Fragment Heavy Chain Mutant (I29F, S52T, Y53F) And Pekin Duck Egg Lysozyme Isoform I (Del-I)","Complex Between Hyhel10 Fab Fragment Heavy Chain Mutant (I29F, S52T, Y53F) And Pekin Duck Egg Lysozyme Isoform I (Del-I)",Anas platyrhynchos,"Burnett,D.L.;Langley,D.B.;Schofield,P.;Hermes,J.R.;Chan,T.D.;Jackson,J.;Bourne,K.;Reed,J.H.;Patterson,K.;Porebski,B.T.;Brink,R.;Christ,D.;Goodnow,C.C.",Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination,19-APR-2017,8_7_7_6_3_9,5VJQ_C_D,Xtal structure,,4,1,10.651813,-12.775936
5CP7_F_G,DVQLRESGPDLVTPSQSLSLTCTVTGYSITSGYSWHWNRQFPGNKLEWMGYIHYSGSTNYNPSLRGRISITRDTSKNQFFLQLNSVTTEDTATYYCARYGGYWGQGTSVTVSS,DVVMTQTPITLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSRVPDRFTGSGAGTDFTLKISRVEAEDLGIYYCWQGTHFPQTFGGGTKLEIK,5CP7_F,5CP7_G,Crystal Structure Of An Antigen-Binding Fragment Of Monoclonal Antibody Against Sulfonamides,Crystal Structure Of An Antigen-Binding Fragment Of Monoclonal Antibody Against Sulfonamides,Mus musculus,"Li,C.;Liang,X.;Wen,K.;Li,Y.;Zhang,X.;Ma,M.;Yu,X.;Yu,W.;Shen,J.;Wang,Z.",Class-Specific Monoclonal Antibodies and Dihydropteroate Synthase in Bioassays Used for the Detection of Sulfonamides: Structural Insights into Recognition Diversity,21-JUL-2015,9_7_6_11_3_9,5CP7_F_G,Xtal structure,,4,1,11.501541,-12.901505
8DWW_H_L,EEQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGNSGYEPLDYWGQGTLVTVS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEI,8DWW_H,8DWW_L,Chikungunya Vlp In Complex With Neutralizing Fab 506.A08 (Asymmetric Unit),Chikungunya Vlp In Complex With Neutralizing Fab 506.A08 (Asymmetric Unit),Chikungunya virus strain Senegal 37997,"Raju,S.;Adams,L.J.;Earnest,J.T.;Warfield,K.;Vang,L.;Crowe,J.E.;Fremont,D.H.;Diamond,M.S.",A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans,31-MAY-2023,8_8_13_6_3_9,8DWW_H_L,Xtal structure,Chikungunya,4,1,15.88219,10.0287695
5WNA_H_L,EEQLVESGGGLVQPGRSLRLSCVGSGLRFEEHAMHWVRQAPGRGLEWVSGISWNSGSVGYADSVKGRFTTSRDNAKDILFLEMNTLRSEDTALYFCAIMVATTKNDFHYYKDVWGKGTTVTVSS,QIVLTQSPATLSLSPGERATLSCRASQSVSNHLAWYQQKPGQAPRLLIYETSNRATGIPPRFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNNWYTFGQGTKLEIK,5WNA_H,5WNA_L,Structure Of Antibody 3D3 Bound To The Central Conserved Region Of Rsv G,Structure Of Antibody 3D3 Bound To The Central Conserved Region Of Rsv G,Human respiratory syncytial virus A2,"Fedechkin,S.O.;George,N.L.;Wolff,J.T.;Kauvar,L.M.;DuBois,R.M.",Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies,31-JUL-2017,8_8_17_6_3_8,5WNA_H_L,Xtal structure,MTDH; LYRIC; 3D3; AEG-1,4,1,13.1655245,11.968484
5VTA_I_G,EFQLQQSGPELVKPGASVKISCKASGYSFTDYNINWMKQSNGKSLEWIGVVIPKYGTTNYNQKFQGKATLTVDQSSSTAYIQLNSLTSEDSAVYYCTRFRVFFDVWGTGTTVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVCNMHWYQQKPGSSPKPWLHGTSNLASGVPVRFSGSGSGTSFSLTISRVEAEDAATYFCQQWSNHPPTFGGGTKLEID,5VTA_I,5VTA_G,Co-Crystal Structure Of Dppiv With A Chemibody Inhibitor,Co-Crystal Structure Of Dppiv With A Chemibody Inhibitor,Mus musculus,"Cheng,A.C.;Doherty,E.M.;Johnstone,S.;DiMauro,E.F.;Dao,J.;Luthra,A.;Ye,J.;Tang,J.;Nixey,T.;Min,X.;Tagari,P.;Miranda,L.P.;Wang,Z.",Structure-guided Discovery of Dual-recognition Chemibodies,16-MAY-2017,8_8_9_5_3_9,5VTA_I_G,Xtal structure,,4,1,2.726254,-3.8994172
CAL48860_CAL48518,EIQLQQSGPELVKPGASVKVSCKASGYSFTDYFIYWVKQSHGKSLEWIGDIDPYNGDTSYNQKFRDKATLTVDQSSTTAFMHLNSLTSEDSAVYFCARGLRFWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGSKLYWLQQEPDGTFKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYASSPYTFGGGTKLAIK,CAL48860,CAL48518,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Nishida,Y.; Okura,T.; Tanimoto,T.; Kurimoto,M.",Anti-interleukin-18 antibody,29-SEP-2006,8_8_6_6_3_9,CAL48860_CAL48518,Unique chain,interleukin-18,4,1,2.4395654,-4.0104313
7F35_F_E,EIQLQQSGPELVKPGTSVKVSCKASGYALTSYTMYWVKQSHGKSLEWIGYIDPYNGGTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCAGWNRYDEDWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRTSETIDSYGNSFMHWYQQKPGQPPKLLIYRASNLKSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQTNEVMYTFGGGTKLEIK,7F35_F,7F35_E,Crystal Structure Of Anti S-Gatifloxacin Antibody Fab Fragment In Complex With S-Gatifloxacin,Crystal Structure Of Anti S-Gatifloxacin Antibody Fab Fragment In Complex With S-Gatifloxacin,Mus musculus,"Wang,L.T.;Xie,W.;Jiao,W.Y.;Zhang,C.;Li,X.;Xu,Z.;Huang,X.;Lei,H.T.;Shen,X.",Conformational adaptability determining antibody recognition to distomer: structure analysis of enantioselective antibody against chiral drug gatifloxacin,15-JUN-2021,8_8_9_10_3_9,7F35_F_E,Xtal structure,,4,1,2.4371169,-3.9977863
5UTZ_F_G,ELQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTPTVTGDWFDPWGRGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNVVFGGGTKLTVL,5UTZ_F,5UTZ_G,Human Il-2/Fab Complex,Human Il-2/Fab Complex,Homo sapiens,"Trotta,E.;Bessette,P.H.;Silveria,S.L.;Ely,L.K.;Jude,K.M.;Le,D.T.;Holst,C.R.;Coyle,A.;Potempa,M.;Lanier,L.L.;Garcia,K.C.;Crellin,N.K.;Rondon,I.J.;Bluestone,J.A.",A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism,15-FEB-2017,10_7_13_8_3_9,5UTZ_F_G,Xtal structure,IL-2; TCGF; IL2,4,1,16.604555,-8.215473
5DSC_E_F,EQLKESGGRLVAPGTPLTLTCTVSGFDISDYAMIWVRQAPGKGLEWIGIIYGVINDLAYAKWAKGRFTISRTSTTVDLKITSPTTEDTATYFCARGYGSMDGYDRLNLWGQGTLVTVSS,AVLTQTPSPVSAAVGGTVTISCRSRQRVYLGDWLSWFQKKPGQPPKLLIYDASFRGDGVSSRFSGSGSGTHFTLTISGVQCDDAATYYCLGGYYDDADDTFGGGTEVVVK,5DSC_E,5DSC_F,Context-Independent Anti-Hypusine Antibody Fabhpu24.B In Complex With Hypusine,Context-Independent Anti-Hypusine Antibody Fabhpu24.B In Complex With Hypusine,synthetic construct,"Zhai,Q.;He,M.;Song,A.;Deshayes,K.;Dixit,V.M.;Carter,P.J.",Structural Analysis and Optimization of Context-Independent Anti-Hypusine Antibodies,17-SEP-2015,8_8_15_8_3_11,5DSC_E_F,Xtal structure,Hypusine,4,1,-0.13582903,19.154425
6XM2_F_E,EQQLQESGPGLVKPSETLSLTCTVTGFSLSSYTVNWVRQPAGKGLEWIGYISYGGSAYYASWANGRFTISKDSSKNQVSLKLSSVTAADTAVYFCARHMQVGGAPTGSMAAFDPWGPGTLVTVSS,EAVLTQSPGTLSLSPGERATLSCQSSQSVYNNNYLSWFQQKPGQPPRLLIYGASTLTSGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCAGGYSGSSDKYAFGGGTKVEIK,6XM2_F,6XM2_E,The Structure Of The 4A11.V7 Antibody In Complex With Human Tgfb2,The Structure Of The 4A11.V7 Antibody In Complex With Human Tgfb2,Homo sapiens,"Sun,T.;Huang,Z.;Liang,W.C.;Yin,J.;Lin,W.Y.;Wu,J.;Vernes,J.M.;Lutman,J.;Caplazi,P.;Jeet,S.;Wong,T.;Wong,M.;DePianto,D.J.;Morshead,K.B.;Sun,K.H.;Modrusan,Z.;Vander Heiden,J.A.;Abbas,A.R.;Zhang,H.;Xu,M.;N'Diaye,E.N.;Roose-Girma,M.;Wolters,P.J.;Yadav,R.;Sukumaran,S.;Ghilardi,N.;Corpuz,R.;Emson,C.;Meng,Y.G.;Ramalingam,T.R.;Lupardus,P.;Brightbill,H.D.;Seshasayee,D.;Wu,Y.;Arron,J.R.",TGFbeta2 and TGFbeta3 isoforms drive fibrotic disease pathogenesis,29-JUN-2020,8_7_19_8_3_12,6XM2_F_E,Xtal structure,,4,1,16.385508,-8.019962
4O51_B_A,ESVEESGGRLVTPGTPLTLTCTVSGFSLSSYPMNWVRQAPGKGLEWIGGIGTSGNIWYASWAKGRFIISRASSTTVDLKVTSPTTEDTATYFCARGLYNDYTVWGPGTLVTVSS,EVLTQTPSSVSAAVGGTVTINCQASQSVYNKNYLAWYQQKPGQPPKRLIYSASTLASGVSSRFKGSGSGTQFTLTISDVQADDVATYYCLGSYDQAAHAFGGGTKVVVE,4O51_B,4O51_A,Crystal Structure Of The Qaa Variant Of Anti-Hinge Rabbit Antibody 2095-2 In Complex With Ides Hinge Peptide,Crystal Structure Of The Qaa Variant Of Anti-Hinge Rabbit Antibody 2095-2 In Complex With Ides Hinge Peptide,Homo sapiens,"Malia,T.J.;Teplyakov,A.;Brezski,R.J.;Luo,J.;Kinder,M.;Sweet,R.W.;Almagro,J.C.;Jordan,R.E.;Gilliland,G.L.",Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge,19-DEC-2013,8_7_10_8_3_10,4O51_B_A,Xtal structure,Hinge,4,1,-0.15034954,19.135075
5DUB_H_L,ESVEESGGRLVTPGTPLTLTCTVSGFSLSTYTMNWVRQAPGKGLEWIGDIYTDGNTYYANWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARDSWDASSYYGLDLWGQGTLVTVSS,MTQTPSSVSAAVGGTVTINCQASEDIKRYLAWYQQKPGQPPKLLIYAASKLASGVSSRFKGSGSGTEYTLTISGVQCDDAATYYCQQGYTSSNVNNAFGGGTEVVVK,5DUB_H,5DUB_L,Context-Independent Anti-Hypusine Antibody Fabhpu98 In Complex With Deoxyhypusine,Context-Independent Anti-Hypusine Antibody Fabhpu98 In Complex With Deoxyhypusine,synthetic construct,"Zhai,Q.;He,M.;Song,A.;Deshayes,K.;Dixit,V.M.;Carter,P.J.",Structural Analysis and Optimization of Context-Independent Anti-Hypusine Antibodies,18-SEP-2015,8_7_15_6_3_12,5DUB_H_L,Xtal structure,Hypusine,4,1,-0.16394764,19.127691
7LK4_F_E,EVELVESGGDLVQPGRSLKLSCAASGFTFSNLAMAWVRQTPTKGLEWVASISPAGITTYYRDSVKGRFTISRDNARNTQYLQMDSLRSEDTATYYCARHTGKSSFFDYWGQGVMVTVSS,DVQMTQSPSYLAASPGESVSISCKATENINTYLAWYQAKPGKTTKLLLYSGSTLQSGTPSRFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNEYPLTFGSGTKLEIK,7LK4_F,7LK4_E,Crystal Structure Of Bak L100A In Complex With Activating Antibody Fragments,Crystal Structure Of Bak L100A In Complex With Activating Antibody Fragments,Rattus norvegicus,"Robin,A.Y.;Miller,M.S.;Iyer,S.;Shi,M.X.;Wardak,A.Z.;Lio,D.;Smith,N.A.;Smith,B.J.;Birkinshaw,R.W.;Czabotar,P.E.;Kluck,R.M.;Colman,P.M.",Structure of the BAK-activating antibody 7D10 bound to BAK reveals an unexpected role for the alpha1-alpha2 loop in BAK activation,01-FEB-2021,8_8_12_6_3_9,7LK4_F_E,Xtal structure,BAK; alpha2; BAK1; CDN1; BCL2L7,4,1,14.854294,9.102179
QMI58169_QMI58187,EVHLVESGGGLVQPGGSLRLSCAASGFTFSDHYMDWVRQAPGKGLEWVGRTRNKANSYTTEYAASVKGRFTISRDDAKNSLYLQMNSLKTEDTAVYYCARVHRWAYCINGVCFGAYSDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPSTFGQGTKLEIK,QMI58169,QMI58187,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_10_21_7_3_9,QMI58169_QMI58187,Unique source,SARS-CoV-2,4,1,13.347868,8.440166
1Q9W_D_C,EVILVESGGGLVQPGGSLRLSCSTSGFTFTDYYMSWVRQPPGKALEWLGFIRNKPKGYTTEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCVRDIYSFGSRDGMDYWGQGTSVTVSS,DIVMSQFPSSLAVSAGEKVTMSCKSSQSLLNSRTRKSYLAWYQQKPGQFPKLLIYWAATRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,1Q9W_D,1Q9W_C,S45-18 Fab Pentasaccharide Bisphosphate Complex,S45-18 Fab Pentasaccharide Bisphosphate Complex,Mus musculus,"Nguyen,H.P.;Seto,N.O.;MacKenzie,C.R.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",Germline antibody recognition of distinct carbohydrate epitopes,26-AUG-2003,8_10_15_12_3_8,1Q9W_D_C,Xtal structure,,4,1,26.049267,4.669147
AEQ73604_AEQ74359,EVKKPGASVRVSCKASGYSFKNYGIHWVRQAPGQGLEWMGWISADNGDTTTALNLRGRVSMTTDTSTNTVYMEVKSLRSDDTAIYFCARDFYSGSYRSFDYWGQGTLVTVS,SSLSASLGDRVTITCRASQHISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFTGSGSGADYTLTISSLQPEDFATYYCQQSYSTSWTFGQGTTVEIK,AEQ73604,AEQ74359,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_14_6_3_9,AEQ73604_AEQ74359,Unique source,tetanus,4,1,1.4680922,5.421614
AEQ73613_AEQ74368,EVKKPGESLKISCQASGYGFTVYWIGWVRQLPGKGLEWLGIIYPGDSDTRYNPSFQGQVTISADKSVSTTYLQWSSLKASDTAIYYCARHLDSYDVFTGYNLGGYMDVWGKGTTVTVS,TLSLSPGERATLSCRASQSVSTNYLAWYRQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGSSPQTFGQGTRLEIK,AEQ73613,AEQ74368,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_21_7_3_9,AEQ73613_AEQ74368,Unique source,tetanus,4,1,-12.772827,5.371344
6ELU_K_L,EVKLEESGGGLVQPGGSLRVSCATSGFTFTDYYMNWVRQPPGKALEWLGFIRNKANGYTTEYSASVKGRFTISRDDSQSILYLQMNTLRAEDSASYYCARDKGWGYAMDYWGQGTSVTVSS,DIVMTQTPPSLAVSLGQRATISCKASQSVDYDADSFMHWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIRPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,6ELU_K,6ELU_L,Structure Of Serum Resistance Associated Protein From T. B. Rhodesiense,Structure Of Serum Resistance Associated Protein From T. B. Rhodesiense,Mus musculus,"Zoll,S.;Lane-Serff,H.;Mehmood,S.;Schneider,J.;Robinson,C.V.;Carrington,M.;Higgins,M.K.",The structure of serum resistance-associated protein and its implications for human African trypanosomiasis,29-SEP-2017,8_10_12_10_3_9,6ELU_K_L,Xtal structure,,4,1,26.031942,4.653153
6JU0_I_M,EVKLEESGGGLVQPGGSMKLSCAASGFIFSDAWMDWVRQSPERGLEWVAEIRSKANGLAPYYAESVKGRFTISRDDSKSSVYLQMNNLRSEDTGIYYCTSTLYYFDYWGQGTTLTVSS,QIVLTQSPAIMSAFPGERVTLTCSASSSVRSSYLCWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWSSYPRTFGGGTKLEIK,6JU0_I,6JU0_M,Mouse Antibody 3.3 Fab In Complex With Peg,Mouse Antibody 3.3 Fab In Complex With Peg,Mus musculus,"Lee,C.C.;Su,Y.C.;Ko,T.P.;Lin,L.L.;Yang,C.Y.;Chang,S.S.;Roffler,S.R.;Wang,A.H.",Structural basis of polyethylene glycol recognition by antibody,12-APR-2019,8_10_9_7_3_9,6JU0_I_M,Xtal structure,polyethylene,4,1,13.4101515,6.9575915
6CSE_H_L,EVKLEESGGGLVQPGGSMKLSCAASGFTSSDFAMDWVRQSPEAGLEWVAEIAASERHYAESVKGRFTISRDDSKSSVYLQMNSLRAEDSGLYYCTRTAGACGQWGTGTTVTVSS,DIAMTQSPASLSASVGETVTITCRTSENIASALAWYQQKQGKSPQLLVMNAKTLAAGVPSRFSGSGSGTAFSLKINSLQPEDFGSYSCQHAAGWLLTFGGGTKLEIK,6CSE_H,6CSE_L,Crystal Structure Of Sodium/Alanine Symporter Agcs With L-Alanine Bound,Crystal Structure Of Sodium/Alanine Symporter Agcs With L-Alanine Bound,Mus musculus,"Ma,J.;Lei,H.T.;Reyes,F.E.;Sanchez-Martinez,S.;Sarhan,M.F.;Hattne,J.;Gonen,T.",Structural basis for substrate binding and specificity of a sodium-alanine symporter AgcS,20-MAR-2018,8_6_9_6_3_9,6CSE_H_L,Xtal structure,,4,1,13.424913,6.9704437
7TXZ_E_F,EVKLEESGGGLVQPGGSMKLSCVASGFSFSYYWMNWVRQSPEKGLEWVAEIRLKSNNYGTHYAESVKGRFTISRDDSKSSVYLQMNNLRPEDTGIYYCTRVITTVFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASESVHDYGISFMNWFQQKPGQPPKLLIYSASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDIAMYFCQQSKEVPYTFGGGTKLEIK,7TXZ_E,7TXZ_F,Nipah Virus Attachment (G) Glycoprotein Ectodomain In Complex With Nah1.3 Neutralizing Antibody Fab Fragment (Local Refinement Of The Distal Region),Nipah Virus Attachment (G) Glycoprotein Ectodomain In Complex With Nah1.3 Neutralizing Antibody Fab Fragment (Local Refinement Of The Distal Region),Nipah henipavirus,"Wang,Z.;Amaya,M.;Addetia,A.;Dang,H.V.;Reggiano,G.;Yan,L.;Hickey,A.C.;DiMaio,F.;Broder,C.C.;Veesler,D.",Architecture and antigenicity of the Nipah virus attachment glycoprotein,09-MAR-2022,8_10_10_10_3_9,7TXZ_E_F,Xtal structure,Ectodomain,4,1,13.410106,7.1001606
5L9D_H_L,EVKLEESGPELVKPGASMKMSCKASGYTFTSYIIHWLKQKPGQGLEWIGYINPYNDGSKYNEKFKGKATLTSDKSSSTAYMELSSLASEDSAVYYCTRNYGSDSLDYWGQGTTLTVSS,DIVLTQTPAIMSASLGERVTMTCTANSSVSSNYFHWYQQKPGSSPKLWIYSTSNLASGVPTRFSGSGSGTSYSLTLSSMEAEDAATYYCHQYHRSPPTFGSGTKLKMK,5L9D_H,5L9D_L,"Afamin Antibody Fragment, N14 Fab, L1- Glycosylated, Crystal Form I, Parsimonious Model","Afamin Antibody Fragment, N14 Fab, L1- Glycosylated, Crystal Form I, Parsimonious Model",Mus musculus,"Naschberger,A.;Furnrohr,B.G.;Lenac Rovis,T.;Malic,S.;Scheffzek,K.;Dieplinger,H.;Rupp,B.","The N14 anti-afamin antibody Fab: a rare VL1 CDR glycosylation, crystallographic re-sequencing, molecular plasticity and conservative versus enthusiastic modelling",10-JUN-2016,8_8_11_7_3_9,5L9D_H_L,Xtal structure,NA14; N14; SSNA1,4,1,0.9561455,-3.8187077
3J7E_B_A,EVKLEQSGAELARPGASVKLSCKASGYTFASYWMQWVKQRPGQGLEWIGAIYPGDGDTWYTQKFKGKATLTADKSSSTAYMQLSSLASEDSAVYYCARPPYYYGTTYYFDYWGQGTTLTVS,DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLDSRNQKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSTPLTFGAGTKLELK,3J7E_B,3J7E_A,Electron Cryo-Microscopy Of Human Papillomavirus 16 And H16.V5 Fab Fragments,Electron Cryo-Microscopy Of Human Papillomavirus 16 And H16.V5 Fab Fragments,Mus musculus,"Lee,H.;Brendle,S.A.;Bywaters,S.M.;Guan,J.;Ashley,R.E.;Yoder,J.D.;Makhov,A.M.;Conway,J.F.;Christensen,N.D.;Hafenstein,S.",A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment,23-JUN-2014,8_8_15_12_3_9,3J7E_B_A,Xtal structure,,4,1,0.435356,-3.855774
6BT3_B_A,EVKLEQSGAELARPGASVKLSCKASGYTFASYWMQWVKQRPGQGLEWIGAIYPGDGDTWYTQKFKGKATLTADKSSSTAYMQLSSLASEDSAVYYCARPPYYYGTTYYFDYWGQGTTLTVSG,DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLDSRNQKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSTPLTFGAGTKLELK,6BT3_B,6BT3_A,High-Resolution Structure Analysis Of Antibody V5 Conformational Epitope On Human Papillomavirus 16,High-Resolution Structure Analysis Of Antibody V5 Conformational Epitope On Human Papillomavirus 16,Human papillomavirus type 16,"Guan,J.;Bywaters,S.M.;Brendle,S.A.;Ashley,R.E.;Makhov,A.M.;Conway,J.F.;Christensen,N.D.;Hafenstein,S.",High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16,05-DEC-2017,8_8_15_12_3_9,6BT3_B_A,Xtal structure,,4,1,0.4411384,-3.8454764
1Y18_D_C,EVKLLESGGGLAQPGGSLKLSCAASGFDFRRYWMTWVRQAPGKGLEWIGDINPDSRTINYMPSLKDKFIISRDNAKNSLYLQLSRLRSEDSALYYCVRLDFDVYNHYYVLDYWGQGTSVTVSS,VVTQESALTTSPGETVTLTCRSSSGAVTTSNYATWVQEKPDHLFTGLIGGTNKRAPGVPARFSGSLIGDRAALTITGAQTEDEAIYFCALWNSNHLVFGGGTKLE,1Y18_D,1Y18_C,Fab Fragment Of Catalytic Elimination Antibody 34E4 E(H50)D Mutant In Complex With Hapten,Fab Fragment Of Catalytic Elimination Antibody 34E4 E(H50)D Mutant In Complex With Hapten,synthetic construct,"Debler,E.W.;Ito,S.;Seebeck,F.P.;Heine,A.;Hilvert,D.;Wilson,I.A.",Structural origins of efficient proton abstraction from carbon by a catalytic antibody,17-NOV-2004,8_8_16_9_3_9,1Y18_D_C,Xtal structure,,4,1,19.632128,9.748648
7L5J_Y_X,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGQINPHSSTINYTPSLRDKFIISRDNAKNTLYLQMTKVRSEDTALYYCARLLRYFYALDYWGQGASVTVSS,QIVLTQSPAIMSASPGEKVTITCSASSSVSYMHWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPFTFGGGTKLEIK,7L5J_Y,7L5J_X,Mouse Norovirus Protruding Domain Complexed With Neutralizing Fab Fragment From Mab A6.2,Mouse Norovirus Protruding Domain Complexed With Neutralizing Fab Fragment From Mab A6.2,Mus musculus,"Williams,A.N.;Sherman,M.B.;Smith,H.Q.;Taube,S.;Pettitt,B.M.;Wobus,C.E.;Smith,T.J.",A Norovirus Uses Bile Salts To Escape Antibody Recognition While Enhancing Receptor Binding,22-DEC-2020,8_8_12_5_3_9,7L5J_Y_X,Xtal structure,,4,1,19.609499,9.727209
3V6O_C_E,EVKLLESGPGLVAPSESLSITCTISGFSLTDDGVSWIRQPPGKGLEWLGVIWGGGSTYFNSLFKSRLSITRDNSKSQVFLEMDSLQTDDTAMYYCAKHDGHETMDYWGQGTSVTVSS,EIVMTQSPKFMSTSIGDRVNITCKATQNVRTAVTWYQQKPGQSPQALIFLASNRHTGVPARFTGSGSGTDFTLTINNVKSEDLADYFCLQHWNYPLTFGSGTKLEIK,3V6O_C,3V6O_E,Leptin Receptor-Antibody Complex,Leptin Receptor-Antibody Complex,Mus musculus,"Carpenter,B.;Hemsworth,G.R.;Wu,Z.;Maamra,M.;Strasburger,C.J.;Ross,R.J.;Artymiuk,P.J.",Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody,20-DEC-2011,8_7_11_6_3_9,3V6O_C_E,Xtal structure,,4,1,22.11526,-6.0976467
1IAI_I_M,EVKLQESGGGLVQPGGSMKLSCVASGFTFNNYWMSWVRQSPEKGLEWVAEIRLNSDNFATHYAESVKGKFIISRDDSKSRLYLQMNSLRAEDTGIYYCVLRPLFYYAVDYWGQGTSVTVSS,DIQLTQSPAFMAASPGEKVTITCSVSSSISSSNLHWYQQKSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWNSYPYTFGGGTKLEIK,1IAI_I,1IAI_M,Idiotype-Anti-Idiotype Fab Complex,Idiotype-Anti-Idiotype Fab Complex,Mus musculus,"Ban,N.;Escobar,C.;Day,J.;Greenwood,A.;McPherson,A.",Preliminary crystallographic study of a complex between an Fab of a monoclonal feline peritonitis virus neutralizing antibody and its anti-idiotypic Fab,28-DEC-1993,8_10_12_7_3_9,1IAI_I_M,Xtal structure,,4,1,13.39941,7.217173
4I2X_D_C,EVKLQQSGPELVKPGASVKISCKASGYSFTSYYIHWVKQRPGQGLEWIGWVFPGSGNTKYNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAVYFCARGNYDRAWFAYWGQGTLVTVSA,DIVITQSPKFMSTSVGDRVSITCKASQDVSTAVAWFQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLEIK,4I2X_D,4I2X_C,Crystal Structure Of Signal Regulatory Protein Gamma (Sirp-Gamma) In Complex With Fabox117,Crystal Structure Of Signal Regulatory Protein Gamma (Sirp-Gamma) In Complex With Fabox117,Homo sapiens,"Nettleship,J.E.;Ren,J.;Scot,D.J.;Rahman,N.;Hatherley,D.;Stuart,D.I.;Barclay,A.N.;Owens,R.J.",Crystal Structure Of Signal Regulatory Protein Gamm (Sirp-Gamma) In Complex With Fabox117,23-NOV-2012,8_8_12_6_3_9,4I2X_D_C,Xtal structure,,4,1,0.09369615,-4.3817315
4ZPV_H_L,EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVATISSGGTYTYYPDSVKGRFTISRDNAENTLYLQMSSLRSEDTAMYYCVRDGNSMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTIICRASQDINNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGSDYSLTISNLEQEDIATYFCQQANTLPPTFGAGTKLELR,4ZPV_H,4ZPV_L,Structure Of Mers-Coronavirus Spike Receptor-Binding Domain (England1 Strain) In Complex With Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 2),Structure Of Mers-Coronavirus Spike Receptor-Binding Domain (England1 Strain) In Complex With Vaccine-Elicited Murine Neutralizing Antibody D12 (Crystal Form 2),Mus musculus,"Wang,L.;Shi,W.;Joyce,M.G.;Modjarrad,K.;Zhang,Y.;Leung,K.;Lees,C.R.;Zhou,T.;Yassine,H.M.;Kanekiyo,M.;Yang,Z.Y.;Chen,X.;Becker,M.M.;Freeman,M.;Vogel,L.;Johnson,J.C.;Olinger,G.;Todd,J.P.;Bagci,U.;Solomon,J.;Mollura,D.J.;Hensley,L.;Jahrling,P.;Denison,M.R.;Rao,S.S.;Subbarao,K.;Kwong,P.D.;Mascola,J.R.;Kong,W.P.;Graham,B.S.",Evaluation of candidate vaccine approaches for MERS-CoV,08-MAY-2015,8_8_9_6_3_9,QDB31465_QDB31466,Xtal structure,MDS032; p31; SLT1; MERS; D12; USE1; CoV,4,1,18.011368,7.110256
3IXX_G_H,EVKLVESGGGLVLPGGSLRLSCATSGFTFTDYYMTWVRQPPGKALEWLGFIGNKANDYTTEYSASVKGRFTISRDDSQSILYLQMSTLRAEDRATYYCATVYGNYPYFDVWGAGTTVAVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKIWIYESSKLASGVPVRFSGSGSGTSYSLTISSMEAEDVATYYCQQWSSHPHPLTFGAGTKLELK,3IXX_G,3IXX_H,The Pseudo-Atomic Structure Of West Nile Immature Virus In Complex With Fab Fragments Of The Anti-Fusion Loop Antibody E53,The Pseudo-Atomic Structure Of West Nile Immature Virus In Complex With Fab Fragments Of The Anti-Fusion Loop Antibody E53,Mus musculus,"Cherrier,M.V.;Kaufmann,B.;Nybakken,G.E.;Lok,S.M.;Warren,J.T.;Chen,B.R.;Nelson,C.A.;Kostyuchenko,V.A.;Holdaway,H.A.;Chipman,P.R.;Kuhn,R.J.;Diamond,M.S.;Rossmann,M.G.;Fremont,D.H.",Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody,26-FEB-2009,8_10_12_5_3_11,3IXX_G_H,Xtal structure,Fusion,4,1,26.044857,4.6651006
2G5B_D_C,EVNLVESGGGLVQPGGSLRLSCATSGFTFIDNYMSWVRQPPGKALEWLGFIRNKVNGYTTEYGPSVKGRFTISRDDSQSILYLQMNTLRTEDSATYYCVRDNGSDYRWYFDVWGAGTTVTVSS,DIVMSQSPSSLAVSAGERVTMTCKSSQSLFNSKTRRNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTEFTLTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,2G5B_D,2G5B_C,Crystal Structure Of The Anti-Bax Monoclonal Antibody 6A7 And A Bax Peptide.,Crystal Structure Of The Anti-Bax Monoclonal Antibody 6A7 And A Bax Peptide.,synthetic construct,"Peyerl,F.W.;Dai,S.;Murphy,G.A.;Crawford,F.;White,J.;Marrack,P.;Kappler,J.W.",Elucidation of some Bax conformational changes through crystallization of an antibody-peptide complex,22-FEB-2006,8_10_14_12_3_8,2G5B_D_C,Xtal structure,Bax,4,1,26.069107,4.639799
6AVR_H_L,EVQLEESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQIPEKRLEWVAKVSSGGGSTYYLDTVQGRFTISRDNAKNTLYLQMSSLNSEDTAMYYCARHNYGSFAYWGQGTLVTVSA,ELVMTQTPATLSVTPGDSVSLSCRASQSISNHLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPHTFGGGTKLEIK,6AVR_H,6AVR_L,Human Alpha-V Beta-3 Integrin (Intermediate Conformation) In Complex With The Therapeutic Antibody Lm609,Human Alpha-V Beta-3 Integrin (Intermediate Conformation) In Complex With The Therapeutic Antibody Lm609,Mus musculus,"Borst,A.J.;James,Z.M.;Zagotta,W.N.;Ginsberg,M.;Rey,F.A.;DiMaio,F.;Backovic,M.;Veesler,D.",The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alphaVbeta3 Integrin via Steric Hindrance,04-SEP-2017,8_8_10_6_3_9,6AVR_H_L,Xtal structure,Integrin,4,1,17.959215,6.9546924
7EJ4_J_N,EVQLEESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQSPEKRLEWVAEISSGGTYTNYPDTATGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCANFGNYEEIAYWGQGTLVTVSA,QIVLTQSPAIMSVSLGERVTMTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYHRSPYTFGGGTKLEIK,7EJ4_J,7EJ4_N,Cryo-Em Structure Of Sars-Cov-2 Spike In Complex With A Neutralizing Antibody Rbd-Chab-25,Cryo-Em Structure Of Sars-Cov-2 Spike In Complex With A Neutralizing Antibody Rbd-Chab-25,Homo sapiens,"Yang,T.J.;Yu,P.Y.;Wu,H.C.;Hsu,S.T.D.",Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25,01-APR-2021,8_8_11_7_3_9,7EJ4_J_N,Xtal structure,SARS-CoV-2; RBD,4,1,18.10194,7.045963
3ZKN_H_L,EVQLKESGPVLVAPSQSLFISCTVSGFSLTRYGVHWVRQSPGKGLEWLGVIWAGGTTNYNSAFMSRLTISKDNSKSQVFLKMNSLQTDDTAIYYCVKAYRNAMDYWGQGTSVTVSS,NIVLSQSPGSLAVSLGQRATISCRASKSVDTYGHSFIHWYQQKPGQPPNLLIHLASNLESGVPARFSGRGSGTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK,3ZKN_H,3ZKN_L,Bace2 Fab Inhibitor Complex,Bace2 Fab Inhibitor Complex,Mus musculus,"Banner,D.W.;Gsell,B.;Benz,J.;Bertschinger,J.;Burger,D.;Brack,S.;Cuppuleri,S.;Debulpaep,M.;Gast,A.;Grabulovski,D.;Hennig,M.;Hilpert,H.;Huber,W.;Kuglstatter,A.;Kusznir,E.;Laeremans,T.;Matile,H.;Miscenic,C.;Rufer,A.C.;Schlatter,D.;Steyaert,J.;Stihle,M.;Thoma,R.;Weber,M.;Ruf,A.","Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones",23-JAN-2013,8_7_10_10_3_9,3ZKN_H_L,Xtal structure,ALP56; CEAP1; BACE2; DRAP; AEPLC,4,1,22.24494,-5.966457
UTJ93901_UTJ93905,EVQLLESGAEVKKPGASVRVSCEASGYTFTKYFIHWVRQAPGHGLEWIGWINTLTSGVNYARNFQGRLTLTRDLSTETVYMDLRNLKSDDTAVYYCARGGRGYDEPWGAYTWLDPWGQGSLVTVSS,SYELTQPASVSGSPGQSITISCTGSSIGSYDLVSWYQQYPGKAPKVIIFEVSKRPSGVSHRFSGSKSGNTAALTISGLQVEDEAIYHCYSYDDMIIFGGGTRLTVL,UTJ93901,UTJ93905,"B cell receptor heavy chain variable region, partial [Homo sapiens]","B cell receptor lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"van Schooten,J.",Identification of novel IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein,18-JUL-2022,8_8_19_7_3_8,UTJ93901_UTJ93905,Unique source,HIV; CD4,4,1,2.3074472,3.653469
3HAE_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYGMGWVRQAPGKGLEWVSSIGSSGGGTAYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGELLPYYGMDVWGQGTTVTVSS,QSELTQPRSVSGSPGQSVTISCTGTSRDVGGYNYVSWYQQHPGKAPKLIIHDVIIRPSGVPDRFSGSKSGNTASLTISGLQAEDEAHYYCWSFAGSYYVFGTGTDVTVL,3HAE_H,3HAE_L,Rational Development Of High-Affinity T-Cell Receptor-Like Antibodies,Rational Development Of High-Affinity T-Cell Receptor-Like Antibodies,Homo sapiens,"Stewart-Jones,G.;Wadle,A.;Hombach,A.;Shenderov,E.;Held,G.;Fischer,E.;Kleber,S.;Nuber,N.;Stenner-Liewen,F.;Bauer,S.;McMichael,A.;Knuth,A.;Abken,H.;Hombach,A.A.;Cerundolo,V.;Jones,E.Y.;Renner,C.",Rational development of high-affinity T-cell receptor-like antibodies,01-MAY-2009,8_8_12_9_3_9,3HAE_H_L,Xtal structure,,4,1,13.55324,9.877569
4PUB_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK,4PUB_H,4PUB_L,Crystal Structure Of Fab Dx-2930,Crystal Structure Of Fab Dx-2930,Homo sapiens,"Kenniston,J.A.;Faucette,R.R.;Martik,D.;Comeau,S.R.;Lindberg,A.P.;Kopacz,K.J.;Conley,G.P.;Chen,J.;Viswanathan,M.;Kastrapeli,N.;Cosic,J.;Mason,S.;DiLeo,M.;Abendroth,J.;Kuzmic,P.;Ladner,R.C.;Edwards,T.E.;TenHoor,C.;Adelman,B.A.;Nixon,A.E.;Sexton,D.J.",Inhibition of plasma kallikrein by a highly specific active site blocking antibody,12-MAR-2014,8_8_15_6_3_8,AOL54849_AOL54833,Xtal structure,kallikrein,4,1,13.736333,9.541265
ABB60088_ABB60089,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYVMWWVRQAPGKGLEWVSYIWPSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSYDFWSNAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGSYLNWYQQKTGKAPKALIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQLEDFATYYCQQSYSTPSFGQGTKVEIK,ABB60088,ABB60089,"immunoglobulin heavy chain variable region DX-1999, partial [Homo sapiens]","immunoglobulin light chain variable region DX-1999 (AL-57), partial [Homo sapiens]",Homo sapiens,"Huang,L.; Shimaoka,M.; Rondon,I.J.; Roy,I.; Chang,Q.; Po,M.; Dransfield,D.T.; Ladner,R.C.; Edge,A.S.; Salas,A.; Wood,C.R.; Springer,T.A.; Cohen,E.H.",Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1,26-JUL-2016,8_8_13_6_3_8,ABB60088_ABB60089,Unique chain,,4,1,13.827773,9.578675
7DPM_A_B,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSVISGSGGSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYCCAKGYYYDSSGYYFREDAFDIWGQGTLVTVSS,DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKLEIK,7DPM_A,7DPM_B,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Mw06 Fab,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Mw06 Fab,Severe acute respiratory syndrome coronavirus 2,"Jiang,W.;Wang,J.;Jiao,S.;Gu,C.;Xu,W.;Chen,B.;Wang,R.;Chen,H.;Xie,Y.;Wang,A.;Li,G.;Zeng,D.;Zhang,J.;Zhang,M.;Wang,S.;Wang,M.;Gui,X.","Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV",20-DEC-2020,8_8_20_6_3_9,7DPM_A_B,Xtal structure,SARS-CoV-2; SARS; CoV,4,1,14.154648,9.938452
8DY2_A_A,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGCGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGCAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK,8DY2_A,8DY2_A,Crystal Structure Of Spfv Glk1,Crystal Structure Of Spfv Glk1,Homo sapiens,"Boucher,L.E.;Prinslow,E.G.;Feldkamp,M.;Yi,F.;Nanjunda,R.;Wu,S.J.;Liu,T.;Lacy,E.R.;Jacobs,S.;Kozlyuk,N.;Del Rosario,B.;Wu,B.;Aquino,P.;Davidson,R.C.;Heyne,S.;Mazzanti,N.;Testa,J.;Diem,M.D.;Gorre,E.;Mahan,A.;Nanda,H.;Gunawardena,H.P.;Gervais,A.;Armstrong,A.A.;Teplyakov,A.;Huang,C.;Zwolak,A.;Chowdhury,P.;Cheung,W.C.;Luo,J.",'Stapling' scFv for multispecific biotherapeutics of superior properties,03-MAY-2023,8_8_12_6_3_9,8DY2_A_A,Xtal structure,,4,1,14.196151,9.765209
6SS6_I_M,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLRADLGLYMDLWGRGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNHYVSWYQQLPGTAPKLLIYDNSERPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSALVFGGGTKLTVL,6SS6_I,6SS6_M,Structure Of Arginase-2 In Complex With The Inhibitory Human Antigen-Binding Fragment Fab C0020187,Structure Of Arginase-2 In Complex With The Inhibitory Human Antigen-Binding Fragment Fab C0020187,HOMO SAPIENS,"Burschowsky, D., Addyman, A., Fiedler, S., Groves, M., Haynes, S., Seewooruthun, C., Carr, M.",Structure Of Arginase-2 In Complex With The Inhibitory Human Antigen-Binding Fragment Fab C0020187,06-SEP-2019,8_8_13_8_3_11,6SS6_I_M,Xtal structure,,4,1,13.914499,9.740395
4Y5X_G_H,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKDRVAVAGKGSYYFDSWGRGTTVTVSS,QSVLTQPPSVSEAPGQRVTIACSGSSSNIGNNAVSWYQQLPGKAPTLLIYYDNLLPSGVSDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNDWVFGGGTKVTVL,4Y5X_G,4Y5X_H,Diabody 305 Complex With Epor,Diabody 305 Complex With Epor,Homo sapiens,"Moraga,I.;Wernig,G.;Wilmes,S.;Gryshkova,V.;Richter,C.P.;Hong,W.J.;Sinha,R.;Guo,F.;Fabionar,H.;Wehrman,T.S.;Krutzik,P.;Demharter,S.;Plo,I.;Weissman,I.L.;Minary,P.;Majeti,R.;Constantinescu,S.N.;Piehler,J.;Garcia,K.C.",Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands,12-FEB-2015,8_8_17_8_3_11,4Y5X_G_H,Xtal structure,,4,1,14.057935,9.958021
5F3H_E_F,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLNPEDFATYYCQQHYSTPWTFGGGTKVEIK,5F3H_E,5F3H_F,Structure Of Myostatin In Complex With Humanized Rk35 Antibody,Structure Of Myostatin In Complex With Humanized Rk35 Antibody,Homo sapiens,"Apgar,J.R.;Mader,M.;Agostinelli,R.;Benard,S.;Bialek,P.;Johnson,M.;Gao,Y.;Krebs,M.;Owens,J.;Parris,K.;St Andre,M.;Svenson,K.;Morris,C.;Tchistiakova,L.",Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody,02-DEC-2015,8_8_9_6_3_9,5F3H_E_F,Xtal structure,myostatin,4,1,14.406989,9.448885
5BK5_H_G,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTLLILESDVGVDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK,5BK5_H,5BK5_G,Crystal Structure Of The Anti-Circumsporozoite Protein 663 Germline Antibody,Crystal Structure Of The Anti-Circumsporozoite Protein 663 Germline Antibody,Homo sapiens,"Triller,G.;Scally,S.W.;Costa,G.;Pissarev,M.;Kreschel,C.;Bosch,A.;Marois,E.;Sack,B.K.;Murugan,R.;Salman,A.M.;Janse,C.J.;Khan,S.M.;Kappe,S.H.;Adegnika,A.A.;Mordmuller,B.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies,12-SEP-2017,8_8_14_11_3_9,5BK5_H_G,Xtal structure,Malarial,4,1,14.005492,9.573235
3GJF_H_L,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYQMSWVRQAPGKGLEWVSGIVSSGGSTAYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGELLPYYGMDVWGQGTTVTVSS,QSELTQPRSVSGSPGQSVTISCTGTSRDVGGYNYVSWYQQHPGKAPKLIIHDVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCWSFAGSYYVFGTGTDVTVL,3GJF_H,3GJF_L,Rational Development Of High-Affinity T-Cell Receptor-Like Antibodies,Rational Development Of High-Affinity T-Cell Receptor-Like Antibodies,Homo sapiens,"Stewart-Jones,G.;Wadle,A.;Hombach,A.;Shenderov,E.;Held,G.;Fischer,E.;Kleber,S.;Stenner-Liewen,F.;Bauer,S.;McMichael,A.;Knuth,A.;Abken,H.;Hombach,A.A.;Cerundolo,V.;Jones,E.Y.;Renner,C.",Rational development of high-affinity T-cell receptor-like antibodies,08-MAR-2009,8_8_12_9_3_9,3GJF_H_L,Xtal structure,,4,1,13.589028,10.018147
5CUS_J_N,EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYYMQWVRQAPGKGLEWVSYIGSSGGVTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGLGDAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQRVTISCSGSLSNIGLNYVSWYQQLPGTAPKLLISRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSPPGEAFGGGTKLTVL,5CUS_J,5CUS_N,Crystal Structure Of Serbb3-Fab3379 Complex,Crystal Structure Of Serbb3-Fab3379 Complex,Homo sapiens,"Lee,S.;Greenlee,E.B.;Amick,J.R.;Ligon,G.F.;Lillquist,J.S.;Natoli EJ,Jr.;Hadari,Y.;Alvarado,D.;Schlessinger,J.",Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration,25-JUL-2015,8_8_11_8_3_11,QPW67074_QPW67075,Xtal structure,ErbB3,4,1,13.792629,9.492627
6K7O_F_G,EVQLLESGGGLVQPGGSLRLSCAASGIDFSNHYYMYWVRQAPGKGLEWIGSIFSGDSASTYYADSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGMSTNDWASDLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASESINSIYLAWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYDWGDVENTFGGGTKVEIK,6K7O_F,6K7O_G,Complex Structure Of Lilrb4 And H128-3 Antibody,Complex Structure Of Lilrb4 And H128-3 Antibody,Homo sapiens,"Gui,X.;Deng,M.;Song,H.;Chen,Y.;Xie,J.;Li,Z.;He,L.;Huang,F.;Xu,Y.;Anami,Y.;Yu,H.;Yu,C.;Li,L.;Yuan,Z.;Xu,X.;Wang,Q.;Chai,Y.;Huang,T.;Shi,Y.;Tsuchikama,K.;Liao,X.C.;Xia,N.;Gao,G.F.;Zhang,N.;Zhang,C.C.;An,Z.",Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development,08-JUN-2019,9_9_13_7_3_12,6K7O_F_G,Xtal structure,LIR5; CD85k; AD2; ILT3; LILRB4; APOE; LIR-5; HM18,4,1,14.007565,9.427087
5BK3_C_D,EVQLLESGGGLVQPGGSLRLSCGASGFIFGHYAMSWVRQAPQKGLEWVSGISGGGESTNYADSVKGRFTISRDNSRNTVYLQMNSLRAEDTAIYYCAKDPGGDSSPAGRTWFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVFFSSNNRTYFAWYQQKPGQPPKVLISWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYFCQQYYSSPITFGQGTRLEIK,5BK3_C,5BK3_D,Crystal Structure Of The Neutralizing Anti-Circumsporozoite Protein 580 Antibody,Crystal Structure Of The Neutralizing Anti-Circumsporozoite Protein 580 Antibody,Homo sapiens,"Triller,G.;Scally,S.W.;Costa,G.;Pissarev,M.;Kreschel,C.;Bosch,A.;Marois,E.;Sack,B.K.;Murugan,R.;Salman,A.M.;Janse,C.J.;Khan,S.M.;Kappe,S.H.;Adegnika,A.A.;Mordmuller,B.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies,12-SEP-2017,8_8_18_12_3_9,5BK3_C_D,Xtal structure,Malarial,4,1,14.129425,9.873311
6WTU_H_I,EVQLLESGGGLVRPGGSQRLSCAASGFTFTPYAMTWVRQAPGKGLEWLSTISGSGGSTSYADSVKGRFTISRDNSKNILYLQMDSLRAEDTALYYCTKDKDEYTFGHNAFDVWGRGTMVTVSS,SYELTQAPSVSVAPGQTARITCGGDNIGRTSVHWYQQKPGQAPVLVIFYDNDRPSGIPERFSGSNSGNMATLSISRVEVGDEADYYCQVWDSNNDHPVFGGGTKLTVV,6WTU_H,6WTU_I,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 273264,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 273264,Plasmodium vivax Sal-1,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,04-MAY-2020,8_8_16_6_3_11,6WTU_H_I,Xtal structure,,4,1,14.062805,10.077101
6WTV_H_I,EVQLLESGGGLVRPGGSQRLSCAASGFTFTPYAMTWVRQAPGKGLEWLSTISGSGGSTYYADSVKGRFTISRDNSKNMLYLQMNSLTAEDTALYYCTKDKDEYTFGHNAFDVWGQGTMVTVSS,SYELTQAPSVSVAPGQTARITCGGDNIGRKTVNWYQQKPGQAPVLVIYYDNDRPSGIPERFSGSNSGNMATLSISRVEVGDEADYYCQVWDSNNDHPVFGGGTKLTVV,6WTV_H,6WTV_I,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 258259,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 258259,Plasmodium vivax Sal-1,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,04-MAY-2020,8_8_16_6_3_11,6WTV_H_I,Xtal structure,,4,1,14.107392,9.977444
7ZFA_M_N,EVQLLESGPGLVKPSETLSLTCTVSGGSISRYSWSWIRQPAGRGLEWIGRMYSSGGTNYNPSLESRVTMSLDTSKKQFSLKLSSVTAADTAVYYCAAASIDQVWGTYRDAFDIWGQGTMVTVSS,AIRMTQSPSSLAASVGDRVTISCRAGQSISSFLHWYQQKVGKAPKLLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAAYYCQQSYENPLTFGGGTKVDIK,7ZFA_M,7ZFA_N,Sars-Cov-2 Omicron Rbd In Complex With Omi-6 And Covox-150 Fabs,Sars-Cov-2 Omicron Rbd In Complex With Omi-6 And Covox-150 Fabs,Homo sapiens,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,01-APR-2022,8_7_18_6_3_9,7ZFA_M_N,Xtal structure,,4,1,16.140005,-7.9542217
UTJ93904_UTJ93908,EVQLLESGPGLVKPSETLSLTCTVSGVPISRHYWNWIRQSPGKGLEWIGYIFFNGNANYNPSLKSRVTISVDMSKNQFSLTLRSVTAADTAVYYCVREKSIAEEDNMVRWFDPWGQGTLVTVSS,SYELTQPPSVSVAPGKTARITCGGNNLGTKSVHWYQQKPGQAPVNVIYYDSDRPSGIPERFSGSKSGNTATLTISRVEAGDEADYYCQVWDSSRDQCVFGIGTKVTVL,UTJ93904,UTJ93908,"B cell receptor heavy chain variable region, partial [Homo sapiens]","B cell receptor lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"van Schooten,J.",Identification of novel IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein,18-JUL-2022,8_7_18_6_3_11,UTJ93904_UTJ93908,Unique source,HIV; CD4,4,1,16.176662,-7.999266
6BZW_C_D,EVQLLESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARITTAYYAMDYWGQGTSVTVSS,ELVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK,6BZW_C,6BZW_D,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Gl Precursor Of The Broadly Neutralizing Antibody Ap33,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Gl Precursor Of The Broadly Neutralizing Antibody Ap33,Hepacivirus C,"Aleman,F.;Tzarum,N.;Kong,L.;Nagy,K.;Zhu,J.;Wilson,I.A.;Law,M.",Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors,26-DEC-2017,8_7_12_10_3_9,6BZW_C_D,Xtal structure,Hepatitis; Antigenic; HCV,4,1,10.717829,-12.798108
AAA63324_AAA63381,EVQLLETGGGLVQPGGSRGLSCEGSGFTFSGFWMSWVRQTPGKTLEWIGDINSDGSAIKYAPSIKDRFTIFRDNDKSTLYLQMSNVRSEDTATYFCIRYSNYWYFDVRGTGSTVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGT,AAA63324,AAA63381,"immunoglobulin lambda-chain, partial [Mus musculus]","immunoglobulin lambda-chain, partial [Mus musculus]",Mus musculus,"Braun,J.; King,L.","Unique V gene usage by B-Ly1 cell lines, and a discordance between isotype switch commitment and variable region hypermutation",07-MAR-1995,8_8_11_9_3_9,AAA63324_AAA63381,Unique source,,4,1,19.561558,9.716521
7ZR7_D_E,EVQLLETGGGLVQPGRSLRLSCAASGFPFDDYAIHWVRLAPGKGLEWVSSISWDSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGAFPGYSSGWYYGLDVWGQGATVTVSS,QSVVTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIFEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGNKGVFGGGTKLTVL,7ZR7_D,7ZR7_E,Omi-42 Fab In Complex With Sars-Cov-2 Beta Spike Glycoprotein,Omi-42 Fab In Complex With Sars-Cov-2 Beta Spike Glycoprotein,Homo sapiens,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,03-MAY-2022,8_8_18_9_3_9,7ZR7_D_E,Xtal structure,,4,1,13.141767,11.993333
7ZCE_E_E,EVQLLQSAGGLVQPGGSLRLSCAASGFTVSANYMSWVRQAPGKGLEWVSVIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDLSVAGAFDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,7ZCE_E,7ZCE_E,Sars-Cov-2 Spike Protein In Complex With The Single Chain Fragment Scfv76,Sars-Cov-2 Spike Protein In Complex With The Single Chain Fragment Scfv76,Homo sapiens,"Milazzo,F.M.;Chaves-Sanjuan,A.;Minenkova,O.;Santapaola,D.;Anastasi,A.M.;Battistuzzi,G.;Chiapparino,C.;Rosi,A.;Merlo Pich,E.;Albertoni,C.;Marra,E.;Luberto,L.;Viollet,C.;Spagnoli,L.G.;Riccio,A.;Rossi,A.;Santoro,M.G.;Ballabio,F.;Paissoni,C.;Camilloni,C.;Bolognesi,M.;De Santis,R.",Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery,12-OCT-2022,8_7_12_7_3_9,7ZCE_E_E,Xtal structure,SARS-CoV-2,4,1,12.541379,10.33881
3CFD_H_L,EVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWLRQLPGNKLEWMGYISYSGRIRYNPSLKRRISITRDTSKNQFFLQLNSVTTEDTATYYCARSDYGNYGRGDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLDQDDIATYFCQQGTTLPPTFGGGTKLEIK,3CFD_H,3CFD_L,Purple-Fluorescent Antibody Ep2-25C10 In Complex With Its Stilbene Hapten,Purple-Fluorescent Antibody Ep2-25C10 In Complex With Its Stilbene Hapten,Mus musculus,"Debler,E.W.;Kaufmann,G.F.;Meijler,M.M.;Heine,A.;Mee,J.M.;Pljevaljcic,G.;Di Bilio,A.J.;Schultz,P.G.;Millar,D.P.;Janda,K.D.;Wilson,I.A.;Gray,H.B.;Lerner,R.A.",Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex,03-MAR-2008,9_7_13_6_3_9,3CFD_H_L,Xtal structure,,4,1,11.4804,-12.915871
6BLI_D_E,EVQLQESGPRLVKPSETLSLTCTVSGGSTSSYFWNWIRQPPGKGLEWIGYIYGSGSADYNPSLKSRVTISIDTSKTQFSLKLTSVTAADTAVYYCARSGFCSDDACYRRGSWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIDNYLNWYQQKPGKAPKLLIYAASGLQSGVPSRFSGSGSGTEFTLTVSSLHPEDFATYYCQQSYSTLTWTFGQGTKVEIK,6BLI_D,6BLI_E,Rsv G Peptide Bound To Fab Cb002.5,Rsv G Peptide Bound To Fab Cb002.5,Human respiratory syncytial virus (strain RSB6256),"Jones,H.G.;Ritschel,T.;Pascual,G.;Brakenhoff,J.P.;Keogh,E.;Furmanova-Hollenstein,P.;Lanckacker,E.;Wadia,J.S.;Gilman,M.S.;Williamson,R.A.;Roymans,D.;van 't,Wo.;Langedijk,J.P.;McLellan,J.S.",Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies,10-NOV-2017,8_7_20_6_3_10,6BLI_D_E,Xtal structure,RSV,4,1,16.108496,-7.7241797
7DR4_C_D,EVQLQQSGAELARPGASVKLSCKASGYTFTTYWIQWVKQRPGQGLEWIGAIYPGDGDTRYIQNFKGKATLTADKSSSTAYMQLSSLASEDSAVYYCARSLATRGFYAMDYWGQGTSVTVSS,DIVMTQSPASLSMAIGEKVTIRCITSTDIDDDMNWYQQKPGEPPKLLISEGNTLRPGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSDNLPYTFGGGTKLEIK,7DR4_C,7DR4_D,Complex Of Anti-Human Il-2 Antibody And Human Il-2,Complex Of Anti-Human Il-2 Antibody And Human Il-2,Homo sapiens,"Kim,J.;Lee,J.Y.;Park,S.Y.;Lee,Y.J.;Kim,M.S.","Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity",25-DEC-2020,8_8_14_6_3_9,UGP63720_UGP63721,Xtal structure,interleukin-2,4,1,0.38399372,-3.9016225
1OAX_J_N,EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNGGGTKYNLKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARMWYYGTYYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPRHLFTGLIGGTNNRAPGVPARFSGSLIGNKAALTITGAQTEDEAIYFCALWYSNHLVFGGGTKLTVL,1OAX_J,1OAX_N,Fv Structure Of The Ige Spe-7 In Complex With Acenaphthenequinone,Fv Structure Of The Ige Spe-7 In Complex With Acenaphthenequinone,Mus musculus,"James,L.C.;Roversi,P.;Tawfik,D.S.",Antibody multispecificity mediated by conformational diversity,21-JAN-2003,8_8_13_9_3_9,1OAX_J_N,Xtal structure,,4,1,-0.77628034,-3.830636
5W23_H_L,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTFFHWVKQRPEQGLEWIGRIDPADGHTKYDPKFQGKATITADTSSNTAFLQLSSLTSVDTAVYYCATTITAVVPTPYNAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRTTISCRASESVDSFDNSFIHWYQQKPGQPPKLLIFLASSLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQSNEDPFTFGSGTKLEIK,5W23_H,5W23_L,Crystal Structure Of Rsv F In Complex With 5C4 Fab,Crystal Structure Of Rsv F In Complex With 5C4 Fab,Mus musculus,"Tian,D.;Battles,M.B.;Moin,S.M.;Chen,M.;Modjarrad,K.;Kumar,A.;Kanekiyo,M.;Graepel,K.W.;Taher,N.M.;Hotard,A.L.;Moore,M.L.;Zhao,M.;Zheng,Z.Z.;Xia,N.S.;McLellan,J.S.;Graham,B.S.",Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein,05-JUN-2017,8_8_17_10_3_9,5W23_H_L,Xtal structure,,4,1,-4.7359614,0.19579335
2R29_H_L,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPANGYSKYDPKFQGKATITADTSSNAAYLQLSSLTSEDTAVYFCARDYEGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVVRYGNSFMHWYQQKPGQPPKLLIYRASSLESGIPTRFSGSGSRTDFTLTINPVEADDVATYYCQQTNVDPWAFGGGTKLEIK,2R29_H,2R29_L,Neutralization Of Dengue Virus By A Serotype Cross-Reactive Antibody Elucidated By Cryoelectron Microscopy And X-Ray Crystallography,Neutralization Of Dengue Virus By A Serotype Cross-Reactive Antibody Elucidated By Cryoelectron Microscopy And X-Ray Crystallography,Mus musculus,"Lok,S.M.;Kostyuchenko,V.;Nybakken,G.E.;Holdaway,H.A.;Battisti,A.J.;Sukupolvi-Petty,S.;Sedlak,D.;Fremont,D.H.;Chipman,P.R.;Roehrig,J.T.;Diamond,M.S.;Kuhn,R.J.;Rossmann,M.G.",Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins,24-AUG-2007,8_8_9_10_3_9,2R29_H_L,Xtal structure,DKFZP586F1318; SH3YL1; Dengue; dengue; Ray,4,1,-4.708819,0.16848388
4S1D_O_P,EVQLQQSGAELVKPGASVKLSCTSSGFNNKDTFFQWVKQRPEEGLEWIGRIDPANGFTKYDPKFQGKATITVDTSSNTAYLQLNSLTSEDTALYYCTRWDTYGAAWFAYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASGNIHNYLSWFQQKQGKSPQLLVYSAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGTYYCQHFWSSIYTFGGGTKLEIK,4S1D_O,4S1D_P,Structure Of Igg1 Fab Fragment In Complex With Biotincytidinamide,Structure Of Igg1 Fab Fragment In Complex With Biotincytidinamide,Mus musculus,"Dengl,S.;Hoffmann,E.;Grote,M.;Wagner,C.;Mundigl,O.;Georges,G.;Thorey,I.;Stubenrauch,K.G.;Bujotzek,A.;Josel,H.P.;Dziadek,S.;Benz,J.;Brinkmann,U.",Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies,13-JAN-2015,8_8_13_6_3_9,4S1D_O_P,Xtal structure,,4,1,-4.719523,0.18233563
7K9J_H_L,EVQLQQSGAELVKPGASVKMSCKASGYTFTSYWITWVKQRPGQGLEWIGDIYPGSGSTKYNEKFRSEATLTVDTSSTTAYMQLSSLTSEDSAVYYCARWDFYGSRTFDYWGQGTTLTVSS,DIVLTQSPAILSVSPGERVSFSCRASQNIGTIIHWYQQRTNGSPRLLIKYASESVSGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSSSWPLTFGAGTKLEL,7K9J_H,7K9J_L,Sars-Cov-2 Spike In Complex With Neutralizing Fab 2H04 (Three Down Conformation),Sars-Cov-2 Spike In Complex With Neutralizing Fab 2H04 (Three Down Conformation),Mus musculus,"Errico,J.M.;Zhao,H.;Chen,R.E.;Liu,Z.;Case,J.B.;Ma,M.;Schmitz,A.J.;Rau,M.J.;Fitzpatrick,J.A.;Shi,P.Y.;Diamond,M.S.;Whelan,S.P.;Ellebedy,A.H.;Fremont,D.H.",Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD,29-SEP-2020,8_8_13_6_3_9,7K9J_H_L,Xtal structure,SARS-CoV-2; RBD,4,1,-0.7460241,-4.0484962
8GNG_H_L,EVQLQQSGAELVKPGSSVKISCKTSGDSFTAYNMNWVKQSHGKSLEWIGNINPYYGSTRYNQKFKGKATLTVDKSSSTAYIQLNSLTSEDSAVYYCAREGNYYDGGSVRYFDYWGQGTTLTVSS,DIVMTQSPASLSASVGDTVTITCRASEFIYSSLTWYQQKQGGSPQLLVYAATNLADAVPSRFSGSGSGTQFSLKINRLQPEDFGTYYCQHFYGSTWAFGGGTKLEIK,8GNG_H,8GNG_L,Crystal Structure Of Human Adenosine A2A Receptor In Complex With Istradefylline.,Crystal Structure Of Human Adenosine A2A Receptor In Complex With Istradefylline.,Mus musculus,"Ohno,Y.;Suzuki,M.;Asada,H.;Kanda,T.;Saki,M.;Miyagi,H.;Yasunaga,M.;Suno,C.;Iwata,S.;Saito,J.I.;Uchida,S.","<i>In vitro</i> pharmacological profile of KW-6356, a novel adenosine A<sub>2A</sub> receptor antagonist/inverse agonist",22-MAR-2023,8_8_17_6_3_9,8GNG_H_L,Xtal structure,A2A,4,1,2.5675557,-4.045489
1AP2_D_C,EVQLQQSGAELVRPGASVKLSCTASGFNIKDDFMHWVKQRPEQGLEWIGRIDPANDNTKYAPKFQDKATIIADTSSNTAYLQLSSLTSEDTAVYYCARREVYSYYSPLDVWGAGTTVTVPS,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLE,1AP2_D,1AP2_C,Single Chain Fv Of C219,Single Chain Fv Of C219,Mus musculus,"Hoedemaeker,F.J.;Signorelli,T.;Johns,K.;Kuntz,D.A.;Rose,D.R.","A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219. Design, expression, and crystal structure at 2.4 A resolution",23-JUL-1997,8_8_14_12_3_9,1AP2_D_C,Xtal structure,,4,1,-4.6733193,0.13949372
12E8_H_L,EVQLQQSGAEVVRSGASVKLSCTASGFNIKDYYIHWVKQRPEKGLEWIGWIDPEIGDTEYVPKFQGKATMTADTSSNTAYLQLSSLTSEDTAVYYCNAGHDYDRGRFPYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLMIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELK,12E8_H,12E8_L,2E8 Fab Fragment,2E8 Fab Fragment,Mus musculus,"Trakhanov,S.;Parkin,S.;Raffai,R.;Milne,R.;Newhouse,Y.M.;Weisgraber,K.H.;Rupp,B.",Structure of a monoclonal 2E8 Fab antibody fragment specific for the low-density lipoprotein-receptor binding region of apolipoprotein E refined at 1.9 A,14-MAR-1998,8_8_13_6_3_9,12E8_H_L,Xtal structure,apolipoprotein,4,1,-4.915778,0.38043588
3WII_H_L,EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKLSHGKSLEWIGDIVPNNGDTTYNQNFRGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARFSNYVYPFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNFLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTISKLEQEDIATYFCQQGNTLPLTFGAGTKLELK,3WII_H,3WII_L,"Crystal Structure Of The Fab Fragment Of B2212A, A Murine Monoclonal Antibody Specific For The Third Fibronectin Domain (Fn3) Of Human Robo1.","Crystal Structure Of The Fab Fragment Of B2212A, A Murine Monoclonal Antibody Specific For The Third Fibronectin Domain (Fn3) Of Human Robo1.",Mus musculus,"Nakayama,T.;Mizohata,E.;Yamashita,T.;Nagatoishi,S.;Nakakido,M.;Iwanari,H.;Mochizuki,Y.;Kado,Y.;Yokota,Y.;Satoh,R.;Tsumoto,K.;Fujitani,H.;Kodama,T.;Hamakubo,T.;Inoue,T.","Structural features of interfacial tyrosine residue in ROBO1 fibronectin domain-antibody complex: Crystallographic, thermodynamic, and molecular dynamic analyses",12-SEP-2013,8_8_12_6_3_9,3WII_H_L,Xtal structure,ROBO1; FLJ21882; SAX3; DUTT1,4,1,2.4223235,-4.2035675
7WG3_E_A,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIHWVKQNHGKSLDWIGGINPNNGGTTYNQEFKGKATLTVDKSSSTAYMEFRSLTSEDSAVYYCARSYYGYVDYWGQGTTLTAAA,QIVLTQSPAIMSASPGEKVTMTCSASSSIYYIHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIK,7WG3_E,7WG3_A,Structural Basis Of Interleukin-17B Receptor In Complex With A Neutralizing Antibody D9 For Guiding Humanization And Affinity Maturation For Cancer Therapy,Structural Basis Of Interleukin-17B Receptor In Complex With A Neutralizing Antibody D9 For Guiding Humanization And Affinity Maturation For Cancer Therapy,Bos taurus,"Lee,W.H.;Chen,X.;Liu,I.J.;Lee,J.H.;Hu,C.M.;Wu,H.C.;Wang,S.K.;Lee,W.H.;Ma,C.",Structural basis of interleukin-17B receptor in complex with a neutralizing antibody for guiding humanization and affinity maturation,09-NOV-2022,8_8_10_5_3_9,7WG3_E_A,Xtal structure,interleukin,4,1,2.427936,-4.422315
6P67_E_F,EVQLQQSGPELVKPGASVKMSCKASGYTFSDYYMHWVKQSHGKSLEWIGYIYPDNGGNGYNQKFKGKATLTVDKSSSTVYMELRSLTSEDSALYYCARGTYYDGSYFDYWGQGTTLTVSS,DIVMTQSHKFMSTLVGDRVSITCKASQDVSTTVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSIPRTFGGGTKLEIK,6P67_E,6P67_F,Crystal Structure Of A Complex Of Human Il-7Ralpha With An Anti-Il-7Ralpha 2B8 Fab,Crystal Structure Of A Complex Of Human Il-7Ralpha With An Anti-Il-7Ralpha 2B8 Fab,Mus musculus,"Hixon,J.A.;Andrews,C.;Kashi,L.;Kohnhorst,C.L.;Senkevitch,E.;Czarra,K.;Barata,J.T.;Li,W.;Schneider,J.P.;Walsh,S.T.;Durum,S.K.",New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models,03-JUN-2019,8_8_13_6_3_9,QHX10755_QHX10756,Xtal structure,leukemia,4,1,2.4380963,-4.2326274
7M51_H_L,EVQLQQSGPVLVKPGASVRMSCKASGYTITDYYLNWVKQSHGKSLEWLGVLNPYSGGSLYSQTFKGKATLTVDRSSSTAYLELNSLTSEDSAVYYCARQLGRGNGLDYWGQGTSVTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSQSVLHSSDQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCHQYLSSYTFGGGTKLEIK,7M51_H,7M51_L,B6 Fab Fragment Bound To The Oc43 Spike Stem Helix Peptide,B6 Fab Fragment Bound To The Oc43 Spike Stem Helix Peptide,Mus musculus,"Sauer,M.M.;Tortorici,M.A.;Park,Y.J.;Walls,A.C.;Homad,L.;Acton,O.J.;Bowen,J.E.;Wang,C.;Xiong,X.;de van,de.;Quispe,J.;Hoffstrom,B.G.;Bosch,B.J.;McGuire,A.T.;Veesler,D.",Structural basis for broad coronavirus neutralization,22-MAR-2021,8_8_12_12_3_8,7M51_H_L,Xtal structure,,4,1,2.4304464,-4.248123
UVK70143_UVK70144,EVQLQQSGTVLARPGTSVKMSCKASGYSFTNYWMHWVKQRPGQGLEWIGSIYPGNSDTNYKQKFKGKAKLTAVTSASTAYMEVNSLTNEDSAVYYCTRFGNYVPFAYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTIGCRASQDIGSYLNWYQQKPDGAVRLLIYYTSRLHSGVPSRFSGSGSGTHFSLTISNLEQEDIGTYFCHQDTKPPYTFGSGTKLEIK,UVK70143,UVK70144,"Immunoglobulin IgG3 heavy chain variable region, partial [Mus musculus]","Immunoglobulin kappa light chain variable region, partial [Mus musculus]",Mus musculus,"Foreman,H.-C.C.; Frank,A.; Stedman,T.T.",5'-Rapid Amplification of cDNA End (RACE) & MiSeq-NGS determination of the variable region sequences from hybridoma-derived monoclonal antibodies against Mycobacterium tuberculosis virulence factors,31-AUG-2022,8_8_11_6_3_9,UVK70143_UVK70144,Unique source,AMACR; P504S; RACE; tuberculosis,4,1,2.6962545,-8.177713
6BZU_G_H,EVQLSESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGGNYYNPSLRSRISITRDTSKNHYYLQLNSVTTEDTATYYCARLSDSLYAMDCWGQGTSVTVSS,ELVLTQSPASLTVSLGQRATMSCRSSESVDAHGYSFLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYSCLKNNEDPWTFGGGTKLEIT,6BZU_G,6BZU_H,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Broadly Neutralizing Antibody 19B3,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Broadly Neutralizing Antibody 19B3,Hepacivirus C,"Aleman,F.;Tzarum,N.;Kong,L.;Nagy,K.;Zhu,J.;Wilson,I.A.;Law,M.",Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors,26-DEC-2017,8_7_12_10_3_9,6BZU_G_H,Xtal structure,Hepatitis; Antigenic; HCV,4,1,10.7018385,-12.8374195
6BZV_C_D,EVQLSESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARLYDGYYAMDYWGQGTSVTVSS,ELVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK,6BZV_C,6BZV_D,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Gl Precursor Of The Broadly Neutralizing Antibody 19B3,Structure Of The Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Region 412-423 Bound To The Gl Precursor Of The Broadly Neutralizing Antibody 19B3,Hepacivirus C,"Aleman,F.;Tzarum,N.;Kong,L.;Nagy,K.;Zhu,J.;Wilson,I.A.;Law,M.",Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors,26-DEC-2017,8_7_12_10_3_9,6BZV_C_D,Xtal structure,Hepatitis; Antigenic; HCV,4,1,10.720818,-12.824255
5DQ9_A_B,EVQLVESGGDLVKPGGSLKLSCAGSGITFSGYGMSWVRQTPDKSLEWVALISNGGSYAYYSDSVKGRFTISRDNAKNTLYLQMSSLRSDDTAIYYCARHKGLRGGTNAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATIFCRASETVDSYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPRTFGGGTKLEIK,5DQ9_A,5DQ9_B,Structure Of S55-3 Fab In Complex With Lipid A,Structure Of S55-3 Fab In Complex With Lipid A,Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Rodriguez,T.;Bra,L.;Kosma,P.;Brade,H.;Evans,S.V.",Lipid A-Antibody Structures Reveal A Widely-Utilize Specific For Negatively Charged Groups Derived From Unrelated V-Genes,14-SEP-2015,8_8_15_10_3_9,5DQ9_A_B,Xtal structure,,4,1,17.748571,7.179898
UID86192_UID86189,EVQLVESGGDLVQPGGSLRLSCVVSGFTFSTYSMNWVRQAPGKGLEWVSYISSSSLSRYYADSVKGRFTISRDNAKNSLSLQLNSLRAEDTAVYYCVRGSITWPTEYYLDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQTIRSDLAWYQQKPGQPPRLIIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDSAVYFCQQYNNWPPLTFGGGTKVEIK,UID86192,UID86189,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Guthmiller,J.J.; Han,J.; Utset,H.A.; Li,L.; Lan,L.Y.-L.; Henry,C.; Stamper,C.T.; McMahon,M.; O'Dell,G.; Fernandez-Quintero,M.L.; Freyn,A.W.; Amanat,F.; Stovicek,O.; Gentles,L.; Richey,S.T.; de la Pena,A.T.; Rosado,V.; Dugan,H.L.; Zheng,N.-Y.; Tepora,M.E.; Bitar,D.J.; Changrob,S.; Strohmeier,S.; Huang,M.; Garcia-Sastre,A.; Liedl,K.R.; Bloom,J.D.; Nachbagauer,R.; Palese,P.; Krammer,F.; Coughlan,L.; Ward,A.B.; Wilson,P.C.",Broadly neutralizing antibodies target a hemagglutinin anchor epitope,11-JAN-2022,8_8_15_6_3_10,UID86192_UID86189,Unique source,hemagglutinin,4,1,15.810608,9.873379
QYB25424_QYB25494,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYYYGMDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQFNSYPHFGPGTKVDIK,QYB25424,QYB25494,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Chen,E.C.; Gilchuk,P.; Zost,S.J.; Suryadevara,N.; Winkler,E.S.; Cabel,C.R.; Binshtein,E.; Chen,R.; Sutton,R.E.; Rodriguez,J.; Day,S.; Myers,L.; Trivette,A.; Williams,J.K.; Davidson,E.; Li,S.; Doranz,B.J.; Campos,S.K.; Carnahan,R.H.; Thorne,C.A.; Diamond,M.S.; Crowe,J.E.",Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals,02-AUG-2021,8_7_11_6_3_8,QYB25424_QYB25494,Unique source,SARS-CoV-2,4,1,12.656131,10.697876
7LKA_C_D,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGTGLFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLDSYPPGTFGPGTKVDIK,7LKA_C,7LKA_D,Crystal Structure Of Sars-Cov-2 Rbd-Targeting Antibody Cov107-23,Crystal Structure Of Sars-Cov-2 Rbd-Targeting Antibody Cov107-23,Homo sapiens,"Tan,T.J.C.;Yuan,M.;Kuzelka,K.;Padron,G.C.;Beal,J.R.;Chen,X.;Wang,Y.;Rivera-Cardona,J.;Zhu,X.;Stadtmueller,B.M.;Brooke,C.B.;Wilson,I.A.;Wu,N.C.",Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain,02-FEB-2021,8_7_11_6_3_10,7LKA_C_D,Xtal structure,IGHV3-53; SARS-CoV-2,4,1,12.5826025,10.310422
6E62_H_L,EVQLVESGGGLLQPGRSLKLSCVASGFTFNNYWMSWIRQAPGKGLEWIASISNIGGTIYYPDSVKGRFTISRDSAQNTLYLQMNSLRSEDTATYYCTRDLRMSDYFDYWGQGTMVTVSS,QFVLSQPNSVSTNLGSTVKLLCKRSTGNIGSNYVSWYQHHEGRSPTTMIYRDDQRPDGVPDRFSGSIDRSSNSALLTIDNVQTEDEAAYFCHSYSTGMYIFGGGTKLTVL,6E62_H,6E62_L,Crystal Structure Of Malaria Transmission-Blocking Antigen Pfs48/45 6C In Complex With Antibody 85Rf45.1,Crystal Structure Of Malaria Transmission-Blocking Antigen Pfs48/45 6C In Complex With Antibody 85Rf45.1,Rattus norvegicus,"Kundu,P.;Semesi,A.;Jore,M.M.;Morin,M.J.;Price,V.L.;Liang,A.;Li,J.;Miura,K.;Sauerwein,R.W.;King,C.R.;Julien,J.P.",Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45,23-JUL-2018,8_8_12_8_3_9,6E62_H_L,Xtal structure,,4,1,14.72102,9.169572
2LTQ_C_B,EVQLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTPEKRLEWVAYISSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARPDYRSYAMDYWGQGTSVTVSS,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLYTFGGGTKLEIK,2LTQ_C,2LTQ_B,High Resolution Structure Of Dsbb C41S By Joint Calculation With Solid-State Nmr And X-Ray Data,High Resolution Structure Of Dsbb C41S By Joint Calculation With Solid-State Nmr And X-Ray Data,Mus musculus,"Tang,M.;Nesbitt,A.E.;Sperling,L.J.;Berthold,D.A.;Schwieters,C.D.;Gennis,R.B.;Rienstra,C.M.",Structure of the disulfide bond generating membrane protein DsbB in the lipid bilayer,30-MAY-2012,8_8_12_12_3_8,2LTQ_F_E,Xtal structure,SH3YL1; DKFZP586F1318; Ray,4,1,17.856041,6.913408
QFQ61658_QFQ61810,EVQLVESGGGLVKPGGSLRLSCAASGFSFGNAWMNWVRQAPGKGLEWVGRIKSKSDGGTTDYAAPVKDRFIISRDDSKKTLYLQMNSLRREDTAVYYCVRGPFYCDTCGPNDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVQWYQQLPGTAPKVLIYGNNNRPSGVPDRFSGSKSGSSASLAITGLQAEDEADYYCQTYDSRLRDQWVFGGGTKLTVL,QFQ61658,QFQ61810,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehrhardt,S.A.; Zehner,M.; Krahling,V.; Cohen-Dvashi,H.; Kreer,C.; Elad,N.; Gruell,H.; Ercanoglu,M.S.; Schommers,P.; Gieselmann,L.; Eggeling,R.; Dahlke,C.; Wolf,T.; Pfeifer,N.; Addo,M.M.; Diskin,R.; Becker,S.; Klein,F.",Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV,23-OCT-2019,8_10_15_9_3_12,QFQ61658_QFQ61810,Unique source,Ebola,4,1,12.945185,8.529616
QFQ61538_QFQ61690,EVQLVESGGGLVKPGGSLRLSCAASGFTFRNAWMNWVRQAPGKGLEWVGRIKSRADGGPTDYAAPVKGRFTISRDDSKNTLYLQMNSLKSEDTAVYYCTTHVPDYNSAYYWVYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVYWYQQLPGTAPKLIIYGNNNRPSGVPDRFSASKSGPSASLAITGLQAEDEADYYCQSYDIRLSDNYVFGTGTKVTVL,QFQ61538,QFQ61690,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehrhardt,S.A.; Zehner,M.; Krahling,V.; Cohen-Dvashi,H.; Kreer,C.; Elad,N.; Gruell,H.; Ercanoglu,M.S.; Schommers,P.; Gieselmann,L.; Eggeling,R.; Dahlke,C.; Wolf,T.; Pfeifer,N.; Addo,M.M.; Diskin,R.; Becker,S.; Klein,F.",Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV,23-OCT-2019,8_10_15_9_3_12,QFQ61538_QFQ61690,Unique source,Ebola,4,1,12.916143,8.547032
5IJK_B_D,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWFNWVRQAPGKGLEWVGRIKTNTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTGEPLVNHITILDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYRTPPLTFGGGTKVEIK,5IJK_B,5IJK_D,Crystal Structure Of Anti-Gliadin 1002-1E03 Fab Fragment In Complex Of Peptide Plqpeqpfp,Crystal Structure Of Anti-Gliadin 1002-1E03 Fab Fragment In Complex Of Peptide Plqpeqpfp,Homo sapiens,"Snir,O.;Chen,X.;Gidoni,M.;du Pre,M.F.;Zhao,Y.;Steinsbo,O.;Lundin,K.E.;Yaari,G.;Sollid,L.M.",Stereotyped antibody responses target posttranslationally modified gluten in celiac disease,02-MAR-2016,8_10_15_12_3_10,5IJK_B_D,Xtal structure,Gliadin,4,1,12.974186,8.502482
5JO5_A_B,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSS,SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,5JO5_A,5JO5_B,Crystal Structure Of 10E8 Ghv-Glv Antigen-Binding Fragment.,Crystal Structure Of 10E8 Ghv-Glv Antigen-Binding Fragment.,Homo sapiens,"Soto,C.;Ofek,G.;Joyce,M.G.;Zhang,B.;McKee,K.;Longo,N.S.;Yang,Y.;Huang,J.;Parks,R.;Eudailey,J.;Lloyd,K.E.;Alam,S.M.;Haynes,B.F.;Mullikin,J.C.;Connors,M.;Mascola,J.R.;Shapiro,L.;Kwong,P.D.",Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8,02-MAY-2016,8_10_22_6_3_12,5JO5_A_B,Xtal structure,HIV,4,1,12.926474,8.540429
6APD_J_L,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGYCSGGSCHFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGFYVFGTGTKVTVL,6APD_J,6APD_L,Crystal Structure Of Rsv F Bound By Am22 And The Infant Antibody Adi-19425,Crystal Structure Of Rsv F Bound By Am22 And The Infant Antibody Adi-19425,Homo sapiens,"Goodwin,E.;Gilman,M.S.;Wrapp,D.;Chen,M.;Ngwuta,J.O.;Moin,S.M.;Bai,P.;Sivasubramanian,A.;Connor,R.I.;Wright,P.F.;Graham,B.S.;McLellan,J.S.;Walker,L.M.",Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation,17-AUG-2017,8_8_15_9_3_12,6APD_J_L,Xtal structure,,4,1,16.061554,10.044314
6WOZ_E_F,EVQLVESGGGLVKPGGSLRLSCEASGFLFSSYSMNWVRQAPGKGLEWVSSITGYSSEVFYTDSVKGRFTVSRDNSKNSLYLQMDSLRAEDTAVYYCARALTIFGVVITDYWFFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGDRATLSCRASQSVTTFLAWYQQKPGQAPRLLIYDVSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWGLTFGGGTKVEIK,6WOZ_E,6WOZ_F,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 251249,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 251249,Plasmodium vivax Sal-1,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,26-APR-2020,8_8_19_6_3_9,6WOZ_E_F,Xtal structure,,4,1,16.14341,10.051951
7SI0_I_J,EVQLVESGGGLVQPDGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASVTYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDSDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,7SI0_I,7SI0_J,Ige-Fc In Complex With 813,Ige-Fc In Complex With 813,Homo sapiens,"Pennington,L.F.;Gasser,P.;Kleinboelting,S.;Zhang,C.;Skiniotis,G.;Eggel,A.;Jardetzky,T.S.",Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex,12-OCT-2021,9_7_14_10_3_9,7SI0_I_J,Xtal structure,,4,1,11.731185,10.509796
2FL5_H_L,EVQLVESGGGLVQPGESLKLSCTASGFSLSNYYMTWVRQAPGKGLEWVTNIRPDETEKFYSDSVKGRFTVSRDNARNSLFNSMSLQRVEDTATYYCARVSDFGDYGPDFWGQGTLVSVTS,YELKQPPSVSVSPGQTARITCSGDVLPKKYAYWYQERSGQAPVLVVYEDSGRPSEIPERFSGSSSGTKATLTISGAQVEDEADYYCYSDISNGYPLFGGGTKLSV,2FL5_H,2FL5_L,Cofactor-Containing Antibodies: Crystal Structure Of The Original Yellow Antibody,Cofactor-Containing Antibodies: Crystal Structure Of The Original Yellow Antibody,Homo sapiens,"Zhu,X.;Wentworth P,Jr.;Kyle,R.A.;Lerner,R.A.;Wilson,I.A.",Cofactor-containing antibodies: crystal structure of the original yellow antibody,05-JAN-2006,8_8_13_6_3_10,2FL5_H_L,Xtal structure,,4,1,11.228559,7.8687596
7XSB_H_L,EVQLVESGGGLVQPGGSLRISCAASGLTFTGYWMNWVRQAPGKGLEWVANIKEDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARLRWLRGNFDHWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTGSNGYIANNYVQWYQQRPGSVPTVVIYEDNQRPSGVPDRFSGSIDSSSNSASLIISGLKTEDEADYYCQSYDTPNVVFGGGTKLTVL,7XSB_H,7XSB_L,Crystal Structure Of Sars-Cov-2 Spike Receptor Binding Domain Bound With P5S-3B11 Fab,Crystal Structure Of Sars-Cov-2 Spike Receptor Binding Domain Bound With P5S-3B11 Fab,Homo sapiens,"Ju,B.;Zhang,Q.;Wang,Z.;Aw,Z.Q.;Chen,P.;Zhou,B.;Wang,R.;Ge,X.;Lv,Q.;Cheng,L.;Zhang,R.;Wong,Y.H.;Chen,H.;Wang,H.;Shan,S.;Liao,X.;Shi,X.;Liu,L.;Chu,J.J.H.;Wang,X.;Zhang,Z.;Zhang,L.",Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants,10-MAY-2023,8_8_12_8_3_9,7XSB_H_L,Xtal structure,SARS-CoV-2,4,1,11.082425,7.7284846
7UAQ_H_L,EVQLVESGGGLVQPGGSLRLACVASGFTFSIYEMNWVRQAPGKGLEWVSYITTSGHARYNADSVKGRFTISRDNSKNSFYLQMNSLRAEDTAIYYCARPQYHYYDTSTYHSYGFDIWGQGTMVTVSS,QLVLTQSPSASASLGASVNLTCTLSSGHNSYAIAWHQQQPEKGPRYLMSLNSDGSHTKGDGIPDRFSGSSSGAERFLTISSLQSEDEADYYCQTWDTGIRVFGGGTRLTVL,7UAQ_H,7UAQ_L,"Structure Of The Sars-Cov-2 Ntd In Complex With C1520, Local Refinement","Structure Of The Sars-Cov-2 Ntd In Complex With C1520, Local Refinement",Homo sapiens,"Wang,Z.;Muecksch,F.;Cho,A.;Gaebler,C.;Hoffmann,H.H.;Ramos,V.;Zong,S.;Cipolla,M.;Johnson,B.;Schmidt,F.;DaSilva,J.;Bednarski,E.;Ben Tanfous,T.;Raspe,R.;Yao,K.;Lee,Y.E.;Chen,T.;Turroja,M.;Milard,K.G.;Dizon,J.;Kaczynska,A.;Gazumyan,A.;Oliveira,T.Y.;Rice,C.M.;Caskey,M.;Bieniasz,P.D.;Hatziioannou,T.;Barnes,C.O.;Nussenzweig,M.C.",Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins,13-MAR-2022,8_8_20_7_7_9,7UAQ_H_L,Xtal structure,SARS,4,1,16.084444,10.008525
7E88_D_E,EVQLVESGGGLVQPGGSLRLSCAASEFIVSRNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTGVYYCARDRGLVSDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINKYLNWYQQKPGKAPKLLIFDASHLETGVPSRFSASGSGTDFTFTISSLQPEDIATYYCHQYDNLPRTFGQGTRLEIK,7E88_D,7E88_E,Crystal Structure Of The Sars-Cov-2 S Rbd In Complex With Bd-515 Fab,Crystal Structure Of The Sars-Cov-2 S Rbd In Complex With Bd-515 Fab,Severe acute respiratory syndrome coronavirus 2,"Cao,Y.;Yisimayi,A.;Bai,Y.;Huang,W.;Li,X.;Zhang,Z.;Yuan,T.;An,R.;Wang,J.;Xiao,T.;Du,S.;Ma,W.;Song,L.;Li,Y.;Li,X.;Song,W.;Wu,J.;Liu,S.;Li,X.;Zhang,Y.;Su,B.;Guo,X.;Wei,Y.;Gao,C.;Zhang,N.;Zhang,Y.;Dou,Y.;Xu,X.;Shi,R.;Lu,B.;Jin,R.;Ma,Y.;Qin,C.;Wang,Y.;Feng,Y.;Xiao,J.;Xie,X.S.",Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines,01-MAR-2021,8_7_10_6_3_9,7E88_D_E,Xtal structure,SARS-CoV-2; RBD,4,1,12.60345,10.310941
5C8J_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVASISPSYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGIWSYWYMVYPHDNYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSRPVTFGQGTKVEIK,5C8J_A,5C8J_B,A Yidc-Like Protein In The Archaeal Plasma Membrane,A Yidc-Like Protein In The Archaeal Plasma Membrane,Methanocaldococcus jannaschii DSM 2661,"Borowska,M.T.;Dominik,P.K.;Anghel,S.A.;Kossiakoff,A.A.;Keenan,R.J.",A YidC-like Protein in the Archaeal Plasma Membrane,25-JUN-2015,8_8_21_6_3_9,5C8J_A_B,Xtal structure,,4,1,9.56922,10.832852
5TDP_D_C,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVREAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQKKPGKAPKLLIYSASFLESGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,5TDP_D,5TDP_C,Crystal Structure Of The Fab Fragment Of Anti-Her2 Antibody 4D5 With Redesigned Heavy And Light Chain Interfaces,Crystal Structure Of The Fab Fragment Of Anti-Her2 Antibody 4D5 With Redesigned Heavy And Light Chain Interfaces,Homo sapiens,"Yin,Y.;Carter,P.J.",Crystal Structure Of The Fab Fragment Of Anti-Her2 4d5 With Redesigned Heavy And Light Chain Interface,19-SEP-2016,8_8_13_6_3_9,5TDP_D_C,Xtal structure,Her2,4,1,10.274048,11.06229
7KF1_D_E,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAKLGIGYYYYGMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIPRSISGYVAWYQQKPGKAPKLLIYWGSYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,7KF1_D,7KF1_E,Crystal Structure Of Bh1 Fab Variant (Cdr H3 Loop Design 14_0130) In Complex With Vegf,Crystal Structure Of Bh1 Fab Variant (Cdr H3 Loop Design 14_0130) In Complex With Vegf,Homo sapiens,"Corbeil,C.;Manenda,M.S.;Sulea,T.;Baardsness,J.;Picard,M.-E.;Hogues,H.;Gaudreault,F.;Deprez,C.;Shi,R.;Purisima,E.O.",ADAPTing Antibody H3 Loops to Cognate Antigens Using Human Germline Derived Sequences,13-OCT-2020,8_8_14_10_3_9,7KF1_D_E,Xtal structure,,4,1,10.27413,11.079604
7KBP_C_C,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLTACDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,7KBP_C,7KBP_C,"Herceptin Diabody With R83T, E85C Mutations","Herceptin Diabody With R83T, E85C Mutations",Homo sapiens,"Chesterman,C.;Arnold,E.",Co-crystallization with diabodies: A case study for the introduction of synthetic symmetry,02-OCT-2020,8_8_13_6_3_9,7KBP_C_C,Xtal structure,,4,1,10.232833,11.038515
5BJZ_D_H,EVQLVESGGGLVQPGGSLRLSCAASGFNLSSSSIHWVRQAPGKGLEWVASIYSYYGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCAREYHSYWSYSWWPRVGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQASLTALLTFGQGTKVEIK,5BJZ_D,5BJZ_H,Crystal Structure Of Maltose Binding Protein In Complex With An Allosteric Synthetic Antibody,Crystal Structure Of Maltose Binding Protein In Complex With An Allosteric Synthetic Antibody,Homo sapiens,"Mukherjee,S.;Griffin,D.H.;Horn,J.R.;Rizk,S.S.;Nocula-Lugowska,M.;Malmqvist,M.;Kim,S.S.;Kossiakoff,A.A.",Engineered synthetic antibodies as probes to quantify the energetic contributions of ligand binding to conformational changes in proteins,12-SEP-2017,8_8_20_6_3_10,5BJZ_D_H,Xtal structure,,4,1,9.519011,10.90659
6W51_O_P,EVQLVESGGGLVQPGGSLRLSCAASGFNVYASGMHWVRQAPGKGLEWVAKIYPDSDYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRDSSFYYVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSAYFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSRYSPVTFGQGTKVEIK,6W51_O,6W51_P,Structure Of The Antibody Fragment H2 In Complex With Hla-A*02:01/P53R175H,Structure Of The Antibody Fragment H2 In Complex With Hla-A*02:01/P53R175H,Homo sapiens,"Hsiue,E.H.;Wright,K.M.;Douglass,J.;Hwang,M.S.;Mog,B.J.;Pearlman,A.H.;Paul,S.;DiNapoli,S.R.;Konig,M.F.;Wang,Q.;Schaefer,A.;Miller,M.S.;Skora,A.D.;Azurmendi,P.A.;Murphy,M.B.;Liu,Q.;Watson,E.;Li,Y.;Pardoll,D.M.;Bettegowda,C.;Papadopoulos,N.;Kinzler,K.W.;Vogelstein,B.;Gabelli,S.B.;Zhou,S.",Targeting a neoantigen derived from a common TP53 mutation,12-MAR-2020,8_8_14_6_3_10,6W51_O_P,Xtal structure,p53; TP53; LFS1,4,1,9.808236,10.711804
4G80_G_H,EVQLVESGGGLVQPGGSLRLSCAASGFNVYYSSIHWVRQAPGKGLEWVAYISPSSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARKQYSYWRDSYWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHQYNSLIFGQGTKVEIK,4G80_G,4G80_H,"Crystal Structure Of Voltage Sensing Domain Of Ci-Vsp With Fragment Antibody (Wt, 3.8 A)","Crystal Structure Of Voltage Sensing Domain Of Ci-Vsp With Fragment Antibody (Wt, 3.8 A)",Ciona intestinalis,"Li,Q.;Wanderling,S.;Paduch,M.;Medovoy,D.;Singharoy,A.;McGreevy,R.;Villalba-Galea,C.A.;Hulse,R.E.;Roux,B.;Schulten,K.;Kossiakoff,A.;Perozo,E.",Structural mechanism of voltage-dependent gating in an isolated voltage-sensing domain,20-JUL-2012,8_8_17_6_3_9,4G80_G_H,Xtal structure,,4,1,9.726732,10.8111925
5VZ1_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFNVYYYYIHWVRQAPGKGLEWVASISPYYGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWSYDQSMSYKSGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSYSLVTFGQGTKVEIK,5VZ1_B,5VZ1_A,"Crystal Structure Of The Apo Antibody Fragment (Fab) Raised Against C-Terminal Domain Of Ebola Nucleoprotein (Ebov, Tafv, Bdbv Strains)","Crystal Structure Of The Apo Antibody Fragment (Fab) Raised Against C-Terminal Domain Of Ebola Nucleoprotein (Ebov, Tafv, Bdbv Strains)",Homo sapiens,"Radwanska,M.J.;Derewenda,U.;Kossiakoff,A.;Derewenda,Z.S.","Crystal structure of the Apo Antibody fragment (Fab) raised against C-terminal domain of Ebola nucleoprotein (EBOV, TAFV, BDBV strains)",26-MAY-2017,8_8_17_6_3_9,5VZ1_B_A,Xtal structure,EBOV; Ebola,4,1,9.675111,10.777665
6VUG_D_C,EVQLVESGGGLVQPGGSLRLSCAASGFSLSTSGIGVTWVRQAPGKGLEWLATIWWDDDNRYADSVKGRFTISADTSKNTAYLQMNCLTAEDTAVYYCAQSAITSVTDSAMDHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSKFPWTFGQGTKVEIK,6VUG_D,6VUG_C,Diabody Bound To A Reverse Transcriptase Aptamer Complex,Diabody Bound To A Reverse Transcriptase Aptamer Complex,Homo sapiens,"Chesterman,C.;Arnold,E.",Co-crystallization with diabodies: A case study for the introduction of synthetic symmetry,17-FEB-2021,10_7_15_6_3_9,6VUG_D_C,Xtal structure,,4,1,9.972009,10.614662
3HR5_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK,3HR5_B,3HR5_A,M1Prime Peptide From Ige Bound By Humanized Antibody 47H4 Fab,M1Prime Peptide From Ige Bound By Humanized Antibody 47H4 Fab,Homo sapiens,"Brightbill,H.D.;Jeet,S.;Lin,Z.;Yan,D.;Zhou,M.;Tan,M.;Nguyen,A.;Yeh,S.;Delarosa,D.;Leong,S.R.;Wong,T.;Chen,Y.;Ultsch,M.;Luis,E.;Ramani,S.R.;Jackman,J.;Gonzalez,L.;Dennis,M.S.;Chuntharapai,A.;DeForge,L.;Meng,Y.G.;Xu,M.;Eigenbrot,C.;Lee,W.P.;Refino,C.J.;Balazs,M.;Wu,L.C.",Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice,08-JUN-2009,8_8_10_11_3_9,AEW31668_AEW31658,Xtal structure,,4,1,14.962819,9.676167
CAR97162_CAR97163,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,CAR97162,CAR97163,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Cooreman,M.; di Padova,F.E.",Il-17 antagonistic antibodies,01-NOV-2008,8_8_20_7_3_9,CAR97162_CAR97163,Unique chain,,4,1,11.143161,7.7900558
7TUS_G_H,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQSPEKGLEWVSEIRLRSDNYATHYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTGIYYCCTYFYSFSYWGQGTLVTVSS,ELQMTQSPSSLSASVGDRVTITCRSSQSLLHTYGSPYLNWYLQKPGQSPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYFCSQGTHLPYTFGGGTKVEIK,7TUS_G,7TUS_H,Sculpting A Uniquely Reactive Cysteine Residue For Site-Specific Antibody Conjugation,Sculpting A Uniquely Reactive Cysteine Residue For Site-Specific Antibody Conjugation,Homo sapiens,"Hwang,D.;Nilchan,N.;Park,H.;Roy,R.N.;Roush,W.R.;Rader,C.",Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation,03-FEB-2022,8_10_9_11_3_9,7TUS_G_H,Xtal structure,,4,1,13.441836,7.5435214
7X8T_C_B,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFNMFWVRQAPGKGLEWVAGIDDDGSYPNYGSAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKSGYGGSWGGYIADDIDAWGQGTLVTVSS,ELTQPPSVSVSPGQTARITCSGDGSYAGSYYYGWYQQKPGQAPVTLIYYNNKRPSGIPERFSGSLSGSTNTLTISGVQAEDEADYYCGSADNSGAAFGGGTKLTVL,7X8T_C,7X8T_B,Frizzled 10 Crd In Complex With Hb9L9.3 Fab,Frizzled 10 Crd In Complex With Hb9L9.3 Fab,Homo sapiens,"Ge,Q.;Teng,M.;Li,X.;Guo,Q.;Tao,Y.",An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies,01-FEB-2023,8_8_19_8_3_9,AOB46190_AOB46188,Xtal structure,,4,1,14.059879,10.431105
6CYF_F_E,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMDWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYFYGMDVWGQGTTVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIK,6CYF_F,6CYF_E,Pcrv Fragment With Bound Fab,Pcrv Fragment With Bound Fab,Homo sapiens,"Tabor,D.E.;Oganesyan,V.;Keller,A.E.;Yu,L.;McLaughlin,R.E.;Song,E.;Warrener,P.;Rosenthal,K.;Esser,M.;Qi,Y.;Ruzin,A.;Stover,C.K.;DiGiandomenico,A.","Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates",05-APR-2018,8_8_17_6_3_9,6CYF_F_E,Xtal structure,PcrV,4,1,13.674017,9.9768305
6TXZ_J_N,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISVSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKANWGFFDYWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYADSVVFGGGTKVTVL,6TXZ_J,6TXZ_N,Fab Part Of M6903 In Complex With Human Tim3,Fab Part Of M6903 In Complex With Human Tim3,Homo sapiens,"Zhang,D.;Jiang,F.;Zaynagetdinov,R.;Huang,H.;Sood,V.D.;Wang,H.;Zhao,X.;Jenkins,M.H.;Ji,Q.;Wang,Y.;Nannemann,D.P.;Musil,D.;Wesolowski,J.;Paoletti,A.;Bartholomew,T.;Derner,M.G.;An,Q.;Iffland,C.;Halle,J.P.","Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody",08-APR-2020,8_8_10_9_3_8,6TXZ_J_N,Xtal structure,P60; GEF5; ARHGEF5; TIM; TIM1,4,1,14.197353,9.76873
CCA64142_CCA64143,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCVRDKRTVTHEHYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSSLAWYQQKPGQAPGLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPMCSFGQGTKLEIK,CCA64142,CCA64143,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"TAKASHI,T.; KATSUNARI,T.; NOBUAKI,H.",Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof,19-APR-2011,8_7_19_7_3_10,CCA64142_CCA64143,Ordered entries,AILIM; CD278; ICOS,4,1,16.419384,11.64216
CCA64140_CCA64141,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCVRDNRKVTHEHYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQNIRSSYLAWYQQKPGQAPGLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPMCSFGQGTKLEIK,CCA64140,CCA64141,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"TAKASHI,T.; KATSUNARI,T.; NOBUAKI,H.",Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof,19-APR-2011,8_7_19_7_3_10,CCA64140_CCA64141,Ordered entries,AILIM; CD278; ICOS,4,1,16.4473,11.641044
7DK2_D_E,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDASEKYYLDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLGILWFGDYPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNSLAWYQQKPGKAPKLLLYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSTPRTFGQGTKVEIK,7DK2_D,7DK2_E,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Mw07 Fab,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Mw07 Fab,Severe acute respiratory syndrome coronavirus 2,"Sun,Y.;Liu,F.J.;Guo,H.T.;Wang,J.;Wang,R.;Zhang,M.;Wang,M.;Chen,S.",Architectural versatility of spike neutralization by a SARS-CoV-2 antibody,22-NOV-2020,8_8_13_6_3_9,7DK2_D_E,Xtal structure,SARS-CoV-2,4,1,11.138022,7.8000736
5VSH_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRYAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQRKPGDAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,5VSH_C,5VSH_D,Ch1/Clambda Fab Based On Pertuzumab,Ch1/Clambda Fab Based On Pertuzumab,Homo sapiens,"Froning,K.J.;Leaver-Fay,A.;Wu,X.;Phan,S.;Gao,L.;Huang,F.;Pustilnik,A.;Bacica,M.;Houlihan,K.;Chai,Q.;Fitchett,J.R.;Hendle,J.;Kuhlman,B.;Demarest,S.J.",Computational design of a specific heavy chain/kappa light chain interface for expressing fully IgG bispecific antibodies,11-MAY-2017,8_8_12_6_3_9,5VSH_C_D,Xtal structure,,4,1,11.041209,10.408934
3P0Y_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWLGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDLATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,3P0Y_H,3P0Y_L,Anti-Egfr/Her3 Fab Dl11 In Complex With Domain Iii Of Egfr Extracellular Region,Anti-Egfr/Her3 Fab Dl11 In Complex With Domain Iii Of Egfr Extracellular Region,Homo sapiens,"Schaefer,G.;Haber,L.;Crocker,L.M.;Shia,S.;Shao,L.;Dowbenko,D.;Totpal,K.;Wong,A.;Lee,C.V.;Stawicki,S.;Clark,R.;Fields,C.;Lewis Phillips,G.D.;Prell,R.A.;Danilenko,D.M.;Franke,Y.;Stephan,J.P.;Hwang,J.;Wu,Y.;Bostrom,J.;Sliwkowski,M.X.;Fuh,G.;Eigenbrot,C.",A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies,29-SEP-2010,8_8_14_6_3_9,APN71945_APN71944,Xtal structure,LCCS2; ERBB; EGFR; ERBB1; HER3; ERBB3; ERRP,4,1,10.148935,10.792811
7XEG_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFTVGWNYMSWVRQAPGKGLEWVSVIYPGGTTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQNIERYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSASSTPEYTFGQGTKLEIK,7XEG_C,7XEG_D,Sars-Cov-2-Beta-Rbd And Cb6-092-Fab Complex,Sars-Cov-2-Beta-Rbd And Cb6-092-Fab Complex,Homo sapiens,"Wang,Y.;Feng,Y.",SARS-CoV-2-Beta-RBD and CB6-092-Fab complex,31-MAY-2023,8_7_13_6_3_11,7XEG_C_D,Xtal structure,SARS-CoV-2; RBD,4,1,12.744646,10.248964
UIK23795_UIK23951,EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMRWVRQAPGKGLEWVSLIYAGGSTFYADSVKGRFIISRHNSKNILYLQMNSLRAEDTAVYFCARDLYVFGMDVWGQGTAVTVSA,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGRAPKLLIYAASTLQSGVPSRFSGSGSGTVFTLTISSLQPEDFATYYCQQLNSDSSTFGQGTKLEIK,UIK23795,UIK23951,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Vanshylla,K.; Fan,C.; Wunsch,M.; Poopalasingam,N.; Meijers,M.; Kreer,C.; Kleipass,F.; Ruchnewitz,D.; Ercanoglu,M.S.; Gruell,H.; Munn,F.; Pohl,K.; Janicki,H.; Nolden,T.; Bartl,S.; Stein,S.C.; Augustin,M.; Dewald,F.; Gieselmann,L.; Schommers,P.; Schulz,T.F.; Sander,L.E.; Koch,M.; Luksza,M.; Lassig,M.; Bjorkman,P.J.; Klein,F.",Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers,13-JAN-2022,8_7_11_6_3_9,UIK23795_UIK23951,Unique source,SARS-CoV-2,4,1,12.524567,10.767262
6XSW_A_B,EVQLVESGGGLVQPGGSLRLSCAASGYAFTDYWMTWVRQAPGKGLEWVAEISPNSGGTNFNEKFKGRFTISVDNAKNSLYLQMNSLRAEDTAVYYCARGEIRYNWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGNNIAWYQQKPGKAPKLLIYYASNRYTGVPSRFSGSGYGTDFTLTISSLQPEDFATYYCQRLYNSPFTFGGGTKVEIK,6XSW_A,6XSW_B,Structure Of The Notch3 Nrr In Complex With An Antibody Fab Fragment,Structure Of The Notch3 Nrr In Complex With An Antibody Fab Fragment,Homo sapiens,"Geles,K.G.;Gao,Y.;Giannakou,A.;Sridharan,L.;Yamin,T.T.;Zhang,J.;Karim,R.;Bard,J.;Piche-Nicholas,N.;Charati,M.;Maderna,A.;Lucas,J.;Golas,J.;Guffroy,M.;Pirie-Shepherd,S.;Roy,M.;Qian,J.;Franks,T.;Zhong,W.;O'Donnell,C.J.;Tchistiakova,L.;Gerber,H.P.;Sapra,P.",NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells,16-JUL-2020,8_8_12_6_3_9,AJN02319_AJN02321,Xtal structure,apoptosis; CADASIL; NOTCH3; CASIL,4,1,10.976622,10.393318
6KR0_D_D,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDLATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,6KR0_D,6KR0_D,Crystal Structure Of Hl Homo-Diabody,Crystal Structure Of Hl Homo-Diabody,Homo sapiens,"Nakazawa,H.;Onodera-Sugano,T.;Sugiyama,A.;Tanaka,Y.;Hattori,T.;Niide,T.;Ogata,H.;Asano,R.;Kumagai,I.;Umetsu,M.",Association behavior and control of the quality of cancer therapeutic bispecific diabodies expressed in Escherichia coli,20-AUG-2019,8_8_15_6_3_9,6KR0_D_D,Xtal structure,,4,1,10.826789,10.483966
7MDJ_A_B,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSDWIHWVRQAPGKGLEWIGEIIPSYGRANYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARERGDGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGTDIHWYQQKPGKAPKLLIKYASESISGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSNRWPFTFGQGTKVEIK,7MDJ_A,7MDJ_B,The Structure Of Kcsa In Complex With A Synthetic Fab,The Structure Of Kcsa In Complex With A Synthetic Fab,Streptomyces lividans,"Rohaim,A.;Slezak,T.;Koh,Y.H.;Blachowicz,L.;Kossiakoff,A.A.;Roux,B.",Engineering of a synthetic antibody fragment for structural and functional studies of K+ channels,05-APR-2021,8_8_11_6_3_9,7MDJ_A_B,Xtal structure,,4,1,10.407264,10.58762
7SHZ_E_F,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASIKYSGETKYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASKPVDGEGDSYLNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,7SHZ_E,7SHZ_F,Ige-Fc In Complex With Hae,Ige-Fc In Complex With Hae,Homo sapiens,"Pennington,L.F.;Gasser,P.;Kleinboelting,S.;Zhang,C.;Skiniotis,G.;Eggel,A.;Jardetzky,T.S.",Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex,11-OCT-2021,9_7_14_10_3_9,AAE39061,Xtal structure,,4,1,11.66777,10.514217
6TCR_H_L,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISRLRPEDFATYYCQQSHEDPYTFGQGTKVEIK,6TCR_H,6TCR_L,"Crystal Structure Of The Omalizumab Fab Ser81Arg, Gln83Arg And Leu158Pro Light Chain Mutant","Crystal Structure Of The Omalizumab Fab Ser81Arg, Gln83Arg And Leu158Pro Light Chain Mutant",Homo sapiens,"Mitropoulou,A.N.;Ceska,T.;Heads,J.T.;Beavil,A.J.;Henry,A.J.;McDonnell,J.M.;Sutton,B.J.;Davies,A.M.",Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization,06-NOV-2019,9_7_14_10_3_9,6TCR_H_L,Xtal structure,IgE,4,1,11.674852,10.510355
8GB5_B_C,EVQLVESGGGLVQPGGSLRLSCSASGFRFSDYWINWVRQAPGKGLEWVGFIKTKADFGTPAYAESVKGRFSISRDDSKNTVYLQMNSLKTEDTAVYYCTRDRGILEWLIIEAGWFDVWGPGVLVTVSS,QSVLTQPPSASGAPGQRVTISCTGSSSNIGAGHYVSWYQQLPGTAPKLLIHENDKRPSGVSDRFSGSRSGASASLTITGLQSGDEADYYCSVWDRSLNTLFGGGTRVTVL,8GB5_B,8GB5_C,Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Neutralizing Antibody 25F9,Crystal Structure Of Sars-Cov-2 Receptor Binding Domain In Complex With Neutralizing Antibody 25F9,Macaca mulatta,"Feng,Y.;Yuan,M.;Powers,J.M.;Hu,M.;Munt,J.E.;Arunachalam,P.S.;Leist,S.R.;Bellusci,L.;Kim,J.;Sprouse,K.R.;Adams,L.E.;Sundaramurthy,S.;Zhu,X.;Shirreff,L.M.;Mallory,M.L.;Scobey,T.D.;Moreno,A.;O'Hagan,D.T.;Kleanthous,H.;Villinger,F.J.;Veesler,D.;King,N.P.;Suthar,M.S.;Khurana,S.;Baric,R.S.;Wilson,I.A.;Pulendran,B.",Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine,24-MAY-2023,8_10_19_9_3_10,8GB5_B_C,Xtal structure,COVID,4,1,13.085379,8.496958
ANY92039_ANY91411,EVQLVESGGGLVQPGGSLRLSCSASGFTVSNYAMHWVRQAPGKGLEYVSAISVNGFSTFYTDSVKGRFTISKDNSKNTLYLQMSSLRPEDTAVYYCVKAESYDFWSGYDWGQGTQVTVSS,DVVMTQSPVSLPVTLGQPASISCRSSQSLVYSDGNTYLSWFQQRPGQSPRRLIYTVSKRDSGVPDRFSGSGSGTDFTLKIRRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK,ANY92039,ANY91411,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_13_11_3_9,ANY92039_ANY91411,Unique source,Influenza,4,1,13.76496,10.008718
6PHH_C_D,EVQLVESGGGLVQPGGSLRLSCVASGFTFSNYNMNWVRQAPGKGLEWLSYISSSSGTIYYADSVKGRFTISRDNAKNSMYLQMNSLRAEDTAVYYCVRVEYYYGSSGYYYDFDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQTLQPFTFGQGTRLEIK,6PHH_C,6PHH_D,Unliganded Human Transmission Blocking Antibody 2544,Unliganded Human Transmission Blocking Antibody 2544,Homo sapiens,"McLeod,B.;Miura,K.;Scally,S.W.;Bosch,A.;Nguyen,N.;Shin,H.;Kim,D.;Volkmuth,W.;Ramisch,S.;Chichester,J.A.;Streatfield,S.;Woods,C.;Schief,W.R.;Emerling,D.;King,C.R.;Julien,J.P.",Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25,25-JUN-2019,8_8_18_10_3_8,6PHH_C_D,Xtal structure,Pfs25,4,1,15.835548,9.866758
UUB73687_UUB73688,EVQLVESGGGLVQPGGTLRLSCVASGFSFSNYWMSWVRQAPGKGLEWVANIKQDGSETHYVDSVKGRFTISRDNAKNSLYLQMNSLRADDTAVYFCVKDRTDWELIRGYFGHWGQGTQITVSS,DIVMTQTPSSLSLSPGDRATLSCRASENIINYLAWYQQRPGQSPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRIIWPPYTFGQGTKVDIK,UUB73687,UUB73688,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Chi,X.; Guo,Y.; Zhang,G.; Sun,H.; Zhang,J.; Li,M.; Chen,Z.; Han,J.; Zhang,Y.; Zhang,X.; Fan,P.; Zhang,Z.; Wang,B.; Zai,X.; Han,X.; Hao,M.; Fang,T.; Xu,J.; Wu,S.; Chen,Y.; Fang,Y.; Dong,Y.; Sun,B.; Zhang,J.; Li,J.; Zhao,G.; Yu,C.; Zhou,Q.; Chen,W.",Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination,02-AUG-2022,8_8_16_6_3_10,UUB73687_UUB73688,Unique source,SARS-CoV-2,4,1,11.109833,7.758837
6WG1_H_L,EVQLVESGGGLVQPGRSLRLSCTTSGFTFGDYAMSWFRQAPGKGLEWVGFIRSKGFGGTAEYAAFVKGRFTISRDDSRSIAYLQMTSLKPEDTAVYYCSRVGVVIATAVYWGQGTLVTVSS,DILMTQTPLSLSVTPGQPASISCKSSQSLLDNDGKTYLYWYLQKPGQSPQLLIYEVSNRFSGVPERFSGSGSGTDFTLKIRRVEAEDVGVYYCMQRIDLPWTFGQGTKVEIK,6WG1_H,6WG1_L,Crystal Structure Of Fab399 In Complex With Npna6 Peptide From Circumsporozoite Protein,Crystal Structure Of Fab399 In Complex With Npna6 Peptide From Circumsporozoite Protein,Plasmodium falciparum,"Pholcharee,T.;Oyen,D.;Flores-Garcia,Y.;Gonzalez-Paez,G.;Han,Z.;Williams,K.L.;Volkmuth,W.;Emerling,D.;Locke,E.;King,C.R.;Zavala,F.;Wilson,I.A.",Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum,04-APR-2020,8_10_12_11_3_9,6WG1_H_L,Xtal structure,C20orf147; NANP; MGC26833; HDHD4; dJ694B14.3,4,1,13.313315,8.821309
6A77_H_L,EVQLVESGGGVVQPGGSLKLSCAASGFTFSTYDMSWVRQTPDKRLELVATINSNGGSTYYPDSVKGRFTSSRDNAKNILYLQMSSLKSEDTAMYYCAREALLRPPYYALDYWGQGTSVTVSS,DIQMTQSPASLSASVGETVTITCGASENIYGALTWYQRKQGKSPQLLIYGAINLADDKSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPFTFGSGTKLEIK,6A77_H,6A77_L,Crystal Structure Of The Fifth Immunoglobulin Domain (Ig5) Of Human Robo1 In Complex With The Fab Fragment Of Murine Monoclonal Antibody B5209B,Crystal Structure Of The Fifth Immunoglobulin Domain (Ig5) Of Human Robo1 In Complex With The Fab Fragment Of Murine Monoclonal Antibody B5209B,Mus musculus,"Yamashita,T.;Mizohata,E.;Nagatoishi,S.;Watanabe,T.;Nakakido,M.;Iwanari,H.;Mochizuki,Y.;Nakayama,T.;Kado,Y.;Yokota,Y.;Matsumura,H.;Kawamura,T.;Kodama,T.;Hamakubo,T.;Inoue,T.;Fujitani,H.;Tsumoto,K.",Affinity Improvement of a Cancer-Targeted Antibody through Alanine-Induced Adjustment of Antigen-Antibody Interface,02-JUL-2018,8_8_15_6_3_9,6A77_H_L,Xtal structure,,4,1,17.686485,7.072603
7TM0_E_D,EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVSS,VIWMTQSPSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFK,7TM0_E,7TM0_D,Sars-Cov-2 S B.1.1.529 Omicron Variant + S309 + S2L20 Global Refinement,Sars-Cov-2 S B.1.1.529 Omicron Variant + S309 + S2L20 Global Refinement,Homo sapiens,"McCallum,M.;Czudnochowski,N.;Rosen,L.E.;Zepeda,S.K.;Bowen,J.E.;Walls,A.C.;Hauser,K.;Joshi,A.;Stewart,C.;Dillen,J.R.;Powell,A.E.;Croll,T.I.;Nix,J.;Virgin,H.W.;Corti,D.;Snell,G.;Veesler,D.",Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement,19-JAN-2022,8_8_15_6_3_9,7TM0_E_D,Xtal structure,SARS-CoV-2,4,1,14.947483,13.341112
4F58_H_L,EVQLVESGGGVVQPGGSLRLSCVASGFSFSDFGMNWVRQAPGKGLEWVAFVPFDRRINYYAESVRGRFTISRDDSKNTVFLQMDSLRPEDTAIYYCAKHRSQWNFWPREGGLDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTTSDVGTYNFVSWYQQHPGKAPKAIIFDVTNRPSGISNRFSGSKFGNTASLTISGLQAEDEADYYCAAYTVASTLLFGGGTKVTVL,4F58_H,4F58_L,Fab Structure Of A Neutralizing Antibody L3 From An Early Subtype A Hiv-1 Infected Patient,Fab Structure Of A Neutralizing Antibody L3 From An Early Subtype A Hiv-1 Infected Patient,Homo sapiens,"Murphy,M.K.;Yue,L.;Pan,R.;Boliar,S.;Sethi,A.;Tian,J.;Pfafferot,K.;Karita,E.;Allen,S.A.;Cormier,E.;Goepfert,P.A.;Borrow,P.;Robinson,J.E.;Gnanakaran,S.;Hunter,E.;Kong,X.P.;Derdeyn,C.A.",Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth,12-MAY-2012,8_8_18_9_3_10,4F58_H_L,Xtal structure,HIV,4,1,14.791326,13.155031
4ORG_A_B,EVQLVESGGGVVQPGKSLRLSCAASQFSFNRYGMHWVRQAPGKGLEWVAAISYDGTDKYHADKVWGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDKWGQGTMVIVSS,PVLTQPPSVSAAPGQKVTISCSGSSSNIGNNFVSWYQQRPGTAPSLLIYETNKRPSGIPDRFSGSKSATSATLAITGLQTGDEADYYCATWAASLTSARVFGTGTKVIVS,4ORG_A,4ORG_B,"Crystal Structure Of Human Fab Cap256-Vrc26.04, A Potent V1V2-Directed Hiv-1 Neutralizing Antibody","Crystal Structure Of Human Fab Cap256-Vrc26.04, A Potent V1V2-Directed Hiv-1 Neutralizing Antibody",Homo sapiens,"Doria-Rose,N.A.;Schramm,C.A.;Gorman,J.;Moore,P.L.;Bhiman,J.N.;DeKosky,B.J.;Ernandes,M.J.;Georgiev,I.S.;Kim,H.J.;Pancera,M.;Staupe,R.P.;Altae-Tran,H.R.;Bailer,R.T.;Crooks,E.T.;Cupo,A.;Druz,A.;Garrett,N.J.;Hoi,K.H.;Kong,R.;Louder,M.K.;Longo,N.S.;McKee,K.;Nonyane,M.;O'Dell,S.;Roark,R.S.;Rudicell,R.S.;Schmidt,S.D.;Sheward,D.J.;Soto,C.;Wibmer,C.K.;Yang,Y.;Zhang,Z.;Mullikin,J.C.;Binley,J.M.;Sanders,R.W.;Wilson,I.A.;Moore,J.P.;Ward,A.B.;Georgiou,G.;Williamson,C.;Abdool Karim,S.S.;Morris,L.;Kwong,P.D.;Shapiro,L.;Mascola,J.R.",Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies,11-FEB-2014,8_8_37_8_3_12,4ORG_A_B,Xtal structure,HIV,4,1,14.989866,14.05924
8H7L_D_G,EVQLVESGGGVVQPGRSLRLSCAASEFTFSSFAMHWVRQAPGKGLEWVALISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVSYPLTKYYYGMDVWGQGTTVTVSS,EIVMTQSPAFMSATPGDKVNISCKASQDIADDMNWYQQKPGEAAIFIIQEATTLVPGISPRFSGSGYGTDFTLTINNIESEDAAYYFCLQHDNFPLTFGGGTKVEIK,8H7L_D,8H7L_G,Cryo-Em Structure Of Sars-Cov-2 Ba.2 Spike Protein In Complex With Ba7535,Cryo-Em Structure Of Sars-Cov-2 Ba.2 Spike Protein In Complex With Ba7535,Homo sapiens,"Zheng,L.;An,Y.;Gao,Y.",Cryo-EM Structure of SARS-CoV-2 BA.2 Spike protein in complex with BA7535,30-AUG-2023,8_8_16_6_3_9,8H7L_D_G,Xtal structure,SARS-CoV-2,4,1,14.18447,13.90597
7ZFE_J_K,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVYWYDGGNKFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDTAPPDYWGQGTLVTVSS,AIRMTQSPGTLSLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPRLTFGGGTKVDIK,7ZFE_J,7ZFE_K,Sars-Cov-2 Omicron Rbd In Complex With Omi-32 Fab And Nanobody C1,Sars-Cov-2 Omicron Rbd In Complex With Omi-32 Fab And Nanobody C1,Lama glama,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,01-APR-2022,8_8_9_7_3_10,7ZFE_J_K,Xtal structure,,4,1,14.944582,13.180063
UUB73683_UUB73684,EVQLVESGGGVVQPGTSLRLSCAASGFSFSHYVMYWVRQAPGKGLDWVAIISFDGSSQYYADSVKGRFTISRDNSKDTLYLQMHSLRPEDTAVYYCAIHGGTYYYDKNILAWGQGTLVTVSS,AIRMTQSPPTLSLSPGERATLSCRASQSVTNYLVWYQQKPGQAPRLLIYDTFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVDIK,UUB73683,UUB73684,"anti-SARS-CoV-2 spike immunoglobulin IgG1 heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike immunoglobulin IgG1 light chain variable region, partial [Homo sapiens]",Homo sapiens,"Chi,X.; Guo,Y.; Zhang,G.; Sun,H.; Zhang,J.; Li,M.; Chen,Z.; Han,J.; Zhang,Y.; Zhang,X.; Fan,P.; Zhang,Z.; Wang,B.; Zai,X.; Han,X.; Hao,M.; Fang,T.; Xu,J.; Wu,S.; Chen,Y.; Fang,Y.; Dong,Y.; Sun,B.; Zhang,J.; Li,J.; Zhao,G.; Yu,C.; Zhou,Q.; Chen,W.",Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination,02-AUG-2022,8_8_15_6_3_9,UUB73683_UUB73684,Unique source,SARS-CoV-2,4,1,14.495102,13.584129
AFF19548_AFF19544,EVQLVESGGGVVRPGGSLRLSCAASGFIFENYGLTWVRQVPGKGLHWVSGMNWNGGDTRYADSVRGRFSMSRDNSNNIAYLQMKNLRVDDTALYYCARGTDYTIDDQGIFYKGSGTFWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVHPKYFAWYQQKPGQSPRLLIYSGSTRAAGIADRFSGGGSGIHFTLTITRVEPEDFAVYFCQQYGGSPYTFGQGTKVELR,AFF19548,AFF19544,"anti-HIV1 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV1 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Bonsignori,M.; Hwang,K.K.; Chen,X.; Tsao,C.Y.; Morris,L.; Gray,E.; Marshall,D.J.; Crump,J.A.; Kapiga,S.H.; Sam,N.E.; Sinangil,F.; Pancera,M.; Yongping,Y.; Zhang,B.; Zhu,J.; Kwong,P.D.; O'Dell,S.; Mascola,J.R.; Wu,L.; Nabel,G.J.; Phogat,S.; Seaman,M.S.; Whitesides,J.F.; Moody,M.A.; Kelsoe,G.; Yang,X.; Sodroski,J.; Shaw,G.M.; Montefiori,D.C.; Kepler,T.B.; Tomaras,G.D.; Alam,S.M.; Liao,H.X.; Haynes,B.F.",Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors,28-MAR-2012,8_8_26_7_3_9,AFF19548_AFF19544,Unique source,HIV; HIV1,4,1,13.28815,11.60733
QFQ61579_QFQ61731,EVQLVESGGNLAKPGGSLRLSCAASGFTFSDAWMTWVRQAPGKGLEWVGRIKSNADGGATEYAAPVRGRFTISRDDSRSSLFLQMNSLKTEDTAVYYCLTPPPRRYWGQGILVTVSS,QSVLTQPPSVSGAPGQRVAISCTGSYSNIGAGYDVHWYQQFPGAAPKLLIYAYTNRPAGVPDRFSGSKSGSSASLVISGLQADDEADYYCQSYDARLRDGEVFGGGTKLTVL,QFQ61579,QFQ61731,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehrhardt,S.A.; Zehner,M.; Krahling,V.; Cohen-Dvashi,H.; Kreer,C.; Elad,N.; Gruell,H.; Ercanoglu,M.S.; Schommers,P.; Gieselmann,L.; Eggeling,R.; Dahlke,C.; Wolf,T.; Pfeifer,N.; Addo,M.M.; Diskin,R.; Becker,S.; Klein,F.",Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV,23-OCT-2019,8_10_8_9_3_12,QFQ61579_QFQ61731,Unique source,Ebola,4,1,13.021805,8.464097
7D5Z_P_O,EVQLVESGGRVVQPGGSLRLSCVTSGFTFSYYPIHWVRQGPGKGLEWVTMMSFDGTSDHCISSVKGRFVMSRDNSRNTLYLEMNKMRLEDTGVYYCARGGWKWPGGAFDVFGPGTVVTVSS,DIVMTQTPPSLSASVGDRVTLTCRASQAIRNNLAWYQHKPGKAPKRLIYAASTLEDGVPSSFSGSGFGTDFTLTINSLQPEDFATYYCLQHSTYPWTFGQGTKVEIK,7D5Z_P,7D5Z_O,Crystal Structure Of Ebv Gh/Gl Bound With Neutralizing Antibody 1D8,Crystal Structure Of Ebv Gh/Gl Bound With Neutralizing Antibody 1D8,Homo sapiens,"Zhu,Q.;Shan,S.;Yu,J.;Wang,X.;Zhang,L.;Zeng,M.",A Neutralizing Antibody Targeting a New Site of Vulnerability on Epstein-Barr Virus gH/gL Protects against Dual-Tropic Infection,28-SEP-2020,8_8_14_6_3_9,7D5Z_P_O,Xtal structure,Epstein,4,1,14.760063,13.097989
AQV03758_AQV03771,EVQLVESGPELKEPGASVKVSCKASGYTFTDYYIHWVRQAPGQGLEWMAWINPTTGRSSFARGFQGRVTMTRETSVSTAYMELRRLRSDDTAVYYCAKAGYIALYVDYSGYPNFNSWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSYDVGSYNLVSWYQQHPGKAPKLIIYEVSQWPSGVSKRFSGSKSGNTASLTISGLQAEDEAHYYCCSYAGSSTVIFGGGTSLTVL,AQV03758,AQV03771,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Bonsignori,M.; Kreider,E.F.; Fera,D.; Meyerhoff,R.R.; Bradley,T.; Wiehe,K.; Alam,S.M.; Aussedat,B.; Walkowicz,W.E.; Hwang,K.K.; Saunders,K.O.; Zhang,R.; Gladden,M.A.; Monroe,A.; Kumar,A.; Xia,S.M.; Cooper,M.; Louder,M.K.; McKee,K.; Bailer,R.T.; Pier,B.W.; Jette,C.A.; Kelsoe,G.; Williams,W.B.; Morris,L.; Kappes,J.; Wagh,K.; Kamanga,G.; Cohen,M.S.; Hraber,P.T.; Montefiori,D.C.; Trama,A.; Liao,H.X.; Kepler,T.B.; Moody,M.A.; Gao,F.; Danishefsky,S.J.; Mascola,J.R.; Shaw,G.M.; Hahn,B.H.; Harrison,S.C.; Korber,B.T.; Haynes,B.F.",Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies,24-MAR-2017,8_8_20_9_3_10,AQV03758_AQV03771,Unique source,HIV,4,1,2.725716,2.8934364
6VVU_J_K,EVQLVESGPGLVKPSETLSLTCTVSRFSLIGYAITWIRQPPGKGLEWIGGISSAATTFYSSWAKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDPRGYGAALDRLDLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQSIKSVYNNRLGWYQQKPGKAPKLLIYETSILTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAGGFDRSGDTTFGQGTKVEIK,6VVU_J,6VVU_K,Anti-Tryptase Fab E104.V1 Bound To Tryptase,Anti-Tryptase Fab E104.V1 Bound To Tryptase,Homo sapiens,"Maun,H.R.;Vij,R.;Walters,B.T.;Morando,A.;Jackman,J.K.;Wu,P.;Estevez,A.;Chen,X.;Franke,Y.;Lipari,M.T.;Dennis,M.S.;Kirchhofer,D.;Ciferri,C.;Loyet,K.M.;Yi,T.;Eigenbrot,C.;Lazarus,R.A.;Koerber,J.T.",Bivalent antibody pliers inhibit beta-tryptase by an allosteric mechanism dependent on the IgG hinge,18-FEB-2020,8_7_16_7_3_11,6VVU_J_K,Xtal structure,tryptase,4,1,16.197945,-7.703369
7T86_H_L,EVQLVETGGGLVKPGGSLRLSCSASRFSFRDYYMTWIRQAPGKGPEWVSHISGSGSTIYYADSVRGRFTISRDNAKSSLYLQMDSLQADDTAVYYCARGGRATSYYWVHWGPGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSGYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKLEIK,7T86_H,7T86_L,Crystal Structure Of Fab Cr5133 / Phospho-Sd Peptide Complex,Crystal Structure Of Fab Cr5133 / Phospho-Sd Peptide Complex,synthetic construct,"Buckley,P.T.;Chan,R.;Fernandez,J.;Luo,J.;Lacey,K.A.;DuMont,A.L.;O'Malley,A.;Brezski,R.J.;Zheng,S.;Malia,T.;Whitaker,B.;Zwolak,A.;Payne,A.;Clark,D.;Sigg,M.;Lacy,E.R.;Kornilova,A.;Kwok,D.;McCarthy,S.;Wu,B.;Morrow,B.;Nemeth-Seay,J.;Petley,T.;Wu,S.;Strohl,W.R.;Lynch,A.S.;Torres,V.J.",Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections,11-JAN-2023,8_8_13_6_3_9,7T86_H_L,Xtal structure,,4,1,15.692126,9.4358225
4R96_D_C,EVQLVQPGVELRNPGASVKVSCKASGYIFTMNSIDWVRQAPGQGLEWMGRIDPEDGGTKYAQKFQGRVTFTADTSTSTAYVELNSLRSEDTAVYYCARVDDYYLGYDYWGQGTQVTVSS,DIVMTQTPTSVTASAGDKVTINCKSSQSVLFSSNQKNYLAWYQQRLGQSPRLLIYWASIRESGVPDRFSGSGSATDFTLTISNFQPEDAAVYYCQQGYSFPYSFGSGTRLEIR,4R96_D,4R96_C,Structure Of A Llama Glama Fab 48A2 Against Human Cmet,Structure Of A Llama Glama Fab 48A2 Against Human Cmet,Lama glama,"Klarenbeek,A.;El Mazouari,K.;Desmyter,A.;Blanchetot,C.;Hultberg,A.;de Jonge,N.;Roovers,R.C.;Cambillau,C.;Spinelli,S.;Del-Favero,J.;Verrips,T.;de Haard,H.J.;Achour,I.","Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform",03-SEP-2014,8_8_12_12_3_9,AUE51326_AUE51350,Xtal structure,Cmet,4,1,1.6152345,4.0449915
QNN93275_QNN93342,EVQLVQSEAEVKRPGESLKISCQTSGYNFPNYWITWVRQMPGKGLEWMGTIDPRDSDTKYSPSFQGQVTISADKSINTAYLQWTSLRASDSATYYCVMWVYILTTGNIWVDVWGPGVLVTVSS,DVVMTQSPLSLPITPGQPASISCRSSQSLVHNNGNTYLTWYQQRPGQPPRRLIYQVSNRDSGVPDRFIGSGAGTDFTLKISRVESEDVGIYYCGQITDFPYSFGQGTKVDIK,QNN93275,QNN93342,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Cottrell,C.A.; van Schooten,J.; Bowman,C.A.; Yuan,M.; Oyen,D.; Shin,M.; Morpurgo,R.; van der Woude,P.; van Breemen,M.; Torres,J.L.; Patel,R.; Gross,J.; Sewall,L.M.; Copps,J.; Ozorowski,G.; Nogal,B.; Sok,D.; Rakasz,E.G.; Labranche,C.; Vigdorovich,V.; Christley,S.; Carnathan,D.G.; Sather,D.N.; Montefiori,D.; Silvestri,G.; Burton,D.R.; Moore,J.P.; Wilson,I.A.; Sanders,R.W.; Ward,A.B.; van Gils,M.J.",Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates,08-SEP-2020,8_8_16_11_3_9,QNN93275_QNN93342,Unique source,HIV,4,1,-12.424315,5.840619
6H0E_C_D,EVQLVQSGAEVKKPGAPVKVSCETSGYRFSDYFVHWVRQAPGQGPEWIGRIRPNSGGTKYAQKFQGRVTMTRDMSMNTAYMELSGLRSDDTAVYYCVRGHCDGTTCSRAYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHRSGHKYLHWYLQRPGQSPQVLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQTLQTPWTFGQGTKVEIK,6H0E_C,6H0E_D,Fab Dmcbtau-22.1 In Complex With Tau Peptide V1088-23,Fab Dmcbtau-22.1 In Complex With Tau Peptide V1088-23,Mus musculus,"van Ameijde,J.;Crespo,R.;Janson,R.;Juraszek,J.;Siregar,B.;Verveen,H.;Sprengers,I.;Nahar,T.;Hoozemans,J.J.;Steinbacher,S.;Willems,R.;Delbroek,L.;Borgers,M.;Dockx,K.;Van Kolen,K.;Mercken,M.;Pascual,G.;Koudstaal,W.;Apetri,A.",Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser(422) containing epitope on pathological tau,09-JUL-2018,8_8_14_11_3_9,6H0E_C_D,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,4,1,2.2635872,3.9750333
6H06_E_F,EVQLVQSGAEVKKPGAPVKVSCETSGYRFSDYNVHWVRQAPGQGPEWIGRISPNSGGTKYAQKFQGRVTMTRDMSMNTAYMELSGLRSDDTAVYYCVRGHCDGTTCSRAYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHRSGHKYLHWYLQRPGQSPQVLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQTLQTPWTFGQGTKVEIK,6H06_E,6H06_F,Fab Cbtau-22.1 In Complex With Tau Peptide V1088-5,Fab Cbtau-22.1 In Complex With Tau Peptide V1088-5,Homo sapiens,"van Ameijde,J.;Crespo,R.;Janson,R.;Juraszek,J.;Siregar,B.;Verveen,H.;Sprengers,I.;Nahar,T.;Hoozemans,J.J.;Steinbacher,S.;Willems,R.;Delbroek,L.;Borgers,M.;Dockx,K.;Van Kolen,K.;Mercken,M.;Pascual,G.;Koudstaal,W.;Apetri,A.",Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser(422) containing epitope on pathological tau,06-JUL-2018,8_8_14_11_3_9,6H06_E_F,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,4,1,2.2708988,3.916198
6VMJ_F_E,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGEINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSASSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIK,6VMJ_F,6VMJ_E,Crystal Structure Of Human Complement Factor D With Anti-Factor D Fab 20D12,Crystal Structure Of Human Complement Factor D With Anti-Factor D Fab 20D12,Homo sapiens,"Dion,M.;Wu,P.;Morando,A.;Bullen,G.;Shatz,W.;Harris,S.F.;Eigenbrot,C.;Loyet,K.M.;Yadav,D.;Tassew,N.;Booler,H.;Scheer,J.;Kelley,R.F.;Tesar,D.B.",Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12,28-JAN-2020,8_8_8_6_3_9,QHX28232_QHX28231,Xtal structure,,4,1,0.99423486,3.7058897
7S4G_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYTFTTYVMHWVRQAPGQGLEWMGYINPYNDGTKYNEKFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCGRRNFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLLSGNQENYLAWHQQKPGQPPKTLITWASTRISGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSYSAPYTFGGGTKVEIK,7S4G_H,7S4G_L,Fab Fragment Bound To The Cter Peptide Of Ly6G6D,Fab Fragment Bound To The Cter Peptide Of Ly6G6D,Homo sapiens,"Wang,P.;Sun,L.L.;Clark,R.;Hristopoulos,M.;Chiu,C.P.C.;Dillon,M.;Lin,W.;Lo,A.A.;Chalsani,S.;Das Thakur,M.;Zimmerman Savill,K.M.;Rouge,L.;Lupardus,P.;Piskol,R.;Husain,B.;Ellerman,D.;Shivva,V.;Leong,S.R.;Ovacik,M.;Totpal,K.;Wu,Y.;Spiess,C.;Lee,G.;Leipold,D.D.;Polson,A.G.",Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer,08-SEP-2021,8_8_7_12_3_9,7S4G_H_L,Xtal structure,C6orf23; Ly6-D; G6D; NG25; LY6G6D; CD3; MEGT1,4,1,1.6183013,3.8172615
8IVW_B_C,EVQLVQSGAEVKKPGATVKISCKVSGFNIKDYYIHWVQQAPGKGLEWMGRIDVEDDETKYAPKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATPIYGSREAWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYRSPPTFGGGTKVEIK,8IVW_B,8IVW_C,Crystal Structure Of Nrp2 In Complex With Anrp2-10 Fab Fragment,Crystal Structure Of Nrp2 In Complex With Anrp2-10 Fab Fragment,Homo sapiens,"Xu,Z.;Goel,H.L.;Burkart,C.;Burman,L.;Chong,Y.E.;Barber,A.G.;Geng,Y.;Zhai,L.;Wang,M.;Kumar,A.;Menefee,A.;Polizzi,C.;Eide,L.;Rauch,K.;Rahman,J.;Hamel,K.;Fogassy,Z.;Klopp-Savino,S.;Paz,S.;Zhang,M.;Cubitt,A.;Nangle,L.A.;Mercurio,A.M.",Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer,08-JAN-2009,8_8_14_7_3_9,8IVW_B_C,Xtal structure,VEGFA; neuropilin; VPF; VEGF-A; VEGF,4,1,0.98687303,2.793534
7Z2M_B_A,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPSDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARYPNYGAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVFSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYFYWGWPFGQGTKLEIK,7Z2M_B,7Z2M_A,Crystal Structure Of The 11.003 Fab In Complex With Human Il-17A,Crystal Structure Of The 11.003 Fab In Complex With Human Il-17A,Homo sapiens,"Levin,I.;Rondeau,J.-M.;Strajbl,M.;Lehmann,S.;Fischman,S.;Kovarik,J.;Nimrod,G.;Huber,T.;Omer,D.;Cebe,R.;Berenshtain,S.;Shlamkovich,T.;Bluvshtein,O.;Grossman,N.;Barak,R.;Zhenin,M.;Fastman,Y.;Twito,S.;Zur,N.;Ofran,Y.",Utilizing the intrinsic plasticity of antibodies - retargeting an anti-IL1b antibody into a functional anti-IL17A by computational design,08-FEB-2023,8_8_11_6_3_9,7Z2M_B_A,Xtal structure,CTLA8; IL-17A; IL17; IL-17; IL17A,4,1,-12.394071,5.7184443
6VBP_J_I,EVQLVQSGAEVKKPGESLRISCKGSGYNFTNYWIGWVRQVPGKGPEWMGLIYPSDSDTRYNPSLQGHVTISADKSLTTAYLRWSSLRASDSATYYCVTSGIYGYLDYWGRGTQVIVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVFHSSNNKNYLAWYQQKPGQSPKLLIHWASARESGVPERISGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK,6VBP_J,6VBP_I,Crystal Structure Of Anti-Hiv-1 Antibody Dh815 Bound To Gp120 V2 Peptide,Crystal Structure Of Anti-Hiv-1 Antibody Dh815 Bound To Gp120 V2 Peptide,Human immunodeficiency virus 1,"Easterhoff,D.;Pollara,J.;Luo,K.;Janus,B.;Gohain,N.;Williams,L.D.;Tay,M.Z.;Monroe,A.;Peachman,K.;Choe,M.;Min,S.;Lusso,P.;Zhang,P.;Go,E.P.;Desaire,H.;Bonsignori,M.;Hwang,K.K.;Beck,C.;Kakalis,M.;O'Connell,R.J.;Vasan,S.;Kim,J.H.;Michael,N.L.;Excler,J.L.;Robb,M.L.;Rerks-Ngarm,S.;Kaewkungwal,J.;Pitisuttithum,P.;Nitayaphan,S.;Sinangil,F.;Tartaglia,J.;Phogat,S.;Wiehe,K.;Saunders,K.O.;Montefiori,D.C.;Tomaras,G.D.;Moody,M.A.;Arthos,J.;Rao,M.;Joyce,M.G.;Ofek,G.;Ferrari,G.;Haynes,B.F.",HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions,19-DEC-2019,8_8_11_12_3_9,6VBP_J_I,Xtal structure,HIV,4,1,-12.371688,5.780272
7RE7_I_J,EVQLVQSGAEVKKPGESLTISCKASGYSFPNYWITWVRQMSGGGLEWMGRIDPGDSYTTYNPSFQGHVTISIDKSTNTAYLHWNSLKASDTAMYYCARYYVSLVDIWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVNNRPSEVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTGSRAVFGGGTKLTVL,7RE7_I,7RE7_J,Tcr Mimic Antibody (Fab Fragment) In Complex With Afp/Hla-A*02,Tcr Mimic Antibody (Fab Fragment) In Complex With Afp/Hla-A*02,Homo sapiens,"Liu,C.;Liu,H.;Dasgupta,M.;Hellman,L.M.;Zhang,X.;Qu,K.;Xue,H.;Wang,Y.;Fan,F.;Chang,Q.;Yu,D.;Ge,L.;Zhang,Y.;Cui,Z.;Zhang,P.;Heller,B.;Zhang,H.;Shi,B.;Baker,B.M.;Liu,C.",Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma,27-JUL-2022,8_8_10_9_3_10,AZJ90112,Xtal structure,,4,1,-12.254572,5.7011747
6WTY_H_I,EVQLVQSGAEVKKPGSSMKVSCKASGGTFNRYVFSWVRQAPGQGLEWMGGILPILETTYYAKNFKGRVTITADESTSTVYMELSSLTSEDTAVYFCARDEHDYVWGSYRPSLTGPWGQGTLVTVSS,QSALTQPPSTSGSPGQSVTISCTGTGIDVGGFSYVSWFQYHPGKAPKLIIFEVTKRPSGVPDRFSGSKSGNTASLTISGLQADDEAEYYCSSYAVNNNFVFGTGTKVTVL,6WTY_H,6WTY_I,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 253245,Plasmodium Vivax Reticulocyte Binding Protein 2B (Pvrbp2B) Bound To Human Monoclonal Antibody 253245,Homo sapiens,"Chan,L.J.;Gandhirajan,A.;Carias,L.L.;Dietrich,M.H.;Vadas,O.;Visentin,R.>.;Franca,C.T.;Menant,S.;Soldati-Favre,D.;Mueller,I.;King,C.L.;Tham,W.H.",Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b,04-MAY-2020,8_8_19_9_3_10,6WTY_H_I,Xtal structure,,4,1,-0.614938,5.7695384
1RZG_C_D,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAINWVRQAPGQGLEWMGGIIPIFNIAHYAQRFQGRVSITADESTSTAYMELSSLRSEDTAVFYCASPYPNDYNDYAPEEGMSWYFDLWGRGTLVTVS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWYQQKPGRAPKLLMYKASSLKSGVPSRFSGSGSGTEFTLTISSLQSDDFATYYCQQHDSSPYTFGQGTKLEIK,1RZG_C,1RZG_D,Crystal Structure Of Human Anti-Hiv-1 Gp120 Reactive Antibody 412D,Crystal Structure Of Human Anti-Hiv-1 Gp120 Reactive Antibody 412D,Homo sapiens,"Huang,C.C.;Venturi,M.;Majeed,S.;Moore,M.J.;Phogat,S.;Zhang,M.Y.;Dimitrov,D.S.;Hendrickson,W.A.;Robinson,J.;Sodroski,J.;Wyatt,R.;Choe,H.;Farzan,M.;Kwong,P.D.",Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120,24-DEC-2003,8_8_23_6_3_9,1RZG_C_D,Xtal structure,gp120; HIV,4,1,-0.9607308,5.688693
7Q6E_H_L,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSSVISWVRQAPGQGLEWMGGIIPLFGSANYAQKFQGRVTITADESTSTAYMEMTSLRSEDTAVYYCAKVSQWALILFWGQGTLVTVSS,AIRMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSPSWTFGQGTKVEIK,7Q6E_H,7Q6E_L,"Beta049 Fab In Complex With Sars-Cov2 Beta-Spike Glycoprotein, The Beta Mab Response Underscores The Antigenic Distance To Other Sars-Cov-2 Variants","Beta049 Fab In Complex With Sars-Cov2 Beta-Spike Glycoprotein, The Beta Mab Response Underscores The Antigenic Distance To Other Sars-Cov-2 Variants",Homo sapiens,"Afonine,P.V.",Real-space refinement in PHENIX for cryo-EM and crystallography,07-NOV-2021,8_8_11_7_3_10,7Q6E_H_L,Xtal structure,Antigenic,4,1,-0.48347145,5.732536
6AL4_B_A,EVQLVQSGAEVKKPGSSVKVSCKASGYAFSSYWMNWVRQAPGQGLEWMGQIWPGDSDTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRETTTVGRYYYAMDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQSVDYSGDSYLNWYQQKPGKAPKLLIYDASNLVSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQSTENPWTFGGGTKLEIK,6AL4_B,6AL4_A,Crystal Structure Of Anti-Cd19 Antibody B43 Fab,Crystal Structure Of Anti-Cd19 Antibody B43 Fab,Homo sapiens,"Teplyakov,A.;Obmolova,G.;Luo,J.;Gilliland,G.L.",Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold,07-AUG-2017,8_8_17_10_3_9,6AL4_B_A,Xtal structure,CD19,4,1,-0.3424367,5.316203
AIM47294_AIM47301,EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGQINPKTGGTNYAQKFQGRVTMTRDTSTSTAYMELSSLRSEDTAIYYCARGGQRLLLLRNYYFYYWGQGVLVTVSS,QSVLTQPPSVSGAPGQKVTISCTGSSSNIGGYDVHWYQQLPGMAPKLLIYDNNERPSGISDRFSGSKSATSASLAITGLQTEDEADYYCQSYDSSLNAWVFGGGTRLTVL,AIM47294,AIM47301,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin lambda chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Navis,M.; Tran,K.; Bale,S.; Phad,G.E.; Guenaga,J.; Wilson,R.; Soldemo,M.; McKee,K.; Sundling,C.; Mascola,J.; Li,Y.; Wyatt,R.T.; Karlsson Hedestam,G.B.",HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization,10-SEP-2014,8_8_17_8_3_11,AIM47294_AIM47301,Unique source,HIV,4,1,1.9058735,3.8232648
7NP1_I_M,EVQLVQSGGGLVKPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGEGGSIVGVTSDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSETEFTLTISSLHPDDFATYYCQQSYSTLPYTFGQGTKVEIK,7NP1_I,7NP1_M,Crystal Structure Of The Sars-Cov-2 Receptor Binding Domain In Complex With Antibody Ion-360,Crystal Structure Of The Sars-Cov-2 Receptor Binding Domain In Complex With Antibody Ion-360,Homo sapiens,"Bullen,G.;Galson,J.D.;Hall,G.;Villar,P.;Moreels,L.;Ledsgaard,L.;Mattiuzzo,G.;Bentley,E.M.;Masters,E.W.;Tang,D.;Millett,S.;Tongue,D.;Brown,R.;Diamantopoulos,I.;Parthiban,K.;Tebbutt,C.;Leah,R.;Chaitanya,K.;Ergueta-Carballo,S.;Pazeraitis,D.;Surade,S.B.;Ashiru,O.;Crippa,L.;Cowan,R.;Bowler,M.W.;Campbell,J.I.;Lee,W.J.;Carr,M.D.;Matthews,D.;Pfeffer,P.;Hufton,S.E.;Sawmynaden,K.;Osbourn,J.;McCafferty,J.;Karatt-Vellatt,A.",Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses,26-FEB-2021,8_7_15_6_3_10,7NP1_I_M,Xtal structure,SARS-CoV-2,4,1,12.688894,10.20438
4D9R_H_L,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,4D9R_H,4D9R_L,Inhibiting Alternative Pathway Complement Activation By Targeting The Exosite On Factor D,Inhibiting Alternative Pathway Complement Activation By Targeting The Exosite On Factor D,Homo sapiens,"Katschke KJ,Jr.;Wu,P.;Ganesan,R.;Kelley,R.F.;Mathieu,M.A.;Hass,P.E.;Murray,J.;Kirchhofer,D.;Wiesmann,C.;van Lookeren,Ca.",Inhibiting alternative pathway complement activation by targeting the factor D exosite,11-JAN-2012,8_8_8_6_3_9,QNC41911_QNC41910,Xtal structure,,4,1,-7.0067525,5.644024
8GOU_I_J,EVRLLESGGGLVQPGGSLRLSCAASGFTFNDYAMSWVRQAPGEGLEWVSTISYSGGSTYYADSVKGRFTISRDNSKNMLYLQMNSLRAEDTALYYCANGVATADWYFDLWGRGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWFQHHPGKAPKLMIYDVTDRPSGVPDRFSGSKSGNTASLTISGLQAEDAADYYCCSYAGTYTVFGGGTKLTVL,8GOU_I,8GOU_J,Omicron Ba.4/5 Sars-Cov-2 S In Complex With Th003 Fab,Omicron Ba.4/5 Sars-Cov-2 S In Complex With Th003 Fab,Homo sapiens,"Guo,Y.;Zhang,G.;Yang,Q.;Xie,X.;Lu,Y.;Cheng,X.;Wang,H.;Liang,J.;Tang,J.;Gao,Y.;Shang,H.;Dai,J.;Shi,Y.;Zhou,J.;Zhou,J.;Guo,H.;Yang,H.;Qi,J.;Liu,L.;Ma,S.;Zhang,B.;Huo,Q.;Xie,Y.;Wu,J.;Dong,F.;Zhang,S.;Lou,Z.;Gao,Y.;Song,Z.;Wang,W.;Sun,Z.;Yang,X.;Xiong,D.;Liu,F.;Chen,X.;Zhu,P.;Wang,X.;Cheng,T.;Rao,Z.",Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection,28-JUN-2023,8_8_13_9_3_9,8GOU_I_J,Xtal structure,SARS-CoV-2,4,1,13.920233,9.702762
7MF7_C_D,EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTLYLEMNNVRTEDTGYYFCARTGKYYDFWSGYPAGEEYFQDWGQGTLVIVSS,ASELTQDPAVSVALKQTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,7MF7_C,7MF7_D,Crystal Structure Of Antibody 10E8V4-P100Ga Fab,Crystal Structure Of Antibody 10E8V4-P100Ga Fab,Homo sapiens,"Do Kwon,Y.;Wang,X.E.;Bender,M.F.;Yang,R.;Li,Y.;McKee,K.;Rawi,R.;O'Dell,S.;Schneck,N.A.;Shaddeau,A.;Zhang,B.;Arnold,F.J.;Connors,M.;Doria-Rose,N.A.;Kwong,P.D.;Lei,Q.P.",Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography,08-APR-2021,8_10_22_6_3_12,7MF7_C_D,Xtal structure,HIV,4,1,12.655825,8.859015
3L7F_H_L,EVTLKESGPVLVKPTETLTLTCTVSGFSLSTYGMGVGWIRQPPGKALEWLAHIWWDDVKRYNPALKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARMGSDYDVWFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASKSISKYLAWYQQKPGQAPRLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNEYPYTFGQGTKLEIK,3L7F_H,3L7F_L,"Structure Of Il-13 Antibody H2L6, A Humanized Variant Of C836","Structure Of Il-13 Antibody H2L6, A Humanized Variant Of C836",Homo sapiens,"Fransson,J.;Teplyakov,A.;Raghunathan,G.;Chi,E.;Cordier,W.;Dinh,T.;Feng,Y.;Giles-Komar,J.;Gilliland,G.;Lollo,B.;Malia,T.J.;Nishioka,W.;Obmolova,G.;Zhao,S.;Zhao,Y.;Swanson,R.V.;Almagro,J.C.",Human framework adaptation of a mouse anti-human IL-13 antibody,28-DEC-2009,10_7_13_6_3_9,3L7F_H_L,Xtal structure,MGC116786; BHR1; MGC116788; IL13; ALRH; MGC116789; IL-13; P600,4,1,12.407853,0.36275193
5K8A_V_M,EVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,5K8A_V,5K8A_M,Nist Fab,Nist Fab,Mus musculus,"Karageorgos,I.;Gallagher,E.S.;Galvin,C.;Gallagher,D.T.;Hudgens,J.W.","Biophysical characterization and structure of the Fab fragment from the NIST reference antibody, RM 8671",27-MAY-2016,10_7_12_5_3_9,5K8A_V_M,Xtal structure,,4,1,12.433964,0.3950829
AEQ73808_AEQ74560,GVKKPGESLTLSCKVSGYTFTNYWIGWVRQLPGKGLELMGNINPGDSDSRYSPSFQGHITISADKSVNTVYLQWSSLKASDTAIYYCARHRGGWAKRGPFDYWGQGTLVT,TLSASVGDRVTITCRASQTINNWLAWYQHKPGKAPKLLIYKASTLENGVPSRFSGSGSGTEFTLTIGSLQPDDFATYYCQQYHDYSPEYTFGQGTKLEIK,AEQ73808,AEQ74560,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_11,AEQ73808_AEQ74560,Unique source,tetanus,4,1,-12.621844,5.4989877
2ZNX_A_A,IQLQESGPSLVKPSQTLSLTCSVTGDSITSDYWSWIRKFPGNRLEYMGYVSYSGSTYYNPSLKSRISITRDTSKNQYYLDLNSVTTEDTATYYCANWDGDYWGQGTLVTVS,DIVLTQSPATLSVTPGNSVSLSCRASQSIGNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPYTFGGGTKLEI,2ZNX_A,2ZNX_A,5-Fluorotryptophan Incorporated Scfv10 Complexed To Hen Egg Lysozyme,5-Fluorotryptophan Incorporated Scfv10 Complexed To Hen Egg Lysozyme,Gallus gallus,"Acchione,M.;Lee,Y.C.;DeSantis,M.E.;Lipschultz,C.A.;Wlodawer,A.;Li,M.;Shanmuganathan,A.;Walter,R.L.;Smith-Gill,S.;Barchi JJ,Jr.",Specific fluorine labeling of the HyHEL10 antibody affects antigen binding and dynamics,02-MAY-2008,8_7_7_6_3_9,2ZNX_A_A,Xtal structure,,4,1,10.683693,-12.807884
3J8W_F_J,LQQSGAELARPGASVKLSCKASGYTFISYWMQWVKQRPGQGLEWIGAIYPGDGATRYTQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARPSYYDYDVTWFAYWGQGTLVTVS,DIVMTQTPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAETLAEGVPSRFSGSGSGTQFSLRINSLQPEDFGSYYCQHHYVSPLTFGAGTKLELK,3J8W_F,3J8W_J,Cryo-Em Reconstruction Of Quasi-Hpv16 Complex With H263.A2 Fab,Cryo-Em Reconstruction Of Quasi-Hpv16 Complex With H263.A2 Fab,Human papillomavirus type 16,"Guan,J.;Bywaters,S.M.;Brendle,S.A.;Lee,H.;Ashley,R.E.;Makhov,A.M.;Conway,J.F.;Christensen,N.D.;Hafenstein,S.",Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization,19-NOV-2014,8_8_15_6_3_9,3J8W_F_J,Xtal structure,,4,1,0.41250327,-3.8913212
8E8L_H_L,LVQSGAELKKPGASVKFSCQASGFTFTTYDIHWVRQAPGQGLEWMGMISPSRDSTIYAQKFQGRVTMTSDTSTSTVYMELTSLRSEDTALYYCATASRPSAWVFRSLYTYYYMDVWGTGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTITDIGYYNYVSWYQQHPGKAPKLIIFDVTNRPSGVSDRFSGSKSGNTASLTISGLQAEDEGDYYCFSHRSNNIRVFGGGTKLTVL,8E8L_H,8E8L_L,9H2 Fab-Poliovirus 1 Complex,9H2 Fab-Poliovirus 1 Complex,Homo sapiens,"Charnesky,A.J.;Faust,J.E.;Lee,H.;Goetschius,D.J.;DiNunno,N.M.;Thapa,V.;Bator,C.M.;Cho,S.H.;Wahid,R.;Mahmood,K.;Chumakov,K.M.;Hafenstein,S.L.",High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,21-JUN-2023,8_8_22_9_3_10,8E8L_H_L,Xtal structure,poliovirus,4,1,1.6314263,3.6899948
6BFQ_H_L,MAQLQESGPGVVKPSETLSLTCSVSDSAIRKYYWSWIRQPPGQGLEYIGYIYASGSSFYNPSFKSRVSMSVDATNNQFYLKLTSVTAADTAVYYCAAITGTTDLWGRGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGINRRLAWYQQKPGKAPKRLIYAVSTLQSGVPSRFNGSGSGTDFTLTVNNVQPDDLAMYFCLQSNNYPLTFGGGTKVEIK,6BFQ_H,6BFQ_L,The Mechanism Of Gm-Csf Inhibition By Human Gm-Csf Auto-Antibodies,The Mechanism Of Gm-Csf Inhibition By Human Gm-Csf Auto-Antibodies,Homo sapiens,"Dhagat,U.;Hercus,T.R.;Broughton,S.E.;Nero,T.L.;Cheung Tung,Sh.;Barry,E.F.;Thomson,C.A.;Bryson,S.;Pai,E.F.;McClure,B.J.;Schrader,J.W.;Lopez,A.F.;Parker,M.W.",The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities,26-OCT-2017,8_7_9_6_3_9,6BFQ_H_L,Xtal structure,GM-CSF; GMCSF; CSF2,4,1,16.35718,-7.693079
UZH31856_UZH31835,QAQLQQSGTELVRPGASVTLSCKASGYKFNDYEIHWVKQTPVHGLEWIGAIVPETGFTAYSQKFRGKALLTADKSSSTVYMDLRSLTSADSAVFYCSRLQLFGYFDVWGTGTTVIVSS,DVLMTQNPLSLPVSLGDQASISCRSSQSVVYSDGNAYLEWYLQKPGQSPKLLIYKASNRFSGVPDRFSASGSGTDFTLRISRVETEDLGLYYCFQGTHIPYTFGGGTKLEMK,UZH31856,UZH31835,"anti-HIV fusion peptide monocolonal anitbody 7321-vFP53.02 heavy chain variable region, partial [Mus musculus]","anti-HIV fusion peptide monocolonal anitbody 7321-vFP53.02 light chain variable region, partial [Mus musculus]",Mus musculus,"Sastry,M.; Changela,A.; Gorman,J.; Xu,K.; Chuang,G.-Y.; Shen,C.-H.; Cheng,C.; Geng,H.; O'Dell,S.; Ou,L.; Rawi,R.; Reveiz,M.; Stewart-Jones,G.B.E.; Wang,S.; Zhang,B.; Zhou,T.; Biju,A.; Chambers,M.; Chen,X.; Corrigan,A.R.; Lin,B.C.; Louder,M.K.; Mckee,K.; Nazzari,A.F.; Parchment,D.K.; Sarfo,E.K.; Stephens,T.; Stuckey,J.; Tsybovsky,Y.; Verardi,R.; Wang,Y.; Zheng,C.-Y.; Production Program,V.; Doria-Rose,N.A.; Mcdermott,A.B.; Mascola,J.R.; Kwong,P.D.",Diverse Murine Vaccinations Reveal Distinct Antibody Classes Targeting Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization,11-APR-2023,8_8_11_11_3_9,UZH31856_UZH31835,Unique word,HIV,4,1,0.23645385,-3.4983666
6K68_C_D,QIQLVQSGPELKKPGETVKISCKASGYTFTDYSVHWVKQVPGKGLKWMGWINTETGEPTYADDFKGRFAFSLESSASTAYLEIHNLTNEDTATYFCALGWLHWGLGTTLTVSS,DIQLTQSPSSLAMSGGQKVTMRCKSSQSLLNSRNERNYLAWYQQKPGQSPKLLVYFASIRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCLQHYNTPWTFGGGTKLEIK,6K68_C,6K68_D,Application Of Anti-Helix Antibodies In Protein Structure Determination (8420-3Mnz),Application Of Anti-Helix Antibodies In Protein Structure Determination (8420-3Mnz),Staphylococcus aureus,"Kim,J.W.;Kim,S.;Lee,H.;Cho,G.;Kim,S.C.;Lee,H.;Jin,M.S.;Lee,J.O.",Application of antihelix antibodies in protein structure determination,01-JUN-2019,8_8_6_12_3_9,6K68_C_D,Xtal structure,Helix,4,1,-7.566723,6.092873
7CVY_N_O,QLQESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAQIRLKSDSYATYYADSVKGRFTVSRDDSKSNVYLQMNSLRAEDTGIYYCTDFYGFGDFFPYWGQGTLVTVSS,DIVMTQSPKFMSTSIGDRVSVTCQASQNVGTNVAWYQQKPGQSPKPLIYSASYRYSGVPGRFTGSGSGTDFTLTINNVQSEDLADYFCQQYNSFPLTFGAGTKLELK,7CVY_N,7CVY_O,Cryo-Em Structure Of Chikungunya Virus In Complex With Fab Fragments Of Mab Chk-124,Cryo-Em Structure Of Chikungunya Virus In Complex With Fab Fragments Of Mab Chk-124,Mus musculus,"Zhou,Q.F.;Fox,J.M.;Earnest,J.T.;Ng,T.S.;Kim,A.S.;Fibriansah,G.;Kostyuchenko,V.A.;Shi,J.;Shu,B.;Diamond,M.S.;Lok,S.M.",Structural basis of Chikungunya virus inhibition by monoclonal antibodies,27-AUG-2020,8_10_12_6_3_9,7CVY_N_O,Xtal structure,Chikungunya,4,1,13.401699,7.1296315
7OX1_A_B,QLQLVESGPGLVKPSQTLSLTCTVSGGSITTGYYAWSWIRQPPGKGLEWMGFIARDGSTSYSPSLKSRTSISRDTSKNQFSLQLSSVTPEDTAVYYCARAGEGRSWYPGYYYGMDYWGKGTLVTVSS,QAVVTQEPSLSVSPGGTVTLTCGLSSGSVTSSNYPGWYQQTPGQAPRVLIYNTNSRHSGVPSRYSGFISGNKAALTITGAEPEDEADYYCHLHKGSTGVFGGGTHLTVL,7OX1_A,7OX1_B,Fab 7D6: Hil-9 Complex,Fab 7D6: Hil-9 Complex,Homo sapiens,"De Vos,T.;Godar,M.;Bick,F.;Papageorgiou,A.C.;Evangelidis,T.;Markovic,I.;Mortier,E.;Dumoutier,L.;Tripsianes,K.;Blanchetot,C.;Savvides,S.N.",Structural basis for the mechanism and antagonism of receptor signaling mediated by Interleukin-9 (IL-9),28-DEC-2022,10_7_19_9_3_9,7OX1_A_B,Xtal structure,P40; IL-9; IL9; HP40,4,1,16.356407,-8.164686
3J8V_F_J,QLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGDGATNYNGKFKGKATLTADKSSSTAFMQISSLTSEDSAVYFCARPYRYDGGVYAMDYWGQGTSVTVS,DIVMTQSPSYLSVSLGGRVTITCKASDHINNWLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDFTLSITSLQTEDVATYHCQQYWSTPLTFGAGTKLELK,3J8V_F,3J8V_J,Cryo-Em Reconstruction Of Quasi-Hpv16 Complex With H16.14J Fab,Cryo-Em Reconstruction Of Quasi-Hpv16 Complex With H16.14J Fab,Mus musculus,"Guan,J.;Bywaters,S.M.;Brendle,S.A.;Lee,H.;Ashley,R.E.;Makhov,A.M.;Conway,J.F.;Christensen,N.D.;Hafenstein,S.",Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization,19-NOV-2014,8_8_15_6_3_9,3J8V_F_J,Xtal structure,,4,1,0.41478893,-4.6988554
3IU3_A_B,QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,3IU3_A,3IU3_B,Crystal Structure Of The Fab Fragment Of Therapeutic Antibody Basiliximab In Complex With Il-2Ra (Cd25) Ectodomain,Crystal Structure Of The Fab Fragment Of Therapeutic Antibody Basiliximab In Complex With Il-2Ra (Cd25) Ectodomain,Homo sapiens,"Du,J.;Yang,H.;Zhang,D.;Wang,J.;Guo,H.;Peng,B.;Guo,Y.;Ding,J.",Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab,29-AUG-2009,8_8_10_5_3_7,QXD44977_QXD44978,Xtal structure,TCGF; IL-2; IL2; Ectodomain,4,1,2.679496,-8.160843
7Y0N_C_L,QMQLVQSGAEVKKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADESTSTAYMELSSRSEDTAVYYCASGAFYYGSGSYPFDYWGQGT,DIQLTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISNLQPEDFATYYCQQSYSAPRTFGQGTKVEIK,7Y0N_C,7Y0N_L,Sars-Cov-2 Wt Spike In Complex With R15 Fab And P14 Nanobody,Sars-Cov-2 Wt Spike In Complex With R15 Fab And P14 Nanobody,Homo sapiens; Severe acute respiratory syndrome coronavirus 2; Vicugna pacos,"Wang, L.",Sars-Cov-2 Wt Spike In Complex With R15 Fab And P14 Nanobody,13-SEP-2023,8_8_16_6_3_9,7Y0O_H_L,Xtal structure,FLJ21108; P14; NAP; NYD-SP19; C20orf33; P14L; CTNNBL1,4,1,-0.89206946,5.705363
7X7O_H_L,QMQLVQSGPEVKKPGTSVKVSCKASGFTFSISAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRFEDTAVYYCAAPYCGGDCSDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGNSPWTFGQGTKVEIK,7X7O_H,7X7O_L,Sars-Cov-2 Spike Rbd In Complex With Neutralizing Antibody Ut28K,Sars-Cov-2 Spike Rbd In Complex With Neutralizing Antibody Ut28K,Homo sapiens,"Ozawa,T.;Tani,H.;Anraku,Y.;Kita,S.;Igarashi,E.;Saga,Y.;Inasaki,N.;Kawasuji,H.;Yamada,H.;Sasaki,S.I.;Somekawa,M.;Sasaki,J.;Hayakawa,Y.;Yamamoto,Y.;Morinaga,Y.;Kurosawa,N.;Isobe,M.;Fukuhara,H.;Maenaka,K.;Hashiguchi,T.;Kishi,H.;Kitajima,I.;Saito,S.;Niimi,H.",Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants,10-MAR-2022,8_8_15_7_3_9,7X7O_H_L,Xtal structure,SARS-CoV-2,4,1,-1.0006585,2.9820082
4JO1_H_L,QSLEESGGDLVQPGASLTLTCKASGFSFGNNYDMCWVRQAPGKGLEWIGCIETGSSDSAAYATWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARNFDLWGPGTLVIVSS,QVLTQTPSSVSTAVGSAVTINCQSSQNVYSNNNLAWFQQKPGQPPRLLIYDASKLASGVPSRFKGSGSGTQFTFTISDVQCDDAATFYCLGGYDCSSGDCAAFGGGTEVVVR,4JO1_H,4JO1_L,Crystal Structure Of Rabbit Mab R56 Fab In Complex With V3 Crown Of Hiv-1 Jr-Fl Gp120,Crystal Structure Of Rabbit Mab R56 Fab In Complex With V3 Crown Of Hiv-1 Jr-Fl Gp120,Human immunodeficiency virus 1,"Pan,R.;Sampson,J.M.;Chen,Y.;Vaine,M.;Wang,S.;Lu,S.;Kong,X.P.",Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected Humans,16-MAR-2013,9_9_6_8_3_13,4JO1_H_L,Xtal structure,HIV,4,1,-0.3889135,18.458166
6X1S_C_D,QSVEESEGGLFKPTDTLTLTCTASGFSLSGHGVIWVRQAPGKGLEWIGSAGAYGRIYYASWAKSRSTITRNTNLNTVTLKMTSLTAADTATYFCARRSDVGTSVGFDSWGPGTLVTISS,DMTQTPSSKSVPVGDTVTINCQASESVYSNNRLSWFQQKPGQPPKLLIYLVSTLASGVPSRFKGSGSGTQFTLTISDVVCDDAATYYCVGYKSSTTDGLAFGGGTEVVVK,6X1S_C,6X1S_D,Structure Of Phis Fab (Sc1-1) In Complex With Phis Mimetic Peptide,Structure Of Phis Fab (Sc1-1) In Complex With Phis Mimetic Peptide,synthetic construct,"Kalagiri,R.;Stanfield,R.L.;Meisenhelder,J.;La Clair,J.J.;Fuhs,S.R.;Wilson,I.A.;Hunter,T.",Structural basis for differential recognition of phosphohistidine-containing peptides by 1-pHis and 3-pHis monoclonal antibodies,19-MAY-2020,8_7_14_8_3_12,6X1S_C_D,Xtal structure,,4,1,-0.27685356,18.828785
4RZC_E_F,QSVKESEGDLVKPGASLTLTCKASGFDFTWYTMNWVRQAPGKGLEWIASIGAGVYGSNYYASWAKGRFTISKASSTTVTLQMTSLTVADTATYFCARDGINGGYDIWGPGTLVTVSS,LVMTQTESPVSAAVGGTVTIKCQSSQSVYNNRLAWYQQKPGQRPKLLIYSASTLASGVPSRFKGSGSGTQFTLTISDLEWGDAATYYCHGGYRSNDDRYAFSGGTELEIL,4RZC_E,4RZC_F,Fv M6P-1 In Complex With Mannose-6-Phosphate,Fv M6P-1 In Complex With Mannose-6-Phosphate,Oryctolagus cuniculus,"Blackler,R.J.;Evans,D.W.;Smith,D.F.;Cummings,R.D.;Brooks,C.L.;Braulke,T.;Liu,X.;Evans,S.V.;Muller-Loennies,S.",Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific mannerdagger,19-DEC-2014,8_9_11_7_3_12,4RZC_E_F,Xtal structure,mannose,4,1,-0.38504717,18.479784
7SUE_H_L,QVHLVQSGAEVKKPGSSVKVSCKASGGTFSSCAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGWEFGSGSYYRTDYYYYAMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVTNRPSGVSNRFSGSRSGNTASLTISGLQAEDEADYYCSSYTSSSLYVFGTGTKVAVL,7SUE_H,7SUE_L,Crystal Structure Of Human Fab S24-188 In The Complex With The N-Teminal Domain Of Nucleocapsid Protein From Sars Cov-2,Crystal Structure Of Human Fab S24-188 In The Complex With The N-Teminal Domain Of Nucleocapsid Protein From Sars Cov-2,Severe acute respiratory syndrome coronavirus 2,"Kim,Y.;Maltseva,N.;Tesar,C.;Jedrzejczak,R.;Dugan,H.;Stamper,C.;Wilson,P.;Joachimiak,A.;Center for Structural Genomics of Infectious Diseases (CSGID)",Crystal Structure of Human Fab S24-188 in the complex with the N-teminal Domain of Nucleocapsid protein from SARS CoV-2,10-AUG-2022,8_8_23_9_3_10,7SUE_H_L,Xtal structure,S24; RPS24; SARS; eS24; CoV,4,1,-0.98149824,6.089146
5YSL_G_H,QVKLQESGAELVKPGASAKAACEASGYTFTSYWIHWVKQRPGQGLDWIGEINTSSGRTNYNERFKNKATLTVDKTSSTAYIQLSSLTSEDSAVYYCAREGFGNQSLDYWGQGTSLTVSS,DIILTQSPAIMSASLGERVTLTCTASSSVSSSYLHWYQQKPGSSPKLWIYSTYNLAGAVPPRFSGSGSGTSYSLTISSMEAEDAATYYCQQYHRSPWTFGGGTKLEIK,5YSL_G,5YSL_H,Crystal Structure Of Antibody 1H1 Fab,Crystal Structure Of Antibody 1H1 Fab,Mus musculus,"Li,X.;Yang,F.;Hu,X.;Tan,F.;Qi,J.;Peng,R.;Wang,M.;Chai,Y.;Hao,L.;Deng,J.;Bai,C.;Wang,J.;Song,H.;Tan,S.;Lu,G.;Gao,G.F.;Shi,Y.;Tian,K.",Two classes of protective antibodies against Pseudorabies virus variant glycoprotein B: Implications for vaccine design,14-NOV-2017,8_8_12_7_3_9,5YSL_G_H,Xtal structure,,4,1,-0.7164524,-3.8672717
AF402255_1,QVKLQQSGAELVKPGASVKLSCKASGYTFNSYFMHWMKQRPVQGLEWIGMIRPNGGTTDYNEKFKNKATLTVDKSSNTAYMQLNSLTSGDSAVYYCARWEGSYYALDYWGQGTTVTVSS,DIELTQSPAIMSATLGEKVTMTCRASSNVKYMYWYQQKSGASPKLWIYYTSNLASGVPGRFSGSGSGTSYSLTISSVEAEDAATYYCQQFTSSPYTFGGGTKLEIK,AF402255_1_H,AF402255_1_L,"single chain antibody 10F7MN, partial [synthetic construct]","single chain antibody 10F7MN, partial [synthetic construct]",synthetic construct,"Kassner,P.D.",Direct Submission,23-JUL-2016,8_8_12_5_3_9,AF402255_1,Same entry,,4,1,-0.74552506,-3.890645
CAN87393,QVKLQQSGGGLVQPGGSLKLSCAASGFTFSSYGMSWFRQTPDKRLELVAIINSNGGTTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARGGGRWLLDYWGQGTTVTVSS,DIELTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQYLSSSTFGGGTKLEIK,CAN87393_H,CAN87393_L,"unnamed protein product, partial [synthetic construct]","unnamed protein product, partial [synthetic construct]",synthetic construct,"Cohen,J.H.; Mahmoud,W.; Tonye Libyh,M.; Godin,N.; Gimenez,A.; Tabary,T.; Donvito,B.",Protein constructs designed for targeting and lysis of cells,04-JUN-2007,8_8_11_12_3_8,CAN87393,Same entry,,4,1,17.630564,7.1693516
4Q6I_H_L,QVKLQQSGPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGKGLKWLGRINTETGEAKYVDDFMGHLAFSLETSASTAYLQINNLKNEDTATYFCARYDGYSWDAMDYWGQGTSVIVSS,DIMLTQSPASLTVSLGQRATMSCRASQSVSTSRYSYMHWYQEKAGQPPQLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEAEDTATYYCQHSWEIPYTFGGGTKLEIK,4Q6I_H,4Q6I_L,"Crystal Structure Of Murine 2D5 Fab, A Potent Anti-Cd4 Hiv-1-Neutralizing Antibody In Complex With Cd4","Crystal Structure Of Murine 2D5 Fab, A Potent Anti-Cd4 Hiv-1-Neutralizing Antibody In Complex With Cd4",Mus musculus,"Pegu,A.;Yang,Z.Y.;Boyington,J.C.;Wu,L.;Ko,S.Y.;Schmidt,S.D.;McKee,K.;Kong,W.P.;Shi,W.;Chen,X.;Todd,J.P.;Letvin,N.L.;Huang,J.;Nason,M.C.;Hoxie,J.A.;Kwong,P.D.;Connors,M.;Rao,S.S.;Mascola,J.R.;Nabel,G.J.",Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor,22-APR-2014,8_8_13_10_3_9,4Q6I_H_L,Xtal structure,HIV; CD4,4,1,-7.4924717,6.099011
QKY76520_QKY76133,QVQLAESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSTSGSYYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGDYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEAEYYCSSYTSSSTLLYVFGTGTKVTVL,QKY76520,QKY76133,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Zost,S.J.; Gilchuk,P.; Chen,R.E.; Case,J.B.; Reidy,J.X.; Trivette,A.; Nargi,R.S.; Sutton,R.E.; Suryadevara,N.; Chen,E.C.; Binshtein,E.; Shrihari,S.; Ostrowski,M.; Chu,H.Y.; Didier,J.E.; MacRenaris,K.W.; Jones,T.; Day,S.; Myers,L.; Lee,F.E.; Nguyen,D.C.; Sanz,I.; Martinez,D.R.; Baric,R.S.; Thackray,L.B.; Diamond,M.S.; Carnahan,R.H.; Crowe,J.E.",Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,01-JUL-2020,8_8_14_9_3_12,QKY76520_QKY76133,Unique source,SARS-CoV-2,4,1,14.321918,13.832304
ANY91655_ANY91145,QVQLAQSENELKKPGASVKVSCKTSGYTFTRFGMSWVRQAPGQGLEWMGWISGYTGDTKYARSFQGRLTLTTDTSTGTAYMELRSLRSDDTAIYYCVRNRVQMEVSPATQSTWYMDLWGRGTLVSVSS,DIQMTQVPVSLSAFVGDRVSITCRASQDISRWLAWYQQKPGRAPKLLIYAASSLQGGVPSRFRGSGSGTEFTLTISGLQPEDFATYYCQQGSTFPYTSVLGT,ANY91655,ANY91145,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_21_6_3_9,ANY91655_ANY91145,Unique source,Influenza,4,1,1.942888,5.3665
6PZY_I_L,QVQLEESGPGLVKPSETLSLTCTVSGYTISSGYYWGWIRQPPGKGLEWIGCNNHRGSSYYNPSLKSRVIISVDTTKNKFSLKLSSVTAADTAVYYCARDPSFWSSTSRTSPYYYGMDVWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGINTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDNLNGWVFGGGTKLTVL,6PZY_I,6PZY_L,Cryoem Derived Model Of Na-73 Fab In Complex With N9 Shanghai2,Cryoem Derived Model Of Na-73 Fab In Complex With N9 Shanghai2,Homo sapiens,"Zhu,X.;Turner,H.L.;Lang,S.;McBride,R.;Bangaru,S.;Gilchuk,I.M.;Yu,W.;Paulson,J.C.;Crowe,J.E.;Ward,A.B.;Wilson,I.A.",Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies,01-AUG-2019,9_7_22_8_3_11,6PZY_I_L,Xtal structure,Influenza,4,1,16.742992,-7.7762904
2UYL_Y_X,QVQLEQPGAELVKPGASVKLSCKASGYTFTSNWINWVKQRPGQGLEWIGHISPGSSSTNYNEKFKSKATLTVDTSSSTAYMQLSSLTSDDSAVYYCGREETVRASFGNWGQGTLVTVSA,ELVMTQTPPSLPVSLGDQASISCRSSQSIVHSNGDTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLEISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK,2UYL_Y,2UYL_X,Crystal Structure Of A Monoclonal Antibody Directed Against An  Antigenic Determinant Common To Ogawa And Inaba Serotypes Of Vibrio  Cholerae O1,Crystal Structure Of A Monoclonal Antibody Directed Against An  Antigenic Determinant Common To Ogawa And Inaba Serotypes Of Vibrio  Cholerae O1,Mus musculus,"Ahmed,F.;Andre-Leroux,G.;Haouz,A.;Boutonnier,A.;Delepierre,M.;Qadri,F.;Nato,F.;Fournier,J.M.;Alzari,P.M.",Crystal structure of a monoclonal antibody directed against an antigenic determinant common to Ogawa and Inaba serotypes of Vibrio cholerae O1,10-APR-2007,8_8_12_11_3_9,2UYL_Y_X,Xtal structure,Antigenic,4,1,-0.40065566,-4.1195183
2GK0_H_L,QVQLKESGPGLVAPSQSLSITCTVSGFSLTNYGVDWVRQPPGKGLEWVGVIWSGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAVYYCAKHWGGYYIPYGMDHWGQGTTVTVSS,ELVMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKINRVEAEDLGVYYCFQGSHLPPTFGGGTKLEIK,2GK0_H,2GK0_L,Structure Of Catalytic Elimination Antibody 13G5 From A Twinned Crystal In Space Group C2,Structure Of Catalytic Elimination Antibody 13G5 From A Twinned Crystal In Space Group C2,Mus musculus,"Muller,R.;Debler,E.W.;Steinmann,M.;Seebeck,F.P.;Wilson,I.A.;Hilvert,D.",Bifunctional catalysis of proton transfer at an antibody active site,31-MAR-2006,8_7_15_11_3_9,2GK0_H_L,Xtal structure,,4,1,22.171602,-6.040923
7S11_K_O,QVQLKESGPGLVQPSQTLSLTCTVSGLSLTTNSVSWIRQPPGKGLEWMGVIWSNGGTDYNSDIKSRLSISRDTSKSQVFLKMNSLQTEDTAMYFCARNFPYPGINFDWGQGVMVTVSS,QAVVTQESALTTLPGGTVTLTCHSSTGAVTTSNYANWIQEKADHSFTAILGGTSNRAPGTPARFSGSLLEGKAALTITGAQVEDEATYFCSLWYSGHLIFGGGTKLTVK,7S11_K,7S11_O,Crystal Structure Of Fab In Complex With Mouse Cd96 Monomer,Crystal Structure Of Fab In Complex With Mouse Cd96 Monomer,Rattus,"Lee,P.S.;Chau,B.;Barman,I.;Bee,C.;Jashnani,A.;Hogan,J.M.;Aguilar,B.;Dollinger,G.;Rajpal,A.;Strop,P.",Antibody blockade of CD96 by distinct molecular mechanisms,31-AUG-2021,8_7_12_9_3_9,7S11_K_O,Xtal structure,CD96; TACTILE,4,1,22.14936,-6.068495
4CAD_E_D,QVQLKQSGAELMKPGASVKISCKATGYKFSSYWIEWVKQRPGHGLEWIGEIFPGSGNTNYNEKFKGKATLTADTSSNTAYMQLSSLTSEDSAVYYCARRGAFYSYGSSYYAMDFWGQGTSVTVSS,DIQLTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGNYYCQHFWSTPWTFGGGTKLELK,4CAD_E,4CAD_D,Mechanism Of Farnesylated Caax Protein Processing By The Integral  Membrane Protease Rce1,Mechanism Of Farnesylated Caax Protein Processing By The Integral  Membrane Protease Rce1,Mus musculus,"Manolaridis,I.;Kulkarni,K.;Dodd,R.B.;Ogasawara,S.;Zhang,Z.;Bineva,G.;Reilly,N.O.;Hanrahan,S.J.;Thompson,A.J.;Cronin,N.;Iwata,S.;Barford,D.",Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1,08-OCT-2013,8_8_18_6_3_9,4CAD_E_D,Xtal structure,,4,1,4.986527,-1.8848687
8D54_A_B,QVQLKQSGTELVRPGTSVKMSCKAAGYTFTDYWIGWVKQRPGHGLEWIGDFYPGGDYTLYSENFMGKASLTADTSSNTAYMQLSSLTSEDSAIYYCARGHYYGYSYAWFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVGEEDAATYYCQQSHEDPWTFGGGTMLEIK,8D54_A,8D54_B,Anti Hiv Gp120/Cd4 Complex Antibody Cg10 Fab,Anti Hiv Gp120/Cd4 Complex Antibody Cg10 Fab,Mus musculus,"Yang,Z.;Dam,K.A.;Gershoni,J.M.;Zolla-Pazner,S.;Bjorkman,P.J.",Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers,14-DEC-2022,8_8_15_10_3_9,8D54_A_B,Xtal structure,HIV; CD4,4,1,-0.20887913,-4.476504
5VN3_M_O,QVQLLESGAEVKKPGSSVKVSCKASGDTFIRYSFTWVRQAPGQGLEWMGRIITILDVAHYAPHLQGRVTITADKSTSTVYLELRNLRSDDTAVYFCAGVYEGEADEGEYDNNGFLKHWGQGTLVTVTS,LELTQSPATLSVSPGERATLSCRASESVSSDLAWYQQKPGQAPRLLIYGASTRATGVPARFSGSGSGAEFTLTISSLQSEDFAVYYCQQYNNWPPRYTFGQGTRLEIK,5VN3_M,5VN3_O,Cryo-Em Model Of B41 Sosip.664 In Complex With Soluble Cd4 (D1-D2) And Fragment Antigen Binding Variable Domain Of 17B,Cryo-Em Model Of B41 Sosip.664 In Complex With Soluble Cd4 (D1-D2) And Fragment Antigen Binding Variable Domain Of 17B,Homo sapiens,"Ozorowski,G.;Pallesen,J.;de Val,N.;Lyumkis,D.;Cottrell,C.A.;Torres,J.L.;Copps,J.;Stanfield,R.L.;Cupo,A.;Pugach,P.;Moore,J.P.;Wilson,I.A.;Ward,A.B.",Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike,28-APR-2017,8_8_21_6_3_11,5VN3_M_O,Xtal structure,HIV,4,1,-0.97376806,5.549571
5YWF_D_C,QVQLMESGPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGKGLKWMGWINTGTGEPTFAADFKGRFAFSLETSASTAYLQINNLKNEDTASYFCARGVGLYGVDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASQSVSTSYMHWYQQKPGQPPRLLIYLVSNLESGVPSRFSGSGSGTDFTLNIHPVEAEDEATYYCQHIR,5YWF_D,5YWF_C,Crystal Structure Of 2H4 Fab,Crystal Structure Of 2H4 Fab,Mus musculus,"Qiu,X.;Lei,Y.;Yang,P.;Gao,Q.;Wang,N.;Cao,L.;Yuan,S.;Huang,X.;Deng,Y.;Ma,W.;Ding,T.;Zhang,F.;Wu,X.;Hu,J.;Liu,S.L.;Qin,C.;Wang,X.;Xu,Z.;Rao,Z.",Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies,29-NOV-2017,8_8_11_7_3_4,FAILED,Xtal structure,,4,1,-7.5125813,6.115392
1H8O_B_B,QVQLQEPGGELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARWGYWGQGTLVTVSA,DIVLTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGAGTKLELK,1H8O_B,1H8O_B,"Selection, Characterization And X-Ray  Structure Of Anti-Ampicillin Single  Chain Fv Fragments From Phage-Displayed Murine Antibody Libraries","Selection, Characterization And X-Ray  Structure Of Anti-Ampicillin Single  Chain Fv Fragments From Phage-Displayed Murine Antibody Libraries",Mus musculus,"Burmester,J.;Spinelli,S.;Pugliese,L.;Krebber,A.;Honegger,A.;Jung,S.;Schimmele,B.;Cambillau,C.;Pluckthun,A.","Selection, characterization and x-ray structure of anti-ampicillin single-chain Fv fragments from phage-displayed murine antibody libraries",14-FEB-2001,8_8_5_6_3_9,1H8O_B_B,Xtal structure,SH3YL1; DKFZP586F1318; Ray,4,1,-0.3740526,-3.7784088
WEG21910_WEG21920,QVQLQESGAGLLKPSETLSLSCTVDGESFNGFFWTWIRQPPGKGLEWIGEINHLASTGYNPSLKSRVTISVDTSKNQFSLKLTSVTAADTAVYYCARGYSYGFAWPNYHYLDVWGKGTTVTVSS,ETTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQHKPGQAPRLLIYGASKRATGIPSRFSGSGSGTDFSLTISSLEPEDFAVYYCQHRSDWRTTFGQGTRLEIK,WEG21910,WEG21920,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martinez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF,Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits,14-MAR-2023,8_7_18_6_3_9,UOS75581_UOS75597,Ordered entries,,4,1,16.55149,-10.343802
6D0U_H_I,QVQLQESGGGLVQPGESLRLSCVGSGSSFGESTLSYYAVSWVRQAPGKGLEWLSIINAGGGDIDYADSVEGRFTISRDNSKETLYLQMTNLRVEDTGVYYCAKHMSMQQVPSAGWEREDLVGDAFDVWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTLTCQASQDIRKFLNWYQQKPGKGPKLLIYDASNLQRGVPSRFSGGGSGTDFTLIISSLQPEDVGTYYCQQYDGLPFTFGGGTKVVIK,6D0U_H,6D0U_I,"Crystal Structure Of C05 V110P/A117E Mutant Bound To H3 Influenza Hemagglutinin, Ha1 Subunit","Crystal Structure Of C05 V110P/A117E Mutant Bound To H3 Influenza Hemagglutinin, Ha1 Subunit",Influenza A virus (A/Hong Kong/1/1968(H3N2)),"Sevy,A.M.;Wu,N.C.;Gilchuk,I.M.;Parrish,E.H.;Burger,S.;Yousif,D.;Nagel,M.B.;Schey,K.L.;Wilson,I.A.;Crowe JE,Jr.;Meiler,J.",Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses,11-APR-2018,13_8_26_6_3_9,6D0U_H_I,Xtal structure,Influenza,4,1,14.191129,10.101352
5A2I_H_H,QVQLQESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTGVGQFAYWGQGTTVTVSA,VVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,5A2I_H,5A2I_H,Crystal Structure Of Scfv-Sm3 In Complex With Apd-Sgalnac-Rp,Crystal Structure Of Scfv-Sm3 In Complex With Apd-Sgalnac-Rp,Homo sapiens,"Martinez-Saez,N.;Castro-Lopez,J.;Valero-Gonzalez,J.;Madariaga,D.;Companon,I.;Somovilla,V.J.;Salvado,M.;Asensio,J.L.;Jimenez-Barbero,J.;Avenoza,A.;Busto,J.H.;Bernardes,G.J.;Peregrina,J.M.;Hurtado-Guerrero,R.;Corzana,F.",Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody,20-MAY-2015,8_10_8_9_3_9,5A2I_H_H,Xtal structure,Ca15-3; ADMCKD; KL-6; ADMCKD1; PUM; MUC1; MCKD; CD227; MCKD1; EMA; PEM; MCD,4,1,13.415829,7.1115255
6PCI_P_S,QVQLQESGPGLGKPSETLSLSCTVSGASIRGYFWNWIRQPPGKGLEWIGYIHSTGSTNYNPSLKSRVTISVDTSKNQVSLNVNSVTAADTAVYFCARGAWNVATVYYYYGMDVWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYFAWYQQKPGQAPRLLISGTSTRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYFCQQYGNSLYTFGQGTKLEIK,6PCI_P,6PCI_S,Ebov Gpdmuc (Makona) In Complex With Rebov-520 And Rebov-548 Fabs,Ebov Gpdmuc (Makona) In Complex With Rebov-520 And Rebov-548 Fabs,Homo sapiens,"Gilchuk,P.;Murin,C.D.;Milligan,J.C.;Cross,R.W.;Mire,C.E.;Ilinykh,P.A.;Huang,K.;Kuzmina,N.;Altman,P.X.;Hui,S.;Gunn,B.M.;Bryan,A.L.;Davidson,E.;Doranz,B.J.;Turner,H.L.;Alkutkar,T.;Flinko,R.;Orlandi,C.;Carnahan,R.;Nargi,R.;Bombardi,R.G.;Vodzak,M.E.;Li,S.;Okoli,A.;Ibeawuchi,M.;Ohiaeri,B.;Lewis,G.K.;Alter,G.;Bukreyev,A.;Saphire,E.O.;Geisbert,T.W.;Ward,A.B.;Crowe JE,Jr.",Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization,17-JUN-2019,8_7_18_7_3_9,6PCI_P_S,Xtal structure,Ebolavirus,4,1,15.987769,-7.860738
UTO68540_UTO68548,QVQLQESGPGLVKPSEALSLTCSVSGVAISRHYWNWIRQPPGKGLEWIGYIFFNGNTNYSPSLKSRVTISVDTSKNEFSLTLRSVTAADTAVYYCAREKSVVEPDNMVRWFDPWGQGTLVTVSS,SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSKSGNTATLTISRVEAGDEADYYCQVWDSSRDHCVFGIGTKVTVL,UTO68540,UTO68548,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"van Schooten,J.",Direct Submission,23-JUL-2022,8_7_18_6_3_11,UTO68540_UTO68548,Unique source,,4,1,16.114098,-7.9498677
UNB14380_UNB14386,QVQLQESGPGLVKPSETLSLTCAVSGGSVSGNWWSWIRQPPGKGLEYIGRISGSDGTTYYRSSLKVTISRDTSKNQFSLRLNSVTAADTAVYYCARKPTWDWFDVWGPGLLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIDNYLNWYQQKPGKAPKRLIFAASSLHNGVPSRFSGSGSGTKFTLTISSLQPEDLGTYYCLQYYSDPYTFGQGTKVEIK,UNB14380,UNB14386,"anti-SIV env immunoglobulin ITS92.02 heavy chain variable region, partial [Macaca mulatta]","anti-SIV env immunoglobulin ITS92.02 light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Welles,H.C.; King,H.; Nettey,L.; Cavett,N.; Gorman,J.; Zhou,T.; Tsybovsky,Y.; Du,R.; Song,K.; Nguyen,R.; Ambrozak,D.; Ransier,A.; Schramm,C.A.; LaBranche,C.; Doria-Rose,N.A.; Swanstrom,A.E.; Hoxie,J.A.; Montefiori,D.C.; Bailor,R.T.; Douek,D.C.; Kwong,P.D.; Mascola,J.R.; Roederer,M.; Mason,R.D.",Direct Submission,16-MAR-2022,8_8_11_6_3_9,UNB14380_UNB14386,Unique word,SIV,4,1,16.332619,-7.362958
6XRJ_E_F,QVQLQESGPGLVKPSETLSLTCAVSGVSINDGYDWTWIRQTPGKGLEWIGYVFGRSGNFNLNPSLRNRGIISKDTCKNQFSLNLNSATAADTAVYFCARGMEGLFAAYNSLDVWGRGLLVTVSS,ALTQPPSVSGSPGQSVIISCTGTSSDIGQYNSVSWYQQHPDKAPKLVIYGVTSRPSGVSDRFSGSKYGDTASLTISGLQAEDEADYYCSSHADENMALFGGGTRLTVL,6XRJ_E,6XRJ_F,"Crystal Structure Of The Disulfide Linked Dh717.1 Fab Dimer, Derived From A Macaque Hiv-1 Vaccine-Induced Env Glycan-Reactive Neutralizing Antibody B Cell Lineage","Crystal Structure Of The Disulfide Linked Dh717.1 Fab Dimer, Derived From A Macaque Hiv-1 Vaccine-Induced Env Glycan-Reactive Neutralizing Antibody B Cell Lineage",Homo sapiens,"Acharya,P.;Williams,W.;Henderson,R.;Janowska,K.;Manne,K.;Parks,R.;Deyton,M.;Sprenz,J.;Stalls,V.;Kopp,M.;Mansouri,K.;Edwards,R.J.;Meyerhoff,R.R.;Oguin,T.;Sempowski,G.;Saunders,K.;Haynes,B.F.",Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques,13-JUL-2020,9_8_16_9_3_10,6XRJ_E_F,Xtal structure,HIV,4,1,16.290424,-7.2495317
6P60_A_B,QVQLQESGPGLVKPSETLSLTCAVTGGSISDAYYWSWIRQFPGKRLEWIGYIYGSTGGTRYNPPLKNRVSISIDTSKNQFSLKLRSVTAADTAVYYCVRDGVATIETTGDHWGQGVLVTVSS,QFVLAQPPSVSGAPGQRVTLSCTGSNSNIGVNYVQWYQQLPGTAPKLLIYENNKRPSGVSDRFSGSQSGTSASLTITGLQSEDEADYYCQCYDISLGAHVFGSGTELTVL,6P60_A,6P60_B,Vaccine-Elicited Nhp Fp-Targeting Neutralizing Antibody A12V163-A.02 In Complex With Hiv Fusion Peptide (Residue 512-519),Vaccine-Elicited Nhp Fp-Targeting Neutralizing Antibody A12V163-A.02 In Complex With Hiv Fusion Peptide (Residue 512-519),Human immunodeficiency virus 1,"Xu,K.;Liu,K.;Kwong,P.D.",Vaccine-elicited NHP FP-targeting neutralizing antibody A12V163-a.02 in complex with HIV fusion peptide (residue 512-519),03-JUN-2020,9_8_14_8_3_11,6P60_A_B,Xtal structure,HIV,4,1,16.353905,-7.3500614
7CGW_A_B,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK,7CGW_A,7CGW_B,Complex Structure Of Pd-1 And Tislelizumab Fab,Complex Structure Of Pd-1 And Tislelizumab Fab,Homo sapiens,"Hong,Y.;Feng,Y.;Sun,H.;Zhang,B.;Wu,H.;Zhu,Q.;Li,Y.;Zhang,T.;Zhang,Y.;Cui,X.;Li,Z.;Song,X.;Li,K.;Liu,M.;Liu,Y.",Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage,02-JUL-2020,8_7_12_6_3_9,UOL71124_UOL71125,Xtal structure,CD274; PD1; B7-H; B7H1; B7-H1; PDCD1LG1; PDL1; PD-L1; PDCD1; SLEB2; hSLE1; CD279; PD-1,4,1,16.126457,-7.7533517
ABB70141_ABB70142,QVQLQESGPGLVKPSETLSLTCTVSGGSISGYYWSWIRQPPGKGLEWIGYIHYSRSTNSNPALKSRVTISSDTSKNQLSLRLSSVTAADTAVYYCARDTYYYDSGDYEDAFDIWGQGTMVTVSS,QLVLTQSPSASASLGASVKLTCTLSSGHSNYAIAWHQQQPGKGPRYLMKVNRDGSHIRGDGIPDRFSGSTSGAERYLTISSLQSEDEADYYCQTWGAGIRVFGGGTKLTVL,ABB70141,ABB70142,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kelly-Quintos,C.; Cavacini,L.A.; Posner,M.R.; Goldmann,D.; Pier,G.B.",Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine,26-JUL-2016,8_7_18_7_7_9,ABB70141_ABB70142,Unique source,,4,1,16.305454,-8.099412
CAA12399,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYHWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKNRVTISVDTSKNQFSLNLRSVTAADTAVYYCARGTYGPAGDAFDIWGQGTTVTVSS,DIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIK,CAA12399_H,CAA12399_L,anti-beta-galactosidase ScFv antibody [synthetic construct],anti-beta-galactosidase ScFv antibody [synthetic construct],synthetic construct,"Martineau,P.; Jones,P.; Winter,G.",Expression of an antibody fragment at high levels in the bacterial cytoplasm,14-MAY-2002,8_7_14_6_3_9,CAA12399,Same entry,beta-galactosidase,4,1,16.082426,-7.8670974
4FQQ_B_A,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARTQQGKRIYGVVSFGDYYYYYYMDVWGKGTTVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPWVFGGGTKLTVL,4FQQ_B,4FQQ_A,Crystal Structure Of Germline Antibody Pgt121-Gl Fab,Crystal Structure Of Germline Antibody Pgt121-Gl Fab,Homo sapiens,"Mouquet,H.;Scharf,L.;Euler,Z.;Liu,Y.;Eden,C.;Scheid,J.F.;Halper-Stromberg,A.;Gnanapragasam,P.N.;Spencer,D.I.;Seaman,M.S.;Schuitemaker,H.;Feizi,T.;Nussenzweig,M.C.;Bjorkman,P.J.",Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies,25-JUN-2012,8_7_26_6_3_12,UOJ62899_UOJ62900,Xtal structure,HIV,4,1,15.652083,-7.943375
4QHK_I_J,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASLPRGQLVNAYFDYWGQGTLVTVSS,YELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSFSTFVFGTGTKVTVL,4QHK_I,4QHK_J,Uca (Unbound) From Ch103 Lineage,Uca (Unbound) From Ch103 Lineage,Homo sapiens,"Fera,D.;Schmidt,A.G.;Haynes,B.F.;Gao,F.;Liao,H.X.;Kepler,T.B.;Harrison,S.C.",Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains,28-MAY-2014,8_7_15_6_3_10,4QHK_I_J,Xtal structure,HIV,4,1,16.231554,-7.846791
QMI58166_QMI58185,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSSNYYWSWIRQPPGKGLEWIGYMYYSGSTKYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREVYYYDRSGYYASDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPQTFGQGTKVEIK,QMI58166,QMI58185,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,10_7_20_7_3_9,QMI58166_QMI58185,Unique source,SARS-CoV-2,4,1,16.567791,-8.260757
4N9G_M_N,QVQLQESGPGLVKPSETLSLTCVVSGGSFSSYYWTWIRQSPGKGLEWIGEMNGNSGYTNYNPSLQSRVTISKDASKNQFSLKLTSLTAADTAVYYCARDAIVMVFTDMRGRVDVWGPGILVTVSS,DIQMSQSPSSLSASVGDTVTITCRASQGISNYLAWYQQKPGKAPKSLIYYTSHLESGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQHNSYPRTFGQGTKVEIK,4N9G_M,4N9G_N,Crystal Structure Of A Computationally Designed Rsv-Presenting Epitope Scaffold And Its Elicited Antibody 17Hd9,Crystal Structure Of A Computationally Designed Rsv-Presenting Epitope Scaffold And Its Elicited Antibody 17Hd9,synthetic construct,"Correia,B.E.;Bates,J.T.;Loomis,R.J.;Baneyx,G.;Carrico,C.;Jardine,J.G.;Rupert,P.;Correnti,C.;Kalyuzhniy,O.;Vittal,V.;Connell,M.J.;Stevens,E.;Schroeter,A.;Chen,M.;Macpherson,S.;Serra,A.M.;Adachi,Y.;Holmes,M.A.;Li,Y.;Klevit,R.E.;Graham,B.S.;Wyatt,R.T.;Baker,D.;Strong,R.K.;Crowe JE,Jr.;Johnson,P.R.;Schief,W.R.",Proof of principle for epitope-focused vaccine design,21-OCT-2013,8_8_18_6_3_9,4N9G_M_N,Xtal structure,,4,1,16.203226,-7.4517517
7RKU_E_F,QVQLQESGPGLVKPSETLSVTCTVSGGSISSSRYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHAAAYYDRSGYYFIEYFQHWGQGTLVTVSS,DIQMTQSPSTLSASVGDSVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNNYRYTFGQGTKLEIK,7RKU_E,7RKU_F,"Structure Of The Sars-Cov-2 Receptor Binding Domain In Complex With The Human Neutralizing Antibody Fab Fragment, C022","Structure Of The Sars-Cov-2 Receptor Binding Domain In Complex With The Human Neutralizing Antibody Fab Fragment, C022",Homo sapiens,"Jette,C.A.;Cohen,A.A.;Gnanapragasam,P.N.;Muecksch,F.;Lee,Y.E.;Huey-Tubman,K.E.;Schmidt,F.;Hatziioannou,T.;Bieniasz,P.D.;Nussenzweig,M.C.;West AP,Jr.;Keeffe,J.R.;Bjorkman,P.J.;Barnes,C.O.",Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies,22-JUL-2021,10_7_21_6_3_9,7RKU_E_F,Xtal structure,COVID,4,1,16.818335,-8.082141
QFQ61610_QFQ61762,QVQLQESGPGLVKPSGTLSLTCAVSGGSISGTNWWTWVRQPPGRGLEWIGEIYYRGSPNYNPSLKSRVTISVDQSKSQFSLKLTSVTAADTAVYYCLRLSHYGGAWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKFLIFSASNLQSGVPSRFSGGGSGTDFTLTISSLQPEDFATYYCQQTYNTPRTFGQGTKVEIK,QFQ61610,QFQ61762,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehrhardt,S.A.; Zehner,M.; Krahling,V.; Cohen-Dvashi,H.; Kreer,C.; Elad,N.; Gruell,H.; Ercanoglu,M.S.; Schommers,P.; Gieselmann,L.; Eggeling,R.; Dahlke,C.; Wolf,T.; Pfeifer,N.; Addo,M.M.; Diskin,R.; Becker,S.; Klein,F.",Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV,23-OCT-2019,9_7_9_6_3_9,QFQ61610_QFQ61762,Unique source,Ebola,4,1,15.863291,-7.5874624
6Q0H_H_L,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHGGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARAPPYCTSASCPDDYYYYYMDVWGKGTTVTVSG,SSELTQDPAVSVALGQTVRITCQGDSLRGYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHPVVFGGGTKLTVL,6Q0H_H,6Q0H_L,Inferred Intermediate I-7 (I-7-0) Of The Human Antibody Lineage 652 In Complex With Influenza Hemagglutinin Head Domain Of A/Beijing/262/95(H1N1),Inferred Intermediate I-7 (I-7-0) Of The Human Antibody Lineage 652 In Complex With Influenza Hemagglutinin Head Domain Of A/Beijing/262/95(H1N1),Homo sapiens,"McCarthy,K.R.;Raymond,D.D.;Do,K.T.;Schmidt,A.G.;Harrison,S.C.",Affinity maturation in a human humoral response to influenza hemagglutinin,01-AUG-2019,9_7_23_6_3_12,6Q0H_H_L,Xtal structure,hemagglutinin; H1N1; Influenza,4,1,15.346303,-7.4672093
8TFP_B_A,QVQLQESGPGLVKPSGTLSLTCTVSGGFISSRNWWSWVRQPPGKGLEWIGEVYHTGITNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCAREVVGPTTGYFDLWGRGTLVTIVS,SYELTQPPSVSVSPGQTARITCSGDTLPKRSGYWYQQKPDQAPLLVINKDTERPSGIPERFSGSKSGTTVTLTISGVQAEDEADYYCQSADSSFTYPSFGGGTKLTVL,8TFP_B,8TFP_A,Fab From C10-S66K Antibody In Complex With Carfentanil,Fab From C10-S66K Antibody In Complex With Carfentanil,Homo sapiens,"Eubanks,L.M.;Pholcharee,T.;Oyen,D.;Natori,Y.;Zhou,B.;Wilson,I.A.;Janda,K.D.",An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity that Reverses Carfentanil-Induced Respiratory Depression,16-AUG-2023,9_7_14_6_3_11,8TFP_B_A,Xtal structure,C12orf57; GRCC10; C10,4,1,15.60737,-7.3638983
8DWX_H_L,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSDDYYWTWIRLPPGKGLEWIGYIFYTGGTYYNPSLKSRVTISLDRSKNQFSLKLSSVTAADTAVYFCARAPETYCSTTNCYKGYFDSWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPRTFGQGTKVEIK,8DWX_H,8DWX_L,Chikungunya Vlp In Complex With Neutralizing Fab 506.C01 (Asymmetric Unit),Chikungunya Vlp In Complex With Neutralizing Fab 506.C01 (Asymmetric Unit),Homo sapiens,"Raju,S.;Adams,L.J.;Earnest,J.T.;Warfield,K.;Vang,L.;Crowe,J.E.;Fremont,D.H.;Diamond,M.S.",A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans,31-MAY-2023,10_7_20_6_3_9,8DWX_H_L,Xtal structure,Chikungunya,4,1,16.670324,-8.251494
QGR24383_QGR24390,QVQLQESGPGLVKSSETLSLSCTVSGASISNFYWSWVRQPPGKGLEWMGSIYYTGTITYNPSLKSRLTMSVDTSKNQFSLKLNSVTAADTAVYSCAGLDRFNWNDEGDCWGQGTLVTVFS,QSVLTQPPSASGTPGQRVTISCSGSRSNLGRNTVNWYQQLPGVAPKLLIYSNNRRPSGVPDRFSGSKSDTSASLAISGLQSEDEADYFCAAWDDSLNGLYVFGTGTKVTVL,QGR24383,QGR24390,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Donofrio,G.C.; Dussupt,V.; Modjarrad,K.; Michael,N.L.; Barouch,D.H.; Joyce,M.G.; Stephenson,K.",Direct Submission,09-DEC-2019,8_7_14_8_3_12,QGR24383_QGR24390,Unique source,,4,1,16.330376,-7.718151
5GKR_A_B,QVQLQESGPGLVKSSETLSLTCTVSGGSISSYFWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISLHTSKNQFSLKLSSVTAADTAVYYCARHRNWLFDYWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKVMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTYVFGTGTKVTVL,5GKR_A,5GKR_B,Crystal Structure Of Sle Patient-Derived Anti-Dna Antibody In Complex With Oligonucleotide,Crystal Structure Of Sle Patient-Derived Anti-Dna Antibody In Complex With Oligonucleotide,Homo sapiens,"Sakakibara,S.;Arimori,T.;Yamashita,K.;Jinzai,H.;Motooka,D.;Nakamura,S.;Li,S.;Takeda,K.;Katayama,J.;El Hussien,M.A.;Narazaki,M.;Tanaka,T.;Standley,D.M.;Takagi,J.;Kikutani,H.",Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus,05-JUL-2016,8_7_10_9_3_10,5GKR_A_B,Xtal structure,Dna,4,1,16.141417,-7.663981
4JAN_A_B,QVQLQESGPGVVKSSETLSLTCTVSGGSMGGTYWSWLRLSPGKGLEWIGYIFHTGETNYSPSLKGRVSISVDTSEDQFSLRLRSVTAADTAVYFCASLPRGQLVNAYFRNWGRGSLVSVT,YELTQPPSVSVSPGQTATITCSGASTNVCWYQVKPGQSPEVVIFENYKRPSGIPDRFSGSKSGSTATLTIRGTQAIDEADYYCQVWDSFSTFVFGSGTQVTVL,4JAN_A,4JAN_B,Crystal Structure Of Broadly Neutralizing Antibody Ch103 In Complex With Hiv-1 Gp120,Crystal Structure Of Broadly Neutralizing Antibody Ch103 In Complex With Hiv-1 Gp120,Homo sapiens,"Liao,H.X.;Lynch,R.;Zhou,T.;Gao,F.;Alam,S.M.;Boyd,S.D.;Fire,A.Z.;Roskin,K.M.;Schramm,C.A.;Zhang,Z.;Zhu,J.;Shapiro,L.;Mullikin,J.C.;Gnanakaran,S.;Hraber,P.;Wiehe,K.;Kelsoe,G.;Yang,G.;Xia,S.M.;Montefiori,D.C.;Parks,R.;Lloyd,K.E.;Scearce,R.M.;Soderberg,K.A.;Cohen,M.;Kamanga,G.;Louder,M.K.;Tran,L.M.;Chen,Y.;Cai,F.;Chen,S.;Moquin,S.;Du,X.;Joyce,M.G.;Srivatsan,S.;Zhang,B.;Zheng,A.;Shaw,G.M.;Hahn,B.H.;Kepler,T.B.;Korber,B.T.;Kwong,P.D.;Mascola,J.R.;Haynes,B.F.",Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus,18-FEB-2013,8_7_15_4_3_10,4JAN_A_B,Xtal structure,HIV,4,1,16.129456,-7.924895
USZ80088_USZ80100,QVQLQESGPGVVRPSQTLSLTCAVSGDTVSSCCFFWTWIRQPPGKGLEWIGNIYSDNDNTNYNPSLKTRISISKDMSKNQFSLKLNSLTATDTAIYYCARESPSRGNFCYAYLYGNCPLHFDLWGQGVLVTVSS,DILLTQSPSSLSGSVGDRVTITCRASQGINSYLNWYQQKPGKAPKLLIYFANRLQSGVPSRFSGSGSGTEFTLTISSLQSEDGATYYCQQYDTFPTFGPGTKLDIK,USZ80088,USZ80100,"anti-SIV immunoglobulin heavy chain variable region, partial [Macaca mulatta]","anti-SIV immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Zhao,F.; Berndsen,Z.T.; Pedreno-Lopez,N.; Burns,A.; Allen,J.D.; Barman,S.; Lee,W.-H.; Chakraborty,S.; Gnanakaran,S.; Sewall,L.M.; Ozorowski,G.; Limbo,O.; Song,G.; Yong,P.; Callaghan,S.; Woolf,J.; Weisgrau,K.L.; Lifson,J.D.; Nedellec,R.; Voigt,T.B.; Laurino,F.; Louw,J.; Rosen,B.C.; Ricciardi,M.; Crispin,M.; Desrosiers,R.C.; Rakasz,E.G.; Watkins,D.I.; Andrabi,R.; Ward,A.B.; Burton,D.R.; Sok,D.",Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus,16-Sep-2022,10_8_25_6_3_8,USZ80088_USZ80100,Unique source,SIV,4,1,16.199219,-7.425868
UDP68852_UDP68822,QVQLQESGPRLVKPSETLSLTCTVSGGSISGSNYFWGWIRQPPGKGLEWIGTIYYGGSTYYNPSLKSRVTISVDTSENQFSLKLSSVTAADTAVYYCANLAWLRGYFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSVSLTISGLKTEDEADYYCQSYDSSNWVFGGGTKLTVL,UDP68852,UDP68822,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Dussupt,V.; Townsley,S.; Donofrio,G.",Direct Submission,03-NOV-2021,10_7_12_8_3_9,UDP68852_UDP68822,Unique source,,4,1,16.558203,-7.9296827
6QNA_E_F,QVQLQESGPSLVKPSQTLSLTCTVSGLSLSDHNVGWIRQAPGKALEWLGVIYKEGDKDYNPALKSRLSITKDNSKSQVSLSLSSVTTEDTATYYCATLGCYFVEGVGYDCTYGLQHTTFHDAWGQGLLVTVSS,QAVLTQPPSVSGSLGQRVSITCSGSSSNIGRWGVNWYQQVPGSGLRTIIYYESSRPSGVPDRFSGSKSGNTATLTISSLQAEDEADYFCATGDYNIAVFGSGTTLIVM,6QNA_E,6QNA_F,Structure Of Bovine Anti-Rsv Hybrid Fab B13Hc-B4Lc,Structure Of Bovine Anti-Rsv Hybrid Fab B13Hc-B4Lc,Bos taurus,"Ren,J.;Nettleship,J.E.;Harris,G.;Mwangi,W.;Rhaman,N.;Grant,C.;Kotecha,A.;Fry,E.;Charleston,B.;Stuart,D.I.;Hammond,J.;Owens,R.J.",The role of the light chain in the structure and binding activity of two cattle antibodies that neutralize bovine respiratory syncytial virus,10-FEB-2019,8_7_27_8_3_9,6QNA_E_F,Xtal structure,Rsv,4,1,15.392425,-8.57463
QST87699_QST87700,QVQLQQPGAELVMPGASVKMSCKASGYTFTDYWMHWVKQRPGQGLEWIGAIDTSDSYTTYNRKFKGKATLTVDESSSTAYMQLISLTSEDSAVYYCARGGGGNSPFAYWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQEPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYASFPLTFGAGTKLELK,QST87699,QST87700,"anti-EV-D68 immunoglobulin heavy chain variable region, partial [Mus musculus]","anti-EV-D68 immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Zhang,C.; Huang,Z.; Dai,W.",Direct Submission,15-MAR-2021,8_8_12_6_3_9,QST87699_QST87700,Unique source,EV-D68,4,1,-0.34887016,-3.614304
7JTR_H_H,QVQLQQPGSELVRPGASVKLSCKASGYTFTNSWMHWVKQRPGQGLEWIGNIFPGNGNTNYDENFKSKATLTVDTSSNTAYMQLSSLTSEDSAVYYCTRGLFAYWGQGTLVTVSA,DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLINNNQKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHFTAPYTFGGGTKLEIK,7JTR_H,7JTR_H,Complex Of Maltose-Binding Protein (Mbp) With Single-Chain Fv (Scfv),Complex Of Maltose-Binding Protein (Mbp) With Single-Chain Fv (Scfv),Mus musculus,"Lenon,M.;Ke,N.;Ren,G.;Meuser,M.E.;Loll,P.J.;Riggs,P.;Berkmen,M.",A useful epitope tag derived from maltose binding protein,18-AUG-2020,8_8_7_12_3_9,7JTR_H_H,Xtal structure,,4,1,-0.43615383,-4.152151
1FSK_I_H,QVQLQQPGTELVRPGASVILSCKASGYTFTSYWINWVKQRPGQGLEWVGNIFPSDSYTNYNQKFKDKATLTVDKSSSTAYMQVNSPTSEDSAVYYCTRGARDTWFAYWGQGTLVTVS,NIVLTQSPKSMSVSVGERVTLSCKASENVDTYVFWFQQKPDQSPKLLLYGPSNRYTGVPDRFTGSGSTTDFTLTISSVQAEDLADYHCGQSYSYPYTFGGGTKLEIK,1FSK_I,1FSK_H,Complex Formation Between A Fab Fragment Of A Monoclonal Igg Antibody And The Major Allergen From Birch Pollen Bet V 1,Complex Formation Between A Fab Fragment Of A Monoclonal Igg Antibody And The Major Allergen From Birch Pollen Bet V 1,Mus musculus,"Mirza,O.;Henriksen,A.;Ipsen,H.;Larsen,J.N.;Wissenbach,M.;Spangfort,M.D.;Gajhede,M.",Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1,11-SEP-2000,8_8_11_6_3_9,1FSK_I_H,Xtal structure,,4,1,-0.40716478,-3.6936264
6FFJ_E_E,QVQLQQSGAELAKPGASMKMSCRASGYSFTSYWIHWLKQRPDQGLEWIGYIDPATAYTESNQKFKDKAILTADRSSNTAFMYLNSLTSEDSAVYYCARESPRLRRGIYYYAMDYWGQGTTVTVSS,DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGAGTKLELK,6FFJ_E,6FFJ_E,Anti-Tumor Antibody 14F7-Derived Single Chain Fragment Variable (Scfv),Anti-Tumor Antibody 14F7-Derived Single Chain Fragment Variable (Scfv),Homo sapiens,"Bjerregaard-Andersen,K.;Johannesen,H.;Abdel-Rahman,N.;Heggelund,J.E.;Hoas,H.M.;Abraha,F.;Bousquet,P.A.;Hoydahl,L.S.;Burschowsky,D.;Rojas,G.;Oscarson,S.;Loset,G.A.;Krengel,U.",Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture,08-JAN-2018,8_8_18_6_3_9,6FFJ_E_E,Xtal structure,ganglioside,4,1,0.07064201,-3.295413
2I9L_F_E,QVQLQQSGAELAKPGASVKMSCKASGYTFTRYWMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTVYMQLSSLTSEDSAVYYCARTTVDGYDFAYWGQGTLVTVSA,DMVMSQSPSSLAVSAGEKVSMSCKSSQTLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLWTFGGGTKLEIK,2I9L_F,2I9L_E,Structure Of Fab 7D11 From A Neutralizing Antibody Against The Poxvirus L1 Protein,Structure Of Fab 7D11 From A Neutralizing Antibody Against The Poxvirus L1 Protein,Vaccinia virus,"Su,H.P.;Golden,J.W.;Gittis,A.G.;Hooper,J.W.;Garboczi,D.N.","Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein",05-SEP-2006,8_8_12_12_3_8,2I9L_F_E,Xtal structure,,4,1,0.13191566,-3.2903092
6EWB_J_K,QVQLQQSGAELMKPGASVKISCTATGYTFITYWIQWVKQRPGHGLEWIGETLPGSGSTNYNEKFKGKATFTADTSSNTAYMQLSSLTSEDSAIYYCARIGRSNDYWGQGTTLTVSS,QIVLTQSPTIMSASPGEKVTMTCSASSSVDYMHWYQQKSGTSPKRWIYDTYKLASGVPARFSGSGSGTSYSLTINSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,6EWB_J,6EWB_K,Crystal Structure Of Gii.4 Unsw 2012 P Domain In Complex With Fab 10E9,Crystal Structure Of Gii.4 Unsw 2012 P Domain In Complex With Fab 10E9,Mus musculus,"Koromyslova,A.D.;Morozov,V.M.;Hefele,L.;Hansman,G.S.",Human Norovirus Neutralized by a Monoclonal Antibody Targeting the HBGA 1 Pocket,03-NOV-2017,8_8_9_5_3_9,6EWB_J_K,Xtal structure,,4,1,4.9911323,-1.8762635
6Z7W_D_C,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNHLIEWVNQRPGQGLEWIGVINPGSGGTKYNEKFKGKATLTADKSSSTAYMQLSRLTSDDSAVYFCARSSEFITTVAADYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSITCKASQNVRTAVAWYQQRPGQSPKALIYLASNRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCLQHWNYPLTFGSGTKLEIK,6Z7W_D,6Z7W_C,Human Insulin In Complex With The Analytical Antibody Hui-018 Fab,Human Insulin In Complex With The Analytical Antibody Hui-018 Fab,Homo sapiens,"Johansson,E.;Wu,X.;Yu,B.;Yang,Z.;Cao,Z.;Wiberg,C.;Jeppesen,C.B.;Poulsen,F.",Insulin binding to the analytical antibody sandwich pair OXI-005 and HUI-018: Epitope mapping and binding properties,02-JUN-2020,8_8_14_6_3_9,6Z7W_D_C,Xtal structure,,4,1,0.17974097,-4.4315467
7AQL_C_C,QVQLQQSGAEVVKPGASVKLACTASGFNIKDTYIHWVKQGPEQGLEWIGRIDPANGNTKYDSKFQDKATITADTSSNTAYLHLSSLTSEDTAVYYCVRGDYDYVYFDYWGQGTTVTVSS,DIQMTQSPSSLSASLGDRVTISCRASQDISNFLDWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISKLEQEDIATYFCQQGNTFPPTFGGGTKLEIK,7AQL_C,7AQL_C,Crystal Structure Of An Anti-Plasminogen Activator Inhibitor-1 (Pai-1) Scfv Antibody Fragment (Scfv-33H1F7),Crystal Structure Of An Anti-Plasminogen Activator Inhibitor-1 (Pai-1) Scfv Antibody Fragment (Scfv-33H1F7),Mus musculus,"Sillen,M.;Weeks,S.D.;Strelkov,S.V.;Declerck,P.J.",Crystal Structure of an Anti-Plasminogen Activator Inhibitor-1 (PAI-1) scFv antibody fragment (scFv-33H1F7),22-OCT-2020,8_8_12_6_3_9,7AQL_C_C,Xtal structure,PLANH1; PAI; SERPINE1; PAI1,4,1,-4.6490808,0.18078583
3NN8_D_E,QVQLQQSGPEDVKPGASVKISCKASGYSLSTSGMGVNWVKQSPGKGLEWLAHIYWDDDKRYNPSLKSRATLTVDKTSSTVYLELRSLTSEDSSVYYCARRGGSSHYYAMDYWGQGTTVTVSS,DIVMTQTPSSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSLVPPTFGAGTKLELK,3NN8_D,3NN8_E,Crystal Structure Of Engineered Antibody Fragment Based On 3D5,Crystal Structure Of Engineered Antibody Fragment Based On 3D5,Mus musculus,"Pai,J.;Culver,J.A.;Drury,J.E.;Lieberman,R.L.;Maynar,J.A.",Peptide-Binding Single Chain Antibody Fragment (Scf Chaperones For Protein Co-Crystallization,23-JUN-2010,10_7_14_11_3_9,3NN8_D_E,Xtal structure,,4,1,1.7891753,-4.3758783
4NKD_C_D,QVQLQQSGPEDVKPGASVKISCKASGYSLTTAGMGVNWVKQSPGKGLEWLAHIYWDDDKRYNPSLKSRATLTVDKSSSTVYLELRSLTSEDSSVYYCARRGGSSHYYAMDYWGQGTTVTVSS,DIVMTQTPSSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSLVPPTFGAGTKLELK,4NKD_C,4NKD_D,Crystal Structure Of Engineered Anti-Ee Scfv Antibody Fragment,Crystal Structure Of Engineered Anti-Ee Scfv Antibody Fragment,Mus musculus,"Kalyoncu,S.;Hyun,J.;Pai,J.C.;Johnson,J.L.;Entzminger,K.;Jain,A.;Heaner DP,Jr.;Morales,I.A.;Truskett,T.M.;Maynard,J.A.;Lieberman,R.L.",Effects of protein engineering and rational mutagenesis on crystal lattice of single chain antibody fragments,12-NOV-2013,10_7_14_11_3_9,4NKD_C_D,Xtal structure,,4,1,1.7833132,-4.356458
4NKM_A_B,QVQLQQSGPEDVKPGASVKISCKASGYSLTTKGMGVNWVKQSPGKGLEWLAHIYWDDDKRYNPSLKSRATLTVDKSSSTVYLELRSLTSEDSSVYYCARRGGSSHYYAMDYWGQGTTVTVSS,DIVMTQTPSSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYYCFQGSLVPPTFGAGTKLELK,4NKM_A,4NKM_B,Crystal Structure Of Engineered Anti-Ee Scfv Antibody Fragment,Crystal Structure Of Engineered Anti-Ee Scfv Antibody Fragment,Mus musculus,"Kalyoncu,S.;Hyun,J.;Pai,J.C.;Johnson,J.L.;Entzminger,K.;Jain,A.;Heaner DP,Jr.;Morales,I.A.;Truskett,T.M.;Maynard,J.A.;Lieberman,R.L.",Effects of protein engineering and rational mutagenesis on crystal lattice of single chain antibody fragments,12-NOV-2013,10_7_14_11_3_9,4NKM_A_B,Xtal structure,,4,1,1.7909014,-4.357231
6HF1_C_B,QVQLQQSGPELVKPGASVKISCKASGYSFTSYYIHWVKQRPGQGLEWIGWIYPGSYNTEYSEKFKGKATLTADTSSSTAYMQLSSLTSEDSAVYYCARSEDWFAYWGQGTLVTVSA,QIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYHQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPLTFGAGTKLELK,6HF1_C,6HF1_B,Mutant Oxidoreductase Fragment Of Mouse Qsox1 In Complex With An Antibody Fab,Mutant Oxidoreductase Fragment Of Mouse Qsox1 In Complex With An Antibody Fab,Mus musculus,"Javitt,G.;Grossman-Haham,I.;Alon,A.;Resnick,E.;Mutsafi,Y.;Ilani,T.;Fass,D.",cis-Proline mutants of quiescin sulfhydryl oxidase 1 with altered redox properties undermine extracellular matrix integrity and cell adhesion in fibroblast cultures,21-AUG-2018,8_8_9_5_3_9,6HF1_C_B,Xtal structure,,4,1,0.061737955,-4.346845
5DFV_C_D,QVQLQQSGPELVKPGASVKISCKASGYTFSSSWMNWVKQRPGKGLEWIGRIYSGDGDAIYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAREGKTGDLLLRSWGQGSALTVSS,DIVLTQSPASLSVSLGQRATISCRASKSVSTSIYSYMHWYQQKPGQPPKLLIKYASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCEHSREFPFTFGTGTKLEIK,5DFV_C,5DFV_D,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With Murine Fab Fragment K04,Crystal Structure Of Human Cd81 Large Extracellular Loop In Complex With Murine Fab Fragment K04,Mus musculus,"Bujotzek,A.;Lipsmeier,F.;Harris,S.F.;Benz,J.;Kuglstatter,A.;Georges,G.",VH-VL orientation prediction for antibody humanization candidate selection: A case study,27-AUG-2015,8_8_13_10_3_9,5DFV_C_D,Xtal structure,,4,1,0.38986862,-4.7370076
6PV8_H_I,QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYALYWVRQSHAKSLEWIGVINPYSGNTNYNQKFKGKATMTVDKSSSTAYMELARLTSDDSAIYYCASGYDGYPYTMDYWGPGASVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSMTYMHWYQQKSGTSPKRWIYDTSQLASGVPARFRGSGSGTSFSLTISSMEAEDAATYYCQQWSSNPLTFGGGTKLELK,6PV8_H,6PV8_I,Human Alpha3Beta4 Nicotinic Acetylcholine Receptor In Complex With At-1001,Human Alpha3Beta4 Nicotinic Acetylcholine Receptor In Complex With At-1001,Mus musculus,"Gharpure,A.;Teng,J.;Zhuang,Y.;Noviello,C.M.;Walsh RM,Jr.;Cabuco,R.;Howard,R.J.;Zaveri,N.T.;Lindahl,E.;Hibbs,R.E.",Agonist Selectivity and Ion Permeation in the alpha3beta4 Ganglionic Nicotinic Receptor,19-JUL-2019,8_8_13_5_3_9,6PV8_H_I,Xtal structure,,4,1,2.966542,-4.5501113
6WJ1_J_K,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSVAWNWIRQSPSRGLEWLGRTYFRSKWYTDYAESLKSRMTINPDTSKNEFSLHLKSVTSDDTAVYYCVRGIIFNWPLGGWSFDLWGRGTLVSVSS,EIVLTQSPGTLSLSPGDSATLSCRASQSVASSYLAWYQQKPGQSPRLLIYATINRAADIPDRFSGSGSGTDFALTISRLEPEDFAVYYCQQFDSSSMYTFGQGTKLEIT,6WJ1_J,6WJ1_K,Crystal Structure Of Fab 54-4H03 Bound To H1 Influenza Hemagglutinin,Crystal Structure Of Fab 54-4H03 Bound To H1 Influenza Hemagglutinin,Homo sapiens,"Wu,N.C.;Andrews,S.F.;Raab,J.E.;O'Connell,S.;Schramm,C.A.;Ding,X.;Chambers,M.J.;Leung,K.;Wang,L.;Zhang,Y.;Mascola,J.R.;Douek,D.C.;Ledgerwood,J.E.;McDermott,A.B.;Wilson,I.A.",Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor,11-APR-2020,10_9_17_7_3_10,6WJ1_J_K,Xtal structure,Influenza,4,1,15.487839,-4.6826406
6ZTF_H_L,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSQSAAWNWIRQSPSRGLEWLGRIYYRSKWYNDYALSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARGEGYGREGFAIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQTISNTLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLSWFTFGQGTKVEIK,6ZTF_H,6ZTF_L,Crystal Structure Of The Anti-Human P-Cadherin Fab Cqy684,Crystal Structure Of The Anti-Human P-Cadherin Fab Cqy684,Homo sapiens,"Sheng,Q.;D'Alessio,J.A.;Menezes,D.L.;Karim,C.;Tang,Y.;Tam,A.;Clark,S.;Ying,C.;Connor,A.;Mansfield,K.G.;Rondeau,J.M.;Ghoddusi,M.;Geyer,F.C.;Gu,J.;McLaughlin,M.E.;Newcombe,R.;Elliot,G.;Tschantz,W.R.;Lehmann,S.;Fanton,C.P.;Miller,K.;Huber,T.;Rendahl,K.G.;Jeffry,U.;Pryer,N.K.;Lees,E.;Kwon,P.;Abraham,J.A.;Damiano,J.S.;Abrams,T.J.","PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies",20-JUL-2020,10_9_13_6_3_8,AYH73371_AYH73372,Xtal structure,P-cadherin,4,1,15.49282,-4.6865554
QSI99020_QSI99051,QVQLQQSGPGLVKPSQTLSLTCTVAGGSISSGTYYWSWIRQPAGKGLEWIGRIYTSGSANYNPSLKSRVTISVDTSKNQFSLRLSSVTAEDTAVYYCAREYSSSYYYFYYMDVWGKGTTVTVSS,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGFGTDFTFTISSLQPEDIATYYCQQFDNLPYTFGQGTKLEIK,QSI99020,QSI99051,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Jennewein,M.F.; MacCamy,A.J.; Akins,N.R.; Feng,J.; Homad,L.J.; Hurlburt,N.K.; Seydoux,E.; Wan,Y.-H.; Stuart,A.B.; Parks,R.; Ward,A.; Ozorowski,G.; Mascola,J.R.; Doria-Rose,N.; Wang,L.; Yang,E.S.; Chu,H.Y.; Whaley,R.E.; Cohen,K.W.; Pancera,M.; McElrath,M.J.; Englund,J.A.; Finzi,A.; Suthar,M.S.; McGuire,A.T.; Stamatatos,L.",Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects,08-MAR-2021,10_7_16_6_3_9,QSI99020_QSI99051,Unique source,SARS-CoV-2; COVID,4,1,16.072884,-8.112993
7SFX_J_K,QVQLQQSGPVLVKPSQTLSLTCAISGDSISSDTTAWSWIRRSPSRGLEWLGWTYYRSKWFNYYAVSVKGRVTINPDTSKNQFSLQLSSVTPEDTAVYYCARGNGNGGMDVWGQGTTVTVSS,SYVLTQPASASVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIFKDSERPSGVPERFSGSSSGTTVTLTISGAQAEDEADYYCQSVDNSGFYQVFGGGTQLTVL,7SFX_J,7SFX_K,10A1 Fab In Complex With Cd99 Peptide,10A1 Fab In Complex With Cd99 Peptide,Homo sapiens,"Romero,L.A.;Hattori,T.;Ali,M.A.;Ketavarapu,G.;Koide,A.;Park,C.Y.;Koide,S.",High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia,04-OCT-2021,10_9_11_6_3_11,7SFX_J_K,Xtal structure,MIC2; CD99,4,1,15.490042,-4.684681
7L77_H_L,QVQLQQWGAGLLKPSETLSLTCALYGRSLNGNYWSWIRQSPGKGLEWIGEINHSGSTYFNPSFKSRVAMSVDTSKSQFSLKLNSVTAADTGIYFCARGKRYSASYSNYFGVWGQGTQVTVSS,DIQMTQSPSTLSASVGDRVDITCRASQSISRWLAWYQQKPGKAPKVLIYEASLLANGVPSRFSGHFNGRESATDFTLTISSLQPDDVATYYCQHYMADPRFGQGTKLEIK,7L77_H,7L77_L,Crystal Structure Of Broadly Hiv-1-Neutralizing Antibody Vrc33.01,Crystal Structure Of Broadly Hiv-1-Neutralizing Antibody Vrc33.01,Homo sapiens,"Zhou,T.",Crystal structure of broadly HIV-1-neutralizing antibody,27-DEC-2020,8_7_16_6_3_8,7L77_H_L,Xtal structure,HIV,4,1,16.688217,-10.516353
7M7B_H_L,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARRWWLRGAFDIWGQGTTVTVSS,NFMLTQPHSVSASPGKTVTIPCTGSSGNIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDNNIQVFGGGTKLTVL,7M7B_H,7M7B_L,Sars-Cov-2 Spike:Fab 3D11 Complex Focused Refinement,Sars-Cov-2 Spike:Fab 3D11 Complex Focused Refinement,Homo sapiens,"Asarnow,D.;Wang,B.;Lee,W.H.;Hu,Y.;Huang,C.W.;Faust,B.;Ng,P.M.;Ngoh,E.Z.;Bohn,M.;Bulkley,D.;Pizzorno,A.;Ary,B.;Tan,H.C.;Lee,C.Y.;Minhat,R.A.;Terrier,O.;Soh,M.K.;Teo,F.J.;Yeap,Y.Y.;Seah,S.G.;Chan,C.E.;Connelly,E.;Young,N.J.;Maurer-Stroh,S.;Renia,L.;Hanson,B.J.;Rosa-Calatrava,M.;Manglik,A.;Cheng,Y.;Craik,C.S.;Wang,C.I.",Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia,27-MAR-2021,8_7_12_8_3_9,7M7B_H_L,Xtal structure,SARS-CoV-2,4,1,16.632809,-10.452813
UTO68534_UTO68558,QVQLQQWGGGLLKPSQTLSLTCAVYRWTFNDHYWSWVRQSPGKGLEWIGEISWGGATNYNPSLKSRVTMSVDTSMSHVSLKMTSVTAADTGVYYCVRVGPGPHMAALDYWGHGSRVLVSS,DIVMTQTPLSSPVTLGQPASISCGSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRISGLPDRFSGSGAETNFTLKISRVEAEDVGLYYCVQGTQFPWTSGQGTKVEIK,UTO68534,UTO68558,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"van Schooten,J.",Direct Submission,23-JUL-2022,8_7_14_11_3_9,UTO68534_UTO68558,Unique source,,4,1,16.701414,-10.527389
5IJV_H_L,QVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGNIDTGGITGYNPGLKSRLSITKDNSKNQVSLSVSSATAEDSATYYCTTVHQKTLEVRSCPDGSRLIGNDCRNEDGDDVNYITTFDYEWYVDAWGQGLLVTVSS,QAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,5IJV_H,5IJV_L,Crystal Structure Of Bovine Fab E03,Crystal Structure Of Bovine Fab E03,Bos taurus,"Stanfield,R.L.;Wilson,I.A.;Smider,V.V.",Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies,02-MAR-2016,8_7_46_8_3_11,5IJV_H_L,Xtal structure,,4,1,13.881356,-9.354684
6E9Q_C_D,QVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGNAGYNPGLKSRLSITQDNSKSQVSLSVSTVTTEDSATYYCTTVHQKTTRNCPAGYSVHYDCSFGDGCTWTCVRHGRASSISVTYTYEWYVDAWGQGLLVTVSS,EAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,6E9Q_C,6E9Q_D,The Crystal Structure Of Bovine Ultralong Antibody Bov-6,The Crystal Structure Of Bovine Ultralong Antibody Bov-6,Bos taurus,"Dong,J.;Finn,J.A.;Larsen,P.A.;Smith,T.P.;Crowe JE,Jr.",Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains,01-MAY-2019,8_7_52_8_3_11,6E9Q_C_D,Xtal structure,,4,1,13.861435,-9.364795
7LYW_C_D,QVQLVESGAEVKKPGASVKVSCKASGYTFTNYAIHWVRQAPGQRLEWMGWINAGRGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDAAVYFCARDESTGDYYYYMDVWGKGTTVTVSS,SYELTQPPSVSVSPGQTASITCSGDRLDDKYASWYQQKAGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSDTYVFGTGTKVTVL,7LYW_C,7LYW_D,Crystal Structure Of The Hcmv Pentamer-Specific Antibody 2-25,Crystal Structure Of The Hcmv Pentamer-Specific Antibody 2-25,Homo sapiens,"Wrapp,D.;Ye,X.;Ku,Z.;Su,H.;Jones,H.G.;Wang,N.;Mishra,A.K.;Freed,D.C.;Li,F.;Tang,A.;Li,L.;Jaijyan,D.K.;Zhu,H.;Wang,D.;Fu,T.M.;Zhang,N.;An,Z.;McLellan,J.S.",Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies,08-MAR-2021,8_8_15_6_3_9,7LYW_C_D,Xtal structure,neuropilin; HCMV,4,1,0.26510385,3.1435359
7ZRC_H_L,QVQLVESGAEVKKPGSSVKVSCKASGGNFNMYTISWVRQAPGRGLEWMGRFIPIANKANYAQNFPGRVTITADKSTSTVYMELRSLTSDDTAVYYCARSGSYDAFDVWGQGTMVTVSS,AIRMTQSPSTLSASVGDRVTITCRASQTINSWLAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYESYSPITFGQGTRLEIK,7ZRC_H,7ZRC_L,Omi-38 Fab In Complex With Sars-Cov-2 Beta Spike,Omi-38 Fab In Complex With Sars-Cov-2 Beta Spike,Homo sapiens,"Nutalai,R.;Zhou,D.;Tuekprakhon,A.;Ginn,H.M.;Supasa,P.;Liu,C.;Huo,J.;Mentzer,A.J.;Duyvesteyn,H.M.E.;Dijokaite-Guraliuc,A.;Skelly,D.;Ritter,T.G.;Amini,A.;Bibi,S.;Adele,S.;Johnson,S.A.;Constantinides,B.;Webster,H.;Temperton,N.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Crook,D.;Pollard,A.J.;Lambe,T.;Goulder,P.;veName>OPTIC consortium, ISARIC4C consortium</CollectiveName>,?.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Mongkolsapaya,J.;Fry,E.E.;Dejnirattisai,W.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Potent cross-reactive antibodies following Omicron breakthrough in vaccinees,04-MAY-2022,8_8_11_6_3_10,7ZRC_H_L,Xtal structure,,4,1,-0.6272346,5.5552
2V7N_B_A,QVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK,2V7N_B,2V7N_A,Unusual Twinning In Crystals Of The Cits Binding Antibody Fab  Fragment F3P4,Unusual Twinning In Crystals Of The Cits Binding Antibody Fab  Fragment F3P4,synthetic construct,"Frey,D.;Huber,T.;Pluckthun,A.;Grutter,M.G.",Structure of the recombinant antibody Fab fragment f3p4,31-JUL-2007,8_8_12_7_3_9,2V7N_B_A,Xtal structure,,4,1,13.895731,10.884097
3NH7_K_O,QVQLVESGGGLVQPGGSLRLSCAASGFTFSNYTLNWVRQAPGKGLEWVSYTSSSGSLTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERWHVRGYFDHWGQGTLVTVSS,IELTQPPSVSVAPGQTARISCSGDSLGSKYVIWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSTFTMSGNGTVFGGGTKLTVL,3NH7_K,3NH7_O,Crystal Structure Of The Neutralizing Fab Fragment Abd1556 Bound To The Bmp Type I Receptor Ia,Crystal Structure Of The Neutralizing Fab Fragment Abd1556 Bound To The Bmp Type I Receptor Ia,Homo sapiens,"Harth,S.;Kotzsch,A.;Hu,J.;Sebald,W.;Mueller,T.D.",A selection fit mechanism in BMP receptor IA as a possible source for BMP ligand-receptor promiscuity,14-JUN-2010,8_8_13_6_3_11,3NH7_K_O,Xtal structure,,4,1,14.460259,9.99692
7OX2_A_L,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSSAMGWVRQAPGKGLEWVSTIVNSITTTYYADSVKGRFTISTDNAKNTLYLQIDSLKSEDTAVYYCGSLAGPYYDYWGQGTQVTVSS,SSALTQPSTVSVSLGQTARITCQGGSLGSYDAHWYQQKPGQAPVLVIHDNNSRPSGIPERFTGSRSGETATLTISGAQTEDEADYYCQSYDSTSDALVFGGGTQLTVL,7OX2_A,7OX2_L,Fab 6E2: Hil-9 Complex,Fab 6E2: Hil-9 Complex,Homo sapiens,"De Vos,T.;Godar,M.;Bick,F.;Papageorgiou,A.C.;Evangelidis,T.;Markovic,I.;Mortier,E.;Dumoutier,L.;Tripsianes,K.;Blanchetot,C.;Savvides,S.N.",Structural basis for the mechanism and antagonism of receptor signaling mediated by Interleukin-9 (IL-9),28-DEC-2022,8_8_10_6_3_11,7OX2_A_L,Xtal structure,P40; IL-9; IL9; HP40,4,1,14.03011,9.518474
7TZH_C_C,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSGISAGGTGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDQDGGKKTDAFDIWGQGTMVTVSS,DIVMTQSPSLLSASVGDRVTITCRASQGINYYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQTGYYPLTFGPGTKVDI,7TZH_C,7TZH_C,Lag3 Ectodomain Structure Reveals Functional Interfaces For Ligand And Antibody Recognition,Lag3 Ectodomain Structure Reveals Functional Interfaces For Ligand And Antibody Recognition,Homo sapiens,"Ming,Q.;Celias,D.P.;Wu,C.;Cole,A.R.;Singh,S.;Mason,C.;Dong,S.;Tran,T.H.;Amarasinghe,G.K.;Ruffell,B.;Luca,V.C.",LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition,15-FEB-2022,8_8_15_6_3_9,7TZH_C_C,Xtal structure,CD223; LAG3; Ectodomain,4,1,13.91844,9.9236355
1FL6_H_L,QVQLVESGGGLVQPGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKANGYTTEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDGSYAMDYWGQGTSVTVSS,ELVMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPRTFGGGTKLEIK,1FL6_H,1FL6_L,The Hapten Complexed Germline Precursor To Sulfide Oxidase Catalytic Antibody 28B4,The Hapten Complexed Germline Precursor To Sulfide Oxidase Catalytic Antibody 28B4,Homo sapiens,"Yin,J.;Mundorff,E.C.;Yang,P.L.;Wendt,K.U.;Hanway,D.;Stevens,R.C.;Schultz,P.G.",A comparative analysis of the immunological evolution of antibody 28B4,11-AUG-2000,8_10_10_11_3_9,1FL6_H_L,Xtal structure,,4,1,26.034508,4.653068
7UCQ_H_H,QVQLVESGGGVVQPGGSLRLSCAASGFTFSSFAMHWARQAPGKGLEWVAYIRYDGTKEFYTDSAKGRFTISRDNSKNTLYLQMDSLRAEDTALYYCAKDLGINSYGYGGLDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERGTLSCRASQNVNRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRAIWPPLTFGGGTKVEIK,7UCQ_H,7UCQ_H,Pfs230 D1 Domain In Complex With 230As-18,Pfs230 D1 Domain In Complex With 230As-18,Homo sapiens,"Tang,W.K.;Coelho,C.H.;Miura,K.;Nguemwo Tentokam,B.C.;Salinas,N.D.;Narum,D.L.;Healy,S.A.;Sagara,I.;Long,C.A.;Duffy,P.E.;Tolia,N.H.",A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine,15-FEB-2023,8_8_16_6_3_10,7UCQ_H_H,Xtal structure,Pfs230D1,4,1,14.934413,13.467213
7UI1_H_H,QVQLVESGGGVVQPGGSLRLSCTASGLIFNKYGIYWVRQAPGKGLEWVAFIRYDGTNQFYADSVKGRFTISRDNSKNKVYLQMNSLRAEDTALYYCAKDRGSIIVFDHWGQGTLVTVSS,EIVLTQSPATLSLSPGERVTLSCRASQAVGIYLAWYQQKPGQAPRLLIYHVSKRDTGVPDRFSGSGSGTDFTLTISSLEPEDFAVYYCQQHRNWPPITFGQGTRLEIK,7UI1_H,7UI1_H,Pfs230 D1D2 Domain In Complex With 230Al-37,Pfs230 D1D2 Domain In Complex With 230Al-37,Homo sapiens,"Tang,W.K.;Coelho,C.H.;Miura,K.;Nguemwo Tentokam,B.C.;Salinas,N.D.;Narum,D.L.;Healy,S.A.;Sagara,I.;Long,C.A.;Duffy,P.E.;Tolia,N.H.",A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine,15-FEB-2023,8_8_12_6_3_10,7UI1_H_H,Xtal structure,Pfs230D1,4,1,15.065822,13.292953
6XOB_S_T,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGIHWVRQAPGKGLEWVAVISYDGRHKYIADPVKGRFTISRDNSKNMLYLQMNSLRTEDTAVYYCAKDTSGWYEFFDSWGQGIPVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVATNVAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQCNDWLTFGQGTKVEIK,6XOB_S,6XOB_T,Cryoem Structure Of Eastern Equine Encephalitis (Eeev) Vlp With Fab Eeev-143.,Cryoem Structure Of Eastern Equine Encephalitis (Eeev) Vlp With Fab Eeev-143.,Homo sapiens,"Williamson,L.E.;Gilliland T,Jr.;Yadav,P.K.;Binshtein,E.;Bombardi,R.;Kose,N.;Nargi,R.S.;Sutton,R.E.;Durie,C.L.;Armstrong,E.;Carnahan,R.H.;Walker,L.M.;Kim,A.S.;Fox,J.M.;Diamond,M.S.;Ohi,M.D.;Klimstra,W.B.;Crowe JE,Jr.",Human Antibodies Protect against Aerosolized Eastern Equine Encephalitis Virus Infection,06-JUL-2020,8_8_13_6_3_8,6XOB_S_T,Xtal structure,,4,1,14.9367895,13.441963
6D01_G_H,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWYDGSKKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRDSSDYYGDAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASNLESGVPLRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNNYWTFGQGTKVEIK,6D01_G,6D01_H,Crystal Structure Of 1210 Fab In Complex With Circumsporozoite Protein Nanp5,Crystal Structure Of 1210 Fab In Complex With Circumsporozoite Protein Nanp5,Plasmodium falciparum,"Imkeller,K.;Scally,S.W.;Bosch,A.;Marti,G.P.;Costa,G.;Triller,G.;Murugan,R.;Renna,V.;Jumaa,H.;Kremsner,P.G.;Sim,B.K.;Hoffman,S.L.;Mordmuller,B.;Levashina,E.A.;Julien,J.P.;Wardemann,H.",Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope,09-APR-2018,8_8_16_6_3_8,6D01_G_H,Xtal structure,,4,1,14.79505,13.7942505
5W1K_L_K,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSSAMHWVRQAPGKGLEWVAVIWSDGSNENYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCATDKTYVSGYTSTWYYFNYWGQGTLVTVSG,IQMTQSPSTLSASVGDRVTITCRASQSIDNWLAWYQQKPGKAPKLLIYTASRLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHRTFGQGTKVEIK,5W1K_L,5W1K_K,Junv Gp1 Cr1-10 Fab Cr1-28 Fab Complex,Junv Gp1 Cr1-10 Fab Cr1-28 Fab Complex,Homo sapiens,"Clark,L.E.;Mahmutovic,S.;Raymond,D.D.;Dilanyan,T.;Koma,T.;Manning,J.T.;Shankar,S.;Levis,S.C.;Briggiler,A.M.;Enria,D.A.;Wucherpfennig,K.W.;Paessler,S.;Abraham,J.",Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses,03-JUN-2017,8_8_19_6_3_4,5W1K_L_K,Xtal structure,,4,1,14.943397,13.687478
6VCA_E_F,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVFWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAVYYCARAPNWDDAFDIWGQGTMVTVSS,QTVVTQEPSFSVSPGGTVTLTCGLSSGSVSTSYYPNWYQQTPGQAPRTLIYSTNTRSSGVPDRFSGSILGNKAALTITGAQADDESDYYCVLFMGSGIWVFGGGTKLTVL,6VCA_E,6VCA_F,Tb38 Complex,Tb38 Complex,Homo sapiens,"Stefano,J.E.;Lord,D.M.;Zhou,Y.;Jaworski,J.;Hopke,J.;Travaline,T.;Zhang,N.;Wong,K.;Lennon,A.;He,T.;Bric-Furlong,E.;Cherrie,C.;Magnay,T.;Remy,E.;Brondyk,W.;Qiu,H.;Radosevic,K.",A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms,20-DEC-2019,8_8_12_9_3_10,6VCA_E_F,Xtal structure,eNT; CALJA; NT5E; CD73; eN; NT5,4,1,14.635387,13.529933
QMI58172_QMI58190,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSGYNYGYSWFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSADALAKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSTDNSGTYPNWVFGGGTKLTVL,QMI58172,QMI58190,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_15_6_3_13,QMI58172_QMI58190,Unique source,SARS-CoV-2,4,1,15.009602,13.611416
7SN3_F_G,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGTNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLAYRDYVWRYFDLWGRGTLVTVSG,EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQQKFGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQCRSNWPPGITFGQGTRLEIK,7SN3_F,7SN3_G,Structure Of Human Sars-Cov-2 Spike Glycoprotein Trimer Bound By Neutralizing Antibody C1C-A3 Fab (Variable Region),Structure Of Human Sars-Cov-2 Spike Glycoprotein Trimer Bound By Neutralizing Antibody C1C-A3 Fab (Variable Region),Homo sapiens,"Nabel,K.G.;Clark,S.A.;Shankar,S.;Pan,J.;Clark,L.E.;Yang,P.;Coscia,A.;McKay,L.G.;Varnum,H.H.;Brusic,V.;Tolan,N.V.;Zhou,G.;Desjardins,M.;Turbett,S.E.;Kanjilal,S.;Sherman,A.C.;Dighe,A.;LaRocque,R.C.;Ryan,E.T.;Tylek,C.;Cohen-Solal,J.F.;Darcy,A.T.;Tavella,D.;Clabbers,A.;Fan,Y.;Griffiths,A.;Correia,I.R.;Seagal,J.;Baden,L.R.;Charles,R.C.;Abraham,J.",Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain,27-OCT-2021,8_8_16_6_3_11,7SN3_F_G,Xtal structure,SARS-CoV-2,4,1,14.986624,13.466923
3ZTJ_G_H,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVISYDANYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSQLRSLLYFEWLSQGYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVTFNYKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYRTPPTFGQGTKVEIK,3ZTJ_G,3ZTJ_H,Structure Of Influenza A Neutralizing Antibody Selected From Cultures  Of Single Human Plasma Cells In Complex With Human H3 Influenza  Haemagglutinin.,Structure Of Influenza A Neutralizing Antibody Selected From Cultures  Of Single Human Plasma Cells In Complex With Human H3 Influenza  Haemagglutinin.,Homo sapiens,"Corti,D.;Voss,J.;Gamblin,S.J.;Codoni,G.;Macagno,A.;Jarrossay,D.;Vachieri,S.G.;Pinna,D.;Minola,A.;Vanzetta,F.;Silacci,C.;Fernandez-Rodriguez,B.M.;Agatic,G.;Bianchi,S.;Giacchetto-Sasselli,I.;Calder,L.;Sallusto,F.;Collins,P.;Haire,L.F.;Temperton,N.;Langedijk,J.P.;Skehel,J.J.;Lanzavecchia,A.",A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,08-JUL-2011,8_8_22_10_3_9,QRJ73680_QRJ73681,Xtal structure,Influenza,4,1,15.123361,13.968101
QMI58173_QMI58186,QVQLVESGGGVVQPGRSLRLSCAASGLTFSSYVMHWVRQAPGKGLDWVGVIWYDGSKKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRDYYDFWSGYDYYYGLDVWGQGTTVTVSS,EIVLTQSPGILSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSGALTFGGGTKVEIK,QMI58173,QMI58186,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_22_7_3_10,QMI58173_QMI58186,Unique source,SARS-CoV-2,4,1,14.190688,13.946038
5Y2L_I_J,QVQLVESGGGVVQPGTSLRLSCEASGFTSSAYAMHWVRQAPGKGLEWVAVITFDGGYQYYADSVKGRFTISRDISRNTLHLHMNSLRAEDTAVYYCARDPLTKLLPFDWVSGGYFDYWGQGTLVTVSS,DIVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYRASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSFTFGQGTKVEIK,5Y2L_I,5Y2L_J,Crystal Structure Of A Group 2 Ha Binding Antibody Af4H1K1 Fab In Complex With The 1968 H3N2 Pandemic (H3-Ac/68) Hemagglutinin,Crystal Structure Of A Group 2 Ha Binding Antibody Af4H1K1 Fab In Complex With The 1968 H3N2 Pandemic (H3-Ac/68) Hemagglutinin,Homo sapiens,"Xiao,H.;Qi,J.;Gao,F.G.",An H3-clade neutralizing antibody screened from an H7N9 patient that binds group 2 influenza A hemagglutinins,26-JUL-2017,8_8_21_7_3_8,5Y2L_I_J,Xtal structure,H3N2,4,1,15.043453,13.903082
6EQC_F_F,QVQLVQSGAEDKKPGASVKVSCKVSGFSLGRYGVHWVRQAPGQGLEWMGVIWRGGTTDYNAKFQGRVTITKDDSKSTVYMELSSLRSEDTAVYYCARQGSNFPLAYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQSVTNDAAWYQKKPGKAPKLLIYQASTRYTGVPSRFSGSGYGTDFTLTISSLQPEDFATYFCHQDYSSPLTFGQGTKVEIK,6EQC_F,6EQC_F,Cryo-Em Reconstruction Of A Complex Of A Binding Protein And Human Adenovirus C5 Hexon,Cryo-Em Reconstruction Of A Complex Of A Binding Protein And Human Adenovirus C5 Hexon,Mus musculus,"Schmid,M.;Ernst,P.;Honegger,A.;Suomalainen,M.;Zimmermann,M.;Braun,L.;Stauffer,S.;Thom,C.;Dreier,B.;Eibauer,M.;Kipar,A.;Vogel,V.;Greber,U.F.;Medalia,O.;Pluckthun,A.",Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control,12-OCT-2017,8_7_11_6_3_9,6EQC_F_F,Xtal structure,,4,1,0.59038377,3.9617097
8SAY_C_D,QVQLVQSGAELKKPGASVKVSCKASGYTLSDYYVHWLRQAPGQGLEWVAWINPTSGRTISPRKFQGRVTMTTDTSMNVAYMELRGLRSDDTAVYFCARGGWISLYVDYSYYPNFDSWGQGTLVSVS,QPVLTQPASVSGSPGQSITISCTGSSSDVGSYNLVSWYQQHPGKAPKLMIYEVNKWASGVSDRFAGSKSGNTASLTISRLQAEDEANYFCSSSTNSATVIFGGGTKLTVL,8SAY_C,8SAY_D,Cryoem Structure Of Dh270.3-Ch848.10.17,Cryoem Structure Of Dh270.3-Ch848.10.17,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SAY_C_D,Xtal structure,HIV,4,1,2.7396247,2.8915086
ANI69935_ANI69939,QVQLVQSGAEMKMPGASVKVSCKASGYTFTGNYIHWVRQAPGQGLEWMGWIAPHSGDTSYAQRFQGRVTMTGDTSLSTAYMELSRLRSDDTAVYYCARGPFPNYYGPGSYWGGLDFWGQGTLVSVSS,EIVMTQSPATLSVSLGERATLSCRTSQNVAYNFAWYQQKPGQAPRLLIYEASSRATGTPARFSGSGFGTEFTLTISSMQSEDFAVYYCQQYNNWPSPFTFGPGTKVHIK,ANI69935,ANI69939,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Simonich,C.A.; Williams,K.L.; Verkerke,H.P.; Williams,J.A.; Nduati,R.; Lee,K.K.; Overbaugh,J.",HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant,08-JUN-2016,8_8_20_6_3_11,ANI69935_ANI69939,Unique source,HIV,4,1,2.2423797,3.501553
6VBQ_E_F,QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYIHWVRQAPGQGLEWMGIINPRRDTTTYAQKFQGRVTMTRDTSTNTVYMELSSLRSDDTAVYFCAKNVGFCNSDSCYVGMDVWGPGTTVTISS,SYELTQPPSMSVSPGQTARITCSADVLPKQYAYWYQQKPGQAPLLLIYKDTERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSTDSSDIYLVFGGGTKLTVL,6VBQ_E,6VBQ_F,Crystal Structure Of Anti-Hiv-1 Antibody Dh822 Bound To Gp120 V2 Peptide,Crystal Structure Of Anti-Hiv-1 Antibody Dh822 Bound To Gp120 V2 Peptide,Human immunodeficiency virus 1,"Easterhoff,D.;Pollara,J.;Luo,K.;Janus,B.;Gohain,N.;Williams,L.D.;Tay,M.Z.;Monroe,A.;Peachman,K.;Choe,M.;Min,S.;Lusso,P.;Zhang,P.;Go,E.P.;Desaire,H.;Bonsignori,M.;Hwang,K.K.;Beck,C.;Kakalis,M.;O'Connell,R.J.;Vasan,S.;Kim,J.H.;Michael,N.L.;Excler,J.L.;Robb,M.L.;Rerks-Ngarm,S.;Kaewkungwal,J.;Pitisuttithum,P.;Nitayaphan,S.;Sinangil,F.;Tartaglia,J.;Phogat,S.;Wiehe,K.;Saunders,K.O.;Montefiori,D.C.;Tomaras,G.D.;Moody,M.A.;Arthos,J.;Rao,M.;Joyce,M.G.;Ofek,G.;Ferrari,G.;Haynes,B.F.",HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions,19-DEC-2019,8_8_18_6_3_11,6VBQ_E_F,Xtal structure,HIV,4,1,1.7800342,3.590794
6FG2_H_L,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDEAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,6FG2_H,6FG2_L,Crystal Structure Of Fab Of Natalizumab In Complex With Fab Of Naa84.,Crystal Structure Of Fab Of Natalizumab In Complex With Fab Of Naa84.,Homo sapiens,"Cassotta,A.;Mikol,V.;Bertrand,T.;Pouzieux,S.;Le Parc,J.;Ferrari,P.;Dumas,J.;Auer,M.;Deisenhammer,F.;Gastaldi,M.;Franciotta,D.;Silacci-Fregni,C.;Fernandez Rodriguez,B.;Giacchetto-Sasselli,I.;Foglierini,M.;Jarrossay,D.;Geiger,R.;Sallusto,F.;Lanzavecchia,A.;Piccoli,L.",A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients,09-JAN-2018,8_8_16_6_3_8,6FG2_H_L,Xtal structure,,4,1,0.6806162,3.397181
6MEK_F_E,QVQLVQSGAEVKKPGASVKVSCKASGYIFTSHGISWVRQAPGQGLEWMGWISVYNGYTNYAQNLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFCARASQIRGVDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQFPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGPWVFGGGTQVTVL,6MEK_F,6MEK_E,Broadly Neutralizing Antibodies Against Hcv Use A Cdrh3 Disulfide Motif To Recognize An E2 Glycoprotein Site That Can Be Targeted For Vaccine Design,Broadly Neutralizing Antibodies Against Hcv Use A Cdrh3 Disulfide Motif To Recognize An E2 Glycoprotein Site That Can Be Targeted For Vaccine Design,Homo sapiens,"Flyak,A.I.;Ruiz,S.;Colbert,M.D.;Luong,T.;Crowe JE,Jr.;Bailey,J.R.;Bjorkman,P.J.",HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design,06-SEP-2018,8_8_11_8_3_12,6MEK_F_E,Xtal structure,HCV,4,1,1.8997059,5.2207556
CCA64138_CCA64139,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,CCA64138,CCA64139,unnamed protein product [Homo sapiens],unnamed protein product [Homo sapiens],Homo sapiens,"TAKASHI,T.; KATSUNARI,T.; NOBUAKI,H.",Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof,19-APR-2011,8_8_18_6_3_9,QPZ09910,Ordered entries,AILIM; CD278; ICOS,4,1,2.3255467,3.5135765
6XLQ_E_F,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRHSDMIGYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQATDFPPTFGGGTKVEIK,6XLQ_E,6XLQ_F,Crystal Structure Of The Human Btn3A1 Ectodomain In Complex With The Ctx-2026 Fab,Crystal Structure Of The Human Btn3A1 Ectodomain In Complex With The Ctx-2026 Fab,Homo sapiens,"Payne,K.K.;Mine,J.A.;Biswas,S.;Chaurio,R.A.;Perales-Puchalt,A.;Anadon,C.M.;Costich,T.L.;Harro,C.M.;Walrath,J.;Ming,Q.;Tcyganov,E.;Buras,A.L.;Rigolizzo,K.E.;Mandal,G.;Lajoie,J.;Ophir,M.;Tchou,J.;Marchion,D.;Luca,V.C.;Bobrowicz,P.;McLaughlin,B.;Eskiocak,U.;Schmidt,M.;Cubillos-Ruiz,J.R.;Rodriguez,P.C.;Gabrilovich,D.I.;Conejo-Garcia,J.R.",BTN3A1 governs antitumor responses by coordinating alphabeta and gammadelta T cells,29-JUN-2020,8_8_16_6_3_9,6XLQ_E_F,Xtal structure,BT3.1; BTN3A1; BTN3.1; CD277; Ectodomain; BTF5,4,1,2.0711253,3.640534
6OL7_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGKNSDYNWDFQHWGQGTLVTVGG,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYEFFGQGTKLEIG,6OL7_H,6OL7_L,Crystal Structure Of Glvrc01 Scfv In Complex With Anti-Idiotype Iv8 Scfv,Crystal Structure Of Glvrc01 Scfv In Complex With Anti-Idiotype Iv8 Scfv,Mus musculus,"Dosenovic,P.;Pettersson,A.K.;Wall,A.;Thientosapol,E.S.;Feng,J.;Weidle,C.;Bhullar,K.;Kara,E.E.;Hartweger,H.;Pai,J.A.;Gray,M.D.;Parks,K.R.;Taylor,J.J.;Pancera,M.;Stamatatos,L.;Nussenzweig,M.C.;McGuire,A.T.",Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses,15-APR-2019,8_8_14_6_3_5,6OL7_H_L,Xtal structure,HIV,4,1,2.5318577,4.098325
5JOF_A_B,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRGSCDYCGDFPWQYWGQGTVVVVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFEFFGLGSELEV,5JOF_A,5JOF_B,Crystal Structure Of Vrc03 Ghvglv Antigen-Binding Fragment.,Crystal Structure Of Vrc03 Ghvglv Antigen-Binding Fragment.,Homo sapiens,"Davenport,T.M.;Gorman,J.;Joyce,M.G.;Zhou,T.;Soto,C.;Guttman,M.;Moquin,S.;Yang,Y.;Zhang,B.;Doria-Rose,N.A.;Hu,S.L.;Mascola,J.R.;Kwong,P.D.;Lee,K.K.",Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies,02-MAY-2016,8_8_16_7_3_5,5JOF_A_B,Xtal structure,HIV,4,1,2.4848487,4.1014466
4IMK_B_C,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,4IMK_B,4IMK_C,Uncrossed Fab Binding To Human Angiopoietin 2,Uncrossed Fab Binding To Human Angiopoietin 2,Homo sapiens,"Fenn,S.;Schiller,C.B.;Griese,J.J.;Duerr,H.;Imhof-Jung,S.;Gassner,C.;Moelleken,J.;Regula,J.T.;Schaefer,W.;Thomas,M.;Klein,C.;Hopfner,K.P.;Kettenberger,H.",Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain,03-JAN-2013,8_8_22_6_3_11,AKW39642,Xtal structure,Ang2; ANGPT2,4,1,2.3382258,3.415594
7UGM_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCATQVKLDSSAGYPFDIWGQGTMVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSAFEYFGGGTKLTVL,7UGM_H,7UGM_L,Crystal Structure Of Bg24-Igl Cdr3Mat Fab,Crystal Structure Of Bg24-Igl Cdr3Mat Fab,Homo sapiens,"Dam,K.A.;Barnes,C.O.;Gristick,H.B.;Schoofs,T.;Gnanapragasam,P.N.P.;Nussenzweig,M.C.;Bjorkman,P.J.",HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design,09-NOV-2022,8_8_16_9_3_5,7UGM_H_L,Xtal structure,HIV; CD4,4,1,2.3749619,3.5660646
QMI58157_QMI58174,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSITTAYMELRRLRSDDTAVYYCARGLGVGCSGGNCYLDYYYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCSSYTSSSTWVFGGGTKLTVL,QMI58157,QMI58174,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_22_9_3_10,QMI58157_QMI58174,Unique source,SARS-CoV-2,4,1,2.143377,3.5301564
AOR52389_AOR52390,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYCARGESGSYFDYWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSFGTGTKVTVL,AOR52389,AOR52390,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Sok,D.; Briney,B.; Jardine,J.G.; Kulp,D.W.; Menis,S.; Pauthner,M.; Wood,A.; Lee,E.-C.; Le,K.M.; Jones,M.; Ramos,A.; Kalyuzhniy,O.; Adachi,Y.; Kubitz,M.; MacPherson,S.; Bradley,A.; Friedrich,G.A.; Schief,W.R.; Burton,D.R.",Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice,21-FEB-2019,8_8_11_9_3_5,AOR52389_AOR52390,Ordered entries,HIV,4,1,2.11992,3.754677
7ND7_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYTQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYSCARDMAFSMVRGSFDYWGQGTLVTVSS,QAVLTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNHWVFGGGTKLTVL,7ND7_H,7ND7_L,Em Structure Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-316 Fab,Em Structure Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-316 Fab,Homo sapiens,"Dejnirattisai,W.;Zhou,D.;Ginn,H.M.;Duyvesteyn,H.M.;Supasa,P.;Case,J.B.;Zhao,Y.;Walter,T.S.;Mentzer,A.J.;Liu,C.;Wang,B.;Paesen,G.C.;Slon-Campos,J.;Lopez-Camacho,C.;Kafai,N.M.;Bailey,A.L.;Chen,R.E.;Ying,B.;Thompson,C.;Bolton,J.;Fyfe,A.;Gupta,S.;Tan,T.K.;Gilbert-Jaramillo,J.;James,W.;Knight,M.;Carroll,M.W.;Skelly,D.;Dold,C.;Peng,Y.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Klenerman,P.;Temperton,N.;Hall,D.R.;Williams,M.A.;Paterson,N.G.;Bertram,F.K.;Siebert,C.A.;Clare,D.K.;Howe,A.;Radecke,J.;Song,Y.;Townsend,A.R.;Huang,K.A.;Fry,E.E.;Mongkolsapaya,J.;Diamond,M.S.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antigenic anatomy of SARS-CoV-2 receptor binding domain,30-JAN-2021,8_8_15_9_3_10,7ND7_H_L,Xtal structure,SARS-CoV-2,4,1,2.1126602,3.7328107
QMI58159_QMI58179,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYTQMFQGRVTMTRDTSISTAYMEVSRLRSDDTAVYYCARDRSWAVVYYYMDVWGKGTTVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLVFGGGTKLTVL,QMI58159,QMI58179,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_15_9_3_10,QMI58159_QMI58179,Unique source,SARS-CoV-2,4,1,2.0474887,3.6797488
7K8Y_G_I,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWISPVSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARAPLFPTGVLAGDYYYYGMDVWGQGTTVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL,7K8Y_G,7K8Y_I,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C121 (State 2)","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C121 (State 2)",Homo sapiens,"Barnes,C.O.;Jette,C.A.;Abernathy,M.E.;Dam,K.A.;Esswein,S.R.;Gristick,H.B.;Malyutin,A.G.;Sharaf,N.G.;Huey-Tubman,K.E.;Lee,Y.E.;Robbiani,D.F.;Nussenzweig,M.C.;West AP,Jr.;Bjorkman,P.J.",SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,27-SEP-2020,8_8_22_9_3_10,7K8Y_G_I,Xtal structure,SARS-CoV-2,4,1,2.1253061,3.4580393
7RDW_G_I,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMNWVRQAPGQGLEWMGWINPNSGDTNYAQKFQGRVTMTRDTSSSTAYMELNRVRSDDTAVYYCARWDWGQYWFFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQVPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHMYTFGQGTKLEIK,7RDW_G,7RDW_I,Crystal Structure Of Fh1 Fab Bound To Hxb2 Hiv-1 Gp120 Core,Crystal Structure Of Fh1 Fab Bound To Hxb2 Hiv-1 Gp120 Core,Homo sapiens,"Gray,M.D.;Feng,J.;Weidle,C.E.;Cohen,K.W.;Ballweber-Fleming,L.;MacCamy,A.J.;Huynh,C.N.;Trichka,J.J.;Montefiori,D.;Ferrari,G.;Pancera,M.;McElrath,M.J.;Stamatatos,L.",Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain,12-JUL-2021,8_8_13_7_3_5,7RDW_G_I,Xtal structure,gp120,4,1,2.266343,3.8247864
7UBS_H_H,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISGYNGNTKYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDKYIPVADPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSAPITFGQGTRLEIK,7UBS_H,7UBS_H,Pfs230 D1 Domain In Complex With 230As-26,Pfs230 D1 Domain In Complex With 230As-26,Homo sapiens,"Tang,W.K.;Coelho,C.H.;Miura,K.;Nguemwo Tentokam,B.C.;Salinas,N.D.;Narum,D.L.;Healy,S.A.;Sagara,I.;Long,C.A.;Duffy,P.E.;Tolia,N.H.",A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine,15-FEB-2023,8_8_14_12_3_9,7UBS_H_H,Xtal structure,Pfs230D1,4,1,1.8670471,5.2998877
7DF1_H_L,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGYYDILTGSRPIFFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNTPITFGQGTRLEIK,7DF1_H,7DF1_L,Crystal Structure Of Human Cd98 Heavy Chain Extracellular Domain In Complex With S1-F4 Scfv,Crystal Structure Of Human Cd98 Heavy Chain Extracellular Domain In Complex With S1-F4 Scfv,Homo sapiens,"Tian,X.;Liu,X.;Ding,J.;Wang,F.;Wang,K.;Liu,J.;Wei,Z.;Hao,X.;Li,Y.;Wei,X.;Zhang,H.;Sui,J.",An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice,07-DEC-2022,8_8_18_12_3_9,7DF1_H_L,Xtal structure,CD98HC; CD98; MDU1; 4F2HC; SLC3A2; 4F2; 4T2HC; NACAE,4,1,1.6038963,3.7198603
7PS2_H_L,QVQLVQSGAEVKKPGESLRISCKGSGHNSPSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLQASDTAIYYCARHVVALTHLYPDYWGQGTLVTVSS,DIQMTQSPATLSVSPGERATLSCRASQSVSSTLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWSTWTFGQGTKVDIK,7PS2_H,7PS2_L,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-29 And Beta-53 Fabs,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Beta Variant Spike Glycoprotein In Complex With Beta-29 And Beta-53 Fabs,Homo sapiens,"Liu,C.;Zhou,D.;Nutalai,R.;Duyvesteyn,H.M.;Tuekprakhon,A.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Mentzer,A.J.;Wang,B.;Case,J.B.;Zhao,Y.;Skelly,D.T.;Chen,R.E.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Malik,T.;Temperton,N.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Clare,D.K.;Howe,A.;Goulder,P.J.;Fry,E.E.;Diamond,M.S.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants,22-SEP-2021,8_8_14_6_3_10,7PS2_H_L,Xtal structure,SARS-CoV-2,4,1,-11.992612,5.4884944
UGO91511_UGO91512,QVQLVQSGAEVKKPGSSVKVSCKASGGTFGISWVRQAPGQGLEWMGRIIPILGTANHAQKFQGRVTITADKSTGTVYMELSSLRSEDTAVYYCARDGDSGSYYETLGFDYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLVFGGGTKLTVL,UGO91511,UGO91512,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Cho,H.; Gonzales-Wartz,K.K.; Huang,D.; Yuan,M.; Peterson,M.; Liang,J.; Beutler,N.; Torres,J.L.; Cong,Y.; Postnikova,E.; Bangaru,S.; Talana,C.A.; Shi,W.; Yang,E.S.; Zhang,Y.; Leung,K.; Wang,L.; Peng,L.; Skinner,J.; Li,S.; Wu,N.C.; Liu,H.; Dacon,C.; Moyer,T.; Cohen,M.; Zhao,M.; Lee,F.E.; Weinberg,R.S.; Douagi,I.; Gross,R.; Schmaljohn,C.; Pegu,A.; Mascola,J.R.; Holbrook,M.; Nemazee,D.; Rogers,T.F.; Ward,A.B.; Wilson,I.A.; Crompton,P.D.; Tan,J.",Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern,15-DEC-2021,5_8_17_9_3_10,UGO91511_UGO91512,Unique source,SARS-CoV-2,4,1,-0.8150199,5.562459
6I8S_G_K,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPTFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARERRQWLEGHFDYWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASEGIYHNLAWYQQKPGKAPKLLIYKASSLASGVPSRFSGSRSGTEFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKVEIK,6I8S_G,6I8S_K,Discovery And Characterisation Of An Antibody That Selectively Modulates The Inhibitory Activity Of Plasminogen Activator Inhibitor-1,Discovery And Characterisation Of An Antibody That Selectively Modulates The Inhibitory Activity Of Plasminogen Activator Inhibitor-1,Homo sapiens,"Vousden,K.A.;Lundqvist,T.;Popovic,B.;Naiman,B.;Carruthers,A.M.;Newton,P.;Johnson,D.J.;Pomowski,A.;Wilkinson,T.;Dufner,P.;de Mendez,I.;Mallinder,P.R.;Murray,C.;Strain,M.;Connor,J.;Murray,L.A.;Sleeman,M.A.;Lowe,D.C.;Huntington,J.A.;Vaughan,T.J.",Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1,21-NOV-2018,8_8_14_6_3_9,6I8S_G_K,Xtal structure,,4,1,-0.6251151,5.731596
7THT_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPMFGIANYAQKFQGRVTITADKSTSTAYLELSSLRSEDTAVYYCARYMVTRDQYYYDMDVWGQGTTVTVS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSPPPTFGQGTKLEI,7THT_H,7THT_L,Cryoem Structure Of Sars-Cov-2 S Protein In Complex With Receptor Binding Domain Antibody Dh1042,Cryoem Structure Of Sars-Cov-2 S Protein In Complex With Receptor Binding Domain Antibody Dh1042,Homo sapiens,"Gobeil,S.M.;Henderson,R.;Stalls,V.;Janowska,K.;Huang,X.;May,A.;Speakman,M.;Beaudoin,E.;Manne,K.;Li,D.;Parks,R.;Barr,M.;Deyton,M.;Martin,M.;Mansouri,K.;Edwards,R.J.;Sempowski,G.D.;Saunders,K.O.;Wiehe,K.;Williams,W.;Korber,B.;Haynes,B.F.;Acharya,P.",Structural diversity of the SARS-CoV-2 Omicron spike,12-JAN-2022,8_8_16_6_3_9,7THT_H_L,Xtal structure,SARS-CoV-2,4,1,-0.94209266,6.0697703
UNJ97204_UNJ97205,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIGMFGTTNYAQKFQGRVTITADEFTSTAYMELSSLRSEDTAVYYCARGGSYYVDYFHHWGQGTLVTVSS,EIVLTQSPGTLSLFSGERATLSCRASQSVSSSSLAWYQQKHGQGPRLIMYGASSRATGIPDRFSGSGFGTDFTITISRLEPEDFAVYYCQQYGSSSGTFGQGTKLEMK,UNJ97204,UNJ97205,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Raab,J.E.; Gorman,J.; Gillespie,R.A.; Cheung,C.S.F.; Rawi,R.; Cominsky,L.Y.; Boyington,J.C.; Creanga,A.; Shen,C.H.; Harris,D.R.; Olia,A.S.; Nazzari,A.F.; Zhou,T.; Houser,K.V.; Chen,G.L.; Mascola,J.R.; Graham,B.S.; Kanekiyo,M.; Ledgerwood,J.E.; Kwong,P.D.; McDermott,A.B.",A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination,24-MAR-2022,8_8_13_7_3_9,UNJ97204_UNJ97205,Unique source,hemagglutinin,4,1,-0.527136,5.5756936
5JZ7_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYGISWVRQAPGQGLEWMGGIIPIFDTGNSAQSFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSRIYDLNPSLTAYYDMDVWGQGTMVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,5JZ7_H,5JZ7_L,Ngf In Complex With Medi578 Scfv,Ngf In Complex With Medi578 Scfv,Homo sapiens,"Dobson,C.L.;Devine,P.W.;Phillips,J.J.;Higazi,D.R.;Lloyd,C.;Popovic,B.;Arnold,J.;Buchanan,A.;Lewis,A.;Goodman,J.;van der,Wa.;Thornton,P.;Vinall,L.;Lowne,D.;Aagaard,A.;Olsson,L.L.;Ridderstad Wollberg,A.;Welsh,F.;Karamanos,T.K.;Pashley,C.L.;Iadanza,M.G.;Ranson,N.A.;Ashcroft,A.E.;Kippen,A.D.;Vaughan,T.J.;Radford,S.E.;Lowe,D.C.",Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo,16-MAY-2016,8_8_21_8_3_11,5JZ7_H_L,Xtal structure,,4,1,-0.8194735,6.1162724
UNJ97156_UNJ97157,QVQLVQSGAEVKKPGSSVKVSCKTSGGIFRSNAISWVRQAPGQGLEWMGGVVAIFGTTNYAQNFQGRVTITADESSSTVYMELSRLRSEDTAVYYCARHSGYHITNTFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGDRATLSCRASQSVPSSYLAWYRHKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFSLTISRVEPEDFAVYYCQQYGSSPYTFGRGTKLDIK,UNJ97156,UNJ97157,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Andrews,S.F.; Raab,J.E.; Gorman,J.; Gillespie,R.A.; Cheung,C.S.F.; Rawi,R.; Cominsky,L.Y.; Boyington,J.C.; Creanga,A.; Shen,C.H.; Harris,D.R.; Olia,A.S.; Nazzari,A.F.; Zhou,T.; Houser,K.V.; Chen,G.L.; Mascola,J.R.; Graham,B.S.; Kanekiyo,M.; Ledgerwood,J.E.; Kwong,P.D.; McDermott,A.B.",A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination,24-MAR-2022,8_8_15_7_3_9,UNJ97156_UNJ97157,Unique source,hemagglutinin,4,1,-0.5483247,5.544078
UIC72090_UIC72400,QVQLVQSGAEVKKPGSSVKVSCRTSGGTVNTLHWVRQAPGQGLEWMGSIFPLLGVPTYAQKFQGRVTVTADRSTSTAYMELRSLRADDTAVYYCAKDGVGWSGHGPSQWSGVDVWGPGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCTSSQSLLHSTGYNYLDWYVQKPGQSPQLLIYLGSIRASGVPDRFSGSGSGTDFTLRISRVEAGDVGIYYCMQALEIPRLTFGGGTKLEIK,UIC72090,UIC72400,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,6_8_20_11_3_10,UIC72090_UIC72400,Unique source,HCV,4,1,-1.0281637,5.896068
UIC72191_UIC72501,QVQLVQSGAEVKKPGSSVKVSCTTSGGSFGRDAVSWVRQAPGQGLEPMGGIIPIFGTSSYAQTFQGRVTFTAGKSTSTAYMELSSLKSEDTAVYYCVRWSFGDYGLFLTEGDYWGQGTLVIVSS,EIVLTQSPASLSLSPGERATLSCRASQSVDKYFAWYQQKPGQAPRLLIYETSKRATGIPARFSGSGSGTDFTLTISNLEPDDFAIYYCHHRGNWPPSFTFGQGTRLEIK,UIC72191,UIC72501,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Weber,T.; Potthoff,J.; Bizu,S.; Labuhn,M.; Dold,L.; Schoofs,T.; Horning,M.; Ercanoglu,M.S.; Kreer,C.; Gieselmann,L.; Vanshylla,K.; Langhans,B.; Janicki,H.; Stroeh,L.J.; Knops,E.; Nierhoff,D.; Spengler,U.; Kaiser,R.; Bjorkman,P.J.; Krey,T.; Bankwitz,D.; Pfeifer,N.; Pietschmann,T.; Flyak,A.I.; Klein,F.",Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization,06-JAN-2022,8_8_17_6_3_11,UIC72191_UIC72501,Unique source,HCV,4,1,-0.49653256,5.7052217
6MEE_A_B,QVQLVQSGAEVKKPGSSVKVSCTTSGGTYINYAISWVRQAPGQGLEWVGGMSPISNTPKYAQKFQGRVTITADESTSTTYMELSSLRPEDTAVYYCARDLLKYCGGGNCHSLLVDPWGQGTLVTVSS,DIVMTQSPSTLSASVGDRVTISCRASQSISSWLAWYQQKPGRAPKLLIYKASSLETGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNTYLFTFGPGTKVDLK,6MEE_A,6MEE_B,Broadly Neutralizing Antibodies Against Hcv Use A Cdrh3 Disulfide Motif To Recognize An E2 Glycoprotein Site That Can Be Targeted For Vaccine Design,Broadly Neutralizing Antibodies Against Hcv Use A Cdrh3 Disulfide Motif To Recognize An E2 Glycoprotein Site That Can Be Targeted For Vaccine Design,Homo sapiens,"Flyak,A.I.;Ruiz,S.;Colbert,M.D.;Luong,T.;Crowe JE,Jr.;Bailey,J.R.;Bjorkman,P.J.",HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design,06-SEP-2018,8_8_20_6_3_9,6MEE_A_B,Xtal structure,HCV,4,1,-0.84765327,5.8247924
AQV03757_AQV03770,QVQLVQSGAEVKNPGASVKVSCAPSGYTFTDFYIHWVRLAPGQGLEWLGWMNPKTGRTNQGQNFQGRVTMTRDTSIGTAYMELRSLTSDDTAVYYCVTGAWISDYYDSSYYPNFDHWGQGTLVTVSS,LPVLTQPASVSGSPGQSITISCTGTIYDVGKFDLVSWYQHHPGKAPKYLIYEVKKWPSGVSHRFSGSKSGNTASLTISGLQVEDEADYYCCSFGGSAAVVCGGGTKVTVL,AQV03757,AQV03770,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Bonsignori,M.; Kreider,E.F.; Fera,D.; Meyerhoff,R.R.; Bradley,T.; Wiehe,K.; Alam,S.M.; Aussedat,B.; Walkowicz,W.E.; Hwang,K.K.; Saunders,K.O.; Zhang,R.; Gladden,M.A.; Monroe,A.; Kumar,A.; Xia,S.M.; Cooper,M.; Louder,M.K.; McKee,K.; Bailer,R.T.; Pier,B.W.; Jette,C.A.; Kelsoe,G.; Williams,W.B.; Morris,L.; Kappes,J.; Wagh,K.; Kamanga,G.; Cohen,M.S.; Hraber,P.T.; Montefiori,D.C.; Trama,A.; Liao,H.X.; Kepler,T.B.; Moody,M.A.; Gao,F.; Danishefsky,S.J.; Mascola,J.R.; Shaw,G.M.; Hahn,B.H.; Harrison,S.C.; Korber,B.T.; Haynes,B.F.",Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies,24-MAR-2017,8_8_20_9_3_10,AQV03757_AQV03770,Unique source,HIV,4,1,2.9079049,2.6966782
6KZ0_H_I,QVQLVQSGAEVKQPGSSVKVSCKTSGDIFSTYGFNWVRQAPGQGLEWMGGIAPVFDTLKYAQRFQGRLLITADESATSVYMELSSLRSDDTAVYYCARAGQGGVVGNYLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPLTFGQGTKVDIK,6KZ0_H,6KZ0_I,Hrv14 3C In Complex With Single Chain Antibody Ggvv,Hrv14 3C In Complex With Single Chain Antibody Ggvv,Homo sapiens,"Meng,B.;Lan,K.;Xie,J.;Lerner,R.A.;Wilson,I.A.;Yang,B.",Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses,27-MAY-2020,8_8_15_6_3_9,6KZ0_H_I,Xtal structure,rhinovirus,4,1,-0.5857254,5.7928357
6MFP_H_L,QVQLVQSGAEVQKPGASVKVSCKASGYTFASYDINWVRQATGQGLEWMGWMNPKTGNTGYAQKFQGRVTLTRNTSISTAYMELTSLRSEDTAVYYCATYRIIAAVGYRYFQYWGQGTLVTVSS,DIQLTQSPSSLSASVGDSVTITCRASQGFGNYLAWYQQRPGKVPEVLIYAATTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPFTFGQGTRLEIK,6MFP_H,6MFP_L,Crystal Structure Of The Rv305 C1-C2 Specific Adcc Potent Antibody Dh677.3 Fab In Complex With Hiv-1 Clade A/E Gp120 And M48U1,Crystal Structure Of The Rv305 C1-C2 Specific Adcc Potent Antibody Dh677.3 Fab In Complex With Hiv-1 Clade A/E Gp120 And M48U1,Homo sapiens,"Easterhoff,D.;Pollara,J.;Luo,K.;Tolbert,W.D.;Young,B.;Mielke,D.;Jha,S.;O'Connell,R.J.;Vasan,S.;Kim,J.;Michael,N.L.;Excler,J.L.;Robb,M.L.;Rerks-Ngarm,S.;Kaewkungwal,J.;Pitisuttithum,P.;Nitayaphan,S.;Sinangil,F.;Tartaglia,J.;Phogat,S.;Kepler,T.B.;Alam,S.M.;Wiehe,K.;Saunders,K.O.;Montefiori,D.C.;Tomaras,G.D.;Moody,M.A.;Pazgier,M.;Haynes,B.F.;Ferrari,G.",Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency,11-SEP-2018,8_8_16_6_3_9,6MFP_H_L,Xtal structure,,4,1,2.0202022,4.2205663
7KDD_D_E,QVQLVQSGAEVRKPGASVKVSCKASGYSLKDHYMVWVRQAPGQGLEWMGWINPQSGGTGYGQKFQGRVTMTRDTSTNTAYMILSSLRSDDTAVYFCARDGAKTVSNSGLSLLYYHNRLDAWGQGTMVTVSS,QSVLTQPPSVSAAPGQMVTISCSGSSSNIGKNYVSWYQQLPGAAPKLLIFDNNKRPSGTPDRFSGSKSGTSATLVITGLQTGDEADYYCGTPDRSLSVIFGGGTKVTVL,7KDD_D,7KDD_E,Hcmv Postfusion Gb In Complex With Sm5-1 Fab,Hcmv Postfusion Gb In Complex With Sm5-1 Fab,Homo sapiens,"Liu,Y.;Heim,K.P.;Che,Y.;Chi,X.;Qiu,X.;Han,S.;Dormitzer,P.R.;Yang,X.",Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion,08-OCT-2020,8_8_24_8_3_10,7KDD_D_E,Xtal structure,cytomegalovirus,4,1,2.3331552,3.473593
3QEH_C_D,QVQLVQSGAEVRKPGASVTVSCKTSGYTFVNFYIVWVRQAPGQGLEWMGVINPFRGDTYFAQKFKGRVTLTRDTSTSTVFMELSSLRSDDTAIYYCARDLEMRDGNNHGSHLEFWGQGTLVTVSS,DIVMTQSPLSLPVTPGEAASISCRSSQSLLHTNGFQYLDWYLQKPGQSPQLLIYLGSNRATGVPHRFSGSGSGTEFTLKISRVEAEDVGVYYCMQAKESPTFGQGTKVEIK,3QEH_C,3QEH_D,"Crystal Structure Of Human N12-I15, An Adcc And Non-Neutralizing Anti-Hiv-1 Env Antibody","Crystal Structure Of Human N12-I15, An Adcc And Non-Neutralizing Anti-Hiv-1 Env Antibody",Homo sapiens,"Guan,Y.;Devico,A.L.;Lewis,G.K.;Pazgier,M.","Crystal Structure Of Human N12-I15, An Adcc And Non-Neutralizing Anti-Hiv-1 Env Antibody",20-JAN-2011,8_8_18_11_3_8,3QEH_C_D,Xtal structure,Hiv-1,4,1,1.4729034,3.9768467
1I9R_K_M,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,1I9R_K,1I9R_M,Structure Of Cd40L In Complex With The Fab Fragment Of Humanized 5C8 Antibody,Structure Of Cd40L In Complex With The Fab Fragment Of Humanized 5C8 Antibody,Homo sapiens,"Karpusas,M.;Lucci,J.;Ferrant,J.;Benjamin,C.;Taylor,F.R.;Strauch,K.;Garber,E.;Hsu,Y.M.",Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody,20-MAR-2001,8_8_11_10_3_9,AEC44851_AEC44847,Xtal structure,TNFRSF5; p50; Bp50; CD40,4,1,0.8600219,3.540989
6IEC_J_K,QVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISPGGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASSADVYNWFDPWGQGTLV,SYELTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHLYVFGTGTKVTVL,6IEC_J,6IEC_K,Structure Of Rvfv Gn And Human Monoclonal Antibody R17,Structure Of Rvfv Gn And Human Monoclonal Antibody R17,Homo sapiens,"Wang,Q.;Ma,T.;Wu,Y.;Chen,Z.;Zeng,H.;Tong,Z.;Gao,F.;Qi,J.;Zhao,Z.;Chai,Y.;Yang,H.;Wong,G.;Bi,Y.;Wu,L.;Shi,R.;Yang,M.;Song,J.;Jiang,H.;An,Z.;Wang,J.;Yilma,T.D.;Shi,Y.;Liu,W.J.;Liang,M.;Qin,C.;Gao,G.F.;Yan,J.",Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus,10-APR-2019,8_8_12_6_3_12,6IEC_J_K,Xtal structure,,4,1,15.67762,9.382684
7SL5_A_B,QVQLVQSGGGVVQPGESLRLSCSGSGFTFNNYIMHWVRQAPGQGLDYVSGIGSDGRNTNYGDSVKGRFTISRDNSKDTLYLQMTSLRAEDTAFYYCVKGLDVLRFLDLSTPSGERLDAFDIWGQGTMVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPHLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLFTFGPGTKVDIE,7SL5_A,7SL5_B,Crystal Structure Of Vp12E7 Fab In Complex With Sars-Cov-2 S Fusion Peptide,Crystal Structure Of Vp12E7 Fab In Complex With Sars-Cov-2 S Fusion Peptide,Severe acute respiratory syndrome coronavirus 2,"Low,J.S.;Jerak,J.;Tortorici,M.A.;McCallum,M.;Pinto,D.;Cassotta,A.;Foglierini,M.;Mele,F.;Abdelnabi,R.;Weynand,B.;Noack,J.;Montiel-Ruiz,M.;Bianchi,S.;Benigni,F.;Sprugasci,N.;Joshi,A.;Bowen,J.E.;Stewart,C.;Rexhepaj,M.;Walls,A.C.;Jarrossay,D.;Morone,D.;Paparoditis,P.;Garzoni,C.;Ferrari,P.;Ceschi,A.;Neyts,J.;Purcell,L.A.;Snell,G.;Corti,D.;Lanzavecchia,A.;Veesler,D.;Sallusto,F.",ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies,20-JUL-2022,8_8_25_6_3_10,7SL5_A_B,Xtal structure,SARS-CoV-2; ACEH; ACE2,4,1,14.945594,13.675071
7BEO_H_L,QVQLVQSGPEVKKPGTSVKVSCKASGFTFTTSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTTTAYMELSSLRSEDTAVYFCAAPHCNSTSCYDAFDIWGQGTMVTVSS,DIQMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFGVYYCQQYGSSPWTFGQGTKVEIK,7BEO_H,7BEO_L,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In A Ternary Complex With Covox-253H55L And Covox-75 Fabs,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In A Ternary Complex With Covox-253H55L And Covox-75 Fabs,Homo sapiens,"Dejnirattisai,W.;Zhou,D.;Ginn,H.M.;Duyvesteyn,H.M.;Supasa,P.;Case,J.B.;Zhao,Y.;Walter,T.S.;Mentzer,A.J.;Liu,C.;Wang,B.;Paesen,G.C.;Slon-Campos,J.;Lopez-Camacho,C.;Kafai,N.M.;Bailey,A.L.;Chen,R.E.;Ying,B.;Thompson,C.;Bolton,J.;Fyfe,A.;Gupta,S.;Tan,T.K.;Gilbert-Jaramillo,J.;James,W.;Knight,M.;Carroll,M.W.;Skelly,D.;Dold,C.;Peng,Y.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Klenerman,P.;Temperton,N.;Hall,D.R.;Williams,M.A.;Paterson,N.G.;Bertram,F.K.;Siebert,C.A.;Clare,D.K.;Howe,A.;Radecke,J.;Song,Y.;Townsend,A.R.;Huang,K.A.;Fry,E.E.;Mongkolsapaya,J.;Diamond,M.S.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antigenic anatomy of SARS-CoV-2 receptor binding domain,24-DEC-2020,8_8_16_7_3_9,7BEO_H_L,Xtal structure,SARS-CoV-2,4,1,-0.98746604,2.9922466
8DGW_H_L,QVQLVQSGTEVRQPGASVRVSCKASGYTFTDSYIHWVRQAPGQGLEWMGIIKPSGGNTRYAQRFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDSRGPGIFWGQGTLVTVSS,QSVLTQPPSVSAAPERKVTISCSGSSSNIGTNFVSWYQQLPGTAPKLLIYENNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDSTPGTWVFGGGTRLTVL,8DGW_H,8DGW_L,Crystal Structure Of Hcov-Hku1 Spike Stem Helix Peptide In Complex With Fab Of Broadly Neutralizing Antibody Cc95.108 Isolated From A Vaccinated Covid-19 Convalescent,Crystal Structure Of Hcov-Hku1 Spike Stem Helix Peptide In Complex With Fab Of Broadly Neutralizing Antibody Cc95.108 Isolated From A Vaccinated Covid-19 Convalescent,Human coronavirus HKU1 (isolate N1),"Zhou,P.;Song,G.;Liu,H.;Yuan,M.;He,W.T.;Beutler,N.;Zhu,X.;Tse,L.V.;Martinez,D.R.;Sch&#xe4;fer,A.;Anzanello,F.;Yong,P.;Peng,L.;Dueker,K.;Musharrafieh,R.;Callaghan,S.;Capozzola,T.;Limbo,O.;Parren,M.;Garcia,E.;Rawlings,S.A.;Smith,D.M.;Nemazee,D.;Jardine,J.G.;Safonova,Y.;Briney,B.;Rogers,T.F.;Wilson,I.A.;Baric,R.S.;Gralinski,L.E.;Burton,D.R.;Andrabi,R.",Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease,25-JAN-2023,8_8_10_8_3_11,8DGW_H_L,Xtal structure,,4,1,1.5752975,3.8124723
5TBD_E_F,QVRLQQSGAELVKPGASVKLSCTASGFNIKDDYMHWVKQRPEQGLEWIGRIDPANGNTQYAPKFQDKATITADTSSNTAYLQLTSLTSEDTAVYYCARGGLLRWGQGTSVTVSS,DVVMTQTPLTLSVTIGQPASISCKSSQSLLHSNGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISSVEAEDLGVYYCWQGTHFPITFGSGTKLEIK,5TBD_E,5TBD_F,Crystal Structure Of Anti-Msp2 Fv Fragment (Mab4D11) In Complex With 3D7-Msp2 215-222,Crystal Structure Of Anti-Msp2 Fv Fragment (Mab4D11) In Complex With 3D7-Msp2 215-222,Plasmodium falciparum 3D7,"Seow,J.;Morales,R.A.;MacRaild,C.A.;Krishnarjuna,B.;McGowan,S.;Dingjan,T.;Jaipuria,G.;Rouet,R.;Wilde,K.L.;Atreya,H.S.;Richards,J.S.;Anders,R.F.;Christ,D.;Drinkwater,N.;Norton,R.S.",Structure and Characterisation of a Key Epitope in the Conserved C-Terminal Domain of the Malaria Vaccine Candidate MSP2,12-SEP-2016,8_8_7_11_3_9,5TBD_E_F,Xtal structure,Msp2,4,1,-4.725773,0.1886883
4JZO_G_H,QVTLKESGAEVKKPGSSVKVSCEASGGTLSNYVITWVRQAPGQGLEWMGGFIPTFRTAMYAQGFQGRVTITADESTSIAYMELTNLRSEDTAVYYCARGPLSRGYYDYWGQGTLVTVSS,SYVLTQPPSVSVSPGQTARITCSGDKLGDKYASWYQQKPGQSPVLVIYQDNKRPSEIPARFSGSNSGNTATLTISGAQAMDEADYYCQAWDSNTGVFGTGTKLTVL,4JZO_G,4JZO_H,Three Dimensional Structure Of Broadly Neutralizing Human Anti - Hepatitis C Virus (Hcv) Glycoprotein E2 Fab Fragment Hc84-27,Three Dimensional Structure Of Broadly Neutralizing Human Anti - Hepatitis C Virus (Hcv) Glycoprotein E2 Fab Fragment Hc84-27,Hepatitis C virus (isolate H),"Krey,T.;Meola,A.;Keck,Z.Y.;Damier-Piolle,L.;Foung,S.K.;Rey,F.A.",Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape,03-APR-2013,8_8_12_6_3_9,4JZO_G_H,Xtal structure,Hepatitis; HCV,4,1,-0.4525916,5.588781
3IFP_E_F,QVTLKESGPGILQPSQTLSLTCSFSGFSLSTNGMGVSWIRQPSGKGLEWLAHIYWDEDKRYNPSLKSRLTISKDTSNNQVFLKITNVDTADTATYYCARRRIIYDVEDYFDYWGQGTTLTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQNIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPLTFGAGTKLELK,3IFP_E,3IFP_F,X-Ray Structure Of Amyloid Beta Peptide:Antibody (Abeta1-7:12B4) Complex,X-Ray Structure Of Amyloid Beta Peptide:Antibody (Abeta1-7:12B4) Complex,Homo sapiens,"Basi,G.S.;Feinberg,H.;Oshidari,F.;Anderson,J.;Barbour,R.;Baker,J.;Comery,T.A.;Diep,L.;Gill,D.;Johnson-Wood,K.;Goel,A.;Grantcharova,K.;Lee,M.;Li,J.;Partridge,A.;Griswold-Prenner,I.;Piot,N.;Walker,D.;Widom,A.;Pangalos,M.N.;Seubert,P.;Jacobsen,J.S.;Schenk,D.;Weis,W.I.",Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease,24-JUL-2009,10_7_15_11_3_9,ABW43664_ABW43663,Xtal structure,SH3YL1; DKFZP586F1318; Ray; Amyloid,4,1,11.47843,1.937188
7V27_B_A,QVTLRESGPTLVKPKQTLTLTCTFSGFSLSTPGGGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSSLTITKDTSKNQVVLTMTNMDPVDTATYYCARLTAADTIFDCWGQGTLVTVSS,QSALTQPASVSGSPGLSITISCTATSSDVGAYNYVSWYQQHPGQAPKLMIYDVSKRPSGVSNRFSGSKSANTASLTISGLQAEDEADYYCSSYTTTSVVFGGGTKLTVL,7V27_B,7V27_A,Rbd/Xg005 Local Refinement,Rbd/Xg005 Local Refinement,Homo sapiens,"Zhan,W.Q.",RBD/XG005 local refinement,10-AUG-2022,10_7_12_9_3_9,7V27_B_A,Xtal structure,RBD,4,1,12.383191,0.34410465
3J8Z_I_M,SGAELARPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLEWIGAIYPGDGYTRYTQKFKGMATLTADKSSSTAYMQLTSLASEDSAVYYCARTYAGYYVGYFDYWGQGTTLTVS,DIVMTQSPSSLAMSAGQKVTMSCKSSQSLFDSRNQKNYLAWYQQKPGQSPTLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQQHYSTPYTFGGGTKLEIK,3J8Z_I,3J8Z_M,Cryo-Em Reconstruction Of Quasi-Hpv16 Complex With H16.1A Fab,Cryo-Em Reconstruction Of Quasi-Hpv16 Complex With H16.1A Fab,Mus musculus,"Guan,J.;Bywaters,S.M.;Brendle,S.A.;Lee,H.;Ashley,R.E.;Makhov,A.M.;Conway,J.F.;Christensen,N.D.;Hafenstein,S.",Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization,20-NOV-2014,8_8_14_12_3_9,3J8Z_I_M,Xtal structure,,4,1,0.416019,-3.8716602
AEQ74230_AEQ74990,TLMKPTQTLTLTCTLSGFSLGTSGVGVAWIRQPPGKALEWLGLFYGNGDKRYSPSLRSRLTITADTSTNQVVLSMTNVDLMDTATYYCARTVLPATFAFDFWGQGTLVT,TLSASVGDRVTITCRASQRITTSLAWYQQKPGKAPKLLIYKASTVERGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYDTYSWTFGQGTKVDIK,AEQ74230,AEQ74990,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_13_6_3_9,AEQ74230_AEQ74990,Unique source,tetanus,4,1,12.329369,0.20025408
4F15_K_L,VKLQESGAVVQPGGSLRLSCAASGFTGSDYDMSWIRQAPGKGLEWVSGILGGSERSYYRDSVKGRSTISRDNSRKTLYLEMNSLRAEDTAVYYCARHSWGAYVQYGMDGWGQGTTVTVSS,DIQMTQSPASLAVSPGQRATITCRASESVSNYGINFINWFQQKPGQPPKLLIYTASNKGTGVPARFSGSGSGTDFTLTINPVEAEDTANYFCQQTKEVPYGTFGGTKLEIK,4F15_K,4F15_L,Molecular Basis Of Infectivity Of 2009 Pandemic H1N1 Influenza A Viruses,Molecular Basis Of Infectivity Of 2009 Pandemic H1N1 Influenza A Viruses,Influenza A virus (A/Korea/01/2009(H1N1)),"Kim,K.H.;Cho,K.J.;Lee,J.H.;Park,Y.H.;Khan,T.G.;Lee,J.Y.;Kang,S.H.;Alam,I.;Hong,K.W.;Kim,S.H.;Unzai,S.;Park,S.Y.;Kim,C.J.;Lee,J.Y.;Khan,C.;Oh,H.B.;Chung,M.S.",Molecular basis of infectivity of 2009 pandemic H1N1 influenza A viruses,06-MAY-2012,8_8_15_10_3_10,4F15_K_L,Xtal structure,H1N1; Influenza,4,1,14.504133,9.96795
4LVH_K_L,VKLQQSGGGVVQPGGSLRLSCAASGFTFSDYDMSWIRQAPGKGLEWVSGILGGSERSYYRDSVKGRFTISRDNSRKTLYLQMNSLRAEDTAVYYCARHGSPGYTLYAWDYWGQGTMVTVSS,DIQMTQSPASLAVSPGQRATITCRASESVSNYGINFINWFQQKPGQPPKLLIYTASNKGTGVPARFSGSGSGTDFTLTINPVEAEDTANYFCQQTKEVPYTFGGGTKLEIK,4LVH_K,4LVH_L,Insight Into Highly Conserved H1 Subtype-Specific Epitopes In Influenza Virus Hemagglutinin,Insight Into Highly Conserved H1 Subtype-Specific Epitopes In Influenza Virus Hemagglutinin,Mus musculus,"Cho,K.J.;Hong,K.W.;Kim,S.H.;Seok,J.H.;Kim,S.;Lee,J.H.;Saelens,X.;Kim,K.H.",Insight into highly conserved H1 subtype-specific epitopes in influenza virus hemagglutinin,26-JUL-2013,8_8_15_10_3_9,4LVH_K_L,Xtal structure,hemagglutinin; Influenza,4,1,14.4598875,9.72009
7CYH_E_D,VKLVESGGGLVKPGGSLRLSCAASGFTFTNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYGGGGTVDYWGQGTLVTVSS,IVLTQSPTLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGIPSRFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRIFGQGTKVEIL,7CYH_E,7CYH_D,Binding Interface Of Sars-Cov-2 Rbd And Its Neutralizing Antibody Hb27,Binding Interface Of Sars-Cov-2 Rbd And Its Neutralizing Antibody Hb27,Homo sapiens,"Wang,X.;Zhu,L.",Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27,03-SEP-2020,8_8_13_10_3_9,7CYH_E_D,Xtal structure,SARS-CoV-2; RBD,4,1,14.794174,9.295842
AEQ74239_AEQ74999,VLVKPTGTLTLTCTVSGFSLSSPRMGVSWIRQPPGKALEWLAHTFSNDENSYTPSLRSRLTISKDTSKSQVVLTMTNMDPVDTGTYYCARINGNVTIFGMVLPRGWFDPWGQGTLVT,SSLSASVGDRVTITCQASQDITNYLNWYQLKPGKAPKLLIYDASNLAPGVPPRFSGSRSGTDFSFTISSLQPEDVATYYCQQYDTLPLSFGGGTKVQIK,AEQ74239,AEQ74999,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,10_7_21_6_3_9,AEQ74239_AEQ74999,Unique source,tetanus,4,1,12.616964,0.032024097
3UC0_I_M,VQLLESGPGLVKPSETLSLTCTVSGGSISDFYWSWLRQSPGKGLEWIGYAHSRVSAYYNPSLKSRVTISVDTSKNQISLRLSAVTAADTALYYCARQGTGTTGVSEDSFDLWGQGTKVIVS,ELQMTQSPSSLSASVGDRVTITCRASQDISIRLNWYQQKPGKAPKLLIYDASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,3UC0_I,3UC0_M,Crystal Structure Of Domain I Of The Envelope Glycoprotein Ectodomain From Dengue Virus Serotype 4 In Complex With The Fab Fragment Of The Chimpanzee Monoclonal Antibody 5H2,Crystal Structure Of Domain I Of The Envelope Glycoprotein Ectodomain From Dengue Virus Serotype 4 In Complex With The Fab Fragment Of The Chimpanzee Monoclonal Antibody 5H2,Pan troglodytes,"Cockburn,J.J.;Navarro Sanchez,M.E.;Goncalvez,A.P.;Zaitseva,E.;Stura,E.A.;Kikuti,C.M.;Duquerroy,S.;Dussart,P.;Chernomordik,L.V.;Lai,C.J.;Rey,F.A.",Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus,25-OCT-2011,8_7_17_6_3_9,3UC0_I_M,Xtal structure,Dengue; Ectodomain; dengue,4,1,16.286983,-7.9826016
5W1K_D_C,VQLQESGPGLVKPSQTLSLTCSVSGGSIGGSSYYWSWIRHHPGKGLEWIGYINYRGITHYNAALKSRVSMSVETSQNHFSLQLTSVTAADTAVYYCARLTSDCSGGNCYQAFDYWGQGSLVSVSG,IVLTQSPGTLSLSPGETATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSGYTFGQGTKLEIK,5W1K_D,5W1K_C,Junv Gp1 Cr1-10 Fab Cr1-28 Fab Complex,Junv Gp1 Cr1-10 Fab Cr1-28 Fab Complex,Homo sapiens,"Clark,L.E.;Mahmutovic,S.;Raymond,D.D.;Dilanyan,T.;Koma,T.;Manning,J.T.;Shankar,S.;Levis,S.C.;Briggiler,A.M.;Enria,D.A.;Wucherpfennig,K.W.;Paessler,S.;Abraham,J.",Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses,03-JUN-2017,10_7_18_7_3_9,5W1K_D_C,Xtal structure,,4,1,16.40788,-8.036543
3WFH_A_B,VQLQQSGAELVKPGASVKLSCKASGYTFTEYFIHWVKQRSGQGLEWIGWFYPGSGSLNYNGKFKDKATFTADKSSSTVYLELSRLTSEDSAVYFCASHAYDKEPYWGQGTLVTVSA,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKINRVEAEDLGIYYCLQGSHVPLTFGAGTTLELK,3WFH_A,3WFH_B,Crystal Structure Of Anti-Prostaglandin E2 Fab Fragment Pge2 Complex,Crystal Structure Of Anti-Prostaglandin E2 Fab Fragment Pge2 Complex,Mus musculus,"Sugahara,M.;Ago,H.;Saino,H.;Miyano,M.;Kurahashi,Y.;Aoy,S.;Takehira,M.;Yutani,K.;Yamamoto,S.",Crystal Structure Of Anti-Prostaglandin E2 Fab Frag Prostaglandin E2,19-JUL-2013,8_8_10_11_3_9,3WFH_A_B,Xtal structure,Prostaglandin,4,1,0.093290806,-4.299753
2GSI_B_A,VQLQQSGAELVRSGASVKLSCTASGFNIKDYYMYWVKLRPEQGLEWIGWIDPENGDTEYVPTFQGKVTMTADTSSNTAYLQLSSLTSEDTAVYYCNAGVITMMGYQAMDYWGQGTTVTTSS,DIVLTQSPASLAVSLGQPATISCGASKSVRTSGYSYMDWNQQKPGQPPRRLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCSHIRELPRSSGGGTKLEIK,2GSI_B,2GSI_A,Crystal Structure Of A Murine Fab In Complex With An 11 Residue Peptide Derived From Staphylococcal Nuclease,Crystal Structure Of A Murine Fab In Complex With An 11 Residue Peptide Derived From Staphylococcal Nuclease,synthetic construct,"Armstrong,A.A.;Amzel,L.M.",Crystal Structure of a Murine Fab in Complex with an 11 Residue Peptide Derived from Staphylococcal Nuclease,26-APR-2006,8_8_15_10_3_9,2GSI_B_A,Xtal structure,,4,1,-4.929313,0.39039576
6DCA_J_N,VQLQQSGPELVKPGASVKISCKTSEYTFTEYTKHWVKQSHGKSLEWIGSINPNNGDTYYNQKFTDKATLTVDKSSTTASMELRSLTFEDSAVYYCAMGDSAWFAYWGQGTLVTVSS,DVQMTQTPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCVQGTHSPLTFGAGTKLELK,6DCA_J,6DCA_N,Fab/Epitope Complex Of Mouse Monoclonal Antibody 6B2 Targeting A Non-Phosphorylated Tau Epitope.,Fab/Epitope Complex Of Mouse Monoclonal Antibody 6B2 Targeting A Non-Phosphorylated Tau Epitope.,Homo sapiens,"Chukwu,J.E.;Congdon,E.E.;Sigurdsson,E.M.;Kong,X.P.",Structural characterization of monoclonal antibodies targeting C-terminal Ser(404) region of phosphorylated tau protein,04-MAY-2018,8_8_10_11_3_9,6DCA_J_N,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,4,1,2.514319,-4.3926396
1LMK_A_A,VQLQQSGTELMKPGRSLKISCKTTGYIFSNYWIEWVKQRPGHGLEWIGKILPGGGSNTYNDKFKGKATFTADTSSNIAYMQLSSLTSEDSAVYYCARGEDYYAYWYVLDYWGQGTTVTVSS,IELTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTSLHWYLKKPGQSPKLLIYKVSTRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPFTFGSGTKLELK,1LMK_A,1LMK_A,The Structure Of A Bivalent Diabody,The Structure Of A Bivalent Diabody,Mus musculus,"Perisic,O.;Webb,P.A.;Holliger,P.;Winter,G.;Williams,R.L.","Crystal structure of a diabody, a bivalent antibody fragment",29-AUG-1994,8_8_15_11_3_9,1LMK_A_A,Xtal structure,,4,1,5.0011787,-1.8687702
7WT7_H_D,VQLVESGGGLVQPGGSLRLSCAASGIIVSSNYMSWVRQGPGKGLEWVSVIYSGGSTYYADSVKARFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREVVGSNSNMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINIYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTINSLQPEDIATYYCQQYDNLPRTFGQGTKVEIK,7WT7_H,7WT7_D,Sars-Cov-2 Omicron Variant Spike In Complex With Fab 9A8 (State 1),Sars-Cov-2 Omicron Variant Spike In Complex With Fab 9A8 (State 1),Homo sapiens,"Liu,S.;Jia,Z.;Nie,J.;Liang,Z.;Xie,J.;Wang,L.;Zhang,L.;Wang,X.;Wang,Y.;Huang,W.",A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD,07-JUN-2023,8_7_13_6_3_9,7WT7_H_D,Xtal structure,SARS-CoV-2; RBD,4,1,12.561317,10.728441
7LY2_N_O,VQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVTVIWYDGSNRYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCARAVAGEWYFDYWGQGTLVTVS,YELTQPPSVSVSPGQTARITCSGDALAKHYAYWYRQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSIGSSWVFGGGTKLTV,7LY2_N,7LY2_O,Sars-Cov-2 S/S2M11/S2M28 Global Refinement,Sars-Cov-2 S/S2M11/S2M28 Global Refinement,Homo sapiens,"McCallum,M.;De Marco,A.;Lempp,F.A.;Tortorici,M.A.;Pinto,D.;Walls,A.C.;Beltramello,M.;Chen,A.;Liu,Z.;Zatta,F.;Zepeda,S.;di Iulio,J.;Bowen,J.E.;Montiel-Ruiz,M.;Zhou,J.;Rosen,L.E.;Bianchi,S.;Guarino,B.;Fregni,C.S.;Abdelnabi,R.;Foo,S.C.;Rothlauf,P.W.;Bloyet,L.M.;Benigni,F.;Cameroni,E.;Neyts,J.;Riva,A.;Snell,G.;Telenti,A.;Whelan,S.P.;Virgin,H.W.;Corti,D.;Pizzuto,M.S.;Veesler,D.",N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2,05-MAR-2021,8_8_12_6_3_11,7LY2_N_O,Xtal structure,SARS-CoV-2,4,1,14.924084,13.298738
7WE7_H_L,VQLVQSGAEVKKPGSSVKVSCKASGDTFSSYTFSWVRQAPGQGLEWMGRSIPIVGKAIYAQEFQGRVTISADRSTTTVYMELSSLRSDDTAVYYCARDQSGFDFFYYDHWGQGTLVAV,QSVLTQPPSASGTPGQRVTISCSGSGSNIGSNTINWYQQLPGTAPKVLIYRNNERPSGVPDRFSGSKSGTSASLTISGLQSEDEAYYHCAAWDDSLNGPVFGGGTKLTVL,7WE7_H,7WE7_L,Sars-Cov-2 Omicron Variant Spike Protein In Complex With Fab Xgv282,Sars-Cov-2 Omicron Variant Spike Protein In Complex With Fab Xgv282,Homo sapiens,"Wang,K.;Jia,Z.;Bao,L.;Wang,L.;Cao,L.;Chi,H.;Hu,Y.;Li,Q.;Zhou,Y.;Jiang,Y.;Zhu,Q.;Deng,Y.;Liu,P.;Wang,N.;Wang,L.;Liu,M.;Li,Y.;Zhu,B.;Fan,K.;Fu,W.;Yang,P.;Pei,X.;Cui,Z.;Qin,L.;Ge,P.;Wu,J.;Liu,S.;Chen,Y.;Huang,W.;Wang,Q.;Qin,C.F.;Wang,Y.;Qin,C.;Wang,X.",Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants,23-DEC-2021,8_8_14_8_3_11,7WE7_H_L,Xtal structure,SARS-CoV-2,4,1,-0.7774267,5.5322475
7WTF_H_L,VQLVQSGAEVKKPGSSVKVSCKASGGTFSNYALSWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARLDGYSFGHDRYYQDGMDDWGPGT,DIQMTQSPSSLSASVGDRVTITCRASQAIRNDLGWYQQKPGKAPKCLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCLQQNIYPRTFGQGTKV,7WTF_H,7WTF_L,Sars-Cov-2 Omicron Variant Spike In Complex With Fab Xgv051,Sars-Cov-2 Omicron Variant Spike In Complex With Fab Xgv051,Homo sapiens,"Wang,L.;Fu,W.;Bao,L.;Jia,Z.;Zhang,Y.;Zhou,Y.;Wu,W.;Wu,J.;Zhang,Q.;Gao,Y.;Wang,K.;Wang,Q.;Qin,C.;Wang,X.","Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages",14-DEC-2022,8_8_20_6_3_9,7WTF_H_L,Xtal structure,SARS-CoV-2,4,1,-0.7966011,6.154325
AF157781_1,VTLDESGGGLQTPGGALSLVCKASGFTFSSYGMQWVRQAPGKGLEFIASISRTGRYTGYGAAVKGRAIISRDNGQSTVRLQLNSLRAEDTGTYFCTKSGCGHSYESGCVDAWGHGTEVIVSS,LTQPSSVSTNPGETVKITCSGSGSNYGWYQQKSPGSAPVTLIYNNNNRPSNIPSRFSGSKSGSTNTLTITGVQADDEAVYFCGGYDSSNRVGIFGAGTTLTVL,AF157781_1_H,AF157781_1_L,"scFV antibody V region, partial [synthetic construct]","scFV antibody V region, partial [synthetic construct]",synthetic construct,"Andris-Widhopf,J.; Rader,C.; Steinberger,P.; Fuller,R.; Barbas,C.F. III",Methods for the generation of chicken monoclonal antibody fragments by phage display,26-JUL-2016,8_8_16_5_3_11,AF157781_1,Same entry,,4,1,14.48416,11.254405
7PI3_W_X,VTLDESGGGLQTPGGALSLVCKGSGFFSFSSYTMQWVRQAPGKGLEWVASISSGGGTNYGAAVKGRATISRDNGQSTLRLQLNNLRAEDTGTYYCAKHGVNGCDWSYSVGCVDAWGHGTEVIVSS,ALTQPSSVSANPGETVKITCSGGSSSYYGWYQQKSPGSAPVTLIYNNQKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYFCGSRDNSGGIFGAGTTLTVL,7PI3_W,7PI3_X,"Pfcyrpa Bound To Fab Fragments From Monoclonal Antibodies Cy.003, Cy.004 And Cy.007","Pfcyrpa Bound To Fab Fragments From Monoclonal Antibodies Cy.003, Cy.004 And Cy.007",Gallus gallus,"Ragotte,R.J.;Pulido,D.;Lias,A.M.;Quinkert,D.;Alanine,D.G.W.;Jamwal,A.;Davies,H.;Nacer,A.;Lowe,E.D.;Grime,G.W.;Illingworth,J.J.;Donat,R.F.;Garman,E.F.;Bowyer,P.W.;Higgins,M.K.;Draper,S.J.",Heterotypic interactions drive antibody synergy against a malaria vaccine candidate,19-AUG-2021,9_7_19_4_3_9,7PI3_W_X,Xtal structure,,4,1,14.469972,11.209761
CBN73453_CBN73447,DVKLVESGGGLVKPGGSLKLSCEASGFTFSSYTLSWVRQTPETRLEWVATISIGGRYTYYPDSVEGRFTISRDNAKNTLYLQMNSLKSEDTAMYYCTRDFNGYSDFWGQGTTLTVSS,DTVMTQSHKFISTSVGDRVSITCKASQVVGSAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYNSYPYTFGGGTKLEIK,CBN73453,CBN73447,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Lejeune,P.; Vrignaud,P.",Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide,21-JUN-2010,8_8_10_6_3_9,CBN73453_CBN73447,Ordered entries,,5,1,17.793709,6.9776516
AEQ73823_AEQ74575,EMKQAGSSVKVSCKASGGSFSNYPFSWVRQAPGQGLEWMGGIIPILGTARYAQKFQGRVTVTVDKSTRTTYMELSDLRSDDTAVYFCALRDGSNFVYFDYWGQGTLVT,TLSASVGDRVTIACRASQFISSFLAWYQQKPGKAPKLLIYKASGLQSGVPSRFSGSGSGTEFNLTISSLQPDDFATYYCQQYNSLQGTFGQGTKLEIK,AEQ73823,AEQ74575,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_13_6_3_9,AEQ73823_AEQ74575,Unique source,tetanus,5,1,0.06703101,5.6921926
6OPA_K_J,EPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVRQPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSVTAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSS,QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVL,6OPA_K,6OPA_J,"Crystal Structure Of Bovine Fab Nc-Cow1 In Complex With Hiv-1 Bg505 Sosip.664, And Human Fabs 35022 And Pgt128","Crystal Structure Of Bovine Fab Nc-Cow1 In Complex With Hiv-1 Bg505 Sosip.664, And Human Fabs 35022 And Pgt128",Homo sapiens,"Stanfield,R.L.;Berndsen,Z.T.;Huang,R.;Sok,D.;Warner,G.;Torres,J.L.;Burton,D.R.;Ward,A.B.;Wilson,I.A.;Smider,V.V.",Structural basis of broad HIV neutralization by a vaccine-induced cow antibody,01-APR-2020,10_13_21_4_3_10,6OPA_K_J,Xtal structure,HIV,5,1,17.006344,-7.699728
7A69_C_B,EVILVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISSGGGNTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARYYRYEAWFASWGQGTLVTVSA,DVLMTQTPVSLSVSLGDQASISCRSSQSIVHSTGNTYLEWYLQKPGQSPKLLIYKISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQASHAPRTFGGGTKLEIK,7A69_C,7A69_B,Nanodisc Reconstituted Human Abcb1 In Complex With Mrk16 Fab And Vincristine,Nanodisc Reconstituted Human Abcb1 In Complex With Mrk16 Fab And Vincristine,Mus musculus,"Nosol,K.;Romane,K.;Irobalieva,R.N.;Alam,A.;Kowal,J.;Fujita,N.;Locher,K.P.",Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1,25-AUG-2020,8_8_12_11_3_9,7A69_C_B,Xtal structure,CLCS; GP170; PGY1; p-170; MDR1; CD243; ABC20; ABCB1; P-gp,5,1,18.149672,7.1567907
AEQ73834_AEQ74586,EVKKPGASVKVSCETSGYAFKKYGVTWVRQAPGHGLEWMGWISPLNGMTNYAQNLQGRVTLTTDISTNTAYLEMRGLKSDDTGVYYCARDYFGSGSVYYFDYWGQGTLVT,FLSASVGDRVVITCRASQDVSTYLNWYQQTPGKAPKVLVYAATILQSGVPSRFSGSGSGTTFTLTISSLQPEDFATYSCQQSYKTPYTFGQGTKLEIK,AEQ73834,AEQ74586,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_9,AEQ73834_AEQ74586,Unique source,tetanus,5,1,1.4289043,5.3296833
AEQ73546_AEQ74299,EVKKPGSSVKVSCKTSGGSFSTYSITWVRQAPGQGLEWMGGINPIFATRDYAQKFQGRVTITADESTRTVYMELRNLRSEDTAVYYCARVFGGTRLYYALNVWGQGTLVTVS,SSLSASVGDRVTITCRASQGISNFLAWHQQKPGQVPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTINGLQPEDVATYYCQKYDSGLIFTFGPGTRVEIK,AEQ73546,AEQ74299,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_15_6_3_10,AEQ73546_AEQ74299,Unique source,tetanus,5,1,0.039530456,5.7301035
1QLE_H_L,EVKLQESGGDLVQPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVASINNGGGRTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCVRHEYYYAMDYWGQGTTVTVSS,DIELTQTPVSLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQFLVYNAKTLGEGVPSRFSGSGSGTQFSLKINSLLPEDFGSYYCQHHYGTPPLTFGGGTKLEIK,1QLE_H,1QLE_L,Cryo-Structure Of The Paracoccus Denitrificans Four-Subunit Cytochrome C  Oxidase In The Completely Oxidized State Complexed With An Antibody Fv Fragment,Cryo-Structure Of The Paracoccus Denitrificans Four-Subunit Cytochrome C  Oxidase In The Completely Oxidized State Complexed With An Antibody Fv Fragment,Mus musculus,"Harrenga,A.;Michel,H.",The cytochrome c oxidase from Paracoccus denitrificans does not change the metal center ligation upon reduction,30-AUG-1999,8_8_11_6_3_10,1QLE_H_L,Xtal structure,,5,1,17.762878,7.1318483
QDM58846_QDM58847,EVKLVESGGDFVKPGGSLKLSCAASGFTFSNSAMSWVRQTPEKRLEWVATINNNGGYTHYPDTLKDRFTISRDNVKNTLYLQMSSLRSEDTALYYCTRQTYWYLDVWGAGTTVTVSS,DVVMSQSPSSLTVSLGEKVTMTCKSSQSLLYSGNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLIISSVKAEDLAVYYCQQFYFYPWTFGGGTKLEIK,QDM58846,QDM58847,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Mcguire,A.",Anti-idiotypic antibodies elicit anti-HIV-1-specific b cell responses,23-JUL-2019,8_8_10_12_3_9,QDM58846_QDM58847,Unique source,HIV,5,1,17.890404,7.2522044
7R8B_C_D,EVKLVESGGGLVQPGGSLRLSCATSGFTFSEFFMEWVRQPPGKRLEWVAVSRNEANDYTTDYSASVKGRFIVSRDTSQNILYLQMNALRAEDTAIYYCARDAWMGFDYWGQGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIQRLIYAAFSLDSGVPKRFSGSRSGSDYSLTISSLESEDLAHYYCLQYASYPCTFGGGTKLEIK,7R8B_C,7R8B_D,The Structure Of Human Abcg5/Abcg8 Supplemented With Cholesterol,The Structure Of Human Abcg5/Abcg8 Supplemented With Cholesterol,Mus musculus,"Sun,Y.;Wang,J.;Long,T.;Qi,X.;Donnelly,L.;Elghobashi-Meinhardt,N.;Esparza,L.;Cohen,J.C.;Xie,X.S.;Hobbs,H.H.;Li,X.",Molecular basis of cholesterol efflux via ABCG subfamily transporters,26-JUN-2021,8_10_10_6_3_9,7R8B_C_D,Xtal structure,,5,1,26.055067,4.678498
7ZXG_B_C,EVMLVESGGDLVKPGGSLKVSCAASGFTFSNYAMSWVRQTPEKRLEWVATISSGASYTHYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCGRQVNRHDRALDAMDYWGQGTSVTVSP,DIVMSQSPSSLAVSVGEKVTMSCKSSQSLFYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPPTFGGGTKLEIK,7ZXG_B,7ZXG_C,Pfs48/45 Bound To Fab Fragment Of Monoclonal Antibody 10D8,Pfs48/45 Bound To Fab Fragment Of Monoclonal Antibody 10D8,Mus musculus,"Ko,K.T.;Lennartz,F.;Mekhaiel,D.;Guloglu,B.;Marini,A.;Deuker,D.J.;Long,C.A.;Jore,M.M.;Miura,K.;Biswas,S.;Higgins,M.K.",Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies,20-MAY-2022,8_8_16_12_3_9,7ZXG_B_C,Xtal structure,,5,1,17.938797,7.2169704
QRI59086_QRI59100,EVQLLESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDHVRPGMNIWGQGTMVTVSS,AIRMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVDIK,QRI59086,QRI59100,"heavy chain variable region, partial [Homo sapiens]","light chain variable region, partial [Homo sapiens]",Homo sapiens,"Huang,K.-Y.A.",Direct Submission,14-FEB-2021,8_7_11_6_3_9,QRI59086_QRI59100,Unique source,,5,1,12.506472,10.5416765
QFQ61582_QFQ61734,EVQLLESGGGLVQPGGSLRLSCEASGFPLRDYAMSWVRQAPGRGLQWVSTIGGNDNAANYADSVKGRFTVSRDNSKSTIYLQMNSLRAEDTALYFCAKSVRLSRPSPFDLWGQGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQHQPGQAPRLLIYEASNRATGIPARFSGSGSGTEFTLTISSLEPEDVAVYYCQQRASWPLTFGGGTKVEIK,QFQ61582,QFQ61734,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Ehrhardt,S.A.; Zehner,M.; Krahling,V.; Cohen-Dvashi,H.; Kreer,C.; Elad,N.; Gruell,H.; Ercanoglu,M.S.; Schommers,P.; Gieselmann,L.; Eggeling,R.; Dahlke,C.; Wolf,T.; Pfeifer,N.; Addo,M.M.; Diskin,R.; Becker,S.; Klein,F.",Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV,23-OCT-2019,8_8_14_6_3_9,QFQ61582_QFQ61734,Unique source,Ebola,5,1,14.0771885,9.588573
6UTE_G_H,EVQLLESGGRLVQPGGSLTLSCAASGFPFSTYAMSWLRQAPGKGLEWVSGITGDSGSTYYAASVKGRFTISRDNSKNTLYLQMNSLTADDTAVYYCAKDRLHSGLGELFSYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVNITCRASQSINQWLAWYQQKPGKAPKFLMYKASTLETGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYFSYPWTFGQGTKVEIK,6UTE_G,6UTE_H,Crystal Structure Of Z032 Fab In Complex With Wnv Ediii,Crystal Structure Of Z032 Fab In Complex With Wnv Ediii,Homo sapiens,"Esswein,S.R.;Gristick,H.B.;Jurado,A.;Peace,A.;Keeffe,J.R.;Lee,Y.E.;Voll,A.V.;Saeed,M.;Nussenzweig,M.C.;Rice,C.M.;Robbiani,D.F.;MacDonald,M.R.;Bjorkman,P.J.",Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody,29-OCT-2019,8_8_15_6_3_9,6UTE_G_H,Xtal structure,Zika,5,1,14.221307,9.811876
6QEX_C_B,EVQLQESGPELVKTGASVKISCKASGYSFSNYYIHWVKQSHGKSLEWIGFISCYNGATFYNQKFKGKATFTVDNSSSTAYMKFNSLTFEDSAVYYCARLPIQFGNFYPMDYWGQGTTVTVSS,QVVMTQSPLSLPVSLGDQASISCRSSQSLLHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHIPPWTFGGGTKLDIK,6QEX_C,6QEX_B,Nanodisc Reconstituted Human Abcb1 In Complex With Uic2 Fab And Taxol,Nanodisc Reconstituted Human Abcb1 In Complex With Uic2 Fab And Taxol,Mus musculus,"Alam,A.;Kowal,J.;Broude,E.;Roninson,I.;Locher,K.P.",Structural insight into substrate and inhibitor discrimination by human P-glycoprotein,08-JAN-2019,8_8_15_11_3_10,6QEX_C_B,Xtal structure,,5,1,2.507523,-4.033341
1JNH_H_G,EVQLQQSGAELARPGASVKLSCRTSGYSFTTYWMQWVRQRPGQGLEWIAAIYPGDDDARYTQKFKGKATLTADRSSSIVYLQLNSLTSEDSAVYSCSRGRSLYYTMDYWGQGTSVTVSS,QAVVTQESALTTSPGETVTLTCRSSSGAITTSHYANWIQEKPDHLFTGLISGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYICALWFSNQFIFGSGTKVTVL,1JNH_H,1JNH_G,Crystal Structure Of Fab-Estradiol Complexes,Crystal Structure Of Fab-Estradiol Complexes,Mus musculus,"Monnet,C.;Bettsworth,F.;Stura,E.A.;Le Du,M.H.;Menez,R.;Derrien,L.;Zinn-Justin,S.;Gilquin,B.;Sibai,G.;Battail-Poirot,N.;Jolivet,M.;Menez,A.;Arnaud,M.;Ducancel,F.;Charbonnier,J.B.",Highly specific anti-estradiol antibodies: structural characterisation and binding diversity,24-JUL-2001,8_8_12_9_3_9,1JNH_H_G,Xtal structure,estradiol,5,1,0.43442705,-3.8751297
6A0Z_H_L,EVQLQQSGAELMKPGASVKISCKATGYTFSGHWIEWVKQRPGHGLEWIGEILPGSGNIHYNEKFKGKATFAADTSSNTAYMQLSSLTSEDSAVYYCARLGTTAVERDWYFDVWGAGTTVTVSL,DIVMTQSQKFMSASVGDRVSVTCKASQNVGTHLAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSGDLADYFCQQYNNFPLTFGAGTKLEIK,6A0Z_H,6A0Z_L,"Crystal Structure Of Broadly Neutralizing Antibody 13D4 Bound To H5N1 Influenza Hemagglutinin, Ha Head Region","Crystal Structure Of Broadly Neutralizing Antibody 13D4 Bound To H5N1 Influenza Hemagglutinin, Ha Head Region",Mus musculus,"Lin,Q.;Li,T.;Chen,Y.;Lau,S.Y.;Wei,M.;Zhang,Y.;Zhang,Z.;Yao,Q.;Li,J.;Li,Z.;Wang,D.;Zheng,Q.;Yu,H.;Gu,Y.;Zhang,J.;Chen,H.;Li,S.;Xia,N.","Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus",06-JUN-2018,8_8_16_6_3_9,6A0Z_H_L,Xtal structure,H5N1; Influenza,5,1,5.017135,-1.8522084
CAA36980_CAA36979,EVQLQQSGAELVEPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPANGNSKYVPKFQGKATITADTSSNTAYLQLTSLTSEDTAVYYCAPFGYYVSDYAMAYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATMSCRAGESVDIFGVGFLHWYQQKPGQPPKLLIYRASNLESGIPVRFSGTGSRTDFTLIIDPVEADDVATYYCQQTNEDPYTFGGGTKLEIK,CAA36980,CAA36979,"anti-CEA mAb T84.66, partial [Mus musculus]","anti-CEA mAb T84.66, partial [Mus musculus]",Mus musculus,"Neumaier,M.; Shively,L.; Chen,F.S.; Gaida,F.J.; Ilgen,C.; Paxton,R.J.; Shively,J.E.; Riggs,A.D.","Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells",26-JUL-2016,8_8_14_10_3_9,QHX11021_QHX11022,Unique chain,CEACAM5; CD66e; CEA,5,1,-4.6866984,0.13188337
8DL6_D_C,EVQLQQSGAELVRPGALVKLSCKASGFNIKDYYMHWVKERPEQGLEWIGWIDPENGNTIYDPKFQGKASITADTSSNTAYLQLSSLTSEDTAVYYCARKRGYYGPYFDYWGQGTTLTVSS,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQKKPGQSPKLLIYSASNRYSGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYGSYPLTFGSGTKLEIK,8DL6_D,8DL6_C,Cryo-Em Structure Of Human Ferroportin/Slc40 Bound To Ca2+ In Nanodisc,Cryo-Em Structure Of Human Ferroportin/Slc40 Bound To Ca2+ In Nanodisc,Mus musculus,"Shen,J.;Wilbon,A.S.;Zhou,M.;Pan,Y.",Mechanism of Ca<sup>2+</sup> transport by ferroportin,25-JAN-2023,8_8_13_6_3_9,8DL6_D_C,Xtal structure,ferroportin,5,1,-4.7611036,0.20263305
BDZ85360_BDZ85425,EVQLQQSGAELVRPGASVKLSCTASGFNIKDSLMHWVKQRPEQGLEWIGWIDPEDGETKYAPKFRDKATVTSDTSSNTAYLQLSSLTSEDTAIYYCTRDYYAGSPYAMDYWGQGTSVTVSS,NIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQKPEQSPKVLIYGASNRYTGVPDRFTGSGSVTDFTLTISSVQAEDLADYYCGQSYSYPLTFGAGTKLELK,BDZ85360,BDZ85425,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Kurosawa,N.",Anti SARS-CoV-2 IgA antibody developed from nonmucosal tissues of mouse,03-MAY-2023,8_8_14_6_3_9,BDZ85360_BDZ85425,Unique source,SARS-CoV-2,5,1,-5.182428,0.41973516
5TLJ_F_E,EVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSDYYGDYGFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDYAGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,5TLJ_F,5TLJ_E,Complex Between Human Cd27 And Fab Fragments Of Antibodies M2177 And M2191,Complex Between Human Cd27 And Fab Fragments Of Antibodies M2177 And M2191,Homo sapiens,"Obmolova,G.;Teplyakov,A.;Malia,T.J.;Wunderler,N.;Kwok,D.;Barone,L.;Sweet,R.;Ort,T.;Scully,M.;Gilliland,G.L.",Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography,11-OCT-2016,8_8_13_10_3_9,5TLJ_F_E,Xtal structure,S152; TNFRSF7; CD27; Tp55,5,1,0.34797046,-4.703302
4GMT_I_M,EVQLQQSGTELKKPGASVKISCKATGYTFSSYWIEWIKQRPGHGLEWIGEILPEIGMTNYNENFKGKATFTANTSSNTVYMQLSSLTSEDSAVYYCARPYDYSWFAYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQEKPGQSPKTLIYSASNRYSGVPDRFTGSASGTDFTLTITNVQSEDLAEYFCQQYNSYPYTFGGGTKLEIK,4GMT_I,4GMT_M,Crystal Structure Of Heterosubtypic Fab S139/1,Crystal Structure Of Heterosubtypic Fab S139/1,Mus musculus,"Lee,P.S.;Yoshida,R.;Ekiert,D.C.;Sakai,N.;Suzuki,Y.;Takada,A.;Wilson,I.A.",Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity,16-AUG-2012,8_8_11_6_3_9,4GMT_I_M,Xtal structure,hemagglutinin,5,1,4.9989634,-1.8701441
4UIM_C_D,EVQLQQSGTVLARPGASVKMSCEASGYTFTSYWMHWLKKRPGQGLEWIGTIYPGNSDSSYNQRFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTRERGLYYGGRSFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLTWYQQKPDGTVKLLIYYTSKLHSGVPSRFSGSGSGTDYSLTISNLEQEDVANYFCQQGNSLPPTFGGGTKLEIK,4UIM_C,4UIM_D,Crystal Structure Of Quinine-Dependent Fab 314.3,Crystal Structure Of Quinine-Dependent Fab 314.3,Mus musculus,"Zhu,J.;Zhu,J.;Bougie,D.W.;Aster,R.H.;Springer,T.A.",Structural basis for quinine-dependent antibody binding to platelet integrin alphaIIbbeta3,30-MAR-2015,8_8_15_6_3_9,4UIM_C_D,Xtal structure,platelet,5,1,2.7147577,-8.196994
7EJZ_H_L,EVQLVESGGGLIQPGGSLRLSCAASGLIVSSNYMSWVRQAPGKGLEWVSVLYAGGSTDYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAAVYGIDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPLFTFGPGTKVDIK,7EJZ_H,7EJZ_L,Complex Structure Of Antibody Bd-503 And Rbd-S477N Of Covid-19,Complex Structure Of Antibody Bd-503 And Rbd-S477N Of Covid-19,Homo sapiens,"Xu,H.;Wang,B.;Zhao,T.N.;Liang,Z.T.;Peng,T.B.;Song,X.H.;Wu,J.J.;Wang,Y.C.;Su,X.D.",Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants,03-APR-2021,8_7_11_6_3_10,7EJZ_H_L,Xtal structure,SARS-CoV-2; RBD,5,1,12.525245,10.827392
8CBX_H_L,EVQLVESGGGLVKPGGSLKLSCAASGFAFGNYDMSWVRQTPEKRLEWVAFIGSGGGRIYYGDTMKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCTRHYNYYYSMDYWGQGTSVIVSS,DIELTQSPAVMSAFPGEEVTMTCSASSSINYMHWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSIFTFGSGTKLEIK,8CBX_H,8CBX_L,Crystal Structure Of Anti-Cortisol Fab Fragment,Crystal Structure Of Anti-Cortisol Fab Fragment,Mus musculus,"Eronen,V.;Tullila,A.;Iljin,K.;Rouvinen,J.;Nevanen,T.K.;Hakulinen,N.",Structural insight to elucidate the binding specificity of the anti-cortisol Fab fragment with glucocorticoids,10-MAY-2023,8_8_12_5_3_7,8CBX_H_L,Xtal structure,cortisol; Cortisol,5,1,17.864859,6.903685
6PE9_H_L,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWVSYISSGRSNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNLGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,6PE9_H,6PE9_L,Crystal Structure Of Cd40 Complexed To Fab516,Crystal Structure Of Cd40 Complexed To Fab516,Homo sapiens,"Argiriadi,M.A.;Benatuil,L.;Dubrovska,I.;Egan,D.A.;Gao,L.;Greischar,A.;Hardman,J.;Harlan,J.;Iyer,R.B.;Judge,R.A.;Lake,M.;Perron,D.C.;Sadhukhan,R.;Sielaff,B.;Sousa,S.;Wang,R.;McRae,B.L.",CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches,20-JUN-2019,8_8_9_12_3_9,QBE00790_QBE00820,Xtal structure,TNFRSF5; p50; Bp50; CD40,5,1,15.668478,9.742271
7PA8_Y_F,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLQWVSSISSSSTYMYYGDSVKGRFTISRDNARNSLYLQMNSLRVEDTAVYYCARYAHDWNVDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGGSSNIGSNPVNWFQQFPGTAPKLLIYANTQRPSGVPDRFSGSKSGTSVSLAISGLQSEDEGDYHCAAWDDSLKGWVFGGGTKLTVL,7PA8_Y,7PA8_F,Jc Polyomavirus Vp1 In Complex With Fab 27C2,Jc Polyomavirus Vp1 In Complex With Fab 27C2,Homo sapiens; JC polyomavirus,"Stroeh, L.J., Harprecht, C., Freytag, J., Stehle, T.",Jc Polyomavirus Vp1 In Complex With Fab 27C2,08-JAN-2009,8_8_11_8_3_11,QHY05580_QHY05581,Xtal structure,,5,1,15.992002,10.028817
7PAA_Z_Z,EVQLVESGGGLVKPGGSLRLSCAASGITFQYYAMNWVRQAPGKGLEWVSSIGGRGDTTYYTDSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKEPFDSSGDHRGVFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNNIGSRSVHWYQHKPGQAPVMIISYDMNRPSGIPERVSGSNYGNTATLTISRVEAGDEADYYCQVWDSRSDHPYVFGTGTRVTVL,7PAA_Z,7PAA_Z,Jc Polyomavirus Vp1 In Complex With Scfv 29B1,Jc Polyomavirus Vp1 In Complex With Scfv 29B1,Homo sapiens; JC polyomavirus,"Harprecht, C., Stroeh, L.J., Freytag, J., Stehle, T.",Jc Polyomavirus Vp1 In Complex With Scfv 29B1,08-JAN-2009,8_8_17_6_3_12,7PAA_Z_Z,Xtal structure,,5,1,14.2167425,9.704605
7KGU_D_C,EVQLVESGGGLVQPGGSLRLSCAASGFNVKYYMMHWVRQAPGKGLEWVAAISPGYDYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRSYWRYSVDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQVYSSPFTFGQGTKVEIK,7KGU_D,7KGU_C,"Structure Of 2Q1-Fab, An Antibody Selective For Idh2R140Q-Hla-B*07:02","Structure Of 2Q1-Fab, An Antibody Selective For Idh2R140Q-Hla-B*07:02",Homo sapiens,"Hwang,M.S.;Miller,M.S.;Thirawatananond,P.;Douglass,J.;Wright,K.M.;Hsiue,E.H.;Mog,B.J.;Aytenfisu,T.Y.;Murphy,M.B.;Aitana Azurmendi,P.;Skora,A.D.;Pearlman,A.H.;Paul,S.;DiNapoli,S.R.;Konig,M.F.;Bettegowda,C.;Pardoll,D.M.;Papadopoulos,N.;Kinzler,K.W.;Vogelstein,B.;Zhou,S.;Gabelli,S.B.",Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens,18-OCT-2020,8_8_11_6_3_9,7KGU_D_C,Xtal structure,HLA,5,1,9.73728,10.7000885
3EOB_H_L,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,3EOB_H,3EOB_L,"Crystal Structure The Fab Fragment Of Efalizumab In Complex With Lfa-1 I Domain, Form Ii","Crystal Structure The Fab Fragment Of Efalizumab In Complex With Lfa-1 I Domain, Form Ii",Homo sapiens,"Li,S.;Wang,H.;Peng,B.;Zhang,M.;Zhang,D.;Hou,S.;Guo,Y.;Ding,J.",Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance,26-SEP-2008,8_8_14_6_3_9,QNB54669_QNB54648,Xtal structure,LFA1A; LFA-1; CD11A; ITGAL,5,1,10.852627,10.438233
4MXW_H_L,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK,4MXW_H,4MXW_L,Structure Of Heterotrimeric Lymphotoxin Lta1B2 Bound To Lymphotoxin Beta Receptor Ltbr And Anti-Lta Fab,Structure Of Heterotrimeric Lymphotoxin Lta1B2 Bound To Lymphotoxin Beta Receptor Ltbr And Anti-Lta Fab,Homo sapiens,"Sudhamsu,J.;Yin,J.;Chiang,E.Y.;Starovasnik,M.A.;Grogan,J.L.;Hymowitz,S.G.",Dimerization of LTbetaR by LTalpha1beta2 is necessary and sufficient for signal transduction,26-SEP-2013,8_8_11_6_3_9,AED84747_AED84746,Xtal structure,Lta,5,1,10.771508,10.422623
2YBR_G_H,EVQLVESGGGLVQPGGSLRLSCTGSGFTFDNYAMHWLRQVPGEGLEWVSGISRSSGDIDYADSVKGRFTISRDDAKKTLSLQMNSLRAEDTAVYYCARGGVGSFDTWGQGTMVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLFSDASNRATGIPARFTGSGSGTDFTLTISSLEPEDFAIYYCQQYRYSPRTFGQGTKVEIK,2YBR_G,2YBR_H,Crystal Structure Of The Human Derived Single Chain Antibody Fragment  (Scfv) 9004G In Complex With Cn2 Toxin From The Scorpion Centruroides  Noxius Hoffmann,Crystal Structure Of The Human Derived Single Chain Antibody Fragment  (Scfv) 9004G In Complex With Cn2 Toxin From The Scorpion Centruroides  Noxius Hoffmann,Centruroides noxius,"Canul-Tec,J.C.;Riano-Umbarila,L.;Rudino-Pinera,E.;Becerril,B.;Possani,L.D.;Torres-Larios,A.",Structural basis of neutralization of the major toxic component from the scorpion Centruroides noxius Hoffmann by a human-derived single-chain antibody fragment,09-MAR-2011,8_8_10_6_3_9,2YBR_G_H,Xtal structure,Toxin,5,1,14.481831,9.56756
4ODU_H_L,EVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKSNNYATYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRHRGAPLYYGNGAWFAYWGQGTLVTVS,DIQMTQSTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKVLIYYTSRLRSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,4ODU_H,4ODU_L,Unliganded Fab Structure Of Lipid A-Specific Antibody S1-15,Unliganded Fab Structure Of Lipid A-Specific Antibody S1-15,Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Rodriguez,T.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",Structural Basis for Antibody Recognition of Lipid A: INSIGHTS TO POLYSPECIFICITY TOWARD SINGLE-STRANDED DNA,10-JAN-2014,8_10_18_6_3_9,4ODU_H_L,Xtal structure,,5,1,13.345247,7.7392178
UOF83925_UOF83926,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISFDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARASITTTDDGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPFSFGPGTKVDIK,UOF83925,UOF83926,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Song,D.",Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron,30-SEP-2022,8_8_14_6_3_9,UOF83925_UOF83926,Unique source,SARS-CoV-2,5,1,14.445555,13.723214
5BVJ_H_G,EVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,5BVJ_H,5BVJ_G,"The Molecular Mode Of Action And Species Specificity Of Canakinumab, A Human Monoclonal Antibody Neutralizing Il-1Beta","The Molecular Mode Of Action And Species Specificity Of Canakinumab, A Human Monoclonal Antibody Neutralizing Il-1Beta",Homo sapiens,"Rondeau,J.M.;Ramage,P.;Zurini,M.;Gram,H.","The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta",05-JUN-2015,8_8_11_6_3_9,5BVJ_H_G,Xtal structure,IL-1beta,5,1,14.8141985,13.058644
QFZ93617_QFZ93621,EVQLVESGGRALRPGGSLRLSCAASGFKFDDYAMSWVRQVPGKGLEFVSGLNWNGDITAYTDSVKGRFTVSRDNAKNSLYLHINSPKPEDTALYYCARTSSWGDYTRGPEPKITWYFDLWGRGTLVTVSS,DIQLTQSPSFLSASVGDRITITCRASQGIDGYLAWYQQRPGKAPNLLIYAASLLQSGVPSRFSGSGYGTEFTLTISSLQPEDFATYYCQHLDSYPLFTFGPGTKVDIK,QFZ93617,QFZ93621,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Stadlbauer,D.; Zhu,X.; McMahon,M.; Turner,J.S.; Wohlbold,T.J.; Schmitz,A.J.; Strohmeier,S.; Yu,W.; Nachbagauer,R.; Mudd,P.A.; Wilson,I.A.; Ellebedy,A.H.; Krammer,F.",Broadly protective human antibodies that target the active site of influenza virus neuraminidase,09-NOV-2019,8_8_23_6_3_10,QFZ93617_QFZ93621,Unique source,neuraminidase,5,1,13.240547,11.8388815
7SJM_H_L,EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK,7SJM_H,7SJM_L,Anti-Htra1 Fab15H6.V4,Anti-Htra1 Fab15H6.V4,Homo sapiens,"Gerhardy,S.;Ultsch,M.;Tang,W.;Green,E.;Holden,J.K.;Li,W.;Estevez,A.;Arthur,C.;Tom,I.;Rohou,A.;Kirchhofer,D.",Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration,07-SEP-2022,8_8_12_5_3_9,QHX57153_QHX57154,Xtal structure,ARMD7; HTRA1; IGFBP5-protease; HtrA; PRSS11,5,1,0.9397176,3.6530592
6OGX_C_D,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK,6OGX_C,6OGX_D,Ternary Complex Of Ox40R (Tnfrsf4) Bound To Fab1 And Fab2,Ternary Complex Of Ox40R (Tnfrsf4) Bound To Fab1 And Fab2,Homo sapiens,"Yang,Y.;Yeh,S.H.;Madireddi,S.;Matochko,W.L.;Gu,C.;Pacheco Sanchez,P.;Ultsch,M.;De Leon,Bo.;Harris,S.F.;Leonard,B.;Scales,S.J.;Zhu,J.W.;Christensen,E.;Hang,J.Q.;Brezski,R.J.;Marsters,S.;Ashkenazi,A.;Sukumaran,S.;Chiu,H.;Cubas,R.;Kim,J.M.;Lazar,G.A.",Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members,03-APR-2019,8_8_10_6_3_9,QPW23589_QPW23590,Xtal structure,,5,1,0.9156668,3.6119406
USW88759_USW88667,EVQLVQSGAEVKKPGESLKISCKASGYNFAYYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGEMTAVFGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQYKILLTWTFGQGTKVEIK,USW88759,USW88667,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Kumar,S.; Patel,A.; Lai,L.; Chakravarthy,C.; Valanparambil,R.; Davis-Gardner,M.E.; Edara,V.V.; Linderman,S.; Reddy,E.S.; Gottimukkala,K.; Nayak,K.; Dixit,K.; Sharma,P.; Bajpai,P.; Singh,V.; Frank,F.; Cheedarla,N.; Verkerke,H.P.; Neish,A.S.; Roback,J.D.; Mantus,G.; Goel,P.K.; Rahi,M.; Davis,C.W.; Wrammert,J.; Suthar,M.S.; Ahmed,R.; Ortlund,E.; Sharma,A.; Murali-Krishna,K.; Chandele,A.",Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody,06-JUL-2022,8_8_12_6_3_10,USW88759_USW88667,Unique source,SARS-CoV-2; RBD,5,1,-12.405913,5.672117
5WK3_W_V,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIDPSDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVGPADVWDSFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLLSPWNSNQLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYLIPSTFGQGTKVEIK,5WK3_W,5WK3_V,Crystal Structure Of The Complex Between Ccl17 And M116 Fab,Crystal Structure Of The Complex Between Ccl17 And M116 Fab,Homo sapiens,"Teplyakov,A.;Obmolova,G.;Gilliland,G.L.",Structural insights into chemokine CCL17 recognition by antibody M116,24-JUL-2017,8_8_14_12_3_9,QRJ97544_QRJ97551,Xtal structure,ABCD-2; SCYA17; TARC; CCL17,5,1,-12.378855,5.734793
3QCU_H_L,EVQLVQSGAEVKKPGESLKISCQAFGYGFINYLIEWIRQMPGQGLEWIGLINPGSDYTNYNENFKGQATLSADKSSSTAYLQWSSLKASDTAMYFCARRFGYYGSGNYFDYWGQGTMVTVSS,DVVMTQTPLSLPVTPGEPASISCTSGQSLVHINGNTYLHWYLQKPGQSPKLLIYKVSNLFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFPFTFGQGTKLEIK,3QCU_H,3QCU_L,Crystal Structure Of The Lt3015 Antibody Fab Fragment In Complex With Lysophosphatidic Acid (14:0),Crystal Structure Of The Lt3015 Antibody Fab Fragment In Complex With Lysophosphatidic Acid (14:0),Homo sapiens,"Fleming,J.K.;Wojciak,J.M.;Campbell,M.A.;Huxford,T.",Biochemical and structural characterization of lysophosphatidic Acid binding by a humanized monoclonal antibody,17-JAN-2011,8_8_15_11_3_9,3QCU_H_L,Xtal structure,,5,1,-12.345028,5.693099
QOV05189_QOV05190,EVQLVQSGAEVKKPGSSVKVSCKASGYTFINHALSWVRQAPGQGLEWVGGIIPIFGLAKYGQKFQDRVTITADESTKTAYMDLRSLRSDDTAVYYCARDTVAVYEDFDWSSPYFFYMDVWGKGTTVTVSS,EIVLTQSPATLSLFPGERATLSCRASQSAGSKSLAWYQHKVGQPPRLLINGASSRATGIPDRFSGSGSGPDFNLTISRLEPEDFAVYYCQRYGTSLVTFGGGTKVEIK,QOV05189,QOV05190,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Madsen,A.; Dai,Y.N.; McMahon,M.; Schmitz,A.J.; Turner,J.S.; Tan,J.; Lei,T.; Alsoussi,W.B.; Strohmeier,S.; Amor,M.; Mohammed,B.M.; Mudd,P.A.; Simon,V.; Cox,R.J.; Fremont,D.H.; Krammer,F.; Ellebedy,A.H.",Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective,04-NOV-2020,8_8_23_7_3_9,QOV05189_QOV05190,Unique source,Influenza,5,1,-0.949757,6.1015096
3U7W_H_L,EVRLSQSGGQMKKPGESMRLSCRASGYEFLNCPINWIRLAPGRRPEWMGWLKPRGGAVNYARKFQGRVTMTRDVYSDTAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGRGAPVTVSS,EIVLTQSPATLSLSPGETAIISCRTSQSGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGADYNLSISNLESGDFGVYYCQQYEFFGQGTKVQV,3U7W_H,3U7W_L,Crystal Structure Of Nih45-46 Fab,Crystal Structure Of Nih45-46 Fab,Homo sapiens,"Diskin,R.;Scheid,J.F.;Marcovecchio,P.M.;West AP,Jr.;Klein,F.;Gao,H.;Gnanapragasam,P.N.;Abadir,A.;Seaman,M.S.;Nussenzweig,M.C.;Bjorkman,P.J.",Increasing the potency and breadth of an HIV antibody by using structure-based rational design,14-OCT-2011,8_8_18_4_3_5,3U7W_H_L,Xtal structure,HIV,5,1,2.7737207,4.179619
1Q72_H_L,EVTLQESGGGLVQPGGSMKLSCAASGFTFSDAWVDWVRQSPGKGLEWVAEIRNKANNHATKYTESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTSVPQLGRGFAYWGQGTLVTVSA,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGYTYLHWFLQRPGQSPQLLIYRVSNLASGVPDRFSGSGSGTAFTLRFSRVEAEDVGVYYCMQHLEYPFTFGSGTKLEIK,1Q72_H,1Q72_L,Anti-Cocaine Antibody M82G2 Complexed With Cocaine,Anti-Cocaine Antibody M82G2 Complexed With Cocaine,Mus musculus,"Pozharski,E.;Moulin,A.;Hewagama,A.;Shanafelt,A.B.;Petsko,G.A.;Ringe,D.",Diversity in hapten recognition: structural study of an anti-cocaine antibody M82G2,15-AUG-2003,8_10_12_11_3_9,1Q72_H_L,Xtal structure,hapten; cocaine,5,1,13.414367,6.9559216
AEQ74197_AEQ74957,GGLVQPGRSLRLSCAASGFSFTDYAMTWVRQAPGKGLEWVSSISYNGETTYYADSVKGRFTISRDNSKNTLYLQINSVRAEDTAVFYCAKADNIVLVPAALTRPVDYWGQGTLVT,SLAVSLGERATINCKSSQSVLYSSNNRNYLAWYQQKPGQPPKLLMYWASTREFGVPDRFSGSGSRTDFTLTISSLQAEDVAVYYCQQYYTTPWTFGQGTKVEIK,AEQ74197,AEQ74957,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_19_12_3_9,AEQ74197_AEQ74957,Unique source,tetanus,5,1,14.564415,10.496579
AEQ73949_AEQ74709,GGVVQPGRSLSLSCAASGFTFNFYGMHWVRQAPGKGLEWVANVWYDGNHKYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCARERGHDTNGQPDNWGQGTLVT,SSLSASVGDRVTITCRASERISNYLNWFHQKPGQVPKLLIYAASSLQSGVPSRLSGSGSGTDFTLTISSLQPEDFGSYYCQQSYSPPFTFGQGTKLEIK,AEQ73949,AEQ74709,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_14_6_3_9,AEQ73949_AEQ74709,Unique source,tetanus,5,1,14.891292,12.817329
7UOJ_H_L,HVQLVQSGGGVKKIGAAVRISCEVSGYNFMDQFINWVRQAPGQGLEWMGWMNPIYGQVNYSWRFQGRVTMTRQLSQDPDDPDWGTAFMELRGLRVDDTAVYYCARGPSGENYPFHYWGQGVRVVVSS,LTQPASMSASPGQSVTISCSGTRHIISAWFQQYPGKPPKLIIFDDDKRPSGVPSRFSASRPGDTASLTISNVQPEDEATYICNTYEFFGGGTKLTVL,7UOJ_H,7UOJ_L,The Cryoem Structure Of N49-P9.6-Fr3 And Pgt121 Fabs In Complex With Bg505 Sosip.664,The Cryoem Structure Of N49-P9.6-Fr3 And Pgt121 Fabs In Complex With Bg505 Sosip.664,Homo sapiens,"Nguyen,D.N.;Tolbert,W.D.;Pazgier,M.",The structure of N49-P9.6-FR3 and PGT121 Fabs in complex with BG505 SOSIP,03-MAY-2023,8_8_13_4_3_5,7SX7_H_L,Xtal structure,,5,1,2.6132097,4.118897
CBN73454_CBN73448,NVQLVESGGGLVQPGGSRKLSCAASGFTFSNFGMHWVRQAPEKGLEWVAYIRSGSGTIYYSDTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARSYYDFGAWFAYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQHKPGQSPKIMIYSASSRYSGVPDRFTGSGSGTLFTLTINNVQSEDLAEYFCQQYNSYPLTFGSGTKLEIK,CBN73454,CBN73448,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Lejeune,P.; Vrignaud,P.",Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide,21-JUN-2010,8_8_13_6_3_9,CBN73454_CBN73448,Ordered entries,,5,1,17.45053,7.8733673
AEQ73561_AEQ74314,PGLVKPSETLPLTCTVSGGSFSTYYWSWIRQSPEKGLEWIGYIQNSVNTNYNPSLKSRVIISVDTSNNQFSLKLRSVTAADTAVYYCARVSGWGPRGGIYFDYWGQGTLVTVS,SSLSASVSDRVTITCRASQSINKFLNWYQQKPGKAPQLLIYAATNLQSGVPSRFSGSGSGTDFTLTISSLQTEDFATYYCQQSYDMPRTFGQGTKVEIK,AEQ73561,AEQ74314,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_7_16_6_3_9,AEQ73561_AEQ74314,Unique source,tetanus,5,1,16.171032,-8.429926
CBN73450_CBN73444,QIQLVQSGPELKKPGETVKISCKASGYTFTNSGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASSAYLQISNLKNEDTATYFCARRGFVYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASESVAIYGNSFLKWFQQKPGQPPKLLIYRASNLESGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQINEDPYTFGGGTKLEIK,CBN73450,CBN73444,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Lejeune,P.; Vrignaud,P.",Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide,21-JUN-2010,8_8_7_10_3_9,CBN73450_CBN73444,Ordered entries,,5,1,-7.534907,6.141254
CBN73449_CBN73443,QIQLVQSGPELKKPGETVKISCKASGYTLTSYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAFLQINNLKNEDTATYFCVRRGFAYWGQGTLVTVSA,NIVLTQSPASLAVSLGQRATISCRASESVEIYGNGFMNWFQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTEFTLTIDPVEADDVATYYCQQINEDPFTFGSGTKLEIK,CBN73449,CBN73443,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Lejeune,P.; Vrignaud,P.",Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide,21-JUN-2010,8_8_7_10_3_9,CBN73449_CBN73443,Ordered entries,,5,1,-7.563582,6.1590805
7LYV_H_L,QLQLQESGPGLVKPSETLSLTCSVSGDAISGSNYYWGWIRQPPGKGLQWIGSIYHTGSTFYNPSFSSRVTLSVDTSKNQFSLKLISVNAADTAVYYCARRIRGYSGTYDWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQDISSYVAWYQQKPGNAPKLLISSASTLPSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQLNNFGPGTTVDIK,7LYV_H,7LYV_L,Crystal Structure Of The Hcmv Pentamer-Specific Antibody 1-103,Crystal Structure Of The Hcmv Pentamer-Specific Antibody 1-103,Homo sapiens,"Wrapp,D.;Ye,X.;Ku,Z.;Su,H.;Jones,H.G.;Wang,N.;Mishra,A.K.;Freed,D.C.;Li,F.;Tang,A.;Li,L.;Jaijyan,D.K.;Zhu,H.;Wang,D.;Fu,T.M.;Zhang,N.;An,Z.;McLellan,J.S.",Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies,08-MAR-2021,10_7_12_6_3_5,7LYV_H_L,Xtal structure,neuropilin; HCMV,5,1,16.649351,-7.8096957
UFQ04591_UFQ04594,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSNFYWGWIRQPPGKGLEWIASITYSGRTFYNPSLKSRVAISVDTSKNQFSLKLSSVTAADTAVYYCARTFPSYYDRSGYHYLNYGMDVWGQGTTVTVSS,NFMLTQPHSMSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSSWVFGGGTKLTVL,UFQ04591,UFQ04594,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Guo,Y.; Shapiro,L.; Ho,D.D.",Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses,26-APR-2022,10_7_22_8_3_9,UFQ04591_UFQ04594,Unique source,,5,1,16.613588,-8.146345
5UQY_D_C,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSVYYSGGASYNPSLKSRATISVDTSKNQFSLNLDSVSAADTAIYYCASIYGSGTFYYYFYMDVWGKGSTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQVISNYLNWYQQKPGKAPKLLIYDTSNLKTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYENLQFTFGPGTKVDIK,5UQY_D,5UQY_C,Crystal Structure Of Marburg Virus Gp In Complex With The Human Survivor Antibody Mr78,Crystal Structure Of Marburg Virus Gp In Complex With The Human Survivor Antibody Mr78,Homo sapiens,"Hashiguchi,T.;Fusco,M.L.;Bornholdt,Z.A.;Lee,J.E.;Flyak,A.I.;Matsuoka,R.;Kohda,D.;Yanagi,Y.;Hammel,M.;Crowe JE,Jr.;Saphire,E.O.",Structural basis for Marburg virus neutralization by a cross-reactive human antibody,08-FEB-2017,10_7_17_6_3_9,5UQY_D_C,Xtal structure,Marburg,5,1,16.37981,-8.171097
7BEL_E_F,QLQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYNWTWIRQPAGKGLEWIGRIYNSGSTNYNPSLKSRVTISVDTSKNQLSLKVRSVTAADTAVYYCARHCSGGTCYPKYYYGMDVWGQGTTVTVSS,QSALTQPPSVSEAPRQRVTISCSGSSSNIGNNAVNWYQQFPGKAPKLLIYYDDLLPSGVSDRFSGSKSGTSASLAISGVQSEDEADYYCAAWDDSLNVVVFGGGTKLTVL,7BEL_E,7BEL_F,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In A Ternary Complex With Covox-88 And Covox-45 Fabs,Crystal Structure Of The Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In A Ternary Complex With Covox-88 And Covox-45 Fabs,Homo sapiens,"Dejnirattisai,W.;Zhou,D.;Ginn,H.M.;Duyvesteyn,H.M.;Supasa,P.;Case,J.B.;Zhao,Y.;Walter,T.S.;Mentzer,A.J.;Liu,C.;Wang,B.;Paesen,G.C.;Slon-Campos,J.;Lopez-Camacho,C.;Kafai,N.M.;Bailey,A.L.;Chen,R.E.;Ying,B.;Thompson,C.;Bolton,J.;Fyfe,A.;Gupta,S.;Tan,T.K.;Gilbert-Jaramillo,J.;James,W.;Knight,M.;Carroll,M.W.;Skelly,D.;Dold,C.;Peng,Y.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Klenerman,P.;Temperton,N.;Hall,D.R.;Williams,M.A.;Paterson,N.G.;Bertram,F.K.;Siebert,C.A.;Clare,D.K.;Howe,A.;Radecke,J.;Song,Y.;Townsend,A.R.;Huang,K.A.;Fry,E.E.;Mongkolsapaya,J.;Diamond,M.S.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antigenic anatomy of SARS-CoV-2 receptor binding domain,23-DEC-2020,10_7_19_8_3_11,7BEL_E_F,Xtal structure,SARS-CoV-2,5,1,16.270174,-8.220076
7XJ8_K_J,QMQLVQSGPEVKKPGTSVKVSCKASGFTFSSSAVQWVRQARGQHLEWIGWIVVGSGNTNYAQKFQERVTLTRDMSTRTAYMELSSLRSEDTAVYYCAAPNCNSTTCHDGFDIWGQGTVVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLGWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLESEDFAVYYCQQYDNSPWTFGQGTKVEIK,7XJ8_K,7XJ8_J,Sars-Cov-2 Ba.1 Spike Trimer In Complex With 55A8 Fab And 58G6 Fab In The Class 2 Conformation,Sars-Cov-2 Ba.1 Spike Trimer In Complex With 55A8 Fab And 58G6 Fab In The Class 2 Conformation,Homo sapiens,"Guo,H.;Gao,Y.;Lu,Y.;Yang,H.;Ji,X.",SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation,19-APR-2023,8_8_16_7_3_9,7XJ8_K_J,Xtal structure,SARS-CoV-2,5,1,-1.0226834,2.9623582
7T77_H_L,QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIKYDGSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGPDYRNGYNYYDFYDGYYNYHYMDVWGKGTTVTVSS,QSALTQPASVSGSPGQSITISCQGTSNDVGGYESVSWYQQHPGKAPKVVIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFGTGTKLTVL,7T77_H,7T77_L,Hiv-1 Envelope Apexgt3.N130 In Complex With Pg9 Fab,Hiv-1 Envelope Apexgt3.N130 In Complex With Pg9 Fab,Homo sapiens,"Willis,J.R.;Berndsen,Z.T.;Ma,K.M.;Steichen,J.M.;Schiffner,T.;Landais,E.;Liguori,A.;Kalyuzhniy,O.;Allen,J.D.;Baboo,S.;Omorodion,O.;Diedrich,J.K.;Hu,X.;Georgeson,E.;Phelps,N.;Eskandarzadeh,S.;Groschel,B.;Kubitz,M.;Adachi,Y.;Mullin,T.M.;Alavi,N.B.;Falcone,S.;Himansu,S.;Carfi,A.;Wilson,I.A.;Yates,J.R.;Paulson,J.C.;Crispin,M.;Ward,A.B.;Schief,W.R.",Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors,08-JAN-2009,8_8_30_9_3_10,7T77_H_L,Xtal structure,HIV,5,1,14.089101,14.041336
AEX57222,QVKLQESGTELAKPGAAVKMSCKASGYTFTDYWMHWVKQRPGQGLEWIGYINPNTAYTDYNQKFKDKATLTADKSSSTAYMQLRSLTSEDSAVYYCAKKTTQTTWGFPFWGQGTTVTVSS,DIVLTQSPKSMAMSVGERVTLSCKASENVDSFVSWYQQKPGQSPKLLIYGASNRYTGVPDRFAGSGSGRDFTLTISSVQAEDLADYHCGQNYRYPLTFGAGTKLEIN,AEX57222_H,AEX57222_L,W2-anti CD30 single chain fusion protein [synthetic construct],W2-anti CD30 single chain fusion protein [synthetic construct],synthetic construct,"Siepert,E.-M.; Gartz,E.; Tur,M.K.; Delbrueck,H.; Buechs,J.; Barth,S.",Introducing short-chained fluorescent tryptophan tags for online detection of functional recombinant protein,16-JAN-2012,8_8_13_6_3_9,AEX57222,Same entry,CD30; TNFRSF8; KI-1; D1S166E,5,1,0.138952,-3.2840295
7CU4_D_E,QVQLLQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASFQENYFTYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYGASSRPTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAASPLTFGGGTKLEIK,7CU4_D,7CU4_E,Fab H6 In Complex With Leptin Receptor,Fab H6 In Complex With Leptin Receptor,HOMO SAPIENS,"Yan, L., Pingdong, T., Richard, A.L., Yang, G.",Fab H6 In Complex With Leptin Receptor,20-AUG-2020,8_8_10_7_3_9,7CU4_D_E,Xtal structure,,5,1,14.874954,13.422392
QNN93282_QNN93349,QVQLQESGPAVVQPSETLSLTCAVSGGSISGGYGWTWIRQAPGKALEWIGNIYGHSGSTNYKSSLKRRLTISTDTSKNQFSLKLTSVTAADTAVYYCARWSTADFDYWGQGVLVTVSS,DIVMTQSPSSLSASVGDTVTITCRASQDITNDLAWYQQKPGKAPKALIYYASNLESGVPSRFSGSGAGTDFTLTISSLQPEDFALYYCQQHNNYPLTFGPGTKVDIK,QNN93282,QNN93349,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Cottrell,C.A.; van Schooten,J.; Bowman,C.A.; Yuan,M.; Oyen,D.; Shin,M.; Morpurgo,R.; van der Woude,P.; van Breemen,M.; Torres,J.L.; Patel,R.; Gross,J.; Sewall,L.M.; Copps,J.; Ozorowski,G.; Nogal,B.; Sok,D.; Rakasz,E.G.; Labranche,C.; Vigdorovich,V.; Christley,S.; Carnathan,D.G.; Sather,D.N.; Montefiori,D.; Silvestri,G.; Burton,D.R.; Moore,J.P.; Wilson,I.A.; Sanders,R.W.; Ward,A.B.; van Gils,M.J.",Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates,08-SEP-2020,9_8_10_6_3_9,QNN93282_QNN93349,Unique source,HIV,5,1,16.488108,-7.4339547
8EED_H_L,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEYIGYISGSSGSTYYNPSLKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARRDRVGSYPYYYGLDSWGQGVLVTVSS,QSVLTQPPSLSASPGASARLPCTLSSDLSVGSKNMYWYQQKPGSAPRLFLYYYSDSDKQLGPGVPNRVSGSKETSSNTAFLLISGLQPEDEADYYCQVYDGSANDVFGSGTKLTVL,8EED_H,8EED_L,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz107-B In Complex With Zikv E Glycoprotein,Crystal Structure Of A Nhp Anti-Zikv Neutralizing Antibody Rhmz107-B In Complex With Zikv E Glycoprotein,Macaca mulatta,"Sankhala,R.S.;Dussupt,V.;Donofrio,G.;Gromowski,G.D.;De La Barrera,R.A.;Larocca,R.A.;Mendez-Rivera,L.;Lee,A.;Choe,M.;Zaky,W.;Mantus,G.;Jensen,J.L.;Chen,W.H.;Gohain,N.;Bai,H.;McCracken,M.K.;Mason,R.D.;Leggat,D.;Slike,B.M.;Tran,U.;Jian,N.;Abbink,P.;Peterson,R.;Mendes,E.A.;Freitas de Oliveira Franca,R.;Calvet,G.A.;Bispo de Filippis,A.M.;McDermott,A.;Roederer,M.;Hernandez,M.;Albertus,A.;Davidson,E.;Doranz,B.J.;Rolland,M.;Robb,M.L.;Lynch,R.M.;Barouch,D.H.;Jarman,R.G.;Thomas,S.J.;Modjarrad,K.;Michael,N.L.;Krebs,S.J.;Joyce,M.G.",Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes,30-AUG-2023,9_8_17_9_7_10,8EED_H_L,Xtal structure,Zika,5,1,16.294794,-7.330779
7AKD_H_L,QVQLQESGPGLVKPSETLSLTCSVSGGSISSHYWSWIRQPPGKGLEWIGYIYYSGSTNHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGVLLWFGEPIFEIWGQGTMVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRLLIYGASTRAPGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEI,7AKD_H,7AKD_L,Structure Of The Sars-Cov-2 Spike Glycoprotein In Complex With The 47D11 Neutralizing Antibody Fab Fragment,Structure Of The Sars-Cov-2 Spike Glycoprotein In Complex With The 47D11 Neutralizing Antibody Fab Fragment,Homo sapiens,"Fedry,J.;Hurdiss,D.L.;Wang,C.;Li,W.;Obal,G.;Drulyte,I.;Du,W.;Howes,S.C.;van Kuppeveld,F.J.;Forster,F.;Bosch,B.J.",Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11,30-SEP-2020,8_7_15_6_3_9,7AKD_H_L,Xtal structure,SARS; SARS-CoV-2; CoV,5,1,16.197287,-7.9027505
6A4K_I_M,QVQLQESGPGLVKPSETLSLTCTVSGGSVNTGSYYWSWIRQPPGKGLEWIAYSSVSGTSNYNPSLKSRVTLTVDTSKNQFSLSVRSVTAADTAVYFCARLNYDILTGYYFFDFWGQGTLVIVSS,QVELTQSPSASASLGTSVKLTCTLSSGHSTYAIAWHQQRPGKGPRYLMNLSSGGRHTRGDGIPDRFSGSSSGADRYLIISSLQSEDEADYYCQTWDAGMVFGGGTKLTVL,6A4K_I,6A4K_M,Human Antibody 32D6 Fab In Complex With H1N1 Influenza A Virus Ha1,Human Antibody 32D6 Fab In Complex With H1N1 Influenza A Virus Ha1,Homo sapiens,"Lee,C.C.;Yang,C.Y.;Lin,L.L.;Ko,T.P.;Chang,A.H.;Chang,S.S.;Wang,A.H.",An Effective Neutralizing Antibody Against Influenza Virus H1N1 from Human B Cells,20-JUN-2018,10_7_16_7_7_8,AVY28919_AVY28920,Xtal structure,H1N1; Influenza,5,1,16.346882,-7.9365478
5O1R_H_L,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSSYWTWIRQTPGKGLEWIGYTSYSGSTKYNPSLKSRVTLSVDMSKNQFSLKLKSVTAADTAVYFCARDRFDVASGSSFDFWGQGTLVTVSS,EIVMTQTPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGTAPKLLTYAASSLGSGVPSRFSGSGSGTDLTLTISSLRPEDFATYYCQQSYGSPTFGQGTKLEIR,5O1R_H,5O1R_L,Human Fab 5H2 Bound To Nhba-C3 From Neisseria Meningitidis Serogroup B,Human Fab 5H2 Bound To Nhba-C3 From Neisseria Meningitidis Serogroup B,Homo sapiens,"Maritan,M.;Veggi,D.;Cozzi,R.;Dello Iacono,L.;Bartolini,E.;Lo Surdo,P.;Maruggi,G.;Spraggon,G.;Bottomley,M.J.;Malito,E.",Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody,19-MAY-2017,10_7_15_6_3_8,5O1R_H_L,Xtal structure,,5,1,16.471384,-8.1061125
QOV05185_QOV05186,QVQLQESGPGLVRPSETLSLTCTVSGDSIGGSYWNWIRQPPGKGLQWIGYIYYTGITNYNPSLKSRVTMSLDTSKNQISLKMDSVTAADTALYFCARGDYSGYDRDVQVELMDVWGKGTTVTVSS,DIQMTQSPSSLSASVRDKVTFVCRASQTISIFLNWYQHKPGEAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISGLQPEDFATYYCQQSYSAPWTFGQGTKVEIK,QOV05185,QOV05186,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Madsen,A.; Dai,Y.N.; McMahon,M.; Schmitz,A.J.; Turner,J.S.; Tan,J.; Lei,T.; Alsoussi,W.B.; Strohmeier,S.; Amor,M.; Mohammed,B.M.; Mudd,P.A.; Simon,V.; Cox,R.J.; Fremont,D.H.; Krammer,F.; Ellebedy,A.H.",Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective,04-NOV-2020,8_7_19_6_3_9,QOV05185_QOV05186,Unique source,Influenza,5,1,15.92196,-7.947281
7UZC_E_F,QVQLQQPGAELVKPGASVKMSCKASGYTFITYWITWVKQRPGQGLEWIGDIYPGGGRTNYNEKFKSKATLTVDTSSSTAYMQLRSLTSEDSAVYYCARYDGNYVGYYYAMDYWGQGTSVTVSS,DIVLTQSPVSLAVSLGQRATISCRASESVDFYGNSFIYWYQQKPGQAPKLLIYRASNLESGIPARFSGSGSRTDFTLTIHPVEADDVATYYCQQSIEDPRTFGGGTKLEIK,7UZC_E,7UZC_F,"Structure Of The Sars-Cov-2 Rbd In Complex With The Mouse Antibody Fab Fragment, M8A-34","Structure Of The Sars-Cov-2 Rbd In Complex With The Mouse Antibody Fab Fragment, M8A-34",Mus musculus,"Fan,C.;Cohen,A.A.;Park,M.;Hung,A.F.;Keeffe,J.R.;Gnanapragasam,P.N.P.;Lee,Y.E.;Gao,H.;Kakutani,L.M.;Wu,Z.;Kleanthous,H.;Malecek,K.E.;Williams,J.C.;Bjorkman,P.J.",Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes,11-JAN-2023,8_8_16_10_3_9,7UZC_E_F,Xtal structure,RBD,5,1,-0.5739344,-3.9453013
CAD12156_CAD12155,QVQLQQPGAELVKPGTSVKLSCKGYGYTFTSYWMHWVKQRPGQGLEWIGEIDPSESNTNYNQKFKGKATLTVDISSSTAYMQLSSLTSEDSAVYYCARGGYDGWDYAIDYWGQGTSVTVSS,DVVVTQTPLSLPVSFGDQVSISCRSSQSLAKSYGNTYLSWYLHKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISTIKPEDLGMYYCLQGTHQPYTFGGGTKLEIK,CAD12156,CAD12155,"unnamed protein product, partial [Mus musculus]","unnamed protein product, partial [Mus musculus]",Mus musculus,"Brettman,L.R.; Fox,J.A.; Allison,D.E.",Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease,20-NOV-2001,8_8_14_11_3_9,CAD12156_CAD12155,Unique chain,,5,1,-0.44670314,-3.6520808
6EYN_D_C,QVQLQQSGAELAKPGASVMLSCKASGYTFNGYWMHWVKQRPGQDLEWIGYINPTTGHTEYNQKFKDKATLTADESSNTAYIELSSLTSDDSAVYYCARQEYRHSWFAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDTYMNWYHQKPGQPPKLLIYAASNLDSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQTNEDPWTFGGGTKLEIK,6EYN_D,6EYN_C,Structure Of The 8D6 (Anti-Ige) Fab,Structure Of The 8D6 (Anti-Ige) Fab,Homo sapiens,"Chen,J.B.;Ramadani,F.;Pang,M.O.;Beavil,R.L.;Holdom,M.D.;Mitropoulou,A.N.;Beavil,A.J.;Gould,H.J.;Chang,T.W.;Sutton,B.J.;McDonnell,J.M.;Davies,A.M.",Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody,13-NOV-2017,8_8_12_10_3_9,AYI42117_AYI42119,Xtal structure,8D6; CD320; 8D6A; TCblR,5,1,0.12605748,-3.29947
CBN73451_CBN73445,QVQLQQSGAELARPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFKGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS,DIVMAQSHKFMSTSVGDRVSITCKASQDVSTVVAWYQQKPGQSPKRLIYSASYRYIGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK,CBN73451,CBN73445,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Lejeune,P.; Vrignaud,P.",Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide,21-JUN-2010,8_8_13_6_3_9,CBN73451_CBN73445,Ordered entries,,5,1,0.40115434,-3.8798132
6CNJ_G_F,QVQLQQSGAEVMKPGASVKISCKGTGYTFSSYWIEWVKQRPGHGLERIGEILPGSGSTNYNEKFRGKATFTADKSSKTAYMQLSSLTSEDSAVYYCARYLPYYYAMDYWGQGTSVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK,6CNJ_G,6CNJ_F,Structure Of The 2Alpha3Beta Stiochiometry Of The Human Alpha4Beta2 Nicotinic Receptor,Structure Of The 2Alpha3Beta Stiochiometry Of The Human Alpha4Beta2 Nicotinic Receptor,Mus musculus,"Walsh RM,Jr.;Roh,S.H.;Gharpure,A.;Morales-Perez,C.L.;Teng,J.;Hibbs,R.E.",Structural principles of distinct assemblies of the human alpha4beta2 nicotinic receptor,08-MAR-2018,8_8_12_11_3_9,6CNJ_G_F,Xtal structure,nicotinic,5,1,4.989269,-1.8798708
CBN73452_CBN73446,QVQLQQSGPELVRPGASVKISCKTSGYAFSGSWMNWVKQRPGQGLEWIGRIYPGDGDIIYNGNFRDKVTLSADKSSNTAYMQLSSLTSVDSAVYFCSRWGTFTPSFDYWGQGTTLTVSS,DIVMTQSHKFLSTSVGDRVSITCKASQDVVTAVAWFQQKPGQSPKLLIYSASHRYTGVPDRFTGSGSGTDFTFTIISVQAEDLAVYYCQQHYTTPTTFGGGTKLDFR,CBN73452,CBN73446,"unnamed protein product, partial [Mus sp.]","unnamed protein product, partial [Mus sp.]",Mus sp.,"Lejeune,P.; Vrignaud,P.",Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide,21-JUN-2010,8_8_12_6_3_9,CBN73452_CBN73446,Ordered entries,,5,1,0.38865304,-4.7532578
6XCN_H_L,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGEGWELPYDYWGQGTLVTVSS,QSALTQPPSASGSPGQSVTISCTGTSSDVGGYKYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSNNFVVFGGGTKLTVL,6XCN_H,6XCN_L,Structure Of The Sars-Cov-2 Spike Glycoprotein In Complex With The C105 Neutralizing Antibody Fab Fragment (State 2),Structure Of The Sars-Cov-2 Spike Glycoprotein In Complex With The C105 Neutralizing Antibody Fab Fragment (State 2),Homo sapiens,"Barnes,C.O.;West AP,Jr.;Huey-Tubman,K.E.;Hoffmann,M.A.;Sharaf,N.G.;Hoffman,P.R.;Koranda,N.;Gristick,H.B.;Gaebler,C.;Muecksch,F.;Lorenzi,J.C.;Finkin,S.;Hagglof,T.;Hurley,A.;Millard,K.G.;Weisblum,Y.;Schmidt,F.;Hatziioannou,T.;Bieniasz,P.D.;Caskey,M.;Robbiani,D.F.;Nussenzweig,M.C.;Bjorkman,P.J.",Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies,08-JUN-2020,8_7_12_9_3_11,6XCN_H_L,Xtal structure,SARS-CoV-2,5,1,12.661781,10.239224
6UUP_A_A,QVQLVESGGGLVQAGGSLRLSCAASRRSSRSWAMHWVRQAPGKGLEWVAVISYDGRLKYYADSVKGRFTISRDNAEYLVYLQMNSLRAEDTAVYYCAAEEGDGGFFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVNWYQQLPGTAPKLLIYRNNERPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDGSLSGRGVFGTGTKLTVL,6UUP_A,6UUP_A,Structure Of Anti-Hcd33 Conditional Scfv,Structure Of Anti-Hcd33 Conditional Scfv,Camelidae mixed library,"Park,S.;Pascua,E.;Lindquist,K.C.;Kimberlin,C.;Deng,X.;Mak,Y.S.;Melton,Z.;Johnson,T.O.;Lin,R.;Boldajipour,B.;Abraham,R.T.;Pons,J.;Sasu,B.J.;Van Blarcom,T.J.;Chaparro-Riggers,J.",Direct control of CAR T cells through small molecule-regulated antibodies,31-OCT-2019,8_8_12_8_3_12,6UUP_A_A,Xtal structure,CXADR; CAR,5,1,14.826535,13.3840685
8DZ5_H_L,QVQLVESGGGVVQPGGSLRLSCAASGFTFSGYGMHWVRQVPGKGLEWVAIIWFDGSQKYYADSVQGRFTISRDNSKKTLFLRMNSLRAEDTAVYYCAKVHDDEPTQDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISTSLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTITSLQPEDFATYYCQQYKRYWTFGQGTKVEIK,8DZ5_H,8DZ5_L,Cryo-Em Structure Of 364 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Cryo-Em Structure Of 364 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Homo sapiens,"Martin,G.M.;Ward,A.B.",Spectrum of PfCSP-antibody cryo-EM structures and the role of homotypic interactions,02-AUG-2023,8_8_12_6_3_8,8DZ5_H_L,Xtal structure,PfCSP,5,1,15.071568,13.47503
CBK51929_CBK51936,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,CBK51929,CBK51936,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Korman,A.J.; Srinivasan,M.; Wang,C.; Selby,M.J.; Chen,B.; Cardarelli,J.M.",Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics,12-MAR-2010,8_8_6_6_3_9,CBK51929_CBK51936,Ordered entries,PD1; PDCD1; SLEB2; hSLE1; CD279; PD-1,5,1,14.955139,13.317236
QXE98036_QXE98040,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAFHWVRQAPGKGLEWVAVISYDGSNQYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCARDLAIAVAGTWHYYNGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVIITCRASQGISSWLAWYQQKPGKAPKVLIYDASSLQSGVPSRFSGSGYGTDFTLTISSLQPEDSATYYCQQAKSFPITFGQGTRLEIK,QXE98036,QXE98040,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Wang,L.; Zhou,T.; Zhang,Y.; Yang,E.S.; Schramm,C.A.; Shi,W.; Pegu,A.; Oloninyi,O.K.; Ransier,A.; Darko,S.; Narpala,S.R.; Hatcher,C.; Martinez,D.R.; Tsybovsky,Y.; Phung,E.; Abiona,O.M.; Cale,E.M.; Chang,L.A.; Corbett,K.S.; DiPiazza,A.T.; Gordon,I.J.; Leung,K.; Liu,T.; Mason,R.D.; Nazzari,A.; Novik,L.; Olia,A.S.; Stephens,T.; Stringham,C.D.; Talana,C.A.; Teng,I.T.; Wagner,D.; Widge,A.T.; Zhang,B.; Roederer,M.; Ledgerwood,J.E.; Ruckwardt,T.J.; Gaudinski,M.R.; Baric,R.S.; Graham,B.S.; McDermott,A.B.; Douek,D.C.; Kwong,P.D.; Mascola,J.R.; Sullivan,N.J.; Misasi,J.",Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants,05-JUL-2021,8_8_20_6_3_9,QXE98036_QXE98040,Unique source,SARS-CoV-2,5,1,14.137522,14.008812
7CZU_H_K,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGQAITMVQGVIGPPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPYTFGQGTKLEIK,7CZU_H,7CZU_K,S Protein Of Sars-Cov-2 In Complex Bound With P5A-1B6_2B,S Protein Of Sars-Cov-2 In Complex Bound With P5A-1B6_2B,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_8_20_6_3_9,7CZU_H_K,Xtal structure,SARS-CoV-2,5,1,14.954405,13.645398
4XX1_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKFYEDSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCAREGAAVRSFYYSYYGMDVWGQGTTVTVSS,YELTQPPSVSVSPGQTASITCSGDKLGNKFTSWYQRKPGQSPVLVIYQDTKRPSGIPERFSGSTSGNTATLTISGTQAMDEADYYCQAWDSSTAWVFGGGTKLEVL,4XX1_H,4XX1_L,Low Resolution Structure Of Lcat In Complex With Fab1,Low Resolution Structure Of Lcat In Complex With Fab1,Homo sapiens,"Piper,D.E.;Romanow,W.G.;Gunawardane,R.N.;Fordstrom,P.;Masterman,S.;Pan,O.;Thibault,S.T.;Zhang,R.;Meininger,D.;Schwarz,M.;Wang,Z.;King,C.;Zhou,M.;Walker,N.P.",The high-resolution crystal structure of human LCAT,29-JAN-2015,8_8_19_6_3_10,4XX1_H_L,Xtal structure,LCAT,5,1,14.099391,14.040864
4ERS_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMYYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLESGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK,4ERS_H,4ERS_L,A Molecular Basis For Negative Regulation Of The Glucagon Receptor,A Molecular Basis For Negative Regulation Of The Glucagon Receptor,Homo sapiens,"Koth,C.M.;Murray,J.M.;Mukund,S.;Madjidi,A.;Minn,A.;Clarke,H.J.;Wong,T.;Chiang,V.;Luis,E.;Estevez,A.;Rondon,J.;Zhang,Y.;Hotzel,I.;Allan,B.B.",Molecular basis for negative regulation of the glucagon receptor,20-APR-2012,8_8_21_6_3_9,4ERS_H_L,Xtal structure,glucagon,5,1,14.190656,13.98732
5CD3_G_H,QVQLVESGTQFRRPGASVRLSCEASGYTFISSFIHWIRQGPGQGLEWMGWMNPRHGAVNYPRRFQGKVTMTRDTSIDTAYMELRDLRSDDTAMYFCVTSRTKDYDWDFVWGQGTLVVVSS,DIQMTQSPVTLSASIGDRVTITCRASQRIDNWVAWYQQKPGRAPKLLIYKASILETGVPSRFSGSGSGTEFTLSINSLQPDDVATYYCQQFEEFGRGTKIDIK,5CD3_G,5CD3_H,Structure Of Immature Vrc01-Class Antibody Drvia7,Structure Of Immature Vrc01-Class Antibody Drvia7,Homo sapiens,"Kong,L.;Ju,B.;Chen,Y.;He,L.;Ren,L.;Liu,J.;Hong,K.;Su,B.;Wang,Z.;Ozorowski,G.;Ji,X.;Hua,Y.;Chen,Y.;Deller,M.C.;Hao,Y.;Feng,Y.;Garces,F.;Wilson,R.;Dai,K.;O'Dell,S.;McKee,K.;Mascola,J.R.;Ward,A.B.;Wyatt,R.T.;Li,Y.;Wilson,I.A.;Zhu,J.;Shao,Y.",Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor,02-JUL-2015,8_8_13_6_3_5,QWX26162_QWX26165,Xtal structure,gp120; HIV,5,1,2.595079,4.086939
QMI58155_QMI58188,QVQLVQSGAEVKKAGSSVKVSCKASGGTFSSHTITWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCASLQTVDTAIEKYYGMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL,QMI58155,QMI58188,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Liu,L.; Wang,P.; Nair,M.S.; Yu,J.; Rapp,M.; Wang,Q.; Luo,Y.; Chan,J.F.; Sahi,V.; Figueroa,A.; Guo,X.V.; Cerutti,G.; Bimela,J.; Gorman,J.; Zhou,T.; Chen,Z.; Yuen,K.Y.; Kwong,P.D.; Sodroski,J.G.; Yin,M.T.; Sheng,Z.; Huang,Y.; Shapiro,L.; Ho,D.D.",Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike,05-AUG-2020,8_8_18_6_3_9,QMI58155_QMI58188,Unique source,SARS-CoV-2,5,1,-0.98382986,6.089474
4NM8_H_L,QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYSMHWVRQAPGQSLEWLGWINTAIGNTQYSQKFQDRVTITRDTSARTSYMELSSLRSGDTAVYFCARGASWDARGWSGYWGKGTLVTVSS,DIQMTQSPDSLAVSLGERATINCKSSQSVFSSSTNKNYLAWYQQKPGQPPKVLIYWSSTRESGVPDRFSASGSGTDFTLTISSLQAADVAVYYCHQYYTAPWTFGQGTKVEIK,4NM8_H,4NM8_L,Crystal Structure Of Broadly Neutralizing Antibody Cr8043 Bound To H3 Influenza Hemagglutinin,Crystal Structure Of Broadly Neutralizing Antibody Cr8043 Bound To H3 Influenza Hemagglutinin,Homo sapiens,"Friesen,R.H.;Lee,P.S.;Stoop,E.J.;Hoffman,R.M.;Ekiert,D.C.;Bhabha,G.;Yu,W.;Juraszek,J.;Koudstaal,W.;Jongeneelen,M.;Korse,H.J.;Ophorst,C.;Brinkman-van der,Li.;Throsby,M.;Kwakkenbos,M.J.;Bakker,A.Q.;Beaumont,T.;Spits,H.;Kwaks,T.;Vogels,R.;Ward,A.B.;Goudsmit,J.;Wilson,I.A.",A common solution to group 2 influenza virus neutralization,14-NOV-2013,8_8_14_12_3_9,4NM8_H_L,Xtal structure,Influenza,5,1,0.3988279,3.2167757
AGW82516_AGW82517,QVQLVQSGAEVKKPGASVKVSCKASGYIFISYFMHWVRQAPGQGLEWMGIINPSSGDTRYAQKFQGRVTMTRDTSTNTVYMELSSLRSDDTAVYYCARRPGGLERHNWLDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISSNLAWYQQKPGQAPRLLIYGASTRATGTPARFSGSGSGTEFTLTISSLQSEDFASYYCQQYNNWPAITFGQGTRLEIK,AGW82516,AGW82517,"monoclonal antibody CH55 heavy chain, partial [Homo sapiens]","monoclonal antibody CH55 light chain, partial [Homo sapiens]",Homo sapiens,"Bonsignori,M.; Pollara,J.; Moody,M.A.; Alpert,M.D.; Chen,X.; Hwang,K.K.; Gilbert,P.B.; Huang,Y.; Gurley,T.C.; Kozink,D.M.; Marshall,D.J.; Whitesides,J.F.; Tsao,C.Y.; Kaewkungwal,J.; Nitayaphan,S.; Pitisuttithum,P.; Rerks-Ngarm,S.; Kim,J.H.; Michael,N.L.; Tomaras,G.D.; Montefiori,D.C.; Lewis,G.K.; DeVico,A.; Evans,D.T.; Ferrari,G.; Liao,H.X.; Haynes,B.F.",Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family,02-OCT-2013,8_8_15_6_3_10,AGW82516_AGW82517,Unique word,HIV,5,1,1.7016537,3.8017683
AMT74515_AMT74531,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAKISGSYSFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFGGGTKVEIK,AMT74515,AMT74531,"immunoglobulin heavy chain VRC01c-HuGL, partial [Homo sapiens]","immunoglobulin light chain VRC01c-HuGL, partial [Homo sapiens]",Homo sapiens,"Jardine,J.G.; Kulp,D.W.; Havenar-Daughton,C.; Sarkar,A.; Briney,B.; Sok,D.; Sesterhenn,F.; Ereno-Orbea,J.; Kalyuzhniy,O.; Deresa,I.; Hu,X.; Spencer,S.; Jones,M.; Georgeson,E.; Adachi,Y.; Kubitz,M.; deCamp,A.C.; Julien,J.P.; Wilson,I.A.; Burton,D.R.; Crotty,S.; Schief,W.R.",HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen,07-APR-2016,8_8_11_12_3_5,AMT74515_AMT74531,Unique source,HIV,5,1,2.0891554,3.821281
7CZY_H_K,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARYIVVVPAAKGFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK,7CZY_H,7CZY_K,S Protein Of Sars-Cov-2 In Complex Bound With P5A-2F11_2B,S Protein Of Sars-Cov-2 In Complex Bound With P5A-2F11_2B,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_8_15_12_3_9,7CZY_H_K,Xtal structure,SARS-CoV-2,5,1,2.0543008,4.246334
7SG4_H_L,QVQLVQSGAEVKKPGASVQVSCQASANTFTNHYIHWVRQAPGQGLEWMGIIYPTGGNTIYAQGFQGRVTMTRDTSLNTIYLELSSLRSEDTAVYYCARDVRVDDSWSGYDLLSGGTYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSVLYSSNNENYLAWYQQKPGQPPKLLIYWASTRESGIPDRFSGSGSGTDFTLTISRLQAEDVAVYYCQQYYSLPRTFGQGTKVEIK,7SG4_H,7SG4_L,Structure Of Sars-Cov S Protein In Complex With Receptor Binding Domain Antibody Dh1047,Structure Of Sars-Cov S Protein In Complex With Receptor Binding Domain Antibody Dh1047,Homo sapiens,"Martinez,D.R.;Schafer,A.;Gobeil,S.;Li,D.;De la,Cr.;Parks,R.;Lu,X.;Barr,M.;Stalls,V.;Janowska,K.;Beaudoin,E.;Manne,K.;Mansouri,K.;Edwards,R.J.;Cronin,K.;Yount,B.;Anasti,K.;Montgomery,S.A.;Tang,J.;Golding,H.;Shen,S.;Zhou,T.;Kwong,P.D.;Graham,B.S.;Mascola,J.R.;Montefiori,D.C.;Alam,S.M.;Sempowski,G.;Sempowski,G.D.;Khurana,S.;Wiehe,K.;Saunders,K.O.;Acharya,P.;Haynes,B.F.;Baric,R.S.",A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice,04-OCT-2021,8_8_24_12_3_9,7SG4_H_L,Xtal structure,,5,1,1.8517028,3.5487316
6RCV_J_I,QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISGYDGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDGPQVGDFDWQVYYYYGMDVWGQGTTVTVSS,AIRMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPNLLISKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNSYLYTFGQGTKVEIR,6RCV_J,6RCV_I,Pfrh5 Bound To Monoclonal Antibodies R5.011 And R5.016,Pfrh5 Bound To Monoclonal Antibodies R5.011 And R5.016,Homo sapiens,"Alanine,D.G.;Quinkert,D.;Kumarasingha,R.;Mehmood,S.;Donnellan,F.R.;Minkah,N.K.;Dadonaite,B.;Diouf,A.;Galaway,F.;Silk,S.E.;Jamwal,A.;Marshall,J.M.;Miura,K.;Foquet,L.;Elias,S.C.;Labbe,G.M.;Douglas,A.D.;Jin,J.;Payne,R.O.;Illingworth,J.J.;Pattinson,D.J.;Pulido,D.;Williams,B.G.;de Jongh,W.A.;Wright,G.J.;Kappe,S.H.;Robinson,C.V.;Long,C.A.;Crabb,B.S.;Gilson,P.R.;Higgins,M.K.;Draper,S.J.",Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies,11-APR-2019,8_8_22_6_3_9,6RCV_J_I,Xtal structure,,5,1,1.8647865,5.149165
AKH36540_AKH36494,QVQLVQSGAEVKKPGSSVKVSCKASGGNFNTYTISWVRQAPGQGLEWMGRIIPIFGIVNPAQKFPGRVTINVDKSTNTAYMELSSLRSEDTAVYYCATSGVGLHFGYFDYWGQGTQVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAHYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGYVFGTGTKVTVL,AKH36540,AKH36494,"anti-HIV-1 V2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-HIV-1 V2 immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Li,L.; Wang,X.H.; Williams,C.; Volsky,B.; Steczko,O.; Seaman,M.S.; Luthra,K.; Nyambi,P.; Nadas,A.; Giudicelli,V.; Lefranc,M.P.; Zolla-Pazner,S.; Gorny,M.K.","A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site",20-MAY-2015,8_8_14_9_3_11,AKH36540_AKH36494,Unique source,HIV; CD4,5,1,-0.7598335,5.629933
6PZZ_K_J,QVQLVQSGAEVKRPGASVKVSCKASGYTFISYGISWVRQAPGQGLEWMGWISAYNGNTNYAQNLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVIPGTAVDYFDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTISCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQQSYSAPFTFGPGTKVDIE,6PZZ_K,6PZZ_J,Cryoem Derived Model Of Na-80 Fab In Complex With N9 Shanghai2,Cryoem Derived Model Of Na-80 Fab In Complex With N9 Shanghai2,Homo sapiens,"Zhu,X.;Turner,H.L.;Lang,S.;McBride,R.;Bangaru,S.;Gilchuk,I.M.;Yu,W.;Paulson,J.C.;Crowe,J.E.;Ward,A.B.;Wilson,I.A.",Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies,01-AUG-2019,8_8_14_6_3_9,6PZZ_K_J,Xtal structure,Influenza,5,1,1.9243062,5.261766
QNN93278_QNN93345,QVQLVQSGGALVQPGASLRLSCAASEFSFSTHDMHWVRQAPGKGLEWVSGINIHGGTYYPDSVKGRFTISRDSAKNSLYLQMSSLRDGDTAVYFCARGGKPIYYSGGYPSWYFDLWGPGTPITISS,DVVMTQSPGFRSVTLKEKVSITCQASQTIGTNLHWYQQKPGQSPKLLIKYSSQSISGVPSRFSGSGSGTDFTLTINSLEADDAATYYCQQTNSFPCTFGPGTKVEIK,QNN93278,QNN93345,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Cottrell,C.A.; van Schooten,J.; Bowman,C.A.; Yuan,M.; Oyen,D.; Shin,M.; Morpurgo,R.; van der Woude,P.; van Breemen,M.; Torres,J.L.; Patel,R.; Gross,J.; Sewall,L.M.; Copps,J.; Ozorowski,G.; Nogal,B.; Sok,D.; Rakasz,E.G.; Labranche,C.; Vigdorovich,V.; Christley,S.; Carnathan,D.G.; Sather,D.N.; Montefiori,D.; Silvestri,G.; Burton,D.R.; Moore,J.P.; Wilson,I.A.; Sanders,R.W.; Ward,A.B.; van Gils,M.J.",Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates,08-SEP-2020,8_7_20_6_3_9,QNN93278_QNN93345,Unique source,HIV,5,1,16.372025,11.567961
7LUE_J_N,QVQLVQSGSEVKKPGASVKVSCKASGYRFSNYGISWVRQAPGQGLEWMGWISAYNGNIKYGNNLQGRVTVTTDTSTATAYMEVRSLTSDDTAVYYCARDVPADGVHFMDVWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSDTNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTTFTLKISRVEAEDVGIYYCMQGSHWAPTFGQGTKVEIK,7LUE_J,7LUE_N,Prefusion Rsv F Glycoprotein Bound By Neutralizing Site V-Directed Antibody Adi-14442,Prefusion Rsv F Glycoprotein Bound By Neutralizing Site V-Directed Antibody Adi-14442,Homo sapiens,"Mukhamedova,M.;Wrapp,D.;Shen,C.H.;Gilman,M.S.;Ruckwardt,T.J.;Schramm,C.A.;Ault,L.;Chang,L.;Derrien-Colemyn,A.;Lucas,S.A.;Ransier,A.;Darko,S.;Phung,E.;Wang,L.;Zhang,Y.;Rush,S.A.;Madan,B.;Stewart-Jones,G.B.;Costner,P.J.;Holman,L.A.;Hickman,S.P.;Berkowitz,N.M.;Doria-Rose,N.A.;Morabito,K.M.;DeKosky,B.J.;Gaudinski,M.R.;Chen,G.L.;Crank,M.C.;Misasi,J.;Sullivan,N.J.;Douek,D.C.;Kwong,P.D.;Graham,B.S.;McLellan,J.S.;Mascola,J.R.",Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses,22-FEB-2021,8_8_14_11_3_9,7LUE_J_N,Xtal structure,,5,1,1.8975443,5.282122
7K7I_X_Y,VKLVESGGGLVKPGGSLKLSCAASGFAFSTYDMSWVRQTPEKRLEWVATISGGGSYTYYPDIVKGRFTISRDNARNTLYLQMSSLRSEDTALYFCVRQYYGSSNYGMDYWGQGTSVTVS,DILLTQSPSILSVSPGERVSFSCRASQSIGTSIHWYQQKPNGSPRLLIQYASQSISGIPSRFSGSGSGTDFTLTINSVESEDIADYYCQHTNGWPYTFGWGD,7K7I_X,7K7I_Y,Density-Fitted Model Structure Of Antibody Variable Domains Of Tytx4 In Complex With Pltb Pentamer Of Typhoid Toxin,Density-Fitted Model Structure Of Antibody Variable Domains Of Tytx4 In Complex With Pltb Pentamer Of Typhoid Toxin,Mus musculus,"Nguyen,T.;Richards,A.F.;Neupane,D.P.;Feathers,J.R.;Yang,Y.A.;Sim,J.H.;Byun,H.;Lee,S.;Ahn,C.;Van Slyke,G.;Fromme,J.C.;Mantis,N.J.;Song,J.",The structural basis of Salmonella A2B5 toxin neutralization by antibodies targeting the glycan-receptor binding subunits,22-SEP-2020,8_8_14_6_3_9,7K7I_X_Y,Xtal structure,Toxin,5,1,18.058725,6.942199
7PI3_T_U,AVTLDESGGGLQTPGGALSLVCKASGFDFSSYAMGWVRQAPGKGLEYVAGIRNDGSFTLYTPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYFCTKSADDGGHYSDFSGEIDAWGHGTEVIVSS,ALTQPSSVSANPGETVKITCSGSTYNYGWYQQKSPGSAPVTVIYYNDKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYYCGNSDSRNVAFGAGTTLTVL,7PI3_T,7PI3_U,"Pfcyrpa Bound To Fab Fragments From Monoclonal Antibodies Cy.003, Cy.004 And Cy.007","Pfcyrpa Bound To Fab Fragments From Monoclonal Antibodies Cy.003, Cy.004 And Cy.007",Gallus gallus,"Ragotte,R.J.;Pulido,D.;Lias,A.M.;Quinkert,D.;Alanine,D.G.W.;Jamwal,A.;Davies,H.;Nacer,A.;Lowe,E.D.;Grime,G.W.;Illingworth,J.J.;Donat,R.F.;Garman,E.F.;Bowyer,P.W.;Higgins,M.K.;Draper,S.J.",Heterotypic interactions drive antibody synergy against a malaria vaccine candidate,19-AUG-2021,8_8_19_4_3_9,7PI3_T_U,Xtal structure,,6,1,14.48437,11.262397
7A0Y_E_F,AVTLDESGGGLQTPGGGLSLVCKASGFTFSDYGMGWVRQAPDKGLEWVAGIYTTGSGTRYGAAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSTGRDYYGGGIDAWGHGTEVIVSS,ALTQPSSVSANPGGTVKITCSGGTYSYGWFQQKSPGSAPVTVIYWNDKRPSNIPSRFSGSKSGSTHTLTITGVRAEDEAVYFCGSADSSGTAIFGAGTTLTVL,7A0Y_E,7A0Y_F,"Structure Of Dimeric Sodium Proton Antiporter Nhaa K300R Variant, At Ph 8.2, Crystallized With Chimeric Fab Antibodies","Structure Of Dimeric Sodium Proton Antiporter Nhaa K300R Variant, At Ph 8.2, Crystallized With Chimeric Fab Antibodies",synthetic construct,"Fippel,A.;Mir,S.H.;Wirth,C.;Gross,N.M.;Lentes,C.J.;Bialas,E.;Frank,F.;Ulbrich,M.H.;Andrade,S.L.A.;Kulik,A.;Hunte,C.",Molecular determinants for substrate uptake in electrogenic sodium/proton antiporters,11-AUG-2020,8_8_15_3_3_10,7A0Y_E_F,Xtal structure,,6,1,14.498836,11.265294
7PI3_R_S,AVTLDESGGGLQTPGGTLSLVCKGSGFTFSSYEMQWVRQAPGKGLEWVADICIGGSYTGYGPAVKGRATISRDDGQSTVRLQLNNLRAEDTGTYYCAKTARSDYCITGLDDIDAWGHGTEVIVSS,ALTQPSSVSANPGETVKITCSGGSSDYGWYQQKSPGSAPVTVIYENNKRPSDIPSRFSGSKFGSTHTLTITGVQADDEAVYFCGSRDTNNGAFGAGTTLTVL,7PI3_R,7PI3_S,"Pfcyrpa Bound To Fab Fragments From Monoclonal Antibodies Cy.003, Cy.004 And Cy.007","Pfcyrpa Bound To Fab Fragments From Monoclonal Antibodies Cy.003, Cy.004 And Cy.007",Gallus gallus,"Ragotte,R.J.;Pulido,D.;Lias,A.M.;Quinkert,D.;Alanine,D.G.W.;Jamwal,A.;Davies,H.;Nacer,A.;Lowe,E.D.;Grime,G.W.;Illingworth,J.J.;Donat,R.F.;Garman,E.F.;Bowyer,P.W.;Higgins,M.K.;Draper,S.J.",Heterotypic interactions drive antibody synergy against a malaria vaccine candidate,19-AUG-2021,8_8_18_5_3_9,7PI3_R_S,Xtal structure,,6,1,14.49079,11.26315
2AI0_K_O,DVKLVESGGGLVKPGGSLRLSCAASGFTFRNYGMSWVRQTPEKRLEWVAAISGNSLYTSYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYFCARHDDYYGKSPYFFDVWGAGTTVTASS,DVLMTQSPLSLPVSLGDQASISCRCSQSIVKSNGHTYLEWYLQKPGRSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDLGVYYCFQGSHIPWTFGGGTKLESK,2AI0_K,2AI0_O,"Anti-Cocaine Antibody 7.5.21, Crystal Form Iii","Anti-Cocaine Antibody 7.5.21, Crystal Form Iii",Mus musculus,"Pozharski,E.;Hewagama,A.;Shanafelt,A.;Ringe,D.;Pets,G.A.",Flexibility Of Packing: Four Crystal Forms Of An Anti-Cocaine Antibody 7.5.21,28-JUL-2005,8_8_16_11_3_9,2AI0_K_O,Xtal structure,Cocaine,6,1,17.983536,7.0032616
3MUG_D_C,EEQLVESGGGVVQPGGSLRLSCLASGFTFHKYGMHWVRQAPGKGLEWVALISDDGMRKYHSDSMWGRVTISRDNSKNTLYLQFSSLKVEDTAMFFCAREAGGPIWHDDVKYYDFNDGYYNYHYMDVWGKGTTVTVSS,SALTQPASVSGSPGQTITISCNGTSSDVGGFDSVSWYQQSPGKAPKVMVFDVSHRPSGISNRFSGSKSGNTASLTISGLHIEDEGDYFCSSLTDRSHRIFGGGTKVTVL,3MUG_D,3MUG_C,"Crystal Structure Of Human Fab Pg16, A Broadly Reactive And Potent Hiv-1 Neutralizing Antibody","Crystal Structure Of Human Fab Pg16, A Broadly Reactive And Potent Hiv-1 Neutralizing Antibody",Homo sapiens,"Pejchal,R.;Walker,L.M.;Stanfield,R.L.;Phogat,S.K.;Koff,W.C.;Poignard,P.;Burton,D.R.;Wilson,I.A.",Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1,03-MAY-2010,8_7_30_9_3_10,3MUG_D_C,Xtal structure,HIV,6,1,13.970751,14.157495
6M87_H_G,EFQLLESGPELVKPGASVKISCKASGYSFTDYNMNWVKQSNGKSLEWIGVINPNSGTTNYNQKFKDKATLTVDQSSSTAYMQLNSLTSEDSAVYYCARGGGFRRGFDSWGQGTTVTVSS,ELVLTQSPAIMSASPGEKVTMTCSASSSVSYVHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQWRTNPPTFGAGTKLEIK,6M87_H,6M87_G,Fab 10A6 In Complex With Mpts,Fab 10A6 In Complex With Mpts,Mus musculus,"Adhikary,R.;Zimmermann,J.;Stanfield,R.L.;Wilson,I.A.;Yu,W.;Oda,M.;Romesberg,F.E.",Structure and Dynamics of Stacking Interactions in an Antibody Binding Site,21-AUG-2018,8_8_12_5_3_9,6M87_H_G,Xtal structure,,6,1,2.7302282,-3.8939798
1UZ6_W_V,EVKLLESGGGLVQPGGSQKLSCAASGFDFSGYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARETGTRFDYWGQGTTLTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLYSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLEVPWTFGGGTKLEIK,1UZ6_W,1UZ6_V,Anti-Lewis X Fab Fragment Uncomplexed,Anti-Lewis X Fab Fragment Uncomplexed,Mus musculus,"van Roon,A.M.;Pannu,N.S.;de Vrind,J.P.;van der,Ma.;van Boom,J.H.;Hokke,C.H.;Deelder,A.M.;Abrahams,J.P.",Structure of an anti-Lewis X Fab fragment in complex with its Lewis X antigen,05-MAR-2004,8_8_10_11_3_9,1UZ6_W_V,Xtal structure,Lewis,6,1,19.580116,9.69924
1LO2_Y_X,EVKLVESGGGLVKPGGSLKLSCAASGFSFRNYGMSWVRQTPEKRLEWVASISYGGLIYYPDSIKGRFTISRDIAQNILYLQMSSLRSEDTAMYHCIRGDSFLVWFTFWGQGTLVTVS,DVLMTQTPLSLPVSLGDQVSIFCTSSQTIVHTNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVETEDLGIYYCFQGSHFPLAFGAGTKLELK,1LO2_Y,1LO2_X,Retro-Diels-Alderase Catalytic Antibody,Retro-Diels-Alderase Catalytic Antibody,Mus musculus,"Hugot,M.;Bensel,N.;Vogel,M.;Reymond,M.T.;Stadler,B.;Reymond,J.L.;Baumann,U.",A structural basis for the activity of retro-Diels-Alder catalytic antibodies: evidence for a catalytic aromatic residue,06-MAY-2002,8_7_12_11_3_9,1LO2_Y_X,Xtal structure,,6,1,18.225567,7.201047
7T0I_D_C,EVKLVESGGGLVQPGGSLRLACATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQSSLYLQMNTLRAEDSATYYCARDHDGYYERFAYWGQGTLVTVSA,DIVMTQSPSSLAVSAGEKVTMNCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFALTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,7T0I_D,7T0I_C,Crystal Structure Of S25-39 Fab Unliganded 3,Crystal Structure Of S25-39 Fab Unliganded 3,Mus musculus,"Blackler,R.J.;Muller-Loennies,S.;Pokorny-Lehrer,B.;Legg,M.S.G.;Brade,L.;Brade,H.;Kosma,P.;Evans,S.V.",Antigen binding by conformational selection in near-germline antibodies,29-NOV-2021,8_10_13_12_3_8,7T0I_D_C,Xtal structure,RPS25; S25,6,1,26.075031,4.6960797
3DUU_B_A,EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTVEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDGYYVDAMDYWGQGTSVTVSS,DIVLTQSPSSLAVSAGERVTMSCKSSQSLFKSRNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTINGVQAEDLAVYYCKQSYNLRTFGGGTKLELK,3DUU_B,3DUU_A,"Crystal Structure Of Sag506-01, Orthorhombic, Twinned, Crystal 2","Crystal Structure Of Sag506-01, Orthorhombic, Twinned, Crystal 2",Mus musculus,"Brooks,C.L.;Blackler,R.J.;Gerstenbruch,S.;Kosma,P.;Muller-Loennies,S.;Brade,H.;Evans,S.V.",Pseudo-symmetry and twinning in crystals of homologous antibody Fv fragments,17-JUL-2008,8_10_12_12_3_8,3DUU_B_A,Xtal structure,,6,1,26.012335,4.6319885
7UZ7_H_L,EVQLKQSVAELVRPGASVKVSCTASGFNIKNIYMHWVKQRPEQGLDWIGRIDPANGNSRYAPKFQDKATITADTSSNTAYLQLSSLTSEDTAIYYCADEGWGFANWGQGTLVTVSA,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKVGQPPKLLIYWASTRDPGVPDRFTGSGFGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKVELK,7UZ7_H,7UZ7_L,"Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Mouse Antibody Fab Fragment, M8A-31","Structure Of The Sars-Cov-2 S 6P Trimer In Complex With The Mouse Antibody Fab Fragment, M8A-31",Mus musculus,"Fan,C.;Cohen,A.A.;Park,M.;Hung,A.F.;Keeffe,J.R.;Gnanapragasam,P.N.P.;Lee,Y.E.;Gao,H.;Kakutani,L.M.;Wu,Z.;Kleanthous,H.;Malecek,K.E.;Williams,J.C.;Bjorkman,P.J.",Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes,07-DEC-2022,8_8_9_12_3_9,7UZ7_H_L,Xtal structure,RBD,6,1,-4.724498,0.1869491
5KZP_F_J,EVQLLESGGGVVQPGRSLRLSCTASGFTFNNYGMHWVRQTPGKGLEWLAVIWFDENNKYYADSVRGRFTISRDNSKNTLFLQMNSLKTEDTAMYYCARDISLVRDAFIYFDFWGLGTLVTVSS,LTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWITFGQGTRLEIK,5KZP_F,5KZP_J,Structure Of The Hcv1-C1 Antibody-Antigen Complex,Structure Of The Hcv1-C1 Antibody-Antigen Complex,Hepacivirus C,"Pierce,B.G.;Boucher,E.N.;Piepenbrink,K.H.;Ejemel,M.;Rapp,C.A.;Thomas WD,Jr.;Sundberg,E.J.;Weng,Z.;Wang,Y.",Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope,25-JUL-2016,8_8_16_6_3_8,5KZP_F_J,Xtal structure,Hepatitis,6,1,14.784955,13.416015
6SVL_O_P,EVQLQQSGAELVRPGALVKLSCKASGFNIKDYYMHWVKQRPEQGLEWIGRIDPENSNNIYDPKFQGKASITADTSSNTAYLQLSSLTSEDTAVYYCARGGFDTNHYAMDYWGQGTSVTVSS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGNYYCQHFWGTPPWTFGGGTKLEIK,6SVL_O,6SVL_P,Human Myeloid-Derived Growth Factor (Mydgf) In Complex With Neutralizing Fab,Human Myeloid-Derived Growth Factor (Mydgf) In Complex With Neutralizing Fab,Homo sapiens,"Ebenhoch,R.;Akhdar,A.;Reboll,M.R.;Korf-Klingebiel,M.;Gupta,P.;Armstrong,J.;Huang,Y.;Frego,L.;Rybina,I.;Miglietta,J.;Pekcec,A.;Wollert,K.C.;Nar,H.",Crystal structure and receptor-interacting residues of MYDGF - a protein mediating ischemic tissue repair,18-SEP-2019,8_8_14_6_3_10,6SVL_O_P,Xtal structure,IL-25; MYDGF; IL-27; IL27w; C19orf10; IL27; R33729_1; SF20; IL25,6,1,-4.7961726,0.24281938
5JOR_D_A,EVQLQQSGPELIKPGASVKMSCEASGYIFTEYYIHWVKQIQGRSLEWIGYVHPKTGDVIYNQNFRGKATLTVNRSSNTAYMELHSLTSEDSAVYYCARWDSWGQGTTLTVSS,DVLLTQTPLSLPVNLGDQASISCRSSQTILHSDGYTYLEWYLQRPGQSPKLLIYRVYKRFSGIPDRFRGSGSGMDFTLTISGVEAEDLGIYYCFQGSYVPRTFGGGTKLEIK,5JOR_D,5JOR_A,Crystal Structure Of Unbound Anti-Glycan Antibody Fab14.22 At 2.2 A,Crystal Structure Of Unbound Anti-Glycan Antibody Fab14.22 At 2.2 A,Mus musculus,"Polonskaya,Z.;Deng,S.;Sarkar,A.;Kain,L.;Comellas-Aragones,M.;McKay,C.S.;Kaczanowska,K.;Holt,M.;McBride,R.;Palomo,V.;Self,K.M.;Taylor,S.;Irimia,A.;Mehta,S.R.;Dan,J.M.;Brigger,M.;Crotty,S.;Schoenberger,S.P.;Paulson,J.C.;Wilson,I.A.;Savage,P.B.;Finn,M.G.;Teyton,L.",T cells control the generation of nanomolar-affinity anti-glycan antibodies,02-MAY-2016,8_8_5_11_3_9,5JOR_D_A,Xtal structure,glycan; Glycan,6,1,1.7356453,-3.9080522
5MHR_P_O,EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNDGPSYNQNFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCAIHYYGISYWYFDVWGAGTTVTVSS,EIVLTQSPTTMAASPGEKIIITCSASSSISSNYLHWYQQKPGCSPKLLIYRTSKLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGSSIYTFGGGTKLEIK,5MHR_P,5MHR_O,T3D Reovirus Sigma1 Complexed With 9Bg5 Fab Fragments,T3D Reovirus Sigma1 Complexed With 9Bg5 Fab Fragments,Mus musculus,"Dietrich,M.H.;Ogden,K.M.;Katen,S.P.;Reiss,K.;Sutherland,D.M.;Carnahan,R.H.;Goff,M.;Cooper,T.;Dermody,T.S.;Stehle,T.",Structural Insights into Reovirus sigma1 Interactions with Two Neutralizing Antibodies,25-NOV-2016,8_8_14_7_3_8,5MHR_P_O,Xtal structure,CD3-DELTA; T3D; CD3D; CD3DELTA,6,1,2.394632,-4.2005696
7MW6_D_E,EVQLQQSGPELVKPGASVKISCKASGYSFTGYSMNWMKQSPEKSLEWIGEINPSTGGTTDNQKFKAKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSRGDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVEYYGTSLMQWYQQKPGQPPKVLIYAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKVPWTFGGGTKLEIK,7MW6_D,7MW6_E,Structure Of The Sars-Cov-2 Spike Trimer With Three Rbds Up In Complex With The Fab Fragment Of Human Neutralizing Antibody Clone 2,Structure Of The Sars-Cov-2 Spike Trimer With Three Rbds Up In Complex With The Fab Fragment Of Human Neutralizing Antibody Clone 2,Homo sapiens,"Hu,Y.;Xiong,Y.","Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant",15-MAY-2021,8_8_7_10_3_9,7MW6_D_E,Xtal structure,SARS-CoV-2,6,1,2.602443,-4.118582
3O0R_H_L,EVQLQQSGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLEWIGAVYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCSRSSLDGYYVKNWCFDVWGQGTTVTVSS,DIQMTQSPPYLAASPGETITINCRASKSIRKYLAWYQEKPGKTNKLLIYSGSTLQFGIPSRFSGSGSGTEFTLTISSLEPEDFAMYYCQQHNEYPLTFGAGTKLELK,3O0R_H,3O0R_L,Crystal Structure Of Nitric Oxide Reductase From Pseudomonas Aeruginosa In Complex With Antibody Fragment,Crystal Structure Of Nitric Oxide Reductase From Pseudomonas Aeruginosa In Complex With Antibody Fragment,Pseudomonas aeruginosa PAO1,"Hino,T.;Matsumoto,Y.;Nagano,S.;Sugimoto,H.;Fukumori,Y.;Murata,T.;Iwata,S.;Shiro,Y.",Structural basis of biological N2O generation by bacterial nitric oxide reductase,20-JUL-2010,8_8_17_6_3_9,3O0R_H_L,Xtal structure,,6,1,2.6939497,-8.175213
AOL02415_AOL02416,EVQLVESGAQVKKPGASVTVSCTASGYKFTGYHMHWVRQAPGRGLEWMGWINPFRGAVKYPQNFRGRVSMTRDTSMEIFYMELSRLTSDDTAVYYCAREMFDSSADWSPWRGMVAWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCAGSSRDVGGFDLVSWYQQHPGKAPKLIIYEVNKRPSGISSRFSASKSGNTASLTISGLQEEDEAHYYCYSYADGVAFGGGTKLTVL,AOL02415,AOL02416,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Gristick,H.B.; von Boehmer,L.; West,A.P. Jr.; Schamber,M.; Gazumyan,A.; Golijanin,J.; Seaman,M.S.; Fatkenheuer,G.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",Structure of a natively-glycosylated HIV-1 Env reveals a new mode for VH1-2 antibody recognition of the CD4 binding site relevant to vaccine design,11-SEP-2016,8_8_19_9_3_8,AOL02415_AOL02416,Unique chain,HIV; CD4,6,1,2.384824,3.7889678
4NHH_H_L,EVQLVESGGGLVKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISSSTYRDYADAVKGRFTVSRDDLEDFVYLQMHKRVEDTAIYYCARKGSDRLDAWGPGTVVTVS,VVMTQSPSTLSASVGDTITITCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFATYHCQHYAGYSATFGQGTRVEIK,4NHH_H,4NHH_L,Structure Of 2G12 Igg Dimer,Structure Of 2G12 Igg Dimer,Homo sapiens,"Wu,Y.;West AP,Jr.;Kim,H.J.;Thornton,M.E.;Ward,A.B.;Bjorkman,P.J.",Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12,05-NOV-2013,8_7_10_6_3_9,4NHH_H_L,Xtal structure,HIV,6,1,15.842565,10.072251
7X3N_B_A,EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCSNRYYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVNTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQYINYPYTFGQGTKLEIK,7X3N_B,7X3N_A,Crystal Structure Of Anti-Mpeg H15-2B Fab,Crystal Structure Of Anti-Mpeg H15-2B Fab,Homo sapiens,"Nguyen,M.T.T.;Shih,Y.C.;Lin,M.H.;Roffler,S.R.;Hsiao,C.Y.;Cheng,T.L.;Lin,W.W.;Lin,E.C.;Jong,Y.J.;Chang,C.Y.;Su,Y.C.",Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group,01-MAR-2023,8_10_5_6_3_9,7X3N_B_A,Xtal structure,polyethylene,6,1,13.332488,8.156545
4XH2_A_B,EVQLVESGGGLVQPGGSLRLSCAASGFNVSSYSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTWYYGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQFKRQKEPITFGQGTKVEIK,4XH2_A,4XH2_B,Crystal Structure Of Human Paxillin Ld4 Motif In Complex With Fab Fragment,Crystal Structure Of Human Paxillin Ld4 Motif In Complex With Fab Fragment,synthetic construct,"Nocula-Lugowska,M.;Lugowski,M.;Salgia,R.;Kossiakoff,A.A.",Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin,04-JAN-2015,8_8_10_6_3_11,4XH2_A_B,Xtal structure,,6,1,9.767399,10.811611
4RRP_L_F,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYSSIHWVRQAPGKGLEWVAYIYPSSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSYSTKLAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSQWYPITFGQGTKVEIK,4RRP_L,4RRP_F,"Crystal Structure Of The Fab Complexed With Antigen Asf1P, Northeast Structural Genomics Consortium (Nesg) Target Pdr16","Crystal Structure Of The Fab Complexed With Antigen Asf1P, Northeast Structural Genomics Consortium (Nesg) Target Pdr16",Homo sapiens,"Kuzin,A.;Lew,S.;Seetharaman,J.;Mao,L.;Xiao,R.;Oconne,P.T.;Maglaqui,M.;Bailey,L.;Everett,J.K.;Acton,T.B.;Monte,G.T.;Hunt,J.F.;Tong,L.",Crystal Structure Of The Fab Complexed With Antigen Northeast Structural Genomics Consortium (Nesg) Tar,06-NOV-2014,8_8_12_6_3_9,4RRP_L_F,Xtal structure,,6,1,9.928054,10.720045
5F6H_I_J,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNSGMIWVRQAPGKGLEWVSYISLSGANTYYADSVKGRFTISRDNSQNTLSLQMNSLRVEDTAMYYCAKEGWSYFDFWGQGVLVTVS,QSALTQPPSVSKSLGQSVTISCTGTSSDIGAYTGVSWYQQHSGTAPRLLIYDVSKRPSGVSDRFSGSKSGNTASLTISGLQTDDEADYYCCSYRTGATYIFGTGTRVTVL,5F6H_I,5F6H_J,Crystal Structure Of Tier 2 Neutralizing Antibody Dh427 From A Rhesus Macaque,Crystal Structure Of Tier 2 Neutralizing Antibody Dh427 From A Rhesus Macaque,Macaca mulatta,"Bradley,T.;Fera,D.;Bhiman,J.;Eslamizar,L.;Lu,X.;Anasti,K.;Zhang,R.;Sutherland,L.L.;Scearce,R.M.;Bowman,C.M.;Stolarchuk,C.;Lloyd,K.E.;Parks,R.;Eaton,A.;Foulger,A.;Nie,X.;Karim,S.S.;Barnett,S.;Kelsoe,G.;Kepler,T.B.;Alam,S.M.;Montefiori,D.C.;Moody,M.A.;Liao,H.X.;Morris,L.;Santra,S.;Harrison,S.C.;Haynes,B.F.",Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site,06-DEC-2015,8_8_10_9_3_10,5F6H_I_J,Xtal structure,HIV,6,1,14.191887,9.447572
6U02_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLDWVANIKQDGSEKYYVDSVKGRFTISRHNAKNSLYLQMNSLRAEDTAVYYCASSTAAEFFDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYAASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLYTFGQGTKLEIK,6U02_H,6U02_L,Cryoem-Derived Model Of Na-63 Fab In Complex With N9 Shanghai2,Cryoem-Derived Model Of Na-63 Fab In Complex With N9 Shanghai2,Homo sapiens,"Zhu,X.;Turner,H.L.;Lang,S.;McBride,R.;Bangaru,S.;Gilchuk,I.M.;Yu,W.;Paulson,J.C.;Crowe JE,Jr.;Ward,A.B.;Wilson,I.A.",Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies,13-AUG-2019,8_8_11_6_3_10,6U02_H_L,Xtal structure,Influenza,6,1,11.110462,7.757363
7S7I_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSYISYRSRTIYYADSVKGRFTISRDNARNSLYLQMNSLRDEDTAVYYCARWGYGSGGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSFTFGPGTKVDIK,7S7I_H,7S7I_L,Crystal Structure Of Fab In Complex With Mica Alpha3 Domain,Crystal Structure Of Fab In Complex With Mica Alpha3 Domain,Homo sapiens,"Hogan,J.M.;Lee,P.S.;Wong,S.C.;West,S.M.;Morishige,W.H.;Bee,C.;Tapia,G.C.;Rajpal,A.;Strop,P.;Dollinger,G.",Residue-Level Characterization of Antibody Binding Epitopes Using Carbene Chemical Footprinting,05-OCT-2022,8_8_12_7_3_8,WFJ32160_WFJ32161,Xtal structure,,6,1,15.740066,9.922913
3AUV_F_F,EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKCLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGCGTKVEIK,3AUV_F,3AUV_F,Predicting Amino Acid Preferences In The Complementarity Determining Regions Of An Antibody-Antigen Recognition Interface,Predicting Amino Acid Preferences In The Complementarity Determining Regions Of An Antibody-Antigen Recognition Interface,Homo sapiens,"Yu,C.M.;Peng,H.P.;Chen,I.C.;Lee,Y.C.;Chen,J.B.;Tsai,K.C.;Chen,C.T.;Chang,J.Y.;Yang,E.W.;Hsu,P.C.;Jian,J.W.;Hsu,H.J.;Chang,H.J.;Hsu,W.L.;Huang,K.F.;Ma,A.C.;Yang,A.S.",Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface,16-FEB-2011,8_8_13_6_3_9,AWT81857,Xtal structure,,6,1,10.174306,10.860764
7XMX_E_F,EVQLVESGGGLVQPGGSLRLSCEASEIIVNRNYMNWVRQAPGKGLEWVSIIYPGGSTFYADSVKGRFTISRDNSKNTMYLQMNSLRAEDTAVYYCARSYGDFYVDFWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTKLTVL,7XMX_E,7XMX_F,Cryo-Em Structure Of Sars-Cov-2 Spike Glycoprotein In Complex With Three F61 Fab,Cryo-Em Structure Of Sars-Cov-2 Spike Glycoprotein In Complex With Three F61 Fab,Homo sapiens,"Li,X.;Pan,Y.;Yin,Q.;Wang,Z.;Shan,S.;Zhang,L.;Yu,J.;Qu,Y.;Sun,L.;Gui,F.;Lu,J.;Jing,Z.;Wu,W.;Huang,T.;Shi,X.;Li,J.;Li,X.;Li,D.;Wang,S.;Yang,M.;Zhang,L.;Duan,K.;Liang,M.;Yang,X.;Wang,X.",Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages,23-NOV-2022,8_7_11_8_3_11,7XMX_E_F,Xtal structure,SARS-CoV-2,6,1,12.678456,10.249081
6DWA_H_L,EVQLVESGGGLVQPGGSLRLSCSASGFSFNSFWMHWVRQVPGKGLVWISFTNNEGTTTAYADSVRGRFIISRDNAKNTLYLEMNNLRGEDTAVYYCARGDGGLDDWGQGTLVTVSS,DIQLTQSPDSLAVSLGERATINCKSSQSIFRTSRNKNLLNWYQQRPGQPPRLLIHWASTRKSGVPDRFSGSGFGTDFTLTITSLQAEDVAIYYCQQYFSPPYTFGQGTKLEIK,6DWA_H,6DWA_L,Structure Of The 4497 Antibody Fab Fragment Bound To A Staphylococcus Aureus Wall Techoic Acid Analog,Structure Of The 4497 Antibody Fab Fragment Bound To A Staphylococcus Aureus Wall Techoic Acid Analog,Homo sapiens,"Fong,R.;Kajihara,K.;Chen,M.;Hotzel,I.;Mariathasan,S.;Hazenbos,W.L.;Lupardus,P.J.",Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid,26-JUN-2018,8_8_9_12_3_9,QKP23072_QKP23071,Xtal structure,,6,1,13.575861,9.676343
CAZ68027_CAZ68026,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,CAZ68027,CAZ68026,"unnamed protein product, partial [Homo sapiens]","unnamed protein product, partial [Homo sapiens]",Homo sapiens,"Kittle,J.D.",Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences,03-JUL-2009,8_8_14_6_3_9,QFN55352,Unique chain,,6,1,13.083784,12.071603
7XMZ_H_L,EVQLVESGGGLVQPGRSLTLSCGASGFTFEDYAMHWVRQAPGKGLEWVSGIDWNSGVIGYADSVKGRFIISRDNAKNSLYLHMRSLTAEDTALYYCAKDVYSESGSGSYYDYWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVAISCSGSTSNIGDNFVSWYQQFPGTAPKLLLYDDARRPSGIPDRFSGSKSGTSATLGITGLQTGDEAVYFCSTWDNSLNVVLFGGGTKLTVL,7XMZ_H,7XMZ_L,Cryo-Em Structure Of Sars-Cov-2 Spike Glycoprotein In Complex With Three D2 Fab,Cryo-Em Structure Of Sars-Cov-2 Spike Glycoprotein In Complex With Three D2 Fab,Homo sapiens,"Li,X.;Pan,Y.;Yin,Q.;Wang,Z.;Shan,S.;Zhang,L.;Yu,J.;Qu,Y.;Sun,L.;Gui,F.;Lu,J.;Jing,Z.;Wu,W.;Huang,T.;Shi,X.;Li,J.;Li,X.;Li,D.;Wang,S.;Yang,M.;Zhang,L.;Duan,K.;Liang,M.;Yang,X.;Wang,X.",Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages,23-NOV-2022,8_8_16_8_3_11,7XMZ_H_L,Xtal structure,SARS-CoV-2,6,1,13.102678,12.04537
QGW50184_QGW50202,EVQLVESGGGLVRPGGSVRLSCAASGFDCSENDMHWVRQVTGKGLEWVASIGGGEMTYYAASAKGRFTVSRQKVKNSLYLQINNLRDDDTGIYYCVRGPSSGWHLHYYFGMDLWGRGTTVTVAS,DIVMTQSPLSLAVTLGEPAALSCRSSQSLLQYNGRNYVDWYLQKPGQSPQLLIYLGSHRASGVPDRFSGSGSGKDFTLKISRVEAEDIGVYYCMETLQTPRLTFGGGTKVEIK,QGW50184,QGW50202,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Setliff,I.; Shiakolas,A.R.; Pilewski,K.A.; Murji,A.A.; Ziki,R.; Janowska,K.; Richardson,S.; Mynhardt,C.; Raju,N.; Ronsard,L.; Kanekiyo,M.; Qin,J.; Kramer,K.J.; Greenplate,A.R.; McDonnell,W.J.; Graham,B.S.; Connors,M.; Lingwood,D.; Acharya,P.; Morris,L.; Georgiev,I.S.",High-throughput mapping of B-cell receptor sequences to antigen specificity,17-DEC-2019,8_7_18_11_3_10,QGW50184_QGW50202,Unique source,,6,1,16.395004,11.643149
6OUS_Q_R,EVQLVESGGGLVRPGRSLRLSCTVSGFSFDDSAMSWVRQAPGKGLEWISFIKSKTYGGTKEYAASVKGRFTISRDDSKNIAYLQMNSLKTEDTAVYYCTRGAPYGGNSDYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQDVRGALAWYQQKPGKAPKLLIFDASSLETGVPSRFSGSGSGTVFTLTISSLQPEDFAAYYCQQFLDFPFTFGQGTRLEIK,6OUS_Q,6OUS_R,Structure Of Fusion Glycoprotein From Human Respiratory Syncytial Virus,Structure Of Fusion Glycoprotein From Human Respiratory Syncytial Virus,Homo sapiens,"Tang,A.;Chen,Z.;Cox,K.S.;Su,H.P.;Callahan,C.;Fridman,A.;Zhang,L.;Patel,S.B.;Cejas,P.J.;Swoyer,R.;Touch,S.;Citron,M.P.;Govindarajan,D.;Luo,B.;Eddins,M.;Reid,J.C.;Soisson,S.M.;Galli,J.;Wang,D.;Wen,Z.;Heidecker,G.J.;Casimiro,D.R.;DiStefano,D.J.;Vora,K.A.",A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein,05-MAY-2019,8_10_18_6_3_9,AYJ11048_AYJ11049,Xtal structure,RSV,6,1,13.226064,8.836831
7V6O_E_D,EVQLVESGGGVVQPGRSLRLSCAASAFTFSNYGMHWVRQAPGKGLEWVAVIWSAGSLKYYADSVKGRFIISRDNSKNTLYLQMDSLRPEDTAVYYCARENTTYYYETSGSWGASYYFDFWGQGTLVTVSS,DIQMTQTPASLSASVGDRVTITCRASQNISSYLNWYQQKPGKAPKVLIYDTSRLQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQQSCTTLRCWTFGQGTKLEIK,7V6O_E,7V6O_D,Mers S Ectodomain Trimer In Complex With Neutralizing Antibody 111 (State 2),Mers S Ectodomain Trimer In Complex With Neutralizing Antibody 111 (State 2),Homo sapiens,"Wang,X.;Zhao,J.;Wang,Z.;Zeng,J.;Zhang,S.;Wang,Y.",MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2),28-SEP-2022,8_8_23_6_3_11,7V6O_E_D,Xtal structure,MERS; Ectodomain,6,1,14.895642,13.5485325
7NDC_H_L,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVALISYDGGNRYYADSVKGRFTISRDNSKNTLYLQMNRLRAEDTAMYYCAKDRDDGWDWYYFMDVWGKGTTVTVSS,DIQLTQSPGTLSLSPGERATLSCRASQSISGNYLAWYQHKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSYTFGQGTKVEIK,7NDC_H,7NDC_L,Em Structure Of Sars-Cov-2 Spike Glycoprotein (All Rbd Down) In Complex With Covox-159,Em Structure Of Sars-Cov-2 Spike Glycoprotein (All Rbd Down) In Complex With Covox-159,Homo sapiens,"Dejnirattisai,W.;Zhou,D.;Ginn,H.M.;Duyvesteyn,H.M.;Supasa,P.;Case,J.B.;Zhao,Y.;Walter,T.S.;Mentzer,A.J.;Liu,C.;Wang,B.;Paesen,G.C.;Slon-Campos,J.;Lopez-Camacho,C.;Kafai,N.M.;Bailey,A.L.;Chen,R.E.;Ying,B.;Thompson,C.;Bolton,J.;Fyfe,A.;Gupta,S.;Tan,T.K.;Gilbert-Jaramillo,J.;James,W.;Knight,M.;Carroll,M.W.;Skelly,D.;Dold,C.;Peng,Y.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Klenerman,P.;Temperton,N.;Hall,D.R.;Williams,M.A.;Paterson,N.G.;Bertram,F.K.;Siebert,C.A.;Clare,D.K.;Howe,A.;Radecke,J.;Song,Y.;Townsend,A.R.;Huang,K.A.;Fry,E.E.;Mongkolsapaya,J.;Diamond,M.S.;Ren,J.;Stuart,D.I.;Screaton,G.R.",The antigenic anatomy of SARS-CoV-2 receptor binding domain,30-JAN-2021,8_8_16_7_3_8,7NDC_H_L,Xtal structure,SARS-CoV-2,6,1,14.184091,13.903431
4YHP_H_L,EVQLVETGGGVVQPGRSLRLSCTASGFTFRDYWMSWVRQAPGKGLEWVADINPDGITRYYIDAVKGRFTISRDNAKSSLYLQMNSLGAEDTAVYYCAREFHSGLGWHFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGTNIGDISVHWYQQRPGQAPLVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDDSINAYVFGTGTKVTVL,4YHP_H,4YHP_L,Crystal Structure Of 309M3-B Fab In Complex With H3K9Me3 Peptide,Crystal Structure Of 309M3-B Fab In Complex With H3K9Me3 Peptide,Homo sapiens,"Hattori,T.;Lai,D.;Dementieva,I.S.;Montano,S.P.;Kurosawa,K.;Zheng,Y.;Akin,L.R.;Swist-Rosowska,K.M.;Grzybowski,A.T.;Koide,A.;Krajewski,K.;Strahl,B.D.;Kelleher,N.L.;Ruthenburg,A.J.;Koide,S.",Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone methylation,27-FEB-2015,8_8_14_6_3_11,4YHP_H_L,Xtal structure,,6,1,11.101122,7.749506
7LF1_F_H,EVQLVQSGAEVKKPGASVKVSCKASGYTFFKYGISWVRQAPGQGLEWMGSISPYTGETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREGAYGYRSPYQNWFDPWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHSLLPRTFGGGTKVEIK,7LF1_F,7LF1_H,Trimeric Human Arginase 1 In Complex With Mab3,Trimeric Human Arginase 1 In Complex With Mab3,Homo sapiens,"Palte,R.L.;Juan,V.;Gomez-Llorente,Y.;Bailly,M.A.;Chakravarthy,K.;Chen,X.;Cipriano,D.;Fayadat-Dilman,L.;Gathiaka,S.;Greb,H.;Hall,B.;Handa,M.;Hsieh,M.;Kofman,E.;Lin,H.;Miller,J.R.;Nguyen,N.;O'Neil,J.;Shaheen,H.;Sterner,E.;Strickland,C.;Sun,A.;Taremi,S.;Scapin,G.",Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action,15-JAN-2021,8_8_18_6_3_9,7LF1_F_H,Xtal structure,,6,1,1.9779105,5.3134255
7LF2_G_I,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMNWVRQAPGQGLEWIGVISPYNGGTTYNQKFKGKATLTVDKSTSTAYMELSSLRSEDTAVYYCVYDLYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQRISNDLHWYQQKPGQAPRLLIKYASQSISGIPSRFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNSWPRTFGGGTKLEIK,7LF2_G,7LF2_I,Trimeric Human Arginase 1 In Complex With Mab4,Trimeric Human Arginase 1 In Complex With Mab4,Homo sapiens,"Palte,R.L.;Juan,V.;Gomez-Llorente,Y.;Bailly,M.A.;Chakravarthy,K.;Chen,X.;Cipriano,D.;Fayadat-Dilman,L.;Gathiaka,S.;Greb,H.;Hall,B.;Handa,M.;Hsieh,M.;Kofman,E.;Lin,H.;Miller,J.R.;Nguyen,N.;O'Neil,J.;Shaheen,H.;Sterner,E.;Strickland,C.;Sun,A.;Taremi,S.;Scapin,G.",Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action,15-JAN-2021,8_8_9_6_3_9,7LF2_G_I,Xtal structure,,6,1,0.89906275,3.690024
8DLW_C_D,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTVSS,EIVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKVEIK,8DLW_C,8DLW_D,Cryo-Em Structure Of Sars-Cov-2 Epsilon (B.1.429) Spike Protein In Complex With Fab S2M11,Cryo-Em Structure Of Sars-Cov-2 Epsilon (B.1.429) Spike Protein In Complex With Fab S2M11,Homo sapiens,"Mannar,D.;Saville,J.W.;Sun,Z.;Zhu,X.;Marti,M.M.;Srivastava,S.S.;Berezuk,A.M.;Zhou,S.;Tuttle,K.S.;Sobolewski,M.D.;Kim,A.;Treat,B.R.;Da Silva Castanha,P.M.;Jacobs,J.L.;Barratt-Boyes,S.M.;Mellors,J.W.;Dimitrov,D.S.;Li,W.;Subramaniam,S.",SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization,31-AUG-2022,8_8_18_7_3_9,8DLW_C_D,Xtal structure,SARS-CoV-2,6,1,2.2671266,3.5934489
7UOT_S_T,EVQLVQSGAEVKKPGASVKVSCKASGYTFTKYGISWVRQAPGQGLEWMGWISAFNGYTRYGQRFQGKVTMTTDTSTNTASLEVRTLTSNDTAVYYCARQYPDQYSSSGWPRLFAMDVWGQGTTVTV,ETTLTQSPATLSVSPGETATLSCRASQNVINNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSMQSEDFAVYYCQQYNDWPRSFGQGTRLD,7UOT_S,7UOT_T,Native Lassa Glycoprotein In Complex With Neutralizing Antibodies 8.9F And 37.2D,Native Lassa Glycoprotein In Complex With Neutralizing Antibodies 8.9F And 37.2D,Homo sapiens,"Li,H.;Buck,T.;Zandonatti,M.;Yin,J.;Moon-Walker,A.;Fang,J.;Koval,A.;Heinrich,M.L.;Rowland,M.M.;Diaz Avalos,R.;Schendel,S.L.;Parekh,D.;Zyla,D.;Enriquez,A.;Harkins,S.;Sullivan,B.;Smith,V.;Chukwudozie,O.;Watanabe,R.;Robinson,J.E.;Garry,R.F.;Branco,L.M.;Hastie,K.M.;Saphire,E.O.",A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus,02-NOV-2022,8_8_21_6_3_9,7UOT_S_T,Xtal structure,,6,1,1.8743277,5.257908
5W08_K_L,EVQLVQSGAEVKKPGASVKVSCKTSGYTFTAYYLHWVRQAPGQGFEWMAWINPNTGDTNYAQKFQGRVTLSRDTSITTAYMELTRLRSDDTAVYYCAKDLTLMYVFDSGWARGAHDYYGMDVWGQGTTVAVSG,PSALTQPASVSGSPGQSVTISCTGTNSDVGTFDLVSWYQQYPGKAPKLIIYEGSRRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSVVFGGGTKLTVL,5W08_K,5W08_L,A/Texas/50/2012(H3N2) Influenza Hemagglutinin In Complex With K03.12 Fab,A/Texas/50/2012(H3N2) Influenza Hemagglutinin In Complex With K03.12 Fab,Homo sapiens,"McCarthy,K.R.;Watanabe,A.;Kuraoka,M.;Do,K.T.;McGee,C.E.;Sempowski,G.D.;Kepler,T.B.;Schmidt,A.G.;Kelsoe,G.;Harrison,S.C.",Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires,30-MAY-2017,8_8_26_9_3_8,5W08_K_L,Xtal structure,Influenza; H3N2,6,1,2.187829,3.5113263
AAR88369_AAR88370,EVQLVQSGAEVKKPGATVKISCKASGYTFSDFYMYWVRQAPGKGLEWMGLIDPEDADTMYAEKFRGRVTITADTSTDTGYLELSSLRSEDTAVYYCAADPWELNAFNVWGQGTLVSVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISTWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFSLTINSLQPEDFATYYCQQANSFFTFGGGTKVEIK,AAR88369,AAR88370,"anti-HIV-1 gp120 immunoglobulin 48d heavy chain, partial [Homo sapiens]","anti-HIV-1 gp120 immunoglobulin 48d kappa light chain, partial [Homo sapiens]",Homo sapiens,"Huang,C.C.; Venturi,M.; Majeed,S.; Moore,M.J.; Phogat,S.; Zhang,M.Y.; Dimitrov,D.S.; Hendrickson,W.A.; Robinson,J.; Sodroski,J.; Wyatt,R.; Choe,H.; Farzan,M.; Kwong,P.D.",Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120,26-JUL-2016,8_8_12_6_3_8,AAR88369_AAR88370,Unique word,gp120; HIV,6,1,1.0349066,2.9477077
8DZH_E_D,EVQLVQSGAEVKKPGESLKISCKGSGFSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGYEDVFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGGRATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPTFGQGTKVEIK,8DZH_E,8DZH_D,Structure Of Sars-Cov-2 Omicron Ba.1.1.529 Spike Trimer With Two Rbds Down In Complex With The Fab Fragment Of Human Neutralizing Antibody Mb.02,Structure Of Sars-Cov-2 Omicron Ba.1.1.529 Spike Trimer With Two Rbds Down In Complex With The Fab Fragment Of Human Neutralizing Antibody Mb.02,Homo sapiens,"Ren,P.;Hu,Y.;Peng,L.;Yang,L.;Suzuki,K.;Fang,Z.;Bai,M.;Zhou,L.;Feng,Y.;Zou,Y.;Xiong,Y.;Chen,S.",Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages,31-AUG-2022,8_8_11_7_3_9,8DZH_E_D,Xtal structure,SARS-CoV-2,6,1,-12.354064,5.7377124
6MI2_D_E,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL,6MI2_D,6MI2_E,Structure Of The Human 4-1Bb / Utomilumab Fab Complex,Structure Of The Human 4-1Bb / Utomilumab Fab Complex,Homo sapiens,"Chin,S.M.;Kimberlin,C.R.;Roe-Zurz,Z.;Zhang,P.;Xu,A.;Liao-Chan,S.;Sen,D.;Nager,A.R.;Oakdale,N.S.;Brown,C.;Wang,F.;Yang,Y.;Lindquist,K.;Yeung,Y.A.;Salek-Ardakani,S.;Chaparro-Riggers,J.",Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab,19-SEP-2018,8_8_9_6_3_11,AGD00369_AGD00372,Xtal structure,ILA; 4-1BB; TNFSF9; 4-1BB-L; CD137; CD137L; TNFRSF9; 4-1BBL,6,1,-12.195685,5.641025
6LXJ_M_N,EVQLVQSGAEVKKPGSSVKVSCKASGGPFSSYGFSWVRQAPGQGLEWMGGIIPVYGTTNYAQKFQGRVTITADESTSTAYMELSSLKSEDTAVYYCARDLQDTPMVDRIIGSYYYYNGLDVWGQGTTVTVSS,QSVLTQPASVSGSPGQSITISCTGASSDVGDYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGDTASLTISGLQAEDEADYYCSSYTRSSSVVFGGGTKLTVL,6LXJ_M,6LXJ_N,Crystal Structure Of Human Z2B3 Fab In Complex With Influenza Virus Neuraminidase From A/Anhui/1/2013 (H7N9),Crystal Structure Of Human Z2B3 Fab In Complex With Influenza Virus Neuraminidase From A/Anhui/1/2013 (H7N9),Homo sapiens,"Jiang,H.;Peng,W.;Qi,J.;Chai,Y.;Song,H.;Bi,Y.;Rijal,P.;Wang,H.;Oladejo,B.O.;Liu,J.;Shi,Y.;Gao,G.F.;Townsend,A.R.;Wu,Y.",Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus,11-FEB-2020,8_8_25_9_3_10,6LXJ_M_N,Xtal structure,neuraminidase; Influenza,6,1,-0.82473344,6.124738
7MFA_U_V,EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTLYLEMNNVRTEDTGYYFCARTGKYYDFWSGYAAGEEYFQDWGQGTLVIVSS,ASELTQDPAVSVALKQTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,7MFA_U,7MFA_V,Crystal Structure Of Antibody 10E8V4-P100Fa+P100Ga Fab,Crystal Structure Of Antibody 10E8V4-P100Fa+P100Ga Fab,Homo sapiens,"Do Kwon,Y.;Wang,X.E.;Bender,M.F.;Yang,R.;Li,Y.;McKee,K.;Rawi,R.;O'Dell,S.;Schneck,N.A.;Shaddeau,A.;Zhang,B.;Arnold,F.J.;Connors,M.;Doria-Rose,N.A.;Kwong,P.D.;Lei,Q.P.",Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography,08-APR-2021,8_10_22_6_3_12,7MFA_U_V,Xtal structure,HIV,6,1,12.675851,8.867119
7MF9_C_D,EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTLYLEMNNVRTEDTGYYFCARTGKYYDFWSGYAPGEEYFQDWGQGTLVIVSS,ASELTQDPAVSVALKQTVTITCRGDSLRSHYASWYQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGNRASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVL,7MF9_C,7MF9_D,Crystal Structure Of Antibody 10E8V4-P100Fa Fab In Space Group C2,Crystal Structure Of Antibody 10E8V4-P100Fa Fab In Space Group C2,Homo sapiens,"Do Kwon,Y.;Wang,X.E.;Bender,M.F.;Yang,R.;Li,Y.;McKee,K.;Rawi,R.;O'Dell,S.;Schneck,N.A.;Shaddeau,A.;Zhang,B.;Arnold,F.J.;Connors,M.;Doria-Rose,N.A.;Kwong,P.D.;Lei,Q.P.",Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography,08-APR-2021,8_10_22_6_3_12,7MF9_C_D,Xtal structure,HIV,6,1,12.63595,8.874775
AEQ73805_AEQ74557,GGVVQPGRSLRLSCAASGITFSGYTIHWVRQAPGKGLQWVAAISYDGHTQLYAESVRGRFTISRDNSKNTLSLQMKSLIVDDTAVYYCARGGPGNVRVNLGRGVFDFWGPGTLVT,SLFAFVGDRVTITCRASQGISNWLAWYQQKPQKAPKSLIYEASSLQSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYYSFPLSFGGGTKLEIN,AEQ73805,AEQ74557,"anti-tetanus toxoid immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-tetanus toxoid immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Poulsen,T.R.; Jensen,A.; Haurum,J.S.; Andersen,P.S.",Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans,25-JUL-2016,8_8_19_6_3_9,AEQ73805_AEQ74557,Unique source,tetanus,6,1,14.832182,12.89447
6NB6_I_M,QAQLVESGGALVQPGRSLRLSCAASGFTFRNYAMHWVRQAPATGLQWLAVITSDGRNKFYADSVKGRFTISREDSKNTLYLQMDSLRGEDTAVYYCVTQRDNSRDYFPHYFHDMDVWGQGTTVAVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGDTYLNWFQQRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGSHWPPTFGQGTKVEIK,6NB6_I,6NB6_M,Sars-Cov Complex With Human Neutralizing S230 Antibody Fab Fragment (State 1),Sars-Cov Complex With Human Neutralizing S230 Antibody Fab Fragment (State 1),Homo sapiens,"Walls,A.C.;Xiong,X.;Park,Y.J.;Tortorici,M.A.;Snijder,J.;Quispe,J.;Cameroni,E.;Gopal,R.;Dai,M.;Lanzavecchia,A.;Zambon,M.;Rey,F.A.;Corti,D.;Veesler,D.",Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion,06-DEC-2018,8_8_20_11_3_9,6NB6_I_M,Xtal structure,,6,1,14.229721,13.927308
1DBB_H_L,QIQLVQSGPELKKPGETVKISCKASGYAFTNYGVNWVKEAPGKELKWMGWINIYTGEPTYVDDFKGRFAFSLETSASTAYLEINNLKNEDTATYFCTRGDYVNWYFDVWGAGTTVTVSS,DVVMTQIPLSLPVNLGDQASISCRSSQSLIHSNGNTYLHWYLQKPGQSPKLLMYKVSNRFYGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQSSHVPPTFGGGTKLEIK,1DBB_H,1DBB_L,Three-Dimensional Structure Of An Anti-Steroid Fab' And Progesterone-Fab' Complex,Three-Dimensional Structure Of An Anti-Steroid Fab' And Progesterone-Fab' Complex,Mus musculus,"Stura,E.A.;Arevalo,J.H.;Feinstein,A.;Heap,R.B.;Taussig,M.J.;Wilson,I.A.",Analysis of an anti-progesterone antibody: variable crystal morphology of the Fab' and steroid-Fab' complexes,11-NOV-1992,8_8_12_11_3_9,AAW13178_AAW13148,Xtal structure,progesterone,6,1,-7.4462266,6.058946
6VL8_E_F,QIQLVQSGPELKKPGETVKISCKASGYTFKNYGMNWVKQAPGKGLKWMGWINTYTGQPIYANDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARDWGPYWGQGTLVIVSA,NIMMTQSPSSLAVSAGEKVTVNCKSSQSVLYSSNQMNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQTEDLAVYYCLQYLSSWTFGGGTKLEIK,6VL8_E,6VL8_F,Anti-Peg Antibody 6-3 Fab Fragment In Complex With Peg,Anti-Peg Antibody 6-3 Fab Fragment In Complex With Peg,Mus musculus,"Huckaby,J.T.;Jacobs,T.M.;Li,Z.;Perna,R.J.;Wang,A.;Nicely,N.I.;Lai,S.K.",Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers,23-JAN-2020,8_8_7_12_3_8,6VL8_E_F,Xtal structure,PEG,6,1,-7.5038834,6.183267
4PLK_H_L,QLQQSGPELVKPGASVKISCKASGYTFTDFNMHWVKQSHGKSLEWIGYIYPYNGITGQNQKFKSKATLTVDNSSSSAYMELRSLTSEDSAVYYCARERFGVGNNYAWFTYWGQGTLVTVSS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLVWYQQKQGKSPQVLVYAATNLPDGVPSRFSGSGSGTQYSLKINSLQSEDSGSYYCQHFWETPFTFGSGTKLEIK,4PLK_H,4PLK_L,Hepatitis E Virus E2S Domain (Genotype I) In Complex With A Neutralizing Antibody 8G12,Hepatitis E Virus E2S Domain (Genotype I) In Complex With A Neutralizing Antibody 8G12,Mus musculus,"Gu,Y.;Tang,X.;Zhang,X.;Song,C.;Zheng,M.;Wang,K.;Zhang,J.;Ng,M.H.;Hew,C.L.;Li,S.;Xia,N.;Sivaraman,J.",Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody,18-MAY-2014,8_8_16_6_3_9,4PLK_H_L,Xtal structure,Hepatitis,6,1,2.4334643,-4.226469
AJC50737,QSLEESGGDLVTPGTPLTLTCTVSGFSLSTYAMNWVRQAPGKGLEWIGVTHSGGYKYYASWAKGRFTISKASTTVDLKIVSPTTEDTATYFCARGSGITGLGLWGPGTLVTVSS,VGDTVTINCQASESISSWLSWYQKKPGQPPKLLIYSASTLASGVPSRFSGSGSGTEFTLTISDLERDDAATYYCQNNGDSSRHGYTFGGGTEVVVK,AJC50737_H,AJC50737_L,"rabbit anti-human cTnI scFv, partial [synthetic construct]","rabbit anti-human cTnI scFv, partial [synthetic construct]",synthetic construct,"Ayyar,B.V.; Hearty,S.; O'Kennedy,R.",Facile domain rearrangement abrogates expression recalcitrance in a rabbit scFv,12-MAR-2015,8_7_11_6_3_12,AJC50737,Same entry,cTnI,6,1,-0.16820864,19.113384
6X1T_H_L,QSVKESEGGLFKPTDTLTLTCTASGFSLNGYGVIWVRQAPGKGLEWIGSAGAYGRIYYPNWARSRATITRNTNLNTVSLKMTSLTAADTATYFCARRTNVSTSVGFDSWGPGTLVTVSS,DMTQTPSSKSVPVGDTVTINCQASESVYSNNRLSWFQQKPGQPPKLLIYLVSTLASGVPSRFKGSGSGTQFTLTISDVVCDDAATYYCVGYKSSTTDGLAFGGGTEVVVK,6X1T_H,6X1T_L,Structure Of Phis Fab (Sc50-3) In Complex With Phis Mimetic Peptide,Structure Of Phis Fab (Sc50-3) In Complex With Phis Mimetic Peptide,synthetic construct,"Kalagiri,R.;Stanfield,R.L.;Meisenhelder,J.;La Clair,J.J.;Fuhs,S.R.;Wilson,I.A.;Hunter,T.",Structural basis for differential recognition of phosphohistidine containing peptides by 1-pHis and 3-pHis monoclonal antibodies,19-MAY-2020,8_7_14_8_3_12,6X1T_H_L,Xtal structure,,6,1,-0.2620645,18.873678
7CN2_G_g,QSVKESEGRLVTPGTPLTLTCTASGFTMSRYHMTWVRQAPGKGLEWIGIIYARNSDTYYANWAKGRFTISKTSTTVDLKITSPTIEDTATYFCARVDSDSSGAFDRLDLWGQGTLVTVSS,DPMLTQTAASVEVAVGGTVTIKCQASQSIGGYLSWYQQKPGQRPKLLIYRASTLASGVPSRFKGSGSGTEYTLTFSGVECADAAAYYCQQGYTSSDINNAFGGGTEVVVK,7CN2_G,7CN2_g,Subparticle Refinement Of Human Papillomavirus Type 16 Pesudovirus In Complex With H16.001 Fab,Subparticle Refinement Of Human Papillomavirus Type 16 Pesudovirus In Complex With H16.001 Fab,Oryctolagus cuniculus,"Huang,W.;He,M.;Ning,T.;Nie,J.;Zhang,F.;Zheng,Q.;Zhang,R.;Xu,Y.;Gu,Y.;Li,S.;Wang,Y.","Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs",29-JUL-2020,8_8_16_6_3_12,7CN2_G_g,Xtal structure,,6,1,-0.1294126,19.163183
QGR24382_QGR24389,QVHLQESGPGLVRPSETLSLTCTVSDGSISSYYWSWIRQPPGKGLEWIGSIYYTGSTNYNPSLKSRVTMSVDTSKNQFSLRLNSVTAADTAMYYCAGLDRYSWNEGGDHWGQGILVSVSS,QPVLTQPPSASGTPGQRVSISCSGSRSNLGKNTVNWYQQLPGTAPKLLIYNHSRRPSGVPERFSGSKSGTSASLAISGLQSEDEADYFCAAWDDSLNGLYVFGTGTKVTVL,QGR24382,QGR24389,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Krebs,S.J.; Donofrio,G.C.; Dussupt,V.; Modjarrad,K.; Michael,N.L.; Barouch,D.H.; Joyce,M.G.; Stephenson,K.",Direct Submission,09-DEC-2019,8_7_14_8_3_12,QGR24382_QGR24389,Unique source,,6,1,16.216074,-7.8338284
UYI35933_UYI36163,QVQLQESGPGLLKPSDTLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWVGSIYSSNGHTNYNPSLKSRVTISTDTSKNQFSLKLSSVTAADTAVYYCAREQDCSGGVCKNWFDVWGPGVLVTVSS,DIQMTQSPSSLSASVGDKVTITCRASQGISSRLAWYQQKPGKAPKLLIYAAFSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAHNTPHSFGQGTKVEIK,UYI35933,UYI36163,"immunoglobulin heavy chain variable region, partial [Macaca mulatta]","immunoglobulin light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Lenart,K.; Hellgren,F.; Ols,S.; Yan,X.; Cagigi,A.; Cerveira,R.A.; Winge,I.; Hanczak,J.; Mueller,S.O.; Jasny,E.; Schwendt,K.; Rauch,S.; Petsch,B.; Lore,K.",A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses,23-OCT-2022,9_8_17_6_3_9,UYI35933_UYI36163,Unique source,COVID,6,1,16.474188,-7.54688
8E6J_H_L,QVQLQESGPGLVKPSETLSLTCTVSGDSISSSYYYWGWIRQSPVKGLEWIGSFFYSGNTNYNPSLKSRVTISVDTSKNQFSLNLRSVTAADTAVYYCARHVTSISSWNRGVYLDSWGRGALVTVSS,DIQMTQSPSSLSTSVGDRVTITCRASQTISTYLNWYQQKPGKAPELLIYVASSLQSGVPSRFSGTGSGTEFTLTISSLQPGDFATYYCQQSYSSPFTFGQGTKVEIK,8E6J_H,8E6J_L,3H03 Fab In Complex With Influenza Virus Neuraminidase From A/Brevig Mission/1/1918 (H1N1),3H03 Fab In Complex With Influenza Virus Neuraminidase From A/Brevig Mission/1/1918 (H1N1),Homo sapiens,"Hansen,L.;McMahon,M.;Turner,H.L.;Zhu,X.;Turner,J.S.;Ozorowski,G.;Stadlbauer,D.;Vahokoski,J.;Schmitz,A.J.;Rizk,A.A.;Alsoussi,W.B.;Strohmeier,S.;Yu,W.;Chore&#xf1;o-Parra,J.A.;Jim&#xe9;nez-Alvarez,L.;Cruz-Lagunas,A.;Z&#xfa;&#xf1;iga,J.;Mudd,P.A.;Cox,R.J.;Wilson,I.A.;Ward,A.B.;Ellebedy,A.H.;Krammer,F.",Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in&#xa0;vitro and in&#xa0;vivo,09-AUG-2023,10_7_18_6_3_9,8E6J_H_L,Xtal structure,H1N1; Influenza,6,1,16.70346,-7.954149
8E6K_H_L,QVQLQESGPGLVKPSETLSLTCTVSGDSVSSTNYYWGWIRQPPGKGLEWIGSIYYRGITYNSPSLMNRVTISLDTAKNQFSLNLSSMTAADTAVYFCANSIAVSGPLYFHHWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSLSGYLNWYQQKPGKAPKLLIYATSTLQRGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSYSTPPYTFGQGTKVEIK,8E6K_H,8E6K_L,2H08 Fab In Complex With Influenza Virus Neuraminidase From A/Brevig Mission/1/1918 (H1N1),2H08 Fab In Complex With Influenza Virus Neuraminidase From A/Brevig Mission/1/1918 (H1N1),Homo sapiens,"Hansen,L.;McMahon,M.;Turner,H.L.;Zhu,X.;Turner,J.S.;Ozorowski,G.;Stadlbauer,D.;Vahokoski,J.;Schmitz,A.J.;Rizk,A.A.;Alsoussi,W.B.;Strohmeier,S.;Yu,W.;Chore&#xf1;o-Parra,J.A.;Jim&#xe9;nez-Alvarez,L.;Cruz-Lagunas,A.;Z&#xfa;&#xf1;iga,J.;Mudd,P.A.;Cox,R.J.;Wilson,I.A.;Ward,A.B.;Ellebedy,A.H.;Krammer,F.",Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in&#xa0;vitro and in&#xa0;vivo,09-AUG-2023,10_7_14_6_3_10,8E6K_H_L,Xtal structure,H1N1; Influenza,6,1,16.633545,-7.921459
7VSU_D_C,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGKNGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,7VSU_D,7VSU_C,Crystal Structure Of Fab Fragment Of Anti-Mesothelin Antibody,Crystal Structure Of Fab Fragment Of Anti-Mesothelin Antibody,Homo sapiens,"Wang,C.;Hong,J.;Yang,Z.;Zhou,X.;Yang,Y.;Kong,Y.;Chen,B.;Wu,H.;Qian,B.Z.;Dimitrov,D.S.;Zhou,X.;Wu,Y.;Ying,T.",Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use,27-OCT-2021,10_7_11_6_3_9,7VSU_D_C,Xtal structure,Mesothelin,6,1,16.334696,-8.054898
4XNM_B_A,QVQLQESGPGLVKPSGTVSLTCAVSGGSISSSYWWSWVRQPPGKGLEWIGEIYHSGNTNYNPSLKSRVTISVDKSKNLFSLKLSSVTAADTAVYYCARVALFDILTGGWFDPWGQGTLVTVSS,YELTQPPSVSVSPGQTVNITCSGDTLGDKYVCWYQQKPGQSPVLVIYQDTKRPSGIPERFSGSNSGDTATLTVSGTQAMDEADYYCQAWDSSSFVFGTGTKVTVL,4XNM_B,4XNM_A,Antibody Influenza H5 Complex,Antibody Influenza H5 Complex,Influenza A virus,"Winarski,K.L.;Thornburg,N.J.;Yu,Y.;Sapparapu,G.;Crowe JE,Jr.;Spiller,B.W.",Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites,15-JAN-2015,9_7_16_6_3_9,4XNM_B_A,Xtal structure,H5N1; Influenza,6,1,15.534846,-7.4146223
7QT0_A_B,QVQLQQPGAELVKPGASVKVSCKASGYTFTNYWMYWVKQRPGQGLEWIGRIHPSDSDTNYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYYCAIEIYDGYNTMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNNYPLTFGAGTKLELK,7QT0_A,7QT0_B,Antibody Fenab136 - Fentanyl Complex,Antibody Fenab136 - Fentanyl Complex,Mus musculus,"Triller,G.;Vlachou,E.P.;Hashemi,H.;van Straaten,M.;Zeelen,J.P.;Kelemen,Y.;Baehr,C.;Marker,C.L.;Ruf,S.;Svirina,A.;Chandra,M.;Urban,K.;Gkeka,A.;Kruse,S.;Baumann,A.;Miller,A.K.;Bartel,M.;Pravetoni,M.;Stebbins,C.E.;Papavasiliou,F.N.;Verdi,J.P.","A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl",24-MAY-2023,8_8_13_6_3_9,7QT0_A_B,Xtal structure,,6,1,-0.3358764,-3.5995517
6TNP_D_C,QVQLQQSDAELVKPGSSVKISCKASGYTFTDHAIHWVKQKPEQGLEWIGHFSPGNTDIKYNDKFKGKATLTVDRSSSTAYMQLNSLTSEDSAVYFCKTSTFFFDYWGQGTTLTVSS,ELVMTQSPSSLTVTAGEKVTMICKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLELK,6TNP_D,6TNP_C,Crystal Structure Of The Scfv-5E5 In Complex With A Tn Glycopeptide,Crystal Structure Of The Scfv-5E5 In Complex With A Tn Glycopeptide,Mus musculus,"Macias-Leon,J.;Bermejo,I.A.;Asin,A.;Garcia-Garcia,A.;Companon,I.;Jimenez-Moreno,E.;Coelho,H.;Mangini,V.;Albuquerque,I.S.;Marcelo,F.;Asensio,J.L.;Bernardes,G.J.L.;Joshi,H.J.;Fiammengo,R.;Blixt,O.;Hurtado-Guerrero,R.;Corzana,F.",Structural Characterization of an Unprecedented Lectin-like Antitumoral anti-MUC1 Antibody,09-DEC-2019,8_8_9_12_3_9,QBE29862_QBE29863,Xtal structure,Ca15-3; ADMCKD; KL-6; ADMCKD1; PUM; MUC1; MCKD; CD227; MCKD1; EMA; PEM; MCD,6,1,0.20493373,-4.3712177
6ERX_F_G,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTSTASMELSSLRSEDTAVYYCARSRDLLLFPHYGMDVWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHWVFGGGTELTVL,6ERX_F,6ERX_G,Crystal Structure Of Human Baff In Complex With Fab Fragment Of Anti-Baff Antibody Belimumab,Crystal Structure Of Human Baff In Complex With Fab Fragment Of Anti-Baff Antibody Belimumab,HOMO SAPIENS,"Lammens, A., Maskos, K., Willen, L., Jiang, X., Schneider, P.",Crystal Structure Of Human Baff In Complex With Fab Fragment Of Anti-Baff Antibody Belimumab,19-OCT-2017,8_8_16_6_3_11,6ERX_F_G,Xtal structure,Baff,6,1,-0.4928606,5.9503613
8DZW_H_L,QVQLVESGGGVVKPGGSLRVSCVVSGFTFSSYRMHWVRQAPGKGLEWVSSITASSSYINYAESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDENTGISHYWFDPWGQGTLVTVSS,QAVVTQPPSVSGAPGQRVIISCTGSGSNLGADYGVHWYQQLPGTAPKLLIYGDRNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRSLNWVFGGGTKLTVL,8DZW_H,8DZW_L,Rsv F Trimer Bound To Rsv-199 Fab,Rsv F Trimer Bound To Rsv-199 Fab,Homo sapiens,"Wen,X.;Suryadevara,N.;Kose,N.;Liu,J.;Zhan,X.;Handal,L.S.;Williamson,L.E.;Trivette,A.;Carnahan,R.H.;Jardetzky,T.S.;Crowe,J.E.",Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode,08-JAN-2009,8_8_15_9_3_10,8DZW_H_L,Xtal structure,,6,1,16.028133,10.037285
5YOY_P_M,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,5YOY_P,5YOY_M,Crystal Structure Of The Human Tumor Necrosis Factor In Complex With Golimumab Fv,Crystal Structure Of The Human Tumor Necrosis Factor In Complex With Golimumab Fv,Homo sapiens,"Ono,M.;Horita,S.;Sato,Y.;Nomura,Y.;Iwata,S.;Nomura,N.",Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab,31-OCT-2017,8_8_19_6_3_10,ABU39128_ABU39129,Xtal structure,,6,1,14.121498,14.029255
6PZW_F_E,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDKRFITMILVGPFDYWGQGTLVTVSS,QSVLTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWHQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCSSYTSSTTNVFGTGTKVTVL,6PZW_F,6PZW_E,Cryoem Derived Model Of Na-22 Fab In Complex With N9 Shanghai2,Cryoem Derived Model Of Na-22 Fab In Complex With N9 Shanghai2,Homo sapiens,"Zhu,X.;Turner,H.L.;Lang,S.;McBride,R.;Bangaru,S.;Gilchuk,I.M.;Yu,W.;Paulson,J.C.;Crowe,J.E.;Ward,A.B.;Wilson,I.A.",Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies,01-AUG-2019,8_8_17_9_3_10,6PZW_F_E,Xtal structure,Influenza,6,1,15.01249,13.748578
7ORB_E_F,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYPLHWVRQAPGKGPEWVAVISQDGGNKYYVDSVKGRFTISRDNSKNTLYLQMNNLRAEDTALYYCARDVVVVVAARNHYYNGMDVWGQGTTVTVSS,DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAKSFPFTFGPGTKVEIK,7ORB_E,7ORB_F,Crystal Structure Of The L452R Mutant Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-75 And Covox-253 Fabs,Crystal Structure Of The L452R Mutant Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-75 And Covox-253 Fabs,Homo sapiens,"Liu,C.;Ginn,H.M.;Dejnirattisai,W.;Supasa,P.;Wang,B.;Tuekprakhon,A.;Nutalai,R.;Zhou,D.;Mentzer,A.J.;Zhao,Y.;Duyvesteyn,H.M.;Lopez-Camacho,C.;Slon-Campos,J.;Walter,T.S.;Skelly,D.;Johnson,S.A.;Ritter,T.G.;Mason,C.;Costa Clemens,S.A.;Gomes Naveca,F.;Nascimento,V.;Nascimento,F.;Fernandes da,Co.;Resende,P.C.;Pauvolid-Correa,A.;Siqueira,M.M.;Dold,C.;Temperton,N.;Dong,T.;Pollard,A.J.;Knight,J.C.;Crook,D.;Lambe,T.;Clutterbuck,E.;Bibi,S.;Flaxman,A.;Bittaye,M.;Belij-Rammerstorfer,S.;Gilbert,S.C.;Malik,T.;Carroll,M.W.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Baillie,V.;Serafin,N.;Ditse,Z.;Da Silva,K.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Madhi,S.;Nunes,M.C.;Goulder,P.;Fry,E.E.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum,04-JUN-2021,8_8_20_6_3_9,7ORB_E_F,Xtal structure,SARS-CoV-2,6,1,14.083905,14.058104
6UMI_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL,6UMI_H,6UMI_L,Crystal Structure Of Erenumab Fab-B,Crystal Structure Of Erenumab Fab-B,Homo sapiens,"Garces,F.;Mohr,C.;Zhang,L.;Huang,C.S.;Chen,Q.;King,C.;Xu,C.;Wang,Z.",Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab),09-OCT-2019,8_7_23_8_3_11,QPW41637_QPW41636,Xtal structure,CGRPR; CRLR; CALCRL,6,1,14.082462,14.071062
8SAX_C_D,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWISLYYDSSGYPNFDYWGQGTLVTVSG,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVIFGGGTKLTVL,8SAX_C,8SAX_D,Cryoem Structure Of Dh270.Uca-Ch848.10.17Dt,Cryoem Structure Of Dh270.Uca-Ch848.10.17Dt,Homo sapiens,"Henderson,R.;Zhou,Y.;Stalls,V.;Wiehe,K.;Saunders,K.O.;Wagh,K.;Anasti,K.;Barr,M.;Parks,R.;Alam,S.M.;Korber,B.;Haynes,B.F.;Bartesaghi,A.;Acharya,P.",Structural basis for breadth development in a HIV-1 neutralizing antibody,19-APR-2023,8_8_20_9_3_10,8SAX_C_D,Xtal structure,HIV,6,1,2.4922655,3.1472332
6OAO_L_L,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDREDGESIYAQKFQGRVTLTEDTSTDSVYMELSNLRSDDTAVYFCATDFGGSYFYAFDIWGQGTMVTVSS,QSVLTQSPSASGTPGQRVTISCSGSSSNIGRNPVNWFQHLPGTAPQLLIYSNDQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCEAWDDSLNGVVFGGGTKLTVL,6OAO_L,6OAO_L,Structure Of Dbp In Complex With Human Neutralizing Antibody 092096,Structure Of Dbp In Complex With Human Neutralizing Antibody 092096,Homo sapiens,"Urusova,D.;Carias,L.;Huang,Y.;Nicolete,V.C.;Popovici,J.;Roesch,C.;Salinas,N.D.;Dechavanne,S.;Witkowski,B.;Ferreira,M.U.;Adams,J.H.;Gross,M.L.;King,C.L.;Tolia,N.H.",Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP,18-MAR-2019,8_8_14_8_3_11,6OAO_L_L,Xtal structure,DBP; DABP,6,1,1.0157146,2.511847
3JUY_A_A,QVQLVQSGAEVKKPGASVKVSCQASGYRFSHFTVHWVRQAPGQRFEWMGWINPYNGNKEFSAKFQDRVTFTADTSANTAYMELRSLRSADTAVYYCARVGEWGWDDSPYDNYYMDVWGKGTTVIVSS,EIVLTQAPGTLSLSPGERATFSCRSSHSIRSRRVAWYQHKPGQAPRLVIHGVSNRASGISDRFSGSGSGTDFTLTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK,3JUY_A,3JUY_A,"Crystal Structure Of A 3B3 Variant, A Broadly Neutralizing Hiv-1 Scfv Antibody","Crystal Structure Of A 3B3 Variant, A Broadly Neutralizing Hiv-1 Scfv Antibody",Homo sapiens,"Clark,K.R.;Walsh,S.T.",Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody,15-SEP-2009,8_8_20_7_3_9,3JUY_A_A,Xtal structure,HIV,6,1,0.45988342,3.1824698
5ZIA_G_L,QVQLVQSGAEVKKPGASVKVSCTASGYTFTGYYLHWVRQAPGQGLEWMGWVNPRSGGTSYPPKFQGRVTMTRDTSINTAYMDLTWLTSDDTAVYYCAVGRIPDVTAFDIWGQGTPVTVSS,DIQMTQSPDSLAVSLGERATINCKSSESLLYDSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSETDFTLTISSLQAEDVAVYHCQQYFSTPWTFGQGTKLEIK,5ZIA_G,5ZIA_L,Crystal Structure Of Human Anti-Tau Antibody Cbtau-24.1 In Complex With Its Phosphorylated Tau Peptide,Crystal Structure Of Human Anti-Tau Antibody Cbtau-24.1 In Complex With Its Phosphorylated Tau Peptide,Homo sapiens,"Zhang,H.;Zhu,X.;Pascual,G.;Wadia,J.S.;Keogh,E.;Hoozemans,J.J.;Siregar,B.;Inganas,H.;Stoop,E.J.;Goudsmit,J.;Apetri,A.;Koudstaal,W.;Wilson,I.A.",Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody,14-MAR-2018,8_8_13_12_3_9,QDB31528_QDB31529,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,6,1,2.3749385,3.842599
7V5K_E_D,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSIYAISWVRQAPGQGLEWMGGIIPIFGTANYAQQFQGRVTITADESTTTAYMELSRLTSEDTAVYYCARQMTAYDYWNPSFDYWGQGTLVTVSS,DIVMTQTPSSLSASVGDRVTITCRASEDITSYLNWYQLKPGKAPMFLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGGGTKVEIK,7V5K_E,7V5K_D,Mers S Ectodomain Trimer In Complex With Neutralizing Antibody 0722 (State 1),Mers S Ectodomain Trimer In Complex With Neutralizing Antibody 0722 (State 1),Homo sapiens,"Wang,X.;Zhao,J.;Wang,Z.;Zeng,J.;Zhang,S.;Wang,Y.",MERS S ectodomain trimer in complex with neutralizing antibody 0722 (state 1),24-AUG-2022,8_8_16_6_3_9,7V5K_E_D,Xtal structure,MERS; Ectodomain,6,1,-0.6662569,5.708738
5VL3_H_L,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,5VL3_H,5VL3_L,Cd22 D1-D3 In Complex With Therapeutic Fab Epratuzumab,Cd22 D1-D3 In Complex With Therapeutic Fab Epratuzumab,Mus musculus,"Ereno-Orbea,J.;Sicard,T.;Cui,H.;Mazhab-Jafari,M.T.;Benlekbir,S.;Guarne,A.;Rubinstein,J.L.;Julien,J.P.",Molecular basis of human CD22 function and therapeutic targeting,24-APR-2017,8_8_9_12_3_8,5VL3_H_L,Xtal structure,CD22; SIGLEC-2; SIGLEC2,6,1,0.6678029,3.8743804
6B3M_C_D,QVQLVQSGAEVKKPGSSVKVSCRASGGIFRSNAISWVRQAPGQGLEWMGNIIAVFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPYYYGNSHLDFWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWFQQKPGQAPRLLIYGASNRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGTSPRTFGQGTKVEIK,6B3M_C,6B3M_D,The Crystal Structure Of A Broadly-Reactive Human Anti-Hemagglutinin Stalk Antibody (70-1F02) In Complex With H5 Hemagglutinin,The Crystal Structure Of A Broadly-Reactive Human Anti-Hemagglutinin Stalk Antibody (70-1F02) In Complex With H5 Hemagglutinin,Homo sapiens,"Nachbagauer,R.;Shore,D.;Yang,H.;Johnson,S.K.;Gabbard,J.D.;Tompkins,S.M.;Wrammert,J.;Wilson,P.C.;Stevens,J.;Ahmed,R.;Krammer,F.;Ellebedy,A.H.",Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge,13-JUN-2018,8_8_14_7_3_9,6B3M_C_D,Xtal structure,H5N1; H1N1; Influenza,6,1,-0.49736997,5.6940885
3FKU_U_U,QVQLVQSGAEVKKPGSSVKVSCTSSEVTFSSFAISWVRQAPGQGLEWLGGISPMFGTPNYAQKFQGRVTITADQSTRTAYMDLRSLRSEDTAVYYCARSPSYICSGGTCVFDHWGQGTLVTVSS,QPGLTQPPSVSKGLRQTATLTCTGNSNNVGNQGAAWLQQHQGHPPKLLSYRNNDRPSGISERFSASRSGNTASLTITGLQPEDEADYYCSTWDSSLSAVVFGGGTKLTVL,3FKU_U,3FKU_U,Crystal Structure Of Influenza Hemagglutinin (H5) In Complex With A Broadly Neutralizing Antibody F10,Crystal Structure Of Influenza Hemagglutinin (H5) In Complex With A Broadly Neutralizing Antibody F10,Homo sapiens,"Sui,J.;Hwang,W.C.;Perez,S.;Wei,G.;Aird,D.;Chen,L.M.;Santelli,E.;Stec,B.;Cadwell,G.;Ali,M.;Wan,H.;Murakami,A.;Yammanuru,A.;Han,T.;Cox,N.J.;Bankston,L.A.;Donis,R.O.;Liddington,R.C.;Marasco,W.A.",Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses,17-DEC-2008,8_8_17_8_3_11,3FKU_U_U,Xtal structure,F10; Influenza,6,1,-0.87575555,5.6731105
5WKO_K_L,QVQLVQSGAEVKKPGSSVQVSCRASGGTFGNYAINWVRQAPGQGLEWMGGISPIFGPPKYAQKFQGRVTISADISSSTAYMDLSSLSSDDTAVYYCARKLEPPYYFYSYMDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYVSTPLTFGGGTKVEIK,5WKO_K,5WKO_L,Crystal Structure Of Antibody 27F3 Recognizing The Ha From A/California/04/2009 (H1N1) Influenza Virus,Crystal Structure Of Antibody 27F3 Recognizing The Ha From A/California/04/2009 (H1N1) Influenza Virus,Influenza A virus (A/Uganda/MUWRP-176/2010(H1N1)),"Lang,S.;Xie,J.;Zhu,X.;Wu,N.C.;Lerner,R.A.;Wilson,I.A.",Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem,25-JUL-2017,8_8_16_7_3_9,5WKO_K_L,Xtal structure,H1N1; Influenza,6,1,-0.79220706,6.0482583
7WOA_D_B,QVQLVQSGAEVKRPGSSVKVSCKASGDTFINYAFSWVRQAPGQGLEWMGRIIPILDIAHYAQKFQGRLTITADKSTDTAYMELTSLKSDDTAVYFCARVFRGSQYWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSINNRHLAWYQQKRGQAPRFLIYGAASRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPTFGQGTKVEIK,7WOA_D,7WOA_B,Sars-Cov-2 Spike In Complex With Igg 553-60 (1-Up Trimer),Sars-Cov-2 Spike In Complex With Igg 553-60 (1-Up Trimer),Homo sapiens,"Zhan,W.;Tian,X.;Zhang,X.;Xing,S.;Song,W.;Liu,Q.;Hao,A.;Hu,Y.;Zhang,M.;Ying,T.;Chen,Z.;Lan,F.;Sun,L.",Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer,20-JUL-2022,8_8_13_7_3_9,7WOA_D_B,Xtal structure,SARS-CoV-2,6,1,-0.8376739,5.4490047
4HKB_C_D,QVQLVQSGAEVRKPGASVKVSCKASGYTFTDNYIHWVRQAPGQGLEWMGWIHPNSGATKYAQKFEGWVTMTRDTSISTVYMELSRSRSDDTAVYYCARAGLEPRSVDYYFYGLDVWGQGTAVTVSS,SALTQPPSVSVAPGQTATITCGGNNIGRKRVDWFQQKPGQAPVLVVYEDSDRPSGIPERFSDSNSGTTATLTISRVEAGDEADYYCQVWDSDSDHVVFGGGTKLTVL,4HKB_C,4HKB_D,Ch67 Fab (Unbound) From The Ch65-67 Lineage,Ch67 Fab (Unbound) From The Ch65-67 Lineage,Homo sapiens,"Schmidt,A.G.;Xu,H.;Khan,A.R.;O'Donnell,T.;Khurana,S.;King,L.R.;Manischewitz,J.;Golding,H.;Suphaphiphat,P.;Carfi,A.;Settembre,E.C.;Dormitzer,P.R.;Kepler,T.B.;Zhang,R.;Moody,M.A.;Haynes,B.F.;Liao,H.X.;Shaw,D.E.;Harrison,S.C.",Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody,15-OCT-2012,8_8_19_6_3_11,4HKB_C_D,Xtal structure,,6,1,2.1662195,3.557887
6N1V_g_i,QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWCQGTVVVVS,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,6N1V_g,6N1V_i,"Cryo-Em Structure At 4.0 A Resolution Of Vaccine-Elicited Antibody A12V163-A.01 In Complex With Hiv-1 Env Bg505 Ds-Sosip, And Antibodies Vrc03 And Pgt122","Cryo-Em Structure At 4.0 A Resolution Of Vaccine-Elicited Antibody A12V163-A.01 In Complex With Hiv-1 Env Bg505 Ds-Sosip, And Antibodies Vrc03 And Pgt122",Homo sapiens,"Kong,R.;Duan,H.;Sheng,Z.;Xu,K.;Acharya,P.;Chen,X.;Cheng,C.;Dingens,A.S.;Gorman,J.;Sastry,M.;Shen,C.H.;Zhang,B.;Zhou,T.;Chuang,G.Y.;Chao,C.W.;Gu,Y.;Jafari,A.J.;Louder,M.K.;O'Dell,S.;Rowshan,A.P.;Viox,E.G.;Wang,Y.;Choi,C.W.;Corcoran,M.M.;Corrigan,A.R.;Dandey,V.P.;Eng,E.T.;Geng,H.;Foulds,K.E.;Guo,Y.;Kwon,Y.D.;Lin,B.;Liu,K.;Mason,R.D.;Nason,M.C.;Ohr,T.Y.;Ou,L.;Rawi,R.;Sarfo,E.K.;Schon,A.;Todd,J.P.;Wang,S.;Wei,H.;Wu,W.;Mullikin,J.C.;Bailer,R.T.;Doria-Rose,N.A.;Karlsson Hedestam,G.B.;Scorpio,D.G.;Overbaugh,J.;Bloom,J.D.;Carragher,B.;Potter,C.S.;Shapiro,L.;Kwong,P.D.;Mascola,J.R.",Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization,12-NOV-2018,8_8_16_5_3_5,6N1V_g_i,Xtal structure,HIV,6,1,2.7857542,4.2227607
URX39989_URX40028,QVQPVQSGAQVQKSGASLTVSCKTSEEDDFMDYYIHWMRQAPGQGLEWMGYINPRGGGVNYSGRLQGRITMTRDTSMNIAYLVLGRLKSDDTAVYYCARQTLVTASTSFAFNNWGQGTLVVVSS,QSALTQPRSVSGSPGQSVTISCTKTGYVCWYQQRPGRAPRLVIYDVTKRPSGVPDRFSGSTSGNTASLTISGLQAEDEADYFCSSYEYFDGVTKLTVL,URX39989,URX40028,"anti-HIV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-HIV immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Barnes,C.O.; Schoofs,T.; Gnanapragasam,P.N.P.; Golijanin,J.; Huey-Tubman,K.E.; Gruell,H.; Schommers,P.; Suh-Toma,N.; Lee,Y.E.; Cetrulo Lorenzi,J.C.; Piechocka-Trocha,A.; Scheid,J.F.; West,A.P. Jr.; Walker,B.D.; Seaman,M.S.; Klein,F.; Nussenzweig,M.C.; Bjorkman,P.J.",A naturally arising broad and potent CD4-binding site antibody with low somatic mutation,15-AUG-2022,9_8_16_2_3_5,URX39989_URX40028,Unique source,HIV; CD4,6,1,2.230702,3.8592758
ACZ97422_ACZ97421,QVQVVQSGAEVRKPGASVKVSCKVSGFTLTGLSIHWVRQAPGKGLEWMGGFGPEENEIIYAQKFQGRVSMTEDTSTNTAYMELSSLRSEDTAVYYCATGGNYYNLWTGYYPLAYWGQGTLVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGKNYVSWYQQLPGAAPKLLIFDDTQRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCGTWDSSLSTGQLFGGGTKLTVL,ACZ97422,ACZ97421,anti-HIV-1 gp120 immunoglobulin heavy chain [Homo sapiens],anti-HIV-1 gp120 immunoglobulin lambda light chain [Homo sapiens],Homo sapiens,"West,A.P. Jr.; Galimidi,R.P.; Foglesong,C.P.; Gnanapragasam,P.N.; Klein,J.S.; Bjorkman,P.J.","Evaluation of CD4-CD4i Antibody Architectures Yields Potent, Broadly Cross-Reactive Anti-Human Immunodeficiency Virus Reagents",16-DEC-2009,8_8_18_8_3_12,ACZ97422_ACZ97421,Unique chain,gp120; HIV; CD4,6,1,1.0392287,2.4813268
7LU9_l_k,QVTLMESGPALVKVTQTLAVTCTFSGFSIRDSGKGVAWIRQPPGGALEWLTSIYWDDTKYHDTSLKPRLTIFRDTSQTQVILILTNMAPLDTATYYCGRINNGGGWKDHIDFWGPGLLVTVSS,ALTQPPSVSKSLEQSVTISCTGTTTGNSVSWYQCHSGTAPRLLIYDVNKRPSGVSDRFSGSKSHNTASLTIFGLQAEDEADYYCGSYGSGGSLLFGGGTRLTVL,7LU9_l,7LU9_k,Cryo-Em Structure Of Dh851.3 Bound To Hiv-1 Ch505 Env,Cryo-Em Structure Of Dh851.3 Bound To Hiv-1 Ch505 Env,Human immunodeficiency virus 1,"Acharya,P.;Williams,W.;Henderson,R.;Janowska,K.;Manne,K.;Parks,R.;Deyton,M.;Sprenz,J.;Stalls,V.;Kopp,M.;Mansouri,K.;Edwards,R.J.;Meyerhoff,R.R.;Oguin,T.;Sempowski,G.;Saunders,K.;Haynes,B.F.",Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques,21-FEB-2021,10_7_15_5_3_10,7LU9_l_k,Xtal structure,HIV,6,1,12.489018,0.466152
AUD54153_AUD54377,SCAASGFTFSSFGMSWVRQTPDKRLEWVATISNGGGYTFYPDNVNGRFSISRDNTRNTLYLQMSSLKSEDSAMYYCLRRERNGGNGFAYWGQGTLVTVSA,VTMSCTSSQSLFNSGKQKNYLTWYQQKPGQPPKLLISWASTGESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSLPLTFGGGTKLELK,AUD54153,AUD54377,"immunoglobulin heavy chain variable region, partial [Mus musculus]","immunoglobulin kappa chain variable region, partial [Mus musculus]",Mus musculus,"Silver,J.N.; Zuo,T.; Chaudhary,N.; Tong,P.; Kumari,R.; Giguere,S.; Granato,A.; Donthula,R.; Wesemann,D.R.",Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation,12-DEC-2017,8_8_13_12_3_9,AUD54153_AUD54377,Unique source,CML; D22S662; PHL; BCR1; BCR; ALL; D22S11,6,1,17.704346,8.375417
8DF1_M_N,SVEESGGDLVKPGASLTLTCTASGFTISSDYYMCWVRQAPGKGLEWIGCIYIGSGTDTYYASWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARDKGWSNAWGFYFQLWGPGTLVTVSS,DPVLTQTPASVEVPVGGTVTINCQASQSIGKYLNWYQQKPGQPPKLLIYSSSSLASGVSSRFKGSGFGTQFTLTISGVQCADAATYYCQQGYSYVDLENGFGGGTELEIL,8DF1_M,8DF1_N,Chi3L1 Bound By Antibody C59,Chi3L1 Bound By Antibody C59,Oryctolagus cuniculus,"Li,L.;Wen,Y.;Wrapp,D.;Jeong,J.;Zhao,P.;Xiong,W.;Atkins,C.L.;Shan,Z.;Hui,D.;McLellan,J.S.;Zhang,N.;Ju,C.;An,Z.",A novel humanized Chi3l1 blocking antibody attenuates acetaminophen-induced liver injury in mice,01-MAR-2023,9_9_16_6_3_12,8DF1_M_N,Xtal structure,,6,1,-0.4292155,18.433176
7T4R_J_I,EEQVLESGGGLVKPGGSLRLSCAASGFTFSPYSVFWVRQAPGKGLEWVSSINSDSTYKYYADSVKGRFTISRDNAENSIFLQMNSLRAEDTAVYYCARDRSYYAFSSGSLSDYYYGLDVWGQGTLVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSQSLLHTNGYNYLDWYVQKPGQSPQLLIYLASNRASGVPDRFSGSGSGTDFTLKISRVETEDVGVYYCMQALQIPRTFGQGTKVEIK,7T4R_J,7T4R_I,Cryoem Structure Of The Hcmv Pentamer Gh/Gl/Ul128/Ul130/Ul131A In Complex With Thbd And Neutralizing Fabs Msl-109 And 13H11,Cryoem Structure Of The Hcmv Pentamer Gh/Gl/Ul128/Ul130/Ul131A In Complex With Thbd And Neutralizing Fabs Msl-109 And 13H11,Homo sapiens,"Kschonsak,M.;Johnson,M.C.;Schelling,R.;Green,E.M.;Rouge,L.;Ho,H.;Patel,N.;Kilic,C.;Kraft,E.;Arthur,C.P.;Rohou,A.L.;Comps-Agrar,L.;Martinez-Martin,N.;Perez,L.;Payandeh,J.;Ciferri,C.",Structural basis for HCMV Pentamer receptor recognition and antibody neutralization,10-DEC-2021,8_8_23_11_3_9,7T4R_J_I,Xtal structure,HCMV,7,1,16.256166,10.1668005
QEP20372_QEP21020,EVHLAESGGGFVQPGGSLRLSCTASGFSFGVYEMNWFRQAPGKGLEWVAYTSSGGDITYYADSVKGRFTISRDNARSSLYLQMSSLRGEDTAVYFCARGRYCSDGTCFGDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRANETVINTYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTVSRLEPEDFAVYYCQQYGSSPGTFGQGTRLDIK,QEP20372,QEP21020,"IGH + IGL c479_heavy_IGHV3-48_IGHD2-15_IGHJ4, partial [Homo sapiens]","IGH + IGL c479_light_IGKV3-20_IGKJ5, partial [Homo sapiens]",Homo sapiens,"Scheepers,C.; Morris,L.",Paired Heavy and Light Chain Sequences from Donor CT15,17-SEP-2019,8_8_15_7_3_9,QEP20372_QEP21020,Ordered entries,FTNB; CT15; PH-30b; PH30; ADAM2,7,1,15.722145,9.9492445
1V7N_K_O,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKVNNHAIHYAESVKGRFTVSRDDSKSSVYLQMNSLRAEDTGIYYCSGWSFLYWGQGTLVTVSA,QVVLTQSPGIMSASPGEKVTITCSASSSVSYMYWFQQKPGTSPKLWIYSTSNLASGVPARFRGSGSGTSYSLTISRMEAEDAATYYCQQRSGYPRTFGGGTKLEIK,1V7N_K,1V7N_O,Human Thrombopoietin Functional Domain Complexed To Neutralizing Antibody Tn1 Fab,Human Thrombopoietin Functional Domain Complexed To Neutralizing Antibody Tn1 Fab,Homo sapiens,"Kuroki,R.;Hirose,M.;Kato,Y.;Feese,M.D.;Tamada,T.;Shigematsu,H.;Watarai,H.;Maeda,Y.;Tahara,T.;Kato,T.;Miyazaki,H.",Crystallization of the functional domain of human thrombopoietin using an antigen-binding fragment derived from neutralizing monoclonal antibody,18-DEC-2003,8_10_7_5_3_9,1V7N_K_O,Xtal structure,,7,1,13.399215,6.9531937
6NJN_I_I,EVKLLESGGGLVQPGGSLKLSCAASGFDFSEYWMSWVRQAPGKGLEWIGEINPDSSSIDYTPSLKDKIIISRDNAKKTLYLQLSKVRSEDTALYYCARPRGNYVVMDYWGQGTSVTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGSSFVHWYQQKPGQPPKLLIFLASKLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQTNEDPYTFGGGTKLEIK,6NJN_I,6NJN_I,Structure Of A Complex,Structure Of A Complex,Mus musculus,"Zhao,Y.;Chen,S.;Swensen,A.C.;Qian,W.J.;Gouaux,E.",Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM,03-JAN-2019,8_8_12_10_3_9,6NJN_I_I,Xtal structure,,7,1,19.596226,9.715687
3OKE_B_A,EVKLVESGGGLVQPGGSLRLACATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQSSLYLQMNTLRAEDSATYYCARDHDGYYERFAYWGQGTLVTVS,DIVMTQSPSSLAVSAGEKVTMNCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFALTISSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,3OKE_B,3OKE_A,Crystal Structure Of S25-39 In Complex With Ko,Crystal Structure Of S25-39 In Complex With Ko,Mus musculus,"Blackler,R.J.;Muller-Loennies,S.;Brooks,C.L.;Evans,D.W.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",A common NH53K mutation in the combining site of antibodies raised against chlamydial LPS glycoconjugates significantly increases avidity,24-AUG-2010,8_10_13_12_3_8,3OKE_B_A,Xtal structure,VWS; IRF6; OFC6; VWS1; S25; LPS; RPS25,7,1,26.081064,4.7021675
6YMQ_A_A,EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYYMGWVRQAPGKGLEWVSGISPSSGYTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYYYGYYYSHMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRSGLHTFGQGTKLEIK,6YMQ_A,6YMQ_A,Trem2 Extracellular Domain (19-131) In Complex With Single-Chain Variable 4 (Scfv-4),Trem2 Extracellular Domain (19-131) In Complex With Single-Chain Variable 4 (Scfv-4),Homo sapiens,"Szykowska,A.;Chen,Y.;Smith,T.B.;Preger,C.;Yang,J.;Qian,D.;Mukhopadhyay,S.;Wigren,E.;Neame,S.J.;Graslund,S.;Persson,H.;Atkinson,P.J.;Di Daniel,E.;Mead,E.;Wang,J.;Davis,J.B.;Burgess-Brown,N.A.;Bullock,A.N.",Selection and structural characterisation of anti-TREM2 scFvs that reduce levels of shed ectodomain,09-APR-2020,8_8_14_6_3_9,6YMQ_A_A,Xtal structure,Trem2b; TREM-2; Trem2c; TREM2; Trem2a,7,1,13.833962,9.398599
7EH5_H_L,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTIYWVKQSLGKSLEWIGGNNPNNDDTTYKQFFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARDGYPYYYALDFWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKSSQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDHFTGSGSGTDFTLTISNVQSADLAEYFCQQYNNYPWTFGGGTKLEIK,7EH5_H,7EH5_L,"Cryo-Em Structure Of Sars-Cov-2 S-D614G Variant In Complex With Neutralizing Antibodies, Rbd-Chab15 And Rbd-Chab45","Cryo-Em Structure Of Sars-Cov-2 S-D614G Variant In Complex With Neutralizing Antibodies, Rbd-Chab15 And Rbd-Chab45",Homo sapiens,"Yang,T.J.;Yu,P.Y.;Chang,Y.C.;Liang,K.H.;Tso,H.C.;Ho,M.R.;Chen,W.Y.;Lin,H.T.;Wu,H.C.;Hsu,S.D.",Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function,28-MAR-2021,8_8_13_6_3_9,7EH5_H_L,Xtal structure,SARS-CoV-2,7,1,2.4736323,-4.3559484
7CZS_I_M,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYPGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARETLAFDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK,7CZS_I,7CZS_M,S Protein Of Sars-Cov-2 In Complex Bound With P5A-1B8_3B,S Protein Of Sars-Cov-2 In Complex Bound With P5A-1B8_3B,Homo sapiens,"Yan,R.;Wang,R.;Ju,B.;Yu,J.;Zhang,Y.;Liu,N.;Wang,J.;Zhang,Q.;Chen,P.;Zhou,B.;Li,Y.;Shen,Y.;Zhang,S.;Tian,L.;Guo,Y.;Xia,L.;Zhong,X.;Cheng,L.;Ge,X.;Zhao,J.;Wang,H.W.;Wang,X.;Zhang,Z.;Zhang,L.;Zhou,Q.",Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies,09-SEP-2020,8_7_9_6_3_9,7CZS_I_M,Xtal structure,SARS-CoV-2,7,1,12.577349,10.2886505
7K8S_H_L,EVQLVESGGGVVQPGRSLRLSCAASGFTFSIYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEGRPSDIVVVVAFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,7K8S_H,7K8S_L,"Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C002 (State 1)","Structure Of The Sars-Cov-2 S 2P Trimer In Complex With The Human Neutralizing Antibody Fab Fragment, C002 (State 1)",Homo sapiens,"Barnes,C.O.;Jette,C.A.;Abernathy,M.E.;Dam,K.A.;Esswein,S.R.;Gristick,H.B.;Malyutin,A.G.;Sharaf,N.G.;Huey-Tubman,K.E.;Lee,Y.E.;Robbiani,D.F.;Nussenzweig,M.C.;West AP,Jr.;Bjorkman,P.J.",SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies,27-SEP-2020,8_8_17_6_3_9,7K8S_H_L,Xtal structure,SARS-CoV-2,7,1,15.044094,13.692692
6IW2_K_L,EVQLVESGPRLVKPSETLSLTCTVSGGSTYNHHWSWIRQPPGRGLEWIGYISYSGKSNYNPSLKSRVTISLEPSTTQFSLKLNSLTAADTAVYYCAREYRDDTNYYYYSLDVWGPGTMVT,QIVMTQSPSTLSASVGDRVTITCRASQSIGSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYNNYSYTFGPGTKLEIK,6IW2_K,6IW2_L,Crystal Structure Of 5A Scfv In Complex With Yfv-17D Se In Prefusion State,Crystal Structure Of 5A Scfv In Complex With Yfv-17D Se In Prefusion State,Homo sapiens,"Lu,X.;Xiao,H.;Li,S.;Pang,X.;Song,J.;Liu,S.;Cheng,H.;Li,Y.;Wang,X.;Huang,C.;Guo,T.;Ter Meulen,J.;Daffis,S.;Yan,J.;Dai,L.;Rao,Z.;Klenk,H.D.;Qi,J.;Shi,Y.;Gao,G.F.",Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope,04-DEC-2018,8_7_17_6_3_9,6IW2_K_L,Xtal structure,,7,1,15.966776,-7.9505873
4HIJ_B_A,INLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVVSSDGRTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCAKEGGDNKFSFDYWGQGTLVTVSS,QLTQSPATLSLSPGERATLSCRASQSVTNYLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRDNWPPDATFGQGTKVEIK,4HIJ_B,4HIJ_A,Anti-Streptococcus Pneumoniae 23F Fab 023.102 With Bound L-Rhamnose-(1-2)-Alpha-D-Galactose-(3-O)-Phosphate-2-Glycerol,Anti-Streptococcus Pneumoniae 23F Fab 023.102 With Bound L-Rhamnose-(1-2)-Alpha-D-Galactose-(3-O)-Phosphate-2-Glycerol,Homo sapiens,"Bryson,S.;Thomson,C.A.;Risnes,L.F.;Dasgupta,S.;Smith,K.;Schrader,J.W.;Pai,E.F.",Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop Variation,11-OCT-2012,8_8_13_6_3_11,4HIJ_B_A,Xtal structure,,7,1,15.002359,13.550764
6UG8_H_L,QVQLKESGPGLVAPSQSLSITCTVSGFSLNSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHSALMSRLRISKDNSKRQVFLKLNSLQTDDTATYYCTKPGSGYAFAYWGQGTLVTVSS,ENVLTQSPAIMSASPGEKVTMTCSASSSVNYMHWYQQKSSTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTIRTMEAEDVATYFCFQASGYPLTFGGGTKLELK,6UG8_H,6UG8_L,Complex Of Ch28/11 Fab And Ssea-4 (Monoclinic Form),Complex Of Ch28/11 Fab And Ssea-4 (Monoclinic Form),Mus musculus,"Soliman,C.;Chua,J.X.;Vankemmelbeke,M.;McIntosh,R.S.;Guy,A.J.;Spendlove,I.;Durrant,L.G.;Ramsland,P.A.",The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody,26-SEP-2019,8_7_11_5_3_9,6UG8_H_L,Xtal structure,,7,1,22.147932,-6.0628858
QBC73905_QBC74338,QVQLLESGPGVVKPSETLSLTCDVSGGTISSGYYYWSWIRQPRGKGLEWIGGIYSNSESTNYNPSLKSRVTISKDTSKNQFSLKLTSVTATDTAVYYCARERVVAHNYYGLDSWGQGVVVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNNLSWYQQKPGKAPKRLIYHASSLDAGVPSRFSGSGSGTDYTLTISSLQPEEIATYYCQQYENFPLTFGGGTKVEIK,QBC73905,QBC74338,"anti-HIV-1 immunoglobulin 0PV-a.s148.wk10 heavy chain variable region, partial [Macaca mulatta]","anti-HIV-1 immunoglobulin 0PV-a.s148.wk10 light chain variable region, partial [Macaca mulatta]",Macaca mulatta,"Kong,R.; Duan,H.; Sheng,Z.; Xu,K.; Acharya,P.; Chen,X.; Cheng,C.; Chuang,G.-Y.; Dingens,A.S.; Gorman,J.; Shen,C.-H.; Zhang,B.; Jafari,A.J.; Louder,M.K.; ODell,S.; Rowshan,A.P.; Viox,E.G.; Zhou,T.; Chao,C.W.; Choi,C.W.; Corcoran,M.; Corrigan,A.R.; Dandey,V.P.; Eng,E.T.; Geng,H.; Foulds,K.E.; Gu,Y.; Guo,Y.; Kwon,Y.D.; Lin,B.; Liu,K.; Mason,R.D.; Nason,M.C.; Ohr,T.Y.; Ou,L.; Rawi,R.; Sarfo,E.K.; Schon,A.; Todd,J.P.; Wang,S.; Wang,Y.; Wei,H.; Wu,W.; Comparative Sequencing Program,N.; Mullikin,J.C.; Bailer,R.T.; Doria-Rose,N.A.; Karlsson Hedestam,G.B.; Scorpio,D.G.; Overbaugh,J.; Bloom,J.D.; Carragher,B.; Potter,C.S.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.",Vaccine-Induced Developmental Pathways in Rhesus Macaques for Neutralizing Antibodies Targeting the HIV-1 Fusion Peptide,19-JUL-2019,10_8_15_6_3_9,QBC73905_QBC74338,Unique word,HIV,7,1,16.180204,-7.4751763
6CH9_Q_R,QVQLRESGPGLVKPSETLSLSCTVSQDSRPSDHSWTWVRQSPGKALEWIGDIHYNGATTYNPSLRSRVRIELDQSIPRFSLKMTSMTAADTGMYYCARNAIRIYGVVALGEWFHYGMDVWGQGTAVTVSS,SSELTQPPSVSVSPGQTARITCSGAPLTSRFTYWYRQKPGQAPVLIISRSSQRSSGWSGRFSASWSGTTVTLTIRGVQADDEADYYCQSSDTSDSYKMFGGGTKLTVL,6CH9_Q,6CH9_R,Crystal Structure Of A Natively-Glycosylated B41 Sosip.664 Hiv-1 Envelope Trimer In Complex With The Broadly-Neutralizing Antibodies Bg18 And 35O22,Crystal Structure Of A Natively-Glycosylated B41 Sosip.664 Hiv-1 Envelope Trimer In Complex With The Broadly-Neutralizing Antibodies Bg18 And 35O22,Homo sapiens,"Barnes,C.O.;Gristick,H.B.;Freund,N.T.;Escolano,A.;Lyubimov,A.Y.;Hartweger,H.;West AP,Jr.;Cohen,A.E.;Nussenzweig,M.C.;Bjorkman,P.J.",Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope,22-FEB-2018,9_7_23_6_3_11,UOJ74413_UOJ74409,Xtal structure,HIV,7,1,15.446288,-7.6526012
8DZ3_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFSFSTYGMHWVRQAPGKGLEWVALIWHDGSKKFYSESVRGRFTISRDNSMDTLYLQMSSLRAEDTAVYYCARDGADYFDSTGGAFDIWGQGTMVIVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFATYYCQQYKTWWTFGQGTKVEIK,8DZ3_H,8DZ3_L,Cryo-Em Structure Of 337 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Cryo-Em Structure Of 337 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Homo sapiens,"Martin,G.M.;Ward,A.B.",Spectrum of PfCSP-antibody cryo-EM structures and the role of homotypic interactions,02-AUG-2023,8_8_17_6_3_8,8DZ3_H_L,Xtal structure,PfCSP,7,1,14.746789,13.603538
7YCN_K_L,QVQLVEWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGLINHSGSTNYNPSLKSRVTISLDTSKNQFSLKLTSVTAADTAVYYCARGLGIFGVVTLSDVWGQGTTVTVSS,NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLRTEDEADYYCQSYDSGIWVFGGGTKLTVL,7YCN_K,7YCN_L,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Iy-2A Fab,Crystal Structure Of Sars-Cov-2 Spike Rbd In Complex With Iy-2A Fab,Homo sapiens,"Huang,K.A.;Chen,X.;Mohapatra,A.;Nguyen,H.T.V.;Schimanski,L.;Tan,T.K.;Rijal,P.;Vester,S.K.;Hills,R.A.;Howarth,M.;Keeffe,J.R.;Cohen,A.A.;Kakutani,L.M.;Wu,Y.M.;Shahed-Al-Mahmud,M.;Chou,Y.C.;Bjorkman,P.J.;Townsend,A.R.;Ma,C.",Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2,01-FEB-2023,8_7_15_8_3_9,7YCN_K_L,Xtal structure,SARS-CoV-2,7,1,16.60268,-10.426695
7WE9_H_J,QVQLVQSGAEVKKPGASLKVSCRASGYTFTSHFIHWVRQAPGQGLEWMGIINPSGGASYAQNFRDRVTMTTDPSTSTVYMELGSLRSEDTAVYYCARAEGSSWLGWFDPWGQGTLVTVSS,SVLTQPPSASGTPGQRVTIPCSGSSSNIGNNYVYWYQQLPGTAPKLLVYGNNQRPSGVPDRFSVSKSGTSASLAISGLRSEDEADYYCAAWDDGLSGSGWVFGGGTKLTVL,7WE9_H,7WE9_J,Sars-Cov-2 Omicron Variant Spike Protein In Complex With Fab Xgv289,Sars-Cov-2 Omicron Variant Spike Protein In Complex With Fab Xgv289,Homo sapiens,"Wang,K.;Jia,Z.;Bao,L.;Wang,L.;Cao,L.;Chi,H.;Hu,Y.;Li,Q.;Zhou,Y.;Jiang,Y.;Zhu,Q.;Deng,Y.;Liu,P.;Wang,N.;Wang,L.;Liu,M.;Li,Y.;Zhu,B.;Fan,K.;Fu,W.;Yang,P.;Pei,X.;Cui,Z.;Qin,L.;Ge,P.;Wu,J.;Liu,S.;Chen,Y.;Huang,W.;Wang,Q.;Qin,C.F.;Wang,Y.;Qin,C.;Wang,X.",Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants,23-DEC-2021,8_7_14_8_3_13,7WE9_H_J,Xtal structure,SARS-CoV-2,7,1,1.6442412,3.8671846
7T4R_P_Q,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWMGIIHPSSGGTSYAQKFQGRVTMTRDTSTSTVSMDLSSLRSEDTAVYYCGRAFRILGLSDVFVNDWGQGTVVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRFSGSGSGTAFTLTILSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK,7T4R_P,7T4R_Q,Cryoem Structure Of The Hcmv Pentamer Gh/Gl/Ul128/Ul130/Ul131A In Complex With Thbd And Neutralizing Fabs Msl-109 And 13H11,Cryoem Structure Of The Hcmv Pentamer Gh/Gl/Ul128/Ul130/Ul131A In Complex With Thbd And Neutralizing Fabs Msl-109 And 13H11,Homo sapiens,"Kschonsak,M.;Johnson,M.C.;Schelling,R.;Green,E.M.;Rouge,L.;Ho,H.;Patel,N.;Kilic,C.;Kraft,E.;Arthur,C.P.;Rohou,A.L.;Comps-Agrar,L.;Martinez-Martin,N.;Perez,L.;Payandeh,J.;Ciferri,C.",Structural basis for HCMV Pentamer receptor recognition and antibody neutralization,10-DEC-2021,8_8_16_6_3_9,7T4R_P_Q,Xtal structure,HCMV,7,1,1.5424601,3.7956862
4UBD_S_T,QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS,EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK,4UBD_S,4UBD_T,Crystal Structure Of A Neutralizing Human Monoclonal Antibody With 1968 H3 Ha,Crystal Structure Of A Neutralizing Human Monoclonal Antibody With 1968 H3 Ha,Homo sapiens,"Wu,Y.;Cho,M.;Shore,D.;Song,M.;Choi,J.;Jiang,T.;Deng,Y.Q.;Bourgeois,M.;Almli,L.;Yang,H.;Chen,L.M.;Shi,Y.;Qi,J.;Li,A.;Yi,K.S.;Chang,M.;Bae,J.S.;Lee,H.;Shin,J.;Stevens,J.;Hong,S.;Qin,C.F.;Gao,G.F.;Chang,S.J.;Donis,R.O.",A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus,12-AUG-2014,8_8_19_7_3_9,4UBD_S_T,Xtal structure,haemagglutinin,7,1,1.885895,5.346409
6MED_G_I,QVQLVQSGAEVKKPGSSVKVSCKASGGTLNSYEITWVRQAPGQGLEWMGGITPIFETTYAQKFQGRVTITADESTSTTYMELSSLRPEDTAVYYCARDGVRYCGGGRCYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQNINNYLNWYQQKPGKAPKVLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHSTVRTFGQGTKVEIK,6MED_G,6MED_I,Broadly Neutralizing Antibodies Against Hcv Use A Cdrh3 Disulfide Motif To Recognize An E2 Glycoprotein Site That Can Be Targeted For Vaccine Design,Broadly Neutralizing Antibodies Against Hcv Use A Cdrh3 Disulfide Motif To Recognize An E2 Glycoprotein Site That Can Be Targeted For Vaccine Design,Homo sapiens,"Flyak,A.I.;Ruiz,S.;Colbert,M.D.;Luong,T.;Crowe JE,Jr.;Bailey,J.R.;Bjorkman,P.J.",HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design,06-SEP-2018,8_7_19_6_3_9,6MED_G_I,Xtal structure,HCV,7,1,-0.938819,5.706088
AQV03759_AQV03772,QVQLVQSGAQMKNPGASVKVSCAPSGYTFTDFYIHWLRQAPGQGLQWMGWMNPQTGRTNTARNFQGRVTMTRDTSIGTAYMELRSLTSDDTAIYYCTTGGWISLYYDSSYYPNFDHWGQGTLLTVSS,QSALTQPASVSGSPGQSITISCTGTKYDVGSHDLVSWYQQYPGKVPKYMIYEVNKRPSGVSNRFSGSKSGNTASLTISGLRAEDEADYYCCSFGGSATVVCGGGTKVTVL,AQV03759,AQV03772,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin lambda chain variable region, partial [Homo sapiens]",Homo sapiens,"Bonsignori,M.; Kreider,E.F.; Fera,D.; Meyerhoff,R.R.; Bradley,T.; Wiehe,K.; Alam,S.M.; Aussedat,B.; Walkowicz,W.E.; Hwang,K.K.; Saunders,K.O.; Zhang,R.; Gladden,M.A.; Monroe,A.; Kumar,A.; Xia,S.M.; Cooper,M.; Louder,M.K.; McKee,K.; Bailer,R.T.; Pier,B.W.; Jette,C.A.; Kelsoe,G.; Williams,W.B.; Morris,L.; Kappes,J.; Wagh,K.; Kamanga,G.; Cohen,M.S.; Hraber,P.T.; Montefiori,D.C.; Trama,A.; Liao,H.X.; Kepler,T.B.; Moody,M.A.; Gao,F.; Danishefsky,S.J.; Mascola,J.R.; Shaw,G.M.; Hahn,B.H.; Harrison,S.C.; Korber,B.T.; Haynes,B.F.",Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies,24-MAR-2017,8_8_20_9_3_10,AQV03759_AQV03772,Unique source,HIV,7,1,2.9299567,2.6681867
ANY91553_ANY91074,QVQLVQSGPEVKKPGASVKVSCKASGYSFSRYGISWVRQAPGQGLEWLGWISGYTGNTNYAQKFQGRVTMTTDTSTSTASMELRSLRSDDTAVYYCARDKKQGEVVLPAASFRWFAPWGQGTLVTVSS,DIQMTQSPVSLSASVGDRVTITCRASQSIGKFLNWYQQKPGRAPKLLIYYASNLETGGPSRFSGRGSETEFSLTISSLQPEDFATYYCQQSNNVPHTFGQGTKLEIK,ANY91553,ANY91074,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_21_6_3_9,ANY91553_ANY91074,Unique source,Influenza,7,1,1.9050341,5.3293867
AMK70317_AMK70318,QVQLVQSGVTLVQPGGSLRVSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGLGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDHRVWAAGYHFDYWGQGALVTVSS,DIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGEAPKLLISDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSSPTFGGGTKVEIK,AMK70317,AMK70318,"immunoglobulin heavy chain V region, partial [Homo sapiens]","immunoglobulin heavy chain V region, partial [Homo sapiens]",Homo sapiens,"Walker,L.M.",Rapid and large-scale isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak,27-FEB-2016,8_8_15_6_3_8,AMK70317_AMK70318,Unique source,Ebola,7,1,14.290366,10.136383
8HEB_E_D,SVEESGGRLVTPGTPLTLTCTVSGFSLSRYAMSWVRQAPGKGLEWIGIIVDSGHTAYASWAKGRFTISRTSTTVDLKMTSLTTEDTATYFCARETGGGAFYVFEFWGPGTVVTVSS,QVLTQTPSSVSAAVGGTVTINCQASEDIYDNLVWYQQKPGQPPKLLIYDASTLAFGVSSRFRGSGSGTHFTLTMRDVQCDDAATYYCQGEFSCSSGDCTAFGGGTEVVVK,8HEB_E,8HEB_D,Sars-Cov-2 Spike Trimer In Complex With Rmab 9H1 Fab In The Class 1 Conformation,Sars-Cov-2 Spike Trimer In Complex With Rmab 9H1 Fab In The Class 1 Conformation,Oryctolagus cuniculus,"Chu,X.;Ding,X.;Yang,Y.;Lu,Y.;Li,T.;Gao,Y.;Zheng,L.;Xiao,H.;Yang,T.;Cheng,H.;Huang,H.;Liu,Y.;Lou,Y.;Wu,C.;Chen,Y.;Yang,H.;Ji,X.;Guo,H.",Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2,26-APR-2023,8_7_14_6_3_13,8HEB_E_D,Xtal structure,SARS-CoV-2,7,1,-0.14153267,19.138569
7TE9_M_N,DVKLQESGGGLVQPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVAYISNGGGGTYYPDTVKGRFTISRDNAKNTLYLQMNSLKEDTAMYYCARPSRGGSSYWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGGKVTITCKASQDINKYIAWYQHKPGKGPRLLIHYTSSLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLYTFGGGTKLEIK,7TE9_M,7TE9_N,Cryo-Em Structure Of Glun1B-2B Nmdar Complexed To Fab2 Class1,Cryo-Em Structure Of Glun1B-2B Nmdar Complexed To Fab2 Class1,Mus musculus,"Tajima,N.;Simorowski,N.;Yovanno,R.A.;Regan,M.C.;Michalski,K.;Gomez,R.;Lau,A.Y.;Furukawa,H.",Development and characterization of functional antibodies targeting NMDA receptors,04-JAN-2022,8_8_15_6_3_8,7TE9_M_N,Xtal structure,,8,1,17.874432,6.9532456
4YZF_G_H,EVKLQESGPGKLQPSQTLSLTCSFSGFSLTTSGIGVGWIRQPSGKGLEWLAHIWWSASKYYNTALKSRLTISKDTSNNQVFLKIASVDTADTATYYCARAYYGNYGGYYFDYWGQGTTLTVSS,DIVMTQSPASLAVSLGQRATISCRASQSVSTSSYSYMNWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPLEEEDTATYYCQHSWEIPWTFGGGTKVEIK,4YZF_G,4YZF_H,Crystal Structure Of The Anion Exchanger Domain Of Human Erythrocyte Band 3,Crystal Structure Of The Anion Exchanger Domain Of Human Erythrocyte Band 3,Mus musculus,"Arakawa,T.;Kobayashi-Yurugi,T.;Alguel,Y.;Iwanari,H.;Hatae,H.;Iwata,M.;Abe,Y.;Hino,T.;Ikeda-Suno,C.;Kuma,H.;Kang,D.;Murata,T.;Hamakubo,T.;Cameron,A.D.;Kobayashi,T.;Hamasaki,N.;Iwata,S.",Crystal structure of the anion exchanger domain of human erythrocyte band 3,25-MAR-2015,10_7_15_10_3_9,4YZF_G_H,Xtal structure,,8,1,11.489942,1.9384179
2AJU_H_L,EVKLSESGPGLVKPSQSLSLTCTVTGYSITTNYAWTWIRQFPGNKLEWMGYIRSSVITRYNPSLKSRISITQDTSKNQFFLQLNSVTTEDTATYYCARYDYYGNTGDYWGQGTSVTVSS,DIVITQDELSNPVTSGESVSISCRSSRSLLYKDGRTYLNWFLQRPGQSPQLLIYLMSTRASGVSDRFSGSGSGTDFTLEISRVKAEDVGVYYCQQFVEYPFTFGSGTKLEIK,2AJU_H,2AJU_L,Cyrstal Structure Of Cocaine Catalytic Antibody 7A1 Fab',Cyrstal Structure Of Cocaine Catalytic Antibody 7A1 Fab',Mus musculus,"Zhu,X.;Dickerson,T.J.;Rogers,C.J.;Kaufmann,G.F.;Mee,J.M.;McKenzie,K.M.;Janda,K.D.;Wilson,I.A.",Complete reaction cycle of a cocaine catalytic antibody at atomic resolution,02-AUG-2005,9_7_12_11_3_9,2AJU_H_L,Xtal structure,cocaine,8,1,11.50252,-12.898014
4RAU_B_A,EVKLVESGGGLVKPGGSLKLSCAASGFAFSRYDMSWVRQTPEKRLEWVATITSGDNYTYYPDSVKGRFTISRDNARNTLYLQMSRLRSEDTALYYCTRQGLLYYAMDYWGQGTSVNVSS,DIQMTQITSSLSASLGDRVTISCSASQGINNYLSWYRQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYFCQQFSKLPYTFGGGTKLEIK,4RAU_B,4RAU_A,Crystal Structure Of Rtofab In Complex With Human Pf4,Crystal Structure Of Rtofab In Complex With Human Pf4,Homo sapiens,"Cai,Z.;Zhu,Z.;Liu,Q.;Greene,M.I.",Crystal Structure Of Rtofab In Complex With Platele 4,11-SEP-2014,8_8_12_6_3_9,4RAU_B_A,Xtal structure,,8,1,17.993717,6.965355
7T0J_H_L,EVKLVESGGGLVQSGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKANGYTTEYSPSVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDHDGYYERFSYWGQGTLVTVSA,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTITSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,7T0J_H,7T0J_L,Crystal Structure Of S25-2 Fab Unliganded 3,Crystal Structure Of S25-2 Fab Unliganded 3,Mus musculus,"Blackler,R.J.;Muller-Loennies,S.;Pokorny-Lehrer,B.;Legg,M.S.G.;Brade,L.;Brade,H.;Kosma,P.;Evans,S.V.",Antigen binding by conformational selection in near-germline antibodies,29-NOV-2021,8_10_13_12_3_8,7T0J_H_L,Xtal structure,RPS25; S25,8,1,26.069168,4.6881776
3IKC_B_A,EVMLVESGGGLVQPGNSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKAKGYTTEYSASVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDISPSYGVYYEGFAYWGQGTLVTVS,DIVMTQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSNNLRTFGGGTKLEIK,3IKC_B,3IKC_A,Structure Of S67-27 In Complex With Kdo(2.8)-7-O-Methyl-Kdo,Structure Of S67-27 In Complex With Kdo(2.8)-7-O-Methyl-Kdo,Mus musculus,"Brooks,C.L.;Blackler,R.J.;Sixta,G.;Kosma,P.;Muller-Loennies,S.;Brade,L.;Hirama,T.;MacKenzie,C.R.;Brade,H.;Evans,S.V.",The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen,05-AUG-2009,8_10_17_12_3_8,3IKC_B_A,Xtal structure,,8,1,26.090754,4.7117033
4MA1_B_C,EVQLKESGPGLVQPSQSLSITCTVSGFSLTTYGVHWVRQSPGKGLEWLGVIWSGGSTDYNAAFISRLSISKDNSKSHVFFKMNSLQANDTAIYYCARMRITTDWFAYWGQGTLVTVS,DILMNQTPLSLPVSLGDQASISCRSSQYIVHRNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPYTFGGGTKLELK,4MA1_B,4MA1_C,Unliganded 3 Crystal Structure Of S25-26 Fab,Unliganded 3 Crystal Structure Of S25-26 Fab,Mus musculus,"Haji-Ghassemi,O.;Muller-Loennies,S.;Saldova,R.;Muniyappa,M.;Brade,L.;Rudd,P.M.;Harvey,D.J.;Kosma,P.;Brade,H.;Evans,S.V.",Groove-type recognition of chlamydiaceae-specific lipopolysaccharide antigen by a family of antibodies possessing an unusual variable heavy chain N-linked glycan,15-AUG-2013,8_7_12_11_3_9,4MA1_B_C,Xtal structure,RPS25; S25,8,1,22.612175,-5.587413
5T1L_B_A,EVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVS,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,5T1L_B,5T1L_A,Cetuximab Fab In Complex With Cqa(Ph)2Dlstrrlkc Peptide,Cetuximab Fab In Complex With Cqa(Ph)2Dlstrrlkc Peptide,synthetic construct,"Bzymek,K.P.;Avery,K.A.;Ma,Y.;Horne,D.A.;Williams,J.C.",Natural and non-natural amino-acid side-chain substitutions: affinity and diffraction studies of meditope-Fab complexes,19-AUG-2016,8_7_13_6_3_9,5T1L_B_A,Xtal structure,,8,1,22.586529,-5.61342
8AS0_B_C,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYNHPMFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDYGLPFTFGQGTKVEIK,8AS0_B,8AS0_C,Pd-1 Extracellular Domain In Complex With Fab Fragment From D12 Antibody,Pd-1 Extracellular Domain In Complex With Fab Fragment From D12 Antibody,Homo sapiens,"Peissert,F.;Pl&#xfc;ss,L.;Giudice,A.M.;Ongaro,T.;Villa,A.;Elsayed,A.;Nadal,L.;Dakhel Plaza,S.;Scietti,L.;Puca,E.;De Luca,R.;Forneris,F.;Neri,D.",Selection of a PD-1 blocking antibody from a novel fully human phage display library,23-NOV-2022,8_8_11_6_3_9,8AS0_B_C,Xtal structure,MDS032; PD1; p31; SLT1; D12; PDCD1; SLEB2; hSLE1; CD279; USE1; PD-1,8,1,14.058759,9.612818
4UIF_K_L,EVQLVESGAEVKKPGSSVKVSCKASGGTFNNYAISWVRQAPGQGLEWMGGIIPIFGGANYAQKFQGRVTITADRSTSTVYMELSGLRSEDTAVYYCARRPQSIFDWNFDLWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNVGSNYVYWYQQLPGTAPKLLIYRNNRRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDSLSGLVFGGGTKLTVL,4UIF_K,4UIF_L,Cryo-Em Structure Of Dengue Virus Serotype 2 In Complex With Antigen- Binding Fragments Of Human Antibody 2D22,Cryo-Em Structure Of Dengue Virus Serotype 2 In Complex With Antigen- Binding Fragments Of Human Antibody 2D22,Homo sapiens,"Fibriansah,G.;Ibarra,K.D.;Ng,T.S.;Smith,S.A.;Tan,J.L.;Lim,X.N.;Ooi,J.S.;Kostyuchenko,V.A.;Wang,J.;de Silva,A.M.;Harris,E.;Crowe JE,Jr.;Lok,S.M.",DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers,30-MAR-2015,8_8_14_8_3_11,4UIF_K_L,Xtal structure,Dengue; dengue,8,1,-0.8113533,5.607952
7MNO_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVASIYSYSGYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARSPWRWSGVSDGGFYYKALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSSLITFGQGTKVEIK,7MNO_H,7MNO_L,Crystal Structure Of The N-Terminal Domain Of Nup358/Ranbp2 (Residues 1-752) I656V Mutant In Complex With Fab Fragment,Crystal Structure Of The N-Terminal Domain Of Nup358/Ranbp2 (Residues 1-752) I656V Mutant In Complex With Fab Fragment,Homo sapiens,"Bley,C.J.;Nie,S.;Mobbs,G.W.;Petrovic,S.;Gres,A.T.;Liu,X.;Mukherjee,S.;Harvey,S.;Huber,F.M.;Lin,D.H.;Brown,B.;Tang,A.W.;Rundlet,E.J.;Correia,A.R.;Chen,S.;Regmi,S.G.;Stevens,T.A.;Jette,C.A.;Dasso,M.;Patke,A.;Palazzo,A.F.;Kossiakoff,A.A.;Hoelz,A.",Architecture of the cytoplasmic face of the nuclear pore,01-MAY-2021,8_8_22_6_3_9,7MNO_H_L,Xtal structure,,8,1,9.577503,10.891911
2QR0_R_Q,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVAYIYPSYSYTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYYGTGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYSYYYYPFTFGQGTKVEIK,2QR0_R,2QR0_Q,Structure Of Vegf Complexed To A Fab Containing Tyr And Ser In The Cdrs,Structure Of Vegf Complexed To A Fab Containing Tyr And Ser In The Cdrs,Homo sapiens,"Fellouse,F.A.;Esaki,K.;Birtalan,S.;Raptis,D.;Cancasci,V.J.;Koide,A.;Jhurani,P.;Vasser,M.;Wiesmann,C.;Kossiakoff,A.A.;Koide,S.;Sidhu,S.S.",High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries,27-JUL-2007,8_8_11_6_3_11,2QR0_R_Q,Xtal structure,,8,1,9.922368,10.683336
3PNW_B_A,EVQLVESGGGLVQPGGSLRLSCAASGFNLSSSYMHWVRQAPGKGLEWVASISSSYGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTVRGSKKPYFSGWAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHGPFYWLFTFGQGTKVEIK,3PNW_B,3PNW_A,Crystal Structure Of The Tudor Domain Of Human Tdrd3 In Complex With An Anti-Tdrd3 Fab,Crystal Structure Of The Tudor Domain Of Human Tdrd3 In Complex With An Anti-Tdrd3 Fab,Homo sapiens,"Persson,H.;Ye,W.;Wernimont,A.;Adams,J.J.;Koide,A.;Koide,S.;Lam,R.;Sidhu,S.S.",CDR-H3 diversity is not required for antigen recognition by synthetic antibodies,19-NOV-2010,8_8_19_6_3_11,3PNW_B_A,Xtal structure,Tdrd3,8,1,9.553525,10.889874
7PG8_I_G,EVQLVESGGGLVQPGGSLRLSCAASGFNLYSSSIHWVRQAPGKGLEWVASISPSSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTSRGWISYGSGLDYWGQGTLVTVFN,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYISYHEPITFGQGTKVEIK,7PG8_I,7PG8_G,Nav_Ae1/Sp1Ctd_Pore-Ant05 Complex,Nav_Ae1/Sp1Ctd_Pore-Ant05 Complex,synthetic construct,"Arrigoni,C.;Lolicato,M.;Shaya,D.;Rohaim,A.;Findeisen,F.;Fong,L.K.;Colleran,C.M.;Dominik,P.;Kim,S.S.;Schuermann,J.P.;DeGrado,W.F.;Grabe,M.;Kossiakoff,A.A.;Minor,D.L.",Quaternary structure independent folding of voltage-gated ion channel pore domain subunits,13-AUG-2021,8_8_16_6_3_11,7PG8_I_G,Xtal structure,,8,1,9.615669,10.860372
6P3S_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYWMTWVRQAPGKGLEWVANINQDGGEKYFVDSVKGRFTISRDNAKNSLFLQMNTLRAEDTAVYYCARGFLERLLLGRQGAYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSMTCRASQIISSSLNWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPELTFGGGTKVEIK,6P3S_C,6P3S_D,Crystal Structure Of Human Fab H5.28 In Complex With Influenza A H5N1 Vietnam Hemagglutinin Head Domain,Crystal Structure Of Human Fab H5.28 In Complex With Influenza A H5N1 Vietnam Hemagglutinin Head Domain,Influenza A virus (A/chicken/Vietnam/32/2004(H5N1)),"Dong,J.;Crowe,J.E.",crystal structure of human Fab H5.28 in complex with influenza A H5N1 Vietnam hemagglutinin head domain,27-MAY-2020,8_8_22_6_3_11,6P3S_C_D,Xtal structure,H5N1; hemagglutinin; Influenza,8,1,11.184379,7.8278074
6ELL_H_L,EVQLVESGGGLVQPGGSLRLSCATSGFDFSRYWMSWVRQAPGKGLVWIGEVNPDSTSINYTPSLKDQFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRPNYYGSRYHYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGSTLPFTFGQGTKLEIK,6ELL_H,6ELL_L,Fab Fragment. Abvance: Increasing Our Knowledge Of Antibody Structural Space To Enable Faster And Better Decision Making In Antibody Drug Discovery,Fab Fragment. Abvance: Increasing Our Knowledge Of Antibody Structural Space To Enable Faster And Better Decision Making In Antibody Drug Discovery,Homo sapiens,"Benz,J.;Georges,G.",AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in antibody drug discovery,29-SEP-2017,8_8_17_6_3_9,6ELL_H_L,Xtal structure,,8,1,19.631035,9.756305
4Z5R_W_V,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK,4Z5R_W,4Z5R_V,Rontalizumab Fab Bound To Interferon-A2,Rontalizumab Fab Bound To Interferon-A2,Homo sapiens,"Maurer,B.;Bosanac,I.;Shia,S.;Kwong,M.;Corpuz,R.;Vandlen,R.;Schmidt,K.;Eigenbrot,C.",Structural basis of the broadly neutralizing anti-interferon-alpha antibody rontalizumab,02-APR-2015,8_8_10_10_3_9,ACW43779_ACW43777,Xtal structure,interferon-alpha,8,1,10.679796,10.495762
5LBS_H_L,EVQLVESGGGLVQPGGSLRLSCSASGFTFSTYSMHWVRQAPGKGLEYVSAITGEGDSAFYADSVKGRFTISRDNSKNTLYFEMNSLRPEDTAVYYCVGGYSNFYYYYTMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISTFLAWYQHKPGQAPRLLIYDASTRATGVPARFSGSRSGTDFTLTISTLEPEDFAVYYCQQRYNWPPYTFGQGTKVEIK,5LBS_H,5LBS_L,Structural Basis Of Zika And Dengue Virus Potent Antibody Cross-Neutralization,Structural Basis Of Zika And Dengue Virus Potent Antibody Cross-Neutralization,Homo sapiens,"Dejnirattisai,W.;Wongwiwat,W.;Supasa,S.;Zhang,X.;Dai,X.;Rouvinski,A.;Jumnainsong,A.;Edwards,C.;Quyen,N.T.;Duangchinda,T.;Grimes,J.M.;Tsai,W.Y.;Lai,C.Y.;Wang,W.K.;Malasit,P.;Farrar,J.;Simmons,C.P.;Zhou,Z.H.;Rey,F.A.;Mongkolsapaya,J.;Screaton,G.R.","A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus",17-JUN-2016,8_8_15_6_3_10,5LBS_H_L,Xtal structure,Dengue; Zika; dengue,8,1,13.701301,10.17802
7BM5_F_E,EVQLVESGGGLVQPGRSLKLSCVASRFTFSNYGMNWIRQTPGKGLEWVAYIGSTSSHIYYAETVKGRFTISRDNAKNTLYLQMTGLRSEDTALYYCVGHVRKLGAFFDYWGQGAMVTVSS,DIQMTQSPASLSASLGETVTIECRASEDIHSRLAWYQQKPGKSPQLLIYNANSLHTGVPSRFSGSGSGTQFSLKINSLQSEDVASYFCLQYYNYPPYTFGAGAKLELR,7BM5_F,7BM5_E,"Crystal Structure Of Fab1, The Fab Fragment Of The Anti-Bama Monoclonal Antibody Mab1","Crystal Structure Of Fab1, The Fab Fragment Of The Anti-Bama Monoclonal Antibody Mab1",Homo sapiens,"White,P.;Haysom,S.F.;Iadanza,M.G.;Higgins,A.J.;Machin,J.M.;Whitehouse,J.M.;Horne,J.E.;Schiffrin,B.;Carpenter-Platt,C.;Calabrese,A.N.;Storek,K.M.;Rutherford,S.T.;Brockwell,D.J.;Ranson,N.A.;Radford,S.E.",The role of membrane destabilisation and protein dynamics in BAM catalysed OMP folding,19-JAN-2021,8_8_13_6_3_10,7BM5_F_E,Xtal structure,bamacan; SMC3L1; OMP; BAM; SMC3; CSPG6; HCAP,8,1,15.475387,9.59611
6SNC_B_A,EVQLVESGPGLVQPWGTLSLTCRVSGDSVSNDNYYWAWIRQTPGRELQVIGTIYYSGTTYYNPSLRNRVTISLDKSVNVVSLRLGSVSAADTAQYYCVRMPSHGFWSTSFSYWYFDLWGRGHFVAVSW,DIQMTQSPSSLSASVGDKVTITCRASQSVTKYLNWYQFKTGQAPRILIYGTYTLLSGVSPRFSGAGSGSLYTLTITNIQPEDFATYYCQQAHSTPWTFGQGTHVAAN,6SNC_B,6SNC_A,Crystal Structure Of Ln01 Fab In Complex With An Hiv-1 Gp41 Peptide,Crystal Structure Of Ln01 Fab In Complex With An Hiv-1 Gp41 Peptide,Human immunodeficiency virus 1,"Pinto,D.;Fenwick,C.;Caillat,C.;Silacci,C.;Guseva,S.;Dehez,F.;Chipot,C.;Barbieri,S.;Minola,A.;Jarrossay,D.;Tomaras,G.D.;Shen,X.;Riva,A.;Tarkowski,M.;Schwartz,O.;Bruel,T.;Dufloo,J.;Seaman,M.S.;Montefiori,D.C.;Lanzavecchia,A.;Corti,D.;Pantaleo,G.;Weissenhorn,W.",Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01,23-AUG-2019,10_7_20_6_3_9,6SNC_B_A,Xtal structure,HIV,8,1,16.764606,-7.90682
4GXU_M_N,EVQLVQSGGGVVQPRRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGRNKYYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTSVYYCARELLMDYYDHIGYSPGPTWGQGTLVTVSS,PVLTQPPSASGSPGQRVTISCSGSSSNIGSYTVNWYQQLPGTAPKLLIYSLNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEAVYYCAAWDDSLSAHVVFGGGTKLTVL,4GXU_M,4GXU_N,Crystal Structure Of Antibody 1F1 Bound To The 1918 Influenza Hemagglutinin,Crystal Structure Of Antibody 1F1 Bound To The 1918 Influenza Hemagglutinin,Homo sapiens,"Tsibane,T.;Ekiert,D.C.;Krause,J.C.;Martinez,O.;Crowe JE,Jr.;Wilson,I.A.;Basler,C.F.",Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses,04-SEP-2012,8_8_19_8_3_12,4GXU_M_N,Xtal structure,H1N1; Influenza,8,1,14.590827,13.635831
6IDK_H_L,MHWVRQAPGKGLEWVSLISYDGSNKYNADSVRGRFSISRDNSKNTLYLQMNSLRLEDTAVYYCVRVRQPWTQAWSTNYFYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGGSSNIGSSYVYWYKQVPGTAPKLLIYRNNERPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLRGQVFGGGTKLTVL,6IDK_H,6IDK_L,Cryo-Em Structure Of Immature Dengue Virus Serotype 3 In Complex With Human Antibody 1H10 Fab At Ph 5.0 (Class I Particle),Cryo-Em Structure Of Immature Dengue Virus Serotype 3 In Complex With Human Antibody 1H10 Fab At Ph 5.0 (Class I Particle),Homo sapiens,"Wirawan,M.;Fibriansah,G.;Marzinek,J.K.;Lim,X.X.;Ng,T.S.;Sim,A.Y.;Zhang,Q.;Kostyuchenko,V.A.;Shi,J.;Smith,S.A.;Verma,C.S.;Anand,G.;Crowe JE,Jr.;Bond,P.J.;Lok,S.M.",Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody,10-SEP-2018,0_8_23_8_3_11,6IDK_H_L,Xtal structure,Dengue,8,1,17.463251,8.44282
7RM0_A_B,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINSNTGEPTYAEEFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWANCGCAMDYWGQGTTVTVSS,DIVMTQSPSSLTVTAGEKVSMSCKSSQSLFTSGKQKNYLTWYQQKPGQPPKLLIYWASTRNSGLPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK,7RM0_A,7RM0_B,Antibody 2E10.E9 In Complex With P. Vivax Csp Peptide Angagnqpgangagnqpg,Antibody 2E10.E9 In Complex With P. Vivax Csp Peptide Angagnqpgangagnqpg,Plasmodium vivax,"Kucharska,I.;Hossain,L.;Ivanochko,D.;Yang,Q.;Rubinstein,J.L.;Pomes,R.;Julien,J.P.",Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats,26-JUL-2021,8_8_12_12_3_9,7RM0_A_B,Xtal structure,circumsporozoite,8,1,-7.5166245,6.159132
7ZMK_B_C,QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSYWMHWVRQARGQRLEWIGVIHPNSGNTKYNEKFRSRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREMWNYGNSWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKSISKYLAWYQQKPGKAPELLIYSGSTLQSGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHNEYPFTFGQGTKLEIK,7ZMK_B,7ZMK_C,Structure Of Human Mfap4 In Complex With The Fab Fragment Of The As0326 Monoclonal Antibody,Structure Of Human Mfap4 In Complex With The Fab Fragment Of The As0326 Monoclonal Antibody,Homo sapiens,"Pilecki,B.",MFAP4-targeted immunotherapy inhibits retinal neovascularization and vascular leakage,01-MAR-2023,8_8_15_6_3_9,7ZMK_B_C,Xtal structure,MFAP4,8,1,1.9649509,4.6859493
6PSC_C_C,QSVEESGGRLVTPGTPLTLACTVSGFSLNTYSMFWVRQAPGKGLQWIGIISNFGVIYYATWAKGRFTISKTSTTVDLKITSPTTEDTATYFCVRKYGSEWGGDLWGPGTLVTVSS,MTQTPASVSEPVGGTVTIKCQASQSISSYLAWYQQKPGQRPRLLIYETSTLASGVPSRFKGSGSGTEFTLTISDLECADAATYYCQSTYENPTYVSFGGGTEVGVK,6PSC_C,6PSC_C,Antibody Scfv-M204 Trimeric State,Antibody Scfv-M204 Trimeric State,Oryctolagus cuniculus,"Abskharon,R.;Seidler,P.M.;Sawaya,M.R.;Cascio,D.;Yang,T.P.;Philipp,S.;Williams,C.K.;Newell,K.L.;Ghetti,B.;DeTure,M.A.;Dickson,D.W.;Vinters,H.V.;Felgner,P.L.;Nakajima,R.;Glabe,C.G.;Eisenberg,D.S.",Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease,17-JUN-2020,8_7_12_6_3_11,6PSC_C_C,Xtal structure,MSTD; MAPTL; PPND; tau; tau-40; DDPAC; MTBT2; MAPT; MTBT1; FTDP-17; MGC138549; PPP1R103; FLJ31424,8,1,-0.14557384,19.139706
6BA5_F_E,QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTWYASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVTISS,ELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQKPGQPPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNVSYRTSFGGGTEVVVK,6BA5_F,6BA5_E,Potent And Selective Antitumor Activity Of A T-Cell Engaging Bispecific Antibody Targeting A Membrane-Proximal Epitope Of Ror1,Potent And Selective Antitumor Activity Of A T-Cell Engaging Bispecific Antibody Targeting A Membrane-Proximal Epitope Of Ror1,Homo sapiens,"Yang,J.;Baskar,S.;Kwong,K.Y.;Kennedy,M.G.;Wiestner,A.;Rader,C.",Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies,12-OCT-2017,8_7_13_6_3_12,6BA5_F_E,Xtal structure,NTRKR1; ROR1,8,1,-0.17271952,19.082977
1RZI_H_G,QVQLLQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPVFGSANYAQKFQGRVTITADEATSTTYMELSSLRSEDTAVYFCAKGGEDGDYLSDPFYYNHGMDVWGQGTTVTVAS,DIQMTQSPSLSASVGDRVTITCRASQSISSYLNWYQQKPGKVPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTSHTFGQGTKLEIK,1RZI_H,1RZI_G,Crystal Structure Of Human Anti-Hiv-1 Gp120-Reactive Antibody 47E Fab,Crystal Structure Of Human Anti-Hiv-1 Gp120-Reactive Antibody 47E Fab,Homo sapiens,"Huang,C.C.;Venturi,M.;Majeed,S.;Moore,M.J.;Phogat,S.;Zhang,M.Y.;Dimitrov,D.S.;Hendrickson,W.A.;Robinson,J.;Sodroski,J.;Wyatt,R.;Choe,H.;Farzan,M.;Kwong,P.D.",Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120,24-DEC-2003,8_8_22_6_3_9,1RZI_H_G,Xtal structure,gp120; HIV,8,1,-0.8020728,6.184221
4R7D_M_N,QVQLQESGPGLVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGTKVEIK,4R7D_M,4R7D_N,Fab Hu 15C1,Fab Hu 15C1,Homo sapiens,"Loyau,J.;Didelot,G.;Malinge,P.;Ravn,U.;Magistrelli,G.;Depoisier,J.F.;Pontini,G.;Poitevin,Y.;Kosco-Vilbois,M.;Fischer,N.;Thore,S.;Rousseau,F.","Robust Antibody-Antigen Complexes Prediction Generated by Combining Sequence Analyses, Mutagenesis, In Vitro Evolution, X-ray Crystallography and In Silico Docking",27-AUG-2014,9_7_11_6_3_9,QHX55222_QHX55221,Xtal structure,,8,1,16.534868,-7.72363
6DWI_P_O,QVQLQHSGGGLEQPGGSLRISCAASGFTFNTNDMSWVRQAPGKGLQWVSTIIGIDDTTHYADSVRGRFTVSRDTSKNMVYLQMNSLRVEDTALYYCVKNSGIYSFWGQGTLVTVSS,DIQMTQSPATLSVSPGETVTLSCRASQSVRTNVAWYRHKAGQAPMILVSGASTRASGAPARFSGSGYGTEFTLTITSLQSEDFAVYYCLQYNTWPRTFGQGTKVEVK,6DWI_P,6DWI_O,Structure Of The 4462 Antibody Fab Fragment Bound To A Staphylococcus Aureus Wall Techoic Acid Analog,Structure Of The 4462 Antibody Fab Fragment Bound To A Staphylococcus Aureus Wall Techoic Acid Analog,Homo sapiens,"Fong,R.;Kajihara,K.;Chen,M.;Hotzel,I.;Mariathasan,S.;Hazenbos,W.L.;Lupardus,P.J.",Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid,26-JUN-2018,8_8_9_6_3_9,6DWI_P_O,Xtal structure,,8,1,14.110172,9.342203
4AT6_H_L,QVQLQQPGPELVTPGASVKMSCTASGYSFSSYNIHWVKQTPGQGLEWIGVIYPGNGDTSYNQKFRDKATLTADKSSSTAYMQLSSLTSEDSAVYHCARGGSGLLAYWGQGTLVTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQETPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHLVFGGGTKLTVL,4AT6_H,4AT6_L,Fab Fragment Of Antiporphyrin Antibody 14H7,Fab Fragment Of Antiporphyrin Antibody 14H7,Mus musculus,"Quilez,R.;de Lauzon,S.;Desfosses,B.;Mansuy,D.;Mahy,J.P.",Artificial peroxidase-like hemoproteins based on antibodies constructed from a specifically designed ortho-carboxy substituted tetraarylporphyrin hapten and exhibiting a high affinity for iron-porphyrins,04-MAY-2012,8_8_10_9_3_9,4AT6_H_L,Xtal structure,hapten,8,1,0.17667559,-3.8851695
3QA3_B_A,QVQLQQSGAELVKPGASVKLSCTPSGFNIKDIYMQWVKQRPEQGLEWIGRIDPANDKTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCASEGHYGYDGYAMDYWGQGTTVTVSS,DIEMTQSPSSLGVSVGEKVTMSCKSSQNLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGTGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,3QA3_B,3QA3_A,Crystal Structure Of A-Domain In Complex With Antibody,Crystal Structure Of A-Domain In Complex With Antibody,Homo sapiens,"Mahalingam,B.;Ajroud,K.;Alonso,J.L.;Anand,S.;Adair,B.D.;Horenstein,A.L.;Malavasi,F.;Xiong,J.P.;Arnaout,M.A.",Stable Coordination of the Inhibitory Ca2+ Ion at the Metal Ion-Dependent Adhesion Site in Integrin CD11b/CD18 by an Antibody-Derived Ligand Aspartate: Implications for Integrin Regulation and Structure-Based Drug Design,10-JAN-2011,8_8_15_12_3_9,QPW42580_QPW42581,Xtal structure,CD18; Integrin; MFI7; LFA-1; MAC-1; ITGB2,8,1,-4.6649055,0.15168276
5Y9J_H_L,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,5Y9J_H,5Y9J_L,Baff In Complex With Belimumab,Baff In Complex With Belimumab,Homo sapiens,"Shin,W.;Lee,H.T.;Lim,H.;Lee,S.H.;Son,J.Y.;Lee,J.U.;Yoo,K.Y.;Ryu,S.E.;Rhie,J.;Lee,J.Y.;Heo,Y.S.",BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus,25-AUG-2017,8_8_16_6_3_11,QYU17901_QYU17900,Xtal structure,BLYS; TNFSF13B; BAFF; THANK; TALL-1; TALL1; TNFSF20; CD257,8,1,-0.49283066,5.7413254
3J2X_D_C,QVQLQQSGPELVKPGVSVKISCKASGYSFTSFYIYWVKQRPGQGLEWIGWIFPGSTNTKYNEKFKGKATLTADTSSSTASMQLSSLTSEDSAVYFCARVDGYAMDYWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMNWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPFTFGSGTKLEIK,3J2X_D,3J2X_C,Electron Cryo-Microscopy Of Chikungunya Vlp In Complex With Neutralizing Antibody Fab M242,Electron Cryo-Microscopy Of Chikungunya Vlp In Complex With Neutralizing Antibody Fab M242,Mus musculus,"Sun,S.;Xiang,Y.;Akahata,W.;Holdaway,H.;Pal,P.;Zhang,X.;Diamond,M.S.;Nabel,G.J.;Rossmann,M.G.",Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization,28-JAN-2013,8_8_10_10_3_9,3J2X_D_C,Xtal structure,Chikungunya,8,1,0.18755178,-4.408102
4H88_H_L,QVQLQQSGTELVMPGASVKMSCKASGYTFTDYWMHWVKQRPGQGLEWIGSIDPSDSYTSHNEKFKGKATLTVDESSSTAYMQLSSLTSEDSAVYFCSRSGYGYYAMEYWGQGTSVTVSS,DIVLTQSPAILSVSPGERVSFSCRASQNIGTSIHWYQQRTNESPRLIIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSNTWPYTFGGGTKLELK,4H88_H,4H88_L,Structure Of Pom1 Fab Fragment Complexed With Mouse Prpc Fragment 120-230,Structure Of Pom1 Fab Fragment Complexed With Mouse Prpc Fragment 120-230,Mus musculus,"Sonati,T.;Reimann,R.R.;Falsig,J.;Baral,P.K.;O'Connor,T.;Hornemann,S.;Yaganoglu,S.;Li,B.;Herrmann,U.S.;Wieland,B.;Swayampakula,M.;Rahman,M.H.;Das,D.;Kav,N.;Riek,R.;Liberski,P.P.;James,M.N.;Aguzzi,A.",The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein,21-SEP-2012,8_8_12_6_3_9,4H88_H_L,Xtal structure,,8,1,-0.37793428,-3.6089008
6E8V_A_B,QVQLRESGPSLVKPSQTLSLTCTASGFSLSDKAVGWVRQAPGKALEWLGSIDTGGSTGYNPGLKSRLSITKDNSESQVSLSVSSVTTEDSATYYCTTVHQYTHKRCPDGYTYGYWCGYGTGSCVGSNCVYYPSRGCYGGYGGCSSFSAGSSYELYVDAWGQGLLVTVSS,EAVLNQPSSVSGSLGQRVSITCSGSSSNVGNGYVSWYQLIPGSAPRTLIYGDTSRASGVPDRFSGSRSGNTATLTISSLQAEDEADYFCASAEDSSSNAVFGSGTTLTVL,6E8V_A,6E8V_B,The Crystal Structure Of Bovine Ultralong Antibody Bov-1,The Crystal Structure Of Bovine Ultralong Antibody Bov-1,Bos taurus,"Dong,J.;Finn,J.A.;Larsen,P.A.;Smith,T.P.L.;Crowe,J.E.",Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains,04-SEP-2019,8_7_63_8_3_11,6E8V_A_B,Xtal structure,,8,1,13.859933,-9.365358
4EVN_M_N,QVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAYVVFGGGTKLTVL,4EVN_M,4EVN_N,Crystal Structure Of Fab Cr6261 (Somatic Heavy Chain With Germline-Reverted Light Chain),Crystal Structure Of Fab Cr6261 (Somatic Heavy Chain With Germline-Reverted Light Chain),Homo sapiens,"Lingwood,D.;McTamney,P.M.;Yassine,H.M.;Whittle,J.R.;Guo,X.;Boyington,J.C.;Wei,C.J.;Nabel,G.J.",Structural and genetic basis for development of broadly neutralizing influenza antibodies,26-APR-2012,8_8_14_8_3_12,4EVN_M_N,Xtal structure,,8,1,-0.55920357,5.811085
QLI62487_QLI62520,QVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKSTLYLQMNSLRVEDTAVYYCARDFGDFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKLEIK,QLI62487,QLI62520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",Homo sapiens,"Rogers,T.F.; Zhao,F.; Huang,D.; Beutler,N.; Burns,A.; He,W.T.; Limbo,O.; Smith,C.; Song,G.; Woehl,J.; Yang,L.; Abbott,R.K.; Callaghan,S.; Garcia,E.; Hurtado,J.; Parren,M.; Peng,L.; Ramirez,S.; Ricketts,J.; Ricciardi,M.J.; Rawlings,S.A.; Wu,N.C.; Yuan,M.; Smith,D.M.; Nemazee,D.; Teijaro,J.R.; Voss,J.E.; Wilson,I.A.; Andrabi,R.; Briney,B.; Landais,E.; Sok,D.; Jardine,J.G.; Burton,D.R.",Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model,22-JUL-2020,8_7_11_6_3_9,QLI62487_QLI62520,Unique source,SARS-CoV-2,8,1,12.702083,10.208601
7WVI_A_B,QVQLVESGGGVVQPGRSLRLSCAASGFPFSSYGMHWVRQAPGKGLEWVAGVSYDGSYKYYADSVKGRFTISRDSSKSTLYLQMNSLRPEDTAVYYCARPSAIFGIYIILNGLDVWGQGTTVTVSS,EIVLTQSPSSVSASVGDRVTITCRATQGISSWLAWYQQKPGKPPKLLIFGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQAHSFPLTFGGGTKVEIK,7WVI_A,7WVI_B,Crystal Structure Of Sia28,Crystal Structure Of Sia28,Homo sapiens,"Chen,Y.;Wang,F.;Yin,L.;Jiang,H.;Lu,X.;Bi,Y.;Zhang,W.;Shi,Y.;Burioni,R.;Tong,Z.;Song,H.;Qi,J.;Gao,G.F.",Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes,18-JAN-2023,8_8_18_6_3_9,7WVI_A_B,Xtal structure,hemagglutinin; H17; FOXRED1,8,1,14.320665,13.857252
QXE98035_QXE98039,QVQLVESGGGVVQPGRSLRLSCAASGFTLSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGWAYWELLPDYYYGMDVWGQGTTVTVSS,QTVVTQEPSFSVSPGGTVTLTCGLSSGSVSTAYFPSWYQQTPGQAPRTLIYGTNTRSSGVPDRFSGSILGNKAALTITGAQADDESDYYCVLYMGRGIVVFGGGTKLTVL,QXE98035,QXE98039,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",Homo sapiens,"Wang,L.; Zhou,T.; Zhang,Y.; Yang,E.S.; Schramm,C.A.; Shi,W.; Pegu,A.; Oloninyi,O.K.; Ransier,A.; Darko,S.; Narpala,S.R.; Hatcher,C.; Martinez,D.R.; Tsybovsky,Y.; Phung,E.; Abiona,O.M.; Cale,E.M.; Chang,L.A.; Corbett,K.S.; DiPiazza,A.T.; Gordon,I.J.; Leung,K.; Liu,T.; Mason,R.D.; Nazzari,A.; Novik,L.; Olia,A.S.; Stephens,T.; Stringham,C.D.; Talana,C.A.; Teng,I.T.; Wagner,D.; Widge,A.T.; Zhang,B.; Roederer,M.; Ledgerwood,J.E.; Ruckwardt,T.J.; Gaudinski,M.R.; Baric,R.S.; Graham,B.S.; McDermott,A.B.; Douek,D.C.; Kwong,P.D.; Mascola,J.R.; Sullivan,N.J.; Misasi,J.",Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants,05-JUL-2021,8_8_19_9_3_10,QXE98035_QXE98039,Unique source,SARS-CoV-2,8,1,14.058284,14.071995
7SFW_Q_R,QVQLVQSGAEVKKPGASVKVSCKSSGYTFTNYIIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRISVTRDTSASAAYMELSSLKSEDTALYYCATLQMDYGGNGDLDYWGQGTLVTVSS,YELTQPPSVSVSPGQTARITCSGDALPKQYVYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDDADYYCQAADSSNTEYVFGTGTKVTVL,7SFW_Q,7SFW_R,Cryoem Structure Of Venezuelan Equine Encephalitis Virus (Veev) Tc-83 Strain Vlp In Complex With Fab Hveev-63 (Focus Refine Of The Asymmetric Unit),Cryoem Structure Of Venezuelan Equine Encephalitis Virus (Veev) Tc-83 Strain Vlp In Complex With Fab Hveev-63 (Focus Refine Of The Asymmetric Unit),Homo sapiens,"Kafai,N.M.;Williamson,L.E.;Binshtein,E.;Sukupolvi-Petty,S.;Gardner,C.L.;Liu,J.;Mackin,S.;Kim,A.S.;Kose,N.;Carnahan,R.H.;Jung,A.;Droit,L.;Reed,D.S.;Handley,S.A.;Klimstra,W.B.;Crowe,J.E.;Diamond,M.S.",Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge,04-OCT-2021,8_8_15_6_3_11,7SFW_Q_R,Xtal structure,,8,1,0.18008009,3.08793
7WQV_B_B,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGGIIPILGTTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARKFGYSGYGATWYFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGNSSNIGAGYDVHWYQQFPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,7WQV_B,7WQV_B,Crystal Structure Of A Neutralizing Monoclonal Antibody (Ab08) In Complex With Sars-Cov-2 Receptor-Binding Domain (Rbd),Crystal Structure Of A Neutralizing Monoclonal Antibody (Ab08) In Complex With Sars-Cov-2 Receptor-Binding Domain (Rbd),Homo sapiens,"Meng,L.;Zha,J.;Li,D.;Zhang,X.",Crystal structure of a neutralizing monoclonal antibody (Ab08) in complex with SARS-CoV-2 receptor-binding domain (RBD),25-JAN-2023,8_8_17_9_3_11,7WQV_B_B,Xtal structure,SARS-CoV-2; RBD,8,1,-0.93646985,5.6308613
8DYT_H_L,QVQLVQSGGGVVQPGRSLRLSCVTSGFTFPAFGMHWVRQAPGKGLEWVAVIWYDGSKKYYADSVRGRFTISRDNSRNTLYLQMHSLRAEDTAVYYCARVKNYESSGYSQCLDYWGQGVLVTVAS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNGNRPSGVPDRFSGSKSGTSVSLAITGLQAEDEADYYCQSYDSSLSAFVFGTGTKVTVL,8DYT_H,8DYT_L,Cryo-Em Structure Of 227 Fab In Complex With (Npna)8 Peptide,Cryo-Em Structure Of 227 Fab In Complex With (Npna)8 Peptide,Homo sapiens,"Martin,G.M.;Ward,A.B.",Spectrum of PfCSP-antibody cryo-EM structures and the role of homotypic interactions,02-AUG-2023,8_8_17_9_3_11,8DYT_H_L,Xtal structure,PfCSP,8,1,15.0776,13.666201
1KN4_H_L,EMQLQQSGAELLRPGTSVKLSCKTSGYIFTSYWIHWVKQRSGQGLEWIARIYPGTGSTYYNEKFKGKATLTADKSSSTAYMQLSTLKSEDSAVYFCTRWGFIPVREDYVMDYWGQGTLVTVSS,DIVMTQSPLTLSVTIGQPASISCKSSQSLLYSNGKTYLNWLLQRPGQSPKRLIHLVSKLDSGVPDRITGSGSGTDFTLKISRVEAADLGVYYCVQGTHFPYTFGGGTKLEI,1KN4_H,1KN4_L,Catalytic Antibody D2.3 Complex,Catalytic Antibody D2.3 Complex,Mus musculus,"D'Souza,L.J.;Gigant,B.;Knossow,M.;Green,B.S.",Remarkable remote chiral recognition in a reaction mediated by a catalytic antibody,18-DEC-2001,8_8_16_11_3_9,1KN4_H_L,Xtal structure,,9,1,0.37330046,-4.241
7V8Q_B_A,EVKLLQSGGGLVQPGGSLKLSCAASGIDFSGYWMSWVRRAPGKGLEWIGEITPDSSTINYAPSLKDEFIISRDNAKNTLYLQMTKVRSDDTALYYCVSYYEGFAYWGQGTLVTVSA,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGRTNNRVPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHFIFGSGTKVTVL,7V8Q_B,7V8Q_A,Crystal Structure Of Antibody 14A In Complex With Muc1 Glycopeptide(Glycot),Crystal Structure Of Antibody 14A In Complex With Muc1 Glycopeptide(Glycot),Homo sapiens,"Han,Y.B.;Xu,L.",Site-specific GalNAc modification on a MUC1 neoantigen epitope forms a basis for high-affinity antibody binding,31-AUG-2022,8_8_9_9_3_9,7V8Q_B_A,Xtal structure,Ca15-3; ADMCKD; KL-6; ADMCKD1; PUM; MUC1; MCKD; CD227; MCKD1; EMA; PEM; MCD,9,1,19.609287,9.725189
ANY91848_ANY91243,EVQLLESGGGLVQPGESLRVSCAASGFTFRDSALSWVRQAPGKGLEWVSAISGNGGATYYADTVKGRFTISRDNSQTTLYLQMNSLRADDTATYYCAKDESPPIYNLMPGYYSTYYYMDVWGKGTTVTVSS,EIVMTQSPVTLSVSPGETATLSCRASQSVRSNLAWYQQKPGQAPRLLIYGASTRATDIPARFSGSGSGTEFTLSISSLQSDDFAVYYCQQYNHWLRTFGQGTKLEIK,ANY91848,ANY91243,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Joyce,M.G.; Wheatley,A.K.; Thomas,P.V.; Chuang,G.Y.; Soto,C.; Bailer,R.T.; Druz,A.; Georgiev,I.S.; Gillespie,R.A.; Kanekiyo,M.; Kong,W.P.; Leung,K.; Narpala,S.N.; Prabhakaran,M.S.; Yang,E.S.; Zhang,B.; Zhang,Y.; Asokan,M.; Boyington,J.C.; Bylund,T.; Darko,S.; Lees,C.R.; Ransier,A.; Shen,C.H.; Wang,L.; Whittle,J.R.; Wu,X.; Yassine,H.M.; Santos,C.; Matsuoka,Y.; Tsybovsky,Y.; Baxa,U.; Mullikin,J.C.; Subbarao,K.; Douek,D.C.; Graham,B.S.; Koup,R.A.; Ledgerwood,J.E.; Roederer,M.; Shapiro,L.; Kwong,P.D.; Mascola,J.R.; McDermott,A.B.",Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses,05-AUG-2016,8_8_24_6_3_9,ANY91848_ANY91243,Unique source,Influenza,9,1,13.874536,10.178036
3KYM_J_I,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYPMFWVRQAPGKGLEWVSWIGPSGGITKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCAREGHNDWYFDLWGRGTLVTVSS,DIQMTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYDKWPLTFGGGTKVEIK,3KYM_J,3KYM_I,Crystal Structure Of Li33 Igg2 Di-Fab,Crystal Structure Of Li33 Igg2 Di-Fab,Homo sapiens,"Pepinsky,R.B.;Silvian,L.;Berkowitz,S.A.;Farrington,G.;Lugovskoy,A.;Walus,L.;Eldredge,J.;Capili,A.;Mi,S.;Graff,C.;Garber,E.",Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis,06-DEC-2009,8_8_12_6_3_9,AFD44323_AFD44324,Xtal structure,LINGO-1,9,1,13.727272,9.472234
7U64_A_B,EVQLQESGPSLVKPSQTLSLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGSTYYNPSLKSRISITRDTSKNQYSLHLNSVTAEDTATFYCARYYGDNYVGAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGISASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPWTFGGGTKLEIK,7U64_A,7U64_B,Crystal Structure Of Anti-Fentanyl Antibody Hy6-F9.6 Fab Complexed With Fentanyl,Crystal Structure Of Anti-Fentanyl Antibody Hy6-F9.6 Fab Complexed With Fentanyl,Mus musculus,"Rodarte,J.V.;Baehr,C.;Hicks,D.;Liban,T.L.;Weidle,C.;Rupert,P.B.;Jahan,R.;Wall,A.;McGuire,A.T.;Strong,R.K.;Runyon,S.;Pravetoni,M.;Pancera,M.",Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding,11-JAN-2023,8_7_14_11_3_9,7U64_A_B,Xtal structure,nicotine,9,1,10.716134,-12.823285
UOF83923_UOF83924,EVQLQQWGAGLLKPSETLSLTCAVYGESFSGYYWSWIRQSPGKGLEWIGQINHSGNTNYNPSLKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARELGHDYWGQGTLVTVSS,EIVMTQSPGTLSLSPGERATLSCRASQSISSSYLAWFQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGDSPLTFGGGTKVDIK,UOF83923,UOF83924,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Song,D.",Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron,30-SEP-2022,8_7_8_7_3_9,UOF83923_UOF83924,Unique source,SARS-CoV-2,9,1,16.683702,-10.501938
QOW17444_QOW17445,EVQLVESGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETMYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVAGTPDLFDYYYGMDVWGQGTTVTVSS,EIVMTQSPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCTQATQFPYTFGQGTKVDIK,QOW17444,QOW17445,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Chen,W.",Direct Submission,07-NOV-2020,8_8_21_11_3_9,QOW17444_QOW17445,Unique source,,9,1,1.02687,2.510237
4HG4_P_Q,EVQLVESGAEVKKPGSSVKVSCKASGGTFITHVFTWVRQAPGQGLEWVGGFIAIFGTSNYAQKFQGRVTITADESTSTAYMELTSLTSEDTAVYYCARGISGSYGWFDPWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDIRKYLNWYQQKPGKAPNLLIYDASNVKTGVPSRFRGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGQGTRLEIK,4HG4_P,4HG4_Q,Crystal Structure Of Fab 2G1 In Complex With A H2N2 Influenza Virus Hemagglutinin,Crystal Structure Of Fab 2G1 In Complex With A H2N2 Influenza Virus Hemagglutinin,Homo sapiens,"Xu,R.;Krause,J.C.;McBride,R.;Paulson,J.C.;Crowe JE,Jr.;Wilson,I.A.",A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin,06-OCT-2012,8_8_13_6_3_9,4HG4_P_Q,Xtal structure,hemagglutinin; H2N2; Influenza,9,1,-0.48536083,5.7092032
BAL04191_BAL04192,EVQLVESGAEVKKPGSSVKVSCRASGTFYKYAINWVRQAPGQGLEWMGGIIPFFGTTNYAQKFQGRLTITADGSTNTAYMQLDSLRSEDTAVYYCAGPSITESHYCLDCAAKDYYYGLDVWGQGTTVTVSS,QSVLTQPPSASGTPGQSVTISCSGSRSNIGGNTVNWYQHLPGMAPKLLIYSSNQRSSGVPDRFSGSKSGTSASLAISGLQSEDDADYYCASWDDSLNGVVFGGGTKLTVL,BAL04191,BAL04192,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin lambda chain, partial [Homo sapiens]",Homo sapiens,"Ohshima,N.; Iba,Y.; Kubota-Koketsu,R.; Asano,Y.; Okuno,Y.; Kurosawa,Y.","Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including h3, h1, h2, and h5",15-OCT-2011,7_8_25_8_3_11,BAL04191_BAL04192,Unique source,,9,1,-0.85303944,6.143447
7NX7_A_B,EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLGAEDTAVYYCARGEGSPGNWFDPWGQGTLVTVSS,DVVMTQSPGTLSLSPGERATLSCRASQSVPSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDTSPRFGGGTKVDIK,7NX7_A,7NX7_B,Crystal Structure Of The K417N Mutant Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-222 And Ey6A Fabs,Crystal Structure Of The K417N Mutant Receptor Binding Domain Of Sars-Cov-2 Spike Glycoprotein In Complex With Covox-222 And Ey6A Fabs,Homo sapiens,"Dejnirattisai,W.;Zhou,D.;Supasa,P.;Liu,C.;Mentzer,A.J.;Ginn,H.M.;Zhao,Y.;Duyvesteyn,H.M.;Tuekprakhon,A.;Nutalai,R.;Wang,B.;Paesen,G.C.;Lopez-Camacho,C.;Slon-Campos,J.;Walter,T.S.;Skelly,D.;Clemens,S.A.C.;Naveca,F.G.;Nascimento,V.;Nascimento,F.;Dold,C.;Levin,R.;Dong,T.;Pollard,A.J.;Knight,J.C.;Crook,D.;Lambe,T.;Clutterbuck,E.;Bibi,S.;Flaxman,A.;Bittaye,M.;Belij-Rammerstorfer,S.;Gilbert,S.;Carroll,M.W.;Klenerman,P.;Barnes,E.;Dunachie,S.J.;Paterson,N.G.;Williams,M.A.;Hall,D.R.;Hulswit,R.J.G.;Bowden,T.A.;Fry,E.E.;Mongkolsapaya,J.;Ren,J.;Stuart,D.I.;Screaton,G.R.",Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2,17-MAR-2021,8_7_13_7_3_8,7NX7_A_B,Xtal structure,SARS-CoV-2,9,1,12.594976,10.232009
8H07_E_J,EVQLVESGGGLIQPGGSLRLSCAVSGFTVSRMSWVRQAPGKGLECVSVIYTGGNTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCVRGSGGIHDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISTWLAWYQQKPGKAPKVLINAASGLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAHSFPPTFGPGTKLEIK,8H07_E,8H07_J,Sars-Cov-2 Ba.4 Variants S Ectodomain Trimer In Complex With Neutralizing Antibody 10-5B And 6-2C,Sars-Cov-2 Ba.4 Variants S Ectodomain Trimer In Complex With Neutralizing Antibody 10-5B And 6-2C,Homo sapiens,"Liu,Y.;Wang,Z.;Zhuang,X.;Zhang,S.;Chen,Z.;Zou,Y.;Sheng,J.;Li,T.;Tai,W.;Yu,J.;Wang,Y.;Zhang,Z.;Chen,Y.;Tong,L.;Yu,X.;Wu,L.;Chen,D.;Zhang,R.;Jin,N.;Shen,W.;Zhao,J.;Tian,M.;Wang,X.;Cheng,G.",Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants,31-MAY-2023,6_7_13_6_3_9,8H07_E_J,Xtal structure,SARS-CoV-2; Ectodomain,9,1,12.567606,10.3812685
8GPU_H_L,EVQLVESGGGLVKPGGSLRLSCAASGFIFSDYYMMWIRQAPGKGLEWISYISSSGSQIYYTESVKGRFTISRDNGKNLLYLQMNSLRGEDTALYYCATETGWRIDTWGQGTLVTVSS,QAVLTQPASVSGSPGQSITISCTGTGSNIETYNLVSWYQRHPGKAPKLILYEVSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYFCCSYADTNIFWVFGGGTHLTVL,8GPU_H,8GPU_L,Yfv_E_Yd6Fab_Prefusion,Yfv_E_Yd6Fab_Prefusion,Homo sapiens,"Li,Y.;Chen,Z.;Wu,L.;Dai,L.;Qi,J.;Chai,Y.;Li,S.;Wang,Q.;Tong,Z.;Ma,S.;Duan,X.;Ren,S.;Song,R.;Liang,M.;Liu,W.;Yan,J.;Gao,G.F.",A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus,08-JAN-2009,8_8_10_9_3_11,8GPU_H_L,Xtal structure,,9,1,15.632298,9.422768
BAO57642_BAO57659,QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARYDYYGSSYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,BAO57642,BAO57659,"immunoglobulin heavy chain, V region, partial [Mus musculus]","immunoglobulin light chain, V region, partial [Mus musculus]",Mus musculus,"Murakami,A.; Moriyama,H.; Osako-Kabasawa,M.; Endo,K.; Nishimura,M.; Udaka,K.; Muramatsu,M.; Honjo,T.; Azuma,T.; Shimizu,T.",Low-affinity IgM antibodies lacking somatic hypermutations are produced in the secondary response of C57BL/6 mice to (4-hydroxy-3-nitrophenyl)acetyl hapten,04-APR-2014,8_8_13_9_3_9,BAO57642_BAO57659,Unique source,hapten,9,1,-0.7463602,-3.8654685
3J2Y_F_E,QVQLQQPGAELVRPGSSVKLSCKASGYTFTSKWMHWVKQRPIQGLEWIGNIDPSDSETHYNQKFKDKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGVTRGYFDVWGTGTTVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVTYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQRTNYPLTFGAGTKLELK,3J2Y_F,3J2Y_E,Electron Cryo-Microscopy Of Chikungunya Vlp In Complex With Neutralizing Antibody Fab 9.8B,Electron Cryo-Microscopy Of Chikungunya Vlp In Complex With Neutralizing Antibody Fab 9.8B,Mus musculus,"Sun,S.;Xiang,Y.;Akahata,W.;Holdaway,H.;Pal,P.;Zhang,X.;Diamond,M.S.;Nabel,G.J.;Rossmann,M.G.",Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization,28-JAN-2013,8_8_11_5_3_9,3J2Y_F_E,Xtal structure,Chikungunya,9,1,-0.38990006,-3.5691185
7MW3_H_L,QVQLQQSAAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPTSGYTEYNQNFKDKTTLTADKSSSTAYMQLNSLTSEDSAVYYCAREGHRVGPAYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQTPGQPPKLLIYGSSNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPYTFGGGTKLEIK,7MW3_H,7MW3_L,Structure Of The Sars-Cov-2 Spike Trimer With Two Rbds Down In Complex With The Fab Fragment Of Human Neutralizing Antibody Clone 6,Structure Of The Sars-Cov-2 Spike Trimer With Two Rbds Down In Complex With The Fab Fragment Of Human Neutralizing Antibody Clone 6,Homo sapiens,"Hu,Y.;Xiong,Y.","Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant",15-MAY-2021,8_8_11_10_3_9,7MW3_H_L,Xtal structure,SARS-CoV-2,9,1,0.13720772,-3.2958705
6PXG_C_D,QVQLQQSGGELVKPGASVKLSCKTSGFTFSSSYISWLKQKPGQSLEWIAWIYAGTGGTEYNQKFTGKAQVTVDTSSSTAYMQFSSLTTEDSAIYYCARGGSSFAMDYWGQGTSVTVSS,QLVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIHTASNQGSGVPARFSGSGSGTDFSLNIHPVEDDDTAMYFCQQSEEVPLTFGAGTKLEIK,6PXG_C,6PXG_D,Crystal Structure Of Mers-Cov Neutralizing Antibody G2 Fab,Crystal Structure Of Mers-Cov Neutralizing Antibody G2 Fab,Mus musculus,"Wang,N.;Rosen,O.;Wang,L.;Turner,H.L.;Stevens,L.J.;Corbett,K.S.;Bowman,C.A.;Pallesen,J.;Shi,W.;Zhang,Y.;Leung,K.;Kirchdoerfer,R.N.;Becker,M.M.;Denison,M.R.;Chappell,J.D.;Ward,A.B.;Graham,B.S.;McLellan,J.S.",Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD,26-JUL-2019,8_8_11_10_3_9,6PXG_C_D,Xtal structure,MERS; CoV,9,1,0.049509566,-4.2799845
6XUN_C_D,QVQLVESGGGSVQPGRSLRLSCEASGFTFEAYAMHWVRQPPGKGLEWVSSINWNSGRIAYADSVKGRFTISRDNARNSLYLQMNSLRLEDTAFYYCAKDIRRFSTGGAEFEYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNFVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSRSGTSASLAISGLRSEDEADYYCAAWDDSLGGHYVFGTGTKVTVL,6XUN_C,6XUN_D,Ab 5B1 Bound To Ca19-9,Ab 5B1 Bound To Ca19-9,Homo sapiens,"Borenstein-Katz,A.;Warszawski,S.;Amon,R.;Eilon,M.;Cohen-Dvashi,H.;Leviatan Ben-Arye,S.;Tasnima,N.;Yu,H.;Chen,X.;Padler-Karavani,V.;Fleishman,S.J.;Diskin,R.",Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies,20-JAN-2020,8_8_16_8_3_12,ARI24848,Xtal structure,CA19,9,1,13.097822,12.06829
8DYY_H_L,QVQLVESGGGVVQPGRSLTLSCAASGFTFSNYGMHWVRQTPGKGLAWVAIIWYDGSKTYYEDSVKGRFTISRDNSKNTLYLQMNSLRVDDTAVYYCARVRHSSSRHGSAFDLWGQGTLVTVSS,VIQMTQSPSTLSASVGDRVTITCRASQSVSTWLAWYQQKPGQGPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSFWTFGQGTKVEIK,8DYY_H,8DYY_L,Cryo-Em Structure Of 334 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Cryo-Em Structure Of 334 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Homo sapiens,"Martin,G.M.;Ward,A.B.",Spectrum of PfCSP-antibody cryo-EM structures and the role of homotypic interactions,02-AUG-2023,8_8_16_6_3_10,8DYY_H_L,Xtal structure,PfCSP,9,1,14.832034,13.676531
QKQ15163_QKQ15247,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINSSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPPRNYYDRSGYYQRAEYFQHWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQRPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNPPLTFGGGTKLEIK,QKQ15163,QKQ15247,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",Homo sapiens,"Brouwer,P.J.M.; Caniels,T.G.; van der Straten,K.; Snitselaar,J.L.; Aldon,Y.; Bangaru,S.; Torres,J.L.; Okba,N.M.A.; Claireaux,M.; Kerster,G.; Bentlage,A.E.A.; van Haaren,M.M.; Guerra,D.; Burger,J.A.; Schermer,E.E.; Verheul,K.D.; van der Velde,N.; van der Kooi,A.; van Schooten,J.; van Breemen,M.J.; Bijl,T.P.L.; Sliepen,K.; Aartse,A.; Derking,R.; Bontjer,I.; Kootstra,N.A.; Wieringa,W.J.; Vidarsson,G.; Haagmans,B.L.; Ward,A.B.; de Bree,G.J.; Sanders,R.W.; van Gils,M.J.",Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability,15-JUN-2020,8_8_22_6_3_9,QKQ15163_QKQ15247,Unique source,SARS-CoV-2; COVID,9,1,1.6859423,3.5987887
7X25_A_C,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGITWVRQAPGQGLEWMGRIIPILGISRSVQKFQGRITITADKSTSTAYMDLSGLTSDDTAVYYCAREGGSGYDFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTIGRLEPEDSAVYYCQQYGSSPWTFGQGTKVEIK,7X25_A,7X25_C,Mers-Cov Spike Complex With S41 Neutralizing Antibody Fab Class4 (2U1D Rbd With 3Fab),Mers-Cov Spike Complex With S41 Neutralizing Antibody Fab Class4 (2U1D Rbd With 3Fab),Homo sapiens,"Zhang,S.;Jia,W.;Zeng,J.;Li,M.;Wang,Z.;Zhou,H.;Zhang,L.;Wang,X.",Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein,18-JAN-2023,8_8_13_7_3_9,7X25_A_C,Xtal structure,MERS; CoV,9,1,-0.8835151,5.5128493
4CC8_F_J,QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWCQGTVVVVSS,EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVH,4CC8_F,4CC8_J,Pre-Fusion Structure Of Trimeric Hiv-1 Envelope Glycoprotein Determined By Cryo-Electron Microscopy,Pre-Fusion Structure Of Trimeric Hiv-1 Envelope Glycoprotein Determined By Cryo-Electron Microscopy,Homo sapiens,"Bartesaghi,A.;Merk,A.;Borgnia,M.J.;Milne,J.L.;Subramaniam,S.",Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy,30-OCT-2013,8_8_16_5_3_5,4CC8_F_J,Xtal structure,HIV,9,1,2.8057282,4.2365417
7TET_H_L,DVKLQESGGGSVKLGGSLKLSCVVSGFTFSTYYMSWVRQTPEKRLELVAVINSNGGNTYYPDNVKGRFTISRDNAENTLYLQMSSLKSEDTALYYCARRDYDGFAMDYWGQGTSVTVSS,DIQLTQSPASLAVSLGQRATISCRASQSVSTSRYSYMHWYQHKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWENPYTFGGGTKLEIK,7TET_H,7TET_L,Cryo-Em Structure Of Glun1B-2B Nmdar In Complex With Fab5 In Non-Active2-Like Conformation,Cryo-Em Structure Of Glun1B-2B Nmdar In Complex With Fab5 In Non-Active2-Like Conformation,Mus musculus,"Tajima,N.;Simorowski,N.;Yovanno,R.A.;Regan,M.C.;Michalski,K.;Gomez,R.;Lau,A.Y.;Furukawa,H.",Development and characterization of functional antibodies targeting NMDA receptors,05-JAN-2022,8_8_12_10_3_9,7TET_H_L,Xtal structure,,10,1,17.61075,6.840975
5Y9F_P_O,DVKLVESGGGLVKPGGSLKLSCAASGFPFSDYTMSWIRQTPEKRLEWVASISSGGTYTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMFYCTRASPYYDYDEGYMDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKSGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPFTFGAGTKLELK,5Y9F_P,5Y9F_O,Crystal Structure Of Hpv59 Pentamer In Complex With The Fab Fragment Of Antibody 28F10,Crystal Structure Of Hpv59 Pentamer In Complex With The Fab Fragment Of Antibody 28F10,Mus musculus,"Li,Z.;Wang,D.;Gu,Y.;Song,S.;He,M.;Shi,J.;Liu,X.;Wei,S.;Li,J.;Yu,H.;Zheng,Q.;Yan,X.;Baker,T.S.;Zhang,J.;McLellan,J.S.;Li,S.;Xia,N.",Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus,24-AUG-2017,8_8_16_11_3_9,5Y9F_P_O,Xtal structure,,10,1,17.87831,6.9832077
AGX28126_AGX28125,EVHLQQSGPELVKPGASVKMSCKTSGYTFTEYTIHWMKQSHGKSLEWIGGIFPNNGDTTYNQKFKVRATLTVGRSSSTAYMDLRSLTSEDSAVYYCVRNYGSSYGYFDVWGAGTTVTVSS,DIVLTQSPGSLTVSLGQRATISCRASESVDNFGKSFMHWYQQKPGQSPKLLIYRASNREFGIPARFNGSGSGTDFALTINPVEADDVATYFCQQSNEDPRTFGGGTKLEIK,AGX28126,AGX28125,"anti-H5N1 hemagglutinin monoclonal anitbody H5M9 heavy chain, partial [Mus musculus]","anti-H5N1 hemagglutinin monoclonal antibody H5M9 light chain, partial [Mus musculus]",Mus musculus,"Zhu,X.; Guo,Y.H.; Jiang,T.; Wang,Y.D.; Chan,K.H.; Li,X.F.; Yu,W.; McBride,R.; Paulson,J.C.; Yuen,K.Y.; Qin,C.F.; Che,X.Y.; Wilson,I.A.",A Unique and Conserved Neutralization Epitope in H5N1 Influenza Viruses Identified by an Antibody against the A/Goose/Guangdong/1/96 Hemagglutinin,04-NOV-2013,8_8_13_10_3_9,AGX28126_AGX28125,Unique chain,H5N1; hemagglutinin; Influenza,10,1,2.4600735,-4.3260984
6EV1_K_L,EVQLQQSGAELAKPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTSEDSAVYYCAPLWPLGTDYWGQGTTLTVSS,DIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGAGTKLELK,6EV1_K,6EV1_L,Crystal Structure Of Antibody Against Schizophyllan,Crystal Structure Of Antibody Against Schizophyllan,Mus musculus,"Sung,K.H.;Josewski,J.;Dubel,S.;Blankenfeldt,W.;Rau,U.","Structural insights into antigen recognition of an anti-beta-(1,6)-beta-(1,3)-D-glucan antibody",01-NOV-2017,8_8_10_5_3_9,6EV1_K_L,Xtal structure,beta-,10,1,0.09054313,-3.312359
7EW5_Q_R,EVQLQQSGAEVVRSGASVKLSCTASGFNIKDYAIHWVKQRPEKGLEWIGAIDPEYGDTEYVPKFQGKATMTADTSSNTAYLQLSSLTSEDTAVYYCNAGHDYDRGRFPYWGQGTLVTVSA,DIVMTQSQKFMSTSVGDRVSITCKASQNVGTAVAWYQQKPGQSPKLMIYFASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELK,7EW5_Q,7EW5_R,Immune Complex Of Hpv6 L1 Pentamer And Neutralizing Antibody 13H5,Immune Complex Of Hpv6 L1 Pentamer And Neutralizing Antibody 13H5,Mus musculus,"Wang,Z.P.;Wang,D.N.;Gu,Y.;Li,S.W.",structure of HPV6 L1 pentamer in complex with neutralizing antibody 13H5,24-MAY-2021,8_8_13_6_3_9,7EW5_Q_R,Xtal structure,,10,1,-4.8891115,0.3668904
5X2O_J_K,EVQLQQSGPELVKPGASMKISCKASGYSFTGYSMNWVKQSHGKNLEWIGLINPYNGDTTYKQKFKGKATLTVDRSSSTAYMELLRLTSEDSAVYYCARSGRGAPTTTTAWFTYWGQGTLVTVSA,DIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPILLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDFATYYCQQTNEDPRTFGGGTKLEIK,5X2O_J,5X2O_K,Crystal Structure Of The Medaka Fish Taste Receptor T1R2A-T1R3 Ligand Binding Domains In Complex With L-Arginine,Crystal Structure Of The Medaka Fish Taste Receptor T1R2A-T1R3 Ligand Binding Domains In Complex With L-Arginine,Mus musculus,"Nuemket,N.;Yasui,N.;Kusakabe,Y.;Nomura,Y.;Atsumi,N.;Akiyama,S.;Nango,E.;Kato,Y.;Kaneko,M.K.;Takagi,J.;Hosotani,M.;Yamashita,A.",Structural basis for perception of diverse chemical substances by T1r taste receptors,02-FEB-2017,8_8_17_10_3_9,5X2O_J_K,Xtal structure,TAS1R3; T1R3,10,1,2.386656,-4.2166224
6M38_H_L,EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQSPEKRLEWVAEISSGGRYIYYSDTVTGRFTISRDNARNILHLEMSSLRSEDTAMYYCARGEVRQRGFDYWGQGTTLTVSS,ENVLTQSPAIMSTSPGEKVTMTCRASSSVGSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQFSGYPLTFGSGTKLEMK,6M38_H,6M38_L,X-Ray Structure Of A Drosophila Dopamine Transporter With Subsiteb Mutations (D121G/S426M) In S-Duloxetine Bound Form,X-Ray Structure Of A Drosophila Dopamine Transporter With Subsiteb Mutations (D121G/S426M) In S-Duloxetine Bound Form,Mus musculus,"Shabareesh,P.;Mallela,A.K.;Joseph,D.",Structural basis of norepinephrine recognition and transport inhibition in neurotransmitter transporters,02-MAR-2020,8_8_12_7_3_9,6M38_H_L,Xtal structure,SH3YL1; DKFZP586F1318; Ray,10,1,17.956951,7.129487
8HC8_H_L,EVQLVESGGGLVKPGGSLRLSCAASGFSFITYNMNWVRQAPGKGLEWVSSISSNILSSTSYIYYADSVKGRFTISRDDAANSLFLQMNSLRVEDTAQYYCARTRSRSVRNCTSATCPVDAFDLWGQGTMVIVSS,DIVLTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPHLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTNLEIK,8HC8_H,8HC8_L,"Sars-Cov-2 Omicron Ba.1 Spike Trimer (6P) In Complex With Yb13-292 Fab, Focused Refinement Of Fab Region","Sars-Cov-2 Omicron Ba.1 Spike Trimer (6P) In Complex With Yb13-292 Fab, Focused Refinement Of Fab Region",Homo sapiens,"Yu,H.;Liu,B.;Zhang,Y.;Gao,X.;Wang,Q.;Xiang,H.;Peng,X.;Xie,C.;Wang,Y.;Hu,P.;Shi,J.;Shi,Q.;Zheng,P.;Feng,C.;Tang,G.;Liu,X.;Guo,L.;Lin,X.;Li,J.;Liu,C.;Huang,Y.;Yang,N.;Chen,Q.;Li,Z.;Su,M.;Yan,Q.;Pei,R.;Chen,X.;Liu,L.;Hu,F.;Liang,D.;Ke,B.;Ke,C.;Li,F.;He,J.;Wang,M.;Chen,L.;Xiong,X.;Tang,X.",Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants,25-JAN-2023,8_12_23_11_3_9,8HC8_H_L,Xtal structure,SARS-CoV-2,10,1,16.23863,10.155879
7PGB_R_S,EVQLVESGGGLVQPGGSLRLSCAASGFNFSSSSIHWVRQAPGKGLEWVASISSSSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGWYYSWWWAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQGDPRLVTFGQGTKVEIK,7PGB_R,7PGB_S,Nav_Ae1/Sp1Ctd_Pore-Sat09 Complex,Nav_Ae1/Sp1Ctd_Pore-Sat09 Complex,synthetic construct,"Arrigoni,C.;Lolicato,M.;Shaya,D.;Rohaim,A.;Findeisen,F.;Fong,L.K.;Colleran,C.M.;Dominik,P.;Kim,S.S.;Schuermann,J.P.;DeGrado,W.F.;Grabe,M.;Kossiakoff,A.A.;Minor,D.L.",Quaternary structure independent folding of voltage-gated ion channel pore domain subunits,13-AUG-2021,8_8_16_6_3_9,7PGB_R_S,Xtal structure,,10,1,9.528268,10.947824
6XJQ_H_L,EVQLVESGGGLVQPGGSLRLSCAASGFSLSSSSMHWVRQAPGKGLEWVASISPYSGSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTKYHYKNYYWWALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVYYSVAWYQQKPGKAPKLLIYSASYLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQYRRRPITFGQGTKVEIK,6XJQ_H,6XJQ_L,Crystal Structure Of A Self-Alkylating Ribozyme - Alkylated Form With Biotinylated Epoxide Substrate,Crystal Structure Of A Self-Alkylating Ribozyme - Alkylated Form With Biotinylated Epoxide Substrate,Homo sapiens,"Krochmal,D.;Shao,Y.;Li,N.S.;DasGupta,S.;Shelke,S.A.;Koirala,D.;Piccirilli,J.A.",Structural basis for substrate binding and catalysis by a self-alkylating ribozyme,24-JUN-2020,8_8_17_6_3_9,6XJQ_H_L,Xtal structure,,10,1,9.515975,10.811436
7PA9_K_L,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSSAMHWVRQAPGKGLEWVAVISYDGNNQLYADSVKGRLTISRDNSKNALYLQLNSLRTEDTAVYFCARDGGGYSFGTYFFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGERVTITCRASQRISNYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPPTFGPGTKVDIK,7PA9_K,7PA9_L,Jc Polyomavirus Vp1 In Complex With Fab 98D3,Jc Polyomavirus Vp1 In Complex With Fab 98D3,Homo sapiens; JC polyomavirus,"Stroeh, L.J., Harprecht, C., Freytag, J., Stehle, T.",Jc Polyomavirus Vp1 In Complex With Fab 98D3,08-JAN-2009,8_8_16_6_3_9,QHY05564_QHY05565,Xtal structure,,10,1,14.653465,13.376984
2RCJ_R_S,EVQLVQSGGGVVQPGRSLRLSCSSSGFIFSSYAMYWVRQAPGKGLEWVAIIWDDGSDQHYADSVKGRFTISRNDSKNTLFLQMDSLRPEDTGVYFCARDGGSSAPDYWGQGTPVTVSS,SVLTQPPSASGTPGQRVTISCTGTSSGSITVNWYQQLPGMAPKLLIYRDAMRPSGVPTRFSGSKSGTSASLAISGLEAEDESDYYCASWNSSDNSYVFGTGTKVTVL,2RCJ_R,2RCJ_S,Solution Structure Of Human Immunoglobulin M,Solution Structure Of Human Immunoglobulin M,Homo sapiens,"Perkins,S.J.;Nealis,A.S.;Sutton,B.J.;Feinstein,A.",Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation,20-SEP-2007,8_8_11_6_3_11,2RCJ_R_S,Xtal structure,,10,1,14.847845,13.224746
6NJN_O_N,QAQLKESGPGLVAPSQSLSITCTVSGFSLTNYGVHWVRQPPGKGLEWLGVIWAGGSTNYNSALMSRVSISKDNSKSQVFLKMNSLQTDDTVMYYCAREDYDYDWHFDVWGAGTTVTVSS,EIQMTQTTSSLSASLGDRVTISCRASQDISNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGIDYSLTINNLEQEDFATYFCQQGNTLPLTFGAGTKLELK,6NJN_O,6NJN_N,Structure Of A Complex,Structure Of A Complex,Mus musculus,"Zhao,Y.;Chen,S.;Swensen,A.C.;Qian,W.J.;Gouaux,E.",Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM,03-JAN-2019,8_7_13_6_3_9,6NJN_O_N,Xtal structure,,10,1,22.156466,-6.056721
6Z3Q_H_L,QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREITMIAWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYLLTFGGGTKVEIK,6Z3Q_H,6Z3Q_L,Structure Of Ev71 In Complex With A Protective Antibody 38-1-10A Fab,Structure Of Ev71 In Complex With A Protective Antibody 38-1-10A Fab,Homo sapiens,"Huang,K.A.;Zhou,D.;Fry,E.E.;Kotacha,A.;Huang,P.;Yang,S.;Tsao,K.;Huang,Y.;Lin,T.;Ren,J.;Stuart,D.I.",Structural and functional analysis of protective antibodies targeting the 3-fold plateau of Enterovirus 71,21-MAY-2020,10_7_12_6_3_9,6Z3Q_H_L,Xtal structure,,10,1,16.812391,-8.040768
7JWP_K_L,QSVEESGGGLVTPGTPLTLTCTVSGIDLSRYAMSWVRQAPGKGLEWIGIFGSLGGIFYASWAKGRFTISKTSPTTVDLKITSPTTEDTATYFCARMPYTTDRDFWGPGTLVTVSS,DIVMTQTPSSTSAAVGGTVTITCQASQSVANNNYLKWYQQKRGQPPKQLIYSVSTLASGVPSRFKGSGSGTQFTLTISDLEADDAATYYCSGYFNNNIGAFGGGTKLEIK,7JWP_K,7JWP_L,Fab Cj11 In Complex Il-18 Peptide Liberated By Caspase Cleavage,Fab Cj11 In Complex Il-18 Peptide Liberated By Caspase Cleavage,Homo sapiens,"Davies,C.W.;Stowe,I.;Phung,Q.T.;Ho,H.;Bakalarski,C.E.;Gupta,A.;Zhang,Y.;Lill,J.R.;Payandeh,J.;Kayagaki,N.;Koerber,J.T.",Discovery of a caspase cleavage-motif antibody reveals new insights into non-canonical inflammasome function,26-AUG-2020,8_7_11_8_3_10,7JWP_K_L,Xtal structure,,10,1,-0.14469332,19.137371
4R7N_I_J,QVQLQESGPGLVKPSDTLSLTCAVSGYPIRFGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDSGNYFPYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGYDFPLTFGGGTKVEIK,4R7N_I,4R7N_J,Fab C2E3,Fab C2E3,Homo sapiens,"Loyau,J.;Didelot,G.;Malinge,P.;Ravn,U.;Magistrelli,G.;Depoisier,J.F.;Pontini,G.;Poitevin,Y.;Kosco-Vilbois,M.;Fischer,N.;Thore,S.;Rousseau,F.","Robust Antibody-Antigen Complexes Prediction Generated by Combining Sequence Analyses, Mutagenesis, In Vitro Evolution, X-ray Crystallography and In Silico Docking",28-AUG-2014,9_7_11_6_3_9,QHX20645_QHX20646,Xtal structure,,10,1,16.4958,-7.671656
7PA6_K_K,QVQLQESGPGLVKPSGTLSLTCAVSGDSISSSNWWSWVRQPPGKGLEWIGEIYHSGGTKYNPSLKSRVTISVDKSKNHFSLKLRSVTAADTAVYYCARNRWFDNNRGGYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLISATSDLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK,7PA6_K,7PA6_K,Jc Polyomavirus Vp1 In Complex With Scfv 27C11,Jc Polyomavirus Vp1 In Complex With Scfv 27C11,Homo sapiens; JC polyomavirus,"Harprecht, C., Stroeh, L.J., Nagel, F., Freytag, J., Stehle, T.",Jc Polyomavirus Vp1 In Complex With Scfv 27C11,08-JAN-2009,9_7_20_6_3_9,AVA99259_AVA99260,Xtal structure,,10,1,15.364009,-7.401937
5T5N_M_L,QVQLQQSGPELVRPGASVKMSCKASGYTFTNYWMHWVKQRPGQALEWIGMIDPSKSETTLNQKFRGKATLNVDKSSNTAYMQLSSLTSEDSAVYYCAREVYYFDYWGQGTTLTVSS,DIQMTQSPASLSASVGETVTITCRASENIYSYLTWYQQKQGKSPQLLVYNAKTLTEGVPSRFSGSGSGTQFSLKINSLQPEDFGGYFCQHHYGTPPTFGGGTKLEVK,5T5N_M,5T5N_L,"Calcium-Activated Chloride Channel Bestrophin-1 (Best1), Triple Mutant: I76A, F80A, F84A; In Complex With An Fab Antibody Fragment, Chloride, And Calcium","Calcium-Activated Chloride Channel Bestrophin-1 (Best1), Triple Mutant: I76A, F80A, F84A; In Complex With An Fab Antibody Fragment, Chloride, And Calcium",Mus musculus,"Vaisey,G.;Miller,A.N.;Long,S.B.",Distinct regions that control ion selectivity and calcium-dependent activation in the bestrophin ion channel,31-AUG-2016,8_8_9_6_3_9,5T5N_M_L,Xtal structure,,10,1,-0.33642277,-3.6457634
UOL67272_UOL67257,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNTYAINWVRQAPGQGLEWMGRIIPMFGIANYAQKFQGTVTFTADKSTSTAYMELSSLRYEDTAVYYCARSAYYSESSGYYLDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSGSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVNSPRTFGQGTKLE,UOL67272,UOL67257,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",Homo sapiens,"Pushparaj,P.; Nicoletto,A.; Sheward,D.J.; Dopico,X.C.; Vidakovics,L.P.; Hanke,L.; Chernyshev,M.; Narang,S.; Kim,S.; Ekstrom,S.; McInerny,G.; Murrell,B.; Corcoran,M.; Karlsson Hedestam,G.B.",Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies,30-SEP-2022,8_8_16_7_3_9,UOL67272_UOL67257,Unique source,SARS-CoV-2,10,1,-0.9288113,5.6094475
AEL31300_AEL31309,QVQLVQSGGGVVQPGRSLRLSCVASGFTFSTYAMHWVRQAPGRGLEWVAVISYDGNYKYYADSVKGRFSISRDNSNNTLHLEMNTLRTEDTALYYCAKDSQLRSLLYFEWLSQGYFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGARATINCKSSQSVTFNYKNYLAWYQQKPGQPPKVLIYWASARESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYRTPPTFGQGTKVEIK,AEL31300,AEL31309,"anti-Influenza A hemagglutinin heavy chain variable region, partial [Homo sapiens]","anti-Influenza A immunoglobulin kappa light chain variable region, partial [Homo sapiens]",Homo sapiens,"Corti,D.; Voss,J.; Gamblin,S.J.; Codoni,G.; Macagno,A.; Jarrossay,D.; Vachieri,S.G.; Pinna,D.; Minola,A.; Vanzetta,F.; Silacci,C.; Fernandez-Rodriguez,B.M.; Agatic,G.; Bianchi,S.; Giacchetto-Sasselli,I.; Calder,L.; Sallusto,F.; Collins,P.; Haire,L.F.; Temperton,N.; Langedijk,J.P.; Skehel,J.J.; Lanzavecchia,A.",A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,25-JUL-2016,8_8_22_10_3_9,AEL31300_AEL31309,Unique source,hemagglutinin; Influenza,10,1,15.089314,13.990713
5GGS_C_D,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,5GGS_C,5GGS_D,Pd-1 In Complex With Pembrolizumab Fab,Pd-1 In Complex With Pembrolizumab Fab,Homo sapiens,"Lee,J.Y.;Lee,H.T.;Shin,W.;Chae,J.;Choi,J.;Kim,S.H.;Lim,H.;Won Heo,T.;Park,K.Y.;Lee,Y.J.;Ryu,S.E.;Son,J.Y.;Lee,J.U.;Heo,Y.S.",Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy,16-JUN-2016,8_8_13_10_3_9,QPU03975_QPU03984,Xtal structure,,10,1,1.1097233,3.6619124
5F96_H_L,QVRLAQYGGGVKRLGATMTLSCVASGYTFNDYYIHWVRQAPGQGFELLGYIDPANGRPDYAGALRERLSFYRDKSMETLYMDLRSLRYDDTAMYYCVRNVGTAGSLLHYDHWGSGSPVIVSS,EIVLTQSPATLSASPGERVTLTCRASRSVRNNVAWYQHKGGQSPRLLIYDASTRAAGVPARFSGSASGTEFTLAISNLESEDFTVYFCLQYNNWWTFGQGTRVDIK,5F96_H,5F96_L,Crystal Structure Of Broadly Neutralizing Vh1-46 Germline-Derived Cd4-Binding Site-Directed Antibody Ch235.12 In Complex With Hiv-1 Clade A/E 93Th057 Gp120,Crystal Structure Of Broadly Neutralizing Vh1-46 Germline-Derived Cd4-Binding Site-Directed Antibody Ch235.12 In Complex With Hiv-1 Clade A/E 93Th057 Gp120,Homo sapiens,"Bonsignori,M.;Zhou,T.;Sheng,Z.;Chen,L.;Gao,F.;Joyce,M.G.;Ozorowski,G.;Chuang,G.Y.;Schramm,C.A.;Wiehe,K.;Alam,S.M.;Bradley,T.;Gladden,M.A.;Hwang,K.K.;Iyengar,S.;Kumar,A.;Lu,X.;Luo,K.;Mangiapani,M.C.;Parks,R.J.;Song,H.;Acharya,P.;Bailer,R.T.;Cao,A.;Druz,A.;Georgiev,I.S.;Kwon,Y.D.;Louder,M.K.;Zhang,B.;Zheng,A.;Hill,B.J.;Kong,R.;Soto,C.;Mullikin,J.C.;Douek,D.C.;Montefiori,D.C.;Moody,M.A.;Shaw,G.M.;Hahn,B.H.;Kelsoe,G.;Hraber,P.T.;Korber,B.T.;Boyd,S.D.;Fire,A.Z.;Kepler,T.B.;Shapiro,L.;Ward,A.B.;Mascola,J.R.;Liao,H.X.;Kwong,P.D.;Haynes,B.F.",Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody,09-DEC-2015,8_8_15_6_3_8,QHY06162_QHY06163,Xtal structure,HIV; CD4,10,1,1.6308646,4.029831
8ADY_H_L,QVTLKESGPTLVKPTQTLTLTCTFSGFSLTTTGEGVGWIRQPPGKALEFLAFIYWNDAKRYNPSLQSRLTITKDASKKQVVLTLTNLDPVDTATYYCARTSGWDIEFEYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASETVSNDKVAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLSISGLEPEDFVVYYCQQYASSPRTFGQGTKVEIK,8ADY_H,8ADY_L,Cryo-Em Structure Of Full-Length Human Immunoglobulin M - F(Ab')2 Conformation 1,Cryo-Em Structure Of Full-Length Human Immunoglobulin M - F(Ab')2 Conformation 1,Homo sapiens,"Chen,Q.;Menon,R.;Calder,L.J.;Tolar,P.;Rosenthal,P.B.",Cryomicroscopy reveals the structural basis for a flexible hinge motion in the immunoglobulin M pentamer,26-OCT-2022,10_7_12_7_3_9,8ADY_H_L,Xtal structure,,10,1,12.387553,0.3113484
2GFB_L_K,DVKLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTIYYADTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCARGDYYGSRGAYWGQGTLVTVS,QIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSRSGSDYSLTISSLESEDFADYYCLQYASSPYTFGGGTKLEI,2GFB_L,2GFB_K,Crystal Structure Of A Catalytic Fab Having Esterase-Like Activity,Crystal Structure Of A Catalytic Fab Having Esterase-Like Activity,Mus musculus,"Zemel,R.;Schindler,D.G.;Tawfik,D.S.;Eshhar,Z.;Green,B.S.",Differences in the biochemical properties of esterolytic antibodies correlate with structural diversity,07-JUL-1994,8_8_12_6_3_9,2GFB_L_K,Xtal structure,,11,1,17.447721,7.8972898
1OAU_J_N,EVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGRGLEWIGRIDPNGGGTKYNEKFKSKATLTVDKPSSTAYMQLSSLTSEDSAVYYCARMWYYGTYYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGNKAALTITGAQTEDEAIYFCALWYSNHLVFGGGTKLTVL,1OAU_J,1OAU_N,Fv Structure Of The Ige Spe-7 In Complex With Dnp-Ser (Immunising Hapten),Fv Structure Of The Ige Spe-7 In Complex With Dnp-Ser (Immunising Hapten),Mus musculus,"James,L.C.;Roversi,P.;Tawfik,D.S.",Antibody multispecificity mediated by conformational diversity,21-JAN-2003,8_8_13_9_3_9,1OAU_J_N,Xtal structure,,11,1,-0.72118795,-3.9005542
5YD4_A_A,EVQLQQSGAELVRPGTSVKMSCKAAGYTFTKYWIGWVKQRPGHGLEWIGDIHPGSFYSNYNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAIYYCARDYYTNYGDWGQGTSVTVSS,DIVMTQAAPSVSVTPGESVSISCRSSKSLLHRNGNTYLFWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPYTFGSGTKLELK,5YD4_A,5YD4_A,Crystal Structure Of The Scfv Antibody 4B08 With Epitope Peptide (Mutation T6A),Crystal Structure Of The Scfv Antibody 4B08 With Epitope Peptide (Mutation T6A),Homo sapiens,"Miyanabe,K.;Akiba,H.;Kuroda,D.;Nakakido,M.;Kusano-Arai,O.;Iwanari,H.;Hamakubo,T.;Caaveiro,J.M.;Tsumoto,K.",Intramolecular H-bonds govern the recognition of a flexible peptide by an antibody,11-SEP-2017,8_8_10_11_3_9,5YD4_A_A,Xtal structure,,11,1,-0.2132353,-4.4900336
QQO86628_QQO86629,EVQLQQSGPELVKPGASVKMSCKASGCTLTNCFMHWMKQKPGQDLEWIGYINPYNDMTKYSENFKGKATLTSDKSSSTAFMELSSLTSEDSAVYYCARGYLLRTGCFDYWGQGTTLTVSS,NIVLTQSPASLAVSLGQRATISCRASESVDSYGYSFMHWYQQKPGQPPKVLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNENPLTFGAGTKLELK,QQO86628,QQO86629,immunoglobulin heavy chain variable region [Mus musculus],"immunoglobulin light chain variable region, partial [Mus musculus]",Mus musculus,"Biering,S.B.; Akey,D.L.; Wong,M.P.; Brown,W.C.; Lo,N.T.N.; Puerta-Guardo,H.; Tramontini Gomes de Sousa,F.; Wang,C.; Konwerski,J.R.; Espinosa,D.A.; Bockhaus,N.J.; Glasner,D.R.; Li,J.; Blanc,S.F.; Juan,E.Y.; Elledge,S.J.; Mina,M.J.; Beatty,P.R.; Smith,J.L.; Harris,E.",Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction,18-JAN-2021,8_8_13_10_3_9,QQO86628_QQO86629,Unique chain,SHP2; PTPN11; BPTP3; SH-PTP2; NS1; PTP2C; SHP-2,11,1,1.0006411,-3.7611682
7LI7_B_C,QVQLQQSGPELVKLGASVRISCKASGYRFSYSWMNWVKQRPGKGLEWIGRIYPGDGDTKYSGKFKGKATLTADKSSSTVYMQLSSLTSEDSAVYFCARSAYGSEGFAMDYWGQGTSVT,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFLNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTYFSLNIHPMEEDDTAVYFCQQTKGVSWTFGGGTKVEI,7LI7_B,7LI7_C,Apo Serotonin Transporter Reconstituted In Lipid Nanodisc In Presence Of Nacl In Occluded Conformation,Apo Serotonin Transporter Reconstituted In Lipid Nanodisc In Presence Of Nacl In Occluded Conformation,Mus musculus,"Yang,D.;Gouaux,E.",Illumination of serotonin transporter mechanism and role of the allosteric site,26-JAN-2021,8_8_14_10_3_9,7LI7_B_C,Xtal structure,,11,1,0.40771103,-4.7405896
8DYX_H_L,QVQLVESGGGVVPPGRSLRLSCATSGFTFSNYGMHWVRQAPGKGLEWVAIIWYDGSRNFYAASVEGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARAAYYDTSGYGDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQTVTISCTGGSSNIGAGYDVHWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRRLSGSWVFGGGTKLTVL,8DYX_H,8DYX_L,Cryo-Em Structure Of 311 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Cryo-Em Structure Of 311 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Homo sapiens,"Martin,G.M.;Ward,A.B.",Spectrum of PfCSP-antibody cryo-EM structures and the role of homotypic interactions,02-AUG-2023,8_8_14_9_3_12,8DYX_H_L,Xtal structure,PfCSP,11,1,15.02652,13.359161
8DZ4_H_L,QVQLVESGGGVVQPGRSLRLSCAASGFTFRNFGMHWVRQTPGKGLEWVAVIWHDGSNKFYADSVEGRFTISRDNSKNMIYLQMNSLRVEDTAIYYCARDSLFYDHDNSGYYGYWGQGTLVTVSS,QIVMTQSPATVSVSPGERATLSCRASRSVTSKLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYFCQQYNNGFTFGPGTKVDFK,8DZ4_H,8DZ4_L,Cryo-Em Structure Of 356 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Cryo-Em Structure Of 356 Fab In Complex With Recombinant Shortened Plasmodium Falciparum Circumsporozoite Protein (Rscsp),Homo sapiens,"Martin,G.M.;Ward,A.B.",Spectrum of PfCSP-antibody cryo-EM structures and the role of homotypic interactions,02-AUG-2023,8_8_17_6_3_8,8DZ4_H_L,Xtal structure,PfCSP,11,1,15.103813,13.514748
6RP8_h_l,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,6RP8_h,6RP8_l,Crystal Structure Of Ipilimumab Fab Complexed With Ctla-4 At 2.6A Resolution,Crystal Structure Of Ipilimumab Fab Complexed With Ctla-4 At 2.6A Resolution,Homo sapiens,"Zhang,F.;Zhou,A.",Crystal Structure of Ipilimumab Fab complexed with CTLA-4 at 2.6A resolution,14-MAY-2019,8_8_11_7_3_9,QCA99105,Xtal structure,IDDM12; CD152; CTLA-4; CELIAC3; CTLA4; CD; GSE,11,1,14.82655,13.187016
6QF6_D_D,QVTLKESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQVGATWAFDIWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNAWVFGGGTKLTVL,6QF6_D,6QF6_D,Structure Of An E.Coli Expressed Anti-Mcl1 Scfv,Structure Of An E.Coli Expressed Anti-Mcl1 Scfv,Homo sapiens,"Luptak,J.",Structure of an E.coli expressed anti-Mcl1 scFv,09-JAN-2019,8_8_12_8_3_11,6QF6_D_D,Xtal structure,Mcl1,11,1,16.037334,10.136242
8GZZ_E_D,SLEESGGDLVKPGASLTLTCTASGFSFSSGYDMCWVRQAPGKGLEWIACIGTGSSGNIYYASWAKGRFTISKTSSTTVTLQMTSLTAADTATYFCARDDADYAGPDYFNLWGPGTLVTVSS,DIVMTQTPASVSEPVGGTVTIKCQASESISNWLAWYQQKPGQPPKLLIYAAFTLASGVPSRFKGSGSGTQFTLTINGVECADAATYYCQQTYSSRDVDNVFGGGTEVVVK,8GZZ_E,8GZZ_D,Local Refinement Of Sars-Cov-2 Omicron Ba.1 Spike Glycoprotein In Complex With Rabbit Monoclonal Antibody 1H1 Fab,Local Refinement Of Sars-Cov-2 Omicron Ba.1 Spike Glycoprotein In Complex With Rabbit Monoclonal Antibody 1H1 Fab,Oryctolagus cuniculus,"Guo,H.;Yang,Y.;Zhao,T.;Lu,Y.;Gao,Y.;Li,T.;Xiao,H.;Chu,X.;Zheng,L.;Li,W.;Cheng,H.;Huang,H.;Liu,Y.;Lou,Y.;Nguyen,H.C.;Wu,C.;Chen,Y.;Yang,H.;Ji,X.",Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants,12-APR-2023,9_9_15_6_3_12,8GZZ_E_D,Xtal structure,SARS-CoV-2,11,1,-0.4006549,18.436478
1NCW_H_L,VQLQQSGPGLVKPSQSLSLTCTVTGYSITSDFAWNWIRQFPGNKLEWMGYINYSGFTSHNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCAGLLWYDGGAGSWGQGTLVTVS,DVVMTQSPKTISVTIGQPASISCKSSQRLLNSNGKTFLNWLLQRPGQSPKRLIYLGTKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIK,1NCW_H,1NCW_L,Cationic Cyclization Antibody 4C6 In Complex With Benzoic Acid,Cationic Cyclization Antibody 4C6 In Complex With Benzoic Acid,Mus musculus,"Zhu,X.;Heine,A.;Monnat,F.;Houk,K.N.;Janda,K.D.;Wilson,I.A.",Structural basis for antibody catalysis of a cationic cyclization reaction,05-DEC-2002,9_7_12_11_3_9,1NCW_H_L,Xtal structure,,11,1,11.453407,-12.970075
2VXS_J_N,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIHGVTRNWGQGTLVTVSS,FMLTQPHSVSESPGKTVTISCTRSSGSLANYYVQWYQQRPGSSPTIVIFANNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDPYSVVFGGGTKLTVL,2VXS_J,2VXS_N,"Structure Of Il-17A In Complex With A Potent, Fully Human  Neutralising Antibody","Structure Of Il-17A In Complex With A Potent, Fully Human  Neutralising Antibody",Homo sapiens,"Gerhardt,S.;Abbott,W.M.;Hargreaves,D.;Pauptit,R.A.;Davies,R.A.;Needham,M.R.;Langham,C.;Barker,W.;Aziz,A.;Snow,M.J.;Dawson,S.;Welsh,F.;Wilkinson,T.;Vaugan,T.;Beste,G.;Bishop,S.;Popovic,B.;Rees,G.;Sleeman,M.;Tuske,S.J.;Coales,S.J.;Hamuro,Y.;Russell,C.","Structure of IL-17A in complex with a potent, fully human neutralizing antibody",09-JUL-2008,8_8_11_8_3_9,2VXS_J_N,Xtal structure,CTLA8; IL-17A; IL17; IL-17; IL17A,12,1,14.078025,9.59755
ANV21772_ANV21961,EVQLLESGGTLVQPGGSLRLSCSASGFTFSDYALSWVRQAPGKGLEWVSSISGGGGTTYYADSVKGRFTISRDNSKNTVWLQMNSLRAEDTAVYYCYGGSYSFDYWGQGTLVTVSS,EIVMTQSPVTLSVSPGERATLSCRASQSVSINLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHNWPPLTFGGGTKVEIK,ANV21772,ANV21961,"immunoglobulin heavy chain, partial [Homo sapiens]","immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Scherer,E.M.; Smith,R.A.; Gallego,D.F.; Carter,J.J.; Wipf,G.C.; Hoyos,M.; Stern,M.; Thurston,T.; Trinklein,N.D.; Wald,A.; Galloway,D.A.",A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects,22-JUL-2016,8_8_9_6_3_10,ANV21772_ANV21961,Unique source,,12,1,14.195406,9.448756
6WGK_A_B,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,6WGK_A,6WGK_B,Fab Portion Of Dupilumab With Crystal Kappa Design And Intrachain Disulfide,Fab Portion Of Dupilumab With Crystal Kappa Design And Intrachain Disulfide,Homo sapiens,"Lieu,R.;Antonysamy,S.;Druzina,Z.;Ho,C.;Kang,N.R.;Pustilnik,A.;Wang,J.;Atwell,S.",Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing,05-APR-2020,8_8_18_11_3_9,AKX27348_AKX27349,Xtal structure,,12,1,13.840929,10.139724
4XGZ_C_D,EVQLVESGGGLVQPGGSLRLSCAASGFNVSYSSIHWVRQAPGKGLEWVASIYSYYGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGYYGAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSSSLITFGQGTKVEIK,4XGZ_C,4XGZ_D,Crystal Structure Of Human Paxillin Ld2 Motif In Complex With Fab Fragment,Crystal Structure Of Human Paxillin Ld2 Motif In Complex With Fab Fragment,Homo sapiens,"Nocula-Lugowska,M.;Lugowski,M.;Salgia,R.;Kossiakoff,A.A.",Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin,04-JAN-2015,8_8_11_6_3_9,4XGZ_C_D,Xtal structure,,12,1,9.734143,10.793777
5UK2_H_H,EVQLVESGGGLVQPGGSLRLSCAASGFTFNIYDMHWVRQAPGKGLEWVSGLTTGGDTSYSGSVRGRFSISRENAKNSLYLQMNNLRAGDTAAYFCVRGVREVGATGGDPFYYAMAVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISGYYLTWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGISPVITFGGGTNVEIK,5UK2_H,5UK2_H,Cryoem Structure Of An Influenza Virus Receptor-Binding Site Antibody-Antigen Interface - Class 4,Cryoem Structure Of An Influenza Virus Receptor-Binding Site Antibody-Antigen Interface - Class 4,Homo sapiens,"Liu,Y.;Pan,J.;Jenni,S.;Raymond,D.D.;Caradonna,T.;Do,K.T.;Schmidt,A.G.;Harrison,S.C.;Grigorieff,N.",CryoEM Structure of an Influenza Virus Receptor-Binding Site Antibody-Antigen Interface,19-JAN-2017,8_7_21_7_3_10,5UK2_H_H,Xtal structure,Influenza,12,1,16.41332,11.63078
6RLO_C_D,EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMYWVRQAPGKGLEWVSGISWNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYFPYFDYWGQGILVTVSS,DIVMTQSPDSLSVSLGERATINCKSSQSVLYSSNNKNYLGWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPSTFGQGTRLEIK,6RLO_C,6RLO_D,Crystal Structure Of At1412Dm Fab Fragment In Complex With Cd9 Large Extracellular Loop,Crystal Structure Of At1412Dm Fab Fragment In Complex With Cd9 Large Extracellular Loop,Homo sapiens,"Neviani,V.;Pos,W.;Schotte,R.;Wagner,K.;Go,D.M.;Fatmawati,C.;Kedde,M.;Claassen,Y.B.;Kroon-Batenburg,L.;Lutz,M.;Verdegaal,E.M.E.;van der Burg,S.H.;Spits,H.;Gros,P.",Structural basis of a homo-dimerization site in tetraspanin CD9 targeted by a melanoma patient-derived antibody,02-MAY-2019,8_8_13_12_3_9,6RLO_C_D,Xtal structure,P24; BA2; MRP-1; TSPAN29; CD9; MIC3,12,1,13.141319,12.030579
6MTN_D_E,QGQLVQSGATTTKPGSSVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVNMTTDTEVPVTSFTSTGAAYMEIRNLTSDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,6MTN_D,6MTN_E,Crystal Structure Of Hiv-1 Bg505 Sosip.664 Prefusion Env Trimer Bound To Small Molecule Hiv-1 Entry Inhibitor Compound 484 In Complex With Human Antibodies 3H109L And 35O22 At 3.0 Angstrom,Crystal Structure Of Hiv-1 Bg505 Sosip.664 Prefusion Env Trimer Bound To Small Molecule Hiv-1 Entry Inhibitor Compound 484 In Complex With Human Antibodies 3H109L And 35O22 At 3.0 Angstrom,Homo sapiens,"Lai,Y.T.;Wang,T.;O'Dell,S.;Louder,M.K.;Schon,A.;Cheung,C.S.;Chuang,G.Y.;Druz,A.;Lin,B.;McKee,K.;Peng,D.;Yang,Y.;Zhang,B.;Herschhorn,A.;Sodroski,J.;Bailer,R.T.;Doria-Rose,N.A.;Mascola,J.R.;Langley,D.R.;Kwong,P.D.",Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry,20-OCT-2018,8_8_16_9_3_10,6MTN_D_E,Xtal structure,HIV,12,1,2.1617033,5.224933
4TOY_H_L,QLVQSGAELKKPGASVKISCKTSGYRFNFYHINWIRQTAGRGPEWMGWISPYSGDKNLAPAFQDRVIMTTDTEVPVTSFTSTGAAYMEIRNLKFDDTGTYFCAKGLLRDGSSTWLPYLWGQGTLLTVSS,QSVLTQSASVSGSLGQSVTISCTGPNSVCCSHKSISWYQWPPGRAPTLIIYEDNERAPGISPRFSGYKSYWSAYLTISDLRPEDETTYYCCSYTHNSGCVFGTGTKVSVL,4TOY_H,4TOY_L,"Structure Of 35O22 Fab, A Hiv-1 Neutralizing Antibody","Structure Of 35O22 Fab, A Hiv-1 Neutralizing Antibody",Homo sapiens,"Huang,J.;Kang,B.H.;Pancera,M.;Lee,J.H.;Tong,T.;Feng,Y.;Imamichi,H.;Georgiev,I.S.;Chuang,G.Y.;Druz,A.;Doria-Rose,N.A.;Laub,L.;Sliepen,K.;van Gils,M.J.;de la,Pe.;Derking,R.;Klasse,P.J.;Migueles,S.A.;Bailer,R.T.;Alam,M.;Pugach,P.;Haynes,B.F.;Wyatt,R.T.;Sanders,R.W.;Binley,J.M.;Ward,A.B.;Mascola,J.R.;Kwong,P.D.;Connors,M.",Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface,06-JUN-2014,8_8_16_9_3_10,UOJ74395,Xtal structure,gp120; HIV,12,1,2.215383,5.2076263
1XF3_B_A,QVKLLESGPELVKPGASVKMSCKASGYTFTSYVMHWVKQKPGQGLEWIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCVRGGYRPYYAMDYWGQGTSVTVSS,LQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGTPLTFGAGTKLELK,1XF3_B,1XF3_A,Structure Of Ligand-Free Fab Dna-1 In Space Group P65,Structure Of Ligand-Free Fab Dna-1 In Space Group P65,Mus musculus,"Schuermann,J.P.;Prewitt,S.P.;Davies,C.;Deutscher,S.L.;Tanner,J.J.",Evidence for structural plasticity of heavy chain complementarity-determining region 3 in antibody-ssDNA recognition,13-SEP-2004,8_8_13_6_3_9,1XF3_B_A,Xtal structure,GOLPH5; ssDNA; P65; GRASP65; FLJ23443; GORASP1,12,1,0.93441594,-3.8505273
7MLY_H_I,QVQLQQSGAELMKPGAAVKISCKATGHTISRYWIDWLKQRPGHGLEWIGEILPGSGSTNYNEKFKGKATFTAEKSSNTAYMQLSSLTSEDSAVYYCAMGVRGNYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRHTGVPGRFTGSGSGTDYTLTISSVQAEDLSLYYCQQHYSTPRTFGGGTKLEIK,7MLY_H,7MLY_I,"Cryo-Em Reveals Partially And Fully Assembled Native Glycine Receptors,Heteromeric Pentamer","Cryo-Em Reveals Partially And Fully Assembled Native Glycine Receptors,Heteromeric Pentamer",Sus scrofa,"Zhu,H.;Gouaux,E.",Architecture and assembly mechanism of native glycine receptors,29-APR-2021,8_8_11_6_3_9,7MLY_H_I,Xtal structure,,12,1,5.01126,-1.8565153
5NJD_T_S,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,5NJD_T,5NJD_S,Structure Of Interleukin 23 In Complex With Briakinumab Fab,Structure Of Interleukin 23 In Complex With Briakinumab Fab,Homo sapiens,"Bloch,Y.;Bouchareychas,L.;Merceron,R.;Skladanowska,K.;Van den,Bo.;Detry,S.;Govindarajan,S.;Elewaut,D.;Haerynck,F.;Dullaers,M.;Adamopoulos,I.E.;Savvides,S.N.",Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rbeta1,28-MAR-2017,8_8_8_8_3_12,AFL29889_AFL29890,Xtal structure,SGRF; IL23A; IL23P19; IL-23A; P19; IL-23,12,1,14.905342,13.315026
3T4Y_B_A,EVKLVESGGGLVQSGGSLRLSCATSGFTFTDYYMSWVRQPPGKALEWLGFIRNKANGYTTEYSPSVKGRFTISRDNSQSILYLQMNTLRAEDSATYYCARDHDGYYERFSYWGQGTLVTVS,DIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTITSVQAEDLAVYYCKQSYNLRTFGGGTKLEIK,3T4Y_B,3T4Y_A,S25-2- Kdo Monosaccharide Complex,S25-2- Kdo Monosaccharide Complex,Mus musculus,"Nguyen,H.P.;Seto,N.O.;MacKenzie,C.R.;Brade,L.;Kosma,P.;Brade,H.;Evans,S.V.",Germline antibody recognition of distinct carbohydrate epitopes,26-JUL-2011,8_10_13_12_3_8,3T4Y_B_A,Xtal structure,RPS25; S25,13,1,26.103859,4.7234006
8HC4_D_E,EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARENGYSGYGAAANFDLWGRGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSVFGGGTKLTVL,8HC4_D,8HC4_E,Sars-Cov-2 Wildtype Spike Trimer (6P) In Complex With 3 Yb9-258 Fabs And 3 R1-32 Fabs (3 Rbd Up),Sars-Cov-2 Wildtype Spike Trimer (6P) In Complex With 3 Yb9-258 Fabs And 3 R1-32 Fabs (3 Rbd Up),Homo sapiens,"Yu,H.;Liu,B.;Zhang,Y.;Gao,X.;Wang,Q.;Xiang,H.;Peng,X.;Xie,C.;Wang,Y.;Hu,P.;Shi,J.;Shi,Q.;Zheng,P.;Feng,C.;Tang,G.;Liu,X.;Guo,L.;Lin,X.;Li,J.;Liu,C.;Huang,Y.;Yang,N.;Chen,Q.;Li,Z.;Su,M.;Yan,Q.;Pei,R.;Chen,X.;Liu,L.;Hu,F.;Liang,D.;Ke,B.;Ke,C.;Li,F.;He,J.;Wang,M.;Chen,L.;Xiong,X.;Tang,X.",Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants,25-JAN-2023,8_8_17_9_3_11,8HC4_D_E,Xtal structure,SARS-CoV-2,13,1,-1.0389456,5.6042285
3B2U_F_G,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,3B2U_F,3B2U_G,Crystal Structure Of Isolated Domain Iii Of The Extracellular Region Of The Epidermal Growth Factor Receptor In Complex With The Fab Fragment Of Imc-11F8,Crystal Structure Of Isolated Domain Iii Of The Extracellular Region Of The Epidermal Growth Factor Receptor In Complex With The Fab Fragment Of Imc-11F8,Homo sapiens,"Li,S.;Kussie,P.;Ferguson,K.M.",Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8,19-OCT-2007,10_7_13_6_3_9,ADA05820_ADA05824,Xtal structure,EGF,13,1,16.459724,-8.062784
8DIU_G_C,EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL,8DIU_G,8DIU_C,Cryo-Em Structure Of Influenza A Virus A/Bayern/7/1995 Hemagglutinin Bound To Cr6261 Fab,Cryo-Em Structure Of Influenza A Virus A/Bayern/7/1995 Hemagglutinin Bound To Cr6261 Fab,Homo sapiens,"Yang,M.;Dranow,D.M.;Edwards,T.E.;Horanyi,P.S.;Lorimer,D.D.",CryoEM structure of influenza A virus A/Bayern/7/1995 hemagglutinin bound to CR6261 Fab,14-DEC-2022,8_8_14_8_3_12,AYI63003,Xtal structure,hemagglutinin; Influenza,14,1,-0.49583045,5.761466
8F6E_D_C,EVQLVESGGGLVQPGGSLRLSCAASGFTIYSSSIHWVRQAPGKGLEWVASIYSSSGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARQSYSGLSPRRHWSYGAMDYWGQGTLVTVFN,DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQIWSWPLITFGQGTKVEIK,8F6E_D,8F6E_C,Cryo-Em Structure Of A Zinc-Loaded Wild-Type Yiip-Fab Complex,Cryo-Em Structure Of A Zinc-Loaded Wild-Type Yiip-Fab Complex,Homo sapiens,"Lopez-Redondo,M.L.;Hussein,A.K.;Stokes,D.L.",Characterization of individual Zn2+ binding sites of YiiP,08-FEB-2023,8_8_21_6_3_10,8F6E_D_C,Xtal structure,,14,1,9.643473,10.918955
7XJ6_E_D,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYSFIWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTTTAYMELSSLRSEDTAVYYCARGTEYGDYDVSHDWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSHTFGQGTKLEIK,7XJ6_E,7XJ6_D,Sars-Cov-2 Ba.1 Spike Trimer In Complex With 55A8 Fab And 58G6 Fab In The Class 1 Conformation,Sars-Cov-2 Ba.1 Spike Trimer In Complex With 55A8 Fab And 58G6 Fab In The Class 1 Conformation,Homo sapiens,"Guo,H.;Gao,Y.;Lu,Y.;Yang,H.;Ji,X.",SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation,19-APR-2023,8_8_14_6_3_9,7XJ6_E_D,Xtal structure,SARS-CoV-2,14,1,-0.91882616,5.531337
CAV14500,EVQLVESGAEVKKPGESLRISCKGSGXIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14500_H,CAV14500_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,FAILED,Same entry,,15,1,-11.889894,5.374388
7BUD_G_I,EVQLVQSGPDVEKPGASVKVSCKASGYTFTSNYIHWVRQAPGQGLEWMGVINPRGGSTASAQKFQGRITMTRDTSTSTVYMELSSLRSDDTAVYYCARGGRALFYDSYTTPRDGGSWWFDPWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVTFTCQASQDIRKYLNWYQQKPGKAPKLLIYDASNLKTGVPSRFSGSGSGTDFTFTISSLQPEDVATYYCQQFDDLPITFGQGTRLQIK,7BUD_G,7BUD_I,Cryo-Em Structure Of Dengue Virus Serotype 2 Complexed With Fab Sign-3C At Ph 8.0,Cryo-Em Structure Of Dengue Virus Serotype 2 Complexed With Fab Sign-3C At Ph 8.0,Homo sapiens,"Zhang,S.;Loy,T.;Ng,T.S.;Lim,X.N.;Chew,S.V.;Tan,T.Y.;Xu,M.;Kostyuchenko,V.A.;Tukijan,F.;Shi,J.;Fink,K.;Lok,S.M.",A Human Antibody Neutralizes Different Flaviviruses by Using Different Mechanisms,06-APR-2020,8_8_25_6_3_9,QFN39739_QFN39740,Xtal structure,Dengue,15,1,1.7021598,3.610782
7E9O_H_L,QVQLLESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGVSWNSGTIGYADSVKGRFTISRDNAKNSLYLHMRSLRAEDTALYYCAKAVEMVRGLMGLGADPEYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPFTFGPGTKVDIK,7E9O_H,7E9O_L,"Cryo-Em Structure Of The Sars-Cov-2 S-6P In Complex With 35B5 Fab(3 Up Rbds, State2)","Cryo-Em Structure Of The Sars-Cov-2 S-6P In Complex With 35B5 Fab(3 Up Rbds, State2)",Homo sapiens,"Wang,X.;Hu,A.;Chen,X.;Zhang,Y.;Yu,F.;Yue,S.;Li,A.;Zhang,J.;Pan,Z.;Yang,Y.;Lin,Y.;Gao,L.;Zhou,J.;Zhao,J.;Li,F.;Shi,Y.;Huang,F.;Yang,X.;Peng,Y.;Tu,L.;Zhang,H.;Zheng,H.;He,J.;Zhang,H.;Xu,L.;Huang,Q.;Zhu,Y.;Deng,K.;Ye,L.",A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD,09-MAR-2022,8_8_23_11_3_9,7E9O_H_L,Xtal structure,SARS-CoV-2; RBD,15,1,13.077425,12.027581
7LXZ_E_D,VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPISSGTSYAQTFQGRVTMTSDTSITTAYMELSRLRSDDTAVYYCARAAPFYDFWSGYSYFDYWGQGTLVTV,IVMMQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSAWTFGQGTKV,7LXZ_E,7LXZ_D,Sars-Cov-2 S/S2M11/S2L28 Global Refinement,Sars-Cov-2 S/S2M11/S2L28 Global Refinement,Homo sapiens,"McCallum,M.;De Marco,A.;Lempp,F.A.;Tortorici,M.A.;Pinto,D.;Walls,A.C.;Beltramello,M.;Chen,A.;Liu,Z.;Zatta,F.;Zepeda,S.;di Iulio,J.;Bowen,J.E.;Montiel-Ruiz,M.;Zhou,J.;Rosen,L.E.;Bianchi,S.;Guarino,B.;Fregni,C.S.;Abdelnabi,R.;Foo,S.C.;Rothlauf,P.W.;Bloyet,L.M.;Benigni,F.;Cameroni,E.;Neyts,J.;Riva,A.;Snell,G.;Telenti,A.;Whelan,S.P.;Virgin,H.W.;Corti,D.;Pizzuto,M.S.;Veesler,D.",N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2,05-MAR-2021,8_8_18_7_3_9,7LXZ_E_D,Xtal structure,SARS-CoV-2,15,1,2.2906663,3.4924614
6AWO_B_C,EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGNINPNNGGTSYNQKFKGKATLTVDKSSTTAYMELRSLTSEDSAVYYCTRSPVRPYYFDYWGQGTTLTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSIPRTFGGGTKLEIK,6AWO_B,6AWO_C,X-Ray Structure Of The Ts3 Human Serotonin Transporter Complexed With Sertraline At The Central Site,X-Ray Structure Of The Ts3 Human Serotonin Transporter Complexed With Sertraline At The Central Site,Mus musculus,"Coleman,J.A.;Gouaux,E.",Structural basis for recognition of diverse antidepressants by the human serotonin transporter,06-SEP-2017,8_8_12_6_3_9,6AWO_B_C,Xtal structure,SH3YL1; DKFZP586F1318; Ray,16,1,2.4283783,-4.28315
5H30_I_M,EVQLVESGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQDRVTITRDTSASTAYMELSSLRSEDTAIYYCARDKVDDYGDYWFPTLWYFDYWGQGTLVTVS,SALTQPASVSGSPGQSITISCTGTSSDVGGFNYVSWFQQHPGKAPKLMLYDVTSRPSGVSSRFSGSKSGNTASLTISGLQAEDEADYYCSSHTSRGTWVFGGGTKLTVL,5H30_I,5H30_M,Cryo-Em Structure Of Zika Virus Complexed With Fab C10 At Ph 6.5,Cryo-Em Structure Of Zika Virus Complexed With Fab C10 At Ph 6.5,Homo sapiens,"Zhang,S.;Kostyuchenko,V.A.;Ng,T.S.;Lim,X.N.;Ooi,J.S.;Lambert,S.;Tan,T.Y.;Widman,D.G.;Shi,J.;Baric,R.S.;Lok,S.M.",Neutralization mechanism of a highly potent antibody against Zika virus,19-OCT-2016,8_8_21_9_3_10,5H30_I_M,Xtal structure,C12orf57; GRCC10; Zika; C10,16,1,0.1796857,3.0790424
6MTN_H_L,QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYWSWIRQSPGKGLEWIGYISDSESTNYNPSLKSRVIISVDTSKNQLSLKLNSVTAADSAIYYCARAQQGKRIYGMVSFGEFFYYYYMDVWGKGTTVTVSS,LSVALGETASISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,6MTN_H,6MTN_L,Crystal Structure Of Hiv-1 Bg505 Sosip.664 Prefusion Env Trimer Bound To Small Molecule Hiv-1 Entry Inhibitor Compound 484 In Complex With Human Antibodies 3H109L And 35O22 At 3.0 Angstrom,Crystal Structure Of Hiv-1 Bg505 Sosip.664 Prefusion Env Trimer Bound To Small Molecule Hiv-1 Entry Inhibitor Compound 484 In Complex With Human Antibodies 3H109L And 35O22 At 3.0 Angstrom,Homo sapiens,"Lai,Y.T.;Wang,T.;O'Dell,S.;Louder,M.K.;Schon,A.;Cheung,C.S.;Chuang,G.Y.;Druz,A.;Lin,B.;McKee,K.;Peng,D.;Yang,Y.;Zhang,B.;Herschhorn,A.;Sodroski,J.;Bailer,R.T.;Doria-Rose,N.A.;Mascola,J.R.;Langley,D.R.;Kwong,P.D.",Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry,20-OCT-2018,8_7_26_6_3_12,6MTN_H_L,Xtal structure,HIV,16,1,15.554311,-7.952498
7LEX_R_P,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREGAYGYRSPYHNWFDPWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQHSLLPRTFGGGTKVEIK,7LEX_R,7LEX_P,Trimeric Human Arginase 1 In Complex With Mab1 - 2 Harg:3 Mab1 Complex,Trimeric Human Arginase 1 In Complex With Mab1 - 2 Harg:3 Mab1 Complex,Homo sapiens,"Palte,R.L.;Juan,V.;Gomez-Llorente,Y.;Bailly,M.A.;Chakravarthy,K.;Chen,X.;Cipriano,D.;Fayadat-Dilman,L.;Gathiaka,S.;Greb,H.;Hall,B.;Handa,M.;Hsieh,M.;Kofman,E.;Lin,H.;Miller,J.R.;Nguyen,N.;O'Neil,J.;Shaheen,H.;Sterner,E.;Strickland,C.;Sun,A.;Taremi,S.;Scapin,G.",Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action,15-JAN-2021,8_8_18_6_3_9,7LEX_R_P,Xtal structure,,16,1,1.8890612,5.215409
7M7H_E_F,EVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWVRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTRGGTLFDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSLQTPRLTFGPGTKVDIK,7M7H_E,7M7H_F,6-Deoxyerythronolide B Synthase (Debs) Module 1 In Complex With Antibody Fragment 1B2: State 1',6-Deoxyerythronolide B Synthase (Debs) Module 1 In Complex With Antibody Fragment 1B2: State 1',Homo sapiens,"Cogan,D.P.;Zhang,K.;Li,X.;Li,S.;Pintilie,G.D.;Roh,S.H.;Craik,C.S.;Chiu,W.;Khosla,C.",Mapping the catalytic conformations of an assembly-line polyketide synthase module,28-MAR-2021,8_10_9_11_3_10,7M7H_E_F,Xtal structure,,17,1,13.278434,8.758366
7LJA_G_F,EVQLQQSGPELVKPGASMKTSCKVSGYSFTGYIMNWVKQRHGKNLEWIGLINPNTGYTTYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAIYYCTRGNYVFDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSNSPPTFGAGAKLELK,7LJA_G,7LJA_F,Human Traak K+ Channel Fheig Mutant A198E In A Tl+ Bound Conductive Conformation,Human Traak K+ Channel Fheig Mutant A198E In A Tl+ Bound Conductive Conformation,Mus musculus,"Rietmeijer,R.A.;Sorum,B.;Li,B.;Brohawn,S.G.",Physical basis for distinct basal and mechanically gated activity of the human K(+) channel TRAAK,28-JAN-2021,8_8_9_5_3_9,7LJA_G_F,Xtal structure,K2p4.1; TRAAK; KCNK4,18,1,2.2920675,-4.1727357
UXF51059_UXF51060,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARGEIQPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGSPGQSVTISCTGTSSDFGGYNSVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNFDVFGTGTKVTVL,UXF51059,UXF51060,"anti SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Wang,Y.; Zhang,X.; Ma,Y.; Wang,Y.; Zhan,W.; Zheng,Q.; Zhang,M.; Ji,P.; Liu,M.; Liu,Q.; Sun,T.; Zhu,T.; Wen,Y.; Sun,L.; Zhao,J.; Wu,F.; Chen,Z.; Huang,J.",Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies,14-OCT-2022,8_7_15_9_3_11,UXF51059_UXF51060,Unique source,SARS-CoV-2,18,1,12.649532,10.764206
7WS1_E_D,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSDSIDYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDRGYEILTPASFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWFQHKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPYTFGQGTKLEIK,7WS1_E,7WS1_D,Structures Of Omicron Spike Complexes Illuminate Broad-Spectrum Neutralizing Antibody Development,Structures Of Omicron Spike Complexes Illuminate Broad-Spectrum Neutralizing Antibody Development,Homo sapiens,"Guo,H.;Gao,Y.;Li,T.;Li,T.;Lu,Y.;Zheng,L.;Liu,Y.;Yang,T.;Luo,F.;Song,S.;Wang,W.;Yang,X.;Nguyen,H.C.;Zhang,H.;Huang,A.;Jin,A.;Yang,H.;Rao,Z.;Ji,X.",Structures of Omicron spike complexes and implications for neutralizing antibody development,28-JAN-2022,8_8_16_6_3_10,7WS1_E_D,Xtal structure,,18,1,13.122977,12.039294
UXF51057_UXF51058,EVQLVESGGGVVQPGGSLRLSCAASGFRFDDHAMHWVRQAPGKGLEWVSVISGDGGSTYYADSVKGRFSISRDDSKNSLYLQMNSLRTEDTALYYCAKDRSYGPPDVFNYEYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNWVFGGGTKLTVL,UXF51057,UXF51058,"anti SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",Homo sapiens,"Wang,Y.; Zhang,X.; Ma,Y.; Wang,Y.; Zhan,W.; Zheng,Q.; Zhang,M.; Ji,P.; Liu,M.; Liu,Q.; Sun,T.; Zhu,T.; Wen,Y.; Sun,L.; Zhao,J.; Wu,F.; Chen,Z.; Huang,J.",Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies,14-OCT-2022,8_8_20_8_3_10,UXF51057_UXF51058,Unique source,SARS-CoV-2,18,1,13.38404,11.256202
4FQR_a_b,EVQLQESGGGLVQPGESLRLSCVGSGSSFGESTLSYYAVSWVRQAPGKGLEWLSIINAGGGDIDYADSVEGRFTISRDNSKETLYLQMTNLRVEDTGVYYCAKHMSMQQVVSAGWERADLVGDAFDVWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTLTCQASQDIRKFLNWYQQKPGKGPKLLIYDASNLQRGVPSRFSGGGSGTDFTLIISSLQPEDVGTYYCQQYDGLPFTFGGGTKVVIK,4FQR_a,4FQR_b,Crystal Structure Of Broadly Neutralizing Antibody C05 Bound To H3 Influenza Hemagglutinin,Crystal Structure Of Broadly Neutralizing Antibody C05 Bound To H3 Influenza Hemagglutinin,Homo sapiens,"Ekiert,D.C.;Kashyap,A.K.;Steel,J.;Rubrum,A.;Bhabha,G.;Khayat,R.;Lee,J.H.;Dillon,M.A.;O'Neil,R.E.;Faynboym,A.M.;Horowitz,M.;Horowitz,L.;Ward,A.B.;Palese,P.;Webby,R.;Lerner,R.A.;Bhatt,R.R.;Wilson,I.A.",Cross-neutralization of influenza A viruses mediated by a single antibody loop,25-JUN-2012,13_8_26_6_3_9,4FQR_a_b,Xtal structure,Influenza,19,1,14.22662,10.062363
2QTJ_D_O,LEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSSLRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSS,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIK,2QTJ_D,2QTJ_O,Solution Structure Of Human Dimeric Immunoglobulin A,Solution Structure Of Human Dimeric Immunoglobulin A,Homo sapiens,"Bonner,A.;Furtado,P.B.;Almogren,A.;Kerr,M.A.;Perkins,S.J.",Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy,02-AUG-2007,8_8_14_6_3_9,2QTJ_A_L,Xtal structure,,21,1,0.2529566,3.1507754
CCD30935_CCD30936,QIHLVQSGTEVKKPGSSVTVSCKAYGVNTFGLYAVNWVRQAPGQSLEYIGQIWRWKSSASHHFRGRVLISAVDLTGSSPPISSLEIKNLTSDDTAVYFCTTTSTYDKWSGLHHDGVMAFSSWGQGTLISVSA,DIQMTQSPSTLSASIGDTVRISCRASQSITGNWVAWYQQRPGKAPRLLIYRGAALLGGVPSRFSGSAAGTDFTLTIGNLQAEDFGTFYCQQYDTYPGTFGQGTKVEVK,CCD30935,CCD30936,"immunoglobulin heavy chain variable region, partial [Homo sapiens]","immunoglobulin kappa chain variable region, partial [Homo sapiens]",Homo sapiens,"Scheid,J.F.; Mouquet,H.; Ueberheide,B.; Diskin,R.; Klein,F.; Oliveira,T.Y.; Pietzsch,J.; Fenyo,D.; Abadir,A.; Velinzon,K.; Hurley,A.; Myung,S.; Boulad,F.; Poignard,P.; Burton,D.R.; Pereyra,F.; Ho,D.D.; Walker,B.D.; Seaman,M.S.; Bjorkman,P.J.; Chait,B.T.; Nussenzweig,M.C.",Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding,25-JUL-2016,9_6_22_7_3_9,CCD30935_CCD30936,Unique source,HIV; CD4,21,1,-0.8456055,5.564278
2H2P_E_F,VRLLESGGGLVQPGGSLKLSCAASGFDYSRYWMSWVRQAPGKGLKWIGEINPVSSTINYTPSLKDKFIISRDNAKDTLYLQISKVRSEDTALYYCARLYYGYGYWYFDVWGAGTTVTVSS,DIVLTQSPAIMSAAPGDKVTMTCSASSSVSYIHWYQQKSGTSPKRWIYDTSKLTSGVPVRFSGSGSGTSYSLTINTMEAEDAATYYCQQWSSHPQTFGGGTKLEI,2H2P_E,2H2P_F,Crystal Structure Of Clc-Ec1 In Complex With Fab Fragment In Secn-,Crystal Structure Of Clc-Ec1 In Complex With Fab Fragment In Secn-,Mus musculus,"Nguitragool,W.;Miller,C.",Uncoupling of a CLC Cl-/H+ exchange transporter by polyatomic anions,19-MAY-2006,8_8_14_5_3_9,2H2P_E_F,Xtal structure,CLC; MGC149659; Gal-10; LGALS10,24,1,19.614386,9.737817
8DD3_J_I,EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYMYWVKQRPEQGLEWIGRIDPANGDTKYDPKFQGKATITTDTFSNTAYLQLSSLTSEDTAVYYCARKGLRWAMDYWGQGTSVTVST,NIVMTQSPKSMSMSVGERVTLSCKASEYVGTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTIGSVQAEDLADYHCGQSYSYPTFGAGTKLELK,8DD3_J,8DD3_I,Human Gabaa Receptor Alpha1-Beta2-Gamma2 Subtype In Complex With Gaba Plus Dmcm,Human Gabaa Receptor Alpha1-Beta2-Gamma2 Subtype In Complex With Gaba Plus Dmcm,Mus musculus,"Zhu,S.;Sridhar,A.;Teng,J.;Howard,R.J.;Lindahl,E.;Hibbs,R.E.",Structural and dynamic mechanisms of GABA<sub>A</sub> receptor modulators with opposing activities,08-JAN-2009,8_8_11_6_3_8,8DD3_J_I,Xtal structure,TUBB4B; TUBB2C; Beta2,30,1,-4.670265,0.102094814
4TNW_V_Z,EVQLQQSGPELVRPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLINPYNGGTSYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARDGDYYRYGRYFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTINFANWVQEKPDHLFTGLIGGINNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL,4TNW_V,4TNW_Z,C. Elegans Glutamate-Gated Chloride Channel (Glucl) In Complex With Fab And Popc In A Lipid-Modulated Conformation,C. Elegans Glutamate-Gated Chloride Channel (Glucl) In Complex With Fab And Popc In A Lipid-Modulated Conformation,Mus musculus,"Hibbs,R.E.;Gouaux,E.",Principles of activation and permeation in an anion-selective Cys-loop receptor,05-JUN-2014,8_8_15_9_3_9,4TNW_V_Z,Xtal structure,,40,1,2.3392596,-4.276647
ABW24719_ABW24720,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRNKVNNHATNYAESVKGRFTISRDDSRSVVYLQMNNLKPEDTGIYYCTGLTFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDNYGISSMNWFQQKAGQPPKFLIYAASKQGSGVPARFSGSGSGTDFSLIIHPVEEDDTAVYFCQQSKGVPYTFGGGTKLEIK,ABW24719,ABW24720,"immunoglobulin gamma heavy chain V and CH1 region, partial [Mus musculus]","immunoglobulin kappa light chain, partial [Mus musculus]",Mus musculus,"Uysal,H.; Bockermann,R.; Nandakumar,K.S.; Sehnert,B.; Bajtner,E.; Engstrom,A.; Serre,G.; Burkhardt,H.; Thunnissen,M.M.; Holmdahl,R.",Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis,26-JUL-2016,8_10_7_10_3_9,ABW24719_ABW24720,Ordered entries,,41,1,13.411185,6.9407544
CAV14493,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,CAV14493_H,CAV14493_L,unnamed protein product [synthetic construct],unnamed protein product [synthetic construct],synthetic construct,"Burnie,J.; Wechner,P.",Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90,17-DEC-2008,8_8_13_6_3_9,ADL98439,Same entry,,42,1,-11.858929,5.3487873
